,Generic Name,Company Name,Presentation,Type of Update,Date of Update,Availability Information,Related Information,Resolved Note,Reason for Shortage,Therapeutic Category,Status,Change Date,Date Discontinued,ndc,Year,Availability Status
0,Acyclovir Ointment,"Mylan Institutional, a Viatris Company","Acyclovir Ointment 5% 15gram Tube, Ointment, 5% 15gram (NDC 0378-8700-06)",New,9/16/2024,,,,,Dermatology,To Be Discontinued,,9/16/2024,,2025,discontinued
1,Acyclovir Ointment,"Mylan Institutional, a Viatris Company","Acyclovir Ointment 5% 5g 2pk, Ointment, 5% 5g (NDC 51079-550-68)",New,9/16/2024,,,,,Dermatology,To Be Discontinued,,9/16/2024,,2025,discontinued
2,Acyclovir Ointment,"Actavis Pharma, Inc.","Zovirax, Ointment, 50 mg/1 g (NDC 0591-1159-30)",New,3/3/2025,,,,,Dermatology,To Be Discontinued,,3/3/2025,,2025,discontinued
3,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-20)",New,4/14/2025,,,,,Rheumatology,To Be Discontinued,,4/14/2025,,2025,discontinued
4,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 20 mg/.2 mL (NDC 61314-476-64)",New,4/14/2025,,,,,Rheumatology,To Be Discontinued,,4/14/2025,,2025,discontinued
5,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 10 mg/.1 mL (NDC 61314-509-64)",New,4/14/2025,,,,,Rheumatology,To Be Discontinued,,4/14/2025,,2025,discontinued
6,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0375-16)",New,3/3/2025,,,,,Rheumatology,To Be Discontinued,,3/3/2025,,2025,discontinued
7,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0375-23)",New,3/3/2025,,,,,Rheumatology,To Be Discontinued,,3/3/2025,,2025,discontinued
8,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0495-40)",New,1/6/2025,,,,,Rheumatology,To Be Discontinued,,1/6/2025,,2025,discontinued
9,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0495-60)",New,1/6/2025,,,,,Rheumatology,To Be Discontinued,,1/6/2025,,2025,discontinued
10,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0575-40)",New,1/6/2025,,,,,Rheumatology,To Be Discontinued,,1/6/2025,,2025,discontinued
11,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0575-60)",New,1/6/2025,,,,,Rheumatology,To Be Discontinued,,1/6/2025,,2025,discontinued
12,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0545-44)",New,1/6/2025,,,,,Rheumatology,To Be Discontinued,,1/6/2025,,2025,discontinued
13,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0545-66)",New,1/6/2025,,,,,Rheumatology,To Be Discontinued,,1/6/2025,,2025,discontinued
14,Adefovir Dipivoxil Tablet,Apotex Corp.,"Adefovir Dipivoxil, Tablet, 10 mg (NDC 60505-3947-3)",New,7/29/2025,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,7/29/2025,,2025,discontinued
15,Albendazole Tablet,Strides Pharma Inc.,"Tablet, 200 mg (NDC 31722-935-02)",New,9/16/2024,,Current Product distributor: Camber Pharmaceuticals. Product temporarily discontinued due to business related reasons.,,,Anti-Infective,To Be Discontinued,,9/16/2024,,2025,discontinued
16,Albuterol Sulfate Solution,Nephron Pharmaceuticals Corporation,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)",Revised,7/2/2025,Available,"Albuterol 0.5% is in stock, though demand remains high; additional supply can be produced as needed.",,Other,Pulmonary/Allergy; Pediatric,Current,,,,2025,available
17,Albuterol Sulfate Solution,"Rising Pharma Holdings, Inc.","Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)",Reverified,8/15/2025,Available,,,,Pediatric; Pulmonary/Allergy,Current,,,,2025,available
18,Albuterol Sulfate Solution,"Ritedose Pharmaceuticals, LLC","Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)",Reverified,8/15/2025,Available,,,,Pediatric; Pulmonary/Allergy,Current,,,,2025,available
19,Albuterol Sulfate Syrup,"Actavis Pharma, Inc.","Syrup, 2 mg/5 mL (NDC 0472-0825-16)",New,11/4/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,11/4/2024,,2025,discontinued
20,Amantadine Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-01)",New,2/5/2025,,A business decision was made to discontinue manufacture of the drug.,,,Antiviral; Neurology,To Be Discontinued,,2/5/2025,,2025,discontinued
21,Amantadine Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-05)",New,2/5/2025,,A business decision was made to discontinue manufacture of the drug.,,,Antiviral; Neurology,To Be Discontinued,,2/5/2025,,2025,discontinued
22,Amantadine Hydrochloride Capsule,Strides Pharma Inc.,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-01)",New,2/12/2025,,Discontinuation of manufacture of drug based on business decision,,,Antiviral; Neurology,To Be Discontinued,,2/12/2025,,2025,discontinued
23,Amantadine Hydrochloride Capsule,Strides Pharma Inc.,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-05)",New,2/12/2025,,Discontinuation of manufacture of drug based on business decision,,,Antiviral; Neurology,To Be Discontinued,,2/12/2025,,2025,discontinued
24,Amantadine Hydrochloride Capsule,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-00)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/2025,,2025,discontinued
25,Amantadine Hydrochloride Capsule,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-50)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/2025,,2025,discontinued
26,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-00)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/2025,,2025,discontinued
27,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-03)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/2025,,2025,discontinued
28,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-50)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/2025,,2025,discontinued
29,Ambrisentan Tablet,Apotex Corp.,"Ambrisentan, Tablet, 5 mg (NDC 60505-4552-3)",New,1/14/2025,,,,,Cardiovascular,To Be Discontinued,,1/14/2025,,2025,discontinued
30,Ambrisentan Tablet,Apotex Corp.,"Ambrisentan, Tablet, 10 mg (NDC 60505-4553-3)",New,1/14/2025,,,,,Cardiovascular,To Be Discontinued,,1/14/2025,,2025,discontinued
31,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)",Reverified,9/3/2025,Available,,,,Gastroenterology,Current,,,,2025,available
32,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)",Reverified,9/3/2025,Available,,,,Gastroenterology,Current,,,,2025,available
33,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)",Reverified,9/3/2025,Available,,,,Gastroenterology,Current,,,,2025,available
34,Amino Acid Injection,Baxter Healthcare,"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)",Reverified,9/3/2025,Available,,,,Gastroenterology,Current,,,,2025,available
35,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)",Revised,9/3/2025,Limited Availability,Capacity constraint - Recovery in November 2025,,Other,Gastroenterology,Current,,,,2025,limited availability
36,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)",Reverified,9/3/2025,Unavailable,Capacity constraint - Recovery in October 2025,,Other,Gastroenterology,Current,,,,2025,not available
37,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)",Reverified,9/3/2025,Available,,,,Gastroenterology,Current,,,,2025,available
38,Amino Acid Injection,B. Braun Medical Inc.,"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)",Reverified,8/21/2025,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,,,2025,available
39,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-05)",Reverified,8/21/2025,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,,,2025,available
40,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Reverified,9/3/2025,Available,,,,Gastroenterology,Current,,,,2025,available
41,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-00)",Reverified,8/21/2025,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,,,2025,available
42,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Gastroenterology,Current,,,,2025,available
43,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Gastroenterology,Current,,,,2025,available
44,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)",Reverified,8/20/2025,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Shortage of an active ingredient,Gastroenterology,Current,,,,2025,not available
45,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)",Reverified,8/20/2025,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Shortage of an active ingredient,Gastroenterology,Current,,,,2025,not available
46,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Reverified,9/3/2025,Available,,,,Gastroenterology,Current,,,,2025,available
47,Aminocaproic Acid Tablet,ANI Pharmaceuticals,"Tablet, 500 mg (NDC 62559-225-30)",New,11/7/2024,,"ANI anticipates ceasing distribution on November 30, 2024.",,,Cardiovascular; Hematology; Other,To Be Discontinued,,11/7/2024,,2025,discontinued
48,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 2.5 mg; 10 mg (NDC 65862-582-01)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
49,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-01)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
50,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-05)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
51,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-01)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
52,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-05)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
53,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-01)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
54,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-05)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
55,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-01)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
56,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-05)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
57,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 40 mg (NDC 65862-587-01)",New,3/4/2025,,,,,Cardiovascular,To Be Discontinued,,3/4/2025,,2025,discontinued
58,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 10 mg; 20 mg (NDC 0078-0364-05)",New,6/24/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/2025,,2025,discontinued
59,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 10 mg; 40 mg (NDC 0078-0379-05)",New,6/24/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/2025,,2025,discontinued
60,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 5 mg; 10 mg (NDC 0078-0405-05)",New,6/24/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/2025,,2025,discontinued
61,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 5 mg; 20 mg (NDC 0078-0406-05)",New,6/24/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/2025,,2025,discontinued
62,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-05)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
63,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-30)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
64,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-90)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
65,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-05)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
66,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-30)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
67,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-90)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
68,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-05)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
69,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-30)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
70,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-90)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
71,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-05)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
72,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-30)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
73,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-90)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
74,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-05)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
75,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-30)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
76,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-90)",New,6/13/2025,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
77,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-73)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
78,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-76)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
79,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-78)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
80,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-73)",Revised,5/2/2025,,,Available,,Anti-Infective,Resolved,5/2/2025,,,2025,
81,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-76)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
82,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-78)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
83,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-55)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
84,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-80)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
85,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-50)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
86,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-75)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
87,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-55)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
88,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-80)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
89,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-50)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
90,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-75)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
91,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-15)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
92,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-80)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
93,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-50)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
94,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-75)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
95,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-15)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
96,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-80)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
97,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-50)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
98,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-75)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
99,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-01)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
100,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-01)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
101,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-01)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
102,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-01)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
103,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-01)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
104,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-01)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
105,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-01)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
106,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-01)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
107,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-46)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
108,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-55)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
109,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-58)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
110,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-46)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
111,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-52)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
112,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-57)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
113,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-46)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
114,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-52)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
115,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-57)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
116,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-46)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
117,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-55)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
118,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-58)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
119,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-73)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
120,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-80)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
121,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-79)",Revised,5/2/2025,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/2025,,,2025,
122,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
123,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
124,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
125,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
126,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
127,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
128,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)",Reverified,9/2/2025,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
129,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)",Reverified,9/2/2025,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
130,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)",Reverified,9/2/2025,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
131,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)",Reverified,9/2/2025,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
132,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)",Reverified,9/2/2025,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
133,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
134,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
135,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
136,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)",Reverified,9/2/2025,Unavailable,Supporting contracted business only; Resupply Q3 2025,,Other,Psychiatry,Current,,,,2025,not available
137,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
138,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
139,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
140,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
141,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
142,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
143,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
144,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
145,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
146,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
147,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
148,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
149,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
150,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
151,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
152,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)",Reverified,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
153,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)",Revised,8/19/2025,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,,,2025,limited availability
154,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)",Revised,8/19/2025,Unavailable,Estimated availability October 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
155,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)",Revised,8/19/2025,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,,,2025,limited availability
156,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)",Revised,8/19/2025,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,,,2025,limited availability
157,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)",Reverified,6/25/2025,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
158,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)",Reverified,6/25/2025,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
159,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)",Reverified,6/25/2025,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
160,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)",Reverified,6/25/2025,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
161,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)",Reverified,6/25/2025,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
162,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)",Reverified,6/25/2025,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
163,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)",Reverified,8/12/2025,Available,,,,Psychiatry,Current,,,,2025,available
164,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)",Reverified,8/12/2025,Available,,,,Psychiatry,Current,,,,2025,available
165,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)",Reverified,8/12/2025,Available,,,,Psychiatry,Current,,,,2025,available
166,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)",Reverified,8/12/2025,Available,,,,Psychiatry,Current,,,,2025,available
167,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)",Reverified,8/12/2025,Available,,,,Psychiatry,Current,,,,2025,available
168,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)",Reverified,8/12/2025,Available,,,,Psychiatry,Current,,,,2025,available
169,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)",Reverified,8/12/2025,Available,,,,Psychiatry,Current,,,,2025,available
170,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)",Reverified,9/2/2025,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
171,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)",Reverified,9/2/2025,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
172,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)",Reverified,9/2/2025,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
173,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)",Reverified,9/2/2025,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
174,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)",Reverified,9/2/2025,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
175,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)",Reverified,9/2/2025,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
176,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)",Reverified,9/2/2025,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
177,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
178,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
179,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
180,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
181,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
182,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
183,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
184,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
185,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
186,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
187,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
188,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)",Revised,8/19/2025,Available,Estimated recovery: December 2025,,Other,Psychiatry,Current,,,,2025,available
189,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
190,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
191,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)",Revised,8/19/2025,Limited Availability,Estimated recovery: October 2025,,Other,Psychiatry,Current,,,,2025,limited availability
192,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)",Revised,8/19/2025,Limited Availability,Estimated recovery: August 2025,,Other,Psychiatry,Current,,,,2025,limited availability
193,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)",Revised,8/19/2025,Limited Availability,Estimated recovery: November 2025,,Other,Psychiatry,Current,,,,2025,limited availability
194,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
195,Amphotericin B Injection,"Leadiant Biosciences, Inc.","Abelcet, Injection, 5 mg/1 mL; 3.4 mg/1 mL; 1.5 mg/1 mL (NDC 57665-101-41)",New,8/8/2025,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,,8/8/2025,,2025,discontinued
196,Atazanavir Sulfate Capsule,Bristol Myers Squibb Co.,"Reyataz, Capsule, 200 mg (NDC 0003-3631-12)",New,6/4/2025,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/2025,,2025,discontinued
197,Atazanavir Sulfate Capsule,Bristol Myers Squibb Co.,"Reyataz, Capsule, 300 mg (NDC 0003-3622-12)",New,6/4/2025,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/2025,,2025,discontinued
198,Atazanavir Sulfate Oral Powder,Bristol Myers Squibb Co.,"Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10)",New,6/4/2025,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/2025,,2025,discontinued
199,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 10 mg (NDC 0002-3227-30)",New,10/22/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/2024,,2025,discontinued
200,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 25 mg (NDC 0002-3228-30)",New,10/22/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/2024,,2025,discontinued
201,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 40 mg (NDC 0002-3229-30)",New,10/22/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/2024,,2025,discontinued
202,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 18 mg (NDC 0002-3238-30)",New,10/22/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/2024,,2025,discontinued
203,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 60 mg (NDC 0002-3239-30)",New,10/22/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/2024,,2025,discontinued
204,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 80 mg (NDC 0002-3250-30)",New,10/22/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/2024,,2025,discontinued
205,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 100 mg (NDC 0002-3251-30)",New,10/22/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/2024,,2025,discontinued
206,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-4910-34)",New,2/19/2025,,,,,Anesthesia; Neurology; Pediatric,To Be Discontinued,,2/19/2025,,2025,discontinued
207,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Neurology; Pediatric,Current,,,,2025,available
208,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)",Reverified,8/19/2025,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2025,available
209,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)",Reverified,8/15/2025,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2025,available
210,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)",Reverified,8/15/2025,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2025,available
211,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 0.5 mg/5 mL (0.1 mg/mL) Syringes (NDC 0409-4910-34)",Revised,8/19/2025,Unavailable,Next Delivery and Estimated Recovery: December 2028,,Other,Anesthesia; Neurology; Pediatric,Current,,,,2025,not available
212,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-4911-34)",Revised,8/15/2025,Unavailable.,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Neurology; Pediatric,Current,,,,2025,not available
213,Atropine Sulfate Injection,"American Regent, Inc.","Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)",Reverified,8/19/2025,Available,old NDC 0517-1010-25,,,Anesthesia; Neurology; Pediatric,Current,,,,2025,available
214,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)",Reverified,7/23/2025,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2025,available
215,Atropine Sulfate Injection,"American Regent, Inc.","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)",Reverified,8/19/2025,Available,old NDC 0517-0401-25,,,Anesthesia; Neurology; Pediatric,Current,,,,2025,available
216,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)",Revised,8/19/2025,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,,,2025,
217,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)",Reverified,8/19/2025,Unavailable,Resupply TBD,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,,,2025,not available
218,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)",Revised,8/19/2025,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,,,2025,
219,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)",Reverified,8/19/2025,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia; Neurology; Pediatric,Current,,,,2025,not available
220,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)",Revised,8/19/2025,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,,,2025,
221,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)",Reverified,8/19/2025,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia; Neurology; Pediatric,Current,,,,2025,not available
222,Atropine Sulfate Injection,"Medefil, Inc.","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 64253-400-91)",Reverified,8/15/2025,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2025,available
223,Azacitidine Injection,Eugia US LLC,"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)",Reverified,8/21/2025,Available,Check wholesalers for inventory,,,Oncology,Current,,,,2025,available
224,Azacitidine Injection,"Meitheal Pharmaceuticals, Inc.","Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)",Reverified,8/19/2025,Available,,,,Oncology,Current,,,,2025,available
225,Azacitidine Injection,Bristol Myers Squibb Co.,"Vidaza, Injection, 100 mg (NDC 59572-102-01)",Reverified,9/3/2025,Available,,,,Oncology,Current,,,,2025,available
226,Azacitidine Injection,"Fresenius Kabi USA, LLC","Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)",Reverified,9/2/2025,Available,Check wholesaler inventory,,,Oncology,Current,,,,2025,available
227,Azacitidine Injection,"Hikma Pharmaceuticals USA, Inc.","Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)",Reverified,7/23/2025,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Oncology,Current,,,,2025,available
228,Azacitidine Injection,"Dr. Reddy's Laboratories, Inc.","Azacitidine, Injection, 100 mg (NDC 43598-305-62)",Reverified,8/15/2025,Available,Available to existing customers,,,Oncology,Current,,,,2025,available
229,Azacitidine Injection,Armas Pharmaceuticals Inc,"Azacitidine, Injection, 100 mg (NDC 72485-201-01)",Reverified,8/19/2025,Available,,,,Oncology,Current,,,,2025,available
230,Azacitidine Injection,Accord Healthcare Inc.,"Azacitidine, Injection, 100 mg (NDC 16729-306-10)",Revised,8/19/2025,Limited Availability,TBD,,Regulatory delay,Oncology,Current,,,,2025,limited availability
231,Azacitidine Injection,"Teva Pharmaceuticals USA, Inc.","Azacitidine, Injection, 100 mg (NDC 68001-313-56)",Revised,8/19/2025,Unavailable,Estimated recovery: TBD,,Other,Oncology,Current,,,,2025,not available
232,Azelaic Acid Gel,Leo Pharma Inc.,"Finacea, Gel, .15 g/1 g (NDC 50222-505-50)",New,1/13/2025,,,,,Dermatology,To Be Discontinued,,1/13/2025,,2025,discontinued
233,Azelastine Hydrochloride; Fluticasone Propionate Nasal Spray,"Mylan Pharmaceuticals Inc., a Viatris Company","Dymista, Nasal Spray, 137 ug; 50 ug (NDC 0378-3458-23)",New,9/4/2025,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,9/4/2025,,2025,discontinued
234,Azithromycin for Suspension,Pfizer Inc.,"Zithromax, for Suspension, 100 mg/5 mL (NDC 59762-3110-1)",New,10/15/2024,,,,,Anti-Infective,To Be Discontinued,,10/15/2024,,2025,discontinued
235,Bacitracin Ophthalmic Ointment,Padagis US LLC,"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)",Revised,7/2/2025,Unavailable,Shortage is estimated for 18 months,,Discontinuation of the manufacture of the drug,Anti-Infective; Ophthalmology,Current,,,,2025,not available
236,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-10)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
237,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-11)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
238,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-15)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
239,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-90)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
240,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-10)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
241,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-11)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
242,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-15)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
243,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-90)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
244,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-0)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
245,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-1)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
246,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-3)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
247,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6869-0)",New,4/23/2025,,,,,Neurology,To Be Discontinued,,4/23/2025,,2025,discontinued
248,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 10 mg (NDC 65862-116-01)",New,2/7/2025,,,,,Cardiovascular,To Be Discontinued,,2/7/2025,,2025,discontinued
249,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 20 mg (NDC 65862-117-01)",New,2/7/2025,,,,,Cardiovascular,To Be Discontinued,,2/7/2025,,2025,discontinued
250,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 40 mg (NDC 65862-118-01)",New,2/7/2025,,,,,Cardiovascular,To Be Discontinued,,2/7/2025,,2025,discontinued
251,Bendamustine Hydrochloride Injection,Apotex Corp.,"Bendamustine Hydrochloride, Injection, 25 mg (NDC 60505-6095-0)",New,1/27/2025,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/27/2025,,2025,discontinued
252,Bendamustine Hydrochloride Injection,Apotex Corp.,"Bendamustine Hydrochloride, Injection, 100 mg (NDC 60505-6096-0)",New,1/27/2025,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/27/2025,,2025,discontinued
253,Bezlotoxumab Injection,Merck Sharp & Dohme LLC,"Zinplava, Injection, 25 mg/1 mL (NDC 0006-3025-00)",New,12/23/2024,,"To be discontinued on January 31, 2025",,,Anti-Infective,To Be Discontinued,,12/23/2024,,2025,discontinued
254,Bleomycin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Bleomycin Sulfate, Injection, 30 [USP'U] (NDC 0409-0323-20)",New,6/13/2025,,Discontinuation of the manufacture of the drug,,,Hematology; Oncology; Pediatric,To Be Discontinued,,6/13/2025,,2025,discontinued
255,Bleomycin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Bleomycin Sulfate, Injection, 15 [USP'U] (NDC 0409-0332-20)",New,6/13/2025,,Discontinuation of the manufacture of the drug,,,Hematology; Oncology; Pediatric,To Be Discontinued,,6/13/2025,,2025,discontinued
256,Bosentan Tablet,Actelion Pharmaceuticals,"Tracleer, Tablet, 62.5 mg (NDC 66215-101-03)",New,6/9/2025,,,,,Cardiovascular,To Be Discontinued,,6/9/2025,,2025,discontinued
257,Bosentan Tablet,Actelion Pharmaceuticals,"Tracleer, Tablet, 125 mg (NDC 66215-102-03)",New,6/9/2025,,,,,Cardiovascular,To Be Discontinued,,6/9/2025,,2025,discontinued
258,Brexanolone Solution,"Sage Therapeutics, Inc.","Zulresso, Solution, 5 mg/1 mL (NDC 72152-547-20)",New,10/29/2024,,,,,Psychiatry,To Be Discontinued,,10/29/2024,,2025,discontinued
259,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)",New,8/25/2025,Available,,,,Cardiovascular,Current,,,,2025,available
260,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)",New,8/25/2025,Available,,,,Cardiovascular,Current,,,,2025,available
261,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)",Reverified,7/23/2025,Available,,,,Cardiovascular,Current,,,,2025,available
262,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)",Reverified,7/23/2025,Available,,,,Cardiovascular,Current,,,,2025,available
263,Bumetanide Injection,"Fresenius Kabi USA, LLC","Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
264,Bumetanide Injection,"Fresenius Kabi USA, LLC","Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
265,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)",Revised,8/8/2025,Available,,,,Cardiovascular,Current,,,,2025,available
266,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)",Revised,8/8/2025,Available,,,,Cardiovascular,Current,,,,2025,available
267,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)",Revised,8/8/2025,Available,,,,Cardiovascular,Current,,,,2025,available
268,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)",Revised,8/8/2025,Available,,,,Cardiovascular,Current,,,,2025,available
269,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, .5 mg (NDC 0832-0540-11)",New,5/2/2025,,,,,Cardiovascular,To Be Discontinued,,5/2/2025,,2025,discontinued
270,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 1 mg (NDC 0832-0541-10)",New,5/2/2025,,,,,Cardiovascular,To Be Discontinued,,5/2/2025,,2025,discontinued
271,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 1 mg (NDC 0832-0541-11)",New,5/2/2025,,,,,Cardiovascular,To Be Discontinued,,5/2/2025,,2025,discontinued
272,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 2 mg (NDC 0832-0542-10)",New,5/2/2025,,,,,Cardiovascular,To Be Discontinued,,5/2/2025,,2025,discontinued
273,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 2 mg (NDC 0832-0542-11)",New,5/2/2025,,,,,Cardiovascular,To Be Discontinued,,5/2/2025,,2025,discontinued
274,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL); 30 mL Single Dose Glass Teartop Vial NOVAPLUS (NDC 0409-1159-10)",New,1/10/2025,,Discontinuation of the manufacture of the drug,,,Anesthesia,To Be Discontinued,,1/10/2025,,2025,discontinued
275,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1610-50)",New,1/10/2025,,"Discontinuation of the manufacture of the drug.
Replaced with NDC 0409-0525-01",,,Anesthesia,To Be Discontinued,,1/10/2025,,2025,discontinued
276,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)",Reverified,8/19/2025,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,,2025,available
277,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)",Reverified,8/19/2025,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,,2025,available
278,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)",Reverified,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: December 2028,,Other,Anesthesia,Current,,,,2025,not available
279,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,,2025,limited availability
280,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
281,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
282,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
283,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)",Reverified,8/19/2025,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,,2025,available
284,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)",Reverified,8/19/2025,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,,2025,available
285,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)",Reverified,8/19/2025,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,,2025,available
286,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
287,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
288,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
289,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
290,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
291,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
292,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
293,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
294,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
295,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
296,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
297,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
298,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
299,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
300,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
301,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
302,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
303,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
304,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
305,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
306,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
307,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
308,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)",Revised,8/15/2025,Limited Available,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia,Current,,,,2025,
309,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
310,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
311,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
312,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
313,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Demand increase for the drug,Anesthesia,Current,,,,2025,limited availability
314,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
315,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1587-50)",Revised,8/15/2025,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,,2025,not available
316,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
317,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,,2025,limited availability
318,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 250 mg/50 mL (5 mg/mL) (NDC 0409-1610-50)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
319,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1582-10)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,,2025,limited availability
320,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1582-29)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
321,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)",Reverified,6/27/2025,Available,,,,Anesthesia,Current,,,,2025,available
322,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2025,not available
323,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2025,not available
324,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,12/19/2024,,,2025,not available
325,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2025,not available
326,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2025,not available
327,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2025,not available
328,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
329,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia,Current,,,,2025,limited availability
330,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
331,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
332,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
333,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
334,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)",Reverified,9/2/2025,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2025,available
335,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)",Reverified,9/2/2025,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2025,available
336,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
337,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
338,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
339,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
340,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
341,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)",Reverified,9/2/2025,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia,Current,,,,2025,available
342,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 4 mg (NDC 49884-658-09)",New,10/15/2024,,,,,Cardiovascular,To Be Discontinued,,10/15/2024,,2025,discontinued
343,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 8 mg (NDC 49884-659-09)",New,10/15/2024,,,,,Cardiovascular,To Be Discontinued,,10/15/2024,,2025,discontinued
344,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 16 mg (NDC 49884-660-09)",New,10/15/2024,,,,,Cardiovascular,To Be Discontinued,,10/15/2024,,2025,discontinued
345,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 32 mg (NDC 49884-661-09)",New,10/15/2024,,,,,Cardiovascular,To Be Discontinued,,10/15/2024,,2025,discontinued
346,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0090-01)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/2025,,2025,discontinued
347,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0109-01)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/2025,,2025,discontinued
348,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0109-10)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/2025,,2025,discontinued
349,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-3)",New,3/28/2025,,Discontinuation due to low sales volume. Supply currently available with November 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,To Be Discontinued,,3/28/2025,,2025,discontinued
350,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-1)",New,3/28/2025,,Discontinuation due to low sales volume. Supply currently available with June 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,To Be Discontinued,,3/28/2025,,2025,discontinued
351,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)",Reverified,8/19/2025,Unavailable,Pending discontinuation of the manufacture of the drug,,Requirements related to complying with good manufacturing practices,Oncology,Current,,,,2025,not available
352,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)",Reverified,8/19/2025,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Oncology,Current,,,,2025,not available
353,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)",Reverified,7/24/2025,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Oncology,Current,,,,2025,not available
354,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)",Reverified,7/24/2025,Limited Availability,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Oncology,Current,,,,2025,limited availability
355,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)",Reverified,7/24/2025,Available,Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,Current,,,,2025,available
356,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)",Reverified,7/24/2025,Available,Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,Current,,,,2025,available
357,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)",Reverified,9/2/2025,Unavailable,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,Other,Oncology,Current,,,,2025,not available
358,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)",Revised,7/28/2025,Unavailable,"Discontinued; Distributed by BPI Labs, LLC",,Discontinuation of the manufacture of the drug,Oncology,Current,,,,2025,not available
359,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)",Revised,7/28/2025,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,,,2025,limited availability
360,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)",Revised,7/28/2025,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,,,2025,limited availability
361,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)",Revised,7/28/2025,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,,,2025,limited availability
362,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)",Reverified,9/2/2025,Unavailable,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,Other,Oncology,Current,,,,2025,not available
363,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,,2025,not available
364,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Oncology,Current,,,,2025,available
365,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)",Revised,8/19/2025,Limited Availability,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Oncology,Current,,,,2025,limited availability
366,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)",Reverified,8/19/2025,Available,,,,Oncology,Current,,,,2025,available
367,Carboplatin Injection,"Fresenius Kabi USA, LLC","Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Oncology,Current,,,,2025,available
368,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)",Revised,8/19/2025,Limited Availability,,,Delay in shipping of the drug,Oncology,Current,,,,2025,limited availability
369,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)",Reverified,8/15/2025,Available,,,,Oncology,Current,,,,2025,available
370,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)",Reverified,8/15/2025,Available,,,,Oncology,Current,,,,2025,available
371,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)",Reverified,8/15/2025,Available,,,,Oncology,Current,,,,2025,available
372,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)",Reverified,8/15/2025,Available,,,,Oncology,Current,,,,2025,available
373,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)",Reverified,8/15/2025,Available,,,,Oncology,Current,,,,2025,available
374,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)",Reverified,8/15/2025,Available,,,,Oncology,Current,,,,2025,available
375,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)",Reverified,8/15/2025,Available,,,,Oncology,Current,,,,2025,available
376,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)",Reverified,8/15/2025,Available,,,,Oncology,Current,,,,2025,available
377,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)",Revised,8/19/2025,Available,,,,Oncology,Current,,,,2025,available
378,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)",Revised,8/19/2025,Available,,,,Oncology,Current,,,,2025,available
379,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)",Revised,8/19/2025,Limited Availability,Estimated recovery: September 2025,,Other,Oncology,Current,,,,2025,limited availability
380,Caspofungin Acetate Injection,Merck Sharp & Dohme Corp.,"Cancidas, Injection, 5 mg/1 mL (NDC 0006-3822-10)",New,9/26/2024,,"To be discontinued on October 31, 2024",,,Anti-Infective,To Be Discontinued,,9/26/2024,,2025,discontinued
381,"Cefotaxime Sodium Powder, for Solution","SteriMax, Inc.","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)",Reverified,8/19/2025,Available,,,,Anti-Infective; Pediatric,Current,,,,2025,available
382,"Cefotaxime Sodium Powder, for Solution","SteriMax, Inc.","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)",Reverified,8/19/2025,Available,,,,Anti-Infective; Pediatric,Current,,,,2025,available
383,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)",Reverified,7/23/2025,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2025,not available
384,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)",Reverified,7/23/2025,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2025,not available
385,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)",Reverified,7/23/2025,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2025,not available
386,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)",Reverified,7/23/2025,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2025,not available
387,Celecoxib Capsule,Apotex Corp.,"Capsule, 50 mg (NDC 60505-3847-6)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2025,discontinued
388,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 mg (NDC 60505-3848-1)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2025,discontinued
389,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 mg (NDC 60505-3848-5)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2025,discontinued
390,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 mg (NDC 60505-3849-1)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2025,discontinued
391,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 mg (NDC 60505-3849-5)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2025,discontinued
392,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 50 mg (NDC 0591-3982-60)",New,8/15/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/2025,,2025,discontinued
393,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 100 mg (NDC 0591-3983-01)",New,8/15/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/2025,,2025,discontinued
394,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 100 mg (NDC 0591-3983-05)",New,8/15/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/2025,,2025,discontinued
395,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 200 mg (NDC 0591-3984-01)",New,8/15/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/2025,,2025,discontinued
396,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 200 mg (NDC 0591-3984-05)",New,8/15/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/2025,,2025,discontinued
397,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 400 mg (NDC 0591-3985-60)",New,8/15/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/2025,,2025,discontinued
398,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-23)",New,5/14/2025,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/2025,,2025,discontinued
399,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-42)",New,5/14/2025,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/2025,,2025,discontinued
400,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-60)",New,5/14/2025,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/2025,,2025,discontinued
401,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 10 mg/5 mL (NDC 0703-2033-03)",New,1/6/2025,,,,,Anesthesia,To Be Discontinued,,1/6/2025,,2025,discontinued
402,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 200 mg/20 mL (NDC 0703-2045-03)",New,1/6/2025,,,,,Anesthesia,To Be Discontinued,,1/6/2025,,2025,discontinued
403,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 20 mg/10 mL (NDC 0703-2056-03)",New,1/6/2025,,,,,Anesthesia,To Be Discontinued,,1/6/2025,,2025,discontinued
404,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-01)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
405,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-03)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
406,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-05)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
407,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-77)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
408,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-01)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
409,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-03)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
410,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-05)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
411,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-11)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
412,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-16)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
413,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-62)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
414,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-77)",New,12/5/2024,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/2024,,2025,discontinued
415,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)",Revised,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,,,2025,not available
416,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: April 2026; Estimated Recovery: June 2026,,Other,Anti-Infective,Current,,,,2025,limited availability
417,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)",Revised,8/15/2025,Available,,,,Anti-Infective,Current,,,,2025,available
418,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)",Revised,8/15/2025,Available,,,,Anti-Infective,Current,,,,2025,available
419,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)",Revised,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,,,2025,not available
420,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 9 g/60 mL (150 mg/mL) (NDC 0009-0728-09)",Revised,8/15/2025,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Demand increase for the drug,Anti-Infective,Current,,,,2025,not available
421,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,,,2025,limited availability
422,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)",Reverified,8/26/2025,Available,,,,Anti-Infective,Current,,,,2025,available
423,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)",Reverified,8/26/2025,Available,,,,Anti-Infective,Current,,,,2025,available
424,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)",Reverified,8/26/2025,Available,,,,Anti-Infective,Current,,,,2025,available
425,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)",Reverified,8/15/2025,Unavailable,Estimated recovery: September 2025,,Demand increase for the drug,Anti-Infective,Current,,,,2025,not available
426,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)",Revised,8/15/2025,Limited Availability,Estimated recovery: October 2025,,Other,Anti-Infective,Current,,,,2025,limited availability
427,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)",Reverified,8/15/2025,Available,,,,Anti-Infective,Current,,,,2025,available
428,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)",Reverified,9/3/2025,Unavailable,Estimated recovery: September 2025,,Demand increase for the drug,Anti-Infective,Current,,,,2025,not available
429,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)",Reverified,9/3/2025,Available,,,,Anti-Infective,Current,,,,2025,available
430,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)",Revised,8/15/2025,Unavailable,Estimated recovery: November 2025,,Demand increase for the drug,Anti-Infective,Current,,,,2025,not available
431,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)",Reverified,8/15/2025,Available,,,,Anti-Infective,Current,,,,2025,available
432,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)",Reverified,8/15/2025,Available,,,,Anti-Infective,Current,,,,2025,available
433,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)",Reverified,8/15/2025,Available,,,,Anti-Infective,Current,,,,2025,available
434,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)",Reverified,8/15/2025,Available,Civica Label,,,Anti-Infective,Current,,,,2025,available
435,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)",Reverified,8/15/2025,Available,Civica Label,,,Anti-Infective,Current,,,,2025,available
436,Clindamycin Phosphate; Benzoyl Peroxide Gel,"Teva Pharmaceuticals USA, Inc.","Clindamycin Phosphate; Benzoyl Peroxide, Gel, 25 mg/1 g; 10 mg/1 g (NDC 0591-3916-68)",New,8/1/2025,,A business decision was made to discontinue manufacture of the product.,,,Dermatology,To Be Discontinued,,8/1/2025,,2025,discontinued
437,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)",Reverified,8/19/2025,Information pending,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,unclear
438,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)",Reverified,8/19/2025,Information pending,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,unclear
439,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
440,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
441,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
442,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
443,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
444,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
445,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
446,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
447,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
448,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
449,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
450,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
451,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, .5 mg (NDC 61269-605-10)",Reverified,9/3/2025,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
452,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 1 mg (NDC 61269-610-10)",Reverified,9/3/2025,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
453,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 2 mg (NDC 61269-620-10)",Reverified,9/3/2025,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
454,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-10)",Reverified,8/19/2025,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
455,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-11)",Reverified,8/19/2025,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
456,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-50)",Reverified,8/19/2025,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
457,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-10)",Reverified,8/19/2025,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
458,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-11)",Reverified,8/19/2025,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
459,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-50)",Reverified,8/19/2025,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
460,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-10)",Reverified,8/19/2025,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
461,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-50)",Reverified,8/19/2025,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
462,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
463,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
464,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
465,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
466,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)",Reverified,8/19/2025,Limited Availability,Estimated recovery: September 2025,,Other,Neurology; Pediatric; Psychiatry,Current,,,,2025,limited availability
467,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)",Reverified,8/19/2025,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
468,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
469,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
470,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
471,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
472,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
473,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
474,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
475,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
476,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)",Reverified,8/19/2025,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2025,available
477,Conivaptan Hydrochloride Injection,Cumberland Pharmaceuticals Inc.,"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)",Reverified,8/15/2025,Unavailable,,,Delay in shipping of the drug,Cardiovascular,Current,,,,2025,not available
478,Cromolyn Sodium Concentrate,"Rising Pharma Holdings, Inc.","Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)",Revised,8/15/2025,Available,,,,Pulmonary/Allergy,Current,,,,2025,available
479,Cromolyn Sodium Concentrate,Micro Labs LTD,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)",Reverified,9/2/2025,Available,,,,Pulmonary/Allergy,Current,,,,2025,available
480,Cromolyn Sodium Concentrate,"Mylan Specialty, a Viatris Company","Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)",Reverified,9/3/2025,Available,,,,Pulmonary/Allergy,Current,,,,2025,available
481,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)",Revised,8/15/2025,Available,Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195,,,Pulmonary/Allergy,Current,,,,2025,available
482,Cyanocobalamin Injection,Accord Healthcare Inc.,"Dodex, Injection, 1000 ug/1 mL (NDC 16729-533-08)",New,1/17/2025,,Permanent discontinuation in the manufacturing of the drug.,,,Hematology,To Be Discontinued,,1/17/2025,,2025,discontinued
483,Cyclosporine Oral Solution,AbbVie Inc.,"Gengraf, Oral Solution, 100 mg/ml (NDC 0074-7269-50)",New,12/5/2024,,"Abbvie has made a business decision to permanently discontinue GENGRAF Oral Solution (cyclosporine oral solution, USP) 100 mg/mL .",,,Transplant,To Be Discontinued,,12/5/2024,,2025,discontinued
484,"Dalfampridine Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Tablet, Extended Release, 10 mg (NDC 62756-429-86)",New,9/20/2024,,,,,Neurology,To Be Discontinued,,9/20/2024,,2025,discontinued
485,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,AstraZeneca AB,"Qtern, Tablet, 5 mg; 5 mg (NDC 0310-6770-30)",New,3/3/2025,,,,,Endocrinology/Metabolism,To Be Discontinued,,,,2025,discontinued
486,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,AstraZeneca AB,"Qtern, Tablet, 10 mg; 5 mg (NDC 0310-6780-30)",New,3/3/2025,,,,,Endocrinology/Metabolism,To Be Discontinued,,3/3/2025,,2025,discontinued
487,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 1 mg (NDC 0173-0897-13)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
488,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 1 mg (NDC 0173-0897-56)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
489,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 2 mg (NDC 0173-0903-13)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
490,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 2 mg (NDC 0173-0903-56)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
491,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 4 mg (NDC 0173-0906-13)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
492,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 4 mg (NDC 0173-0906-56)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
493,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 6 mg (NDC 0173-0911-13)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
494,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 6 mg (NDC 0173-0911-56)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
495,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 8 mg (NDC 0173-0914-13)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
496,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 8 mg (NDC 0173-0914-56)",New,11/21/2024,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/2024,,2025,discontinued
497,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 10 mg (NDC 23155-578-01)",New,8/12/2025,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/2025,,2025,discontinued
498,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 25 mg (NDC 23155-579-01)",New,8/12/2025,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/2025,,2025,discontinued
499,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 50 mg (NDC 23155-580-01)",New,8/12/2025,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/2025,,2025,discontinued
500,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 75 mg (NDC 23155-581-01)",New,8/12/2025,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/2025,,2025,discontinued
501,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 100 mg (NDC 23155-582-01)",New,8/12/2025,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/2025,,2025,discontinued
502,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 150 mg (NDC 23155-583-25)",New,8/12/2025,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/2025,,2025,discontinued
503,Desmopressin Acetate Injection,Sun Pharmaceutical Industries Limited,"Desmopressin Acetate, Injection, 4 ug/1 mL (NDC 62756-529-40)",New,12/5/2024,,Discontinuing for business reasons,,,Endocrinology/Metabolism,To Be Discontinued,,12/5/2024,,2025,discontinued
504,Desmopressin Acetate Spray,Ferring,"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)",Reverified,6/27/2025,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2025,not available
505,Desmopressin Acetate Spray,Ferring,"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)",Reverified,6/27/2025,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2025,not available
506,Desmopressin Acetate Spray,Apotex Corp.,"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)",Reverified,7/24/2025,Available,,,,Hematology,Current,,,,2025,available
507,Desmopressin Acetate Spray,Ferring,"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)",Reverified,6/27/2025,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2025,not available
508,Desonide Cream,"Actavis Pharma, Inc.","Desowen, Cream, .5 mg/1 g (NDC 0472-0804-15)",New,5/28/2025,,,,,Dermatology,To Be Discontinued,,5/28/2025,,2025,discontinued
509,Desonide Cream,"Actavis Pharma, Inc.","Desowen, Cream, .5 mg/1 g (NDC 0472-0804-60)",New,5/28/2025,,,,,Dermatology,To Be Discontinued,,5/28/2025,,2025,discontinued
510,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,not available
511,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-109-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
512,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
513,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 100 mg/10 mL (NDC 55150-305-10)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,not available
514,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)",Reverified,9/3/2025,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
515,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)",Reverified,9/3/2025,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
516,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)",Reverified,9/3/2025,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
517,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)",Reverified,9/3/2025,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
518,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-237-01)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,not available
519,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-238-05)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,not available
520,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-239-30)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,not available
521,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)",Reverified,8/19/2025,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
522,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)",Reverified,9/2/2025,Available,Check wholesalers for inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
523,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
524,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
525,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)",Reverified,9/2/2025,Available,Check wholesalers for inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
526,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
527,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)",Revised,7/23/2025,Available,Currently available.  Additional product will be made available as it is released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
528,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)",Reverified,7/23/2025,Unavailable,Additional lots will be available in the April 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,not available
529,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)",Reverified,7/23/2025,Available,Currently available.  Additional product will be made available as it is released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2025,available
530,Dexmedetomidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)",Reverified,7/23/2025,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
531,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)",Reverified,9/2/2025,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
532,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)",Reverified,9/2/2025,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
533,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
534,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
535,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)",Reverified,6/27/2025,Available,,,,Anesthesia,Current,,,,2025,available
536,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)",Reverified,6/27/2025,Available,,,,Anesthesia,Current,,,,2025,available
537,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)",Reverified,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
538,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)",Reverified,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
539,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)",Reverified,8/19/2025,Unavailable,,,Requirements related to complying with good manufacturing practices,Anesthesia,Current,,,,2025,not available
540,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)",Reverified,8/19/2025,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia,Current,,,,2025,not available
541,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)",Reverified,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
542,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
543,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)",Revised,9/3/2025,Limited Availability,Recovery in November 2025,,Demand increase for the drug,Anesthesia,Current,,,,2025,limited availability
544,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
545,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
546,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Other,Anesthesia,Current,,,,2025,not available
547,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
548,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
549,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)",Reverified,9/2/2025,Available,Short-dated supply (8 months from expiry) available upon request. Check wholesaler for inventory.,,,Anesthesia,Current,,,,2025,available
550,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)",Reverified,7/16/2025,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,,2025,available
551,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)",Reverified,7/16/2025,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,,2025,available
552,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)",Reverified,7/16/2025,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,,2025,available
553,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)",Reverified,7/16/2025,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,,2025,available
554,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
555,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)",Reverified,9/2/2025,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
556,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
557,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
558,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
559,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
560,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)",Reverified,6/27/2025,Available,,,,Anesthesia,Current,,,,2025,available
561,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)",Reverified,6/27/2025,Available,,,,Anesthesia,Current,,,,2025,available
562,Dexmedetomidine Hydrochloride Injection,"Meitheal Pharmaceuticals, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
563,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)",Reverified,7/28/2025,Available,Distributed by DRL,,,Anesthesia,Current,,,,2025,available
564,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)",Reverified,7/28/2025,Available,Distributed by DRL,,,Anesthesia,Current,,,,2025,available
565,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)",Reverified,6/27/2025,Available,,,,Anesthesia,Current,,,,2025,available
566,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)",Reverified,6/27/2025,Available,,,,Anesthesia,Current,,,,2025,available
567,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL  (NDC 0781-3493-95)",Reverified,9/2/2025,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,,,2025,available
568,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL  (NDC 0781-3494-95)",Reverified,9/2/2025,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,,,2025,available
569,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)",Reverified,9/2/2025,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,,,2025,available
570,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)",Reverified,7/28/2025,Available,Marketed by Piramal Critical Care Inc.: 800-414-1901,,,Anesthesia,Current,,,,2025,available
571,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
572,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
573,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
574,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
575,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)",Revised,8/15/2025,Unavailable,Unavailable. Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,,2025,not available
576,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: November 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,,2025,limited availability
577,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
578,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)",Reverified,9/2/2025,Unavailable,Distributed by Avenacy; Contact information: 877-283-6229,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
579,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
580,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
581,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
582,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
583,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
584,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
585,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
586,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)",Reverified,9/2/2025,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,not available
587,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
588,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
589,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
590,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
591,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
592,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 2.5 g/50mL (5%, 50mg/mL) (NDC 0409-7100-66)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
593,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 5 g/100mL (5%) Plastic (NDC 0409-7100-67)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
594,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 12.5 g/250mL (5%) (NDC 0409-7100-02)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
595,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
596,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
597,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
598,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
599,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)",Reverified,9/2/2025,Available,Check wholealers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
600,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
601,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
602,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
603,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
604,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
605,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
606,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
607,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
608,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
609,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
610,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
611,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
612,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
613,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
614,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
615,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9143-30)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
616,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9147-30)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
617,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
618,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
619,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
620,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
621,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
622,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
623,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
624,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
625,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
626,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)",Revised,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
627,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)",Revised,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
628,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
629,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
630,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
631,Dextrose Monohydrate 50% Injection,"Amphastar Pharmaceuticals, Inc.","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)",Reverified,8/19/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
632,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)",Revised,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
633,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,not available
634,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
635,Dextrose Monohydrate 70% Injection,Otsuka ICU Medical LLC,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
636,Dextrose Monohydrate 70% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
637,Dextrose Monohydrate 70% Injection,Otsuka ICU Medical LLC,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
638,Dextrose Monohydrate 70% Injection,Baxter Healthcare,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2025,available
639,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 125 ug (NDC 57664-437-88)",New,12/5/2024,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/2024,,2025,discontinued
640,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 125 ug (NDC 57664-437-18)",New,12/5/2024,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/2024,,2025,discontinued
641,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 250 ug (NDC 57664-441-18)",New,12/5/2024,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/2024,,2025,discontinued
642,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 250 ug (NDC 57664-441-88)",New,12/5/2024,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/2024,,2025,discontinued
643,Dihydroergotamine Mesylate Injection,Padagis US LLC,"Injection, 1 mg/1 mL (NDC 0574-0850-05)",New,9/16/2024,,,,,Neurology,To Be Discontinued,,9/16/2024,,2025,discontinued
644,Dihydroergotamine Mesylate Injection,Padagis US LLC,"Injection, 1 mg/1 mL (NDC 0574-0850-10)",New,9/16/2024,,,,,Neurology,To Be Discontinued,,9/16/2024,,2025,discontinued
645,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-11)",New,4/28/2025,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
646,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-15)",New,4/28/2025,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
647,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-01)",New,4/28/2025,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
648,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-11)",New,4/28/2025,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
649,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-15)",New,4/28/2025,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
650,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-01)",New,4/28/2025,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
651,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-11)",New,4/28/2025,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
652,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-15)",New,4/28/2025,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
653,Dobutamine Hydrochloride Injection,Pfizer Inc.,"Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)",New,8/27/2025,,Discontinuation of the manufacture of the drug,,,Cardiovascular; Pediatric; Renal,To Be Discontinued,,8/27/2025,,2025,discontinued
654,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)",Reverified,9/3/2025,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,,2025,available
655,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)",Reverified,9/3/2025,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,,2025,available
656,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)",Reverified,9/3/2025,Available,"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988",,,Cardiovascular; Pediatric; Renal,Current,,,,2025,available
657,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular; Pediatric; Renal,Current,,,,2025,not available
658,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)",Reverified,9/3/2025,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,,2025,available
659,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)",Revised,8/15/2025,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,,2025,not available
660,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)",Revised,8/15/2025,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,12/19/2024,,,2025,not available
661,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)",Revised,8/15/2025,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,12/19/2024,,,2025,not available
662,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)",Revised,8/15/2025,Available,,,,Cardiovascular; Pediatric; Renal,Current,12/19/2024,,,2025,available
663,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)",Revised,8/15/2025,Available,,,,Cardiovascular; Pediatric; Renal,Current,12/19/2024,,,2025,available
664,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN‚Äö√Ñ√∂‚àö√´¬¨¬¢ Glass Fliptop Vial Novaplus¬¨¬®‚àö√ú  (NDC 0409-0016-01)",New,6/24/2025,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,6/24/2025,,2025,discontinued
665,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN‚Äö√Ñ√∂‚àö√´¬¨¬¢ Glass Fliptop Vial Novaplus¬¨¬®‚àö√ú  (NDC 0409-2026-01)",New,6/24/2025,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,6/24/2025,,2025,discontinued
666,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 10 mg/1 mL (NDC 0409-1732-01)",New,1/15/2025,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/15/2025,,2025,discontinued
667,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 10 mg/1 mL (NDC 0409-7870-01)",New,1/15/2025,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/15/2025,,2025,discontinued
668,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-01)",New,1/28/2025,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
669,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-03)",New,1/28/2025,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
670,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-05)",New,1/28/2025,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
671,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-06)",New,1/28/2025,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
672,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-01)",New,1/28/2025,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
673,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-03)",New,1/28/2025,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
674,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-05)",New,1/28/2025,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
675,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-06)",New,1/28/2025,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
676,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)",New,8/27/2025,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,,,2025,discontinued
677,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)",Revised,8/15/2025,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular,Current,,,,2025,not available
678,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2025,not available
679,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)",Revised,8/15/2025,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Cardiovascular,Current,,,,2025,not available
680,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)",Revised,8/15/2025,Available,,,,Cardiovascular,Current,,,,2025,available
681,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)",Revised,8/15/2025,Available,,,,Cardiovascular,Current,,,,2025,available
682,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
683,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)",Revised,7/23/2025,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2025,not available
684,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)",Revised,7/23/2025,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2025,not available
685,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
686,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
687,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
688,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)",New,5/2/2025,,,,,Anti-Infective,To Be Discontinued,,,,2025,discontinued
689,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)",New,5/2/2025,,,,,Anti-Infective,To Be Discontinued,,5/2/2025,,2025,discontinued
690,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)",New,6/13/2025,,,,,Anti-Infective,To Be Discontinued,,6/13/2025,,2025,discontinued
691,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)",New,6/13/2025,,,,,Anti-Infective,To Be Discontinued,,6/13/2025,,2025,discontinued
692,Drospirenone; Ethinyl Estradiol Tablet,"Teva Pharmaceuticals USA, Inc.","Yasmin, Tablet, Kit (NDC 0555-9131-67)",New,6/13/2025,,,,,Reproductive,To Be Discontinued,,6/13/2025,,2025,discontinued
693,Drospirenone; Ethinyl Estradiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ocella, Tablet, Kit (NDC 0555-9131-67)",New,5/2/2025,,,,,Reproductive,To Be Discontinued,,5/2/2025,,2025,discontinued
694,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, .75 mg/.5 mL (NDC 0002-1433-80)",Revised,6/13/2025,,,Available,,Endocrinology/Metabolism,Resolved,6/13/2025,,,2025,
695,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 1.5 mg/.5 mL (NDC 0002-1434-80)",Revised,6/13/2025,,,Available,,Endocrinology/Metabolism,Resolved,6/13/2025,,,2025,
696,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 3 mg/.5 mL (NDC 0002-2236-80)",Revised,6/13/2025,,,Available,,Endocrinology/Metabolism,Resolved,6/13/2025,,,2025,
697,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 4.5 mg/.5 mL (NDC 0002-3182-80)",Revised,6/13/2025,,,Available,,Endocrinology/Metabolism,Resolved,6/13/2025,,,2025,
698,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 20 mg (NDC 0002-3235-60)",New,10/18/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/2024,,2025,discontinued
699,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 30 mg (NDC 0002-3240-30)",New,10/18/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/2024,,2025,discontinued
700,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 30 mg (NDC 0002-3240-90)",New,10/18/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/2024,,2025,discontinued
701,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 60 mg (NDC 0002-3270-30)",New,10/18/2024,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/2024,,2025,discontinued
702,Echothiophate Iodide Ophthalmic Solution,Fera Pharmaceuticals,"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)",Reverified,6/27/2025,Available,Available through limited distribution by Walgreens Specialty Pharmacy.,,,Ophthalmology,Current,,,,2025,available
703,Edaravone Injection,"Mitsubishi Tanabe Pharma America, Inc.","Radicava, Injection, 30 mg/100 mL (NDC 70510-2171-2)",New,12/5/2024,,"A business decision was made to discontinue manufacture of this product. Distribution will end as early as April 1, 2025. The discontinuation of Radicava (edaravone) injection will not impact the commercial availability of Radicava ORS (edaravone) oral suspension.",,,Neurology,To Be Discontinued,,12/5/2024,,2025,discontinued
704,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
705,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)",Reverified,9/2/2025,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2025,not available
706,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
707,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
708,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,12/19/2024,,,2025,available
709,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
710,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
711,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,12/19/2024,,,2025,available
712,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
713,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
714,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
715,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,12/19/2024,,,2025,available
716,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
717,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
718,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
719,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
720,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
721,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)",Reverified,9/2/2025,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,,,2025,available
722,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
723,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
724,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)",Reverified,9/2/2025,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,,,2025,available
725,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
726,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, .5 mg (NDC 0173-0517-00)",New,1/31/2025,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/2025,,2025,discontinued
727,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, 1.5 mg (NDC 0173-0519-00)",New,1/31/2025,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/2025,,2025,discontinued
728,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, 1 mL/1 mL (NDC 0173-0857-02)",New,1/31/2025,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/2025,,2025,discontinued
729,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-60)",New,2/14/2025,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/2025,,2025,discontinued
730,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-93)",New,2/14/2025,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/2025,,2025,discontinued
731,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-60)",New,2/14/2025,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/2025,,2025,discontinued
732,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-93)",New,2/14/2025,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/2025,,2025,discontinued
733,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, .3 mg (NDC 61570-072-01)",New,7/29/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/2025,,2025,discontinued
734,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, .625 mg (NDC 61570-073-01)",New,7/29/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/2025,,2025,discontinued
735,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, 1.25 mg (NDC 61570-074-01)",New,7/29/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/2025,,2025,discontinued
736,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, 2.5 mg (NDC 61570-075-50)",New,7/29/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/2025,,2025,discontinued
737,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 1 mg (NDC 0093-5537-56)",New,6/26/2025,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/2025,,2025,discontinued
738,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 2 mg (NDC 0093-5538-01)",New,6/26/2025,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/2025,,2025,discontinued
739,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 3 mg (NDC 0093-5539-01)",New,6/26/2025,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/2025,,2025,discontinued
740,Ethinyl Estradiol; Ethinyl Diacetate Tablet,"Teva Pharmaceuticals USA, Inc.","Zovia 1/50E-28, Tablet, Kit (NDC 0093-8073-16)",New,6/13/2025,,,,,Reproductive,To Be Discontinued,,6/13/2025,,2025,discontinued
741,Ethinyl Estradiol; Etonogestrel Ring,"Teva Pharmaceuticals USA, Inc.","Ethinyl Estradiol; Etonogestrel, Ring, .015 mg/1 d; .12 mg/1 d (NDC 0093-7679-02)",New,6/16/2025,,Discontinuation of the manufacture of the drug,,,Reproductive,To Be Discontinued,,6/16/2025,,2025,discontinued
742,"Ethinyl Estradiol; Norethindrone Tablet, Chewable","Teva Pharmaceuticals USA, Inc.","Tablet, Chewable, Kit (NDC 52544-064-31)",New,1/10/2025,,,,,Reproductive,To Be Discontinued,,1/10/2025,,2025,discontinued
743,Ethionamide Tablet,Pfizer Inc.,"Trecator, Tablet, 250 mg (NDC 0008-4117-01)",New,7/16/2025,,"Discontinuation of the manufacture of the drug.

Supply expected to exhaust September 2025",,,Anti-Infective,To Be Discontinued,,7/16/2025,,2025,discontinued
744,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/1 mL (NDC 65219-445-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,,,2025,available
745,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 40 mg/20 mL (NDC 65219-445-20)",Reverified,9/2/2025,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,,,2025,available
746,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)",Revised,7/23/2025,Available,Distributed by Civica,,,Anesthesia,Current,,,,2025,available
747,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)",Revised,7/23/2025,Available,Distributed by Civica,,,Anesthesia,Current,,,,2025,available
748,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 65219-447-20)",Reverified,9/2/2025,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi 800-551-7176,,,Anesthesia,Current,,,,2025,available
749,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)",Reverified,9/2/2025,Available,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",,,Anesthesia,Current,,,,2025,available
750,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)",Reverified,9/2/2025,Available,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",,,Anesthesia,Current,,,,2025,available
751,Etomidate Injection,Eugia US LLC,"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)",Reverified,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
752,Etomidate Injection,Eugia US LLC,"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)",Reverified,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
753,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)",Reverified,7/28/2025,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesia,Current,,,,2025,available
754,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)",Reverified,7/28/2025,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesia,Current,,,,2025,available
755,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)",Revised,7/23/2025,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
756,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)",Revised,7/23/2025,Available,Currently available.  Additional product will be made available as it is released.,,,Anesthesia,Current,,,,2025,available
757,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)",Revised,7/23/2025,Available,Novaplus,,,Anesthesia,Current,,,,2025,available
758,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)",Revised,7/23/2025,Available,Novaplus,,,Anesthesia,Current,,,,2025,available
759,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
760,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
761,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
762,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)",Revised,8/15/2025,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Other,Anesthesia,Current,,,,2025,not available
763,"Exenatide Synthetic Injectable Suspension, Extended Release",AstraZeneca AB,"Bydureon BCise, Injectable Suspension, Extended Release, 2 mg/.85 mL (NDC 0310-6540-04)",New,10/28/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/28/2024,,2025,discontinued
764,Exenatide Synthetic Injection,AstraZeneca AB,"Byetta, Injection, 300MCG/1.2ML (250MCG/ML) (NDC 0310-6512-01)",New,10/25/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/25/2024,,2025,discontinued
765,Exenatide Synthetic Injection,AstraZeneca AB,"Byetta, Injection, 600MCG/2.4ML (250MCG/ML) (NDC 0310-6524-01)",New,10/25/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/25/2024,,2025,discontinued
766,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-05)",New,6/27/2025,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/2025,,2025,discontinued
767,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-19)",New,6/27/2025,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/2025,,2025,discontinued
768,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-30)",New,6/27/2025,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/2025,,2025,discontinued
769,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-08)",New,1/6/2025,,,,,Cardiovascular,To Be Discontinued,,1/6/2025,,2025,discontinued
770,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-30)",New,1/6/2025,,,,,Cardiovascular,To Be Discontinued,,1/6/2025,,2025,discontinued
771,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-08)",New,1/6/2025,,,,,Cardiovascular,To Be Discontinued,,1/6/2025,,2025,discontinued
772,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-30)",New,1/6/2025,,,,,Cardiovascular,To Be Discontinued,,1/6/2025,,2025,discontinued
773,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-08)",New,1/6/2025,,,,,Cardiovascular,To Be Discontinued,,1/6/2025,,2025,discontinued
774,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-30)",New,1/6/2025,,,,,Cardiovascular,To Be Discontinued,,1/6/2025,,2025,discontinued
775,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-08)",New,1/6/2025,,,,,Cardiovascular,To Be Discontinued,,1/6/2025,,2025,discontinued
776,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-30)",New,1/6/2025,,,,,Cardiovascular,To Be Discontinued,,1/6/2025,,2025,discontinued
777,Febuxostat Tablet,Takeda Pharmaceuticals USA Inc.,"Uloric, Tablet, 80 mg (NDC 64764-677-30)",New,1/22/2025,,Anticipate continued distribution to wholesalers until March 2026,,,Other,To Be Discontinued,,1/22/2025,,2025,discontinued
778,Febuxostat Tablet,Takeda Pharmaceuticals USA Inc.,"Uloric, Tablet, 40 mg (NDC 64764-918-30)",New,1/22/2025,,Anticipate continued distribution to wholesalers until March 2026,,,Other,To Be Discontinued,,1/22/2025,,2025,discontinued
779,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)",Reverified,9/2/2025,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
780,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)",Reverified,9/2/2025,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
781,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
782,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)",Reverified,9/2/2025,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
783,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
784,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)",Revised,7/23/2025,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
785,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
786,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
787,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
788,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction; Pediatric,Current,1/2/2025,,,2025,available
789,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
790,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
791,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)",Revised,7/23/2025,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
792,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)",Revised,7/23/2025,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
793,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)",Revised,7/23/2025,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
794,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)",Revised,7/23/2025,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
795,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)",Revised,7/23/2025,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
796,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)",Revised,7/23/2025,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
797,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)",Revised,7/23/2025,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
798,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 100 ug (NDC 63459-541-28)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
799,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 200 ug (NDC 63459-542-28)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
800,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 400 ug (NDC 63459-544-28)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
801,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 600 ug (NDC 63459-546-28)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
802,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 800 ug (NDC 63459-548-28)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
803,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 200 ug (NDC 0093-7865-65)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
804,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 400 ug (NDC 0093-7866-65)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
805,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 600 ug (NDC 0093-7867-65)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
806,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 800 ug (NDC 0093-7868-65)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
807,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 1200 ug (NDC 0093-7869-65)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
808,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 1600 ug (NDC 0093-7870-65)",New,9/24/2024,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/2024,,2025,discontinued
809,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-05)",New,8/19/2025,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/2025,,2025,discontinued
810,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-56)",New,8/19/2025,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/2025,,2025,discontinued
811,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-98)",New,8/19/2025,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/2025,,2025,discontinued
812,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 100 mg (NDC 0049-3420-30)",New,9/27/2024,,Discontinuation Of The Manufacture Of The Drug,,,Anti-Infective,To Be Discontinued,,9/27/2024,,2025,discontinued
813,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 200 mg (NDC 0049-3430-30)",New,9/27/2024,,Discontinuation Of The Manufacture Of The Drug,,,Anti-Infective,To Be Discontinued,,9/27/2024,,2025,discontinued
814,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 10 mg (NDC 0777-3104-02)",New,10/3/2024,,,,,Psychiatry,To Be Discontinued,,10/3/2024,,2025,discontinued
815,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 20 mg (NDC 0777-3105-02)",New,10/3/2024,,,,,Psychiatry,To Be Discontinued,,10/3/2024,,2025,discontinued
816,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 20 mg (NDC 0777-3105-30)",New,10/3/2024,,,,,Psychiatry,To Be Discontinued,,10/3/2024,,2025,discontinued
817,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 40 mg (NDC 0777-3107-30)",New,10/3/2024,,,,,Psychiatry,To Be Discontinued,,10/3/2024,,2025,discontinued
818,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)",Reverified,8/19/2025,Available,,,,Neurology; Other,Current,,,,2025,available
819,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)",Reverified,8/19/2025,Available,,,,Neurology; Other,Current,,,,2025,available
820,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)",Reverified,8/19/2025,Available,,,,Oncology; Other,Current,,,,2025,available
821,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)",Reverified,8/19/2025,Available,,,,Neurology; Other,Current,,,,2025,available
822,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)",Reverified,8/19/2025,Unavailable,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,,,2025,not available
823,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)",Reverified,8/19/2025,Unavailable,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,,,2025,not available
824,Flurbiprofen Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0093-0711-01)",New,11/13/2024,,A business decision was made to discontinue manufacture of the product.,,,Analgesia/Addiction,To Be Discontinued,,11/13/2024,,2025,discontinued
825,Flurbiprofen Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0093-0711-05)",New,11/13/2024,,A business decision was made to discontinue manufacture of the product.,,,Analgesia/Addiction,To Be Discontinued,,11/13/2024,,2025,discontinued
826,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 55 ug; 14 ug (NDC 59310-805-06)",New,6/13/2025,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/2025,,2025,discontinued
827,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 113 ug; 14 ug (NDC 59310-812-06)",New,6/13/2025,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/2025,,2025,discontinued
828,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 232 ug; 14 ug (NDC 59310-822-06)",New,6/13/2025,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/2025,,2025,discontinued
829,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,,,2025,limited availability
830,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
831,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
832,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
833,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)",Revised,8/19/2025,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2025,not available
834,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)",Revised,8/19/2025,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2025,not available
835,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)",Revised,8/19/2025,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2025,not available
836,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL; 2mL vial (NDC 83634-302-02)",Reverified,9/3/2025,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,,,2025,available
837,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL; 4mL vial (NDC 83634-302-04)",Reverified,9/3/2025,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,,,2025,available
838,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 83634-302-10)",Reverified,9/3/2025,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,,,2025,available
839,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-02)",Reverified,8/26/2025,"Unavailable, Please use Sagent label",Use Sagent NDC 25021-311-02,,Other,Cardiovascular,Current,,,,2025,
840,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-04)",Reverified,8/26/2025,Unavailable,Use Sagent NDC 25021-311-04,,Other,Cardiovascular,Current,,,,2025,not available
841,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-10)",Reverified,8/26/2025,"Unavailable, Please use Sagent label",Use Sagent NDC 25021-311-10,,Other,Cardiovascular,Current,,,,2025,
842,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,8/26/2025,Available,,,,Cardiovascular,Current,,,,2025,available
843,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,8/26/2025,Available,,,,Cardiovascular,Current,,,,2025,available
844,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,8/26/2025,Available,,,,Cardiovascular,Current,,,,2025,available
845,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
846,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
847,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
848,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
849,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
850,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
851,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)",Reverified,9/3/2025,Unavailable,Estimated recovery: end of 2025,,Other,Cardiovascular,Current,,,,2025,not available
852,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
853,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)",Reverified,9/3/2025,Limited Availability,On allocation through Q3 2025,,Other,Cardiovascular,Current,,,,2025,limited availability
854,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
855,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
856,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
857,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Other,Cardiovascular,Current,,,,2025,limited availability
858,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Other,Cardiovascular,Current,,,,2025,limited availability
859,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)",Reverified,8/15/2025,Available,,,,Cardiovascular,Current,,,,2025,available
860,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,,,2025,limited availability
861,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,,,2025,limited availability
862,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,7/28/2025,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,,,2025,available
863,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,7/28/2025,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,,,2025,available
864,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,7/28/2025,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,,,2025,available
865,Gefitinib Tablet,Apotex Corp.,"Gefitinib, Tablet, 250 mg (NDC 60505-4512-3)",New,2/5/2025,,,,,Oncology,To Be Discontinued,,2/5/2025,,2025,discontinued
866,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-01)",New,2/6/2025,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/2025,,2025,discontinued
867,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-10)",New,2/6/2025,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/2025,,2025,discontinued
868,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-01)",New,2/6/2025,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/2025,,2025,discontinued
869,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-10)",New,2/6/2025,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/2025,,2025,discontinued
870,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 2.5 mg (NDC 0591-0900-30)",New,2/6/2025,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/2025,,2025,discontinued
871,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucotrol XL, Tablet, Extended Release, 5 mg (NDC 0049-0174-03)",New,3/17/2025,,Supply expected to exhaust early April 2025,,,Endocrinology/Metabolism,To Be Discontinued,,3/17/2025,,2025,discontinued
872,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucatrol XL, Tablet, Extended Release, 10 mg tablets; bottle of 500 (NDC 0049-0178-08)",New,7/24/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/24/2025,,2025,discontinued
873,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 1.5 mg (NDC 0093-8034-01)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/2025,,2025,discontinued
874,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-01)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/2025,,2025,discontinued
875,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-05)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/2025,,2025,discontinued
876,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 6 mg (NDC 0093-8036-01)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/2025,,2025,discontinued
877,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 10147-0921-3)",New,4/7/2025,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 5/31/2025,,,Psychiatry,To Be Discontinued,,4/7/2025,,2025,discontinued
878,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haloperidol Decanoate, Injection, 100 mg/1 mL (NDC 10147-0922-5)",New,4/7/2025,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 10/31/2025,,,Psychiatry,To Be Discontinued,,4/7/2025,,2025,discontinued
879,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haldol, Injection, 50 mg/1 mL (NDC 50458-253-03)",New,4/7/2025,,Last batch expiration date 5/31/2025,,,Psychiatry,To Be Discontinued,,4/7/2025,,2025,discontinued
880,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haldol, Injection, 100 mg/1 mL (NDC 50458-254-14)",New,4/7/2025,,Last batch expiration date 8/31/2025,,,Psychiatry,To Be Discontinued,,4/7/2025,,2025,discontinued
881,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 5000 [USP'U]/1 mL (NDC 0409-1402-12)",New,4/29/2025,,Discontinuation of the manufacture of the drug.,,,Hematology,To Be Discontinued,,4/29/2025,,2025,discontinued
882,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)",Reverified,8/21/2025,Available,,,,Hematology,Current,,,,2025,available
883,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Hematology,Current,,,,2025,available
884,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Hematology,Current,,,,2025,available
885,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18)",Reverified,9/3/2025,Unavailable,Product Discontinued - Product code AHB0953U replaced by Product Code 2B0953,,Discontinuation of the manufacture of the drug,Hematology,Current,,,,2025,not available
886,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)",Reverified,8/21/2025,Available,,,,Hematology,Current,,,,2025,available
887,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)",Reverified,9/3/2025,Available,,,,Hematology,Current,,,,2025,available
888,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)",Reverified,9/3/2025,Limited Availability,Recovery TBD,,Demand increase for the drug,Hematology,Current,,,,2025,limited availability
889,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)",Reverified,8/15/2025,Available,,,,Hematology,Current,1/2/2025,,,2025,available
890,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)",Reverified,8/15/2025,Available,,,,Hematology,Current,1/2/2025,,,2025,available
891,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 10 mg/1 g (NDC 0472-0321-26)",New,3/24/2025,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/2025,,2025,discontinued
892,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-20)",New,3/24/2025,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/2025,,2025,discontinued
893,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-30)",New,3/24/2025,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/2025,,2025,discontinued
894,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2025,limited availability
895,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2025,limited availability
896,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,12/19/2024,,,2025,limited availability
897,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,12/19/2024,,,2025,limited availability
898,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2025,limited availability
899,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2025,limited availability
900,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2025,limited availability
901,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
902,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)",Revised,8/15/2025,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Other,Analgesia/Addiction,Current,,,,2025,not available
903,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Analgesia/Addiction,Current,,,,2025,limited availability
904,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)",Reverified,9/2/2025,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,,2025,not available
905,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)",Revised,8/19/2025,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,,2025,available
906,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)",Revised,8/19/2025,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,,2025,available
907,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)",Revised,8/19/2025,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,,2025,available
908,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)",Revised,7/23/2025,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,1/3/2025,,,2025,available
909,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)",Revised,7/23/2025,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2025,available
910,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: September 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,1/2/2025,,,2025,limited availability
911,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,1/2/2025,,,2025,available
912,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,1/2/2025,,,2025,available
913,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mg/1 mL (NDC 0409-2552-01)",Revised,1/13/2025,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To Be Discontinued,1/13/2025,1/13/2025,,2025,discontinued
914,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,1/2/2025,,,2025,available
915,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,1/2/2025,,,2025,available
916,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,1/2/2025,,,2025,available
917,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2025,available
918,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)",Reverified,9/2/2025,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,,2025,not available
919,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)",Reverified,9/2/2025,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Other,Analgesia/Addiction,Current,,,,2025,not available
920,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)",Reverified,9/2/2025,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
921,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)",Reverified,9/2/2025,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Other,Analgesia/Addiction,Current,,,,2025,not available
922,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)",Reverified,9/2/2025,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,,2025,not available
923,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2025,available
924,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)",Revised,9/2/2025,Available,Check wholesalers for inventory,,Other,Analgesia/Addiction,Current,,,,2025,available
925,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2025,available
926,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect‚Äö√Ñ√∂‚àö√´¬¨¬¢ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)",Revised,8/15/2025,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
927,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect‚Äö√Ñ√∂‚àö√´¬¨¬¢ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
928,Hydroxocobalamin Injection,BTG International Inc.,"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)",Revised,8/5/2025,Limited Availability,"Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.",,Requirements related to complying with good manufacturing practices,Other,Current,,,,2025,limited availability
929,Hydroxypropyl Cellulose (1600000 Wamw) Insert,Bausch & Lomb Incorporated,"Lacrisert, Insert, 5 mg (NDC 24208-800-60)",Revised,7/16/2025,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,,,2025,not available
930,Ibandronate Sodium Injection,Norvium Bioscience LLC,"Ibandronate Sodium, Injection, 3 mg/3 mL (NDC 67457-524-33)",New,3/5/2025,,,,,Endocrinology/Metabolism,To Be Discontinued,,3/5/2025,,2025,discontinued
931,Ibutilide Fumarate Injection,Norvium Bioscience LLC,"Ibutilide Fumarate, Injection, .1 mg/1 mL (NDC 67457-366-10)",New,3/5/2025,,,,,Cardiovascular,To Be Discontinued,,3/5/2025,,2025,discontinued
932,Idarubicin Hydrochloride Injection,Pfizer Inc.,"Idamycin, Injection, 1 mg/1 mL (NDC 0013-2576-91)",New,2/6/2025,,Replaced with NDC 0013-2576-05,,,Oncology,To Be Discontinued,,2/6/2025,,2025,discontinued
933,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-13)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
934,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-81)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
935,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-83)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
936,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-88)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
937,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-13)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
938,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-64)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
939,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-83)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
940,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-88)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
941,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 68001-490-05)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
942,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 68001-491-04)",New,12/5/2024,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/2024,,2025,discontinued
943,Indium In-111 Chloride  Injection,Curium US LLC,"Injection, 0.5 mL/vial (5 mCi at time of calibration) (NDC 69945-132-06)",New,9/24/2024,,Product discontinued due to business related reasons,,,Medical Imaging,To Be Discontinued,,9/24/2024,,2025,discontinued
944,Indocyanine Green Injection,Renew Pharmaceuticals Limited,"Indocyanine Green, Injection, 25 mg (NDC 70100-424-02)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
945,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-15)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
946,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-14)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
947,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-13)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
948,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-25)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
949,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-24)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
950,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-23)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
951,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-16)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
952,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-26)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
953,Indocyanine Green Injection,Renew Pharmaceuticals Limited,"IC-GREEN, Injection, 25 mg (NDC 70100-825-02)",Revised,8/26/2025,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/2025,,,2025,
954,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 10 mL Insulin Aspart vial (NDC 73070-100-11)",New,7/21/2025,,"Unbranded Insulin Aspart 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/2025,,2025,discontinued
955,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 3 mL Insulin Aspart PenFill¬¨¬®‚àö√ú cartridge (NDC 73070-102-15)",New,7/21/2025,,"Unbranded Insulin Aspart 3 mL PenFill¬¨¬®‚àö√ú cartridge will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/2025,,2025,discontinued
956,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 3 mL Insulin Aspart FlexPen¬¨¬®‚àö√ú (NDC 73070-103-15)",New,7/21/2025,,"Unbranded Insulin Aspart 3 mL FlexPen¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/2025,,2025,discontinued
957,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,"Novo Nordisk, Inc.","Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11)",New,7/21/2025,,"Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/2025,,2025,discontinued
958,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,"Novo Nordisk, Inc.","Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 3 mL vial Insulin aspart protamine and insulin aspart Mix 70/30 FlexPen¬¨¬®‚àö√ú (NDC 73070-203-15)",New,7/21/2025,,"Unbranded Insulin aspart protamine and insulin aspart FlexPen¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/2025,,2025,discontinued
959,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 10 mL Insulin Degludec vial (NDC 73070-400-11)",New,7/21/2025,,"Unbranded Insulin Degludec 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/2025,,2025,discontinued
960,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 3 mL Insulin Degludec 100 units/mL (U-100) FlexTouch¬¨¬®‚àö√ú (NDC 73070-403-15)",New,7/21/2025,,"Unbranded Insulin Degludec 3 mL U-100 FlexTouch¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/2025,,2025,discontinued
961,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 3 mL Insulin Degludec 200 units/mL (U-200) FlexTouch¬¨¬®‚àö√ú (NDC 73070-503-15)",New,7/21/2025,,"Unbranded Insulin Degludec 3 mL U-200 FlexTouch¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/2025,,2025,discontinued
962,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-49)",New,9/20/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/2024,,2025,discontinued
963,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-52)",New,9/20/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/2024,,2025,discontinued
964,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-54)",New,9/20/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/2024,,2025,discontinued
965,Irinotecan Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)",New,8/4/2025,,Product not anticipated to be available beyond mid-late October 2025,,,Oncology,To Be Discontinued,,8/4/2025,,2025,discontinued
966,Irinotecan Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)",New,8/4/2025,,Product not anticipated to be available beyond mid-late September 2025,,,Oncology,To Be Discontinued,,8/4/2025,,2025,discontinued
967,Irinotecan Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 40 mg per 2 mL (20mg per mL) (NDC 63323-193-52)",New,9/30/2024,,,,,Oncology,To Be Discontinued,,9/30/2024,,2025,discontinued
968,Irinotecan Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg per 5 mL (20mg per mL) (NDC 63323-193-55)",New,9/30/2024,,,,,Oncology,To Be Discontinued,,9/30/2024,,2025,discontinued
969,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0555-0066-02)",New,11/21/2024,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/2024,,2025,discontinued
970,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-01)",New,11/21/2024,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/2024,,2025,discontinued
971,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-02)",New,11/21/2024,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/2024,,2025,discontinued
972,Isoniazid Tablet,Genus Lifesciences,"Isoniazid, Tablet, 300 mg (NDC 64950-217-03)",New,7/1/2025,,Product expected to be available until August 2025.,,,Anti-Infective,To Be Discontinued,,7/1/2025,,2025,discontinued
973,Isoniazid Tablet,Genus Lifesciences,"Isoniazid, Tablet, 300 mg (NDC 64950-217-10)",New,7/1/2025,,Product expected to be available until August 2025.,,,Anti-Infective,To Be Discontinued,,7/1/2025,,2025,discontinued
974,Isosorbide Mononitrate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 20 mg (NDC 0228-2620-11)",New,11/13/2024,,A business decision was made to discontinue manufacture of this product.,,,Cardiovascular,To Be Discontinued,,11/13/2024,,2025,discontinued
975,Isosorbide Mononitrate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 10 mg (NDC 0228-2631-11)",New,11/13/2024,,A business decision was made to discontinue manufacture of this product.,,,Cardiovascular,To Be Discontinued,,11/13/2024,,2025,discontinued
976,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-2051-05)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
977,Ketamine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 65219-184-20)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
978,Ketamine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 65219-188-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
979,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 25021-682-20)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
980,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 25021-683-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
981,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 25021-684-05)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
982,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-438-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
983,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 55150-439-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
984,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 55150-440-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
985,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/5 mL (100 mg/mL) (NDC 0409-0040-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
986,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/10 mL (50 mg/mL) (NDC 0409-2053-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
987,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 0143-9509-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
988,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 10 mg/1 mL (NDC 42023-113-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
989,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 100 mg/1 mL (NDC 42023-115-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
990,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 50 mg/1 mL (NDC 42023-114-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
991,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 0143-9508-10)",Revised,4/2/2025,,,Available,,Anesthesia,Resolved,4/2/2025,,,2025,
992,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)",Reverified,8/26/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
993,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)",Reverified,8/26/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
994,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)",Reverified,8/26/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
995,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Analgesia/Addiction,Current,,,,2025,limited availability
996,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
997,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Analgesia/Addiction,Current,,,,2025,limited availability
998,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)",Revised,7/23/2025,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,,,2025,not available
999,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)",Revised,7/23/2025,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,,,2025,not available
1000,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)",Revised,7/23/2025,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,,,2025,not available
1001,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)",Reverified,9/2/2025,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,,,2025,available
1002,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)",Reverified,9/2/2025,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,,,2025,available
1003,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)",Reverified,9/2/2025,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,,,2025,available
1004,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)",Reverified,9/3/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1005,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)",Reverified,9/3/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1006,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,,,2025,not available
1007,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,,,2025,not available
1008,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,,,2025,not available
1009,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)",Reverified,7/28/2025,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Analgesia/Addiction,Current,,,,2025,available
1010,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)",Reverified,7/28/2025,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Analgesia/Addiction,Current,,,,2025,available
1011,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)",Reverified,6/27/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1012,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)",Reverified,6/27/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1013,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)",Reverified,6/27/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1014,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-03)",Reverified,7/28/2025,Available,"Athenex is not active, supplying through Sagent NDC 25021-701-01",,,Analgesia/Addiction,Current,,,,2025,available
1015,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 70860-700-02)",Reverified,7/28/2025,Available,"Athenex is not active, supplying through Sagent NDC  25021-700-01",,,Analgesia/Addiction,Current,,,,2025,available
1016,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-04)",Reverified,7/28/2025,Available,"Athenex is not active, supplying through Sagent NDC 25021-701-02",,,Analgesia/Addiction,Current,,,,2025,available
1017,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-02)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1018,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-03)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1019,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-09)",Reverified,8/20/2025,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1020,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0117-04)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1021,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 250 mL bag, 36 count (NDC 0338-0117-02)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1022,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 500 mL bag, 24 count (NDC 0338-0117-03)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1023,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-04)",Reverified,9/3/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1024,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-03)",Reverified,9/3/2025,Unavailable,Product Discontinued,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,not available
1025,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7500-00)",Reverified,8/21/2025,Unavailable,Product not yet launched,,Other,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,not available
1026,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-00)",Revised,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1027,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-10)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1028,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-20)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1029,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-00)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1030,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-10)",Reverified,8/21/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,,2025,available
1031,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 350 mg (NDC 70436-119-80)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1032,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 50 mg (NDC 70436-116-82)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1033,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 100 mg (NDC 70436-117-80)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1034,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 200 mg (NDC 70436-118-80)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1035,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 500 mg (NDC 70436-120-80)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1036,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 25021-813-10)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1037,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 25021-814-30)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1038,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 25021-815-30)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1039,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 25021-816-30)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1040,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 63323-710-50)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1041,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 63323-711-00)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1042,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 71288-160-10)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1043,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 71288-161-20)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1044,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 71288-162-30)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1045,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 71288-163-30)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1046,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 500 mg/50 mL (NDC 71288-164-50)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1047,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 0143-9555-01)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1048,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 0143-9554-01)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1049,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 0143-9553-01)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1050,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 0143-9552-01)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1051,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-10)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1052,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-50)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1053,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 100 mg/10 mL (NDC 67457-528-10)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1054,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 200 mg/20 mL (NDC 67457-529-20)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1055,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 350 mg/17.5 mL (NDC 67457-530-35)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1056,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 25021-828-50)",Revised,7/8/2025,,,Available,,Oncology; Pediatric,Resolved,7/8/2025,,,2025,
1057,Levalbuterol Hydrochloride Solution,"Teva Pharmaceuticals USA, Inc.","Solution, 1.25 mg/.5 mL (NDC 0093-4147-56)",New,10/15/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,10/15/2024,,2025,discontinued
1058,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 25 ug (NDC 72305-025-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1059,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 25 ug (NDC 72305-025-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1060,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 50 ug (NDC 72305-050-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1061,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 50 ug (NDC 72305-050-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1062,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 75 ug (NDC 72305-075-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1063,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 75 ug (NDC 72305-075-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1064,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 88 ug (NDC 72305-088-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1065,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 88 ug (NDC 72305-088-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1066,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 100 ug (NDC 72305-100-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1067,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 100 ug (NDC 72305-100-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1068,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 112 ug (NDC 72305-112-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1069,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 112 ug (NDC 72305-112-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1070,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 125 ug (NDC 72305-125-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1071,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 125 ug (NDC 72305-125-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1072,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 137 ug (NDC 72305-137-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1073,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 137 ug (NDC 72305-137-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1074,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 150 ug (NDC 72305-150-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1075,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 150 ug (NDC 72305-150-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1076,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 175 ug (NDC 72305-175-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1077,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 175 ug (NDC 72305-175-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1078,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 200 ug (NDC 72305-200-30)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1079,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 200 ug (NDC 72305-200-90)",New,7/10/2025,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/2025,,2025,discontinued
1080,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1081,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1082,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1083,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1084,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)",Revised,7/23/2025,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia,Current,,,,2025,available
1085,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)",Revised,7/23/2025,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia,Current,,,,2025,available
1086,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)",Revised,7/23/2025,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Anesthesia,Current,,,,2025,available
1087,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)",Revised,7/23/2025,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Anesthesia,Current,,,,2025,available
1088,Lidocaine Hydrochloride Injection,"Spectra Medical Devices, LLC","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1089,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,,,,2025,limited availability
1090,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)",Reverified,9/2/2025,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2025,not available
1091,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1092,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)",Reverified,9/3/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1093,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)",Reverified,8/21/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1094,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)",Reverified,8/21/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1095,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)",Reverified,8/21/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1096,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-158-72)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1097,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1098,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-160-72)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1099,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1100,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1101,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1102,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1103,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1104,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)",Reverified,9/2/2025,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2025,not available
1105,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1106,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1107,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1108,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1109,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1110,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1111,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1112,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1113,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1114,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1115,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1116,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1117,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1118,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2025,limited availability
1119,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1120,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)",Revised,8/15/2025,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Pediatric,Current,12/19/2024,,,2025,not available
1121,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)",Revised,8/15/2025,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Pediatric,Current,12/19/2024,,,2025,not available
1122,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,12/19/2024,,,2025,available
1123,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1124,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,,,,2025,limited availability
1125,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1126,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1127,Lidocaine Hydrochloride Injection,"Amphastar Pharmaceuticals, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)",Reverified,8/19/2025,Available,old NDC 0548-3390-00,,,Anesthesia; Pediatric,Current,,,,2025,available
1128,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)",Reverified,9/2/2025,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2025,not available
1129,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)",Reverified,9/2/2025,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2025,not available
1130,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1131,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1132,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1133,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1134,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1135,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1136,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,,2025,available
1137,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)",Reverified,9/2/2025,Unavailable,Next release date not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2025,not available
1138,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)",Revised,8/15/2025,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,12/19/2024,,,2025,not available
1139,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1140,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)",Reverified,8/15/2025,Available,,,,Anesthesia; Pediatric,Current,,,,2025,available
1141,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1142,Lidocaine Hydrochloride Injection,Afaxys Pharma,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 50102-400-10)",Revised,3/5/2025,,,,,Anesthesia; Pediatric,To Be Discontinued,3/5/2025,3/5/2025,,2025,discontinued
1143,Lidocaine Hydrochloride Injection,"Huons Co., Ltd. (South Korea)","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)",Reverified,6/27/2025,Available,,,,Anesthesia,Current,,,,2025,available
1144,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)",Reverified,8/19/2025,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X2ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,,,2025,available
1145,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)",Reverified,8/19/2025,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,,,2025,available
1146,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)",Reverified,8/19/2025,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X10ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,,,2025,available
1147,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)",Reverified,8/19/2025,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X2ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,,,2025,available
1148,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)",Reverified,8/19/2025,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,,,2025,available
1149,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)",Reverified,8/19/2025,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X10ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,,,2025,available
1150,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)",Reverified,8/19/2025,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 4% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,,,2025,available
1151,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-3500-49)",Revised,8/29/2025,,,Available,,Anesthesia,Resolved,8/29/2025,,,2025,
1152,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-0548-44)",Revised,8/29/2025,,,Available,,Anesthesia,Resolved,8/29/2025,,,2025,
1153,Lidocaine Hydrochloride Solution,PAI Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-4950-40)",Revised,8/29/2025,,,Available,,Anesthesia,Resolved,8/29/2025,,,2025,
1154,Lidocaine Hydrochloride Solution,Rubicon Research Private Limited,"Lidocaine Hydrochloride, Solution, 20 mg/1 mL (NDC 72888-125-26)",Revised,8/29/2025,,,Available,,Anesthesia,Resolved,8/29/2025,,,2025,
1155,Lidocaine Hydrochloride Solution,PAI Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-0950-03)",Revised,8/29/2025,,,Available,,Anesthesia,Resolved,8/29/2025,,,2025,
1156,Lidocaine Hydrochloride Solution,Chartwell Molecular Holdings LLC,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 62135-712-42)",Revised,8/29/2025,,,Available,,Anesthesia,Resolved,8/29/2025,,,2025,
1157,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 30 gram tubes (NDC 64380-789-23)",New,1/28/2025,,,,,Anesthesia,To Be Discontinued,,1/28/2025,,2025,discontinued
1158,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 35.44 gram tubes (NDC 64380-789-32)",New,1/28/2025,,,,,Anesthesia,To Be Discontinued,,1/28/2025,,2025,discontinued
1159,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 50 gram jar (NDC 64380-789-33)",New,1/28/2025,,,,,Anesthesia,To Be Discontinued,,1/28/2025,,2025,discontinued
1160,Lidocaine Patch,"Actavis Pharma, Inc.","Lidocaine, Patch, 5% (NDC 0591-2679-30)",New,7/17/2025,,Discontinuation is for the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´NovaPlus‚Äö√Ñ√∂‚àö√ë‚àöœÄ label product only.,,,Analgesia/Addiction,To Be Discontinued,,7/17/2025,,2025,discontinued
1161,Linezolid Solution,Pfizer Inc.,"Zyvox, Solution, 600 mg/300 mL (NDC 0009-4992-02)",New,10/11/2024,,,,,Anti-Infective,To Be Discontinued,,10/11/2024,,2025,discontinued
1162,Linezolid Solution,Pfizer Inc.,"Zyvox, Solution, 200 mg/100 mL (NDC 0009-5137-04)",New,10/11/2024,,,,,Anti-Infective,To Be Discontinued,,10/11/2024,,2025,discontinued
1163,Liraglutide Injection,"Novo Nordisk, Inc.","Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)",Reverified,7/15/2025,Available,,,,Endocrinology/Metabolism,Current,,,,2025,available
1164,Liraglutide Injection,"Hikma Pharmaceuticals USA, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)",Reverified,7/23/2025,Available,Product will be made available as it is released.,,,Endocrinology/Metabolism,Current,,,,2025,available
1165,Liraglutide Injection,"Hikma Pharmaceuticals USA, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)",Reverified,7/23/2025,Available,Product will be made available as it is released.,,,Endocrinology/Metabolism,Current,,,,2025,available
1166,Liraglutide Injection,"Meitheal Pharmaceuticals, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)",Reverified,8/19/2025,Available,,,,Endocrinology/Metabolism,Current,,,,2025,available
1167,Liraglutide Injection,"Meitheal Pharmaceuticals, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)",Reverified,8/19/2025,Available,,,,Endocrinology/Metabolism,Current,,,,2025,available
1168,Liraglutide Injection,"Novo Nordisk, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)",Reverified,7/15/2025,Available,Distributed by Teva,,,Endocrinology/Metabolism,Current,,,,2025,available
1169,Liraglutide Injection,"Novo Nordisk, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)",Reverified,7/15/2025,Available,Distributed by Teva,,,Endocrinology/Metabolism,Current,,,,2025,available
1170,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)",Reverified,7/15/2025,Limited Availability,Estimated shortage duration TBD,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,,2025,limited availability
1171,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)",Reverified,7/15/2025,Limited Availability,Estimated shortage duration TBD,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,,2025,limited availability
1172,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)",Reverified,8/5/2025,Available,,,,Psychiatry,Current,,,,2025,available
1173,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)",Reverified,8/5/2025,Available,,,,Psychiatry,Current,,,,2025,available
1174,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)",Reverified,8/5/2025,Available,,,,Psychiatry,Current,,,,2025,available
1175,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)",Reverified,8/5/2025,Available,,,,Psychiatry,Current,,,,2025,available
1176,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)",Reverified,8/5/2025,Available,,,,Psychiatry,Current,,,,2025,available
1177,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)",Reverified,8/5/2025,Available,,,,Psychiatry,Current,,,,2025,available
1178,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)",Reverified,8/5/2025,Available,,,,Psychiatry,Current,,,,2025,available
1179,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1180,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1181,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1182,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1183,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1184,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1185,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1186,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)",Reverified,7/24/2025,Available,Product currently available,,,Psychiatry,Current,,,,2025,available
1187,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)",Reverified,7/24/2025,Available,Product currently available,,,Psychiatry,Current,,,,2025,available
1188,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)",Reverified,7/24/2025,Available,Product currently available,,,Psychiatry,Current,,,,2025,available
1189,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)",Reverified,7/24/2025,Available,Product currently available,,,Psychiatry,Current,,,,2025,available
1190,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)",Reverified,7/24/2025,Available,Product currently available,,,Psychiatry,Current,,,,2025,available
1191,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)",Reverified,7/24/2025,Limited Availability,"Limited quantity available, next resupply in late July 2025",,Other,Psychiatry,Current,,,,2025,limited availability
1192,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)",Reverified,7/24/2025,Limited Availability,"Limited quantity available, next resupply in late July 2025",,Other,Psychiatry,Current,,,,2025,limited availability
1193,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1194,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1195,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1196,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1197,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1198,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1199,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1200,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1201,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1202,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1203,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1204,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1205,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1206,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1207,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1208,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1209,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1210,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1211,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1212,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1213,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1214,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)",Reverified,7/23/2025,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1215,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)",Reverified,7/23/2025,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1216,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)",Reverified,7/23/2025,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1217,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)",Reverified,7/23/2025,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1218,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)",Reverified,7/23/2025,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1219,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)",Reverified,7/23/2025,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1220,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)",Reverified,9/2/2025,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1221,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)",Reverified,9/2/2025,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1222,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)",Revised,9/2/2025,Unavailable,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1223,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)",Revised,9/2/2025,Unavailable,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1224,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)",Reverified,9/2/2025,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1225,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)",Reverified,9/2/2025,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1226,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)",Reverified,9/2/2025,Unavailable,Unavailable,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1227,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)",Reverified,8/5/2025,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1228,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)",Reverified,8/5/2025,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1229,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)",Reverified,8/5/2025,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1230,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)",Reverified,8/5/2025,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1231,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)",Reverified,8/5/2025,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1232,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)",Reverified,8/5/2025,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1233,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)",Reverified,8/5/2025,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1234,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)",Reverified,8/5/2025,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1235,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)",Reverified,8/5/2025,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1236,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)",Reverified,8/5/2025,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1237,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)",Reverified,8/5/2025,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1238,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)",Reverified,8/5/2025,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1239,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)",Reverified,8/5/2025,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1240,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1241,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1242,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1243,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1244,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1245,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1246,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1247,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)",Reverified,9/2/2025,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1248,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)",Reverified,9/2/2025,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1249,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)",Reverified,9/2/2025,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1250,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)",Reverified,9/2/2025,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1251,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)",Reverified,9/2/2025,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1252,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)",Reverified,9/2/2025,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1253,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)",Reverified,9/2/2025,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1254,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)",Revised,8/1/2025,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1255,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1256,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1257,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1258,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1259,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)",Revised,8/19/2025,Limited Availability,Estimated recovery: August 2025,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1260,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1261,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1262,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1263,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1264,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1265,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1266,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1267,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)",Reverified,8/15/2025,Available,,,,Psychiatry,Current,,,,2025,available
1268,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,,2025,limited availability
1269,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,,2025,limited availability
1270,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,,2025,limited availability
1271,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,,2025,limited availability
1272,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,,2025,limited availability
1273,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,,2025,limited availability
1274,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)",Revised,7/16/2025,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,available
1275,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)",Revised,7/16/2025,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,available
1276,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)",Revised,7/16/2025,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,available
1277,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)",Revised,7/16/2025,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,available
1278,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)",Revised,7/16/2025,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,available
1279,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)",Revised,7/16/2025,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,available
1280,Lodoxamide Tromethamine Solution,Novartis Pharmaceuticals Corporation,"Alomide, Solution, 1 mg/1 mL (NDC 0078-0736-10)",New,12/9/2024,,"Novartis has made a business decision to permanently discontinue ALOMIDE¬¨¬®‚àö√ú (lodoxamide tromethamine) ophthalmic solution, 0.1%

Discontinuation of the product is due in part to manufacturing concerns.

Short-dated material is available until January 2025.",,,Ophthalmology,To Be Discontinued,,12/9/2024,,2025,discontinued
1281,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)",Revised,7/23/2025,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,,2025,not available
1282,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)",Revised,8/15/2025,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Neurology,Current,,,,2025,not available
1283,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)",Reverified,8/19/2025,Limited Availability,,,Demand increase for the drug,Neurology,Current,,,,2025,limited availability
1284,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)",Revised,7/23/2025,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,,2025,not available
1285,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)",Revised,7/23/2025,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,,2025,not available
1286,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)",Revised,7/23/2025,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,,2025,not available
1287,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)",Revised,7/23/2025,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,,2025,not available
1288,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)",Revised,7/23/2025,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,,2025,not available
1289,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)",Revised,7/23/2025,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,,2025,not available
1290,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)",Revised,7/23/2025,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,,2025,not available
1291,Mefloquine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Mefloquine Hydrochloride, Tablet, 250 mg (NDC 0555-0171-78)",Revised,8/21/2025,,,Available,,Anti-Infective,Resolved,8/21/2025,,,2025,
1292,Mefloquine Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Mefloquine Hydrochloride, Tablet, 250 mg (NDC 62135-973-25)",Revised,8/21/2025,,,Available,,Anti-Infective,Resolved,8/21/2025,,,2025,
1293,Memantine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Memantine Hydrochloride, Tablet, 5 mg (NDC 0832-1112-60)",New,4/28/2025,,,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
1294,Memantine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Memantine Hydrochloride, Tablet, 10 mg (NDC 0832-1113-60)",New,4/28/2025,,,,,Neurology,To Be Discontinued,,4/28/2025,,2025,discontinued
1295,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 5 mg (NDC 0591-3870-44)",New,11/21/2024,,,,,Neurology,To Be Discontinued,,11/21/2024,,2025,discontinued
1296,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 5 mg (NDC 0591-3870-60)",New,11/21/2024,,,,,Neurology,To Be Discontinued,,11/21/2024,,2025,discontinued
1297,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 10 mg (NDC 0591-3875-44)",New,11/21/2024,,,,,Neurology,To Be Discontinued,,11/21/2024,,2025,discontinued
1298,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 10 mg (NDC 0591-3875-60)",New,11/21/2024,,,,,Neurology,To Be Discontinued,,11/21/2024,,2025,discontinued
1299,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, Kit (NDC 0591-3900-87)",New,11/21/2024,,,,,Neurology,To Be Discontinued,,11/21/2024,,2025,discontinued
1300,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)",Revised,7/23/2025,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,,2025,not available
1301,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)",Revised,7/23/2025,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,,2025,not available
1302,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)",Revised,7/23/2025,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,,2025,not available
1303,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)",Revised,8/15/2025,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,,,2025,not available
1304,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)",Revised,8/15/2025,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,,,2025,not available
1305,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)",Revised,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
1306,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)",Revised,8/15/2025,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2025,not available
1307,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)",Revised,8/15/2025,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2025,not available
1308,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)",Revised,8/15/2025,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2025,not available
1309,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)",Revised,8/15/2025,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2025,not available
1310,Methamphetamine Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 68308-115-01)",Reverified,8/15/2025,Available,Available to existing customers,,,Psychiatry,Current,,,,2025,available
1311,Methamphetamine Hydrochloride Tablet,"Hikma Pharmaceuticals USA, Inc.","Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 0054-0389-25)",Revised,8/1/2025,Available,,,,Psychiatry,Current,,,,2025,available
1312,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 10 mg/.4 mL (NDC 82497-010-04)",New,8/29/2025,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/2025,,2025,discontinued
1313,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 12.5 mg/.4 mL (NDC 82497-012-04)",New,8/29/2025,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/2025,,2025,discontinued
1314,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 15 mg/.4 mL (NDC 82497-015-04)",New,8/29/2025,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/2025,,2025,discontinued
1315,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 17.5 mg/.4 mL (NDC 82497-017-04)",New,8/29/2025,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/2025,,2025,discontinued
1316,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 20 mg/.4 mL (NDC 82497-020-04)",New,8/29/2025,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/2025,,2025,discontinued
1317,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 22.5 mg/.4 mL (NDC 82497-022-04)",New,8/29/2025,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/2025,,2025,discontinued
1318,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 25 mg/.4 mL (NDC 82497-025-04)",New,8/29/2025,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/2025,,2025,discontinued
1319,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Injection, 25 mg/1 mL (NDC 61703-161-05)",New,1/8/2025,,Discontinuation of the manufacture of the drug,,,Oncology; Rheumatology,To Be Discontinued,,1/8/2025,,2025,discontinued
1320,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)",Reverified,7/23/2025,Available,Currently available.  Additional product will be made available as it is released.,,,Rheumatology; Oncology,Current,,,,2025,available
1321,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Rheumatology; Oncology,Current,,,,2025,available
1322,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)",Revised,8/19/2025,Available,Estimated recovery: December 2025,,Other,Rheumatology; Oncology,Current,,,,2025,available
1323,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)",Revised,8/19/2025,Unavailable,Estimated recovery: October 2025,,Other,Rheumatology; Oncology,Current,,,,2025,not available
1324,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)",Revised,8/19/2025,Limited Availability,Estimated recovery: January 2026,,Other,Rheumatology; Oncology,Current,,,,2025,limited availability
1325,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)",Reverified,8/15/2025,Available,,,,Rheumatology; Oncology,Current,,,,2025,available
1326,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Rheumatology; Oncology,Current,,,,2025,limited availability
1327,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)",Reverified,8/15/2025,Available,,,,Rheumatology; Oncology,Current,,,,2025,available
1328,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)",Reverified,8/15/2025,Available,,,,Rheumatology; Oncology,Current,,,,2025,available
1329,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)",Reverified,8/15/2025,Available,,,,Rheumatology; Oncology,Current,,,,2025,available
1330,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)",Reverified,9/2/2025,Available,Check wholesaler for inventory,,,Rheumatology; Oncology,Current,,,,2025,available
1331,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)",Reverified,9/2/2025,Available,Check whlolesaler for inventory,,,Rheumatology; Oncology,Current,,,,2025,available
1332,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)",Revised,8/19/2025,Unavailable,Resupply: estimated 14 days,,Shortage of an active ingredient,Rheumatology; Oncology,Current,,,,2025,not available
1333,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)",Revised,8/19/2025,Unavailable,Resupply: estimated 14 days,,Shortage of an active ingredient,Rheumatology; Oncology,Current,,,,2025,not available
1334,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 10 mg (NDC 68968-5552-3)",Reverified,8/19/2025,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1335,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 15 mg (NDC 68968-5553-3)",Reverified,8/19/2025,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1336,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 20 mg (NDC 68968-5554-3)",Reverified,8/19/2025,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1337,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 30 mg (NDC 68968-5555-3)",Reverified,8/19/2025,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1338,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)",Revised,8/19/2025,Available,Available. Distributed by Padagis US LLC,,,Psychiatry,Current,,,,2025,available
1339,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)",Revised,8/19/2025,Unavailable,Estimated availability: end October 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1340,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)",Revised,8/19/2025,Unavailable,Estimated availability: early September 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1341,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)",Revised,8/19/2025,Unavailable,Estimated availability: early September 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1342,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 10mg/9hrs (NDC 0378-8260-93)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1343,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 15mg/9hrs (NDC 0378-8261-93)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1344,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 20mg/9hrs (NDC 0378-8262-93)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1345,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 30mg/9hrs (NDC 0378-8263-93)",Reverified,9/3/2025,Available,,,,Psychiatry,Current,,,,2025,available
1346,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)",Reverified,9/4/2025,Available,,,,Psychiatry,Current,,,,2025,available
1347,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)",Reverified,9/4/2025,Available,,,,Psychiatry,Current,,,,2025,available
1348,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)",Reverified,9/4/2025,Available,,,,Psychiatry,Current,,,,2025,available
1349,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)",Reverified,9/4/2025,Available,,,,Psychiatry,Current,,,,2025,available
1350,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)",Reverified,9/4/2025,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,,,2025,not available
1351,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)",Reverified,9/4/2025,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,,,2025,not available
1352,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)",Reverified,9/4/2025,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,,,2025,not available
1353,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)",Reverified,9/4/2025,Available,,,,Psychiatry,Current,,,,2025,available
1354,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)",Reverified,9/4/2025,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,,,2025,not available
1355,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)",Reverified,9/4/2025,Available,,,,Psychiatry,Current,,,,2025,available
1356,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)",Reverified,9/4/2025,Available,,,,Psychiatry,Current,,,,2025,available
1357,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1358,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers. Short term backorder expected in September with recovery in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1359,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 0406-0127-01)",Revised,9/2/2025,Unavailable,Backorder expected with next release expected in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1360,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 0406-0136-01)",Reverified,9/2/2025,Limited Availability,Allocation to all customers. Short term backorder expected in September with recovery in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,limited availability
1361,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 0406-0154-01)",Reverified,9/2/2025,Unavailable,Backorder. Next release expected in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,,,2025,not available
1362,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1363,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1364,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)",Reverified,9/2/2025,Unavailable,other,,Other,Psychiatry,Current,,,,2025,not available
1365,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1366,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 18 mg (NDC 62037-725-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1367,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 27 mg (NDC 62037-734-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1368,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 36 mg (NDC 62037-726-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1369,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 54 mg (NDC 62037-727-01)",Revised,8/19/2025,Available,,,,Psychiatry,Current,,,,2025,available
1370,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 43598-438-01)",Reverified,8/15/2025,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,,,2025,not available
1371,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 43598-439-01)",Reverified,8/15/2025,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,,,2025,not available
1372,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 43598-440-01)",Reverified,8/15/2025,Available,Available to existing customers,,,Psychiatry,Current,,,,2025,available
1373,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 43598-441-01)",Reverified,8/15/2025,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,,,2025,not available
1374,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)",Reverified,9/4/2025,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,,2025,limited availability
1375,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)",Reverified,9/4/2025,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,,2025,limited availability
1376,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)",Reverified,9/4/2025,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,,2025,limited availability
1377,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)",Reverified,9/4/2025,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,,2025,limited availability
1378,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)",Reverified,9/4/2025,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,,2025,limited availability
1379,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)",Reverified,9/4/2025,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,,2025,limited availability
1380,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)",Reverified,9/4/2025,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,,2025,limited availability
1381,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1382,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1383,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1384,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)",Reverified,9/2/2025,Available,,,,Psychiatry,Current,,,,2025,available
1385,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)",Revised,8/20/2025,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2025,not available
1386,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)",Revised,8/20/2025,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2025,not available
1387,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)",Revised,8/20/2025,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2025,not available
1388,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)",Revised,8/20/2025,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2025,not available
1389,Methylprednisolone Acetate Injection,Eugia US LLC,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Rheumatology,Current,,,,2025,not available
1390,Methylprednisolone Acetate Injection,Eugia US LLC,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Rheumatology,Current,,,,2025,not available
1391,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)",Reverified,8/26/2025,Available,,,,Rheumatology,Current,,,,2025,available
1392,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)",Reverified,8/26/2025,Available,,,,Rheumatology,Current,,,,2025,available
1393,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)",Reverified,8/26/2025,Available,,,,Rheumatology,Current,,,,2025,available
1394,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)",Reverified,9/2/2025,Available,,,,Rheumatology,Current,,,,2025,available
1395,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)",Reverified,6/27/2025,Available,,,,Rheumatology,Current,,,,2025,available
1396,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)",Reverified,6/27/2025,Available,,,,Rheumatology,Current,,,,2025,available
1397,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)",Reverified,6/27/2025,Available,,,,Rheumatology,Current,,,,2025,available
1398,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)",Reverified,6/27/2025,Available,,,,Rheumatology,Current,,,,2025,available
1399,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)",Reverified,8/15/2025,Available,,,,Rheumatology,Current,,,,2025,available
1400,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Rheumatology,Current,,,,2025,limited availability
1401,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)",Revised,8/15/2025,Available,,,,Rheumatology,Current,,,,2025,available
1402,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)",Revised,8/15/2025,Unavailable,Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Rheumatology,Current,,,,2025,not available
1403,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)",Reverified,8/15/2025,Available,,,,Rheumatology,Current,,,,2025,available
1404,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)",Reverified,8/15/2025,Available,,,,Rheumatology,Current,,,,2025,available
1405,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)",Revised,8/15/2025,Unavailable,Next Delivery: October 2025; Estimated Recovery: March 2026,,Demand increase for the drug,Rheumatology,Current,,,,2025,not available
1406,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)",Reverified,8/15/2025,Available,,,,Rheumatology,Current,,,,2025,available
1407,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)",Revised,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Rheumatology,Current,,,,2025,not available
1408,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)",Reverified,8/15/2025,Available,,,,Rheumatology,Current,,,,2025,available
1409,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)",Revised,8/15/2025,Available,,,,Rheumatology,Current,,,,2025,available
1410,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)",Revised,8/15/2025,Available,,,,Rheumatology,Current,,,,2025,available
1411,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)",Revised,8/15/2025,Unavailable,Next Delivery: September 2025; Estimated Recovery: June 2026,,Demand increase for the drug,Rheumatology,Current,,,,2025,not available
1412,Methylprednisolone Sodium Succinate Injection,Pfizer Inc.,"Solu-Medrol, Injection, 1 g/1 mL (NDC 0009-0698-02)",New,10/10/2024,,,,,Rheumatology,To Be Discontinued,,10/10/2024,,2025,discontinued
1413,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-01)",New,6/3/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/2025,,2025,discontinued
1414,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-99)",New,6/3/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/2025,,2025,discontinued
1415,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-01)",New,6/3/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/2025,,2025,discontinued
1416,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-59)",New,6/3/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/2025,,2025,discontinued
1417,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-99)",New,6/3/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/2025,,2025,discontinued
1418,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-01)",New,6/3/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/2025,,2025,discontinued
1419,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-39)",New,6/3/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/2025,,2025,discontinued
1420,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-99)",New,6/3/2025,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/2025,,2025,discontinued
1421,Metronidazole Injection,InfoRLife SA,"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)",Reverified,8/26/2025,Limited Availability,Labeler: Hospira Inc.,,Other,Anti-Infective,Current,,,,2025,limited availability
1422,Metronidazole Injection,InfoRLife SA,"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)",Reverified,8/26/2025,Available,Labeler: Sagent Pharmaceuticals,,,Anti-Infective,Current,,,,2025,available
1423,Metronidazole Injection,B. Braun Medical Inc.,"Metro I.v. In Plastic Container, Injection, 500 mg/100 mL (NDC 0264-5535-32)",Reverified,8/21/2025,Limited Availability,Temporary discontinuation of the manufacture of the drug. Some lots are available through exhaustion of inventory,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2025,limited availability
1424,Metronidazole Injection,Baxter Healthcare,"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)",Reverified,9/3/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1425,Metronidazole Injection,Gland Pharma Limited,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)",Reverified,7/28/2025,Unavailable,,,Shortage of an active ingredient,Anti-Infective,Current,,,,2025,not available
1426,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)",Reverified,7/16/2025,Available,Please check wholesalers and distributors for inventory.,,,Anesthesia; Neurology,Current,,,,2025,available
1427,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)",Reverified,7/16/2025,Available,Please check wholesalers and distributors for inventory.,,,Anesthesia; Neurology,Current,,,,2025,available
1428,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)",Reverified,9/3/2025,Available,,,,Anesthesia; Neurology,Current,,,,2025,available
1429,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)",Reverified,9/3/2025,Available,,,,Anesthesia; Neurology,Current,,,,2025,available
1430,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)",Reverified,9/3/2025,Available,,,,Anesthesia; Neurology,Current,,,,2025,available
1431,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia; Neurology,Current,,,,2025,not available
1432,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2025,available
1433,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2025,available
1434,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2025,available
1435,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2025,available
1436,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2025,not available
1437,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2025,available
1438,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,,2025,available
1439,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,,2025,available
1440,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,,2025,available
1441,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,,2025,available
1442,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,,2025,available
1443,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)",Reverified,8/15/2025,Available,,,,Anesthesia; Neurology,Current,,,,2025,available
1444,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2025,limited availability
1445,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)",Reverified,8/15/2025,Available,,,,Anesthesia; Neurology,Current,,,,2025,available
1446,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)",Reverified,8/15/2025,Available,,,,Anesthesia; Neurology,Current,,,,2025,available
1447,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)",Reverified,8/15/2025,Available,,,,Anesthesia; Neurology,Current,,,,2025,available
1448,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)",Revised,8/15/2025,Unavailable,Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia; Neurology,Current,,,,2025,not available
1449,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)",Reverified,8/15/2025,Available,,,,Anesthesia; Neurology,Current,,,,2025,available
1450,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-10)",Reverified,7/28/2025,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,,2025,available
1451,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-05)",Reverified,7/28/2025,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,,2025,available
1452,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-17)",Reverified,7/28/2025,Unavailable,Alvogen,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2025,not available
1453,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-91)",Reverified,7/28/2025,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,,2025,available
1454,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 70860-600-02)",Reverified,7/28/2025,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,,2025,available
1455,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 47781-588-68)",Reverified,7/28/2025,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,,2025,available
1456,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 2.5 mg (NDC 0245-0211-01)",New,4/28/2025,,,,,Cardiovascular,To Be Discontinued,,4/28/2025,,2025,discontinued
1457,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 2.5 mg (NDC 0245-0211-11)",New,4/28/2025,,,,,Cardiovascular,To Be Discontinued,,4/28/2025,,2025,discontinued
1458,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 0245-0212-01)",New,4/28/2025,,,,,Cardiovascular,To Be Discontinued,,4/28/2025,,2025,discontinued
1459,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 0245-0212-11)",New,4/28/2025,,,,,Cardiovascular,To Be Discontinued,,4/28/2025,,2025,discontinued
1460,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 10 mg (NDC 0245-0213-01)",New,4/28/2025,,,,,Cardiovascular,To Be Discontinued,,4/28/2025,,2025,discontinued
1461,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 10 mg (NDC 0245-0213-11)",New,4/28/2025,,,,,Cardiovascular,To Be Discontinued,,4/28/2025,,2025,discontinued
1462,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 55154-5623-0)",New,4/28/2025,,,,,Cardiovascular,To Be Discontinued,,4/28/2025,,2025,discontinued
1463,Minocycline Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Minocycline Hydrochloride, Capsule, 75 mg (NDC 0591-3153-01)",New,5/23/2025,,Permanent discontinuation of manufacture due to business decision.,,,Anti-Infective,To Be Discontinued,,5/23/2025,,2025,discontinued
1464,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 50 mg (NDC 64380-154-01)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/2025,,2025,discontinued
1465,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 75 mg (NDC 64380-155-01)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/2025,,2025,discontinued
1466,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 100 mg (NDC 64380-156-01)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/2025,,2025,discontinued
1467,Mitomycin Injection,Accord Healthcare Inc.,"Mitomycin, Injection, 20 mg/40 mL (NDC 16729-108-11)",New,1/17/2025,,Permanent discontinuation in the manufacturing of the drug.,,,Anti-Infective,To Be Discontinued,,1/17/2025,,2025,discontinued
1468,Montelukast Sodium Granule,Organon,"Singulair, Granule, 4 mg (NDC 78206-171-01)",New,3/24/2025,,,,,Pulmonary/Allergy,To Be Discontinued,,3/24/2025,,2025,discontinued
1469,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-23)",New,7/8/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/2025,,2025,discontinued
1470,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)",New,7/8/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/2025,,2025,discontinued
1471,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)",New,7/8/2025,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/2025,,2025,discontinued
1472,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)",Revised,9/2/2025,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,,2025,not available
1473,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2025,available
1474,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)",Reverified,8/19/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1475,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)",Reverified,9/2/2025,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
1476,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)",Revised,9/2/2025,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,,2025,not available
1477,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)",Reverified,9/2/2025,Unavailable,Not available at this time.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
1478,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2025,available
1479,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph (Morphine Sulfate Injection, USP), Injection, 1 mg/1 mL (NDC 0641-6019-10)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2025,available
1480,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph (Morphine Sulfate Injection, USP), Injection, .5 mg/1 mL (NDC 0641-6020-10)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2025,available
1481,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2025,available
1482,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2025,available
1483,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)",Revised,8/15/2025,Unavailable,Next Delivery: September 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,,,2025,not available
1484,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)",Revised,8/15/2025,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,,,2025,not available
1485,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)",Revised,8/15/2025,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,1/3/2025,,,2025,not available
1486,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)",Reverified,8/15/2025,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2025,not available
1487,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1488,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,1/3/2025,,,2025,available
1489,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,1/3/2025,,,2025,available
1490,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)",Reverified,8/15/2025,Available,,,,Analgesia/Addiction,Current,1/3/2025,,,2025,available
1491,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2025,available
1492,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)",Reverified,7/23/2025,Unavailable,Additional lots will be available in the May 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
1493,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)",Reverified,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2025,available
1494,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, USP), Injection, 200 mg/20 mL (NDC 66794-160-02)",Reverified,8/19/2025,Limited Availability,On allocation,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,limited availability
1495,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, USP), Injection, 500 mg/20 mL (NDC 66794-162-02)",Reverified,8/19/2025,Limited Availability,On allocation,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,limited availability
1496,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-01)",Reverified,8/19/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1497,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-10)",Reverified,8/19/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1498,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-50)",Reverified,9/2/2025,Available,Marketed by Tagi Pharma,,,Analgesia/Addiction,Current,,,,2025,available
1499,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-30)",Reverified,9/2/2025,Available,Marketed by Tagi Pharma,,,Analgesia/Addiction,Current,,,,2025,available
1500,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-50)",Reverified,9/2/2025,Available,Marketed by Precision Dose,,,Analgesia/Addiction,Current,,,,2025,available
1501,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-30)",Reverified,9/2/2025,Available,Marketed by Precision Dose,,,Analgesia/Addiction,Current,,,,2025,available
1502,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-88)",Revised,8/20/2025,Limited Availability,Q3 2025,,Other,Analgesia/Addiction,Current,,,,2025,limited availability
1503,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-83)",Revised,8/20/2025,Limited Availability,Q3 2025,,Other,Analgesia/Addiction,Current,,,,2025,limited availability
1504,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-08)",Revised,8/20/2025,Unavailable,Currently not marketed,,Other,Analgesia/Addiction,Current,,,,2025,not available
1505,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-18)",Revised,8/20/2025,Unavailable,Currently not marketed,,Other,Analgesia/Addiction,Current,,,,2025,not available
1506,Naltrexone Hydrochloride Tablet,SpecGx LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-01)",Revised,9/2/2025,Limited Availability,Long term allocations to all customers with intermittent backorder expected through 2025.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,limited availability
1507,Naltrexone Hydrochloride Tablet,SpecGx LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-03)",Revised,9/2/2025,Available,Long term allocations to all customers with intermittent backorder expected through 2025.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,available
1508,Naltrexone Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 62135-242-60)",Reverified,8/19/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1509,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)",Revised,9/3/2025,Unavailable,Manufacturing delay; Recovery in October 2025,,Other,Cardiovascular,Current,,,,2025,not available
1510,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)",Revised,9/3/2025,Unavailable,Manufacturing delay; Recovery in September 2025,,Other,Cardiovascular,Current,,,,2025,not available
1511,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)",Reverified,9/3/2025,Unavailable,Manufacturing delay; Recovery in October 2025,,Other,Cardiovascular,Current,,,,2025,not available
1512,Nitroglycerin Injection,"American Regent, Inc.","Nitroglycerin, Injection, 5 mg/1 mL (NDC 0517-4810-25)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1513,Norepinephrine Bitartrate Injection,"Sun Pharmaceutical Industries, Inc.","Injection, 1 mg/1 mL (NDC 47335-615-44)",New,9/20/2024,,,,,Cardiovascular,To Be Discontinued,,9/20/2024,,2025,discontinued
1514,Nortriptyline Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Nortriptyline Hydrochloride, Capsule, 75 mg (NDC 0093-0813-05)",New,5/23/2025,,Permanent discontinuation of specific package size/ SKU for business reasons.,,,Psychiatry,To Be Discontinued,,5/23/2025,,2025,discontinued
1515,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-15)",New,4/28/2025,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/2025,,2025,discontinued
1516,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-30)",New,4/28/2025,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/2025,,2025,discontinued
1517,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-60)",New,4/28/2025,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/2025,,2025,discontinued
1518,Ondansetron Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 4 mg (NDC 45963-538-30)",New,11/4/2024,,,,,Gastroenterology,To Be Discontinued,,11/4/2024,,2025,discontinued
1519,Ondansetron Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 8 mg (NDC 45963-539-30)",New,11/4/2024,,,,,Gastroenterology,To Be Discontinued,,11/4/2024,,2025,discontinued
1520,Oseltamivir Phosphate Capsule,"Genentech, Inc","Tamiflu, Capsule, 30 mg (NDC 0004-0802-85)",New,7/8/2025,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,7/8/2025,,2025,discontinued
1521,Oxaliplatin Injection,Novast Labs,"Oxaliplatin, Injection, 50 mg/10 mL (NDC 50742-405-10)",New,4/22/2025,,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,,,Oncology,To Be Discontinued,,4/22/2025,,2025,discontinued
1522,Oxaliplatin Injection,Novast Labs,"Oxaliplatin, Injection, 100 mg/20 mL (NDC 50742-406-20)",New,4/22/2025,,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,,,Oncology,To Be Discontinued,,4/22/2025,,2025,discontinued
1523,Oxaliplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 50 mg/10 mL (NDC 0703-3985-01)",New,10/11/2024,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/11/2024,,2025,discontinued
1524,Oxaliplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 100 mg/20 mL (NDC 0703-3986-01)",New,10/11/2024,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/11/2024,,2025,discontinued
1525,Oxaliplatin Injection,Sandoz Inc.,"Injection, 5 mg/1 mL (NDC 0781-9315-70)",New,10/16/2024,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/16/2024,,2025,discontinued
1526,Oxaliplatin Injection,Sandoz Inc.,"Injection, 5 mg/1 mL (NDC 0781-9317-80)",New,10/16/2024,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/16/2024,,2025,discontinued
1527,Oxaprozin Tablet,"Hospira, Inc., a Pfizer Company","Daypro, Tablet, 600 mg (NDC 0025-1381-31)",New,7/17/2025,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To Be Discontinued,,7/17/2025,,2025,discontinued
1528,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 10 mg (NDC 0228-2067-10)",Revised,7/3/2025,,,Available,,Neurology; Psychiatry,Resolved,7/3/2025,,,2025,
1529,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 15 mg (NDC 0228-2069-10)",Revised,7/3/2025,,,Available,,Neurology; Psychiatry,Resolved,7/3/2025,,,2025,
1530,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 30 mg (NDC 0228-2073-10)",Revised,7/3/2025,,,Available,,Neurology; Psychiatry,Resolved,7/3/2025,,,2025,
1531,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-00)",New,5/14/2025,,,,,Renal,To Be Discontinued,,5/14/2025,,2025,discontinued
1532,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-01)",New,5/14/2025,,,,,Renal,To Be Discontinued,,5/14/2025,,2025,discontinued
1533,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-10)",New,5/14/2025,,,,,Renal,To Be Discontinued,,5/14/2025,,2025,discontinued
1534,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-50)",New,5/14/2025,,,,,Renal,To Be Discontinued,,5/14/2025,,2025,discontinued
1535,Palivizumab Injection,Swedish Orphan Biovitrum AB,"Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01)",New,8/13/2025,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,8/13/2025,,2025,discontinued
1536,Palivizumab Injection,Swedish Orphan Biovitrum AB,"Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)",New,8/13/2025,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,8/13/2025,,2025,discontinued
1537,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-40)",New,12/5/2024,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/2024,,2025,discontinued
1538,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-44)",New,12/5/2024,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/2024,,2025,discontinued
1539,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-45)",New,12/5/2024,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/2024,,2025,discontinued
1540,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Reverified,8/15/2025,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,,2025,limited availability
1541,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Reverified,8/15/2025,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,,2025,limited availability
1542,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Reverified,8/15/2025,Unavailable,The 100 Mcg Cartridge Is No Longer Available And Takeda Is Unable To Resupply Prior To Ceasing Of Manufacturing Of Natpara At The End Of 2024.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,,2025,not available
1543,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Reverified,8/15/2025,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,,2025,limited availability
1544,Peginterferon alfa-2a Injection,pharmaand GmbH (pharma&),"Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)",Revised,8/19/2025,Limited Availability,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",,Shortage of an active ingredient,Antiviral,Current,,,,2025,limited availability
1545,Peginterferon alfa-2a Injection,pharmaand GmbH (pharma&),"Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)",Revised,8/19/2025,Limited Availability,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",,Shortage of an active ingredient,Antiviral,Current,,,,2025,limited availability
1546,Pemetrexed Ditromethamine Injection,Pfizer Inc.,"Pemetrexed Ditromethamine, Injection, 100 mg Single Dose Vial (NDC 0409-1060-01)",New,7/17/2025,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,,7/17/2025,,2025,discontinued
1547,Pemetrexed Ditromethamine Injection,Pfizer Inc.,"Pemetrexed Ditromethamine, Injection, 500 mg Single Dose Vial (NDC 0409-1061-01)",New,7/17/2025,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,,7/17/2025,,2025,discontinued
1548,Penicillin G Benzathine Injection,Laboratorios Atral,"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)",Reverified,7/18/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1549,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 1,200,000 units (NDC 81284-521-01)",Reverified,7/18/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1550,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 2,400,000 units (NDC 81284-522-01)",Reverified,7/18/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1551,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)",Revised,8/25/2025,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Anti-Infective,Current,,,,2025,not available
1552,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)",Revised,8/25/2025,Limited Availability,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,,2025,limited availability
1553,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)",Revised,8/25/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,,2025,not available
1554,Peritoneal Dialysis Solution,Baxter Healthcare,"Peritoneal Dialysis, Solution, Various NDCs (NDC 0941-0679-05)",Revised,7/7/2025,,,Available,,Renal,Resolved,7/7/2025,,,2025,
1555,Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Peritoneal Dialysis, Solution, Various NDCs (NDC 46163-206-94)",Revised,7/7/2025,,,Available,,Renal,Resolved,7/7/2025,,,2025,
1556,Phentermine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Adipex-P, Tablet, 37.5 mg (NDC 57844-140-01)",New,6/13/2025,,,,,Other,To Be Discontinued,,6/13/2025,,2025,discontinued
1557,Phentermine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Adipex-P, Tablet, 37.5 mg (NDC 57844-140-56)",New,6/13/2025,,,,,Other,To Be Discontinued,,6/13/2025,,2025,discontinued
1558,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 30gm (NDC 0187-5100-01)",New,2/28/2025,,Authorized generic is still marketed and available under NDC 68682-110-01,,,Dermatology,To Be Discontinued,,2/28/2025,,2025,discontinued
1559,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 60gm (NDC 0187-5101-02)",New,2/28/2025,,Authorized generics is still marketed and available under NDC 68682-111-02,,,Dermatology,To Be Discontinued,,2/28/2025,,2025,discontinued
1560,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 100gm (NDC 0187-5102-03)",New,2/28/2025,,Authorized generics is still marketed and available under NDC 68682-112-03,,,Dermatology,To Be Discontinued,,2/28/2025,,2025,discontinued
1561,Pirfenidone Capsule,"Genentech, Inc","Esbriet, Capsule, 267 mg (NDC 50242-121-01)",New,2/5/2025,,,,,Pulmonary/Allergy,To Be Discontinued,,2/5/2025,,2025,discontinued
1562,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-01)",New,5/19/2025,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/2025,,2025,discontinued
1563,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-05)",New,5/19/2025,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/2025,,2025,discontinued
1564,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-01)",New,5/19/2025,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/2025,,2025,discontinued
1565,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-05)",New,5/19/2025,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/2025,,2025,discontinued
1566,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-10)",New,5/19/2025,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/2025,,2025,discontinued
1567,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-90)",New,5/19/2025,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/2025,,2025,discontinued
1568,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-11)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1569,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-10)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1570,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-11)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1571,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-10)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1572,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-01)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1573,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-11)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1574,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-15)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1575,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-01)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1576,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-15)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1577,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-11)",New,7/23/2025,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/2025,,2025,discontinued
1578,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 5 meq (NDC 0591-2682-01)",New,7/17/2025,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/2025,,2025,discontinued
1579,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 10 meq (NDC 0591-2729-01)",New,7/17/2025,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/2025,,2025,discontinued
1580,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 15 meq (NDC 0591-2742-01)",New,7/17/2025,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/2025,,2025,discontinued
1581,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-10)",New,6/13/2025,,,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
1582,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-98)",New,6/13/2025,,,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
1583,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-10)",New,6/13/2025,,,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
1584,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-98)",New,6/13/2025,,,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
1585,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-10)",New,6/13/2025,,,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
1586,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-98)",New,6/13/2025,,,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
1587,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-10)",New,6/13/2025,,,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
1588,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-98)",New,6/13/2025,,,,,Cardiovascular,To Be Discontinued,,6/13/2025,,2025,discontinued
1589,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 1 mg (NDC 0069-4310-71)",New,4/28/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023,,,Cardiovascular,To Be Discontinued,4/28/2023,4/28/2023,,2025,discontinued
1590,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 2 mg (NDC 0069-4370-71)",New,4/28/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/2023,4/28/2023,,2025,discontinued
1591,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 5 mg (NDC 0069-4380-71)",New,4/28/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/2023,4/28/2023,,2025,discontinued
1592,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)",Reverified,8/4/2025,Unavailable,Next lots scheduled for release August 2025.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,,2025,not available
1593,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)",Reverified,8/4/2025,Available,,,,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,,2025,available
1594,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)",Revised,7/23/2025,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2025,not available
1595,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)",Revised,7/23/2025,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2025,not available
1596,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)",Revised,7/23/2025,Unavailable,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2025,not available
1597,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)",Revised,7/23/2025,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2025,available
1598,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 25 mg/1 mL (NDC 0641-6084-25)",Revised,7/23/2025,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2025,not available
1599,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 50 mg/1 mL (NDC 0641-6085-25)",Revised,7/23/2025,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2025,not available
1600,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6082-25)",Revised,7/23/2025,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2025,available
1601,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 50 mg/1 mL (NDC 0641-6083-25)",Revised,7/23/2025,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2025,available
1602,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 225 mg (NDC 0832-0740-60)",New,5/14/2025,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/2025,,2025,discontinued
1603,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 325 mg (NDC 0832-0741-60)",New,5/14/2025,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/2025,,2025,discontinued
1604,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 425 mg (NDC 0832-0742-60)",New,5/14/2025,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/2025,,2025,discontinued
1605,Propranolol Hydrochloride Injection,"Fresenius Kabi USA, LLC","Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2025,available
1606,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)",Reverified,7/23/2025,Unavailable,,,Shortage of an active ingredient,Cardiovascular,Current,,,,2025,not available
1607,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1608,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1609,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1610,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1611,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)",Reverified,6/27/2025,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2025,not available
1612,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)",Reverified,6/27/2025,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2025,not available
1613,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)",Reverified,6/27/2025,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2025,not available
1614,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)",Reverified,6/27/2025,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2025,not available
1615,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)",Reverified,8/19/2025,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2025,not available
1616,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)",Reverified,8/19/2025,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2025,not available
1617,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)",Reverified,8/19/2025,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2025,not available
1618,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)",Reverified,8/19/2025,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2025,not available
1619,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)",Reverified,6/25/2025,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2025,discontinued
1620,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Reverified,6/25/2025,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2025,discontinued
1621,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Reverified,6/25/2025,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2025,discontinued
1622,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)",Reverified,6/25/2025,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2025,discontinued
1623,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 40 mg (NDC 0071-0535-23)",Reverified,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,,2025,not available
1624,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 10 mg (NDC 0071-0530-23)",Reverified,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,,2025,not available
1625,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 20 mg (NDC 0071-0532-23)",Reverified,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,,2025,not available
1626,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 5 mg (NDC 0071-0527-23)",Reverified,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,,2025,not available
1627,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)",Reverified,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,,2025,not available
1628,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)",Reverified,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,,2025,not available
1629,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)",Reverified,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,,2025,not available
1630,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)",Reverified,6/25/2025,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2025,discontinued
1631,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)",Reverified,6/25/2025,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2025,discontinued
1632,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)",Reverified,6/25/2025,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2025,discontinued
1633,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1634,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1635,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)",Reverified,8/19/2025,Available,,,,Cardiovascular,Current,,,,2025,available
1636,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-01)",New,1/8/2025,,,,,Other,To Be Discontinued,,1/8/2025,,2025,discontinued
1637,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-10)",New,1/8/2025,,,,,Other,To Be Discontinued,,1/8/2025,,2025,discontinued
1638,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-30)",New,1/8/2025,,,,,Other,To Be Discontinued,,1/8/2025,,2025,discontinued
1639,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 50268-708-15)",New,1/8/2025,,,,,Other,To Be Discontinued,,1/8/2025,,2025,discontinued
1640,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 72162-2169-3)",New,1/8/2025,,,,,Other,To Be Discontinued,,1/8/2025,,2025,discontinued
1641,Ramipril Capsule,Pfizer Inc.,"Altace, Capsule, 2.5 mg (NDC 61570-111-01)",New,1/30/2025,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,1/30/2025,,2025,discontinued
1642,Ramipril Capsule,Pfizer Inc.,"Altace, Capsule, 10 mg (NDC 61570-120-01)",New,1/30/2025,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,1/30/2025,,2025,discontinued
1643,"Ranolazine Granules, Extended Release","Sun Pharmaceutical Industries, Inc.","Aspruzyo Sprinkle, Granules, Extended Release, 500 mg (NDC 47335-624-60)",New,9/20/2024,,,,,Cardiovascular,To Be Discontinued,,9/20/2024,,2025,discontinued
1644,"Ranolazine Granules, Extended Release","Sun Pharmaceutical Industries, Inc.","Aspruzyo Sprinkle, Granules, Extended Release, 1000 mg (NDC 47335-625-60)",New,9/20/2024,,,,,Cardiovascular,To Be Discontinued,,9/20/2024,,2025,discontinued
1645,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 2 mg (NDC 72078-035-02)",Reverified,9/3/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1646,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 5 mg (NDC 72078-036-05)",Reverified,9/3/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1647,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)",Reverified,7/23/2025,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
1648,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)",Reverified,7/23/2025,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
1649,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)",Reverified,7/23/2025,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2025,not available
1650,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2025,available
1651,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2025,available
1652,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2025,available
1653,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)",Reverified,9/3/2025,Available,,,,Analgesia/Addiction,Current,,,,2025,available
1654,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 150 mg (NDC 42806-801-30)",Reverified,9/2/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1655,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 150 mg (NDC 42806-801-01)",Reverified,9/2/2025,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2025,not available
1656,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-30)",Reverified,9/2/2025,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2025,not available
1657,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-60)",Reverified,9/2/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1658,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-01)",Reverified,9/2/2025,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2025,not available
1659,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-05)",Reverified,9/2/2025,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2025,not available
1660,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 150 mg (NDC 68180-658-06)",Reverified,8/19/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1661,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-06)",Reverified,8/19/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1662,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-07)",Reverified,8/19/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1663,Rifampin Injection,"Fresenius Kabi USA, LLC","Rifampin, Injection, 600 mg (NDC 63323-351-20)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anti-Infective,Current,,,,2025,available
1664,Rifampin Injection,Sanofi-Aventis U.S. LLC,"Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)",Reverified,6/27/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1665,Rifampin Injection,"Mylan Institutional, a Viatris Company","Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)",Reverified,9/3/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1666,"Rifapentine Tablet, Film Coated",Sanofi-Aventis U.S. LLC,"Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)",Reverified,6/27/2025,Available,,,,Anti-Infective,Current,,,,2025,available
1667,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)",Reverified,9/2/2025,Available,,,,Neurology,Current,,,,2025,available
1668,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)",Reverified,9/2/2025,Available,,,,Neurology,Current,,,,2025,available
1669,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2)",Reverified,9/2/2025,Unavailable,Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to viscosity testing,,Requirements related to complying with good manufacturing practices,Neurology,Current,,,,2025,not available
1670,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)",Reverified,9/2/2025,Available,,,,Neurology,Current,,,,2025,available
1671,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)",Reverified,8/19/2025,Limited Availability,On allocation,,Demand increase for the drug,Anesthesia,Current,,,,2025,limited availability
1672,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1673,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1674,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1675,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)",Reverified,9/2/2025,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1676,Rocuronium Bromide Injection,Eugia US LLC,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1677,Rocuronium Bromide Injection,Eugia US LLC,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1678,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1679,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1680,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1681,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)",Reverified,7/23/2025,Available,Additional lots will be available.  Product will be made available as it is released.,,,Anesthesia,Current,,,,2025,available
1682,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)",Reverified,7/23/2025,Available,,,,Anesthesia,Current,,,,2025,available
1683,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1684,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)",Reverified,9/2/2025,Unavailable,Backordered. Next release October 2025. Check wholesaers for inventory.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1685,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)",Reverified,9/4/2025,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,,,2025,available
1686,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)",Reverified,9/4/2025,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,,,2025,available
1687,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)",Reverified,8/26/2025,Available,,,,Anesthesia,Current,,,,2025,available
1688,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)",Reverified,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1689,Rocuronium Bromide Injection,Sandoz Inc.,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
1690,Rocuronium Bromide Injection,Sandoz Inc.,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
1691,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
1692,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
1693,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
1694,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)",Reverified,8/15/2025,Available,,,,Anesthesia,Current,,,,2025,available
1695,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)",Reverified,8/26/2025,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2025,available
1696,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)",Reverified,8/26/2025,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2025,available
1697,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1698,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1699,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1700,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1701,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1702,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1703,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)",Reverified,8/19/2025,Available,,,,Anesthesia,Current,,,,2025,available
1704,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)",Reverified,8/26/2025,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2025,available
1705,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)",Reverified,8/26/2025,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2025,available
1706,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)",Reverified,8/26/2025,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2025,available
1707,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)",Reverified,8/26/2025,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2025,available
1708,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)",Reverified,9/2/2025,Limited Availability,Check wholesalers for inventory; Marketed by Baxter,,Other,Anesthesia,Current,,,,2025,limited availability
1709,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory; Marketed by Baxter,,,Anesthesia,Current,,,,2025,available
1710,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)",Reverified,9/2/2025,Limited Availability,Limited supply; Check wholesalers for inventory; Marketed by Baxter,,Other,Anesthesia,Current,,,,2025,limited availability
1711,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory; Marketed by Baxter,,,Anesthesia,Current,,,,2025,available
1712,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1713,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1714,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1715,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1716,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1717,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)",Revised,8/21/2025,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1718,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)",Revised,8/21/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1719,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)",Revised,9/3/2025,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1720,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)",Revised,9/3/2025,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1721,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)",Revised,9/3/2025,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1722,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)",Revised,9/3/2025,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2025,not available
1723,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)",Revised,9/3/2025,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1724,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)",Revised,9/3/2025,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1725,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)",Revised,9/3/2025,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1726,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)",Revised,9/3/2025,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1727,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)",Revised,9/3/2025,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2025,available
1728,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1729,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1730,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1731,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1732,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1733,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1734,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1735,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1736,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1737,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1738,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)",Revised,9/3/2025,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,,2025,not available
1739,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1740,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)",Revised,9/3/2025,Available,,,,Anesthesia,Current,,,,2025,available
1741,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-01)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1742,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-03)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1743,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-05)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1744,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-01)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1745,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-03)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1746,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-05)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1747,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-01)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1748,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-03)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1749,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-05)",New,1/22/2025,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/2025,,2025,discontinued
1750,Silodosin Capsule,AbbVie Inc.,"Rapaflo, Capsule, 4 mg (NDC 0023-6147-30)",New,2/20/2025,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,,,Urology,To Be Discontinued,,2/20/2025,,2025,discontinued
1751,Silodosin Capsule,AbbVie Inc.,"Rapaflo, Capsule, 8 mg (NDC 0023-6142-30)",New,2/20/2025,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,,,Urology,To Be Discontinued,,2/20/2025,,2025,discontinued
1752,Silver Nitrate Solution,"Teva Pharmaceuticals USA, Inc.","Solution, .005 g/1 mL (NDC 0093-9614-13)",New,10/15/2024,,,,,Dermatology,To Be Discontinued,,10/15/2024,,2025,discontinued
1753,Sodium Acetate Injection,"Fresenius Kabi USA, LLC","Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Total Parenteral Nutrition,Current,,,,2025,available
1754,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2025,available
1755,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2025,available
1756,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2025,available
1757,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)",Reverified,9/2/2025,Available,,,,Total Parenteral Nutrition,Current,,,,2025,available
1758,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)",Reverified,9/2/2025,Available,,,,Total Parenteral Nutrition,Current,,,,2025,available
1759,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2025,available
1760,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2025,available
1761,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2025,available
1762,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 69784-232-01)",Reverified,9/2/2025,Limited Availability,Limited Availability,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2025,limited availability
1763,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 69784-229-10)",Reverified,9/2/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2025,available
1764,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)",Revised,9/2/2025,Available,Next batch release expected in 2 weeks.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
1765,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)",Reverified,9/2/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
1766,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/2025,,,2025,limited availability
1767,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/2025,,,2025,available
1768,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/2025,,,2025,not available
1769,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)",Reverified,8/15/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
1770,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)",Revised,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: March 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/2025,,,2025,not available
1771,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)",Revised,8/15/2025,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/2025,,,2025,not available
1772,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)",Revised,8/15/2025,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/2025,,,2025,not available
1773,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)",Revised,8/15/2025,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/2025,,,2025,not available
1774,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc.","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)",Reverified,8/19/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
1775,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
1776,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)",Reverified,9/2/2025,Unavailable,Backordered. Next release October 2025. Check wholesalers for inventory.,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,not available
1777,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)",Revised,9/2/2025,Limited Availability,Over 3 weeks in Channel. Next release 9/8/25,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,limited availability
1778,Sodium Bicarbonate Injection,Long Grove Pharmaceuticals LLC,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)",Reverified,6/27/2025,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2025,available
1779,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-00)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1780,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-10)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1781,Sodium Chloride 0.9% Injection,Fresenius Medical Care North America,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 46163-300-10)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Gastroenterology; Renal,To Be Discontinued,,6/10/2025,,2025,discontinued
1782,Sodium Chloride 0.9% Injection,Fresenius Medical Care North America,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 49230-300-10)",New,6/10/2025,,Discontinuation of the manufacture of the drug,,,Gastroenterology; Renal,To Be Discontinued,,6/10/2025,,2025,discontinued
1783,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-02)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1784,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-10)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1785,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-20)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1786,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 63323-186-00)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1787,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-10)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1788,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-12)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1789,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-20)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1790,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-50)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1791,Sodium Chloride 0.9% Injection,"Medefil, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 64253-202-30)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1792,Sodium Chloride 0.9% Injection,"Hikma Pharmaceuticals USA, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 0641-0497-25)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1793,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9%, Injection, 4 meq/1 mL (NDC 63323-095-61)",Revised,8/8/2025,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,8/8/2025,,,2025,
1794,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-13)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1795,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-36)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1796,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-37)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1797,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-23)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1798,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-20)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1799,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-81)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1800,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-27)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1801,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-30)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1802,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-10)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1803,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-12)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1804,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-05)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1805,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-07)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1806,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1510-1)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1807,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1505-1)",Revised,8/8/2025,,,Available,,Other,Resolved,8/8/2025,,,2025,
1808,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-00)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1809,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-10)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1810,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-20)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1811,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-09)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1812,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-32)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1813,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-31)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1814,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-36)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1815,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-66)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1816,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-67)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1817,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-02)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1818,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-21)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1819,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-31)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1820,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-01)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1821,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-41)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1822,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-11)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1823,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-466-60)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1824,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-468-50)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1825,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-472-20)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1826,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-474-10)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1827,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-18)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1828,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-41)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1829,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-48)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1830,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-31)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1831,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-02)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1832,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-03)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1833,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-04)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1834,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-10)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1835,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-11)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1836,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-38)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1837,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1838,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1839,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1840,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-11)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1841,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 450 mg/100 mL (NDC 0338-9151-30)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1842,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-9159-30)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1843,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-18)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1844,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1845,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1846,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1847,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-00)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1848,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-10)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1849,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-03)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1850,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-09)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1851,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 50 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1852,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 100 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1853,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 250 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1854,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 500 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1855,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 1000 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1856,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-61)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1857,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-02)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1858,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-55)",Revised,8/8/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/2025,,,2025,
1859,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-02)",Revised,7/2/2025,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1860,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-03)",Revised,7/2/2025,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1861,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-04)",Revised,7/2/2025,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1862,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-22)",Revised,7/2/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1863,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-03)",Revised,7/2/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1864,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-09)",Revised,7/2/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1865,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-36)",Revised,7/2/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1866,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-60)",Revised,7/2/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1867,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-50)",Revised,7/2/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1868,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-10)",Revised,7/2/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1869,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-00)",Revised,7/2/2025,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/2025,,,2025,
1870,Sodium Chloride 23.4% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride, Injection, 400 mEq/100 mL (4 mEq/mL) (NDC 0409-1141-02)",Revised,7/2/2025,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,7/2/2025,,,2025,
1871,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-099-63)",Revised,7/2/2025,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,7/2/2025,,,2025,
1872,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-093-30)",Revised,7/2/2025,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,7/2/2025,,,2025,
1873,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 5 mg/1.5 mL (NDC 0169-7704-21)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1874,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 10 mg/1.5 mL (NDC 0169-7705-21)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1875,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 15 mg/1.5 mL (NDC 0169-7708-21)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1876,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1877,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 5 mg/1.5 mL (NDC 0781-3001-07)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1878,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 10 mg/1.5 mL (NDC 0781-3004-07)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1879,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 12 mg/cartridge (NDC 0002-8148-01)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1880,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 24 mg/cartridge (NDC 0002-8149-01)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1881,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 5 mg/mL, w/ preservative (NDC 0013-2626-81)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1882,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 12 mg/mL, w/ preservative (NDC 0013-2646-81)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1883,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.2 mg preservative free (NDC 0013-2649-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1884,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.4 mg preservative free (NDC 0013-2650-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1885,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.6 mg preservative free (NDC 0013-2651-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1886,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.8 mg preservative free (NDC 0013-2652-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1887,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.0 mg preservative free (NDC 0013-2653-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1888,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.2 mg preservative free (NDC 0013-2654-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1889,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.4 mg preservative free (NDC 0013-2655-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1890,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.6 mg preservative free (NDC 0013-2656-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1891,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.8 mg preservative free (NDC 0013-2657-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1892,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 2.0 mg preservative free (NDC 0013-2658-02)",Revised,8/28/2025,,,Available,,Endocrinology/Metabolism,Resolved,8/28/2025,,,2025,
1893,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 6 mg (0002-8147-01): 1 TRAY in 1 CARTON (0002-8147-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7554-01) * 2.88 mL in 1 SYRINGE (0002-7618-01) (NDC 0002-8147-01)",New,10/29/2024,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/2024,,2025,discontinued
1894,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 12 mg (0002-8148-01): 1 TRAY in 1 CARTON (0002-8148-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7555-01) * 2.88 mL in 1 SYRINGE (0002-7619-01) (NDC 0002-8148-01)",New,10/29/2024,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/2024,,2025,discontinued
1895,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 24 mg (0002-8149-01): 1 TRAY in 1 CARTON (0002-8149-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7556-01) * 2.88 mL in 1 SYRINGE (0002-7619-01) (NDC 0002-8149-01)",New,10/29/2024,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/2024,,2025,discontinued
1896,Sterile Water Injection,"Hikma Pharmaceuticals USA, Inc.","Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)",Reverified,7/23/2025,Available,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,,Other,Current,,,,2025,available
1897,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)",Reverified,8/15/2025,Available,,,,Other,Current,,,,2025,available
1898,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)",Reverified,8/15/2025,Available,,,,Other,Current,,,,2025,available
1899,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)",Reverified,8/15/2025,Available,,,,Other,Current,,,,2025,available
1900,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)",Reverified,8/15/2025,Available,,,,Other,Current,,,,2025,available
1901,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Other,Current,,,,2025,available
1902,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Other,Current,,,,2025,available
1903,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Other,Current,,,,2025,available
1904,Sterile Water Injection,"Medefil, Inc.","Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)",Reverified,8/15/2025,Available,,,,Other,Current,,,,2025,available
1905,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)",Revised,8/15/2025,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Other,Current,,,,2025,limited availability
1906,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)",Reverified,9/2/2025,Available,Check wholesalers for inventory,,,Other,Current,,,,2025,available
1907,Sterile Water Injection,Nephron Pharmaceuticals Corporation,"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)",Reverified,7/2/2025,Unavailable,Product can be manufactured as requested,,Other,Other,Current,,,,2025,not available
1908,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)",Reverified,8/20/2025,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,,,2025,not available
1909,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)",Reverified,8/20/2025,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,,,2025,limited availability
1910,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)",Reverified,8/20/2025,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,,,2025,limited availability
1911,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)",Reverified,8/20/2025,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,,,2025,limited availability
1912,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)",Reverified,9/3/2025,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2025,available
1913,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)",Reverified,9/3/2025,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2025,available
1914,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)",Reverified,9/3/2025,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2025,available
1915,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",Reverified,8/21/2025,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2025,available
1916,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",Reverified,8/21/2025,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2025,available
1917,"Streptozocin Powder, For Solution","ESTEVE PHARMACEUTICALS, S.A.","Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)",Revised,6/30/2025,Available,,,,Oncology,Current,,,,2025,available
1918,"Streptozocin Powder, For Solution","Teva Pharmaceuticals USA, Inc.","Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)",Revised,8/19/2025,Unavailable,Estimated recovery: TBD,,Other,Oncology,Current,,,,2025,not available
1919,Sufentanil Citrate Injection,"Hospira, Inc., a Pfizer Company","Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)",Revised,8/15/2025,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2025,available
1920,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)",Reverified,7/23/2025,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
1921,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)",Revised,7/23/2025,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
1922,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)",Revised,7/23/2025,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,,,2025,not available
1923,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .25 mg (NDC 0069-0296-30)",New,1/13/2025,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0353-30",,,Oncology,To Be Discontinued,,1/13/2025,,2025,discontinued
1924,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .1 mg (NDC 0069-1031-30)",New,1/13/2025,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0252-30",,,Oncology,To Be Discontinued,,1/13/2025,,2025,discontinued
1925,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, 1 mg (NDC 0069-1195-30)",New,1/13/2025,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0757-30",,,Oncology,To Be Discontinued,,1/13/2025,,2025,discontinued
1926,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .35 mg (NDC 0069-1235-30)",New,1/13/2025,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0454-30",,,Oncology,To Be Discontinued,,1/13/2025,,2025,discontinued
1927,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .5 mg (NDC 0069-1501-30)",New,1/13/2025,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0546-30",,,Oncology,To Be Discontinued,,1/13/2025,,2025,discontinued
1928,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .75 mg (NDC 0069-1751-30)",New,1/13/2025,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0655-30",,,Oncology,To Be Discontinued,,1/13/2025,,2025,discontinued
1929,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-01)",New,4/10/2025,,,,,Urology,To Be Discontinued,,4/10/2025,,2025,discontinued
1930,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-10)",New,4/10/2025,,,,,Urology,To Be Discontinued,,4/10/2025,,2025,discontinued
1931,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-92)",New,4/10/2025,,,,,Urology,To Be Discontinued,,4/10/2025,,2025,discontinued
1932,Tbo-filgrastim Injection,"Cephalon, LLC","Granix, Injection, 480 ug/1.6 mL (NDC 63459-920-59)",New,6/13/2025,,,,,Hematology,To Be Discontinued,,6/13/2025,,2025,discontinued
1933,Technetium TC-99M Pyrophosphate Kit Injection,Curium US LLC,"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)",Reverified,9/2/2025,Unavailable,Unavailable,,Shortage of an active ingredient,Medical Imaging,Current,,,,2025,not available
1934,Technetium TC-99M Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)",Revised,8/20/2025,Limited Availability,Additional supply anticipated early 2026,,Shortage of an active ingredient,Medical Imaging,Current,,,,2025,limited availability
1935,Technetium TC-99M Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)",Revised,8/20/2025,Limited Availability,Additional supply anticipated early 2026,,Shortage of an active ingredient,Medical Imaging,Current,,,,2025,limited availability
1936,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 20 mg (NDC 0597-0039-37)",New,10/22/2024,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/2024,,2025,discontinued
1937,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 40 mg (NDC 0597-0040-37)",New,10/22/2024,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/2024,,2025,discontinued
1938,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 80 mg (NDC 0597-0041-37)",New,10/22/2024,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/2024,,2025,discontinued
1939,Teriflunomide Tablet,Apotex Corp.,"Teriflunomide, Tablet, 7 mg (NDC 60505-4477-3)",New,1/28/2025,,,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
1940,Teriflunomide Tablet,Apotex Corp.,"Teriflunomide, Tablet, 14 mg (NDC 60505-4478-3)",New,1/28/2025,,,,,Neurology,To Be Discontinued,,1/28/2025,,2025,discontinued
1941,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0009-0086-10)",New,9/25/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/2024,,2025,discontinued
1942,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0409-6562-02)",New,9/25/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/2024,,2025,discontinued
1943,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0409-6562-22)",New,9/25/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/2024,,2025,discontinued
1944,"Testosterone Gel; Gel, Metered","Actavis Pharma, Inc.","Testosterone, Gel; Gel, Metered, 16.2 mg/1 g (NDC 0591-2925-30)",New,6/16/2025,,Discontinuation of the manufacture of the drug,,,Urology,To Be Discontinued,,6/16/2025,,2025,discontinued
1945,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-83)",New,12/9/2024,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/2024,,2025,discontinued
1946,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-18)",New,12/9/2024,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/5/2024,,2025,discontinued
1947,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-83)",New,12/9/2024,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/2024,,2025,discontinued
1948,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-88)",New,12/9/2024,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/2024,,2025,discontinued
1949,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-08)",New,12/9/2024,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/2024,,2025,discontinued
1950,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-18)",New,12/9/2024,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/2024,,2025,discontinued
1951,Tigecycline Injection,"Fresenius Kabi USA, LLC","Injection, 50 mg/5 mL (NDC 63323-960-10)",New,12/9/2024,,Check wholesalers for inventory.,,,Anti-Infective,To Be Discontinued,,12/9/2024,,2025,discontinued
1952,Tigecycline Injection,Sandoz Inc.,"Tigecycline, Injection, 50 mg/10 mL (NDC 0781-3481-92)",New,1/17/2025,,,,,Anti-Infective,To Be Discontinued,,1/17/2025,,2025,discontinued
1953,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-28)",New,6/16/2025,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/2025,,2025,discontinued
1954,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-63)",New,6/16/2025,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/2025,,2025,discontinued
1955,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/5 mL (NDC 0093-4085-63)",New,6/16/2025,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/2025,,2025,discontinued
1956,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-77)",New,2/26/2025,,,,,Urology,To Be Discontinued,,2/26/2025,,2025,discontinued
1957,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-93)",New,2/26/2025,,,,,Urology,To Be Discontinued,,2/26/2025,,2025,discontinued
1958,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-77)",New,2/26/2025,,,,,Urology,To Be Discontinued,,2/26/2025,,2025,discontinued
1959,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-93)",New,2/26/2025,,,,,Urology,To Be Discontinued,,2/26/2025,,2025,discontinued
1960,Tolterodine Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Detrol, Tablet, 1 mg (NDC 58151-098-91)",New,2/26/2025,,,,,Urology,To Be Discontinued,,2/26/2025,,2025,discontinued
1961,Tolterodine Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Detrol, Tablet, 2 mg (NDC 58151-099-91)",New,2/26/2025,,,,,Urology,To Be Discontinued,,2/26/2025,,2025,discontinued
1962,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 25 mg (NDC 0245-1071-30)",New,4/24/2025,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/2025,,2025,discontinued
1963,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 50 mg (NDC 0245-1072-30)",New,4/24/2025,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/2025,,2025,discontinued
1964,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 200 mg (NDC 0245-1073-30)",New,4/24/2025,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/2025,,2025,discontinued
1965,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 100 mg (NDC 0245-1074-30)",New,4/24/2025,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/2025,,2025,discontinued
1966,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 150 mg (NDC 0245-1075-30)",New,4/24/2025,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/2025,,2025,discontinued
1967,Travoprost Solution/Drops,Sandoz Inc.,"Travatan Z, Solution/Drops, 2.5 mL (NDC 0781-6185-56)",New,3/18/2025,,Business related decision to discontinue the product,,,Ophthalmology,To Be Discontinued,,3/18/2025,,2025,discontinued
1968,Travoprost Solution/Drops,Sandoz Inc.,"Travatan Z, Solution/Drops, 5 mL (NDC 0781-6185-75)",New,3/18/2025,,Business related decision to discontinue the product,,,Ophthalmology,To Be Discontinued,,3/18/2025,,2025,discontinued
1969,Tretinoin Cream,"Mylan Pharmaceuticals Inc., a Viatris Company","Avita, Cream, .25 mg/1 g (NDC 0472-0117-20)",New,2/4/2025,,,,,Dermatology,To Be Discontinued,,2/4/2025,,2025,discontinued
1970,Tretinoin Cream,"Mylan Pharmaceuticals Inc., a Viatris Company","Avita, Cream, .25 mg/1 g (NDC 0472-0117-45)",New,2/4/2025,,,,,Dermatology,To Be Discontinued,,2/4/2025,,2025,discontinued
1971,Triamcinolone Acetonide Injection,"Harrow Eye, LLC","Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)",Reverified,6/27/2025,Limited Availability,Estimated duration: 12 months,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2025,limited availability
1972,Triamcinolone Hexacetonide Injection,Medexus,"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)",Reverified,6/27/2025,Unavailable,,,Delay in shipping of the drug,Rheumatology,Current,,,,2025,not available
1973,Ursodiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ursodiol, Tablet, 250 mg (NDC 0591-2998-01)",New,3/28/2025,,A business decision was made to discontinue manufacture of the drug.,,,Other,To Be Discontinued,,3/28/2025,,2025,discontinued
1974,Ursodiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ursodiol, Tablet, 500 mg (NDC 0591-3005-01)",New,3/28/2025,,A business decision was made to discontinue manufacture of the drug.,,,Other,To Be Discontinued,,3/28/2025,,2025,discontinued
1975,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)",Revised,7/23/2025,Unavailable,Additional Lots scheduled to be available in the October 2025 timeframe.,,Demand increase for the drug,Neurology,Current,,,,2025,not available
1976,Valproate Sodium Injection,"Fresenius Kabi USA, LLC","Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)",Reverified,9/2/2025,Available,Checkwholesalers for inventory,,,Neurology,Current,,,,2025,available
1977,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, .5 mg (NDC 0378-5089-73)",New,2/6/2025,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/2025,,2025,discontinued
1978,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, 1 mg (NDC 0378-5090-73)",New,2/6/2025,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/2025,,2025,discontinued
1979,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, 0.5mg/1mg  (NDC 0378-5091-85)",New,2/6/2025,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/2025,,2025,discontinued
1980,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 120 mg (NDC 0591-2880-01)",New,1/23/2025,,,,,Cardiovascular,To Be Discontinued,,1/23/2025,,2025,discontinued
1981,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 180 mg (NDC 0591-2882-01)",New,1/23/2025,,,,,Cardiovascular,To Be Discontinued,,1/23/2025,,2025,discontinued
1982,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 240 mg (NDC 0591-2884-01)",New,1/23/2025,,,,,Cardiovascular,To Be Discontinued,,1/23/2025,,2025,discontinued
1983,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 360 mg (NDC 0591-2886-01)",New,1/23/2025,,,,,Cardiovascular,To Be Discontinued,,1/23/2025,,2025,discontinued
1984,Voriconazole Tablet,Pfizer Inc.,"Vfend, Tablet, 50 mg (NDC 0049-3170-30)",New,7/28/2025,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,,7/28/2025,,2025,discontinued
1985,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 500 mg (NDC 72786-101-01)",New,9/27/2024,,,,,Hematology,To Be Discontinued,,9/27/2024,,2025,discontinued
1986,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-102-02)",New,9/27/2024,,,,,Hematology,To Be Discontinued,,9/27/2024,,2025,discontinued
1987,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-102-03)",New,9/27/2024,,,,,Hematology,To Be Discontinued,,9/27/2024,,2025,discontinued
1988,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-111-03)",New,9/27/2024,,,,,Hematology,To Be Discontinued,,9/27/2024,,2025,discontinued
1989,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-111-02)",New,9/27/2024,,,,,Hematology,To Be Discontinued,,9/27/2024,,2025,discontinued
1990,Zileuton Tablet,"Chiesi USA, Inc.","Zyflo, Tablet, 600 mg (NDC 10122-901-12)",New,4/1/2025,,,,,Pulmonary/Allergy,To Be Discontinued,,4/1/2025,,2025,discontinued
1991,Abciximab (ReoPro) Injection,"Janssen Biotech, Inc.",2mg/mL (NDC 57894-200-01),Revised,8/15/2019,,Janssen has made a business decision to discontinue manufacture of the drug product.,,,Cardiovascular,To be Discontinued,8/15/2019,8/15/2019,,2019,discontinued
1992,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 25 mg (NDC 50419-863-51),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/2019,2/1/2019,,2019,discontinued
1993,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 50 mg (NDC 50419-861-51),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/2019,2/1/2019,,2019,discontinued
1994,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 100 mg (NDC 50419-862-51),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/2019,2/1/2019,,2019,discontinued
1995,Acarbose (Precose) Tablets,Bayer,Unit Dose 50 mg (NDC 50419-861-48),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/2019,2/1/2019,,2019,discontinued
1996,Acyclovir (Zovirax) Tablets and Capsules,Mylan Pharmaceuticals Inc.,Acyclovir (Zovirax) 200mg Capsules 100s (NDC 40076-991-55),New,12/21/2018,,,,,Anti-Infective,To be Discontinued,12/21/2018,12/21/2018,,2019,discontinued
1997,Acyclovir (Zovirax) Tablets and Capsules,Mylan Pharmaceuticals Inc.,Acyclovir (Zovirax) 400mg Tablets 100s (NDC 40076-949-55),New,12/21/2018,,,,,Anti-Infective,To be Discontinued,12/21/2018,12/21/2018,,2019,discontinued
1998,Acyclovir (Zovirax) Tablets and Capsules,Mylan Pharmaceuticals Inc.,Acyclovir (Zovirax) 800mg Tablets 100s (NDC 40076-945-55),New,12/21/2018,,,,,Anti-Infective,To be Discontinued,12/21/2018,12/21/2018,,2019,discontinued
1999,"Acyclovir Capsules, USP",Teva Pharmaceuticals,"200 mg, 100 count (NDC 0093-8940-01)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2019,discontinued
2000,"Acyclovir Capsules, USP",Teva Pharmaceuticals,"200 mg, 500 count (NDC 0093-8940-05)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2019,discontinued
2001,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"400 mg, 100 count (NDC 0093-8943-01)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2019,discontinued
2002,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"400 mg, 500 count (NDC 0093-8943-05)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2019,discontinued
2003,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"800 mg, 100 count (NDC 0093-8947-01)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2019,discontinued
2004,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"800 mg, 500 count, (NDC 0093-8947-05)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2019,discontinued
2005,Albuterol Sulfate and Ipratropium Bromide Inhalation Solution,Teva Pharmaceuticals,0.3 mg mg/3 mL and 0.5 mg/3 mL (NDC 0591-3817-39),New,7/3/2019,,This product discontinuation is a business related decision.,,,Pulmonary/Allergy,To be Discontinued,7/3/2019,7/3/2019,,2019,discontinued
2006,Alogliptin Tablets,Perrigo Company PLC,"12.5mg, 30 Tablets (NDC 45802-0103-65)",Revised,12/10/2019,On backorder – expected release the week of late December/early January,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2019,not available
2007,Alogliptin Tablets,Perrigo Company PLC,"25mg, 30 Tablets (NDC 45802-0150-65)",Revised,12/10/2019,On backorder – expected release the week of 12/16/2019,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2019,not available
2008,Alogliptin Tablets,Perrigo Company PLC,"6.25mg, 30 Tablets (NDC 45802-0087-65)",Revised,12/10/2019,On backorder – expected release the week of 01/27/2020,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2019,not available
2009,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"6.25 mg, 30 Tablets (NDC 64764-625-30)",New,8/15/2019,Product available.,,,,Endocrinology/Metabolism,Current,,,,2019,available
2010,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"12.5 mg, 30 Tablets (NDC 64764-125-30)",New,8/15/2019,Product available.,,,,Endocrinology/Metabolism,Current,,,,2019,available
2011,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"25 mg, 30 Tablets (NDC 64764-250-30)",New,8/15/2019,Product available.,,,,Endocrinology/Metabolism,Current,,,,2019,available
2012,Amino Acids,B. Braun Medical Inc.,"15% Amino Acid (Plenamine) Pharmacy Bulk Package in 1,000 mL plastic container, catalog S4500, (NDC 0264-4500-00)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2013,Amino Acids,B. Braun Medical Inc.,"15% Amino Acid (Plenamine) in 1,000mL glass container, catalog S3200-SS, (NDC 0264-3200-55)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,9/24/2019,,2019,
2014,Amino Acids,B. Braun Medical Inc.,"10% FreAmine III (Amino Acid Injection) in 1,000mL glass container, catalog S9010-SS, (NDC 0264-9010-55)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2015,Amino Acids,B. Braun Medical Inc.,"TrophAmine (10% Amino Acid Injection) in 500mL glass container, catalog S9341-SS, (NDC 0264-9341-55)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2016,Amino Acids,B. Braun Medical Inc.,"TrophAmine (6% Amino Acid Injection) in 500mL glass container, catalog S9361-SS, (NDC 0264-9361-55)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2017,Amino Acids,"ICU Medical, Inc.","AMINOSYN™-PF 7%, Sulfite-Free, 500 mL (NDC 0409-4178-03)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2018,Amino Acids,"ICU Medical, Inc.","AMINOSYN II 10%, Sulfite-Free, (Pediatric Formula) 1000 mL (NDC 0409-4179-05)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2019,Amino Acids,"ICU Medical, Inc.",Aminosyn II 10% Sulfite-Free BLK PK 2000 mL (NDC 0409-7172-17),Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2020,Amino Acids,"ICU Medical, Inc.",Aminosyn II 15% Sulfite-Free BLK PK 2000 mL (NDC 0409-7171-17),Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2021,Amino Acids,Baxter Healthcare,"PREMASOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 2B0009 10% 1000 mL (NDC 0338-1130-04), 2B0010 10% 2000 mL (NDC 0338-1130-06),
2B0012 10% 500 mL (NDC 0338-1130-03)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2022,Amino Acids,Baxter Healthcare,"10% TRAVASOL (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 1B6624 10% 1000 mL (NDC 0338-0644-04),
1B6623 10% 500 mL (NDC 0338-0644-03),
1B6626P 10% 2000 mL (NDC 0338-0644-06)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2023,Amino Acids,Baxter Healthcare,"15% CLINISOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 2B6189 15% 2000 mL (NDC 0338-0502-06), 2B6187 15% 500 mL (NDC 0338-0502-03)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2024,Amino Acids,Baxter Healthcare,"20% PROSOL - sulfite-free (Amino Acid) Injection, 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Code 2B6186 (NDC 0338-0499-06)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2025,Amino Acids,Baxter Healthcare,CLINIMIX E sulfite-free (Amino Acid with Electrolytes in Dextrose with Calcium) Injection in CLARITY Dual Chamber Container,Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2026,Amino Acids,Baxter Healthcare,CLINIMIX sulfite-free (Amino Acid in Dextrose) Injection in CLARITY Dual Chamber Container,Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2027,Amino Acids,Baxter Healthcare,SYNTHAMIN 17 without Electrolytes - 10% Amino Acids Intravenous Infusion 3000 mL. Product code FKB6642.  Pack factor 3  (NDC 0338-9575-03),Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2028,Amino Acids,Baxter Healthcare,"CLINIMIX N9G15E-Solution for Infusion, 1000 mL (2.75% Amino Acid in 7.5% Glucose with Electrolytes). Product code FKB6669C - Pack factor of 8 (NDC 0338-9570-08)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2029,Amino Acids,Baxter Healthcare,"CLINIMIX N9G20E-Solution for Infusion, 1000 mL  (2.75% Amino Acid in 10% Glucose with Electrolytes) Product code FKB6670C - Pack factor of 8 
(NDC 0338-9566-08)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2030,Amino Acids,Baxter Healthcare,"CLINIMIX N14G30E-Solution for Infusion, 2000 mL (4.25% Amino Acid in 15% Dextrose with Electrolytes) Product code FKB6654V - Pack factor of 4 (NDC 0338-9587-04)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2019,
2031,"Aminophylline Injection, USP","Hospira, Inc.",250 mg/10mL (25 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-5921-01),Reverified,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Pulmonary/Allergy,Current,,,,2019,limited availability
2032,"Aminophylline Injection, USP","Hospira, Inc.",500 mg/20mL (25 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-5922-01),Reverified,12/20/2019,Available,,,Other,Pulmonary/Allergy,Current,,,,2019,available
2033,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 60 count bottle (NDC 0185-0144-60)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2034,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 90 count bottle (NDC 0185-0144-09)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2035,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 500 count bottle (NDC 0185-0144-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2036,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 500 count bottle (NDC 0245-0145-15)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2037,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 30 count bottle (NDC 0245-0145-30)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2038,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-2610-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2039,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 1000 count bottle (NDC 0378-2610-10)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2040,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"25 mg, 100 count bottle (NDC 0378-2625-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2041,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"25 mg, 1000 count bottle (NDC 0378-2625-10)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2042,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 100 count bottle (NDC 0378-2650-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2043,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 1000 count bottle (NDC 0378-2650-10)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2044,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"75 mg, 100 count bottle (NDC 0378-2675-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2045,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-2685-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2046,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 100 count bottle (NDC 0378-2695-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2047,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,2.5 mg/10 mg (NDC 0093-7370-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2019,discontinued
2048,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/10 mg (NDC 0093-7371-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2019,discontinued
2049,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/20 mg (NDC 0093-7372-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2019,discontinued
2050,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/40 mg (NDC 0093-7670-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2019,discontinued
2051,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,10 mg/20 mg (NDC 0093-7373-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2019,discontinued
2052,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,10 mg/40 mg (NDC 0093-7671-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2019,discontinued
2053,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",5 mg/20 mg tablets (NDCs 0093-7027-56 and 0093-7027-98),New,3/11/2019,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/2019,3/11/2019,,2019,discontinued
2054,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",5 mg/40 mg tablets (NDCs 0093-7028-56 and 0093-7028-98),New,3/11/2019,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/2019,3/11/2019,,2019,discontinued
2055,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",10 mg/20 mg tablets (NDCs 0093-7029-56 and 0093-7029-98),New,3/11/2019,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/2019,3/11/2019,,2019,discontinued
2056,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",10 mg/20 mg tablets (NDCs 0093-7030-56 and 0093-7030-98),New,3/11/2019,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/2019,3/11/2019,,2019,discontinued
2057,Amoxicillin (Moxatag) Extended Release Tablets,"Pragma Pharmaceuticals, LLC",775 mg tablets (NDCs 69442-030-10 and NDCs 69442-030-30),New,12/19/2018,,"The last batches will expire September 30, 2019.",,,Anti-Infective,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
2058,Amoxicillin Powder for Suspension,Teva Pharmaceuticals,"125 mg/5 mL powder for suspension (NDCs 0093-4150-73, 0093-4150-79 and 0093-4150-80)",New,6/3/2019,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,6/3/2019,6/3/2019,,2019,discontinued
2059,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"5 mg, 100 Count Bottle (NDC 68382-950-01)",New,9/12/2019,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,limited availability
2060,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"7.5 mg, 100 Count Bottle (NDC 68382-951-01)",New,9/12/2019,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,limited availability
2061,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"10 mg, 100 Count Bottle (NDC 68382-952-01)",New,9/12/2019,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,limited availability
2062,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"12.5 mg, 100 Count Bottle (NDC 68382-953-01)",New,9/12/2019,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,limited availability
2063,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"15 mg, 100 Count Bottle (NDC 68382-954-01)",New,9/12/2019,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,limited availability
2064,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"20 mg, 100 Count Bottle (NDC 68382-955-01)",New,9/12/2019,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,limited availability
2065,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"30 mg, 100 Count Bottle (NDC 68382-956-01)",New,9/12/2019,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,limited availability
2066,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"30 mg, 100 Count Bottle (NDC 0185-0864-01)",Reverified,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2067,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"20 mg, 100 Count Bottle (NDC 0185-0853-01)",Reverified,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2068,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"10 mg, 100 Count Bottle (NDC 0185-0842-01)",Reverified,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2069,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"5 mg, 100 Count Bottle (NDC 0185-0831-01)",Reverified,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2070,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 10mg 100 (NDC 57844-0110-01),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2071,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 12.5mg 100 (NDC 57844-0112-01),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2072,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 15mg 100 (NDC 57844-0115-01),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2073,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 20mg 100 (NDC 57844-0120-01),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2074,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 30mg 100 (NDC 57844-0130-01),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2075,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 5mg 100 (NDC 57844-0105-01),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2076,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 7.5mg 100 (NDC 57844-0117-01),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2077,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,5mg [1.25/1.25/1.25/1.25mg] 100s (NDC 0378-4541-01),Reverified,11/26/2019,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2019,not available
2078,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,7.5mg [1.875/1.875/1.875/1.875mg] 100s (NDC 0378-4542-01),Reverified,11/26/2019,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2019,not available
2079,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,10mg [2.5/2.5/2.5/2.5mg] 100s (NDC 0378-4543-01),Reverified,11/26/2019,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2019,not available
2080,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,12.5mg [3.125/3.125/3.125/3.125mg] 100s (NDC 0378-4544-01),Reverified,11/26/2019,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2019,not available
2081,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,15mg [3.75/3.75/3.75/3.75mg] 100s (NDC 0378-4545-01),Reverified,11/26/2019,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2019,not available
2082,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,20mg [5/5/5/5mg] 100s (NDC 0378-4546-01),Reverified,11/26/2019,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2019,not available
2083,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,30mg [7.5/7.5/7.5/7.5mg] 100s (NDC 0378-4547-01),Reverified,11/26/2019,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2019,not available
2084,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01)",New,9/12/2019,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,,2019,limited availability
2085,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01)",New,9/12/2019,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,,2019,limited availability
2086,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01)",New,9/12/2019,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,,2019,limited availability
2087,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01)",New,9/12/2019,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,,2019,limited availability
2088,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01)",New,9/12/2019,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,,2019,limited availability
2089,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,12.5  mg 100 count (NDC 0555-0776-02),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2090,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,15  mg 100 count (NDC 0555-0777-02),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2091,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,7.5  mg 100 count (NDC 0555-0775-02),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2092,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,10  mg 100 count (NDC 0555-0972-02),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2093,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,20 mg 100 count (NDC 0555-0973-02),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2094,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,30 mg 100 count (NDC 0555-0974-02),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2095,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,5 mg 100 count (NDC 0555-0971-02),Reverified,12/16/2019,Product is Available,,,,Psychiatry,Current,,,,2019,available
2096,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,1 MG 100 Capsules (NDC 0172-5240-60),Reverified,12/16/2019,Allocating inventory,Rolling backorders into December 2019; Expected recovery March 2020,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2019,limited availability
2097,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,0.5 MG 100 Capsules (NDC 0172-5241-60),Reverified,12/16/2019,Allocating inventory,Rolling backorders into December 2019; Expected recovery March 2020,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2019,limited availability
2098,Anagrelide Hydrochloride Capsules,Shire US Inc. now part of Takeda,"AGRYLIN 0.5 mg Capsule,100 capsules in 1 bottle (NDC 54092-063-01)",Reverified,12/2/2019,Available,Takeda is actively working to mitigate a recent unexpected increase in demand for the product.,,Demand increase for the drug,Hematology,Current,,,,2019,available
2099,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,0.5 mg per capsule Bottles of 100 (NDC 13668-453-01),Revised,12/13/2019,Estimated availability: January 2020,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2019,not available
2100,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,"1 mg per capsule, Bottles of 100 (NDC 13668-462-01)",Revised,12/13/2019,Available and shipping,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2019,available
2101,Aprepitant (Emend) Capsules,Merck Sharp & Dohme Corp.,40-mg capsules unit-of-use package of 1 (NDC 0006-0464-10),New,12/3/2018,,,,,Gastroenterology,To be Discontinued,12/3/2018,12/3/2018,,2019,discontinued
2102,Aprepitant (Emend) Capsules,Merck Sharp & Dohme Corp.,40-mg capsules unit-of-use package of 5 (NDC 0006-0464-05),New,12/3/2018,,,,,Gastroenterology,To be Discontinued,12/3/2018,12/3/2018,,2019,discontinued
2103,Asparaginase Erwinia Chrysanthemi (Erwinaze),"Jazz Pharmaceuticals, Inc.","ERWINAZE 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial 5 vial carton (NDC 57902-249-05)",Revised,12/9/2019,Available.  For further information and to sign up for supply alerts by Jazz Pharmaceuticals please visit Erwinazesupply.com https://erwinazesupply.com/,,,Other,Hematology;Oncology;Pediatric,Current,,,,2019,available
2104,Asparaginase Erwinia Chrysanthemi (Erwinaze),"Jazz Pharmaceuticals, Inc.","ERWINAZE 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial 1 vial (NDC 57902-249-01)",Revised,12/9/2019,Available.  For further information and to sign up for supply alerts by Jazz Pharmaceuticals please visit Erwinazesupply.com https://erwinazesupply.com/,,,Other,Hematology;Oncology;Pediatric,Current,,,,2019,available
2105,"Atracurium Besylate Injection, USP",Mylan Institutional,"10 mg/mL, 10 mL, 10PK (NDC 67457-698-10)",New,9/24/2019,,,,,Anesthesia,To be Discontinued,9/24/2019,9/24/2019,,2019,discontinued
2106,"Atracurium Besylate Injection, USP",Mylan Institutional,"10 mg/mL, 5 mL, 10 PK (NDC 67457-699-05)",New,9/24/2019,,,,,Anesthesia,To be Discontinued,9/24/2019,9/24/2019,,2019,discontinued
2107,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC",8 mg per 20 mL (0.4 mg per mL); MDV; (NDC 63323-580-20),Reverified,12/20/2019,Available,Check wholesaler inventory,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2019,available
2108,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS","0.1 mg/mL; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3339-1, Old NDC 0548-3339-00)",Reverified,12/16/2019,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2019,available
2109,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); Ansyr Plastic Syringe
(NDC 0409-1630-10)",Revised,12/20/2019,Next Delivery: March 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology;Pediatric,Current,,,,2019,not available
2110,Atropine Sulfate Injection,"Hospira, Inc.","0.25 mg/5 mL (0.05 mg/mL); Ansyr Plastic Syringe
(NDC 0409-9630-05)",Revised,12/20/2019,Next Delivery: March 2020; Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology;Pediatric,Current,,,,2019,not available
2111,Atropine Sulfate Injection,"Hospira, Inc.",0.5 mg/5 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4910-34),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology;Pediatric,Current,,,,2019,not available
2112,Atropine Sulfate Injection,"Hospira, Inc.",1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4911-34),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology;Pediatric,Current,,,,2019,not available
2113,Atropine Sulfate Injection,American Regent/Luitpold,"0.4 mg/mL, 1 mL single-dose vial, package of 25
(NDC 00517-0401-25)",Reverified,11/27/2019,Limited Availability,"American Regent is currently releasing the 0.4mg/mL, 1 mL vial, NDC 00517-0401-25",,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2019,limited availability
2114,Atropine Sulfate Injection,American Regent/Luitpold,"1 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-1010-25)",Reverified,11/27/2019,Limited Availability,"American Regent is currently releasing the 1mg/mL, 1 mL vial, (NDC 00517-1010-25)",,Other,Anesthesia;Neurology;Pediatric,Current,,,,2019,limited availability
2115,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.4 mg/mL, 20 mL vial (NDC 0641-6006-10)",Revised,12/13/2019,"January 2020, has inventory",,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2019,available
2116,Atropine Sulfate Ophthalmic Ointment,Bausch Health,"1% (10 mg/g), 3.5 g tube (NDC 24208-825-55)",Revised,12/13/2019,Availability limited to product already in pharmacies until resumption of manufacturing in January 2020 and distribution in February 2020,Currently qualifying alternate supplier of inactive ingredient,,Shortage of an inactive ingredient,Ophthalmology,Current,,,,2019,limited availability
2117,Avelox® (moxifloxacin HCl) Tablets,Bayer,Bottles of 30 Tablets (NDC 50419-530-01),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Anti-Infective,To be Discontinued,2/1/2019,2/1/2019,,2019,discontinued
2118,Azacitidine Injection,Teva Pharmaceuticals,100 mg/1 unit (NDC 0591-2897-49),New,10/30/2019,,The product has not been marketed for an extended period of time. Teva made a business decision to discontinue this product.,,,Oncology,To be Discontinued,10/30/2019,10/30/2019,,2019,discontinued
2119,Azithromycin (Azasite) Ophthalmic Solution 1%,Akorn Pharmaceuticals,Azasite (Azithromycin Ophthalmic Solution) 1% 2.5 mL in 5 mL bottle (NDC 17478-307-03),Revised,9/11/2019,,,,,Ophthalmology,Resolved,9/11/2019,,,2019,
2120,Bacitracin Ophthalmic Ointment,Perrigo Pharmaceuticals,Bacitracin Ophthalmic Ointment 3.5 g (NDC 0574-4022-35),Reverified,12/10/2019,On backorder. Expected release early January 2020,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2019,not available
2121,Belatacept (Nulojix) Lyophilized Powder for Injection,Bristol Myers Squibb Co.,20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13),Reverified,12/16/2019,"No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of NULOJIX via the US NULOJIX Distribution Program, initiated 15-Feb-2017. Starting in August 2018, the restrictions of the NDP will be eased to allow for expansion of use to appropriate new patients if the treating physician determines that Nulojix is the best treatment option for the patient.  For further information, contact BMS Medical Information.",Increased demand for the drug exacerbated by a delay in transition to a more efficient manufacturing process.,,Demand increase for the drug,Transplant,Current,,,,2019,limited availability
2122,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 69202-780-08),New,9/18/2019,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/2019,9/18/2019,,2019,discontinued
2123,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 69202-780-88),New,9/18/2019,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/2019,9/18/2019,,2019,discontinued
2124,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 23594-780-08),New,9/18/2019,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/2019,9/18/2019,,2019,discontinued
2125,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 23594-780-88),New,9/18/2019,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/2019,9/18/2019,,2019,discontinued
2126,Bisoprolol Fumarate Tablets,Unichem Pharmaceuticals (USA) Inc.,"5 mg, 30 count bottle (NDC 29300-126-13)",Revised,6/14/2019,,,Available,,Cardiovascular,Resolved,6/14/2019,,,2019,
2127,Bisoprolol Fumarate Tablets,Unichem Pharmaceuticals (USA) Inc.,"5 mg, 100 count bottle (NDC 29300-126-01)",Revised,6/14/2019,,,Available,,Cardiovascular,Resolved,6/14/2019,,,2019,
2128,Bisoprolol Fumarate Tablets,Unichem Pharmaceuticals (USA) Inc.,"10 mg, 30 count bottle (NDC 29300-127-13)",Revised,6/14/2019,,,Available,,Cardiovascular,Resolved,6/14/2019,,,2019,
2129,Bisoprolol Fumarate Tablets,Unichem Pharmaceuticals (USA) Inc.,"10 mg, 100 count bottle (NDC 29300-127-01)",Revised,6/14/2019,,,Available,,Cardiovascular,Resolved,6/14/2019,,,2019,
2130,Bosentan Tablets,"Janssen Research and Development, LLC",62.5 mg tablets (NDC 10148-625-60),New,10/15/2019,,,,,Cardiovascular,To be Discontinued,10/15/2019,10/15/2019,,2019,discontinued
2131,Bosentan Tablets,"Janssen Research and Development, LLC",125 mg tablets (NDC 10148-125-60),New,10/15/2019,,,,,Cardiovascular,To be Discontinued,10/15/2019,10/15/2019,,2019,discontinued
2132,Budesonide Capsules,Teva Pharmaceuticals,3 mg capsules (NDC 0093-7445-01),New,12/23/2019,,,,,Gastroenterology,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
2133,"Bumetanide Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 4 mL vial (NDC 0641-6008-10)",Revised,12/13/2019,"Temporary back-order, additional lots available end of December/January 2020",,,Demand increase for the drug,Cardiovascular,Current,,,,2019,limited availability
2134,"Bumetanide Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 10 mL vial (NDC 0641-6007-10)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured in the October - November 2019 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2135,"Bumetanide Injection, USP","Hospira, Inc.",1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04),Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: January 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
2136,"Bumetanide Injection, USP","Hospira, Inc.",2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10),Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: November 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
2137,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-461-57),Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2138,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.5% (250 mg per 50 mL) (5 mg per mL) MDV (NDC 63323-463-57),Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2139,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.25% (25 mg per 10 mL) (2.5 mg per mL) SDV (NDC 63323-468-17),Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2140,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI .25% (75 mg per 30 mL) (2.5 mg per mL) SDV (NDC 63323-468-37),Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2141,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (50 mg per 10 mL) (5 mg per mL) SDV (NDC 63323-462-17),Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2142,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) SDV (NDC 63323-462-37),Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2143,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) Sterile-Pak, SDV (NDC 63323-462-31)",Revised,12/20/2019,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2144,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.75% (225 mg per 30 mL) (7.5 mg per mL)  SDV  (NDC 63323-460-37),Revised,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2145,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-01),Reverified,12/20/2019,Next Delivery: February 2020; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2146,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-17),Reverified,12/20/2019,Next Delivery: March 2020; Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2147,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9043-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: May 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2148,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-01),Reverified,12/20/2019,Next Delivery: March 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2149,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-17),Reverified,12/20/2019,Next Delivery: March 2020; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2150,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9046-01),Reverified,12/20/2019,Next Delivery: March 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2151,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-10)",Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: June 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2152,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-30)",Reverified,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,limited availability
2153,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-10)",Reverified,12/20/2019,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2154,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-29)",Reverified,12/20/2019,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2155,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1752-50)",Reverified,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: June 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,limited availability
2156,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1755-50)",Reverified,12/20/2019,Next Delivery: January 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2157,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-465-57),Reverified,12/20/2019,Available,All Bupivacaine presentations are on intermittent back order and will be released as the product becomes available.  Product will ship into the wholesalers.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2158,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine 0.5% (250 mg per 50 mL) (5 mg per mL)                    MDV (NDC 63323-467-57),Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2159,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.25% (25 mg per 10 mL) (2.5 mg per mL) MPF,         SDV (NDC 63323-464-17)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2160,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine MPF 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF, SDV (NDC 63323-464-37)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2161,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF,             Sterile-Pak, SDV (NDC 63323-464-31)",Reverified,12/20/2019,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2162,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (50 mg per 10 mL) (5 mg per mL)  MPF,                 SDV  (NDC 63323-466-17)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2163,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                 SDV (NDC 63323-466-37)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2164,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                Sterile-Pak, SDV (NDC 63323-466-31)",Reverified,12/20/2019,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2165,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.75% (75 mg per 10 mL) (7.5 mg per mL) MPF,             SDV (NDC 63323-472-17)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2166,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.75% (225 mg per 30 mL) (7.5 mg per mL) MPF,     SDV (NDC 63323-472-37)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2167,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 10 mL Single Dose Vials (NDC 55150-167-10),Revised,11/7/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2168,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 30 mL Single Dose Vials (NDC 55150-168-30),Revised,11/7/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2169,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 10 mL Single Dose Vials (NDC 55150-169-10),Revised,11/7/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2170,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-170-30),Revised,12/11/2019,Currently backordered,Next shipment TBD,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
2171,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 10 mL Single Dose Vials (NDC 55150-171-10),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2172,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 30 mL Single Dose Vials (NDC 55150-172-30),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2173,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 50 mL Multiple Dose Vials (NDC 55150-249-50),Revised,12/11/2019,Available,Check wholesaler for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2174,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 50 mL Multiple Dose Vials (NDC 55150-250-50),Revised,12/11/2019,Available,Check wholesaler for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2175,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-01),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2176,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-02),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
2177,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1160-01),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
2178,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-01),Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2179,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-02),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: February 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,limited availability
2180,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1163-01),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,limited availability
2181,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",75 mg/10 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-01),Revised,12/20/2019,Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2182,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",225 mg/30 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-02),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
2183,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL); Glass Ampul (NDC 00409-3613-01),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
2184,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 25 mg/10 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-10),Revised,12/20/2019,Next Delivery and Estimated Recovery: April 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2185,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 75 mg/30 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-30),Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: February 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2186,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1587-50),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2187,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-10),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: February 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2188,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-29),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2189,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1610-50),Revised,12/20/2019,Next Delivery: March 2020; Estimated Recovery: May 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2190,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 75 mg/10 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-10),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: June 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2191,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 225 mg/30 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-29),Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: April 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2192,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine Spinal 15 mg/2 mL (7.5 mg/mL); Glass Ampul (NDC 00409- 1761-02),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
2193,"Bupivacaine Hydrochloride Injection, USP",Baxter Healthcare,"Bupivacaine HCL in 8.25% Dextrose lnjection, USP (7.5 mg/mL) 2 mL Single Dose Ampule (10 x 2 mL)(NDC 36000-092-10)",Reverified,12/11/2019,Available,SPINAL 0.75% - Sterile Hyperbaric Solution for Spinal Anesthesia,,,Anesthesia,Current,,,,2019,available
2194,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.25% 5 mL single-dose ampules (NDC 59923-717-05),New,9/12/2019,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2019,available
2195,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.25% 10 mL single-dose ampules (NDC 59923-719-10),New,9/12/2019,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2019,available
2196,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.5% 5 mL single-dose ampules (NDC 59923-718-05),New,9/12/2019,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2019,available
2197,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.5% 10 mL single-dose ampules (NDC 59923-720-10),New,9/12/2018,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2019,available
2198,Buprenorphine Hydrochloride Sublingual Tablets,Mylan Pharmaceuticals Inc.,"2 mg, 30 count bottle (NDC 0378-0923-93)",New,5/2/2019,,,,,Analgesia/Addiction,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2199,Buprenorphine Hydrochloride Sublingual Tablets,Mylan Pharmaceuticals Inc.,"8 mg, 30 count bottle (NDC 0378-0924-93)",New,5/2/2019,,,,,Analgesia/Addiction,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2200,Bupropion Hydrochloride (Zyban) Tablets,GlaxoSmithKline,150 mg  (NDC 0173-0556-01),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately July 2019.,,,Psychiatry,To be Discontinued,6/28/2019,6/28/2019,,2019,discontinued
2201,Bupropion Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 90 count bottle (NDC 0378-2008-77)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2202,Bupropion Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"300 mg, 500 count bottle (NDC 0378-2009-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2203,Buspirone HCl Tablets,Amneal Pharmaceutical,"10mg, 100 (NDC 69238-1117-01)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2204,Buspirone HCl Tablets,Amneal Pharmaceutical,"10mg, 500 (NDC 69238-1117-05)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2205,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 100 (NDC 69238-1118-01)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2206,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 500 (NDC 69238-1118-05)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2207,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 60 (NDC 69238-1118-06)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2208,Buspirone HCl Tablets,Amneal Pharmaceutical,"30mg, 60 (NDC 69238-1119-06)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2209,Buspirone HCl Tablets,Amneal Pharmaceutical,"5mg, 100 (NDC 69238-1115-01)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2210,Buspirone HCl Tablets,Amneal Pharmaceutical,"5mg, 500 (NDC 69238-1115-05)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2211,Buspirone HCl Tablets,Amneal Pharmaceutical,"7.5mg, 100 (NDC 69238-1116-01)",Reverified,12/17/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2212,Buspirone HCl Tablets,Strides Pharma Inc.,"15 mg, 60 count bottle (NDC 64380-743-03)",Revised,5/16/2019,Currently out of stock. Re-supply by the first week of June 2019.,,,Demand increase for the drug,Psychiatry,Current,,,,2019,not available
2213,Buspirone HCl Tablets,Strides Pharma Inc.,"15 mg, 180 count bottle (NDC 64380-743-18)",Revised,5/16/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2214,Buspirone HCl Tablets,Accord Healthcare Inc.,"5 mg, 100 count bottle (NDC 16729-200-01)",Revised,12/11/2019,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2215,Buspirone HCl Tablets,Accord Healthcare Inc.,"5 mg, 500 count bottle (NDC 16729-200-16)",Revised,12/11/2019,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2216,Buspirone HCl Tablets,Accord Healthcare Inc.,"7.5 mg, 100 count bottle (NDC 16729-201-01)",Revised,12/11/2019,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2217,Buspirone HCl Tablets,Accord Healthcare Inc.,"10 mg, 100 count bottle (NDC 16729-202-01)",Revised,12/11/2019,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2218,Buspirone HCl Tablets,Accord Healthcare Inc.,"10 mg, 500 count bottle (NDC 16729-202-16)",Revised,12/11/2019,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2219,Buspirone HCl Tablets,Accord Healthcare Inc.,"15 mg, 60 count bottle (NDC 16729-203-12)",Revised,12/11/2019,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2220,Buspirone HCl Tablets,Accord Healthcare Inc.,"15 mg, 100 count bottle (NDC 16729-203-01)",Revised,12/11/2019,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2221,Buspirone HCl Tablets,Accord Healthcare Inc.,"30 mg, 60 count bottle (NDC 16729-289-12)",Revised,12/11/2019,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2222,Buspirone HCl Tablets,Impax Laboratories,"5 mg, 100 count bottle (NDC 0115-1690-01)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2223,Buspirone HCl Tablets,Impax Laboratories,"5 mg, 500 count bottle (NDC 0115-1690-02)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2224,Buspirone HCl Tablets,Impax Laboratories,"5 mg, 1000 count bottle (NDC 0115-1690-03)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2225,Buspirone HCl Tablets,Impax Laboratories,"10 mg, 100 count bottle (NDC 0115-1691-01)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2226,Buspirone HCl Tablets,Impax Laboratories,"10 mg, 500 count bottle (NDC 0115-1691-02)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2227,Buspirone HCl Tablets,Impax Laboratories,"10 mg, 1000 count bottle (NDC 0115-1691-03)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2228,Buspirone HCl Tablets,Impax Laboratories,"15 mg, 60 count bottle (NDC 0115-1692-13)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2229,Buspirone HCl Tablets,Impax Laboratories,"15 mg, 180 count bottle (NDC 0115-1692-19)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2230,Buspirone HCl Tablets,Impax Laboratories,"15 mg, 500 count bottle (NDC 0115-1692-02)",Reverified,1/29/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
2231,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 100 count bottle (NDC 49884-725-01)",Reverified,11/26/2019,Available,"Manufactured and marketed by Par Pharmaceutical. For product availability inquiries, call 1-800-828-9393, option # 5 then option # 2",,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2232,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 500 count bottle (NDC 49884-725-05)",Reverified,11/26/2019,Available,"Manufactured and marketed by Par Pharmaceutical. For product availability inquiries, call 1-800-828-9393, option # 5 then option # 2",,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2233,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-1140-01)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2234,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-1140-05)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2235,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, unit-dose blister pack, 100 count (NDC 51079-985-20)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2236,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 100 count bottle (NDC 0378-1145-01)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2237,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-1150-01)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2238,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-1150-05)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2239,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, unit-dose blister pack, 100 count (NDC 51079-986-20)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2240,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 60 count bottle (NDC 0378-1165-91)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2241,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 180 count bottle (NDC 0378-1165-80)",Reverified,11/26/2019,Unavailable. Re-supply: November 2019,,,Other,Psychiatry,Current,,,,2019,not available
2242,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 500 count bottle (NDC 0378-1165-05)",Reverified,11/26/2019,Unavailable. Re-supply: November 2019,,,Other,Psychiatry,Current,,,,2019,not available
2243,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, unit-dose blister pack, 100 count (NDC 51079-960-20)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2244,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 60 count bottle (NDC 0378-1175-91)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2245,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"30 mg, unit-dose blister pack, 100 count (NDC 51079-994-20)",Reverified,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2246,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 100 count bottle (NDC 64380-741-06)",Revised,5/16/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2247,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 500 count bottle (NDC 64380-741-07)",Revised,5/16/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2248,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 1000 count bottle (NDC 64380-741-08)",Revised,5/16/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2249,Buspirone HCl Tablets,Strides Pharma Inc.,"7.5 mg, 100 count bottle (NDC 64380-787-06)",Revised,5/16/2019,Currently out of stock. Re-supply by the first week of June 2019.,,,Demand increase for the drug,Psychiatry,Current,,,,2019,not available
2250,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 100 count bottle (NDC 64380-742-06)",Revised,5/16/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2251,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 500 count bottle (NDC 64380-742-07)",Revised,5/16/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2252,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 1000 count bottle (NDC 64380-742-08)",Revised,5/16/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2253,Buspirone HCl Tablets,Strides Pharma Inc.,"30 mg, 60 count bottle (NDC 64380-744-03)",Revised,5/16/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2254,Buspirone HCl Tablets,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0093-0053-01)",Revised,12/16/2019,Available,,,,Psychiatry,Current,,,,2019,available
2255,Buspirone HCl Tablets,Teva Pharmaceuticals,"5 mg, 500 count bottle (NDC 0093-0053-05)",Revised,12/16/2019,Available,,,,Psychiatry,Current,,,,2019,available
2256,Buspirone HCl Tablets,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0093-0054-01)",Revised,12/16/2019,Available,,,,Psychiatry,Current,,,,2019,available
2257,Buspirone HCl Tablets,Teva Pharmaceuticals,"10 mg, 500 count bottle (NDC 0093-0054-05)",Revised,12/16/2019,Available,,,Increase in demand,Psychiatry,Current,,,,2019,available
2258,Buspirone HCl Tablets,Teva Pharmaceuticals,"15 mg, 100 count bottle (NDC 0093-1003-01)",Revised,12/16/2019,Available,,,Increase in demand,Psychiatry,Current,,,,2019,available
2259,Buspirone HCl Tablets,Teva Pharmaceuticals,"15 mg, 500 count bottle (NDC 0093-1003-05)",Revised,12/16/2019,Available,,,Increase in demand,Psychiatry,Current,,,,2019,available
2260,Buspirone HCl Tablets,Teva Pharmaceuticals,"30 mg, 60 count bottle (NDC 0093-5200-06)",Revised,12/16/2019,Available,,,Increase in demand,Psychiatry,Current,,,,2019,available
2261,Buspirone HCl Tablets,Teva Pharmaceuticals,"30 mg, 500 count bottle (NDC 0093-5200-05)",Revised,12/16/2019,Available,,,Increase in demand,Psychiatry,Current,,,,2019,available
2262,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"5 mg, 100 count bottle (NDC 68382-180-01)",Revised,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2263,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"5 mg, 500 count bottle (NDC 68382-180-05)",Revised,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2264,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"10 mg, 100 count bottle (NDC 68382-181-01)",Revised,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2265,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"10 mg, 500 count bottle (NDC 68382-181-05)",Revised,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2266,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"15 mg, 100 count bottle (NDC 68382-182-01)",Revised,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2267,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"15 mg, 500 count bottle (NDC 68382-182-05)",Revised,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2268,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"30 mg, 60 count bottle (NDC 68382-183-14)",Revised,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2269,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"30 mg, 500 count bottle (NDC 68382-183-05)",Revised,12/18/2019,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2019,available
2270,Calcitriol Injection USP 1MCG /ML,Akorn Pharmaceuticals,"Calcitriol Injection USP, 1 mcg/mL, 1 mL ampule  (NDC 17478-931-01)",Revised,12/2/2019,Available,,,Other,Endocrinology/Metabolism,Current,,,,2019,available
2271,"Calcium Chloride Injection, USP","Hospira, Inc.",1 g/10 mL (100 mg/mL); Ansyr Plastic Syringe (NDC 00409-1631-10),Reverified,12/20/2019,Next Delivery: April 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric,Current,,,,2019,not available
2272,"Calcium Chloride Injection, USP","Hospira, Inc.",1 g/10 mL (100 mg/mL); LifeShield Abboject Glass Syringe (NDC 00409-4928-34),Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric,Current,,,,2019,not available
2273,"Calcium Chloride Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","Calcium Chloride Inj. USP, 10%, 10mL Luer-Jet Prefilled Syringe, (NDC 0548-3304-00), new (NDC 76329-3304-1)",Revised,11/6/2019,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Gastroenterology;Pediatric,Current,,,,2019,limited availability
2274,"Calcium Chloride Injection, USP","Medefil, Inc.","Calcium Chloride Inj. USP, 10%, 10mL Prefilled Syringe, (NDC 64253-900-36)",Revised,12/11/2019,Available,Check wholesaler for inventory,,Other,Gastroenterology;Pediatric,Current,,,,2019,available
2275,"Calcium Chloride Injection, USP",American Regent/Luitpold,"10% Calcium Chloride Injection, USP, 1 gram/10mL (100mg/mL), single dose vial, (NDC 0517-6710-01)",Reverified,11/27/2019,Limited availability.,,,Requirements related to complying with good manufacturing practices,Gastroenterology;Pediatric,Current,,,,2019,limited availability
2276,"Capreomycin Injection, USP",Akorn Pharmaceuticals,"Capastat Sulfate (Capreomycin for Injection USP) Eq to 1 g Capreomycin activity, 10mL (NDC 17478-080-50)",Revised,12/2/2019,Available,,,Delay in shipping of the drug,Anti-Infective,Current,,,,2019,available
2277,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,100 mg capsules (NDC 29033-019-12),New,6/19/2019,,,,,Neurology,To be Discontinued,6/19/2019,6/19/2019,,2019,discontinued
2278,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,200 mg capsules (NDC 29033-020-12),New,6/19/2019,,,,,Neurology,To be Discontinued,6/19/2019,6/19/2019,,2019,discontinued
2279,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,300 mg capsules (NDC 29033-004-12),New,6/19/2019,,,,,Neurology,To be Discontinued,6/19/2019,6/19/2019,,2019,discontinued
2280,Carbidopa and Levodopa Extended Release Tablets,Mylan Pharmaceuticals Inc.,"Carbidopa and Levodopa Extended Release Tablets, 25/100 mg (NDC 0378-0088-01)",Revised,7/12/2019,,,,,Neurology,Resolved,7/12/2019,,,2019,
2281,Carbidopa and Levodopa Extended Release Tablets,Mylan Pharmaceuticals Inc.,"Carbidopa and Levodopa Extended Release Tablets, 50/200 mg (NDC 0378-0094-01)",Revised,7/12/2019,,,,,Neurology,Resolved,7/12/2019,,,2019,
2282,Carbidopa and Levodopa Extended Release Tablets,Merck Sharp & Dohme Corp.,"Carbidopa levodopa (50 mg of carbidopa and 200 mg of levodopa)  (SINEMET CR 50-200) sustained-release tablets, (NDC 0006-3919-68)bottles of 100",New,7/17/2019,,To be discontinued on or near November 2019.,,,Neurology,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2283,Carbidopa and Levodopa Extended Release Tablets,Merck Sharp & Dohme Corp.,"Carbidopa levodopa  (25 mg of carbidopa and 100 mg of levodopa) (SINEMET CR 25-100 ) sustained-release tablets, (NDC 0006-3918-68) bottles of 100",New,7/17/2019,,To be discontinued on or near February 2020.,Available,,Neurology,To be Discontinued,7/17/2019,,,2019,discontinued
2284,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 50MG/200MG 100CT; (NDC 1672907901),Revised,7/12/2019,,,Stocks available to support current customer demand,,Neurology,Resolved,7/12/2019,,,2019,
2285,Carbidopa and Levodopa Extended Release Tablets,Sun Pharmaceutical Industries Inc.,Carbidopa and Levodopa Extended Release Tablets  25-100 mg (NDC  62756-461-88 ),Revised,7/12/2019,,,Available,,Neurology,Resolved,7/12/2019,,,2019,
2286,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 50MG/200MG 1000CT; (NDC 1672907917),Revised,7/12/2019,,,Stocks available to support current customer demand,,Neurology,Resolved,7/12/2019,,,2019,
2287,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 25MG/100MG 100CT; (NDC 1672907801),Revised,7/12/2019,,,Due to manufacturing constraints; we estimate the delay to continue until January 2020,,Neurology,Resolved,7/12/2019,,,2019,
2288,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 25MG/100MG 1000CT; (NDC 1672907817),Revised,7/12/2019,,,Due to manufacturing constraints; we estimate the delay to continue until January 2020,,Neurology,Resolved,7/12/2019,,,2019,
2289,Carbidopa and Levodopa Extended Release Tablets,Sun Pharmaceutical Industries Inc.,Carbidopa and Levodopa Extended Release Tablets  50-200 (NDC 62756-457-88),Revised,7/12/2019,,,Available,,Neurology,Resolved,7/12/2019,,,2019,
2290,Carbinoxamine Maleate,"Endo Pharmaceuticals, Inc.",4 mg/5 mL oral solution (NDCs 64376-612-16 and 64376-612-40),Revised,9/11/2019,,,,,Pulmonary/Allergy,To be Discontinued,9/11/2019,9/11/2019,,2019,discontinued
2291,Carbinoxamine Maleate,"Endo Pharmaceuticals, Inc.",4 mg tablets (NDC 64376-605-01),Revised,9/11/2019,,,,,Pulmonary/Allergy,To be Discontinued,9/11/2019,9/11/2019,,2019,discontinued
2292,Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose,"Chiesi USA, Inc.",Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose (NDC 10122-326-10),New,3/20/2018,,The decision to discontinue the 0.2 mg/mL in 5% Dextrose formulation was business related.  Other formulations of Cardene IV remain available.,,,Cardiovascular,To be Discontinued,3/20/2018,3/20/2018,,2019,discontinued
2293,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 250 mg 30 count bottle (NDC 0037-2250-30)",Reverified,11/26/2019,Available,Distributed by Meda Pharmaceuticals,,Available,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2294,"Carisoprodol Tablets, USP",Ingenus Pharmaceuticals LLC,"350 mg, 100 count tablets (NDC 50742-656-01)",Reverified,9/19/2019,Available,Distributed by Ingenus Pharmaceuticals LLC,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2295,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 16714-510-01)",Reverified,10/1/2019,Available,Distributed by Northstar Rx LLC,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2296,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 16714-510-02)",Reverified,10/1/2019,Available,Distributed by Northstar Rx LLC,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2297,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 16714-510-03)",Reverified,10/1/2019,Available,Distributed by Northstar Rx LLC,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2298,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 61442-451-01)",Reverified,10/1/2019,Available,"Distributed by Carlsbad Technology, Inc.",,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2299,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 61442-451-05)",Reverified,10/1/2019,Available,"Distributed by Carlsbad Technology, Inc.",,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2300,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 61442-451-10)",Reverified,10/1/2019,Available,"Distributed by Carlsbad Technology, Inc.",,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2301,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 59746-705-01)",Reverified,10/1/2019,Unavailable,Distributed by Jubilant Cadista; Stopped distribution,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,not available
2302,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 59746-705-05)",Reverified,10/1/2019,Unavailable,Distributed by Jubilant Cadista; Stopped distribution,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,not available
2303,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 59746-705-05)",Reverified,10/1/2019,Unavailable,Distributed by Jubilant Cadista; Stopped distribution,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,not available
2304,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 100 count (NDC 0591-5513-01)",Reverified,12/16/2019,Available,,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2305,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 500 count (NDC 0591-5513-05)",Reverified,12/16/2019,Available,,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2306,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 1000 count (NDC 0591-5513-10)",Reverified,12/16/2019,Available,,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2307,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 100 count (NDC 50228-109-01)",Reverified,9/23/2019,Available,Labeler: ScieGen,,Other,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2308,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 500 count (NDC 50228-109-05)",Reverified,9/23/2019,Available,Labeler: ScieGen,,Other,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2309,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 50228-109-10)",Reverified,9/23/2019,Available,Labeler: ScieGen,,Other,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2310,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 60429-508-10)",Reverified,9/23/2019,Available,Labeler: GSMS (Golden State Medical Supply),,Other,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2311,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 100 count (NDC 42543-700-01)",Reverified,9/23/2019,Unavailable,"Labeler: Vensun, stopped distribution",,Other,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,not available
2312,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 500 count (NDC 42543-700-05)",Reverified,9/23/2019,Unavailable,"Labeler: Vensun, stopped distribution",,Other,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,not available
2313,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 42543-700-10)",Reverified,9/23/2019,Unavailable,"Labeler: Vensun, stopped distribution",,Other,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,not available
2314,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100’s count bottle (NDC 00603-2582-21),New,4/26/2019,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,discontinued
2315,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",500's count bottle (NDC 00603-2582-28),New,4/26/2019,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,discontinued
2316,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100's count bottle (NDC 00603-2582-32),New,4/26/2019,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,discontinued
2317,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 250 mg, 30 count bottle (NDC 0037-2250-30); 100 count bottle (NDC 0037-2250-10)",Reverified,11/26/2019,Available,Distributed by Meda Pharmaceuticals,,Available,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2318,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 350 mg, 100 count bottle (NDC 0037-2001-01)",Reverified,11/26/2019,Available,Distributed by Meda Pharmaceuticals,,Available,Analgesia/Addiction;Musculoskeletal,Current,,,,2019,available
2319,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100’s count bottle (NDC 00603-2582-21),New,3/18/2019,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/2019,3/18/2019,,2019,discontinued
2320,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",500's count bottle (NDC 00603-2582-28),New,3/18/2019,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/2019,3/18/2019,,2019,discontinued
2321,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100's count bottle (NDC 00603-2582-32),New,3/18/2019,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/2019,3/18/2019,,2019,discontinued
2322,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1100-1),New,3/12/2019,Available,,,,Anti-Infective,Current,,,,2019,available
2323,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",300 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1300-1),New,3/13/2019,Available,,,,Anti-Infective,Current,,,,2019,available
2324,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 10 g (10 vials) (NDC 60505-6143-04),Reverified,11/27/2019,Available,,,,Anti-Infective,Current,,,,2019,available
2325,Cefazolin Injection,Sagent Pharmaceuticals,1g 25 vials (NDC 25021-101-10),Revised,12/20/2019,Available. On allocation. Estimated availability March,,,Manufacturing delay,Anti-Infective,Current,,,,2019,limited availability
2326,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 1 g (25 vials) (NDC 60505-6142-05),Reverified,11/27/2019,Available,,,,Anti-Infective,Current,,,,2019,available
2327,Cefazolin Injection,Sagent Pharmaceuticals,10g 10 vials (NDC 25021-102-99),Revised,12/20/2019,Available. On allocation. Estimated availability January,,,Manufacturing delay,Anti-Infective,Current,,,,2019,limited availability
2328,Cefazolin Injection,Sagent Pharmaceuticals,500mg 25 vials (NDC 25021-100-10),Revised,12/20/2019,Available. On allocation,,,Manufacturing delay,Anti-Infective,Current,,,,2019,limited availability
2329,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 2 gram/50 mL in DUPLEX Catalog 3105-11 (NDC 00264-3105-11),Reverified,12/11/2019,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,,2019,limited availability
2330,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 1 gram/50 mL in DUPLEX Catalog 3103-11 (NDC 0264-3103-11),Reverified,12/11/2019,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,,2019,limited availability
2331,Cefazolin Injection,WG Critical Care,500mg Cefazolin SDV (NDC 44567-706-25),Revised,11/4/2019,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,available
2332,Cefazolin Injection,WG Critical Care,1g Cefazolin SDV (NDC 44567-707-25),Revised,11/4/2019,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,available
2333,Cefazolin Injection,WG Critical Care,10g Cefazolin PBP (NDC 44567-708-10),Revised,11/4/2019,On backorder - Product continues to be manufactured with monthly releases.,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,limited availability
2334,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,,2019,not available
2335,Cefazolin Injection,"Hospira, Inc.",1g Single-dose ADD-Vantage Vial (NDC 00409-2585-01),Reverified,12/20/2019,Available,,,Other,Anti-Infective,Current,,,,2019,available
2336,Cefazolin Injection,"Hospira, Inc.",10 g Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-0806-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,,2019,not available
2337,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9923-90),Reverified,12/13/2019,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2019,available
2338,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9924-90),Reverified,12/13/2019,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2019,available
2339,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mg/ 100 mL vial (NDC 0143-9983-03),Reverified,12/13/2019,This presentation is temporarily on backorder.,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,not available
2340,Cefazolin Injection,Sandoz,Cefazolin Na Injection 500 mg (NDC 0781-3450-95),Reverified,12/18/2019,Available,,,,Anti-Infective,Current,,,,2019,available
2341,Cefazolin Injection,Sandoz,Cefazolin Na Injection 1 g (NDC 0781-3451-96),Reverified,12/18/2019,Available,,,,Anti-Infective,Current,,,,2019,available
2342,Cefazolin Injection,Sandoz,Cefazolin Na Injection 10 g (NDC 0781-3452-95),Reverified,12/18/2019,Limited availablity until February 2020,,,,Anti-Infective,Current,,,,2019,limited availability
2343,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 1 gram/50 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3503)(NDC 0338-3503-41)",Reverified,12/11/2019,Available,,,,Anti-Infective,Current,,,,2019,available
2344,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 2 gram/100 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3508)(NDC 0338-3508-41)",Reverified,12/11/2019,Product on allocation for existing customers,,,Demand increase for the drug,Anti-Infective,Current,,,,2019,limited availability
2345,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (10 vials) (NDC 60505-6146-04),Reverified,11/27/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
2346,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (1 vial) (NDC 60505-6146-00),Reverified,11/27/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
2347,Cefepime Injection,Apotex Corp.,Cefepime for Injection 2 g (10 vials) (NDC 60505-6147-04),Reverified,11/27/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
2348,Cefepime Injection,Apotex Corp.,Cefepime for Injection 2 g (1 vial) (NDC 60505-6147-00),Reverified,11/27/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
2349,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (1 vial) (NDC 60505-0834-00),Revised,3/1/2019,,"Product was manufactured by Hospira, no longer distributed by Apotex",,,Anti-Infective;Pediatric,To be Discontinued,3/1/2019,3/1/2019,,2019,discontinued
2350,Cefepime Injection,B. Braun Medical Inc.,Cefepime 1 g (NDC 0264-3193-11),Reverified,12/11/2019,Product on allocation to contracted custormers,,,Other,Anti-Infective;Pediatric,Current,,,,2019,limited availability
2351,Cefepime Injection,B. Braun Medical Inc.,Cefepime 2 g (NDC 0264-3195-11),Reverified,12/11/2019,Product on allocation to contracted customers,,,Other,Anti-Infective;Pediatric,Current,,,,2019,limited availability
2352,Cefepime Injection,Sagent Pharmaceuticals,1 g vial (NDC 25021-121-20),Reverified,12/20/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
2353,Cefepime Injection,Sagent Pharmaceuticals,2 g vial (NDC 25021-122-50),Reverified,12/20/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
2354,Cefepime Injection,"Fresenius Kabi USA, LLC","1 g single dose vial, sterile powder (NDC 63323-326-20)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,available
2355,Cefepime Injection,"Fresenius Kabi USA, LLC","2 g single dose vial, sterile powder (NDC 63323-340-20)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,available
2356,Cefepime Injection,Baxter Healthcare,"Cefepime Injection, 1 gram/50mL, GALAXY Container (NDC 0338-1301-41)",Reverified,12/11/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
2357,Cefepime Injection,Baxter Healthcare,"Cefepime Injection, 2 gram/100mL, GALAXY Container (NDC 0338-1301-48)",Reverified,12/11/2019,On allocation,,,Other,Anti-Infective;Pediatric,Current,,,,2019,limited availability
2358,Cefepime Injection,"Hospira, Inc.",Maxipime 2 g; Single Dose ADD-Vantage Glass Vial (NDC 00409-0218-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
2359,Cefepime Injection,"Hospira, Inc.",Maxipime 1 g; Single Dose ADD-Vantage Glass Vial (NDC 00409-0217-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
2360,Cefepime Injection,"Hospira, Inc.",Maxipime 1 g; Single Dose Glass Fliptop Vial (NDC 00409-0219-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
2361,Cefepime Injection,"Hospira, Inc.",Maxipime 2 g; Single Dose Glass Fliptop Vial (NDC 00409-0220-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
2362,Cefepime Injection,WG Critical Care,1 g vial (NDC 44567-0240-10),Reverified,11/4/2019,Available,Please check wholesalers and distributors for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,available
2363,Cefepime Injection,WG Critical Care,2 g vial (NDC 44567-0241-10),Reverified,11/4/2019,Available,Please check wholesalers and distributors for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,available
2364,Cefepime Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak Pharmacy Bulk Package (NDC 66288-8100-1),Revised,3/27/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
2365,Cefotaxime Sodium Injection,Apollo Pharmaceuticals Inc.,"2g/vial, (NDC 21586-012-2)",New,8/28/2019,Available,"Apollo in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact FFF Enterprises at 1-800-843-7477",,Other,Anti-Infective;Pediatric,Current,,,,2019,available
2366,Cefotaxime Sodium Injection,Apollo Pharmaceuticals Inc.,"1g/vial, (NDC 21586-011-2)",New,8/28/2019,Available,"Apollo in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact FFF Enterprises at 1-800-843-7477",,Other,Anti-Infective;Pediatric,Current,,,,2019,available
2367,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9930-10),Reverified,12/13/2019,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2019,not available
2368,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9931-25),Reverified,12/13/2019,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2019,not available
2369,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2 g/ 10 mL vial (NDC 0143-9933-25),Reverified,12/13/2019,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2019,not available
2370,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 g/ 100 mL vial (NDC 0143-9935-01),Reverified,12/13/2019,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2019,not available
2371,Cefotetan Disodium Injection,B. Braun Medical Inc.,1 gram/50 mL in DUPLEX (NDC 00264-3173-11),Revised,12/11/2019,Product available,,,Other,Anti-Infective,Current,,,,2019,available
2372,Cefotetan Disodium Injection,B. Braun Medical Inc.,2 gram/50 mL in DUPLEX (NDC 00264-3175-11),Revised,12/11/2019,Product available,,,Other,Anti-Infective,Current,,,,2019,available
2373,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",1 g SDV (NDC 63323-0385-10),Reverified,12/20/2019,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,,2019,available
2374,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",2 g SDV (NDC 63323-0386-20),Reverified,12/20/2019,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,,2019,available
2375,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",10 g PBP (NDC 63323-0396-61),Reverified,12/20/2019,No release date available at this time.,,,Manufacturing delay,Anti-Infective,Current,,,,2019,not available
2376,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),Revised,1/10/2018,Available,,,,Anti-Infective,Current,,,,2019,available
2377,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 1g Vial 10 (NDC 52565-0052-10),Revised,1/10/2018,Available,,,,Anti-Infective,Current,,,,2019,available
2378,"Cefoxitin for Injection, USP",Apotex Corp.,1 g (25 vials) (NDC 60505-0759-05),Reverified,11/27/2019,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2019,discontinued
2379,"Cefoxitin for Injection, USP",Apotex Corp.,2 g (25 vials) (NDC 60505-0760-05),Reverified,11/27/2019,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2019,discontinued
2380,"Cefoxitin for Injection, USP",Apotex Corp.,10 g (10 vials) (NDC 60505-0761-04),Reverified,11/27/2019,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2019,discontinued
2381,"Cefoxitin for Injection, USP","Fresenius Kabi USA, LLC",1 g per vial; SDV; (NDC 63323-341-25),Reverified,12/20/2019,Backordered.  Next release January 2020.,Check wholesalers for inventory,,Manufacturing delays,Anti-Infective,Current,,,,2019,not available
2382,"Cefoxitin for Injection, USP","Fresenius Kabi USA, LLC",2 grams per vial; SDV; (NDC 63323-342-25),Reverified,12/20/2019,Backordered.  Next release January 2020.,Check wholesalers for inventory,,Manufacturing delays,Anti-Infective,Current,,,,2019,not available
2383,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"10 g, package of 10 vials (NDC 25021-111-99)",Reverified,12/20/2019,On backorder. Product continues to be manufactured with monthly releases. Estimated availability Feb-2020,,,Demand increase for the drug,Anti-Infective,Current,,,,2019,not available
2384,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"1 g, package of 10 vials (NDC 25021-109-10)",Reverified,12/20/2019,Available. On allocation,,,Manufacturing delay,Anti-Infective,Current,,,,2019,limited availability
2385,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"2 g, package of 10 vials (NDC 25021-110-20)",Reverified,12/20/2019,On allocation. Product continues to be manufactured with monthly releases. Estimated availability Jan-2020,,,Demand increase for the drug,Anti-Infective,Current,,,,2019,limited availability
2386,"Cefoxitin for Injection, USP",WG Critical Care,1 g (NDC 44567-245-25),Revised,11/4/2019,On backorder.  Next release December.,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,not available
2387,"Cefoxitin for Injection, USP",WG Critical Care,2 g (NDC 44567-246-25),Revised,11/4/2019,On backorder.  Next release December.,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,not available
2388,"Cefoxitin for Injection, USP",WG Critical Care,10 g (NDC 44567-247-10),Revised,11/4/2019,On backorder.  Next release December.,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,not available
2389,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1g vial (NDC 0143-9878-25),Revised,12/13/2019,Available,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,available
2390,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2g vial (NDC 0143-9877-25),Revised,12/13/2019,Available,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,available
2391,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10g vial (NDC 0143-9876-10),Revised,12/13/2019,Available,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2019,available
2392,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 1g Bag 24 x 50mL (NDC 24987-0412-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2019,discontinued
2393,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 2g Bag 24 x 50mL (NDC 24987-0413-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2019,discontinued
2394,Cefuroxime Sodium (Zinacef) Injection,"Teligent Pharma, Inc.",Cefuroxime Sodium (Zinacef) Premix Sol Frozen 1.5g Bag 24 x 50mL (NDC 24987-0425-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2019,discontinued
2395,Cetirizine Hydrochloride,Torrent Pharma Inc.,5 mg/5 mL oral syrup (NDC 13668-596-07),New,4/24/2019,,,,,Pulmonary/Allergy,To be Discontinued,4/24/2019,4/24/2019,,2019,discontinued
2396,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,5 mg (NDC 43547-251-10),New,11/19/2019,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/2019,11/19/2019,,2019,discontinued
2397,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,10 mg (NDC 43547-252-10),New,11/19/2019,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/2019,11/19/2019,,2019,discontinued
2398,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,25 mg (NDC 43547-253-10),New,11/19/2019,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/2019,11/19/2019,,2019,discontinued
2399,Chloroquine Phosphate Tablets,"Rising Pharmaceuticals, Inc.",500 mg (NDC 64980-178-02),Revised,3/25/2016,,,Available,,Anti-Infective;Pediatric,Resolved,3/25/2015,,,2019,
2400,Chlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0150-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2401,Chlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0162-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2402,Chlorpheniramine Maleate; Hydrocodone Bitartrate; Pseudoephedrine Hydrochloride Oral Solution,"Paddock Laboratories, LLC",4 mg/5 mL; 5 mg/5 mL; 60 mg/5 mL (NDC 0574-1103-16),New,6/12/2019,,,,,Pulmonary/Allergy,To be Discontinued,6/12/2019,6/12/2019,,2019,discontinued
2403,Chlorpropamide Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-0197-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2404,Chlorpropamide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0210-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2405,Ciprofloxacin Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 50 count bottle (NDC 0378-1743-89)",New,5/2/2019,,,,,Anti-Infective,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2406,Ciprofloxacin Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"1000 mg, 50 count bottle (NDC 0378-1745-89)",New,5/2/2019,,,,,Anti-Infective,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2407,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",300 mg per 2 mL (150 mg per mL); SDV; (NDC 63323-282-02),New,5/10/2019,,3 & 6 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/2019,5/10/2019,,2019,discontinued
2408,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",600 mg per 4 mL (150 mg per mL); SDV; (NDC 63323-282-04),New,5/10/2019,,6 & 8 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/2019,5/10/2019,,2019,discontinued
2409,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",900 mg per 6 mL (150 mg per mL); SDV; (NDC 63323-282-06),New,5/10/2019,,3 & 5 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/2019,5/10/2019,,2019,discontinued
2410,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",9 grams per Pharmacy Bulk Package (150 mg per mL); (NDC 63323-282-60),New,5/10/2019,,8 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/2019,5/10/2019,,2019,discontinued
2411,Clindamycin Phosphate and Benzoyl Peroxide (Duac) Topical Gel,GlaxoSmithKline,10 mg; 50 mg  (NDC 0145-2371-05),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately November 2019.,,,Dermatology,To be Discontinued,6/28/2019,6/28/2019,,2019,discontinued
2412,Clomiphene Citrate,Teva Pharmaceuticals,50 mg/1 unit tablet (NDC 0093-0041-65),New,6/10/2019,,,,,Reproductive,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
2413,Clomiphene Citrate,Teva Pharmaceuticals,50 mg/1 unit tablet (NDC 0093-0041-03),New,6/10/2019,,,,,Reproductive,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
2414,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg  (90s)(NDC 0378-1910-77),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2415,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (100s)(NDC 0378-1910-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2416,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (1000s)(NDC 0378-1910-10),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2417,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (90s)(NDC 0378-1912-77),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2418,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (100s)(NDC 0378-1912-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2419,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (1000s)(NDC 0378-1912-10),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2420,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (100s)(NDC 0378-1914-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2421,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (500s)(NDC 0378-1914-05),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2422,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0185-0063-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2423,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0185-0063-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2424,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0185-0063-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2425,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0781-8018-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2426,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0781-8018-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2427,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0781-8018-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2428,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-752-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2429,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-752-02)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2430,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-469-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2431,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-469-02)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2432,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0185-0064-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2433,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0185-0064-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2434,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0185-0064-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2435,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0781-5567-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2436,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0781-5567-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2437,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0781-5567-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2438,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg Tablet, 100 CT Bottle (NDC 18860-104-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2439,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","12.5 mg tablet, 100 CT Bottle (NDC 18860-101-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2440,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablets, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-102-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2441,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablet, 100  CT bottle (NDC 18860-102-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2442,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-104-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2443,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-105-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2444,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 100 CT Bottle (NDC 18860-105-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2445,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-106-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2446,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablets, 100 CT Bottle (NDC 18860-106-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
2447,"Cycloserine Capsules, USP",Purdue GMP Center,250mg capsules blister pack x 30 (NDC 13845-1202-2),Revised,4/17/2019,,,Available,,Anti-Infective,Resolved,4/17/2019,,,2019,
2448,Cysteine Hydrochloride Injection,"Exela Pharma Sciences, LLC",Elcys (Cysteine Hydrochloride injection) 500mg/10ml Single-dose vials (NDC 51754-1007-1) Packaged as 10 per carton (NDC 51754-1007-3),Revised,9/3/2019,,,Available,,Other;Pediatric,Resolved,9/3/2019,,,2019,
2449,Daclatasvir Tablets,Bristol Myers Squibb Co.,60 mg tablets (NDC 0003-0215-01),Revised,1/4/2019,,Planned cease distribution is June 2019.,,,Antiviral,To be Discontinued,1/4/2019,1/4/2019,,2019,discontinued
2450,Daclatasvir Tablets,Bristol Myers Squibb Co.,30 mg tablets (NDC 0003-0213-01),Revised,1/4/2019,,Planned cease distribution is June 2019.,,,Antiviral,To be Discontinued,1/4/2019,1/4/2019,,2019,discontinued
2451,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 15 mg Bottle of 30, (NDC 10370-171-11)",New,10/30/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/2019,10/30/2019,,2019,discontinued
2452,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 15 mg Bottle of 90 (NDC 10370-171-09)",New,10/30/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/2019,10/30/2019,,2019,discontinued
2453,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 10370-170-11)",New,10/30/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/2019,10/30/2019,,2019,discontinued
2454,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 7.5 mg Bottle of 90 (NDC 10370-170-09)",New,10/30/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/2019,10/30/2019,,2019,discontinued
2455,Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets,Abbvie,"200mg; 8.33mg; 50mg; 33.33 tablets, (NDC 0074-0063-28)",New,5/22/2018,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary.",,,Antiviral,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
2456,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","500 mg per vial, Single use vial, Carton of 4 vials (NDC 52609-4505-6)",Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2019,
2457,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","2 g per vial, Single use vial, Carton of 4 vials (NDC 52609-4504-6)",Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2019,
2458,"Deferoxamine Mesylate for Injection, USP","Hospira, Inc.",500 mg; Single Dose Glass Fliptop Vial (NDC 00409-2336-10),Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2019,
2459,"Deferoxamine Mesylate for Injection, USP","Hospira, Inc.",2 g; Single Dose Glass Fliptop Vial (NDC 00409-2337-25),Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2019,
2460,"Deferoxamine Mesylate for Injection, USP","Fresenius Kabi USA, LLC","500 mg per vial, 10 mL vial (NDC 63323-597-10)",Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2019,
2461,Delavirdine Mesylate (RESCRIPTOR) Tablets,ViiV Healthcare,200 mg tablets; bottles of 180 tablets (NDC 49702-225-17),New,6/26/2019,,This decision is business-related and the anticipated final date for availability to patients is January 2020.,,,Antiviral,To be Discontinued,6/26/2019,6/26/2019,,2019,discontinued
2462,Desloratadine Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-4017-01)",New,5/2/2019,,,,,Pulmonary/Allergy,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2463,Desloratadine Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-4017-05)",New,5/2/2019,,,,,Pulmonary/Allergy,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2464,Desogestrel and Ethinyl Estradiol Tablets (ORTHO-CEPT),Janssen Pharmaceuticals,ORTHO-CEPT (NDC 50458-196-15),Revised,10/8/2014,,Product will be delisted. Last distribution March 2015.,,Discontinuation of the manufacture of the drug.,,To Be Discontinued,10/8/2014,,,2019,discontinued
2465,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection SDV [4 mg / 1 ml] 25PK (NDC 67457-423-12),Reverified,11/26/2019,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2466,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [20 mg / 5 ml] 25PK (NDC 67457-422-54),Reverified,11/26/2019,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2467,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [120 mg / 30 ml] 25 PK (NDC 67457-421-30),Reverified,11/26/2019,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2468,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [100 mg / 10 ml] 10PK (NDC 67457-420-10),Reverified,11/26/2019,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2469,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),4 mg/1 mL SDV (NDC 55150-237-01),Revised,10/7/2019,Currently available,Check wholesalers for inventory,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2470,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/5 mL MDV  (NDC 55150-238-05),Revised,10/7/2019,Backordered — next shipment anticipated late Oct. 2019.,Intermittent availability expected.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,not available
2471,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),120 mg/30 mL MDV (NDC 55150-239-30),Revised,10/7/2019,Backordered — next shipment anticipated late Oct. 2019.,Intermittent availability expected.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,not available
2472,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL, 1 mL Single Dose Vial (Preservative Free)(NDC 70069-021-25)",New,2/8/2019,Currently in Stock (we have capacity constraint but product available at this time). Estimated Release Dates: Released Product Available,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2473,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",20 mg per 5 mL (4 mg per mL); MDV;  Amber vial (NDC 63323-165-05),Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Delay in manufacturing,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2474,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",100 mg per 10 mL (10 mg per mL); MDV;  Amber Vial (NDC 63323-516-10),Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Delay in manufacturing,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2475,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",120 mg per 30 mL (4 mg per mL); MDV; Amber Vial (NDC 63323-165-30),Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Delay in manufacturing,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2476,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",4 mg per mL (4 mg per mL); SDV; Amber Vial (NDC 63323-165-01),Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Delay in manufacturing,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2477,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",10 mg per mL (10 mg per mL); SDV; Preservative Free; Amber Vial (NDC 63323-506-01),Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2478,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6145-25)",Revised,12/13/2019,"Available, additional lots manufactured Jan/feb 2020.",,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2479,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 5 mL vial (NDC 0641-6146-25)",Revised,12/13/2019,"Available, additional lots manufactured Jan/feb 2020.",,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2480,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-0367-25)",Revised,12/13/2019,"Available, additional lots manufactured Jan/feb 2020.",,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2019,available
2481,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,10 mg 100 Count (NDC 0093-5277-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
2482,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,2.5 mg 100 Count (NDC 0093-5275-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
2483,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,5 mg 100 Count (NDC 0093-5276-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
2484,Dexrazoxane Injection,Gland Pharma,500 mg per vial (NDC 72266-101-01,Reverified,12/10/2019,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Oncology;Pediatric,Current,,,,2019,available
2485,Dexrazoxane Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",250 mg per vial (NDC 0143-9247-01),Reverified,12/13/2019,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2019,available
2486,Dexrazoxane Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9248-01),Reverified,12/13/2019,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured in the June 2019 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2019,not available
2487,Dexrazoxane Injection,Mylan Institutional,250 mg Kit (NDC 67457-207-25),Revised,12/20/2019,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2019,available
2488,Dexrazoxane Injection,Mylan Institutional,500 mg Kit (NDC 67457-208-50),Revised,12/20/2019,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2019,available
2489,Dexrazoxane Injection,Pfizer Pharmaceuticals,Zinecard 250 mg; Single Dose Vial (NDC 00013-8717-62),Reverified,12/20/2019,Available,,,Other,Oncology;Pediatric,Current,,,,2019,available
2490,Dexrazoxane Injection,Pfizer Pharmaceuticals,Zinecard 500 mg; Single Dose Vial (NDC 00013-8727-89),Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Oncology;Pediatric,Current,,,,2019,not available
2491,Dexrazoxane Injection,Clinigen Healthcare Ltd,Totect® (Dexrazoxane) for injection; 1 vial (500 mg)(NDC 66220-110-01),Revised,5/10/2019,Available,,,Available,Oncology;Pediatric,Current,,,,2019,available
2492,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-1070-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2493,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100s (NDC 0378-1071-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2494,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-1072-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2495,Dextrose 25% Injection,"Hospira, Inc.",250 mg/mL (25%); Ansyr Plastic Syringe (NDC 0409-1775-10),Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2019,limited availability
2496,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in VIAFLO container Product codes:  UE0062D (250mL, NDC 0338-0062-30); UE0063D (500mL, NDC 0338-0066-20); UE0064D (1000mL, NDC 0338-0070-10)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2497,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 25 mL, in VIAFLEX Plastic Container. Quad Pack.  Product code 2B0080  (NDC 0338-0017-10)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2498,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, in VIAFLEX Plastic Container.  Single Pack. Product code EZPB0041 (NDC 0338-9147-30)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2499,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLEX Plastic Container.  Product code 2B0062Q  (NDC 0338-0017-02)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2500,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLEX Plastic Container.  Product code 2B0063Q  (NDC 0338-0017-03)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2501,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 1000 mL VIAFLEX Plastic Container. Product code 2B0064X  (NDC 0338-0017-04)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2502,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL AVIVA Container.  Product code 6E0062 (NDC 0338-6346-02)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2503,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL AVIVA Container. Product code 6E0063  (NDC 0338-6346-03)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2504,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-02),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2505,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-03),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2506,Dextrose 5% Injection Bags,"ICU Medical, Inc.",1000 mL (NDC 0409-7922-09),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2507,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL VisIV™ Container (NDC 0409-7922-25),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2508,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-53),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2509,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-55),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2510,Dextrose 5% Injection Bags,"ICU Medical, Inc.",150 mL (NDC 0409-7922-61),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2511,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL VisIV™ Container (NDC 0409-7923-06),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2512,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL VisIV™ Container (NDC 0409-7923-11),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2513,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL (NDC 0409-7923-13),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2514,Dextrose 5% Injection Bags,"ICU Medical, Inc.","25 mL, Quad Pack (NDC 0409-7923-20)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2515,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL (NDC 0409-7923-23),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2516,Dextrose 5% Injection Bags,"ICU Medical, Inc.","50 mL, Quad Pack (NDC 0409-7923-36)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2517,Dextrose 5% Injection Bags,"ICU Medical, Inc.","100 mL, Quad Pack (NDC 0409-7923-37)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2518,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 100mL 
(NDC 63323-624-61)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2519,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 250mL 
(NDC 63323-624-74)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2520,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL, in VIAFLEX Plastic Container: Single Pack (NDC 0338-0017-41)
Quad Pack (NDC 0338-0017-11)
Multi Pack (NDC 0338-0017-31)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2521,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL, in VIAFLEX Plastic Container: Single Pack (NDC 0338-0017-48)
Quad Pack (NDC 0338-0017-18
Multi Pack (NDC 0338-0017-38)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2522,Dextrose 5% Injection Bags,"Hospira, Inc.",50 mL (5%); ADD-Vantage Flexible Container (NDC 00409-7100-66),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2523,Dextrose 5% Injection Bags,"Hospira, Inc.",100 mL (5%); ADD-Vantage Flexible Container (NDC 00409-7100-67),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2524,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 500mL 
(NDC 63323-624-75)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2525,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 1000mL 
(NDC 63323-624-10)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2526,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in MINI-BAG Plus container, 50 mL,  Product code 2B0040 (NDC 0338-0551-11)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2527,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in MINI-BAG Plus container, 100 mL,  Product code 2B0041 (NDC 0338-0551-18)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2019,
2528,Dextrose 50% Injection,"Amphastar Pharmaceuticals, Inc./IMS","DEXTROSE INJECTION, USP, 50%, [500 mg / mL](NDC 76329-3301-1)",Reverified,12/16/2019,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/2019,,,2019,limited availability
2529,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); LifeShield Abboject Glass Syringe (NDC 0409-4902-34),Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: June 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/2019,,,2019,not available
2530,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); Single Dose Glass Fliptop Vial (NDC 0409-6648-02),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/2019,,,2019,not available
2531,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); Ansyr Plastic Syringe (NDC 0409-7517-16),Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: June 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2019,not available
2532,"Diazepam Injection, USP","Beloteca, Inc.","Diazepam Injection, USP 10 mg/2 mL (5 mg/mL) Prefilled Single-dose Syringe with Luer Lock (NDC 69339-136-32)",Revised,12/17/2019,,,,,Neurology,Resolved,12/17/2019,,,2019,
2533,"Diazepam Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1273-32),Revised,12/17/2019,,,,,Neurology,Resolved,12/17/2019,,,2019,
2534,"Diazepam Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-3213-12),Revised,12/17/2019,,,,,Neurology,Resolved,12/17/2019,,,2019,
2535,Diclofenac Sodium Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0355-01),New,4/4/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction;Rheumatology,To be Discontinued,4/4/2018,4/4/2018,,2019,discontinued
2536,Dicyclomine Hydrochloride (BENTYL®) Capsule & Tablet,Allergan Sales LLC,10 mg capsules in bottles of 100 (NDC 58914-012-10),New,3/29/2019,,Product discontinued October 2017,,,Gastroenterology,To be Discontinued,3/29/2019,3/29/2019,,2019,discontinued
2537,Dicyclomine Hydrochloride (BENTYL®) Capsule & Tablet,Allergan Sales LLC,20 mg tablets in bottles of 100 (NDC 58914-013-10),New,3/29/2019,,Product discontinued December 2016,,,Gastroenterology,To be Discontinued,3/29/2019,3/29/2019,,2019,discontinued
2538,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 10mg C 100s (NDC 0378-1610-01),Reverified,11/26/2019,Out of Stock. Resupply is Q4 2019.,,,Other,Gastroenterology,Current,,,,2019,not available
2539,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 10mg C 500s (NDC 0378-1610-05),Reverified,11/26/2019,Out of Stock. Resupply is Q4 2019.,,,Other,Gastroenterology,Current,,,,2019,not available
2540,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 20mg T 100s (NDC 0378-1620-01),Reverified,11/26/2019,Available,,,Other,Gastroenterology,Current,,,,2019,available
2541,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 20mg T 500s (NDC 0378-1620-05),Reverified,11/26/2019,Out of Stock. Resupply is Q4 2019.,,,Other,Gastroenterology,Current,,,,2019,not available
2542,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Capsules USP, 10 mg (100 count bottles) (NDC 0527-0586-01)",Revised,9/12/2019,Available,,,,Gastroenterology,Current,,,,2019,available
2543,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Capsules USP, 10 mg (1000 count bottles) (NDC 0527-0586-10)",Revised,9/12/2019,Available,,,,Gastroenterology,Current,,,,2019,available
2544,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Tablets USP, 20 mg (100 count bottles) (NDC 0527-1282-01)",Revised,9/12/2019,Available,,,,Gastroenterology,Current,,,,2019,available
2545,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Tablets USP, 20 mg (1000 count bottles) (NDC 0527-1282-10)",Revised,9/12/2019,Available,,,,Gastroenterology,Current,,,,2019,available
2546,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 10MG CAPSULES 100 count (NDC 0591-0794-01),Reverified,12/16/2019,Available,Cannot support additional business currently.,,,Gastroenterology,Current,,,,2019,available
2547,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 10MG CAPSULES 1000 count (NDC 0591-0794-10),Reverified,12/16/2019,Available,Cannot support additional business currently.,,,Gastroenterology,Current,,,,2019,available
2548,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 20MG TABLETS 100 count (NDC 0591-0795-01),Reverified,12/16/2019,Available,Cannot support additional business currently.,,,Gastroenterology,Current,,,,2019,available
2549,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 20MG TABLETS 1000 count (NDC 0591-0795-10),Reverified,12/16/2019,Available,Cannot support additional business currently.,,,Gastroenterology,Current,,,,2019,available
2550,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Caps, USP, 10mg 1000s (NDC 0143-3126-10)",Reverified,12/13/2019,Available,,,,Gastroenterology,Current,,,,2019,available
2551,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Caps, USP, 10mg 100s (NDC 0143-3126-01)",Reverified,12/13/2019,Available,,,,Gastroenterology,Current,,,,2019,available
2552,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Tabs, USP, 20mg 1000s (NDC 0143-1227-10)",Reverified,12/13/2019,Available,,,,Gastroenterology,Current,,,,2019,available
2553,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Tabs, USP, 20mg 100s (NDC 0143-1227-01)",Reverified,12/13/2019,Available,,,,Gastroenterology,Current,,,,2019,available
2554,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 200 mg, 30 count bottles (NDC 0555-0588-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2019,discontinued
2555,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 250 mg, 30 count bottles (NDC 0555-0589-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2019,discontinued
2556,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 400 mg, 30 count bottles (NDC 0555-0590-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2019,discontinued
2557,Diethylpropion Hydrochloride Controlled-Release Tablets,Teva Pharmaceuticals,75 mg tablets (NDC 0591-0782-01),New,6/11/2019,,This product discontinuation is a business related decision.,,,Endocrinology/Metabolism,To be Discontinued,6/11/2019,6/11/2019,,2019,discontinued
2558,Diethylpropion Hydrochloride Tablets,Teva Pharmaceuticals,25 mg tablets (NDC 0591-0783-01),New,6/11/2019,,This product discontinuation is a business related decision.,,,Endocrinology/Metabolism,To be Discontinued,6/11/2019,6/11/2019,,2019,discontinued
2559,Difluprednate (Durezol) Ophthalmic Emulsion,Novartis,0.05% 5mL in 8mL bottle (NDC 0065-9204-07),Revised,10/15/2019,,,,,Ophthalmology,Resolved,10/15/2019,,,2019,
2560,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 5 mL vial  (NDC 0641-6013-10)",Revised,12/13/2019,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2561,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial (NDC 0641-6014-10)",Revised,12/13/2019,Temporarily backorderd. Additional lots available end of December 2019 and additional product manufactured Jan/Feb 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,not available
2562,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 30 mL vial (NDC 0641-6015-10)",Revised,12/13/2019,Temporarily backorderd. Additional lots available end of December 2019 and additional product manufactured Jan/Feb 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,not available
2563,Diltiazem Hydrochloride,"Hospira, Inc.",100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03),Reverified,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,limited availability
2564,Diltiazem Hydrochloride,"Hospira, Inc.",25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
2565,Diltiazem Hydrochloride,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02),Reverified,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,limited availability
2566,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10)",Revised,12/2/2019,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2567,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 25 mg / 5 mL, 10 mL, 10 vials (NDC 17478-0817-10)",Revised,12/2/2019,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2568,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 1 vial (NDC 17478-0817-25)",Revised,12/2/2019,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2569,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 10 vials (NDC 17478-0817-26)",Revised,12/2/2019,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2570,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",Revised,12/2/2019,Unavailable. Estimated recovery Dec 2019,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,not available
2571,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",Revised,12/2/2019,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2572,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",Revised,12/2/2019,Unavailable. Estimated recovery Dec 2019,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,not available
2573,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 0.5 mg / mL, 30 gram, 10 vials (NDC 17478-0817-05)",Revised,12/2/2019,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2574,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,60 mg (NDC 0378-6060-01),Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2575,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,90 mg (NDC 0378-6090-01),Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2576,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,120 mg (NDC 0378-6120-01),Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2577,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-5220-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2578,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"120 mg, 500 count bottle (NDC 0378-5220-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2579,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"180 mg, 100 count bottle (NDC 0378-5280-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2580,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"180 mg, 500 count bottle (NDC 0378-5280-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2581,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"240 mg, 100 count bottle (NDC 0378-5340-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2582,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"240 mg, 500 count bottle (NDC 0378-5340-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2583,Diphenhydramine Injection,"Hospira, Inc.",50 mg/mL Carpuject™ Luer Lock Glass Syringe (NDC 00409-2290-31),Reverified,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Pediatric;Pulmonary/Allergy,Current,,,,2019,not available
2584,Diphenhydramine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL vial (NDC 0641-0376-25)",Reverified,12/13/2019,Available,,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,,2019,available
2585,Diphenhydramine Injection,Mylan Institutional,500 mg / 10mL(NDC 67457-124-10),Reverified,11/26/2019,Available,,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,,2019,available
2586,Diphenhydramine Injection,"Fresenius Kabi USA, LLC","50 mg per vial, Single dose, Amber vial (NDC 63323-664-01)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,,2019,available
2587,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100s (NDC 0378-4140-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2588,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100s (NDC 0378-4141-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2589,Disulfiram Tablets,Teva Pharmaceuticals,"250 mg, 100 count (NDC 0093-5035-01)",Reverified,12/16/2019,Availability and estimated duration of supply interruption is unknown,,,Other,Analgesia/Addiction,Current,,,,2019,unclear
2590,Disulfiram Tablets,Teva Pharmaceuticals,"500 mg, 100 count (NDC 0093-5036-01)",Reverified,12/16/2019,Availability and estimated duration of supply interruption is unknown,,,Other,Analgesia/Addiction,Current,,,,2019,unclear
2591,Disulfiram Tablets,"Alvogen, Inc.","250 mg, 30 count (NDC 47781-607-30)",Revised,11/20/2019,Next delivery: February 2020,,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2019,not available
2592,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,500 mg Bottle of 500 (NDC 10370-511-50),New,10/31/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/2019,10/31/2019,,2019,discontinued
2593,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,500 mg Bottle of 100 (NDC 10370-511-10),New,10/31/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/2019,10/31/2019,,2019,discontinued
2594,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,250 mg Bottle of 100 (NDC 10370-510-10),New,10/31/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/2019,10/31/2019,,2019,discontinued
2595,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,250 mg Bottle of 500 (NDC 10370-510-50),New,10/31/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/2019,10/31/2019,,2019,discontinued
2596,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/250 mL (1 mg/mL); Flexible Container (NDC 00409-2346-32),Reverified,12/20/2019,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2019,available
2597,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/250 mL (2 mg/mL); Flexible Container (NDC 00409-2347-32),Reverified,12/20/2019,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2019,available
2598,Dobutamine Hydrochloride Injection,"Hospira, Inc.",1000 mg/250 mL (4 mg/mL); Flexible Container (NDC 00409-3724-32),Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: May 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2019,not available
2599,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-20),Reverified,12/20/2019,Next Delivery: March 2020; Estimated Recovery: June 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2019,not available
2600,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),Reverified,12/20/2019,Next Delivery and Estimated Recovery: December 2019,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2019,not available
2601,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-01),Reverified,12/20/2019,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2019,available
2602,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-02),Reverified,12/20/2019,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2019,available
2603,Dobutamine Hydrochloride Injection,Baxter Healthcare,"250 mg/250 mL (NDC 0338-1073-02) Product code 2B0791, 500 mg/250 mL (NDC 0338-1075-02) Product code 2B0792, 1000 mg/250 mL (NDC 0338-1077-02) Product code 2B0793",Reverified,12/11/2019,Available,,,,Cardiovascular;Pediatric;Renal,Current,,,,2019,available
2604,"Docusate Sodium Capsules, USP",Par Pharmaceutical,"100mg, count bottle (NDC 0603-0150-21)",New,4/9/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,4/9/2019,4/9/2019,,2019,discontinued
2605,"Docusate Sodium Capsules, USP",Par Pharmaceutical,"100mg, count bottle (NDC 0603-0150-32)",New,4/9/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,4/9/2019,4/9/2019,,2019,discontinued
2606,Dopamine Hydrochloride Injection,Baxter Healthcare,"800 mcg/mL (250 mL bag) Product code 2B0832 (NDC 0338-1005-02), 800 mcg/mL (500 mL bag)  Product code 2B0833 (NDC 0338-1005-03), 1600 mcg/mL (250 mL bag) Product code 2B0842 (NDC 0338-1007-02), 1600 mcg/mL (500 mL bag) Product code 2B0843 (NDC 0338-1007-03), 3200 mcg/mL (250 mL bag) Product code 2B0846 (NDC 0338-1009-02)",Reverified,12/11/2019,Available,,,,Cardiovascular,Current,,,,2019,available
2607,Dopamine Hydrochloride Injection,"Hospira, Inc.","400 mg/250 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-22)",Revised,12/20/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2608,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/500 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-24)",Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,limited availability
2609,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/250 mL (3,200 mcg/mL); Flexible Container (NDC 00409-7810-22)",Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,limited availability
2610,Dopamine Hydrochloride Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-5820-01),Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,limited availability
2611,Dopamine Hydrochloride Injection,"Hospira, Inc.",400 mg/10 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9104-20),Revised,12/20/2019,Next Delivery and Estimated Recovery: June 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
2612,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 17478-605-10)",Revised,12/20/2019,Available,,,,Ophthalmology,Current,,,,2019,available
2613,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 50383-233-10)",Revised,12/20/2019,"Limit availability / Recovery expected Q1, 2020","Manufacturer interruption production issues.  Marketed by Hi-Tech Pharmacal Co., Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,,2019,limited availability
2614,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt-PF® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 0.2 mL single use, 60 count (NDC 17478-604-30)",Revised,12/20/2019,Available,"Marketed by Akorn, Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,,2019,available
2615,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 61314-030-02)",Reverified,12/18/2019,Supply available,"Labeled under Sandoz Inc. To order, contact Sandoz Inc. at 1-800-525-8747",,Demand increase for the product,Ophthalmology,Current,,,,2019,available
2616,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 24208-486-10)",Revised,12/13/2019,Intermittent backorders through Q1 2020. Estimated availability: Late January 2020/February 2020,"Marketed by Bausch & Lomb Inc. To order, contact Bausch & Lomb, a division of Valeant Pharmaceuticals North America at pharcs@valeant.com",,Other,Ophthalmology,Current,,,,2019,limited availability
2617,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 0591-2482-79)",Reverified,12/16/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,,,2019,not available
2618,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride and Timolol Maleate 20 mg and 5 mg/mL, 10 mL (0591-2482-79)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing this product.,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2019,discontinued
2619,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Aurobindo Pharma,"Dorzolamide HCl and Timolol Maleate (Cosopt® PF) Ophthalmic Solution 2%/0.5% Preservative Free, 2mL single use container (NDC 65862-0947-60)",Reverified,12/13/2019,Available,Available,,Other,Ophthalmology,Current,,,,2019,available
2620,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2019,discontinued
2621,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2019,discontinued
2622,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",Reverified,12/16/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,4/20/2018,4/20/2018,,2019,not available
2623,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",Reverified,12/16/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,4/20/2018,4/20/2018,,2019,not available
2624,Dorzolamide Hydrochloride Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 50383-232-10)",Revised,12/2/2019,"Limit availability / Recovery expected Q1, 2020","Manufacturer interruption production issues. Distributed by Hi-Tech Pharmacal Co., Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,,2019,limited availability
2625,Dorzolamide Hydrochloride Ophthalmic Solution,Merck Sharp & Dohme Corp.,"TRUSOPT® dorzolamide hydrochloride ophthalmic solution 2%, 10 mL in an 18 mL capacity bottle (NDC 0006-3519-36)",Reverified,6/1/2018,Product is available,"For additional information please contact: Merck National Service Center, Telephone Number: 1-800-672-6372",,Demand increase for the drug,Ophthalmology,Current,,,,2019,available
2626,Dorzolamide Hydrochloride Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride USP 2%, 10 mL (NDC 24208-485-10)",Revised,12/13/2019,Currently on backorder. Estimated availability: January 2020,"Marketed by Bausch & Lomb Inc. To order, contact Bausch & Lomb, a division of Bausch Health US, LLC at pharcs@bauschhealth.com",,Other,Ophthalmology,Current,,,,2019,not available
2627,Dorzolamide Hydrochloride Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 61314-019-10)",Reverified,12/18/2019,Supply available,"Labeled under Sandoz Inc. To order, contact Sandoz Inc. at 1-800-525-8747",,Demand increase for the product,Ophthalmology,Current,,,,2019,available
2628,Doxycycline Capsules,Teva Pharmaceuticals,50 mg capsules (NDC 0591-0410-01),New,4/29/2019,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/2019,4/29/2019,,2019,discontinued
2629,Doxycycline Capsules,Teva Pharmaceuticals,75 mg capsules (NDC 0591-2404-01),New,4/29/2019,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/2019,4/29/2019,,2019,discontinued
2630,Doxycycline Capsules,Teva Pharmaceuticals,100 mg capsules (NDC 0591-0411-50),New,4/29/2019,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/2019,4/29/2019,,2019,discontinued
2631,Doxycycline Hyclate Capsules,Teva Pharmaceuticals,50 mg  (NDC 0591-5535-50),New,10/15/2019,,This product is being discontinued due to a business decision.,,,Anti-Infective,To be Discontinued,10/15/2019,10/15/2019,,2019,discontinued
2632,Doxycycline Hyclate Capsules,Teva Pharmaceuticals,100 mg (NDCs 0591-5440-50 and 0591-5440-05),New,10/15/2019,,This product is being discontinued due to a business decision.,,,Anti-Infective,To be Discontinued,10/15/2019,10/15/2019,,2019,discontinued
2633,Doxycycline Hyclate Delayed Release Tablets,Mylan Pharmaceuticals Inc.,150 mg tablets (NDC 0378-3030-01),New,9/9/2019,,,,,Anti-Infective,To be Discontinued,9/9/2019,9/9/2019,,2019,discontinued
2634,Dronabinol Capsules,"Endo Pharmaceuticals, Inc.","2.5 mg capsules (NDC 498840-867-02), 5 mg capsules (NDC 498840-868-02), 10 mg capsules (NDC 498840-869-02)",New,2/7/2019,,,,,Gastroenterology,To be Discontinued,2/7/2019,2/7/2019,,2019,discontinued
2635,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Pfizer Pharmaceuticals,6.25 mg package for 0.125% (NDC 0046-1065-05),Reverified,12/20/2019,Next delivery and Estimated recovery: Q3 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Ophthalmology,Current,,,,2019,not available
2636,Eflornithine Hydrochloride (Vaniqa) Cream,Allergan,13.9% (NDC 0023-4857-45),Revised,6/12/2019,,,,,Dermatology,Resolved,6/12/2019,,,2019,
2637,Emedastine Difumarate (Emadine) 0.05% Ophthalmic Solution,Novartis,Emadine (emedastine difumarate) 0.05% ophthalmic solution 5mL in 1 Bottle (NDC 0065-0325-05),New,1/29/2019,,Novartis Pharmaceuticals has made a business decision to permanently discontinue this product.,,,Ophthalmology;Pulmonary/Allergy,To be Discontinued,1/29/2019,1/29/2019,,2019,discontinued
2638,"Enalaprilat Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2.5mg/2mL, vial (NDC 0143-9786-10)",Revised,12/13/2019,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2019,not available
2639,"Enalaprilat Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1.25mg/mL, vial  (NDC 0143-9787-10)",Revised,12/13/2019,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2019,not available
2640,"Enalaprilat Injection, USP","Hospira, Inc.",1.25 mg/mL; Single Dose Glass Fliptop Vial (NDC 00409-2122-01),Reverified,12/20/2019,Next Delivery: March 2020;  Estimated Recovery: June 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
2641,"Enalaprilat Injection, USP","Hospira, Inc.",2.5 mg/2 mL (1.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2122-02),Reverified,12/20/2019,Next Delivery: March 2020;  Estimated Recovery: June 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
2642,Epinastine Hydrochloride (Elestat®) Ophthalmic Solution,Allergan,5 mL in 10 mL bottle (NDC 00023-9201-05),New,8/19/2019,,,,,Ophthalmology,To be Discontinued,8/19/2019,8/19/2019,,2019,discontinued
2643,"Epinephrine Injection, 0.1 mg/mL","Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 00409-4921-34, pack of 10; NDC 0409-4921-20, individual)",Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pulmonary/Allergy,Current,,,,2019,limited availability
2644,"Epinephrine Injection, 0.1 mg/mL","Amphastar Pharmaceuticals, Inc./IMS","1:10,000, 10mL Luer-Jet Prefilled Syringe
(NDC 76329-3316-1)(old NDC 0548-3316-00)",Reverified,12/16/2019,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Cardiovascular;Pulmonary/Allergy,Current,,,,2019,limited availability
2645,"Epinephrine Injection, Auto-Injector",Mylan Specialty,"0.3 mg (EpiPen® NDC 49502-500-02, pack of 2; NDC 49502-500-01, individual) (Authorized Generic NDC 49502-102-02, pack of 2; NDC 49502-102-01, individual)",Reverified,11/26/2019,Available,"Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from pharmacy to pharmacy. Mylan, the distributor, is expediting shipments to wholesalers upon receipt from Pfizer. Patients who are experiencing difficulty accessing product should continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.",,Manufacturing delays,Pulmonary/Allergy,Current,,,,2019,available
2646,"Epinephrine Injection, Auto-Injector",Mylan Specialty,0.15 mg (EpiPen® NDC 49502-501-02) (Authorized Generic NDC 49502-101-02),Reverified,11/26/2019,Available,"Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from pharmacy to pharmacy. Mylan, the distributor, is expediting shipments to wholesalers upon receipt from Pfizer. Patients who are experiencing difficulty accessing product should continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.",,Manufacturing delays,Pulmonary/Allergy,Current,,,,2019,available
2647,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)",Revised,12/13/2019,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,,2019,limited availability
2648,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)",Revised,12/13/2019,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,,2019,limited availability
2649,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)",Reverified,12/13/2019,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2019,available
2650,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)",Reverified,12/13/2019,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2019,available
2651,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)",Reverified,12/13/2019,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2019,available
2652,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)",Reverified,12/16/2019,Available,,,,Pulmonary/Allergy,Current,,,,2019,available
2653,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.3 mg single-dose, pre-filled syringes (NDC 0781-3442-20)",Reverified,12/17/2019,Available,,,,Pulmonary/Allergy,Current,,,,2019,available
2654,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.15 mg single-dose, pre-filled syringes (NDC 0781-3448-20)",Reverified,12/17/2019,Available,,,,Pulmonary/Allergy,Current,,,,2019,available
2655,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.15 MG Epinephrine Injection, USP auto-injector (NDC 0093-5985-27)",Reverified,12/16/2019,Available,,,,Pulmonary/Allergy,Current,,,,2019,available
2656,Epirubicin Hydrochloride Injection,Teva Pharmaceuticals,2 mg/1 mL  (NDCs 45963-608-60 and 45963-608-68),New,7/17/2019,,This product discontinuation is a business related decision.  Anticipated discontinuance time is first quarter of the year 2020.,,,Oncology,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2657,Epirubicin Hydrochloride Injection,Cipla Limited,2 mg/1 mL  (NDCs 25021-203-25 and 59923-701-25),New,7/17/2019,,Anticipated unavailability of product is September 2019.,,,Oncology,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2658,Eprosartan Mesylate Tablets,Mylan Pharmaceuticals Inc.,Eprosartan Mesylate 600mg T 30s (NDC 0378-6629-93),Reverified,11/26/2019,Out of stock. Resupply TBD,,,Other,Cardiovascular,Current,,,,2019,not available
2659,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,0.75 mg/mL (NDCs 0085-1136-02 and 0085-1136-03),New,11/18/2019,,The following presentation will continue to be available: 0.75 mg/mL (NDC 0085-1136-01 ),,,Cardiovascular,To be Discontinued,11/18/2019,11/18/2019,,2019,discontinued
2660,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,2 mg/mL (NDCs 0085-1177-03 and 0085-1177-05),New,11/18/2019,,The following presentations will continue to be available: 2 mg/mL (NDCs 0085-1177-01 and 0085-1177-02),,,Cardiovascular,To be Discontinued,11/18/2019,11/18/2019,,2019,discontinued
2661,"Erythromycin Lactobionate for Injection, USP","Hospira, Inc.",500 mg Single Dose Glass Fliptop Vial (NDC 00409-6482-01),Revised,12/20/2019,Available,,,Other,Anti-Infective,Current,,,,2019,available
2662,"Erythromycin Lactobionate for Injection, USP","Hospira, Inc.",500 mg Single-dose ADD-Vantage® Vial (NDC 00409-6476-44),Revised,12/20/2019,Available,,,Other,Anti-Infective,Current,,,,2019,available
2663,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35),Revised,12/2/2019,Limited availability.,"Expected availability Dec, 2019",,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2019,limited availability
2664,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC17478-070-01),Revised,12/2/2019,On backorder,"Expected availability Oct 1, 2019",,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2019,not available
2665,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-824-35)(Premier),Revised,12/2/2019,No longer distributing,,,,Ophthalmology,Current,,,,2019,discontinued
2666,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC 17478-824-01)(Premier),Revised,12/2/2019,No longer distributing,,,,Ophthalmology,Current,,,,2019,discontinued
2667,Erythromycin Ophthalmic Ointment,Bausch Health,3.5 g in 1 Tube (NDC 24208-910-55),Reverified,12/13/2019,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,Demand increase for the drug,Ophthalmology,Current,,,,2019,available
2668,Erythromycin Ophthalmic Ointment,Bausch Health,1 g in cartons of 50 (NDC 24208-910-19),Reverified,12/13/2019,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,Demand increase for the drug,Ophthalmology,Current,,,,2019,available
2669,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"1 gram, 50-count (NDC 00574-4024-50)",Revised,12/10/2019,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,,2019,available
2670,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 1-count (NDC 00574-4024-35)",Revised,12/10/2019,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,,2019,available
2671,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 24-count (NDC 00574-4024-39)",Revised,12/10/2019,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,,2019,available
2672,Escitalopram (Lexapro) 5 mg/5 mL Oral Solution,Allergan Sales LLC,Lexapro oral solution 240 mL bottle 5 mg/5mL (NDC 0456-2101-08),New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2673,Escitalopram (Lexapro) 5 mg/5 mL Oral Solution,Allergan Sales LLC,Escitalopram Oxalate oral solution 240 mL bottle (NDC 0591-4151-38),New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2674,Ethinyl Estradiol and Levonorgestrel (Myzilra),"Endo Pharmaceuticals, Inc.","0.03mg, 0.04mg, 0.03mg, 0.05mg, 0.075mg, 0.125mg; 6 blister pack in 1 carton (NDC 0603-7625-17)",New,5/10/2019,,Discontinued due to business reasons.,,,Reproductive,To be Discontinued,5/10/2019,5/10/2019,,2019,discontinued
2675,Ethinyl Estradiol and Levonorgestrel (Myzilra),"Endo Pharmaceuticals, Inc.","0.03mg, 0.04mg, 0.03mg, 0.05mg, 0.075mg, 0.125mg; 3 blister pack in 1 carton (NDC 0603-7625-49)",New,5/10/2019,,Discontinued due to business reasons.,,,Reproductive,To be Discontinued,5/10/2019,5/10/2019,,2019,discontinued
2676,Ethiodized Oil (Lipiodol) Injection,Guerbet LLC,Box of one 10 mL ampoule (NDC 67684-1901-1),Revised,8/1/2019,,,Available,,Medical Imaging;Oncology,Resolved,8/1/2019,,,2019,
2677,Ethiodized Oil (Lipiodol) Injection,Guerbet LLC,Box of one 10 mL ampoule (NDC 67684-1901-1),Revised,7/31/2019,,,,,Medical Imaging;Oncology,Resolved,7/31/2019,,,2019,
2678,"Ethosuximide Oral Solution, USP",Teva Pharmaceuticals,"250 mg/5mL, 474 mL Bottle (NDC 0093-9660-16)",New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
2679,Etoposide Injection,Accord Healthcare Inc.,ETOPOSIDE INJ USP 20MG/ML 5ML (NDC 16729-114-31),Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2680,Etoposide Injection,Accord Healthcare Inc.,ETOPOSIDE INJ USP 20MG/ML (Nova Plus) 5ML (NDC 16729-262-31),Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2681,Etoposide Injection,Accord Healthcare Inc.,ETOPOSIDE INJ. USP 20MG/ML 25 ML (NDC 16729-114-08),Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2682,Etoposide Injection,Accord Healthcare Inc.,ETOPOSIDE INJ. USP 20MG/ML 50 ML (NDC 16729-114-11),Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2683,Etoposide Injection,"Fresenius Kabi USA, LLC","100 mg per 5 mL, 20 mg per mL, MDV (NDC 63323-104-05)",Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2684,Etoposide Injection,"Fresenius Kabi USA, LLC","500 mg per 25 mL, 20 mg per mL, MDV (NDC 63323-104-25)",Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2685,Etoposide Injection,"Fresenius Kabi USA, LLC","1 gram per 50 mL, 20 mg per mL, MDV (NDC 63323-104-50)",Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2686,Etoposide Injection,Teva Pharmaceuticals,100 mg/5 mL Multiple-dose Vials (NDC 0703-5653-01),Revised,8/16/2019,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,8/16/2019,8/16/2019,,2019,discontinued
2687,Etoposide Injection,Teva Pharmaceuticals,500 mg/25 mL Multiple-dose Vials (NDC 0703-5656-01),Revised,8/16/2019,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,8/16/2019,8/16/2019,,2019,discontinued
2688,Etoposide Injection,Teva Pharmaceuticals,1 gram/50 mL Multiple-dose Vials (NDC 0703-5657-01),Revised,8/16/2019,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,8/16/2019,8/16/2019,,2019,discontinued
2689,Etoposide Injection,West-Ward Pharmaceuticals,"20 mg/mL, 5 mL vial (NDC 0143-9510-01)",Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2690,Etoposide Injection,West-Ward Pharmaceuticals,"20 mg/mL, 25 mL vial (NDC 0143-9511-01)",Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2691,Etoposide Injection,West-Ward Pharmaceuticals,"20 mg/mL, 50 mL vial (NDC 0143-9512-01)",Revised,6/12/2019,,,,,Oncology,Resolved,6/12/2019,,,2019,
2692,Etoposide Phosphate (Etopophos) Injection,Bristol Myers Squibb Co.,Etopophos Injection 100 mg (1VL) 10.6 mL US (NDC 0015-3404-20),Revised,6/12/2019,, ,,,Oncology,Resolved,6/12/2019,,,2019,
2693,Exenatide (BYDUREON) Extended Release for Injectable Suspension,AstraZeneca,"BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use;  Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)",New,4/3/2018,,"The planned permanent discontinuance of the Bydureon Single Dose Tray inventory from the U.S. market is September 30, 2018.  There are currently 2 other delivery options for exenatide-extended-release:  the Bydureon® Dual Chamber Pen presentation (NDC 0310-6530-04) and Bydureon® BCise™ (NDC 0310-6540-04).",,,Endocrinology/Metabolism,To be Discontinued,4/3/2018,4/3/2018,,2019,discontinued
2694,Fenofibric Acid Delayed-Release Capsules,Par Pharmaceutical,Fenofibric Acid Delayed-Release Capsules 45mg 90s (NDC 10370-209-09),New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
2695,Fenofibric Acid Delayed-Release Capsules,Par Pharmaceutical,Fenofibric Acid Delayed-Release Capsules 135mg 90s (NDC 10370-210-09),New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
2696,Fenofibric Acid Delayed-Release Capsules,Mylan Pharmaceuticals Inc.,"45 mg, 90 count bottle (NDC 0378-2589-77)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2697,Fenofibric Acid Delayed-Release Capsules,Mylan Pharmaceuticals Inc.,"135 mg, 90 count bottle (NDC 0378-2590-77)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2698,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 25 pack (NDC 17478-0030-55),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2699,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1276-32),Revised,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,not available
2700,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-32),Revised,12/20/2019,Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,not available
2701,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-35),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2702,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",1000 mcg/20 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-38),Revised,12/20/2019,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,discontinued
2703,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-22),Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,limited availability
2704,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-25),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2705,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",500 mcg/10 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-28),Revised,12/20/2019,Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,not available
2706,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","1,000 mcg/20 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-31)",Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,limited availability
2707,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","2,500 mcg/50 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-61)",Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,limited availability
2708,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 2 mL ampul (NDC 0641-6024-10),Revised,12/13/2019,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2709,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 5 mL ampul (NDC 0641-6025-10),Revised,12/13/2019,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2710,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL ampul (NDC 0641-6026-05),Revised,12/13/2019,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2711,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 2 mL vial
(NDC 0641-6027-25)",Revised,12/13/2019,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2712,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 5 mL vial
(NDC 0641-6028-25)",Revised,12/13/2019,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2713,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL vial (NDC 0641-6029-25),Revised,12/13/2019,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,not available
2714,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL  50 mL vial
(NDC 0641-6030-01)",Revised,12/13/2019,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,not available
2715,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule 10 pack (NDC 17478-0030-02),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2716,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule; 25 pack (NDC 17478-0030-25),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2717,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 10 pack (NDC 17478-0030-05),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2718,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,20 mL ampule (NDC 17478-0030-20),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
2719,Finasteride Tablets,Mylan Pharmaceuticals Inc.,5 mg tablet (NDC 0378-5036-05)(NDC 0378-5036-77)(NDC 0378-5036-93),New,5/23/2018,,The discontinuation of this product is a business decision,,,Urology,To be Discontinued,5/23/2018,5/23/2018,,2019,discontinued
2720,Fludrocortisone Acetate Tablets,Teva Pharmaceuticals,"0.1 mg, 100 count bottle (NDC 0555-0997-02)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2019,
2721,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 100 count bottle (NDC 0115-7033-01)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2019,
2722,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 500 count bottle (NDC 0115-7033-02)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2019,
2723,Flumazenil Injection,Mylan,"1 mg in 10 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-444-10)",Revised,7/19/2019,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,7/19/2019,7/19/2019,,2019,discontinued
2724,Flumazenil Injection,Mylan,"0.5 mg in 5 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-447-53)",New,12/16/2019,,Expected Discontinuation April 2020,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,12/16/2019,12/16/2019,,2019,discontinued
2725,Fluorescein Injection,Novartis,Fluorescite (fluorescein injection) 10% 5 mL vial (NDC 0065-0092-65),Reverified,12/11/2019,Available,,,Other,Ophthalmology,Current,,,,2019,available
2726,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR® (fluorescein injection, USP) 10%, 100 mg/mL in a 5 mL single use vial (NDC 17478-253-10)",Revised,12/2/2019,Available,Continue to allocate available inventory,,Shortage of an active ingredient,Ophthalmology,Current,,,,2019,available
2727,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR® (fluorescein injection, USP) 25%, 250 mg/mL in a 2 mL single use vial (NDC 17478-250-20)",Revised,12/2/2019,Available,Continue to allocate available inventory,,Shortage of an active ingredient,Ophthalmology,Current,,,,2019,available
2728,Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution,Altaire,"Altafluor Solution Fluorescein sodium 0.25% and Benoxinate HCl 0.4%, 5 mL bottle (NDC 59390-0218-05)",Revised,12/10/2019,,,,,Ophthalmology,Resolved,12/10/2019,,,2019,
2729,Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution,Altaire,"Flurox Solution  Fluorescein sodium 2.5mg (0.25%), benoxinate hydrochloride 4mg (0.4%), 5mL bottle (NDC 54799-508-05)",Revised,12/11/2019,,,,,Ophthalmology,Resolved,12/11/2019,,,2019,
2730,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 100 Strips per box (ndc 17238-900-11),Revised,10/23/2019,Available,,,,Ophthalmology,Current,,,,2019,available
2731,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 300 Strips per box (NDC 17238-900-30),Revised,10/23/2019,Available,,,,Ophthalmology,Current,,,,2019,available
2732,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 1.0 mg 100 sterile strips (NDC 17478-404-01),Revised,12/2/2019,On backorder,Availability Q12020,,Other,Ophthalmology,Current,,,,2019,not available
2733,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 0.6 mg 300 sterile strips (NDC 17478-403-03),Revised,12/2/2019,On backorder,Availability Q12020,,Other,Ophthalmology,Current,,,,2019,not available
2734,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 100 count bottle (NDC 0781-2823-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2735,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 1000 count bottle (NDC 0781-2823-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2736,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 100 count bottle (NDC 0781-2822-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2737,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 1000 count bottle (NDC 0781-2822-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2738,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 100 count bottle (NDC 0781-2824-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2739,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 1000 count bottle (NDC 0781-2824-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2740,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 30 count bottle (NDC 0781-2824-31)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
2741,Fluoxetine Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 28 count bottle (NDC 0378-5410-28)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2742,Fluoxetine Capsules,Mylan Pharmaceuticals Inc.,"20 mg, 28 count bottle (NDC 0378-5420-28)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2743,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-6004-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2744,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 500 count bottle (NDC 0378-6004-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2745,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"2.5 mg, 100 count bottle (NDC 0378-6009-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2746,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"2.5 mg, 500 count bottle (NDC 0378-6009-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2747,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-6074-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2748,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-6074-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2749,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-6097-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2750,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-6097-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2751,Flurazepam Hydrochloride Capsules,Mylan Pharmaceuticals Inc.,Flurazepam HCl 15mg C 100s (NDC 0378-4415-01),Reverified,11/26/2019,Out of Stock. Resupply is Q4 2019.,,,Other,Psychiatry,Current,,,,2019,not available
2752,Flurazepam Hydrochloride Capsules,Mylan Pharmaceuticals Inc.,Flurazepam HCl 30mg C 100s (NDC 0378-4430-01),Reverified,11/26/2019,Out of Stock. Resupply is Q1 2020.,,,Other,Psychiatry,Current,,,,2019,not available
2753,Flurbiprofen Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 100 count bottle (NDC 0378-0076-01)",New,5/2/2019,,,,,Rheumatology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2754,Flurbiprofen Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-0093-01)",New,5/2/2019,,,,,Rheumatology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2755,"Flutamide Capsules, USP",Teva Pharmaceuticals,125 mg 180 count (NDC 0591-2466-18),New,6/10/2019,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
2756,Fluvastatin Sodium Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 30 count bottle (NDC 0378-5121-93)",New,5/2/2019,,,,,Endocrinology/Metabolism;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2757,Fluvastatin Sodium Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-5121-01)",New,5/2/2019,,,,,Endocrinology/Metabolism;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2758,Fluvoxamine ER Capsules,Par Pharmaceutical,100 mg. 30’s count (NDC 10370-175-11),Revised,12/6/2019,On backorder. Estimated availability January 2020,,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,not available
2759,Fluvoxamine ER Capsules,Par Pharmaceutical,150 mg. 30’s count (NDC 10370-176-11),Revised,12/16/2019,On backorder. Estimated availability January 2020,,,Shortage of an active ingredient,Psychiatry,Current,,,,2019,not available
2760,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03)",Reverified,12/16/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2761,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03)",Reverified,12/16/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2762,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 100 (NDC 0603-3162-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2763,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 1000 (NDC 0603-3162-32)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2764,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 2500 (NDC 0603-3162-30)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2765,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 600 mg, 100 count (NDC 0093-4443-01)",New,12/6/2018,"This was a business-related decision to discontinue manufacturing these products. TEVA is replacing this same strength product under NDC 0228-2636-11 Gabapentin Tablets, 600mg, 100 count.",,,,Neurology,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
2766,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 600 mg, 500 count (NDC 0093-4443-05)",New,12/6/2018,"This was a business-related decision to discontinue manufacturing these products. TEVA is replacing this same strength product under NDC 0228-2636-50 Gabapentin Tablets, 600mg, 500 count.",,,,Neurology,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
2767,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 600 mg, 1000 count (NDC 0093-4443-10)",New,12/6/2018,This was a business-related decision to discontinue manufacturing these products.,,,,Neurology,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
2768,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 800 mg, 100 count (NDC 0093-4444-01)",New,12/6/2018,"This was a business-related decision to discontinue manufacturing these products. TEVA is replacing this same strength product under NDC 0228-2637-11 Gabapentin Tablets, 800mg, 100 count.",,,,Neurology,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
2769,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 800 mg, 500 count (NDC 0093-4444-05)",New,12/6/2018,"This was a business-related decision to discontinue manufacturing these products. TEVA is replacing this same strength product under NDC 0228-2637-50 Gabapentin Tablets, 600mg, 500 count.",,,,Neurology,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
2770,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 5 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-81)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2771,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 10 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-82)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2772,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 15 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-83)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2773,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 20 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-84)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2774,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 10 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-36)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2775,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 15 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-37)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2776,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 20 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-38)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2777,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Pharmacy Bulk Package 50 mL Pharmacy Bulk Package, rubber stoppered, 10 per box (NDC 50419-188-58)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2778,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Pharmacy Bulk Package 100 mL Pharmacy Bulk Package, rubber stoppered, 10 per box (NDC 50419-188-11)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
2779,Galantamine Hydrobromide Tablets,Janssen Pharmaceuticals,4 mg tablets (NDCs 50458-396-60 and 10147-0881-6),New,10/29/2018,,The last batches will be distributed April 2019.,,,Neurology,To be Discontinued,10/29/2018,10/29/2018,,2019,discontinued
2780,Galantamine Hydrobromide Tablets,Janssen Pharmaceuticals,8 mg tablets (NDCs 50458-397-60 and 10147-0882-6),New,10/29/2018,,The last batches will be distributed April 2019.,,,Neurology,To be Discontinued,10/29/2018,10/29/2018,,2019,discontinued
2781,Galantamine Hydrobromide Tablets,Janssen Pharmaceuticals,12 mg tablets (NDCs 50458-398-60 and 10147-0883-6),New,10/29/2018,,The last batches will be distributed April 2019.,,,Neurology,To be Discontinued,10/29/2018,10/29/2018,,2019,discontinued
2782,Gemcitabine Hydrochloride Injection,Mylan,"1 g, single dose vial (NDC 67457-462-01)",New,12/16/2019,,Expected Discontinuation March/April 2020,,,Oncology,To be Discontinued,12/16/2019,12/16/2019,,2019,discontinued
2783,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 7 Tablets in 1 Blister Pack (NDC 44004-321-07)",Reverified,12/18/2019,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,,2019,unclear
2784,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 5 Tablets in 1 Blister Pack (NDC 44004-321-05)",Reverified,12/18/2019,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,,2019,unclear
2785,Glimepiride Tablets,Teva Pharmaceuticals,1 mg 100 Count (NDC 0093-7254-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
2786,Glimepiride Tablets,Teva Pharmaceuticals,2 mg 100 Count (NDC 0093-7255-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
2787,Glimepiride Tablets,Teva Pharmaceuticals,4 mg 100 Count (NDC 0093-7256-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
2788,Glimepiride Tablets,Teva Pharmaceuticals,4 mg 250 Count (NDC 0093-7256-52),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
2789,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-1061-01)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2790,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"2 mg, 100 count bottle (NDC 0378-1062-01)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2791,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"3 mg, 100 count bottle (NDC 0378-1063-01)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2792,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"4 mg, 100 count bottle (NDC 0378-1065-01)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2793,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 1 mg, 100 Count (NDC 42806-048-01)",New,6/12/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2794,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 2 mg, 100 Count (NDC 42806-296-01)",New,6/12/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2795,Guanfacine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-1160-01),Reverified,11/26/2019,Unavailable. Estimated recovery: Q1 2020.,,,Other,Cardiovascular,Current,,,,2019,not available
2796,Guanfacine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-1190-01),Reverified,11/26/2019,Unavailable. Estimated recovery: Q1 2020.,,,Other,Cardiovascular,Current,,,,2019,not available
2797,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,1mg tablets 100 count bottle (NDC 0591-0444-01),Reverified,12/16/2019,"Available, however limited supply until mid December 2019",,,Shortage of an active ingredient,Cardiovascular,Current,,,,2019,limited availability
2798,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,2 mg tablets 100 count bottle (NDC 0591-0453-01),Reverified,12/16/2019,Available,,,,Cardiovascular,Current,,,,2019,available
2799,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,1 mg bottles of 30 (NDC 65162-711-03); 1 mg bottles of 100 (NDC 65162-711-10),Reverified,12/17/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2800,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,2 mg bottles of 30 (NDC 65162-713-03); 2 mg bottles of 100 (NDC 65162-713-10); 2 mg bottles of 500 (NDC 65162-713-50),Reverified,12/17/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2801,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,0.5 mg (NDC 0378-0351-01) and (NDC 0378-0351-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2802,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-0257-01) and (NDC 0378-0257-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2803,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0214-01) and (NDC 0378-0214-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2804,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-0327-01) and (NDC 0378-0327-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2805,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0334-01),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2806,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,20 mg (NDC 0378-0355-01),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2807,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 100 CT (NDC 68382-079-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2019,
2808,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 1000 CT (NDC 68382-079-10),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2019,
2809,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 10MG 100 CT (NDC 68382-080-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2019,
2810,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 20MG 100 CT (NDC 68382-081-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2019,
2811,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-13-9101),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2812,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-83-9101),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2813,Haloperidol Tablets,Sandoz,0.5 mg 100 count unit dose (NDC 0781-13-9113),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2814,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-13-9201),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2815,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-83-9201),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2816,Haloperidol Tablets,Sandoz,1 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2817,Haloperidol Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-13-9801),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2818,Haloperidol Tablets,Sandoz,2 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2819,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-13-9610),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2820,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-83-9610),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2821,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-13-9601),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2822,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-83-9601),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2823,Haloperidol Tablets,Sandoz,5 mg 100 count unit dose (NDC 0781-13-9613),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2824,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-13-9701),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2825,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-83-9701),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2826,Haloperidol Tablets,Sandoz,10 mg 100 count unit dose (NDC 0781-13-9713),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2827,Haloperidol Tablets,Sandoz,20 mg 100 count bottle (NDC 0781-83-9301),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2019,
2828,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium BP 2,000 IU/L  in 0.9% w/v Sodium Chloride IV Infusion in VIAFLEX container  (1,000 units / 500 mL)  Product code FKB0953G (NDC 0338-9556-20)",Revised,12/11/2019,Available,Baxter Healthcare Corporation in conjunction with FDA has initiated temporary importation of Heparin IV Infusion into the U.S. market to address drug shortages.,,,Hematology,Current,,,,2019,available
2829,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 2,000 USP units in 1000 mL.  Product code 2B0944  (NDC 0338-0433-04)",Revised,12/11/2019,Available,,,,Hematology,Current,,,,2019,available
2830,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 1,000 USP units in 500 mL.  Product code 2B0953 (NDC 0338-0431-03)",Revised,12/11/2019,Unavailable,,,Other,Hematology,Current,,,,2019,not available
2831,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","1,000 Units/500 mL (2 Units/mL); Flexible Container (NDC 00409-7620-03)",Reverified,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Hematology,Current,,,,2019,limited availability
2832,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","2,000 Units/1000 mL (2 Units/mL); Flexible Container (NDC 00409-7620-59)",Reverified,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Hematology,Current,,,,2019,limited availability
2833,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection, 1,000 units / 500 mL (2 units / mL) in VIAFLEX Plastic Container.  AHB0953U  (NDC 0338-0424-18)",New,12/11/2019,Available,,,,Hematology,Current,,,,2019,available
2834,Hydrochlorothiazide (Microzide) Capsules,Allergan Sales LLC,12.5 mg (NDC 52544-622-01),New,10/22/2019,,"The authorized generic, Hydrochlorothiazide Capsules, USP, 12.5 mg remains commercially available.",,,Cardiovascular,To be Discontinued,10/22/2019,10/22/2019,,2019,discontinued
2835,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,20 mg/25 mg (NDC 0378-2025-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
2836,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,12.5 mg/ 20 mg (NDC 0378-2012-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
2837,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,10 mg/ 12.5 mg (NDC 0378-1012-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
2838,Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution,Perrigo Pharmaceuticals,Hydrocodone Bitartrate (5 mg/5 mL) and Homatropine Methylbromide (1.5 mg/5 mL)(NDC 0574-1105-16),New,6/5/2018,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,6/5/2018,6/5/2018,,2019,discontinued
2839,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 12 suppositories (NDC 59741-301-12),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
2840,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 24 suppositories (NDC 59741-301-24),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
2841,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 100 suppositories (NDC 59741-301-01),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
2842,"Hydrocortisone Butyrate Cream USP, 0.1%",Teva Pharmaceuticals,"Hydrocortisone Butyrate Cream USP, 0.1% (Lipophilic), 45 g/Tube, (NDC 0472-0490-45)",New,12/21/2018,,This was a business-related decision to discontinue manufacturing these products.,,,Dermatology,To be Discontinued,12/21/2018,12/21/2018,,2019,discontinued
2843,"Hydrocortisone Butyrate Cream USP, 0.1%",Teva Pharmaceuticals,"Hydrocortisone Butyrate Cream USP, 0.1% (Lipophilic), 60 g/Tube, (NDC 0472-0490-60)",New,12/21/2018,,This was a business-related decision to discontinue manufacturing these products.,,,Dermatology,To be Discontinued,12/21/2018,12/21/2018,,2019,discontinued
2844,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"5 mg, bottle of 50 (NDC 0603-3899-19)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2845,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"10 mg, bottle of 100 (NDC 0603-3900-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2846,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"20 mg, bottle of 100 (NDC 0603-3901-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2847,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"32 mg, 100 count (NDC 0591-3631-01)",New,6/20/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/2019,6/20/2019,,2019,discontinued
2848,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"16 mg, 100 count (NDC 0591-3630-01)",New,6/20/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/2019,6/20/2019,,2019,discontinued
2849,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"12 mg, 100 count (NDC 0591-3739-01)",New,6/20/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/2019,6/20/2019,,2019,discontinued
2850,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"8 mg, 100 count (NDC 0591-3629-01)",New,6/20/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/2019,6/20/2019,,2019,discontinued
2851,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)                                                                                           Microvault",Reverified,12/20/2019,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2019,available
2852,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-11)                                                                                                                                                                                     Microvault",Reverified,12/20/2019,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2019,available
2853,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","1 mg per 1 mL, Single dose vial, (NDC 63323-852-25)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2854,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-853-25)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2855,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-854-10)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2856,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-10)",Reverified,12/20/2019,Backordered.  Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,not available
2857,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","50 mg per 5 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-15)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2858,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","500 mg per 50 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-50)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2859,"Hydromorphone Hydrochloride Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 1 mL vial (NDC 0641-0121-25)",Revised,12/13/2019,Inventory is currently available.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2860,"Hydromorphone Hydrochloride Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0641-2341-41)",Revised,12/13/2019,Temporarily on backorder.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,not available
2861,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",0.5 mg/0.5 mL (1 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-05),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2862,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/1 mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-10),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
2863,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1312-10),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
2864,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1283-31),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2865,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1312-30),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2866,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",4 mg/1 mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1304-31),Revised,12/20/2019,Next Delivery and Estimated Recovery: January 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
2867,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/mL); Glass Ampul (NDC 00409-2552-01),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,limited availability
2868,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Glass Ampul (NDC 00409-3356-01),Revised,12/20/2019,Next Delivery: April 2020; Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
2869,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",4 mg/1 mL (4 mg/mL); Glass Ampul (NDC 00409-2540-01),Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
2870,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3365-01),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2871,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-01),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,limited availability
2872,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",50 mg/5 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-05),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2873,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",500 mg/50 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-50),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2874,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)",Revised,12/2/2019,Unavailable. Estimataed recovery Dec 2019,"Expected availability Dec, 2019",,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,not available
2875,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)",Revised,12/2/2019,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2876,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)",Revised,12/2/2019,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2877,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-05)",Reverified,12/20/2019,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,unclear
2878,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-10)                                                                                                                                       Blister pack",Reverified,12/20/2019,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,unclear
2879,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe (NDC 76045-010-10)",Reverified,12/20/2019,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,not available
2880,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 4 mg per 1 mL, prefilled syringe (NDC 76045-011-10)",Reverified,12/20/2019,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,not available
2881,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1ML (NDC0703-0110-03),Reverified,12/16/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2882,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1ML (NDC 0703-0113-03),Reverified,12/16/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2883,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1 ML (NDC 0703-0018-01),Reverified,12/16/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2884,Hydroxyprogesterone Caproate Injection,American Regent/Luitpold,"Hydroxyprogesterone Caproate Injection, USP 250mg/mL 1mL Single Dose Vial (NDC 0517-1767-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2885,Hydroxyprogesterone Caproate Injection,Slayback Pharma,"Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml (NDC 71225-104-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2886,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single dose auto-injector 1.1mL for subcutaneous injection: (NDC 64011-247-02),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2887,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2888,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Multi-dose vial 5mL for intramuscular injection: (NDC 64011-243-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2889,Hydroxyprogesterone Caproate Injection,Prasco Laboratories,Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2890,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),Hydroxyprogesterone Caproate Injection USP 250 mg/1 mL single-dose vial (NDC 55150-309-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2891,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),"Hydroxyprogesterone Caproate Injection USP 1,250 mg/5 mL multiple-dose vial (NDC 55150-310-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2892,Hydroxyprogesterone Caproate Injection,Slayback Pharma,Hydroxyprogesterone Caproate Injection 250 mg/ 1 ml (NDC 71225-105-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2019,
2893,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,100 mg 100 count (NDC 0555-0324-02),Reverified,12/16/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2894,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 100 count (NDC 0555-0323-02),Reverified,12/16/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2895,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 500 count (NDC 0555-0323-04),Reverified,12/16/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2896,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 100 count (NDC 0555-0302-02),Reverified,12/16/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2897,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 500 count (NDC 0555-0302-04),Reverified,12/16/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2898,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 100 count (NDC 0185-0674-01),Reverified,12/18/2019,Limited monthly supply through September due to increase in demand.  Working to increase production to meet current demand.,,,Demand increase for the drug,Psychiatry,Current,,,,2019,limited availability
2899,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 500 count (NDC 0185-0674-05),Reverified,12/18/2019,Limited monthly supply through September due to increase in demand.  Working to increase production to meet current demand.,,,Demand increase for the drug,Psychiatry,Current,,,,2019,limited availability
2900,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01),Revised,12/13/2019,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,,2019,limited availability
2901,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02),Revised,12/13/2019,Expected to be on allocation until sometime in 1Q20.,,,OIther,Psychiatry,Current,,,,2019,limited availability
2902,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01),Revised,12/13/2019,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,,2019,limited availability
2903,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02),Revised,12/13/2019,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,,2019,limited availability
2904,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66),Reverified,12/20/2019,Next delivery and Estimated recovery: July 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Psychiatry,Current,,,,2019,not available
2905,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66),Reverified,12/20/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2906,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01),New,11/15/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2907,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05),New,11/15/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2908,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01),New,11/15/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2909,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05),New,11/15/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
2910,Ifosfamide/Mesna Kit,Teva Pharmaceuticals,1 gram/20 mL; 1 gram/10 mL  (NDCs 0703-4100-48 and 0703-4100-58),New,10/18/2019,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,10/18/2019,10/18/2019,,2019,discontinued
2911,Ifosfamide/Mesna Kit,Teva Pharmaceuticals,3 gram/60 mL; 1 gram/10 mL (NDC 0703-4100-68 ),New,10/18/2019,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,10/18/2019,10/18/2019,,2019,discontinued
2912,"Imipenem and Cilastatin for Injection, USP",Merck Sharp & Dohme Corp.,500 mg  imipenem  equivalent  and  500 mg  cilastatin  equivalent  and  20 mg  sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3516-59),Revised,12/18/2017,Product is available,"For additional information, please contact: Merck National Service Center at 1-800-672-6372",,Demand increase for the drug,Anti-Infective,Current,,,,2019,available
2913,"Imipenem and Cilastatin for Injection, USP","Fresenius Kabi USA, LLC","250 mg/250 mg per vial, single dose vial, sterile powder (NDC 63323-349-25)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,,2019,available
2914,"Imipenem and Cilastatin for Injection, USP","Fresenius Kabi USA, LLC","500 mg/500 mg per vial, single dose vial, sterile powder (NDC  63323-322-25)",Reverified,12/20/2019,Available,Check wholesaler inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,,2019,available
2915,"Imipenem and Cilastatin for Injection, USP","Hospira, Inc.",500 mg/500 mg; Single Dose Glass Fliptop Vial (NDC 00409-3507-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,,2019,not available
2916,"Imipenem and Cilastatin for Injection, USP","Hospira, Inc.",250 mg/250 mg; Single Dose Glass Fliptop Vial (NDC 00409-3508-01),Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,,2019,not available
2917,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 100s (NDC 0378-0143-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2918,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 1000s (NDC 0378-0143-10)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2919,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 100s (NDC 0378-0147-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2920,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 500s (NDC 0378-0147-05)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
2921,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4350-01),New,9/12/2019,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2019,discontinued
2922,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent ((NDC 0085-4351-01)),New,9/12/2019,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2019,discontinued
2923,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01),New,9/12/2019,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2019,discontinued
2924,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Solution for Injection (Interferon alfa-2b) 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1168-01),New,9/12/2019,,To be discontinued in 2021,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2019,discontinued
2925,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Solution for Injection (Interferon alfa-2b) 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1133-01),New,9/12/2019,,To be discontinued in 2021,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2019,discontinued
2926,Isocarboxazid Tablets,Validus Pharmaceuticals LLC,10mg (NDC 30698-032-01),Reverified,12/10/2019,"Due to the current critical shortage of Isocarboxazid Tablets in the United States (US) market, Validus Pharmaceuticals LLC is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of Isocarboxazid Tablets. Validus has initiated temporary importation of another manufacturer’s Isocarboxazid Tablets into the U.S. market.  This product is manufactured and marketed in Denmark by MediLink. MediLink's Marplan is commercially available under a new NDC 72604-032-01.",,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,,2019,available
2927,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 100 (NDC 0603-4110-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2928,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 500 (NDC 0603-4110-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2929,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 1000 (NDC 0603-4110-32)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2930,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 100 (NDC 0603-4111-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2931,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 500 (NDC 0603-4111-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2932,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 1000 (NDC 0603-4111-32)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2933,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"120 mg, bottle of 100 (NDC 0603-4112-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
2934,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9509-10)",Reverified,12/13/2019,Inventory is currently available.,,,,Anesthesia,Current,,,,2019,available
2935,Ketamine Injection,Mylan Institutional,200 mg / 20 mL (NDC 67457-181-20),Reverified,11/26/2019,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2936,Ketamine Injection,Mylan Institutional,500 mg / 10 mL (NDC 67457-001-10),Reverified,11/26/2019,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2937,Ketamine Injection,Mylan Institutional,1000 mg / 10 mL (NDC 67457-108-10),Reverified,11/26/2019,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2938,Ketamine Injection,"Hospira, Inc.",500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2051-05),Reverified,12/20/2019,Next Delivery: February 2020; Estimated Recovery: June 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2939,Ketamine Injection,"Hospira, Inc.",500 mg/10 mL (50 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2053-10),Reverified,12/20/2019,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,not available
2940,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL vial (NDC 0143-9508-10)",Reverified,12/13/2019,Inventory is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2941,Ketamine Injection,Par Pharmaceutical,"10 mg/mL, 20 mL MDV (NDC 42023-113-10)",Reverified,12/16/2019,Product is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2942,Ketamine Injection,Par Pharmaceutical,"100 mg/mL, 5 mL MDV (NDC 42023-115-10)",Reverified,12/16/2019,Product is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2943,Ketamine Injection,Par Pharmaceutical,"50 mg/mL, 10 mL MDV (NDC 42023-114-10)",Reverified,12/16/2019,Product is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
2944,Ketoconazole Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100 count bottle (NDC 0378-0261-01)",New,5/2/2019,,,,,Anti-Infective,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
2945,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",New,11/25/2019,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
2946,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 69336-127-10)",Revised,11/25/2019,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,,2019,available
2947,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 69336-127-11)",Revised,11/25/2019,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,,2019,available
2948,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",Revised,11/25/2019,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,,2019,discontinued
2949,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",Revised,11/25/2019,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,,2019,discontinued
2950,Ketoprofen Capsules,Mylan Pharmaceuticals Inc.,"200 mg Extended-Release Capsules, bottle of 100 (NDC 0378-8200-01)",Reverified,11/26/2019,Available,,,Other,Analgesia/Addiction;Rheumatology,Current,12/23/2016,,,2019,available
2951,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",New,11/25/2019,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
2952,Ketoprofen Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0093-3193-01)",Reverified,12/16/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2019,not available
2953,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 100 count bottle (NDC 0093-3195-01)",Reverified,12/16/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2019,not available
2954,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 500 count bottle (NDC 0093-3195-05)",Reverified,12/16/2019,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2019,not available
2955,Ketorolac Tromethamine Injection,Gland Pharma,15 mg/mL vial (NDC 70860-700-01 and 70860-700-02),Reverified,12/16/2019,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Analgesia/Addiction,Current,,,,2019,available
2956,Ketorolac Tromethamine Injection,Gland Pharma,30 mg/mL vial (NDC 70860-701-01 and 70860-701-03),Reverified,12/16/2019,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Analgesia/Addiction,Current,,,,2019,available
2957,Ketorolac Tromethamine Injection,Gland Pharma,60 mg/mL vial (NDC 70860-701-02 and 70860-701-04),Reverified,12/16/2019,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Analgesia/Addiction,Current,,,,2019,available
2958,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 15MG/ML 25X1ML (NDC 25021-700-01),Reverified,12/20/2019,Backordered. Estimated availability TBD,,,Manufacturing delays,Analgesia/Addiction,Current,,,,2019,not available
2959,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X2ML (NDC 25021-701-02),Reverified,12/20/2019,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,,2019,not available
2960,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X1ML (NDC 25021-701-01),Reverified,12/20/2019,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,,2019,not available
2961,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-2287-23),Revised,12/20/2019,Next Delivery: August 2020; Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
2962,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-31),Revised,12/20/2019,Next Delivery: March 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
2963,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-61),Revised,12/20/2019,Next Delivery: August 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
2964,Ketorolac Tromethamine Injection,"Hospira, Inc.",15 mg/mL (15 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3793-01),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2965,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3795-01),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2966,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3796-01),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2967,Ketorolac Tromethamine Injection,Virtus Pharmaceuticals,30MG/ML (NDC 69543-0386-25),New,3/26/2018,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
2968,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","15 mg/mL, 1 mL vial (NDC 0641-6041-25)",Revised,12/13/2019,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,unclear
2969,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 1 mL vial (NDC 0641-6042-25)",Revised,12/13/2019,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,unclear
2970,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 2 mL vial (NDC 0641-6043-25)",Revised,12/13/2019,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,unclear
2971,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose Amber Vial, (NDC 63323-161-01)",Revised,12/20/2019,Available,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2019,available
2972,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-01)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2019,not available
2973,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-02)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2019,not available
2974,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 30 mg/ mL.  Single dose glass flip top vial - 25 units per carton (NDC 0338-0072-25)",New,12/12/2019,Unavailable (anticipated delivery in January 2020),FOR INTRAVENOUS AND INTRAMUSCULAR USE. 30mg/mL (1 mL fill volume/ 2 mL container),,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,not available
2975,Ketorolac Tromethamine Injection,Gland Pharma,"30 mg/mL, 1 mL vial (NDC 72266-118-25)",Reverified,12/16/2019,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
2976,Ketorolac Tromethamine Injection,Gland Pharma,"30 mg/mL, 2 mL vial (NDC 72266-119-25)",Reverified,12/16/2019,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Analgesia/Addiction,Current,,,,2019,available
2977,Labetalol Hydrochloride Injection,Gland Pharma,"5mg/mL, 20 mL vial (NDC 72266-102-01)",Reverified,12/11/2019,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,,2019,available
2978,Labetalol Hydrochloride Injection,Gland Pharma,"5 mg/mL, 40 mL vial (NDC 72266-103-01)",Reverified,12/11/2019,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,,2019,available
2979,Labetalol Hydrochloride Injection,"Hospira, Inc.",100 mg/20 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2267-20),Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: February 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
2980,Labetalol Hydrochloride Injection,"Hospira, Inc.",200 mg/40 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2267-54),Reverified,12/20/2019,Next Delivery and Estimated Recovery: January 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
2981,Labetalol Hydrochloride Injection,"Hospira, Inc.",20 mg/4 mL (5 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2339-34),Reverified,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,limited availability
2982,Labetalol Hydrochloride Injection,Akorn Pharmaceuticals,5mg/mL (100mg/20mL) Multi-Dose vial (NDC 17478-420-20),Revised,12/2/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2983,Labetalol Hydrochloride Injection,Akorn Pharmaceuticals,5mg/mL (200mg/40mL) Multi-Dose vial (NDC 17478-420-40 ),Revised,12/2/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
2984,Labetalol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 20 mL multidose vial (NDC 0143-9622-01)",Revised,12/13/2019,This presentation is temporarily on backorder.,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,not available
2985,Labetalol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 40 mL multidose vial (NDC 0143-9623-01)",Revised,12/13/2019,Currently available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
2986,Lamivudine and Zidovudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine and Zidovudine Tablets 150mg and 300mg (NDC 0378-5180-91),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2019,discontinued
2987,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 100mg (NDC 0378-5168-93),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2019,discontinued
2988,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 150mg (NDC 0378-5169-91),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2019,discontinued
2989,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 300mg (NDC 0378-5170-93),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2019,discontinued
2990,Lamotrigine Tablets,Teva Pharmaceuticals,25 mg tablets (NDCs 0093-0032-05 and 0093-0039-01),New,12/21/2018,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,12/21/2018,12/21/2018,,2019,discontinued
2991,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 100 (NDC 69097-148-07),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
2992,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 500 (NDC NDC 69097-148-12),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
2993,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 1000 (NDC 69097-148-15),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
2994,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 100 (NDC 69097-149-07),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
2995,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 500 (NDC 69097-149-12),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
2996,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 1000 (NDC 69097-149-15),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
2997,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 60 (NDC 69097-151-03),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
2998,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 500 (NDC 69097-151-12),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
2999,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 1000 (NDC 69097-151-15),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
3000,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 60 (NDC 69097-152-03),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
3001,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 500 (NDC 69097-152-12),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
3002,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 1000 (NDC 69097-152-15),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2019,discontinued
3003,Lamotrigine Tablets,Teva Pharmaceuticals,100 mg (NDCs 0093-0463-01 and 0093-0463-05),New,10/15/2019,,This product is being discontinued due to a business decision.,,,Neurology,To be Discontinued,10/15/2019,10/15/2019,,2019,discontinued
3004,Lanoxin (digoxin) Tablets,Concordia Pharmaceuticals Inc.,Lanoxin (digoxin) 187.5 mcg (0.1875 mg) tablets; 100-count bottles (NDC 59212-245-55),New,5/22/2018,,"A business decision was made to discontinue manufacture and supply of the Lanoxin 187.5 mcg (0.1875 mg) strength tablets.  All existing lots on the market are good through expiry. The anticipated final date of availability for sale is June 30, 2018 (NDC 59212-245-55).",,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
3005,Latanoprost Ophthalmic Solution 0.005%,Sandoz,2.5 mL Bottle (NDC 61314-547-01),Reverified,12/18/2019,Available,,,,Ophthalmology,Current,,,,2019,available
3006,Latanoprost Ophthalmic Solution 0.005%,Pfizer Pharmaceuticals,"2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle (NDC 59762-0333-2)",Reverified,12/20/2019,Next Delivery: December 2019;  Estimated Recovery: March 2020,Limited Supply Available.  Please check with your wholesaler for available inventory,,Demand increase for the drug,Ophthalmology,Current,,,,2019,not available
3007,Latanoprost Ophthalmic Solution 0.005%,Bausch Health,"2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle (NDC 24208-463-25)",Reverified,12/13/2019,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,,Ophthalmology,Current,,,,2019,available
3008,Lesinurad (ZURAMPIC) Tablets,Ironwood Pharmaceuticals Inc.,ZURAMPIC® (lesinurad) 200 mg tablets 5 count bottle (NDC 70785-011-05),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.",,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3009,Lesinurad (ZURAMPIC) Tablets,Ironwood Pharmaceuticals Inc.,ZURAMPIC® (lesinurad) 200 mg tablets 30 count bottle (NDC 70785-011-30),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.",,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3010,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200mg tablets 5 count bottle (NDC 70785-021-05),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3011,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200 mg tablets 30 count bottle (NDC 70785-021-30),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3012,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200 mg tablets 90 count bottle (NDC 70785-021-90),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3013,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 5 count bottle (NDC 70785-022-05),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3014,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 30 count bottle (NDC 70785-022-30),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3015,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 90 count bottle (NDC 70785-022-90),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3016,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,480 mg injection (NDC 0006-5004-01),Revised,12/2/2019,Available,,,Other,Antiviral,Current,,,,2019,available
3017,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,240 mg injection (NDC 0006-5003-01),Revised,12/2/2019,Available,,,Other,Antiviral,Current,,,,2019,available
3018,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,500mg vial (NDC 25021-828-50),Reverified,12/20/2019,On allocation. Estimated availability Mar-2020,,,Manufacturing delay,Oncology;Pediatric,Current,,,,2019,limited availability
3019,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",200 mg SDV (NDC 63323-710-50),Revised,12/20/2019,Available,Check Wholesaler Inventory,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2019,available
3020,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",500 mg SDV (NDC 63323-711-00),Revised,12/20/2019,Backordered. Next release January 2020.,Check Wholesaler Inventory,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2019,not available
3021,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,50 mg vial (NDC 25021-813-10),Reverified,12/20/2019,Backordered. Estimated availability May-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2019,not available
3022,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,100mg vial (NDC 25021-814-30),Reverified,12/20/2019,Backordered. Estimated availability May-2021,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2019,not available
3023,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,200mg vial (NDC 25021-815-30),Reverified,12/20/2019,On allocation. Estimated availability Mar-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2019,limited availability
3024,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,350mg vial (NDC 25021-816-30),Reverified,12/20/2019,On allocation. Estimated availability Mar-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2019,limited availability
3025,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,"100mg/vial, 20mL (NDC 0703-5140-01)",Reverified,12/16/2019,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2019,available
3026,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,350mg/vial 30mL (NDC 0703-5145-01),Reverified,12/16/2019,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2019,available
3027,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,Lupron Depot 3.75 mg PDS kit (NDC 0074-3641-03),Revised,12/17/2019,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/2019,12/9/2019,,2019,available
3028,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot Ped, 3Month, 11.25 mg kit (NDC 0074-3379-03)",Revised,12/17/2019,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/2019,12/9/2019,,2019,available
3029,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot Ped, 3Month, 30 mg kit (NDC 0074-9694-03)",Revised,12/17/2019,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/2019,12/9/2019,,2019,available
3030,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot, 3Month, 11.25 mg PDS kit (NDC 0074-3663-03)",Revised,12/17/2019,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/2019,12/9/2019,,2019,available
3031,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot, 3Month, 22.5 mg PDS kit (NDC 0074-3346-03)",Revised,12/17/2019,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/2019,12/9/2019,,2019,available
3032,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot, 4Month, 30 mg PDS kit (NDC 0074-3683-03)",Revised,12/17/2019,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/2019,12/9/2019,,2019,available
3033,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot, 6Month 45 mg PDS kit (NDC 0074-3473-03)",Revised,12/17/2019,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/2019,12/9/2019,,2019,available
3034,Leuprolide Acetate Injection,Sandoz,Leuprolide Acetate Injection 1mg/0.2ml (14mg/2.8ml)(NDC 0781-4003-32),Revised,5/10/2019,,,Available,,Oncology,Resolved,5/10/2019,,,2019,
3035,"Levetiracetam Extended-Release Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra XR) Extended-Release Tablets, 500 mg 60 ct. bottle; (NDC 69102-200-60)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2019,discontinued
3036,"Levetiracetam Extended-Release Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra XR) Extended-Release Tablets, 750 mg 60 ct. bottle; (NDC 69102-201-60)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2019,discontinued
3037,"Levetiracetam Extended-Release Oral Tablets, USP",Teva Pharmaceuticals,500mg (NDC 0591-3635-60),New,6/7/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Neurology,To be Discontinued,6/7/2019,6/7/2019,,2019,discontinued
3038,"Levetiracetam Extended-Release Oral Tablets, USP",Teva Pharmaceuticals,750mg (NDC 0591-3699-60),New,6/7/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Neurology,To be Discontinued,6/7/2019,6/7/2019,,2019,discontinued
3039,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 500 mg (60 ct. bottle)(NDC 60505-3280-06),Revised,11/27/2019,"Backorder, Estimated Resupply February 2020",,,Demand increase for the drug,Neurology,Current,,,,2019,not available
3040,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 750 mg (60 ct. bottle)(NDC 60505-3517-06),Revised,11/27/2019,"Backorder, Estimated Resupply February 2020",,,Demand increase for the drug,Neurology,Current,,,,2019,not available
3041,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,500mg tablet 60 count bottle (NDC 4733557386),Revised,12/3/2019,"Back-order, Estimated re-supply: TBD",,,Demand increase for the drug,Neurology,Current,,,,2019,not available
3042,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,750mg tablet 60 count bottle (NDC 4733557686),Revised,12/3/2019,"Back-order, Estimated re-supply: TBD",,,Demand increase for the drug,Neurology,Current,,,,2019,not available
3043,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,500mg  60 count bottle (NDC 68180-117-07),Reverified,12/17/2019,Continuous production but will be on/off backorder,,,Shortage of active ingredient,Neurology,Current,,,,2019,limited availability
3044,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,750mg 60 count bottle (NDC 68180-118-07),Reverified,12/17/2019,Continuous production but will be on/off backorder,,,Shortage of active ingredient,Neurology,Current,,,,2019,limited availability
3045,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,500mg extended-release (NDC 50474-598-66),Reverified,12/3/2019,Available,,,,Neurology,Current,,,,2019,available
3046,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,750mg extended-release (NDC 50474-599-66),Reverified,12/3/2019,Available,,,,Neurology,Current,,,,2019,available
3047,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 60’s (NDC 43547-0345-06)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3048,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 500’s (NDC 43547-0345-50)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3049,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 60’s (NDC 43547-0346-06)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3050,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 500’s (NDC 43547-0346-50)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3051,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"250mg, 120 count bottle (NDC 13668-014-12)",Revised,12/13/2019,Available,,,,Neurology,Current,,,,2019,available
3052,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"500mg, 120 count bottle (NDC 13668-015-12)",Revised,12/13/2019,Available,,,,Neurology,Current,,,,2019,available
3053,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 120 count bottle (NDC 13668-016-12)",Revised,12/13/2019,Available,,,,Neurology,Current,,,,2019,available
3054,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 500 count bottle (NDC 13668-016-05)",Revised,12/13/2019,Available,,,,Neurology,Current,,,,2019,available
3055,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"1000 mg, 60 count bottle (NDC 13668-017-60)",Revised,12/13/2019,Available,,,Shortage of Active Ingredient,Neurology,Current,,,,2019,available
3056,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"250MG, (NDC 50474-594-40)",Reverified,12/3/2019,Available,,,,Neurology,Current,,,,2019,available
3057,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"500MG, (NDC 50474-595-40)",Reverified,12/3/2019,Available,,,,Neurology,Current,,,,2019,available
3058,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"750MG, (NDC 50474-596-40)",Reverified,12/3/2019,Available,,,,Neurology,Current,,,,2019,available
3059,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"1000MG, (NDC 50474-597-66)",Reverified,12/3/2019,Available,,,,Neurology,Current,,,,2019,available
3060,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"250mg, 120 count (NDC 65862024508)",Reverified,12/13/2019,Available,,,,Neurology,Current,,,,2019,available
3061,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"500mg , 120 count (NDC 65862024608)",Reverified,12/13/2019,Available,,,,Neurology,Current,,,,2019,available
3062,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"1000mg, 60 count (NDC 65862031560)",Reverified,12/13/2019,Available,,,,Neurology,Current,,,,2019,available
3063,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"750mg, 120 count (NDC 65862024708)",Reverified,12/13/2019,Available,,,,Neurology,Current,,,,2019,available
3064,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 90 Count Bottes (68180-112-09)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3065,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 120 Count Bottes (68180-112-16)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3066,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 500 Count Bottes (68180-112-02)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3067,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 90 Count Bottes (68180-113-09)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3068,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 90 Count Bottes (68180-114-09)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3069,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 500 Count Bottes (68180-114-02)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3070,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 120 Count Bottes (68180-113-16)",Reverified,12/17/2019,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,2019,not available
3071,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 500 Count Bottes (68180-113-02)",Reverified,12/17/2019,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,2019,not available
3072,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 120 Count Bottes (68180-114-16)",Reverified,12/17/2019,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,2019,not available
3073,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 1000 mg – 60 Count Bottes (68180-115-07)",Reverified,12/17/2019,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,2019,not available
3074,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 120 count (NDC 31722053612)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3075,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 500 count (NDC 31722053605)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3076,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 120 count (NDC 31722053712)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3077,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 500 count (NDC 31722053705)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3078,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 120 count (NDC 31722053812)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3079,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 500 count (NDC 31722053805)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2019,available
3080,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 250mg – 120’s (NDC 43547-0221-15)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3081,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 120’s (NDC 43547-0222-15)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3082,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 1000’s (NDC 43547-0222-11)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3083,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 750mg – 120’s (NDC 43547-0223-15)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3084,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 1000mg – 60’s (NDC 43547-0224-06)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2019,not available
3085,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 120 count (NDC 0378-5613-78)",Revised,11/26/2019,"Unavailable, recovery in January 2020",,,Shortage of active ingredient,Neurology,Current,,,,2019,not available
3086,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 500 count (NDC 0378-5613-05)",Revised,11/26/2019,"Unavailable, recovery in January 2020",,,Shortage of active ingredient,Neurology,Current,,,,2019,not available
3087,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 500 count (NDC 0378-5615-05)",Revised,11/26/2019,"Unavailable, recovery in January 2020",,,Shortage of active ingredient,Neurology,Current,,,,2019,not available
3088,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 120 count (NDC 0378-5615-78)",Revised,11/26/2019,Available,,,Shortage of active ingredient,Neurology,Current,,,,2019,available
3089,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 120 count (NDC 0378-5617-78)",Revised,11/26/2019,Available,,,Shortage of active ingredient,Neurology,Current,,,,2019,available
3090,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 500 count (NDC 0378-5617-05)",Revised,11/26/2019,Available,,,Shortage of active ingredient,Neurology,Current,,,,2019,available
3091,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 1000 mg, 60 count (NDC 0378-5619-91)",Revised,11/26/2019,Available,,,Shortage of active ingredient,Neurology,Current,,,,2019,available
3092,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 500 mg (120 count; (NDC 69102-104-01)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2019,discontinued
3093,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 750 mg (120 count; (NDC 69102-102-01)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2019,discontinued
3094,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 1000 mg 60 count; (NDC  69102-103-01)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2019,discontinued
3095,Levoleucovorin Calcium Injection,Mylan Pharmaceuticals Inc.,10 mg/1 mL (17.5 mL)(NDC 67457-600-20),New,6/25/2019,,,,,Oncology,To be Discontinued,6/25/2019,6/25/2019,,2019,discontinued
3096,Levoleucovorin Calcium Injection,Mylan Pharmaceuticals Inc.,10 mg/1 mL (25 mL)(NDC 67457-601-30),New,6/25/2019,,,,,Oncology,To be Discontinued,6/25/2019,6/25/2019,,2019,discontinued
3097,Levonorgestrel and Ethinyl Estradiol Tablets 0.1mg/0.02mg,Mylan Pharmaceuticals Inc.,"0.1mg/0.02mg Tablets, NDC (0378-7298-53)",New,1/2/2019,,,,,Reproductive,To be Discontinued,1/2/2019,1/2/2019,,2019,discontinued
3098,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 5 mL (NDC 0591-3012-26)",New,4/27/2018,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/2018,4/27/2018,,2019,discontinued
3099,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 30 mL (NDC 0591-3012-30)",New,4/27/2018,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/2018,4/27/2018,,2019,discontinued
3100,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/500 mL (4mg/mL) in VIAFLEX Plus container. Product code 2B0973 (NDC 0338-0409-03)",Reverified,12/11/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3101,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/250 mL (8mg/mL) in VIAFLEX Plus container. Product code 2B0962 (NDC 0338-0411-02)",Reverified,12/11/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3102,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.8% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5982 (NDC 00264-9598-20),Revised,12/11/2019,Product available,,,Other,Cardiovascular,Current,,,,2019,available
3103,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5942 (NDC 00264-9594-20),Revised,12/11/2019,Product available,,,Other,Cardiovascular,Current,,,,2019,available
3104,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 500mL Excel Plastic container P5941 (NDC 00264-9594-10),Revised,12/11/2019,Product on allocation to contracted customers,,,Other,Cardiovascular,Current,,,,2019,limited availability
3105,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Ampoule (NDC 55150-158-72),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3106,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Ampoule (NDC 55150-159-74),Revised,12/11/2019,Currently on backorder,Next shipment expected Jan. 2020,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
3107,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Ampoule (NDC 55150-160-72),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3108,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Single Dose Vial (NDC 55150-161-02),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3109,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Single Dose Vial (NDC 55150-162-05),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3110,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 30 mL Single Dose Vial (NDC 55150-163-30),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3111,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Single Dose Vial (NDC 55150-164-02),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3112,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 5 mL Single Dose Vial (NDC 55150-165-05),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3113,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)",Reverified,12/20/2019,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3114,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Ansyr Plastic Syringe (NDC 0409-9137-05),Revised,12/20/2019,Next Delivery: April 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3115,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",1.5%; 20mL Sterile Pack Amp (NDC 0409-4056-01),Revised,12/20/2019,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2019,discontinued
3116,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",20 mg/2 mL (10 mg/mL); Glass Ampul (NDC 0409-4713-32),Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3117,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","200 mg/20 mL (10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-01, pack of 25; NDC 0409-4276-16, individual)",Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3118,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/30 mL (10 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4279-02),Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: April 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3119,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-02),Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3120,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",1%; 30 mL Sterile Pack vial (NDC 0409-4270-01),Revised,12/20/2019,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2019,discontinued
3121,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",40 mg/2 mL (20 mg/mL); Glass Ampul (NDC 0409-4282-01),Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3122,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); Glass Ampul (NDC 0409-4282-02),Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3123,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4904-34),Revised,12/20/2019,Next Delivery and Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3124,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (20 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4903-34),Revised,12/20/2019,Next Delivery: January 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3125,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (20 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-2066-05),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,limited availability
3126,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","400 mg/20 mL (20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-01, pack of 25; NDC 0409-4277-16, individual)",Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3127,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","1,000 mg/50 mL (20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-02)",Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3128,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Glass Ampul (NDC 0409-4283-01),Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3129,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",Xylocaine Cardiac 100 mg/5 mL (20 mg/mL); Ansyr Plastic Syringe (NDC 0409-1323-05),Revised,12/20/2019,Next Delivery: March 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3130,Lidocaine Hydrochloride (Xylocaine) Injection,"Amphastar Pharmaceuticals, Inc./IMS","2%, 5mL Luer-Jet Prefilled Syringe (NDC 76329-3390-1)
(old NDC 0548-3390-00)",Reverfied,12/16/2019,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,limited availability
3131,Lidocaine Hydrochloride (Xylocaine) Injection,American Regent/Luitpold,"1%, 50 mL vial package of 25 (NDC 00517-0625-25)",Reverified,11/27/2019,Unavailable-No product available for release. No plan to manufacture.,"American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection, USP",,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2019,discontinued
3132,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 10 mL ampule (NDC 63323-0493-97)",Reverified,12/20/2019,Backordered. Next release date not available at this time.,All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3133,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 20 mL ampule (NDC 63323-0493-91)",Reverified,12/20/2019,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3134,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% Lidocaine 2% injection 20 mg/mL, 2 mL vial (NDC 63323-0202-02)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3135,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% injection 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3136,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-17)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3137,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 20 mL vial (NDC 63323-0486-27)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3138,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-57)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3139,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-10)
discontinued",Reverified,12/20/2019,No release date available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3140,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20)-NDC discontinued",Reverified,12/20/2019,No release date available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3141,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-50)-NDC discontinued",Reverified,12/20/2019,No release date available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3142,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 2 mL vial (NDC 63323-0495-27)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3143,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 5 mL vial (NDC 63323-0495-07)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3144,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 10 mL ampule (NDC 63323-0496-97)",Reverified,12/20/2019,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3145,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4275-01),Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,limited availability
3146,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/2 mL (50 mg/mL); Glass Ampul (NDC 0409-4712-01),Revised,12/20/2019,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3147,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4278-01),Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,limited availability
3148,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Glass Ampul (NDC 0409-4713-02),Revised,12/20/2019,Next Delivery and  Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3149,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL, 50 mL vial (NDC 63323-0484-57)",Reverified,12/20/2019,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3150,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3151,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 2 mL vial (NDC 63323-0201-02)",Reverified,12/20/2019,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3152,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 10 mL vial (NDC 63323-0201-10)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3153,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 20 mL vial (NDC 63323-0485-27)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3154,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 50 mL vial (NDC 63323-0485-57)",Reverified,12/20/2019,Backordered. Next release December 2019.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3155,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL vial (NDC 63323-0492-27)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3156,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)",Reverified,12/20/2019,Backordered. No release expectations at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3157,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)",Reverified,12/20/2019,Backordered. No release expectations at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,not available
3158,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL vial (NDC 63323-0492-57)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3159,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial (NDC 63323-0492-37)",Reverified,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2019,available
3160,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/20 mL (15 mg/mL); Glass Ampul (NDC 0409-4776-01),Revised,12/20/2019,Next Delivery and Estimated Recovery: February 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3161,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Multi Dose Vial (NDC 55150-251-10),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3162,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Multi Dose Vial (NDC 55150-252-20),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3163,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 10 mL Multi Dose Vial (NDC 55150-254-10),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3164,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 20 mL Multi Dose Vial (NDC 55150-255-20),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3165,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 5 mL vial, Preservative Free (NDC 0143-9595-25)",Revised,12/13/2019,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3166,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 5 mL vial, Preservative Free (NDC 0143-9594-25)",Revised,12/13/2019,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3167,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 50 mL vial, Preserved (NDC 0143-9577-10)",Revised,12/13/2019,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3168,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 50 mL vial, Preserved (NDC 0143-9575-10)",Revised,12/13/2019,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3169,Lidocaine Hydrochloride (Xylocaine) Injection,"Spectra Medical Devices, Inc.",1% 5 mL ampule (NDC 65282-1605-1),New,6/14/2018,"Currently available, in stock Production is ongoing",,,Other,Anesthesia,Current,,,,2019,available
3170,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100 mg MDV (NDC 63323-0482-17)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2019,not available
3171,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100mg SDV, MPF (NDC 63323-0487-17)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2019,not available
3172,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 150 mg, SDV, MPF (NDC 63323-0488-17)",Revised,12/20/2019,Available,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2019,available
3173,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 200 mg, SDV, MPF (NDC 63323-0489-17)",Revised,12/20/2019,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2019,not available
3174,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","0.5% w/EPI 1:100,000; 1.8 mL Carpule (NDC 00409-0996-01)",Revised,12/20/2019,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2019,discontinued
3175,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2.5 g/50 mL (0.5%; 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3177-01)",Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3176,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","200 mg/20 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-01)",Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3177,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","300 mg/30 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-02)",Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,limited availability
3178,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","500 mg/50 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3178-03)",Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,limited availability
3179,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","75 mg/5 mL (1.5%; 1:200,000); Glass Ampul (NDC 0409-1209-01)",Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3180,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","450 mg/30 mL (1.5%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3181-01)",Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3181,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-01)",Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3182,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","600 mg/30 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-02)",Revised,12/20/2019,Available,,,Other,Anesthesia;Pediatric,Current,,,,2019,available
3183,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","1 g/50 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-03)",Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,limited availability
3184,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3183-01)",Revised,12/20/2019,Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2019,not available
3185,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2% w/EPI 1:50,000; 1.8mL syringe (NDC 00409-7263-01)",Revised,12/20/2019,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2019,discontinued
3186,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 5mcg tablets (NDC 0378-3611-01),New,3/28/2018,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/2018,3/28/2018,,2019,discontinued
3187,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 25mcg tablets (NDC 0378-3612-01),New,3/28/2018,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/2018,3/28/2018,,2019,discontinued
3188,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-1/4 (NDC 0456-0040-01),New,12/6/2018,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
3189,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-1/2 (NDC 0456-0045-01),New,12/6/2018,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
3190,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-1 (NDC 0456-0050-01),New,12/6/2018,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
3191,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-2 (NDC 0456-0055-01),New,12/6/2018,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
3192,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-3 (NDC 0456-0060-01),New,12/6/2018,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
3193,Lisinopril (Prinivil) Tablets,Merck Sharp & Dohme Corp.,"5-mg tablets, unit-of-use bottle/90 (NDC 0006-0019-54)",New,3/11/2019,,To be discontinued on or near April 2019.,,,Cardiovascular,To be Discontinued,3/11/2019,,,2019,discontinued
3194,Lisinopril Tablets,Mylan Pharmaceuticals Inc.,2.5 mg (NDC 0378-2072-01); 5 mg (NDC 0378-2073-01); 5 mg (NDC 0378-2073-10); 10 mg (NDC 0378-2074-01); 10 mg (NDC 0378-2074-10); 20 mg (NDC 0378-2075-01); 20 mg (NDC 0378-2075-10); 30 mg (NDC 0378-2077-01); 40 mg (NDC 0378-2076-01; 40 mg (NDC 0378-2076-05),New,4/11/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,4/11/2018,4/11/2018,,2019,discontinued
3195,"Lorazepam Injection, USP","Hospira, Inc.",4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31),Reverified,12/20/2019,Next delivery: January 2020 Estimated Recovery: December 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,,2019,not available
3196,"Lorazepam Injection, USP","Hospira, Inc.",2 mg/mL; Carpuject Luer Lock Glass Syringe  (NDC 00409-1985-30),Reverified,12/20/2019,Available,,,Other,Neurology,Current,,,,2019,available
3197,"Lorazepam Injection, USP","Hospira, Inc.",2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02),Reverified,12/20/2019,Available,,,Other,Neurology,Current,,,,2019,available
3198,"Lorazepam Injection, USP","Hospira, Inc.",4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02),Reverified,12/20/2019,Available,,,Other,Neurology,Current,,,,2019,available
3199,"Lorazepam Injection, USP","Hospira, Inc.",20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02),Reverified,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,,2019,limited availability
3200,"Lorazepam Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)",Reverified,12/16/2019,Available,,,Other,Neurology,Current,,,,2019,available
3201,"Lorazepam Injection, USP",Akorn Pharmaceuticals,Lorazepam Injection 2 mg/mL (NDC 17478-040-01),Revised,12/2/2019,Available,,,Demand increase for the drug,Neurology,Current,,,,2019,available
3202,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2019,available
3203,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2019,available
3204,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2019,available
3205,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2019,available
3206,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2019,available
3207,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2019,available
3208,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2019,available
3209,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2019,available
3210,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
3211,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
3212,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
3213,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
3214,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 100 count bottle (NDC 0527-1394-01)",New,11/25/2019,"Out of stock, estimated availability in January/February 2020",Additional lots are scheduled for release in the January/February timeframe. Product will be made available as it is released.,,Other,Psychiatry,Current,,,,2019,not available
3215,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/2019,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
3216,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 100 count bottle (NDC 0527-1395-01)",New,11/25/2019,Allocating inventory,Additional lots are scheduled for release in the January/February timeframe.,,Other,Psychiatry,Current,,,,2019,limited availability
3217,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/2019,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
3218,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 100 count bottle (NDC 0527-1396-01)",New,11/25/2019,Allocating Inventory,Additional lots are scheduled for release in the January/February timeframe.,,Other,Psychiatry,Current,,,,2019,limited availability
3219,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/2019,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
3220,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 100 count bottle (NDC 0527-1397-01)",New,11/25/2019,Allocating Inventory,Additional lots are scheduled for release in the January/February timeframe.,,Other,Psychiatry,Current,,,,2019,limited availability
3221,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/2019,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2019,not available
3222,Loxapine Capsules,Mylan,"5 mg, 100 count bottle (NDC 0378-7005-01)",New,11/25/2019,End Q1 2020,,,Other,Psychiatry,Current,,,,2019,not available
3223,Loxapine Capsules,Mylan,"10 mg, 100 count bottle (NDC 0378-7010-01)",New,11/25/2019,End Q1 2020,,,Other,Psychiatry,Current,,,,2019,not available
3224,Loxapine Capsules,Mylan,"25 mg, 100 count bottle (NDC 0378-7025-01)",New,11/25/2019,End Q1 2020,,,Other,Psychiatry,Current,,,,2019,not available
3225,Loxapine Capsules,Mylan,"50 mg, 100 count bottle (NDC 0378-7050-01)",New,11/25/2019,End Q1 2020,,,Other,Psychiatry,Current,,,,2019,not available
3226,Loxapine Capsules,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0591-0369-01)",Reverified,12/16/2019,Product is available,,,,Psychiatry,Current,,,,2019,available
3227,Loxapine Capsules,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0591-0370-01)",Reverified,12/16/2019,Availability and estimated duration of supply interruption is unknown,,,Other,Psychiatry,Current,,,,2019,unclear
3228,Loxapine Capsules,Teva Pharmaceuticals,"25 mg, 100 count bottle (NDC 0591-0371-01)",Reverified,12/16/2019,Product is available,,,,Psychiatry,Current,,,,2019,available
3229,Loxapine Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0591-0372-01)",Reverified,12/16/2019,Product is available,,,,Psychiatry,Current,,,,2019,available
3230,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 100 count (NDC 42806-012-01)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2019,discontinued
3231,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 1000 count (NDC 42806-012-10)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2019,discontinued
3232,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 100 count (NDC 42806-014-01)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2019,discontinued
3233,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 1000 count (NDC 42806-014-10)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2019,discontinued
3234,Megestrol Acetate (Megace) Oral Suspension,"Endo Pharmaceuticals, Inc.",MEGACE®ES 625mg/5ml Suspension (NDC 63481-160-38),New,8/21/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,8/21/2019,8/21/2019,,2019,discontinued
3235,Megestrol Acetate (Megace) Oral Suspension,Bristol Myers Squibb Co.,40 mg/mL Oral Suspension (NDC 00015-508-42),New,5/6/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/6/2019,5/6/2019,,2019,discontinued
3236,Mesna Injection,Teva Pharmaceuticals,100 mg/mL (NDC 0703-4805-03),New,6/21/2019,,This product discontinuation is a business related decision.,,,Oncology,To be Discontinued,6/21/2019,6/21/2019,,2019,discontinued
3237,"Metaproterenol Sulfate Tablets, USP",Par Pharmaceutical,"10mg, 100 count (NDC 49884-0258-01)",New,7/12/2019,,Business decision to discontinue marketing in the US.,,,Pulmonary/Allergy,To be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3238,"Metaproterenol Sulfate Tablets, USP",Par Pharmaceutical,"20mg, 100 count (NDC 49884-0259-01)",New,7/12/2019,,Business decision to discontinue marketing in the US.,,,Pulmonary/Allergy,To be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3239,Metformin Hydrochloride (Glucophage XR) Tablets Extended Release,Bristol Myers Squibb Co.,"500mg 100/bottle, (NDC 0087-6063-13)",New,2/27/2019,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/2019,2/27/2019,,2019,discontinued
3240,Metformin Hydrochloride (Glucophage XR) Tablets Extended Release,Bristol Myers Squibb Co.,750mg 100/bottle (NDC 0087-6064-13),New,2/27/2019,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/2019,2/27/2019,,2019,discontinued
3241,Metformin Hydrochloride (Glucophage) Tablets,Bristol Myers Squibb Co.,"500mg 100/bottle, (NDC  0087-6060-05)",New,2/27/2019,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/2019,2/27/2019,,2019,discontinued
3242,Metformin Hydrochloride (Glucophage) Tablets,Bristol Myers Squibb Co.,"500mg 500/bottle, (NDC 0087-6060-10)",New,2/27/2019,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/2019,2/27/2019,,2019,discontinued
3243,Metformin Hydrochloride (Glucophage) Tablets,Bristol Myers Squibb Co.,"850mg 100/bottle, (NDC 0087-6070-05)",New,2/27/2019,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/2019,2/27/2019,,2019,discontinued
3244,Metformin Hydrochloride (Glucophage) Tablets,Bristol Myers Squibb Co.,"1000mg 100/bottle, (NDC 0087-6071-11)",New,2/27/2019,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/2019,2/27/2019,,2019,discontinued
3245,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 750 mg per tablet, (NDC 0093-7212-01), 100 count per bottle",New,7/22/2019,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/2019,7/22/2019,,2019,discontinued
3246,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 500 mg per tablet, (NDC 0093-7267-01), 100 count per bottle",New,7/22/2019,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/2019,7/22/2019,,2019,discontinued
3247,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 500 mg per tablet, (NDC 0093-7267-10), 1000 count per bottle",New,7/22/2019,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/2019,7/22/2019,,2019,discontinued
3248,Methadone Hydrochloride Injection,Mylan Institutional,Methadone Hydrochloride Injection (Solution in Multi Dose Vials) [200 mg / 20 ml](NDC 67457-217-20),Reverified,11/26/2019,Available,,,Other,Analgesia/Addiction;Anesthesia,Current,,,,2019,available
3249,Methadone Hydrochloride Injection,Akorn Pharmaceuticals,"Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) , 20 mL multidose vials (NDC 17478-380-20)",Revised,12/11/2019,Backordered. Estimated recovery February/March 2020,,,Other,Analgesia/Addiction;Anesthesia,Current,,,,2019,not available
3250,"Methocarbamol Tablet, USP","Endo Pharmaceuticals, Inc.","Robaxin® 500mg, 100 Tablets (NDC 52244-429-10)",New,8/21/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction;Musculoskeletal,To be Discontinued,8/21/2019,8/21/2019,,2019,discontinued
3251,Methocarbamol Tablets,"Oxford Pharmaceuticals, LLC","500 mg, 100 ct (NDC 69584-611-10); 500 ct (NDC 69584-611-50); 1000 ct (NDC 69584-611-90)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3252,Methocarbamol Tablets,"Oxford Pharmaceuticals, LLC","750 mg, 100 ct (NDC 69584-612-10); 500 ct (NDC 69584-612-50); 1000 ct (NDC 69584-612-90)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3253,Methocarbamol Tablets,"Solco Healthcare US, LLC","500 mg, 100 ct (NDC 43547-0405-10); 500 ct (NDC 43547-0405-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3254,Methocarbamol Tablets,"Solco Healthcare US, LLC","750 mg, 100 ct (NDC 43547-0226-10); 500 ct (NDC 43547-0226-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3255,Methocarbamol Tablets,Granules Pharmaceuticals Inc.,"500 mg, 100 ct (NDC 70010-754-01); 500 ct (NDC 70010-754-05)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3256,Methocarbamol Tablets,Granules Pharmaceuticals Inc.,"750 mg, 100 ct (NDC 70010-770-01); 500 ct (NDC 70010-770-05)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3257,Methocarbamol Tablets,"AustarPharma, LLC","Distributed by Golden State Medical Supply, Inc.: 500 mg, 100 ct (NDC 60429-118-01); 500 ct (NDC 60429-118-05) Distributed by Virus Pharmaceuticals: 500 mg, 100 ct (NDC 69543-134-10); 500 ct (NDC 69543-134-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3258,Methocarbamol Tablets,"AustarPharma, LLC","Distributed by Golden State Medical Supply, Inc.: 750 mg, 100 ct (NDC 60429-119-01); 500 ct (NDC 60429-119-05) Distributed by Virtus Pharmaceuticals: 750 mg, 100 ct (NDC 69543-135-10); 500 ct (NDC 69543-135-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3259,Methocarbamol Tablets,Camber Pharmaceuticals Inc.,"500 mg, 100 ct (NDC 31722-533-01); 500 ct (NDC 31722-533-05)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3260,Methocarbamol Tablets,Camber Pharmaceuticals Inc.,"750 mg, 100 ct (NDC 31722-534-01); 500 ct (NDC 31722-534-05)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3261,Methocarbamol Tablets,Bayshore Pharmaceuticals,"500 mg, 100 ct (NDC 76385-123-01); 500 ct (NDC 76385-123-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3262,Methocarbamol Tablets,Bayshore Pharmaceuticals,"750 mg, 100 ct (NDC 76385-124-01); 500 ct (NDC 76385-124-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2019,
3263,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 2 mL vial (NDC 0143-9519-10)",Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3264,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X40ML (NDC 00703-3678-01),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3265,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X40ML Premier label  (NDC 00703-3678-81),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3266,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X10ML (NDC 00703-3675-01),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3267,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML SDV 10X2ML (NDC 00703-3671-03),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3268,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","1 gram per vial, 50 mL vial, SDV (NDC 63323-122-50)",Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3269,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","250 mg per 10 mL, vial (NDC 63323-123-10)",Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3270,Methotrexate Sodium Injection,"Hospira, Inc.",50 mg/2 mL (25 mg/mL); Glass Fliptop Vial (NDC 61703-0350-38),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3271,Methotrexate Sodium Injection,"Hospira, Inc.",1 g/40 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 61703-0408-41),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3272,Methotrexate Sodium Injection,Mylan Institutional,1000 mg/40 mL (NDC 67457-480-40),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3273,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 2mL (NDC 16729-277-30),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3274,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 40 mL (NDC 16729-277-35),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3275,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 10 mL (NDC 16729-277-03),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2019,
3276,Methotrexate Sodium Injection,Mylan,"250 mg in 10 mL (25 mg/mL), single dose vial (NDC 67457-466-10)",New,12/16/2019,,Expected Discontinuation April 2020,,,Dermatology;Oncology;Pediatric;Rheumatology,To be Discontinued,12/16/2019,12/16/2019,,2019,discontinued
3277,"Methotrexate Tablets, USP","Endo Pharmaceuticals, Inc.","Methotrexate Sodium 2.5 mg Tablet, 36 count (NDC 67253-320-36)",New,9/13/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Dermatology;Oncology;Rheumatology,To be Discontinued,9/13/2019,9/13/2019,,2019,discontinued
3278,"Methotrexate Tablets, USP","Endo Pharmaceuticals, Inc.","Methotrexate Sodium 2.5 mg Tablet, 100 count (NDC 67253-320-10)",New,9/13/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Dermatology;Oncology;Rheumatology,To be Discontinued,9/13/2019,9/13/2019,,2019,discontinued
3279,"Methscopolamine Bromide, Tablets, USP",Par Pharmaceutical,"2.5 mg, 100 count (NDC  64376-603-01)",New,7/18/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,7/18/2019,7/18/2019,,2019,discontinued
3280,"Methscopolamine Bromide, Tablets, USP",Par Pharmaceutical,"5 mg, 60 count (NDC 64376-604-61)",New,7/18/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,7/18/2019,7/18/2019,,2019,discontinued
3281,Methyclothiazide Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-0160-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3282,Methyldopa Tablets,Teva Pharmaceuticals,500 mg/1 unit (NDC 0093-2932-05),New,6/10/2019,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
3283,Methyldopa Tablets,Teva Pharmaceuticals,500 mg/1 unit (NDC 0093-2932-01),New,6/10/2019,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
3284,Methyldopa Tablets,Teva Pharmaceuticals,250 mg/1 unit (NDC 0093-2931-10),New,6/10/2019,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
3285,Methyldopa Tablets,Teva Pharmaceuticals,250 mg/1 unit (NDC 0093-2931-01),New,6/10/2019,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
3286,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 100s (16729-03-001),Reverified,12/13/2019,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,2019,limited availability
3287,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 500s (16729-03-016),Reverified,12/13/2019,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,2019,limited availability
3288,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 100s (16729-03-101),Reverified,12/13/2019,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,2019,limited availability
3289,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 500s (16729-03-116),Reverified,12/13/2019,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,2019,limited availability
3290,Methyldopa Tablets,Mylan Pharmaceuticals Inc.,250 mg (NDC 0378-0611-01),Reverified,11/26/2019,Unavailable. Estimated recovery: Q1 2020,,,Other,Cardiovascular,Current,,,,2019,not available
3291,Methyldopa Tablets,Mylan Pharmaceuticals Inc.,500 mg (NDC 0378-0421-01),Reverified,11/26/2019,Unavailable. Estimated recovery: Q1 2020,,,Other,Cardiovascular,Current,,,,2019,not available
3292,Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets,"Tris Pharma, Inc.",20 mg (NDC 24478-074-01),Revised,8/9/2019,,,,,Pediatric;Psychiatry,Resolved,8/9/2019,,,2019,
3293,Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets,"Tris Pharma, Inc.",30 mg (NDC 24478-075-01),Revised,8/9/2019,,,,,Pediatric;Psychiatry,Resolved,8/9/2019,,,2019,
3294,Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets,"Tris Pharma, Inc.",40 mg (NDC 24478-076-01),Revised,8/9/2019,,,,,Pediatric;Psychiatry,Resolved,8/9/2019,,,2019,
3295,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",300 mg/60 mL (NDC 24478-321-02),Reverified,12/13/2019,Available,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,Other,Pediatric;Psychiatry,Current,,,,2019,available
3296,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",600 mg/120mL (NDC 24478-322-04),Reverified,12/13/2019,Available,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,Other,Pediatric;Psychiatry,Current,,,,2019,available
3297,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",750 mg/150 mL (NDC 24478-323-05),Reverified,12/13/2019,Available,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,Other,Pediatric;Psychiatry,Current,,,,2019,available
3298,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",900 mg/180 mL (NDC 24478-324-06),Reverified,12/13/2019,Available,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,Other,Pediatric;Psychiatry,Current,,,,2019,available
3299,"Methylphenidate Hydrochloride Extended-Release Tablets, USP CII",Teva Pharmaceuticals,36 mg 30 count (NDC 0591-2717-30),New,5/17/2019,,Teva made a business related decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
3300,"Methylphenidate Hydrochloride Extended-Release Tablets, USP CII",Teva Pharmaceuticals,54 mg 30 count (NDC 0591-2718-30),New,5/17/2019,,Teva made a business related decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
3301,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,5 mg 100 count (NDC 0591-5882-01),New,5/17/2019,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
3302,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,10 mg 100 count (NDC 0591-5883-01),New,5/17/2019,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
3303,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,20 mg 100 count (NDC 0591-5884-01),New,5/17/2019,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2019,discontinued
3304,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg tablets (NDC 0591-0790-01),New,12/5/2019,,,,,Neurology,To be Discontinued,12/5/2019,12/5/2019,,2019,discontinued
3305,"Metoclopramide Injection, USP",Heritage Pharma,10mg/2mL (NDC 23155-240-41),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2019,
3306,"Metoclopramide Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3414-01),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2019,
3307,"Metoclopramide Injection, USP","Fresenius Kabi USA, LLC","10 mg per 2 mL, single use, prefilled syringe (NDC 76045-101-20)",Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2019,
3308,"Metoclopramide Injection, USP",Teva Pharmaceuticals,5 mg/ 1 ml (NDC 0703-4502-04),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2019,
3309,"Metoclopramide Injection, USP",Teva Pharmaceuticals,5 mg/ 1 ml (NDC 0703-4502-84),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2019,
3310,"Metoprolol Tartrate Injection, USP",Gland Pharma,"1 mg/mL, 5 mL vial (NDC 72266-122-25)",Reverified,12/16/2019,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,,2019,available
3311,"Metoprolol Tartrate Injection, USP",Gland Pharma,1 mg/mL 5mL vial (NDC 70860-300-05 and 70860-300-41),Reverified,12/16/2019,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Cardiovascular,Current,,,,2019,available
3312,"Metoprolol Tartrate Injection, USP",Gland Pharma,5 mg per 5 mL Single Dose Vial (NDC 47781-587-17),Reverified,12/16/2019,Available,Distributed by Alvogen Inc. (Company Contact Information:  973-532-7840),,Available,Cardiovascular,Current,,,,2019,available
3313,"Metoprolol Tartrate Injection, USP",Baxter Healthcare,1 mg/mL - 5 mL Sterile Single Use Glass Vial (10 x 5 mL). For Intravenous Use (NDC 36000-033-10),Reverified,12/11/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3314,"Metoprolol Tartrate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 5 mL, SDV, PF (NDC 63323-660-05)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Manufacturing delays,Cardiovascular,Current,,,,2019,available
3315,"Metoprolol Tartrate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1mg/mL – 10mL vials, (NDC 0143-9660-10)",Reverified,12/13/2019,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
3316,"Metoprolol Tartrate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1mg/mL – 5ml vials (NDC 0143-9873-25),Reverified,12/13/2019,This presentation is temporarily on backorder.,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,not available
3317,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1778-05),Reverified,12/20/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
3318,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1778-35),Reverified,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
3319,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Glass Ampul (NDC 00409-2285-05),Reverified,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2019,not available
3320,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,50 mg tablets (NDCs 0591-0462-01 and 0591-0462-10),New,12/16/2019,,,,,Cardiovascular,To be Discontinued,12/16/2019,12/16/2019,,2019,discontinued
3321,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,100 mg tablets (NDCs 0591-0463-01 and 0591-0463-10),New,12/16/2019,,,,,Cardiovascular,To be Discontinued,12/16/2019,12/16/2019,,2019,discontinued
3322,"Metronidazole Injection, USP",Baxter Healthcare,"Metronidazole Injection, USP, 500 mg/100 mL, in VIAFLEX Plus Container (NDC 0338-1055-48)",Reverified,12/11/2019,Available,,,,Anti-Infective,Current,,,,2019,available
3323,"Metronidazole Injection, USP","Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 00409-7811-24),Reverified,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,,2019,limited availability
3324,"Metronidazole Injection, USP","Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 00409-7811-37),Reverified,12/20/2019,Available,,,Other,Anti-Infective,Current,,,,2019,available
3325,"Metronidazole Injection, USP",B. Braun Medical Inc.,Metronidazole Injection 500mg (5mg/mL) 100mL D5353-5224 (NDC 0264-5535-32),Revised,1/22/2019,Product available for contracted  customers,,,Manufacturing interruptions and demand increase,Anti-Infective,Current,,,,2019,limited availability
3326,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",15mg tablets (NDC 0591-2469-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2019,discontinued
3327,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",30mg tablets (NDC 0591-2470-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2019,discontinued
3328,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",45mg tablets (NDC 0591-2471-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2019,discontinued
3329,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 30 count bottle (NDC 0093-7206-56),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3330,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 30 count bottle (NDC 0591-1117-30),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3331,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 1000 count bottle (NDC 0591-1117-10),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3332,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 30 count bottle (NDC 0093-7207-56),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3333,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 30 count bottle (NDC 0591-1118-30),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3334,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 1000 count bottle (NDC 0591-1118-10),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3335,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,45 mg 30 count bottle (NDC 0591-1119-30),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3336,Modafinil Tablets,Par Pharmaceutical,"100 mg, bottle of 30 (NDC 49884-534-11)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3337,Moexipril Hydrochloride/Hydrochlorothiazide Tablets,Teva Pharmaceuticals,7.5 mg; 12.5 mg tablets (NDC 0093-5213-01),New,11/6/2018,,This product discontinuation is a business-related decision.,,,Cardiovascular,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3338,Moexipril Hydrochloride/Hydrochlorothiazide Tablets,Teva Pharmaceuticals,15 mg; 12.5 mg tablets (NDC 0093-5214-01),New,11/6/2018,,This product discontinuation is a business-related decision.,,,Cardiovascular,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3339,Moexipril Hydrochloride/Hydrochlorothiazide Tablets,Teva Pharmaceuticals,15 mg; 25 mg tablets (NDC 0093-5215-01),New,11/6/2018,,This product discontinuation is a business-related decision.,,,Cardiovascular,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3340,Mometasone Furoate (Elocon) Topical Cream,Merck Sharp & Dohme Corp.,0.1% 15 gram tube  (NDC 0085-3149-01),New,7/29/2019,,,,,Dermatology,To be Discontinued,7/29/2019,7/29/2019,,2019,discontinued
3341,Mometasone Furoate (Elocon) Topical Cream,Merck Sharp & Dohme Corp.,0.1% 50 gram tube  (NDC 0085-3149-03),New,7/29/2019,,,,,Dermatology,To be Discontinued,7/29/2019,7/29/2019,,2019,discontinued
3342,Montelukast Sodium Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-5201-93),New,3/20/2018,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,3/20/2018,3/20/2018,,2019,discontinued
3343,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,20 mg/0.8 mg; 30 capsules per bottle (NDC 60793-430-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2019,discontinued
3344,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,30 mg/1.2 mg; 30 capsules per bottle (NDC 60793-431-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2019,discontinued
3345,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,50 mg/2 mg; 30 capsules per bottle (NDC 60793-433-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2019,discontinued
3346,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,60 mg/2.4 mg; 30 capsules per bottle (NDC 60793-434-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2019,discontinued
3347,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,80 mg/3.2 mg; 30 capsules per bottle (NDC 60793-435-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2019,discontinued
3348,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,100 mg/4 mg; 30 capsules per bottle (NDC 60793-437-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2019,discontinued
3349,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"15 mg, bottle of 100 (NDC 60951-652-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3350,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"30 mg, bottle of 100 (NDC 60951-653-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3351,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"60 mg, bottle of 100 (NDC 60951-655-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3352,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"100 mg, bottle of 100 (NDC 60951-658-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3353,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"200 mg, bottle of 100 (NDC 60951-659-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3354,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-2658-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
3355,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 100s (NDC 0378-2659-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
3356,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"60 mg, 100s (NDC 0378-2660-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
3357,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100s (NDC 0378-2661-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
3358,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100s (NDC 0378-2662-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
3359,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-452-01)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3360,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-454-01)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3361,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 1 mL, Single dose vial, (NDC 63323-455-01)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3362,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","8 mg per 1 mL, Single dose vial, (NDC 63323-458-01)",Reverified,12/20/2019,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3363,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, (NDC 63323-451-01)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3364,"Morphine Sulfate Injection, USP","Amphastar Pharmaceuticals, Inc./IMS",Morphine Sulfate 1 mg/mL 30 mg in 30 mL PUMP-JET®  SUITABLE FOR USE WITH COMPATIBLE I.V. INFUSION PUMPS,Revised,12/16/2019,Available,,,,Analgesia/Addiction,Current,,,,2019,available
3365,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6125-25)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3366,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","8 mg/mL, 1 mL vial (NDC 0641-6126-25)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3367,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-6127-25)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3368,"Morphine Sulfate Injection, USP","Hospira, Inc.",250 mg/10 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1135-02),Revised,12/20/2019,Next Delivery: March 2020; Estimated Recovery: April 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
3369,"Morphine Sulfate Injection, USP","Hospira, Inc.",2 mg/mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1890-01),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
3370,"Morphine Sulfate Injection, USP","Hospira, Inc.",2 mg/mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1890-11),Revised,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
3371,"Morphine Sulfate Injection, USP","Hospira, Inc.",4 mg/mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1891-01),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
3372,"Morphine Sulfate Injection, USP","Hospira, Inc.",4 mg/mL (4 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1891-11),Revised,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
3373,"Morphine Sulfate Injection, USP","Hospira, Inc.",8 mg/mL (8 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1892-01),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
3374,"Morphine Sulfate Injection, USP","Hospira, Inc.",8 mg/mL (8 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1892-11),Revised,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
3375,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1893-01),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
3376,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1893-11),Revised,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
3377,"Morphine Sulfate Injection, USP","Hospira, Inc.",5 mg/10 mL (0.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3814-12),Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
3378,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/10 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3815-12),Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,limited availability
3379,"Morphine Sulfate Injection, USP","Hospira, Inc.","1,000 mg/20 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-03)",Revised,12/20/2019,Available,,,Other,Analgesia/Addiction,Current,,,,2019,available
3380,"Morphine Sulfate Injection, USP","Hospira, Inc.","2,500 mg/50 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-05)",Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
3381,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-10)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3382,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-005-10)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3383,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 1 mL, Single-use prefilled syringe (NDC 76045-006-10)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3384,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","8 mg per 1 mL, Single-use prefilled syring (NDC 76045-007-10)",Reverified,12/20/2019,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,not available
3385,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single-use prefilled syringe (NDC 76045-008-10)",Reverified,12/20/2019,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,not available
3386,"Morphine Sulfate Injection, USP","ICU Medical, Inc.",1mg/mL 30mL PCA glass vial (NDC 0409-2029-02),Reverified,12/16/2019,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Analgesia/Addiction,Current,,,,2019,not available
3387,"Morphine Sulfate Injection, USP","ICU Medical, Inc.",5mg/mL 30mL PCA GLASS VIAL (CII)(NDC 0409-6028-04),New,10/2/2019,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To be Discontinued,10/2/2019,10/2/2019,,2019,discontinued
3388,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 1 mg/mL, 10 mL ampul (NDC 0641-6019-10)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3389,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 0.5 mg/mL, 10 mL ampul (NDC 0641-6020-10)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3390,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 10 mg/mL, 20 mL ampul (NDC 0641-6039-01)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3391,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 25 mg/mL, 20 mL ampul (NDC 0641-6040-01)",Revised,12/13/2019,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2019,available
3392,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 10 mL Single Dose Dual Glass Fliptop Vials (NDC 61703-0434-82),Revised,12/20/2019,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,not available
3393,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 2 x 50 mL Pharmacy Bulk Package Dual Glass Fliptop Vials (NDC 61703-0422-83),Revised,12/20/2019,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,not available
3394,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Pediatric; Single Dose Glass Fliptop Vial (NDC 61703-0421-53),Revised,12/20/2019,Next Delivery: November 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,not available
3395,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)",Reverified,12/11/2019,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,available
3396,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)",Reverified,12/11/2019,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,available
3397,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5650-2)",Reverified,12/11/2019,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,available
3398,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)",Reverified,12/11/2019,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,available
3399,Mupirocin Calcium Nasal Ointment,GlaxoSmithKline,2% Nasal Ointment 1 gram tube Package of 10 (NDC 0029152611),Revised,12/13/2019,,,,,Anti-Infective,To be Discontinued,12/13/2019,12/13/2019,,2019,discontinued
3400,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-3124-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
3401,Nafcillin Sodium Injection,Sandoz,2 gram vial packaged in 10s (NDC 0781-3125-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
3402,Nafcillin Sodium Injection,Sandoz,Pharmacy Bulk Package bottle (NDC 0781-3126-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
3403,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-9124-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
3404,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9224-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
3405,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9225-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
3406,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3128-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
3407,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3129-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2019,discontinued
3408,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 1% 60 gm (NDC 40085-201-60),New,5/15/2019,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/2019,5/15/2019,,2019,discontinued
3409,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 1% 90 gm (NDC 40085-201-90),New,5/15/2019,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/2019,5/15/2019,,2019,discontinued
3410,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 2% 45 gm (NDC 40085-203-45),New,5/15/2019,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/2019,5/15/2019,,2019,discontinued
3411,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 2% 60 gm (NDC 40085-203-60),New,5/15/2019,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/2019,5/15/2019,,2019,discontinued
3412,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",10 mg/mL; 1 mL Glass Ampul (NDC 00409-1463-01),Reverified,12/20/2019,Next Delivery: June 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
3413,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",20 mg/mL; 1 mL Glass Ampul (NDC 00409-1465-01),Reverified,12/20/2019,Next Delivery: June 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,not available
3414,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1464-01),Reverified,12/20/2019,Limited Supply Available. Next Delivery: June 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,limited availability
3415,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1467-01),Reverified,12/20/2019,Limited Supply Available. Next Delivery: June 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2019,limited availability
3416,Naratriptan Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg  (NDC 0378-4450-59),New,7/17/2019,,,,,Neurology,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
3417,Nebivolol Hydrochloride and Valsartan (BYVALSAN) Tablets,Allergan,"5 mg, 80 mg per tablet; (NDCs 0023-5874-90; 0023-5874-84; 0023-5874-32; 0023-5874-31; 0023-5874-30; 0023-5874-07)",New,12/19/2018,,,,,Cardiovascular,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3418,Nelarabine (Arranon) Injection,Novartis,250 mg/50 mL (NDC 0078-0683-06),Reverified,12/11/2019,Available,,,Demand increase for the drug,Hematology,Current,,,,2019,available
3419,"Neomycin and Polymyxin B Sulfates Solution For Irrigation, USP",Teva Pharmaceuticals,"40 mg and 200,000 units (1 mL ampule) (NDC 0591-2190-45)",New,6/10/2019,,Discontinuation of the manufacture of the drug.,,,Anti-Infective;Urology,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
3420,Nesiritide Powder (NATRECOR) for Injection,Janssen Pharmaceuticals,1.5 mg (NDC 65847-205-25),New,2/5/2018,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To be Discontinued,2/5/2018,2/5/2018,,2019,discontinued
3421,Nevirapine Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg tablets (NDC 0378-6950-77),New,1/31/2019,,,,,Antiviral,To be Discontinued,1/31/2019,1/31/2019,,2019,discontinued
3422,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"30mg, 100 count bottle (NDC 10370-677-01)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3423,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"30mg, 500 count bottle (NDC 10370-677-05)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3424,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"60mg, 100 count bottle (NDC 10370-678-01)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3425,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"60mg, 500 count bottle (NDC 10370-678-05)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3426,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"90 mg, 100 count bottle (NDC 10370-679-01)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3427,"Nifedipine Extended-Release Tablet, USP",Teva Pharmaceuticals,"Nifedipine extended-release tablets, 90 mg, 500 count (NDC 45963-152-50)",New,6/7/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,6/7/2019,6/7/2019,,2019,discontinued
3428,"Nifedipine Extended-Release Tablet, USP",Teva Pharmaceuticals,"Nifedipine extended-release tablets, 90 mg, 100 count (NDC 45963-152-02)",New,6/7/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,6/7/2019,6/7/2019,,2019,discontinued
3429,Nizatidine Capsules,Mylan Pharmaceuticals Inc.,"150 mg, 60 count bottle (NDC 0378-5150-91)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3430,Nizatidine Capsules,Mylan Pharmaceuticals Inc.,"300 mg, 30 count bottle (NDC 0378-5300-93)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3431,Norethindrone (NOR QD) Tablets,Allergan,"Nor QD, 0.35 mg norethindrone, Tablets, (NDC  52544-235-28)",New,2/23/2018,,"An authorized generic of the product is currently available as Nora-BE, NDC 52544-629-28.",,,Reproductive,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
3432,Norethindrone Acetate and Ethinyl Estradiol plus Ferrous Fumarate Chewable Tablets 0.1mg/0.02mg + 75mg (Minastrin 24Fe),Mylan Pharmaceuticals Inc.,"0.1mg/0.02mg + 75mg Tablets, NDC (0378-7315-53)",New,1/2/2019,,,,,Reproductive,To be Discontinued,1/2/2019,1/2/2019,,2019,discontinued
3433,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate) (NDC 0023-5970-05) 5 Blister Pack in 1 Carton > 1 Kit in 1 Blister Pack",New,1/11/2019,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/2019,1/11/2019,,2019,discontinued
3434,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 0430-0010-05) 5 Blister Pack in 1 Carton > 1 Kit in 1 Blister Pack",New,1/11/2019,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/2019,1/11/2019,,2019,discontinued
3435,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 0430-0482-14) 72 Carton in 1 Case > 5 Cello Pack in 1 Carton > 1 Blister Pack in 1 Cello Pack > 1 Kit in 1 Blister Pack",New,1/11/2019,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/2019,1/11/2019,,2019,discontinued
3436,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 0430-0482-95) 30 Tray in 1 Case > 6 Carton in 1 Tray > 1 Cello Pack in 1 Carton > 1 Blister Pack in 1 Cello Pack > 1 Kit in 1 Blister Pack",New,1/11/2019,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/2019,1/11/2019,,2019,discontinued
3437,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 54868-6161-0) 1 Blister Pack in 1 Cello Pack > 1 Kit in 1 Blister Pack",New,1/11/2019,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/2019,1/11/2019,,2019,discontinued
3438,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 68180-897-13) 5 Pouch in 1 Carton > 1 Blister Pack in 1 Pouch > 1 Kit in 1 Blister Pack",New,1/11/2019,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/2019,1/11/2019,,2019,discontinued
3439,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)( NDC 68180-898-13) 72 Carton in 1 Case > 5 Cello Pack in 1 Carton > 1 Blister Pack in 1 Cello Pack > 1 Kit in 1 Blister Pack",New,1/11/2019,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/2019,1/11/2019,,2019,discontinued
3440,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)( NDC68180-899-13) 5 Blister Pack in 1 Carton > 1 Kit in 1 Blister Pack",New,1/11/2019,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/2019,1/11/2019,,2019,discontinued
3441,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Mylan Pharmaceuticals Inc.,"0.02 mg norethindrone acetate / 1 mg ethinyl estradiol / 75 mg ferrous fumarate; 28 tablets per blister pack, 3 blisters per carton (NDC 0378-7301-53)",New,5/23/2019,,,,,Reproductive,To be Discontinued,5/23/2019,5/23/2019,,2019,discontinued
3442,Normosol-M and 5% Dextrose Injection,"ICU Medical, Inc.",Normosol-M and 5% Dextrose Injection (NDC 0409-7965-03),New,12/6/2018,,Discontinuation of the manufacture of the drug.,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
3443,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 15 g (NDC 0603-7818-74)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3444,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 30 g (NDC 0603-7818-78)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3445,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 60 g (NDC 0603-7818-88)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/2019,4/15/2019,,2019,discontinued
3446,"Nystatin Cream, USP",Teva Pharmaceuticals,"100,000 USP units per gram, 15 g (NDC 0472-0163-15)",New,11/15/2019,,Teva made a business decision to discontinue the product.,,,Dermatology,To be Discontinued,11/15/2019,11/15/2019,,2019,discontinued
3447,"Nystatin Cream, USP",Teva Pharmaceuticals,"100,000 units per gram, 30 g (NDC 0472-0163-30)",New,11/15/2019,,Teva made a business decision to discontinue the product.,,,Dermatology,To be Discontinued,11/15/2019,11/15/2019,,2019,discontinued
3448,Nystatin Oral Suspension,Wockhardt,"Nystatin Oral Solution 100,000 units/1mL; 473 mL bottles (NDC 60432-0537-16)",Reverified,12/10/2019,Available,,,Other,Anti-Infective;Pediatric,Current,,,,2019,available
3449,Nystatin Oral Suspension,Wockhardt,"Nystatin Oral Solution 100,000 units/1mL; 60 mL bottles (NDC 60432-0537-60)",Reverified,12/10/2019,Available,,,Other,Anti-Infective;Pediatric,Current,,,,2019,available
3450,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 500,000 units/5 ml; 5mL unit dose cup; 50 unit dose cups/ case (NDC 66689-037-50)",Revised,11/13/2019,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,,2019,available
3451,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 500,000 units/5 ml; 5mL unit dose cup; 100 unit dose cups/ case (NDC 66689-037-99)",Revised,11/13/2019,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,,2019,available
3452,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 100,000 units/ml; 60 mL Bottle (NDC 66689-008-02)",Revised,11/13/2019,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,,2019,available
3453,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 100,000 units/ml; 480 mL Bottle (NDC 66689-008-16)",Revised,11/13/2019,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,,2019,available
3454,Nystatin Oral Suspension,"Pharmaceutical Associates, Inc","Nystatin Oral Suspension, USP 500,000 Units/5 mL 5 mL Unit Dose Cups Case of 40 – 5 mL UDC (NDC 00121-4810-40); Case of 100 – 5 mL UDC (NDC 00121-4810-00); 2 oz. Bottles (NDC 00121-0810-02); 16 oz. Bottles (NDC 00121-0810-16)",New,1/8/2019,Product availability will be limited as we resume production.,Resolution of product quality and manufacturing concerns.,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3455,Olaratumab (Lartruvo) Injection,Eli Lilly and Co.,500mg/50 ML x 1 vial (NDC 0002-8926-01),New,10/2/2019,,Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.,,,Oncology,To be Discontinued,10/2/2019,10/2/2019,,2019,discontinued
3456,Olaratumab (Lartruvo) Injection,Eli Lilly and Co.,190mg/19 ML x 1 vial (NDC 0002-7190-01),New,10/2/2019,,Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.,,,Oncology,To be Discontinued,10/2/2019,10/2/2019,,2019,discontinued
3457,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"20mg/12.5mg, 30 count bottle (NDC 0378-1413-93)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3458,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"20mg/12.5mg, 90 count bottle (NDC 0378-1413-77)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3459,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/12.5mg, 30 count bottle (NDC 0378-1422-93)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3460,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/12.5mg, 90 count bottle (NDC 0378-1422-77)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3461,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/25mg, 30 count bottle (NDC 0378-1425-93)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3462,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/25mg, 90 count bottle (NDC 0378-1425-77)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3463,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"5mg, 30 ct. (NDC 65852-0741-30)",Revised,12/13/2019,Temporarily discontinued,,,,Cardiovascular,Current,,,,2019,discontinued
3464,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"20mg, 30 ct. (NDC 65862-0742-30)",Revised,12/13/2019,Temporarily discontinued,,,API Supply Issue,Cardiovascular,Current,,,,2019,discontinued
3465,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"20mg, 90 ct. (NDC 65862-0742-90)",Revised,12/13/2019,Temporarily discontinued,,,API Supply Issue,Cardiovascular,Current,,,,2019,discontinued
3466,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"40mg, 30 ct. (NDC 65862-0743-30)",Revised,12/13/2019,Temporarily discontinued,,,API Supply Issue,Cardiovascular,Current,,,,2019,discontinued
3467,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"40mg., 90 ct. (NDC 65862-0743-90)",Revised,12/13/2019,Temporarily discontinued,,,API Supply Issue,Cardiovascular,Current,,,,2019,discontinued
3468,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"5mg, Bottle of 30 counts (NDC 62332-131-30)",Reverified,12/18/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3469,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"20mg, Bottle of 30 counts (NDC 62332-132-30)",Reverified,12/18/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3470,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"20mg, Bottle of 90 counts (NDC 62332-132-90)",Reverified,12/18/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3471,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"40mg, Bottle of 30 counts (NDC 62332-133-30)",Reverified,12/18/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3472,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"40mg, Bottle of 90 counts (NDC 62332-133-90)",Reverified,12/18/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3473,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,5mg (NDC 68462-0436-30),Revised,12/12/2019,Temporarily on backorder. Supply available mid-December 2019,,,API shortage,Cardiovascular,Current,,,,2019,limited availability
3474,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,20mg (NDC 68462-0437-30),Revised,12/12/2019,Available,,,API shortage,Cardiovascular,Current,,,,2019,available
3475,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,20mg (NDC 68462-0437-90),Revised,12/12/2019,Available,,,API shortage,Cardiovascular,Current,,,,2019,available
3476,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,40mg (NDC 68462-0438-30),Revised,12/12/2019,Temporarily on backorder. Estimated availability: mid-December 2019,,,API shortage,Cardiovascular,Current,,,,2019,not available
3477,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,40mg (NDC 68462-0438-90),Revised,12/12/2019,Available,,,API shortage,Cardiovascular,Current,,,,2019,available
3478,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil  5mg T 30s (NDC 0378-7012-93),Reverified,11/26/2019,Out of Stock. Resupply is Q1 2020.,,,,Cardiovascular,Current,,,,2019,not available
3479,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 20mg T 30s (NDC 0378-7112-93),Reverified,11/26/2019,Out of Stock. Resupply is Q1 2020.,,,Other,Cardiovascular,Current,,,,2019,not available
3480,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 20mg T 90s (NDC 0378-7112-77),Reverified,11/26/2019,Out of Stock. Resupply is Q1 2020.,,,Other,Cardiovascular,Current,,,,2019,not available
3481,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 40mg T 30s (NDC 0378-7124-93),Reverified,11/26/2019,Out of Stock. Resupply is Q1 2020.,,,,Cardiovascular,Current,,,,2019,not available
3482,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 40mg T 90s (NDC 0378-7124-77),Reverified,11/26/2019,Out of Stock. Resupply is Q1 2020.,,,Other,Cardiovascular,Current,,,,2019,not available
3483,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"5mg, 30T (NDC 1672-9320-10)",Revised,12/11/2019,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,,2019,available
3484,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"5mg, 90T (NDC 1672-9320-15)",Revised,12/11/2019,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,,2019,available
3485,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"20mg, 30T (NDC 1672-9321-10)",Revised,12/11/2019,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,,2019,available
3486,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"20mg, 90T (NDC 1672-9321-15)",Revised,12/11/2019,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,,2019,available
3487,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"40mg, 30T (NDC 1672-9322-10)",Revised,12/11/2019,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,,2019,available
3488,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"40mg, 90T (NDC 1672-9322-15)",Revised,12/11/2019,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,,2019,available
3489,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,5mg tablet (NDC 13668-248-30),Reverified,12/13/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3490,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,20mg tablet (NDC 13668-249-30),Reverified,12/13/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3491,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,20mg tablet (NDC 13668-249-90),Reverified,12/13/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3492,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,40mg tablet (NDC 13668-250-30),Reverified,12/13/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3493,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,40mg tablet (NDC 13668-250-90),Reverified,12/13/2019,Available,,,,Cardiovascular,Current,,,,2019,available
3494,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","5mg, 30 Unit (NDC 65597-101-30)",Reverified,12/10/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
3495,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","20mg, 30 Unit (NDC 65597-103-30)",Reverified,12/10/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
3496,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","20mg, 90 Unit (NDC 65597-103-90)",Reverified,12/10/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
3497,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","40mg, 30 Unit (NDC 65597-104-30)",Reverified,12/10/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
3498,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","40mg, 90 Unit (NDC 65597-104-90)",Reverified,12/10/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
3499,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 20mg 30 Tabs (NDC 67877-0446-30),New,3/12/2019,Availability: TBD,,,Other,Cardiovascular,Current,,,,2019,unclear
3500,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 20mg 90 Tabs (NDC 67877-0446-90),New,3/12/2019,Availability: TBD,,,Other,Cardiovascular,Current,,,,2019,unclear
3501,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 40mg 30 Tabs (NDC 67877-0447-30),New,3/12/2019,Availability: TBD,,,Other,Cardiovascular,Current,,,,2019,unclear
3502,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 40mg 90 Tabs (NDC 67877-0447-90),New,3/12/2019,Availability: TBD,,,Other,Cardiovascular,Current,,,,2019,unclear
3503,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 5mg 30 Tabs (NDC 67877-0445-30),New,3/12/2019,Availability: TBD,,,Other,Cardiovascular,Current,,,,2019,unclear
3504,Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets,Abbvie,212.5mg; 75mg; 50mg (NDC 0074-3082-28),New,5/22/2018,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary",,,Antiviral,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
3505,Omega-3-Acid Ethyl Esters,Par Pharmaceutical,"900 mg/1 unit capsule, liquid filled (NDC 49884-019-08)",New,5/10/2019,,Par has made a business decision to discontinue the drug product.,,,Gastroenterology,To be Discontinued,5/10/2019,5/10/2019,,2019,discontinued
3506,Omega-3-Acid Ethyl Esters,Par Pharmaceutical,900mg/1 unit capsule (NDC 0254-3010-08),New,5/10/2019,,Par has made a business decision to discontinue the drug product.,,,Gastroenterology,To be Discontinued,5/10/2019,5/10/2019,,2019,discontinued
3507,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC 0093-5294-56), (30 count Bottle)",New,7/17/2019,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
3508,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC (0093-5294-98) (90 count Bottle)",New,7/17/2019,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
3509,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC 0093-5294-10) (1000 count Bottle )",New,7/17/2019,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
3510,Ondansetron Hydrochloride Injection,Gland Pharma,"2 mg/mL, 2 mL vial (NDC 72266-123-25)",Reverified,12/16/2019,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,,2019,available
3511,Ondansetron Hydrochloride Injection,Gland Pharma,"2 mg/mL, 20 mL vial (NDC 72266-124-01)",Reverified,12/16/2019,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,,2019,available
3512,Ondansetron Hydrochloride Injection,Baxter Healthcare,"Ondansetron Injection, USP (2 mg/mL) 2 mL Single Use Glass Vial (25 x 2 mL) (NDC 36000-012-25)",Reverified,12/11/2019,Available,For IV or IM injection,,,Gastroenterology,Current,,,,2019,available
3513,Ondansetron Hydrochloride Injection,Gland Pharma,2 mg/mL 2mL vial (NDC 70860-776-02),Reverified,12/16/2019,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Gastroenterology,Current,,,,2019,available
3514,Ondansetron Hydrochloride Injection,Gland Pharma,2 mg/mL 20mL vial (NDC 70860-777-20),Reverified,12/16/2019,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Gastroenterology,Current,,,,2019,available
3515,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, amber vial, 4 mg per 2 mL (NDC 63323-373-02)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3516,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Multi dose, amber vial, 40 mg per 20 mL (NDC 63323-374-20)",Reverified,12/20/2019,Backordered.  Next release January 2020.,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,not available
3517,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, Simplist syringe, 4 mg per 2 mL (NDC 76045-103-20)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3518,Ondansetron Hydrochloride Injection,Apotex Corp.,Ondansetron 2mg/mL 2mL vials Box of 25 vials (NDC 60505-6130-05),Reverified,11/27/2019,Available,,,Available,Gastroenterology,Current,,,,2019,available
3519,Ondansetron Hydrochloride Injection,Heritage Pharma,"Inj4mg/2mL, 25 (NDC 23155-549-31)",Revised,11/20/2019,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3520,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-41),Revised,11/20/2019,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3521,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-42),Revised,11/20/2019,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3522,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9890-01)",Revised,10/9/2019,Inventory is currently available.,Additional lots are scheduled for manufacturing in the October – November 2019 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3523,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 2 mL vial, 25 count (NDC 55150-125-02)",Reverified,12/11/2019,"Currently on backorder, next shipment expected Dec. 2019",Intermittent availability expected,,Demand increase for the drug,Gastroenterology,Current,,,,2019,not available
3524,Ondansetron Hydrochloride Injection,Heritage Pharma,"4mg/2mL, 10 (NDC 23155-547-41 )",Revised,11/20/2019,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3525,Ondansetron Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-4759-01),Reverified,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2019,limited availability
3526,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 2 mL vial (NDC 0641-6078-25)",Revised,10/9/2019,Inventory is currently available,Additional lots are scheduled for manufacturing in the October – November 2019 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3527,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-4755-03),Reverified,12/20/2019,Available,,,Other,Gastroenterology,Current,,,,2019,available
3528,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1120-12),Reverified,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2019,not available
3529,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 20 mL vial, 1 count (NDC 55150-126-20)",Reverified,12/11/2019,"Currently on backorder, next shipment expected Dec. 2019",Intermittent availability expected,,Demand increase for the drug,Gastroenterology,Current,,,,2019,not available
3530,Ondansetron Hydrochloride Injection,Teva Pharmaceuticals,"EQ 2MG BASE/ML, INJECTION, SOLUTION,20 mL Vials, (NDC 0703-7226-03)",New,10/12/2018,,This was a business-related decision to discontinue manufacturing these products,,,Gastroenterology,To be Discontinued,10/12/2018,10/12/2018,,2019,discontinued
3531,Ondansetron Hydrochloride Injection,Teva Pharmaceuticals,"EQ 2MG BASE/ML, INJECTION, SOLUTION, 20 mL Vial, (NDC 0703-7226-01)",New,10/12/2018,,This was a business-related decision to discontinue manufacturing these products,,,Gastroenterology,To be Discontinued,10/12/2018,10/12/2018,,2019,discontinued
3532,Ondansetron Hydrochloride Injection,Teva Pharmaceuticals,"EQ 2MG BASE/ML, INJECTION, SOLUTION, 2 mL Vial, (NDC 0703-7221-04)",New,10/12/2018,,This was a business-related decision to discontinue manufacturing these products,,,Gastroenterology,To be Discontinued,10/12/2018,10/12/2018,,2019,discontinued
3533,Ondansetron Hydrochloride Injection,Teva Pharmaceuticals,"EQ 2MG BASE/ML, INJECTION, SOLUTION,  2 mL Vial, (NDC 0703-7221-01)",New,10/12/2018,,This was a business-related decision to discontinue manufacturing these products,,,Gastroenterology,To be Discontinued,10/12/2018,10/12/2018,,2019,discontinued
3534,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,40mg/20mL EA 1 Vial (NDC 25021-782-20),Reverified,12/20/2019,Available,,,,Gastroenterology,Current,,,,2019,available
3535,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,4mg/2mL PK 25 Vials (NDC 25021-777-02),Reverified,12/20/2019,Available,,,,Gastroenterology,Current,,,,2019,available
3536,Orphenadrine Citrate Injection,Teva Pharmaceuticals,30mg/mL injection (NDCs 0591-3222-47 and 0591-3222-02),New,10/25/2018,,This product discontinuation is a business-related decision.,,,Analgesia/Addiction,To be Discontinued,10/25/2018,10/25/2018,,2019,discontinued
3537,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-6605-01)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3538,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-6605-05)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3539,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-6610-01)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3540,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-6610-05)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3541,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100 count bottle (NDC 0378-6615-01)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3542,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"5 mg, 100 count bottle (NDC 0093-5206-01)",New,3/29/2019,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/2019,3/29/2019,,2019,discontinued
3543,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"10 mg, 100 count bottle (NDC 0093-5207-01)",New,3/29/2019,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/2019,3/29/2019,,2019,discontinued
3544,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"15 mg, 100 count bottle (NDC 0093-5208-01)",New,3/29/2019,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/2019,3/29/2019,,2019,discontinued
3545,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,30 mg/1 unit (NDC 0228-2879-11),New,11/7/2019,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/2019,11/7/2019,,2019,discontinued
3546,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,15 mg/1 unit (NDC 0228-2878-11),New,11/7/2019,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/2019,11/7/2019,,2019,discontinued
3547,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,5 mg/1 unit (NDC 0228-2876-11),New,11/7/2019,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/2019,11/7/2019,,2019,discontinued
3548,Oxymorphone Hydrochloride,Teva Pharmaceuticals,5 mg/1 unit (NDC 0093-5861-01),New,6/10/2019,,Business related decision to discontinue these products,,,Analgesia/Addiction;Anesthesia,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
3549,Oxymorphone Hydrochloride,Teva Pharmaceuticals,10 mg/1 unit (NDC 0093-5862-01),New,6/10/2019,,Business related decision to discontinue these products,,,Analgesia/Addiction;Anesthesia,To be Discontinued,6/10/2019,6/10/2019,,2019,discontinued
3550,"Oxytocin (Pitocin) Synthetic Injection, USP",Par Pharmaceutical,Pitocin Single Pack 10 mL Vial (NDC 42023-116-01),New,11/1/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Reproductive,To be Discontinued,11/1/2019,11/1/2019,,2019,discontinued
3551,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",100 USP Units per 10 mL (10 USP units per mL); Multiple dose vial;  (NDC 63323-012-10),Revised,12/20/2019,Available,Check wholesalers for inventory,,Delay in manufacturing,Reproductive,Current,,,,2019,available
3552,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",300 USP Units per 30 mL (10 USP Units per mL); Multiple dose vial; (NDC 63323-012-30),Revised,12/20/2019,Backordered.  Next release January 2020.,,,Delay in manufacturing,Reproductive,Current,,,,2019,not available
3553,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",10 USP Units per mL (10 USP units per mL); (NDC 63323-012-01)( NDC 63323-0012-11),Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory for both NDC's,,Delay in manufacturing,Reproductive,Current,,,,2019,not available
3554,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of six 50 mL Pharmacy Bulk Packages, each containing 10 units of oxytocin per mL (total = 500 units of oxytocin per vial), (NDC 42023-130-06)",Revised,12/16/2019,Available,,,,Reproductive,Current,,,,2019,available
3555,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin, (NDC 42023-116-25)",Revised,12/16/2019,"On backorder at this time due to increased demand, new material will be released in January 2020",,,,Reproductive,Current,,,,2019,not available
3556,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of twenty-five 10 mL multiple-dose vial, each containing 10 units of oxytocin per mL (total = 100 units of oxytocin per vial) (NDC 42023-116-02)",Revised,12/16/2019,"On backorder at this time due to increased demand, new material will be released in January 2020.",,,,Reproductive,Current,,,,2019,not available
3557,"Paclitaxel Injection, USP",Mylan Institutional,"100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17)",New,11/22/2019,,19-Dec,,,Oncology,To be Discontinued,11/22/2019,11/22/2019,,2019,discontinued
3558,"Paclitaxel Injection, USP",HQ Specialty Pharma,30 mg/5 mL (NDC 44567-504-1),New,7/3/2019,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/2019,7/3/2019,,2019,discontinued
3559,"Paclitaxel Injection, USP",HQ Specialty Pharma,100 mg/16.7 mL (NDC 44567-505-1),New,7/3/2019,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/2019,7/3/2019,,2019,discontinued
3560,"Paclitaxel Injection, USP",HQ Specialty Pharma,300 mg/50 mL (6 mg/mL)(NDC 44567-506-1),New,7/3/2019,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/2019,7/3/2019,,2019,discontinued
3561,Pantoprazole Sodium for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg, 10 vials (NDC 0143-9284-10)",Revised,12/13/2019,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3562,Pantoprazole Sodium for Injection,Aurobindo Pharma,"40 mg, 10 vials (NDC 55150-202-10)",Reverified,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2019,available
3563,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-0923-55)",Reverified,12/20/2019,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2019,not available
3564,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-0923-60)",Reverified,12/20/2019,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2019,not available
3565,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-2001-10; Amerinet)",Reverified,12/20/2019,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2019,not available
3566,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-2001-25; Amerinet)",Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2019,not available
3567,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-4001-10; PremierPro)",Reverified,12/20/2019,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2019,not available
3568,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-4001-25; PremierPro)",Reverified,12/20/2019,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2019,not available
3569,Pantoprazole Sodium for Injection,Sun Pharmaceutical Industries Inc.,"40 mg, 10 vials (NDC 62756-129-44)",New,10/29/2019,Available,,,,Gastroenterology,Current,,,,2019,available
3570,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges),Reverified,12/18/2019,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2019,unclear
3571,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,50mcg   Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges),Reverified,12/18/2019,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2019,unclear
3572,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,75mcg   Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges),Reverified,12/18/2019,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2019,unclear
3573,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,100mcg   Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges),Reverified,12/18/2019,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2019,unclear
3574,Pegademase bovine (Adagen) Injection,"Leadiant Biosciences, Inc.",ADAGEN (pegademase bovine) Injection 250 units per mL (NDC 57665-001-01),New,1/18/2019,,"The discontinuation of the manufacture of Adagen is due to the permanent shortage of the active ingredient. The discontinuation of the product is not due to product quality, safety, or efficacy concerns. Based on the demand in mid-January 2019, the inventory is estimated to runout by late-March 2019. Physicians can continue to treat ADA-SCID patients with another approved treatment for ADA-SCID.",,,Other;Pediatric,To be Discontinued,1/18/2019,1/18/2019,,2019,discontinued
3575,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4347-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2019,discontinued
3576,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4348-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2019,discontinued
3577,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4349-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2018.  For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2019,discontinued
3578,PEGINTRON (peginterferon alfa-2b) Injection,Merck Sharp & Dohme Corp.,"PEGINTRON injection (peginterferon alfa-2b) 50 mcg per 0.5 mL; box containing one 50 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs (NDC 00085-4353-01)",New,9/12/2019,,To be discontinued on or near May 2021,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2019,discontinued
3579,Penicillamine (Depen) Titratable Tablets,Mylan Pharmaceuticals Inc.,"Penicillamine tablets, 250 mg (NDC 0037-4401-01)",Revised,10/1/2019,,,,,Endocrinology/Metabolism;Gastroenterology;Inborn Errors;Pediatric;Renal;Rheumatology,Resolved,10/1/2019,,,2019,
3580,Pentamidine Isethionate (Nebupent) For Inhalation Solution,"Fresenius Kabi USA, LLC","300 mg per vial, SDV, PF (NDC 63323-877-15)",Revised,9/13/2019,,,,,Anti-Infective,Resolved,9/13/2019,,,2019,
3581,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 100s (NDC 0378-0357-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
3582,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 500s (NDC 0378-0357-05)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/2018,5/8/2018,,2019,discontinued
3583,Peritoneal Dialysis Solutions,Baxter Healthcare,Peritoneal Dialysis Solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD) therapy (Dianeal and Extraneal),Reverified,12/11/2019,Available.  Please see link.,,,,Pediatric;Renal,Current,,,,2019,available
3584,Peritoneal Dialysis Solutions,Baxter Healthcare,Peritoneal Dialysis Solutions for Automated Peritoneal Dialysis (APD) therapy (Dianeal and Extraneal),Reverified,12/11/2019,Available. Please see link.,,,,Pediatric;Renal,Current,,,,2019,available
3585,Peritoneal Dialysis Solutions,Fresenius Medical Care North America,Peritoneal Dialysis Solutions (Delflex and Stay Safe),New,8/8/2014,Available,,,Other,Pediatric;Renal,Current,,,,2019,available
3586,Phenobarbital Oral Solution,Torrent Pharma Inc.,1 pint 473mL (NDC 16571-330-16),New,11/25/2019,,,,,Neurology,To be Discontinued,11/25/2019,11/25/2019,,2019,discontinued
3587,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 2 mL vial (NDC 0641-0493-25)",Revised,9/3/2019,,,Available,,Neurology,Resolved,9/3/2019,,,2019,
3588,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 5 mL vial (NDC 0641-2555-45)",Revised,9/3/2019,,,Available,,Neurology,Resolved,9/3/2019,,,2019,
3589,"Physostigmine Salicylate Injection, USP",Akorn Pharmaceuticals,"Physostigmine Salicylate Injection, USP  1mg/mL (10amps/box, 2mL each) (NDC 17478-510-02)",Revised,12/2/2019,Available,,,Other,Neurology,Current,,,,2019,available
3590,Pimozide (Orap) Tablets,Teva Pharmaceuticals,1 mg tablet (NDC 57844-151-01),New,12/18/2018,,This was a business-related decision to discontinue manufacturing this product.,,,Psychiatry,To be Discontinued,12/18/2018,12/18/2018,,2019,discontinued
3591,Pimozide (Orap) Tablets,Teva Pharmaceuticals,2 mg tablet (NDC 57844-198-01),New,12/18/2018,,This was a business-related decision to discontinue manufacturing this product.,,,Psychiatry,To be Discontinued,12/18/2018,12/18/2018,,2019,discontinued
3592,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0781-9210-95) Novaplus",Reverified,12/18/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3593,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0781-9214-95) Novaplus",Reverified,12/18/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3594,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0781-9213-95) Novaplus",Reverified,12/18/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3595,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 0781-9350-95) Novaplus",Reverified,12/16/2019,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,,2019,discontinued
3596,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 2.25 g/50 mL, frozen IV bag (NDC 0206-8860-02)",Reverified,12/20/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3597,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 3.375 g/50 mL, frozen IV bag (NDC 0206-8861-02)",Reverified,12/20/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3598,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 4.5 g/100 mL, frozen IV bag (NDC 0206-8862-02)",Reverified,12/20/2019,Next Delivery and Estimated Recovery: December 2019,,,,Anti-Infective;Pediatric,Current,,,,2019,not available
3599,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"3.375 g, single dose vial, box of 10 (NDC 67457-522-37)",Reverified,11/26/2019,Available,,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,available
3600,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"2.25 g, single dose vial, box of 10 (NDC 55150-119-30)",Reverified,12/10/2019,Available,Marketed by AuroMedics Pharma LLC. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3601,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"3.375 g, single dose vial, box of 10 (NDC 55150-120-30)",Reverified,12/10/2019,Available,Marketed by AuroMedics Pharma LLC. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3602,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"4.5 g, single dose vial, box of 10 (NDC 55150-121-50)",Reverified,12/10/2019,Available,Marketed by AuroMedics Pharma LLC. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3603,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 63323-309-20)",Reverified,12/16/2019,Available,"Marketed by Fresenius Kabi USA, LLC. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3604,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","3.375 g, single dose vial, box of 10 (NDC 63323-983-21)",Revised,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,available
3605,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","4.5 g, single dose vial, box of 10 (NDC 63323-0982-52)",Revised,12/20/2019,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,available
3606,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 63323-304-74)",Reverified,12/16/2019,Available,"Marketed by Fresenius Kabi USA, LLC. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3607,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0409-3374-02) ADD-Vantage",Reverified,12/18/2019,Next Delivery: September 2019; Estimated Recovery: October 2019,Marketed by Hospira. Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
3608,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn 2.25 g, single dose vial, box of 10 (NDC 0206-8852-16)",Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
3609,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 3.375 g, single dose vial, box of 10 (NDC 0206-8854-16)",Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
3610,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 4.5 g, single dose vial, box of 10 (NDC 0206-8855-16)",Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
3611,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 40.5 g, pharmacy bulk vial (NDC 0206-8859-10)",Reverified,12/20/2019,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,,2019,not available
3612,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"2.25 g, single dose vial, box of 10 (NDC 25021-164-30)",Reverified,12/10/2019,Available,"Marketed by Sagent Pharmaceuticals. To order, contact Sagent at 1-866-625-1618.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3613,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"3.375 g, single dose vial, box of 10 (NDC 25021-165-30)",Reverified,12/10/2019,Available,"Marketed by Sagent Pharmaceuticals. To order, contact Sagent at 1-866-625-1618.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3614,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"4.5 g, single dose vial, box of 10 (NDC 25021-166-48)",Reverified,12/10/2019,Available,"Marketed by Sagent Pharmaceuticals. To order, contact Sagent at 1-866-625-1618.",,Manufacturing delay,Anti-Infective;Pediatric,Current,,,,2019,available
3615,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 44567-801-10)",Reverified,12/16/2019,Available,"Marketed by WG Critical Care. Product continues to be manufactured, please check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3616,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 44567-802-10)",Reverified,12/16/2019,Available,"Marketed by WG Critical Care. Product continues to be manufactured, please check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3617,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 44567-803-10)",Reverified,12/16/2019,Available,"Marketed by WG Critical Care. Product continues to be manufactured, please check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3618,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 44567-804-01)",Reverified,12/16/2019,Available,"Marketed by WG Critical Care. Product continues to be manufactured, please check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3619,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0781-3114-95)",Reverified,12/18/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3620,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0781-3113-95)",Reverified,12/18/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3621,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0781-3110-95)",Reverified,12/18/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3622,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"4.5 g, single dose vial, box of 10 (NDC 67457-523-45)",Reverified,11/26/2019,Available,,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,available
3623,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 0781-3344-95)",Reverified,12/16/2019,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,,2019,discontinued
3624,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"2.25 g, single dose vial, box of 10 (NDC 67457-521-22)",Reverified,11/26/2019,Available,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3625,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 0781-3350-95)",Reverified,12/16/2019,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,,2019,discontinued
3626,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 0781-3367-95)",Reverified,12/16/2019,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,,2019,discontinued
3627,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 0781-9367-95) Novaplus",Reverified,12/16/2019,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,,2019,discontinued
3628,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 0781-9344-95) Novaplus",Reverified,12/16/2019,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,,2019,discontinued
3629,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"2.25 g, single dose vial, box of 10 (NDC 39822-0123-2)",Revised,12/11/2019,Available - Less than one year dating,"Marketed by X-GEN Pharmaceuticals, Inc. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3630,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"4.5 g, single dose vial, box of 10 (NDC 39822-0127-6)",Revised,12/11/2019,Available - Less than one year dating,"Marketed by X-GEN Pharmaceuticals, Inc. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3631,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"40.5 g, pharmacy bulk vial (NDC 39822-0139-7)",Revised,12/11/2019,Available - Less than one year dating,"Marketed by X-GEN Pharmaceuticals, Inc. To order, contact X-GEN at 1-866-390-4411",,,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3632,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"3.375 g, single dose vial, box of 10 (NDC 39822-0125-4)",Revised,12/11/2019,Available - Less than one year dating,"Marketed by X-GEN Pharmaceuticals, Inc. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3633,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"4.5 g, single dose vial, box of 10 (NDC 64679-012-01)",Revised,12/12/2019,Stock sold out and new batches on backorder until week of 12/23/2019,,,,Anti-Infective;Pediatric,Current,,,,2019,not available
3634,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"4.5 g, single dose vial (NDC 64679-012-02)",Revised,12/12/2019,Stock sold out and new batches on backorder until week of 12/23/2019,,,,Anti-Infective;Pediatric,Current,,,,2019,not available
3635,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"2.25 g, single dose vial, box of 10 (NDC 64679-034-01)",Revised,12/12/2019,"Stock sold out. Product has arrived, will be available for sale wk of 12/9/19",,,,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3636,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"2.25 g, single dose vial (NDC 64679-034-02)",Revised,12/12/2019,"Stock sold out. Product has arrived, will be available for sale wk of 12/9/19",,,,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3637,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"3.375 g, single dose vial, box of 10 (NDC 61990-0120-2)",Revised,12/11/2019,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3638,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"13.5 g, pharmacy bulk vial (NDC 61990-0140-2)",Revised,12/11/2019,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3639,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"40.5 g, pharmacy bulk vial (NDC 61990-0150-2)",Revised,12/11/2019,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3640,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 70860-121-30)",Reverified,12/16/2019,Available,"To order, contact Athenex at 855-273-0154",,,Anti-Infective;Pediatric,Current,,,,2019,available
3641,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 70860-122-50)",Reverified,12/16/2019,Available,"To order, contact Athenex at 855-273-0154",,,Anti-Infective;Pediatric,Current,,,,2019,available
3642,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 70860-123-99)",Reverified,12/16/2019,Available,"To order, contact Athenex at 855-273-0154",,,Anti-Infective;Pediatric,Current,,,,2019,available
3643,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0409-3378-13) ADD-Vantage",Reverified,12/18/2019,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3644,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0409-3379-04) ADD-Vantage",Reverified,12/18/2019,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3645,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0409-3383-02)",Reverified,12/18/2019,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3646,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0409-3385-13)",Reverified,12/18/2019,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3647,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0409-3390-04)",Reverified,12/18/2019,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3648,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"13.5 g, pharmacy bulk bottle (NDC 0409-2999-14)",Reverified,12/18/2019,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3649,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","2.25 g, single-dose vial (NDC 63323-981-21)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2019,not available
3650,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"3.375 g, single dose vial, box of 10 (NDC 64679-056-01)",Revised,12/12/2019,"Stock sold out. Product has arrived, will be available for sale wk of 12/9/19",,,,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3651,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"3.375 g, single dose vial (NDC 64679-056-02)",Revised,12/12/2019,"Stock sold out. Product has arrived, will be available for sale wk of 12/9/19",,,,Anti-Infective;Pediatric,Current,,,,2019,limited availability
3652,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"40.5 g, pharmacy bulk vial (NDC 64679-0679-01)",Revised,12/12/2019,No backorder,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3653,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"40.5 g, pharmacy bulk vial, box of 10 (NDC 64679-0679-02)",Revised,12/12/2019,No backorder,,,,Anti-Infective;Pediatric,Current,,,,2019,available
3654,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"2.25 g, single dose vial, box of 10 (NDC 61990-0110-2)",Revised,12/11/2019,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3655,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"4.5 g, single dose vial, box of 10 (NDC 61990-0130-2)",Revised,12/11/2019,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,,2019,available
3656,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 70860-120-20)",Reverified,12/16/2019,Available,"To order, contact Athenex at 855-273-0154",,,Anti-Infective;Pediatric,Current,,,,2019,available
3657,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","2.25 g, single dose vial, box of 10 (NDC 60505-6156-4)",Reverified,10/30/2019,Available,"Marketed by Apotex Corp. To order, contact Apotex at 800-706-5575.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3658,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","3.375 g, single dose vial, box of 10 (NDC 60505-6157-4)",Reverified,10/30/2019,Available,"Marketed by Apotex Corp. To order, contact Apotex at 800-706-5575.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3659,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","4.5 g, single dose vial, box of 10 (NDC 60505-6159-4)",Reverified,10/30/2019,Available,"Marketed by Apotex Corp. To order, contact Apotex at 800-706-5575.",,,Anti-Infective;Pediatric,Current,,,,2019,available
3660,"Polyethylene Glycol 3350 Powder, for Oral Solution",Perrigo Pharmaceuticals,"Polyethylene Glycol Powder for solution 17G  (NDC 0574-0412-07, 0574-0412-05, 0574-0412-02)",New,12/6/2018,,,,,Gastroenterology,To be Discontinued,12/6/2018,12/6/2018,,2019,discontinued
3661,"Potassium Acetate Injection, USP","Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3294-51)",Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,limited availability
3662,"Potassium Acetate Injection, USP","Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 00409-8183-01)",Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,limited availability
3663,"Potassium Acetate Injection, USP","Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial NovaPlus (NDC 00409-3294-25)",Revised,12/20/2019,Limited Supply Available. Next Delivery and Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,limited availability
3664,"Potassium Acetate Injection, USP","Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial NovaPlus (NDC 00409-8183-25)",Revised,12/20/2019,Next Delivery: February 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,not available
3665,"Potassium Acetate Injection, USP","Exela Pharma Sciences, LLC",Potassium Acetate Inj. 40mEq (2mEq/ml) 20mL (NDC 51754-2001-4),Revised,12/10/2019,On allocation due to increased demand.,"Please check with wholesaler for availability. Additional production underway. Direct shipment to hospitals at 200 vials max per week are available from Exela. Customer Service # 828-758-5474, then press #2",,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2019,limited availability
3666,Potassium Chloride Injection,"ICU Medical, Inc.",10 mEq/50 mL (Legacy Hospira NDC 0409-7075-14) (ICU Medical NDC 0990-7075-14),Revised,6/21/2019,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3667,Potassium Chloride Injection,"ICU Medical, Inc.","20 mEq/100 mL (Legacy Hospira NDC 0409-7075-26)
(ICU Medical NDC 0990-7075-26)",Revised,6/21/2019,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3668,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 0.45% NaCl (NDC 0409-9257-39),Revised,6/21/2019,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3669,Potassium Chloride Injection,"Hospira, Inc.",10 mEq/5 mL (2 mEq/mL); Single Dose Glass Fliptop Vial (NDC 00409-6635-01),Revised,6/21/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3670,Potassium Chloride Injection,Baxter Healthcare,30 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0673-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3671,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 5 mL vials, (NDC 63323-0965-05)",Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3672,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 10 mL vials, (NDC 63323-0965-10)",Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3673,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 15 mL vials, (NDC 63323-0965-15)",Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3674,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 20 mL vials, (NDC 63323-0965-20)",Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3675,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 30 mL vials, (NDC 63323-0967-30)",Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3676,Potassium Chloride Injection,B. Braun Medical Inc.,250mL Potassium Chloride Injection Concentrate (2 mEq K/mL)(NDC 0264-1940-20),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3677,Potassium Chloride Injection,Baxter Healthcare,10 mEq/100 mL in sterile water (NDC 00338-0709-48),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3678,Potassium Chloride Injection,Baxter Healthcare,20 mEq/100 mL in sterile water (NDC 00338-0705-48),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3679,Potassium Chloride Injection,Baxter Healthcare,40 mEq/100 mL in sterile water (NDC 00338-0703-48),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3680,Potassium Chloride Injection,Baxter Healthcare,20 mEq/50 mL in sterile water (NDC 00338-0703-41),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3681,Potassium Chloride Injection,Baxter Healthcare,10 mEq/50 mL in sterile water (NDC 00338-0705-41),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3682,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in lactated ringers and dextrose 5% (NDC 00338-0811-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3683,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0803-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3684,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0691-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3685,Potassium Chloride Injection,Baxter Healthcare,40 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0675-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3686,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 5% dextrose (NDC 00338-0683-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3687,Potassium Chloride Injection,Baxter Healthcare,40 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0695-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3688,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3689,Potassium Chloride Injection,Baxter Healthcare,"20 mEq/L in 5% dextrose and 0.45% sodium chloride, 500 mL (NDC 00338-0671-03)",Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3690,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 0.45% sodium chloride (NDC 00338-0704-34),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3691,Potassium Chloride Injection,Baxter Healthcare,40 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0807-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3692,Potassium Chloride Injection,Baxter Healthcare,"20 mEq/L in 5% dextrose and 0.2% sodium chloride, 500 mL (NDC 00338-0663-03)",Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3693,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3694,Potassium Chloride Injection,Baxter Healthcare,10 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0669-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3695,Potassium Chloride Injection,"Hospira, Inc.",20 mEq/10 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-6651-06),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3696,Potassium Chloride Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-6653-05),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3697,Potassium Chloride Injection,"ICU Medical, Inc.","10 mEq/100 mL (Legacy Hospira NDC 0409-7074-26)
(ICU Medical NDC 0990-7074-26)",Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3698,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/50 mL (NDC 0409-7077-14),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3699,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/100 mL (NDC 0409-7077-26),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3700,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL (NDC 0409-7116-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3701,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 0.9% NaCl (NDC 0409-7115-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3702,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% dextrose (NDC 0409-7905-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3703,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% Dex/Lact Ringers (NDC 0409-7111-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3704,Potassium Chloride Injection,"ICU Medical, Inc.","10 mEq/ 500 mL in 5% dex 0.45% NaCl
(NDC 0409-7902-03)",Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3705,Potassium Chloride Injection,"ICU Medical, Inc.","20 mEq/1000 mL in 5% dex& 0.225% NaCl
(NDC 0409-7901-09)",Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3706,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7902-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3707,Potassium Chloride Injection,"ICU Medical, Inc.",30 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7903-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3708,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7904-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3709,Potassium Chloride Injection,"ICU Medical, Inc.",10 mEq/1000 mL in 5% dex & 0.45% NaCl (NDC 0409-7993-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3710,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% dex & 0.9% NaCl (NDC 0409-7107-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3711,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL in 5% dex & 0.9% NaCl (NDC 0409-7109-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2019,
3712,Potassium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol per 5 mL, Potassium 22 mEq per 5 mL,single dose vial (NDC 63323-086-05)",Revised,5/23/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,5/23/2019,,,2019,
3713,Potassium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol per 15 mL, Potassium 66 mEq per 15 mL, single dose vial (NDC 63323-086-15)",Revised,5/23/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,5/23/2019,,,2019,
3714,Potassium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 150 mmol per 50 mL, Potassium 220 mEq per 50 mL, single dose vial (NDC 63323-086-50)",Revised,5/23/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,5/23/2019,,,2019,
3715,Potassium Phosphate Injection,"Hospira, Inc.",Phosphorus 45mM per 15mL; Single Dose Glass Fliptop Vial (NDC 00409-7295-01),Revised,5/29/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,5/29/2019,,,2019,
3716,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.25 mg tablets (NDCs 0597-0184-61 and 0597-0184-90),New,11/6/2018,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3717,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.125 mg tablets (NDC 0597-0183-90),New,11/6/2018,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3718,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.5 mg tablets (NDCs 0597-0185-61 and 0597-0185-90),New,11/6/2018,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3719,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.75 mg tablets (NDC 0597-0101-90),New,11/6/2018,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3720,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",1 mg tablets (NDCs 0597-0190-61 and 0597-0190-90),New,11/6/2018,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3721,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",1.5 mg tablets (NDCs 0597-0191-61 and 0597-0191-90),New,11/6/2018,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/2018,11/6/2018,,2019,discontinued
3722,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (Pred Forte) (NDC 11980-180-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3723,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3724,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (NDC 60758-119-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3725,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (NDC 60758-119-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3726,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 5mL in 1 bottle (NDC 61314-637-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3727,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 10mL in 1 bottle (NDC 61314-637-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3728,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 15mL in 1 bottle (NDC 61314-637-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3729,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3730,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (NDC 60758-119-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2019,
3731,"Primaquine Phosphate Tablet, EQ 15mg Base",Sanofi,"Primaquine; Film-coated tablet, 15 mg/1 unit, bottles of 100, (NDC 0024-1596-01)",Revised,12/10/2019,,,,,Anti-Infective,Resolved,12/10/2019,,,2019,
3732,"Primaquine Phosphate Tablet, EQ 15mg Base",Bayshore Pharmaceuticals,"Primaquine Phosphate USP,  26.3 mg (15mg base)Tablets, (NDC 76385-102-01), 100 Count Bottle",Revised,12/10/2019,,,,,Anti-Infective,Resolved,12/10/2019,,,2019,
3733,"Primidone Tablets, USP",Par Pharmaceutical,"50mg, count bottle (NDC 0603-5371-21)",New,4/9/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/9/2019,4/9/2019,,2019,discontinued
3734,"Primidone Tablets, USP",Par Pharmaceutical,"50mg, count bottle (NDC 0603-5371-28)",New,4/9/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/9/2019,4/9/2019,,2019,discontinued
3735,"Procainamide Hydrochloride Injection, USP","Amphastar Pharmaceuticals, Inc./IMS",100 mg/1 mL injection; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3399-5),Reverified,12/16/2019,Available,,,Other,Cardiovascular;Renal,Current,,,,2019,available
3736,"Procainamide Hydrochloride Injection, USP","Hospira, Inc.","1,000 mg/10 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1902-01)",Reverified,12/20/2019,Available,,,Other,Cardiovascular;Renal,Current,,,,2019,available
3737,"Procainamide Hydrochloride Injection, USP","Hospira, Inc.","1,000 mg/2 mL (500 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1903-01)",Reverified,12/20/2019,Next Delivery and Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Renal,Current,,,,2019,not available
3738,"Procainamide Hydrochloride Injection, USP","Nexus Pharmaceuticals, Inc.","500 mg/mL, 2 mL (NDC 14789-900-02)",New,10/19/2017,Available,,,Other,Cardiovascular;Renal,Current,,,,2019,available
3739,"Procainamide Hydrochloride Injection, USP","Nexus Pharmaceuticals, Inc.","100 mg/mL, 10 mL (NDC 14789-900-10)",New,10/19/2017,Available,,,Other,Cardiovascular;Renal,Current,,,,2019,available
3740,"Progesterone Injection, USP",Teva Pharmaceuticals,50MG 1X10ML (NDC 0591-3128-79),Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2019,
3741,"Progesterone Injection, USP","Fresenius Kabi USA, LLC","500 mg per 10 mL, MDV (NDC 63323-0261-10)",Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2019,
3742,"Progesterone Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL (NDC 0143-9725-01)",Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2019,
3743,"Progesterone Injection, USP",AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),500 mg/10 mL multiple dose vial (NDC 55150-306-10),Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2019,
3744,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL vial (NDC 0641-0928-25)",Revised,12/13/2019,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,available
3745,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL ,1 mL vial (NDC 0641-0929-25)",Revised,12/13/2019,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,available
3746,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL ampul (NDC 0641-1495-35)",Revised,12/13/2019,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,available
3747,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL ampul (NDC 0641-1496-35)",Revised,12/13/2019,On backorder.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,not available
3748,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL vial (NDC 0641-6084-25)",Revised,12/13/2019,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,available
3749,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL ,1 mL vial (NDC 0641-6085-25)",Revised,12/13/2019,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,available
3750,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL ampul (NDC 0641-6082-25)",Revised,12/13/2019,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,available
3751,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL, 1 mL ampul (NDC 0641-6083-25)",Revised,12/13/2019,On backorder.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,not available
3752,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","25 mg/mL, Carton of 25 ampuls (NDC 39822-5525-3)",Reverified,12/11/2019,Available,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,available
3753,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","50 mg/mL, Carton of 25 ampuls (NDC 39822-5550-6)",Reverified,12/11/2019,Available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2019,available
3754,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2019,discontinued
3755,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2019,discontinued
3756,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2019,discontinued
3757,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2019,discontinued
3758,Promethazine Suppository,Mylan Pharmaceuticals Inc.,Promethazine Suppositories 12.5mg Bx12 (NDC 40085-218-12),New,12/13/2018,,A business decision was made to discontinue manufacture of the drug product,,,Anesthesia;Gastroenterology;Pediatric;Pulmonary/Allergy,To be Discontinued,12/13/2018,12/13/2018,,2019,discontinued
3759,Promethazine Suppository,Mylan Pharmaceuticals Inc.,Promethazine Suppositories 25mg Bx12 (NDC 40085-219-12),New,12/13/2018,,A business decision was made to discontinue manufacture of the drug product,,,Anesthesia;Gastroenterology;Pediatric;Pulmonary/Allergy,To be Discontinued,12/13/2018,12/13/2018,,2019,discontinued
3760,Promethazine Suppository,Mylan Pharmaceuticals Inc.,Promethazine Suppositories 50mg Bx12,New,12/13/2018,,A business decision was made to discontinue manufacture of the drug product,,,Anesthesia;Gastroenterology;Pediatric;Pulmonary/Allergy,To be Discontinued,12/13/2018,12/13/2018,,2019,discontinued
3761,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,5 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0527-40),New,11/12/2019,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/2019,11/12/2019,,2019,discontinued
3762,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,10 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0530-40),New,11/12/2019,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/2019,11/12/2019,,2019,discontinued
3763,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,20 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0532-40),New,11/12/2019,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/2019,11/12/2019,,2019,discontinued
3764,Quinidine Gluconate Injection,Eli Lilly and Co.,"QUINIDINE GLUCONATE, 80 mg/1 mL,10 mL/vial Injectable (NDC 0002-1407-01)",Revised,9/19/2019,,Discontinuation of the manufacture of the drug. The product distribution has ceased given the product's labeled expiry of March 2019. FDA and CDC are developing a strategy to ensure continued access to essential medicine for the treatment of severe malaria in the United States.,,,Anti-Infective;Cardiovascular,To be Discontinued,9/19/2019,9/19/2019,,2019,discontinued
3765,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 30 count bottle (NDC 0378-6709-93)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3766,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 90 count bottle (NDC 0378-6709-77)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3767,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 500 count bottle (NDC 0378-6709-05)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3768,"Ranitidine Injection, USP",Mylan Institutional,"Ranitidine Injection 25 mg/mL, 2ml vial; 10 pack; (NDC 67457-397-99)",Revised,12/19/2019,Unavailable.,,,,Gastroenterology,Current,,,,2019,not available
3769,"Ranitidine Injection, USP",Mylan Institutional,"Ranitidine Injection 25 mg/mL, 6 mL vial; 1 pack; (NDC 67457-398-62)",Revised,12/19/2019,Unavailable.,,,,Gastroenterology,Current,,,,2019,not available
3770,"Ranitidine Injection, USP",Zydus Pharmaceuticals USA Inc.,Ranitidine HCl Injection 25mg/mL (10x2mL SD vials)(NDC 68382-422-02),Reverified,12/18/2019,Available,,,Other,Gastroenterology,Current,,,,2019,available
3771,"Ranitidine Injection, USP",Zydus Pharmaceuticals USA Inc.,Ranitidine HCl Injection 25mg/mL (6mL MD vial)(NDC 68382-423-06),Reverified,12/18/2019,Unavailable,,,Other,Gastroenterology,Current,,,,2019,not available
3772,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 2ML VIAL (NDC 52565-101-01),Reverified,10/29/2019,Unavailable,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,not available
3773,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 40ML VIAL (NDC 52565-096-01),Reverified,10/29/2019,Unavailable,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,not available
3774,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 6ML VIAL (NDC 52565-102-01),Reverified,10/29/2019,Unavailable,,,Demand increase for the drug,Gastroenterology,Current,,,,2019,not available
3775,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","1 mg per vial, SDV (NDC 63323-723-03)",Reverified,12/20/2019,Available,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,available
3776,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","2 mg per vial, SDV (NDC 63323-724-05)",Reverified,12/20/2019,Available,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,available
3777,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","5 mg per vial, SDV (NDC 63323-725-10)",Reverified,12/20/2019,Available,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2019,available
3778,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,1 mg (NDC 67457-198-03),Reverified,11/26/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
3779,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,2 mg (NDC 67457-198-05),Reverified,11/26/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
3780,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,5 mg (NDC 67457-198-10),Reverified,11/26/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2019,available
3781,Repaglinide Tablets,Sandoz,1mg tablets (NDC 0781-5149-01),New,2/2/2018,,,,,Endocrinology/Metabolism,To be Discontinued,2/2/2018,2/2/2018,,2019,discontinued
3782,Ribavirin (Rebetol) Oral Solution,Merck Sharp & Dohme Corp.,40 mg/mL (NDC 0085-1318-01),New,4/16/2019,,To be discontinued on or near June 2019.,,,Antiviral,To be Discontinued,4/16/2019,4/16/2019,,2019,discontinued
3783,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC","200 mg (NDCs 66435-101-14, 66435-101-16, 66435-101-18, 66435-101-42, 66435-101-56, 66435-101-70, 66435-101-84, 66435-102-16, 66435-102-95, 54738-950-16)",New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3784,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",400 mg (NDCs 66435-103-56 and 66435-103-95),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3785,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC","600 mg (NDCs 66435-104-56, 66435-104-92, 54738-952-56)",New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3786,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",600 mg dose pack (NDCs 66435-108-56 and 66435-108-99),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3787,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",800 mg dose pack (NDCs 66435-105-56 and 66435-105-99),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3788,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",1000 mg dose pack (NDCs 66435-106-56 and 66435-106-99),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3789,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",1200 mg dose pack (NDCs 66435-107-56 and 66435-107-99),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2019,discontinued
3790,Risedronate Sodium Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 1 count blister card (NDC 0378-4150-32)",New,5/2/2019,,,,,Other,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3791,Risedronate Tablets,Allergan Sales LLC,5 mg tablets (NDC 0430-0471-15),New,12/9/2019,,,,,Musculoskeletal,To be Discontinued,12/9/2019,12/9/2019,,2019,discontinued
3792,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3793,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3794,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3795,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3796,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3797,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3798,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3799,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3800,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3801,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3802,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3803,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3804,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3805,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3806,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3807,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3808,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 3 mg (NDC 50458-330-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3809,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 2 mg (NDC 50458-320-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3810,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 1 mg (NDC 50458-300-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3811,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.5 mg (NDC 50458-302-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3812,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3813,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-01),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2019,discontinued
3814,Rizatriptan Benzoate Orally Disintegrating Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 9 count bottle (NDC 0378-3701-59)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3815,Rizatriptan Benzoate Orally Disintegrating Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 9 count bottle (NDC 0378-3702-59)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3816,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 5mL vial (NDC 70860-651-05),Revised,11/2/2018,Available,,,Available,Anesthesia,Resolved,11/2/2018,,,2019,available
3817,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 10mL vial (NDC 70860-651-10),Revised,11/2/2018,Available,,,Available,Anesthesia,Resolved,11/2/2018,,,2019,available
3818,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 0.25 mg, 100 count bottles (NDC 0007-4890-20)",New,12/19/2018,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately April 2019.,,,Neurology,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3819,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) QUIP Tablets, 0.5 mg, 100 count bottles (NDC 0007-4891-20)",New,12/19/2018,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately May 2019.,,,Neurology,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3820,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 1 mg, 100 count bottles (NDC 0007-4892-20)",New,12/19/2018,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately January 2019.,,,Neurology,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3821,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 2 mg, 100 count bottles (NDC 0007-4893-20)",New,12/19/2018,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately January 2019.,,,Neurology,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3822,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 3 mg, 100 count bottles (NDC 0007-4895-20)",New,12/19/2018,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately April 2019.,,,Neurology,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3823,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 4 mg, 100 count bottles (NDC 0007-4896-20)",New,12/19/2018,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately May 2019.,,,Neurology,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3824,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 5 mg, 100 count bottles (NDC 0007-4894-20)",New,12/19/2018,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately March 2019.,,,Neurology,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3825,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) XL Tablets, 2 mg, 30 count bottles (NDC 0007-4885-13)",New,12/19/2018,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately March 2019.,,,Neurology,To be Discontinued,12/19/2018,12/19/2018,,2019,discontinued
3826,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,4 mg  (NDC 0007-4887-13),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/2019,6/28/2019,,2019,discontinued
3827,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,6 mg  (NDC 0007-4883-13),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/2019,6/28/2019,,2019,discontinued
3828,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,8 mg  (NDC 0007-4888-13),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/2019,6/28/2019,,2019,discontinued
3829,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,12 mg  (NDC 0007-4882-13),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/2019,6/28/2019,,2019,discontinued
3830,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x100mL (NDC 25021-671-82),Reverified,12/20/2019,Available,,,,Anesthesia,Current,,,,2019,available
3831,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x200mL (NDC 25021-671-87),Reverified,12/20/2019,Available,,,,Anesthesia,Current,,,,2019,available
3832,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-10),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
3833,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-20),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
3834,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9301-30),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
3835,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/20 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9302-20),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: February 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2019,limited availability
3836,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-10),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
3837,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-20),Revised,12/20/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
3838,Ropivacaine Hydrochloride Injection,Akorn Pharmaceuticals,"0.5% 5mg/mL, 30mL, 1 Vial (NDC 17478-0081-30)",Reverified,12/2/2019,Available,,,Other,Anesthesia,Current,,,,2019,available
3839,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 20 mL Single Dose Vials (NDC 55150-195-20),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3840,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 100 mL Single Dose Infusion Bottles (NDC 55150-196-99),Revised,12/11/2019,Currently on backorder,Next shipment expected Feb. 2020,,Demand increase for the drug,Anesthesia,Current,,,,2019,not available
3841,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 20 mL Single Dose Vials (NDC 55150-197-20),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3842,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-198-30),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3843,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 20 mL Single Dose Vials (NDC 55150-199-20),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3844,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Single Dose Vials (NDC 55150-200-10),Revised,12/11/2019,Short-dated product available exp. Aug. 2020,Next shipment TBD,,Demand increase for the drug,Anesthesia,Current,,,,2019,limited availability
3845,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Single Dose Vials (NDC 55150-201-20),Revised,12/11/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2019,available
3846,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-10)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,not available
3847,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-20)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3848,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-286-20)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3849,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-287-20)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3850,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Plastic Ampule, Sterile-Pak (63323-288-10)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3851,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-288-20)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3852,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Free Flex Bag (NDC 63323-285-61)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3853,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Free Flex Bag (NDC 63323-285-63)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,not available
3854,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-285-65)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,not available
3855,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-285-64)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,not available
3856,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (500 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-286-00)",Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,not available
3857,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (1,000 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-286-63)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3858,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Single Dose Vial (NDC 63323-285-13)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3859,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Single Dose Vial (NDC 63323-285-23)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3860,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Single Dose Vial (NDC 63323-286-35)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3861,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Single Dose Vial (NDC 63323-286-23)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3862,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Single Dose Vial (NDC 63323-287-21)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3863,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Single Dose Vial (NDC 63323-288-11)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3864,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Single Dose Vial (NDC 63323-288-21)",Revised,12/20/2019,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2019,available
3865,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Sterile-Pack, Single Dose Vial (NDC 63323-286-31)",Revised,12/20/2019,Backordered. Next release date not available at this time.,,,Manufacturing Delay,Anesthesia,Current,,,,2019,not available
3866,Sacrosidase (Sucraid) Oral Solution,"QOL Medical, LLC","8,500 I.U./mL 118 mL per bottle, 2 bottles/box  (NDC  67871-111-04)",Revised,5/6/2019,,,Available,,Gastroenterology;Inborn Errors,Resolved,5/6/2019,,,2019,
3867,Saquinavir Mesylate (Invirase) 200mg Capsules,"Genentech, Inc",200 mg capsules (NDC 0004-0245-15),New,2/6/2018,,"Roche intends to stop-shipping Saquinavir Mesylate (Invirase) 200 mg Capsules on March 31, 2018 with product availability continuing until the September 2018 expiry date.  Saquinavir Mesylate (Invirase) 500mg Tablets are still available.",,,Antiviral,To be Discontinued,2/6/2018,2/6/2018,,2019,discontinued
3868,Sclerosol Intrapleural Aerosol,Lymol Medical Corp.,Sclerosol 4 GM (NDC 63256-100-30),Reverified,12/11/2019,Unavailable,,,Other,Pulmonary/Allergy,Current,,,,2019,not available
3869,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 10 count (NDC 10019-553-03),Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3870,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 24 count (NDC 10019-553-04),Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3871,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 4 count (NDC 66758-208-54),Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3872,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 4-Count Pack (NDC 45802-580-84)",Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3873,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 10-Count Pack (NDC 45802-580-46)",Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3874,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 24-Count Pack (NDC 45802-580-62)",Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3875,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 4s (NDC 0378-6470-99),Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3876,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 10s (NDC 0378-6470-97),Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3877,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 24s (NDC 0378-6470-44),Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2019,
3878,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/12.5 mL; vial (NDC 0069-0338-01),Revised,10/24/2019,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2019,
3879,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,20 mg; tablets (NDC 0069-4190-68),Revised,10/24/2019,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2019,
3880,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/mL (powder); bottle (NDC 0069-0336-21),Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2019,
3881,Sildenafil Citrate (REVATIO),Novitium Pharma LLC,"10 mg/mL, (NDC 70954-168-10)",Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2019,
3882,Simeprevir Capsules,Janssen Pharmaceuticals,150mg capsules (NDC 59676-225-28),New,5/23/2018,,,,,Antiviral,To be Discontinued,5/23/2018,5/23/2018,,2019,discontinued
3883,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,5 mg (NDC 0093-7152-98),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2019,discontinued
3884,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,10 mg (NDCs 0093-7153-93 / 0093-7153-56 / 0093-7153-19 / 0093-7153-31 / 0093-7153-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2019,discontinued
3885,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,20 mg (NDCs 0093-7154-93 / 0093-7154-56 / 0093-7154-31 / 0093-7154-19 / 0093-7154-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2019,discontinued
3886,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,40 mg (NDCs 0093-7155-93 / 0093-7155-56 / 0093-7155-31 / 0093-7155-19 / 0093-7155-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2019,discontinued
3887,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,80 mg (NDCs 0093-7156-98 / 0093-7156-93 / 0093-7156-56 / 0093-7156-19 / 0093-7156-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2019,discontinued
3888,Simvastatin (Zocor) Tablets,Merck Sharp & Dohme Corp.,5 mg Tablets bottles of 30 (NDC 0006-0726-31),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2019,discontinued
3889,Sincalide (Kinevac) Lyophilized Powder for Injection,Bracco Diagnostics,Supplied in packages of 10 single dose vials containing 5 mcg of sincalide per vial (NDC 0270-0556-15),Revised,9/18/2019,Available,,,Delay in shipping of the drug,Medical Imaging;Other,Current,12/17/2015,,,2019,available
3890,"Sodium Acetate Injection, USP","Fresenius Kabi USA, LLC",32.8% 400 mEq 100mL PBP (NDC 63323-0032-00),Revised,12/20/2019,Backordered. Next release January 2020.,Check wholesalers for inventory,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,,2019,not available
3891,"Sodium Acetate Injection, USP","Hospira, Inc.",100 mEq/50 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-05),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Total Parenteral Nutrition,Current,,,,2019,limited availability
3892,"Sodium Acetate Injection, USP","Hospira, Inc.",200 mEq/100 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-06),Revised,12/20/2019,Limited Supply Available. Next Delivery: January 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Total Parenteral Nutrition,Current,,,,2019,limited availability
3893,"Sodium Acetate Injection, USP","Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-7299-73),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Total Parenteral Nutrition,Current,,,,2019,limited availability
3894,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02),Revised,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2019,not available
3895,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Infant; 5 mEq/10 mL (4.2%; 0.5 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-5534-34),Revised,12/20/2019,Next Delivery: February 2020; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2019,not available
3896,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",44.6 mEq/50 mL (7.5%; 0.9 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-4916-34),Revised,12/20/2019,Next Delivery: November 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2019,not available
3897,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",50 mEq/50 mL (8.4%; 1 mEq/mL); Single Dose Glass Fliptop Vial (NDC 0409-6625-02),Revised,12/20/2019,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2019,available
3898,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",50 mEq/50 mL (8.4%; 1 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-6637-34),Revised,12/20/2019,Next Delivery: December 2019; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2019,not available
3899,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Pediatric; 10 mEq/10 mL (8.4%; 1 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-4900-34),Revised,12/20/2019,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2019,limited availability
3900,"Sodium Bicarbonate Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1)",Reverified,12/16/2019,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2019,limited availability
3901,"Sodium Bicarbonate Injection, USP","Athenex Pharmaceutical Division, LLC (Athenex)","Sodium Bicarbonate Injection, 8.4% (1mEq/mL), 10mL per vial, 10 vials per carton (NDC 71456-001-01)",Reverified,12/16/2019,Available,"Due to the current critical shortage of Sodium Bicarbonate Injection, USP in the United States (US) market, Athenex Pharmaceutical Division, LLC (Athenex) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of Sodium Bicarbonate Injection. Athenex has initiated temporary importation of another manufacturer’s 8.4% Sodium Bicarbonate Injection (1 mEq/mL) 10 mL into the U.S. market. This product is manufactured and marketed in Australia by Phebra Pty Ltd (Phebra).",,Available,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2019,available
3902,"Sodium Bicarbonate Injection, USP","Fresenius Kabi USA, LLC","4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05)",Revised,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2019,available
3903,"Sodium Bicarbonate Injection, USP","Fresenius Kabi USA, LLC","8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL)  (84 mg per mL)(NDC 63323-089-50)",Revised,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2019,available
3904,"Sodium Bicarbonate Injection, USP","Exela Pharma Sciences, LLC","Sodium Bicarbonate Inj. USP, 8.4%, 50mL (NDC 51754-5001-1)",Revised,12/13/2019,Available direct or through Premier's ProvideGx program at this time and through CIVICA Rx program in Q1 2020.,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2019,available
3905,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 76297-001-11)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3906,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 76297-001-21)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3907,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 76297-001-31)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3908,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC NDC 76297-001-01)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3909,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC NDC 76297-001-41)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3910,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container (Legacy Hospira NDC 0409-7984-23)
(ICU Medical NDC 0990-7984-23)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3911,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 100 mL VIAFLEX Plastic Container.  Single pack (NDC 0338-0049-48, product code 2B1307)Quad Pack (NDC 0338-0049-18, product code 2B1302) Multi Pack (NDC 0338-0049-38, product code 2B1309)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3912,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 50 mL VIAFLEX Plastic Container.  Single Pack (NDC 0338-0049-41, product code 2B1306) Quad Pack (NDC 0338-0049-11, product code 2B1301) Multi Pack (NDC 0338-0049-31, product code 2B1308)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3913,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 25 mL VIAFLEX Plastic Container Quad Pack (NDC 0338-0049-10). Product code 2B1300",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3914,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 50mL (NDC 63323-623-53)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3915,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 100mL (NDC 63323-623-61)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3916,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 250mL (NDC 63323-623-74)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3917,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 500mL (NDC 63323-623-75)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3918,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 1000mL (NDC 63323-623-76)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3919,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 50 mL MINI-BAG Plus Container, VIAFLEX Plastic Container Product code 2B0042  (NDC 0338-0553-11)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3920,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 100 mL MINI-BAG Plus Container, VIAFLEX Plastic Container Product code 2B0043 (NDC 0338-0553-18)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3921,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 100mL fill in 150mL PAB S8004-5264 (NDC 0264-1800-32),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3922,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 50mL fill in 100mL PAB S8004-5384 (NDC 0264-1800-31),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3923,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 25mL fill in 100mL PAB S8004-5410 (NDC 0264-1800-36),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3924,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",50 mL (5-Pack); ADD-Vantage Flexible Container (NDC 00409-7101-66),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3925,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",100 mL (5-Pack); ADD-Vantage Flexible Container (NDC 00409-7101-67),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3926,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",250 mL (Dual Pack); ADD-Vantage Flexible Container (NDC 00409-7101-02),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3927,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride in Waiter for Injection, 100 mL, in VIAFLEX Container Product code ABB1307U (NDC 0338-9525-72)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3928,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 1000 mL.  Product code JB1324 (NDC 00338-9612-12)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3929,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 250 mL, in VIAFLEX Container.   Product code FZB1322 (NDC 0338-9517-50)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3930,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 500 mL, in VIAFLEX Container.   Product code FZB1323 (NDC 0338-9517-30)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3931,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 1,000 mL, in VIAFLEX Container.   Product code FZB1324 (NDC 0338-9517-16)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3932,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"Sodium Chloride 0.9% w/v Intravenous Infusion BP in the Ecoflac® plus 1,000 mL Product Code 9999-00, (NDC 0264-9999-00)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3933,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,Sodium Chloride 0.9% w/v Intravenous Infusion BP in the Ecoflac® plus container sizes: 500 mL (NDC 0264-9999-10),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3934,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-13)
(ICU Medical NDC 0990-7984-13)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3935,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container-4 pack (Legacy Hospira NDC 0409-7984-37)
(ICU Medical NDC 0990-7984-37)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3936,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 250mL bag, PVC/DEHP-free (NDC 00264-7800-20)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3937,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 500mL bag, PVC/DEHP-free (NDC 00264-7800-10)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3938,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 1000mL bag, PVC/DEHP-free (NDC 00264-7800-00)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3939,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",150mL flexible container (NDC 0409-7983-61),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3940,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","250mL Vis-IV container, PVC/DEHP-free (NDC 0409-7983-25)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3941,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","250mL flexible container (Legacy Hospira NDC 0409-7983-02)
(ICU Medical NDC 0990-7983-02)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3942,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",250mL flexible container 2 port (NDC 0409-7983-53),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3943,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",500mL flexible container 2 port (NDC 0409-7983-55),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3944,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",500mL flexible container (NDC 0409-7983-03),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3945,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",1000mL flexible container (NDC 0409-7983-09),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3946,Sodium Chloride 0.9% Injection Bags,Fresenius Medical Care North America,1000ml (NDC 49230-300-10),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3947,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-11)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3948,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-36)
(ICU Medical NDC 0990-7984-36)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3949,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",25 mL flexible container (NDC 0409-7984-20),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3950,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-06)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3951,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,250 mL Product code 2B1322Q (NDC 00338-0049-02),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3952,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,500 mL  Product code 2B1323Q (NDC 00338-0049-03),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3953,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1323D (NDC 0338-9543-04)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3954,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,1000 mL Product code 2B1324X (NDC 00338-0049-04),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3955,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1324D (NDC 0338-9543-06)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3956,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL, Non-PVC, Dripless Access Container (DAC) VIAFLO Container Product code UE1322D (NDC 0338-9543-02)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2019,
3957,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",30 mL vials (NDC 63323-0187-30),Revised,12/20/2019,Available,Check Wholesaler Inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2019,available
3958,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",100 mL vials (NDC 63323-0088-61),Revised,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2019,available
3959,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",200 mL vials (NDC 63323-0088-63),Revised,12/20/2019,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2019,available
3960,Sodium Chloride 23.4% Injection,"Hospira, Inc.",400 mEq/100 mL (4 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-1141-02),Revised,12/20/2019,Next Delivery and Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2019,not available
3961,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose plastic vial, 0.9%, (18 mg per 2 mL)(9 mg per mL) (NDC 63323-186-02)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Increase in Demand,Other,Current,,,,2019,available
3962,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (90 mg per 10 mL)(9 mg per mL) (NDC 63323-186-10)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,,2019,available
3963,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (180 mg per 20 mL)(9 mg per mL) (NDC 63323-186-20)",Reverified,12/20/2019,Available,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,,2019,available
3964,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose tear top vial, 0.9%, (900 mg per 100 mL)(9 mg per mL) (NDC 63323-186-00)",Reverified,12/20/2019,Backordered.  Next release date not available at this time.,,,Increase in Demand,Other,Current,,,,2019,not available
3965,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose Plastic Fliptop Vial (NDC 00409-4888-10),Reverified,12/20/2019,Available,,,Other,Other,Current,,,,2019,available
3966,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose LifeShield Plastic Fliptop Vial (NDC 00409-4888-12),Reverified,12/20/2019,Available,,,Other,Other,Current,,,,2019,available
3967,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-20),Reverified,12/20/2019,Available,,,Other,Other,Current,,,,2019,available
3968,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-50),Reverified,12/20/2019,Available,,,Demand increase for the drug,Other,Current,,,,2019,available
3969,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.9%, 2 mL vial (NDC 0641-0497-25)",Reverified,12/13/2019,Inventory is currently available.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Other,Current,,,,2019,available
3970,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Medefil, Inc.","Sodium Chloride Injection, USP, 0.9%, in a plastic syringe (10 mL) (NDC 64253-202-30)",Reverified,12/11/2019,Available,Check wholesalers for inventory,,Available,Other,Current,,,,2019,available
3971,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-32),Reverified,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,,2019,not available
3972,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-33),Reverified,12/20/2019,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,,2019,not available
3973,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-35),Reverified,12/20/2019,Next Delivery and Estimated Recovery:  August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,,2019,not available
3974,Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol/mL, 5 mL, Sodium 20 mEq/5mL vials (NDC 63323-170-05)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,8/7/2019,,,2019,
3975,Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL (NDC 63323-170-15)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,8/7/2019,,,2019,
3976,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-5123-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3977,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-5124-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3978,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"160 mg, 100 count bottle (NDC 0378-5125-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
3979,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 100 (NDC 0228-2803-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
3980,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 500 (NDC 0228-2803-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
3981,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 100 (NDC 0228-2672-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
3982,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 500 (NDC 0228-2672-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
3983,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 100 (NDC 0228-2673-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
3984,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 500 (NDC 0228-2673-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2019,discontinued
3985,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 100 (NDC 0603-5763-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3986,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 500 (NDC 0603-5763-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3987,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 1000 (NDC 0603-5763-32)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3988,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 2500 (NDC 0603-5763-30)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3989,"Spironolactone Tablets, USP",Par Pharmaceutical,"50 mg, bottle of 100 (NDC 0603-5764-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3990,"Spironolactone Tablets, USP",Par Pharmaceutical,"50 mg, bottle of 500 (NDC 0603-5764-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3991,"Spironolactone Tablets, USP",Par Pharmaceutical,"100 mg, bottle of 100 (NDC 0603-5765-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3992,"Spironolactone Tablets, USP",Par Pharmaceutical,"100 mg, bottle of 500 (NDC 0603-5765-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2019,discontinued
3993,Stavudine (Zerit) Powder for Oral Solution,Bristol Myers Squibb Co.,1mg/mL (NDC 0003-1968-01),New,10/15/2018,,,,,Antiviral,To be Discontinued,10/15/2018,10/15/2018,,2019,discontinued
3994,Stavudine Capsules,Mylan Pharmaceuticals Inc.,20mg capsules (NDC 0378-5041-91),New,4/30/2018,,,,,Antiviral,To be Discontinued,4/30/2018,4/30/2018,,2019,discontinued
3995,Stavudine Capsules,Mylan Pharmaceuticals Inc.,40 mg  (NDC0378-5043-91),New,7/17/2019,,,,,Antiviral,To be Discontinued,7/17/2019,7/17/2019,,2019,discontinued
3996,Sterile Talc Powder,Lymol Medical Corp.,Sterile Talc Powder (NDC 63256-200-05),Revised,6/12/2019,,,,,Pulmonary/Allergy,Resolved,6/12/2019,,,2019,
3997,Sterile Talc Powder,Novatech SA,"STERITALC® (talc), powder, for intrapleural use 2 grams, in a 50 mL single-dose vial (NDC 62327-222-02)",Revised,6/12/2019,,,,,Pulmonary/Allergy,Resolved,6/12/2019,,,2019,
3998,Sterile Talc Powder,Novatech SA,"STERITALC® (talc), powder, for intrapleural use 3 grams, in a 10 mL single-dose vial (NDC 62327-333-03)",Revised,6/12/2019,,,,,Pulmonary/Allergy,Resolved,6/12/2019,,,2019,
3999,Sterile Talc Powder,Novatech SA,"STERITALC® (talc), powder, for intrapleural use 4 grams, in a 50 mL single-dose vial (NDC 62327-444-04)",Revised,6/12/2019,,,,,Pulmonary/Allergy,Resolved,6/12/2019,,,2019,
4000,Sterile Water,"Hospira, Inc.",10 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-10),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4001,Sterile Water,"Fresenius Kabi USA, LLC","Single dose vial, 5 mL fill (NDC 63323-185-05)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4002,Sterile Water,B. Braun Medical Inc.,Sterile Water for Injection in 250mL EXCEL container (NDC  0264-7850-20),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4003,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP (For Drug Diluent Use Only), 1000 mL VIAFLEX Plastic Container. Product code 2B0304X (NDC 0338-0013-04)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4004,Sterile Water,"ICU Medical, Inc.",Sterile Water for Injection 1000 mL (NDC 0409-7990-09),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4005,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 10 mL fill (NDC 63323-185-10)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4006,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 20 mL fill (NDC 63323-185-20)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4007,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 50 mL fill (NDC 63323-185-50)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4008,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, tear top vial, 100 mL (NDC 63323-185-00)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4009,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package.   Product code 2B0306 (NDC 0338-0013-06)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4010,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 3000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package.  Product code 2B0307  (NDC 0338-0013-08)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4011,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 5000 mL VIAFLEX Plastic Container, Pharmacy Bulk Package. Product code 2B0309 (NDC 0338-0013-29)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4012,Sterile Water,B. Braun Medical Inc.,Sterile Water for Injection in 500mL EXCEL container (NDC  0264-7850-10),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4013,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 1,000mL EXCEL container  (NDC 0264-7850-00)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4014,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 2,000mL Titan container (NDC  0264-7385-50)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4015,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 3,000mL Titan container (NDC  0264-7385-60)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4016,Sterile Water,"Hospira, Inc.",20 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-20),Revised,8/2/2019,, ,,,Other,Resolved,8/2/2019,,,2019,
4017,Sterile Water,"Hospira, Inc.",50 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-50),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4018,Sterile Water,"Hospira, Inc.",100 mL; Single Dose Glass Fliptop Vial (NDC 00409-4887-99),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4019,Sterile Water,"ICU Medical, Inc.",Sterile Water for Injection 2000 mL (NDC 0409-7118-07),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4020,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 1000 mL (NDC 0409-7973-05),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4021,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 2000 mL (NDC 0409-7973-08),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4022,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 2000 mL (NDC 0409-7973-07),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4023,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation USP, 1000 mL Aqualite ™ Plastic Pour Bottle (NDC 0409-7139-09)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4024,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP, Aqualite 500 mL (NDC 0409-6139-03)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4025,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP 1500 mL (NDC 0409-7139-36)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4026,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP, Aqualite 250 mL (NDC 0409-6139-22)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4027,Sterile Water,American Regent/Luitpold,5 mL vial (NDC 00517-3005-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4028,Sterile Water,American Regent/Luitpold,10 mL vial (NDC 00517-3010-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4029,Sterile Water,American Regent/Luitpold,20 mL vial (NDC 00517-3020-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4030,Sterile Water,West-Ward Pharmaceuticals,10 mL Single Dose Vial (NDC 0641-6147-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2019,
4031,Sumatriptan (Sumavel DosePro) Injection,"Endo Pharmaceuticals, Inc.",Sumavel DosePro (sumatriptan injection) 6mg/0.5mL (NDC 63481-367-06),New,2/27/2018,,A business decision has been made to discontinue Sumavel DosePro 6 mg/0.5mL.,,,Neurology,To be Discontinued,2/27/2018,2/27/2018,,2019,discontinued
4032,Sumatriptan Succinate Injection,Teva Pharmaceuticals,6 mg/0.5 mL  (NDC 0703-7351-01),New,12/5/2019,,,,,Neurology,To be Discontinued,12/5/2019,12/5/2019,,2019,discontinued
4033,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"0.5 mg, 100s (NDC 0378-2045-01)",Revised,11/26/2019,Available,,,,Transplant,Current,,,,2019,available
4034,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"1 mg, 100s (NDC 0378-2046-01)",Revised,11/26/2019,Unavailable. Estimated recovery: November 2019,,,,Transplant,Current,,,,2019,not available
4035,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-2047-01)",Revised,11/26/2019,Unavailable. Estimated recovery: December 2019,,,,Transplant,Current,,,,2019,not available
4036,Tacrolimus Capsules,Accord Healthcare Inc.,0.5 mg 100 count (NDC 1672904101),Reverified,12/12/2019,Shortage duration from July 2019 to May 2020. We would be temporarily discontinuing this product until May 2020. We will allocate any product we do have available based on API availability,,,Limited API availability,Transplant,Current,,,,2019,limited availability
4037,Tacrolimus Capsules,Accord Healthcare Inc.,1 mg 100 count (NDC 1672904201),Reverified,12/12/2019,Shortage duration from July 2019 to May 2020. We would be temporarily discontinuing this product until May 2020. We will allocate any product we do have available based on API availability,,,Limited API availability,Transplant,Current,,,,2019,limited availability
4038,Tacrolimus Capsules,Accord Healthcare Inc.,5 mg 100 count (NDC 1672904301),Reverified,12/12/2019,Shortage duration from July 2019 to May 2020. We would be temporarily discontinuing this product until May 2020. We will allocate any product we do have available based on API availability,,,Limited API availability,Transplant,Current,,,,2019,limited availability
4039,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 30 count (NDC 68992-3075-3),Revised,8/12/2019,Available,,,,Transplant,Current,,,,2019,available
4040,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 100 count (NDC 68992-3075-1),Revised,8/12/2019,Available,,,,Transplant,Current,,,,2019,available
4041,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 30 count (NDC 68992-3010-3),Revised,8/12/2019,Available,,,,Transplant,Current,,,,2019,available
4042,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 100 count (NDC 68992-3010-1),Revised,8/12/2019,Available,,,,Transplant,Current,,,,2019,available
4043,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 30 count (NDC 68992-3040-3),Revised,8/12/2019,Available,,,,Transplant,Current,,,,2019,available
4044,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 100 count (NDC 68992-3040-1),Revised,8/12/2019,Available,,,,Transplant,Current,,,,2019,available
4045,Tacrolimus Capsules,Strides Pharma Inc.,1 mg 100 count bottles (NDC 64338-721-06),Revised,12/2/2019,Available,Product available on allocation.,,Demand increase for the drug,Transplant,Current,,,,2019,available
4046,Tacrolimus Capsules,Strides Pharma Inc.,0.5 mg 100 count bottles (NDC 64380-720-06),Revised,12/2/2019,"Currently, we do not distribute this product strength and NDC. We are evaluating options to potentially re-launch this product strength.",,,,Transplant,Current,,,,2019,not available
4047,Tacrolimus Capsules,Strides Pharma Inc.,5 mg 100 count bottles (NDC 64380-722-06),Revised,12/2/2019,"Currently, we do not distribute this product strength and NDC. We are evaluating options to potentially re-launch this product strength.",,,,Transplant,Current,,,,2019,not available
4048,Tacrolimus Capsules,Sandoz,0.5 mg 100 count bottle (NDC 0781-2102-01),Reverified,12/18/2019,Available,,,,Transplant,Current,,,,2019,available
4049,Tacrolimus Capsules,Sandoz,1 mg 100 count bottle (NDC 0781-2103-04),Reverified,12/18/2019,Available,,,,Transplant,Current,,,,2019,available
4050,Tacrolimus Capsules,Sandoz,5 mg 100 count bottle (NDC 0781-2104-01),Reverified,12/18/2019,Available,,,,Transplant,Current,,,,2019,available
4051,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 0.5 mg 100 count bottle (NDC 0469-0607-73),Revised,6/21/2019,Available; product under allocation,,,,Transplant,Current,,,,2019,limited availability
4052,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 5 mg 100 count bottle (NDC 0469-0657-73),Revised,6/21/2019,Available; product under allocation,,,,Transplant,Current,,,,2019,limited availability
4053,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 1 mg 100 count bottle (NDC 0469-0617-73),Revised,6/21/2019,Available; product under allocation,,,,Transplant,Current,,,,2019,limited availability
4054,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 0.5 mg 30 count bottle (NDC 0469-0647-73),Revised,6/21/2019,Available; product under allocation,,,,Transplant,Current,,,,2019,limited availability
4055,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 1 mg 30 count bottle (NDC 0469-0677-73),Revised,6/21/2019,Available; product under allocation,,,,Transplant,Current,,,,2019,limited availability
4056,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 5 mg 30 count bottle (NDC 0469-0687-73),Revised,6/21/2019,Available; product under allocation,,,,Transplant,Current,,,,2019,limited availability
4057,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 0.2 mg unit dose packets (NDC 0469-1230-50),Revised,6/21/2019,Available; product under allocation,,,,Transplant,Current,,,,2019,limited availability
4058,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 1 mg unit dose packets (NDC 0469-1330-50),Revised,6/21/2019,Available; product under allocation,,,,Transplant,Current,,,,2019,limited availability
4059,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-30),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4060,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-01),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4061,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-05),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4062,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg unit dose (NDC 55111-525-78),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4063,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-30),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4064,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-01),Reverified,11/7/2019,Available,Releasing product as it beceomes available,,,Transplant,Current,,,,2019,available
4065,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-05),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4066,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg unit dose (NDC 55111-526-78),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4067,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-30),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4068,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-01),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4069,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-05),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4070,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg unit dose (NDC 55111-527-78),Reverified,11/7/2019,Available,Releasing product as it becomes available,,,Transplant,Current,,,,2019,available
4071,"Talwin (Pentazocine Lactate Injection, USP, CIV)","Hospira, Inc.",30 mg/mL; 1 mL glass ampul (NDC 00409-1941-01),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To be Discontinued,4/16/2018,4/16/2018,,2019,discontinued
4072,Technetium Tc99m Succimer Injection (DMSA),Theragnostics Inc.,ROTOP DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection). One vial contains 1.74 mg powder with the active substance: 1.0 mg succimer.  Five vials included in a carton (NDC 71647-001-01),Reverified,12/10/2019,Available,"Due to the current critical shortage of DMSA Kit for the Preparation of Technetium Tc99m Succimer, Theragnostics Inc. (Theragnostics) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of the drug.  Theragnostics has initiated temporary importation of DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection into the U.S. market. This product is marketed in Germany and is manufactured in Dresden, Germany by ROTOP Pharmaka GmbH for Theragnostics.",,Other,Medical Imaging,Current,,,,2019,available
4073,Technetium Tc99m Succimer Injection (DMSA),GE Healthcare,DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection (NDC 17156-525-01),Revised,12/20/2019,,,,,Medical Imaging,To be Discontinued,12/20/2019,12/20/2019,,2019,discontinued
4074,Telmisartan and Amlodipine (Twynsta) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.","Telmisartan and Amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister (NDC 0597-0127-37)",New,3/6/2018,,"Discontinuation is the result of a business decision made by Boehringer lngelheim Pharmaceuticals, Inc. All other strengths of Twynsta® tablets are still available.",,,Cardiovascular,To be Discontinued,3/6/2018,3/6/2018,,2019,discontinued
4075,Testosterone Buccal System,"Endo Pharmaceuticals, Inc.","Striant® 30 mg, 6 blister cards, 60 buccal system  (NDC 52244-030-60)",New,8/21/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Reproductive,To be Discontinued,8/21/2019,8/21/2019,,2019,discontinued
4076,Testosterone Gel 1%,Par Pharmaceutical,"2.5 g, 30 packets (NDC 49884-418-72)",New,4/29/2019,,Par has made a business decision to discontinue the drug product.,,,Reproductive,To be Discontinued,4/29/2019,4/29/2019,,2019,discontinued
4077,Testosterone Gel 1%,Par Pharmaceutical,"5 g, 30 packets (NDC 49884-510-72)",New,4/29/2019,,Par has made a business decision to discontinue the drug product.,,,Reproductive,To be Discontinued,4/29/2019,4/29/2019,,2019,discontinued
4078,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,50 mg (NDC 0378-0616-01),Revised,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
4079,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0618-01),Revised,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
4080,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0612-01),Revised,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
4081,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,25 mg (NDC 0378-0614-01),Revised,11/26/2019,Available,,,Other,Psychiatry,Current,,,,2019,available
4082,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-1001-01)",Revised,11/26/2019,Unavailable. Estimated re-supply: March 2020.,,,Other,Psychiatry,Current,,,,2019,not available
4083,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"2 mg, 100 count bottle (NDC 0378-2002-01)",Revised,11/26/2019,Unavailable. Estimated re-supply: March 2020.,,,Other,Psychiatry,Current,,,,2019,not available
4084,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-3005-01)",Revised,11/26/2019,Available,,,,Psychiatry,Current,,,,2019,available
4085,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-5010-01)",Revised,11/26/2019,Available,,,,Psychiatry,Current,,,,2019,available
4086,Thiothixene Capsules,Novitium Pharma LLC,"1 mg, 100 count bottle (NDC 70954-014-10)",Reverified,8/15/2019,Available ; Will cater to the entire market demand,,,Other,Psychiatry,Current,,,,2019,available
4087,Thiothixene Capsules,Novitium Pharma LLC,"2 mg, 100 count bottle (NDC 70954-015-10)",Reverified,8/15/2019,Available ; Will cater to the entire market demand,,,Other,Psychiatry,Current,,,,2019,available
4088,Thiothixene Capsules,Novitium Pharma LLC,"5 mg, 100 count bottle (NDC 70954-016-10)",Reverified,8/15/2019,Available ; Will cater to the entire market demand,,,Other,Psychiatry,Current,,,,2019,available
4089,Thiothixene Capsules,Novitium Pharma LLC,"10 mg, 100 count bottle (NDC 70954-017-10)",Reverified,8/15/2019,Available ; Will cater to the entire market demand,,,Other,Psychiatry,Current,,,,2019,available
4090,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count (NDC 0378-0055-01)",Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4091,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count (NDC 0378-0221-01)",Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4092,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 100 count (NDC 0378-0715-01)",Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4093,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,4 mg (NDC 0378-0724-19),New,11/21/2019,,,,,Neurology,To be Discontinued,11/21/2019,11/21/2019,,2019,discontinued
4094,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0722-19),New,11/21/2019,,,,,Neurology,To be Discontinued,11/21/2019,11/21/2019,,2019,discontinued
4095,Tolazamide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0217-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4096,Tolazamide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0551-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4097,Tolbutamide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0215-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4098,Tolterodine Tartrate (Detrol LA) Extended Release Capsules,Pfizer Pharmaceuticals,"2 mg, blisters (NDC 0009-5190-04)",New,10/1/2019,,Discontinuation of the manufacture of the drug.,,,Urology,To be Discontinued,10/1/2019,10/1/2019,,2019,discontinued
4099,Tolterodine Tartrate (Detrol LA) Extended Release Capsules,Pfizer Pharmaceuticals,"4 mg, blisters (NDC 0009-5191-04)",New,10/1/2019,,Discontinuation of the manufacture of the drug.,,,Urology,To be Discontinued,10/1/2019,10/1/2019,,2019,discontinued
4100,Tositumomab and Iodine I 131 Tositumomab (Bexxar),GlaxoSmithKline,,Revised,2/18/2014,,,"BEXXAR (Tositumomab and Iodine I 131 Tositumomab) is being discontinued.  The product discontinuation is not related to product safety or any FDA action.   BEXXAR will no longer be available effective February 20, 2014.",,Oncology,To Be Discontinued,2/18/2014,2/18/2014,,2019,discontinued
4101,Trandolapril Tablets,Teva Pharmaceuticals,"4 mg tablets, 100 count (NDC 16252-543-90)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2019,discontinued
4102,Trandolapril Tablets,Teva Pharmaceuticals,"2 mg tablets, 100 count (NDC 16252-542-90)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2019,discontinued
4103,Trandolapril Tablets,Teva Pharmaceuticals,"1 mg tablets, 100 count (NDC 16252-541-30)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2019,discontinued
4104,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 30 Tablets per Bottle,  (NDC 60505-3638-3)",New,12/4/2019,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/2019,12/4/2019,,2019,discontinued
4105,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 100 Tablets per Bottle,  (NDC 60505-3638-1)",New,12/4/2019,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/2019,12/4/2019,,2019,discontinued
4106,"Triamcinolone Acetonide (Triesence) Injection, Suspension",Novartis,Triesence (Triamcinolone acetonide injectable suspension) Vial 40mg/mL 1mL in 1 vial (NDC 0065-0534-01),Revised,12/11/2019,Unavailable. Estimated Shortage Duration: December 2019,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2019,not available
4107,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1 mg/1g (NDC 40085-029-80),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2019,discontinued
4108,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1mg/1g (NDC 40085-029-16),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2019,discontinued
4109,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,0.25mg/1g (NDC 40085-028-80),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2019,discontinued
4110,Triamterene and Hydrochlorothiazide (Dyazide) Capsules,GlaxoSmithKline,25 mg; 37.5 mg (NDC 0007-3650-30),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately October 2019.,,,Cardiovascular,To be Discontinued,6/28/2019,6/28/2019,,2019,discontinued
4111,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 0781-5068-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
4112,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 0781-5068-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
4113,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 0781-5067-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
4114,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 0781-5067-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
4115,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 68001-0216-00)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
4116,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 68001-0216-03)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
4117,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 68001-0215-00)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
4118,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 68001-0215-03)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2019,discontinued
4119,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-2401-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4120,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-2402-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4121,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-2405-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4122,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-2410-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4123,Trifluoperazine Hydrochloride Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-8028-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4124,Trifluoperazine Hydrochloride Tablets,Sandoz,1 mg 100 count bottle (NDC 0832-0494-11),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4125,Trifluoperazine Hydrochloride Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-8032-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4126,Trifluoperazine Hydrochloride Tablets,Sandoz,2 mg 100 count bottle (NDC 0832-0495-11),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4127,Trifluoperazine Hydrochloride Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-8034-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4128,Trifluoperazine Hydrochloride Tablets,Sandoz,5 mg 100 count bottle (NDC 0832-0496-11),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4129,Trifluoperazine Hydrochloride Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-8036-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4130,Trifluoperazine Hydrochloride Tablets,Sandoz,10 mg 100 count bottle (NDC 0832-0497-11),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2019,
4131,Trifluridine Ophthalmic Solution,Sandoz,Trifluridine 1% 7.5 mL (NDC 61314-044-75),Revised,12/18/2019,"Limited supply available, on allocation, release of recently received stock expected end-4Q2019.",,,Shortage of an active ingredient,Ophthalmology,Current,,,,2019,limited availability
4132,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,1 gram  (NDCs 0093-7259-98 and 0093-7259-56),New,11/15/2019,,This product is being discontinued due to a business decision.,,,Antiviral,To be Discontinued,11/15/2019,11/15/2019,,2019,discontinued
4133,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,500 mg tablets (NDCs 45963-558-30 and 45963-558-08),New,2/21/2019,,,,,Antiviral,To be Discontinued,2/21/2019,2/21/2019,,2019,discontinued
4134,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,1 G tablets (NDCs 45963-559-30 and 45963-559-08),New,2/21/2019,,,,,Antiviral,To be Discontinued,2/21/2019,2/21/2019,,2019,discontinued
4135,Valsartan Tablets,Amneal Pharmaceutical,"40 mg, 30 ct bottle (NDC 65162-837-03); 60 ct bottle (NDC 65162-837-06); 500 ct bottle (NDC 65162-837-50)",New,8/16/2018,"Estimated release September 7, 2018",,,Other,Cardiovascular,Current,,,,2019,not available
4136,Valsartan Tablets,Amneal Pharmaceutical,"80 mg, 90 ct bottle (NDC 65162-838-09); 500 ct bottle (NDC 65162-838-50); 1000 ct bottle (NDC 65162-838-11)",New,8/16/2018,"Estimated release September 7, 2018",,,Other,Cardiovascular,Current,,,,2019,not available
4137,Valsartan Tablets,Amneal Pharmaceutical,"160 mg, 90 ct bottle (NDC 65162-839-09); 500 ct bottle (NDC 65162-839-50); 1000 ct bottle (NDC 65162-839-11)",New,8/16/2018,"Estimated release September 7, 2018",,,Other,Cardiovascular,Current,,,,2019,not available
4138,Valsartan Tablets,Amneal Pharmaceutical,"320 mg, 90 ct bottle (NDC 65162-840-09); 500 ct bottle (NDC 65162-840-50); 1000 ct bottle (NDC 65162-840-11)",New,8/16/2018,"Estimated release September 7, 2018",,,Other,Cardiovascular,Current,,,,2019,not available
4139,Valsartan Tablets,Camber Pharmaceuticals Inc.,40 mg (NDC 31722-745-30),Reverified,12/17/2019,Currently not marketing this product,Subject to nationwide voluntary recall,,Shortage of an active ingredient,Cardiovascular,Current,,,,2019,discontinued
4140,Valsartan Tablets,Camber Pharmaceuticals Inc.,80 mg (NDC 31722-746-90),Reverified,12/17/2019,Currently not marketing this product,Subject to nationwide voluntary recall,,Shortage of an active ingredient,Cardiovascular,Current,,,,2019,discontinued
4141,Valsartan Tablets,Camber Pharmaceuticals Inc.,160 mg (NDC 31722-746-90),Reverified,12/17/2019,Currently not marketing this product,Subject to nationwide voluntary recall,,Shortage of an active ingredient,Cardiovascular,Current,,,,2019,discontinued
4142,Valsartan Tablets,Camber Pharmaceuticals Inc.,320 mg (NDC 31722-748-90),Reverified,12/17/2019,Currently not marketing this product,Subject to nationwide voluntary recall,,Shortage of an active ingredient,Cardiovascular,Current,,,,2019,discontinued
4143,Valsartan Tablets,Ohm Laboratories Inc.,40 mg (NDC 51660-140-30),New,8/3/2018,Manufacturing resumes from September  2018 dependent on API supplies.,Manufacturing stopped temporarily and currently not supplying.,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,unclear
4144,Valsartan Tablets,Ohm Laboratories Inc.,80 mg (NDC 51660-141-90),New,8/3/2018,Manufacturing resumes from September  2018 dependent on API supplies.,Manufacturing stopped temporarily and currently not supplying.,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,unclear
4145,Valsartan Tablets,Ohm Laboratories Inc.,160 mg (NDC 51660-142-90),New,8/3/2018,Manufacturing resumes from September  2018 dependent on API supplies.,Manufacturing stopped temporarily and currently not supplying.,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,unclear
4146,Valsartan Tablets,Ohm Laboratories Inc.,320 mg (NDC 51660-143-90),New,8/3/2018,Manufacturing resumes from September  2018 dependent on API supplies.,Manufacturing stopped temporarily and currently not supplying.,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,unclear
4147,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 40mg x 30's Bottle Pack (NDC 33342006207),Reverified,6/11/2019,Available,,,Available,Cardiovascular,Current,,,,2019,available
4148,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 80mg x 90's Bottle Pack (NDC 33342006310),Reverified,6/11/2019,Available,,,Available,Cardiovascular,Current,,,,2019,available
4149,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 160mg x 30's Bottle Pack (NDC 33342006410),Reverified,6/11/2019,Available,,,Available,Cardiovascular,Current,,,,2019,available
4150,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 320mg x 30's Bottle Pack (NDC 33342006510),Reverified,6/11/2019,Available,,,Available,Cardiovascular,Current,,,,2019,available
4151,Valsartan Tablets,"Solco Healthcare US, LLC",40mg 30’s (NDC 43547-0367-03),Revised,12/13/2019,Currently not marketing this product,,,Other,Cardiovascular,Current,,,,2019,discontinued
4152,Valsartan Tablets,"Solco Healthcare US, LLC",160mg 90’s (NDC 43547-0369-09),Revised,12/13/2019,Currently not marketing this product,"Valsartan tablets are the subject of a nationwide voluntary recall for all lots, which was announced on July 13, 2018.",,Other,Cardiovascular,Current,,,,2019,discontinued
4153,Valsartan Tablets,"Solco Healthcare US, LLC",80mg 90’s (NDC 43547-0368-09),Revised,12/13/2019,Currently not marketing this product,"Valsartan tablets are the subject of a nationwide voluntary recall for all lots, which was announced on July 13, 2018.",,Other,Cardiovascular,Current,,,,2019,discontinued
4154,Valsartan Tablets,"Solco Healthcare US, LLC",320mg 90’s (NDC 43547-0370-09),Revised,12/13/2019,Currently not marketing this product,"Valsartan tablets are the subject of a nationwide voluntary recall for all lots, which was announced on July 13, 2018.",,Other,Cardiovascular,Current,,,,2019,discontinued
4155,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 40 mg. - 30/Bottle (NDC 65862-0570-30),Revised,12/13/2019,Temporarily discontinued,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,discontinued
4156,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 80 mg. - 90/Bottle (NDC 65862-0571-90),Revised,12/13/2019,Temporarily discontinued,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,discontinued
4157,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 160 mg. - 90/Bottle (NDC 65862-0572-90),Revised,12/13/2019,Temporarily discontinued,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,discontinued
4158,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 320 mg. - 90/Bottle (NDC 65862-0573-90 ),Revised,12/13/2019,Temporarily discontinued,,,Demand increase for the drug,Cardiovascular,Current,,,,2019,discontinued
4159,Valsartan Tablets,Mylan Pharmaceuticals Inc.,40 mg (30’s) (NDC 0378-5807-93),Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4160,Valsartan Tablets,Mylan Pharmaceuticals Inc.,160 mg (90’s) (NDC 0378-5814-77),Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4161,Valsartan Tablets,Mylan Pharmaceuticals Inc.,80 mg (90’s) (NDC 0378-5813-77),Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4162,Valsartan Tablets,Mylan Pharmaceuticals Inc.,320 mg (90’s) (NDC 0378-5815-77),Reverified,11/26/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4163,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",40 mg (30's) (NDC 59746-0360-30),Revised,6/17/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4164,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",80 mg (90's) (NDC 59746-0361-90),Revised,6/17/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4165,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",160 mg (90's) (NDC 59746-0362-90),Revised,6/17/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4166,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",320 mg (90's) (NDC 59746-0363-90),Revised,6/17/2019,Available,,,Other,Cardiovascular,Current,,,,2019,available
4167,Valsartan Tablets,Teva Pharmaceuticals,"Valsartan Tablets, USP 40mg, 90 count, (NDC 0591-2167-19)",New,8/3/2018,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,8/3/2018,8/3/2018,,2019,discontinued
4168,Valsartan Tablets,Torrent Pharma Inc.,40 mg (NDC 13668-067-30),Reverified,12/13/2019,Unavailable,Subject to nationwide voluntary recall,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,not available
4169,Valsartan Tablets,Torrent Pharma Inc.,80 mg (NDC 13668-068-90),Reverified,12/13/2019,Unavailable,Subject to nationwide voluntary recall,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,not available
4170,Valsartan Tablets,Torrent Pharma Inc.,160 mg (NDC 13668-069-90),Reverified,12/13/2019,Unavailable,Subject to nationwide voluntary recall,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,not available
4171,Valsartan Tablets,Torrent Pharma Inc.,320 mg (NDC 13668-070-90),Reverified,12/13/2019,Unavailable,Subject to nationwide voluntary recall,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,not available
4172,Valsartan Tablets,Novartis,DIOVAN® scored tablets 40mg 30s 1 bottle of 30 tablets (NDC 0078-0423-15),Reverified,12/11/2019,Available,Novartis’ Diovan Tablets are readily available and currently not in shortage,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
4173,Valsartan Tablets,Novartis,DIOVAN® tablets 80mg 1 bottle of 90 tablets (NDC 0078-0358-34),Reverified,12/11/2019,Available,Novartis’ Diovan Tablets are readily available and currently not in shortage,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
4174,Valsartan Tablets,Novartis,DIOVAN® tablets 160mg 1 bottle of 90 tablets (NDC 0078-0359-34),Reverified,12/11/2019,Available,Novartis’ Diovan Tablets are readily available and currently not in shortage,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
4175,Valsartan Tablets,Novartis,DIOVAN® tablets 320mg 1 bottle of 90 count (NDC 0078-0360-34),Reverified,12/11/2019,Available,Novartis’ Diovan Tablets are readily available and currently not in shortage,,Demand increase for the drug,Cardiovascular,Current,,,,2019,available
4176,Valsartan Tablets,Novartis,Valsartan Tablets 40 mg 1 bottle of 90 tablets (NDC 0781-5607-31),Reverified,12/11/2019,Manufacture of the drug  has been discontinued,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,discontinued
4177,Valsartan Tablets,Novartis,Valsartan Tablets 80 mg 1 bottle of 90 tablets (NDC 0781-5608-92),Reverified,12/11/2019,Manufacture of the drug  has been discontinued,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,discontinued
4178,Valsartan Tablets,Novartis,Valsartan Tablets 160 mg 1 bottle of 90 tablets (NDC 0781-5618-92),Reverified,12/11/2019,Manufacture of the drug  has been discontinued,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,discontinued
4179,Valsartan Tablets,Novartis,Valsartan Tablets 320 mg 1 bottle of 90 tablets (NDC 0781-5619-92),Reverified,12/11/2019,Manufacture of the drug  has been discontinued,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2019,discontinued
4180,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 30 counts (NDC 62332-044-30),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4181,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 90 counts (NDC 62332-044-90),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4182,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 500 counts (NDC 62332-044-71),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4183,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 30 counts (NDC 62332-045-30),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4184,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 90 counts (NDC 62332-045-90),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4185,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 500 counts (NDC 62332-045-71),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4186,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 30 counts (NDC 62332-046-30),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4187,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 90 counts (NDC 62332-046-90),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4188,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 500 counts (NDC 62332-046-71),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4189,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 30 count (NDC 62332-047-30),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4190,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 90 count (NDC 62332-047-90),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4191,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 500 counts (NDC 62332-047-71),Revised,12/18/2019,Product available to existing customers.,,,Other,Cardiovascular,Current,,,,2019,limited availability
4192,Vardenafil Hydrochloride (Levitra) Tablets,Bayer,Levitra® (vardenafil HCL) tablets 2.5 mg tablet strength (NDC 0173-0828-13),New,5/15/2018,,"Bayer will continue to market the 5 mg, 10 mg and 20 mg tablet strengths.",,,Other;Reproductive,To be Discontinued,5/15/2018,5/15/2018,,2019,discontinued
4193,Vardenafil Hydrochloride (Levitra) Tablets,Bayer,"5mg, 30 count (NDC 0173-0829-13)",New,7/25/2019,,Bayer will continue to market the 10 mg and 20 mg tablet strengths.,,,Reproductive,To be Discontinued,7/25/2019,7/25/2019,,2019,discontinued
4194,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"120mg, 100 count, (NDC 0093-3043-01)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2019,discontinued
4195,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"180mg, 500 count, (NDC 0093-3044-05)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2019,discontinued
4196,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"180mg, 100 count, (NDC 0093-3044-01)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2019,discontinued
4197,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"240mg, 100 count, (NDC 0093-3045-01)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2019,discontinued
4198,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"240mg, 500 count, (NDC 0093-3045-05)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2019,discontinued
4199,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"100 mg capsule, 100 count bottle (NDC 0378-6201-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4200,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"200 mg capsule, 100 count bottle (NDC 0378-6202-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4201,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"200 mg capsule, 500 count bottle (NDC 0378-6202-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4202,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"300 mg capsule, 100 count bottle (NDC 0378-6203-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4203,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"300 mg capsule, 500 count bottle (NDC 0378-6203-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4204,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-0512-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4205,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-0772-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4206,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 500 count bottle (NDC 0378-0772-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2019,discontinued
4207,Vinblastine Sulfate Injection,"Fresenius Kabi USA, LLC",10 mg per 10 mL (1 mg per mL); MDV (NDC 63323-0278-10),Revised,12/20/2019,Available on allocation for direct and drop ship orders.  Please contact customer service (888)-386-1300.  Next release January 2020.,Check wholesalers for inventory,,Manufacturing delays,Oncology,Current,,,,2019,limited availability
4208,"Vincristine Sulfate (VINCASAR PFS) Injection, USP",Teva Pharmaceuticals,"Vincasar PFS -- vincristine sulfate injection, solution, 1 MG/ 1 ML (NDC 0703-4402-11)",New,7/5/2019,,Teva made a business decion to discontinue the product.,,,Oncology,To be Discontinued,7/5/2019,7/5/2019,,2019,discontinued
4209,"Vincristine Sulfate (VINCASAR PFS) Injection, USP",Teva Pharmaceuticals,VINCASAR PFS (vincristine sulfate injection USP) 2 mg/2 mL Vial (1 mg/mL) (NDC 0703-4412-11),New,3/20/2019,,Teva made a business decision to discontinue this product size (2mL).,,,Oncology,To be Discontinued,3/20/2019,,,2019,discontinued
4210,"Vincristine Sulfate Injection, USP (Preservative-Free)","Hospira, Inc.",1 mg/mL Single Dose Glass Fliptop Vial (NDC 61703-0309-06),Reverified,12/20/2019,Next Delivery: December 2019; Estimated Recovery: January 2020,"Shortage per manufacturer: Manufacturing delay. Product available to order and being released for direct shipment to health care providers to meet patient needs. Please contact Pfizer Supply Continuity Team between 7:00am – 6:00pm CT at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]), for additional support.",,Other,Oncology,Current,,,,2019,not available
4211,"Vincristine Sulfate Injection, USP (Preservative-Free)","Hospira, Inc.",2 mg/2 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 61703-0309-16),Reverified,12/20/2019,Next Delivery and Estimated Recovery: December 2019,"Shortage per manufacturer: Manufacturing delay. November deliveries received. Please check with wholesaler for available inventory. Product available to order for direct shipment to health care providers to meet patient needs. Please contact Pfizer Supply Continuity Team between 7:00am – 6:00pm CT at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]), for additional support.",,Other,Oncology,Current,,,,2019,not available
4212,Vinorelbine Tartrate Injection,"Pierre Fabre Pharmaceuticals, Inc.","10 mg/mL Single Dose Glass, Vial (NDC 64370-532-01)",New,11/8/2019,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,11/8/2019,11/8/2019,,2019,discontinued
4213,Vinorelbine Tartrate Injection,"Pierre Fabre Pharmaceuticals, Inc.","50 mg/5mL Single Dose Glass, Vial (NDC 64370-532-02)",New,11/8/2019,,"Limited availability; distribution to end December 31, 2019. Discontinuation of the manufacture of the drug.",,,Oncology,To be Discontinued,11/8/2019,11/8/2019,,2019,discontinued
4214,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-06),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,4/16/2018,4/16/2018,,2019,discontinued
4215,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-09),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,4/16/2018,4/16/2018,,2019,discontinued
4216,Zoledronic Acid (Zometa) Injection,Novartis,Zometa (zoledronic acid) VIAL 4mg/5mL 5mL in 1 Vial (NDC 0078-0387-25),New,10/29/2018,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue commercial sale of the product Zometa Vial 4mg/5mL. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns. There are therapeutic equivalents available.",,,Oncology,To be Discontinued,10/29/2018,10/29/2018,,2019,discontinued
4217,Zoledronic Acid (Zometa) Injection,Novartis,Zometa (zoledronic acid) VIAL 4mg/100mL 100mL in 1 Vial (NDC 0078-0590-61),New,10/29/2018,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue commercial sale of the product Zometa Vial 4mg/100mL. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.There are therapeutic equivalents available.",,,Oncology,To be Discontinued,10/29/2018,10/29/2018,,2019,discontinued
4218,Zoledronic Acid Injection,Teva Pharmaceuticals,"0.8 mg/mL, 4 mg 5 mL/Vial (NDC 45963-440-55)",New,5/1/2019,,Discontinuation of the manufacture of the drug.,,,Musculoskeletal;Oncology,To be Discontinued,5/1/2019,5/1/2019,,2019,discontinued
4219,Zolpidem Tartrate (Edluar) Sublingual Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0037-6010-30),Revised,11/21/2018,,,Available,,Psychiatry,Resolved,11/21/2018,,,2019,
4220,Zolpidem Tartrate Extended Release Tablets,Teva Pharmaceuticals,6.25 mg tablets (NDC 0228-3481-11),New,2/22/2019,,,,,Psychiatry,To be Discontinued,2/22/2019,2/22/2019,,2019,discontinued
4221,Zolpidem Tartrate Tablets,Wockhardt,5 mg  (NDCs 64679-0714-01 and 64679-0714-04),New,7/18/2019,,,,,Psychiatry,To be Discontinued,7/18/2019,7/18/2019,,2019,discontinued
4222,Zolpidem Tartrate Tablets,Wockhardt,10 mg  (NDCs 64679-0715-01 and 64679-0715-04),New,7/18/2019,,,,,Psychiatry,To be Discontinued,7/18/2019,7/18/2019,,2019,discontinued
4223,Abacavir Sulfate and Lamivudine Tablets,Teva Pharmaceuticals,600 mg and 300 mg  (NDC 0093-5382-56),New,10/2/2020,,,,,Antiviral,To be Discontinued,10/2/2020,10/2/2020,,2020,discontinued
4224,Abciximab (ReoPro) Injection,"Janssen Biotech, Inc.",2mg/mL (NDC 57894-200-01),Revised,8/15/2019,,Janssen has made a business decision to discontinue manufacture of the drug product.,,,Cardiovascular,To be Discontinued,8/15/2019,8/15/2019,,2020,discontinued
4225,Abiraterone Acetate Tablets,"Janssen Research and Development, LLC",250 mg tablets (NDC 57894-155-12),New,6/5/2020,,,,,Oncology,To be Discontinued,6/5/2020,6/5/2020,,2020,discontinued
4226,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 25 mg (NDC 50419-863-51),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/2019,2/1/2019,,2020,discontinued
4227,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 50 mg (NDC 50419-861-51),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/2019,2/1/2019,,2020,discontinued
4228,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 100 mg (NDC 50419-862-51),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/2019,2/1/2019,,2020,discontinued
4229,Acarbose (Precose) Tablets,Bayer,Unit Dose 50 mg (NDC 50419-861-48),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/2019,2/1/2019,,2020,discontinued
4230,Acetaminophen/Tramadol Hydrochloride (Ultracet) Tablets,Janssen Pharmaceuticals,325 mg/1 unit || 37.5 mg/1 unit (NDC 50458-650-60),New,4/1/2020,,"The Company has made a business decision to permanently discontinue Ultracet. Product should be maintained on the formularies until the last batch produced expires (31 Oct 2022), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
4231,Acrivastine and Pseudoephedrine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.","Semprex-D Capsules, 8 mg/ 60mg , 100 capsules, (NDC 52244-404-10)",New,6/2/2020,,Endo has made a business decision to permanently discontinue the drug product.,,,Pulmonary/Allergy,To be Discontinued,6/2/2020,6/2/2020,,2020,discontinued
4232,"Acyclovir Capsules, USP",Teva Pharmaceuticals,"200 mg, 100 count (NDC 0093-8940-01)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2020,discontinued
4233,"Acyclovir Capsules, USP",Teva Pharmaceuticals,"200 mg, 500 count (NDC 0093-8940-05)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2020,discontinued
4234,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"400 mg, 100 count (NDC 0093-8943-01)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2020,discontinued
4235,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"400 mg, 500 count (NDC 0093-8943-05)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2020,discontinued
4236,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"800 mg, 100 count (NDC 0093-8947-01)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2020,discontinued
4237,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"800 mg, 500 count, (NDC 0093-8947-05)",New,3/21/2019,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/2019,3/21/2019,,2020,discontinued
4238,Adalimumab (Humira) Pre-filled Syringe,Abbvie,10 mg/0.2 mL pre-filled syringe (NDC 0074-6347-02),New,7/27/2020,,The company has discontinued manufacture of these products based on a market assessment and product demand.,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,7/27/2020,7/27/2020,,2020,discontinued
4239,Adalimumab (Humira) Pre-filled Syringe,Abbvie,20 mg/0.4 mL pre-filled syringe (NDC 0074-9374-02),New,7/27/2020,,The company has discontinued manufacture of these products based on a market assessment and product demand.,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,7/27/2020,7/27/2020,,2020,discontinued
4240,Albuterol Sulfate and Ipratropium Bromide Inhalation Solution,Teva Pharmaceuticals,0.3 mg mg/3 mL and 0.5 mg/3 mL (NDC 0591-3817-39),New,7/3/2019,,This product discontinuation is a business related decision.,,,Pulmonary/Allergy,To be Discontinued,7/3/2019,7/3/2019,,2020,discontinued
4241,Alfentanil Injection,"Hospira, Inc.",1 mg/2 mL (500 mcg/mL) Glass Ampul (NDC 00409-2266-02),New,3/25/2020,,Discontinuation of the manufacture of the drug. Current supply exhausted.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,3/25/2020,3/25/2020,,2020,discontinued
4242,Alfentanil Injection,"Hospira, Inc.",2.5 mg/5 mL (500 mcg/mL) Glass Ampul (NDC 00409-2266-05),New,3/25/2020,,Discontinuation of the manufacture of the drug. Current supply expected to deplete by May/June 2020 timeframe.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,3/25/2020,3/25/2020,,2020,discontinued
4243,Alogliptin Tablets,Perrigo Company PLC,"12.5mg, 30 Tablets (NDC 45802-0103-65)",Revised,10/5/2020,,,,,Endocrinology/Metabolism,Resolved,10/5/2020,,,2020,
4244,Alogliptin Tablets,Perrigo Company PLC,"25mg, 30 Tablets (NDC 45802-0150-65)",Revised,10/5/2020,,,,,Endocrinology/Metabolism,Resolved,10/5/2020,,,2020,
4245,Alogliptin Tablets,Perrigo Company PLC,"6.25mg, 30 Tablets (NDC 45802-0087-65)",Revised,10/5/2020,,,,,Endocrinology/Metabolism,Resolved,10/5/2020,,,2020,
4246,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"6.25 mg, 30 Tablets (NDC 64764-625-30)",Revised,10/5/2020,,,,,Endocrinology/Metabolism,Resolved,10/5/2020,,,2020,
4247,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"12.5 mg, 30 Tablets (NDC 64764-125-30)",Revised,10/5/2020,,,,,Endocrinology/Metabolism,Resolved,10/5/2020,,,2020,
4248,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"25 mg, 30 Tablets (NDC 64764-250-30)",Revised,10/5/2020,,,,,Endocrinology/Metabolism,Resolved,10/5/2020,,,2020,
4249,Amantadine Hydrochloride Capsules,Sandoz,100 mg capsules  (NDCs 0781-2320-01 and 0781-2320-05),New,7/16/2020,,,,,Antiviral;Neurology,To be Discontinued,7/16/2020,7/16/2020,,2020,discontinued
4250,Amifostine Injection,"Clinigen, Inc.",ETHYOL® (amifostine) for injection: 3 x 500 mg vials (NDC 76310-017-50),New,5/21/2020,Shortage anticipated from June 2020; Estimated shortage duration:  Unknown,,,Other,Oncology;Other,Current,,,,2020,limited availability
4251,Amino Acids,B. Braun Medical Inc.,"15% Amino Acid (Plenamine) Pharmacy Bulk Package in 1,000 mL plastic container, catalog S4500, (NDC 0264-4500-00)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4252,Amino Acids,B. Braun Medical Inc.,"15% Amino Acid (Plenamine) in 1,000mL glass container, catalog S3200-SS, (NDC 0264-3200-55)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,9/24/2019,,2020,
4253,Amino Acids,B. Braun Medical Inc.,"10% FreAmine III (Amino Acid Injection) in 1,000mL glass container, catalog S9010-SS, (NDC 0264-9010-55)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4254,Amino Acids,B. Braun Medical Inc.,"TrophAmine (10% Amino Acid Injection) in 500mL glass container, catalog S9341-SS, (NDC 0264-9341-55)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4255,Amino Acids,B. Braun Medical Inc.,"TrophAmine (6% Amino Acid Injection) in 500mL glass container, catalog S9361-SS, (NDC 0264-9361-55)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4256,Amino Acids,"ICU Medical, Inc.","AMINOSYN™-PF 7%, Sulfite-Free, 500 mL (NDC 0409-4178-03)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4257,Amino Acids,"ICU Medical, Inc.","AMINOSYN II 10%, Sulfite-Free, (Pediatric Formula) 1000 mL (NDC 0409-4179-05)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4258,Amino Acids,"ICU Medical, Inc.",Aminosyn II 10% Sulfite-Free BLK PK 2000 mL (NDC 0409-7172-17),Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4259,Amino Acids,"ICU Medical, Inc.",Aminosyn II 15% Sulfite-Free BLK PK 2000 mL (NDC 0409-7171-17),Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4260,Amino Acids,Baxter Healthcare,"PREMASOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 2B0009 10% 1000 mL (NDC 0338-1130-04), 2B0010 10% 2000 mL (NDC 0338-1130-06),
2B0012 10% 500 mL (NDC 0338-1130-03)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4261,Amino Acids,Baxter Healthcare,"10% TRAVASOL (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 1B6624 10% 1000 mL (NDC 0338-0644-04),
1B6623 10% 500 mL (NDC 0338-0644-03),
1B6626P 10% 2000 mL (NDC 0338-0644-06)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4262,Amino Acids,Baxter Healthcare,"15% CLINISOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 2B6189 15% 2000 mL (NDC 0338-0502-06), 2B6187 15% 500 mL (NDC 0338-0502-03)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4263,Amino Acids,Baxter Healthcare,"20% PROSOL - sulfite-free (Amino Acid) Injection, 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Code 2B6186 (NDC 0338-0499-06)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4264,Amino Acids,Baxter Healthcare,CLINIMIX E sulfite-free (Amino Acid with Electrolytes in Dextrose with Calcium) Injection in CLARITY Dual Chamber Container,Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4265,Amino Acids,Baxter Healthcare,CLINIMIX sulfite-free (Amino Acid in Dextrose) Injection in CLARITY Dual Chamber Container,Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4266,Amino Acids,Baxter Healthcare,SYNTHAMIN 17 without Electrolytes - 10% Amino Acids Intravenous Infusion 3000 mL. Product code FKB6642.  Pack factor 3  (NDC 0338-9575-03),Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4267,Amino Acids,Baxter Healthcare,"CLINIMIX N9G15E-Solution for Infusion, 1000 mL (2.75% Amino Acid in 7.5% Glucose with Electrolytes). Product code FKB6669C - Pack factor of 8 (NDC 0338-9570-08)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4268,Amino Acids,Baxter Healthcare,"CLINIMIX N9G20E-Solution for Infusion, 1000 mL  (2.75% Amino Acid in 10% Glucose with Electrolytes) Product code FKB6670C - Pack factor of 8 
(NDC 0338-9566-08)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4269,Amino Acids,Baxter Healthcare,"CLINIMIX N14G30E-Solution for Infusion, 2000 mL (4.25% Amino Acid in 15% Dextrose with Electrolytes) Product code FKB6654V - Pack factor of 4 (NDC 0338-9587-04)",Revised,9/24/2019,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/2019,,,2020,
4270,"Aminophylline Injection, USP","Hospira, Inc.",250 mg/10mL (25 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-5921-01),Reverified,11/20/2020,Available,,,Other,Pulmonary/Allergy,Current,,,,2020,available
4271,"Aminophylline Injection, USP","Hospira, Inc.",500 mg/20mL (25 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-5922-01),Reverified,11/20/2020,Available,,,Other,Pulmonary/Allergy,Current,,,,2020,available
4272,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 60 count bottle (NDC 0185-0144-60)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
4273,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 90 count bottle (NDC 0185-0144-09)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
4274,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 500 count bottle (NDC 0185-0144-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
4275,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 500 count bottle (NDC 0245-0145-15)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
4276,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 30 count bottle (NDC 0245-0145-30)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
4277,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-2610-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4278,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 1000 count bottle (NDC 0378-2610-10)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4279,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"25 mg, 100 count bottle (NDC 0378-2625-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4280,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"25 mg, 1000 count bottle (NDC 0378-2625-10)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4281,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 100 count bottle (NDC 0378-2650-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4282,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 1000 count bottle (NDC 0378-2650-10)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4283,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"75 mg, 100 count bottle (NDC 0378-2675-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4284,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-2685-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4285,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 100 count bottle (NDC 0378-2695-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4286,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,2.5 mg/10 mg (NDC 0093-7370-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2020,discontinued
4287,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/10 mg (NDC 0093-7371-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2020,discontinued
4288,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/20 mg (NDC 0093-7372-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2020,discontinued
4289,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/40 mg (NDC 0093-7670-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2020,discontinued
4290,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,10 mg/20 mg (NDC 0093-7373-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2020,discontinued
4291,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,10 mg/40 mg (NDC 0093-7671-01),New,6/5/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/2019,6/5/2019,,2020,discontinued
4292,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",5 mg/20 mg tablets (NDCs 0093-7027-56 and 0093-7027-98),New,3/11/2019,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/2019,3/11/2019,,2020,discontinued
4293,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",5 mg/40 mg tablets (NDCs 0093-7028-56 and 0093-7028-98),New,3/11/2019,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/2019,3/11/2019,,2020,discontinued
4294,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",10 mg/20 mg tablets (NDCs 0093-7029-56 and 0093-7029-98),New,3/11/2019,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/2019,3/11/2019,,2020,discontinued
4295,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",10 mg/20 mg tablets (NDCs 0093-7030-56 and 0093-7030-98),New,3/11/2019,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/2019,3/11/2019,,2020,discontinued
4296,Amoxapine Tablets,Teva Pharmaceuticals,"50 mg, 100 tablets (NDC 0591-5714-01)",Reverified,11/19/2020,Available,,,,Psychiatry,Current,3/9/2020,,,2020,available
4297,Amoxapine Tablets,Teva Pharmaceuticals,"25 mg, 100 tablets (NDC 0591-5713-01)",Reverified,11/19/2020,On backorder,Recovery March 2021,,Other,Psychiatry,Current,3/9/2020,,,2020,not available
4298,Amoxapine Tablets,Teva Pharmaceuticals,"100 mg, 100 tablets (NDC 0591-5715-01)",Reverified,11/19/2020,Available,,,,Psychiatry,Current,3/9/2020,,,2020,available
4299,Amoxapine Tablets,Teva Pharmaceuticals,"150 mg, 100 tablets (NDC 0591-5716-01)",Reverified,11/19/2020,Available,,,,Psychiatry,Current,3/9/2020,,,2020,available
4300,Amoxicillin Powder for Suspension,Teva Pharmaceuticals,"125 mg/5 mL powder for suspension (NDCs 0093-4150-73, 0093-4150-79 and 0093-4150-80)",New,6/3/2019,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,6/3/2019,6/3/2019,,2020,discontinued
4301,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"5 mg, 100 Count Bottle (NDC 68382-950-01)",Reverified,10/13/2020,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2020,limited availability
4302,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"7.5 mg, 100 Count Bottle (NDC 68382-951-01)",Reverified,10/13/2020,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2020,limited availability
4303,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"10 mg, 100 Count Bottle (NDC 68382-952-01)",Reverified,10/13/2020,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2020,limited availability
4304,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"12.5 mg, 100 Count Bottle (NDC 68382-953-01)",Reverified,10/13/2020,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2020,limited availability
4305,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"15 mg, 100 Count Bottle (NDC 68382-954-01)",Reverified,10/13/2020,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2020,limited availability
4306,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"20 mg, 100 Count Bottle (NDC 68382-955-01)",Reverified,10/13/2020,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2020,limited availability
4307,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"30 mg, 100 Count Bottle (NDC 68382-956-01)",Reverified,10/13/2020,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,,2020,limited availability
4308,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"30 mg, 100 Count Bottle (NDC 0185-0864-01)",Reverified,11/13/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4309,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"20 mg, 100 Count Bottle (NDC 0185-0853-01)",Reverified,11/13/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4310,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"10 mg, 100 Count Bottle (NDC 0185-0842-01)",Reverified,11/13/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4311,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"5 mg, 100 Count Bottle (NDC 0185-0831-01)",Reverified,11/13/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4312,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 10mg 100 (NDC 57844-0110-01),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4313,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 12.5mg 100 (NDC 57844-0112-01),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4314,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 15mg 100 (NDC 57844-0115-01),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4315,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 20mg 100 (NDC 57844-0120-01),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4316,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 30mg 100 (NDC 57844-0130-01),Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
4317,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 5mg 100 (NDC 57844-0105-01),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4318,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 7.5mg 100 (NDC 57844-0117-01),Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
4319,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,5mg [1.25/1.25/1.25/1.25mg] 100s (NDC 0378-4541-01),Reverified,11/10/2020,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2020,not available
4320,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,7.5mg [1.875/1.875/1.875/1.875mg] 100s (NDC 0378-4542-01),Reverified,11/10/2020,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2020,not available
4321,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,10mg [2.5/2.5/2.5/2.5mg] 100s (NDC 0378-4543-01),Reverified,11/10/2020,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2020,not available
4322,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,12.5mg [3.125/3.125/3.125/3.125mg] 100s (NDC 0378-4544-01),Reverified,11/10/2020,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2020,not available
4323,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,15mg [3.75/3.75/3.75/3.75mg] 100s (NDC 0378-4545-01),Reverified,11/10/2020,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2020,not available
4324,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,20mg [5/5/5/5mg] 100s (NDC 0378-4546-01),Reverified,11/10/2020,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2020,not available
4325,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,30mg [7.5/7.5/7.5/7.5mg] 100s (NDC 0378-4547-01),Reverified,11/10/2020,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,,2020,not available
4326,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01)",Reverified,9/25/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4327,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01)",Reverified,9/25/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4328,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01)",Reverified,9/25/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4329,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01)",Reverified,9/25/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4330,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01)",Reverified,9/25/2020,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
4331,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,12.5  mg 100 count (NDC 0555-0776-02),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4332,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,15  mg 100 count (NDC 0555-0777-02),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4333,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,7.5  mg 100 count (NDC 0555-0775-02),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4334,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,10  mg 100 count (NDC 0555-0972-02),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4335,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,20 mg 100 count (NDC 0555-0973-02),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4336,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,30 mg 100 count (NDC 0555-0974-02),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4337,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,5 mg 100 count (NDC 0555-0971-02),Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
4338,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,1 MG 100 Capsules (NDC 0172-5240-60),Reverified,11/19/2020,"Limited inventory, on allocation",,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2020,limited availability
4339,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,0.5 MG 100 Capsules (NDC 0172-5241-60),Reverified,11/19/2020,"Limited inventory, on allocation",,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2020,limited availability
4340,Anagrelide Hydrochloride Capsules,Shire US Inc. now part of Takeda,"AGRYLIN 0.5 mg Capsule,100 capsules in 1 bottle (NDC 54092-063-01)",Reverified,10/27/2020,Available,Takeda is actively working to mitigate a recent unexpected increase in demand for the product.,,Demand increase for the drug,Hematology,Current,,,,2020,available
4341,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,0.5 mg per capsule Bottles of 100 (NDC 13668-453-01),Reverified,9/14/2020,Available and shipping,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2020,available
4342,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,"1 mg per capsule, Bottles of 100 (NDC 13668-462-01)",Reverified,9/14/2020,Available and shipping,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,,2020,available
4343,Anastrozole Tablets,Apotex Corp.,1 mg tablets (NDC 60505-2985-3),New,1/21/2020,,,,,Oncology,To be Discontinued,1/21/2020,1/21/2020,,2020,discontinued
4344,Argatroban Injection,Novartis,"250 mg/2.5 mL (100 mg/mL), single dose vial (NDC 0078-0930-61)",New,1/15/2020,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue the product Argatroban Injection, Vial 250 mg/2.5 mL.",,,Hematology,To be Discontinued,1/15/2020,1/15/2020,,2020,discontinued
4345,Asparaginase Erwinia Chrysanthemi (Erwinaze),"Jazz Pharmaceuticals, Inc.","ERWINAZE 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial 5 vial carton (NDC 57902-249-05)",Revised,11/6/2020,Available,,,Other,Hematology;Oncology;Pediatric,Current,,,,2020,available
4346,Asparaginase Erwinia Chrysanthemi (Erwinaze),"Jazz Pharmaceuticals, Inc.","ERWINAZE 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial 1 vial (NDC 57902-249-01)",Revised,11/6/2020,Available,,,Other,Hematology;Oncology;Pediatric,Current,,,,2020,available
4347,Aspirin/Dipyridamole (Aggrenox) Extended Release Capsules,"Boehringer Ingelheim Pharmaceuticals, Inc.",25mg/200mg capsules (NDC 0597-0001-60),New,5/26/2020,,"Business decision made by the applicant, BIPI. BIPI will no longer be supplying the market with AGGRENOX capsules after June 11, 2020.",,,Cardiovascular,To be Discontinued,5/26/2020,5/26/2020,,2020,discontinued
4348,"Atracurium Besylate Injection, USP",Mylan Institutional,"10 mg/mL, 10 mL, 10PK (NDC 67457-698-10)",New,9/24/2019,,,,,Anesthesia,To be Discontinued,9/24/2019,9/24/2019,,2020,discontinued
4349,"Atracurium Besylate Injection, USP",Mylan Institutional,"10 mg/mL, 5 mL, 10 PK (NDC 67457-699-05)",New,9/24/2019,,,,,Anesthesia,To be Discontinued,9/24/2019,9/24/2019,,2020,discontinued
4350,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC",8 mg per 20 mL (0.4 mg per mL); MDV; (NDC 63323-580-20),Reverified,11/16/2020,Available,Check wholesaler inventory,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2020,available
4351,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS","0.1 mg/mL; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3339-1, Old NDC 0548-3339-00)",Reverified,10/30/2020,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2020,available
4352,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); Ansyr Plastic Syringe
(NDC 0409-1630-10)",Reverified,11/20/2020,Limited Supply Available. Next Delivery: December 2020; Estimated Recovery: March 2021,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2020,limited availability
4353,Atropine Sulfate Injection,"Hospira, Inc.","0.25 mg/5 mL (0.05 mg/mL); Ansyr Plastic Syringe
(NDC 0409-9630-05)",Reverified,11/20/2020,Available,,,Other,Anesthesia;Neurology;Pediatric,Current,,,,2020,available
4354,Atropine Sulfate Injection,"Hospira, Inc.",0.5 mg/5 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4910-34),Reverified,11/20/2020,Available,,,Other,Anesthesia;Neurology;Pediatric,Current,,,,2020,available
4355,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4911-34, pack of 10; NDC 0409-4911-11, individual)",Reverified,11/20/2020,Available,,,Other,Anesthesia;Neurology;Pediatric,Current,,,,2020,available
4356,Atropine Sulfate Injection,American Regent/Luitpold,"1 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-1010-25)",Revised,7/10/2020,Limited Availability,"American Regent is currently releasing the 1mg/mL, 1 mL vial, (NDC 00517-1010-25)",,Other,Anesthesia;Neurology;Pediatric,Current,,,,2020,limited availability
4357,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.4 mg/mL, 20 mL vial (NDC 0641-6006-10)",Revised,8/20/2020,Available,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2020,available
4358,Atropine Sulfate Injection,American Regent/Luitpold,"0.4 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-0401-25)",Revised,7/10/2020,Limited availability,"American Regent is currently releasing the 0.4mg/mL, 1 mL vial, NDC 00517-0401-25",,Other,Anesthesia;Neurology;Pediatric,Current,,,,2020,limited availability
4359,Atropine Sulfate Ophthalmic Ointment,Bausch Health,"1% (10 mg/g), 3.5 g tube (NDC 24208-825-55)",Revised,7/22/2020,Availability limited to product already in pharmacies until resumption of manufacturing in the second half of 2020,Currently qualifying alternate supplier of inactive ingredient,,Shortage of an inactive ingredient,Ophthalmology,Current,,,,2020,limited availability
4360,Avelox® (moxifloxacin HCl) Tablets,Bayer,Bottles of 30 Tablets (NDC 50419-530-01),New,2/1/2019,,Business decision to discontinue marketing in the US.,,,Anti-Infective,To be Discontinued,2/1/2019,2/1/2019,,2020,discontinued
4361,"AVYCAZ® (ceftazidime and avibactam) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution 1 Single-use vials (NDC 0456-2700-01)",New,2/26/2020,Currently unavailable.  Duration of the shortage is yet to be determined.,,,Other,Anti-Infective,Current,,,,2020,not available
4362,"AVYCAZ® (ceftazidime and avibactam) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution Carton containing 10 vials  (NDC 0456-2700-10)",New,2/26/2020,Currently unavailable.  Duration of the shortage is yet to be determined.,,,Other,Anti-Infective,Current,,,,2020,not available
4363,Azacitidine Injection,Teva Pharmaceuticals,100 mg/1 unit (NDC 0591-2897-49),New,10/30/2019,,The product has not been marketed for an extended period of time. Teva made a business decision to discontinue this product.,,,Oncology,To be Discontinued,10/30/2019,10/30/2019,,2020,discontinued
4364,Azithromycin (Azasite) Ophthalmic Solution 1%,Akorn Pharmaceuticals,Azasite (Azithromycin Ophthalmic Solution) 1% 2.5 mL in 5 mL bottle (NDC 17478-307-03),Revised,9/11/2019,,,,,Ophthalmology,Resolved,9/11/2019,,,2020,
4365,Azithromycin Tablets,Aurobindo Pharma,250mg 6x3 Blister Pack/ Carton (NDC 65862064163),Reverified,10/2/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4366,Azithromycin Tablets,Lupin,250 mg – Carton of 3 Blister Cards (6 Tablets per Blister Card) (NDC  6818016013),Reverified,10/2/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4367,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 250 mg tablets; Unit Dose package of 50 (NDC 0069-4061-89),Reverified,11/20/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4368,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 500 mg tablets; Unit Dose package of 50 (NDC 0069-3070-86),Reverified,11/20/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4369,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 250 mg tablets; bottle of 30 (NDC 0069-3060-30),Reverified,11/20/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4370,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 250 mg tablets; boxes of 3 (Z-PAKS of 6) (NDC 0069-3060-75),Reverified,11/20/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4371,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 500 mg tablets; bottles of 30 (NDC 0069-3070-30),Reverified,11/20/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4372,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 500 mg tablets; boxes of 3 (TRI-PAKS of 3 tablets) (NDC 0069-3070-75),Reverified,11/20/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4373,Azithromycin Tablets,Pfizer Pharmaceuticals,250 mg tablets; Blister of 3x6 (NDC 59762-2198-3),Reverified,11/20/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4374,Azithromycin Tablets,Pfizer Pharmaceuticals,250 mg tablets; Bottle of 30 (NDC 59762-2198-7),Reverified,11/20/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4375,Azithromycin Tablets,Sandoz,600 mg 30 count bottle (NDC 0781-5793-31),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4376,Azithromycin Tablets,Sandoz,500 mg 30 count bottle (NDC 0781-8090-31),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4377,Azithromycin Tablets,Sandoz,500 mg 3 count unit dose (NDC 0781-8090-03),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4378,Azithromycin Tablets,Sandoz,250 mg 30 count bottle (NDC 0781-8089-31),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4379,Azithromycin Tablets,Sandoz,250 mg 6 count unit dose (NDC 0781-8089-26),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4380,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"600 mg, 30/bottle (NDC 51224-222-30)",Revised,8/20/2020,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4381,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"500 mg, 30/bottle (NDC 51224-122-30)",Revised,8/20/2020,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4382,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"250 mg, 30/bottle (NDC 51224-022-30)",Revised,8/20/2020,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4383,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"500 mg, Cartons of 1 blister card, 3 tablets per blister card (NDC 51224-122-03)",Revised,8/20/2020,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4384,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"500 mg, Cartons of 3 blister card, 3 tablets per blister card (NDC 51224-122-09)",Revised,8/20/2020,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4385,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"250 mg, Cartons of 1 blister card, 6 tablets per blister card (NDC 51224-022-06)",Revised,8/20/2020,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4386,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"250 mg, Cartons of 3 blister cards, 6 tablets per blister card (NDC 51224-022-18)",Revised,8/20/2020,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4387,Azithromycin Tablets,Teva Pharmaceuticals,250  mg 30 count (NDC 50111-787-10),Reverified,11/19/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4388,Azithromycin Tablets,Teva Pharmaceuticals,250  mg 6 x 1 blister pack (NDC 50111-787-51),Reverified,11/19/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4389,Azithromycin Tablets,Teva Pharmaceuticals,500  mg 3 x 1 blister pack (NDC 50111-788-55),Reverified,11/19/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4390,Azithromycin Tablets,Teva Pharmaceuticals,500  mg 30 count (NDC 50111-788-10),Reverified,11/19/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4391,Azithromycin Tablets,Teva Pharmaceuticals,600  mg 30 count (NDC 50111-789-10),Reverified,11/19/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4392,Azithromycin Tablets,Teva Pharmaceuticals,250  mg 18 3 x 6 blister pack (NDC 50111-787-66),Reverified,11/19/2020,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4393,Azithromycin Tablets,Teva Pharmaceuticals,500  mg 3 x 3 blister pack (NDC 50111-788-67),Reverified,11/19/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4394,Azithromycin Tablets,Wockhardt,250 MG 3X6T (NDC 64679-0961-05),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4395,Azithromycin Tablets,Wockhardt,250 mg 30T (NDC 64679-961-01),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4396,Azithromycin Tablets,Wockhardt,250 mg Unit dose package of 100  (NDC 64679-961-02),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4397,Azithromycin Tablets,Wockhardt,250 mg Cartons of 3 blister cards (6 tablets per blister card) (NDC 64679-961-05),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4398,Azithromycin Tablets,Wockhardt,250 mg 500-ct bottle (NDC 64679-961-07),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4399,Azithromycin Tablets,Wockhardt,"500 mg 500 mg, 30T (NDC 64679-0964-01)",Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4400,Azithromycin Tablets,Wockhardt,"500 mg 500 mg, 3X3T (NDC 64679-0964-05)",Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4401,Azithromycin Tablets,Wockhardt,500 mg Unit dose package of 100  (NDC 64679-964-02),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4402,Azithromycin Tablets,Wockhardt,500 mg Cartons of 3 blister cards (3 tablets per blister card) (NDC 64679-964-05),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4403,Azithromycin Tablets,Wockhardt,500 mg 500-ct bottle (NDC 64679-964-07),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4404,Azithromycin Tablets,Wockhardt,600 mg Bottles of 30 (NDC 64679-962-01),Reverified,4/23/2020,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,,2020,not available
4405,Azithromycin Tablets,Bionpharma Inc.,250 mg bottles of 30 (NDC 69452-171-13),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4406,Azithromycin Tablets,Bionpharma Inc.,250 mg Carton of 6 (1 Card of 6 Tablets) (NDC 69452-171-04),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4407,Azithromycin Tablets,Bionpharma Inc.,250 mg Carton of 18 (3 Cards of 6 Tablets) (NDC 69452-171-73),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4408,Azithromycin Tablets,Bionpharma Inc.,500 mg bottles of 30 (NDC 69452-172-13),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4409,Azithromycin Tablets,Bionpharma Inc.,500 mg Carton of 3 (1 Card of 3 Tablets) (NDC 69452-172-74),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4410,Azithromycin Tablets,Bionpharma Inc.,500 mg Carton of 9 (3 Cards of 3 Tablets) (NDC 69452-172-72),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4411,Azithromycin Tablets,Alembic Pharmaceuticals,250 mg bottles of 30 (NDC 62332-251-30),Revised,8/21/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
4412,Azithromycin Tablets,Alembic Pharmaceuticals,250 mg carton of 3 blister cards (6 tablets per blister card) (NDC 62332-251-06),Revised,8/21/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
4413,Azithromycin Tablets,Alembic Pharmaceuticals,500 mg bottle of 30 (NDC 62332-252-30),Revised,8/21/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
4414,Azithromycin Tablets,Alembic Pharmaceuticals,500 mg carton of 3 blister cards (3 tablets per blister card) (NDC 62332-252-03),Revised,8/21/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
4415,Azithromycin Tablets,HEC Pharm USA Inc.,500 mg carton of 1 blister card (3 tablets per blister card) (NDC 0527-2750-17),New,4/22/2020,Available,"HEC and its distributor Lannett Company, Inc. in conjunction with FDA has initiated a temporary importation of German approved Azithromycin tablets into the U.S. market to address drug shortage. To place an order, please contact Lannett at (215) 333-9000.",,,Anti-Infective,Current,,,,2020,available
4416,Azithromycin Tablets,Aurobindo Pharma,500mg 1x3 Blister Pack/Carton (NDC 65862064264),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4417,Azithromycin Tablets,Lupin,250 mg Bottle of 30’s (NDC 6818016006),Reverified,10/2/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4418,Azithromycin Tablets,Lupin,500 mg Carton of 3 Blister Cards (3 Tablets per Blister Card) (NDC 6818016113),Reverified,10/2/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4419,Azithromycin Tablets,Lupin,"Azithromycin Tablets, 500 mg Bottle of 30's (NDC 6818016106)",Reverified,10/2/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4420,Azithromycin Tablets,Lupin,"Azithromycin Tablets, 600 mg Bottle of 30’s (NDC 6818016206)",Reverified,10/2/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4421,Azithromycin Tablets,Aurobindo Pharma,250mg 30 count bottles (NDC 65862064130),Reverified,10/2/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4422,Azithromycin Tablets,Aurobindo Pharma,250mg 1x6 Blister Pack/ Carton (NDC 65862064169),Reverified,10/2/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4423,Azithromycin Tablets,Aurobindo Pharma,500mg 3x3 Blister Pack/ Carton (NDC 65862064290),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4424,Azithromycin Tablets,Aurobindo Pharma,500mg 30 count bottles (NDC 65862064230),Revised,8/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4425,Bacitracin Ophthalmic Ointment,Perrigo Pharmaceuticals,Bacitracin Ophthalmic Ointment 3.5 g (NDC 0574-4022-35),Revised,4/29/2020,,,Available,,Ophthalmology,Resolved,4/29/2020,,,2020,
4426,Belatacept (Nulojix) Lyophilized Powder for Injection,Bristol Myers Squibb Co.,20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13),Reverified,12/16/2019,"No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of NULOJIX via the US NULOJIX Distribution Program, initiated 15-Feb-2017. Starting in August 2018, the restrictions of the NDP will be eased to allow for expansion of use to appropriate new patients if the treating physician determines that Nulojix is the best treatment option for the patient.  For further information, contact BMS Medical Information.",Increased demand for the drug exacerbated by a delay in transition to a more efficient manufacturing process.,,Demand increase for the drug,Transplant,Current,,,,2020,limited availability
4427,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 69202-780-08),New,9/18/2019,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/2019,9/18/2019,,2020,discontinued
4428,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 69202-780-88),New,9/18/2019,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/2019,9/18/2019,,2020,discontinued
4429,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 23594-780-08),New,9/18/2019,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/2019,9/18/2019,,2020,discontinued
4430,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 23594-780-88),New,9/18/2019,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/2019,9/18/2019,,2020,discontinued
4431,Bethanechol Chloride Tablets,Teva Pharmaceuticals,10 mg  (NDC 50111-324-01),New,5/1/2020,,,,,Urology,To be Discontinued,5/1/2020,5/1/2020,,2020,discontinued
4432,Bethanechol Chloride Tablets,Teva Pharmaceuticals,5 mg  (NDC 50111-323-01),New,5/1/2020,,,,,Urology,To be Discontinued,5/1/2020,5/1/2020,,2020,discontinued
4433,Bethanechol Chloride Tablets,Teva Pharmaceuticals,25 mg  (NDC 50111-325-01),New,5/1/2020,,,,,Urology,To be Discontinued,5/1/2020,5/1/2020,,2020,discontinued
4434,Bethanechol Chloride Tablets,Teva Pharmaceuticals,50 mg  (NDC 50111-326-01),New,5/1/2020,,,,,Urology,To be Discontinued,5/1/2020,5/1/2020,,2020,discontinued
4435,Bethanechol Chloride Tablets,Teva Pharmaceuticals,5 mg capsules (NDC 51285-697-02),New,1/13/2020,,,,,Urology,To be Discontinued,1/13/2020,1/13/2020,,2020,discontinued
4436,Bethanechol Chloride Tablets,Teva Pharmaceuticals,10 mg capsules (NDC 51285-690-02),New,1/13/2020,,,,,Urology,To be Discontinued,1/13/2020,1/13/2020,,2020,discontinued
4437,Betrixaban (Bevyxxa) Capsules,"Portola Pharmaceuticals, Inc.",40 mg capsules (NDC 69853-0202-1),New,5/1/2020,,,,,Hematology,To be Discontinued,5/1/2020,5/1/2020,,2020,discontinued
4438,Betrixaban (Bevyxxa) Capsules,"Portola Pharmaceuticals, Inc.",80 mg capsules (NDC 69853-0201-1),New,5/1/2020,,,,,Hematology,To be Discontinued,5/1/2020,5/1/2020,,2020,discontinued
4439,Bosentan Tablets,"Janssen Research and Development, LLC",62.5 mg tablets (NDC 10148-625-60),New,10/15/2019,,,,,Cardiovascular,To be Discontinued,10/15/2019,10/15/2019,,2020,discontinued
4440,Bosentan Tablets,"Janssen Research and Development, LLC",125 mg tablets (NDC 10148-125-60),New,10/15/2019,,,,,Cardiovascular,To be Discontinued,10/15/2019,10/15/2019,,2020,discontinued
4441,Budesonide Capsules,Teva Pharmaceuticals,3 mg capsules (NDC 0093-7445-01),New,12/23/2019,,,,,Gastroenterology,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
4442,"Bumetanide Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 4 mL vial (NDC 0641-6008-10)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,not available
4443,"Bumetanide Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 10 mL vial (NDC 0641-6007-10)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,not available
4444,"Bumetanide Injection, USP","Hospira, Inc.",1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2020,limited availability
4445,"Bumetanide Injection, USP","Hospira, Inc.",2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10),Revised,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
4446,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-461-57),Revised,11/16/2020,Backordered.  Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4447,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.5% (250 mg per 50 mL) (5 mg per mL) MDV (NDC 63323-463-57),Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4448,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.25% (25 mg per 10 mL) (2.5 mg per mL) SDV (NDC 63323-468-17),Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4449,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI .25% (75 mg per 30 mL) (2.5 mg per mL) SDV (NDC 63323-468-37),Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4450,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (50 mg per 10 mL) (5 mg per mL) SDV (NDC 63323-462-17),Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4451,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) SDV (NDC 63323-462-37),Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4452,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) Sterile-Pak, SDV (NDC 63323-462-31)",Revised,11/16/2020,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4453,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.75% (225 mg per 30 mL) (7.5 mg per mL)  SDV  (NDC 63323-460-37),Revised,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4454,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-01),Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4455,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-17),Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4456,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9043-01),Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4457,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-01),Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4458,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-17),Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4459,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9046-01),Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4460,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-10)",Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4461,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-30)",Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4462,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-10)",Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4463,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-29)",Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4464,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1752-50)",Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4465,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1755-50)",Reverified,11/20/2020,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2020,not available
4466,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-465-57),Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4467,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine 0.5% (250 mg per 50 mL) (5 mg per mL)                    MDV (NDC 63323-467-57),Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4468,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.25% (25 mg per 10 mL) (2.5 mg per mL) MPF,         SDV (NDC 63323-464-17)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4469,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine MPF 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF, SDV (NDC 63323-464-37)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4470,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF,             Sterile-Pak, SDV (NDC 63323-464-31)",Reverified,11/16/2020,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4471,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (50 mg per 10 mL) (5 mg per mL)  MPF,                 SDV  (NDC 63323-466-17)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4472,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                 SDV (NDC 63323-466-37)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4473,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                Sterile-Pak, SDV (NDC 63323-466-31)",Reverified,11/16/2020,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4474,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.75% (75 mg per 10 mL) (7.5 mg per mL) MPF,             SDV (NDC 63323-472-17)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4475,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.75% (225 mg per 30 mL) (7.5 mg per mL) MPF,     SDV (NDC 63323-472-37)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4476,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 10 mL Single Dose Vials (NDC 55150-167-10),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4477,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 30 mL Single Dose Vials (NDC 55150-168-30),Revised,11/20/2020,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4478,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 10 mL Single Dose Vials (NDC 55150-169-10),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4479,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-170-30),Revised,11/20/2020,Currently on backorder - next shipment anticipated end of Nov 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4480,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 10 mL Single Dose Vials (NDC 55150-171-10),Revised,11/20/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4481,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 30 mL Single Dose Vials (NDC 55150-172-30),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4482,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 50 mL Multiple Dose Vials (NDC 55150-249-50),Revised,11/20/2020,Available,Check wholesaler for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4483,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 50 mL Multiple Dose Vials (NDC 55150-250-50),Revised,11/20/2020,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4484,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-01),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4485,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-02),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4486,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1160-01),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4487,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-01),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4488,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-02),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4489,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1163-01),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4490,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",75 mg/10 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-01),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4491,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",225 mg/30 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-02),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4492,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409-3613-01),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4493,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 25 mg/10 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-10),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4494,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 75 mg/30 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-30),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4495,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1587-50),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4496,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-10),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4497,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-29),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4498,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1610-50),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4499,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 75 mg/10 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-10),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4500,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 225 mg/30 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-29),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4501,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409- 1761-02),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
4502,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.25% 5 mL single-dose ampules (NDC 59923-717-05),New,9/12/2019,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2020,available
4503,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.25% 10 mL single-dose ampules (NDC 59923-719-10),New,9/12/2019,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2020,available
4504,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.5% 5 mL single-dose ampules (NDC 59923-718-05),New,9/12/2019,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2020,available
4505,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.5% 10 mL single-dose ampules (NDC 59923-720-10),New,9/12/2018,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2020,available
4506,"Bupivacaine Hydrochloride Injection, USP",Baxter Healthcare,"Bupivacaine Spinal, USP (7.5 mg/mL in 8.25% dextrose) 2 mL Single Dose Ampule (10 x 2 mL)(NDC 36000-092-10)",Reverified,10/28/2020,Stocked out - recovery TBD,SPINAL 0.75% - Sterile Hyperbaric Solution for Spinal Anesthesia,,Manufacturing Delay,Anesthesia,Current,,,,2020,not available
4507,Buprenorphine Hydrochloride Sublingual Tablets,Mylan Pharmaceuticals Inc.,"2 mg, 30 count bottle (NDC 0378-0923-93)",New,5/2/2019,,,,,Analgesia/Addiction,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4508,Buprenorphine Hydrochloride Sublingual Tablets,Mylan Pharmaceuticals Inc.,"8 mg, 30 count bottle (NDC 0378-0924-93)",New,5/2/2019,,,,,Analgesia/Addiction,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4509,Bupropion Hydrochloride (Zyban) Tablets,GlaxoSmithKline,150 mg  (NDC 0173-0556-01),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately July 2019.,,,Psychiatry,To be Discontinued,6/28/2019,6/28/2019,,2020,discontinued
4510,Bupropion Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 90 count bottle (NDC 0378-2008-77)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4511,Bupropion Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"300 mg, 500 count bottle (NDC 0378-2009-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4512,Buspirone HCl Tablets,Amneal Pharmaceutical,"10mg, 100 (NDC 69238-1117-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4513,Buspirone HCl Tablets,Amneal Pharmaceutical,"10mg, 500 (NDC 69238-1117-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4514,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 100 (NDC 69238-1118-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4515,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 500 (NDC 69238-1118-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4516,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 60 (NDC 69238-1118-06)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4517,Buspirone HCl Tablets,Amneal Pharmaceutical,"30mg, 60 (NDC 69238-1119-06)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4518,Buspirone HCl Tablets,Amneal Pharmaceutical,"5mg, 100 (NDC 69238-1115-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4519,Buspirone HCl Tablets,Amneal Pharmaceutical,"5mg, 500 (NDC 69238-1115-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4520,Buspirone HCl Tablets,Amneal Pharmaceutical,"7.5mg, 100 (NDC 69238-1116-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4521,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"5 mg, 100 count bottle (NDC 23155-023-01",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4522,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"5 mg, 500 count bottle (NDC 23155-023-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4523,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"10 mg, 100 count bottle (NDC 23155-024-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4524,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"10 mg, 500 count bottle (NDC 23155-024-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4525,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"15 mg, 60 count bottle (NDC 23155-025-06)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4526,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"15 mg, 100 count bottle (NDC 23155-025-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4527,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"15 mg, 180 count bottle (NDC 23155-025-08)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4528,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"15 mg, 500 count bottle (NDC 23155-025-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4529,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"30 mg, 60 count bottle (NDC 23155-097-06)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4530,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"30 mg, 500 count bottle (NDC 23155-097-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4531,Buspirone HCl Tablets,Strides Pharma Inc.,"15 mg, 60 count bottle (NDC 64380-743-03)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4532,Buspirone HCl Tablets,Strides Pharma Inc.,"15 mg, 180 count bottle (NDC 64380-743-18)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4533,Buspirone HCl Tablets,Accord Healthcare Inc.,"5 mg, 100 count bottle (NDC 16729-200-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4534,Buspirone HCl Tablets,Accord Healthcare Inc.,"5 mg, 500 count bottle (NDC 16729-200-16)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4535,Buspirone HCl Tablets,Accord Healthcare Inc.,"7.5 mg, 100 count bottle (NDC 16729-201-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4536,Buspirone HCl Tablets,Accord Healthcare Inc.,"10 mg, 100 count bottle (NDC 16729-202-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4537,Buspirone HCl Tablets,Accord Healthcare Inc.,"10 mg, 500 count bottle (NDC 16729-202-16)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4538,Buspirone HCl Tablets,Accord Healthcare Inc.,"15 mg, 60 count bottle (NDC 16729-203-12)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4539,Buspirone HCl Tablets,Accord Healthcare Inc.,"15 mg, 100 count bottle (NDC 16729-203-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4540,Buspirone HCl Tablets,Accord Healthcare Inc.,"30 mg, 60 count bottle (NDC 16729-289-12)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4541,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 100 count bottle (NDC 49884-725-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4542,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 500 count bottle (NDC 49884-725-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4543,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-1140-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4544,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-1140-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4545,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, unit-dose blister pack, 100 count (NDC 51079-985-20)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4546,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 100 count bottle (NDC 0378-1145-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4547,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-1150-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4548,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-1150-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4549,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, unit-dose blister pack, 100 count (NDC 51079-986-20)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4550,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 60 count bottle (NDC 0378-1165-91)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4551,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 180 count bottle (NDC 0378-1165-80)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4552,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 500 count bottle (NDC 0378-1165-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4553,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, unit-dose blister pack, 100 count (NDC 51079-960-20)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4554,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 60 count bottle (NDC 0378-1175-91)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4555,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"30 mg, unit-dose blister pack, 100 count (NDC 51079-994-20)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4556,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 100 count bottle (NDC 64380-741-06)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4557,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 500 count bottle (NDC 64380-741-07)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4558,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 1000 count bottle (NDC 64380-741-08)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4559,Buspirone HCl Tablets,Strides Pharma Inc.,"7.5 mg, 100 count bottle (NDC 64380-787-06)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4560,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 100 count bottle (NDC 64380-742-06)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4561,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 500 count bottle (NDC 64380-742-07)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4562,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 1000 count bottle (NDC 64380-742-08)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4563,Buspirone HCl Tablets,Strides Pharma Inc.,"30 mg, 60 count bottle (NDC 64380-744-03)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4564,Buspirone HCl Tablets,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0093-0053-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4565,Buspirone HCl Tablets,Teva Pharmaceuticals,"5 mg, 500 count bottle (NDC 0093-0053-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4566,Buspirone HCl Tablets,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0093-0054-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4567,Buspirone HCl Tablets,Teva Pharmaceuticals,"10 mg, 500 count bottle (NDC 0093-0054-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4568,Buspirone HCl Tablets,Teva Pharmaceuticals,"15 mg, 100 count bottle (NDC 0093-1003-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4569,Buspirone HCl Tablets,Teva Pharmaceuticals,"15 mg, 500 count bottle (NDC 0093-1003-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4570,Buspirone HCl Tablets,Teva Pharmaceuticals,"30 mg, 60 count bottle (NDC 0093-5200-06)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4571,Buspirone HCl Tablets,Teva Pharmaceuticals,"30 mg, 500 count bottle (NDC 0093-5200-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4572,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"5 mg, 100 count bottle (NDC 68382-180-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4573,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"5 mg, 500 count bottle (NDC 68382-180-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4574,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"10 mg, 100 count bottle (NDC 68382-181-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4575,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"10 mg, 500 count bottle (NDC 68382-181-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4576,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"15 mg, 100 count bottle (NDC 68382-182-01)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4577,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"15 mg, 500 count bottle (NDC 68382-182-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4578,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"30 mg, 60 count bottle (NDC 68382-183-14)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4579,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"30 mg, 500 count bottle (NDC 68382-183-05)",Revised,1/16/2020,,,Available,,Psychiatry,Resolved,1/16/2020,,,2020,
4580,Busulfan Injection,Teva Pharmaceuticals,6 mg/mL  (NDC 45963-640-77),New,5/6/2020,,,,,Hematology,To be Discontinued,5/6/2020,5/6/2020,,2020,discontinued
4581,Calcitriol Injection USP 1MCG /ML,Akorn Pharmaceuticals,"Calcitriol Injection USP, 1 mcg/mL, 1 mL ampule  (NDC 17478-931-01)",Revised,12/2/2019,Available,,,Other,Endocrinology/Metabolism,Current,,,,2020,available
4582,"Calcium Chloride Injection, USP","Hospira, Inc.",1 g/10 mL (100 mg/mL); Ansyr Plastic Syringe (NDC 00409-1631-10),Reverified,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric,Current,,,,2020,limited availability
4583,"Calcium Chloride Injection, USP","Hospira, Inc.",1 g/10 mL (100 mg/mL); LifeShield Abboject Glass Syringe (NDC 00409-4928-34),Reverified,11/20/2020,Available,,,Other,Gastroenterology;Pediatric,Current,,,,2020,available
4584,"Calcium Chloride Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","Calcium Chloride Inj. USP, 10%, 10mL Luer-Jet Prefilled Syringe, (NDC 0548-3304-00), new (NDC 76329-3304-1)",Reverified,10/30/2020,Available,,,Demand increase for the drug,Gastroenterology;Pediatric,Current,,,,2020,available
4585,"Calcium Chloride Injection, USP","Medefil, Inc.","Calcium Chloride Inj. USP, 10%, 10mL Prefilled Syringe, (NDC 64253-900-36)",Reverified,5/8/2020,Available,Check wholesaler for inventory,,Other,Gastroenterology;Pediatric,Current,,,,2020,available
4586,"Calcium Chloride Injection, USP",American Regent/Luitpold,"10% Calcium Chloride Injection, USP, 1 gram/10mL (100mg/mL), single dose vial, (NDC 0517-6710-10)",Reverified,9/29/2020,Available,,,,Gastroenterology;Pediatric,Current,,,,2020,available
4587,"Capreomycin Injection, USP",Akorn Pharmaceuticals,"Capastat Sulfate (Capreomycin for Injection USP) Eq to 1 g Capreomycin activity, 10mL (NDC 17478-080-50)",Revised,7/15/2020,Available,"Available until 2Q 2021. After that, no further supply will be available",,Shortage of an active ingredient,Anti-Infective,Current,,,,2020,available
4588,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,100 mg capsules (NDC 29033-019-12),New,6/19/2019,,,,,Neurology,To be Discontinued,6/19/2019,6/19/2019,,2020,discontinued
4589,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,200 mg capsules (NDC 29033-020-12),New,6/19/2019,,,,,Neurology,To be Discontinued,6/19/2019,6/19/2019,,2020,discontinued
4590,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,300 mg capsules (NDC 29033-004-12),New,6/19/2019,,,,,Neurology,To be Discontinued,6/19/2019,6/19/2019,,2020,discontinued
4591,Carbidopa and Levodopa Extended Release Tablets,Mylan Pharmaceuticals Inc.,"Carbidopa and Levodopa Extended Release Tablets, 25/100 mg (NDC 0378-0088-01)",Revised,7/12/2019,,,,,Neurology,Resolved,7/12/2019,,,2020,
4592,Carbidopa and Levodopa Extended Release Tablets,Mylan Pharmaceuticals Inc.,"Carbidopa and Levodopa Extended Release Tablets, 50/200 mg (NDC 0378-0094-01)",Revised,7/12/2019,,,,,Neurology,Resolved,7/12/2019,,,2020,
4593,Carbidopa and Levodopa Extended Release Tablets,Merck Sharp & Dohme Corp.,"Carbidopa levodopa (50 mg of carbidopa and 200 mg of levodopa)  (SINEMET CR 50-200) sustained-release tablets, (NDC 0006-3919-68)bottles of 100",New,7/17/2019,,To be discontinued on or near November 2019.,,,Neurology,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
4594,Carbidopa and Levodopa Extended Release Tablets,Merck Sharp & Dohme Corp.,"Carbidopa levodopa  (25 mg of carbidopa and 100 mg of levodopa) (SINEMET CR 25-100 ) sustained-release tablets, (NDC 0006-3918-68) bottles of 100",New,7/17/2019,,To be discontinued on or near February 2020.,Available,,Neurology,To be Discontinued,7/17/2019,,,2020,discontinued
4595,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 50MG/200MG 100CT; (NDC 1672907901),Revised,7/12/2019,,,Stocks available to support current customer demand,,Neurology,Resolved,7/12/2019,,,2020,
4596,Carbidopa and Levodopa Extended Release Tablets,Sun Pharmaceutical Industries Inc.,Carbidopa and Levodopa Extended Release Tablets  25-100 mg (NDC  62756-461-88 ),Revised,7/12/2019,,,Available,,Neurology,Resolved,7/12/2019,,,2020,
4597,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 50MG/200MG 1000CT; (NDC 1672907917),Revised,7/12/2019,,,Stocks available to support current customer demand,,Neurology,Resolved,7/12/2019,,,2020,
4598,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 25MG/100MG 100CT; (NDC 1672907801),Revised,7/12/2019,,,Due to manufacturing constraints; we estimate the delay to continue until January 2020,,Neurology,Resolved,7/12/2019,,,2020,
4599,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 25MG/100MG 1000CT; (NDC 1672907817),Revised,7/12/2019,,,Due to manufacturing constraints; we estimate the delay to continue until January 2020,,Neurology,Resolved,7/12/2019,,,2020,
4600,Carbidopa and Levodopa Extended Release Tablets,Sun Pharmaceutical Industries Inc.,Carbidopa and Levodopa Extended Release Tablets  50-200 (NDC 62756-457-88),Revised,7/12/2019,,,Available,,Neurology,Resolved,7/12/2019,,,2020,
4601,Carbinoxamine Maleate,"Endo Pharmaceuticals, Inc.",4 mg/5 mL oral solution (NDCs 64376-612-16 and 64376-612-40),Revised,9/11/2019,,,,,Pulmonary/Allergy,To be Discontinued,9/11/2019,9/11/2019,,2020,discontinued
4602,Carbinoxamine Maleate,"Endo Pharmaceuticals, Inc.",4 mg tablets (NDC 64376-605-01),Revised,9/11/2019,,,,,Pulmonary/Allergy,To be Discontinued,9/11/2019,9/11/2019,,2020,discontinued
4603,Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose,"Chiesi USA, Inc.",Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose (NDC 10122-326-10),New,3/20/2018,,The decision to discontinue the 0.2 mg/mL in 5% Dextrose formulation was business related.  Other formulations of Cardene IV remain available.,,,Cardiovascular,To be Discontinued,3/20/2018,3/20/2018,,2020,discontinued
4604,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100’s count bottle (NDC 00603-2582-21),New,3/18/2019,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/2019,3/18/2019,,2020,discontinued
4605,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",500's count bottle (NDC 00603-2582-28),New,3/18/2019,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/2019,3/18/2019,,2020,discontinued
4606,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100's count bottle (NDC 00603-2582-32),New,3/18/2019,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/2019,3/18/2019,,2020,discontinued
4607,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 250 mg 30 count bottle (NDC 0037-2250-30)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4608,"Carisoprodol Tablets, USP",Ingenus Pharmaceuticals LLC,"350 mg, 100 count tablets (NDC 50742-656-01)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4609,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 100 count (NDC 0591-5513-01)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4610,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 500 count (NDC 0591-5513-05)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4611,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 1000 count (NDC 0591-5513-10)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4612,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 100 count (NDC 50228-109-01)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4613,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 500 count (NDC 50228-109-05)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4614,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 50228-109-10)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4615,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 60429-508-10)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4616,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 100 count (NDC 42543-700-01)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4617,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 500 count (NDC 42543-700-05)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4618,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 42543-700-10)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4619,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100’s count bottle (NDC 00603-2582-21),Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4620,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",500's count bottle (NDC 00603-2582-28),Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4621,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100's count bottle (NDC 00603-2582-32),Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4622,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 250 mg, 30 count bottle (NDC 0037-2250-30); 100 count bottle (NDC 0037-2250-10)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4623,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 350 mg, 100 count bottle (NDC 0037-2001-01)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4624,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 16714-510-01)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4625,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 16714-510-02)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4626,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 16714-510-03)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4627,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 61442-451-01)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4628,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 61442-451-05)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4629,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 61442-451-10)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4630,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 59746-705-01)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4631,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 59746-705-05)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4632,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 59746-705-05)",Revised,5/19/2020,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/2020,,,2020,
4633,"Carisoprodol, Aspirin, and Codeine Phosphate Tablets USP",Ingenus Pharmaceuticals LLC,200 mg/325 mg/16 mg (NDC 50742-256-01),New,9/1/2020,,,,,Musculoskeletal,To be Discontinued,9/1/2020,9/1/2020,,2020,discontinued
4634,Caspofungin Acetate Injection,Mylan Institutional,50 mg (NDC 67457-831-50),New,7/23/2020,,,,,Anti-Infective;Pediatric,To be Discontinued,7/23/2020,7/23/2020,,2020,discontinued
4635,Cefazolin Injection,"Hospira, Inc.",1g Single-dose ADD-Vantage Vial (NDC 00409-2585-01,Reverified,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: February 2021,,,Demand increase for the drug,Anti-Infective,Current,,,,2020,limited availability
4636,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 10 g (10 vials) (NDC 60505-6143-04),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4637,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1100-1),Reverified,11/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4638,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",300 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1300-1),Reverified,11/20/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4639,Cefazolin Injection,Sagent Pharmaceuticals,1g 25 vials (NDC 25021-101-10),Reverified,10/22/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4640,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 1 gram/50 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3503)(NDC 0338-3503-41)",Revised,10/28/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4641,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 2 gram/100 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3508)(NDC 0338-3508-41)",Revised,10/28/2020,Product on allocation for existing customers,,,Other,Anti-Infective,Current,,,,2020,limited availability
4642,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 1 g (25 vials) (NDC 60505-6142-05),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4643,Cefazolin Injection,Sagent Pharmaceuticals,10g 10 vials (NDC 25021-102-99),Reverified,10/22/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4644,Cefazolin Injection,Sagent Pharmaceuticals,500mg 25 vials (NDC 25021-100-10),Reverified,10/22/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4645,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 2 gram/50 mL in DUPLEX Catalog 3105-11 (NDC 00264-3105-11),Reverified,9/8/2020,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,,2020,limited availability
4646,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 1 gram/50 mL in DUPLEX Catalog 3103-11 (NDC 0264-3103-11),Reverified,9/8/2020,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,,2020,limited availability
4647,Cefazolin Injection,WG Critical Care,500mg Cefazolin SDV (NDC 44567-706-25),Reverified,11/18/2020,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4648,Cefazolin Injection,WG Critical Care,1g Cefazolin SDV (NDC 44567-707-25),Reverified,11/18/2020,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4649,Cefazolin Injection,WG Critical Care,10g Cefazolin PBP (NDC 44567-708-10),Reverified,11/18/2020,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4650,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Reverified,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2020,discontinued
4651,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Revised,10/2/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/2/2020,10/2/2020,,2020,discontinued
4652,Cefazolin Injection,"Hospira, Inc.",10 g Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-0806-01),Revised,10/2/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/2/2020,10/2/2020,,2020,discontinued
4653,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9923-90),Reverified,7/22/2020,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4654,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9924-90),Reverified,7/22/2020,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4655,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mg/ 100 mL vial (NDC 0143-9983-03),Reverified,7/22/2020,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4656,Cefazolin Injection,Sandoz,Cefazolin Na Injection 500 mg (NDC 0781-3450-95),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4657,Cefazolin Injection,Sandoz,Cefazolin Na Injection 1 g (NDC 0781-3451-96),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4658,Cefazolin Injection,Sandoz,Cefazolin Na Injection 10 g (NDC 0781-3452-95),Reverified,11/13/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4659,Cefdinir Capsules,Sandoz,300 mg capsules  (NDC 0781-2176-60),New,7/9/2020,,,,,Anti-Infective,To be Discontinued,7/9/2020,7/9/2020,,2020,discontinued
4660,Cefepime Injection,"Hospira, Inc.",1g; Single Dose Vial (NDC 00409-9566-01),Reverified,11/20/2020,Available,,,Other,Anti-Infective;Pediatric,Current,,,,2020,available
4661,Cefepime Injection,"Hospira, Inc.",2g; Single Dose Vial (NDC 00409-9735-01),Reverified,11/20/2020,Available,,,Other,Anti-Infective;Pediatric,Current,,,,2020,available
4662,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (10 vials) (NDC 60505-6146-04),Reverified,11/13/2020,Available,,,,Anti-Infective;Pediatric,Current,,,,2020,available
4663,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (1 vial) (NDC 60505-6146-00),Reverified,11/13/2020,Available,,,,Anti-Infective;Pediatric,Current,,,,2020,available
4664,Cefepime Injection,Apotex Corp.,Cefepime for Injection 2 g (10 vials) (NDC 60505-6147-04),Reverified,11/13/2020,Available,,,,Anti-Infective;Pediatric,Current,,,,2020,available
4665,Cefepime Injection,Apotex Corp.,Cefepime for Injection 2 g (1 vial) (NDC 60505-6147-00),Reverified,11/13/2020,Available,,,,Anti-Infective;Pediatric,Current,,,,2020,available
4666,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (1 vial) (NDC 60505-0834-00),Revised,3/1/2019,,"Product was manufactured by Hospira, no longer distributed by Apotex",,,Anti-Infective;Pediatric,To be Discontinued,3/1/2019,3/1/2019,,2020,discontinued
4667,Cefepime Injection,B. Braun Medical Inc.,Cefepime 1 g (NDC 0264-3193-11),Reverified,9/9/2020,Product on allocation to contracted custormers,,,Other,Anti-Infective;Pediatric,Current,,,,2020,limited availability
4668,Cefepime Injection,B. Braun Medical Inc.,Cefepime 2 g (NDC 0264-3195-11),Reverified,9/9/2020,Product on allocation to contracted customers,,,Other,Anti-Infective;Pediatric,Current,,,,2020,limited availability
4669,Cefepime Injection,Sagent Pharmaceuticals,1 g vial (NDC 25021-121-20),Revised,10/22/2020,Available.,,,,Anti-Infective;Pediatric,Current,,,,2020,available
4670,Cefepime Injection,Sagent Pharmaceuticals,2 g vial (NDC 25021-122-50),Revised,10/22/2020,On Allocation. Estimated availability Nov 2020,,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2020,limited availability
4671,Cefepime Injection,"Fresenius Kabi USA, LLC","1 g single dose vial, sterile powder (NDC 63323-326-20)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2020,available
4672,Cefepime Injection,"Fresenius Kabi USA, LLC","2 g single dose vial, sterile powder (NDC 63323-340-20)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2020,available
4673,Cefepime Injection,Baxter Healthcare,"Cefepime Injection, 1 gram/50mL, GALAXY Container (NDC 0338-1301-41)",Reverified,10/28/2020,Available,,,,Anti-Infective;Pediatric,Current,,,,2020,available
4674,Cefepime Injection,Baxter Healthcare,"Cefepime Injection, 2 gram/100mL, GALAXY Container (NDC 0338-1301-48)",Reverified,10/28/2020,Available,,,,Anti-Infective;Pediatric,Current,,,,2020,available
4675,Cefepime Injection,"Hospira, Inc.",Maxipime 2 g; Single Dose ADD-Vantage Glass Vial (NDC 00409-0218-01),Revised,8/25/2020,,Discontinuation of the manufacture of the drug,,,Anti-Infective;Pediatric,To be Discontinued,8/25/2020,8/25/2020,,2020,discontinued
4676,Cefepime Injection,"Hospira, Inc.",Maxipime 1 g; Single Dose ADD-Vantage Glass Vial (NDC 00409-0217-01),Revised,8/25/2020,,Discontinuation of the manufacture of the drug,,,Anti-Infective;Pediatric,To be Discontinued,8/25/2020,8/25/2020,,2020,discontinued
4677,Cefepime Injection,"Hospira, Inc.",Maxipime 1 g; Single Dose Glass Fliptop Vial (NDC 00409-0219-01),Revised,8/25/2020,,Discontinuation of the manufacture of the drug,,,Anti-Infective;Pediatric,To be Discontinued,8/25/2020,8/25/2020,,2020,discontinued
4678,Cefepime Injection,"Hospira, Inc.",Maxipime 2 g; Single Dose Glass Fliptop Vial (NDC 00409-0220-01),Revised,8/25/2020,,Discontinuation of the manufacture of the drug,,,Anti-Infective;Pediatric,To be Discontinued,8/25/2020,8/25/2020,,2020,discontinued
4679,Cefepime Injection,WG Critical Care,1 g vial (NDC 44567-0240-10),Reverified,11/18/2020,Available,Please check wholesalers and distributors for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2020,available
4680,Cefepime Injection,WG Critical Care,2 g vial (NDC 44567-0241-10),Reverified,11/18/2020,Available,Please check wholesalers and distributors for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2020,available
4681,Cefepime Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak Pharmacy Bulk Package (NDC 66288-8100-1),Reverified,11/20/2020,Available,,,,Anti-Infective;Pediatric,Current,,,,2020,available
4682,Cefotaxime Sodium Injection,"SteriMax, Inc.","2g/vial, (NDC 21586-012-2)",Revised,11/16/2020,Available,"SteriMax in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact FFF Enterprises at 1-800-843-7477",,Other,Anti-Infective;Pediatric,Current,,,,2020,available
4683,Cefotaxime Sodium Injection,"SteriMax, Inc.","1g/vial, (NDC 21586-011-2)",Revised,11/16/2020,Available,"SteriMax in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact FFF Enterprises at 1-800-843-7477",,Other,Anti-Infective;Pediatric,Current,,,,2020,available
4684,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9930-10),Revised,7/22/2020,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2020,not available
4685,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9931-25),Revised,7/22/2020,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2020,not available
4686,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2 g/ 10 mL vial (NDC 0143-9933-25),Revised,7/22/2020,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2020,not available
4687,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 g/ 100 mL vial (NDC 0143-9935-01),Revised,7/22/2020,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2020,not available
4688,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),Reverified,11/10/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4689,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 1g Vial 10 (NDC 52565-0052-10),Revised,3/31/2020,,Low volume available; short-dated product; Teligent has made a business decision to discontinue manufacture of this presentation.,,,Anti-Infective,To be Discontinued,3/31/2020,3/31/2020,,2020,discontinued
4690,Cefotetan Disodium Injection,B. Braun Medical Inc.,1 gram/50 mL in DUPLEX (NDC 00264-3173-11),Revised,8/28/2020,Product not available,,,Other,Anti-Infective,Current,,,,2020,not available
4691,Cefotetan Disodium Injection,B. Braun Medical Inc.,2 gram/50 mL in DUPLEX (NDC 00264-3175-11),Revised,8/28/2020,Product not available,,,Other,Anti-Infective,Current,,,,2020,not available
4692,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",1 g SDV (NDC 63323-0385-10),Revised,11/16/2020,8 mos expiry available by request. Next release December 2020.,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,,2020,limited availability
4693,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",2 g SDV (NDC 63323-0386-20),Revised,11/16/2020,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,,2020,available
4694,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",10 g PBP (NDC 63323-0396-61),Revised,11/16/2020,No release date available at this time.,,,Manufacturing delay,Anti-Infective,Current,,,,2020,not available
4695,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1g vial (NDC 0143-9878-25),Revised,7/22/2020,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4696,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2g vial (NDC 0143-9877-25),Revised,7/22/2020,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4697,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10g vial (NDC 0143-9876-10),Revised,7/22/2020,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4698,"Cefoxitin for Injection, USP",Apotex Corp.,1 g (25 vials) (NDC 60505-0759-05),Reverified,11/13/2020,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2020,discontinued
4699,"Cefoxitin for Injection, USP",Apotex Corp.,2 g (25 vials) (NDC 60505-0760-05),Reverified,11/13/2020,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2020,discontinued
4700,"Cefoxitin for Injection, USP",Apotex Corp.,10 g (10 vials) (NDC 60505-0761-04),Reverified,11/13/2020,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2020,discontinued
4701,"Cefoxitin for Injection, USP","Fresenius Kabi USA, LLC",1 g per vial; SDV; (NDC 63323-341-25),Revised,11/16/2020,Available,Check wholesalers for inventory,,Manufacturing delays,Anti-Infective,Current,,,,2020,available
4702,"Cefoxitin for Injection, USP","Fresenius Kabi USA, LLC",2 grams per vial; SDV; (NDC 63323-342-25),Revised,11/16/2020,Available,Check wholesalers for inventory,,Manufacturing delays,Anti-Infective,Current,,,,2020,available
4703,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"10 g, package of 10 vials (NDC 25021-111-99)",Revised,10/22/2020,Available,,,,Anti-Infective,Current,,,,2020,available
4704,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"1 g, package of 10 vials (NDC 25021-109-10)",Revised,10/22/2020,On backorder. Estimated availability Dec 2020,,,Manufacturing delay,Anti-Infective,Current,,,,2020,not available
4705,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"2 g, package of 10 vials (NDC 25021-110-20)",Revised,10/22/2020,On allocation. Estimated availability Nov 2020,,,Manufacturing delay,Anti-Infective,Current,,,,2020,limited availability
4706,"Cefoxitin for Injection, USP",WG Critical Care,1 g (NDC 44567-245-25),Reverified,11/18/2020,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4707,"Cefoxitin for Injection, USP",WG Critical Care,2 g (NDC 44567-246-25),Reverified,11/18/2020,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4708,"Cefoxitin for Injection, USP",WG Critical Care,10 g (NDC 44567-247-10),Reverified,11/18/2020,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
4709,"Cefoxitin for Injection, USP",B. Braun Medical Inc.,Cefoxitin Injection 2 gram/50 mL in DUPLEX Catalog 3125-11 (NDC NDC 00264-3125-11),Revised,9/8/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
4710,"Cefoxitin for Injection, USP",B. Braun Medical Inc.,Cefoxitin Injection 1 gram/50 mL in DUPLEX Catalog 3123-11 (NDC 0264-3123-11),Revised,9/8/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
4711,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 1g Bag 24 x 50mL (NDC 24987-0412-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2020,discontinued
4712,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 2g Bag 24 x 50mL (NDC 24987-0413-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2020,discontinued
4713,Cefuroxime Sodium (Zinacef) Injection,"Teligent Pharma, Inc.",Cefuroxime Sodium (Zinacef) Premix Sol Frozen 1.5g Bag 24 x 50mL (NDC 24987-0425-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2020,discontinued
4714,Cetirizine Hydrochloride,Torrent Pharma Inc.,5 mg/5 mL oral syrup (NDC 13668-596-07),New,4/24/2019,,,,,Pulmonary/Allergy,To be Discontinued,4/24/2019,4/24/2019,,2020,discontinued
4715,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,5 mg (NDC 43547-251-10),New,11/19/2019,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/2019,11/19/2019,,2020,discontinued
4716,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,10 mg (NDC 43547-252-10),New,11/19/2019,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/2019,11/19/2019,,2020,discontinued
4717,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,25 mg (NDC 43547-253-10),New,11/19/2019,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/2019,11/19/2019,,2020,discontinued
4718,Chloroquine Phosphate Tablets,Natco Pharma Limited,"250 mg, 50 count bottle (NDC 64980-177-50); distributed by Rising Pharmaceuticals, to order contact: 201-961-9000",Revised,5/8/2020,,,Available,,Anti-Infective,Resolved,5/8/2020,,,2020,
4719,Chloroquine Phosphate Tablets,Natco Pharma Limited,"500 mg, 25 count bottle (NDC 64980-178-02); distributed by Rising Pharmaceuticals, to order contact: 201-961-9000",Revised,5/8/2020,,,Available,,Anti-Infective,Resolved,5/8/2020,,,2020,
4720,Chlorothiazide (Diuril) Oral Suspension,Bausch Health,250 mg/5 mL (50 mg/mL) 237 mL (NDC 65649-311-12),New,8/12/2020,Product availability is planned for 18-Sep-2020.,"Distributor-Salix Pharmaceuticals, Inc.: 1-800-321-4576",,Shortage of an inactive ingredient,Cardiovascular;Pediatric,Current,,,,2020,not available
4721,Chlorothiazide Injection,Mylan Institutional,500 mg (NDC 67457-263-30),New,4/8/2020,,Expected discontinuation May 2020,,,Cardiovascular,To be Discontinued,4/8/2020,4/8/2020,,2020,discontinued
4722,Chlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0150-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4723,Chlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0162-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4724,Chlorpheniramine Maleate; Hydrocodone Bitartrate; Pseudoephedrine Hydrochloride Oral Solution,"Paddock Laboratories, LLC",4 mg/5 mL; 5 mg/5 mL; 60 mg/5 mL (NDC 0574-1103-16),New,6/12/2019,,,,,Pulmonary/Allergy,To be Discontinued,6/12/2019,6/12/2019,,2020,discontinued
4725,Chlorpropamide Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-0197-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4726,Chlorpropamide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0210-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4727,Ciprofloxacin Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 50 count bottle (NDC 0378-1743-89)",New,5/2/2019,,,,,Anti-Infective,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4728,Ciprofloxacin Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"1000 mg, 50 count bottle (NDC 0378-1745-89)",New,5/2/2019,,,,,Anti-Infective,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4729,Cisatracurium Besylate Injection,Teva Pharmaceuticals,200 mg/20 mL (10 mg/mL) Single-dose vials (NDC 0703-2045-03),Reverified,11/19/2020,Product is available,"Teva is experiencing a significant increase in demand, due in part to the pandemic",,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4730,Cisatracurium Besylate Injection,Teva Pharmaceuticals,20 mg/10 mL (2 mg/mL) Multiple-dose vials (NDC 0703-2056-03),Reverified,11/19/2020,Product is available,"Teva is experiencing a significant increase in demand, due in part to the pandemic",,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4731,Cisatracurium Besylate Injection,Teva Pharmaceuticals,10 mg/5 mL (2 mg/mL) Single-dose vials (NDC 0703-2033-03),Reverified,11/19/2020,Product is available,"Teva is experiencing a significant increase in demand, due in part to the pandemic",,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4732,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/mL 10 vials (NDC 70069-141-10),New,4/8/2020,Limited supply available. Please contact wholesaler for availability. Somerset is ramping up production to meet increased demand.,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
4733,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/ml 10 vials (NDC 70069-161-10),New,4/8/2020,Limited supply available. Please contact wholesaler for availability. Somerset is ramping up production to meet increased demand.,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
4734,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",10mg/mL 10 vials (NDC 70069-151-10),New,4/8/2020,Limited supply available. Please contact wholesaler for availability. Somerset is ramping up production to meet increased demand.,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
4735,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",10 mg per 5 mL single dose vial (NDC 71288-712-06),Revised,7/22/2020,"Backordered. Next Delivery: July 2020, August 2020 and November 2020.",Prioritized manufacturing and increased production due to overall demand.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4736,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",200 mg per 20 mL single dose vial (NDC 71288-713-21),Revised,7/22/2020,"Backordered. Next Delivery: July 2020, August 2020 and November 2020.",Prioritized manufacturing and increased production due to overall demand.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4737,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",20 mg per 10 mL  multi dose vial (NDC 71288-712-11),Revised,7/22/2020,"Backordered. Next Delivery: July 2020, August 2020 and November 2020.",Prioritized manufacturing and increased production due to overall demand.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4738,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","10 mg (base) per 5 mL (2 mg per mL), Single dose vial, PF, (NDC 63323-416-05)",Revised,11/16/2020,Backordered. Next release Q2 - 2021.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4739,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","20 mg per 10 mL (2 mg per mL), Multiple dose vial, (NDC 63323-417-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4740,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), Single dose vial, PF, (NDC 63323-418-20)",Revised,11/16/2020,Backordered. Next release Q2 2021.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4741,Cisatracurium Besylate Injection,Sandoz,2mg/ml; 5mL (NDC 0781-3150-95),Reverified,11/13/2020,Available,,,,Anesthesia,Current,,,,2020,available
4742,Cisatracurium Besylate Injection,Sandoz,2mg/mL; 10mL (NDC 0781-3152-95),Reverified,11/13/2020,Available,,,,Anesthesia,Current,,,,2020,available
4743,Cisatracurium Besylate Injection,Sandoz,1-mg/mL; 20mL (NDC 0781-3153-95_,Reverified,11/13/2020,Available,,,,Anesthesia,Current,,,,2020,available
4744,Cisatracurium Besylate Injection,"Hospira, Inc.",10mg/5mL (2mg/mL) Single Dose Vial (NDC 00409-1098-02),Revised,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: December 2020,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
4745,Cisatracurium Besylate Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose Vial (NDC 00409-1103-01),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: March 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
4746,Cisatracurium Besylate Injection,"Hospira, Inc.",20mg/10mL (2mg/mL) Multi-Dose Vial (NDC 00409-1208-01),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: March 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
4747,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 5 mL Single-dose vial (NDC 0074-4378-05, 0074-4378-24, 0074-4378-36)",Revised,11/19/2020,Product available,Please check with your wholesaler for available inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4748,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 10 mL Multiple-dose vial (NDC 0074-4380-10, 0074-4380-79, 0074-4380-81)",Revised,11/19/2020,Product available,Please check with your wholesaler for available inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4749,Cisatracurium Besylate Injection,Abbvie,"10 mg/mL, 20 mL Single-dose vial (NDC 0074-4382-20, 0074-4382-91, 0074-4382-93)",Revised,11/19/2020,Limited availability,Please check with your wholesaler for available inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
4750,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg / 10 mL Multiple-Dose Vial, Package of 10 vials (ndc 55150-286-10)",Reverified,11/20/2020,Available,Check wholesaler for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4751,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical solution 1 x 60 pledgets (NDC 0009-3116-14),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2020,discontinued
4752,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical solution 1 x 60 mL applicator bottle (NDC 0009-3116-02),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2020,discontinued
4753,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical gel 1 x 60 g tube (NDC 0009-3331-01),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2020,discontinued
4754,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical gel 1 x 30 g tube (NDC 0009-3331-02),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2020,discontinued
4755,"Clindamycin Injection, USP",Mylan Institutional,6 mL / vial (NDC 67457-816-06),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2020,discontinued
4756,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",300 mg per 2 mL (150 mg per mL); SDV; (NDC 63323-282-02),New,5/10/2019,,3 & 6 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/2019,5/10/2019,,2020,discontinued
4757,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",600 mg per 4 mL (150 mg per mL); SDV; (NDC 63323-282-04),New,5/10/2019,,6 & 8 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/2019,5/10/2019,,2020,discontinued
4758,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",900 mg per 6 mL (150 mg per mL); SDV; (NDC 63323-282-06),New,5/10/2019,,3 & 5 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/2019,5/10/2019,,2020,discontinued
4759,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",9 grams per Pharmacy Bulk Package (150 mg per mL); (NDC 63323-282-60),New,5/10/2019,,8 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/2019,5/10/2019,,2020,discontinued
4760,Clindamycin Phosphate and Benzoyl Peroxide (Duac) Topical Gel,GlaxoSmithKline,10 mg; 50 mg  (NDC 0145-2371-05),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately November 2019.,,,Dermatology,To be Discontinued,6/28/2019,6/28/2019,,2020,discontinued
4761,Clomiphene Citrate,Teva Pharmaceuticals,50 mg/1 unit tablet (NDC 0093-0041-65),New,6/10/2019,,,,,Reproductive,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
4762,Clomiphene Citrate,Teva Pharmaceuticals,50 mg/1 unit tablet (NDC 0093-0041-03),New,6/10/2019,,,,,Reproductive,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
4763,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg  (90s)(NDC 0378-1910-77),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4764,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (100s)(NDC 0378-1910-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4765,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (1000s)(NDC 0378-1910-10),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4766,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (90s)(NDC 0378-1912-77),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4767,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (100s)(NDC 0378-1912-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4768,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (1000s)(NDC 0378-1912-10),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4769,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (100s)(NDC 0378-1914-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4770,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (500s)(NDC 0378-1914-05),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4771,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0185-0063-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4772,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0185-0063-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4773,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0185-0063-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4774,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0781-8018-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4775,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0781-8018-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4776,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0781-8018-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4777,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-752-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4778,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-752-02)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4779,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-469-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4780,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-469-02)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4781,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0185-0064-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4782,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0185-0064-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4783,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0185-0064-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4784,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0781-5567-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4785,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0781-5567-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4786,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0781-5567-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
4787,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg Tablet, 100 CT Bottle (NDC 18860-104-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4788,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","12.5 mg tablet, 100 CT Bottle (NDC 18860-101-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4789,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablets, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-102-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4790,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablet, 100  CT bottle (NDC 18860-102-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4791,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-104-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4792,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-105-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4793,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 100 CT Bottle (NDC 18860-105-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4794,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-106-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4795,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablets, 100 CT Bottle (NDC 18860-106-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
4796,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BK0/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON-PVC. (NDC 24571-113-06)",Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4797,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK0/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-108-06)",Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4798,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (DC 24571-114-06)",Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4799,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-105-06)",Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4800,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/3.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-103-06)",Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4801,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-102-06)",Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4802,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol B22GK4/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-111-06)",Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4803,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM BK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-116-06),Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4804,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM B22K4/0 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-117-06),Reverified,10/28/2020,Available,,,,Renal,Current,,,,2020,available
4805,Coumadin Tablets,Bristol Myers Squibb Co.,1 mg (NDC 0056-0169-70),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4806,Coumadin Tablets,Bristol Myers Squibb Co.,1 mg (NDC 0056-0169-75),New,4/24/2020,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4807,Coumadin Tablets,Bristol Myers Squibb Co.,2 mg (NDC 056-0170-70),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4808,Coumadin Tablets,Bristol Myers Squibb Co.,2 mg (NDC 0056-0170-75),New,4/24/2020,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4809,Coumadin Tablets,Bristol Myers Squibb Co.,2 1/2 mg (NDC 0056-0176-70),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4810,Coumadin Tablets,Bristol Myers Squibb Co.,2 1/2 mg (NDC 0056-0176-75),New,4/24/2020,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4811,Coumadin Tablets,Bristol Myers Squibb Co.,3 mg (NDC 0056-0188-70),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4812,Coumadin Tablets,Bristol Myers Squibb Co.,3 mg (NDC 0056-0188-75),New,4/24/2020,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4813,Coumadin Tablets,Bristol Myers Squibb Co.,4 mg (NDC 0056-0168-70),New,4/24/2020,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4814,Coumadin Tablets,Bristol Myers Squibb Co.,4 mg (NDC 0056-0168-75),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4815,Coumadin Tablets,Bristol Myers Squibb Co.,5 mg (NDC 0056-0172-70),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4816,Coumadin Tablets,Bristol Myers Squibb Co.,5 mg (NDC 0056-0172-75),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4817,Coumadin Tablets,Bristol Myers Squibb Co.,6 mg (NDC 0056-0189-70),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4818,Coumadin Tablets,Bristol Myers Squibb Co.,6 mg (NDC 0056-0189-75),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4819,Coumadin Tablets,Bristol Myers Squibb Co.,7 1/2  mg (NDC 0056-0173-70),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4820,Coumadin Tablets,Bristol Myers Squibb Co.,7 1/2 mg (NDC 0056-0173-75),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4821,Coumadin Tablets,Bristol Myers Squibb Co.,10 mg (NDC 0056-0174-70),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4822,Coumadin Tablets,Bristol Myers Squibb Co.,10 mg (NDC 0056-0174-75),New,4/24/2020,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
4823,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 2ML (NDC 0065-0359-02)",New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4824,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 5ML (NDC 0065-0359-05)",New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4825,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 0.5% 15ML (NDC 0065-0395-15),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4826,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 2ML (NDC 0065-0396-02),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4827,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 5ML (NDC 0065-0396-05),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4828,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 2ML (NDC 0065-0397-02),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4829,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 5ML (NDC 0065-0397-05),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4830,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 15ML (NDC 0065-0397-15),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4831,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 15ML (NDC 61314-396-01),New,11/9/2020,Available,"Product distributed by Sandoz. Company Contact Information:
800-525-8747",,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4832,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 2ML (NDC 61314-396-03),New,11/9/2020,Available,"Product distributed by Sandoz. Company Contact Information:
800-525-8747",,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
4833,Cyclopentolate Ophthalmic Solution,Bausch & Lomb Incorporated,"Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%, 2 mL bottle (NDC 24208-735-01) and 15 mL bottle (NDC 24208-735-06)",New,11/9/2020,Product available for existing clients/business,"Distributed by Bausch + Lomb, a division of Bausch Health US, LLC – 1-800-321-4576",,Other,Ophthalmology,Current,,,,2020,limited availability
4834,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 15mL 1 Bottle (NDC 17478-097-12)",New,11/9/2020,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,,2020,not available
4835,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 2mL, 1 Bottle (NDC 17478-097-02)",New,11/9/2020,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,,2020,not available
4836,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 5mL 1 Bottle/EA (NDC 17478-097-10)",New,11/9/2020,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,,2020,not available
4837,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Opht Sol 1% 10mg/mL, 2mL, 1 Bottle (NDC 17478-100-02)",New,11/9/2020,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,,2020,not available
4838,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Ophth 1% 10mg/mL, 15mL, 1 Bottle (NDC 17478-100-12)",New,11/9/2020,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,,2020,not available
4839,Cysteamine Hydrochloride Ophthalmic Solution,"Leadiant Biosciences, Inc.","0.44%, 15 mL bottle (NDC 54482-020-01)",New,10/27/2020,Shortage anticipated from November 2020; Estimated shortage duration:  Unknown,"For more information please contact 1-866-634-2765, Leadiant@tmac.com, or go to  www.leadiant.com",,Delay in manufacturing,Ophthalmology,Current,,,,2020,unclear
4840,Cysteine Hydrochloride Injection,"Exela Pharma Sciences, LLC",Elcys (Cysteine Hydrochloride injection) 500mg/10ml Single-dose vials (NDC 51754-1007-1) Packaged as 10 per carton (NDC 51754-1007-3),Revised,9/3/2019,,,Available,,Other;Pediatric,Resolved,9/3/2019,,,2020,
4841,Darifenacin Extended-release Tablets,Teva Pharmaceuticals,"7.5 mg, 30 count bottle (NDC 0591-4375-30)",New,6/26/2020,,Discontinuation of manufacturing,,,Urology,To be Discontinued,6/26/2020,6/26/2020,,2020,discontinued
4842,Darifenacin Extended-release Tablets,Teva Pharmaceuticals,"15 mg, 30 count bottle (NDC 0591-4380-30)",New,6/26/2020,,Discontinuation of manufacturing,,,Urology,To be Discontinued,6/26/2020,6/26/2020,,2020,discontinued
4843,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"Extended release, 7.5 mg, 90 count bottle (NDC 0591-4375-19)",New,6/17/2020,,Discontinuance of Manufacturing,,,Urology,To be Discontinued,6/17/2020,6/17/2020,,2020,discontinued
4844,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"15 mg, 30 count bottle (NDC: 0591-4380-30)",New,6/17/2020,,Discontinuance of Manufacturing,,,Urology,To be Discontinued,6/17/2020,6/17/2020,,2020,discontinued
4845,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 30 (NDC 0430-0171-15)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2020,discontinued
4846,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of  90 (NDC 0430-0171-23)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2020,discontinued
4847,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg , 337500 TABLETS in 1 DRUM (NDC 0430-0171-00)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2020,discontinued
4848,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 7 (NDC 0430-0171-96)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2020,discontinued
4849,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 0430-0170-15)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2020,discontinued
4850,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of  90 (NDC 0430-0170-23)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2020,discontinued
4851,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, 337500 TABLETS in 1 DRUM (NDC 0430-0170-00)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2020,discontinued
4852,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, Bottle of 7 (NDC 0430-0170-96)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2020,discontinued
4853,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 15 mg Bottle of 30, (NDC 10370-171-11)",New,10/30/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/2019,10/30/2019,,2020,discontinued
4854,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 15 mg Bottle of 90 (NDC 10370-171-09)",New,10/30/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/2019,10/30/2019,,2020,discontinued
4855,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 10370-170-11)",New,10/30/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/2019,10/30/2019,,2020,discontinued
4856,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 7.5 mg Bottle of 90 (NDC 10370-170-09)",New,10/30/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/2019,10/30/2019,,2020,discontinued
4857,Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets,Abbvie,"200mg; 8.33mg; 50mg; 33.33 tablets, (NDC 0074-0063-28)",New,5/22/2018,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary.",,,Antiviral,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
4858,Deferasirox Tablets,Teva Pharmaceuticals,180 mg/1 (NDC 00093-3516-56),New,7/20/2020,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/2020,7/20/2020,,2020,discontinued
4859,Deferasirox Tablets,Teva Pharmaceuticals,90 mg/1 (NDC 00093-3517-56),New,7/20/2020,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/2020,7/20/2020,,2020,discontinued
4860,Deferasirox Tablets,Teva Pharmaceuticals,360 mg/1 (NDC 00093-3515-56),New,7/20/2020,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/2020,7/20/2020,,2020,discontinued
4861,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","500 mg per vial, Single use vial, Carton of 4 vials (NDC 52609-4505-6)",Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2020,
4862,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","2 g per vial, Single use vial, Carton of 4 vials (NDC 52609-4504-6)",Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2020,
4863,"Deferoxamine Mesylate for Injection, USP","Hospira, Inc.",500 mg; Single Dose Glass Fliptop Vial (NDC 00409-2336-10),Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2020,
4864,"Deferoxamine Mesylate for Injection, USP","Hospira, Inc.",2 g; Single Dose Glass Fliptop Vial (NDC 00409-2337-25),Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2020,
4865,"Deferoxamine Mesylate for Injection, USP","Fresenius Kabi USA, LLC","500 mg per vial, 10 mL vial (NDC 63323-597-10)",Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2020,
4866,Delavirdine Mesylate (RESCRIPTOR) Tablets,ViiV Healthcare,200 mg tablets; bottles of 180 tablets (NDC 49702-225-17),New,6/26/2019,,This decision is business-related and the anticipated final date for availability to patients is January 2020.,,,Antiviral,To be Discontinued,6/26/2019,6/26/2019,,2020,discontinued
4867,"Demeclocycline Hydrochloride Tablets, USP",Teva Pharmaceuticals,150 mg 100 count (NDC 0555-0701-02),New,4/21/2020,,Teva had evaluated the market and decided to discontinue the product.,,,Anti-Infective,To be Discontinued,4/21/2020,4/21/2020,,2020,discontinued
4868,"Demeclocycline Hydrochloride Tablets, USP",Teva Pharmaceuticals,300 mg 48 count (NDC 0555-0702-84),New,4/21/2020,,Teva had evaluated the market and decided to discontinue the product.,,,Anti-Infective,To be Discontinued,4/21/2020,4/21/2020,,2020,discontinued
4869,Desloratadine Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-4017-01)",New,5/2/2019,,,,,Pulmonary/Allergy,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4870,Desloratadine Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-4017-05)",New,5/2/2019,,,,,Pulmonary/Allergy,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
4871,Desogestrel and Ethinyl Estradiol Tablets (ORTHO-CEPT),Janssen Pharmaceuticals,ORTHO-CEPT (NDC 50458-196-15),Revised,10/8/2014,,Product will be delisted. Last distribution March 2015.,,Discontinuation of the manufacture of the drug.,,To Be Discontinued,10/8/2014,,,2020,discontinued
4872,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection SDV [4 mg / 1 ml] 25PK (NDC 67457-423-12),Reverified,11/10/2020,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4873,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [20 mg / 5 ml] 25PK (NDC 67457-422-54),Reverified,11/10/2020,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4874,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [120 mg / 30 ml] 25 PK (NDC 67457-421-30),Reverified,11/10/2020,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4875,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [100 mg / 10 ml] 10PK (NDC 67457-420-10),Reverified,11/10/2020,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4876,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),4 mg/1 mL SDV (NDC 55150-237-01),Revised,11/20/2020,Backordered — next shipment TBD,Sporadic availability expected.,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,not available
4877,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/5 mL MDV  (NDC 55150-238-05),Revised,11/20/2020,Backordered — next shipment TBD,Sporadic availability expected.,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,not available
4878,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),120 mg/30 mL MDV (NDC 55150-239-30),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4879,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL, 1 mL Single Dose Vial (Preservative Free)(NDC 70069-021-25)",Reverified,9/11/2020,Currently in Stock (we have capacity constraint but product available at this time). Estimated Release Dates: Released Product Available,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4880,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",20 mg per 5 mL (4 mg per mL); MDV;  Amber vial (NDC 63323-165-05),Revised,11/16/2020,"3, 4, 5 month expiry available by request.  Next release November 2020.",Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,limited availability
4881,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",100 mg per 10 mL (10 mg per mL); MDV;  Amber Vial (NDC 63323-516-10),Revised,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4882,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",120 mg per 30 mL (4 mg per mL); MDV; Amber Vial (NDC 63323-165-30),Revised,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4883,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",4 mg per mL (4 mg per mL); SDV; Amber Vial (NDC 63323-165-01),Revised,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4884,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",10 mg per mL (10 mg per mL); SDV; Preservative Free; Amber Vial (NDC 63323-506-01),Revised,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4885,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6145-25)",Reverified,9/17/2020,This presentation is temporarily on backorder.,Shortage duration is unknown at this time.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,not available
4886,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 5 mL vial (NDC 0641-6146-25)",Reverified,9/17/2020,This presentation is temporarily on backorder.,Shortage duration is unknown at this time.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,not available
4887,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-0367-25)",Reverified,9/17/2020,This presentation is temporarily on backorder.,Shortage duration is unknown at this time.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,not available
4888,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),10 mg/1 mL SDV (NDC 55150-304-25),Revised,11/20/2020,Initial availability targeted for end of November 2020,Sporadic availability expected.,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,not available
4889,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),100 mg/10 mL MDV (contains preservative)(NDC 55150-305-10),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4890,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-106-10)",Reverified,10/23/2020,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4891,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-109-10)",Reverified,10/23/2020,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2020,available
4892,Dexmedetomidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mcg/mL, 2 mL vial (NDC 0143-9532-25)",Revised,8/20/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4893,Dexmedetomidine Injection,Sandoz,"200 mcg/2 mL (100 mcg/mL) vial, box of 10 (NDC 0781-3297-95)",New,4/13/2020,,Permanent Discontinuation,,,Anesthesia,To be Discontinued,4/13/2020,4/13/2020,,2020,discontinued
4894,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-239-93)",Revised,11/3/2020,Available,,,,Anesthesia,Current,,,,2020,available
4895,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-432-93), Novaplus",Revised,11/3/2020,Available,,,,Anesthesia,Current,,,,2020,available
4896,Dexmedetomidine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 55150-209-02)",Revised,11/20/2020,Currently on backorder - next shipment anticipated end of Nov 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4897,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 0338-9555-24)",Reverified,10/28/2020,Available,,,,Anesthesia,Current,,,,2020,available
4898,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 0338-9557-12)",Reverified,10/28/2020,Available,,,,Anesthesia,Current,,,,2020,available
4899,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 43066-555-24), Novaplus",Reverified,10/28/2020,Available,,,,Anesthesia,Current,,,,2020,available
4900,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 43066-557-12), Novaplus",Reverified,10/28/2020,Available,,,,Anesthesia,Current,,,,2020,available
4901,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 63323-671-20)",Reverified,11/16/2020,Backordered. Next release December 2020.,,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4902,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 25 (NDC 63323-671-50)",Reverified,11/16/2020,Backordered. Next release December 2020.,,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4903,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 63323-671-00)",Reverified,11/16/2020,Backordered. Next release December 2020.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4904,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 63323-421-02)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4905,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/4 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-600-04)",Revised,11/18/2020,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4906,Dexmedetomidine Injection,HQ Specialty Pharma,"1000 mcg/10 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-601-04)",Revised,11/18/2020,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4907,Dexmedetomidine Injection,HQ Specialty Pharma,"200 mcg/50 mL (4 mcg/mL), single dose bag, box of 24 (NDC 44567-602-24)",Revised,11/18/2020,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4908,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/100 mL (4 mcg/mL), box of 24 (NDC 44567-603-24)",Revised,11/18/2020,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4909,Dexmedetomidine Injection,Jiangsu Hengrui Medicine Co. Ltd.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 70860-605-03)",Reverified,10/27/2020,Available,"Distributed by Athenex. To order, contact Athenex at 855-273-0154.",,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4910,Dexmedetomidine Injection,Mylan Institutional,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 67457-251-02)",Reverified,11/10/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4911,Dexmedetomidine Injection,Par Pharmaceutical,"100 mcg/mL, 2 mL single dose vial, box of 25 (NDC 42023-146-25)",Reverified,11/5/2020,Available,Please check wholesalers for supply,,,Anesthesia,Current,,,,2020,available
4912,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 0409-1660-20)",Reverified,11/20/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4913,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 20 (NDC 0409-1660-50)",Reverified,11/20/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4914,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 0409-1660-10)",Reverified,11/20/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4915,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 0409-1638-02)",Reverified,11/20/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
4916,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 50 mL single dose bottle, box of 20 (NDC 71225-126-05)",Revised,10/27/2020,"Currently on backorder, estimated to continue until Dec 2020.",,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4917,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 100 mL single dose bottle, box of 10 (NDC 71225-126-06)",Revised,10/27/2020,"Currently on backorder, estimated to continue until Dec 2020.",,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
4918,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,10 mg 100 Count (NDC 0093-5277-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
4919,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,2.5 mg 100 Count (NDC 0093-5275-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
4920,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,5 mg 100 Count (NDC 0093-5276-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
4921,Dexrazoxane Injection,Gland Pharma,500 mg per vial (NDC 72266-101-01); distributed by Fosun Pharma USA Inc.,Revised,2/26/2020,,,Available,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4922,Dexrazoxane Injection,Gland Pharma,"500 mg per vial (NDC 51991-942-98); distributed by Breckenridge Pharmaceutical, Inc.",New,2/26/2020,,,,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4923,Dexrazoxane Injection,Gland Pharma,"500 mg per vial (NDC 47781-578-07); distributed by Alvogen, Inc.",New,2/26/2020,,,,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4924,Dexrazoxane Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",250 mg per vial (NDC 0143-9247-01); distributed by West-Ward,Revised,2/26/2020,,,Available,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4925,Dexrazoxane Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9248-01); distributed by West-Ward,Revised,2/26/2020,,,Available,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4926,Dexrazoxane Injection,Mylan Institutional,250 mg Kit (NDC 67457-207-25),Revised,2/26/2020,,,Available,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4927,Dexrazoxane Injection,Mylan Institutional,500 mg Kit (NDC 67457-208-50),Revised,2/26/2020,,,Available,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4928,Dexrazoxane Injection,Pfizer Pharmaceuticals,Zinecard 250 mg; Single Dose Vial (NDC 0013-8717-62),Revised,2/26/2020,,,Available,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4929,Dexrazoxane Injection,Clinigen Healthcare Ltd,Totect® (Dexrazoxane) for injection; 1 vial (500 mg)(NDC 66220-110-01); distributed by Cumberland Pharmaceuticals,Revised,2/26/2020,,,Available,,Oncology;Pediatric,Resolved,2/26/2020,,,2020,
4930,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-1070-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4931,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100s (NDC 0378-1071-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4932,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-1072-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
4933,Dextrose 25% Injection,"Hospira, Inc.",250 mg/mL (25%); Ansyr Plastic Syringe (NDC 0409-1775-10),Reverified,11/20/2020,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2020,available
4934,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in VIAFLO container Product codes:  UE0062D (250mL, NDC 0338-0062-30); UE0063D (500mL, NDC 0338-0066-20); UE0064D (1000mL, NDC 0338-0070-10)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4935,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 25 mL, in VIAFLEX Plastic Container. Quad Pack.  Product code 2B0080  (NDC 0338-0017-10)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4936,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, in VIAFLEX Plastic Container.  Single Pack. Product code EZPB0041 (NDC 0338-9147-30)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4937,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLEX Plastic Container.  Product code 2B0062Q  (NDC 0338-0017-02)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4938,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLEX Plastic Container.  Product code 2B0063Q  (NDC 0338-0017-03)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4939,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 1000 mL VIAFLEX Plastic Container. Product code 2B0064X  (NDC 0338-0017-04)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4940,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL AVIVA Container.  Product code 6E0062 (NDC 0338-6346-02)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4941,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL AVIVA Container. Product code 6E0063  (NDC 0338-6346-03)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4942,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-02),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4943,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-03),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4944,Dextrose 5% Injection Bags,"ICU Medical, Inc.",1000 mL (NDC 0409-7922-09),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4945,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL VisIV™ Container (NDC 0409-7922-25),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4946,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-53),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4947,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-55),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4948,Dextrose 5% Injection Bags,"ICU Medical, Inc.",150 mL (NDC 0409-7922-61),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4949,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL VisIV™ Container (NDC 0409-7923-06),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4950,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL VisIV™ Container (NDC 0409-7923-11),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4951,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL (NDC 0409-7923-13),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4952,Dextrose 5% Injection Bags,"ICU Medical, Inc.","25 mL, Quad Pack (NDC 0409-7923-20)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4953,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL (NDC 0409-7923-23),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4954,Dextrose 5% Injection Bags,"ICU Medical, Inc.","50 mL, Quad Pack (NDC 0409-7923-36)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4955,Dextrose 5% Injection Bags,"ICU Medical, Inc.","100 mL, Quad Pack (NDC 0409-7923-37)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4956,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 100mL 
(NDC 63323-624-61)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4957,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 250mL 
(NDC 63323-624-74)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4958,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL, in VIAFLEX Plastic Container: Single Pack (NDC 0338-0017-41)
Quad Pack (NDC 0338-0017-11)
Multi Pack (NDC 0338-0017-31)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4959,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL, in VIAFLEX Plastic Container: Single Pack (NDC 0338-0017-48)
Quad Pack (NDC 0338-0017-18
Multi Pack (NDC 0338-0017-38)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4960,Dextrose 5% Injection Bags,"Hospira, Inc.",50 mL (5%); ADD-Vantage Flexible Container (NDC 00409-7100-66),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4961,Dextrose 5% Injection Bags,"Hospira, Inc.",100 mL (5%); ADD-Vantage Flexible Container (NDC 00409-7100-67),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4962,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 500mL 
(NDC 63323-624-75)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4963,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 1000mL 
(NDC 63323-624-10)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4964,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in MINI-BAG Plus container, 50 mL,  Product code 2B0040 (NDC 0338-0551-11)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4965,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in MINI-BAG Plus container, 100 mL,  Product code 2B0041 (NDC 0338-0551-18)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2020,
4966,Dextrose 50% Injection,"Amphastar Pharmaceuticals, Inc./IMS","DEXTROSE INJECTION, USP, 50%, [500 mg / mL](NDC 76329-3301-1)",Reverified,10/30/2020,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/2019,,,2020,available
4967,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); LifeShield Abboject Glass Syringe (NDC 0409-4902-34),Revised,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/2019,,,2020,limited availability
4968,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); Single Dose Glass Fliptop Vial (NDC 0409-6648-02),Revised,11/20/2020,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/2019,,,2020,available
4969,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); Ansyr Plastic Syringe (NDC 0409-7517-16),Revised,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2020,limited availability
4970,"Diazepam Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1273-32),Revised,12/17/2019,,,,,Neurology,Resolved,12/17/2019,,,2020,
4971,"Diazepam Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-3213-12),Revised,12/17/2019,,,,,Neurology,Resolved,12/17/2019,,,2020,
4972,"Diazepam Injection, USP","Beloteca, Inc.","Diazepam Injection, USP 10 mg/2 mL (5 mg/mL) Prefilled Single-dose Syringe with Luer Lock (NDC 69339-136-32)",Revised,12/17/2019,,,,,Neurology,Resolved,12/17/2019,,,2020,
4973,Diclofenac Sodium Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0355-01),New,4/4/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction;Rheumatology,To be Discontinued,4/4/2018,4/4/2018,,2020,discontinued
4974,Diclofenac Sodium Topical Gel,"Endo Pharmaceuticals, Inc.",1% topical gel (NDC 49884-935-47),New,2/13/2020,,,,,Analgesia/Addiction,To be Discontinued,2/13/2020,2/13/2020,,2020,discontinued
4975,Diclofenac Sodium Topical Solution,Apotex Corp.,2% topical solution (NDC 60505-0399-5),New,5/6/2020,,,,,Analgesia/Addiction,To be Discontinued,5/6/2020,5/6/2020,,2020,discontinued
4976,Dicyclomine Hydrochloride (BENTYL®) Capsule & Tablet,Allergan Sales LLC,10 mg capsules in bottles of 100 (NDC 58914-012-10),New,3/29/2019,,Product discontinued October 2017,,,Gastroenterology,To be Discontinued,3/29/2019,3/29/2019,,2020,discontinued
4977,Dicyclomine Hydrochloride (BENTYL®) Capsule & Tablet,Allergan Sales LLC,20 mg tablets in bottles of 100 (NDC 58914-013-10),New,3/29/2019,,Product discontinued December 2016,,,Gastroenterology,To be Discontinued,3/29/2019,3/29/2019,,2020,discontinued
4978,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Caps, USP, 10mg 1000s (NDC 0143-3126-10)",Reverified,7/22/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4979,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Caps, USP, 10mg 100s (NDC 0143-3126-01)",Reverified,7/22/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4980,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Tabs, USP, 20mg 1000s (NDC 0143-1227-10)",Reverified,7/22/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4981,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Tabs, USP, 20mg 100s (NDC 0143-1227-01)",Reverified,7/22/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4982,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 10mg C 100s (NDC 0378-1610-01),Reverified,11/10/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
4983,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 10mg C 500s (NDC 0378-1610-05),Reverified,11/10/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
4984,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 20mg T 100s (NDC 0378-1620-01),Reverified,11/10/2020,Out of Stock. Resupply TBD.,,,Other,Gastroenterology,Current,,,,2020,not available
4985,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 20mg T 500s (NDC 0378-1620-05),Reverified,11/10/2020,Out of Stock. Resupply TBD.,,,Other,Gastroenterology,Current,,,,2020,not available
4986,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Capsules USP, 10 mg (100 count bottles) (NDC 0527-0586-01)",Reverified,11/12/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4987,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Capsules USP, 10 mg (1000 count bottles) (NDC 0527-0586-10)",Reverified,11/12/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4988,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Tablets USP, 20 mg (100 count bottles) (NDC 0527-1282-01)",Reverified,11/12/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4989,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Tablets USP, 20 mg (1000 count bottles) (NDC 0527-1282-10)",Reverified,11/12/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4990,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 10MG CAPSULES 100 count (NDC 0591-0794-01),Reverified,11/19/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4991,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 10MG CAPSULES 1000 count (NDC 0591-0794-10),Reverified,11/19/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4992,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 20MG TABLETS 100 count (NDC 0591-0795-01),Reverified,11/19/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4993,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 20MG TABLETS 1000 count (NDC 0591-0795-10),Reverified,11/19/2020,Available,,,,Gastroenterology,Current,,,,2020,available
4994,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 200 mg, 30 count bottles (NDC 0555-0588-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2020,discontinued
4995,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 250 mg, 30 count bottles (NDC 0555-0589-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2020,discontinued
4996,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 400 mg, 30 count bottles (NDC 0555-0590-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2020,discontinued
4997,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,"VIDEX EC Cpasules, 125 mg (NDC 0087-6671-17)",New,2/24/2020,,"This discontinnuation is due to a marketing decision. Discontinuation date: March 31, 2020",,,Antiviral,To be Discontinued,2/24/2020,2/24/2020,,2020,discontinued
4998,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,"VIDEX EC Capsules, 200 mg (NDC 0087-6672-17)",New,2/24/2020,,"This discontinuation is due to a marketing decision. Discontinuation date: February 14, 2020",,,Antiviral,To be Discontinued,2/24/2020,2/24/2020,,2020,discontinued
4999,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,"VIDEX EC Capsules, 250 mg (NDC 0087-6673-17)",New,2/24/2020,,"This discontinuation is due to a marketing decision. Discontinuation date: March 31, 2020",,,Antiviral,To be Discontinued,2/24/2020,2/24/2020,,2020,discontinued
5000,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,"VIDEX EC Capsules, 400 mg (NDC 0087-6674-17)",New,2/24/2020,,"This discontinuation is due to a marketing decision. Discontinuation date: November 20, 2019",,,Antiviral,To be Discontinued,2/24/2020,2/24/2020,,2020,discontinued
5001,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,VIDEX PED PWD 2 g (1 bottle) 4 oz (NDC 0087-6632-41),New,2/24/2020,,"This discontinuation is due to a marketing decision. Discontinuation date: March 31, 2020",,,Antiviral,To be Discontinued,2/24/2020,2/24/2020,,2020,discontinued
5002,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,VIDEX PED PWD 4 g (1 bottle) 8 oz (NDC 0087-6633-41),New,2/24/2020,,"This discontinuation is due to a marketing decision. Discontinuation date: May 31, 2019",,,Antiviral,To be Discontinued,2/24/2020,2/24/2020,,2020,discontinued
5003,Diethylpropion Hydrochloride Controlled-Release Tablets,Teva Pharmaceuticals,75 mg tablets (NDC 0591-0782-01),New,6/11/2019,,This product discontinuation is a business related decision.,,,Endocrinology/Metabolism,To be Discontinued,6/11/2019,6/11/2019,,2020,discontinued
5004,Diethylpropion Hydrochloride Tablets,Teva Pharmaceuticals,25 mg tablets (NDC 0591-0783-01),New,6/11/2019,,This product discontinuation is a business related decision.,,,Endocrinology/Metabolism,To be Discontinued,6/11/2019,6/11/2019,,2020,discontinued
5005,Difluprednate (Durezol) Ophthalmic Emulsion,Novartis,0.05% 5mL in 8mL bottle (NDC 0065-9204-07),Revised,10/15/2019,,,,,Ophthalmology,Resolved,10/15/2019,,,2020,
5006,Diltiazem Hydrochloride,"Athenex Pharmaceutical Division, LLC (Athenex)",25 mg/5mL vial (NDC 70860-301-05),Reverified,10/27/2020,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2020,available
5007,Diltiazem Hydrochloride,"Athenex Pharmaceutical Division, LLC (Athenex)",50 mg/10mL vial (NDC 70860-301-10),Reverified,10/27/2020,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2020,available
5008,Diltiazem Hydrochloride,"Athenex Pharmaceutical Division, LLC (Athenex)",125 mg/25mL vial (NDC 70860-301-25),Reverified,10/27/2020,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2020,available
5009,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 5 mL vial  (NDC 0641-6013-10)",Revised,7/22/2020,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5010,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial (NDC 0641-6014-10)",Revised,7/22/2020,Product is currently on allocation.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,limited availability
5011,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 30 mL vial (NDC 0641-6015-10)",Revised,7/22/2020,This presentation is temporarily on backorder,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,not available
5012,Diltiazem Hydrochloride,"Hospira, Inc.",100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5013,Diltiazem Hydrochloride,"Hospira, Inc.",25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01),Reverified,11/20/2020,Next Delivery and Estimated Recovery: February 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2020,not available
5014,Diltiazem Hydrochloride,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5015,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10)",Revised,2/7/2020,Backorder. Estimated recovery March 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,,2020,not available
5016,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 25 mg / 5 mL, 10 mL, 10 vials (NDC 17478-0817-10)",Revised,2/7/2020,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,2/7/2020,2/7/2020,,2020,discontinued
5017,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 1 vial (NDC 17478-0817-25)",Revised,2/7/2020,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,2/7/2020,2/7/2020,,2020,discontinued
5018,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 10 vials (NDC 17478-0817-26)",Revised,2/7/2020,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,2/7/2020,2/7/2020,,2020,discontinued
5019,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",Revised,2/7/2020,Backorder. Estimated recovery March 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,,2020,not available
5020,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",Revised,2/7/2020,Backorder. Estimated recovery March 2020,,,Demand increase for the drug,Cardiovascular,Current,,,,2020,not available
5021,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",Revised,2/7/2020,Backorder. Estimated recovery March 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,,2020,not available
5022,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 0.5 mg / mL, 30 gram, 10 vials (NDC 17478-0817-05)",Revised,2/7/2020,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,2/7/2020,,,2020,discontinued
5023,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,60 mg (NDC 0378-6060-01),Revised,2/20/2020,,,,,Cardiovascular,Resolved,2/20/2020,,,2020,
5024,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,90 mg (NDC 0378-6090-01),Revised,2/20/2020,,,,,Cardiovascular,Resolved,2/20/2020,,,2020,
5025,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,120 mg (NDC 0378-6120-01),Revised,2/20/2020,,,,,Cardiovascular,Resolved,2/20/2020,,,2020,
5026,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-5220-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5027,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"120 mg, 500 count bottle (NDC 0378-5220-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5028,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"180 mg, 100 count bottle (NDC 0378-5280-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5029,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"180 mg, 500 count bottle (NDC 0378-5280-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5030,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"240 mg, 100 count bottle (NDC 0378-5340-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5031,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"240 mg, 500 count bottle (NDC 0378-5340-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5032,Dimercaprol (Bal in Oil) Injection USP,Akorn Pharmaceuticals,"3 mL (100 mg/mL) ampules, box of 10 (NDC 17478-526-03)",Revised,11/10/2020,Product is currently on backorder. Estimated shortage duration is until Jan 2021,Estimated recovery 1Q2021,,Other,Hematology;Other,Current,,,,2020,not available
5033,Diphenhydramine Injection,"Hospira, Inc.",50 mg/mL Carpuject™ Luer Lock Glass Syringe (NDC 00409-2290-31),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Pediatric;Pulmonary/Allergy,Current,,,,2020,discontinued
5034,Diphenhydramine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL vial (NDC 0641-0376-25)",Revised,7/22/2020,Inventory is currently available,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,,2020,available
5035,Diphenhydramine Injection,Mylan Institutional,500 mg / 10mL(NDC 67457-124-10),Reverified,11/10/2020,Available,,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,,2020,available
5036,Diphenhydramine Injection,"Fresenius Kabi USA, LLC","50 mg per vial, Single dose, Amber vial (NDC 63323-664-01)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,,2020,available
5037,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100s (NDC 0378-4140-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
5038,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100s (NDC 0378-4141-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
5039,Disulfiram Tablets,Teva Pharmaceuticals,"250 mg, 100 count (NDC 0093-5035-01)",New,11/20/2020,,Teva made a business decision to discontinue the product.,,,Analgesia/Addiction,To be Discontinued,11/20/2020,11/20/2020,,2020,discontinued
5040,Disulfiram Tablets,Teva Pharmaceuticals,"500 mg, 100 count (NDC 0093-5036-01)",New,11/20/2020,,Teva made a business decision to discontinue the product.,,,Analgesia/Addiction,To be Discontinued,11/20/2020,11/20/2020,,2020,discontinued
5041,Disulfiram Tablets,"Alvogen, Inc.","250 mg, 30 count (NDC 47781-607-30)",Revised,8/24/2020,,,,,Analgesia/Addiction,Resolved,8/24/2020,8/24/2020,,2020,
5042,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,500 mg Bottle of 500 (NDC 10370-511-50),New,10/31/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/2019,10/31/2019,,2020,discontinued
5043,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,500 mg Bottle of 100 (NDC 10370-511-10),New,10/31/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/2019,10/31/2019,,2020,discontinued
5044,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,250 mg Bottle of 100 (NDC 10370-510-10),New,10/31/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/2019,10/31/2019,,2020,discontinued
5045,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,250 mg Bottle of 500 (NDC 10370-510-50),New,10/31/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/2019,10/31/2019,,2020,discontinued
5046,Dobutamine Hydrochloride Injection,Pfizer Pharmaceuticals,500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),New,4/3/2020,,Discontinuation of the manufacture of the drug.,,,Cardiovascular;Pediatric;Renal,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
5047,Dobutamine Hydrochloride Injection,Baxter Healthcare,"250 mg/250 mL (NDC 0338-1073-02) Product code 2B0791, 500 mg/250 mL (NDC 0338-1075-02) Product code 2B0792, 1000 mg/250 mL (NDC 0338-1077-02) Product code 2B0793",Reverified,10/28/2020,Available,,,,Cardiovascular;Pediatric;Renal,Current,,,,2020,available
5048,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/250 mL (1 mg/mL); Flexible Container (NDC 00409-2346-32),Revised,11/20/2020,Next Delivery: January 2021; Estimated Recovery: June 2021,Check Wholesaler for Availablility Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2020,not available
5049,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/250 mL (2 mg/mL); Flexible Container (NDC 00409-2347-32),Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: October 2021,Check Wholesaler for Availablility Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2020,not available
5050,Dobutamine Hydrochloride Injection,"Hospira, Inc.",1000 mg/250 mL (4 mg/mL); Flexible Container (NDC 00409-3724-32),Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: May 2021,Check Wholesaler for Availablility Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2020,not available
5051,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-20),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,,2020,discontinued
5052,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,,2020,discontinued
5053,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-01),Revised,11/20/2020,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2020,available
5054,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-02),Revised,11/20/2020,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2020,available
5055,Docetaxel Injection,Teva Pharmaceuticals,20 mg/mL  (NDC 45963-790-56),New,3/31/2020,,,,,Oncology,To be Discontinued,3/31/2020,3/31/2020,,2020,discontinued
5056,"Docusate Sodium Capsules, USP",Par Pharmaceutical,"100mg, count bottle (NDC 0603-0150-21)",New,4/9/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,4/9/2019,4/9/2019,,2020,discontinued
5057,"Docusate Sodium Capsules, USP",Par Pharmaceutical,"100mg, count bottle (NDC 0603-0150-32)",New,4/9/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,4/9/2019,4/9/2019,,2020,discontinued
5058,Donepezil Hydrochloride Tablets,Teva Pharmaceuticals,23mg tablets (NDCs 0228-4529-03 and 0228-4529-09),New,2/13/2020,,,,,Neurology,To be Discontinued,2/13/2020,2/13/2020,,2020,discontinued
5059,Dopamine Hydrochloride Injection,"Hospira, Inc.","400 mg/250 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-22)",Revised,11/20/2020,Next Delivery: February 2021; Estimated Recovery: September 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2020,not available
5060,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/500 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-24)",Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: May 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2020,not available
5061,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/250 mL (3,200 mcg/mL); Flexible Container (NDC 00409-7810-22)",Revised,11/20/2020,Limited Supply Available. Next Delivery: March 2021; Estimated Recovery: September 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2020,limited availability
5062,Dopamine Hydrochloride Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-5820-01),Revised,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5063,Dopamine Hydrochloride Injection,"Hospira, Inc.",400 mg/10 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9104-20),Revised,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5064,Dopamine Hydrochloride Injection,Baxter Healthcare,"800 mcg/mL (250 mL bag) Product code 2B0832 (NDC 0338-1005-02), 800 mcg/mL (500 mL bag)  Product code 2B0833 (NDC 0338-1005-03), 1600 mcg/mL (250 mL bag) Product code 2B0842 (NDC 0338-1007-02), 1600 mcg/mL (500 mL bag) Product code 2B0843 (NDC 0338-1007-03), 3200 mcg/mL (250 mL bag) Product code 2B0846 (NDC 0338-1009-02)",Reverified,10/28/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5065,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 17478-605-10)",Revised,6/8/2020,Available,,,,Ophthalmology,Current,,,,2020,available
5066,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 50383-233-10)",Revised,6/8/2020,Limit availability / Recovery expected July 2020.,"Manufacturer interruption production issues.  Marketed by Hi-Tech Pharmacal Co., Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,,2020,limited availability
5067,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt-PF® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 0.2 mL single use, 60 count (NDC 17478-604-30)",Revised,6/8/2020,Available,"Marketed by Akorn, Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,,2020,available
5068,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 61314-030-02)",Reverified,11/13/2020,Supply Available,"Labeled under Sandoz Inc. To order, contact Sandoz Inc. at 1-800-525-8747",,Demand increase for the product,Ophthalmology,Current,,,,2020,available
5069,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 24208-486-10)",Revised,6/9/2020,Available,"Marketed by Bausch & Lomb Inc. To order, contact Bausch & Lomb, a division of Valeant Pharmaceuticals North America at pharcs@valeant.com",,Other,Ophthalmology,Current,,,,2020,available
5070,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 0591-2482-79)",Reverified,11/19/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,,,2020,not available
5071,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride and Timolol Maleate 20 mg and 5 mg/mL, 10 mL (0591-2482-79)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing this product.,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2020,discontinued
5072,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Aurobindo Pharma,"Dorzolamide HCl and Timolol Maleate (Cosopt® PF) Ophthalmic Solution 2%/0.5% Preservative Free, 2mL single use container (NDC 65862-0947-60)",Reverified,9/25/2020,Available,Available,,Other,Ophthalmology,Current,,,,2020,available
5073,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2020,discontinued
5074,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2020,discontinued
5075,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",Reverified,11/19/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,4/20/2018,4/20/2018,,2020,not available
5076,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",Reverified,11/19/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,4/20/2018,4/20/2018,,2020,not available
5077,Dorzolamide Hydrochloride Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 50383-232-10)",Revised,10/14/2020,Available,"Manufacturer interruption production issues. Distributed by Hi-Tech Pharmacal Co., Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,,Ophthalmology,Current,,,,2020,available
5078,Dorzolamide Hydrochloride Ophthalmic Solution,Merck Sharp & Dohme Corp.,"TRUSOPT® dorzolamide hydrochloride ophthalmic solution 2%, 10 mL in an 18 mL capacity bottle (NDC 0006-3519-36)",Reverified,6/1/2018,Product is available,"For additional information please contact: Merck National Service Center, Telephone Number: 1-800-672-6372",,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
5079,Dorzolamide Hydrochloride Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride USP 2%, 10 mL (NDC 24208-485-10)",Revised,12/13/2019,Currently on backorder. Estimated availability: January 2020,"Marketed by Bausch & Lomb Inc. To order, contact Bausch & Lomb, a division of Bausch Health US, LLC at pharcs@bauschhealth.com",,Other,Ophthalmology,Current,,,,2020,not available
5080,Dorzolamide Hydrochloride Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 61314-019-10)",Reverified,11/13/2020,Supply available,"Labeled under Sandoz Inc. To order, contact Sandoz Inc. at 1-800-525-8747",,Demand increase for the product,Ophthalmology,Current,,,,2020,available
5081,Doxorubicin Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg/mL, 10 mL single-dose vial (NDC 63323-883-10)",New,3/5/2020,,Product available. Check wholesalers for inventory or contact Customer Service to place a direct order. 10 mL will be discontinued when inventory is depleted.,,,Oncology;Pediatric,To Be Discontinued,3/5/2020,3/5/2020,,2020,discontinued
5082,Doxycycline Capsules,Teva Pharmaceuticals,50 mg capsules (NDC 0591-0410-01),New,4/29/2019,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/2019,4/29/2019,,2020,discontinued
5083,Doxycycline Capsules,Teva Pharmaceuticals,75 mg capsules (NDC 0591-2404-01),New,4/29/2019,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/2019,4/29/2019,,2020,discontinued
5084,Doxycycline Capsules,Teva Pharmaceuticals,100 mg capsules (NDC 0591-0411-50),New,4/29/2019,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/2019,4/29/2019,,2020,discontinued
5085,Doxycycline Hyclate Capsules,Teva Pharmaceuticals,50 mg  (NDC 0591-5535-50),New,10/15/2019,,This product is being discontinued due to a business decision.,,,Anti-Infective,To be Discontinued,10/15/2019,10/15/2019,,2020,discontinued
5086,Doxycycline Hyclate Capsules,Teva Pharmaceuticals,100 mg (NDCs 0591-5440-50 and 0591-5440-05),New,10/15/2019,,This product is being discontinued due to a business decision.,,,Anti-Infective,To be Discontinued,10/15/2019,10/15/2019,,2020,discontinued
5087,Doxycycline Hyclate Delayed Release Tablets,Mylan Pharmaceuticals Inc.,150 mg tablets (NDC 0378-3030-01),New,9/9/2019,,,,,Anti-Infective,To be Discontinued,9/9/2019,9/9/2019,,2020,discontinued
5088,Doxycycline Hyclate Injection,"Fresenius Kabi USA, LLC",100 mg per vial; amber vial; preservative free; lyophilized powder (NDC 63323-130-11),Revised,10/23/2020,Backordered.  Next release expected November 2020.,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective,Current,,,,2020,not available
5089,Doxycycline Hyclate Injection,Mylan Institutional,100 mg (Lyophilizate in Vials)(NDC 67457-437-10),Revised,11/10/2020,Available,Increased supply in 2020 to meet increased demand,,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
5090,Dronabinol Capsules,"Endo Pharmaceuticals, Inc.","2.5 mg capsules (NDC 498840-867-02), 5 mg capsules (NDC 498840-868-02), 10 mg capsules (NDC 498840-869-02)",New,2/7/2019,,,,,Gastroenterology,To be Discontinued,2/7/2019,2/7/2019,,2020,discontinued
5091,Dutasteride Capsules,Apotex Corp.,0.5 mg capsules (NDCs 60505-3877-9 and 60505-3877-3),New,1/7/2020,,,,,Urology,To be Discontinued,1/7/2020,1/7/2020,,2020,discontinued
5092,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Pfizer Pharmaceuticals,6.25 mg package for 0.125% (NDC 0046-1065-05),Reverified,11/20/2020,Available,,,Other,Ophthalmology,Current,,,,2020,available
5093,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Pfizer Pharmaceuticals,6.25 mg package for 0.125% (NDC 0046-1065-05),New,10/27/2020,,"Pfizer anticipates stock available through May 1st, 2021.",,,Ophthalmology,To be Discontinued,10/27/2020,10/27/2020,,2020,discontinued
5094,"Enalaprilat Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2.5mg/2mL, vial (NDC 0143-9786-10)",Revised,7/22/2020,Inventory is currently available.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5095,"Enalaprilat Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1.25mg/mL, vial  (NDC 0143-9787-10)",Revised,7/22/2020,Inventory is currently available.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5096,"Enalaprilat Injection, USP","Hospira, Inc.",1.25 mg/mL; Single Dose Glass Fliptop Vial (NDC 00409-2122-01),New,3/24/2020,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,,3/24/2020,,2020,discontinued
5097,"Enalaprilat Injection, USP","Hospira, Inc.",2.5 mg/2 mL (1.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2122-02),New,3/24/2020,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,,3/24/2020,,2020,discontinued
5098,Entecavir Tablets,Teva Pharmaceuticals,0.5mg tablets (NDCs 0093-5786-98 and 0093-5786-56),New,2/14/2020,,,,,Antiviral,To be Discontinued,2/14/2020,2/14/2020,,2020,discontinued
5099,Entecavir Tablets,Teva Pharmaceuticals,1mg tablets (NDC 0093-5787-56),New,2/14/2020,,,,,Antiviral,To be Discontinued,2/14/2020,2/14/2020,,2020,discontinued
5100,Epinastine Hydrochloride (Elestat®) Ophthalmic Solution,Allergan,5 mL in 10 mL bottle (NDC 00023-9201-05),New,8/19/2019,,,,,Ophthalmology,To be Discontinued,8/19/2019,8/19/2019,,2020,discontinued
5101,"Epinephrine Injection, 0.1 mg/mL","Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 00409-4921-34, pack of 10; NDC 0409-4921-20, individual)",Revised,11/20/2020,Available,,,,Cardiovascular;Pulmonary/Allergy,Current,,,,2020,available
5102,"Epinephrine Injection, 0.1 mg/mL","Amphastar Pharmaceuticals, Inc./IMS","1:10,000, 10mL Luer-Jet Prefilled Syringe
(NDC 76329-3316-1)(old NDC 0548-3316-00)",Reverified,10/30/2020,Available,,,,Cardiovascular;Pulmonary/Allergy,Current,,,,2020,available
5103,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)",Reverified,11/19/2020,Available,,,,Pulmonary/Allergy,Current,,,,2020,available
5104,"Epinephrine Injection, Auto-Injector",Mylan Specialty,"0.3 mg (EpiPen® NDC 49502-500-02, pack of 2; NDC 49502-500-01, individual) (Authorized Generic NDC 49502-102-02, pack of 2; NDC 49502-102-01, individual)",Reverified,11/10/2020,Available,"Production output from Mylan’s manufacturing partner Meridian Medical Technologies, a Pfizer company, has improved in recent months. Supplies are routinely shipping and, as a result, are more consistently available at the pharmacy level. In the event patients experience difficulty accessing product, they can continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.",,,Pulmonary/Allergy,Current,,,,2020,available
5105,"Epinephrine Injection, Auto-Injector",Mylan Specialty,0.15 mg (EpiPen® NDC 49502-501-02) (Authorized Generic NDC 49502-101-02),Reverified,11/10/2020,Available,"Production output from Mylan’s manufacturing partner Meridian Medical Technologies, a Pfizer company, has improved in recent months. Supplies are routinely shipping and, as a result, are more consistently available at the pharmacy level. In the event patients experience difficulty accessing product, they can continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.",,,Pulmonary/Allergy,Current,,,,2020,available
5106,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)",Revised,6/1/2020,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,,2020,limited availability
5107,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)",Revised,6/1/2020,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,,2020,limited availability
5108,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)",Reverified,6/15/2020,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2020,available
5109,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)",Reverified,6/15/2020,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2020,available
5110,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)",Reverified,6/15/2020,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2020,available
5111,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.3 mg single-dose, pre-filled syringes (NDC 0781-3442-20)",Reverified,12/17/2019,Available,,,,Pulmonary/Allergy,Current,,,,2020,available
5112,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.15 mg single-dose, pre-filled syringes (NDC 0781-3448-20)",Reverified,12/17/2019,Available,,,,Pulmonary/Allergy,Current,,,,2020,available
5113,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.15 MG Epinephrine Injection, USP auto-injector (NDC 0093-5985-27)",Reverified,11/19/2020,Available,,,,Pulmonary/Allergy,Current,,,,2020,available
5114,Epirubicin Hydrochloride Injection,Teva Pharmaceuticals,2 mg/1 mL  (NDCs 45963-608-60 and 45963-608-68),New,7/17/2019,,This product discontinuation is a business related decision.  Anticipated discontinuance time is first quarter of the year 2020.,,,Oncology,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5115,Epirubicin Hydrochloride Injection,Cipla Limited,2 mg/1 mL  (NDCs 25021-203-25 and 59923-701-25),New,7/17/2019,,Anticipated unavailability of product is September 2019.,,,Oncology,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5116,Eprosartan Mesylate Tablets,Mylan Pharmaceuticals Inc.,Eprosartan Mesylate 600mg T 30s (NDC 0378-6629-93),Revised,3/16/2020,,Mylan has made a business decision to discontinue this product.,,,Cardiovascular,To be Discontinued,3/16/2020,3/16/2020,,2020,discontinued
5117,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,0.75 mg/mL (NDCs 0085-1136-02 and 0085-1136-03),New,11/18/2019,,The following presentation will continue to be available: 0.75 mg/mL (NDC 0085-1136-01 ),,,Cardiovascular,To be Discontinued,11/18/2019,11/18/2019,,2020,discontinued
5118,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,2 mg/mL (NDCs 0085-1177-03 and 0085-1177-05),New,11/18/2019,,The following presentations will continue to be available: 2 mg/mL (NDCs 0085-1177-01 and 0085-1177-02),,,Cardiovascular,To be Discontinued,11/18/2019,11/18/2019,,2020,discontinued
5119,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,20 mg/10ml (2 mg/ml)(NDC 0085-1177-01),New,10/21/2020,,To be discontinued on or near October 2020.,,,Cardiovascular,To be Discontinued,10/21/2020,10/21/2020,,2020,discontinued
5120,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,75 mg/100ml (0.75 mg/ml)(NDC 0085-1136-01),New,10/21/2020,,To be discontinued on or near October 2020.,,,Cardiovascular,To be Discontinued,10/21/2020,10/21/2020,,2020,discontinued
5121,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,200 mg/100ml (2 mg/ml)(NDC 0085-1177-02),New,10/21/2020,,Discontinued,,,Cardiovascular,To be Discontinued,10/21/2020,10/21/2020,,2020,discontinued
5122,Ergotamine Tartrate and Caffeine (Cafergot) Tablets,Sandoz,1mg/100mg (NDC 0781-5405-01),New,7/2/2020,,Discontinuation of drug manufacturing,,,Neurology,To be Discontinued,7/2/2020,7/2/2020,,2020,discontinued
5123,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",25 mg tablets (NDC 50242-062-01),New,9/29/2020,,,,,Oncology,To be Discontinued,9/29/2020,9/29/2020,,2020,discontinued
5124,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",100 mg tablets (NDC 50242-063-01),New,9/29/2020,,,,,Oncology,To be Discontinued,9/29/2020,9/29/2020,,2020,discontinued
5125,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",150 mg tablets (NDC 50242-064-01),New,9/29/2020,,,,,Oncology,To be Discontinued,9/29/2020,9/29/2020,,2020,discontinued
5126,"Erythromycin Lactobionate for Injection, USP","Hospira, Inc.",500 mg Single Dose Glass Fliptop Vial (NDC 00409-6482-01),Reverified,11/20/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
5127,"Erythromycin Lactobionate for Injection, USP","Hospira, Inc.",500 mg Single-dose ADD-Vantage® Vial (NDC 00409-6476-44),Reverified,11/20/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
5128,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35),Revised,12/2/2019,Limited availability.,"Expected availability Dec, 2019",,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2020,limited availability
5129,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC17478-070-01),Revised,12/2/2019,On backorder,"Expected availability Oct 1, 2019",,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2020,not available
5130,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-824-35)(Premier),Revised,12/2/2019,No longer distributing,,,,Ophthalmology,Current,,,,2020,discontinued
5131,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC 17478-824-01)(Premier),Revised,12/2/2019,No longer distributing,,,,Ophthalmology,Current,,,,2020,discontinued
5132,Erythromycin Ophthalmic Ointment,Bausch Health,3.5 g in 1 Tube (NDC 24208-910-55),Reverified,12/13/2019,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
5133,Erythromycin Ophthalmic Ointment,Bausch Health,1 g in cartons of 50 (NDC 24208-910-19),Reverified,12/13/2019,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
5134,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"1 gram, 50-count (NDC 00574-4024-50)",Revised,12/10/2019,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
5135,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 1-count (NDC 00574-4024-35)",Revised,12/10/2019,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
5136,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 24-count (NDC 00574-4024-39)",Revised,12/10/2019,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
5137,Escitalopram (Lexapro) 5 mg/5 mL Oral Solution,Allergan Sales LLC,Lexapro oral solution 240 mL bottle 5 mg/5mL (NDC 0456-2101-08),New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5138,Escitalopram (Lexapro) 5 mg/5 mL Oral Solution,Allergan Sales LLC,Escitalopram Oxalate oral solution 240 mL bottle (NDC 0591-4151-38),New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5139,Ethambutol Hydrochloride Tablets,Teva Pharmaceuticals,400 mg  (NDC 0555-0923-02),New,9/28/2020,,,,,Anti-Infective,To be Discontinued,9/28/2020,9/28/2020,,2020,discontinued
5140,Ethinyl Estradiol and Levonorgestrel (Myzilra),"Endo Pharmaceuticals, Inc.","0.03mg, 0.04mg, 0.03mg, 0.05mg, 0.075mg, 0.125mg; 6 blister pack in 1 carton (NDC 0603-7625-17)",New,5/10/2019,,Discontinued due to business reasons.,,,Reproductive,To be Discontinued,5/10/2019,5/10/2019,,2020,discontinued
5141,Ethinyl Estradiol and Levonorgestrel (Myzilra),"Endo Pharmaceuticals, Inc.","0.03mg, 0.04mg, 0.03mg, 0.05mg, 0.075mg, 0.125mg; 3 blister pack in 1 carton (NDC 0603-7625-49)",New,5/10/2019,,Discontinued due to business reasons.,,,Reproductive,To be Discontinued,5/10/2019,5/10/2019,,2020,discontinued
5142,Ethinyl Estradiol; Norgestrel Tablets,Teva Pharmaceuticals,0.05 mg; 0.5mg  (NDC 52544-848-28),New,5/8/2020,,,,,Reproductive,To be Discontinued,5/8/2020,5/8/2020,,2020,discontinued
5143,Ethiodized Oil (Lipiodol) Injection,Guerbet LLC,Box of one 10 mL ampoule (NDC 67684-1901-1),Revised,8/1/2019,,,Available,,Medical Imaging;Oncology,Resolved,8/1/2019,,,2020,
5144,Ethiodized Oil (Lipiodol) Injection,Guerbet LLC,Box of one 10 mL ampoule (NDC 67684-1901-1),Revised,7/31/2019,,,,,Medical Imaging;Oncology,Resolved,7/31/2019,,,2020,
5145,"Ethosuximide Oral Solution, USP",Teva Pharmaceuticals,"250 mg/5mL, 474 mL Bottle (NDC 0093-9660-16)",New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5146,Etomidate (Amidate) Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL) Abboject Glass Syringe (NDC 00409-8060-29),New,3/24/2020,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,3/24/2020,3/24/2020,,2020,discontinued
5147,Etomidate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 10 mL vial (NDC 55150-221-10)",Revised,11/20/2020,Currently on backorder - next shipment anticipated mid Dec 20,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
5148,Etomidate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 20 mL vial (NDC 55150-222-10)",Revised,11/20/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5149,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 10 mL vial (NDC 70860-652-10)",Reverified,10/27/2020,Unavailable,Distributed by Athenex Pharmaceutical. To contact: 855-273-0154.,,,Anesthesia,Current,,,,2020,not available
5150,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 70860-652-20)",Reverified,10/27/2020,Unavailable,Distributed by Athenex Pharmaceutical. To contact: 855-273-0154.,,,Anesthesia,Current,,,,2020,not available
5151,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 10 mL vial (NDC 72266-146-10)",Reverified,10/27/2020,Available,Distributed by Fosun Pharma. To contact: 866-611-3762,,,Anesthesia,Current,,,,2020,available
5152,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-147-10)",Reverified,10/27/2020,Available,Distributed by Fosun Pharma. To contact: 866-611-3762,,,Anesthesia,Current,,,,2020,available
5153,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9506-10)",Revised,9/9/2020,Available,,,,Anesthesia,Current,,,,2020,available
5154,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9507-10)",Revised,9/9/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
5155,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9310-10), Novaplus",Revised,9/9/2020,TBD,,,,Anesthesia,Current,,,,2020,unclear
5156,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9311-10), Novaplus",Revised,9/9/2020,TBD,,,,Anesthesia,Current,,,,2020,unclear
5157,Etomidate Injection,Mylan Institutional,"2 mg/mL, 10 mL vial (NDC 67457-902-10)",Revised,11/10/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
5158,Etomidate Injection,Mylan Institutional,"2 mg/mL, 20 mL vial (NDC 67457-903-20)",Revised,11/10/2020,Available,,,,Anesthesia,Current,,,,2020,available
5159,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 10 mL vial (NDC 0409-6695-01)",Reverified,11/20/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5160,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 20 mL vial (NDC 0409-6695-02)",Reverified,11/20/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5161,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 20 mL syringe (NDC 0409-8060-29)",Reverified,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia,Current,,,,2020,discontinued
5162,Exenatide (BYDUREON) Extended Release for Injectable Suspension,AstraZeneca,"BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use;  Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)",New,4/3/2018,,"The planned permanent discontinuance of the Bydureon Single Dose Tray inventory from the U.S. market is September 30, 2018.  There are currently 2 other delivery options for exenatide-extended-release:  the Bydureon® Dual Chamber Pen presentation (NDC 0310-6530-04) and Bydureon® BCise™ (NDC 0310-6540-04).",,,Endocrinology/Metabolism,To be Discontinued,4/3/2018,4/3/2018,,2020,discontinued
5163,Ezetimibe Tablets,Apotex Corp.,10 mg (NDC 60505-2945-9) || (NDC 60505-2945-3) || (NDC 60505-2945-5),New,7/31/2020,,To be discontinued due to API supply issues.,,,Cardiovascular,To be Discontinued,7/31/2020,7/31/2020,,2020,discontinued
5164,Famotidine Injection,Mylan Institutional,Famotidine Injection (Solution in Single Dose Vials) [20 mg / 2 ml] 25PK (NDC 67457-433-22),Reverified,11/10/2020,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
5165,Famotidine Injection,Baxter Healthcare,"Famotidine Injection premix, 20mg/50 mL in GALAXY Plastic Container (NDC 0338-5197-41)",Reverified,10/28/2020,Available,,,,Gastroenterology,Current,,,,2020,available
5166,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 2 mL vial (NDC 0641-6022-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
5167,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 4 mL vial (NDC 0641-6023-25)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5168,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6021-10)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5169,Famotidine Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 63323-739-12)",Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5170,Famotidine Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), mutilple dose vial, (NDC 63323-738-09)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
5171,Famotidine Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL(10 mg per mL), multiple dose vial, (NDC 63323-738-20)",Revised,11/16/2020,Backordered. Next release Q4 2020.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5172,Famotidine Injection,Mylan Institutional,Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [40 mg / 4 ml] 10PK (NDC 67457-448-43),Reverified,11/10/2020,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
5173,Famotidine Injection,Mylan Institutional,Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [200 mg / 20 ml] 10PK (NDC 67457-457-20),Reverified,11/10/2020,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
5174,Famotidine Tablets,Teva Pharmaceuticals,20 MG 100 Count (NDC 0172-5728-60),Reverified,11/19/2020,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5175,Famotidine Tablets,Teva Pharmaceuticals,20 MG 1000 Count (NDC 0172-5728-80),Reverified,11/19/2020,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5176,Famotidine Tablets,Teva Pharmaceuticals,20 MG 500 Count (NDC 0172-5728-70),Reverified,11/19/2020,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5177,Famotidine Tablets,Teva Pharmaceuticals,40 MG 100 Count (NDC 0172-5729-60),Reverified,11/19/2020,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5178,Famotidine Tablets,Teva Pharmaceuticals,40 MG 500 Count (NDC 0172-5729-70),Reverified,11/19/2020,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
5179,Famotidine Tablets,Aurobindo Pharma,20 mg - 100/Bottle (NDC 65862-859-01),Reverified,9/25/2020,Available,,,,Gastroenterology,Current,,,,2020,available
5180,Famotidine Tablets,Aurobindo Pharma,40 mg - 100/Bottle (NDC 65862-860-01),Reverified,9/25/2020,Available,,,,Gastroenterology,Current,,,,2020,available
5181,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 100 counts (NDC 62332-001-31),New,5/4/2020,Available,,,,Gastroenterology,Current,,,,2020,available
5182,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 1000 counts (NDC 62332-001-91),New,5/4/2020,Available,,,,Gastroenterology,Current,,,,2020,available
5183,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 100 counts (NDC 62332-002-31),New,5/4/2020,Available,,,,Gastroenterology,Current,,,,2020,available
5184,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 500 counts (NDC 62332-002-71),New,5/4/2020,Available,,,,Gastroenterology,Current,,,,2020,available
5185,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 1000 counts (NDC 62332-002-91),New,5/4/2020,Available,,,,Gastroenterology,Current,,,,2020,available
5186,Famotidine Tablets,"Carlsbad Technology, Inc.",20mg 100 count (NDC 61442-121-01),New,5/4/2020,"We do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can.","We are still shipping products. However, we are limited due to manufacturing capabilities, as well as limited resources such as active ingredient.",,Demand increase for the drug and shortage of an active ingredient,Gastroenterology,Current,,,,2020,limited availability
5187,Famotidine Tablets,"Carlsbad Technology, Inc.",20 mg 1000 count (NDC 61442-121-10),New,5/4/2020,"We do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can.","We are still shipping products. However, we are limited due to manufacturing capabilities, as well as limited resources such as active ingredient.",,Demand increase for the drug and shortage of an active ingredient,Gastroenterology,Current,,,,2020,limited availability
5188,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 100 count (NDC 61442-122-01),New,5/4/2020,"We do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can.","We are still shipping products. However, we are limited due to manufacturing capabilities, as well as limited resources such as active ingredient.",,Demand increase for the drug and shortage of an active ingredient,Gastroenterology,Current,,,,2020,limited availability
5189,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 1000 count (NDC 61442-122-10),New,5/4/2020,"We do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can.","We are still shipping products. However, we are limited due to manufacturing capabilities, as well as limited resources such as active ingredient.",,Demand increase for the drug and shortage of an active ingredient,Gastroenterology,Current,,,,2020,limited availability
5190,Fenofibric Acid Delayed-Release Capsules,Par Pharmaceutical,Fenofibric Acid Delayed-Release Capsules 45mg 90s (NDC 10370-209-09),New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5191,Fenofibric Acid Delayed-Release Capsules,Par Pharmaceutical,Fenofibric Acid Delayed-Release Capsules 135mg 90s (NDC 10370-210-09),New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5192,Fenofibric Acid Delayed-Release Capsules,Mylan Pharmaceuticals Inc.,"45 mg, 90 count bottle (NDC 0378-2589-77)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5193,Fenofibric Acid Delayed-Release Capsules,Mylan Pharmaceuticals Inc.,"135 mg, 90 count bottle (NDC 0378-2590-77)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5194,"Fenoldopam Mesylate (Corlopam) Injection, USP","Hospira, Inc.",20 mg/2 mL (10 mg/mL); Glass Ampul (NDC 00409-2304-02),New,11/16/2020,,"Discontinuation of the manufacture of the ampul, equivalent vial available.",,,Cardiovascular,To be Discontinued,11/16/2020,11/16/2020,,2020,discontinued
5195,"Fenoldopam Mesylate (Corlopam) Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Glass Ampul (NDC 00409-2304-01),New,11/16/2020,,"Discontinuation of the manufacture of the ampul, equivalent vial available.",,,Cardiovascular,To be Discontinued,11/16/2020,11/16/2020,,2020,discontinued
5196,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,100 ug/1 h (NDC 50458-094-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5197,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,75 ug/1 h (NDC 50458-093-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5198,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,50 ug/1 h (NDC 50458-092-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5199,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,25 ug/1 h (NDC 50458-091-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5200,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,100 ug/1 unit (NDC 50458-106-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5201,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,75 ug/1 unit (NDC 50458-105-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5202,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,50 ug/1 unit (NDC 50458-104-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5203,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,25 ug/1 unit (NDC 50458-102-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5204,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,12.5 ug/1 unit (NDC 50458-101-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5205,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,12.5 ug/1 h (NDC 50458-090-05),New,4/1/2020,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
5206,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","1,000 mcg per 20 mL (50 mcg per mL) (0.05 mg per mL)  SDV (NDC 63323-806-20)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5207,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","2,500 mcg per 50 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-50)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5208,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-01),Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5209,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",100 mcg per 2 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-02),Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5210,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",250 mcg per 5 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-05),Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5211,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1276-32),Revised,11/20/2020,Next Delivery and Estimated Recovery: January 2023,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,not available
5212,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-32),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5213,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-35),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5214,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",1000 mcg/20 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-38),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,discontinued
5215,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-22),Revised,11/20/2020,Available,,,,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5216,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-25),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5217,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",500 mcg/10 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-28),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5218,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","1,000 mcg/20 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-31)",Revised,11/20/2020,Limited Supply Available.,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,limited availability
5219,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","2,500 mcg/50 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-61)",Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: February 2021,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,limited availability
5220,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 2 mL ampul (NDC 0641-6024-10),Revised,7/22/2020,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,not available
5221,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 5 mL ampul (NDC 0641-6025-10),Revised,7/22/2020,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,not available
5222,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL ampul (NDC 0641-6026-05),Revised,7/22/2020,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,not available
5223,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 2 mL vial
(NDC 0641-6027-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5224,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 5 mL vial
(NDC 0641-6028-25)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,not available
5225,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL vial (NDC 0641-6029-25),Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,not available
5226,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL  50 mL vial
(NDC 0641-6030-01)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2020,not available
5227,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule 10 pack (NDC 17478-0030-02),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5228,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule; 25 pack (NDC 17478-0030-25),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5229,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 10 pack (NDC 17478-0030-05),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5230,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,20 mL ampule (NDC 17478-0030-20),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5231,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 25 pack (NDC 17478-0030-55),Revised,12/2/2019,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2020,available
5232,Finasteride Tablets,Mylan Pharmaceuticals Inc.,5 mg tablet (NDC 0378-5036-05)(NDC 0378-5036-77)(NDC 0378-5036-93),New,5/23/2018,,The discontinuation of this product is a business decision,,,Urology,To be Discontinued,5/23/2018,5/23/2018,,2020,discontinued
5233,Finasteride Tablets,Teva Pharmaceuticals,"1mg tablet (NDC 45963-600-03, 45963-600-09)",New,9/18/2020,,This product discontinuation is a business related decision.,,,Urology,To be Discontinued,9/18/2020,9/18/2020,,2020,discontinued
5234,Finasteride Tablets,Teva Pharmaceuticals,5mg tablet (NDC 45963-500-02),New,9/18/2020,,This product discontinuation is a business related decision.,,,Urology,To be Discontinued,9/18/2020,9/18/2020,,2020,discontinued
5235,Finasteride Tablets,Teva Pharmaceuticals,5 mg 30 CT (NDC 45963-500-30),New,9/18/2020,,"Teva’s Finasteride 5 mg Tablets marketed under NDC 0093-7355-56, NDC 0093-7355-05 & NDC 0093-7355-98 are not affected by this discontinuation.",,,Urology,To be Discontinued,9/18/2020,9/18/2020,,2020,discontinued
5236,Finasteride Tablets,Teva Pharmaceuticals,5 mg 90 CT (NDC 45963-500-08),New,9/18/2020,,"Teva’s Finasteride 5 mg Tablets marketed under NDC 0093-7355-56, NDC 0093-7355-05 & NDC 0093-7355-98 are not affected by this discontinuation.",,,Urology,To be Discontinued,9/18/2020,9/18/2020,,2020,discontinued
5237,"Floxuridine for Injection, USP","Fresenius Kabi USA, LLC",500 mg per vial (NDC 63323-145-07_,New,9/30/2020,,"Discontinued: May 30, 2019",,,Oncology,To be Discontinued,9/30/2020,9/30/2020,,2020,discontinued
5238,"Floxuridine for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9270-01),Reverified,10/9/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the Late October 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,,2020,not available
5239,"Fludarabine Phosphate for Injection, USP","Hospira, Inc.",50 mg Single Dose Glass Fliptop Vial (NDC 61703-0344-18),New,2/10/2020,,Discontinuation of the manufacture of the drug due to Active Pharmaceutical Ingredient Supplier market exit. Current supply expected to exhaust August 2020.,,,Oncology,To be Discontinued,2/10/2020,2/10/2020,,2020,discontinued
5240,Fludrocortisone Acetate Tablets,Teva Pharmaceuticals,"0.1 mg, 100 count bottle (NDC 0555-0997-02)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2020,
5241,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 100 count bottle (NDC 0115-7033-01)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2020,
5242,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 500 count bottle (NDC 0115-7033-02)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2020,
5243,Flumazenil Injection,Mylan,"0.5 mg in 5 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-447-53)",New,12/16/2019,,Expected Discontinuation April 2020,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,12/16/2019,12/16/2019,,2020,discontinued
5244,Flumazenil Injection,Mylan,"1 mg in 10 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-444-10)",Revised,7/19/2019,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,7/19/2019,7/19/2019,,2020,discontinued
5245,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR® (fluorescein injection, USP) 10%, 100 mg/mL in a 5 mL single use vial (NDC 17478-253-10)",Revised,12/2/2019,Available,Continue to allocate available inventory,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
5246,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR® (fluorescein injection, USP) 25%, 250 mg/mL in a 2 mL single use vial (NDC 17478-250-20)",Revised,12/2/2019,Available,Continue to allocate available inventory,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,available
5247,Fluorescein Injection,Novartis,Fluorescite (fluorescein injection) 10% 5 mL vial (NDC 0065-0092-65),Reverified,12/11/2019,Available,,,Other,Ophthalmology,Current,,,,2020,available
5248,Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution,Altaire,"Altafluor Solution Fluorescein sodium 0.25% and Benoxinate HCl 0.4%, 5 mL bottle (NDC 59390-0218-05)",Revised,12/10/2019,,,,,Ophthalmology,Resolved,12/10/2019,,,2020,
5249,Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution,Altaire,"Flurox Solution  Fluorescein sodium 2.5mg (0.25%), benoxinate hydrochloride 4mg (0.4%), 5mL bottle (NDC 54799-508-05)",Revised,12/11/2019,,,,,Ophthalmology,Resolved,12/11/2019,,,2020,
5250,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 100 Strips per box (ndc 17238-900-11),Reverified,2/13/2020,Available,,,,Ophthalmology,Current,,,,2020,available
5251,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 300 Strips per box (NDC 17238-900-30),Reverified,2/12/2020,Available,,,,Ophthalmology,Current,,,,2020,available
5252,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 1.0 mg 100 sterile strips (NDC 17478-404-01),Revised,12/2/2019,On backorder,Availability Q12020,,Other,Ophthalmology,Current,,,,2020,not available
5253,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 0.6 mg 300 sterile strips (NDC 17478-403-03),Revised,12/2/2019,On backorder,Availability Q12020,,Other,Ophthalmology,Current,,,,2020,not available
5254,Fluorouracil Injection,Teva Pharmaceuticals,5g/100mL injection (NDC 0703-3019-12),Revised,2/20/2020,,,,,Oncology,To be Discontinued,2/20/2020,2/20/2020,,2020,discontinued
5255,Fluorouracil Injection,Teva Pharmaceuticals,2.5g/50mL injection (NDC 0703-3018-12),Revised,2/20/2020,,Actively selling. Remaining inventory estimated to last until April 2020,,,Oncology,To be Discontinued,2/20/2020,2/20/2020,,2020,discontinued
5256,Fluorouracil Injection,Teva Pharmaceuticals,50mg/1mL injection (NDC 0703-3015-13),Revised,2/20/2020,,Actively selling. Remaining inventory estimated to last until April 2020,,,Oncology,To be Discontinued,2/20/2020,2/20/2020,,2020,discontinued
5257,Fluoxetine Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 28 count bottle (NDC 0378-5410-28)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5258,Fluoxetine Capsules,Mylan Pharmaceuticals Inc.,"20 mg, 28 count bottle (NDC 0378-5420-28)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5259,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 100 count bottle (NDC 0781-2823-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
5260,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 1000 count bottle (NDC 0781-2823-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
5261,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 100 count bottle (NDC 0781-2822-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
5262,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 1000 count bottle (NDC 0781-2822-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
5263,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 100 count bottle (NDC 0781-2824-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
5264,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 1000 count bottle (NDC 0781-2824-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
5265,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 30 count bottle (NDC 0781-2824-31)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
5266,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-6004-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5267,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 500 count bottle (NDC 0378-6004-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5268,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"2.5 mg, 100 count bottle (NDC 0378-6009-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5269,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"2.5 mg, 500 count bottle (NDC 0378-6009-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5270,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-6074-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5271,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-6074-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5272,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-6097-01)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5273,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-6097-05)",New,5/2/2019,,,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5274,Flurazepam Hydrochloride Capsules,Mylan Pharmaceuticals Inc.,Flurazepam HCl 15mg C 100s (NDC 0378-4415-01),Reverified,11/10/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5275,Flurazepam Hydrochloride Capsules,Mylan Pharmaceuticals Inc.,Flurazepam HCl 30mg C 100s (NDC 0378-4430-01),Reverified,11/10/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5276,Flurbiprofen Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 100 count bottle (NDC 0378-0076-01)",New,5/2/2019,,,,,Rheumatology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5277,Flurbiprofen Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-0093-01)",New,5/2/2019,,,,,Rheumatology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5278,"Flutamide Capsules, USP",Teva Pharmaceuticals,125 mg 180 count (NDC 0591-2466-18),New,6/10/2019,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
5279,Fluvastatin Sodium Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 30 count bottle (NDC 0378-5121-93)",New,5/2/2019,,,,,Endocrinology/Metabolism;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5280,Fluvastatin Sodium Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-5121-01)",New,5/2/2019,,,,,Endocrinology/Metabolism;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5281,Fluvoxamine ER Capsules,Par Pharmaceutical,100 mg. 30’s count (NDC 10370-175-11),Revised,4/7/2020,On backorder. Estimated availability end of April 2020,,,Delay in shipping of the drug,Psychiatry,Current,,,,2020,not available
5282,Fluvoxamine ER Capsules,Par Pharmaceutical,150 mg. 30’s count (NDC 10370-176-11),Revised,4/7/2020,On backorder. Estimated availability end of April 2020,,,Delay in shipping of the drug,Psychiatry,Current,,,,2020,not available
5283,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03)",Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5284,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03)",Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5285,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 100 (NDC 0603-3162-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5286,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 1000 (NDC 0603-3162-32)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5287,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 2500 (NDC 0603-3162-30)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5288,"Furosemide Injection, USP",Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 10 mL Single Dose Glass Vial (25 x 10 mL) (NDC 36000-284-25)",Reverified,10/28/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5289,"Furosemide Injection, USP",Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 2 mL Single Dose Glass Vial (25 x 2 mL)(NDC 36000-282-25)",Reverified,10/28/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5290,"Furosemide Injection, USP",Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 4 mL Single Dose Glass Vial (25 x 4 mL)(NDC 36000-283-25)",Reverified,10/28/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5291,"Furosemide Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,20 mg/mL (NDC 23155-473-41),Reverified,11/6/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5292,"Furosemide Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,40 mg/4mL (NDC 23155-473-42),Reverified,11/6/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5293,"Furosemide Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,100 mg/10mL (NDC 23155-473-44),Reverified,11/6/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5294,"Furosemide Injection, USP","Hospira, Inc.",20 mg/2 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-02),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5295,"Furosemide Injection, USP","Hospira, Inc.",40 mg/4 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-04),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5296,"Furosemide Injection, USP","Hospira, Inc.",100 mg/10 mL (10 mg/mL): Single Dose Glass Fliptop Vial (NDC 0409-6102-10),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5297,"Furosemide Injection, USP","Hospira, Inc.",100 mg/10 mL (10 mg/mL; Ansyr Plastic syringe (NDC 0409-1639-10),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5298,"Furosemide Injection, USP","Hospira, Inc.",40 mg/4 mL (10 mg/mL); Ansyr Plastic syringe (NDC 0409-9631-04),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5299,"Furosemide Injection, USP","Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-02)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5300,"Furosemide Injection, USP","Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-04)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5301,"Furosemide Injection, USP","Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-10)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5302,"Furosemide Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/2 mL single-dose vial (NDC 55150-322-25),Reverified,11/20/2020,Backordered — next shipments anticipated Jan 21,Intermittent availability expected.,,Delay in shipping of the drug,Cardiovascular,Current,,,,2020,not available
5303,"Furosemide Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),40 mg/4 mL single-dose vial (NDC 55150-323-25),Reverified,11/20/2020,Backordered — next shipments anticipated Jan 21,Intermittent availability expected.,,Delay in shipping of the drug,Cardiovascular,Current,,,,2020,not available
5304,"Furosemide Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),100 mg/10 mL single-dose vial (NDC 55150--324-25),Reverified,11/20/2020,Backordered — next shipments anticipated Jan 21,Intermittent availability expected.,,Delay in shipping of the drug,Cardiovascular,Current,,,,2020,not available
5305,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 5 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-81)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5306,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 10 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-82)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5307,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 15 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-83)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5308,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 20 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-84)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5309,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 10 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-36)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5310,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 15 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-37)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5311,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 20 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-38)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5312,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Pharmacy Bulk Package 50 mL Pharmacy Bulk Package, rubber stoppered, 10 per box (NDC 50419-188-58)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5313,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Pharmacy Bulk Package 100 mL Pharmacy Bulk Package, rubber stoppered, 10 per box (NDC 50419-188-11)",New,7/17/2019,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
5314,Gemcitabine Hydrochloride Injection,Apotex Corp.,"200 mg/5.26 mL (38 mg/mL), single dose vial (NDC 60505-6113-6)",New,1/8/2020,,Apotex made a business decision to discontinue this product.,,,Oncology,To be Discontinued,1/8/2020,1/8/2020,,2020,discontinued
5315,Gemcitabine Hydrochloride Injection,Apotex Corp.,"1 g/26.3 mL (38 mg/mL), single dose vial (NDC 60505-6114-0)",New,1/8/2020,,Apotex made a business decision to discontinue this product.,,,Oncology,To be Discontinued,1/8/2020,1/8/2020,,2020,discontinued
5316,Gemcitabine Hydrochloride Injection,Apotex Corp.,"2 g/52.6 mL (38 mg/mL), single dose vial (NDC 60505-6115-2)",New,1/8/2020,,Apotex made a business decision to discontinue this product.,,,Oncology,To be Discontinued,1/8/2020,1/8/2020,,2020,discontinued
5317,Gemcitabine Hydrochloride Injection,Mylan Institutional,"1 g, single dose vial (NDC 67457-462-01)",New,12/16/2019,,Expected Discontinuation March/April 2020,,,Oncology,To be Discontinued,12/16/2019,12/16/2019,,2020,discontinued
5318,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"1 g, single dose vial (NDC 45963-619-59)",New,1/16/2020,,Actively selling; Remaining inventory estimated to last through April 2020,,,Oncology,To be Discontinued,1/16/2020,1/16/2020,,2020,discontinued
5319,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"200 mg/5.26 mL (38 mg/mL), single dose vial (NDC 45963-623-57)",New,1/16/2020,,Actively selling; Remaining inventory estimated to last through March 2020,,,Oncology,To be Discontinued,1/16/2020,1/16/2020,,2020,discontinued
5320,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"1 g/26.3 mL (38 mg/mL), single dose vial (NDC 45963-624-58)",New,1/16/2020,,Actively selling; Remaining inventory estimated to last through July 2020,,,Oncology,To be Discontinued,1/16/2020,1/16/2020,,2020,discontinued
5321,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"2 g/52.6 mL (38 mg/mL), single dose vial (NDC 45963-636-60)",New,1/16/2020,,Actively selling; Remaining inventory estimated to last through March 2020,,,,To be Discontinued,1/16/2020,1/16/2020,,2020,discontinued
5322,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"200 mg, single dose vial (NDC 45963-612-57)",New,1/7/2020,,,,,Oncology,To be Discontinued,1/7/2020,1/7/2020,,2020,discontinued
5323,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"2 g, single dose vial (NDC 45963-620-60)",New,1/7/2020,,,,,Oncology,To be Discontinued,1/7/2020,1/7/2020,,2020,discontinued
5324,Gemcitabine Hydrochloride Injection,Mylan Institutional,"200 mg, single dose vial (NDC 67457-464-20)",New,6/26/2020,,Expected discontinuation December 2020,,,Oncology,To be Discontinued,6/26/2020,6/26/2020,,2020,discontinued
5325,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 7 Tablets in 1 Blister Pack (NDC 44004-321-07)",Reverified,11/5/2020,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,,2020,unclear
5326,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 5 Tablets in 1 Blister Pack (NDC 44004-321-05)",Reverified,11/5/2020,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,,2020,unclear
5327,Glimepiride Tablets,Teva Pharmaceuticals,1 mg 100 Count (NDC 0093-7254-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5328,Glimepiride Tablets,Teva Pharmaceuticals,2 mg 100 Count (NDC 0093-7255-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5329,Glimepiride Tablets,Teva Pharmaceuticals,4 mg 100 Count (NDC 0093-7256-01),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5330,Glimepiride Tablets,Teva Pharmaceuticals,4 mg 250 Count (NDC 0093-7256-52),New,5/17/2019,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5331,Glipizide Tablets,Teva Pharmaceuticals,"5mg tablets (NDC 0591-0460-10), (NDC 0591-0460-05), (NDC 0591-0460-01)",New,5/28/2020,,"Teva had evaluated the market and made decision to discontinue the product. No inventory remains for Glipizide 5 mg tablets 100 count NDC: 0591-0460-01. For the remaining presentations, allocations are being made based on customer Rx trends.",,,Endocrinology/Metabolism,To be Discontinued,5/28/2020,5/28/2020,,2020,discontinued
5332,Glipizide Tablets,Teva Pharmaceuticals,"10mg tablets, (NDC 0591-0461-10), (NDC 0591-0461-01), (NDC 0591-0461-05)",New,5/28/2020,,"Teva had evaluated the market and made decision to discontinue the product. No inventory remains for Glipizide 5 mg tablets 100 count NDC: 0591-0460-01. For the remaining presentations, allocations are being made based on customer Rx trends.",,,Endocrinology/Metabolism,To be Discontinued,5/28/2020,5/28/2020,,2020,discontinued
5333,Glycopyrrolate (Seebri Neohaler) Inhalation Powder,Sunovion Pharmaceuticals Inc.,"15.6mcg  (NDCs 63402-815-06, 63402-815-12, and 63402-815-60)",New,3/10/2020,,,,,Pulmonary/Allergy,To be Discontinued,3/10/2020,3/10/2020,,2020,discontinued
5334,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-1061-01)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5335,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"2 mg, 100 count bottle (NDC 0378-1062-01)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5336,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"3 mg, 100 count bottle (NDC 0378-1063-01)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5337,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"4 mg, 100 count bottle (NDC 0378-1065-01)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5338,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 1 mg, 100 Count (NDC 42806-048-01)",New,6/12/2019,Available,,,Other,Cardiovascular,Current,,,,2020,available
5339,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 2 mg, 100 Count (NDC 42806-296-01)",New,6/12/2019,Available,,,Other,Cardiovascular,Current,,,,2020,available
5340,Guanfacine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-1160-01),Reverified,11/10/2020,Unavailable. Estimated recovery TBD.,,,Other,Cardiovascular,Current,,,,2020,not available
5341,Guanfacine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-1190-01),Reverified,11/10/2020,Unavailable. Estimated recovery TBD.,,,Other,Cardiovascular,Current,,,,2020,not available
5342,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,1mg tablets 100 count bottle (NDC 0591-0444-01),Reverified,11/19/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5343,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,2 mg tablets 100 count bottle (NDC 0591-0453-01),Reverified,11/19/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5344,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,1 mg bottles of 30 (NDC 65162-711-03); 1 mg bottles of 100 (NDC 65162-711-10),Reverified,8/17/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5345,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,2 mg bottles of 30 (NDC 65162-713-03); 2 mg bottles of 100 (NDC 65162-713-10); 2 mg bottles of 500 (NDC 65162-713-50),Reverified,8/17/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5346,Guanidine Hydrochloride Tablets,Merck Sharp & Dohme Corp.,125 mg tablets (NDC 0085-0492-01),New,9/28/2020,,To be discontinued on or near October 2020.,,,Neurology,To be Discontinued,9/28/2020,9/28/2020,,2020,discontinued
5347,Haloperidol Lactate (Haldol) Injection,"Janssen Biotech, Inc.","5 mg/mL, 10 ampule in 1 box, > 1 mL in 1 ampule, (NDC 50458-255-01)",New,11/13/2020,,Product discontinuation as per business decision,,,Psychiatry,To be Discontinued,11/13/2020,11/13/2020,,2020,discontinued
5348,Haloperidol Lactate Injection,Patriot Pharmaceuticals,"5 mg/mL, 10 ampule in 1 box,> 1 mL in 1 ampule, (NDC 10147-0911-1)",New,11/13/2020,,Product discontinuation as per business decision,,,Psychiatry,To be Discontinued,11/13/2020,11/13/2020,,2020,discontinued
5349,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,0.5 mg (NDC 0378-0351-01) and (NDC 0378-0351-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5350,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-0257-01) and (NDC 0378-0257-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5351,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0214-01) and (NDC 0378-0214-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5352,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-0327-01) and (NDC 0378-0327-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5353,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0334-01),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5354,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,20 mg (NDC 0378-0355-01),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5355,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 100 CT (NDC 68382-079-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2020,
5356,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 1000 CT (NDC 68382-079-10),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2020,
5357,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 10MG 100 CT (NDC 68382-080-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2020,
5358,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 20MG 100 CT (NDC 68382-081-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2020,
5359,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-13-9101),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5360,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-83-9101),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5361,Haloperidol Tablets,Sandoz,0.5 mg 100 count unit dose (NDC 0781-13-9113),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5362,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-13-9201),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5363,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-83-9201),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5364,Haloperidol Tablets,Sandoz,1 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5365,Haloperidol Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-13-9801),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5366,Haloperidol Tablets,Sandoz,2 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5367,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-13-9610),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5368,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-83-9610),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5369,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-13-9601),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5370,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-83-9601),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5371,Haloperidol Tablets,Sandoz,5 mg 100 count unit dose (NDC 0781-13-9613),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5372,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-13-9701),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5373,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-83-9701),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5374,Haloperidol Tablets,Sandoz,10 mg 100 count unit dose (NDC 0781-13-9713),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5375,Haloperidol Tablets,Sandoz,20 mg 100 count bottle (NDC 0781-83-9301),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2020,
5376,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 2,000 USP units in 1000 mL.  Product code 2B0944  (NDC 0338-0433-04)",Reverified,10/28/2020,Available,,,,Hematology,Current,,,,2020,available
5377,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 1,000 USP units in 500 mL.  Product code 2B0953 (NDC 0338-0431-03)",Reverified,10/28/2020,Unavailable,Product code 2B0953 was replaced with code AHB0953U,,Other,Hematology,Current,,,,2020,not available
5378,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","1,000 Units/500 mL (2 Units/mL); Flexible Container (NDC 00409-7620-03)",Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: July 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Hematology,Current,,,,2020,limited availability
5379,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","2,000 Units/1000 mL (2 Units/mL); Flexible Container (NDC 00409-7620-59)",Revised,11/20/2020,Available,,,Other,Hematology,Current,,,,2020,available
5380,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection, 1,000 units / 500 mL (2 units / mL) in VIAFLEX Plastic Container.  Product code AHB0953U (NDC 0338-0424-18)",Reverified,10/28/2020,Available,Product code AHB0953U replaces code 2B0953,,,Hematology,Current,,,,2020,available
5381,Heparin Sodium and Sodium Chloride 0.9% Injection,Sagent Pharmaceuticals,1000 units/mL 10mL pack 25 (NDC 25021-400-10),Reverified,10/22/2020,Available.,,,,Hematology,Current,,,,2020,available
5382,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","1,000 Units/500 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-77)",Reverified,10/23/2020,Expected availability February 2021,,,Other,Hematology,Current,,,,2020,not available
5383,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","2,000 Units/1000 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-10)",Reverified,10/23/2020,Expected availability February 2021,,,Other,Hematology,Current,,,,2020,not available
5384,"Hydralazine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","20 mg per mL, SDV (NDC 63323-614-01)",Revised,10/23/2020,Backordered.  Next release expected November 2020.,Check wholesaler for inventory,,Manufacturing Delay,Cardiovascular,Current,,,,2020,not available
5385,"Hydralazine Hydrochloride Injection, USP",Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 10) (NDC 17478-934-01)",Revised,11/3/2020,Not available,Not available,,Other,Cardiovascular,Current,,,,2020,not available
5386,"Hydralazine Hydrochloride Injection, USP",Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 25) (NDC 17478-934-15)",Revised,11/3/2020,On allocation / Recovery expected March 2021,Manufacturer interruption production issues.,,Other,Cardiovascular,Current,,,,2020,limited availability
5387,"Hydralazine Hydrochloride Injection, USP",Mylan Institutional,20 mg / 1 ml] 25PK (NDC 67457-291-01),Reverified,11/10/2020,Intermittent supply,,,Demand increase for the drug,Cardiovascular,Current,,,,2020,limited availability
5388,"Hydralazine Hydrochloride Injection, USP","X-GEN Pharmaceuticals, Inc.",20 mg/mL per vial (NDC 39822-0500-4),Revised,9/9/2020,Not available and no plans to manufacture at this time.,,,Other,Cardiovascular,Current,,,,2020,discontinued
5389,Hydrochlorothiazide (Microzide) Capsules,Allergan Sales LLC,12.5 mg (NDC 52544-622-01),New,10/22/2019,,"The authorized generic, Hydrochlorothiazide Capsules, USP, 12.5 mg remains commercially available.",,,Cardiovascular,To be Discontinued,10/22/2019,10/22/2019,,2020,discontinued
5390,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,20 mg/25 mg (NDC 0378-2025-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
5391,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,12.5 mg/ 20 mg (NDC 0378-2012-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
5392,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,10 mg/ 12.5 mg (NDC 0378-1012-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
5393,Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution,Perrigo Pharmaceuticals,Hydrocodone Bitartrate (5 mg/5 mL) and Homatropine Methylbromide (1.5 mg/5 mL)(NDC 0574-1105-16),New,6/5/2018,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,6/5/2018,6/5/2018,,2020,discontinued
5394,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 12 suppositories (NDC 59741-301-12),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5395,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 24 suppositories (NDC 59741-301-24),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5396,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 100 suppositories (NDC 59741-301-01),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5397,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,5 mg tablet; bottle of 50 (NDC 59762-0073-1),Revised,11/20/2020,Next Delivery: December 2020; Estimated Recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism,Current,,,,2020,unclear
5398,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,10 mg tablet; bottle of 100 (NDC 59762-0074-1),Revised,11/20/2020,Next Delivery: December 2020; Estimated Recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism,Current,,,,2020,unclear
5399,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,20 mg tablet; bottle of 100 (NDC 59762-0075-1),Revised,11/20/2020,Next Delivery: December 2020; Estimated Recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism,Current,,,,2020,unclear
5400,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,Cortef 20 mg tablet; bottle of 100 (NDC 0009-0044-01),Revised,11/20/2020,Available,,,Other,Endocrinology/Metabolism,Current,,,,2020,available
5401,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,Cortef 5 mg tablet; bottle of 50 (NDC 0009-0012-01),Revised,11/20/2020,Next Delivery and Estimated Recovery: October 2020,,,Other,Endocrinology/Metabolism,Current,,,,2020,not available
5402,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,Cortef 10 mg tablet; bottle of 100 (NDC 0009-0031-01),Revised,11/20/2020,Available,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2020,available
5403,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","5 mg, 50 count bottles (NDC 42543-140-50)",Reverified,10/5/2020,Available,ANDA Holder: Strides Pharma,,Other,Endocrinology/Metabolism,Current,,,,2020,available
5404,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","10 mg, 100 count bottles (NDC 42543-141-01)",Reverified,10/5/2020,Available,ANDA Holder: Strides Pharma,,Other,Endocrinology/Metabolism,Current,,,,2020,available
5405,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","20 mg, 100 count bottles (NDC 42543-142-01)",Reverified,10/5/2020,Available,ANDA Holder: Strides Pharma,,Other,Endocrinology/Metabolism,Current,,,,2020,available
5406,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"5 mg, bottle of 50 (NDC 0603-3899-19)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5407,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"10 mg, bottle of 100 (NDC 0603-3900-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5408,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"20 mg, bottle of 100 (NDC 0603-3901-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5409,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","5 mg, 50 count bottles (NDC 64380-970-25)",New,10/5/2020,Available,,,,Endocrinology/Metabolism,Current,,,,2020,available
5410,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","10 mg, 100 count bottles (NDC 64380-971-06)",New,10/5/2020,Available,,,,Endocrinology/Metabolism,Current,,,,2020,available
5411,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","20 mg, 100 count bottles (NDC 64380-972-06)",New,10/5/2020,Available,,,,Endocrinology/Metabolism,Current,,,,2020,available
5412,"Hydrocortisone Tablets, USP",Amneal Pharmaceutical,100mg/100 count (NDC 00115-1697-01),New,5/15/2020,Unavailable,,,Limited API availability,Endocrinology/Metabolism,Current,,,,2020,not available
5413,"Hydrocortisone Tablets, USP",Amneal Pharmaceutical,20mg/100 count (NDC 00115-1700-01),New,5/15/2020,Limited availability,,,Limited API availability,Endocrinology/Metabolism,Current,,,,2020,limited availability
5414,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"32 mg, 100 count (NDC 0591-3631-01)",New,6/20/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/2019,6/20/2019,,2020,discontinued
5415,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"16 mg, 100 count (NDC 0591-3630-01)",New,6/20/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/2019,6/20/2019,,2020,discontinued
5416,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"12 mg, 100 count (NDC 0591-3739-01)",New,6/20/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/2019,6/20/2019,,2020,discontinued
5417,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"8 mg, 100 count (NDC 0591-3629-01)",New,6/20/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/2019,6/20/2019,,2020,discontinued
5418,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)                                                                                           Microvault",Revised,11/16/2020,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2020,available
5419,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-11)                                                                                                                                                                                     Microvault",Revised,11/16/2020,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2020,available
5420,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","1 mg per 1 mL, Single dose vial, (NDC 63323-852-25)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5421,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-853-25)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5422,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-854-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5423,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5424,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","50 mg per 5 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-15)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5425,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","500 mg per 50 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-50)",Revised,11/16/2020,Backorderd. Next release December 2020.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5426,"Hydromorphone Hydrochloride Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 1 mL vial (NDC 0641-0121-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5427,"Hydromorphone Hydrochloride Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0641-2341-41)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5428,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-05)",Revised,11/16/2020,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,unclear
5429,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-10)                                                                                                                                       Blister pack",Revised,11/16/2020,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,unclear
5430,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe (NDC 76045-010-10)",Revised,11/16/2020,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5431,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 4 mg per 1 mL, prefilled syringe (NDC 76045-011-10)",Revised,11/16/2020,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5432,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1ML (NDC0703-0110-03),Reverified,11/19/2020,Available,,,,Analgesia/Addiction,Current,,,,2020,available
5433,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1ML (NDC 0703-0113-03),Reverified,11/19/2020,Available,,,,Analgesia/Addiction,Current,,,,2020,available
5434,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1 ML (NDC 0703-0018-01),Reverified,11/19/2020,Available,,,,Analgesia/Addiction,Current,,,,2020,available
5435,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",0.5 mg/0.5 mL (1 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-05),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5436,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/1 mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-10),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
5437,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1312-10),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
5438,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1283-31),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5439,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1312-30),Revised,11/20/2020,Next Delivery and Estimated Recovery: November 2020,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5440,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",4 mg/1 mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1304-31),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5441,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/mL); Glass Ampul (NDC 00409-2552-01),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5442,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Glass Ampul (NDC 00409-3356-01),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
5443,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",4 mg/1 mL (4 mg/mL); Glass Ampul (NDC 00409-2540-01),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
5444,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3365-01),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5445,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-01),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5446,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",50 mg/5 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-05),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5447,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",500 mg/50 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-50),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5448,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)",Revised,12/2/2019,Unavailable. Estimataed recovery Dec 2019,"Expected availability Dec, 2019",,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5449,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)",Revised,12/2/2019,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5450,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)",Revised,12/2/2019,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5451,Hydroxychloroquine Sulfate Tablets,Teva Pharmaceuticals,"200 mg, 500 count bottle (NDC 0591-3041-05)",Revised,6/26/2020,,,"Distributed by Actavis Pharma (Teva);  500 count bottle: on backorder, recovery to be determined.",,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5452,Hydroxychloroquine Sulfate Tablets,Sandoz,"200 mg, 100 count bottle (NDC 16714-753-01)",Revised,6/26/2020,,,Northstar Rx label; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5453,Hydroxychloroquine Sulfate Tablets,Alkaloida Chemical Co. Zrt.,"200 mg, 100 count bottle (NDC 57664-761-88); 500 count bottle (NDC 57664-761-13)",Revised,6/26/2020,,,Distributed by Sun Pharmaceutical. Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5454,Hydroxychloroquine Sulfate Tablets,Amneal Pharmaceutical,"200 mg, 100 count bottle (NDC 69238-1544-1)",Revised,6/26/2020,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5455,Hydroxychloroquine Sulfate Tablets,Appco Pharma LLC,"200 mg, 100 count bottle (NDC 43598-721-01); 500 count bottle (NDC 43598-721-05)",Revised,6/26/2020,,,Distributed by Dr. Reddy’s Laboratories Inc.; Limited supply subject to allocation; duration to be determined,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5456,Hydroxychloroquine Sulfate Tablets,Concordia Pharmaceuticals Inc.,"200 mg, 100 count bottle (NDC 66993-057-02); 500 count bottle (NDC 66993-057-04)",Revised,6/26/2020,,,Distributed by Prasco Laboratories; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5457,Hydroxychloroquine Sulfate Tablets,Concordia Pharmaceuticals Inc.,"Plaquenil 200 mg, 100 count bottle (NDC 59212-562-10)",Revised,6/26/2020,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5458,Hydroxychloroquine Sulfate Tablets,Laurus Labs Limited,"200 mg, 100 count bottle (NDC42385-927-01); 500 count bottle (NDC 42385-927-05)",Revised,6/26/2020,,,Distributed by Rising Pharmaceuticals; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5459,Hydroxychloroquine Sulfate Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100 count bottle (NDC 0378-0373-01)",Revised,6/26/2020,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5460,Hydroxychloroquine Sulfate Tablets,Sandoz,"200 mg, 100 count bottle (NDC 0781-5994-01); 500 count bottle (NDC 0781-5994-05)",Revised,6/26/2020,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5461,Hydroxychloroquine Sulfate Tablets,Teva Pharmaceuticals,"200 mg, 100 count bottle (NDC 0591-3041-01)",Revised,6/26/2020,,,Distributed by Actavis Pharma (Teva); 100 count bottle: Limited supply subject to allocation; duration to be determined.,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5462,Hydroxychloroquine Sulfate Tablets,Zydus Pharmaceuticals USA Inc.,"200 mg, 100 count bottle (NDC 68382-096-01); 500 count bottle (NDC 68382-096-05)",Revised,6/26/2020,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5463,Hydroxychloroquine Sulfate Tablets,Zydus Pharmaceuticals USA Inc.,"200 mg, 100 count bottle (NDC 16714-110-01)",Revised,6/26/2020,,,Northstar Rx label; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5464,Hydroxychloroquine Sulfate Tablets,Ipca Laboratories Limited,"200 mg, 100 count bottle (NDC 76385-144-01)",New,6/26/2020,,,Distributed by Bayshore Pharmaceuticals; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5465,Hydroxychloroquine Sulfate Tablets,Accord Healthcare Inc.,"200 mg, 500 count bottle (NDC 16729-485-16)",New,6/26/2020,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/2020,,,2020,
5466,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),Hydroxyprogesterone Caproate Injection USP 250 mg/1 mL single-dose vial (NDC 55150-309-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5467,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),"Hydroxyprogesterone Caproate Injection USP 1,250 mg/5 mL multiple-dose vial (NDC 55150-310-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5468,Hydroxyprogesterone Caproate Injection,Slayback Pharma,Hydroxyprogesterone Caproate Injection 250 mg/ 1 ml (NDC 71225-105-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5469,Hydroxyprogesterone Caproate Injection,American Regent/Luitpold,"Hydroxyprogesterone Caproate Injection, USP 250mg/mL 1mL Single Dose Vial (NDC 0517-1767-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5470,Hydroxyprogesterone Caproate Injection,Slayback Pharma,"Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml (NDC 71225-104-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5471,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single dose auto-injector 1.1mL for subcutaneous injection: (NDC 64011-247-02),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5472,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5473,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Multi-dose vial 5mL for intramuscular injection: (NDC 64011-243-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5474,Hydroxyprogesterone Caproate Injection,Prasco Laboratories,Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2020,
5475,Hydroxypropyl (Lacrisert) Cellulose Ophthalmic Insert,"Bausch Health Americas, Inc.","Lacrisert, 5 mg per ophthalmic insert, 60 unit dose blister pack (NDC 24208-800-60)",Reverified,10/1/2020,"Product is on back order, estimated release not sooner than December 2020",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,,2020,not available
5476,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66),Revised,11/20/2020,Next delivery and Estimated recovery: January 2021,Shortage per manufacturer: Manufacturing Delay,,Other,Psychiatry,Current,,,,2020,not available
5477,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66),Revised,11/20/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5478,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01),Reverified,11/6/2020,Available,,,,Psychiatry,Current,,,,2020,available
5479,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05),Reverified,11/6/2020,Available,,,,Psychiatry,Current,,,,2020,available
5480,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01),Reverified,11/6/2020,Available,,,,Psychiatry,Current,,,,2020,available
5481,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05),Reverified,11/6/2020,Available,,,,Psychiatry,Current,,,,2020,available
5482,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,100 mg 100 count (NDC 0555-0324-02),Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5483,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 100 count (NDC 0555-0323-02),Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5484,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 500 count (NDC 0555-0323-04),Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5485,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 100 count (NDC 0555-0302-02),Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5486,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 500 count (NDC 0555-0302-04),Reverified,11/19/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
5487,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 100 count (NDC 0185-0674-01),Reverified,11/13/2020,Supply Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
5488,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 500 count (NDC 0185-0674-05),Reverified,11/13/2020,Supply Available,,,Demand increase for the drug,Psychiatry,Current,,,,2020,available
5489,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01),Reverified,2/20/2020,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,,2020,limited availability
5490,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02),Reverified,2/20/2020,Expected to be on allocation until sometime in 1Q20.,,,OIther,Psychiatry,Current,,,,2020,limited availability
5491,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01),Reverified,2/20/2020,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,,2020,limited availability
5492,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02),Reverified,2/20/2020,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,,2020,limited availability
5493,Ifosfamide/Mesna Kit,Teva Pharmaceuticals,1 gram/20 mL; 1 gram/10 mL  (NDCs 0703-4100-48 and 0703-4100-58),New,10/18/2019,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,10/18/2019,10/18/2019,,2020,discontinued
5494,Ifosfamide/Mesna Kit,Teva Pharmaceuticals,3 gram/60 mL; 1 gram/10 mL (NDC 0703-4100-68 ),New,10/18/2019,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,10/18/2019,10/18/2019,,2020,discontinued
5495,"Imipenem and Cilastatin for Injection, USP",Merck Sharp & Dohme Corp.,500 mg  imipenem  equivalent  and  500 mg  cilastatin  equivalent  and  20 mg  sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3516-59),Revised,12/18/2017,Product is available,"For additional information, please contact: Merck National Service Center at 1-800-672-6372",,Demand increase for the drug,Anti-Infective,Current,,,,2020,available
5496,"Imipenem and Cilastatin for Injection, USP","Fresenius Kabi USA, LLC","250 mg/250 mg per vial, single dose vial, sterile powder (NDC 63323-349-25)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,,2020,available
5497,"Imipenem and Cilastatin for Injection, USP","Fresenius Kabi USA, LLC","500 mg/500 mg per vial, single dose vial, sterile powder (NDC  63323-322-25)",Reverified,11/16/2020,Available,Check wholesaler for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,,2020,available
5498,Indacterol Maleate (Arcapta Neohaler) Inhalation Powder,Sunovion Pharmaceuticals Inc.,75mcg  (NDCs 63402-675-06 and 63402-675-30),New,3/10/2020,,,,,Pulmonary/Allergy,To be Discontinued,3/10/2020,3/10/2020,,2020,discontinued
5499,Indacterol Maleate and Glycopyrrolate (Utibron Neohaler) Inhalation Powder,Sunovion Pharmaceuticals Inc.,"15.6mcg; 27.5mcg  (NDCs 63402-681-06, 63402-681-12, and 63402-681-60)",New,3/10/2020,,,,,Pulmonary/Allergy,To be Discontinued,3/10/2020,3/10/2020,,2020,discontinued
5500,Indinavir (CRIXIVAN) Capsules,Merck Sharp & Dohme Corp.,"400 mg capsules, unit-of-use bottles of 180 (with desiccant)(NDC 0006-0573-62)",New,3/31/2020,,To be discontinued on or near August 2020.,,,Antiviral,To be Discontinued,3/31/2020,3/31/2020,,2020,discontinued
5501,Indinavir (CRIXIVAN) Capsules,Merck Sharp & Dohme Corp.,200 mg capsules (NDC 0006-0571-43),New,9/21/2020,,,,,Antiviral,To be Discontinued,9/21/2020,9/21/2020,,2020,discontinued
5502,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 100s (NDC 0378-0143-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
5503,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 1000s (NDC 0378-0143-10)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
5504,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 100s (NDC 0378-0147-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
5505,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 500s (NDC 0378-0147-05)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
5506,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4350-01),New,9/12/2019,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2020,discontinued
5507,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent ((NDC 0085-4351-01)),New,9/12/2019,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2020,discontinued
5508,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01),New,9/12/2019,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2020,discontinued
5509,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Solution for Injection (Interferon alfa-2b) 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1168-01),New,9/12/2019,,To be discontinued in 2021,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2020,discontinued
5510,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Solution for Injection (Interferon alfa-2b) 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1133-01),New,9/12/2019,,To be discontinued in 2021,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2020,discontinued
5511,Isocarboxazid Tablets,Validus Pharmaceuticals LLC,10mg (NDC 30698-032-01),Revised,1/10/2020,,,,,Psychiatry,Resolved,1/10/2020,,,2020,
5512,Isoniazid Tablets,Teva Pharmaceuticals,300 mg 1000 count (NDC 0555-0071-05),New,10/27/2020,,Teva made a business decision to discontinue the 1000 count presentation. The other presentations of Isoniazid Tablets product remain active.,,,Anti-Infective,To be Discontinued,10/27/2020,10/27/2020,,2020,discontinued
5513,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 100 (NDC 0603-4110-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5514,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 500 (NDC 0603-4110-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5515,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 1000 (NDC 0603-4110-32)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5516,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 100 (NDC 0603-4111-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5517,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 500 (NDC 0603-4111-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5518,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 1000 (NDC 0603-4111-32)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5519,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"120 mg, bottle of 100 (NDC 0603-4112-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5520,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9509-10)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured in the July - August 2020 timeframe.  Product will be made available as it is released.,,,Anesthesia,Current,,,,2020,not available
5521,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL vial (NDC 0143-9508-10)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5522,Ketamine Injection,Mylan Institutional,200 mg / 20 mL (NDC 67457-181-20),Reverified,11/10/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5523,Ketamine Injection,Mylan Institutional,500 mg / 10 mL (NDC 67457-001-10),Reverified,11/10/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5524,Ketamine Injection,Mylan Institutional,1000 mg / 10 mL (NDC 67457-108-10),Reverified,11/10/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5525,Ketamine Injection,"Hospira, Inc.",500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2051-05),Reverified,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
5526,Ketamine Injection,"Hospira, Inc.",500 mg/10 mL (50 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2053-10),Reverified,11/20/2020,Next Delivery and Estimated Recovery: January 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
5527,Ketamine Injection,Par Pharmaceutical,"10 mg/mL, 20 mL MDV (NDC 42023-113-10)",Revised,7/28/2020,Backordered due to increased demand.  Expected recovered date is September 2020.,,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
5528,Ketamine Injection,Par Pharmaceutical,"100 mg/mL, 5 mL MDV (NDC 42023-115-10)",Revised,7/28/2020,Available,Please check wholesalers for supply,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5529,Ketamine Injection,Par Pharmaceutical,"50 mg/mL, 10 mL MDV (NDC 42023-114-10)",Revised,7/28/2020,Available,Please check wholesalers for supply,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5530,Ketoconazole Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100 count bottle (NDC 0378-0261-01)",New,5/2/2019,,,,,Anti-Infective,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5531,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",New,11/25/2019,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5532,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 69336-127-10)",Reverified,9/28/2020,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,,2020,available
5533,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 69336-127-11)",Reverified,9/28/2020,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,,2020,available
5534,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",Reverified,9/28/2020,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,,2020,discontinued
5535,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",Reverified,9/28/2020,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,,2020,discontinued
5536,Ketoprofen Capsules,Mylan Pharmaceuticals Inc.,"200 mg Extended-Release Capsules, bottle of 100 (NDC 0378-8200-01)",Reverified,11/10/2020,Available,,,Other,Analgesia/Addiction;Rheumatology,Current,12/23/2016,,,2020,available
5537,Ketoprofen Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0093-3193-01)",Reverified,11/19/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2020,not available
5538,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 100 count bottle (NDC 0093-3195-01)",Reverified,11/19/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2020,not available
5539,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 500 count bottle (NDC 0093-3195-05)",Reverified,11/19/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2020,not available
5540,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",New,11/25/2019,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5541,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","50 mg, 100 count bottle (NDC 23155-021-01)",Reverified,9/28/2020,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2020,available
5542,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","75 mg, 100 count bottle (NDC 23155-022-01)",Reverified,9/28/2020,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2020,available
5543,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","15 mg/mL, 1 mL vial (NDC 0641-6041-25)",Reverified,7/22/2020,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,unclear
5544,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 1 mL vial (NDC 0641-6042-25)",Reverified,7/22/2020,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,unclear
5545,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 2 mL vial (NDC 0641-6043-25)",Reverified,7/22/2020,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,unclear
5546,Ketorolac Tromethamine Injection,Virtus Pharmaceuticals,30MG/ML (NDC 69543-0386-25),New,3/26/2018,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5547,Ketorolac Tromethamine Injection,Gland Pharma Limited,15 mg/mL vial (NDC 70860-700-01 and 70860-700-02),Reverified,9/28/2020,"Backordered, next shipment in November","Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5548,Ketorolac Tromethamine Injection,Gland Pharma Limited,30 mg/mL vial (NDC 70860-701-01 and 70860-701-03),Reverified,9/28/2020,"Backordered, next shipment in November","Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5549,Ketorolac Tromethamine Injection,Gland Pharma Limited,60 mg/mL vial (NDC 70860-701-02 and 70860-701-04),Reverified,9/28/2020,"Backordered, next shipment in November","Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5550,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 15MG/ML 25X1ML (NDC 25021-700-01),Reverified,10/22/2020,Backordered. Estimated availability TBD,,,Manufacturing delays,Analgesia/Addiction,Current,,,,2020,not available
5551,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X2ML (NDC 25021-701-02),Reverified,10/22/2020,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,,2020,not available
5552,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X1ML (NDC 25021-701-01),Reverified,10/22/2020,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,,2020,not available
5553,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-2287-23),Reverified,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
5554,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-31),Reverified,11/20/2020,Next Delivery and Estimated Recovery: January 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2020,not available
5555,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-61),Reverified,11/20/2020,Next Delivery and Estimated Recovery: January 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2020,not available
5556,Ketorolac Tromethamine Injection,"Hospira, Inc.",15 mg/mL (15 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3793-01),Reverified,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,limited availability
5557,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3795-01),Reverified,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5558,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3796-01),Reverified,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
5559,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose Amber Vial, (NDC 63323-161-01)",Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2020,not available
5560,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-01)",Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2020,not available
5561,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-02)",Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2020,not available
5562,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 30 mg/ mL.  Single dose glass flip top vial - 25 units per carton (NDC 0338-0072-25)",Revised,10/28/2020,Available,FOR INTRAVENOUS AND INTRAMUSCULAR USE. 30mg/mL (1 mL fill volume/ 2 mL container),,,Analgesia/Addiction,Current,,,,2020,available
5563,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-107-10)",Revised,11/16/2020,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2020,available
5564,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-104-10)",Revised,11/16/2020,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2020,available
5565,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","60 mg per 2 mL, Single Dose, Simplist Syringe, (NDC 76045-105-20)",Revised,11/16/2020,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2020,available
5566,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 15 mg/mL. Single dose glass flip top vial. 10 units per carton (NDC 0338-0069-10)",Revised,10/28/2020,"Stocked out, Recovery mid-November 2020",FOR INTRAVENOUS AND INTRAMUSCULAR USE. 15 mg/mL (1 mL fill volume/ 2 mL container),,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
5567,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 1 mL vial (NDC 72266-118-25)",Reverified,9/28/2020,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
5568,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 2 mL vial (NDC 72266-119-25)",Reverified,9/28/2020,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Analgesia/Addiction,Current,,,,2020,available
5569,Labetalol Hydrochloride Injection,Gland Pharma,"5mg/mL, 20 mL vial (NDC 72266-102-01)",Reverified,12/11/2019,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,,2020,available
5570,Labetalol Hydrochloride Injection,Gland Pharma,"5 mg/mL, 40 mL vial (NDC 72266-103-01)",Reverified,12/11/2019,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,,2020,available
5571,Labetalol Hydrochloride Injection,"Hospira, Inc.",100 mg/20 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2267-20),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5572,Labetalol Hydrochloride Injection,"Hospira, Inc.",200 mg/40 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2267-54),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5573,Labetalol Hydrochloride Injection,"Hospira, Inc.",20 mg/4 mL (5 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2339-34),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5574,Labetalol Hydrochloride Injection,Akorn Pharmaceuticals,5mg/mL (100mg/20mL) Multi-Dose vial (NDC 17478-420-20),Revised,12/2/2019,Available,,,Other,Cardiovascular,Current,,,,2020,available
5575,Labetalol Hydrochloride Injection,Akorn Pharmaceuticals,5mg/mL (200mg/40mL) Multi-Dose vial (NDC 17478-420-40 ),Revised,12/2/2019,Available,,,Other,Cardiovascular,Current,,,,2020,available
5576,Labetalol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 20 mL multidose vial (NDC 0143-9622-01)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,not available
5577,Labetalol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 40 mL multidose vial (NDC 0143-9623-01)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5578,Lamivudine and Zidovudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine and Zidovudine Tablets 150mg and 300mg (NDC 0378-5180-91),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2020,discontinued
5579,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 100mg (NDC 0378-5168-93),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2020,discontinued
5580,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 150mg (NDC 0378-5169-91),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2020,discontinued
5581,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 300mg (NDC 0378-5170-93),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2020,discontinued
5582,Lamotrigine Tablets,Teva Pharmaceuticals,100 mg (NDCs 0093-0463-01 and 0093-0463-05),New,10/15/2019,,This product is being discontinued due to a business decision.,,,Neurology,To be Discontinued,10/15/2019,10/15/2019,,2020,discontinued
5583,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 100 (NDC 69097-148-07),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5584,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 500 (NDC NDC 69097-148-12),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5585,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 1000 (NDC 69097-148-15),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5586,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 100 (NDC 69097-149-07),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5587,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 500 (NDC 69097-149-12),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5588,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 1000 (NDC 69097-149-15),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5589,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 60 (NDC 69097-151-03),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5590,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 500 (NDC 69097-151-12),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5591,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 1000 (NDC 69097-151-15),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5592,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 60 (NDC 69097-152-03),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5593,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 500 (NDC 69097-152-12),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5594,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 1000 (NDC 69097-152-15),New,9/20/2019,,,,,Neurology,To be Discontinued,9/20/2019,9/20/2019,,2020,discontinued
5595,Lanoxin (digoxin) Tablets,Concordia Pharmaceuticals Inc.,Lanoxin (digoxin) 187.5 mcg (0.1875 mg) tablets; 100-count bottles (NDC 59212-245-55),New,5/22/2018,,"A business decision was made to discontinue manufacture and supply of the Lanoxin 187.5 mcg (0.1875 mg) strength tablets.  All existing lots on the market are good through expiry. The anticipated final date of availability for sale is June 30, 2018 (NDC 59212-245-55).",,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
5596,Latanoprost Ophthalmic Solution 0.005%,Sandoz,2.5 mL Bottle (NDC 61314-547-01),Revised,4/6/2020,,,,,Ophthalmology,Resolved,4/6/2020,,,2020,
5597,Latanoprost Ophthalmic Solution 0.005%,Pfizer Pharmaceuticals,"2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle (NDC 59762-0333-2)",Revised,4/6/2020,,,,,Ophthalmology,Resolved,4/6/2020,,,2020,
5598,Latanoprost Ophthalmic Solution 0.005%,Bausch Health,"2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle (NDC 24208-463-25)",Revised,4/6/2020,,,,,Ophthalmology,Resolved,4/6/2020,,,2020,
5599,Lesinurad (ZURAMPIC) Tablets,Ironwood Pharmaceuticals Inc.,ZURAMPIC® (lesinurad) 200 mg tablets 5 count bottle (NDC 70785-011-05),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.",,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5600,Lesinurad (ZURAMPIC) Tablets,Ironwood Pharmaceuticals Inc.,ZURAMPIC® (lesinurad) 200 mg tablets 30 count bottle (NDC 70785-011-30),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.",,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5601,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200mg tablets 5 count bottle (NDC 70785-021-05),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5602,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200 mg tablets 30 count bottle (NDC 70785-021-30),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,Endocrinology/Metabolism,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5603,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200 mg tablets 90 count bottle (NDC 70785-021-90),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5604,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 5 count bottle (NDC 70785-022-05),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5605,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 30 count bottle (NDC 70785-022-30),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5606,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 90 count bottle (NDC 70785-022-90),New,4/15/2019,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
5607,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,480 mg injection (NDC 0006-5004-01),Revised,12/2/2019,Available,,,Other,Antiviral,Current,,,,2020,available
5608,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,240 mg injection (NDC 0006-5003-01),Revised,12/2/2019,Available,,,Other,Antiviral,Current,,,,2020,available
5609,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,500mg vial (NDC 25021-828-50),Reverified,10/22/2020,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,,,,2020,not available
5610,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,"100mg/vial, 20mL (NDC 0703-5140-01)",Reverified,11/19/2020,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2020,available
5611,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,350mg/vial 30mL (NDC 0703-5145-01),Reverified,11/19/2020,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2020,available
5612,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",200 mg SDV (NDC 63323-710-50),Reverified,11/16/2020,Available,Check Wholesaler Inventory,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2020,available
5613,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",500 mg SDV (NDC 63323-711-00),Reverified,11/16/2020,Available,Check Wholesaler Inventory,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2020,available
5614,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,50 mg vial (NDC 25021-813-10),Reverified,10/22/2020,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2020,not available
5615,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,100mg vial (NDC 25021-814-30),Reverified,10/22/2020,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2020,not available
5616,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,200mg vial (NDC 25021-815-30),Reverified,10/22/2020,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2020,not available
5617,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,350mg vial (NDC 25021-816-30),Reverified,10/22/2020,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2020,not available
5618,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-50)",New,5/15/2020,Backordered. Next release July 2020.,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,,2020,not available
5619,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg, 10 mL vial (NDC 0143-9555-01)",New,7/16/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2020,available
5620,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg, 20 mL vial (NDC 0143-9554-01)",New,7/16/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2020,available
5621,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","200 mg, 30 mL vial (NDC 0143-9553-01)",New,7/16/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2020,available
5622,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","350 mg, 50 mL vial (NDC 0143-9552-01)",New,7/16/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2020,available
5623,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 22.5 mg (NDC 62935-223-05),Reverified,11/18/2020,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5624,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 30 mg (NDC 62935-303-30),Reverified,11/18/2020,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5625,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 45 mg (NDC 62935-453-45),Reverified,11/18/2020,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5626,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Fensolvi 45 mg (NDC 62935-153-50),Reverified,11/18/2020,Available,Call customer service: 1-888-FENSOLVI,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5627,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 7.5 mg Kit (NDC 62935-753-75),Reverified,11/18/2020,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5628,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 30mg (NDC 0074-9694-03)",Revised,11/3/2020,On backorder. Units expected to be received by November. Further replenishment expected to be received in December,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,,2020,not available
5629,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 22.5 mg PDS Kit (NDC 0074-3346-03)",Revised,11/3/2020,On backorder; Additional lots coming in late November 2020,,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,not available
5630,Leuprolide Acetate Injection,Abbvie,Lupron Depot 6 Months 45mg PDS Kit (NDC 0074-3473-03),Revised,11/3/2020,On backorder. Units expected in October,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,,2020,not available
5631,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 7.5 mg PDS Kit (NDC 0074-3642-03)",Revised,11/3/2020,Available; Additional Units expected to release by mid-November,,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,limited availability
5632,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 4 Months 30 mg PDS Kit (NDC 0074-3683-03)",Revised,11/3/2020,On backorder. Units expected to be released by mid-November,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,,2020,not available
5633,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 3.75 mg PDS Kit (NDC 0074-3641-03)",Revised,11/3/2020,Available; Additional units released early October 2020,,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5634,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 11.25 mg PDS Kit (NDC 0074-3663-03)",Revised,11/3/2020,On backorder. Next units expected to release by mid-November,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,,2020,not available
5635,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 11.25 mg PDS Kit (NDC 0074-2282-03)",Revised,11/3/2020,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5636,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 15 mg PDS Kit (NDC 0074-2440-03)",Revised,11/3/2020,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5637,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 7.5 mg PDS Kit (NDC 0074-2108-03)",Revised,11/3/2020,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2020,available
5638,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 11.25mg (NDC 0074-3779-03)",Revised,11/3/2020,On backorder. Units expected to be released in December,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,,2020,not available
5639,"Levetiracetam Extended-Release Oral Tablets, USP",Teva Pharmaceuticals,500mg (NDC 0591-3635-60),New,6/7/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Neurology,To be Discontinued,6/7/2019,6/7/2019,,2020,discontinued
5640,"Levetiracetam Extended-Release Oral Tablets, USP",Teva Pharmaceuticals,750mg (NDC 0591-3699-60),New,6/7/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Neurology,To be Discontinued,6/7/2019,6/7/2019,,2020,discontinued
5641,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 500 mg (60 ct. bottle)(NDC 60505-3280-06),Reverified,11/13/2020,Available,,,Demand increase for the drug,Neurology,Current,,,,2020,available
5642,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 750 mg (60 ct. bottle)(NDC 60505-3517-06),Reverified,11/13/2020,Available,,,Demand increase for the drug,Neurology,Current,,,,2020,available
5643,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,500mg tablet 60 count bottle (NDC 4733557386),Reveriifed,5/5/2020,"Back-order, Estimated re-supply: TBD",,,Shortage of active ingredient,Neurology,Current,,,,2020,not available
5644,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,750mg tablet 60 count bottle (NDC 4733557686),Reveriifed,5/5/2020,"Back-order, Estimated re-supply: TBD",,,Shortage of active ingredient,Neurology,Current,,,,2020,not available
5645,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,500mg  60 count bottle (NDC 68180-117-07),Reverified,4/30/2020,Continuous production but will be on/off backorder,,,Shortage of active ingredient,Neurology,Current,,,,2020,limited availability
5646,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,750mg 60 count bottle (NDC 68180-118-07),Reverified,4/30/2020,Continuous production but will be on/off backorder,,,Shortage of active ingredient,Neurology,Current,,,,2020,limited availability
5647,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,500mg extended-release (NDC 50474-598-66),Revised,4/21/2020,Available,,,,Neurology,Current,,,,2020,available
5648,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,750mg extended-release (NDC 50474-599-66),Revised,4/21/2020,Available,,,,Neurology,Current,,,,2020,available
5649,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 60’s (NDC 43547-0345-06)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5650,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 500’s (NDC 43547-0345-50)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5651,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 60’s (NDC 43547-0346-06)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5652,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 500’s (NDC 43547-0346-50)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5653,"Levetiracetam Extended-Release Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra XR) Extended-Release Tablets, 500 mg 60 ct. bottle; (NDC 69102-200-60)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2020,discontinued
5654,"Levetiracetam Extended-Release Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra XR) Extended-Release Tablets, 750 mg 60 ct. bottle; (NDC 69102-201-60)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2020,discontinued
5655,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"250mg, 120 count bottle (NDC 13668-014-12)",Reverified,2/18/2020,Available,,,,Neurology,Current,,,,2020,available
5656,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"500mg, 120 count bottle (NDC 13668-015-12)",Reverified,2/18/2020,Available,,,,Neurology,Current,,,,2020,available
5657,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 120 count bottle (NDC 13668-016-12)",Reverified,2/18/2020,Available,,,,Neurology,Current,,,,2020,available
5658,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 500 count bottle (NDC 13668-016-05)",Reverified,2/18/2020,Available,,,,Neurology,Current,,,,2020,available
5659,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"1000 mg, 60 count bottle (NDC 13668-017-60)",Reverified,2/18/2020,Available,,,Shortage of Active Ingredient,Neurology,Current,,,,2020,available
5660,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"250MG, (NDC 50474-594-40)",Revised,4/21/2020,Available,,,,Neurology,Current,,,,2020,available
5661,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"500MG, (NDC 50474-595-40)",Revised,4/21/2020,Available,,,,Neurology,Current,,,,2020,available
5662,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"750MG, (NDC 50474-596-40)",Revised,4/21/2020,Available,,,,Neurology,Current,,,,2020,available
5663,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"1000MG, (NDC 50474-597-66)",Revised,4/21/2020,Available,,,,Neurology,Current,,,,2020,available
5664,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"250mg, 120 count (NDC 65862024508)",Reverified,9/25/2020,Available,,,,Neurology,Current,,,,2020,available
5665,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"500mg , 120 count (NDC 65862024608)",Reverified,9/25/2020,Available,,,,Neurology,Current,,,,2020,available
5666,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"1000mg, 60 count (NDC 65862031560)",Reverified,9/25/2020,Available,,,,Neurology,Current,,,,2020,available
5667,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"750mg, 120 count (NDC 65862024708)",Reverified,9/25/2020,Available,,,,Neurology,Current,,,,2020,available
5668,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 90 Count Bottes (68180-112-09)",Reverified,4/30/2020,Available,,,,Neurology,Current,,,,2020,available
5669,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 120 Count Bottes (68180-112-16)",Reverified,4/30/2020,Available,,,,Neurology,Current,,,,2020,available
5670,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 500 Count Bottes (68180-112-02)",Reverified,4/30/2020,Available,,,,Neurology,Current,,,,2020,available
5671,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 90 Count Bottes (68180-113-09)",Reverified,4/30/2020,Available,,,,Neurology,Current,,,,2020,available
5672,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 90 Count Bottes (68180-114-09)",Reverified,4/30/2020,Available,,,,Neurology,Current,,,,2020,available
5673,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 500 Count Bottes (68180-114-02)",Reverified,4/30/2020,Available,,,,Neurology,Current,,,,2020,available
5674,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 120 Count Bottes (68180-113-16)",Reverified,4/30/2020,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,2020,not available
5675,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 500 Count Bottes (68180-113-02)",Reverified,4/30/2020,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,2020,not available
5676,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 120 Count Bottes (68180-114-16)",Reverified,4/30/2020,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,2020,not available
5677,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 1000 mg – 60 Count Bottes (68180-115-07)",Reverified,4/30/2020,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,2020,not available
5678,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 120 count (NDC 31722053612)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2020,available
5679,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 500 count (NDC 31722053605)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2020,available
5680,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 120 count (NDC 31722053712)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2020,available
5681,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 500 count (NDC 31722053705)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2020,available
5682,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 120 count (NDC 31722053812)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2020,available
5683,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 500 count (NDC 31722053805)",Reverified,12/17/2019,Available,,,,Neurology,Current,,,,2020,available
5684,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 250mg – 120’s (NDC 43547-0221-15)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5685,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 120’s (NDC 43547-0222-15)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5686,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 1000’s (NDC 43547-0222-11)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5687,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 750mg – 120’s (NDC 43547-0223-15)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5688,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 1000mg – 60’s (NDC 43547-0224-06)",Reverified,12/11/2019,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,,2020,not available
5689,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 120 count (NDC 0378-5613-78)",Reverified,11/10/2020,Available,,,Shortage of active ingredient,Neurology,Current,,,,2020,available
5690,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 500 count (NDC 0378-5613-05)",Reverified,11/10/2020,Available,,,Shortage of active ingredient,Neurology,Current,,,,2020,available
5691,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 500 count (NDC 0378-5615-05)",Reverified,11/10/2020,Available,,,Shortage of active ingredient,Neurology,Current,,,,2020,available
5692,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 120 count (NDC 0378-5615-78)",Reverified,11/10/2020,Available,,,Shortage of active ingredient,Neurology,Current,,,,2020,available
5693,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 120 count (NDC 0378-5617-78)",Reverified,11/10/2020,Available,,,Shortage of active ingredient,Neurology,Current,,,,2020,available
5694,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 500 count (NDC 0378-5617-05)",Reverified,11/10/2020,Available,,,Shortage of active ingredient,Neurology,Current,,,,2020,available
5695,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 1000 mg, 60 count (NDC 0378-5619-91)",Reverified,11/10/2020,Available,,,Shortage of active ingredient,Neurology,Current,,,,2020,available
5696,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 500 mg (120 count; (NDC 69102-104-01)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2020,discontinued
5697,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 750 mg (120 count; (NDC 69102-102-01)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2020,discontinued
5698,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 1000 mg 60 count; (NDC  69102-103-01)",New,9/3/2019,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/2019,9/3/2019,,2020,discontinued
5699,Levocetirizine Dihydrochloride Tablets,Apotex Corp.,5 mg tablets (NDCs 60505-3713-9 and 60505-3713-5),New,1/21/2020,,,,,Pulmonary/Allergy,To be Discontinued,1/21/2020,1/21/2020,,2020,discontinued
5700,Levofloxacin Tablets,Sandoz,250 mg 100 count bottle (NDC 0781-5790-01),New,2/26/2020,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
5701,Levofloxacin Tablets,Sandoz,250 mg 50 count bottle (NDC 0781-5790-50),New,2/26/2020,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
5702,Levofloxacin Tablets,Sandoz,500 mg 50 count bottle (NDC 0781-5791-50),New,2/26/2020,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
5703,Levofloxacin Tablets,Sandoz,500 mg 100 count bottle (NDC 0781-5791-01),New,2/26/2020,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
5704,Levofloxacin Tablets,Sandoz,750 mg 20 count bottle (NDC 0781-5792-20),New,2/26/2020,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
5705,Levofloxacin Tablets,Sandoz,750 mg 50 count bottle (NDC 0781-5792-50),New,2/26/2020,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
5706,Levoleucovorin Calcium Injection,Mylan Pharmaceuticals Inc.,10 mg/1 mL (17.5 mL)(NDC 67457-600-20),New,6/25/2019,,,,,Oncology,To be Discontinued,6/25/2019,6/25/2019,,2020,discontinued
5707,Levoleucovorin Calcium Injection,Mylan Pharmaceuticals Inc.,10 mg/1 mL (25 mL)(NDC 67457-601-30),New,6/25/2019,,,,,Oncology,To be Discontinued,6/25/2019,6/25/2019,,2020,discontinued
5708,Levoleucovorin Calcium Injection,Teva Pharmaceuticals,10 mg/ml (NDC 45963-762-57),New,5/20/2020,,Teva made a business decision to discontinue the manufacturing of this product.,,,Oncology,To be Discontinued,5/20/2020,5/20/2020,,2020,discontinued
5709,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 5 mL (NDC 0591-3012-26)",New,4/27/2018,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/2018,4/27/2018,,2020,discontinued
5710,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 30 mL (NDC 0591-3012-30)",New,4/27/2018,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/2018,4/27/2018,,2020,discontinued
5711,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/500 mL (4mg/mL) in VIAFLEX Plus container. Product code 2B0973 (NDC 0338-0409-03)",Reverified,9/23/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5712,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/250 mL (8mg/mL) in VIAFLEX Plus container. Product code 2B0962 (NDC 0338-0411-02)",Reverified,9/23/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5713,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.8% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5982 (NDC 00264-9598-20),Revised,9/10/2020,Product available,,,Other,Cardiovascular,Current,,,,2020,available
5714,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5942 (NDC 00264-9594-20),Revised,9/10/2020,Product available,,,Other,Cardiovascular,Current,,,,2020,available
5715,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 500mL Excel Plastic container P5941 (NDC 00264-9594-10),Revised,9/10/2020,Product available,,,Other,Cardiovascular,Current,,,,2020,available
5716,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Ampoule (NDC 55150-158-72),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5717,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Ampoule (NDC 55150-159-74),Revised,11/20/2020,Available,Next shipment expected Jan. 2020,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5718,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Ampoule (NDC 55150-160-72),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5719,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Single Dose Vial (NDC 55150-161-02),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5720,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Single Dose Vial (NDC 55150-162-05),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5721,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 30 mL Single Dose Vial (NDC 55150-163-30),Revised,11/20/2020,Currently on backorder - next shipment anticipated mid Dec 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
5722,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Single Dose Vial (NDC 55150-164-02),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5723,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 5 mL Single Dose Vial (NDC 55150-165-05),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5724,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Ansyr Plastic Syringe (NDC 0409-9137-05),Revised,11/20/2020,Next Delivery and Estimated Recovery: August 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2020,not available
5725,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",1.5%; 20mL Sterile Pack Amp (NDC 0409-4056-01),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2020,discontinued
5726,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",20 mg/2 mL (10 mg/mL); Glass Ampul (NDC 0409-4713-32),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5727,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","200 mg/20 mL (10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-01, pack of 25; NDC 0409-4276-16, individual)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5728,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/30 mL (10 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4279-02),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5729,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-02),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5730,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",1%; 30 mL Sterile Pack vial (NDC 0409-4270-01),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2020,discontinued
5731,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",40 mg/2 mL (20 mg/mL); Glass Ampul (NDC 0409-4282-01),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5732,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); Glass Ampul (NDC 0409-4282-02),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5733,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4904-34),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2020,limited availability
5734,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (20 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4903-34),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: May 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2020,limited availability
5735,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (20 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-2066-05),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5736,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","400 mg/20 mL (20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-01, pack of 25; NDC 0409-4277-16, individual)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5737,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","1,000 mg/50 mL (20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-02)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5738,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Glass Ampul (NDC 0409-4283-01),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5739,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",Xylocaine Cardiac 100 mg/5 mL (20 mg/mL); Ansyr Plastic Syringe (NDC 0409-1323-05),Revised,11/20/2020,Next Delivery and Estimated Recovery: July 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2020,not available
5740,Lidocaine Hydrochloride (Xylocaine) Injection,"Amphastar Pharmaceuticals, Inc./IMS","2%, 5mL Luer-Jet Prefilled Syringe (NDC 76329-3390-1)
(old NDC 0548-3390-00)",Reverified,10/30/2020,Available,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5741,Lidocaine Hydrochloride (Xylocaine) Injection,American Regent/Luitpold,"1%, 50 mL vial package of 25 (NDC 00517-0625-25)",Reverified,7/8/2020,Unavailable-No product available for release. No plan to manufacture.,"American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection, USP",,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2020,discontinued
5742,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 10 mL ampule (NDC 63323-0493-97)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5743,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 20 mL ampule (NDC 63323-0493-91)",Reverified,11/16/2020,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5744,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% Lidocaine 2% injection 20 mg/mL, 2 mL vial (NDC 63323-0202-02)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5745,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% injection 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5746,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-17)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5747,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 20 mL vial (NDC 63323-0486-27)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5748,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-57)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5749,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-10)
discontinued",Reverified,11/16/2020,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5750,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20)-NDC discontinued",Reverified,11/16/2020,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5751,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-50)-NDC discontinued",Reverified,11/16/2020,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5752,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 2 mL vial (NDC 63323-0495-27)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5753,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 5 mL vial (NDC 63323-0495-07)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5754,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 10 mL ampule (NDC 63323-0496-97)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5755,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4275-01),Revised,11/20/2020,Next Delivery: January 2021; Estimated Recovery: January 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2020,not available
5756,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/2 mL (50 mg/mL); Glass Ampul (NDC 0409-4712-01),Revised,11/20/2020,Next Delivery: September 2022; Estimated Recovery: December 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2020,not available
5757,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4278-01),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5758,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)",Reverified,11/16/2020,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5759,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL, 50 mL vial (NDC 63323-0484-57)",Reverified,11/16/2020,Not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5760,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5761,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 2 mL vial (NDC 63323-0201-02)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5762,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 10 mL vial (NDC 63323-0201-10)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5763,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 20 mL vial (NDC 63323-0485-27)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5764,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 50 mL vial (NDC 63323-0485-57)",Reverified,11/16/2020,Backordered. Next release December 2019.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5765,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL vial (NDC 63323-0492-27)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5766,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)",Reverified,11/16/2020,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5767,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)",Reverified,11/16/2020,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,not available
5768,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL vial (NDC 63323-0492-57)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5769,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial (NDC 63323-0492-37)",Reverified,11/16/2020,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,available
5770,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Glass Ampul (NDC 0409-4713-02),Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: December 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2020,not available
5771,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/20 mL (15 mg/mL); Glass Ampul (NDC 0409-4776-01),Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5772,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Multi Dose Vial (NDC 55150-251-10),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5773,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Multi Dose Vial (NDC 55150-252-20),Revised,11/20/2020,Currently on backorder - next shipment anticipated in Jan 21,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
5774,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 10 mL Multi Dose Vial (NDC 55150-254-10),Revised,11/20/2020,Currently on backorder,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
5775,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 20 mL Multi Dose Vial (NDC 55150-255-20),Revised,11/20/2020,Currently on backorder - next shipment anticipated in Jan 21,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
5776,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 5 mL vial, Preservative Free (NDC 0143-9595-25)",Reverified,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5777,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 5 mL vial, Preservative Free (NDC 0143-9594-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5778,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 50 mL vial, Preserved (NDC 0143-9577-10)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5779,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 50 mL vial, Preserved (NDC 0143-9575-10)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5780,Lidocaine Hydrochloride (Xylocaine) Injection,"Spectra Medical Devices, Inc.",1% 5 mL ampule (NDC 65282-1605-1),New,6/14/2018,"Currently available, in stock Production is ongoing",,,Other,Anesthesia,Current,,,,2020,available
5781,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% MDV 1000mg/50mL (NDC 55150-025-650),New,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
5782,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","0.5% w/EPI 1:100,000; 1.8 mL Carpule (NDC 00409-0996-01)",Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2020,discontinued
5783,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2.5 g/50 mL (0.5%; 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3177-01)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5784,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","200 mg/20 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-01)",Revised,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: January 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,limited availability
5785,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","300 mg/30 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-02)",Revised,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2020,limited availability
5786,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","500 mg/50 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3178-03)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5787,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","75 mg/5 mL (1.5%; 1:200,000); Glass Ampul (NDC 0409-1209-01)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5788,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","450 mg/30 mL (1.5%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3181-01)",Revised,11/20/2020,Limited Supply Available.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2020,limited availability
5789,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-01)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5790,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","600 mg/30 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-02)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5791,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","1 g/50 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-03)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5792,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3183-01)",Revised,11/20/2020,Available,,,Other,Anesthesia;Pediatric,Current,,,,2020,available
5793,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2% w/EPI 1:50,000; 1.8mL syringe (NDC 00409-7263-01)",Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2020,discontinued
5794,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100 mg MDV (NDC 63323-0482-17)",Revised,11/16/2020,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2020,not available
5795,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100mg SDV, MPF (NDC 63323-0487-17)",Revised,11/16/2020,Backordered. Next release December 2020.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2020,not available
5796,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 150 mg, SDV, MPF (NDC 63323-0488-17)",Revised,11/16/2020,Available,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2020,available
5797,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 200 mg, SDV, MPF (NDC 63323-0489-17)",Revised,11/16/2020,Backorered. Next release December 2020.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2020,not available
5798,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 5mcg tablets (NDC 0378-3611-01),New,3/28/2018,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/2018,3/28/2018,,2020,discontinued
5799,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 25mcg tablets (NDC 0378-3612-01),New,3/28/2018,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/2018,3/28/2018,,2020,discontinued
5800,Lisinopril (Prinivil) Tablets,Merck Sharp & Dohme Corp.,"5-mg tablets, unit-of-use bottle/90 (NDC 0006-0019-54)",New,3/11/2019,,To be discontinued on or near April 2019.,,,Cardiovascular,To be Discontinued,3/11/2019,,,2020,discontinued
5801,Lisinopril Tablets,Mylan Pharmaceuticals Inc.,2.5 mg (NDC 0378-2072-01); 5 mg (NDC 0378-2073-01); 5 mg (NDC 0378-2073-10); 10 mg (NDC 0378-2074-01); 10 mg (NDC 0378-2074-10); 20 mg (NDC 0378-2075-01); 20 mg (NDC 0378-2075-10); 30 mg (NDC 0378-2077-01); 40 mg (NDC 0378-2076-01; 40 mg (NDC 0378-2076-05),New,4/11/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,4/11/2018,4/11/2018,,2020,discontinued
5802,Lithium Oral Solution,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",8 mEq/5 mL 500 mL bottle (ndc 0054-3527-63),Revised,5/18/2020,"Unavailable, Estimated Shortage: TBD",,,Shortage of an active ingredient,Psychiatry,Current,,,,2020,not available
5803,"Lorazepam Injection, USP","Hospira, Inc.",4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31),Reverified,11/20/2020,Next Delivery and Estimated Recovery: January 2021,Shortage per manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,,2020,not available
5804,"Lorazepam Injection, USP","Hospira, Inc.",2 mg/mL; Carpuject Luer Lock Glass Syringe  (NDC 00409-1985-30),Reverified,11/20/2020,Available,,,,Neurology,Current,,,,2020,available
5805,"Lorazepam Injection, USP","Hospira, Inc.",2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02),Reverified,11/20/2020,Available,,,Other,Neurology,Current,,,,2020,available
5806,"Lorazepam Injection, USP","Hospira, Inc.",4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02),Reverified,11/20/2020,Next Delivery and Estimated Recovery: February 2023,Shortage per manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,,2020,not available
5807,"Lorazepam Injection, USP","Hospira, Inc.",20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02),Reverified,11/20/2020,Next Delivery and Estimated Recovery: February 2023,Shortage per manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,,2020,not available
5808,"Lorazepam Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)",Reverified,10/30/2020,Available,,,Other,Neurology,Current,,,,2020,available
5809,"Lorazepam Injection, USP",Akorn Pharmaceuticals,Lorazepam Injection 2 mg/mL (NDC 17478-040-01),Revised,12/2/2019,Available,,,Demand increase for the drug,Neurology,Current,,,,2020,available
5810,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2020,available
5811,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)",Revised,7/22/2020,This presentation is temporarily on backorder,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2020,not available
5812,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2020,available
5813,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2020,available
5814,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2020,available
5815,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2020,not available
5816,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2020,available
5817,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2020,available
5818,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5819,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5820,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5821,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
5822,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 100 count bottle (NDC 0527-1394-01)",Revised,11/12/2020,Allocating Inventory. Additional lots are scheduled for release in the January timeframe. Product will be made available as it is released (allocating inventory).,Manufacturing capacity constraint,,Other,Psychiatry,Current,,,,2020,limited availability
5823,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",Revised,11/12/2020,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2020,not available
5824,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 100 count bottle (NDC 0527-1395-01)",Revised,11/12/2020,Allocating Inventory. Additional lots are scheduled for release in the December timeframe. Product will be made available as it is released (allocating inventory).,Manufacturing capacity constraint,,Other,Psychiatry,Current,,,,2020,limited availability
5825,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",Revised,11/12/2020,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2020,not available
5826,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 100 count bottle (NDC 0527-1396-01)",Revised,11/12/2020,Unavailable. Additional lots are scheduled for release in the December timeframe. Product will be made available as it is released (allocating inventory).,Manufacturing capacity constraint,,Other,Psychiatry,Current,,,,2020,limited availability
5827,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",Revised,11/12/2020,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2020,not available
5828,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 100 count bottle (NDC 0527-1397-01)",Revised,11/12/2020,Allocating Inventory. Additional lots are scheduled for release in the December timeframe. Product will be made available as it is released (allocating inventory).,Manufacturing capacity constraint,,Other,Psychiatry,Current,,,,2020,limited availability
5829,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",Revised,11/12/2020,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2020,not available
5830,Loxapine Capsules,Mylan,"5 mg, 100 count bottle (NDC 0378-7005-01)",Reverified,11/9/2020,Unavailable. Re-supply TBD.,,,Other,Psychiatry,Current,,,,2020,not available
5831,Loxapine Capsules,Mylan,"10 mg, 100 count bottle (NDC 0378-7010-01)",Reverified,11/9/2020,Unavailable. Re-supply TBD.,,,Other,Psychiatry,Current,,,,2020,not available
5832,Loxapine Capsules,Mylan,"25 mg, 100 count bottle (NDC 0378-7025-01)",Reverified,11/9/2020,Unavailable. Re-supply TBD.,,,Other,Psychiatry,Current,,,,2020,not available
5833,Loxapine Capsules,Mylan,"50 mg, 100 count bottle (NDC 0378-7050-01)",Reverified,11/9/2020,Unavailable. Re-supply TBD.,,,Other,Psychiatry,Current,,,,2020,not available
5834,Loxapine Capsules,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0591-0369-01)",Reverified,11/19/2020,"On backorder, (recovery expected Jan 2021)",Cannot support additional business currently.,,Other,Psychiatry,Current,,,,2020,not available
5835,Loxapine Capsules,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0591-0370-01)",Reverified,11/19/2020,Available,,,,Psychiatry,Current,,,,2020,available
5836,Loxapine Capsules,Teva Pharmaceuticals,"25 mg, 100 count bottle (NDC 0591-0371-01)",Reverified,11/19/2020,"On backorder, (recovery expected Jan 2021)",Cannot support additional business currently.,,Other,Psychiatry,Current,,,,2020,not available
5837,Loxapine Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0591-0372-01)",Reverified,11/19/2020,"On backorder, (recovery expected Jan 2021)",Cannot support additional business currently.,,Other,Psychiatry,Current,,,,2020,not available
5838,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 100 count (NDC 42806-012-01)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2020,discontinued
5839,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 1000 count (NDC 42806-012-10)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2020,discontinued
5840,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 100 count (NDC 42806-014-01)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2020,discontinued
5841,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 1000 count (NDC 42806-014-10)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2020,discontinued
5842,"Medroxyprogesterone Acetate (Depo-Provera) Injection, Suspension",Pfizer Pharmaceuticals,"400 mg/mL, 1 carton containing one 2.5 mL vial (NDC 0009-0626-01)",New,10/27/2020,,Discontinuation of the manufacturing of the drug.,,,Reproductive,To be Discontinued,10/27/2020,10/27/2020,,2020,discontinued
5843,Medroxyprogesterone Acetate (Provera) Tablet,Pfizer Pharmaceuticals,"10 mg, bottles of 500 (NDC 0009-0050-11)",New,2/12/2020,,Discontinuation of the manufacture of the drug.,,,Reproductive,To be Discontinued,2/12/2020,2/12/2020,,2020,discontinued
5844,Megestrol Acetate (Megace) Oral Suspension,"Endo Pharmaceuticals, Inc.",MEGACE®ES 625mg/5ml Suspension (NDC 63481-160-38),New,8/21/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,8/21/2019,8/21/2019,,2020,discontinued
5845,Megestrol Acetate (Megace) Oral Suspension,Bristol Myers Squibb Co.,40 mg/mL Oral Suspension (NDC 00015-508-42),New,5/6/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/6/2019,5/6/2019,,2020,discontinued
5846,Mesalamine (CANASA®)  Suppositories,Allergan,"1 gm, Rectal Suppositories, 42 suppositories in 1 box (NDC 58914-501-42)",New,7/30/2020,,"Additional products remain available:   
NDC 58914-501-56 (30 suppositories in 1 box); NDC 58914-501-33 (3 suppositories in 1 box); NDC 59762-0118-3",,,Gastroenterology,To be Discontinued,7/30/2020,7/30/2020,,2020,discontinued
5847,Mesna Injection,Teva Pharmaceuticals,100 mg/mL (NDC 0703-4805-03),New,6/21/2019,,This product discontinuation is a business related decision.,,,Oncology,To be Discontinued,6/21/2019,6/21/2019,,2020,discontinued
5848,"Metaproterenol Sulfate Tablets, USP",Par Pharmaceutical,"10mg, 100 count (NDC 49884-0258-01)",New,7/12/2019,,Business decision to discontinue marketing in the US.,,,Pulmonary/Allergy,To be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
5849,"Metaproterenol Sulfate Tablets, USP",Par Pharmaceutical,"20mg, 100 count (NDC 49884-0259-01)",New,7/12/2019,,Business decision to discontinue marketing in the US.,,,Pulmonary/Allergy,To be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
5850,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 750 mg per tablet, (NDC 0093-7212-01), 100 count per bottle",New,7/22/2019,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/2019,7/22/2019,,2020,discontinued
5851,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 500 mg per tablet, (NDC 0093-7267-01), 100 count per bottle",New,7/22/2019,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/2019,7/22/2019,,2020,discontinued
5852,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 500 mg per tablet, (NDC 0093-7267-10), 1000 count per bottle",New,7/22/2019,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/2019,7/22/2019,,2020,discontinued
5853,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,750mg tablets (NDC 2037-577-10) and (NDC 62037-577-01 ),New,6/24/2020,,Teva made a business decision to discontinue the product.,,,Endocrinology/Metabolism,To be Discontinued,6/24/2020,6/24/2020,,2020,discontinued
5854,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,500mg tablets (NDC 62037-571-01) and (NDC 62037-571-10),New,6/24/2020,,Teva made a business decision to discontinue the product.,,,Endocrinology/Metabolism,To be Discontinued,6/24/2020,6/24/2020,,2020,discontinued
5855,Metformin Hydrochloride Tablets,Sandoz,"500 mg, bottle count 100 (NDC 42806-213-01)",New,4/15/2020,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2020,4/15/2020,,2020,discontinued
5856,Metformin Hydrochloride Tablets,Sandoz,"500 mg, bottle count 500 (NDC 42806-213-05)",New,4/15/2020,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2020,4/15/2020,,2020,discontinued
5857,Metformin Hydrochloride Tablets,Sandoz,"500 mg, bottle count 1000 (NDC 42806-213-10)",New,4/15/2020,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2020,4/15/2020,,2020,discontinued
5858,Metformin Hydrochloride Tablets,Sandoz,"850 mg, bottle count 100 (NDC 42806-215-01)",New,4/15/2020,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2020,4/15/2020,,2020,discontinued
5859,Metformin Hydrochloride Tablets,Sandoz,"850 mg, bottle count 500 (NDC 42806-215-05)",New,4/15/2020,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2020,4/15/2020,,2020,discontinued
5860,Metformin Hydrochloride Tablets,Sandoz,"1000 mg, bottle count 500 (NDC 42806-221-05)",New,4/15/2020,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/2020,4/15/2020,,2020,discontinued
5861,Methadone Hydrochloride Injection,Mylan Institutional,Methadone Hydrochloride Injection (Solution in Multi Dose Vials) [200 mg / 20 ml](NDC 67457-217-20),Reverified,11/10/2020,Available,Short dated inventory,,Other,Analgesia/Addiction;Anesthesia,Current,,,,2020,available
5862,Methadone Hydrochloride Injection,Akorn Pharmaceuticals,"Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) , 20 mL multidose vials (NDC 17478-380-20)",Revised,2/18/2020,Backordered. Estimated recovery March 2020,,,Other,Analgesia/Addiction;Anesthesia,Current,,,,2020,not available
5863,"Methocarbamol Tablet, USP","Endo Pharmaceuticals, Inc.","Robaxin® 500mg, 100 Tablets (NDC 52244-429-10)",New,8/21/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction;Musculoskeletal,To be Discontinued,8/21/2019,8/21/2019,,2020,discontinued
5864,"Methocarbamol Tablet, USP","Endo Pharmaceuticals, Inc.",750 mg tablets (NDC 52244-449-10),New,10/27/2020,,,,,Analgesia/Addiction,To be Discontinued,10/27/2020,10/27/2020,,2020,discontinued
5865,Methocarbamol Tablets,"Oxford Pharmaceuticals, LLC","500 mg, 100 ct (NDC 69584-611-10); 500 ct (NDC 69584-611-50); 1000 ct (NDC 69584-611-90)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5866,Methocarbamol Tablets,"Oxford Pharmaceuticals, LLC","750 mg, 100 ct (NDC 69584-612-10); 500 ct (NDC 69584-612-50); 1000 ct (NDC 69584-612-90)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5867,Methocarbamol Tablets,"Solco Healthcare US, LLC","500 mg, 100 ct (NDC 43547-0405-10); 500 ct (NDC 43547-0405-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5868,Methocarbamol Tablets,"Solco Healthcare US, LLC","750 mg, 100 ct (NDC 43547-0226-10); 500 ct (NDC 43547-0226-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5869,Methocarbamol Tablets,Granules Pharmaceuticals Inc.,"500 mg, 100 ct (NDC 70010-754-01); 500 ct (NDC 70010-754-05)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5870,Methocarbamol Tablets,Granules Pharmaceuticals Inc.,"750 mg, 100 ct (NDC 70010-770-01); 500 ct (NDC 70010-770-05)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5871,Methocarbamol Tablets,"AustarPharma, LLC","Distributed by Golden State Medical Supply, Inc.: 500 mg, 100 ct (NDC 60429-118-01); 500 ct (NDC 60429-118-05) Distributed by Virus Pharmaceuticals: 500 mg, 100 ct (NDC 69543-134-10); 500 ct (NDC 69543-134-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5872,Methocarbamol Tablets,"AustarPharma, LLC","Distributed by Golden State Medical Supply, Inc.: 750 mg, 100 ct (NDC 60429-119-01); 500 ct (NDC 60429-119-05) Distributed by Virtus Pharmaceuticals: 750 mg, 100 ct (NDC 69543-135-10); 500 ct (NDC 69543-135-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5873,Methocarbamol Tablets,Camber Pharmaceuticals Inc.,"500 mg, 100 ct (NDC 31722-533-01); 500 ct (NDC 31722-533-05)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5874,Methocarbamol Tablets,Camber Pharmaceuticals Inc.,"750 mg, 100 ct (NDC 31722-534-01); 500 ct (NDC 31722-534-05)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5875,Methocarbamol Tablets,Bayshore Pharmaceuticals,"500 mg, 100 ct (NDC 76385-123-01); 500 ct (NDC 76385-123-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5876,Methocarbamol Tablets,Bayshore Pharmaceuticals,"750 mg, 100 ct (NDC 76385-124-01); 500 ct (NDC 76385-124-50)",Revised,12/13/2019,,,,,Analgesia/Addiction,Resolved,12/13/2019,,,2020,
5877,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 2 mL vial (NDC 0143-9519-10)",Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5878,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X40ML (NDC 00703-3678-01),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5879,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X40ML Premier label  (NDC 00703-3678-81),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5880,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X10ML (NDC 00703-3675-01),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5881,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML SDV 10X2ML (NDC 00703-3671-03),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5882,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","1 gram per vial, 50 mL vial, SDV (NDC 63323-122-50)",Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5883,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","250 mg per 10 mL, vial (NDC 63323-123-10)",Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5884,Methotrexate Sodium Injection,"Hospira, Inc.",50 mg/2 mL (25 mg/mL); Glass Fliptop Vial (NDC 61703-0350-38),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5885,Methotrexate Sodium Injection,"Hospira, Inc.",1 g/40 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 61703-0408-41),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5886,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 2mL (NDC 16729-277-30),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5887,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 40 mL (NDC 16729-277-35),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5888,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 10 mL (NDC 16729-277-03),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5889,Methotrexate Sodium Injection,Mylan Institutional,1000 mg/40 mL (NDC 67457-480-40),Revised,12/17/2019,,,,,Oncology,Resolved,12/17/2019,,,2020,
5890,Methotrexate Sodium Injection,Mylan,"250 mg in 10 mL (25 mg/mL), single dose vial (NDC 67457-466-10)",Revised,3/3/2020,,Expected Discontinuation March 2020,,,Dermatology;Oncology;Pediatric;Rheumatology,To be Discontinued,12/16/2019,12/16/2019,,2020,discontinued
5891,"Methotrexate Tablets, USP","Endo Pharmaceuticals, Inc.","Methotrexate Sodium 2.5 mg Tablet, 36 count (NDC 67253-320-36)",New,9/13/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Dermatology;Oncology;Rheumatology,To be Discontinued,9/13/2019,9/13/2019,,2020,discontinued
5892,"Methotrexate Tablets, USP","Endo Pharmaceuticals, Inc.","Methotrexate Sodium 2.5 mg Tablet, 100 count (NDC 67253-320-10)",New,9/13/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Dermatology;Oncology;Rheumatology,To be Discontinued,9/13/2019,9/13/2019,,2020,discontinued
5893,Methscopolamine Bromide Tablets,Par Pharmaceutical,"5 mg tablets, bottle of 60 (NDC 64376-604-61)",New,1/27/2020,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,1/27/2020,1/27/2020,,2020,discontinued
5894,Methscopolamine Bromide Tablets,Par Pharmaceutical,"2.5 mg tablets, bottle of 100 (NDC 64376-603-01)",New,1/27/2020,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,1/27/2020,1/27/2020,,2020,discontinued
5895,"Methscopolamine Bromide, Tablets, USP",Par Pharmaceutical,"2.5 mg, 100 count (NDC  64376-603-01)",New,7/18/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,7/18/2019,7/18/2019,,2020,discontinued
5896,"Methscopolamine Bromide, Tablets, USP",Par Pharmaceutical,"5 mg, 60 count (NDC 64376-604-61)",New,7/18/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,7/18/2019,7/18/2019,,2020,discontinued
5897,Methyclothiazide Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-0160-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5898,Methyldopa Tablets,Teva Pharmaceuticals,500 mg/1 unit (NDC 0093-2932-05),New,6/10/2019,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
5899,Methyldopa Tablets,Teva Pharmaceuticals,500 mg/1 unit (NDC 0093-2932-01),New,6/10/2019,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
5900,Methyldopa Tablets,Teva Pharmaceuticals,250 mg/1 unit (NDC 0093-2931-10),New,6/10/2019,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
5901,Methyldopa Tablets,Teva Pharmaceuticals,250 mg/1 unit (NDC 0093-2931-01),New,6/10/2019,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
5902,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 100s (16729-03-001),Reverified,12/13/2019,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,2020,limited availability
5903,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 500s (16729-03-016),Reverified,12/13/2019,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,2020,limited availability
5904,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 100s (16729-03-101),Reverified,12/13/2019,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,2020,limited availability
5905,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 500s (16729-03-116),Reverified,12/13/2019,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,2020,limited availability
5906,Methyldopa Tablets,Mylan Pharmaceuticals Inc.,250 mg (NDC 0378-0611-01),Reverified,11/10/2020,Unavailable. Estimated recovery TBD.,,,Other,Cardiovascular,Current,,,,2020,not available
5907,Methyldopa Tablets,Mylan Pharmaceuticals Inc.,500 mg (NDC 0378-0421-01),Reverified,11/10/2020,Unavailable. Estimated recovery TBD.,,,Other,Cardiovascular,Current,,,,2020,not available
5908,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",300 mg/60 mL (NDC 24478-321-02),Revised,10/7/2020,,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,,Pediatric;Psychiatry,Resolved,10/7/2020,,,2020,
5909,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",600 mg/120mL (NDC 24478-322-04),Revised,10/7/2020,,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,,Pediatric;Psychiatry,Resolved,10/7/2020,,,2020,
5910,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",750 mg/150 mL (NDC 24478-323-05),Revised,10/7/2020,,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,,Pediatric;Psychiatry,Resolved,10/7/2020,,,2020,
5911,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",900 mg/180 mL (NDC 24478-324-06),Revised,10/7/2020,,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,,Pediatric;Psychiatry,Resolved,10/7/2020,,,2020,
5912,"Methylphenidate Hydrochloride Extended-Release Tablets, USP CII",Teva Pharmaceuticals,36 mg 30 count (NDC 0591-2717-30),New,5/17/2019,,Teva made a business related decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5913,"Methylphenidate Hydrochloride Extended-Release Tablets, USP CII",Teva Pharmaceuticals,54 mg 30 count (NDC 0591-2718-30),New,5/17/2019,,Teva made a business related decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5914,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,5 mg 100 count (NDC 0591-5882-01),New,5/17/2019,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5915,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,10 mg 100 count (NDC 0591-5883-01),New,5/17/2019,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5916,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,20 mg 100 count (NDC 0591-5884-01),New,5/17/2019,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/2019,5/17/2019,,2020,discontinued
5917,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg tablets (NDC 0591-0790-01),New,12/5/2019,,,,,Neurology,To be Discontinued,12/5/2019,12/5/2019,,2020,discontinued
5918,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg  (NDC 0591-0790-21),New,8/17/2020,,,,,Rheumatology,To be Discontinued,8/17/2020,8/17/2020,,2020,discontinued
5919,"Metoclopramide Injection, USP",Heritage Pharma,10mg/2mL (NDC 23155-240-41),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2020,
5920,"Metoclopramide Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3414-01),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2020,
5921,"Metoclopramide Injection, USP","Fresenius Kabi USA, LLC","10 mg per 2 mL, single use, prefilled syringe (NDC 76045-101-20)",Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2020,
5922,"Metoclopramide Injection, USP",Teva Pharmaceuticals,5 mg/ 1 ml (NDC 0703-4502-04),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2020,
5923,"Metoclopramide Injection, USP",Teva Pharmaceuticals,5 mg/ 1 ml (NDC 0703-4502-84),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2020,
5924,"Metoprolol Tartrate Injection, USP",Gland Pharma Limited,5 mg per 5 mL Single Dose Vial (NDC 47781-587-17),Reverified,10/27/2020,Available,Distributed by Alvogen Inc. (Company Contact Information:  973-532-7840),,Available,Cardiovascular,Current,,,,2020,available
5925,"Metoprolol Tartrate Injection, USP",Baxter Healthcare,1 mg/mL - 5 mL Sterile Single Use Glass Vial (10 x 5 mL). For Intravenous Use (NDC 36000-033-10),Reverified,9/23/2020,Available,,,,Cardiovascular,Current,,,,2020,available
5926,"Metoprolol Tartrate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 5 mL, SDV, PF (NDC 63323-660-05)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Manufacturing delays,Cardiovascular,Current,,,,2020,available
5927,"Metoprolol Tartrate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1mg/mL – 10mL vials, (NDC 0143-9660-10)",Reverified,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5928,"Metoprolol Tartrate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1mg/mL – 5ml vials (NDC 0143-9873-25),Reverified,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2020,available
5929,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1778-05),Reverified,11/20/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
5930,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1778-35),Reverified,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2020,discontinued
5931,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Glass Ampul (NDC 00409-2285-05),Reverified,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2020,discontinued
5932,"Metoprolol Tartrate Injection, USP",Gland Pharma Limited,"1 mg/mL, 5 mL vial (NDC 72266-122-25)",Reverified,10/27/2020,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,,2020,available
5933,"Metoprolol Tartrate Injection, USP",Gland Pharma Limited,1 mg/mL 5mL vial (NDC 70860-300-05 and 70860-300-41),Reverified,10/27/2020,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Cardiovascular,Current,,,,2020,available
5934,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,50 mg tablets (NDCs 0591-0462-01 and 0591-0462-10),New,12/16/2019,,,,,Cardiovascular,To be Discontinued,12/16/2019,12/16/2019,,2020,discontinued
5935,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,100 mg tablets (NDCs 0591-0463-01 and 0591-0463-10),New,12/16/2019,,,,,Cardiovascular,To be Discontinued,12/16/2019,12/16/2019,,2020,discontinued
5936,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,250 mg tablets 1 x 100 bottle (NDC 0025-1831-31),New,10/20/2020,,Discontinuation of the manufacture of the drug.,,,,To be Discontinued,10/20/2020,10/20/2020,,2020,discontinued
5937,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,250 mg tablets 1 x 50 bottle (NDC 0025-1831-50),New,10/20/2020,,Discontinuation of the manufacture of the drug.,,,,To be Discontinued,10/20/2020,10/20/2020,,2020,discontinued
5938,"Metronidazole Injection, USP",Baxter Healthcare,"Metronidazole Injection, USP, 500 mg/100 mL, in VIAFLEX Plus Container (NDC 0338-1055-48)",Reverified,9/23/2020,Available,,,,Anti-Infective,Current,,,,2020,available
5939,"Metronidazole Injection, USP","Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 00409-7811-24),Reverified,11/20/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
5940,"Metronidazole Injection, USP","Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 00409-7811-37),Reverified,11/20/2020,Available,,,Other,Anti-Infective,Current,,,,2020,available
5941,"Metronidazole Injection, USP",B. Braun Medical Inc.,Metronidazole Injection 500mg (5mg/mL) 100mL D5353-5224 (NDC 0264-5535-32),Reverified,9/8/2020,Product available for contracted  customers,,,Manufacturing interruptions and demand increase,Anti-Infective,Current,,,,2020,limited availability
5942,"Midazolam Injection, USP",Akorn Pharmaceuticals,10 ML Vial - Pack of 10 (NDC 17478-0524-10),New,4/2/2020,Limited supply. On allocation for 2020.,Cannot supply market demand.,,Other,Anesthesia;Neurology,Current,,,,2020,limited availability
5943,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","1 mg/mL, 10 mL vial, 10 count (NDC 63323-0411-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5944,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","1 mg/mL, 2 mL prefilled syringe, 24 count (NDC 76045-0001-20)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5945,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","1 mg/mL, 2 mL vial, 25 count (NDC 63323-0411-12)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5946,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","1 mg/mL, 5 mL vial, 25 count (NDC 63323-0411-25)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5947,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 1 mL fill in 2 mL vial, 25 count (NDC 63323-0412-25)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5948,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 10 mL vial, 10 count (NDC 63323-0412-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5949,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 1 mL prefilled syringe, 24 count (NDC 76045-0002-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5950,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 2 mL vial, 25 count (NDC 63323-0412-02)",Revised,11/16/2020,8 month dating (expiry 7/31/2021) available by request.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,limited availability
5951,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 5 mL vial, 10 count (NDC 63323-0412-05)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5952,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 10 mL vial, 10 count (NDC 00641-6056-10)",Revised,10/23/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5953,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 2 mL vial, 25 count (NDC 00641-6057-25)",Revised,10/23/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5954,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 5 mL vial, 10 count (NDC 0641-6059-25)",Revised,10/23/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5955,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 1 mL vial, 25 count (NDC 00641-6061-25)",Revised,10/23/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5956,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial, 10 count (NDC 00641-6060-10)",Revised,10/23/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5957,"Midazolam Injection, USP","Hospira, Inc.",2 mg/2mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-17),Revised,11/20/2020,Available,,,,Anesthesia;Neurology,Current,,,,2020,available
5958,"Midazolam Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-05),Revised,11/20/2020,Available,,,,Anesthesia;Neurology,Current,,,,2020,available
5959,"Midazolam Injection, USP","Hospira, Inc.",5 mg/mL (5 mg/mL)  Single Dose Glass Fliptop Vial (NDC 00409-2308-01),Revised,11/20/2020,Available,,,Other,Anesthesia;Neurology,Current,,,,2020,available
5960,"Midazolam Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-05),Revised,11/20/2020,Available,,,Other,Anesthesia;Neurology,Current,,,,2020,available
5961,"Midazolam Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2308-02),Revised,11/20/2020,Available,,,Other,Anesthesia;Neurology,Current,,,,2020,available
5962,"Midazolam Injection, USP","Hospira, Inc.",25 mg/5 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-03),Revised,11/20/2020,Available,,,Other,Anesthesia;Neurology,Current,,,,2020,available
5963,"Midazolam Injection, USP","Hospira, Inc.",10 mg/10 mL (1 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2587-05),Revised,11/20/2020,Available,,,,Anesthesia;Neurology,Current,,,,2020,available
5964,"Midazolam Injection, USP","Hospira, Inc.",2 mg/2 mL (1 mg/mL) CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2306-62),Revised,11/20/2020,Next delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology,Current,,,,2020,not available
5965,"Midazolam Injection, USP","Hospira, Inc.",5 mg/mL CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2307-60),Revised,11/20/2020,Next delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology,Current,,,,2020,not available
5966,"Midazolam Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,50 mg/10mL vial (NDC 23155-601-42),Revised,11/6/2020,On backorder – increase demand due to Covid-19; resupply date end of November 2020,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,not available
5967,"Midazolam Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,25 mg/5mL vial (NDC 23155-601-41),Revised,11/6/2020,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5968,"Midazolam Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,2 mg/2mL vial (NDC 23155-600-41),Revised,11/6/2020,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5969,"Midazolam Injection, USP",Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 70860-601-10),Revised,10/27/2020,Available,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5970,"Midazolam Injection, USP",Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 70860-601-05),Revised,10/27/2020,No stock available. Resupply December 2020,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,not available
5971,"Midazolam Injection, USP",Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 47781-589-17),Revised,10/27/2020,"No stock available, Resupply July 2020",Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,not available
5972,"Midazolam Injection, USP",Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 47781-589-91),Revised,10/27/2020,Available,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5973,"Midazolam Injection, USP",Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 70860-600-02),Revised,10/27/2020,"No stock available, Resupply December 2020","Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,not available
5974,"Midazolam Injection, USP",Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 47781-588-68),Revised,10/27/2020,Stock available. Additional resupply June 2020,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2020,available
5975,Miglitol Tablets,"Hospira, Inc.",25 mg (NDC 0009-5012-01),New,11/17/2020,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/2020,11/17/2020,,2020,discontinued
5976,Miglitol Tablets,"Hospira, Inc.",50 mg (NDC 0009-5013-01),New,11/17/2020,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/2020,11/17/2020,,2020,discontinued
5977,Miglitol Tablets,"Hospira, Inc.",100 mg (NDC 0009-5014-01),New,11/17/2020,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/2020,11/17/2020,,2020,discontinued
5978,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,55 mg 30 count (NDC 00093-7741-56),New,3/24/2020,,Estimated Inventory Depletion: June 2020,,,Anti-Infective,To be Discontinued,3/24/2020,3/24/2020,,2020,discontinued
5979,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,115 mg 30 count (NDC 00093-2133-56),New,3/24/2020,,Estimated Inventory Depletion: April 2020,,,Anti-Infective,To be Discontinued,3/24/2020,3/24/2020,,2020,discontinued
5980,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,65 mg 30 count (NDC 00093-2134-56),New,3/24/2020,,Estimated Inventory Depletion: May 2020,,,Anti-Infective,To be Discontinued,3/24/2020,3/24/2020,,2020,discontinued
5981,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,105 mg 30 count (NDC 00093-7743-56),New,3/24/2020,,No Inventory Remains,,,Anti-Infective,To be Discontinued,3/24/2020,3/24/2020,,2020,discontinued
5982,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,80 mg 30 count (NDC 00093-7742-56),New,3/24/2020,,No Inventory Remains,,,Anti-Infective,To be Discontinued,3/24/2020,3/24/2020,,2020,discontinued
5983,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",15mg tablets (NDC 0591-2469-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2020,discontinued
5984,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",30mg tablets (NDC 0591-2470-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2020,discontinued
5985,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",45mg tablets (NDC 0591-2471-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2020,discontinued
5986,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 30 count bottle (NDC 0093-7206-56),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5987,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 30 count bottle (NDC 0591-1117-30),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5988,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 1000 count bottle (NDC 0591-1117-10),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5989,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 30 count bottle (NDC 0093-7207-56),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5990,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 30 count bottle (NDC 0591-1118-30),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5991,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 1000 count bottle (NDC 0591-1118-10),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5992,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,45 mg 30 count bottle (NDC 0591-1119-30),New,5/2/2019,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
5993,Misoprostol Tablets,Teva Pharmaceuticals,"100 mcg, 120 count (NDC 0172-4430-59)",New,8/11/2020,,Business decision to discontinue. The product has been unavailable since May 2011.,,,Gastroenterology,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
5994,Misoprostol Tablets,Teva Pharmaceuticals,"100 mcg, 60 count (NDC 0172-4430-49)",New,8/11/2020,,Business decision to discontinue. The product has been unavailable since May 2011.,,,Gastroenterology,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
5995,Misoprostol Tablets,Teva Pharmaceuticals,"200 mcg, 100 count (NDC 0172-4431-60)",New,8/11/2020,,Business decision to discontinue. The product has been unavailable since May 2011.,,,Gastroenterology,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
5996,Modafinil Tablets,Par Pharmaceutical,"100 mg, bottle of 30 (NDC 49884-534-11)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
5997,Mometasone Furoate (Elocon) Topical Cream,Merck Sharp & Dohme Corp.,0.1% 15 gram tube  (NDC 0085-3149-01),New,7/29/2019,,,,,Dermatology,To be Discontinued,7/29/2019,7/29/2019,,2020,discontinued
5998,Mometasone Furoate (Elocon) Topical Cream,Merck Sharp & Dohme Corp.,0.1% 50 gram tube  (NDC 0085-3149-03),New,7/29/2019,,,,,Dermatology,To be Discontinued,7/29/2019,7/29/2019,,2020,discontinued
5999,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,4 mg  (NDCs 0093-7424-98 and 0093-7424-56),New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,7/28/2020,7/28/2020,,2020,discontinued
6000,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,5 mg  (NDCs 0093-7425-98 and 0093-7425-56),New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,7/28/2020,7/28/2020,,2020,discontinued
6001,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,"10 mg (NDCs 0093-7426-10, 0093-7426-56, and 0093-7426-98)",New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,7/28/2020,7/28/2020,,2020,discontinued
6002,Montelukast Sodium Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-5201-93),New,3/20/2018,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,3/20/2018,3/20/2018,,2020,discontinued
6003,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,20 mg/0.8 mg; 30 capsules per bottle (NDC 60793-430-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2020,discontinued
6004,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,30 mg/1.2 mg; 30 capsules per bottle (NDC 60793-431-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2020,discontinued
6005,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,50 mg/2 mg; 30 capsules per bottle (NDC 60793-433-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2020,discontinued
6006,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,60 mg/2.4 mg; 30 capsules per bottle (NDC 60793-434-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2020,discontinued
6007,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,80 mg/3.2 mg; 30 capsules per bottle (NDC 60793-435-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2020,discontinued
6008,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,100 mg/4 mg; 30 capsules per bottle (NDC 60793-437-20),New,10/7/2019,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/2019,10/7/2019,,2020,discontinued
6009,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"15 mg, bottle of 100 (NDC 60951-652-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6010,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"30 mg, bottle of 100 (NDC 60951-653-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6011,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"60 mg, bottle of 100 (NDC 60951-655-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6012,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"100 mg, bottle of 100 (NDC 60951-658-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6013,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"200 mg, bottle of 100 (NDC 60951-659-70)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6014,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-2658-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
6015,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 100s (NDC 0378-2659-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
6016,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"60 mg, 100s (NDC 0378-2660-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
6017,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100s (NDC 0378-2661-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
6018,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100s (NDC 0378-2662-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
6019,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-452-01)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6020,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-454-01)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6021,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 1 mL, Single dose vial, (NDC 63323-455-01)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6022,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","8 mg per 1 mL, Single dose vial, (NDC 63323-458-01)",Revised,11/16/2020,Backordered. Next release December 2020.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
6023,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, (NDC 63323-451-01)",Revised,11/16/2020,Backordered. Next release December 2020.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
6024,"Morphine Sulfate Injection, USP","Amphastar Pharmaceuticals, Inc./IMS",Morphine Sulfate 1 mg/mL 30 mg in 30 mL PUMP-JET®  SUITABLE FOR USE WITH COMPATIBLE I.V. INFUSION PUMPS (NDC 76329-1911-1),Reverified,10/30/2020,Available,,,,Analgesia/Addiction,Current,,,,2020,available
6025,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6125-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6026,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","8 mg/mL, 1 mL vial (NDC 0641-6126-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6027,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-6127-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6028,"Morphine Sulfate Injection, USP","Hospira, Inc.",250 mg/10 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1135-02),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
6029,"Morphine Sulfate Injection, USP","Hospira, Inc.",2 mg/mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1890-01),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
6030,"Morphine Sulfate Injection, USP","Hospira, Inc.",2 mg/mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1890-11),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
6031,"Morphine Sulfate Injection, USP","Hospira, Inc.",4 mg/mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1891-01),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
6032,"Morphine Sulfate Injection, USP","Hospira, Inc.",4 mg/mL (4 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1891-11),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
6033,"Morphine Sulfate Injection, USP","Hospira, Inc.",8 mg/mL (8 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1892-01),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
6034,"Morphine Sulfate Injection, USP","Hospira, Inc.",8 mg/mL (8 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1892-11),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
6035,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1893-01),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
6036,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1893-11),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2020,discontinued
6037,"Morphine Sulfate Injection, USP","Hospira, Inc.",5 mg/10 mL (0.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3814-12),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
6038,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/10 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3815-12),Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
6039,"Morphine Sulfate Injection, USP","Hospira, Inc.","1,000 mg/20 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-03)",Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
6040,"Morphine Sulfate Injection, USP","Hospira, Inc.","2,500 mg/50 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-05)",Revised,11/20/2020,Available,,,Other,Analgesia/Addiction,Current,,,,2020,available
6041,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6042,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-005-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6043,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 1 mL, Single-use prefilled syringe (NDC 76045-006-10)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6044,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","8 mg per 1 mL, Single-use prefilled syring (NDC 76045-007-10)",Revised,11/16/2020,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
6045,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single-use prefilled syringe (NDC 76045-008-10)",Revised,11/16/2020,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
6046,"Morphine Sulfate Injection, USP","ICU Medical, Inc.",1mg/mL 30mL PCA glass vial (NDC 0409-2029-02),Revised,4/30/2020,,,,,Analgesia/Addiction,To be Discontinued,4/30/2020,4/30/2020,,2020,discontinued
6047,"Morphine Sulfate Injection, USP","ICU Medical, Inc.",5mg/mL 30mL PCA GLASS VIAL (CII)(NDC 0409-6028-04),New,10/2/2019,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To be Discontinued,10/2/2019,10/2/2019,,2020,discontinued
6048,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 1 mg/mL, 10 mL ampul (NDC 0641-6019-10)",Revised,7/22/2020,This presentation is temporarily on backorder .,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
6049,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 0.5 mg/mL, 10 mL ampul (NDC 0641-6020-10)",Revised,7/22/2020,This presentation is temporarily on backorder .,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,not available
6050,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 10 mg/mL, 20 mL ampul (NDC 0641-6039-01)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6051,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 25 mg/mL, 20 mL ampul (NDC 0641-6040-01)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2020,available
6052,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-11)",Revised,10/8/2020,Backordered. Next release October 2020.,Check wholesalers for inventory,,Other,Analgesia/Addiction,Current,,,,2020,not available
6053,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-11)",Revised,10/8/2020,Availble,Check wholesalers for inventory,,Available,Analgesia/Addiction,Current,,,,2020,available
6054,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 10 mL Single Dose Dual Glass Fliptop Vials (NDC 61703-0434-82),Reverified,11/20/2020,Next Delivery and Estimated Recovery: September 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,not available
6055,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 2 x 50 mL Pharmacy Bulk Package Dual Glass Fliptop Vials (NDC 61703-0422-83),Reverified,11/20/2020,Next Delivery and Estimated Recovery: September 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,not available
6056,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Pediatric; Single Dose Glass Fliptop Vial (NDC 61703-0421-53),Reverified,11/20/2020,Next Delivery and Estimated Recovery: September 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,not available
6057,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)",Reverified,9/23/2020,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,available
6058,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)",Reverified,9/23/2020,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,available
6059,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5650-2)",Reverified,9/23/2020,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,available
6060,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)",Reverified,9/23/2020,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,available
6061,Mupirocin Calcium Nasal Ointment,GlaxoSmithKline,2% Nasal Ointment 1 gram tube Package of 10 (NDC 0029152611),Revised,12/13/2019,,,,,Anti-Infective,To be Discontinued,12/13/2019,12/13/2019,,2020,discontinued
6062,Mycophenolic Acid Delayed Release Tablets,Teva Pharmaceuticals,180mg tablets (NDC 0093-7031-89),New,3/11/2020,,,,,Transplant,To be Discontinued,3/11/2020,3/11/2020,,2020,discontinued
6063,Mycophenolic Acid Delayed Release Tablets,Teva Pharmaceuticals,360mg tablets (NDC 0093-7032-89),New,3/11/2020,,,,,Transplant,To be Discontinued,3/11/2020,3/11/2020,,2020,discontinued
6064,Nadolol Tablets,Ingenus Pharmaceuticals LLC,20 mg (100 ct) (NDC 50742-178-01),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2020,discontinued
6065,Nadolol Tablets,Ingenus Pharmaceuticals LLC,20 mg (1000 ct) (NDC 50742-178-10 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2020,discontinued
6066,Nadolol Tablets,Ingenus Pharmaceuticals LLC,40 mg (100 ct) (NDC 50742-179-01 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2020,discontinued
6067,Nadolol Tablets,Ingenus Pharmaceuticals LLC,40 mg (1000 ct) (NDC 50742-179-10 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2020,discontinued
6068,Nadolol Tablets,Ingenus Pharmaceuticals LLC,80 mg (100 ct) (NDC 50742-180-01 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2020,discontinued
6069,Nadolol Tablets,Ingenus Pharmaceuticals LLC,80 mg (1000 ct) (NDC 50742-180-10 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2020,discontinued
6070,Nadolol Tablets,Teva Pharmaceuticals,"20 mg, 100 count (NDC 0591-2694-01)",New,8/11/2020,,Business decision to discontinue. The 20 mg and 80 mg tablets have been unavailable since Mar 2016 and the 40 mg tablets have been unavailable since Dec 2015,,,Cardiovascular,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6071,Nadolol Tablets,Teva Pharmaceuticals,"40 mg, 100 count (NDC 0591-2697-01)",New,8/11/2020,,Business decision to discontinue. The 20 mg and 80 mg tablets have been unavailable since Mar 2016 and the 40 mg tablets have been unavailable since Dec 2015,,,Cardiovascular,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6072,Nadolol Tablets,Teva Pharmaceuticals,"80 mg, 100 count (NDC 0591-2685-01)",New,8/11/2020,,Business decision to discontinue. The 20 mg and 80 mg tablets have been unavailable since Mar 2016 and the 40 mg tablets have been unavailable since Dec 2015,,,Cardiovascular,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6073,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-3124-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
6074,Nafcillin Sodium Injection,Sandoz,2 gram vial packaged in 10s (NDC 0781-3125-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
6075,Nafcillin Sodium Injection,Sandoz,Pharmacy Bulk Package bottle (NDC 0781-3126-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
6076,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-9124-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
6077,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9224-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
6078,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9225-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
6079,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3128-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
6080,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3129-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2020,discontinued
6081,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 1% 60 gm (NDC 40085-201-60),New,5/15/2019,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/2019,5/15/2019,,2020,discontinued
6082,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 1% 90 gm (NDC 40085-201-90),New,5/15/2019,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/2019,5/15/2019,,2020,discontinued
6083,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 2% 45 gm (NDC 40085-203-45),New,5/15/2019,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/2019,5/15/2019,,2020,discontinued
6084,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 2% 60 gm (NDC 40085-203-60),New,5/15/2019,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/2019,5/15/2019,,2020,discontinued
6085,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",10 mg/mL; 1 mL Glass Ampul (NDC 00409-1463-01),Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage of an active ingredient,,Other,Analgesia/Addiction,Current,,,,2020,not available
6086,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",20 mg/mL; 1 mL Glass Ampul (NDC 00409-1465-01),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage of an active ingredient,,Other,Analgesia/Addiction,Current,,,,2020,limited availability
6087,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1464-01),Revised,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Shortage of an active ingredient,,Other,Analgesia/Addiction,Current,,,,2020,limited availability
6088,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1467-01),Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage of an active ingredient,,Other,Analgesia/Addiction,Current,,,,2020,not available
6089,Naratriptan Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg  (NDC 0378-4450-59),New,7/17/2019,,,,,Neurology,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
6090,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,50 mg 100 Tablets (NDC 0093-7178-01),Reverified,11/19/2020,Availability is unknown at this time.,API availability,,Other,Psychiatry,Current,,,,2020,unclear
6091,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,100 mg 60 Tablets (NDC 0093-1024-06),Reverified,11/19/2020,Availability is unknown at this time.,API availability,,Other,Psychiatry,Current,,,,2020,unclear
6092,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,150 mg 60 Tablets (NDC 0093-7113-06),Reverified,11/19/2020,Availability is unknown at this time.,API availabliity,,Other,Psychiatry,Current,,,,2020,unclear
6093,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,200 mg 60 Tablets (NDC 0093-1025-06),Reverified,11/19/2020,Availablity is unknown at this time.,API availability,,Other,Psychiatry,Current,,,,2020,unclear
6094,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,250 mg 60 Tablets (NDC 0093-1026-06),Reverified,11/19/2020,Availability is unknown at this time.,API availability,,Other,Psychiatry,Current,,,,2020,unclear
6095,Nelarabine (Arranon) Injection,Novartis,250 mg/50 mL (NDC 0078-0683-06),Revised,1/7/2020,,,,,Hematology,Resolved,1/7/2020,,,2020,
6096,"Neomycin and Polymyxin B Sulfates Solution For Irrigation, USP",Teva Pharmaceuticals,"40 mg and 200,000 units (1 mL ampule) (NDC 0591-2190-45)",New,6/10/2019,,Discontinuation of the manufacture of the drug.,,,Anti-Infective;Urology,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
6097,Nesiritide Powder (NATRECOR) for Injection,Janssen Pharmaceuticals,1.5 mg (NDC 65847-205-25),New,2/5/2018,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To be Discontinued,2/5/2018,2/5/2018,,2020,discontinued
6098,Nevirapine (Viramune) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",200 mg tablets (NDC 0597-0046-60),New,5/29/2020,,,,,Antiviral,To be Discontinued,5/29/2020,5/29/2020,,2020,discontinued
6099,Nevirapine Extended Release Tablets,Sandoz,"400 mg, bottle of 30 tablets (NDC 0781-5893-31)",New,1/24/2020,,,,,Antiviral,To be Discontinued,1/24/2020,1/24/2020,,2020,discontinued
6100,Nevirapine Extended Release Tablets,Sandoz,"400 mg, bottle of 500 tablets (NDC 0781-5893-05)",New,1/24/2020,,,,,Antiviral,To be Discontinued,1/24/2020,1/24/2020,,2020,discontinued
6101,Nevirapine Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg tablets (NDC 0378-6950-77),New,1/31/2019,,,,,Antiviral,To be Discontinued,1/31/2019,1/31/2019,,2020,discontinued
6102,"Nifedipine Extended-Release Tablet, USP",Teva Pharmaceuticals,"Nifedipine extended-release tablets, 90 mg, 500 count (NDC 45963-152-50)",New,6/7/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,6/7/2019,6/7/2019,,2020,discontinued
6103,"Nifedipine Extended-Release Tablet, USP",Teva Pharmaceuticals,"Nifedipine extended-release tablets, 90 mg, 100 count (NDC 45963-152-02)",New,6/7/2019,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,6/7/2019,6/7/2019,,2020,discontinued
6104,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"30mg, 100 count bottle (NDC 10370-677-01)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
6105,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"30mg, 500 count bottle (NDC 10370-677-05)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
6106,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"60mg, 100 count bottle (NDC 10370-678-01)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
6107,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"60mg, 500 count bottle (NDC 10370-678-05)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
6108,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"90 mg, 100 count bottle (NDC 10370-679-01)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
6109,Nizatidine Capsules,Mylan Pharmaceuticals Inc.,"150 mg, 60 count bottle (NDC 0378-5150-91)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6110,Nizatidine Capsules,Mylan Pharmaceuticals Inc.,"300 mg, 30 count bottle (NDC 0378-5300-93)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6111,Nizatidine Capsules,Glenmark Pharmaceuticals,"150 mg, 60 count bottle (NDC 68462-0425-60)",New,3/9/2020,,,,,Gastroenterology,To be Discontinued,3/9/2020,3/9/2020,,2020,discontinued
6112,Nizatidine Capsules,Glenmark Pharmaceuticals,"300 mg, 30 count bottle (NDC 68462-0426-30)",New,3/9/2020,,,,,Gastroenterology,To be Discontinued,3/9/2020,3/9/2020,,2020,discontinued
6113,Nizatidine Capsules,Teva Pharmaceuticals,"300 mg, 30 count bottle (NDC 0591-3138-30)",Reverified,11/19/2020,Supply Interruption,Duration of the supply interruption is unknown at this time.,,Other,Gastroenterology,Current,3/27/2020,,,2020,unclear
6114,Nizatidine Capsules,Teva Pharmaceuticals,"150 mg, 60 count bottle (NDC 0591-3137-60)",Reverified,11/19/2020,Supply Interruption,Duration of the supply interruption is unknown at this time.,,Other,Gastroenterology,Current,3/27/2020,,,2020,unclear
6115,Nizatidine Capsules,Glenmark Pharmaceuticals,"300 mg, 30 count bottle (NDC 68462-0426-30)",New,3/27/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,,Gastroenterology,Current,3/27/2020,,,2020,not available
6116,Nizatidine Capsules,Glenmark Pharmaceuticals,"150 mg, 60 count bottle (NDC 68462-0425-60)",New,3/27/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,,Gastroenterology,Current,3/27/2020,,,2020,not available
6117,Norethindrone (NOR QD) Tablets,Allergan,"Nor QD, 0.35 mg norethindrone, Tablets, (NDC  52544-235-28)",New,2/23/2018,,"An authorized generic of the product is currently available as Nora-BE, NDC 52544-629-28.",,,Reproductive,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6118,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Mylan Pharmaceuticals Inc.,"0.02 mg norethindrone acetate / 1 mg ethinyl estradiol / 75 mg ferrous fumarate; 28 tablets per blister pack, 3 blisters per carton (NDC 0378-7301-53)",New,5/23/2019,,,,,Reproductive,To be Discontinued,5/23/2019,5/23/2019,,2020,discontinued
6119,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 15 g (NDC 0603-7818-74)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
6120,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 30 g (NDC 0603-7818-78)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
6121,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 60 g (NDC 0603-7818-88)",New,4/15/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/2019,4/15/2019,,2020,discontinued
6122,"Nystatin Cream, USP",Teva Pharmaceuticals,"100,000 USP units per gram, 15 g (NDC 0472-0163-15)",New,11/15/2019,,Teva made a business decision to discontinue the product.,,,Dermatology,To be Discontinued,11/15/2019,11/15/2019,,2020,discontinued
6123,"Nystatin Cream, USP",Teva Pharmaceuticals,"100,000 units per gram, 30 g (NDC 0472-0163-30)",New,11/15/2019,,Teva made a business decision to discontinue the product.,,,Dermatology,To be Discontinued,11/15/2019,11/15/2019,,2020,discontinued
6124,Nystatin Oral Suspension,Wockhardt,"Nystatin Oral Solution 100,000 units/1mL; 473 mL bottles (NDC 60432-0537-16)",Revised,5/6/2020,,,,,Anti-Infective;Pediatric,Resolved,5/6/2020,,,2020,
6125,Nystatin Oral Suspension,Wockhardt,"Nystatin Oral Solution 100,000 units/1mL; 60 mL bottles (NDC 60432-0537-60)",Revised,5/6/2020,,,,,Anti-Infective;Pediatric,Resolved,5/6/2020,,,2020,
6126,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 500,000 units/5 ml; 5mL unit dose cup; 50 unit dose cups/ case (NDC 66689-037-50)",Revised,5/6/2020,,,,,Anti-Infective;Pediatric,Resolved,5/6/2020,,,2020,
6127,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 500,000 units/5 ml; 5mL unit dose cup; 100 unit dose cups/ case (NDC 66689-037-99)",Revised,5/6/2020,,,,,Anti-Infective;Pediatric,Resolved,5/6/2020,,,2020,
6128,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 100,000 units/ml; 60 mL Bottle (NDC 66689-008-02)",Revised,5/6/2020,,,,,Anti-Infective;Pediatric,Resolved,5/6/2020,,,2020,
6129,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 100,000 units/ml; 480 mL Bottle (NDC 66689-008-16)",Revised,5/6/2020,,,,,Anti-Infective;Pediatric,Resolved,5/6/2020,,,2020,
6130,Nystatin Oral Suspension,"Pharmaceutical Associates, Inc","Nystatin Oral Suspension, USP 500,000 Units/5 mL 5 mL Unit Dose Cups Case of 40 – 5 mL UDC (NDC 00121-4810-40); Case of 100 – 5 mL UDC (NDC 00121-4810-00); 2 oz. Bottles (NDC 00121-0810-02); 16 oz. Bottles (NDC 00121-0810-16)",Revised,5/6/2020,,,,,Anti-Infective;Pediatric,Resolved,5/6/2020,,,2020,
6131,Ocriplasmin (Jetrea) Injection,"Thrombogenics, Inc.",1.25 mg/ml (NDC 24856-002-01),New,4/24/2020,,ThromboGenics has decided for business reasons to discontinue manufacture of the drug product for the United States.,,,Ophthalmology,To be Discontinued,4/24/2020,4/24/2020,,2020,discontinued
6132,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,12mg/50mg per capsule (NDC Package Code 0002-3234-30),New,7/15/2020,,The product distribution will continue until end of December 2020.,,,Psychiatry,To be Discontinued,7/15/2020,7/15/2020,,2020,discontinued
6133,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,6mg/50mg per capsule (NDC Package Code 0002-3233-30),New,7/15/2020,,The product distribution will continue until end of December 2020.,,,Psychiatry,To be Discontinued,7/15/2020,7/15/2020,,2020,discontinued
6134,Olaratumab (Lartruvo) Injection,Eli Lilly and Co.,500mg/50 ML x 1 vial (NDC 0002-8926-01),New,10/2/2019,,Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.,,,Oncology,To be Discontinued,10/2/2019,10/2/2019,,2020,discontinued
6135,Olaratumab (Lartruvo) Injection,Eli Lilly and Co.,190mg/19 ML x 1 vial (NDC 0002-7190-01),New,10/2/2019,,Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.,,,Oncology,To be Discontinued,10/2/2019,10/2/2019,,2020,discontinued
6136,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"20mg/12.5mg, 30 count bottle (NDC 0378-1413-93)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6137,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"20mg/12.5mg, 90 count bottle (NDC 0378-1413-77)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6138,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/12.5mg, 30 count bottle (NDC 0378-1422-93)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6139,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/12.5mg, 90 count bottle (NDC 0378-1422-77)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6140,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/25mg, 30 count bottle (NDC 0378-1425-93)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6141,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/25mg, 90 count bottle (NDC 0378-1425-77)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6142,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"5mg, 30 ct. (NDC 65852-0741-30)",Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6143,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"20mg, 30 ct. (NDC 65862-0742-30)",Revised,3/5/2020,,,,API Supply Issue,Cardiovascular,Resolved,3/5/2020,,,2020,
6144,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"20mg, 90 ct. (NDC 65862-0742-90)",Revised,3/5/2020,,,,API Supply Issue,Cardiovascular,Resolved,3/5/2020,,,2020,
6145,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"40mg, 30 ct. (NDC 65862-0743-30)",Revised,3/5/2020,,,,API Supply Issue,Cardiovascular,Resolved,3/5/2020,,,2020,
6146,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"40mg., 90 ct. (NDC 65862-0743-90)",Revised,3/5/2020,,,,API Supply Issue,Cardiovascular,Resolved,3/5/2020,,,2020,
6147,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"5mg, Bottle of 30 counts (NDC 62332-131-30)",Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6148,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"20mg, Bottle of 30 counts (NDC 62332-132-30)",Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6149,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"20mg, Bottle of 90 counts (NDC 62332-132-90)",Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6150,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"40mg, Bottle of 30 counts (NDC 62332-133-30)",Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6151,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"40mg, Bottle of 90 counts (NDC 62332-133-90)",Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6152,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,5mg (NDC 68462-0436-30),Revised,3/5/2020,,,,API shortage,Cardiovascular,Resolved,3/5/2020,,,2020,
6153,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,20mg (NDC 68462-0437-30),Revised,3/5/2020,,,,API shortage,Cardiovascular,Resolved,3/5/2020,,,2020,
6154,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,20mg (NDC 68462-0437-90),Revised,3/5/2020,,,,API shortage,Cardiovascular,Resolved,3/5/2020,,,2020,
6155,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,40mg (NDC 68462-0438-30),Revised,3/5/2020,,,,API shortage,Cardiovascular,Resolved,3/5/2020,,,2020,
6156,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,40mg (NDC 68462-0438-90),Revised,3/5/2020,,,,API shortage,Cardiovascular,Resolved,3/5/2020,,,2020,
6157,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil  5mg T 30s (NDC 0378-7012-93),Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6158,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 20mg T 30s (NDC 0378-7112-93),Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6159,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 20mg T 90s (NDC 0378-7112-77),Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6160,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 40mg T 30s (NDC 0378-7124-93),Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6161,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 40mg T 90s (NDC 0378-7124-77),Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6162,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"5mg, 30T (NDC 1672-9320-10)",Revised,3/5/2020,,,,Limited API availability,Cardiovascular,Resolved,3/5/2020,,,2020,
6163,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"5mg, 90T (NDC 1672-9320-15)",Revised,3/5/2020,,,,Limited API availability,Cardiovascular,Resolved,3/5/2020,,,2020,
6164,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"20mg, 30T (NDC 1672-9321-10)",Revised,3/5/2020,,,,Limited API availability,Cardiovascular,Resolved,3/5/2020,,,2020,
6165,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"20mg, 90T (NDC 1672-9321-15)",Revised,3/5/2020,,,,Limited API availability,Cardiovascular,Resolved,3/5/2020,,,2020,
6166,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"40mg, 30T (NDC 1672-9322-10)",Revised,3/5/2020,,,,Limited API availability,Cardiovascular,Resolved,3/5/2020,,,2020,
6167,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"40mg, 90T (NDC 1672-9322-15)",Revised,3/5/2020,,,,Limited API availability,Cardiovascular,Resolved,3/5/2020,,,2020,
6168,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,5mg tablet (NDC 13668-248-30),Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6169,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,20mg tablet (NDC 13668-249-30),Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6170,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,20mg tablet (NDC 13668-249-90),Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6171,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,40mg tablet (NDC 13668-250-30),Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6172,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,40mg tablet (NDC 13668-250-90),Revised,3/5/2020,,,,,Cardiovascular,Resolved,3/5/2020,,,2020,
6173,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","5mg, 30 Unit (NDC 65597-101-30)",Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6174,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","20mg, 30 Unit (NDC 65597-103-30)",Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6175,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","20mg, 90 Unit (NDC 65597-103-90)",Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6176,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","40mg, 30 Unit (NDC 65597-104-30)",Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6177,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","40mg, 90 Unit (NDC 65597-104-90)",Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6178,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 20mg 30 Tabs (NDC 67877-0446-30),Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6179,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 20mg 90 Tabs (NDC 67877-0446-90),Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6180,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 40mg 30 Tabs (NDC 67877-0447-30),Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6181,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 40mg 90 Tabs (NDC 67877-0447-90),Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6182,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 5mg 30 Tabs (NDC 67877-0445-30),Revised,3/5/2020,,,,Other,Cardiovascular,Resolved,3/5/2020,,,2020,
6183,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pataday 2mg/mL 5mL in 1 bottle (NDC 0065-0272-11),New,2/26/2020,,The product will be available via OTC.,,,Ophthalmology,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
6184,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pataday 2mg/mL 2.5mL in 1 bottle (NDC 0065-0272-25),New,2/26/2020,,The product will be available via OTC.,,,Ophthalmology,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
6185,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pataday 2mg/mL 2.5mL in 1 bottle (NDC 61314-272-25),New,2/26/2020,,The product will be available via OTC.,,,Ophthalmology,To be Discontinued,2/26/2020,2/26/2020,,2020,discontinued
6186,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pazeo Ophthalmic Solution 7mg/mL 2.5mL in 1 bottle (NDC 0065-4273-25),New,8/11/2020,,"Discontinuation of this product is not due to manufacturing, product quality, safety, or efficacy concerns.",,,Ophthalmology,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6187,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pazeo Ophthalmic Solution 7mg/mL 5mL in 1 bottle (NDC 0065-4273-27),New,8/11/2020,,"Discontinuation of this product is not due to manufacturing, product quality, safety, or efficacy concerns.",,,Ophthalmology,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6188,Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets,Abbvie,212.5mg; 75mg; 50mg (NDC 0074-3082-28),New,5/22/2018,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary",,,Antiviral,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
6189,Omega-3-Acid Ethyl Esters,Par Pharmaceutical,"900 mg/1 unit capsule, liquid filled (NDC 49884-019-08)",New,5/10/2019,,Par has made a business decision to discontinue the drug product.,,,Gastroenterology,To be Discontinued,5/10/2019,5/10/2019,,2020,discontinued
6190,Omega-3-Acid Ethyl Esters,Par Pharmaceutical,900mg/1 unit capsule (NDC 0254-3010-08),New,5/10/2019,,Par has made a business decision to discontinue the drug product.,,,Gastroenterology,To be Discontinued,5/10/2019,5/10/2019,,2020,discontinued
6191,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC 0093-5294-56), (30 count Bottle)",New,7/17/2019,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
6192,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC (0093-5294-98) (90 count Bottle)",New,7/17/2019,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
6193,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC 0093-5294-10) (1000 count Bottle )",New,7/17/2019,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
6194,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 2 mL vial (NDC 72266-123-25)",Reverified,10/27/2020,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,,2020,available
6195,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-124-01)",Reverified,10/27/2020,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,,2020,available
6196,Ondansetron Hydrochloride Injection,Baxter Healthcare,"Ondansetron Injection, USP (2 mg/mL) 2 mL Single Use Glass Vial (25 x 2 mL) (NDC 36000-012-25)",Reverified,9/23/2020,Available,For IV or IM injection,,,Gastroenterology,Current,,,,2020,available
6197,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 2mL vial (NDC 70860-776-02),Reverified,10/27/2020,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6198,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 20mL vial (NDC 70860-777-20),Reverified,10/27/2020,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Gastroenterology,Current,,,,2020,available
6199,Ondansetron Hydrochloride Injection,Heritage Pharma,"Inj4mg/2mL, 25 (NDC 23155-549-31)",Reverified,11/6/2020,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6200,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-41),Reverified,11/6/2020,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6201,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-42),Reverified,11/6/2020,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6202,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, amber vial, 4 mg per 2 mL (NDC 63323-373-02)",Revised,11/16/2020,7 months expiry (expiry 6/30/2021) dating available by request.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2020,limited availability
6203,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Multi dose, amber vial, 40 mg per 20 mL (NDC 63323-374-20)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6204,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, Simplist syringe, 4 mg per 2 mL (NDC 76045-103-20)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6205,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9890-01)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6206,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 2 mL vial, 25 count (NDC 55150-125-02)",Reverified,11/20/2020,On long term backorder,On long term backorder,,Delay in shipping of the drug,Gastroenterology,Current,,,,2020,not available
6207,Ondansetron Hydrochloride Injection,Heritage Pharma,"4mg/2mL, 10 (NDC 23155-547-41 )",Reverified,11/6/2020,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6208,Ondansetron Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-4759-01),Reverified,11/20/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
6209,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 2 mL vial (NDC 0641-6078-25)",Revised,7/22/2020,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2020,not available
6210,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-4755-03),Reverified,11/20/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
6211,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1120-12),Reverified,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology,Current,,,,2020,discontinued
6212,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 20 mL vial, 1 count (NDC 55150-126-20)",Reverified,11/20/2020,On long term backorder,On long term backorder,,Delay in shipping of the drug,Gastroenterology,Current,,,,2020,not available
6213,Ondansetron Hydrochloride Injection,Apotex Corp.,Ondansetron 2mg/mL 2mL vials Box of 25 vials (NDC 60505-6130-05),Reverified,11/13/2020,Available,,,Available,Gastroenterology,Current,,,,2020,available
6214,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,40mg/20mL EA 1 Vial (NDC 25021-782-20),Reverified,10/22/2020,Available,,,,Gastroenterology,Current,,,,2020,available
6215,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,4mg/2mL PK 25 Vials (NDC 25021-777-02),Reverified,10/22/2020,Available,,,,Gastroenterology,Current,,,,2020,available
6216,Oxalaplatin Injection,Gland Pharma Limited,"50 mg/10 mL, 10 vials per pack (NDC 72266-125-10)",New,9/28/2020,,"50 mg/10 mL and 100 mg/20 mL, 1 vial per packs (NDCs 72266-161-01 and 72266-162-01, respectively) will continue to be available; Gland Pharma Limited, Distributed by Fosun Pharma USA Inc. (Company Contact Information: 833-291-9645)",,,Oncology,To be Discontinued,9/28/2020,9/28/2020,,2020,discontinued
6217,Oxalaplatin Injection,Gland Pharma Limited,"100 mg/20 mL, 10 vials per pack (NDC 72266-126-10)",New,9/28/2020,,"50 mg/10 mL and 100 mg/20 mL, 1 vial per packs (NDCs 72266-161-01 and 72266-162-01, respectively) will continue to be available; Gland Pharma Limited, Distributed by Fosun Pharma USA Inc. (Company Contact Information: 833-291-9645)",,,Oncology,To be Discontinued,9/28/2020,9/28/2020,,2020,discontinued
6218,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"5 mg, 100 count bottle (NDC 0093-5206-01)",New,3/29/2019,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/2019,3/29/2019,,2020,discontinued
6219,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"10 mg, 100 count bottle (NDC 0093-5207-01)",New,3/29/2019,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/2019,3/29/2019,,2020,discontinued
6220,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"15 mg, 100 count bottle (NDC 0093-5208-01)",New,3/29/2019,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/2019,3/29/2019,,2020,discontinued
6221,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-6605-01)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6222,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-6605-05)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6223,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-6610-01)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6224,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-6610-05)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6225,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100 count bottle (NDC 0378-6615-01)",New,5/2/2019,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6226,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,30 mg/1 unit (NDC 0228-2879-11),New,11/7/2019,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/2019,11/7/2019,,2020,discontinued
6227,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,15 mg/1 unit (NDC 0228-2878-11),New,11/7/2019,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/2019,11/7/2019,,2020,discontinued
6228,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,5 mg/1 unit (NDC 0228-2876-11),New,11/7/2019,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/2019,11/7/2019,,2020,discontinued
6229,Oxymorphone Hydrochloride,Teva Pharmaceuticals,5 mg/1 unit (NDC 0093-5861-01),New,6/10/2019,,Business related decision to discontinue these products,,,Analgesia/Addiction;Anesthesia,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
6230,Oxymorphone Hydrochloride,Teva Pharmaceuticals,10 mg/1 unit (NDC 0093-5862-01),New,6/10/2019,,Business related decision to discontinue these products,,,Analgesia/Addiction;Anesthesia,To be Discontinued,6/10/2019,6/10/2019,,2020,discontinued
6231,"Oxytocin (Pitocin) Synthetic Injection, USP",Par Pharmaceutical,Pitocin Single Pack 10 mL Vial (NDC 42023-116-01),New,11/1/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Reproductive,To be Discontinued,11/1/2019,11/1/2019,,2020,discontinued
6232,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",100 USP Units per 10 mL (10 USP units per mL); Multiple dose vial;  (NDC 63323-012-10),Revised,11/16/2020,Available,Check wholesalers for inventory.,,Delay in manufacturing,Reproductive,Current,,,,2020,available
6233,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",300 USP Units per 30 mL (10 USP Units per mL); Multiple dose vial; (NDC 63323-012-30),Revised,11/16/2020,Available,Check wholesalers for inventory.,,Delay in manufacturing,Reproductive,Current,,,,2020,available
6234,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",10 USP Units per mL (10 USP units per mL); (NDC 63323-012-01)( NDC 63323-0012-11),Revised,11/16/2020,8 month expiry dating available by request. Next release November 2020.,Check wholesalers for inventory.,,Delay in manufacturing,Reproductive,Current,,,,2020,not available
6235,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of six 50 mL Pharmacy Bulk Packages, each containing 10 units of oxytocin per mL (total = 500 units of oxytocin per vial), (NDC 42023-130-06)",Revised,3/30/2020,Available,,,,Reproductive,Current,,,,2020,available
6236,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin, (NDC 42023-116-25)",Revised,3/30/2020,Available,,,,Reproductive,Current,,,,2020,available
6237,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of twenty-five 10 mL multiple-dose vial, each containing 10 units of oxytocin per mL (total = 100 units of oxytocin per vial) (NDC 42023-116-02)",Revised,3/30/2020,Available,,,,Reproductive,Current,,,,2020,available
6238,"Paclitaxel Injection, USP",HQ Specialty Pharma,30 mg/5 mL (NDC 44567-504-1),New,7/3/2019,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/2019,7/3/2019,,2020,discontinued
6239,"Paclitaxel Injection, USP",HQ Specialty Pharma,100 mg/16.7 mL (NDC 44567-505-1),New,7/3/2019,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/2019,7/3/2019,,2020,discontinued
6240,"Paclitaxel Injection, USP",HQ Specialty Pharma,300 mg/50 mL (6 mg/mL)(NDC 44567-506-1),New,7/3/2019,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/2019,7/3/2019,,2020,discontinued
6241,"Paclitaxel Injection, USP",Mylan Institutional,"100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17)",New,11/22/2019,,19-Dec,,,Oncology,To be Discontinued,11/22/2019,11/22/2019,,2020,discontinued
6242,"Paclitaxel Injection, USP","Fresenius Kabi USA, LLC",30 mg/5 mL (6 mg/mL) MDV (NDC 63323-763-05),Revised,3/30/2020,,Product available. Check wholesalers for inventory or contact Customer Service to place a direct order. Product will be discontinued when inventory is depleted.,,,Oncology,To be Discontinued,3/6/2020,3/6/2020,,2020,discontinued
6243,"Paclitaxel Injection, USP",Mylan Institutional,"30 mg in 5 mL (6 mg/mL), multi-dose vial (NDC 67457-471-52)",Revised,3/30/2020,,Expected discontinuation October 2020 (short dating),,,Oncology,To be Discontinued,3/30/2020,3/30/2020,,2020,discontinued
6244,"Paclitaxel Injection, USP",Mylan Institutional,"300 mg in 50 mL (6 mg/mL), multi-dose vial (NDC 67457-434-51)",Revised,3/30/2020,,Expected discontinuation October 2020 (short dating),,,Oncology,To be Discontinued,3/30/2020,3/30/2020,,2020,discontinued
6245,Pantoprazole Sodium for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg, 10 vials (NDC 0143-9284-10)",Reverified,7/22/2020,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6246,Pantoprazole Sodium for Injection,Sun Pharmaceutical Industries Inc.,"40 mg, 10 vials (NDC 62756-129-44)",New,10/29/2019,Available,,,,Gastroenterology,Current,,,,2020,available
6247,Pantoprazole Sodium for Injection,Aurobindo Pharma,"40 mg, 10 vials (NDC 55150-202-10)",Reverified,9/25/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2020,available
6248,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-0923-55)",Revised,11/20/2020,Limited Supply Available.  Next Delivery: November 2020; Estimated Recovery: December 2020,,,Other,Gastroenterology,Current,,,,2020,limited availability
6249,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-0923-60)",Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: May 2021,,,Other,Gastroenterology,Current,,,,2020,not available
6250,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-2001-10; Amerinet)",Revised,11/20/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
6251,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-2001-25; Amerinet)",Revised,11/20/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
6252,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-4001-10; PremierPro)",Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: November 2020,,,Other,Gastroenterology,Current,,,,2020,not available
6253,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-4001-25; PremierPro)",Revised,11/20/2020,Next Delivery: December 2020; Estimated Recovery: April 2021,,,Other,Gastroenterology,Current,,,,2020,not available
6254,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 0781-3232-95)",Reverified,11/13/2020,Available,,,,Gastroenterology,Current,,,,2020,available
6255,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges),Reverified,1/28/2020,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2020,unclear
6256,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,50mcg   Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges),Reverified,1/28/2020,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2020,unclear
6257,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,75mcg   Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges),Reverified,1/28/2020,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2020,unclear
6258,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,100mcg   Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges),Reverified,1/28/2020,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2020,unclear
6259,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4347-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2020,discontinued
6260,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4348-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2020,discontinued
6261,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4349-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2018.  For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2020,discontinued
6262,PEGINTRON (peginterferon alfa-2b) Injection,Merck Sharp & Dohme Corp.,"PEGINTRON injection (peginterferon alfa-2b) 50 mcg per 0.5 mL; box containing one 50 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs (NDC 00085-4353-01)",New,9/12/2019,,To be discontinued on or near May 2021,,,Antiviral;Oncology,To be Discontinued,9/12/2019,9/12/2019,,2020,discontinued
6263,Penicillamine (Depen) Titratable Tablets,Mylan Pharmaceuticals Inc.,"Penicillamine tablets, 250 mg (NDC 0037-4401-01)",Revised,10/1/2019,,,,,Endocrinology/Metabolism;Gastroenterology;Inborn Errors;Pediatric;Renal;Rheumatology,Resolved,10/1/2019,,,2020,
6264,Penicillin V Potassium Tablets,Sandoz,"500 mg, 100 tablets (NDC 0781-1655-01)",New,3/19/2020,,,,,Anti-Infective,To be Discontinued,3/19/2020,3/19/2020,,2020,discontinued
6265,Penicillin V Potassium Tablets,Sandoz,"500 mg, 1000 tablets (NDC 0781-1655-10)",New,3/19/2020,,,,,Anti-Infective,To be Discontinued,3/19/2020,3/19/2020,,2020,discontinued
6266,Penicillin V Potassium Tablets,Sandoz,"250 mg, 100 tablets (NDC 0781-1205-01)",New,3/19/2020,,,,,Anti-Infective,To be Discontinued,3/19/2020,3/19/2020,,2020,discontinued
6267,Penicillin V Potassium Tablets,Sandoz,"250 mg, 1000 tablets (NDC 0781-1205-10)",New,3/19/2020,,,,,Anti-Infective,To be Discontinued,3/19/2020,3/19/2020,,2020,discontinued
6268,Pentamidine Isethionate (Nebupent) For Inhalation Solution,"Fresenius Kabi USA, LLC","300 mg per vial, SDV, PF (NDC 63323-877-15)",Revised,9/13/2019,,,,,Anti-Infective,Resolved,9/13/2019,,,2020,
6269,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 100s (NDC 0378-0357-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
6270,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 500s (NDC 0378-0357-05)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/2018,5/8/2018,,2020,discontinued
6271,Peritoneal Dialysis Solutions,Baxter Healthcare,Peritoneal Dialysis Solutions for Automated Peritoneal Dialysis (APD) therapy (Dianeal and Extraneal),Revised,3/2/2020,,,,,Pediatric;Renal,Resolved,3/2/2020,,,2020,
6272,Peritoneal Dialysis Solutions,Fresenius Medical Care North America,Peritoneal Dialysis Solutions (Delflex and Stay Safe),Revised,3/2/2020,,,,,Pediatric;Renal,Resolved,3/2/2020,,,2020,
6273,Peritoneal Dialysis Solutions,Baxter Healthcare,Peritoneal Dialysis Solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD) therapy (Dianeal and Extraneal),Revised,3/2/2020,,,,,Pediatric;Renal,Resolved,3/2/2020,,,2020,
6274,Phenobarbital Oral Solution,Torrent Pharma Inc.,1 pint 473mL (NDC 16571-330-16),New,11/25/2019,,,,,Neurology,To be Discontinued,11/25/2019,11/25/2019,,2020,discontinued
6275,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 2 mL vial (NDC 0641-0493-25)",Revised,9/3/2019,,,Available,,Neurology,Resolved,9/3/2019,,,2020,
6276,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 5 mL vial (NDC 0641-2555-45)",Revised,9/3/2019,,,Available,,Neurology,Resolved,9/3/2019,,,2020,
6277,"Physostigmine Salicylate Injection, USP",Akorn Pharmaceuticals,"Physostigmine Salicylate Injection, USP  1mg/mL (10amps/box, 2mL each) (NDC 17478-510-02)",Revised,12/2/2019,Available,,,Other,Neurology,Current,,,,2020,available
6278,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","5 mg: Bottles of 100 tablets, (NDC 62559-560-01)",Revised,4/24/2020,Currently Unavailable; Estimated Resupply: 2Q 2021,Finished Goods can be manufactured upon receipt of API.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2020,not available
6279,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","10 mg; Bottles of 100 tablets, (NDC 62559-561-01)",Revised,4/24/2020,Currently Unavailable; Estimated Resupply: 2Q 2021,Finished Goods can be manufactured upon receipt of API.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2020,not available
6280,Pindolol Tablets,Bayshore Pharmaceuticals,5 mg/ 100 count (NDC 76385-131-01),Revised,11/18/2020,Available,,,,Cardiovascular,Current,,,,2020,available
6281,Pindolol Tablets,Bayshore Pharmaceuticals,10 mg/ 100 count (NDC 76385-132-01),Revised,11/18/2020,Available,,,,Cardiovascular,Current,,,,2020,available
6282,Pindolol Tablets,Sun Pharmaceutical Industries Inc.,"Pindolol Tablets, 5mg and 10mg (100 count bottles)(NDC 57664-655-88, 57664-656-88)",New,2/21/2020,No product available. Product can be manufactured upon availability of API. Concrete estimated release dates cannot be provided at this moment.,,,Shortage of active ingredient,Cardiovascular,Current,,,,2020,not available
6283,Pindolol Tablets,Mylan Pharmaceuticals Inc.,Pindolol 5mg Tabs 100s (NDC 0378-0052-01),Revised,11/17/2020,Unavailable. Re-supply Q1 2021.,,,,Cardiovascular,Current,,,,2020,not available
6284,Pindolol Tablets,Mylan Pharmaceuticals Inc.,Pindolol 10mg Tabs 100s (NDC 0378-0127-01),Revised,11/17/2020,Unavailable. Re-supply Q1 2021.,,,,Cardiovascular,Current,,,,2020,not available
6285,Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets,Sandoz,500mg;15mg tablets (NDC 0781-5626-60),New,2/10/2020,,,,,Endocrinology/Metabolism,To be Discontinued,2/10/2020,2/10/2020,,2020,discontinued
6286,Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets,Sandoz,850mg;15mg tablets (NDC 0781-5627-60),New,2/10/2020,,,,,Endocrinology/Metabolism,To be Discontinued,2/10/2020,2/10/2020,,2020,discontinued
6287,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"2.25 g, single dose vial, box of 10 (NDC 64679-034-01",Revised,2/21/2020,,,,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6288,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"2.25 g, single dose vial, box of 10 (NDC 61990-0110-2)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6289,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"4.5 g, single dose vial, box of 10 (NDC 61990-0130-2)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6290,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 70860-120-20); distributed by Athenex",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6291,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"3.375 g, single dose vial, box of 10 (NDC 61990-0120-2)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6292,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"13.5 g, pharmacy bulk vial (NDC 61990-0140-1)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6293,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"40.5 g, pharmacy bulk vial (NDC 61990-0150-1)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6294,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 70860-121-30); distributed by Athenex",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6295,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 70860-122-50); distributed by Athenex",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6296,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 70860-123-99); distributed by Athenex",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6297,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0409-3378-13) ADD-Vantage; distributed by Hospira",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6298,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0409-3379-04) ADD-Vantage; distributed by Hospira",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6299,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0409-3383-02); distributed by Hospira",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6300,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0409-3385-13); distributed by Hospira",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6301,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0409-3390-04); distributed by Hospira",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6302,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"13.5 g, pharmacy bulk bottle (NDC 0409-2999-14); distributed by Hospira",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6303,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","2.25 g, single-dose vial (NDC 63323-981-21)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6304,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"3.375 g, single dose vial, box of 10 (NDC 64679-056-01)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6305,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"3.375 g, single dose vial (NDC 64679-056-02)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6306,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"40.5 g, pharmacy bulk vial, box of 10 (NDC 64679-679-02)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6307,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","2.25 g, single dose vial, box of 10 (NDC 60505-6156-4); distributed by Apotex",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6308,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","3.375 g, single dose vial, box of 10 (NDC 60505-6157-4); distributed by Apotex",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6309,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","4.5 g, single dose vial, box of 10 (NDC 60505-6159-4); distributed by Apotex",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6310,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0781-9210-95) Novaplus",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6311,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0781-9214-95) Novaplus",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6312,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0781-9213-95) Novaplus",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6313,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"3.375 g, single dose vial, box of 10 (NDC 67457-522-37)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6314,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"4.5 g, single dose vial, box of 10 (NDC 67457-523-45)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6315,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"2.25 g, single dose vial, box of 10 (NDC 67457-521-22)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6316,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 2.25 g/50 mL, frozen IV bag (NDC 0206-8860-02)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6317,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 3.375 g/50 mL, frozen IV bag (NDC 0206-8861-02)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6318,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 4.5 g/100 mL, frozen IV bag (NDC 0206-8862-02)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6319,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"2.25 g, single dose vial, box of 10 (NDC 55150-119-30); distributed by AuroMedics Pharma LLC",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6320,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"3.375 g, single dose vial, box of 10 (NDC 55150-120-30); distributed by AuroMedics Pharma LLC",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6321,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"4.5 g, single dose vial, box of 10 (NDC 55150-121-50); distributed by AuroMedics Pharma LLC",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6322,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 63323-309-20); distributed by Fresenius Kabi",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6323,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","3.375 g, single dose vial, box of 10 (NDC 63323-983-21)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6324,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","4.5 g, single dose vial, box of 10 (NDC 63323-982-52)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6325,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 63323-304-74); distributed by Fresenius Kabi",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6326,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0409-3374-02) ADD-Vantage; distributed by Hospira",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6327,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"2.25 g, single dose vial, box of 10 (NDC 25021-164-30); distributed by Sagent Pharmaceuticals",Reverified,10/9/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6328,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"3.375 g, single dose vial, box of 10 (NDC 25021-165-30); distributed by Sagent Pharmaceuticals",Reverified,10/9/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6329,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"4.5 g, single dose vial, box of 10 (NDC 25021-166-48); distributed by Sagent Pharmaceuticals",Reverified,10/9/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6330,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 44567-801-10); distributed by WG Critical Care",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6331,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 44567-802-10); distributed by WG Critical Care",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6332,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 44567-803-10); distributed by WG Critical Care",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6333,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 44567-804-01); distributed by WG Critical Care",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6334,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0781-3114-95)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6335,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0781-3113-95)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6336,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0781-3110-95)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6337,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"4.5 g, single dose vial, box of 10 (NDC 64679-012-01)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6338,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"4.5 g, single dose vial (NDC 64679-012-02)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6339,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"40.5 g, pharmacy bulk vial (NDC 64679-679-01)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6340,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"2.25 g, single dose vial (NDC 64679-034-02)",Revised,2/21/2020,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/2020,,,2020,
6341,"Potassium Acetate Injection, USP","Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3294-51)",Reverified,11/20/2020,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,available
6342,"Potassium Acetate Injection, USP","Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 00409-8183-01)",Reverified,11/20/2020,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,available
6343,"Potassium Acetate Injection, USP","Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial NovaPlus (NDC 00409-3294-25)",Reverified,11/20/2020,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,available
6344,"Potassium Acetate Injection, USP","Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial NovaPlus (NDC 00409-8183-25)",Reverified,11/20/2020,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,available
6345,"Potassium Acetate Injection, USP","Exela Pharma Sciences, LLC",Potassium Acetate Inj. 40mEq (2mEq/ml) 20mL (NDC 51754-2001-4),Revised,12/10/2019,On allocation due to increased demand.,"Please check with wholesaler for availability. Additional production underway. Direct shipment to hospitals at 200 vials max per week are available from Exela. Customer Service # 828-758-5474, then press #2",,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2020,limited availability
6346,Potassium Chloride Injection,"ICU Medical, Inc.",10 mEq/50 mL (Legacy Hospira NDC 0409-7075-14) (ICU Medical NDC 0990-7075-14),Revised,6/21/2019,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6347,Potassium Chloride Injection,Baxter Healthcare,30 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0673-04),Revised,6/21/2019,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6348,Potassium Chloride Injection,"ICU Medical, Inc.",30 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7903-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6349,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7904-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6350,Potassium Chloride Injection,"ICU Medical, Inc.",10 mEq/1000 mL in 5% dex & 0.45% NaCl (NDC 0409-7993-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6351,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% dex & 0.9% NaCl (NDC 0409-7107-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6352,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL in 5% dex & 0.9% NaCl (NDC 0409-7109-09),Revised,6/21/2019,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6353,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 0.45% NaCl (NDC 0409-9257-39),Revised,6/21/2019,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6354,Potassium Chloride Injection,"ICU Medical, Inc.","20 mEq/100 mL (Legacy Hospira NDC 0409-7075-26)
(ICU Medical NDC 0990-7075-26)",Revised,6/21/2019,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6355,Potassium Chloride Injection,"Hospira, Inc.",10 mEq/5 mL (2 mEq/mL); Single Dose Glass Fliptop Vial (NDC 00409-6635-01),Revised,6/21/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/2019,,,2020,
6356,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",4.5 mg tablets (NDC 10370-255-11),New,1/27/2020,,,,,Neurology,To be Discontinued,1/27/2020,1/27/2020,,2020,discontinued
6357,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (Pred Forte) (NDC 11980-180-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6358,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6359,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (NDC 60758-119-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6360,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (NDC 60758-119-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6361,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 5mL in 1 bottle (NDC 61314-637-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6362,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 10mL in 1 bottle (NDC 61314-637-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6363,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 15mL in 1 bottle (NDC 61314-637-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6364,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6365,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (NDC 60758-119-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2020,
6366,"Primaquine Phosphate Tablet, EQ 15mg Base",Sanofi,"Primaquine; Film-coated tablet, 15 mg/1 unit, bottles of 100, (NDC 0024-1596-01)",Revised,12/10/2019,,,,,Anti-Infective,Resolved,12/10/2019,,,2020,
6367,"Primaquine Phosphate Tablet, EQ 15mg Base",Bayshore Pharmaceuticals,"Primaquine Phosphate USP,  26.3 mg (15mg base)Tablets, (NDC 76385-102-01), 100 Count Bottle",Revised,12/10/2019,,,,,Anti-Infective,Resolved,12/10/2019,,,2020,
6368,"Primidone Tablets, USP",Par Pharmaceutical,"50mg, count bottle (NDC 0603-5371-21)",New,4/9/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/9/2019,4/9/2019,,2020,discontinued
6369,"Primidone Tablets, USP",Par Pharmaceutical,"50mg, count bottle (NDC 0603-5371-28)",New,4/9/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/9/2019,4/9/2019,,2020,discontinued
6370,Prinivil Tablets,Merck Sharp & Dohme Corp.,"10-mg tablets, unit-of-use bottle/90 (NDC0006-0106-54)",New,2/20/2020,,To be discontinued on or near March 2020.,,,Cardiovascular,To be Discontinued,2/20/2020,2/20/2020,,2020,discontinued
6371,Prinivil Tablets,Merck Sharp & Dohme Corp.,"20-mg tablets, unit-of-use bottle/90 (NDC 0006-0207-54)",New,2/20/2020,,To be discontinued on or near March 2020.,,,Cardiovascular,To be Discontinued,2/20/2020,2/20/2020,,2020,discontinued
6372,"Procainamide Hydrochloride Injection, USP","Hospira, Inc.","1,000 mg/10 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1902-01)",Reverified,11/20/2020,Available,,,Other,Cardiovascular;Renal,Current,,,,2020,available
6373,"Procainamide Hydrochloride Injection, USP","Hospira, Inc.","1,000 mg/2 mL (500 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1903-01)",Reverified,11/20/2020,Available,,,Other,Cardiovascular;Renal,Current,,,,2020,available
6374,"Procainamide Hydrochloride Injection, USP","Amphastar Pharmaceuticals, Inc./IMS",100 mg/1 mL injection; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3399-5),Reverified,10/30/2020,Available,,,Other,Cardiovascular;Renal,Current,,,,2020,available
6375,"Procainamide Hydrochloride Injection, USP","Nexus Pharmaceuticals, Inc.","500 mg/mL, 2 mL (NDC 14789-900-02)",New,10/19/2017,Available,,,Other,Cardiovascular;Renal,Current,,,,2020,available
6376,"Procainamide Hydrochloride Injection, USP","Nexus Pharmaceuticals, Inc.","100 mg/mL, 10 mL (NDC 14789-900-10)",New,10/19/2017,Available,,,Other,Cardiovascular;Renal,Current,,,,2020,available
6377,"Progesterone Injection, USP",Teva Pharmaceuticals,50MG 1X10ML (NDC 0591-3128-79),Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2020,
6378,"Progesterone Injection, USP","Fresenius Kabi USA, LLC","500 mg per 10 mL, MDV (NDC 63323-0261-10)",Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2020,
6379,"Progesterone Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL (NDC 0143-9725-01)",Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2020,
6380,"Progesterone Injection, USP",AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),500 mg/10 mL multiple dose vial (NDC 55150-306-10),Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2020,
6381,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL vial (NDC 0641-0928-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6382,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL ,1 mL vial (NDC 0641-0929-25)",Revised,7/22/2020,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6383,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL ampul (NDC 0641-1495-35)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6384,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL ampul (NDC 0641-1496-35)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6385,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL vial (NDC 0641-6084-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6386,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL ,1 mL vial (NDC 0641-6085-25)",Revised,7/22/2020,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6387,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL ampul (NDC 0641-6082-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6388,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL, 1 mL ampul (NDC 0641-6083-25)",Revised,7/22/2020,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6389,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","25 mg/mL, Carton of 25 ampuls (NDC 39822-5525-3)",Reverified,12/11/2019,Available,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6390,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","50 mg/mL, Carton of 25 ampuls (NDC 39822-5550-6)",Reverified,12/11/2019,Available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2020,available
6391,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2020,discontinued
6392,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2020,discontinued
6393,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2020,discontinued
6394,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2020,discontinued
6395,Promethazine Suppository,Teva Pharmaceuticals,"25 mg/1 unit, (NDC 0591-2992-39 )",New,4/28/2020,,"Teva evaluated the market and decided to discontinue the product. For Promethazine Hydrochloride 25 mg/1 unit, NDC 0591-2992-39, allocations are being made based on customer Rx trends. Product availability is anticipated until May, 2020",,,Anesthesia;Pulmonary/Allergy,To be Discontinued,4/28/2020,4/28/2020,,2020,discontinued
6396,Promethazine Suppository,Teva Pharmaceuticals,"12.5 mg/1 unit, (NDC 0591-2985-39)",New,4/28/2020,,"Teva evaluated the market and decided to discontinue the product. For Promethazine Hydrochloride 25 mg/1 unit, NDC 0591-2992-39, allocations are being made based on customer Rx trends. Product availability is anticipated until May, 2020",,,Anesthesia;Pulmonary/Allergy,To be Discontinued,4/28/2020,4/28/2020,,2020,discontinued
6397,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), single patient use only, 10 mL (NDC 63323-269-10)",Reverified,11/16/2020,Shipping / Check wholesaler inventory,,,,Anesthesia,Current,,,,2020,unclear
6398,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), single patient use only, 20 mL (NDC 63323-269-29)",Reverified,11/16/2020,Shipping / Check wholesaler inventory,,,Demand increase for the drug,Anesthesia,Current,,,,2020,unclear
6399,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL), single patient use only, 50 mL (NDC 63323-269-50)",Reverified,11/16/2020,Allocating to wholesalers / Check wholesaler inventory,COVID-19 demand,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6400,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","1000 mg per 100 mL (10 mg per mL), single patient use only, 100 mL (NDC 63323-269-65)",Reverified,11/16/2020,Allocating to wholesalers / Check wholesaler inventory,COVID-19 demand,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6401,Propofol Injectable Emulsion,Sagent Pharmaceuticals,200mg per 20ml (NDC 25021-608-20),Reverified,10/22/2020,Available. On Allocation,,,Demand increase due to Covid-19,Anesthesia,Current,,,,2020,limited availability
6402,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 10X100ML VL (NDC 0591-2136-68),Reverified,11/19/2020,Limited supply available. Next Delivery and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,,2020,limited availability
6403,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-30),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: March 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6404,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-33),Revised,11/20/2020,Limited Supply Available. Next Delivery and Estimated Recovery: January 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6405,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-24),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6406,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",200mg/20mL  10ct (NDC 43598-265-58),Reverified,11/13/2020,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6407,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, individual (NDC 43598-265-20)",Reverified,11/13/2020,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6408,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",500mg/50mL  20ct (NDC 43598-548-21),Reverified,11/13/2020,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6409,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","500mg/50mL vial, individual (NDC 43598-548-50)",Reverified,11/13/2020,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6410,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 20X50ML VL (NDC 0591-2136-51),Reverified,11/19/2020,Limited supply available. Next Delivery and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,,2020,limited availability
6411,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 25X20ML VL (NDC 0591-2136-95),Reverified,11/19/2020,Limited supply available. Next Delivery and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,,2020,limited availability
6412,Propofol Injectable Emulsion,Sagent Pharmaceuticals,500mg per 50ml (NDC 250-21-608-50),Reverified,10/22/2020,Available. On Allocation,,,Demand increase due to Covid-19,Anesthesia,Current,,,,2020,limited availability
6413,Propofol Injectable Emulsion,Sagent Pharmaceuticals,1000mg per 100ml (NDC 25021-608-51),Reverified,10/22/2020,Available. On Allocation,,,Demand increase due to Covid-19,Anesthesia,Current,,,,2020,limited availability
6414,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6194-10)",New,7/23/2020,This presentation is currently available.,Additional lots are scheduled for manufacturing.   Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
6415,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 50 mL vial (NDC 0641-6195-20",New,7/23/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the August – September 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
6416,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 100 mL vial (NDC 0641-6196-10",New,7/23/2020,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the August – September 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
6417,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, 10ct (NDC 43598-549-10)",Reverified,11/13/2020,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6418,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, individual (NDC 43598-549-52)",Reverified,11/13/2020,"Limited supply, resupply TBD",Manufacturer extended lead times.,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6419,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, 25ct (NDC 43598-265-25)",Reverified,11/13/2020,"Limited supply, resupply TBD",Manufacturer extended lead times.,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6420,"Pyrazinamide Tablets, USP",DAVA Pharmaceuticals Inc.,"500 mg, Bottle of 100 (NDC 67253-660-10)",New,4/20/2020,,Distributed by Par Pharmaceuticals.,,,Anti-Infective,To be Discontinued,4/20/2020,4/20/2020,,2020,discontinued
6421,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,5 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0527-40),New,11/12/2019,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/2019,11/12/2019,,2020,discontinued
6422,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,10 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0530-40),New,11/12/2019,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/2019,11/12/2019,,2020,discontinued
6423,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,20 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0532-40),New,11/12/2019,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/2019,11/12/2019,,2020,discontinued
6424,Quinidine Gluconate Injection,Eli Lilly and Co.,"QUINIDINE GLUCONATE, 80 mg/1 mL,10 mL/vial Injectable (NDC 0002-1407-01)",Revised,9/19/2019,,Discontinuation of the manufacture of the drug. The product distribution has ceased given the product's labeled expiry of March 2019. FDA and CDC are developing a strategy to ensure continued access to essential medicine for the treatment of severe malaria in the United States.,,,Anti-Infective;Cardiovascular,To be Discontinued,9/19/2019,9/19/2019,,2020,discontinued
6425,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 30 count bottle (NDC 0378-6709-93)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6426,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 90 count bottle (NDC 0378-6709-77)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6427,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 500 count bottle (NDC 0378-6709-05)",New,5/2/2019,,,,,Gastroenterology,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6428,"Ranitidine Injection, USP",Mylan Institutional,"Ranitidine Injection 25 mg/mL, 2ml vial; 10 pack; (NDC 67457-397-99)",Revised,4/3/2020,,,,,Gastroenterology,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6429,"Ranitidine Injection, USP",Mylan Institutional,"Ranitidine Injection 25 mg/mL, 6 mL vial; 1 pack; (NDC 67457-398-62)",Revised,4/3/2020,,,,,Gastroenterology,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6430,"Ranitidine Injection, USP",Zydus Pharmaceuticals USA Inc.,Ranitidine HCl Injection 25mg/mL (10x2mL SD vials)(NDC 68382-422-02),Revised,4/3/2020,,,,,Gastroenterology,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6431,"Ranitidine Injection, USP",Zydus Pharmaceuticals USA Inc.,Ranitidine HCl Injection 25mg/mL (6mL MD vial)(NDC 68382-423-06),Revised,4/3/2020,,,,,Gastroenterology,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6432,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 2ML VIAL (NDC 52565-101-01),Revised,4/3/2020,,,,,Gastroenterology,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6433,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 40ML VIAL (NDC 52565-096-01),Revised,4/3/2020,,,,,Gastroenterology,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6434,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 6ML VIAL (NDC 52565-102-01),Revised,4/3/2020,,,,,Gastroenterology,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6435,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,150mg 60 count bottle (NDC 68462-248-60),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6436,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,150mg 100 count bottle (NDC 68462-248-01),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6437,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,150mg 500 count bottle (NDC 68462-248-05),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6438,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,300mg 30 count bottle (NDC 68462-249-30),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6439,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,300mg 100 count bottle (NDC 68462-249-01),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6440,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,300mg 250 count bottle (NDC 68462-249-20),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6441,Ranitidine Tablets/Capsules,Appco Pharma LLC,150mg 60 count bottle (NDC 62559-690-60),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6442,Ranitidine Tablets/Capsules,Appco Pharma LLC,150mg 500 count bottle (NDC 62559-690-05),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6443,Ranitidine Tablets/Capsules,Appco Pharma LLC,300mg 30 count bottle (NDC 62559-691-30),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6444,Ranitidine Tablets/Capsules,"Dr. Reddy's Laboratories, Inc.",150mg 60 count bottle (NDC 5511112960),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6445,Ranitidine Tablets/Capsules,"Dr. Reddy's Laboratories, Inc.",150mg 500 count bottle (NDC 5511112905),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6446,Ranitidine Tablets/Capsules,"Dr. Reddy's Laboratories, Inc.",300mg 30 count bottle (NDC 5511113030),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6447,Ranitidine Tablets/Capsules,"Dr. Reddy's Laboratories, Inc.",300mg 100 count bottle (NDC 5511113001),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6448,Ranitidine Tablets/Capsules,Novitium Pharma LLC,"150 mg, Bottle of 60 capsules (NDC 70954-001-20)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6449,Ranitidine Tablets/Capsules,Novitium Pharma LLC,"150 mg, Bottle of 500 capsules (NDC 70954-001-40)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6450,Ranitidine Tablets/Capsules,Novitium Pharma LLC,"300 mg, Bottle of 30 capsules (NDC 70954-002-10)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6451,Ranitidine Tablets/Capsules,Novitium Pharma LLC,"300 mg, Bottle of 100 capsule (NDC 70954-002-40)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6452,Ranitidine Tablets/Capsules,Ajanta Pharma USA Inc,150 mg 60’s count bottle (NDC 27241-109-06),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6453,Ranitidine Tablets/Capsules,Ajanta Pharma USA Inc,150 mg 500’s count bottle (NDC 27241-109-50),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6454,Ranitidine Tablets/Capsules,Ajanta Pharma USA Inc,300 mg 30’s count bottle (NDC 27241-110-03),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6455,Ranitidine Tablets/Capsules,Ajanta Pharma USA Inc,300 mg 100’s count bottle (NDC 27241-110-10),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6456,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"150 mg, 60 count bottle (NDC 64380-0803-03)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6457,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"150 mg, 100 count bottle (NDC 64380-0803-06)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6458,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"150 mg, 500 count bottle (NDC 64380-0803-07)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6459,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"150 mg, 1000 count bottle (NDC 64380-0803-08)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6460,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"300 mg, 30 count bottle (NDC 64380-0804-04)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6461,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"300 mg, 100 count bottle (NDC 64380-0804-06)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6462,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"300 mg, 250 count bottle (NDC 64380-0804-38)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6463,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 60 count (NDC 65162-253-06)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6464,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 100 count (NDC 65162-253-10)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6465,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 180 count (NDC 65162-253-18)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6466,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 500 count (NDC 65162-253-50)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6467,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 1000 count (NDC 65162-253-11)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6468,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 1000 count (NDC 65162-253-11)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6469,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"300 mg, 30 count (NDC 65162-254-03)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6470,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"300 mg, 100 count (NDC 65162-254-10)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6471,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"300 mg, 250 count (NDC 65162-254-25)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6472,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"300 mg, 250 count (NDC 53746-254-02)",Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6473,Ranitidine Tablets/Capsules,Sandoz,150 mg 500 ct bottle (NDC 0781-2855-05),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6474,Ranitidine Tablets/Capsules,Sandoz,150 mg 60 ct bottle (NDC 0781-2855-60),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6475,Ranitidine Tablets/Capsules,Sandoz,300 mg 30 ct bottle (NDC 0781-2865-31),Revised,4/3/2020,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6476,Ranitidine Tablets/Capsules,Teva Pharmaceuticals,150 mg / 300 mg (NDC 0172-4357-49) and (NDC 0172-4358-46),New,4/30/2020,,Teva made a business decision to discontinue these products. Teva has not marketed the subject products for an extended period of time.,,,Gastroenterology;Pediatric,To be Discontinued,4/30/2020,4/30/2020,,2020,discontinued
6477,Ranitidine Tablets/Capsules,Teva Pharmaceuticals,150 mg/1 unit (NDC 0172-4357-70),New,4/30/2020,,Teva made a business decision to discontinue these products. Teva has not marketed the subject products for an extended period of time.,,,Gastroenterology;Pediatric,To be Discontinued,4/30/2020,4/30/2020,,2020,discontinued
6478,Ranitidine Tablets/Capsules,Teva Pharmaceuticals,300 mg/1 unit (NDC 0172-4358-60),New,4/30/2020,,Teva made a business decision to discontinue these products. Teva has not marketed the subject products for an extended period of time.,,,Gastroenterology;Pediatric,To be Discontinued,4/30/2020,4/30/2020,,2020,discontinued
6479,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,500 mg  (NDC 45963-418-50),New,7/6/2020,,,,,Cardiovascular,To be Discontinued,7/6/2020,7/6/2020,,2020,discontinued
6480,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,1000 mg  (NDC 45963-419-50),New,7/6/2020,,,,,Cardiovascular,To be Discontinued,7/6/2020,7/6/2020,,2020,discontinued
6481,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","1 mg per vial, SDV (NDC 63323-723-03)",Revised,3/2/2020,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/2020,,,2020,
6482,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","2 mg per vial, SDV (NDC 63323-724-05)",Revised,3/2/2020,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/2020,,,2020,
6483,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","5 mg per vial, SDV (NDC 63323-725-10)",Revised,3/2/2020,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/2020,,,2020,
6484,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,1 mg (NDC 67457-198-03),Revised,3/2/2020,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/2020,,,2020,
6485,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,2 mg (NDC 67457-198-05),Revised,3/2/2020,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/2020,,,2020,
6486,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,5 mg (NDC 67457-198-10),Revised,3/2/2020,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/2020,,,2020,
6487,Repaglinide Tablets,Sandoz,1mg tablets (NDC 0781-5149-01),New,2/2/2018,,,,,Endocrinology/Metabolism,To be Discontinued,2/2/2018,2/2/2018,,2020,discontinued
6488,Ribavirin (Rebetol) Oral Solution,Merck Sharp & Dohme Corp.,40 mg/mL (NDC 0085-1318-01),New,4/16/2019,,To be discontinued on or near June 2019.,,,Antiviral,To be Discontinued,4/16/2019,4/16/2019,,2020,discontinued
6489,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC","200 mg (NDCs 66435-101-14, 66435-101-16, 66435-101-18, 66435-101-42, 66435-101-56, 66435-101-70, 66435-101-84, 66435-102-16, 66435-102-95, 54738-950-16)",New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
6490,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",400 mg (NDCs 66435-103-56 and 66435-103-95),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
6491,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC","600 mg (NDCs 66435-104-56, 66435-104-92, 54738-952-56)",New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
6492,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",600 mg dose pack (NDCs 66435-108-56 and 66435-108-99),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
6493,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",800 mg dose pack (NDCs 66435-105-56 and 66435-105-99),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
6494,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",1000 mg dose pack (NDCs 66435-106-56 and 66435-106-99),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
6495,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",1200 mg dose pack (NDCs 66435-107-56 and 66435-107-99),New,7/12/2019,,,,,Antiviral,To Be Discontinued,7/12/2019,7/12/2019,,2020,discontinued
6496,Rifampin (Rifadin) Capsules,Sanofi-Aventis,150 mg capsules (NDC 0068-0510-30),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,6/15/2020,6/15/2020,,2020,discontinued
6497,Rifampin (Rifadin) Capsules,Sanofi-Aventis,300 mg capsules (NDC 0068-0508-60),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,6/15/2020,6/15/2020,,2020,discontinued
6498,Rifampin/Isoniazid (Rifamate) Capsules,Sanofi-Aventis,150 mg/300 mg capsules (NDC 0068-0509-60),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,6/15/2020,6/15/2020,,2020,discontinued
6499,Rifampin/Isoniazid/Pyrazinamide (Rifater) Tablets,Sanofi-Aventis,150 mg/300 mg/120 mg tablets (NDC 0088-0576-41),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,6/15/2020,6/15/2020,,2020,discontinued
6500,Rifapentine Tablets,Sanofi,"Rifapentine (Piftin) Tablets, 150 mg (NDC 0088-2102-24)",New,3/25/2020,On allocation with intermittent supply.,,,Demand increase for the drug,Anti-Infective,Current,3/25/2020,,,2020,limited availability
6501,Risedronate Sodium Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 1 count blister card (NDC 0378-4150-32)",New,5/2/2019,,,,,Other,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6502,Risedronate Tablets,Allergan Sales LLC,5 mg tablets (NDC 0430-0471-15),New,12/9/2019,,,,,Musculoskeletal,To be Discontinued,12/9/2019,12/9/2019,,2020,discontinued
6503,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6504,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6505,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6506,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6507,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6508,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6509,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6510,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6511,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6512,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6513,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6514,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6515,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6516,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6517,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6518,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6519,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 3 mg (NDC 50458-330-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6520,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 2 mg (NDC 50458-320-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6521,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 1 mg (NDC 50458-300-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6522,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.5 mg (NDC 50458-302-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6523,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6524,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-01),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2020,discontinued
6525,Rivastigmine Tartrate Capsules,Teva Pharmaceuticals,"1.5 mg capsules, 60 count (NDC 0591-3208-60)",New,3/10/2020,,Discontinuation of the manufacture of the drug.,,,Neurology,To be Discontinued,3/10/2020,3/10/2020,,2020,discontinued
6526,Rivastigmine Tartrate Capsules,Teva Pharmaceuticals,"3 mg capsules, 60 count (NDC 0591-3209-60)",New,3/10/2020,,Discontinuation of the manufacture of the drug.,,,Neurology,To be Discontinued,3/10/2020,3/10/2020,,2020,discontinued
6527,Rivastigmine Tartrate Capsules,Teva Pharmaceuticals,"4.5 mg capsules, 60 count (NDC 0591-3210-60)",New,3/10/2020,,Discontinuation of the manufacture of the drug.,,,Neurology,To be Discontinued,3/10/2020,3/10/2020,,2020,discontinued
6528,Rivastigmine Tartrate Capsules,Teva Pharmaceuticals,"6 mg capsules, 60 count (NDC 0591-3211-60)",New,3/10/2020,,Discontinuation of the manufacture of the drug.,,,Neurology,To be Discontinued,3/10/2020,3/10/2020,,2020,discontinued
6529,Rizatriptan Benzoate Orally Disintegrating Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 9 count bottle (NDC 0378-3701-59)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6530,Rizatriptan Benzoate Orally Disintegrating Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 9 count bottle (NDC 0378-3702-59)",New,5/2/2019,,,,,Neurology;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6531,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 5mL vial (NDC 70860-651-05),Revised,11/2/2018,Available,,,Available,Anesthesia,Resolved,11/2/2018,,,2020,available
6532,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 10mL vial (NDC 70860-651-10),Revised,11/2/2018,Available,,,Available,Anesthesia,Resolved,11/2/2018,,,2020,available
6533,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,4 mg  (NDC 0007-4887-13),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/2019,6/28/2019,,2020,discontinued
6534,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,6 mg  (NDC 0007-4883-13),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/2019,6/28/2019,,2020,discontinued
6535,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,8 mg  (NDC 0007-4888-13),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/2019,6/28/2019,,2020,discontinued
6536,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,12 mg  (NDC 0007-4882-13),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/2019,6/28/2019,,2020,discontinued
6537,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,500 mg per 100 mL (5 mg per mL 0.5%) (NDC 25021-652-82 ),Reverified,10/22/2020,Available,,,,Anesthesia,Current,,,,2020,available
6538,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,"1,000 mg per 200 mL (5 mg per mL 0.5%) (NDC 25021-652-87)",Reverified,10/22/2020,Available,,,,Anesthesia,Current,,,,2020,available
6539,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x100mL (NDC 25021-671-82),Reverified,10/22/2020,Available,,,,Anesthesia,Current,,,,2020,available
6540,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x200mL (NDC 25021-671-87),Reverified,10/22/2020,Available,,,,Anesthesia,Current,,,,2020,available
6541,Ropivacaine Hydrochloride Injection,Akorn Pharmaceuticals,"0.5% 5mg/mL, 30mL, 1 Vial (NDC 17478-0081-30)",Reverified,12/2/2019,Available,,,Other,Anesthesia,Current,,,,2020,available
6542,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-10),Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: January 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
6543,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-20),Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: February 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
6544,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9301-30),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
6545,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/20 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9302-20),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
6546,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-10),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
6547,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-20),Revised,11/20/2020,Limited Supply Available. Next Delivery: January 2021; Estimated Recovery: February 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2020,limited availability
6548,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 20 mL Single Dose Vials (NDC 55150-195-20),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
6549,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 100 mL Single Dose Infusion Bottles (NDC 55150-196-99),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
6550,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 20 mL Single Dose Vials (NDC 55150-197-20),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
6551,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-198-30),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
6552,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 20 mL Single Dose Vials (NDC 55150-199-20),Revised,11/20/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
6553,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Single Dose Vials (NDC 55150-200-10),Revised,11/20/2020,Currently on backorder - next shipment anticipated late Dec 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
6554,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Single Dose Vials (NDC 55150-201-20),Revised,11/20/2020,Currently on backorder - next shipment anticipated late Dec 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
6555,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-10)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6556,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-20)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6557,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-286-20)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6558,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-287-20)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6559,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Plastic Ampule, Sterile-Pak (63323-288-10)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6560,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-288-20)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6561,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Free Flex Bag (NDC 63323-285-61)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6562,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Free Flex Bag (NDC 63323-285-63)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6563,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-285-65)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6564,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-285-64)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6565,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (500 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-286-00)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6566,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (1,000 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-286-63)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6567,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Single Dose Vial (NDC 63323-285-13)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6568,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Single Dose Vial (NDC 63323-285-23)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6569,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Single Dose Vial (NDC 63323-286-35)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6570,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Single Dose Vial (NDC 63323-286-23)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6571,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Single Dose Vial (NDC 63323-287-21)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6572,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Single Dose Vial (NDC 63323-288-11)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2020,available
6573,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Single Dose Vial (NDC 63323-288-21)",Revised,11/16/2020,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2020,available
6574,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Sterile-Pack, Single Dose Vial (NDC 63323-286-31)",Revised,11/16/2020,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2020,available
6575,Saquinavir Mesylate (Invirase) 200mg Capsules,"Genentech, Inc",200 mg capsules (NDC 0004-0245-15),New,2/6/2018,,"Roche intends to stop-shipping Saquinavir Mesylate (Invirase) 200 mg Capsules on March 31, 2018 with product availability continuing until the September 2018 expiry date.  Saquinavir Mesylate (Invirase) 500mg Tablets are still available.",,,Antiviral,To be Discontinued,2/6/2018,2/6/2018,,2020,discontinued
6576,Sclerosol Intrapleural Aerosol,Lymol Medical Corp.,Sclerosol 4 GM (NDC 63256-100-30),Reverified,12/11/2019,Unavailable,,,Other,Pulmonary/Allergy,Current,,,,2020,not available
6577,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 10 count (NDC 10019-553-03),Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6578,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 24 count (NDC 10019-553-04),Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6579,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 4 count (NDC 66758-208-54),Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6580,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 4-Count Pack (NDC 45802-580-84)",Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6581,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 10-Count Pack (NDC 45802-580-46)",Revised,12/11/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6582,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 24-Count Pack (NDC 45802-580-62)",Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6583,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 4s (NDC 0378-6470-99),Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6584,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 10s (NDC 0378-6470-97),Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6585,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 24s (NDC 0378-6470-44),Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2020,
6586,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,"20mg/ml, 60ml  (NDC 16714-601-01)",Revised,7/10/2020,Unavailable,Northstar Rx label. Product Distributed by: McKesson (972-446-4800),,Other,Psychiatry,Current,,,,2020,not available
6587,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,20mg/ml (NDC 64980-409-06),Revised,7/10/2020,Currently available,Distributed by Rising Pharmaceuticals Contact Rising Pharmaceuticals : +1 (201) 961-9000,,Other,Psychiatry,Current,,,,2020,available
6588,"Sertraline Hydrochloride Oral Solution, USP",Pfizer Pharmaceuticals,"Sertraline Hydrochloride 60 mL (20 mg/mL) oral concentrate, with 12% alcohol; bottle with calibrated dropper (NDC 59762-0067-1)",Reverified,11/20/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
6589,"Sertraline Hydrochloride Oral Solution, USP",Pfizer Pharmaceuticals,"Zoloft (sertraline hydrochloride) 60 mL (20 mg/mL) oral concentrate, with 12% alcohol; bottle with calibrated dropper (NDC 0049-0050-01)",Reverified,11/20/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
6590,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,"20mg/ml, 60ml  (NDC 16714-601-02)",New,7/10/2020,Available,Northstar Rx label. Product Distributed by: McKesson (972-446-4800 ),,Demand increase for the drug,Psychiatry,Current,,,,2020,available
6591,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 30 count (NDC 16729-215-10)",Revised,8/31/2020,Available,,,,Pediatric;Psychiatry,Current,,,,2020,available
6592,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 90 count (NDC 16729-215-15)",Revised,8/31/2020,Available,,,,Pediatric;Psychiatry,Current,,,,2020,available
6593,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 500 count (NDC 16729-215-16)",Revised,8/31/2020,Limited supply/out of stock. Cannot supoort monthly demand. Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,,2020,limited availability
6594,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 90 count (NDC 16729-216-15)",Revised,8/31/2020,Limited supply/out of stock. Cannot supoort monthly demand. Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,,2020,limited availability
6595,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 500 count (NDC 16729-216-16)",Revised,8/31/2020,Limited supply / out of stock.  Cannot support monthly demand.  Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,,2020,limited availability
6596,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 90 count (NDC 16729-217-15)",Revised,8/31/2020,Limited supply / out of stock.  Cannot support monthly demand. Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,,2020,limited availability
6597,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 500 count (NDC 16729-217-16)",Revised,8/31/2020,Limited supply / out of stock.  Cannot support monthly demand. Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,,2020,limited availability
6598,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 65862-011-30)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6599,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 65862-011-01)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6600,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 65862-011-05)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6601,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 65862-012-30)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6602,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 65862-012-01)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6603,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 65862-012-05)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6604,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 65862-013-30)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6605,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 65862-013-01)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6606,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 65862-013-05)",Reverified,8/31/2020,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,,2020,available
6607,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 16714-611-01)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6608,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 16714-611-04)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6609,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 16714-611-05)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6610,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 1000 count (NDC 16714-611-06)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6611,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 16714-612-01)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6612,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 16714-612-04)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6613,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 16714-612-05)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6614,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 1000 count (NDC 16714-612-06)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6615,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 16714-613-01)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6616,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 16714-613-04)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6617,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 16714-613-05)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6618,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 1000 count (NDC 16714-613-06)",Reverified,8/31/2020,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,,2020,available
6619,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 25 mg; Bottle of 30 tablets (NDC 0049-4960-30),Reverified,11/20/2020,Available,,,Other,Pediatric;Psychiatry,Current,,,,2020,available
6620,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 50 mg; Bottle of 30 tablets (NDC 0049-4900-30),Reverified,11/20/2020,Available,,,Other,Pediatric;Psychiatry,Current,,,,2020,available
6621,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 50 mg; Blister of 10 tablets (NDC 0049-4900-41),Reverified,11/20/2020,Available,,,Other,Pediatric;Psychiatry,Current,,,,2020,available
6622,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 100 mg; Bottle of 30 tablets (NDC 0049-4910-30),Reverified,11/20/2020,Available,,,Other,Pediatric;Psychiatry,Current,,,,2020,available
6623,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 100 mg; Blister of 10 tablets (NDC 0049-4910-41),Reverified,11/20/2020,Available,,,Other,Pediatric;Psychiatry,Current,,,,2020,available
6624,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,25 mg; Bottle of 30 tablets (NDC 59762-6347-1),Reverified,11/20/2020,Available,,,Other,Pediatric;Psychiatry,Current,,,,2020,available
6625,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,50 mg; Bottle of 30 tablets (NDC 59762-6443-1),Reverified,11/20/2020,Available,,,Other,Pediatric;Psychiatry,Current,,,,2020,available
6626,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,50 mg; Bottle of 100 tablets (NDC 59762-6443-2),Reverified,11/20/2020,Next Delivery and Estimated Recovery: March 2022,,,Demand increase for the drug,Pediatric;Psychiatry,Current,,,,2020,not available
6627,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,50 mg; Bottle of 500 tablets (NDC 59762-6443-3),Reverified,11/20/2020,Next Delivery and Estimated Recovery: March 2022,,,Other,Pediatric;Psychiatry,Current,,,,2020,not available
6628,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,100 mg; Bottle of 30 tablets (NDC 59762-5160-1),Reverified,11/20/2020,Available,,,Other,Pediatric;Psychiatry,Current,,,,2020,available
6629,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,100 mg; Bottle of 100 tablets (NDC 59762-5160-2),Reverified,11/20/2020,Available,,,Demand Increase for the drug,Pediatric;Psychiatry,Current,,,,2020,available
6630,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,100 mg; Bottle of 500 tablets (NDC 59762-5160-3),Reverified,11/20/2020,Next Delivery and Estimated Recovery: March 2022,,,Other,Pediatric;Psychiatry,Current,,,,2020,not available
6631,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 30 count (NDC 68180-351-06)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6632,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 90 count  (NDC 68180-351-09)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6633,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 1000 count (NDC 68180-351-03)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6634,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 30 count (NDC 68180-352-06)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6635,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 90 count (NDC 68180-352-09)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6636,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 500 count (NDC 68180-352-02)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6637,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 5000 count (NDC 68180-352-05)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6638,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 30 count (NDC 68180-353-06)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6639,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 90 count (NDC 68180-353-09)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6640,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 500 count (NDC 68180-353-02)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6641,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 5000 count (NDC 68180-353-05)",Reverified,9/1/2020,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,,2020,limited availability
6642,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 69097-833-02)",Revised,9/2/2020,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,,2020,available
6643,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 69097-833-05)",Revised,9/2/2020,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,,2020,available
6644,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 69097-833-12)",Revised,9/2/2020,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,,2020,available
6645,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 69097-834-02)",Revised,9/2/2020,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,,2020,available
6646,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 69097-834-12)",Revised,9/2/2020,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,,2020,available
6647,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 69097-835-02)",Revised,9/2/2020,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,,2020,available
6648,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 69097-835-12)",Revised,9/2/2020,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,,2020,available
6649,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 76282-212-30)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6650,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 60 count (NDC 76282-212-60)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6651,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 76282-212-90)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6652,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 100 count (NDC 76282-212-01)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6653,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 180 count (NDC 76282-212-18)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6654,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 76282-212-05)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6655,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 76282-213-30)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6656,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 60 count (NDC 76282-213-60)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6657,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 90 count (NDC 76282-213-90)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6658,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 100 count (NDC 76282-213-01)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6659,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 180 count (NDC 76282-213-18)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6660,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 76282-213-05)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6661,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 76282-214-30)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6662,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 60 count (NDC 76282-214-60)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6663,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 90 count (NDC 76282-214-90)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6664,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 100 count (NDC 76282-214-01)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6665,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 180 count (NDC 76282-214-18)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6666,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 76282-214-05)",Revised,9/2/2020,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,,2020,available
6667,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/12.5 mL; vial (NDC 0069-0338-01),Revised,10/24/2019,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2020,
6668,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,20 mg; tablets (NDC 0069-4190-68),Revised,10/24/2019,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2020,
6669,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/mL (powder); bottle (NDC 0069-0336-21),Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2020,
6670,Sildenafil Citrate (REVATIO),Novitium Pharma LLC,"10 mg/mL, (NDC 70954-168-10)",Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2020,
6671,Simeprevir Capsules,Janssen Pharmaceuticals,150mg capsules (NDC 59676-225-28),New,5/23/2018,,,,,Antiviral,To be Discontinued,5/23/2018,5/23/2018,,2020,discontinued
6672,Simvastatin (Zocor) Tablets,Merck Sharp & Dohme Corp.,5 mg Tablets bottles of 30 (NDC 0006-0726-31),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2020,discontinued
6673,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,5 mg (NDC 0093-7152-98),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2020,discontinued
6674,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,10 mg (NDCs 0093-7153-93 / 0093-7153-56 / 0093-7153-19 / 0093-7153-31 / 0093-7153-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2020,discontinued
6675,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,20 mg (NDCs 0093-7154-93 / 0093-7154-56 / 0093-7154-31 / 0093-7154-19 / 0093-7154-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2020,discontinued
6676,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,40 mg (NDCs 0093-7155-93 / 0093-7155-56 / 0093-7155-31 / 0093-7155-19 / 0093-7155-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2020,discontinued
6677,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,80 mg (NDCs 0093-7156-98 / 0093-7156-93 / 0093-7156-56 / 0093-7156-19 / 0093-7156-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2020,discontinued
6678,Sincalide (Kinevac) Lyophilized Powder for Injection,Bracco Diagnostics,Supplied in packages of 10 single dose vials containing 5 mcg of sincalide per vial (NDC 0270-0556-15),Revised,9/18/2019,Available,,,Delay in shipping of the drug,Medical Imaging;Other,Current,12/17/2015,,,2020,available
6679,"Sodium Acetate Injection, USP","Fresenius Kabi USA, LLC",32.8% 400 mEq 100mL PBP (NDC 63323-0032-00),Reverified,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,,2020,available
6680,"Sodium Acetate Injection, USP","Hospira, Inc.",100 mEq/50 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-05),Reverified,11/20/2020,Available,,,Other,Total Parenteral Nutrition,Current,,,,2020,available
6681,"Sodium Acetate Injection, USP","Hospira, Inc.",200 mEq/100 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-06),Reverified,11/20/2020,Available,,,Other,Total Parenteral Nutrition,Current,,,,2020,available
6682,"Sodium Acetate Injection, USP","Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-7299-73),Reverified,11/20/2020,Available,,,Other,Total Parenteral Nutrition,Current,,,,2020,available
6683,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2020,discontinued
6684,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Infant; 5 mEq/10 mL (4.2%; 0.5 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-5534-34),Revised,11/20/2020,Next Delivery and Estimated Recovery: January 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2020,not available
6685,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",44.6 mEq/50 mL (7.5%; 0.9 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-4916-34),Revised,11/20/2020,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2020,available
6686,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",50 mEq/50 mL (8.4%; 1 mEq/mL); Single Dose Glass Fliptop Vial (NDC 0409-6625-02),Revised,11/20/2020,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2020,available
6687,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",50 mEq/50 mL (8.4%; 1 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-6637-34),Revised,11/20/2020,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2020,limited availability
6688,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Pediatric; 10 mEq/10 mL (8.4%; 1 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-4900-34),Revised,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2020,discontinued
6689,"Sodium Bicarbonate Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1)",Reverified,10/30/2020,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2020,available
6690,"Sodium Bicarbonate Injection, USP","Fresenius Kabi USA, LLC","4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05)",Revised,11/16/2020,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2020,available
6691,"Sodium Bicarbonate Injection, USP","Fresenius Kabi USA, LLC","8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL)  (84 mg per mL)(NDC 63323-089-50)",Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2020,not available
6692,"Sodium Bicarbonate Injection, USP","Exela Pharma Sciences, LLC","Sodium Bicarbonate Inj. USP, 8.4%, 50mL (NDC 51754-5001-1)",Revised,12/13/2019,Available direct or through Premier's ProvideGx program at this time and through CIVICA Rx program in Q1 2020.,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2020,available
6693,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 76297-001-11)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6694,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 76297-001-21)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6695,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 76297-001-31)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6696,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC NDC 76297-001-01)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6697,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC NDC 76297-001-41)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6698,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 50 mL MINI-BAG Plus Container, VIAFLEX Plastic Container Product code 2B0042  (NDC 0338-0553-11)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6699,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 100 mL MINI-BAG Plus Container, VIAFLEX Plastic Container Product code 2B0043 (NDC 0338-0553-18)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6700,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride in Waiter for Injection, 100 mL, in VIAFLEX Container Product code ABB1307U (NDC 0338-9525-72)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6701,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 1000 mL.  Product code JB1324 (NDC 00338-9612-12)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6702,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 100mL fill in 150mL PAB S8004-5264 (NDC 0264-1800-32),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6703,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 50mL fill in 100mL PAB S8004-5384 (NDC 0264-1800-31),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6704,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 25mL fill in 100mL PAB S8004-5410 (NDC 0264-1800-36),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6705,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",50 mL (5-Pack); ADD-Vantage Flexible Container (NDC 00409-7101-66),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6706,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",100 mL (5-Pack); ADD-Vantage Flexible Container (NDC 00409-7101-67),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6707,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",250 mL (Dual Pack); ADD-Vantage Flexible Container (NDC 00409-7101-02),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6708,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 100 mL VIAFLEX Plastic Container.  Single pack (NDC 0338-0049-48, product code 2B1307)Quad Pack (NDC 0338-0049-18, product code 2B1302) Multi Pack (NDC 0338-0049-38, product code 2B1309)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6709,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 50 mL VIAFLEX Plastic Container.  Single Pack (NDC 0338-0049-41, product code 2B1306) Quad Pack (NDC 0338-0049-11, product code 2B1301) Multi Pack (NDC 0338-0049-31, product code 2B1308)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6710,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 25 mL VIAFLEX Plastic Container Quad Pack (NDC 0338-0049-10). Product code 2B1300",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6711,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 50mL (NDC 63323-623-53)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6712,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 100mL (NDC 63323-623-61)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6713,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 250mL (NDC 63323-623-74)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6714,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 500mL (NDC 63323-623-75)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6715,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 1000mL (NDC 63323-623-76)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6716,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,Sodium Chloride 0.9% w/v Intravenous Infusion BP in the Ecoflac® plus container sizes: 500 mL (NDC 0264-9999-10),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6717,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-13)
(ICU Medical NDC 0990-7984-13)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6718,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container-4 pack (Legacy Hospira NDC 0409-7984-37)
(ICU Medical NDC 0990-7984-37)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6719,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 250mL bag, PVC/DEHP-free (NDC 00264-7800-20)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6720,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 500mL bag, PVC/DEHP-free (NDC 00264-7800-10)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6721,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 1000mL bag, PVC/DEHP-free (NDC 00264-7800-00)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6722,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",150mL flexible container (NDC 0409-7983-61),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6723,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","250mL Vis-IV container, PVC/DEHP-free (NDC 0409-7983-25)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6724,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","250mL flexible container (Legacy Hospira NDC 0409-7983-02)
(ICU Medical NDC 0990-7983-02)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6725,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",250mL flexible container 2 port (NDC 0409-7983-53),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6726,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",500mL flexible container 2 port (NDC 0409-7983-55),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6727,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",500mL flexible container (NDC 0409-7983-03),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6728,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",1000mL flexible container (NDC 0409-7983-09),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6729,Sodium Chloride 0.9% Injection Bags,Fresenius Medical Care North America,1000ml (NDC 49230-300-10),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6730,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"Sodium Chloride 0.9% w/v Intravenous Infusion BP in the Ecoflac® plus 1,000 mL Product Code 9999-00, (NDC 0264-9999-00)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6731,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 250 mL, in VIAFLEX Container.   Product code FZB1322 (NDC 0338-9517-50)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6732,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 500 mL, in VIAFLEX Container.   Product code FZB1323 (NDC 0338-9517-30)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6733,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 1,000 mL, in VIAFLEX Container.   Product code FZB1324 (NDC 0338-9517-16)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6734,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,250 mL Product code 2B1322Q (NDC 00338-0049-02),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6735,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,500 mL  Product code 2B1323Q (NDC 00338-0049-03),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6736,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1323D (NDC 0338-9543-04)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6737,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,1000 mL Product code 2B1324X (NDC 00338-0049-04),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6738,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1324D (NDC 0338-9543-06)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6739,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL, Non-PVC, Dripless Access Container (DAC) VIAFLO Container Product code UE1322D (NDC 0338-9543-02)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6740,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container (Legacy Hospira NDC 0409-7984-23)
(ICU Medical NDC 0990-7984-23)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6741,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-11)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6742,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-36)
(ICU Medical NDC 0990-7984-36)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6743,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",25 mL flexible container (NDC 0409-7984-20),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6744,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-06)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2020,
6745,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",30 mL vials (NDC 63323-0187-30),Revised,11/16/2020,Backordered. Next release November 2020.,,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2020,not available
6746,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",100 mL vials (NDC 63323-0088-61),Revised,11/16/2020,Backordered. Next release November 2020.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2020,not available
6747,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",200 mL vials (NDC 63323-0088-63),Revised,11/16/2020,Backordered. Next release January 2021.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2020,not available
6748,Sodium Chloride 23.4% Injection,"Hospira, Inc.",400 mEq/100 mL (4 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-1141-02),Revised,11/20/2020,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2020,not available
6749,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-32),Reverified,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2020,discontinued
6750,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-33),Reverified,11/20/2020,Next Delivery and Estimated Recovery: February 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,,2020,not available
6751,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-35),Reverified,11/20/2020,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2020,discontinued
6752,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.9%, 2 mL vial (NDC 0641-0497-25)",Reverified,7/22/2020,Inventory is currently available.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Other,Current,,,,2020,available
6753,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose plastic vial, 0.9%, (18 mg per 2 mL)(9 mg per mL) (NDC 63323-186-02)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Increase in Demand,Other,Current,,,,2020,available
6754,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (90 mg per 10 mL)(9 mg per mL) (NDC 63323-186-10)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,,2020,available
6755,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (180 mg per 20 mL)(9 mg per mL) (NDC 63323-186-20)",Reverified,11/16/2020,Available,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,,2020,available
6756,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose tear top vial, 0.9%, (900 mg per 100 mL)(9 mg per mL) (NDC 63323-186-00)",Reverified,11/16/2020,Backordered.  Next release date not available at this time.,,,Increase in Demand,Other,Current,,,,2020,not available
6757,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose Plastic Fliptop Vial (NDC 00409-4888-10),Reverified,11/20/2020,Available,,,Other,Other,Current,,,,2020,available
6758,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose LifeShield Plastic Fliptop Vial (NDC 00409-4888-12),Reverified,11/20/2020,Available,,,Other,Other,Current,,,,2020,available
6759,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-20),Reverified,11/20/2020,Available,,,Other,Other,Current,,,,2020,available
6760,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-50),Reverified,11/20/2020,Available,,,Demand increase for the drug,Other,Current,,,,2020,available
6761,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Medefil, Inc.","Sodium Chloride Injection, USP, 0.9%, in a plastic syringe (10 mL) (NDC 64253-202-30)",Reverified,12/11/2019,Available,Check wholesalers for inventory,,Available,Other,Current,,,,2020,available
6762,"Sodium Lactate Injection, USP","Hospira, Inc.",50 mEq/10 mL (5 mEq/10 mL); Single Dose Plastic Fliptop Vial (NDC 00409-6664-02),New,1/9/2020,,Discontinuation of the manufacture of the drug.,,,Endocrinology/Metabolism;Gastroenterology,To be Discontinued,1/9/2020,1/9/2020,,2020,discontinued
6763,Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol/mL, 5 mL, Sodium 20 mEq/5mL vials (NDC 63323-170-05)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,8/7/2019,,,2020,
6764,Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL (NDC 63323-170-15)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,8/7/2019,,,2020,
6765,Somatropin Recombinant (Humatrope) Injection,Eli Lilly and Co.,5 mg kit (NDC 0002-7335-11) contains 5 mg/mL in 1 vial (NDC 0002-7349-01) of Humatrope and 5 mL in 1 vial (NDC 0002-7336-01) of Sterile Diluent,New,7/7/2020,,Other Somatropin Recombinant (Humatrope) Injection products will continue to be available to treat patients.  The product distribution will continue until end of December 2020.,,,Hematology,To be Discontinued,7/7/2020,7/7/2020,,2020,discontinued
6766,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-5123-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6767,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-5124-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6768,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"160 mg, 100 count bottle (NDC 0378-5125-01)",New,5/2/2019,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6769,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 100 (NDC 0228-2803-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
6770,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 500 (NDC 0228-2803-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
6771,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 100 (NDC 0228-2672-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
6772,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 500 (NDC 0228-2672-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
6773,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 100 (NDC 0228-2673-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
6774,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 500 (NDC 0228-2673-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2020,discontinued
6775,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 100 (NDC 0603-5763-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6776,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 500 (NDC 0603-5763-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6777,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 1000 (NDC 0603-5763-32)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6778,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 2500 (NDC 0603-5763-30)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6779,"Spironolactone Tablets, USP",Par Pharmaceutical,"50 mg, bottle of 100 (NDC 0603-5764-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6780,"Spironolactone Tablets, USP",Par Pharmaceutical,"50 mg, bottle of 500 (NDC 0603-5764-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6781,"Spironolactone Tablets, USP",Par Pharmaceutical,"100 mg, bottle of 100 (NDC 0603-5765-21)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6782,"Spironolactone Tablets, USP",Par Pharmaceutical,"100 mg, bottle of 500 (NDC 0603-5765-28)",New,4/19/2019,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/2019,4/19/2019,,2020,discontinued
6783,Stavudine Capsules,Mylan Pharmaceuticals Inc.,40 mg  (NDC0378-5043-91),New,7/17/2019,,,,,Antiviral,To be Discontinued,7/17/2019,7/17/2019,,2020,discontinued
6784,Stavudine Capsules,Mylan Pharmaceuticals Inc.,20mg capsules (NDC 0378-5041-91),New,4/30/2018,,,,,Antiviral,To be Discontinued,4/30/2018,4/30/2018,,2020,discontinued
6785,Sterile Water,American Regent/Luitpold,5 mL vial (NDC 00517-3005-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6786,Sterile Water,American Regent/Luitpold,10 mL vial (NDC 00517-3010-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6787,Sterile Water,American Regent/Luitpold,20 mL vial (NDC 00517-3020-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6788,Sterile Water,West-Ward Pharmaceuticals,10 mL Single Dose Vial (NDC 0641-6147-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6789,Sterile Water,B. Braun Medical Inc.,Sterile Water for Injection in 500mL EXCEL container (NDC  0264-7850-10),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6790,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 1,000mL EXCEL container  (NDC 0264-7850-00)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6791,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 2,000mL Titan container (NDC  0264-7385-50)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6792,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 3,000mL Titan container (NDC  0264-7385-60)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6793,Sterile Water,"Hospira, Inc.",20 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-20),Revised,8/2/2019,, ,,,Other,Resolved,8/2/2019,,,2020,
6794,Sterile Water,"Hospira, Inc.",50 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-50),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6795,Sterile Water,"Hospira, Inc.",100 mL; Single Dose Glass Fliptop Vial (NDC 00409-4887-99),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6796,Sterile Water,"ICU Medical, Inc.",Sterile Water for Injection 2000 mL (NDC 0409-7118-07),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6797,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 1000 mL (NDC 0409-7973-05),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6798,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 2000 mL (NDC 0409-7973-08),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6799,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 2000 mL (NDC 0409-7973-07),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6800,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation USP, 1000 mL Aqualite ™ Plastic Pour Bottle (NDC 0409-7139-09)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6801,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP, Aqualite 500 mL (NDC 0409-6139-03)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6802,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP 1500 mL (NDC 0409-7139-36)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6803,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP, Aqualite 250 mL (NDC 0409-6139-22)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6804,Sterile Water,"Hospira, Inc.",10 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-10),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6805,Sterile Water,"Fresenius Kabi USA, LLC","Single dose vial, 5 mL fill (NDC 63323-185-05)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6806,Sterile Water,B. Braun Medical Inc.,Sterile Water for Injection in 250mL EXCEL container (NDC  0264-7850-20),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6807,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP (For Drug Diluent Use Only), 1000 mL VIAFLEX Plastic Container. Product code 2B0304X (NDC 0338-0013-04)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6808,Sterile Water,"ICU Medical, Inc.",Sterile Water for Injection 1000 mL (NDC 0409-7990-09),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6809,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 10 mL fill (NDC 63323-185-10)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6810,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 20 mL fill (NDC 63323-185-20)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6811,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 50 mL fill (NDC 63323-185-50)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6812,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, tear top vial, 100 mL (NDC 63323-185-00)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6813,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package.   Product code 2B0306 (NDC 0338-0013-06)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6814,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 3000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package.  Product code 2B0307  (NDC 0338-0013-08)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6815,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 5000 mL VIAFLEX Plastic Container, Pharmacy Bulk Package. Product code 2B0309 (NDC 0338-0013-29)",Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2020,
6816,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 100 Count (NDC 00591-0796-01),Reverified,11/19/2020,Available,,,,Gastroenterology,Current,,,,2020,available
6817,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 1000 Count (NDC 00591-0796-10),Reverified,11/19/2020,Available,,,,Gastroenterology,Current,,,,2020,available
6818,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 500 Count (NDC 00591-0796-05),Reverified,11/19/2020,Available,,,,Gastroenterology,Current,,,,2020,available
6819,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 100 (NDC 0013-0101-10),Revised,11/20/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
6820,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 300 (NDC 0013-0101-20),Revised,11/20/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
6821,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 100 (NDC 0013-0102-50),Revised,11/20/2020,Next Delivery and Estimated Recovery: December 2020,,,Other,Gastroenterology,Current,,,,2020,not available
6822,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 300 (NDC 0013-0102-20),Revised,11/20/2020,Available,,,Other,Gastroenterology,Current,,,,2020,available
6823,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 100 (NDC 59762-0104-1/59762-0104-5),Revised,11/20/2020,Next Delivery: March 2021; Estimated recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2020,unclear
6824,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 300 (NDC 59762-0104-6),Revised,11/20/2020,Next Delivery: January 2021; Estimated recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2020,unclear
6825,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 100 (NDC 59762-5000-1/59762-5000-5),Revised,11/20/2020,Next Delivery: March 2021; Estimated Recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2020,unclear
6826,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 300 (NDC 59762-5000-6),Revised,11/20/2020,Next Delivery: January 2021; Estimated recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2020,unclear
6827,Sumatriptan (Sumavel DosePro) Injection,"Endo Pharmaceuticals, Inc.",Sumavel DosePro (sumatriptan injection) 6mg/0.5mL (NDC 63481-367-06),New,2/27/2018,,A business decision has been made to discontinue Sumavel DosePro 6 mg/0.5mL.,,,Neurology,To be Discontinued,2/27/2018,2/27/2018,,2020,discontinued
6828,Sumatriptan Succinate (Imitrex) Injection,GlaxoSmithKline,"6 mg, single dose vial (NDC 0173-0449-02)",New,4/3/2020,,A business decision was made to discontinue manufacture of the drug product. The anticipated date that GSK will cease distribution of the product is approximately August 2020.,,,Neurology,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6829,Sumatriptan Succinate Injection,Mylan Institutional,"6 mg/0.5 mL, single-dose vial (NDC 67457-880-05)",New,2/21/2020,,Expected discontinuation August 2020 (short dating),,,Neurology,To be Discontinued,2/21/2020,2/21/2020,,2020,discontinued
6830,Sumatriptan Succinate Injection,Teva Pharmaceuticals,6 mg/0.5 mL  (NDC 0703-7351-01),New,12/5/2019,,,,,Neurology,To be Discontinued,12/5/2019,12/5/2019,,2020,discontinued
6831,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-01),Reverified,11/13/2020,Can only supply contracted customers,Manufacturer extended lead times.,,Demand increase for the drug,Transplant,Current,,,,2020,limited availability
6832,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-01),Reverified,11/13/2020,Can only supply contracted customers,Manufacturer extended lead times.,,Demand increase for the drug,Transplant,Current,,,,2020,limited availability
6833,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-01),Reverified,11/13/2020,Can only supply contracted customers,Manufacturer extended lead times.,,Demand increase for the drug,Transplant,Current,,,,2020,limited availability
6834,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"0.5 mg, 100s (NDC 0378-2045-01)",Reverified,11/10/2020,Available,,,,Transplant,Current,,,,2020,available
6835,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"1 mg, 100s (NDC 0378-2046-01)",Reverified,11/10/2020,Available,,,,Transplant,Current,,,,2020,available
6836,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-2047-01)",Reverified,11/10/2020,Available,,,,Transplant,Current,,,,2020,available
6837,Tacrolimus Capsules,Accord Healthcare Inc.,0.5 mg 100 count (NDC 1672904101),Revised,9/14/2020,Limited supply availability. Product will be allocated until Q1 2021,,,Limited API availability,Transplant,Current,,,,2020,limited availability
6838,Tacrolimus Capsules,Accord Healthcare Inc.,1 mg 100 count (NDC 1672904201),Revised,9/14/2020,Limited supply availability. Product will be allocated until Q1 2021,,,Limited API availability,Transplant,Current,,,,2020,limited availability
6839,Tacrolimus Capsules,Accord Healthcare Inc.,5 mg 100 count (NDC 1672904301),Revised,9/14/2020,Limited supply availability. Product will be allocated until Q1 2021,,,Limited API availability,Transplant,Current,,,,2020,limited availability
6840,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 30 count (NDC 68992-3075-3),Reverified,9/30/2020,Available,,,,Transplant,Current,,,,2020,available
6841,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 100 count (NDC 68992-3075-1),Reverified,9/30/2020,Available,,,,Transplant,Current,,,,2020,available
6842,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 30 count (NDC 68992-3010-3),Reverified,9/30/2020,Available,,,,Transplant,Current,,,,2020,available
6843,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 100 count (NDC 68992-3010-1),Reverified,9/30/2020,Available,,,,Transplant,Current,,,,2020,available
6844,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 30 count (NDC 68992-3040-3),Reverified,9/30/2020,Available,,,,Transplant,Current,,,,2020,available
6845,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 100 count (NDC 68992-3040-1),Reverified,9/30/2020,Available,,,,Transplant,Current,,,,2020,available
6846,Tacrolimus Capsules,Strides Pharma Inc.,1 mg 100 count bottles (NDC 64338-721-06),Revised,11/9/2020,Available,,,,Transplant,Current,,,,2020,available
6847,Tacrolimus Capsules,Strides Pharma Inc.,0.5 mg 100 count bottles (NDC 64380-720-06),Revised,11/9/2020,Available,,,,Transplant,Current,,,,2020,available
6848,Tacrolimus Capsules,Strides Pharma Inc.,5 mg 100 count bottles (NDC 64380-722-06),Revised,11/9/2020,Available,,,,Transplant,Current,,,,2020,available
6849,Tacrolimus Capsules,Sandoz,0.5 mg 100 count bottle (NDC 0781-2102-01),Revised,11/13/2020,Intermittent supply until Feb/Mar 2021,,,Demand increase for the drug,Transplant,Current,,,,2020,limited availability
6850,Tacrolimus Capsules,Sandoz,1 mg 100 count bottle (NDC 0781-2103-04),Revised,11/13/2020,Intermittent supply until Feb/Mar 2021,,,Demand increase for the drug,Transplant,Current,,,,2020,limited availability
6851,Tacrolimus Capsules,Sandoz,5 mg 100 count bottle (NDC 0781-2104-01),Revised,11/13/2020,Available,,,Demand increase for the drug,Transplant,Current,,,,2020,available
6852,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 0.5 mg 100 count bottle (NDC 0469-0607-73),Reverified,9/11/2020,Available,,,,Transplant,Current,,,,2020,available
6853,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 5 mg 100 count bottle (NDC 0469-0657-73),Reverified,9/11/2020,Available,,,,Transplant,Current,,,,2020,available
6854,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 1 mg 100 count bottle (NDC 0469-0617-73),Reverified,9/11/2020,Available,,,,Transplant,Current,,,,2020,available
6855,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 0.5 mg 30 count bottle (NDC 0469-0647-73),Reverified,9/11/2020,Available,,,,Transplant,Current,,,,2020,available
6856,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 1 mg 30 count bottle (NDC 0469-0677-73),Reverified,9/11/2020,Available,,,,Transplant,Current,,,,2020,available
6857,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 5 mg 30 count bottle (NDC 0469-0687-73),Reverified,9/11/2020,Available,,,,Transplant,Current,,,,2020,available
6858,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 0.2 mg unit dose packets (NDC 0469-1230-50),Reverified,9/11/2020,Available,,,,Transplant,Current,,,,2020,available
6859,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 1 mg unit dose packets (NDC 0469-1330-50),Reverified,9/11/2020,Available,,,,Transplant,Current,,,,2020,available
6860,Tacrolimus Capsules,"BPI Labs, LLC",1 mg 100 count bottle (NDC 54288-135-01),Reverified,9/9/2020,Available,,,,Transplant,Current,,,,2020,available
6861,"Talwin (Pentazocine Lactate Injection, USP, CIV)","Hospira, Inc.",30 mg/mL; 1 mL glass ampul (NDC 00409-1941-01),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To be Discontinued,4/16/2018,4/16/2018,,2020,discontinued
6862,Technetium Tc99m Succimer Injection (DMSA),GE Healthcare,DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection (NDC 17156-525-01),Revised,12/20/2019,,,,,Medical Imaging,To be Discontinued,12/20/2019,12/20/2019,,2020,discontinued
6863,Technetium Tc99m Succimer Injection (DMSA),Theragnostics Inc.,ROTOP DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection). One vial contains 1.74 mg powder with the active substance: 1.0 mg succimer.  Five vials included in a carton (NDC 71647-001-01),Reverified,12/10/2019,Available,"Due to the current critical shortage of DMSA Kit for the Preparation of Technetium Tc99m Succimer, Theragnostics Inc. (Theragnostics) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of the drug.  Theragnostics has initiated temporary importation of DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection into the U.S. market. This product is marketed in Germany and is manufactured in Dresden, Germany by ROTOP Pharmaka GmbH for Theragnostics.",,Other,Medical Imaging,Current,,,,2020,available
6864,Telmisartan and Amlodipine (Twynsta) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.","Telmisartan and Amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister (NDC 0597-0127-37)",New,3/6/2018,,"Discontinuation is the result of a business decision made by Boehringer lngelheim Pharmaceuticals, Inc. All other strengths of Twynsta® tablets are still available.",,,Cardiovascular,To be Discontinued,3/6/2018,3/6/2018,,2020,discontinued
6865,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"5 mg child-resistent sachets, 5 count (NDC 0085-3004-03)",New,1/23/2020,,To be discontinued on or near March 2020.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6866,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"5 mg child-resistent sachets, 14 count (NDC 0085-3004-04)",New,1/23/2020,,To be discontinued on or near March 2020.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6867,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"20 mg child-resistent sachets, 5 count (NDC 0085-1519-03)",New,1/23/2020,,To be discontinued on or near Jun 2020.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6868,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"20 mg child-resistent sachets, 14 count (NDC 0085-1519-04)",New,1/23/2020,,Discontinued in 2018.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6869,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"140 mg child-resistent sachets, 5 count (NDC 0085-1425-03)",New,1/23/2020,,To be discontinued on or near Aug 2020.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6870,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"180 mg child-resistent sacehts, 14 count (NDC 0085-1430-04)",New,1/23/2020,,Discontinued in 2018.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6871,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"5 mg, 5 capsules (NDC 0781-2691-75)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6872,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"5 mg, 14 capsules (NDC 0781-2691-44)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6873,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"20 mg, 5 capsules (NDC 0781-2692-75)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6874,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"20 mg, 14 capsules (NDC 0781-2692-44)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6875,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"100 mg, 5 capsules (NDC 0781-2693-75)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6876,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"100 mg, 14 capsules (MDC 0781-2693-44)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6877,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"140 mg, 5 capsules (NDC 0781-2694-75)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6878,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"140 mg, 14 capsules (NDC 0781-2694-44)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6879,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"180 mg, 5 capsules (NDC 0781-2695-75)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6880,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"180 mg, 14 capsules (NDC 0781-2695-44)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6881,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"250 mg, 5 capsules (NDC 0781-2696-75)",New,1/23/2020,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/2020,1/23/2020,,2020,discontinued
6882,Temozolomide Capsules,Teva Pharmaceuticals,5 mg  (NDCs 0093-7599-41 and 0093-7599-57),New,5/8/2020,,,,,Oncology,To be Discontinued,5/8/2020,5/8/2020,,2020,discontinued
6883,Temozolomide Capsules,Teva Pharmaceuticals,20 mg  (NDCs 0093-7600-41 and 0093-7600-57),New,5/8/2020,,,,,Oncology,To be Discontinued,5/8/2020,5/8/2020,,2020,discontinued
6884,Temozolomide Capsules,Teva Pharmaceuticals,100 mg  (NDCs 0093-7601-41 and 0093-7601-57),New,5/8/2020,,,,,Oncology,To be Discontinued,5/8/2020,5/8/2020,,2020,discontinued
6885,Temozolomide Capsules,Teva Pharmaceuticals,140 mg (NDCs 0093-7638-41 and 0093-7638-57),New,5/8/2020,,,,,Oncology,To be Discontinued,5/8/2020,5/8/2020,,2020,discontinued
6886,Temozolomide Capsules,Teva Pharmaceuticals,180 mg (NDCs 0093-7639-41 and 0093-7639-57),New,5/8/2020,,,,,Oncology,To be Discontinued,5/8/2020,5/8/2020,,2020,discontinued
6887,Temozolomide Capsules,Teva Pharmaceuticals,250 mg (NDC 0093-7602-57),New,5/8/2020,,,,,Oncology,To be Discontinued,5/8/2020,5/8/2020,,2020,discontinued
6888,Testosterone Buccal System,"Endo Pharmaceuticals, Inc.","Striant® 30 mg, 6 blister cards, 60 buccal system  (NDC 52244-030-60)",New,8/21/2019,,Endo has made a business decision to permanently discontinue the drug product.,,,Reproductive,To be Discontinued,8/21/2019,8/21/2019,,2020,discontinued
6889,Testosterone Gel 1%,Par Pharmaceutical,"2.5 g, 30 packets (NDC 49884-418-72)",New,4/29/2019,,Par has made a business decision to discontinue the drug product.,,,Reproductive,To be Discontinued,4/29/2019,4/29/2019,,2020,discontinued
6890,Testosterone Gel 1%,Par Pharmaceutical,"5 g, 30 packets (NDC 49884-510-72)",New,4/29/2019,,Par has made a business decision to discontinue the drug product.,,,Reproductive,To be Discontinued,4/29/2019,4/29/2019,,2020,discontinued
6891,Testosterone Topical Gel,"Endo Pharmaceuticals, Inc.",50mg/5g topical gel (NDC 0254-1012-11),New,4/3/2020,,,,,Reproductive,To be Discontinued,4/3/2020,4/3/2020,,2020,discontinued
6892,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"100 mg, 100 count (NDC 50111-0483-01)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6893,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"100 mg, 500 count (NDC 50111-0483-02)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6894,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"200 mg, 100 count (NDC 50111-0482-01)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6895,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"200 mg, 500 count (NDC 50111-0482-02)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6896,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"200 mg, 100 count (NDC 50111-0482-03)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6897,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"300 mg, 100 count (NDC 50111-0459-01)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6898,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"300 mg, 500 count (NDC 50111-0459-02)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6899,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"300 mg, 1000 count (NDC 50111-0459-03)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6900,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"450 mg, 100 count (NDC 50111-0518-01)",New,8/11/2020,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/2020,8/11/2020,,2020,discontinued
6901,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0612-01),Revised,1/7/2020,,,,,Psychiatry,Resolved,1/7/2020,,,2020,
6902,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,25 mg (NDC 0378-0614-01),Revised,1/7/2020,,,,,Psychiatry,Resolved,1/7/2020,,,2020,
6903,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,50 mg (NDC 0378-0616-01),Revised,1/7/2020,,,,,Psychiatry,Resolved,1/7/2020,,,2020,
6904,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0618-01),Revised,1/7/2020,,,,,Psychiatry,Resolved,1/7/2020,,,2020,
6905,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-1001-01)",Reverified,11/10/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
6906,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"2 mg, 100 count bottle (NDC 0378-2002-01)",Reverified,11/10/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
6907,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-3005-01)",Reverified,11/10/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
6908,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-5010-01)",Reverified,11/10/2020,Available,,,Other,Psychiatry,Current,,,,2020,available
6909,Thiothixene Capsules,Novitium Pharma LLC,"1 mg, 100 count bottle (NDC 70954-014-10)",Reverified,5/20/2020,Available,,,,Psychiatry,Current,,,,2020,available
6910,Thiothixene Capsules,Novitium Pharma LLC,"2 mg, 100 count bottle (NDC 70954-015-10)",Reverified,5/20/2020,Available,,,,Psychiatry,Current,,,,2020,available
6911,Thiothixene Capsules,Novitium Pharma LLC,"5 mg, 100 count bottle (NDC 70954-016-10)",Reverified,5/20/2020,Available,,,,Psychiatry,Current,,,,2020,available
6912,Thiothixene Capsules,Novitium Pharma LLC,"10 mg, 100 count bottle (NDC 70954-017-10)",Reverified,5/20/2020,Available,,,,Psychiatry,Current,,,,2020,available
6913,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","TIMOPTIC-XE®, 0.25% timolol equivalent gel forming solution, 5 mL in a 7.5 mL bottle (NDC 24208-814-25)",New,5/29/2020,"New lots TIMOPTIC-XE® of 0.25% solution available not sooner than January 2021, conditional to manufacturing capacity.",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,,2020,unclear
6914,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","TIMOPTIC-XE®, 0.5% timolol equivalent, gel forming solution 5 mL in a 7.5 mL bottle (NDC 24208-816-05)",New,5/29/2020,"New lots TIMOPTIC-XE® of 0.5% solution available not sooner than January 2021, conditional to manufacturing capacity.",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,,2020,limited availability
6915,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% timolol gel forming solution, 5 mL in a 7.5 mL bottle (NDC 24208-818-25)",New,5/29/2020,"New lots  of 0.25% solution available not sooner than January 2021, conditional to manufacturing capacity",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,,2020,limited availability
6916,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Gel Forming Solution, equivalent and 0.5%, 5 mL in a 7.5 mL bottle (NDC 24208-819-05)",New,5/29/2020,"New lots  of 0.5% solution available not sooner than January 2021, conditional to manufacturing capacity.",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,,2020,not available
6917,Timolol Maleate Ophthalmic Gel Forming Solution,Sandoz,"Timolol Maleate Ophthalmic Gel Forming Solution 0.5%, 5 mL bottle (NDC 61314-225-05)",Revised,11/13/2020,Supply not available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,not available
6918,Timolol Maleate Ophthalmic Gel Forming Solution,Sandoz,Timolol Maleate Ophthalmic Gel Forming Solution 0.25% 5 mL bottle (NDC 61314-224-05),Revised,11/13/2020,Limited Short dated material available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,limited availability
6919,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 5 mL bottle, (NDC 61314-227-05)",Revised,11/13/2020,Supply Available,,,API shortage,Ophthalmology,Current,,,,2020,available
6920,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 10 mL bottle (NDC 61314-227-10)",Revised,11/13/2020,Supply Available,,,API shortage,Ophthalmology,Current,,,,2020,available
6921,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 15 mL bottle (NDC 61314-227-15)",Revised,11/13/2020,Supply Available,,,API shortage,Ophthalmology,Current,,,,2020,available
6922,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 5 mL bottle, ()NDC 61314-226-05",Revised,11/13/2020,Supply Available,,,API shortage,Ophthalmology,Current,,,,2020,available
6923,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 10 mL bottle, (NDC 61314-226-10)",Revised,11/13/2020,Supply Available,,,API shortage,Ophthalmology,Current,,,,2020,available
6924,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 15 mL bottle, (NDC 61314-226-15)",Revised,11/13/2020,Supply Available,,,API shortage,Ophthalmology,Current,,,,2020,available
6925,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 2.5mL bottle (NDC 60505-1005-04),Reverified,10/1/2020,Available,,,,Ophthalmology,Current,,,,2020,available
6926,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 5mL bottle (NDC 60505-1005-01),Reverified,10/1/2020,Available,,,,Ophthalmology,Current,,,,2020,available
6927,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 7.5 mL bottle (NDC 24208-004-01)",New,5/29/2020,Available,,,Other,Ophthalmology,Current,,,,2020,available
6928,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 10 ml bottle (NDC 24208-004-03)",New,5/29/2020,"Back-order, Estimated availability June 2020",,,Other,Ophthalmology,Current,,,,2020,not available
6929,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%,  2.5ml (NDC 68682-045-25)",New,5/29/2020,Available,Distributed under Oceanside Pharmaceuticals,,Other,Ophthalmology,Current,,,,2020,available
6930,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%, 5ml (NDC 68682-045-50)",New,5/29/2020,Available,Distributed under Oceanside Pharmaceuticals,,Other,Ophthalmology,Current,,,,2020,available
6931,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 5mL (NDC 64980-513-05),Reverified,9/14/2020,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
6932,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25%  10 mL (NDC 64980-513-01),Reverified,9/14/2020,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
6933,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 15 mL (NDC 64980-513-15),Reverified,9/14/2020,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
6934,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 5mL (NDC 64980-514-05),Reverified,9/14/2020,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
6935,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 10mL (NDC 64980-514-01),Reverified,9/14/2020,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
6936,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 15mL (NDC 64980-514-15),Reverified,9/14/2020,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,,2020,available
6937,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x5ml BTL (NDC 60758-802-05),Revised,10/14/2020,Available,"Distributed by Pacific Pharma, Inc.",,,Ophthalmology,Current,,,,2020,available
6938,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x10ml BTL (NDC 60758-802-10),Revised,10/14/2020,Available,"Distributed by Pacific Pharma, Inc.",,,Ophthalmology,Current,,,,2020,available
6939,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x5ml BTL (NDC 60758-801-05),Revised,10/14/2020,Available,"Distributed by Pacific Pharma, Inc.",,,Ophthalmology,Current,,,,2020,available
6940,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x10ml BTL (NDC 60758-801-10),Revised,10/14/2020,Available,"Distributed by Pacific Pharma, Inc.",,,Ophthalmology,Current,,,,2020,available
6941,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5% 5mg/mL, 5mL, 1 Bottle/EA (NDC 17478-0288-10)",Revised,9/14/2020,Available,,,Other,Ophthalmology,Current,,,,2020,available
6942,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 10mL, 1 Bottle / EA (NDC 17478-0288-11)",Revised,9/14/2020,Available,,,Other,Ophthalmology,Current,,,,2020,available
6943,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 15mL, 1 Bottle / EA (NDC 17478-0288-12)",Revised,9/14/2020,Available,,,Other,Ophthalmology,Current,,,,2020,available
6944,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count (NDC 0378-0055-01)",Reverified,11/10/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
6945,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count (NDC 0378-0221-01)",Reverified,11/10/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
6946,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 100 count (NDC 0378-0715-01)",Reverified,11/10/2020,Available,,,Other,Cardiovascular,Current,,,,2020,available
6947,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,4 mg (NDC 0378-0724-19),New,11/21/2019,,,,,Neurology,To be Discontinued,11/21/2019,11/21/2019,,2020,discontinued
6948,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0722-19),New,11/21/2019,,,,,Neurology,To be Discontinued,11/21/2019,11/21/2019,,2020,discontinued
6949,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-51)",Reverified,11/16/2020,Backordered.  Next release expected November 2020.,Delay in manufacturing,,Other,Anti-Infective;Pediatric,Current,,,,2020,not available
6950,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-55), Novaplus",Reverified,11/16/2020,Backordered.  Next release expected November 2020.,Delay in manufacturing,,Other,Anti-Infective;Pediatric,Current,,,,2020,not available
6951,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, bottle (NDC 39822-0412-1)",New,8/24/2020,Available,XGen continues to manufacture at full capacity.  Plans are underway to increase production.  Timeline TBD.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2020,available
6952,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, pack of 6 bottles (NDC 39822-0412-6)",New,8/24/2020,Available,XGen continues to manufacture at full capacity.  Plans are underway to increase production.  Timeline TBD.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,,2020,available
6953,Tolazamide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0217-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6954,Tolazamide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0551-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6955,Tolbutamide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0215-01)",New,5/2/2019,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
6956,Tolcapone Tablets,"Endo Pharmaceuticals, Inc.",100mg tablets (NDC 49884-254-09),New,10/5/2020,,,,,Neurology,To be Discontinued,10/5/2020,10/5/2020,,2020,discontinued
6957,Tolterodine Tartrate (Detrol LA) Extended Release Capsules,Pfizer Pharmaceuticals,"2 mg, blisters (NDC 0009-5190-04)",New,10/1/2019,,Discontinuation of the manufacture of the drug.,,,Urology,To be Discontinued,10/1/2019,10/1/2019,,2020,discontinued
6958,Tolterodine Tartrate (Detrol LA) Extended Release Capsules,Pfizer Pharmaceuticals,"4 mg, blisters (NDC 0009-5191-04)",New,10/1/2019,,Discontinuation of the manufacture of the drug.,,,Urology,To be Discontinued,10/1/2019,10/1/2019,,2020,discontinued
6959,Tositumomab and Iodine I 131 Tositumomab (Bexxar),GlaxoSmithKline,,Revised,2/18/2014,,,"BEXXAR (Tositumomab and Iodine I 131 Tositumomab) is being discontinued.  The product discontinuation is not related to product safety or any FDA action.   BEXXAR will no longer be available effective February 20, 2014.",,Oncology,To Be Discontinued,2/18/2014,2/18/2014,,2020,discontinued
6960,Tramadol Hydrochloride (Ultram) Tablets,Janssen Pharmaceuticals,50 mg/1 unit (NDC 50458-659-60),New,4/1/2020,,"The Company has made a business decision to permanently discontinue Ultram tablets. Product should be maintained on the formularies until the last batch produced expires (30 Sept 2022), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/2020,4/1/2020,,2020,discontinued
6961,Trandolapril Tablets,Teva Pharmaceuticals,"4 mg tablets, 100 count (NDC 16252-543-90)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2020,discontinued
6962,Trandolapril Tablets,Teva Pharmaceuticals,"2 mg tablets, 100 count (NDC 16252-542-90)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2020,discontinued
6963,Trandolapril Tablets,Teva Pharmaceuticals,"1 mg tablets, 100 count (NDC 16252-541-30)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2020,discontinued
6964,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 30 Tablets per Bottle,  (NDC 60505-3638-3)",New,12/4/2019,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/2019,12/4/2019,,2020,discontinued
6965,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 100 Tablets per Bottle,  (NDC 60505-3638-1)",New,12/4/2019,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/2019,12/4/2019,,2020,discontinued
6966,Trazodone Tablets,Accord Healthcare Inc.,"50 mg tablets, bottle of 100 (NDC 16729-299-01); bottle of 1000 (NDC 16729-299-17)",New,4/20/2020,,,,,Psychiatry,To be Discontinued,4/20/2020,4/20/2020,,2020,discontinued
6967,Trazodone Tablets,Accord Healthcare Inc.,"100 mg tablets, bottle of 100 (NDC 16729-300-01); bottle of 1000 (NDC 16729-300-17)",New,4/20/2020,,,,,Psychiatry,To be Discontinued,4/20/2020,4/20/2020,,2020,discontinued
6968,Trazodone Tablets,Accord Healthcare Inc.,"150 mg tablets, bottle of 100 (NDC 16729-301-01); bottle of 1000 (NDC 16729-301-17)",New,4/20/2020,,,,,Psychiatry,To be Discontinued,4/20/2020,4/20/2020,,2020,discontinued
6969,Trazodone Tablets,Accord Healthcare Inc.,"300 mg tablets, bottle of 100 (NDC 16729-302-01)",New,4/20/2020,,,,,Psychiatry,To be Discontinued,4/20/2020,4/20/2020,,2020,discontinued
6970,"Triamcinolone Acetonide (Triesence) Injection, Suspension",Novartis,Triesence (Triamcinolone acetonide injectable suspension) Vial 40mg/mL 1mL in 1 vial (NDC 0065-0543-01),Revised,9/22/2020,Available,There are no therapeutic equivalents.,,,Ophthalmology,Current,,,,2020,available
6971,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1 mg/1g (NDC 40085-029-80),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2020,discontinued
6972,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1mg/1g (NDC 40085-029-16),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2020,discontinued
6973,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,0.25mg/1g (NDC 40085-028-80),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2020,discontinued
6974,Triamterene and Hydrochlorothiazide (Dyazide) Capsules,GlaxoSmithKline,25 mg; 37.5 mg (NDC 0007-3650-30),New,6/28/2019,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately October 2019.,,,Cardiovascular,To be Discontinued,6/28/2019,6/28/2019,,2020,discontinued
6975,Triamterene and Hydrochlorothiazide (Dyazide) Capsules,GlaxoSmithKline,25 mg; 37.5 mg (NDC 0007-3650-22),New,11/16/2020,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately December 2020.,,,Cardiovascular,To be Discontinued,11/16/2020,11/16/2020,,2020,discontinued
6976,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 0781-5068-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6977,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 0781-5068-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6978,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 0781-5067-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6979,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 0781-5067-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6980,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 68001-0216-00)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6981,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 68001-0216-03)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6982,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 68001-0215-00)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6983,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 68001-0215-03)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2020,discontinued
6984,Trifluoperazine Hydrochloride Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-8028-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6985,Trifluoperazine Hydrochloride Tablets,Sandoz,1 mg 100 count bottle (NDC 0832-0494-11),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6986,Trifluoperazine Hydrochloride Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-8032-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6987,Trifluoperazine Hydrochloride Tablets,Sandoz,2 mg 100 count bottle (NDC 0832-0495-11),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6988,Trifluoperazine Hydrochloride Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-8034-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6989,Trifluoperazine Hydrochloride Tablets,Sandoz,5 mg 100 count bottle (NDC 0832-0496-11),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6990,Trifluoperazine Hydrochloride Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-8036-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6991,Trifluoperazine Hydrochloride Tablets,Sandoz,10 mg 100 count bottle (NDC 0832-0497-11),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6992,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-2401-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6993,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-2402-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6994,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-2405-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6995,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-2410-01),Revised,12/10/2019,,,,,Psychiatry,Resolved,12/10/2019,,,2020,
6996,Trifluridine Ophthalmic Solution,Sandoz,Trifluridine 1% 7.5 mL (NDC 61314-044-75),Reverified,11/13/2020,Short-dated supply available; Fresh supply expected for delivery by end of October,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2020,limited availability
6997,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,1 gram  (NDCs 0093-7259-98 and 0093-7259-56),New,11/15/2019,,This product is being discontinued due to a business decision.,,,Antiviral,To be Discontinued,11/15/2019,11/15/2019,,2020,discontinued
6998,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,500 mg tablets (NDCs 45963-558-30 and 45963-558-08),New,2/21/2019,,,,,Antiviral,To be Discontinued,2/21/2019,2/21/2019,,2020,discontinued
6999,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,1 G tablets (NDCs 45963-559-30 and 45963-559-08),New,2/21/2019,,,,,Antiviral,To be Discontinued,2/21/2019,2/21/2019,,2020,discontinued
7000,Valsartan Tablets,Amneal Pharmaceutical,"40 mg, 30 ct bottle (NDC 65162-837-03); 60 ct bottle (NDC 65162-837-06); 500 ct bottle (NDC 65162-837-50)",Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7001,Valsartan Tablets,Amneal Pharmaceutical,"80 mg, 90 ct bottle (NDC 65162-838-09); 500 ct bottle (NDC 65162-838-50); 1000 ct bottle (NDC 65162-838-11)",Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7002,Valsartan Tablets,Amneal Pharmaceutical,"160 mg, 90 ct bottle (NDC 65162-839-09); 500 ct bottle (NDC 65162-839-50); 1000 ct bottle (NDC 65162-839-11)",Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7003,Valsartan Tablets,Amneal Pharmaceutical,"320 mg, 90 ct bottle (NDC 65162-840-09); 500 ct bottle (NDC 65162-840-50); 1000 ct bottle (NDC 65162-840-11)",Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7004,Valsartan Tablets,Camber Pharmaceuticals Inc.,40 mg (NDC 31722-745-30),Revised,3/4/2020,,,,Shortage of an active ingredient,Cardiovascular,Resolved,3/4/2020,,,2020,
7005,Valsartan Tablets,Camber Pharmaceuticals Inc.,80 mg (NDC 31722-746-90),Revised,3/4/2020,,,,Shortage of an active ingredient,Cardiovascular,Resolved,3/4/2020,,,2020,
7006,Valsartan Tablets,Camber Pharmaceuticals Inc.,160 mg (NDC 31722-746-90),Revised,3/4/2020,,,,Shortage of an active ingredient,Cardiovascular,Resolved,3/4/2020,,,2020,
7007,Valsartan Tablets,Camber Pharmaceuticals Inc.,320 mg (NDC 31722-748-90),Revised,3/4/2020,,,,Shortage of an active ingredient,Cardiovascular,Resolved,3/4/2020,,,2020,
7008,Valsartan Tablets,Ohm Laboratories Inc.,40 mg (NDC 51660-140-30),Revised,3/4/2020,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7009,Valsartan Tablets,Ohm Laboratories Inc.,80 mg (NDC 51660-141-90),Revised,3/4/2020,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7010,Valsartan Tablets,Ohm Laboratories Inc.,160 mg (NDC 51660-142-90),Revised,3/4/2020,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7011,Valsartan Tablets,Ohm Laboratories Inc.,320 mg (NDC 51660-143-90),Revised,3/4/2020,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7012,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 40mg x 30's Bottle Pack (NDC 33342006207),Revised,3/4/2020,,,,Available,Cardiovascular,Resolved,3/4/2020,,,2020,
7013,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 80mg x 90's Bottle Pack (NDC 33342006310),Revised,3/4/2020,,,,Available,Cardiovascular,Resolved,3/4/2020,,,2020,
7014,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 160mg x 30's Bottle Pack (NDC 33342006410),Revised,3/4/2020,,,,Available,Cardiovascular,Resolved,3/4/2020,,,2020,
7015,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 320mg x 30's Bottle Pack (NDC 33342006510),Revised,3/4/2020,,,,Available,Cardiovascular,Resolved,3/4/2020,,,2020,
7016,Valsartan Tablets,"Solco Healthcare US, LLC",40mg 30’s (NDC 43547-0367-03),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7017,Valsartan Tablets,"Solco Healthcare US, LLC",160mg 90’s (NDC 43547-0369-09),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7018,Valsartan Tablets,"Solco Healthcare US, LLC",80mg 90’s (NDC 43547-0368-09),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7019,Valsartan Tablets,"Solco Healthcare US, LLC",320mg 90’s (NDC 43547-0370-09),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7020,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 40 mg. - 30/Bottle (NDC 65862-0570-30),Revised,3/4/2020,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7021,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 80 mg. - 90/Bottle (NDC 65862-0571-90),Revised,3/4/2020,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7022,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 160 mg. - 90/Bottle (NDC 65862-0572-90),Revised,3/4/2020,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7023,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 320 mg. - 90/Bottle (NDC 65862-0573-90 ),Revised,3/4/2020,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7024,Valsartan Tablets,Mylan Pharmaceuticals Inc.,40 mg (30’s) (NDC 0378-5807-93),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7025,Valsartan Tablets,Mylan Pharmaceuticals Inc.,160 mg (90’s) (NDC 0378-5814-77),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7026,Valsartan Tablets,Mylan Pharmaceuticals Inc.,80 mg (90’s) (NDC 0378-5813-77),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7027,Valsartan Tablets,Mylan Pharmaceuticals Inc.,320 mg (90’s) (NDC 0378-5815-77),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7028,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",40 mg (30's) (NDC 59746-0360-30),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7029,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",80 mg (90's) (NDC 59746-0361-90),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7030,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",160 mg (90's) (NDC 59746-0362-90),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7031,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",320 mg (90's) (NDC 59746-0363-90),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7032,Valsartan Tablets,Teva Pharmaceuticals,"Valsartan Tablets, USP 40mg, 90 count, (NDC 0591-2167-19)",New,8/3/2018,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,8/3/2018,8/3/2018,,2020,discontinued
7033,Valsartan Tablets,Torrent Pharma Inc.,40 mg (NDC 13668-067-30),Revised,1/16/2020,,,,,Cardiovascular,To be Discontinued,1/16/2020,1/16/2020,,2020,discontinued
7034,Valsartan Tablets,Torrent Pharma Inc.,80 mg (NDC 13668-068-90),Revised,1/16/2020,,,,,Cardiovascular,To be Discontinued,1/16/2020,1/16/2020,,2020,discontinued
7035,Valsartan Tablets,Torrent Pharma Inc.,160 mg (NDC 13668-069-90),Revised,1/16/2020,,,,,Cardiovascular,To be Discontinued,1/16/2020,1/16/2020,,2020,discontinued
7036,Valsartan Tablets,Torrent Pharma Inc.,320 mg (NDC 13668-070-90),Revised,1/16/2020,,,,,Cardiovascular,To be Discontinued,1/16/2020,1/16/2020,,2020,discontinued
7037,Valsartan Tablets,Novartis,DIOVAN® scored tablets 40mg 30s 1 bottle of 30 tablets (NDC 0078-0423-15),Revised,3/4/2020,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7038,Valsartan Tablets,Novartis,DIOVAN® tablets 80mg 1 bottle of 90 tablets (NDC 0078-0358-34),Revised,3/4/2020,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7039,Valsartan Tablets,Novartis,DIOVAN® tablets 160mg 1 bottle of 90 tablets (NDC 0078-0359-34),Revised,3/4/2020,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7040,Valsartan Tablets,Novartis,DIOVAN® tablets 320mg 1 bottle of 90 count (NDC 0078-0360-34),Revised,3/4/2020,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7041,Valsartan Tablets,Novartis,Valsartan Tablets 40 mg 1 bottle of 90 tablets (NDC 0781-5607-31),Revised,3/4/2020,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7042,Valsartan Tablets,Novartis,Valsartan Tablets 80 mg 1 bottle of 90 tablets (NDC 0781-5608-92),Revised,3/4/2020,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7043,Valsartan Tablets,Novartis,Valsartan Tablets 160 mg 1 bottle of 90 tablets (NDC 0781-5618-92),Revised,3/4/2020,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7044,Valsartan Tablets,Novartis,Valsartan Tablets 320 mg 1 bottle of 90 tablets (NDC 0781-5619-92),Revised,3/4/2020,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/2020,,,2020,
7045,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 30 counts (NDC 62332-044-30),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7046,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 90 counts (NDC 62332-044-90),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7047,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 500 counts (NDC 62332-044-71),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7048,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 30 counts (NDC 62332-045-30),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7049,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 90 counts (NDC 62332-045-90),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7050,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 500 counts (NDC 62332-045-71),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7051,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 30 counts (NDC 62332-046-30),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7052,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 90 counts (NDC 62332-046-90),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7053,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 500 counts (NDC 62332-046-71),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7054,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 30 count (NDC 62332-047-30),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7055,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 90 count (NDC 62332-047-90),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7056,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 500 counts (NDC 62332-047-71),Revised,3/4/2020,,,,Other,Cardiovascular,Resolved,3/4/2020,,,2020,
7057,Vardenafil Hydrochloride (Levitra) Tablets,Bayer,Levitra® (vardenafil HCL) tablets 2.5 mg tablet strength (NDC 0173-0828-13),New,5/15/2018,,"Bayer will continue to market the 5 mg, 10 mg and 20 mg tablet strengths.",,,Other;Reproductive,To be Discontinued,5/15/2018,5/15/2018,,2020,discontinued
7058,Vardenafil Hydrochloride Tablets,Bayer,"Levitra 5 mg, 30 count (NDC 0173-0829-13)",Revised,9/1/2020,,Bayer will continue to market the 20 mg tablet strength.,,,Reproductive,To be Discontinued,7/25/2019,7/25/2019,,2020,discontinued
7059,Vardenafil Hydrochloride Tablets,Bayer,Levitra 10 mg (NDC 0173-0830-13),Revised,9/1/2020,,Discontinuation of the manufacture of the drug.,,,Other;Reproductive,To be Discontinued,9/1/2020,9/1/2020,,2020,discontinued
7060,Vardenafil Hydrochloride Tablets,Bayer,Staxyn 10 mg (NDC 0173-0822-04),Revised,9/1/2020,,Discontinuation of the manufacture of the drug.,,,Other;Reproductive,To be Discontinued,9/1/2020,9/1/2020,,2020,discontinued
7061,Vecuronium Bromide for Injection,Teva Pharmaceuticals,10 mg* 10 X 10 mL *1 mg/mL when reconstituted to 10 mL (NDC 0703-2914-03),Reverified,11/19/2020,Available. We are satisfying historical committed customer demand.,,,,Anesthesia,Current,,,,2020,available
7062,Vecuronium Bromide for Injection,"Hospira, Inc.",10 mg Single Dose Glass Fliptop Vial (NDC 00409-1632-01),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
7063,Vecuronium Bromide for Injection,"Hospira, Inc.",20 mg Single Dose Glass Fliptop Vial (NDC 00409-1634-01),Revised,11/20/2020,Available,,,Other,Anesthesia,Current,,,,2020,available
7064,Vecuronium Bromide for Injection,Mylan Institutional,Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [10 mg](NDC 67457-438-10),Revised,10/14/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
7065,Vecuronium Bromide for Injection,Mylan Institutional,Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [20 mg](NDC 67457-475-20),Revised,10/14/2020,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2020,available
7066,Vecuronium Bromide for Injection,Gland Pharma Limited,10 mg/vial (NDC 63323-781-10),Reverified,10/27/2020,Currently on backorder; estimate shortage thru Q4 2020.,Distributed by marketing partner: Fresenius Kabi  LLC (888-386-1300),,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
7067,Vecuronium Bromide for Injection,Gland Pharma Limited,20 mg/vial (NDC 63323-782-20),Reverified,10/27/2020,Currently on backorder; estimate shortage thru Q4 2020.,Distributed by marketing partner: Fresenius Kabi  LLC (888-386-1300),,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
7068,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,10 mg (NDC 47335-931-44),Revised,9/17/2020,Available,,,Demand increase of the drug,Anesthesia,Current,,,,2020,available
7069,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,20 mg (NDC 47335-932-44),Revised,9/17/2020,Available,,,Demand increase of the drug,Anesthesia,Current,,,,2020,available
7070,Vecuronium Bromide for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"10 mg/vial, packages of 10 (NDC 55150-235-10)",Revised,11/20/2020,Currently on backorder - next shipment anticipated end of Oct 20,Production increase in response to increased demand.,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
7071,Vecuronium Bromide for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg/vial, packages of 10 (NDC 55150-236-20)",Revised,11/20/2020,Currently on backorder - next shipment anticipated Jan 21,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,,2020,not available
7072,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"120mg, 100 count, (NDC 0093-3043-01)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2020,discontinued
7073,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"180mg, 500 count, (NDC 0093-3044-05)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2020,discontinued
7074,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"180mg, 100 count, (NDC 0093-3044-01)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2020,discontinued
7075,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"240mg, 100 count, (NDC 0093-3045-01)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2020,discontinued
7076,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"240mg, 500 count, (NDC 0093-3045-05)",New,2/22/2019,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/2019,2/22/2019,,2020,discontinued
7077,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"100 mg capsule, 100 count bottle (NDC 0378-6201-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
7078,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"200 mg capsule, 100 count bottle (NDC 0378-6202-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
7079,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"200 mg capsule, 500 count bottle (NDC 0378-6202-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
7080,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"300 mg capsule, 100 count bottle (NDC 0378-6203-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
7081,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"300 mg capsule, 500 count bottle (NDC 0378-6203-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
7082,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-0512-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
7083,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-0772-01)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
7084,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 500 count bottle (NDC 0378-0772-05)",New,5/2/2019,,,,,Cardiovascular,To be Discontinued,5/2/2019,5/2/2019,,2020,discontinued
7085,Vinblastine Sulfate Injection,"Fresenius Kabi USA, LLC",10 mg per 10 mL (1 mg per mL); MDV (NDC 63323-0278-10),Revised,3/3/2020,Available,,,,Oncology,Resolved,,,,2020,available
7086,"Vincristine Sulfate (VINCASAR PFS) Injection, USP",Teva Pharmaceuticals,"Vincasar PFS -- vincristine sulfate injection, solution, 1 MG/ 1 ML (NDC 0703-4402-11)",New,7/5/2019,,Teva made a business decion to discontinue the product.,,,Oncology,To be Discontinued,7/5/2019,7/5/2019,,2020,discontinued
7087,"Vincristine Sulfate (VINCASAR PFS) Injection, USP",Teva Pharmaceuticals,VINCASAR PFS (vincristine sulfate injection USP) 2 mg/2 mL Vial (1 mg/mL) (NDC 0703-4412-11),New,3/20/2019,,Teva made a business decision to discontinue this product size (2mL).,,,Oncology,To be Discontinued,3/20/2019,,,2020,discontinued
7088,"Vincristine Sulfate Injection, USP (Preservative-Free)","Hospira, Inc.",1 mg/mL Single Dose Glass Fliptop Vial (NDC 61703-0309-06),Revised,1/30/2020,,,,,Oncology,Resolved,1/30/2020,,,2020,
7089,"Vincristine Sulfate Injection, USP (Preservative-Free)","Hospira, Inc.",2 mg/2 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 61703-0309-16),Revised,1/30/2020,,,,,Oncology,Resolved,1/30/2020,,,2020,
7090,Vinorelbine Tartrate Injection,"Pierre Fabre Pharmaceuticals, Inc.","10 mg/mL Single Dose Glass, Vial (NDC 64370-532-01)",New,11/8/2019,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,11/8/2019,11/8/2019,,2020,discontinued
7091,Vinorelbine Tartrate Injection,"Pierre Fabre Pharmaceuticals, Inc.","50 mg/5mL Single Dose Glass, Vial (NDC 64370-532-02)",New,11/8/2019,,"Limited availability; distribution to end December 31, 2019. Discontinuation of the manufacture of the drug.",,,Oncology,To be Discontinued,11/8/2019,11/8/2019,,2020,discontinued
7092,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-06),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,4/16/2018,4/16/2018,,2020,discontinued
7093,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-09),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,4/16/2018,4/16/2018,,2020,discontinued
7094,Zoledronic Acid Injection,Teva Pharmaceuticals,"0.8 mg/mL, 4 mg 5 mL/Vial (NDC 45963-440-55)",New,5/1/2019,,Discontinuation of the manufacture of the drug.,,,Musculoskeletal;Oncology,To be Discontinued,5/1/2019,5/1/2019,,2020,discontinued
7095,Zolpidem Tartrate (Edluar) Sublingual Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0037-6010-30),Revised,11/21/2018,,,Available,,Psychiatry,Resolved,11/21/2018,,,2020,
7096,Zolpidem Tartrate Extended Release Tablets,Teva Pharmaceuticals,6.25 mg tablets (NDC 0228-3481-11),New,2/22/2019,,,,,Psychiatry,To be Discontinued,2/22/2019,2/22/2019,,2020,discontinued
7097,Zolpidem Tartrate Extended Release Tablets,Teva Pharmaceuticals,12.5 mg  (NDC 0228-3482-11),New,5/1/2020,,,,,Psychiatry,To be Discontinued,5/1/2020,5/1/2020,,2020,discontinued
7098,Zolpidem Tartrate Tablets,Wockhardt,5 mg  (NDCs 64679-0714-01 and 64679-0714-04),New,7/18/2019,,,,,Psychiatry,To be Discontinued,7/18/2019,7/18/2019,,2020,discontinued
7099,Zolpidem Tartrate Tablets,Wockhardt,10 mg  (NDCs 64679-0715-01 and 64679-0715-04),New,7/18/2019,,,,,Psychiatry,To be Discontinued,7/18/2019,7/18/2019,,2020,discontinued
7100,Abacavir Sulfate and Lamivudine Tablets,Teva Pharmaceuticals,600 mg and 300 mg  (NDC 0093-5382-56),New,10/2/2020,,,,,Antiviral,To be Discontinued,10/2/2020,10/2/2020,,2021,discontinued
7101,Abiraterone Acetate Tablets,"Janssen Research and Development, LLC",250 mg tablets (NDC 57894-155-12),New,6/5/2020,,,,,Oncology,To be Discontinued,6/5/2020,6/5/2020,,2021,discontinued
7102,Acetazolamide Injection,"Mylan Institutional, a Viatris company","500 mg, Lyophilisate in Single Dose Vials 1PK (NDC 67457-853-50)",Reverified,11/29/2021,Available,,,Demand increase for the drug,Cardiovascular;Ophthalmology,Current,,,,2021,available
7103,Acetazolamide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9503-01),Reverified,10/12/2021,Inventory is currently available.,Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular;Ophthalmology,Current,,,,2021,available
7104,Acetazolamide Injection,"X-GEN Pharmaceuticals, Inc.",500mg per vial (NDC 39822-0190-1),Revised,7/8/2021,Available,Check wholesaler inventory,,Demand increase for the drug,Cardiovascular;Ophthalmology,Current,,,,2021,available
7105,Acitretin Capsules,GlaxoSmithKline,25 mg (NDC 0145-0091-25),New,4/23/2021,,This product discontinuation is a business-related decision. The anticipated date that GSK will cease distribution of the product is approximately September 2021.,,,Dermatology,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
7106,Acitretin Capsules,GlaxoSmithKline,10 mg (NDC 0145-0090-25),New,4/23/2021,,This product discontinuation is a business-related decision. The anticipated date that GSK will cease distribution of the product is approximately September 2021.,,,Dermatology,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
7107,Acrivastine and Pseudoephedrine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.","Semprex-D Capsules, 8 mg/ 60mg , 100 capsules, (NDC 52244-404-10)",New,6/2/2020,,Endo has made a business decision to permanently discontinue the drug product.,,,Pulmonary/Allergy,To be Discontinued,6/2/2020,6/2/2020,,2021,discontinued
7108,Acyclovir Ointment 5%,"Tolmar Pharmaceuticals, Inc.",15 mg (NDC 63646-300-15),New,12/15/2020,,,,,Dermatology,To be Discontinued,12/15/2020,12/15/2020,,2021,discontinued
7109,Acyclovir Ointment 5%,"Tolmar Pharmaceuticals, Inc.",30 mg (NDC 63646-300-30),New,12/15/2020,,,,,Dermatology,To be Discontinued,12/15/2020,12/15/2020,,2021,discontinued
7110,Adalimumab (Humira) Pre-filled Syringe,Abbvie,10 mg/0.2 mL pre-filled syringe (NDC 0074-6347-02),New,7/27/2020,,The company has discontinued manufacture of these products based on a market assessment and product demand.,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,7/27/2020,7/27/2020,,2021,discontinued
7111,Adalimumab (Humira) Pre-filled Syringe,Abbvie,20 mg/0.4 mL pre-filled syringe (NDC 0074-9374-02),New,7/27/2020,,The company has discontinued manufacture of these products based on a market assessment and product demand.,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,7/27/2020,7/27/2020,,2021,discontinued
7112,Adapalene/Benzoyl Peroxide Topical Gel,Teva Pharmaceuticals,0.1/2.5% PMP 45 g (NDC 0472-0310-38),New,1/27/2021,,Discontinuation of the manufacture of the drug.,,,Dermatology,To be Discontinued,1/27/2021,1/27/2021,,2021,discontinued
7113,"Albuterol Sulfate Aerosol, Metered","Endo Pharmaceuticals, Inc.",90 mcg  (NDC 0254-1007-52),New,7/6/2021,,,,,Pulmonary/Allergy,To be Discontinued,7/6/2021,7/6/2021,,2021,discontinued
7114,Alprostadil Suppository,"Mylan Specialty, a Viatris Company",125 mcg (NDC 0037-8110-06),New,6/14/2021,,,,,Urology,To be Discontinued,6/14/2021,6/14/2021,,2021,discontinued
7115,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Liquid Regular Strength, 95 mg/15mL, 358 mg/15mL, Mint 12oz, (NDC 0135-0094-41)",New,8/6/2021,,This product discontinuation is a business-related decision.,,,Gastroenterology,To be Discontinued,8/6/2021,8/6/2021,,2021,discontinued
7116,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Liquid Regular Strength, 95 mg/15mL, 358 mg/15mL, Mint 6oz, (NDC 0135-0094-42)",New,8/6/2021,,This product discontinuation is a business-related decision.,,,Gastroenterology,To be Discontinued,8/6/2021,8/6/2021,,2021,discontinued
7117,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Chewable Tablet, Regular Strength, 80 mg/1, 14.2 mg/1, 100ct Bottle, (NDC 0135-0096-26)",New,8/6/2021,,This product discontinuation is a business-related decision.,,,Gastroenterology,To be Discontinued,8/6/2021,8/6/2021,,2021,discontinued
7118,Amantadine Hydrochloride Capsules,Teva Pharmaceuticals,100 mg capsules (NDC 0591-4930-01 & 0591-4930-05),New,1/4/2021,,A business decision was made to discontinue this presentation.,,,Antiviral;Neurology,To be Discontinued,1/4/2021,1/4/2021,,2021,discontinued
7119,Amantadine Hydrochloride Capsules,Sandoz,100 mg capsules  (NDCs 0781-2320-01 and 0781-2320-05),New,7/16/2020,,,,,Antiviral;Neurology,To be Discontinued,7/16/2020,7/16/2020,,2021,discontinued
7120,Amifostine Injection,"Clinigen, Inc.",ETHYOL® (amifostine) for injection: 3 x 500 mg vials (NDC 76310-017-50),New,5/21/2020,Shortage anticipated from June 2020; Estimated shortage duration:  Unknown,,,Other,Oncology;Other,Current,,,,2021,limited availability
7121,Amino Acids,B. Braun Medical Inc.,"Plenamine 15% Amino Acids Injection 1,000mL S4500 (NDC 00264-4500-00)",Reverified,8/9/2021,Product on allocation to contracted customers,,,Other,Gastroenterology,Current,9/24/2019,,,2021,limited availability
7122,Amino Acids,"ICU Medical, Inc.",Aminosyn II 15% Sulfite-Free BLK PK 2000 mL (Legacy Hospira NDC 0409-7171-17)(ICU Medical NDC 0990-7171-17),Reverified,11/10/2021,Available to contracted customers only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Gastroenterology,Current,,,,2021,limited availability
7123,Amino Acids,"ICU Medical, Inc.",Aminosyn II 10% Sulfite-Free BLK PK 2000 mL (NDC 0409-7172-17) (ICU Medical NDC 0990-7172-17),Reverified,11/10/2021,Available to contracted customers only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Gastroenterology,Current,,,,2021,limited availability
7124,Amino Acids,"ICU Medical, Inc.","AMINOSYN™-PF 7%, Sulfite-Free, 500 mL (NDC 0409-4178-03)",Reverified,11/10/2021,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Gastroenterology,Current,,,,2021,not available
7125,Amino Acids,"ICU Medical, Inc.","AMINOSYN II 10%, Sulfite-Free, (Pediatric Formula) 1000 mL (Legacy Hospira NDC 0409-4179-05) (ICU Medical NDC 0990-4179-05)",Reverified,11/10/2021,Available to contracted customers only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Gastroenterology,Current,,,,2021,limited availability
7126,Amino Acids,Baxter Healthcare,"15% CLINISOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion. Product Codes: 2B6189 15% 2000 mL (NDC 0338-0502-06), 2B6187 15% 500 mL (NDC 0338-0502-03)",Reverified,11/23/2021,Available,,,,Gastroenterology,Current,,,,2021,available
7127,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 60 count bottle (NDC 0185-0144-60)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7128,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 90 count bottle (NDC 0185-0144-09)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7129,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 500 count bottle (NDC 0185-0144-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7130,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 500 count bottle (NDC 0245-0145-15)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7131,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 30 count bottle (NDC 0245-0145-30)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7132,Amitriptyline Hydrochloride Tablets,"Mylan Specialty, a Viatris Company",10 mg (NDCs 0378-2610-01 and 0378-2610-10),New,8/2/2021,,,,,Psychiatry,To be Discontinued,8/2/2021,8/2/2021,,2021,discontinued
7133,Amitriptyline Hydrochloride Tablets,"Mylan Specialty, a Viatris Company",25 mg (NDCs 0378-2625-01 and 0378-2625-10),New,8/2/2021,,,,,Psychiatry,To be Discontinued,8/2/2021,8/2/2021,,2021,discontinued
7134,Amoxapine Tablets,Teva Pharmaceuticals,"50 mg, 100 tablets (NDC 0591-5714-01)",Revised,11/8/2021,Available,,,,Psychiatry,Current,3/9/2020,,,2021,available
7135,Amoxapine Tablets,Teva Pharmaceuticals,"25 mg, 100 tablets (NDC 0591-5713-01)",Revised,11/8/2021,On backorder,Recovery Dec 2021,,Other,Psychiatry,Current,3/9/2020,,,2021,not available
7136,Amoxapine Tablets,Teva Pharmaceuticals,"100 mg, 100 tablets (NDC 0591-5715-01)",Revised,11/8/2021,Available,,,,Psychiatry,Current,3/9/2020,,,2021,available
7137,Amoxapine Tablets,Teva Pharmaceuticals,"150 mg, 30 tablets (NDC 00591-5716-30)",Revised,11/8/2021,Available,Recovery Oct 2021,,,Psychiatry,Current,3/9/2020,,,2021,available
7138,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"5 mg, 100 Count Bottle (NDC 68382-950-01)",Revised,7/12/2021,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/2021,7/12/2021,,2021,discontinued
7139,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"7.5 mg, 100 Count Bottle (NDC 68382-951-01)",Revised,7/12/2021,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/2021,7/12/2021,,2021,discontinued
7140,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"10 mg, 100 Count Bottle (NDC 68382-952-01)",Revised,7/12/2021,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/2021,7/12/2021,,2021,discontinued
7141,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"12.5 mg, 100 Count Bottle (NDC 68382-953-01)",Revised,7/12/2021,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/2021,7/12/2021,,2021,discontinued
7142,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"15 mg, 100 Count Bottle (NDC 68382-954-01)",Revised,7/12/2021,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/2021,7/12/2021,,2021,discontinued
7143,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"20 mg, 100 Count Bottle (NDC 68382-955-01)",Revised,7/12/2021,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/2021,7/12/2021,,2021,discontinued
7144,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"30 mg, 100 Count Bottle (NDC 68382-956-01)",Revised,7/12/2021,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/2021,7/12/2021,,2021,discontinued
7145,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"30 mg, 100 Count Bottle (NDC 0185-0864-01)",Reverified,11/16/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7146,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"20 mg, 100 Count Bottle (NDC 0185-0853-01)",Reverified,11/16/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7147,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"10 mg, 100 Count Bottle (NDC 0185-0842-01)",Reverified,11/16/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7148,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"5 mg, 100 Count Bottle (NDC 0185-0831-01)",Reverified,11/16/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7149,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 10mg 100 (NDC 57844-0110-01),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7150,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 12.5mg 100 (NDC 57844-0112-01),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7151,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 15mg 100 (NDC 57844-0115-01),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7152,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 20mg 100 (NDC 57844-0120-01),Reverified,11/8/2021,Currently unavailable. Expected resupply end of September and product recovery October 2021,,,,Psychiatry,Current,,,,2021,not available
7153,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 30mg 100 (NDC 57844-0130-01),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7154,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 5mg 100 (NDC 57844-0105-01),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7155,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 7.5mg 100 (NDC 57844-0117-01),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7156,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",5mg [1.25/1.25/1.25/1.25mg] 100s (NDC 0378-4541-01),Reverified,11/29/2021,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
7157,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",7.5mg [1.875/1.875/1.875/1.875mg] 100s (NDC 0378-4542-01),Reverified,11/29/2021,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
7158,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",10mg [2.5/2.5/2.5/2.5mg] 100s (NDC 0378-4543-01),Reverified,11/29/2021,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
7159,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",12.5mg [3.125/3.125/3.125/3.125mg] 100s (NDC 0378-4544-01),Reverified,11/29/2021,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
7160,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",15mg [3.75/3.75/3.75/3.75mg] 100s (NDC 0378-4545-01),Reverified,11/29/2021,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
7161,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",20mg [5/5/5/5mg] 100s (NDC 0378-4546-01),Reverified,11/29/2021,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
7162,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",30mg [7.5/7.5/7.5/7.5mg] 100s (NDC 0378-4547-01),Reverified,11/29/2021,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
7163,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01)",Reverified,11/10/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7164,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01)",Reverified,11/10/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7165,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01)",Reverified,11/10/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7166,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01)",Reverified,11/10/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7167,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01)",Reverified,11/10/2021,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2021,available
7168,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,12.5  mg 100 count (NDC 0555-0776-02),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7169,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,15  mg 100 count (NDC 0555-0777-02),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7170,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,7.5  mg 100 count (NDC 0555-0775-02),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7171,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,10  mg 100 count (NDC 0555-0972-02),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7172,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,20 mg 100 count (NDC 0555-0973-02),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7173,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,30 mg 100 count (NDC 0555-0974-02),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7174,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,5 mg 100 count (NDC 0555-0971-02),Reverified,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
7175,Ampicillin for Injection,"Mylan Institutional, a Viatris company",250 mg (NDC 67457-353-10),New,9/23/2021,,,,,Anti-Infective,To be Discontinued,9/23/2021,9/23/2021,,2021,discontinued
7176,Ampicillin for Injection,"Mylan Institutional, a Viatris company",500 mg (NDC 67457-350-10),New,9/23/2021,,,,,Anti-Infective,To be Discontinued,9/23/2021,9/23/2021,,2021,discontinued
7177,"Ampicillin for Injection, USP","Hospira, Inc.",250 mg/vial; Single Dose Vial (powder) (NDC 00409-3719-01),New,12/14/2020,,Discontinuation of the manufacture of the drug,,,Antiviral,To be Discontinued,12/14/2020,12/14/2020,,2021,discontinued
7178,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,1 MG 100 Capsules (NDC 0172-5240-60),Revised,7/20/2021,,,,,Hematology,Resolved,7/20/2021,,,2021,
7179,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,0.5 MG 100 Capsules (NDC 0172-5241-60),Revised,7/20/2021,,,,,Hematology,Resolved,7/20/2021,,,2021,
7180,Anagrelide Hydrochloride Capsules,Takeda Pharmaceuticals USA Inc.,"AGRYLIN 0.5 mg Capsule,100 capsules in 1 bottle (NDC 54092-063-01)",Revised,7/20/2021,,,Available,,Hematology,Resolved,7/20/2021,,,2021,
7181,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,0.5 mg per capsule Bottles of 100 (NDC 13668-453-01),Revised,7/20/2021,,,Available,,Hematology,Resolved,7/20/2021,,,2021,
7182,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,"1 mg per capsule, Bottles of 100 (NDC 13668-462-01)",Revised,7/20/2021,,,Available,,Hematology,Resolved,7/20/2021,,,2021,
7183,Asenapine (Saphris®) Sublingual Tablets,Allergan,5 mg (NDC 0456-2405-63),New,3/3/2021,,The company has made a business decision to discontinue manufacturing this product. All other Saphris® SKU’s remain available.,,,Psychiatry,To be Discontinued,3/3/2021,3/3/2021,,2021,discontinued
7184,Asenapine (Saphris®) Sublingual Tablets,Allergan,10 mg (NDC 0456-2410-63),New,3/3/2021,,The company has made a business decision to discontinue manufacturing this product. All other Saphris® SKU’s remain available.,,,Psychiatry,To be Discontinued,3/3/2021,3/3/2021,,2021,discontinued
7185,Asenapine Maleate (Saphris®) Sublingual Tablets,Allergan,Box of 100 (10 blisters with 10 tablets) (NDC 00456-2405-63),New,2/8/2021,,The company has made a business decision to discontinue manufacturing this product.  All other Saphris® SKU’s remain available.,,,Psychiatry,To be Discontinued,2/8/2021,2/8/2021,,2021,discontinued
7186,Asenapine Maleate (Saphris®) Sublingual Tablets,Allergan,Box of 100 (10 blisters with 10 tablets) (NDC 0456-2410-63),New,2/8/2021,,The company has made a business decision to discontinue manufacturing this product.  All other Saphris® SKU’s remain available.,,,Psychiatry,To be Discontinued,2/8/2021,2/8/2021,,2021,discontinued
7187,Aspirin/Dipyridamole (Aggrenox) Extended Release Capsules,"Boehringer Ingelheim Pharmaceuticals, Inc.",25mg/200mg capsules (NDC 0597-0001-60),New,5/26/2020,,"Business decision made by the applicant, BIPI. BIPI will no longer be supplying the market with AGGRENOX capsules after June 11, 2020.",,,Cardiovascular,To be Discontinued,5/26/2020,5/26/2020,,2021,discontinued
7188,Atazanavir Capsules,Bristol Myers Squibb Co.,150mg (NDC 0003-3624-12),New,4/28/2021,,"Product available until December 31, 2021.",,,Antiviral,To be Discontinued,4/28/2021,4/28/2021,,2021,discontinued
7189,Atropine Sulfate Injection,American Regent/Luitpold,"0.4 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-0401-25)",Reverified,5/19/2021,Available,"American Regent is currently releasing the 0.4mg/mL, 1 mL vial, NDC 00517-0401-25",,Other,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7190,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.4 mg/mL, 1 mL single dose vial, pack of 25 (NDC 16729-525-08)",New,9/10/2021,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7191,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.4 mg/mL, 20 mL multi-dose vial, pack of 10 (NDC 16729-512-43)",New,9/10/2021,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7192,Atropine Sulfate Injection,Accord Healthcare Inc.,"1 mg/mL, 1 mL single dose vial, pack of 25 (NDC 16729-526-08)",New,9/10/2021,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7193,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.05 mg/mL, 5 mL prefilled syringe, pack of 10 (NDC 16729-483-03)",New,9/10/2021,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7194,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.1 mg/mL, 10 mL prefilled syringe, pack of 10 (NDC 16729-484-45)",New,9/10/2021,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7195,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.1 mg/mL, 5 mL prefilled syringe, pack of 10 (NDC 16729-484-90)",New,9/10/2021,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7196,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC",8 mg per 20 mL (0.4 mg per mL); MDV; (NDC 63323-580-20),Reverified,11/23/2021,5 month expiry (4/2022 expiry) dating available  by request.,Check wholesaler inventory,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2021,limited availability
7197,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS",0.1 mg/mL; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3340-1),Revised,11/2/2021,Backorder due to the increase in demands,,,,Anesthesia;Neurology;Pediatric,Current,,,,2021,not available
7198,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); Ansyr Plastic Syringe
(NDC 0409-1630-10)",Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2021,limited availability
7199,Atropine Sulfate Injection,"Hospira, Inc.","0.25 mg/5 mL (0.05 mg/mL); Ansyr Plastic Syringe
(NDC 0409-9630-05)",Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2021,limited availability
7200,Atropine Sulfate Injection,"Hospira, Inc.",0.5 mg/5 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4910-34),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2021,not available
7201,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4911-34, pack of 10; NDC 0409-4911-11, individual)",Revised,11/18/2021,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7202,Atropine Sulfate Injection,American Regent/Luitpold,"1 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-1010-25)",Reverified,5/19/2021,Available,"American Regent is currently releasing the 1mg/mL, 1 mL vial, (NDC 00517-1010-25)",,Other,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7203,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.4 mg/mL, 20 mL vial (NDC 0641-6006-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2021,available
7204,Atropine Sulfate Ophthalmic Ointment,Bausch Health,"1% (10 mg/g), 3.5 g tube (NDC 24208-825-55)",Revised,9/20/2021,,,Available,,Ophthalmology,Resolved,9/20/2021,,,2021,
7205,Azacitidine for Injection,"Meitheal Pharmaceuticals, Inc.",100 mg per vial (NDC 71288-115-30),New,10/7/2021,Available,Check wholesalers for inventory,,,Oncology,Current,,,,2021,available
7206,Azacitidine for Injection,Teva Pharmaceuticals,100 mg/vial Lyophilized Powder (NDC 68001-0313-56),Reverified,11/8/2021,No supply disruption - we are meeting current demand.,Product is manufactured and labeled for Blue Point Laboratories,,,Oncology,Current,,,,2021,available
7207,Azacitidine for Injection,Breckenridge Pharmaceutical,100 mg per vial (NDC 51991-797-98),Reverified,9/29/2021,Available,,,,Oncology,Current,,,,2021,available
7208,Azacitidine for Injection,Cipla Limited,100 mg per vial (NDC 69097-805-40),Revised,6/8/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,,2021,available
7209,Azacitidine for Injection,Celgene Corporation,"100 mg single-dose vial in cartons of 1 vial, (NDC 0781-3253-94)",Revised,10/1/2021,Available,"Distributed by Sandoz, Inc. Contact number 800-525-8747",,,Oncology,Current,,,,2021,available
7210,Azacitidine for Injection,Celgene Corporation,"100 mg single-dose vial in cartons of 1 vial, (NDC 0781-9253-94)",Revised,10/1/2021,Available,"NOVAPLUS labeling. Distributed by Sandoz, Inc. Contact number 800-525-8747",,,Oncology,Current,,,,2021,available
7211,Azacitidine for Injection,Celgene Corporation,"VIDAZA, , 100 mg single-dose vial in cartons of 1 vial, (NDC 59572-102-01)",Revised,10/1/2021,Available,,,,Oncology,Current,,,,2021,available
7212,Azacitidine for Injection,"Fresenius Kabi USA, LLC","100 mg per vial, single dose vial, PF, (NDC 63323-771-39)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,,2021,available
7213,Azacitidine for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg per vial, (NDC 0143-9606-01)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,,2021,available
7214,Azacitidine for Injection,"Dr. Reddy's Laboratories, Inc.","100 mg per vial, (NDC 43598-305-62)",Revised,11/8/2021,Low inventory,Partial shipments on allocation through December,,Demand increase for the drug,Oncology,Current,,,,2021,limited availability
7215,Azacitidine for Injection,Armas Pharmaceuticals Inc,100 mg per vial (NDC 72485-201-01),Reverified,5/19/2021,Limited availability,Additional lots are manufactured. Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,,2021,limited availability
7216,Azacitidine for Injection,Accord Healthcare Inc.,100 mg per vial (NDC 16729-306-10),Revised,6/10/2021,Limited availability.,,,Shortage of an active ingredient,Oncology,Current,,,,2021,limited availability
7217,Azacitidine for Injection,"Mylan Institutional, a Viatris company",100 mg per vial (NDC 67457-254-30),Reverified,11/29/2021,Unavailable,,,Other,Oncology,Current,,,,2021,not available
7218,Azithromycin (Azasite) Ophthalmic Solution 1%,Akorn Pharmaceuticals,Azasite (Azithromycin Ophthalmic Solution) 1% 2.5 mL in 5 mL bottle (NDC 17478-307-03),Revised,9/11/2019,,,,,Ophthalmology,Resolved,9/11/2019,,,2021,
7219,Azithromycin for Injection,"Mylan Institutional, a Viatris company",500 mg (NDC 67457-860-50),New,4/26/2021,,,,,Anti-Infective,To be Discontinued,4/26/2021,4/26/2021,,2021,discontinued
7220,Bacitracin Ophthalmic Ointment,Padagis US LLC,3.5 g (NDC 0574-4022-35),New,9/10/2021,,,,,Ophthalmology,To be Discontinued,9/10/2021,9/10/2021,,2021,discontinued
7221,Belatacept (Nulojix) Lyophilized Powder for Injection,Bristol Myers Squibb Co.,20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13),Revised,2/25/2021,"No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of Nulojix via the US NULOJIX Distribution Program, initiated 2/15/2017. Starting in August 2018, the restrictions of the NDP were eased to allow for expansion of use to appropriate new patients if the treating physician determines that Nulojix is the best treatment option for the patient. For further information, contact BMS Medical Information.",Increased demand for the drug exacerbated by a delay in transition to a more efficient manufacturing process.,,Demand increase for the drug,Transplant,Current,,,,2021,limited availability
7222,Benzonatate Capsules,Pfizer Pharmaceuticals,Tessalon 100 mg perles; Bottle of 100 (NDC 0069-0122-01),New,6/8/2021,,Discontinuation of the manufacture of the drug.,,,Pulmonary/Allergy,To be Discontinued,6/8/2021,6/8/2021,,2021,discontinued
7223,Budesonide Capsules,Teva Pharmaceuticals,3 mg capsules (NDC 0093-7445-01),New,12/23/2019,,,,,Gastroenterology,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
7224,Bumetanide Injection,"Hospira, Inc.",1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: March 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,limited availability
7225,Bumetanide Injection,"Hospira, Inc.",2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10),Revised,11/18/2021,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,limited availability
7226,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 4 mL vial (NDC 0641-6008-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7227,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 10 mL vial (NDC 0641-6007-10)",Revised,10/12/2021,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing and available in the October  - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,not available
7228,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",0.5 mg 100 Tablets (NDC 14539-700-01),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7229,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",0.5 mg 500 Tablets (NDC 14539-700-05),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7230,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",0.5 mg 1000 Tablets (NDC 14539-700-10),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7231,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",1 mg 100 Tablets (NDC 14539-701-01),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7232,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",1 mg 500 Tablets (NDC 14539-701-05),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7233,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",1 mg 1000 Tablets (NDC 14539-701-10),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7234,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",2 mg 100 Tablets (NDC 14539-702-01),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7235,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",2 mg 500 Tablets (NDC 14539-702-05),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7236,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",2 mg 1000 Tablets (NDC 14539-702-10),New,2/18/2021,,,,,Renal,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7237,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-461-57),Revised,11/23/2021,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7238,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.5% (250 mg per 50 mL) (5 mg per mL) MDV (NDC 63323-463-57),Revised,11/23/2021,Backordered.  Next release January 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7239,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.25% (25 mg per 10 mL) (2.5 mg per mL) SDV (NDC 63323-468-17),Revised,11/23/2021,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7240,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI .25% (75 mg per 30 mL) (2.5 mg per mL) SDV (NDC 63323-468-37),Revised,11/23/2021,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7241,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (50 mg per 10 mL) (5 mg per mL) SDV (NDC 63323-462-17),Revised,11/23/2021,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7242,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) SDV (NDC 63323-462-37),Revised,11/23/2021,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7243,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC","Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) Sterile-Pak, SDV (NDC 63323-462-31)",Revised,11/23/2021,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7244,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.75% (225 mg per 30 mL) (7.5 mg per mL)  SDV  (NDC 63323-460-37),Revised,11/23/2021,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7245,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-01),Revised,11/18/2021,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
7246,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-17),Revised,11/18/2021,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
7247,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9043-01),Revised,11/18/2021,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
7248,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-01),Revised,11/18/2021,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
7249,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-17),Revised,11/18/2021,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
7250,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9046-01),Revised,11/18/2021,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
7251,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-10)",Revised,11/18/2021,Limited Supply Available. Next Delivery: February 2022; Estimated Recovery: March 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,limited availability
7252,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-30)",Revised,11/18/2021,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: January 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,limited availability
7253,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-10)",Revised,11/18/2021,Limited Supply Available. Next Delivery: April 2022; Estimated Recovery: May 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,limited availability
7254,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-29)",Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,limited availability
7255,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1752-50)",Revised,11/18/2021,Next Delivery: December 2021; Estimated Recovery: April 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
7256,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1755-50)",Revised,11/18/2021,Next Delivery: December 2021; Estimated Recovery: May 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
7257,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 10 mL Single Dose Vials (NDC 55150-167-10),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7258,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 30 mL Single Dose Vials (NDC 55150-168-30),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7259,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 10 mL Single Dose Vials (NDC 55150-169-10),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7260,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-170-30),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7261,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 10 mL Single Dose Vials (NDC 55150-171-10),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7262,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 30 mL Single Dose Vials (NDC 55150-172-30),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7263,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 50 mL Multiple Dose Vials (NDC 55150-249-50),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7264,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 50 mL Multiple Dose Vials (NDC 55150-250-50),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7265,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-01),Revised,11/18/2021,Next Delivery: January 2022; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7266,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-02),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7267,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1160-01),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7268,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-01),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7269,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-02),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7270,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1163-01),Revised,11/18/2021,Available,,,Other,Anesthesia,Current,,,,2021,available
7271,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",75 mg/10 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-01),Revised,11/18/2021,Available,,,Other,Anesthesia,Current,,,,2021,available
7272,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",225 mg/30 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-02),Revised,11/18/2021,Available,,,Other,Anesthesia,Current,,,,2021,available
7273,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409-3613-01),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7274,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 25 mg/10 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-10),Revised,11/18/2021,Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7275,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 75 mg/30 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-30),Revised,11/18/2021,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7276,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1587-50),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7277,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-10),Revised,11/18/2021,Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7278,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-29),Revised,11/18/2021,Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7279,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1610-50),Revised,11/18/2021,Limited Supply Available. Next Delivery: April 2022; Estimated Recovery: August 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7280,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 75 mg/10 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-10),Revised,11/18/2021,Available,,,Other,Anesthesia,Current,,,,2021,available
7281,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 225 mg/30 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-29),Revised,11/18/2021,Limited Supply Available.,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7282,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Sensorcaine 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-465-57),Revised,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7283,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Sensorcaine 0.5% (250 mg per 50 mL) (5 mg per mL)                    MDV (NDC 63323-467-57),Revised,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7284,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.25% (25 mg per 10 mL) (2.5 mg per mL) MPF,         SDV (NDC 63323-464-17)",Revised,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7285,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine MPF 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF, SDV (NDC 63323-464-37)",Revised,11/23/2021,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7286,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF,             Sterile-Pak, SDV (NDC 63323-464-31)",Revised,11/23/2021,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7287,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (50 mg per 10 mL) (5 mg per mL)  MPF,                 SDV  (NDC 63323-466-17)",Revised,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7288,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                 SDV (NDC 63323-466-37)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7289,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                Sterile-Pak, SDV (NDC 63323-466-31)",Revised,11/23/2021,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7290,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.75% (75 mg per 10 mL) (7.5 mg per mL) MPF,             SDV (NDC 63323-472-17)",Revised,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7291,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.75% (225 mg per 30 mL) (7.5 mg per mL) MPF,     SDV (NDC 63323-472-37)",Revised,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7292,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409- 1761-02),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7293,Bupivacaine Hydrochloride Injection,Baxter Healthcare,"Bupivacaine Spinal, USP (7.5 mg/mL in 8.25% dextrose) 2 mL Single Dose Ampule (10 x 2 mL)(NDC 36000-092-10)",Reverified,11/23/2021,Stocked out - recovery TBD,SPINAL 0.75% - Sterile Hyperbaric Solution for Spinal Anesthesia,,Manufacturing Delay,Anesthesia,Current,,,,2021,not available
7294,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.25% 5 mL single-dose ampules (NDC 59923-717-05),Reverified,5/19/2021,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2021,available
7295,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.25% 10 mL single-dose ampules (NDC 59923-719-10),Reverified,5/19/2021,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2021,available
7296,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.5% 5 mL single-dose ampules (NDC 59923-718-05),Reverified,5/19/2021,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2021,available
7297,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.5% 10 mL single-dose ampules (NDC 59923-720-10),Reverified,5/19/2021,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,,2021,available
7298,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","HCl 0.75% & Dextrose 8.25%, Injectable spinal (NDC 73293-0002)",New,6/21/2021,Available,"Drug Product is distributed by HUONS USA, please contact Tel : (949)656-6751 or E-mail: jmchoi@huonsglobal.com for supply related inquires.",,,Anesthesia,Current,,,,2021,available
7299,Busulfan Injection,American Regent/Luitpold,6 mg/mL  (NDC 0517-0920-08),New,8/6/2021,,,,,Hematology,To be Discontinued,8/6/2021,8/6/2021,,2021,discontinued
7300,Busulfan Injection,Apotex Corp.,6mg/mL (NDCs 60505-6177-0 and 60505-6177-8),New,10/15/2021,,,,,Hematology,To be Discontinued,10/15/2021,10/15/2021,,2021,discontinued
7301,Calcitriol Injection 1MCG/ML,Akorn Pharmaceuticals,"Calcitriol Injection USP, 1 mcg/mL, 1 mL ampule  (NDC 17478-931-01)",Revised,10/6/2021,,,Available,,Endocrinology/Metabolism,Resolved,10/6/2021,,,2021,
7302,Calcium Disodium Versenate Injection,Bausch Health,1000 mg/5 mL (200 mg/mL) (NDC 99207-240-05),Reverified,10/25/2021,Not currently available. Estimated Shortage duration TBD,,,Requirements related to complying with good manufacturing practices,Other,Current,,,,2021,not available
7303,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","1,000 mg calcium gluconate per 10 mL (100 mg/mL), single dose vial (NDC 63323-360-01, 1 vial; NDC 63323-360-19, 25 vials)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
7304,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","5,000 mg calcium gluconate per 50 mL (100 mg/mL), single dose vial (NDC 63323-360-03, 1 vial; NDC 63323-360-59, 25 vials)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Demand increase for the drug,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
7305,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","10,000 mg calcium gluconate per 100 mL (100 mg/mL), pharmacy bulk package vial (NDC 63323-360-05, 1 vial; NDC 63323-360-61, 20 vials)",Revised,11/23/2021,Backordered. Next release January 2022,Check wholesaler inventory,,Demand increase for the drug,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2021,not available
7306,Calcium Gluconate Injection,HQ Specialty Pharma,1000 mg/50 mL (20 mg/mL) single-dose bag (NDC 44567-620-24),Revised,6/22/2021,Available,Marketed by WG Critical Care,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
7307,Calcium Gluconate Injection,HQ Specialty Pharma,2000 mg/100 mL (20 mg/mL) single-dose bag (NDC 44567-621-24),Revised,6/22/2021,Available,Marketed by WG Critical Care,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
7308,Capreomycin Injection,Akorn Pharmaceuticals,"Capastat Sulfate (Capreomycin for Injection USP) Eq to 1 g Capreomycin activity, 10mL (NDC 17478-080-50)",Revised,5/5/2021,,,,,Anti-Infective,To be Discontinued,5/5/2021,5/5/2021,,2021,discontinued
7309,Captopril Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",12.5mg; 25mg; 50mg; 100mg (NDC 0378-3007-10; 0378-3007-01; 0378-3012-10; 0378-3012-01; 0378-3017-10; 0378-3017-01; 0378-3022-01),New,8/9/2021,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To be Discontinued,8/9/2021,8/9/2021,,2021,discontinued
7310,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 25mg/15mg 100s Tabs (NDC 00378-0081-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,8/9/2021,8/9/2021,,2021,discontinued
7311,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 25mg/25mg 100s Tabs (NDC 00378-0083-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,8/9/2021,8/9/2021,,2021,discontinued
7312,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 50mg/15mg 100s Tabs (NDC 00378-0084-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,8/9/2021,8/9/2021,,2021,discontinued
7313,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 50mg/25mg 100s Tabs (NDC 00378-0086-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,8/9/2021,8/9/2021,,2021,discontinued
7314,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"50/12.5/200 mg, Bottle of 100 Tablets (NDC 64679-0782-04)",New,3/3/2021,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/2021,3/3/2021,,2021,discontinued
7315,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"75/18.75/200 mg, Bottle of 100 Tablets (NDC 64679-0783-04)",New,3/3/2021,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/2021,3/3/2021,,2021,discontinued
7316,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"100/25/200 mg, Bottle of 100 Tablets (NDC64679-0784-04)",New,3/3/2021,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/2021,3/3/2021,,2021,discontinued
7317,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"125/31.25/200 mg, Bottle of 100 Tablets (NDC 64679-0785-04)",New,3/3/2021,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/2021,3/3/2021,,2021,discontinued
7318,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"150/37.5/200 mg, Bottle of 100 Tablets (NDC 64679-0786-04)",New,3/3/2021,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/2021,3/3/2021,,2021,discontinued
7319,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"200/50/200 mg, Bottle of 100 Tablets (NDC 64679-0787-04)",New,3/3/2021,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/2021,3/3/2021,,2021,discontinued
7320,Carboplatin Injection,Ingenus Pharmaceuticals LLC,450 mg/45 mL (NDC 50742-448-45),New,4/7/2021,,Discontinued manufacturing due to lack of commercial viability in the market,,,Oncology,To be Discontinued,4/7/2021,4/7/2021,,2021,discontinued
7321,Carboplatin Injection,Ingenus Pharmaceuticals LLC,600 mg/60 mL (10 mg/mL)(NDC 50742-447-60),New,4/7/2021,,Discontinued manufacturing due to lack of commercial viability in the market,,,Oncology,To be Discontinued,4/7/2021,4/7/2021,,2021,discontinued
7322,Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose,"Chiesi USA, Inc.",Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose (NDC 10122-326-10),New,3/20/2018,,The decision to discontinue the 0.2 mg/mL in 5% Dextrose formulation was business related.  Other formulations of Cardene IV remain available.,,,Cardiovascular,To be Discontinued,3/20/2018,3/20/2018,,2021,discontinued
7323,"Carisoprodol, Aspirin, and Codeine Phosphate Tablets USP",Ingenus Pharmaceuticals LLC,200 mg/325 mg/16 mg (NDC 50742-256-01),New,9/1/2020,,,,,Musculoskeletal,To be Discontinued,9/1/2020,9/1/2020,,2021,discontinued
7324,Caspofungin Acetate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",50 mg (NDC 67457-831-50),New,7/23/2020,,,,,Anti-Infective;Pediatric,To be Discontinued,7/23/2020,7/23/2020,,2021,discontinued
7325,Cefazolin Injection,"Hospira, Inc.",1g Single-dose ADD-Vantage Vial (NDC 00409-2585-01,Reverified,11/18/2021,Available,,,Other,Anti-Infective,Current,,,,2021,available
7326,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 1 g (25 vials) (NDC 60505-6142-05),Reverified,10/27/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7327,Cefazolin Injection,Sagent Pharmaceuticals,10g 10 vials (NDC 25021-102-99),Reverified,10/22/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7328,Cefazolin Injection,Sagent Pharmaceuticals,500mg 25 vials (NDC 25021-100-10),Reverified,10/22/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7329,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 2 gram/50 mL in DUPLEX Catalog 3105-11 (NDC 00264-3105-11),Reverified,7/15/2021,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,,2021,limited availability
7330,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 1 gram/50 mL in DUPLEX Catalog 3103-11 (NDC 0264-3103-11),Reverified,7/15/2021,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,,2021,limited availability
7331,Cefazolin Injection,WG Critical Care,500mg SDV (NDC 44567-706-25),Reverified,8/31/2021,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2021,available
7332,Cefazolin Injection,WG Critical Care,1g SDV (NDC 44567-707-25),Reverified,8/31/2021,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2021,available
7333,Cefazolin Injection,WG Critical Care,10g PBP (NDC 44567-708-10),Reverified,8/31/2021,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,,2021,available
7334,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2021,discontinued
7335,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Revised,10/2/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/2/2020,10/2/2020,,2021,discontinued
7336,Cefazolin Injection,"Hospira, Inc.",10 g Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-0806-01),Revised,10/2/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/2/2020,10/2/2020,,2021,discontinued
7337,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9923-90),Reverified,10/12/2021,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2021,available
7338,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9924-90),Reverified,10/12/2021,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2021,available
7339,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mg/ 100 mL vial (NDC 0143-9983-03),Reverified,10/12/2021,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,,2021,available
7340,Cefazolin Injection,Sandoz,Cefazolin Na Injection 500 mg (NDC 0781-3450-95),Reverified,11/16/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7341,Cefazolin Injection,Sandoz,Cefazolin Na Injection 1 g (NDC 0781-3451-96),Reverified,11/16/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7342,Cefazolin Injection,Sandoz,Cefazolin Na Injection 10 g (NDC 0781-3452-95),Reverified,11/16/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7343,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 10 g (10 vials) (NDC 60505-6143-04),Reverified,10/27/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7344,Cefazolin Injection,Sagent Pharmaceuticals,1g 25 vials (NDC 25021-101-10),Reverified,10/22/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7345,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 1 gram/50 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3503)(NDC 0338-3503-41)",Reverified,11/23/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7346,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 2 gram/100 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3508)(NDC 0338-3508-41)",Reverified,11/23/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7347,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1100-1),Reverified,11/18/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7348,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",300 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1300-1),Reverified,11/18/2021,Available,,,,Anti-Infective,Current,,,,2021,available
7349,Cefdinir Capsules,Sandoz,300 mg capsules  (NDC 0781-2176-60),New,7/9/2020,,,,,Anti-Infective,To be Discontinued,7/9/2020,7/9/2020,,2021,discontinued
7350,Cefdinir Powder for Suspension,Sandoz,125 mg/5 mL (NDCs 0781-6077-46 and 0781-6077-61),New,10/29/2021,,,,,Anti-Infective,To be Discontinued,10/29/2021,10/29/2021,,2021,discontinued
7351,Cefdinir Powder for Suspension,Sandoz,250 mg/5 mL (NDCs 0781-6078-46 and 0781-6078-61),New,10/29/2021,,,,,Anti-Infective,To be Discontinued,10/29/2021,10/29/2021,,2021,discontinued
7352,Cefotaxime Sodium Injection,"SteriMax, Inc.","2g/vial, (NDC 21586-012-2)",Reverified,10/14/2021,Available,"SteriMax in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact Direct Success at Distribution@DSuccess.com or 1-877-404-3338.",,Other,Anti-Infective;Pediatric,Current,,,,2021,available
7353,Cefotaxime Sodium Injection,"SteriMax, Inc.","1g/vial, (NDC 21586-011-2)",Reverified,10/14/2021,Available,"SteriMax in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact Direct Success at Distribution@DSuccess.com or 1-877-404-3338.",,Other,Anti-Infective;Pediatric,Current,,,,2021,available
7354,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9930-10),Reverified,10/12/2021,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2021,not available
7355,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9931-25),Reverified,10/12/2021,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2021,not available
7356,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2 g/ 10 mL vial (NDC 0143-9933-25),Reverified,10/12/2021,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2021,not available
7357,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 g/ 100 mL vial (NDC 0143-9935-01),Reverified,10/12/2021,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2021,not available
7358,Cefotetan Disodium Injection,B. Braun Medical Inc.,1 gram/50 mL in DUPLEX (NDC 00264-3173-11),Reverified,5/19/2021,Product not available; Expected recovery: December 2021,,,Other,Anti-Infective,Current,,,,2021,not available
7359,Cefotetan Disodium Injection,B. Braun Medical Inc.,2 gram/50 mL in DUPLEX (NDC 00264-3175-11),Reverified,5/19/2021,Product not available; Expected recovery: December 2021,,,Other,Anti-Infective,Current,,,,2021,not available
7360,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",1 g SDV (NDC 63323-0385-10),Reverified,11/23/2021,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,,2021,available
7361,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",2 g SDV (NDC 63323-0386-20),Reverified,11/23/2021,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,,2021,available
7362,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",10 g PBP (NDC 63323-0396-61),Reverified,11/23/2021,No release date available at this time.,,,Manufacturing delay,Anti-Infective,Current,,,,2021,not available
7363,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),Reverified,10/13/2021,Discontinued,,,,Anti-Infective,Current,,,,2021,discontinued
7364,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),New,3/25/2021,,Business decision to discontinue manufacture of the product,,,Anti-Infective,To be Discontinued,3/25/2021,3/25/2021,,2021,discontinued
7365,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1g vial (NDC 0143-9878-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7366,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2g vial (NDC 0143-9877-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7367,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10g vial (NDC 0143-9876-10),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7368,Cefoxitin for Injection,Apotex Corp.,1 g (25 vials) (NDC 60505-0759-05),Revised,11/18/2021,,,,,Anti-Infective,Resolved,11/18/2021,,,2021,
7369,Cefoxitin for Injection,Apotex Corp.,10 g (10 vials) (NDC 60505-0761-04),Revised,11/18/2021,,,,,Anti-Infective,Resolved,11/18/2021,,,2021,
7370,Cefoxitin for Injection,"Fresenius Kabi USA, LLC",1 g per vial; SDV; (NDC 63323-341-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7371,Cefoxitin for Injection,"Fresenius Kabi USA, LLC",2 grams per vial; SDV; (NDC 63323-342-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7372,Cefoxitin for Injection,Sagent Pharmaceuticals,"10 g, package of 10 vials (NDC 25021-111-99)",Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7373,Cefoxitin for Injection,Sagent Pharmaceuticals,"1 g, package of 10 vials (NDC 25021-109-10)",Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7374,Cefoxitin for Injection,Sagent Pharmaceuticals,"2 g, package of 10 vials (NDC 25021-110-20)",Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7375,Cefoxitin for Injection,WG Critical Care,1 g (NDC 44567-245-25),Revised,11/18/2021,Available,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,available
7376,Cefoxitin for Injection,WG Critical Care,2 g (NDC 44567-246-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7377,Cefoxitin for Injection,WG Critical Care,10 g (NDC 44567-247-10),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7378,Cefoxitin for Injection,B. Braun Medical Inc.,Cefoxitin Injection 2 gram/50 mL in DUPLEX Catalog 3125-11 (NDC NDC 00264-3125-11),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7379,Cefoxitin for Injection,B. Braun Medical Inc.,Cefoxitin Injection 1 gram/50 mL in DUPLEX Catalog 3123-11 (NDC 0264-3123-11),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,11/18/2021,,,2021,
7380,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 1g Bag 24 x 50mL (NDC 24987-0412-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2021,discontinued
7381,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 2g Bag 24 x 50mL (NDC 24987-0413-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2021,discontinued
7382,"Ceftazidime and Avibactam (AVYCAZ®) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution 1 Single-use vials (NDC 0456-2700-01)",Revised,2/8/2021,The product is available through direct distribution from the manufacturer. Please contact your wholesaler or customer service.,,,Regulatory delay,Anti-Infective,Current,,,,2021,unclear
7383,"Ceftazidime and Avibactam (AVYCAZ®) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution Carton containing 10 vials  (NDC 0456-2700-10)",Revised,2/8/2021,The product is available through direct distribution from the manufacturer.  Please contact your wholesaler or customer service.,,,Regulatory delay,Anti-Infective,Current,,,,2021,unclear
7384,Ceftolozane and Tazobactam (Zerbaxa) Injection,Merck Sharp & Dohme Corp.,Supplied in single-dose vials containing ceftolozane 1 g (equivalent to 1.147 g of ceftolozane sulfate) and tazobactam 0.5 g (equivalent to 0.537 g of tazobactam sodium) per vial. Vials are supplied in cartons containing 10 vials (NDC 67919-030-01),Reverified,11/15/2021,"unavailable, resupply expected approximately December 2021",,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,,2021,not available
7385,Cefuroxime Sodium (Zinacef) Injection,"Teligent Pharma, Inc.",Cefuroxime Sodium (Zinacef) Premix Sol Frozen 1.5g Bag 24 x 50mL (NDC 24987-0425-00),New,3/20/2018,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/2018,3/20/2018,,2021,discontinued
7386,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"10 mg, 1000 count (NDC 0555-0033-05)",Reverified,11/8/2021,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,,2021,available
7387,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"10 mg, 100 count (NDC 0555-0033-02)",Reverified,11/8/2021,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,,2021,available
7388,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"25 mg, 100 count (NDC 0555-0159-02)",Reverified,11/8/2021,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,,2021,available
7389,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"5 mg, 500 count (NDC 0555-0158-04)",Reverified,11/8/2021,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,,2021,available
7390,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"25 mg, 500 count (NDC 0555-0159-04)",Reverified,11/8/2021,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,,2021,available
7391,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"5 mg, 100 count (NDC 0555-0158-02)",Reverified,11/8/2021,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,,2021,available
7392,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","10mg, 100ct (NDC 42806-562-01)",Revised,11/18/2021,Available,,,,Neurology;Psychiatry,Current,,,,2021,available
7393,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","25mg, 100ct (NDC 42806-563-01)",Revised,11/18/2021,Available,,,,Neurology;Psychiatry,Current,,,,2021,available
7394,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","5mg, 100ct (NDC 42806-564-01)",New,11/18/2021,Available,,,,Neurology;Psychiatry,Current,,,,2021,available
7395,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,5 mg (NDC 43547-251-10),New,11/19/2019,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/2019,11/19/2019,,2021,discontinued
7396,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,10 mg (NDC 43547-252-10),New,11/19/2019,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/2019,11/19/2019,,2021,discontinued
7397,Chloroprocaine Hydrochloride Injection,B. Braun Medical Inc.,"Clorotekal® (Chloroprocaine HCl Injection, USP) 5mL ampules 50 mg/5 mL (10 mg/mL) Catalog D7055 (NDC 0264-7055-05)",New,5/17/2021,Product available,,,Other,Anesthesia,Current,,,,2021,available
7398,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nescacaine 1% (300 mg per 30 mL) (10 mg per mL); MDV; (NDC 63323-475-37),Revised,11/23/2021,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2021,available
7399,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nescacaine 2% (600 mg per 30 mL) (20 mg per mL); MDV; (NDC 63323-476-37),Revised,11/23/2021,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2021,available
7400,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nesacaine 2% (400 mg per 20 mL) (20 mg per mL); SDV; (NDC 63323-477-27),Revised,11/23/2021,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2021,available
7401,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nesacaine 3% (600 mg per 20 mL) (30 mg per mL); SDV; (NDC 63323-478-27),Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2021,not available
7402,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% (20 mg/mL), 20 mL vial (NDC 0143-9209-10)",New,5/17/2021,Inventory is currently available.,Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7403,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","3% (30 mg/mL), 20 mL vial (NDC 0143-9210-10)",New,5/17/2021,This presentation is temporarily on backorder.,Additional lots will be available in the June 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7404,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"10 mg/5 mL Single Dose Vial, Package of 10 vials (NDC 55150-284-10)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7405,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg / 10 mL Multiple-Dose Vial, Package of 10 vials (ndc 55150-286-10)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7406,Cisatracurium Besylate Injection,Teva Pharmaceuticals,200 mg/20 mL (10 mg/mL) Single-dose vials (NDC 0703-2045-03),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7407,Cisatracurium Besylate Injection,Teva Pharmaceuticals,20 mg/10 mL (2 mg/mL) Multiple-dose vials (NDC 0703-2056-03),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7408,Cisatracurium Besylate Injection,Teva Pharmaceuticals,10 mg/5 mL (2 mg/mL) Single-dose vials (NDC 0703-2033-03),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7409,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/mL 10 vials (NDC 70069-141-10),Revised,7/27/2021,,,,,Anesthesia,Resolved,7/27/2021,,,2021,
7410,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/ml 10 vials (NDC 70069-161-10),Revised,7/27/2021,,,,,Anesthesia,Resolved,7/27/2021,,,2021,
7411,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",10mg/mL 10 vials (NDC 70069-151-10),Revised,7/27/2021,,,,,Anesthesia,Resolved,7/27/2021,,,2021,
7412,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",10 mg per 5 mL single dose vial (NDC 71288-712-06),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7413,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",200 mg per 20 mL single dose vial (NDC 71288-713-21),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7414,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",20 mg per 10 mL  multi dose vial (NDC 71288-712-11),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7415,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","10 mg (base) per 5 mL (2 mg per mL), Single dose vial, PF, (NDC 63323-416-05)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7416,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","20 mg per 10 mL (2 mg per mL), Multiple dose vial, (NDC 63323-417-10)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7417,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), Single dose vial, PF, (NDC 63323-418-20)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7418,Cisatracurium Besylate Injection,Sandoz,2mg/ml; 5mL (NDC 0781-3150-95),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7419,Cisatracurium Besylate Injection,Sandoz,2mg/mL; 10mL (NDC 0781-3152-95),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7420,Cisatracurium Besylate Injection,Sandoz,1-mg/mL; 20mL (NDC 0781-3153-95_,Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7421,Cisatracurium Besylate Injection,"Hospira, Inc.",10mg/5mL (2mg/mL) Single Dose Vial (NDC 00409-1098-02),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7422,Cisatracurium Besylate Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose Vial (NDC 00409-1103-01),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7423,Cisatracurium Besylate Injection,"Hospira, Inc.",20mg/10mL (2mg/mL) Multi-Dose Vial (NDC 00409-1208-01),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7424,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 5 mL Single-dose vial (NDC 0074-4378-05, 0074-4378-24, 0074-4378-36)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7425,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 10 mL Multiple-dose vial (NDC 0074-4380-10, 0074-4380-79, 0074-4380-81)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7426,Cisatracurium Besylate Injection,Abbvie,"10 mg/mL, 20 mL Single-dose vial (NDC 0074-4382-20, 0074-4382-91, 0074-4382-93)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,7/27/2021,,,2021,
7427,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical solution 1 x 60 pledgets (NDC 0009-3116-14),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2021,discontinued
7428,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical solution 1 x 60 mL applicator bottle (NDC 0009-3116-02),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2021,discontinued
7429,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical gel 1 x 60 g tube (NDC 0009-3331-01),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2021,discontinued
7430,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical gel 1 x 30 g tube (NDC 0009-3331-02),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2021,discontinued
7431,"Clindamycin and Benzoyl Peroxide Gel, 1%/5%","Tolmar Pharmaceuticals, Inc.",45g jar (NDC 0781-7263-68); 35g pump (NDC 0781-7275-43); 50g jar (NDC 0781-7287-50); 50g pump (NDC 0781-7291-46),New,9/30/2021,,"A business decision was made to discontinue manufacture of the drug product. Distributed by: Sandoz, Inc.. Sandoz Customer Service Number: 1-800-525-8747",,,Dermatology,To be Discontinued,9/30/2021,9/30/2021,,2021,discontinued
7432,Clindamycin Injection,"Mylan Institutional, a Viatris company",6 mL/vial (NDC 67457-816-06),New,10/23/2020,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/2020,10/23/2020,,2021,discontinued
7433,Clindamycin Injection,"Mylan Institutional, a Viatris company","150 mg/1 mL; 4 mL in 1 vial, Single dose; 25 vial/carton (NDC 67457-815-04)",New,1/8/2021,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,1/8/2021,1/8/2021,,2021,discontinued
7434,Clindamycin Injection,"Mylan Institutional, a Viatris company",300 mg/ 2 mL; Solution in Single Dose Vials (containing preservatives) (NDC 67457-814-02),New,6/1/2021,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,6/1/2021,6/1/2021,,2021,discontinued
7435,"Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5%","Tolmar Pharmaceuticals, Inc.",45 g tube (NDC 0781-7161-19),New,9/30/2021,,"A business decision was made to discontinue manufacture of the drug product. Distributed by: Sandoz, Inc.. Sandoz Customer Service Number: 1-800-525-8747",,,Dermatology,To be Discontinued,9/30/2021,9/30/2021,,2021,discontinued
7436,Clindamycin Phosphate Topical Solution 1%,"Teligent Pharma, Inc.",30mL (NDC 52565-018-29),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7437,Clindamycin Phosphate Topical Solution 1%,"Teligent Pharma, Inc.",60mL (NDC 52565-018-59),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7438,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-039-15),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7439,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-039-30),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7440,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",45g (NDC 52565-039-45),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7441,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-039-60),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7442,Clobetasol Propionate Topical Foam,Ingenus Pharmaceuticals LLC,0.05% (NDCs 50742-304-01 and 50742-304-50),New,11/16/2021,,,,,Dermatology,To be Discontinued,11/16/2021,11/16/2021,,2021,discontinued
7443,Clobetasol Propionate Topical Solution 0.05%,"Tolmar Pharmaceuticals, Inc.",25 mL (NDC 63646-500-25),New,12/8/2020,,,,,Dermatology,To be Discontinued,12/8/2020,12/8/2020,,2021,discontinued
7444,"Clobetasol Propionate Topical Solution, 0.05%","Tolmar Pharmaceuticals, Inc.",25 mL bottle (NDC 63646-500-25),New,11/1/2021,,,,,Dermatology,To be Discontinued,11/1/2021,11/1/2021,,2021,discontinued
7445,"Clobetasol Propionate Topical Solution, 0.05%","Tolmar Pharmaceuticals, Inc.",50 mL bottle (NDC 63646-500-50),New,11/1/2021,,,,,Dermatology,To be Discontinued,11/1/2021,11/1/2021,,2021,discontinued
7446,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg  (90s)(NDC 0378-1910-77),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7447,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (100s)(NDC 0378-1910-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7448,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (1000s)(NDC 0378-1910-10),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7449,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (90s)(NDC 0378-1912-77),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7450,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (100s)(NDC 0378-1912-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7451,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (1000s)(NDC 0378-1912-10),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7452,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (100s)(NDC 0378-1914-01),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7453,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (500s)(NDC 0378-1914-05),New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7454,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0185-0063-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7455,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0185-0063-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7456,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0185-0063-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7457,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0781-8018-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7458,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0781-8018-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7459,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0781-8018-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7460,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-752-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7461,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-752-02)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7462,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-469-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7463,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-469-02)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7464,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0185-0064-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7465,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0185-0064-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7466,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0185-0064-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7467,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0781-5567-01)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7468,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0781-5567-05)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7469,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0781-5567-10)",New,6/5/2018,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7470,Clonidine Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.1 mg tablets (NDC 0597-0006-01),New,1/6/2021,,,,,Cardiovascular,To be Discontinued,1/6/2021,1/6/2021,,2021,discontinued
7471,Clonidine Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.2 mg tablets (NDC 0597-0007-01),New,1/6/2021,,,,,Cardiovascular,To be Discontinued,1/6/2021,1/6/2021,,2021,discontinued
7472,Clonidine Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.3 mg tablets (NDC 0597-0011-01),New,1/6/2021,,,,,Cardiovascular,To be Discontinued,1/6/2021,1/6/2021,,2021,discontinued
7473,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","12.5 mg tablet, 100 CT Bottle (NDC 18860-101-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7474,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablets, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-102-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7475,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablet, 100  CT bottle (NDC 18860-102-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7476,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-104-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7477,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-105-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7478,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 100 CT Bottle (NDC 18860-105-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7479,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-106-01)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7480,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablets, 100 CT Bottle (NDC 18860-106-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7481,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg Tablet, 100 CT Bottle (NDC 18860-104-10)",New,11/22/2019,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
7482,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BK0/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON-PVC. (NDC 24571-113-06)",Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7483,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK0/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-108-06)",Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7484,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (DC 24571-114-06)",Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7485,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-105-06)",Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7486,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/3.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-103-06)",Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7487,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-102-06)",Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7488,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol B22GK4/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-111-06)",Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7489,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM BK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-116-06),Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7490,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM B22K4/0 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-117-06),Reverified,11/23/2021,Available on allocation,,,,Renal,Current,,,,2021,limited availability
7491,Cortisone Acetate Tablets,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg, bottles of 100 (NDC 0143-9700-01)",Reverified,11/2/2021,Currently Unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient,Endocrinology/Metabolism;Rheumatology,Current,,,,2021,not available
7492,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 2ML (NDC 0065-0359-02)",New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7493,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 5ML (NDC 0065-0359-05)",New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7494,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 0.5% 15ML (NDC 0065-0395-15),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7495,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 2ML (NDC 0065-0396-02),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7496,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 5ML (NDC 0065-0396-05),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7497,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 2ML (NDC 0065-0397-02),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7498,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 5ML (NDC 0065-0397-05),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7499,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 15ML (NDC 0065-0397-15),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7500,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 15ML (NDC 61314-396-01),New,11/9/2020,Available,"Product distributed by Sandoz. Company Contact Information:
800-525-8747",,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7501,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 2ML (NDC 61314-396-03),New,11/9/2020,Available,"Product distributed by Sandoz. Company Contact Information:
800-525-8747",,Shortage of an active ingredient,Ophthalmology,Current,,,,2021,available
7502,Cyclopentolate Ophthalmic Solution,Bausch & Lomb Incorporated,"Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%, 2 mL bottle (NDC 24208-735-01) and 15 mL bottle (NDC 24208-735-06)",Revised,6/24/2021,On backorder. Estimated availability: Mid-September 2021,"Distributed by Bausch + Lomb, a division of Bausch Health US, LLC – 1-800-321-4576",,Other,Ophthalmology,Current,,,,2021,not available
7503,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 15mL 1 Bottle (NDC 17478-097-12)",Revised,6/24/2021,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,,2021,not available
7504,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 2mL, 1 Bottle (NDC 17478-097-02)",Revised,6/24/2021,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,,2021,not available
7505,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 5mL 1 Bottle/EA (NDC 17478-097-10)",Revised,6/24/2021,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,,2021,not available
7506,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Opht Sol 1% 10mg/mL, 2mL, 1 Bottle (NDC 17478-100-02)",Revised,6/24/2021,On backorder. Estimated availability: August 2021,,,Other,Ophthalmology,Current,,,,2021,not available
7507,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Ophth 1% 10mg/mL, 15mL, 1 Bottle (NDC 17478-100-12)",Revised,6/24/2021,On backorder. Estimated availability: August 2021,,,Other,Ophthalmology,Current,,,,2021,not available
7508,Cysteamine Hydrochloride Ophthalmic Solution,"Leadiant Biosciences, Inc.","0.44%, 15 mL bottle (NDC 54482-020-01)",Revised,12/21/2020,In shortage; Estimated shortage duration:  Unknown,"Delay in manufacturing. For more information please contact 1-866-634-2765, Leadiant@tmac.com, or go to  www.leadiant.com",,Other,Ophthalmology,Current,,,,2021,limited availability
7509,Cysteine Hydrochloride Injection,"Exela Pharma Sciences, LLC",Elcys (Cysteine Hydrochloride injection) 500mg/10ml Single-dose vials (NDC 51754-1007-1) Packaged as 10 per carton (NDC 51754-1007-3),Revised,9/3/2019,,,Available,,Other;Pediatric,Resolved,9/3/2019,,,2021,
7510,Cytarabine Injection,"Mylan Institutional, a Viatris company","2 g/20 mL (100 mg/mL), vial (NDC 67457-452-20)",New,5/21/2021,,,,,Oncology;Pediatric,To be Discontinued,5/21/2021,5/21/2021,,2021,discontinued
7511,Cytarabine Injection,"Mylan Institutional, a Viatris company","100 mg/5 mL (20 mg/mL), vial (NDC 67457-455-52)",New,5/21/2021,,,,,Oncology;Pediatric,To be Discontinued,5/21/2021,5/21/2021,,2021,discontinued
7512,Cytarabine Injection,"Mylan Institutional, a Viatris company","1000 mg/50 mL (20 mg/mL), vial (NDC 67457-454-50)",New,5/21/2021,,,,,Oncology;Pediatric,To be Discontinued,5/21/2021,5/21/2021,,2021,discontinued
7513,Cytarabine Injection,"Fresenius Kabi USA, LLC","2 g/20 mL (100 mg/mL), single dose vial (NDC 63323-120-20)",New,9/24/2021,Backordered.  Next release October 2021.,Manufacturing delay.  Check wholesaler inventory,,Other,Oncology;Pediatric,Current,,,,2021,not available
7514,Cytarabine Injection,"Hospira, Inc.","100 mg/5 mL (20 mg/mL), single dose vial (NDC 61703-305-38)",Revised,11/18/2021,Available,,,Other,Oncology;Pediatric,Current,,,,2021,available
7515,Cytarabine Injection,"Hospira, Inc.","2 g/20 mL (100 mg/mL), single dose vial (NDC 61703-319-22)",Revised,11/18/2021,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,limited availability
7516,Cytarabine Injection,"Hospira, Inc.","500 mg/25 mL (20 mg/mL), multiple dose vial (NDC 61703-304-36)",Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: January 2022,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,limited availability
7517,Cytarabine Injection,"Hospira, Inc.","1,000 mg/50 mL (20 mg/mL), pharmacy bulk vial (NDC 61703-303-46)",Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,limited availability
7518,Cytarabine Injection,"Meitheal Pharmaceuticals, Inc.","2 g/20 mL (100 mg/mL), single dose vial (NDC 71288-109-20)",New,9/24/2021,"Currently, no inventory",Manufacturing delay,,Other,Oncology;Pediatric,Current,,,,2021,not available
7519,Cytarabine Injection,"Mylan Institutional, a Viatris company","2 g/20 mL (100 mg/mL), single dose vial (NDC 67457-452-20)",Reverified,11/10/2021,Unavailable,,,,Oncology;Pediatric,Current,,,,2021,not available
7520,Cytarabine Injection,"Mylan Institutional, a Viatris company","100 mg/5 mL (20 mg/mL), single dose vial (NDC 67457-455-52)",Reverified,11/10/2021,Unavailable,,,,Oncology;Pediatric,Current,,,,2021,not available
7521,Cytarabine Injection,"Mylan Institutional, a Viatris company","1000 mg/50 mL (20 mg/mL), pharmacy bulk vial (NDC 67457-454-50)",Reverified,11/10/2021,Unavailable,,,,Oncology;Pediatric,Current,,,,2021,not available
7522,Cytotec (Misoprostol) Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 120 (NDC 0025-1451-20),New,6/11/2021,,Discontinuation of the manufacture of the drug.,,,Gastroenterology,To be Discontinued,6/11/2021,,,2021,discontinued
7523,"Dacarbazine for Injection, USP","Hospira, Inc.",200 mg Single Dose ONCO-TAIN™ Glass Fliptop Vial (NDC 61703-0327-22),New,1/14/2021,,Discontinuation of the manufacture of the drug,,,Oncology,To be Discontinued,1/14/2021,1/14/2021,,2021,discontinued
7524,Dacarbazine Injection,Teva Pharmaceuticals,200 mg 10x20mL (NDC 00703-5075-03),New,10/20/2021,Limited quantities are available,,,Other,Oncology,Current,,,,2021,limited availability
7525,Dacarbazine Injection,Teva Pharmaceuticals,200 mg 1x20mL (NDC 00703-5075-01),New,10/20/2021,Limited quantities are available,,,Other,Oncology,Current,,,,2021,limited availability
7526,Dacarbazine Injection,"Fresenius Kabi USA, LLC","100 mg per vial, Single Dose Amber Vial (NDC 63323-127-10)",Reverified,11/23/2021,Backordered. Next release November 2021.,,,Manufacturing delay,Oncology,Current,,,,2021,not available
7527,Dacarbazine Injection,"Fresenius Kabi USA, LLC","200 mg per vial, Single Dose Amber Vial (NDC 63323-128-20)",Reverified,11/23/2021,Backordered. Next release November 2021.,,,Manufacturing delay,Oncology,Current,,,,2021,not available
7528,Dacarbazine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",200 mg/vial (NDC 0143-9245-10),Revised,10/27/2021,This presentation is temporarily on backorder.,Additional lots will be available in the beginning of November 2021.  Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,,2021,not available
7529,Daptomycin Injection,Merck Sharp & Dohme Corp.,500 mg (NDC 67919-011-01),New,10/8/2021,,,,,Anti-Infective,To be Discontinued,10/8/2021,10/8/2021,,2021,discontinued
7530,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"Extended release, 7.5 mg, 90 count bottle (NDC 0591-4375-19)",New,6/17/2020,,Discontinuance of Manufacturing,,,Urology,To be Discontinued,6/17/2020,6/17/2020,,2021,discontinued
7531,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"15 mg, 30 count bottle (NDC: 0591-4380-30)",New,6/17/2020,,Discontinuance of Manufacturing,,,Urology,To be Discontinued,6/17/2020,6/17/2020,,2021,discontinued
7532,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 30 (NDC 0430-0171-15)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2021,discontinued
7533,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of  90 (NDC 0430-0171-23)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2021,discontinued
7534,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg , 337500 TABLETS in 1 DRUM (NDC 0430-0171-00)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2021,discontinued
7535,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 7 (NDC 0430-0171-96)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2021,discontinued
7536,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 0430-0170-15)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2021,discontinued
7537,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of  90 (NDC 0430-0170-23)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2021,discontinued
7538,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, 337500 TABLETS in 1 DRUM (NDC 0430-0170-00)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2021,discontinued
7539,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, Bottle of 7 (NDC 0430-0170-96)",New,6/4/2020,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/2020,6/4/2020,,2021,discontinued
7540,Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets,Abbvie,"200mg; 8.33mg; 50mg; 33.33 tablets, (NDC 0074-0063-28)",New,5/22/2018,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary.",,,Antiviral,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
7541,Deferasirox Tablets,Teva Pharmaceuticals,180 mg/1 (NDC 00093-3516-56),New,7/20/2020,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/2020,7/20/2020,,2021,discontinued
7542,Deferasirox Tablets,Teva Pharmaceuticals,90 mg/1 (NDC 00093-3517-56),New,7/20/2020,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/2020,7/20/2020,,2021,discontinued
7543,Deferasirox Tablets,Teva Pharmaceuticals,360 mg/1 (NDC 00093-3515-56),New,7/20/2020,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/2020,7/20/2020,,2021,discontinued
7544,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","500 mg per vial, Single use vial, Carton of 4 vials (NDC 52609-4505-6)",Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2021,
7545,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","2 g per vial, Single use vial, Carton of 4 vials (NDC 52609-4504-6)",Revised,9/10/2019,,,,,Hematology,Resolved,9/10/2019,,,2021,
7546,Desmopressin Acetate Nasal Spray,Ferring,"1.5 mg/mL, (NDC 0053-6871-00)",Revised,5/14/2021,Unavailable,,,Other,Hematology,Current,,,,2021,not available
7547,Desmopressin Acetate Nasal Spray,Apotex Corp.,10 mcg/0.1mL (NDC 60505-0815-0),Reverified,6/24/2021,Available,,,,Hematology,Current,,,,2021,available
7548,Desmopressin Acetate Nasal Spray,Ferring,10 mcg/0.1mL (NDCs 55566-2500-0 and 69918-501-05),New,5/14/2021,Unavailable,,,Other,Hematology,Current,,,,2021,not available
7549,Desogestrel and Ethinyl Estradiol Tablets (ORTHO-CEPT),Janssen Pharmaceuticals,ORTHO-CEPT (NDC 50458-196-15),Revised,10/8/2014,,Product will be delisted. Last distribution March 2015.,,Discontinuation of the manufacture of the drug.,,To Be Discontinued,10/8/2014,,,2021,discontinued
7550,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection SDV [4 mg / 1 ml] 25PK (NDC 67457-423-12),Reverified,11/29/2021,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7551,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [20 mg / 5 ml] 25PK (NDC 67457-422-54),Reverified,11/29/2021,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7552,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [120 mg / 30 ml] 25 PK (NDC 67457-421-30),Reverified,11/29/2021,Intermittent supply,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,limited availability
7553,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [100 mg / 10 ml] 10PK (NDC 67457-420-10),Reverified,11/29/2021,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7554,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),4 mg/1 mL SDV (NDC 55150-237-01),Revised,11/5/2021,Backordered — next shipment TBD,Sporadic availability expected.,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,not available
7555,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/5 mL MDV  (NDC 55150-238-05),Revised,11/5/2021,Backordered — next shipment TBD,Sporadic availability expected.,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,not available
7556,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),120 mg/30 mL MDV (NDC 55150-239-30),Revised,11/5/2021,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,not available
7557,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL, 1 mL Single Dose Vial (Preservative Free)(NDC 70069-021-25)",Reverified,5/19/2021,Currently in Stock (we have capacity constraint but product available at this time). Estimated Release Dates: Released Product Available,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7558,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",20 mg per 5 mL (4 mg per mL); MDV;  Amber vial (NDC 63323-165-05),Revised,11/23/2021,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7559,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",100 mg per 10 mL (10 mg per mL); MDV;  Amber Vial (NDC 63323-516-10),Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,not available
7560,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",120 mg per 30 mL (4 mg per mL); MDV; Amber Vial (NDC 63323-165-30),Revised,11/23/2021,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7561,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",4 mg per mL (4 mg per mL); SDV; Amber Vial (NDC 63323-165-01),Revised,11/23/2021,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7562,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",10 mg per mL (10 mg per mL); SDV; Preservative Free; Amber Vial (NDC 63323-506-01),Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,not available
7563,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6145-25)",Reverified,10/12/2021,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7564,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 5 mL vial (NDC 0641-6146-25)",Reverified,10/12/2021,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7565,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-0367-25)",Reverified,10/12/2021,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,available
7566,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-106-10)",Revised,11/23/2021,8 month expiry (7/2022 expiry) dating available by request.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,limited availability
7567,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-109-10)",Revised,11/23/2021,8 month expiry (7/2022 expiry) dating available by request.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,limited availability
7568,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),10 mg/1 mL SDV (NDC 55150-304-25),Revised,11/5/2021,Currently on backorder - next shipment anticipated early Nov,Check wholesalers for inventory,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,not available
7569,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),100 mg/10 mL MDV (contains preservative)(NDC 55150-305-10),Revised,11/5/2021,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2021,not available
7570,Dexmedetomidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mcg/mL, 2 mL vial (NDC 0143-9532-25)",Reverified,10/12/2021,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7571,Dexmedetomidine Injection,Amneal Pharmaceutical,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single-dose bottle (NDC 70121-1388-8 box of 20; NDC 70121-1388-1 individual)",New,4/6/2021,Available,,,,Anesthesia,Current,,,,2021,available
7572,Dexmedetomidine Injection,Amneal Pharmaceutical,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single-dose bottle (NDC 70121-1389-7 box of 10; NDC 70121-1389-1 individual)",New,4/6/2021,Available,,,,Anesthesia,Current,,,,2021,available
7573,Dexmedetomidine Injection,Gland Pharma Limited,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 43598-976-58)",Reverified,11/5/2021,Inventory available,Marketed by Dr. Reddy’s Laboratories Inc. Check wholesalers for inventory.,,,Anesthesia,Current,,,,2021,available
7574,Dexmedetomidine Injection,Gland Pharma Limited,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 43598-975-58)",Reverified,11/5/2021,Inventory available,Marketed by Dr. Reddy’s Laboratories Inc. Check wholesalers for inventory..,,,Anesthesia,Current,,,,2021,available
7575,Dexmedetomidine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"200mcg/50mL, single dose bag (NDC 55150-296-10)",Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7576,Dexmedetomidine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"400mcg/100mL, single dose bag (NDC 55150-297-10)",Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7577,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","0.2 mg / 50 ml (Solution in Single Use Vials/Bottles), 20PK (NDC 67457-924-50)",Revised,11/29/2021,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7578,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","0.4 mg / 100 ml (Solution in Single Use Vials/Bottles), 10PK (NDC 67457-925-10)",Revised,11/29/2021,Available,,,Demand increase for the drug,,Current,,,,2021,available
7579,Dexmedetomidine Injection,Par Pharmaceutical,"200 mcg/50 mL (4 mcg/mL), 50 mL single dose vial, box of 25 (NDC 42023-186-20)",Reverified,11/3/2021,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,,2021,unclear
7580,Dexmedetomidine Injection,Par Pharmaceutical,"400 mcg/100 mL (4 mcg/mL), 100 mL single dose vial, box of 10 (NDC 42023-187-10)",Reverified,11/3/2021,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,,2021,unclear
7581,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-239-93)",Revised,9/13/2021,Available,,,,Anesthesia,Current,,,,2021,available
7582,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-432-93), Novaplus",Revised,9/13/2021,Available,,,,Anesthesia,Current,,,,2021,available
7583,Dexmedetomidine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 55150-209-02)",Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7584,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 0338-9555-24)",Reverified,11/23/2021,Available,,,,Anesthesia,Current,,,,2021,available
7585,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 0338-9557-12)",Reverified,11/23/2021,Available,,,,Anesthesia,Current,,,,2021,available
7586,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 43066-555-24), Novaplus",Reverified,11/23/2021,Available,,,,Anesthesia,Current,,,,2021,available
7587,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 43066-557-12), Novaplus",Reverified,11/23/2021,Available,,,,Anesthesia,Current,,,,2021,available
7588,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 63323-671-20)",Reverified,11/23/2021,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7589,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 25 (NDC 63323-671-50)",Reverified,11/23/2021,5 month expiry (4/2022 expiry) dating available by request.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7590,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 63323-671-00)",Reverified,11/23/2021,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
7591,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 63323-421-02)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7592,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/4 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-600-04)",Reverified,8/31/2021,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7593,Dexmedetomidine Injection,HQ Specialty Pharma,"1000 mcg/10 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-601-04)",Reverified,8/31/2021,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7594,Dexmedetomidine Injection,HQ Specialty Pharma,"200 mcg/50 mL (4 mcg/mL), single dose bag, box of 24 (NDC 44567-602-24)",Reverified,8/31/2021,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7595,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/100 mL (4 mcg/mL), box of 24 (NDC 44567-603-24)",Reverified,8/31/2021,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7596,Dexmedetomidine Injection,Jiangsu Hengrui Medicine Co. Ltd.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 70860-605-03)",Reverified,11/5/2021,Available,"Distributed by Athenex. To order, contact Athenex at 855-273-0154.",,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7597,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 67457-251-02)",Revised,11/29/2021,Short dated stock (4/2022 expiry) available by request. Additional manufacturer in progress.,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7598,Dexmedetomidine Injection,Par Pharmaceutical,"100 mcg/mL, 2 mL single dose vial, box of 25 (NDC 42023-146-25)",Reverified,11/3/2021,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,,2021,unclear
7599,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 0409-1660-20)",Reverified,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,,Anesthesia,Current,,,,2021,limited availability
7600,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 20 (NDC 0409-1660-50)",Reverified,11/18/2021,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7601,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 0409-1660-10)",Reverified,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery; July 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
7602,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 0409-1638-02)",Reverified,11/18/2021,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7603,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 50 mL single dose bottle, box of 20 (NDC 71225-126-05)",Revised,5/20/2021,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7604,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 100 mL single dose bottle, box of 10 (NDC 71225-126-06)",Revised,5/20/2021,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
7605,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-1070-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7606,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100s (NDC 0378-1071-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7607,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-1072-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7608,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLEX Plastic Container.  Product code 2B0062Q  (NDC 0338-0017-02)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7609,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLEX Plastic Container.  Product code 2B0063Q  (NDC 0338-0017-03)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7610,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 1000 mL VIAFLEX Plastic Container. Product code 2B0064X  (NDC 0338-0017-04)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7611,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL AVIVA Container.  Product code 6E0062 (NDC 0338-6346-02)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7612,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL AVIVA Container. Product code 6E0063  (NDC 0338-6346-03)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7613,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-02),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7614,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-03),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7615,Dextrose 5% Injection Bags,"ICU Medical, Inc.",1000 mL (NDC 0409-7922-09),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7616,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL VisIV™ Container (NDC 0409-7922-25),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7617,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-53),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7618,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-55),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7619,Dextrose 5% Injection Bags,"ICU Medical, Inc.",150 mL (NDC 0409-7922-61),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7620,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL VisIV™ Container (NDC 0409-7923-06),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7621,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL VisIV™ Container (NDC 0409-7923-11),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7622,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL (NDC 0409-7923-13),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7623,Dextrose 5% Injection Bags,"ICU Medical, Inc.","25 mL, Quad Pack (NDC 0409-7923-20)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7624,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL (NDC 0409-7923-23),Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7625,Dextrose 5% Injection Bags,"ICU Medical, Inc.","50 mL, Quad Pack (NDC 0409-7923-36)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7626,Dextrose 5% Injection Bags,"ICU Medical, Inc.","100 mL, Quad Pack (NDC 0409-7923-37)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7627,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 25 mL, in VIAFLEX Plastic Container. Quad Pack.  Product code 2B0080  (NDC 0338-0017-10)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7628,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, in VIAFLEX Plastic Container.  Single Pack. Product code EZPB0041 (NDC 0338-9147-30)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7629,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in VIAFLO container Product codes:  UE0062D (250mL, NDC 0338-0062-30); UE0063D (500mL, NDC 0338-0066-20); UE0064D (1000mL, NDC 0338-0070-10)",Revised,9/23/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/2019,,,2021,
7630,Diclofenac Sodium Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0355-01),New,4/4/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction;Rheumatology,To be Discontinued,4/4/2018,4/4/2018,,2021,discontinued
7631,Diclofenac Sodium Topical Solution,"Teligent Pharma, Inc.",1.5% 60mL bottle (NDC 52565-002-59),New,2/18/2021,,Long-term back order with no date of return; Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7632,Diclofenac Sodium Topical Solution,"Teligent Pharma, Inc.",1.5% 150mL bottle (NDC 51565-002-05),New,2/18/2021,,Long-term back order with no date of return; Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To be Discontinued,2/18/2021,2/18/2021,,2021,discontinued
7633,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 200 mg, 30 count bottles (NDC 0555-0588-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2021,discontinued
7634,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 250 mg, 30 count bottles (NDC 0555-0589-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2021,discontinued
7635,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 400 mg, 30 count bottles (NDC 0555-0590-01)",New,5/9/2018,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/2018,5/9/2018,,2021,discontinued
7636,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",15g (NDC 52565-063-15),New,7/6/2021,,,,,Dermatology,To be Discontinued,7/6/2021,7/6/2021,,2021,discontinued
7637,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",30g (NDC 52565-063-30),New,7/6/2021,,,,,Dermatology,To be Discontinued,7/6/2021,7/6/2021,,2021,discontinued
7638,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",60g (NDC 52565-063-60),New,7/6/2021,,,,,Dermatology,To be Discontinued,7/6/2021,7/6/2021,,2021,discontinued
7639,Difluprednate (Durezol) Ophthalmic Emulsion,Novartis,0.05% 5mL in 8mL bottle (NDC 0065-9204-07),Revised,10/15/2019,,,,,Ophthalmology,Resolved,10/15/2019,,,2021,
7640,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Adult (500mcg in 2ml) Ampule (NDC 0515-260-10),Revised,10/6/2021,Available,,,Delay in shipping of the drug,Cardiovascular,Current,,,,2021,available
7641,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Adult (500mcg in 2ml) vial (NDC 70515-261-10),Revised,10/6/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7642,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Pediatric (100mcg in 1ml) ampoule (NDC 70515-262-10),Revised,10/6/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7643,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Pediatric (100mcg in 1ml) vial (NDC 70515-263-10),Revised,10/6/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7644,Digoxin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","250 mcg/mL, 2 mL  (NDC 0641-1410-35)",New,6/4/2021,This presentation is on backorder.,Product recovery is undetermined at this time.,,Other,Cardiovascular,Current,,,,2021,not available
7645,Digoxin Injection,Sandoz,500mcg/2 mL; 10 ampules (NDC 0781-3059-95),Reverified,11/16/2021,Available; Intermittent Backorder,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,limited availability
7646,Diltiazem Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1171-02),New,6/8/2021,,,,,Cardiovascular,To be Discontinued,6/8/2021,6/8/2021,,2021,discontinued
7647,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",25 mg/5mL vial (NDC 70860-301-05),Reverified,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2021,available
7648,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",50 mg/10mL vial (NDC 70860-301-10),Reverified,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2021,available
7649,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",125 mg/25mL vial (NDC 70860-301-25),Reverified,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2021,available
7650,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 5 mL vial  (NDC 0641-6013-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7651,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial (NDC 0641-6014-10)",Revised,10/12/2021,Inventory is currently available,Additional lots are scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7652,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 30 mL vial (NDC 0641-6015-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7653,Diltiazem Hydrochloride Injection,"Hospira, Inc.",100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03),Reverified,11/18/2021,Available,,,Other,Cardiovascular,Current,,,,2021,available
7654,Diltiazem Hydrochloride Injection,"Hospira, Inc.",25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01),Revised,3/23/2021,,,,,Cardiovascular,To be Discontinued,3/23/2021,3/23/2021,,2021,discontinued
7655,Diltiazem Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2021,discontinued
7656,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10)",Revised,2/12/2021,On backorder. Expected release: April 2021,,,,Cardiovascular,Current,,,,2021,not available
7657,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",Revised,2/12/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7658,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",Revised,2/12/2021,Discontinued,,,,Cardiovascular,Current,,,,2021,discontinued
7659,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",Revised,2/12/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7660,Dimercaprol (Bal in Oil) Injection,Akorn Pharmaceuticals,"3 mL (100 mg/mL) ampules, box of 10 (NDC 17478-526-03)",Revised,6/29/2021,,,Available,,Hematology;Other,Resolved,6/29/2021,,,2021,
7661,"Diphenhydramine Hydrochloride Injection, USP",Pfizer Pharmaceuticals,50 mg/mL Carpuject™ Luer Lock Glass Syringe (NDC 00409-2290-31),New,12/28/2020,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To be Discontinued,12/28/2020,12/28/2020,,2021,discontinued
7662,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace CR, 100 mg capsules, bottle of 100 (NDC 0025-2732-31)",Reverified,11/18/2021,Next Delivery and Estimated Recovery: January 2022,Manufacturing Delay. Please contact Pfizer Customer Service for assistance.,,Other,Cardiovascular,Current,,,,2021,not available
7663,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace CR, 150 mg capsules, bottle of 100 (NDC 0025-2742-31)",Reverified,11/18/2021,Next Delivery and Estimated Recovery: January 2022,Manufacturing Delay. Please contact Pfizer Customer Service for assistance.,,Other,Cardiovascular,Current,,,,2021,not available
7664,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"100 mg capsules, bottle of 100 (NDC 59762-0386-1)",Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: March 2022,Shortage per Manufacturer: Manufacturing delay,,Other,Cardiovascular,Current,,,,2021,not available
7665,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"150 mg capsules, bottle of 100 (NDC 59762-0400-1)",Reverified,11/18/2021,Next Delivery and Estimated Recovery: February 2022,Greenstone label,,,Cardiovascular,Current,,,,2021,not available
7666,Disopyramide Phosphate (Norpace) Capsules,Teva Pharmaceuticals,"100 mg capsules, bottle of 100 (NDC 0093-3127-01)",Reverified,11/8/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7667,Disopyramide Phosphate (Norpace) Capsules,Teva Pharmaceuticals,"150 mg capsules, bottle of 100 (NDC 0093-3129-01)",Reverified,11/8/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7668,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace IR, 100 mg capsules; bottle of 100 (NDC 0025-2752-31)",Reverified,11/18/2021,Next Delivery: January 2022; Estimated Recovery: February 2022,Shortage per Manufacturer: Manufacturing delay,,Other,Cardiovascular,Current,,,,2021,not available
7669,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace IR, 150 mg capsules; bottle of 100 (NDC 0025-2762-31)",Reverified,11/18/2021,Next Delivery: January 2022; Estimated Recovery: February 2022,,,,Cardiovascular,Current,,,,2021,not available
7670,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100s (NDC 0378-4140-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7671,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100s (NDC 0378-4141-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
7672,Disulfiram Tablets,Teva Pharmaceuticals,"250 mg, 100 count (NDC 0093-5035-01)",New,11/20/2020,,Teva made a business decision to discontinue the product.,,,Analgesia/Addiction,To be Discontinued,11/20/2020,11/20/2020,,2021,discontinued
7673,Disulfiram Tablets,Teva Pharmaceuticals,"500 mg, 100 count (NDC 0093-5036-01)",New,11/20/2020,,Teva made a business decision to discontinue the product.,,,Analgesia/Addiction,To be Discontinued,11/20/2020,11/20/2020,,2021,discontinued
7674,Dobutamine Hydrochloride Injection,Baxter Healthcare,"250 mg/250 mL (NDC 0338-1073-02) Product code 2B0791, 500 mg/250 mL (NDC 0338-1075-02) Product code 2B0792, 1000 mg/250 mL (NDC 0338-1077-02) Product code 2B0793",Reverified,11/23/2021,Available,,,,Cardiovascular;Pediatric;Renal,Current,,,,2021,available
7675,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/250 mL (1 mg/mL); Flexible Container (NDC 00409-2346-32),Revised,11/18/2021,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2021,available
7676,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/250 mL (2 mg/mL); Flexible Container (NDC 00409-2347-32),Revised,11/18/2021,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Cardiovascular;Pediatric;Renal,Current,,,,2021,limited availability
7677,Dobutamine Hydrochloride Injection,"Hospira, Inc.",1000 mg/250 mL (4 mg/mL); Flexible Container (NDC 00409-3724-32),Revised,11/18/2021,Limited Supply Available. Next Delivery: January 2022; Estimated Recovery: March 2022,,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2021,limited availability
7678,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-20),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,,2021,discontinued
7679,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,,2021,discontinued
7680,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-01),Revised,11/18/2021,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Cardiovascular;Pediatric;Renal,Current,,,,2021,not available
7681,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-02),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Cardiovascular;Pediatric;Renal,Current,,,,2021,limited availability
7682,Docetaxel Injection,Ingenus Pharmaceuticals LLC,20 mg/2 mL (10 mg/mL)(NDC 50742-428-02),New,4/7/2021,,Discontinued manufacturing due to lack of commercial viability in the market,,,Oncology,To be Discontinued,4/7/2021,4/7/2021,,2021,discontinued
7683,Dofetilide Capsules,Pfizer Pharmaceuticals,125 mcg (0.125 mg) capsules; Bottle of 60 (NDC 59762-0037-2),New,5/21/2021,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,5/21/2021,5/21/2021,,2021,discontinued
7684,Dofetilide Capsules,Pfizer Pharmaceuticals,250 mcg (0.25 mg) capsules; Bottle of 60 (NDC 59762-0038-2),New,5/21/2021,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,5/21/2021,5/21/2021,,2021,discontinued
7685,Dofetilide Capsules,Pfizer Pharmaceuticals,500 mcg (0.5 mg) capsules; Bottle of 60 (NDC 59762-0039-2),New,5/21/2021,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,5/21/2021,5/21/2021,,2021,discontinued
7686,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg/mL, 5 mL vial (NDC 0143-9252-25)",Reverified,10/12/2021,This presentation is currently available.,Additional lots are scheduled for manufacturing.   Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7687,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg/mL, 10 mL vial (NDC 0143-9254-25)",Reverified,10/12/2021,This presentation is currently available.,Additional lots are scheduled for manufacturing.   Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7688,Dopamine Hydrochloride Injection,"Hospira, Inc.","400 mg/250 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-22)",Revised,11/18/2021,Available,,,Other,Cardiovascular,Current,,,,2021,available
7689,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/500 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-24)",Revised,11/18/2021,Next Delivery and Estimated Recovery: February 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,not available
7690,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/250 mL (3,200 mcg/mL); Flexible Container (NDC 00409-7810-22)",Revised,11/18/2021,Next Delivery: March 2022; Estimated Recovery: April 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,not available
7691,Dopamine Hydrochloride Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-5820-01),Revised,11/18/2021,Available,,,Other,Cardiovascular,Current,,,,2021,available
7692,Dopamine Hydrochloride Injection,"Hospira, Inc.",400 mg/10 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9104-20),Revised,11/18/2021,Available,,,Other,Cardiovascular,Current,,,,2021,available
7693,Dopamine Hydrochloride Injection,Baxter Healthcare,"800 mcg/mL (250 mL bag) Product code 2B0832 (NDC 0338-1005-02), 800 mcg/mL (500 mL bag)  Product code 2B0833 (NDC 0338-1005-03), 1600 mcg/mL (250 mL bag) Product code 2B0842 (NDC 0338-1007-02), 1600 mcg/mL (500 mL bag) Product code 2B0843 (NDC 0338-1007-03), 3200 mcg/mL (250 mL bag) Product code 2B0846 (NDC 0338-1009-02)",Reverified,11/23/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7694,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 17478-605-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7695,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 50383-233-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7696,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt-PF® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 0.2 mL single use, 60 count (NDC 17478-604-30)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7697,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 61314-030-02)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7698,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 24208-486-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7699,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 0591-2482-79)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7700,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride and Timolol Maleate 20 mg and 5 mg/mL, 10 mL (0591-2482-79)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing this product.,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2021,discontinued
7701,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Aurobindo Pharma,"Dorzolamide HCl and Timolol Maleate (Cosopt® PF) Ophthalmic Solution 2%/0.5% Preservative Free, 2mL single use container (NDC 65862-0947-60)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7702,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2021,discontinued
7703,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",New,4/20/2018,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/2018,4/20/2018,,2021,discontinued
7704,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",Revised,4/29/2021,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/29/2021,4/29/2021,,2021,discontinued
7705,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",Revised,4/29/2021,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/29/2021,4/29/2021,,2021,discontinued
7706,Dorzolamide Hydrochloride Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 61314-019-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7707,Dorzolamide Hydrochloride Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 50383-232-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7708,Dorzolamide Hydrochloride Ophthalmic Solution,Merck Sharp & Dohme Corp.,"TRUSOPT® dorzolamide hydrochloride ophthalmic solution 2%, 10 mL in an 18 mL capacity bottle (NDC 0006-3519-36)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7709,Dorzolamide Hydrochloride Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride USP 2%, 10 mL (NDC 24208-485-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,5/10/2021,,,2021,
7710,Doxycycline Hyclate Powder for Suspension,"Hospira, Inc.",25mg/5mL (NDC 0069-0970-65),New,11/15/2021,,,,,Anti-Infective,To be Discontinued,11/15/2021,11/15/2021,,2021,discontinued
7711,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Pfizer Pharmaceuticals,6.25 mg package for 0.125% (NDC 0046-1065-05),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,,,2021,discontinued
7712,Efavirenz Tablets,"Mylan Specialty, a Viatris Company",600 mg (NDC 0378-2233-93),New,11/2/2021,,,,,Antiviral,To be Discontinued,11/2/2021,11/2/2021,,2021,discontinued
7713,Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate (Atripla) Tablets,"Gilead Sciences, LLC",600 mg; 200 mg; 300 mg (NDC 15584-0101-1),New,2/4/2021,,Date of permanent discontinuation of manufacture is July 2021.  Product expected to be available until December 2021.,,,Antiviral,To be Discontinued,2/4/2021,2/4/2021,,2021,discontinued
7714,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2.5mg/2mL, vial (NDC 0143-9786-10)",Revised,10/12/2021,This presentation is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7715,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1.25mg/mL, vial  (NDC 0143-9787-10)",Revised,10/12/2021,This presentation is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7716,Enoxaparin Sodium Injection,Teva Pharmaceuticals,30 mg/0.3mL (NDCs 0703-8530-21 and 0703-8530-23),New,1/28/2021,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/2021,1/28/2021,,2021,discontinued
7717,Enoxaparin Sodium Injection,Teva Pharmaceuticals,40 mg/0.4 mL (NDCs 0703-8540-21 and 0703-8540-23),New,1/28/2021,,Product expected to be available until October 2021,,,Hematology,To be Discontinued,1/28/2021,1/28/2021,,2021,discontinued
7718,Enoxaparin Sodium Injection,Teva Pharmaceuticals,60 mg/0.6 mL (NDCs 0703-8560-21 and 0703-8560-23),New,1/28/2021,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/2021,1/28/2021,,2021,discontinued
7719,Enoxaparin Sodium Injection,Teva Pharmaceuticals,80 mg/0.8 mL (NDCs 0703-8680-21 and 0703-8680-23),New,1/28/2021,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/2021,1/28/2021,,2021,discontinued
7720,Enoxaparin Sodium Injection,Teva Pharmaceuticals,100 mg/1 mL (NDCs 0703-8580-21 and 0703-8580-23),New,1/28/2021,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/2021,1/28/2021,,2021,discontinued
7721,Enoxaparin Sodium Injection,Teva Pharmaceuticals,120 mg/0.8 mL (NDCs 0703-8610-21 and 0703-8610-23),New,1/28/2021,,Product expected to be available until August 2021,,,Hematology,To be Discontinued,1/28/2021,1/28/2021,,2021,discontinued
7722,Enoxaparin Sodium Injection,Teva Pharmaceuticals,150 mg/1 mL (NDCs 0703-8510-21 and 0703-8510-23),New,1/28/2021,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/2021,1/28/2021,,2021,discontinued
7723,"Epinephrine Injection, 0.1 mg/mL","Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4933-01) (old NDC 00409-4921-34, pack of 10; NDC 0409-4921-20, individual)",Revised,11/18/2021,Next Delivery and Estimated Recovery: TBD,,,Demand increase for the drug,Cardiovascular;Pulmonary/Allergy,Current,,,,2021,unclear
7724,"Epinephrine Injection, 0.1 mg/mL","Amphastar Pharmaceuticals, Inc./IMS","0.1mg/mL, 10mL, (NDC 76329-3316-1)",Revised,11/2/2021,Backorder due to the increase in demands,,,Demand increase for the drug,Cardiovascular;Pulmonary/Allergy,Current,,,,2021,not available
7725,"Epinephrine Injection, Auto-Injector","Mylan Specialty, a Viatris Company",0.3 mg EpiPen® (NDC 49502-500-02); Authorized Generic (NDC 49502-102-02),Reverified,11/29/2021,Available,Product is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2021,available
7726,"Epinephrine Injection, Auto-Injector","Mylan Specialty, a Viatris Company",0.15 mg EpiPen® (NDC 49502-501-02); Authorized Generic (NDC 49502-101-02),Reverified,11/29/2021,Available,Product is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2021,available
7727,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)",Revised,4/28/2021,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,,2021,limited availability
7728,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)",Reverified,12/14/2020,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,,2021,limited availability
7729,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)",Reverified,1/27/2021,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2021,available
7730,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)",Reverified,1/27/2021,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2021,available
7731,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)",Reverified,1/27/2021,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,,2021,available
7732,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)",Reverified,11/8/2021,Limited inventory on allocation.  Expected recovery mid-November.,,,,Pulmonary/Allergy,Current,,,,2021,limited availability
7733,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.3 mg single-dose, pre-filled syringes (NDC 0781-3442-20)",Reverified,12/17/2019,Available,,,,Pulmonary/Allergy,Current,,,,2021,available
7734,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.15 mg single-dose, pre-filled syringes (NDC 0781-3448-20)",Reverified,12/17/2019,Available,,,,Pulmonary/Allergy,Current,,,,2021,available
7735,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.15 MG Epinephrine Injection, USP auto-injector (NDC 0093-5985-27)",Reverified,11/8/2021,Limited inventory on allocation.  Expected recovery mid-October.,,,,Pulmonary/Allergy,Current,,,,2021,limited availability
7736,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,20 mg/10ml (2 mg/ml)(NDC 0085-1177-01),New,10/21/2020,,To be discontinued on or near October 2020.,,,Cardiovascular,To be Discontinued,10/21/2020,10/21/2020,,2021,discontinued
7737,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,75 mg/100ml (0.75 mg/ml)(NDC 0085-1136-01),New,10/21/2020,,To be discontinued on or near October 2020.,,,Cardiovascular,To be Discontinued,10/21/2020,10/21/2020,,2021,discontinued
7738,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,200 mg/100ml (2 mg/ml)(NDC 0085-1177-02),New,10/21/2020,,Discontinued,,,Cardiovascular,To be Discontinued,10/21/2020,10/21/2020,,2021,discontinued
7739,Ergotamine Tartrate and Caffeine (Cafergot) Tablets,Sandoz,1mg/100mg (NDC 0781-5405-01),New,7/2/2020,,Discontinuation of drug manufacturing,,,Neurology,To be Discontinued,7/2/2020,7/2/2020,,2021,discontinued
7740,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",25 mg tablets (NDC 50242-062-01),New,9/29/2020,,,,,Oncology,To be Discontinued,9/29/2020,9/29/2020,,2021,discontinued
7741,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",100 mg tablets (NDC 50242-063-01),New,9/29/2020,,,,,Oncology,To be Discontinued,9/29/2020,9/29/2020,,2021,discontinued
7742,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",150 mg tablets (NDC 50242-064-01),New,9/29/2020,,,,,Oncology,To be Discontinued,9/29/2020,9/29/2020,,2021,discontinued
7743,Erythromycin Ethylsuccinate Powder for Suspension,"Endo Pharmaceuticals, Inc.",200 mg/5 mL  (NDC 0254-1020-47),New,2/8/2021,,,,,Anti-Infective,To be Discontinued,2/8/2021,2/8/2021,,2021,discontinued
7744,Erythromycin Ethylsuccinate Powder for Suspension,"Endo Pharmaceuticals, Inc.",400 mg/5 mL (NDC 0254-1021-47),New,2/8/2021,,,,,Anti-Infective,To be Discontinued,2/8/2021,2/8/2021,,2021,discontinued
7745,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35),Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7746,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC17478-070-31),Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7747,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-824-35)(Premier),Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7748,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC 17478-824-01)(Premier),Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7749,Erythromycin Ophthalmic Ointment,Bausch Health,3.5 g in 1 Tube (NDC 24208-910-55),Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7750,Erythromycin Ophthalmic Ointment,Bausch Health,1 g in cartons of 50 (NDC 24208-910-19),Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7751,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"1 gram, 50-count (NDC 00574-4024-50)",Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7752,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 1-count (NDC 00574-4024-35)",Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7753,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 24-count (NDC 00574-4024-39)",Revised,5/19/2021,,,Available,,Ophthalmology,Resolved,5/19/2021,,,2021,
7754,Esomeprazole Sodium for Injection,"Mylan Institutional, a Viatris company","40 mg vial, box of 10 (NDC 67457-392-99)",New,9/16/2021,,,,,Gastroenterology;Pediatric,To be Discontinued,9/16/2021,9/16/2021,,2021,discontinued
7755,Estradiol (Alora) Patch,Allergan,(NDC 0023-5885-12),New,3/24/2021,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
7756,Estradiol (Alora) Patch,Allergan,(NDC 0023-5886-15),New,3/24/2021,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
7757,Estradiol (Alora) Patch,Allergan,(NDC 0023-5887-17),New,3/24/2021,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
7758,Estradiol (Alora) Patch,Allergan,(NDC 0023-5888-11),New,3/24/2021,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
7759,Ethacrynic Acid Tablets,"Endo Pharmaceuticals, Inc.",25 mg/1 (NDC 49884-276-01),New,12/17/2020,,Discontinued due to business reasons,,,Cardiovascular;Renal,To be Discontinued,12/17/2020,12/17/2020,,2021,discontinued
7760,Ethambutol Hydrochloride Tablets,Teva Pharmaceuticals,400 mg  (NDC 0555-0923-02),New,9/28/2020,,,,,Anti-Infective,To be Discontinued,9/28/2020,9/28/2020,,2021,discontinued
7761,Ethambutol Hydrochloride Tablets,Teva Pharmaceuticals,400mg  (NDC 0555-0923-02),New,11/5/2021,,,,,Anti-Infective,To be Discontinued,11/5/2021,11/5/2021,,2021,discontinued
7762,Etomidate Injection,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",20 mg/10mL carton of 10 (NDC 23155-160-41),Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7763,Etomidate Injection,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",40 mg/20 mL carton of 10 (NDC 23155-160-42),Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7764,Etomidate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 10 mL vial (NDC 55150-221-10)",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7765,Etomidate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"40 mg/mL, 20 mL vial (NDC 55150-222-20)",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7766,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 10 mL vial (NDC 72266-146-10)",Revised,4/22/2021,,,Distributed by Fosun Pharma; Available,,Anesthesia,Resolved,4/22/2021,4/22/2021,,2021,
7767,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-147-10)",Revised,4/22/2021,,,Distributed by Fosun Pharma; Available,,Anesthesia,Resolved,4/22/2021,4/22/2021,,2021,
7768,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9506-10)",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7769,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9507-10)",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7770,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9310-10), Novaplus",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7771,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9311-10), Novaplus",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7772,Etomidate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg/mL, 10 mL vial (NDC 67457-902-10)",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7773,Etomidate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg/mL, 20 mL vial (NDC 67457-903-20)",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7774,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 10 mL vial (NDC 0409-6695-01)",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7775,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 20 mL vial (NDC 0409-6695-02)",Revised,4/22/2021,,,Available,,Anesthesia,Resolved,4/22/2021,,,2021,
7776,Etoposide Injection,Accord Healthcare Inc.,20mg/mL (NDC 16729-262-31),New,2/16/2021,,Last lot of this NDC available in the market currently expires in October 2021.,,,Oncology,To be Discontinued,2/16/2021,2/16/2021,,2021,discontinued
7777,Exenatide (BYDUREON) Extended Release for Injectable Suspension,AstraZeneca,"BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use;  Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)",New,4/3/2018,,"The planned permanent discontinuance of the Bydureon Single Dose Tray inventory from the U.S. market is September 30, 2018.  There are currently 2 other delivery options for exenatide-extended-release:  the Bydureon® Dual Chamber Pen presentation (NDC 0310-6530-04) and Bydureon® BCise™ (NDC 0310-6540-04).",,,Endocrinology/Metabolism,To be Discontinued,4/3/2018,4/3/2018,,2021,discontinued
7778,Famotidine Injection,"Athenex Pharmaceutical Division, LLC (Athenex)","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 70860-751-02 and 41)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7779,Famotidine Injection,"Athenex Pharmaceutical Division, LLC (Athenex)","200 mg per 20 mL(10 mg per mL), multiple dose vial with preservatives, (NDC 70860-751-20 and 41)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7780,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Single Dose Vials) [20 mg / 2 ml] 25PK (NDC 67457-433-22),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7781,Famotidine Injection,Baxter Healthcare,"Famotidine Injection premix, 20mg/50 mL in GALAXY Plastic Container (NDC 0338-5197-41)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7782,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 2 mL vial (NDC 0641-6022-25)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7783,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 4 mL vial (NDC 0641-6023-25)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7784,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6021-10)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7785,Famotidine Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 63323-739-12)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7786,Famotidine Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), mutilple dose vial, (NDC 63323-738-09)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7787,Famotidine Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL(10 mg per mL), multiple dose vial, (NDC 63323-738-20)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7788,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [40 mg / 4 ml] 10PK (NDC 67457-448-43),Revisee,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7789,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [200 mg / 20 ml] 10PK (NDC 67457-457-20),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7790,Famotidine Tablets,Teva Pharmaceuticals,20 MG 100 Count (NDC 0172-5728-60),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7791,Famotidine Tablets,Teva Pharmaceuticals,20 MG 1000 Count (NDC 0172-5728-80),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7792,Famotidine Tablets,Teva Pharmaceuticals,20 MG 500 Count (NDC 0172-5728-70),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7793,Famotidine Tablets,Teva Pharmaceuticals,40 MG 100 Count (NDC 0172-5729-60),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7794,Famotidine Tablets,Teva Pharmaceuticals,40 MG 500 Count (NDC 0172-5729-70),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7795,Famotidine Tablets,Aurobindo Pharma,20 mg - 100/Bottle (NDC 65862-859-01),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7796,Famotidine Tablets,Aurobindo Pharma,40 mg - 100/Bottle (NDC 65862-860-01),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7797,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 100 counts (NDC 62332-001-31),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7798,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 1000 counts (NDC 62332-001-91),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7799,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 100 counts (NDC 62332-002-31),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7800,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 500 counts (NDC 62332-002-71),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7801,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 1000 counts (NDC 62332-002-91),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7802,Famotidine Tablets,"Carlsbad Technology, Inc.",20mg 100 count (NDC 61442-121-01),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7803,Famotidine Tablets,"Carlsbad Technology, Inc.",20 mg 1000 count (NDC 61442-121-10),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7804,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 100 count (NDC 61442-122-01),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7805,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 1000 count (NDC 61442-122-10),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,11/10/2021,,,2021,
7806,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",40 mg (NDC 55111-796-30),New,11/22/2021,,,,,Rheumatology,To be Discontinued,11/22/2021,11/22/2021,,2021,discontinued
7807,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",80 mg (NDC 55111-797-30),New,11/22/2021,,,,,Rheumatology,To be Discontinued,11/22/2021,11/22/2021,,2021,discontinued
7808,"Fenoldopam Mesylate (Corlopam) Injection, USP","Hospira, Inc.",20 mg/2 mL (10 mg/mL); Glass Ampul (NDC 00409-2304-02),New,11/16/2020,,"Discontinuation of the manufacture of the ampul, equivalent vial available.",,,Cardiovascular,To be Discontinued,11/16/2020,11/16/2020,,2021,discontinued
7809,"Fenoldopam Mesylate (Corlopam) Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Glass Ampul (NDC 00409-2304-01),New,11/16/2020,,"Discontinuation of the manufacture of the ampul, equivalent vial available.",,,Cardiovascular,To be Discontinued,11/16/2020,11/16/2020,,2021,discontinued
7810,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) Single Dose Simplist PFS  (NDC 63323-808-11),Reverified,11/23/2021,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7811,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 1 mL vial
(NDC 0641-6247-25)",New,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7812,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","1,000 mcg per 20 mL (50 mcg per mL) (0.05 mg per mL)  SDV (NDC 63323-806-20)",Reverified,11/23/2021,Backordered. Next release January 2022.,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7813,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","2,500 mcg per 50 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-50)",Reverified,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7814,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-01),Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7815,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",100 mcg per 2 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-02),Reverified,11/23/2021,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7816,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",250 mcg per 5 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-05),Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7817,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1276-32),Revised,11/18/2021,Next Delivery and Estimated Recovery: January 2023,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7818,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-32),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7819,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-35),Revised,11/18/2021,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7820,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",1000 mcg/20 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-38),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,discontinued
7821,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-22),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: May 2022,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,limited availability
7822,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-25),Revised,11/18/2021,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7823,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",500 mcg/10 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-28),Revised,11/18/2021,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7824,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","1,000 mcg/20 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-31)",Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: March 2022,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,limited availability
7825,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","2,500 mcg/50 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-61)",Revised,11/18/2021,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: May 2022,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,limited availability
7826,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 2 mL ampul (NDC 0641-6024-10),Revised,10/12/2021,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7827,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 5 mL ampul (NDC 0641-6025-10),Revised,10/12/2021,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7828,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL ampul (NDC 0641-6026-05),Revised,10/12/2021,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7829,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 2 mL vial
(NDC 0641-6027-25)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7830,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 5 mL vial
(NDC 0641-6028-25)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7831,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL vial (NDC 0641-6029-25),Revised,10/12/2021,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing and available in the November - December 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,not available
7832,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL  50 mL vial
(NDC 0641-6030-01)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7833,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule 10 pack (NDC 17478-0030-02),Revised,2/12/2021,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7834,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule; 25 pack (NDC 17478-0030-25),Revised,2/12/2021,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,,2021,discontinued
7835,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 10 pack (NDC 17478-0030-05),Revised,2/12/2021,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2021,available
7836,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,20 mL ampule (NDC 17478-0030-20),Revised,2/12/2021,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,,2021,discontinued
7837,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 25 pack (NDC 17478-0030-55),Revised,2/12/2021,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,,2021,discontinued
7838,Finasteride Tablets,Mylan Pharmaceuticals Inc.,5 mg tablet (NDC 0378-5036-05)(NDC 0378-5036-77)(NDC 0378-5036-93),New,5/23/2018,,The discontinuation of this product is a business decision,,,Urology,To be Discontinued,5/23/2018,5/23/2018,,2021,discontinued
7839,Finasteride Tablets,Teva Pharmaceuticals,5 mg 30 CT (NDC 45963-500-30),New,9/18/2020,,"Teva’s Finasteride 5 mg Tablets marketed under NDC 0093-7355-56, NDC 0093-7355-05 & NDC 0093-7355-98 are not affected by this discontinuation.",,,Urology,To be Discontinued,9/18/2020,9/18/2020,,2021,discontinued
7840,Finasteride Tablets,Teva Pharmaceuticals,5 mg 90 CT (NDC 45963-500-08),New,9/18/2020,,"Teva’s Finasteride 5 mg Tablets marketed under NDC 0093-7355-56, NDC 0093-7355-05 & NDC 0093-7355-98 are not affected by this discontinuation.",,,Urology,To be Discontinued,9/18/2020,9/18/2020,,2021,discontinued
7841,Finasteride Tablets,Teva Pharmaceuticals,"1mg tablet (NDC 45963-600-03, 45963-600-09)",New,9/18/2020,,This product discontinuation is a business related decision.,,,Urology,To be Discontinued,9/18/2020,9/18/2020,,2021,discontinued
7842,Finasteride Tablets,Teva Pharmaceuticals,5mg tablet (NDC 45963-500-02),New,9/18/2020,,This product discontinuation is a business related decision.,,,Urology,To be Discontinued,9/18/2020,9/18/2020,,2021,discontinued
7843,Floxuridine for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9270-01),Revised,10/12/2021,This presentation is temporarily on backorder.,,,Other,Oncology,Current,,,,2021,not available
7844,"Floxuridine for Injection, USP","Fresenius Kabi USA, LLC",500 mg per vial (NDC 63323-145-07_,New,9/30/2020,,"Discontinued: May 30, 2019",,,Oncology,To be Discontinued,9/30/2020,9/30/2020,,2021,discontinued
7845,Fludrocortisone Acetate Tablets,Teva Pharmaceuticals,"0.1 mg, 100 count bottle (NDC 0555-0997-02)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2021,
7846,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 100 count bottle (NDC 0115-7033-01)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2021,
7847,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 500 count bottle (NDC 0115-7033-02)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,8/7/2019,,,2021,
7848,Flumazenil Injection,Mylan,"0.5 mg in 5 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-447-53)",New,12/16/2019,,Expected Discontinuation April 2020,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,12/16/2019,12/16/2019,,2021,discontinued
7849,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-054-15),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7850,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-054-30),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7851,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-054-60),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7852,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-040-15),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7853,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-040-30),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7854,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-040-60),New,6/21/2021,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/2021,6/21/2021,,2021,discontinued
7855,Fluocinonide Topical Solution,Teva Pharmaceuticals,0.5 mg/mL  (NDC 0472-0829-02),New,8/3/2021,,,,,Dermatology,To be Discontinued,8/3/2021,8/3/2021,,2021,discontinued
7856,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 1.0 mg 100 sterile strips (NDC 17478-404-01),Revised,6/4/2021,,,Available,,Ophthalmology,Resolved,6/4/2021,,,2021,
7857,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 0.6 mg 300 sterile strips (NDC 17478-403-03),Revised,6/4/2021,,,Available,,Ophthalmology,Resolved,6/4/2021,,,2021,
7858,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 100 Strips per box (ndc 17238-900-11),Revised,6/4/2021,,,Available,,Ophthalmology,Resolved,6/4/2021,,,2021,
7859,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 300 Strips per box (NDC 17238-900-30),Revised,6/4/2021,,,Available,,Ophthalmology,Resolved,6/4/2021,,,2021,
7860,Fluorometholone Ophthalmic Ointment,Abbvie,FML (flourometholone) Ointment 0.1% 1 TUBE in 1 CARTON  3.5 g in 1 TUBE (NDC 0023-0316-04),New,9/13/2021,,Discontinuation of the manufacture of the drug,,,Ophthalmology,To be Discontinued,9/13/2021,9/13/2021,,2021,discontinued
7861,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 100 count bottle (NDC 0781-2823-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7862,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 1000 count bottle (NDC 0781-2823-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7863,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 100 count bottle (NDC 0781-2822-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7864,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 1000 count bottle (NDC 0781-2822-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7865,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 100 count bottle (NDC 0781-2824-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7866,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 1000 count bottle (NDC 0781-2824-10)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7867,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 30 count bottle (NDC 0781-2824-31)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
7868,Fluoxetine Tablets,Allergan Pharmaceuticals International Limited,"Fluoxetine (Sarafem) Tablets, 10 mg (NDC 0430-0210-14)",New,12/22/2020,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/22/2020,12/22/2020,,2021,discontinued
7869,Fluoxetine Tablets,Allergan Pharmaceuticals International Limited,"Fluoxetine (Sarafem) Tablets, 20 mg (NDC 0430-0220-14)",New,12/22/2020,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/22/2020,12/22/2020,,2021,discontinued
7870,Fluticasone Inhalational Powder,GlaxoSmithKline,"100 mcg, 28 blisters (NDC 0173-0602-00)",New,4/23/2021,,This product discontinuation is a business-related decision. GSK has ceased distribution of this product. The 60-blister presentation will continue to be available.,,,Pulmonary/Allergy,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
7871,Fluticasone Inhalational Powder,GlaxoSmithKline,"250 mcg, 28 blisters (NDC 0173-0601-00)",New,4/23/2021,,This product discontinuation is a business-related decision. The anticipated date that GSK will cease distribution of the product is approximately July 2021. The 60-blister presentation will continue to be available.,,,Pulmonary/Allergy,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
7872,Fluvoxamine ER Capsules,Par Pharmaceutical,100 mg. 30’s count (NDC 10370-175-11),Revised,1/15/2021,Product available,,,Delay in shipping of the drug,Psychiatry,Current,,,,2021,available
7873,Fluvoxamine ER Capsules,Par Pharmaceutical,150 mg. 30’s count (NDC 10370-176-11),Revised,1/15/2021,On backorder. Estimated availability February 2021,,,Delay in shipping of the drug,Psychiatry,Current,,,,2021,not available
7874,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03)",Reverified,11/8/2021,Product is available,,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,,2021,available
7875,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03)",Reverified,11/8/2021,Available,,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,,2021,available
7876,Fosphenytoin Sodium Injection,"Mylan Institutional, a Viatris company","100 mg/2 mL, package of 25 vials (NDC 67457-516-25)",New,9/3/2021,,,,,Neurology;Pediatric,To be Discontinued,9/3/2021,9/3/2021,,2021,discontinued
7877,Fosphenytoin Sodium Injection,"Mylan Institutional, a Viatris company","500 mg/10 mL, package of 10 vials (NDC 67457-517-01)",New,8/4/2021,,,,,Neurology;Pediatric,To be Discontinued,8/4/2021,8/4/2021,,2021,discontinued
7878,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",20 mg/2mL vial (NDC 70860-302-41 and 70860-302-02),New,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2021,available
7879,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",40 mg/4mL vial (NDC 70860-302-42 and 70860-302-04),New,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2021,available
7880,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",100 mg/10mL vial (NDC 70860-302-43 and 70860-302-10),New,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,,2021,available
7881,Furosemide Injection,Gland Pharma Limited,"2 mL in 1 vial, 25 vials/carton (NDC 25021-311-02)",Reverified,7/16/2021,Available,Marketing partner: Sagent Pharmaceuticals,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7882,Furosemide Injection,Gland Pharma Limited,"4 mL in 1 vial, 25 vials/carton (NDC 25021-311-04)",Reverified,7/16/2021,Available,Marketing partner: Sagent Pharmaceuticals,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7883,Furosemide Injection,Gland Pharma Limited,"10 mL in 1 vial, 25 vials/carton (NDC 25021-311-10)",Reverified,7/16/2021,Available,Marketing partner: Sagent Pharmaceuticals,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7884,Furosemide Injection,Sagent Pharmaceuticals,20 mg/2 mL single-dose vial (NDC 25021-311-02),Reverified,10/22/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7885,Furosemide Injection,Sagent Pharmaceuticals,40 mg/4 mL single-dose vial (NDC25021-311-04),Reverified,10/22/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7886,Furosemide Injection,Sagent Pharmaceuticals,100 mg/10 mL single-dose vial (NDC 25021-311-10),Reverified,10/22/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7887,Furosemide Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-02)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7888,Furosemide Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-04)",Reverified,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,not available
7889,Furosemide Injection,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-10)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
7890,Furosemide Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/2 mL single-dose vial (NDC 55150-322-25),Reverified,11/5/2021,"Currently on backorder, next shipment TBD",Check wholesalers for inventory,,Delay in shipping of the drug,Cardiovascular,Current,,,,2021,not available
7891,Furosemide Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),40 mg/4 mL single-dose vial (NDC 55150-323-25),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Cardiovascular,Current,,,,2021,available
7892,Furosemide Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),100 mg/10 mL single-dose vial (NDC 55150-324-25),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Cardiovascular,Current,,,,2021,available
7893,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 10 mL Single Dose Glass Vial (25 x 10 mL) (NDC 36000-284-25)",Reverified,11/23/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7894,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 2 mL Single Dose Glass Vial (25 x 2 mL)(NDC 36000-282-25)",Reverified,11/23/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7895,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 4 mL Single Dose Glass Vial (25 x 4 mL)(NDC 36000-283-25)",Reverified,11/23/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7896,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,20 mg/mL (NDC 23155-473-41),Reverified,10/13/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7897,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,40 mg/4mL (NDC 23155-473-42),Reverified,10/13/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7898,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,100 mg/10mL (NDC 23155-473-44),Reverified,10/13/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7899,Furosemide Injection,"Hospira, Inc.",20 mg/2 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-02),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Other,Cardiovascular,Current,,,,2021,limited availability
7900,Furosemide Injection,"Hospira, Inc.",40 mg/4 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-04),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,limited availability
7901,Furosemide Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL): Single Dose Glass Fliptop Vial (NDC 0409-6102-10),Revised,11/18/2021,Available,,,Other,Cardiovascular,Current,,,,2021,available
7902,Furosemide Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL; Ansyr Plastic syringe (NDC 0409-1639-10),Revised,11/18/2021,Limited Supply Available.,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,limited availability
7903,Furosemide Injection,"Hospira, Inc.",40 mg/4 mL (10 mg/mL); Ansyr Plastic syringe (NDC 0409-9631-04),Revised,11/18/2021,Limited Supply Available.,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,limited availability
7904,Furosemide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",80mg (NDC 0378-0232-05),New,4/7/2021,,,,,Cardiovascular,To be Discontinued,4/7/2021,4/7/2021,,2021,discontinued
7905,Gemcitabine Hydrochloride Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","200 mg, single dose vial (NDC 67457-464-20)",New,6/26/2020,,Expected discontinuation December 2020,,,Oncology,To be Discontinued,6/26/2020,6/26/2020,,2021,discontinued
7906,Gemcitabine Hydrochloride Injection,Mylan Institutional,"1 g, single dose vial (NDC 67457-462-01)",New,12/16/2019,,Expected Discontinuation March/April 2020,,,Oncology,To be Discontinued,12/16/2019,12/16/2019,,2021,discontinued
7907,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 7 Tablets in 1 Blister Pack (NDC 44004-321-07)",Reverified,11/10/2021,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,,2021,unclear
7908,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 5 Tablets in 1 Blister Pack (NDC 44004-321-05)",Reverified,11/10/2021,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,,2021,unclear
7909,Gentamicin Sulfate and Prednisolone Acetate Ophthalmic Ointment,Abbvie,PRED-G- gentamicin sulfate 0.3% and prednisolone acetate 0.6% ointment 1 TUBE in 1 CARTON  3.5 g in 1 TUBE (NDC 0023-0066-04),New,9/13/2021,,Discontinuation of the manufacture of the drug,,,Ophthalmology,To be Discontinued,9/13/2021,9/13/2021,,2021,discontinued
7910,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","80 mg per 2 mL (40 mg per mL), MDV, (NDC 63323-010-02)",Revised,11/23/2021,Backordered. Next release January 2022.,Check wholesaler inventory,,Manufacturing delay,Anti-Infective,Current,,,,2021,not available
7911,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","800 mg per 20 mL (40 mg per mL), MDV, (NDC 63323-010-20)",Revised,11/23/2021,Available,Check wholesaler inventory,,,Anti-Infective,Current,,,,2021,available
7912,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Pediatric SDV, (NDC 63323-173-02)",Revised,11/23/2021,Available,Check wholesaler inventory,,Manufacturing delay,Anti-Infective,Current,,,,2021,available
7913,Gentamicin Sulfate Injection,"Hospira, Inc.",80 mg/2 mL (40 mg/mL); 2 mL Single Dose Glass Fliptop Vial (NDC 00409-1207-03),Revised,11/18/2021,Next Delivery: December 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Anti-Infective,Current,,,,2021,not available
7914,Gentamicin Sulfate Injection,"Hospira, Inc.",80 mg/2 mL (40 mg/mL) Single Dose Glass Fliptop Vial NovaPlus (NDC 00409-1207-25),Revised,11/18/2021,Available,,,Other,Anti-Infective,Current,,,,2021,available
7915,Glipizide Tablets,Teva Pharmaceuticals,"5mg tablets (NDC 0591-0460-10), (NDC 0591-0460-05), (NDC 0591-0460-01)",New,5/28/2020,,"Teva had evaluated the market and made decision to discontinue the product. No inventory remains for Glipizide 5 mg tablets 100 count NDC: 0591-0460-01. For the remaining presentations, allocations are being made based on customer Rx trends.",,,Endocrinology/Metabolism,To be Discontinued,5/28/2020,5/28/2020,,2021,discontinued
7916,Glipizide Tablets,Teva Pharmaceuticals,"10mg tablets, (NDC 0591-0461-10), (NDC 0591-0461-01), (NDC 0591-0461-05)",New,5/28/2020,,"Teva had evaluated the market and made decision to discontinue the product. No inventory remains for Glipizide 5 mg tablets 100 count NDC: 0591-0460-01. For the remaining presentations, allocations are being made based on customer Rx trends.",,,Endocrinology/Metabolism,To be Discontinued,5/28/2020,5/28/2020,,2021,discontinued
7917,Guanfacine Hydrochloride Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",1 mg (NDC 0378-1160-01),Reverified,11/29/2021,Unavailable,,,Other,Cardiovascular,Current,,,,2021,not available
7918,Guanfacine Hydrochloride Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",2 mg (NDC 0378-1190-01),Reverified,11/29/2021,Unavailable,,,Other,Cardiovascular,Current,,,,2021,not available
7919,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,1mg tablets 100 count bottle (NDC 0591-0444-01),Revised,11/8/2021,Available,,,,Cardiovascular,Current,,,,2021,available
7920,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,2 mg tablets 100 count bottle (NDC 0591-0453-01),Revised,11/8/2021,On backorder,Recovery: December 2021,,,Cardiovascular,Current,,,,2021,not available
7921,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,1 mg bottles of 30 (NDC 65162-711-03); 1 mg bottles of 100 (NDC 65162-711-10),Reverified,8/17/2020,Available,,,Other,Cardiovascular,Current,,,,2021,available
7922,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,2 mg bottles of 30 (NDC 65162-713-03); 2 mg bottles of 100 (NDC 65162-713-10); 2 mg bottles of 500 (NDC 65162-713-50),Reverified,8/17/2020,Available,,,Other,Cardiovascular,Current,,,,2021,available
7923,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 1 mg, 100 Count (NDC 42806-048-01)",Reverified,2/23/2021,Available,,,Other,Cardiovascular,Current,,,,2021,available
7924,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 2 mg, 100 Count (NDC 42806-296-01)",Reverified,2/23/2021,Available,,,Other,Cardiovascular,Current,,,,2021,available
7925,Guanidine Hydrochloride Tablets,Merck Sharp & Dohme Corp.,125 mg tablets (NDC 0085-0492-01),New,9/28/2020,,To be discontinued on or near October 2020.,,,Neurology,To be Discontinued,9/28/2020,9/28/2020,,2021,discontinued
7926,Haloperidol Lactate (Haldol) Injection,"Janssen Biotech, Inc.","5 mg/mL, 10 ampule in 1 box, > 1 mL in 1 ampule, (NDC 50458-255-01)",New,11/13/2020,,Product discontinuation as per business decision,,,Psychiatry,To be Discontinued,11/13/2020,11/13/2020,,2021,discontinued
7927,Haloperidol Lactate Injection,Patriot Pharmaceuticals,"5 mg/mL, 10 ampule in 1 box,> 1 mL in 1 ampule, (NDC 10147-0911-1)",New,11/13/2020,,Product discontinuation as per business decision,,,Psychiatry,To be Discontinued,11/13/2020,11/13/2020,,2021,discontinued
7928,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,0.5 mg (NDC 0378-0351-01) and (NDC 0378-0351-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7929,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-0257-01) and (NDC 0378-0257-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7930,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0214-01) and (NDC 0378-0214-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7931,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-0327-01) and (NDC 0378-0327-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7932,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0334-01),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7933,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,20 mg (NDC 0378-0355-01),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7934,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 100 CT (NDC 68382-079-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2021,
7935,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 1000 CT (NDC 68382-079-10),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2021,
7936,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 10MG 100 CT (NDC 68382-080-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2021,
7937,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 20MG 100 CT (NDC 68382-081-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,11/20/2019,,,2021,
7938,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-13-9101),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7939,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-83-9101),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7940,Haloperidol Tablets,Sandoz,0.5 mg 100 count unit dose (NDC 0781-13-9113),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7941,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-13-9201),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7942,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-83-9201),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7943,Haloperidol Tablets,Sandoz,1 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7944,Haloperidol Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-13-9801),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7945,Haloperidol Tablets,Sandoz,2 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7946,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-13-9610),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7947,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-83-9610),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7948,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-13-9601),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7949,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-83-9601),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7950,Haloperidol Tablets,Sandoz,5 mg 100 count unit dose (NDC 0781-13-9613),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7951,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-13-9701),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7952,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-83-9701),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7953,Haloperidol Tablets,Sandoz,10 mg 100 count unit dose (NDC 0781-13-9713),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7954,Haloperidol Tablets,Sandoz,20 mg 100 count bottle (NDC 0781-83-9301),Revised,11/20/2019,,,,,Psychiatry,Resolved,11/20/2019,,,2021,
7955,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 2,000 USP units in 1000 mL.  Product code 2B0944  (NDC 0338-0433-04)",Revised,11/23/2021,Available,,,Manufacturing Delay,Hematology,Current,,,,2021,available
7956,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 1,000 USP units in 500 mL.  Product code 2B0953 (NDC 0338-0431-03)",Revised,11/23/2021,Unavailable,Product code 2B0953 was replaced with code AHB0953U,,Other,Hematology,Current,,,,2021,not available
7957,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","1,000 Units/500 mL (2 Units/mL); Flexible Container (NDC 00409-7620-03)",Reverified,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Hematology,Current,,,,2021,limited availability
7958,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","2,000 Units/1000 mL (2 Units/mL); Flexible Container (NDC 00409-7620-59)",Reverified,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Hematology,Current,,,,2021,limited availability
7959,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection, 1,000 units / 500 mL (2 units / mL) in VIAFLEX Plastic Container.  Product code AHB0953U (NDC 0338-0424-18)",Revised,11/23/2021,Available,Product code AHB0953U replaces code 2B0953,,,Hematology,Current,,,,2021,available
7960,Heparin Sodium and Sodium Chloride 0.9% Injection,Sagent Pharmaceuticals,1000 units/mL 10mL pack 25 (NDC 25021-400-10),Revised,10/22/2021,On backorder.,,,Demand increase for the drug,Hematology,Current,,,,2021,not available
7961,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","1,000 Units/500 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-77)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Other,Hematology,Current,,,,2021,available
7962,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","2,000 Units/1000 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-10)",Revised,11/23/2021,Backordered. Next release January 2022.,Check wholesaler for inventory,,Other,Hematology,Current,,,,2021,not available
7963,Histrelin Acetate Implant,"Endo Pharmaceuticals, Inc.",Vantas 50 mg Implantation Kit (NDC 67979-500-01),Revised,9/21/2021,,Endo has made a business decision to discontinue manufacture of this product.,,,Oncology,To be Discontinued,9/21/2021,9/21/2021,,2021,discontinued
7964,Hydralazine Hydrochloride Injection,American Regent/Luitpold,20mg/ml SDV ( NDC 0517 - 0901-25 ),Revised,6/29/2021,,,Available,,Cardiovascular,Resolved,6/29/2021,,,2021,
7965,Hydralazine Hydrochloride Injection,"Fresenius Kabi USA, LLC","20 mg per mL, SDV (NDC 63323-614-01)",Revised,6/29/2021,,,Available,,Cardiovascular,Resolved,6/29/2021,,,2021,
7966,Hydralazine Hydrochloride Injection,Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 10) (NDC 17478-934-01)",Revised,6/29/2021,,,,,Cardiovascular,Resolved,6/29/2021,,,2021,
7967,Hydralazine Hydrochloride Injection,Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 25) (NDC 17478-934-15)",Revised,6/29/2021,,,,,Cardiovascular,Resolved,6/29/2021,,,2021,
7968,Hydralazine Hydrochloride Injection,"Mylan Institutional, a Viatris company",20 mg / 1 ml] 25PK (NDC 67457-291-01),Revised,6/29/2021,,,,,Cardiovascular,Resolved,6/29/2021,,,2021,
7969,Hydralazine Hydrochloride Injection,"X-GEN Pharmaceuticals, Inc.",20 mg/mL per vial (NDC 39822-0500-4),Revised,6/29/2021,,,,,Cardiovascular,Resolved,6/29/2021,,,2021,
7970,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,20 mg/25 mg (NDC 0378-2025-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
7971,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,12.5 mg/ 20 mg (NDC 0378-2012-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
7972,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,10 mg/ 12.5 mg (NDC 0378-1012-01),New,5/22/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
7973,Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution,Perrigo Pharmaceuticals,Hydrocodone Bitartrate (5 mg/5 mL) and Homatropine Methylbromide (1.5 mg/5 mL)(NDC 0574-1105-16),New,6/5/2018,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,6/5/2018,6/5/2018,,2021,discontinued
7974,Hydrocodone/Homatropine Tablets,Lupin,5/1.5 mg (NDC 43386-0118-03),New,12/28/2020,,This discontinuation is a business decision. We have no plans to re-enter the market at this time.,,,Pulmonary/Allergy,To be Discontinued,12/28/2020,12/28/2020,,2021,discontinued
7975,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 12 suppositories (NDC 59741-301-12),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
7976,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 24 suppositories (NDC 59741-301-24),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
7977,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 100 suppositories (NDC 59741-301-01),New,11/25/2019,,,,,Other;Urology,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
7978,Hydrocortisone Tablets,Pfizer Pharmaceuticals,5 mg tablet; bottle of 50 (NDC 59762-0073-1),Reverified,11/18/2021,Available,,,Other,Endocrinology/Metabolism,Current,,,,2021,available
7979,Hydrocortisone Tablets,Pfizer Pharmaceuticals,10 mg tablet; bottle of 100 (NDC 59762-0074-1),Reverified,11/18/2021,Available,,,Other,Endocrinology/Metabolism,Current,,,,2021,available
7980,Hydrocortisone Tablets,Pfizer Pharmaceuticals,20 mg tablet; bottle of 100 (NDC 59762-0075-1),Reverified,11/18/2021,Available,,,Other,Endocrinology/Metabolism,Current,,,,2021,available
7981,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 20 mg tablet; bottle of 100 (NDC 0009-0044-01),Reverified,11/18/2021,Available,,,Other,Endocrinology/Metabolism,Current,,,,2021,available
7982,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 5 mg tablet; bottle of 50 (NDC 0009-0012-01),Reverified,11/18/2021,Available,,,Other,Endocrinology/Metabolism,Current,,,,2021,available
7983,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 10 mg tablet; bottle of 100 (NDC 0009-0031-01),Reverified,11/18/2021,Available,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2021,available
7984,Hydrocortisone Tablets,"Vensun Pharmaceuticals, Inc.","5 mg, 50 count bottles (NDC 64380-970-25)",Reverified,11/2/2021,Available,,,,Endocrinology/Metabolism,Current,,,,2021,available
7985,Hydrocortisone Tablets,"Vensun Pharmaceuticals, Inc.","10 mg, 100 count bottles (NDC 64380-971-06)",Reverified,11/2/2021,Available,,,,Endocrinology/Metabolism,Current,,,,2021,available
7986,Hydrocortisone Tablets,"Vensun Pharmaceuticals, Inc.","20 mg, 100 count bottles (NDC 64380-972-06)",Reverified,11/2/2021,Available,,,,Endocrinology/Metabolism,Current,,,,2021,available
7987,Hydrocortisone Tablets,Amneal Pharmaceutical,100mg/100 count (NDC 00115-1697-01),Reverified,5/24/2021,Available,,,,Endocrinology/Metabolism,Current,,,,2021,available
7988,Hydrocortisone Tablets,Amneal Pharmaceutical,20mg/100 count (NDC 00115-1700-01),Reverified,5/24/2021,Available,,,,Endocrinology/Metabolism,Current,,,,2021,available
7989,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.2 mg per 1 mL, prefilled syringe, MicroVault packaging (NDC 76045-121-11)",Revised,11/23/2021,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,available
7990,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe, MicroVault packaging (NDC 76045-010-11)",Revised,11/23/2021,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,available
7991,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)                                                                                           Microvault",Revised,11/23/2021,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,available
7992,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-11)                                                                                                                                                                                     Microvault",Revised,11/23/2021,Backordered. Next release November 2021.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,not available
7993,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","1 mg per 1 mL, Single dose vial, (NDC 63323-852-25)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
7994,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-853-25)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
7995,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-854-10)",Revised,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
7996,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-10)",Revised,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
7997,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","50 mg per 5 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-15)",Revised,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
7998,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-50)",Revised,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
7999,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-05)",Revised,11/23/2021,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,unclear
8000,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-10)                                                                                                                                       Blister pack",Revised,11/23/2021,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,unclear
8001,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe (NDC 76045-010-10)",Revised,11/23/2021,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8002,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 4 mg per 1 mL, prefilled syringe (NDC 76045-011-10)",Revised,11/23/2021,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8003,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1ML (NDC0703-0110-03),Reverified,11/8/2021,Available,,,,Analgesia/Addiction,Current,,,,2021,available
8004,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1ML (NDC 0703-0113-03),Reverified,11/8/2021,Available,,,,Analgesia/Addiction,Current,,,,2021,available
8005,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1 ML (NDC 0703-0018-01),Reverified,11/8/2021,Available,,,,Analgesia/Addiction,Current,,,,2021,available
8006,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 1 mL vial (NDC 0641-0121-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8007,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0641-2341-41)",Reverified,10/12/2021,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8008,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",0.5 mg/0.5 mL (1 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-05),Reverified,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2021,limited availability
8009,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/1 mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-10),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8010,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1312-10),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8011,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1283-31),Reverified,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8012,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1312-30),Reverified,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2021,limited availability
8013,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",4 mg/1 mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1304-31),Reverified,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8014,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/mL); Glass Ampul (NDC 00409-2552-01),Reverified,11/18/2021,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8015,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Glass Ampul (NDC 00409-3356-01),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8016,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",4 mg/1 mL (4 mg/mL); Glass Ampul (NDC 00409-2540-01),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8017,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3365-01),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8018,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-01),Reverified,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8019,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-05),Reverified,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8020,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-50),Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8021,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)",Reverified,5/19/2021,Available,,,,Analgesia/Addiction,Current,,,,2021,available
8022,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)",Reverified,5/19/2021,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8023,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)",Reverified,5/19/2021,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8024,Hydroxocobalamin Injection,SERB SA,"Hydroxocobalamin Injection (Cyanokit) intravenous powder for solution for injection, 5 gram, vial, (NDC 11704-0370-01)",Reverified,11/12/2021,Available,Product Is distributed by Meridian Medical Technologies.  Contact number: 1-800-638-8093,Other,Other,Endocrinology/Metabolism,Current,,,,2021,available
8025,Hydroxocobalamin Injection,Teva Pharmaceuticals,"Hydroxocobalamin Injection 1000MCG/ML, 1X30ML(NDC 0591-2888-30)",Reverified,11/8/2021,Available,,,Other,Endocrinology/Metabolism,Current,,,,2021,available
8026,Hydroxychloroquine Sulfate Tablets,Teva Pharmaceuticals,"200 mg, 500 count bottle (NDC 0591-3041-05)",New,12/7/2020,,Teva made a business decision to discontinue this product.,,,Anti-Infective;Rheumatology,To be Discontinued,12/7/2020,12/7/2020,,2021,discontinued
8027,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),Hydroxyprogesterone Caproate Injection USP 250 mg/1 mL single-dose vial (NDC 55150-309-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8028,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),"Hydroxyprogesterone Caproate Injection USP 1,250 mg/5 mL multiple-dose vial (NDC 55150-310-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8029,Hydroxyprogesterone Caproate Injection,Slayback Pharma,Hydroxyprogesterone Caproate Injection 250 mg/ 1 ml (NDC 71225-105-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8030,Hydroxyprogesterone Caproate Injection,American Regent/Luitpold,"Hydroxyprogesterone Caproate Injection, USP 250mg/mL 1mL Single Dose Vial (NDC 0517-1767-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8031,Hydroxyprogesterone Caproate Injection,Slayback Pharma,"Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml (NDC 71225-104-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8032,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single dose auto-injector 1.1mL for subcutaneous injection: (NDC 64011-247-02),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8033,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8034,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Multi-dose vial 5mL for intramuscular injection: (NDC 64011-243-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8035,Hydroxyprogesterone Caproate Injection,Prasco Laboratories,Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/2019,,,,,Reproductive,Resolved,8/2/2019,,,2021,
8036,Hydroxypropyl (Lacrisert) Cellulose Ophthalmic Insert,"Bausch Health Americas, Inc.","Lacrisert, 5 mg per ophthalmic insert, 60 unit dose blister pack (NDC 24208-800-60)",Revised,9/8/2021,"Unavailable, Resupply expected February 2022",,,Other,Ophthalmology,Current,,,,2021,not available
8037,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,100 mg 100 count (NDC 0555-0324-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8038,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 100 count (NDC 0555-0323-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8039,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 500 count (NDC 0555-0323-04),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8040,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 100 count (NDC 0555-0302-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8041,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 500 count (NDC 0555-0302-04),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8042,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 100 count (NDC 0185-0674-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8043,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 500 count (NDC 0185-0674-05),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8044,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8045,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8046,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8047,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8048,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8049,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8050,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8051,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8052,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8053,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66),Revised,2/17/2021,,,,,Psychiatry,Resolved,2/17/2021,,,2021,
8054,Imipenem and Cilastatin for Injection,Merck Sharp & Dohme Corp.,500 mg  imipenem  equivalent  and  500 mg  cilastatin  equivalent  and  20 mg  sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3516-59),Reverified,11/15/2021,Product is available,"For additional information, please contact: Merck National Service Center at 1-800-672-6372",,Demand increase for the drug,Anti-Infective,Current,,,,2021,available
8055,Imipenem and Cilastatin for Injection,"Fresenius Kabi USA, LLC","250 mg/250 mg per vial, single dose vial, sterile powder (NDC 63323-349-25)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,,2021,available
8056,Imipenem and Cilastatin for Injection,"Fresenius Kabi USA, LLC","500 mg/500 mg per vial, single dose vial, sterile powder (NDC  63323-322-25)",Reverified,11/23/2021,Available,Check wholesaler for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,,2021,available
8057,Indinavir (CRIXIVAN) Capsules,Merck Sharp & Dohme Corp.,200 mg capsules (NDC 0006-0571-43),New,9/21/2020,,,,,Antiviral,To be Discontinued,9/21/2020,9/21/2020,,2021,discontinued
8058,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 100s (NDC 0378-0143-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8059,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 1000s (NDC 0378-0143-10)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8060,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 100s (NDC 0378-0147-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8061,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 500s (NDC 0378-0147-05)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8062,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4350-01)",New,4/23/2021,,To be discontinued on or near March 2022,,,Antiviral,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8063,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4351-01)",New,4/23/2021,,To be discontinued on or near March 2022,,,Antiviral,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8064,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01)",New,4/23/2021,,To be discontinued on or near March 2022,,,Antiviral,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8065,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Solution for Injection (Interferon alfa-2b), 18 million IU multidose vial (22.8 million IU per 3.8 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1168-01)",New,4/23/2021,,To be discontinued on or near July 2021,,,Antiviral,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8066,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Solution for Injection (Interferon alfa-2b), 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1133-01)",New,4/23/2021,,To be discontinued on or near June 2021,,,Antiviral,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8067,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 41% (Isovue 200), 10x50mL vial, (NDC 0270-1314-30)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8068,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 41% (Isovue 200M), 10x20mL vial, (NDC 0270-1411-25)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8069,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250),  10x150mL bottle, (NDC 0270-1317-09)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8070,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250),  10x50mL bottle, (NDC 0270-1317-05)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8071,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250 PBP),  10x200mL bottle, (NDC 0270-1317-41)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8072,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300), 10x75mL bottle, (NDC 0270-1315-47)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8073,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300 PBP), 6x500mL bottle, (NDC 0270-1315-98)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8074,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300 PBP), 10x200mL bottle, (NDC 0270-1315-41)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8075,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 76% (IsoVue 370 PBP), 6x500mL bottle, (NDC 0270-1316-98)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8076,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 76% (IsoVue 370 PBP), 10x200mL bottle, (NDC 0270-1316-41)",New,7/1/2021,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/2021,7/1/2021,,2021,discontinued
8077,Ipratropium Bromide Inhalation Solution,Teva Pharmaceuticals,"0.5 mg/2.5 mL  (NDCs 0591-3798-30, 0591-3798-60, and 0591-3798-83)",New,12/15/2020,,,,,Pulmonary/Allergy,To be Discontinued,12/15/2020,12/15/2020,,2021,discontinued
8078,Isoniazid Injection,Sandoz,10 mL (100 mg/mL) Multiple dose vial (NDC 0781-3056-70),Reverified,11/16/2021,Unavailable. Estimated recovery: TBD,,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,,2021,not available
8079,Isoniazid Tablets,Teva Pharmaceuticals,300 mg 1000 count (NDC 0555-0071-05),New,10/27/2020,,Teva made a business decision to discontinue the 1000 count presentation. The other presentations of Isoniazid Tablets product remain active.,,,Anti-Infective,To be Discontinued,10/27/2020,10/27/2020,,2021,discontinued
8080,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9509-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Anesthesia,Current,,,,2021,available
8081,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL vial (NDC 0143-9508-10)",Revised,10/12/2021,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8082,Ketamine Injection,Par Pharmaceutical,"10 mg/mL, 20 mL MDV (NDC 42023-113-10)",Revised,7/7/2021,Product Available – Please Check Wholesalers for Availability,,,,Anesthesia,Current,,,,2021,unclear
8083,Ketamine Injection,Par Pharmaceutical,"100 mg/mL, 5 mL MDV (NDC 42023-115-10)",Revised,7/7/2021,Product Available – Please Check Wholesalers for Availability,,,,Anesthesia,Current,,,,2021,unclear
8084,Ketamine Injection,Par Pharmaceutical,"50 mg/mL, 10 mL MDV (NDC 42023-114-10)",Revised,7/7/2021,Product Available – Please Check Wholesalers for Availability,,,Demand increase for the drug,Anesthesia,Current,,,,2021,unclear
8085,Ketamine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),200 mg / 20 mL (NDC 67457-181-20),Reverified,11/5/2021,Available,Mylan label; Sporadic availability expected.,,,Anesthesia,Current,,,,2021,available
8086,Ketamine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),500 mg / 10 mL (NDC 67457-001-10),Reverified,11/5/2021,Currently on backorder - next shipment anticipated in November,Sporadic availability expected.,,,Anesthesia,Current,,,,2021,not available
8087,Ketamine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1000 mg / 10 mL (NDC 67457-108-10),Reverified,11/5/2021,Currently on backorder - next shipment anticipated in November,Mylan label; Sporadic availability expected.,,,Anesthesia,Current,,,,2021,not available
8088,Ketamine Injection,"Hospira, Inc.",500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2051-05),Revised,11/18/2021,Limited Supply Available. Next Delivery: April 2022; Estimated Recovery: August 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
8089,Ketamine Injection,"Hospira, Inc.",500 mg/10 mL (50 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2053-10),Revised,11/18/2021,Next Delivery and Estimated Recovery: February 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8090,Ketoprofen Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","200 mg Extended-Release Capsules, bottle of 100 (NDC 0378-8200-01)",Reverified,11/29/2021,Available,,,Other,Analgesia/Addiction;Rheumatology,Current,12/23/2016,,,2021,available
8091,Ketoprofen Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0093-3193-01)",Reverified,11/8/2021,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2021,not available
8092,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 100 count bottle (NDC 0093-3195-01)",Reverified,11/8/2021,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2021,not available
8093,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 500 count bottle (NDC 0093-3195-05)",Reverified,11/8/2021,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2021,not available
8094,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",New,11/25/2019,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
8095,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 69336-127-10)",Revised,1/19/2021,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,,2021,available
8096,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 69336-127-11)",Revised,1/19/2021,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,,2021,available
8097,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",Revised,1/19/2021,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2021,available
8098,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",Revised,1/19/2021,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,,2021,discontinued
8099,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",New,11/25/2019,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
8100,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","50 mg, 100 count bottle (NDC 23155-021-01)",Revised,1/19/2021,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2021,available
8101,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","75 mg, 100 count bottle (NDC 23155-022-01)",Revised,1/19/2021,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2021,available
8102,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 1 mL vial (NDC 72266-118-25)",Reverified,11/5/2021,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8103,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 2 mL vial (NDC 72266-119-25)",Reverified,11/5/2021,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Analgesia/Addiction,Current,,,,2021,available
8104,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 30 mg/ mL.  Single dose glass flip top vial - 25 units per carton (NDC 0338-0072-25)",Reverified,11/23/2021,Limited Supply,FOR INTRAVENOUS AND INTRAMUSCULAR USE. 30mg/mL (1 mL fill volume/ 2 mL container),,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,limited availability
8105,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-107-10)",Revised,11/23/2021,Backordered. Next release January 2022.,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2021,not available
8106,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-104-10)",Revised,11/23/2021,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2021,available
8107,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","60 mg per 2 mL, Single Dose, Simplist Syringe, (NDC 76045-105-20)",Revised,11/23/2021,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2021,available
8108,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 15 mg/mL. Single dose glass flip top vial. 10 units per carton (NDC 0338-0069-10)",Reverified,11/23/2021,Limited Supply,FOR INTRAVENOUS AND INTRAMUSCULAR USE. 15 mg/mL (1 mL fill volume/ 2 mL container),,,Analgesia/Addiction,Current,,,,2021,limited availability
8109,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","15 mg/mL, 1 mL vial (NDC 0641-6041-25)",Reverified,10/12/2021,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,unclear
8110,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 1 mL vial (NDC 0641-6042-25)",Reverified,10/12/2021,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,unclear
8111,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 2 mL vial (NDC 0641-6043-25)",Reverified,10/12/2021,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,unclear
8112,Ketorolac Tromethamine Injection,Gland Pharma Limited,15 mg/mL vial (NDC 70860-700-01 and 70860-700-02),Reverified,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8113,Ketorolac Tromethamine Injection,Gland Pharma Limited,30 mg/mL vial (NDC 70860-701-01 and 70860-701-03),Reverified,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8114,Ketorolac Tromethamine Injection,Gland Pharma Limited,60 mg/mL vial (NDC 70860-701-02 and 70860-701-04),Reverified,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8115,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 15MG/ML 25X1ML (NDC 25021-700-01),Reverified,10/22/2021,Backordered. Estimated availability TBD,,,Manufacturing delays,Analgesia/Addiction,Current,,,,2021,not available
8116,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X2ML (NDC 25021-701-02),Reverified,10/22/2021,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,,2021,not available
8117,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X1ML (NDC 25021-701-01),Reverified,10/22/2021,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,,2021,not available
8118,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-2287-23),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8119,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-31),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8120,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-61),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8121,Ketorolac Tromethamine Injection,"Hospira, Inc.",15 mg/mL (15 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3793-01),Reverified,11/18/2021,Next Delivery: December 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8122,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3795-01),Reverified,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,limited availability
8123,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3796-01),Reverified,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8124,Ketorolac Tromethamine Injection,Virtus Pharmaceuticals,30MG/ML (NDC 69543-0386-25),New,3/26/2018,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8125,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose Amber Vial, (NDC 63323-161-01)",Revised,11/23/2021,Backordered. Next release not available at this time.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2021,not available
8126,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-01)",Revised,11/23/2021,Backordered.  Next release December 2021.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2021,not available
8127,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-02)",Revised,11/23/2021,Backordered.  Next release December 2021.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/2015,,,2021,not available
8128,Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection,Sun Pharmaceutical Industries Inc.,5 Vial Kit (NDC 45567-0030-1),Revised,11/16/2021,Currently unavailable. Distribution is anticipated in late December 2021 to early January 2022.,Issues that led the shortage have been addressed but the timing for complete market recovery is unknown at this time.,,Other,Medical Imaging,Current,,,,2021,not available
8129,Lamivudine and Tenofovir Disoproxil Fumarate Tablets,"Celltrion, Inc.",300 mg; 300 mg (NDC 72606-002-01),New,9/1/2021,,,,,Antiviral,To be Discontinued,9/1/2021,9/1/2021,,2021,discontinued
8130,Lamivudine and Zidovudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine and Zidovudine Tablets 150mg and 300mg (NDC 0378-5180-91),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2021,discontinued
8131,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 100mg (NDC 0378-5168-93),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2021,discontinued
8132,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 150mg (NDC 0378-5169-91),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2021,discontinued
8133,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 300mg (NDC 0378-5170-93),New,3/16/2018,,,,,Antiviral,To be Discontinued,3/16/2018,3/16/2018,,2021,discontinued
8134,Lanoxin (digoxin) Tablets,Concordia Pharmaceuticals Inc.,Lanoxin (digoxin) 187.5 mcg (0.1875 mg) tablets; 100-count bottles (NDC 59212-245-55),New,5/22/2018,,"A business decision was made to discontinue manufacture and supply of the Lanoxin 187.5 mcg (0.1875 mg) strength tablets.  All existing lots on the market are good through expiry. The anticipated final date of availability for sale is June 30, 2018 (NDC 59212-245-55).",,,Cardiovascular,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
8135,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,480 mg injection (NDC 0006-5004-01),Revised,9/14/2021,,,Available,,Antiviral,Resolved,9/14/2021,9/14/2021,,2021,
8136,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,240 mg injection (NDC 0006-5003-01),Revised,9/14/2021,,,Available,,Antiviral,Resolved,9/14/2021,9/14/2021,,2021,
8137,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,"100mg/vial, 20mL (NDC 0703-5140-01)",Reverified,11/8/2021,Backordered – Estimated date of availability TBD,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2021,not available
8138,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,350mg/vial 30mL (NDC 0703-5145-01),Reverified,11/8/2021,Backordered – Estimated date of availability TBD,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2021,not available
8139,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",200 mg SDV (NDC 63323-710-50),Revised,11/23/2021,Available,Check Wholesaler Inventory,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/2013,,,2021,available
8140,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",500 mg SDV (NDC 63323-711-00),Revised,11/23/2021,Backordered. Next release December 2021.,Check Wholesaler Inventory,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2021,not available
8141,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,50 mg vial (NDC 25021-813-10),Revised,10/22/2021,Backordered. Estimated availability December 2021,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2021,not available
8142,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,100mg vial (NDC 25021-814-30),Revised,10/22/2021,Available,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/2013,,,2021,available
8143,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,200mg vial (NDC 25021-815-30),Revised,10/22/2021,Available.,,,,Oncology;Pediatric,Current,9/25/2013,,,2021,available
8144,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,350mg vial (NDC 25021-816-30),Revised,10/22/2021,Available.,,,,Oncology;Pediatric,Current,9/25/2013,,,2021,available
8145,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,500mg vial (NDC 25021-828-50),Revised,10/22/2021,Available,,,Manufacturing delay,Oncology;Pediatric,Current,,,,2021,available
8146,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg, 10 mL vial (NDC 0143-9555-01)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,available
8147,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg, 20 mL vial (NDC 0143-9554-01)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,available
8148,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","200 mg, 30 mL vial (NDC 0143-9553-01)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,available
8149,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","350 mg, 50 mL vial (NDC 0143-9552-01)",Revised,10/12/2021,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,not available
8150,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-10)",Revised,11/23/2021,Backordered. Next release January 2022.,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,,2021,not available
8151,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-50)",Revised,11/23/2021,Backordered. Next release January 2022.,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,,2021,not available
8152,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",100 mg vial (NDC 67457-528-10),Reverified,11/29/2021,Intermittent Supply,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,limited availability
8153,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",200 mg vial (NDC 67457-529-20),Reverified,11/29/2021,Intermittent Supply,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,limited availability
8154,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",350 mg vial (NDC 67457-530-35),Reverified,11/29/2021,Intermittent Supply,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2021,limited availability
8155,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 22.5 mg (NDC 62935-223-05),Reverified,7/29/2021,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8156,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 30 mg (NDC 62935-303-30),Reverified,7/29/2021,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8157,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 45 mg (NDC 62935-453-45),Reverified,7/29/2021,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8158,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Fensolvi 45 mg (NDC 62935-153-50),Reverified,7/29/2021,Available,Call customer service: 1-888-FENSOLVI,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8159,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 7.5 mg Kit (NDC 62935-753-75),Reverified,7/29/2021,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8160,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 30mg (NDC 0074-9694-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8161,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 22.5 mg PDS Kit (NDC 0074-3346-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8162,Leuprolide Acetate Injection,Abbvie,Lupron Depot 6 Months 45mg PDS Kit (NDC 0074-3473-03),Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8163,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 7.5 mg PDS Kit (NDC 0074-3642-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8164,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 4 Months 30 mg PDS Kit (NDC 0074-3683-03)",Revised,11/8/2021,Not Available; Next replenishment anticipated January 2022,,,Other,Endocrinology/Metabolism;Oncology,Current,,,,2021,not available
8165,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 3.75 mg PDS Kit (NDC 0074-3641-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8166,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 11.25 mg PDS Kit (NDC 0074-3663-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8167,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 11.25 mg PDS Kit (NDC 0074-2282-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8168,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 15 mg PDS Kit (NDC 0074-2440-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8169,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 7.5 mg PDS Kit (NDC 0074-2108-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8170,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 11.25mg (NDC 0074-3779-03)",Revised,11/8/2021,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2021,available
8171,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 500 mg (60 ct. bottle)(NDC 60505-3280-06),Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8172,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 750 mg (60 ct. bottle)(NDC 60505-3517-06),Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8173,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,500mg tablet 60 count bottle (NDC 4733557386),Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8174,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,750mg tablet 60 count bottle (NDC 4733557686),Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8175,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,500mg  60 count bottle (NDC 68180-117-07),Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8176,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,750mg 60 count bottle (NDC 68180-118-07),Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8177,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,500mg extended-release (NDC 50474-598-66),Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8178,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,750mg extended-release (NDC 50474-599-66),Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8179,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 60’s (NDC 43547-0345-06)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8180,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 500’s (NDC 43547-0345-50)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8181,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 60’s (NDC 43547-0346-06)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8182,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 500’s (NDC 43547-0346-50)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8183,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"250MG, (NDC 50474-594-40)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8184,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"500MG, (NDC 50474-595-40)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8185,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"750MG, (NDC 50474-596-40)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8186,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"1000MG, (NDC 50474-597-66)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8187,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"250mg, 120 count (NDC 65862024508)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8188,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"500mg , 120 count (NDC 65862024608)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8189,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"1000mg, 60 count (NDC 65862031560)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8190,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"750mg, 120 count (NDC 65862024708)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8191,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 90 Count Bottes (68180-112-09)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8192,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 120 Count Bottes (68180-112-16)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8193,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 500 Count Bottes (68180-112-02)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8194,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 90 Count Bottes (68180-113-09)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8195,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 90 Count Bottes (68180-114-09)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8196,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 500 Count Bottes (68180-114-02)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8197,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 120 Count Bottes (68180-113-16)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8198,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 500 Count Bottes (68180-113-02)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8199,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 120 Count Bottes (68180-114-16)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8200,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 1000 mg – 60 Count Bottes (68180-115-07)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8201,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 120 count (NDC 31722053612)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8202,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 500 count (NDC 31722053605)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8203,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 120 count (NDC 31722053712)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8204,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 500 count (NDC 31722053705)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8205,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 120 count (NDC 31722053812)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8206,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 500 count (NDC 31722053805)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8207,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 250mg – 120’s (NDC 43547-0221-15)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8208,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 120’s (NDC 43547-0222-15)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8209,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 1000’s (NDC 43547-0222-11)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8210,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 750mg – 120’s (NDC 43547-0223-15)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8211,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 1000mg – 60’s (NDC 43547-0224-06)",Revised,3/16/2021,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/2021,,,2021,
8212,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 120 count (NDC 0378-5613-78)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8213,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 500 count (NDC 0378-5613-05)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8214,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 500 count (NDC 0378-5615-05)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8215,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 120 count (NDC 0378-5615-78)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8216,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 120 count (NDC 0378-5617-78)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8217,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 500 count (NDC 0378-5617-05)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8218,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 1000 mg, 60 count (NDC 0378-5619-91)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8219,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"250mg, 120 count bottle (NDC 13668-014-12)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8220,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"500mg, 120 count bottle (NDC 13668-015-12)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8221,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 120 count bottle (NDC 13668-016-12)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8222,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 500 count bottle (NDC 13668-016-05)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8223,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"1000 mg, 60 count bottle (NDC 13668-017-60)",Revised,3/16/2021,,,,,Neurology,Resolved,3/16/2021,,,2021,
8224,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 5 mL (NDC 0591-3012-26)",New,4/27/2018,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/2018,4/27/2018,,2021,discontinued
8225,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 30 mL (NDC 0591-3012-30)",New,4/27/2018,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/2018,4/27/2018,,2021,discontinued
8226,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/500 mL (4mg/mL) in VIAFLEX Plus container. Product code 2B0973 (NDC 0338-0409-03)",Reverified,11/23/2021,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2021,available
8227,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/250 mL (8mg/mL) in VIAFLEX Plus container. Product code 2B0962 (NDC 0338-0411-02)",Reverified,11/23/2021,Available,,,,Cardiovascular,Current,,,,2021,available
8228,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.8% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5982 (NDC 00264-9598-20),Reverified,5/6/2021,Product available,,,Other,Cardiovascular,Current,,,,2021,available
8229,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5942 (NDC 00264-9594-20),Reverified,5/6/2021,Product available,,,Other,Cardiovascular,Current,,,,2021,available
8230,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 500mL Excel Plastic container P5941 (NDC 00264-9594-10),Reverified,5/6/2021,Product available,,,Other,Cardiovascular,Current,,,,2021,available
8231,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Ampoule (NDC 55150-158-72),Revised,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8232,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Ampoule (NDC 55150-159-74),Revised,11/5/2021,Available,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8233,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Ampoule (NDC 55150-160-72),Revised,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8234,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Single Dose Vial (NDC 55150-161-02),Revised,11/5/2021,Currently on backorder - next shipment anticipated early Nov,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8235,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Single Dose Vial (NDC 55150-162-05),Revised,11/5/2021,Currently on backorder - next shipment anticipated in November,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8236,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 30 mL Single Dose Vial (NDC 55150-163-30),Revised,11/5/2021,Available,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8237,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Single Dose Vial (NDC 55150-164-02),Revised,11/5/2021,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8238,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 5 mL Single Dose Vial (NDC 55150-165-05),Revised,11/5/2021,Available,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8239,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL, 50 mL vial (NDC 63323-0484-57)",Reverified,11/23/2021,Not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8240,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8241,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 2 mL vial (NDC 63323-0201-02)",Reverified,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8242,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 10 mL vial (NDC 63323-0201-10)",Reverified,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8243,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 20 mL vial (NDC 63323-0485-27)",Reverified,11/23/2021,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8244,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 50 mL vial (NDC 63323-0485-57)",Reverified,11/23/2021,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8245,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL vial (NDC 63323-0492-27)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8246,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)",Reverified,11/23/2021,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8247,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)",Reverified,11/23/2021,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8248,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL vial (NDC 63323-0492-57)",Reverified,11/23/2021,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8249,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial (NDC 63323-0492-37)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8250,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); Ansyr Plastic Syringe (NDC 0409-9137-05),Revised,11/18/2021,Available,,,Other,Anesthesia;Pediatric,Current,,,,2021,available
8251,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",20 mg/2 mL (1%; 10 mg/mL); Glass Ampul (NDC 0409-4713-32),Revised,11/18/2021,Available,,,Other,Anesthesia;Pediatric,Current,,,,2021,available
8252,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","200 mg/20 mL (1%; 10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-01, pack of 25; NDC 0409-4276-16, individual)",Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: October 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8253,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/30 mL (1%; 10 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4279-02),Revised,11/18/2021,Next Delivery: March 2022; Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8254,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","500 mg/50 mL (1%; 10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-02; NDC 0409-4276-17, individual)",Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8255,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",40 mg/2 mL (2%; 20 mg/mL); Glass Ampul (NDC 0409-4282-01),Revised,11/18/2021,Next Delivery: May 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8256,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/10 mL (2%; 20 mg/mL); Glass Ampul (NDC 0409-4282-02),Revised,11/18/2021,Next Delivery: January 2022; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8257,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4904-34),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,limited availability
8258,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (2%; 20 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4903-34),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2021,limited availability
8259,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (2%; 20 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-2066-05),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: May 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8260,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","400 mg/20 mL (2%; 20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-01, pack of 25; NDC 0409-4277-16, individual)",Revised,11/18/2021,Next Delivery: January 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8261,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","1,000 mg/50 mL (2%; 20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-02)",Revised,11/18/2021,Next Delivery: March 2022; Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8262,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/5 mL (4%; 40 mg/mL); Glass Ampul (NDC 0409-4283-01),Revised,11/18/2021,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8263,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",Xylocaine Cardiac 100 mg/5 mL (2%; 20 mg/mL); Ansyr Plastic Syringe (NDC 0409-1323-05),Revised,11/18/2021,Next Delivery: January 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2021,not available
8264,Lidocaine Hydrochloride (Xylocaine) Injection,"Amphastar Pharmaceuticals, Inc./IMS","2%, 5mL Luer-Jet Prefilled Syringe (NDC 76329-3390-1)
(old NDC 0548-3390-00)",Reverified,11/2/2021,Available,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8265,Lidocaine Hydrochloride (Xylocaine) Injection,American Regent/Luitpold,"1%, 50 mL vial package of 25 (NDC 00517-0625-25)",Reverified,3/30/2021,Unavailable-No product available for release. No plan to manufacture.,"American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection, USP",,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2021,discontinued
8266,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 10 mL ampule (NDC 63323-0493-97)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8267,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 20 mL ampule (NDC 63323-0493-91)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8268,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% Lidocaine 2% injection 20 mg/mL, 2 mL vial (NDC 63323-0202-02)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8269,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% injection 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8270,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-17)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8271,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 20 mL vial (NDC 63323-0486-27)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8272,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-57)",Reverified,11/23/2021,Backordred. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8273,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-10)
discontinued",Reverified,11/23/2021,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8274,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20)-NDC discontinued",Reverified,11/23/2021,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8275,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-50)-NDC discontinued",Reverified,11/23/2021,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8276,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 2 mL vial (NDC 63323-0495-27)",Reverified,11/23/2021,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8277,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 5 mL vial (NDC 63323-0495-07)",Reverified,11/23/2021,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,available
8278,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 10 mL ampule (NDC 63323-0496-97)",Reverified,11/23/2021,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8279,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (0.5%; 5 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4275-01),Revised,11/18/2021,Unavailable. Next Delivery and Estimated Recovery: January 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2021,not available
8280,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/2 mL (5%; 50 mg/mL) and 7.5% Dextrose; Glass Ampul (NDC 0409-4712-01),Revised,11/18/2021,Unavailable. Next Delivery: September 2022; Estimated Recovery: December 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2021,not available
8281,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (0.5%; 5 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4278-01),Revised,11/18/2021,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8282,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); Glass Ampul (NDC 0409-4713-02),Revised,11/18/2021,Available,,,Other,Anesthesia;Pediatric,Current,,,,2021,available
8283,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)",Reverified,11/23/2021,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8284,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Multi Dose Vial (NDC 55150-251-10),Revised,11/5/2021,Currently on backorder - next shipment TBD,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8285,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Multi Dose Vial (NDC 55150-252-20),Revised,11/5/2021,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8286,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 10 mL Multi Dose Vial (NDC 55150-254-10),Revised,11/5/2021,Currently on backorder - next shipment anticipated end of Nov,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8287,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 20 mL Multi Dose Vial (NDC 55150-255-20),Revised,11/5/2021,Currently on backorder - next shipment anticipated end of Nov,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8288,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 5 mL vial, Preservative Free (NDC 0143-9595-25)",Revised,10/12/2021,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8289,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 5 mL vial, Preservative Free (NDC 0143-9594-25)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8290,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 50 mL vial, Preserved (NDC 0143-9577-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8291,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 50 mL vial, Preserved (NDC 0143-9575-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8292,Lidocaine Hydrochloride (Xylocaine) Injection,"Spectra Medical Devices, Inc.",1% 5 mL ampule (NDC 65282-1605-1),New,6/14/2018,"Currently available, in stock Production is ongoing",,,Other,Anesthesia,Current,,,,2021,available
8293,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/20 mL (1.5%; 15 mg/mL); Glass Ampul (NDC 0409-4776-01),Revised,11/18/2021,Available,,,Other,Anesthesia;Pediatric,Current,,,,2021,available
8294,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% MDV 1000mg/50mL (NDC 55150-256-50),Revised,11/5/2021,Currently on backorder - next shipment anticipated end of Nov,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8295,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","0.5% w/EPI 1:100,000; 1.8 mL Carpule (NDC 00409-0996-01)",Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2021,discontinued
8296,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2.5 g/50 mL (0.5%; 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3177-01)",Reverified,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,limited availability
8297,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","200 mg/20 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-01)",Reverified,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: March 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,limited availability
8298,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","300 mg/30 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-02)",Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8299,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","500 mg/50 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3178-03)",Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8300,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","75 mg/5 mL (1.5%; 1:200,000); Glass Ampul (NDC 0409-1209-01)",Reverified,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,limited availability
8301,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","450 mg/30 mL (1.5%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3181-01)",Reverified,11/18/2021,Next Delivery and Estimated Recovery: July 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8302,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-01)",Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8303,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","600 mg/30 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-02)",Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8304,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","1 g/50 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-03)",Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8305,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3183-01)",Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2021,not available
8306,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2% w/EPI 1:50,000; 1.8mL syringe (NDC 00409-7263-01)",Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2021,discontinued
8307,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100 mg MDV (NDC 63323-0482-17)",Reverified,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2021,not available
8308,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100mg SDV, MPF (NDC 63323-0487-17)",Reverified,11/23/2021,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2021,not available
8309,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 150 mg, SDV, MPF (NDC 63323-0488-17)",Reverified,11/23/2021,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2021,not available
8310,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 200 mg, SDV, MPF (NDC 63323-0489-17)",Reverified,11/23/2021,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2021,not available
8311,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 5mcg tablets (NDC 0378-3611-01),New,3/28/2018,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/2018,3/28/2018,,2021,discontinued
8312,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 25mcg tablets (NDC 0378-3612-01),New,3/28/2018,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/2018,3/28/2018,,2021,discontinued
8313,Lipid Injection,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (20 grams per 100 mL) (NDC 63323--820-00)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,not available
8314,Lipid Injection,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (50 grams per 250 mL) (NDC 63323--820-74)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,not available
8315,Lipid Injection,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (100 grams per 500 mL) (NDC 63323-820-50)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,not available
8316,Lipid Injection,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20%, PBP (0.2 grams per mL) (200 grams per 1000 mL) (NDC 63323-820-10)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,not available
8317,Lipid Injection,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 100 mL, Product Code EADB9520, (NDC 0338-954-005)",Revised,11/23/2021,Available,NDC 0338-954-005,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,available
8318,Lipid Injection,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 1000 mL, Product Code EADB9524, (NDC 0338-954-008)",Revised,11/23/2021,Available,NDC 0338-954-008,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,available
8319,Lipid Injection,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 250 mL, Product Code EADB9521, (NDC 0338-954-006)",Revised,11/23/2021,Available,NDC 0338-954-006,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,available
8320,Lipid Injection,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 500 mL, Product Code EADB9523, (NDC 0338-954-007)",Revised,11/23/2021,Available,NDC 0338-954-007,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,available
8321,Lipid Injection,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 100 mL, Product Code 2B6061, (NDC 0338-051-958)",Revised,11/23/2021,"Limited Supply, on Allocation; Recovery Q4",NDC 0338-051-958. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,limited availability
8322,Lipid Injection,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 250 mL, Product Code 2B6062, (NDC 0338-051-909)",Revised,11/23/2021,"Limited Supply on Allocation, Recovery Q4",NDC 0338-051-909. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,limited availability
8323,Lipid Injection,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 1000 mL, Pharmacy Bulk Package, Product Code 2B6064, (NDC 0338-051-914)",New,10/26/2021,Limited Supply on Allocation,NDC 0338-051-914. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,limited availability
8324,Lipid Injection,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 500 mL, Product Code 2B6063, (NDC 0338-051-913)",New,10/26/2021,Limited Supply on Allocation,NDC 0338-051-913. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,limited availability
8325,Lipid Injection,Baxter Healthcare,"Intralipid 30% IV Fat Emulsion, 500 mL, Pharmacy Bulk Package, Product Code 2B6065, (NDC 0338-052-013)",New,10/26/2021,Limited Supply on Allocation,NDC 0338-052-013. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,limited availability
8326,Lipid Injection,B. Braun Medical Inc.,"Nutrilipid (20% IV Fat Emulsion) in 1,000mL Bag Catalog S4600 (NDC 00264-4460-00)",New,10/27/2021,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,limited availability
8327,Lipid Injection,B. Braun Medical Inc.,Nutrilipid (20% IV Fat Emulsion) in 500mL Bag Catalog S4601 (NDC 0264-4460-10),New,10/27/2021,"Product on back order, next release expected end Nov 2021",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,not available
8328,Lipid Injection,B. Braun Medical Inc.,Nutrilipid (20% IV Fat Emulsion) in 250mL Bag Catalog S4603 (NDC 00264-4460-30),New,10/27/2021,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2021,limited availability
8329,Lisinopril Tablets,Mylan Pharmaceuticals Inc.,2.5 mg (NDC 0378-2072-01); 5 mg (NDC 0378-2073-01); 5 mg (NDC 0378-2073-10); 10 mg (NDC 0378-2074-01); 10 mg (NDC 0378-2074-10); 20 mg (NDC 0378-2075-01); 20 mg (NDC 0378-2075-10); 30 mg (NDC 0378-2077-01); 40 mg (NDC 0378-2076-01; 40 mg (NDC 0378-2076-05),New,4/11/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,4/11/2018,4/11/2018,,2021,discontinued
8330,Lithium Oral Solution,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",8 mEq/5 mL 500 mL bottle (NDC 0054-3527-63),Reverified,11/5/2021,"Unavailable, Estimated Shortage: TBD",,,Shortage of an active ingredient,Psychiatry,Current,,,,2021,not available
8331,Lorazepam Injection,"Hospira, Inc.",4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,,2021,discontinued
8332,Lorazepam Injection,"Hospira, Inc.",2 mg/mL; Carpuject Luer Lock Glass Syringe  (NDC 00409-1985-30),Reverified,11/18/2021,Available,,,Other,Neurology,Current,,,,2021,available
8333,Lorazepam Injection,"Hospira, Inc.",2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02),Reverified,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Neurology,Current,,,,2021,limited availability
8334,Lorazepam Injection,"Hospira, Inc.",4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,,2021,discontinued
8335,Lorazepam Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,,2021,discontinued
8336,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc./IMS","LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)",Reverified,11/2/2021,Available,,,Other,Neurology,Current,,,,2021,available
8337,Lorazepam Injection,Akorn Pharmaceuticals,Lorazepam Injection 2 mg/mL (NDC 17478-040-01),Reverified,5/19/2021,Available,,,Demand increase for the drug,Neurology,Current,,,,2021,available
8338,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
8339,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
8340,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
8341,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
8342,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
8343,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
8344,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
8345,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
8346,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
8347,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
8348,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
8349,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
8350,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 100 count bottle (NDC 0527-1394-01)",Revised,6/21/2021,Available,,,,Psychiatry,Current,,,,2021,available
8351,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",Revised,6/21/2021,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2021,not available
8352,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 100 count bottle (NDC 0527-1395-01)",Revised,6/21/2021,Available,,,,Psychiatry,Current,,,,2021,available
8353,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",Revised,6/21/2021,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2021,not available
8354,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 100 count bottle (NDC 0527-1396-01)",Revised,6/21/2021,Available,,,Other,Psychiatry,Current,,,,2021,available
8355,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",Revised,6/21/2021,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2021,not available
8356,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 100 count bottle (NDC 0527-1397-01)",Revised,6/21/2021,Available,,,,Psychiatry,Current,,,,2021,available
8357,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",Revised,6/21/2021,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,,2021,not available
8358,Loxapine Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100 count bottle (NDC 0378-7005-01)",Reverified,11/29/2021,Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
8359,Loxapine Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","10 mg, 100 count bottle (NDC 0378-7010-01)",Reverified,11/29/2021,Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
8360,Loxapine Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","25 mg, 100 count bottle (NDC 0378-7025-01)",Reverified,11/29/2021,Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
8361,Loxapine Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","50 mg, 100 count bottle (NDC 0378-7050-01)",Reverified,11/29/2021,Unavailable,,,Other,Psychiatry,Current,,,,2021,not available
8362,Loxapine Capsules,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0591-0369-01)",Revised,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
8363,Loxapine Capsules,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0591-0370-01)",Revised,11/8/2021,Recovery: Feb 2022,January 2022 recovery,,Other,Psychiatry,Current,,,,2021,unclear
8364,Loxapine Capsules,Teva Pharmaceuticals,"25 mg, 100 count bottle (NDC 0591-0371-01)",Revised,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
8365,Loxapine Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0591-0372-01)",Revised,11/8/2021,Available,,,,Psychiatry,Current,,,,2021,available
8366,Mannitol Injection,"Fresenius Kabi USA, LLC",25% (12.5 grams per 50 mL)(250 mg per mL) Single dose vial (NDC 63323-024-25),Reverified,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Renal,Current,,,,2021,not available
8367,Mannitol Injection,"Hospira, Inc.",12.5 g/50 mL (25%); Single Dose Glass Fliptop Vial (NDC 0409-4031-01),Revised,11/18/2021,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: June 2022,,,Demand increase for the drug,Renal,Current,,,,2021,limited availability
8368,Mannitol Injection,Baxter Healthcare,"10% OSMITROL Injection (10% Mannitol Injection, USP) 500 mL Viaflex Plastic Container Product Code 2D5613Q (NDC 0338-0535-03)",New,9/29/2021,Available,,,,Renal,Current,,,,2021,available
8369,Mannitol Injection,Baxter Healthcare,"20% OSMITROL Injection (20% Mannitol Injection, USP) 500 mL Viaflex Plastic Container Product Code 2D5633Q (NDC 0338-0357-03); 250 mL Viaflex Plastic Container Product Code 2D5632Q (NDC 0338-0357-02)",New,9/29/2021,Available,,,,Renal,Current,,,,2021,available
8370,Mannitol Injection,"ICU Medical, Inc.","20% Mannitol Injection, USP 500 mL (Legacy Hospira NDC 0409-7715-03)(ICU Medical NDC 0990-7715-03)",Revised,11/10/2021,On allocation,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Renal,Current,,,,2021,limited availability
8371,Mannitol Injection,"ICU Medical, Inc.","20% Mannitol Injection, USP 250 mL (Legacy Hospira NDC 0409-7715-02)(ICU Medical NDC 0990-7715-02)",Revised,11/10/2021,On allocation,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Renal,Current,,,,2021,limited availability
8372,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 100 count (NDC 42806-012-01)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2021,discontinued
8373,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 1000 count (NDC 42806-012-10)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2021,discontinued
8374,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 100 count (NDC 42806-014-01)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2021,discontinued
8375,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 1000 count (NDC 42806-014-10)",New,2/28/2018,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/2018,2/28/2018,,2021,discontinued
8376,"Medroxyprogesterone Acetate (Depo-Provera) Injection, Suspension",Pfizer Pharmaceuticals,"400 mg/mL, 1 carton containing one 2.5 mL vial (NDC 0009-0626-01)",New,10/27/2020,,Discontinuation of the manufacturing of the drug.,,,Reproductive,To be Discontinued,10/27/2020,10/27/2020,,2021,discontinued
8377,Meloxicam Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",7.5 mg tablets (NDCs 0597-0029-01 and 0597-0029-94),New,11/1/2021,,,,,Analgesia/Addiction,To be Discontinued,11/1/2021,11/1/2021,,2021,discontinued
8378,Meloxicam Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",15 mg tablets (NDCs 0597-0030-01 and 0597-0030-56),New,11/1/2021,,,,,Analgesia/Addiction,To be Discontinued,11/1/2021,11/1/2021,,2021,discontinued
8379,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine) 1% (500 mg per 50 mL), (10 mg per mL), MDV, (NDC 63323-0283-57)",Revised,11/23/2021,Available,Check wholesaler inventory,,,Anesthesia,Current,,,,2021,available
8380,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine) 2% (1,000 mg per 50 mL), (20 mg per mL), MDV, (NDC 63323-0296-57)",Revised,11/23/2021,Available,Check wholesaler inventory,,,Anesthesia,Current,,,,2021,available
8381,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 1% (300 mg per 30 mL), (10 mg per mL), SDV, (NDC 63323-0260-37)",Revised,11/23/2021,Available,Check wholesaler inventory,,,Anesthesia,Current,,,,2021,available
8382,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 1.5% (450 mg per 30 mL), (15 mg per mL), SDV, (NDC 63323-0293-37)",Revised,11/23/2021,Available,,,Manufacturing delay,Anesthesia,Current,,,,2021,available
8383,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 2% (400 mg per 20 mL), (20 mg per mL), SDV, (NDC 63323-0294-27)",Revised,11/23/2021,Backordered. Next release December 2021.,,,Manufacturing delay,Anesthesia,Current,,,,2021,not available
8384,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",300 mg/30 mL (10 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1036-30),Reverified,11/18/2021,Next Delivery and estimated recovery: May 2022,Shortage per manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
8385,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",400 mg/20 mL (20 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1067-20),Reverified,11/18/2021,Next Delivery and estimated recovery: April 2022,Shortage per manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
8386,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",450 mg/30 mL (15 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1041-30),Reverified,11/18/2021,Next Delivery and estimated recovery: June 2022,Shortage per manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2021,not available
8387,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 0409-1038-50),Reverified,11/18/2021,Available,,,Other,Anesthesia,Current,,,,2021,available
8388,Mesalamine (CANASA®)  Suppositories,Allergan,"1 gm, Rectal Suppositories, 42 suppositories in 1 box (NDC 58914-501-42)",New,7/30/2020,,"Additional products remain available:   
NDC 58914-501-56 (30 suppositories in 1 box); NDC 58914-501-33 (3 suppositories in 1 box); NDC 59762-0118-3",,,Gastroenterology,To be Discontinued,7/30/2020,7/30/2020,,2021,discontinued
8389,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,750mg tablets (NDC 2037-577-10) and (NDC 62037-577-01 ),New,6/24/2020,,Teva made a business decision to discontinue the product.,,,Endocrinology/Metabolism,To be Discontinued,6/24/2020,6/24/2020,,2021,discontinued
8390,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,500mg tablets (NDC 62037-571-01) and (NDC 62037-571-10),New,6/24/2020,,Teva made a business decision to discontinue the product.,,,Endocrinology/Metabolism,To be Discontinued,6/24/2020,6/24/2020,,2021,discontinued
8391,Methadone Hydrochloride Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",Methadone Hydrochloride Injection (Solution in Multi Dose Vials) [200 mg / 20 ml](NDC 67457-217-20),Revised,6/8/2021,,,Available,,Analgesia/Addiction;Anesthesia,Resolved,6/8/2021,,,2021,
8392,Methadone Hydrochloride Injection,Akorn Pharmaceuticals,"Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) , 20 mL multidose vials (NDC 17478-380-20)",Revised,6/8/2021,,,Available,,Analgesia/Addiction;Anesthesia,Resolved,6/8/2021,,,2021,
8393,Methimazole Tablets,Pfizer Pharmaceuticals,Tapazole 5 mg tablets; bottle of 100 (NDC 60793-104-01),New,11/5/2021,,Discontinuation of the manufacture of the drug.,,,Endocrinology/Metabolism,To be Discontinued,11/5/2021,11/5/2021,,2021,discontinued
8394,Methimazole Tablets,Pfizer Pharmaceuticals,Tapazole 10 mg tablets; bottle of 100 (NDC 60793-105-01),New,11/5/2021,,Discontinuation of the manufacture of the drug.,,,Endocrinology/Metabolism,To be Discontinued,11/5/2021,11/5/2021,,2021,discontinued
8395,"Methocarbamol Tablet, USP","Endo Pharmaceuticals, Inc.",750 mg tablets (NDC 52244-449-10),New,10/27/2020,,,,,Analgesia/Addiction,To be Discontinued,10/27/2020,10/27/2020,,2021,discontinued
8396,Methohexital Sodium (Brevital) Injection,Par Pharmaceutical,"500 mg/vial, 50 mL multiple dose vial, box of 1 (NDC 42023-105-01)",Revised,11/15/2021,,,Available,,Anesthesia,Resolved,11/15/2021,,,2021,
8397,Methoxsalen Capsules,Teva Pharmaceuticals,10mg  (NDC 45963-325-50),New,3/22/2021,,,,,Dermatology,To be Discontinued,3/22/2021,3/22/2021,,2021,discontinued
8398,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 100s (16729-03-001),Revised,2/5/2021,Limited availability,,,API procurement delay,Cardiovascular,Current,,,,2021,limited availability
8399,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 500s (16729-03-016),Revised,2/5/2021,Limited availability,,,API procurement delay,Cardiovascular,Current,,,,2021,limited availability
8400,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 100s (16729-03-101),Revised,2/5/2021,Limited availability,,,API procurement delay,Cardiovascular,Current,,,,2021,limited availability
8401,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 500s (16729-03-116),Revised,2/5/2021,Limited availability,,,API procurement delay,Cardiovascular,Current,,,,2021,limited availability
8402,Methyldopa Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",250 mg (NDC 0378-0611-01),Revised,10/8/2021,,,,,Cardiovascular,To be Discontinued,10/8/2021,10/8/2021,,2021,discontinued
8403,Methyldopa Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",500 mg (NDC 0378-0421-01),Revised,10/8/2021,,,,,Cardiovascular,To be Discontinued,10/8/2021,10/8/2021,,2021,discontinued
8404,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg tablets (NDC 0591-0790-01),New,12/5/2019,,,,,Neurology,To be Discontinued,12/5/2019,12/5/2019,,2021,discontinued
8405,"Metoclopramide Injection, USP",Heritage Pharma,10mg/2mL (NDC 23155-240-41),Revised,10/18/2019,,,,,Gastroenterology,Resolved,10/18/2019,,,2021,
8406,Metoclopramide Tablets,Par Pharmaceutical,"10 mg, 500S (NDC 49884-0689-01",New,7/6/2021,,Discontinued due to business reasons.,,,Gastroenterology,To be Discontinued,7/6/2021,7/6/2021,,2021,discontinued
8407,Metoclopramide Tablets,Par Pharmaceutical,"10 mg, 500S (NDC 49884-0689-05)",New,7/6/2021,,Discontinued due to business reasons.,,,Gastroenterology,To be Discontinued,7/6/2021,7/6/2021,,2021,discontinued
8408,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,50 mg tablets (NDCs 0591-0462-01 and 0591-0462-10),New,12/16/2019,,,,,Cardiovascular,To be Discontinued,12/16/2019,12/16/2019,,2021,discontinued
8409,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,100 mg tablets (NDCs 0591-0463-01 and 0591-0463-10),New,12/16/2019,,,,,Cardiovascular,To be Discontinued,12/16/2019,12/16/2019,,2021,discontinued
8410,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,250 mg tablets 1 x 100 bottle (NDC 0025-1831-31),New,10/20/2020,,Discontinuation of the manufacture of the drug.,,,,To be Discontinued,10/20/2020,10/20/2020,,2021,discontinued
8411,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,250 mg tablets 1 x 50 bottle (NDC 0025-1831-50),New,10/20/2020,,Discontinuation of the manufacture of the drug.,,,,To be Discontinued,10/20/2020,10/20/2020,,2021,discontinued
8412,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,500 mg tablets 1 x 100 bottle (NDC 0025-1821-31),New,10/13/2021,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/13/2021,10/13/2021,,2021,discontinued
8413,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,500 mg tablets 1 x 50 bottle (NDC 0025-1821-50),New,10/13/2021,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/13/2021,10/13/2021,,2021,discontinued
8414,Midazolam Injection,Akorn Pharmaceuticals,10 ML Vial - Pack of 10 (NDC 17478-0524-10),Revised,10/22/2021,Available,,,,Anesthesia;Neurology,Current,,,,2021,available
8415,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 10 mL vial, 10 count (NDC 63323-0411-10)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8416,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 2 mL prefilled syringe, 24 count (NDC 76045-0001-20)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8417,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 2 mL vial, 25 count (NDC 63323-0411-12)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8418,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 5 mL vial, 25 count (NDC 63323-0411-25)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8419,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 1 mL fill in 2 mL vial, 25 count (NDC 63323-0412-25)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8420,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 10 mL vial, 10 count (NDC 63323-0412-10)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8421,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 1 mL prefilled syringe, 24 count (NDC 76045-0002-10)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8422,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 2 mL vial, 25 count (NDC 63323-0412-02)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8423,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 5 mL vial, 10 count (NDC 63323-0412-05)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8424,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 10 mL vial, 10 count (NDC 00641-6056-10)",Reverified,10/12/2021,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8425,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 2 mL vial, 25 count (NDC 00641-6057-25)",Reverified,10/12/2021,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8426,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 5 mL vial, 10 count (NDC 0641-6059-25)",Reverified,10/12/2021,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8427,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 1 mL vial, 25 count (NDC 00641-6061-25)",Reverified,10/12/2021,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8428,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial, 10 count (NDC 00641-6060-10)",Reverified,10/12/2021,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8429,Midazolam Injection,"Hospira, Inc.",2 mg/2mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-17),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: October 2022,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,not available
8430,Midazolam Injection,"Hospira, Inc.",5 mg/5 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-05),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,limited availability
8431,Midazolam Injection,"Hospira, Inc.",5 mg/mL (5 mg/mL)  Single Dose Glass Fliptop Vial (NDC 00409-2308-01),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,limited availability
8432,Midazolam Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-05),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,limited availability
8433,Midazolam Injection,"Hospira, Inc.",10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2308-02),Revised,11/18/2021,Available,,,Other,Anesthesia;Neurology,Current,,,,2021,available
8434,Midazolam Injection,"Hospira, Inc.",25 mg/5 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-03),Revised,11/18/2021,Available,,,Other,Anesthesia;Neurology,Current,,,,2021,available
8435,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,50 mg/10mL vial (NDC 23155-601-42),Revised,10/13/2021,Available,,,Other,Anesthesia;Neurology,Current,,,,2021,available
8436,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,25 mg/5mL vial (NDC 23155-601-41),Revised,10/13/2021,Available,,,Other,Anesthesia;Neurology,Current,,,,2021,available
8437,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,2 mg/2mL vial (NDC 23155-600-41),Revised,10/13/2021,Available; On allocation due to increased demand,,,Other,Anesthesia;Neurology,Current,,,,2021,limited availability
8438,Midazolam Injection,"Hospira, Inc.",10 mg/10 mL (1 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2587-05),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,limited availability
8439,Midazolam Injection,"Hospira, Inc.",2 mg/2 mL (1 mg/mL) CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2306-62),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Neurology,Current,,,,2021,discontinued
8440,Midazolam Injection,"Hospira, Inc.",5 mg/mL CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2307-60),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Neurology,Current,,,,2021,discontinued
8441,Midazolam Injection,Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 70860-601-10),Reverified,11/5/2021,Available,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8442,Midazolam Injection,Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 70860-601-05),Reverified,11/5/2021,Available,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8443,Midazolam Injection,Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 47781-589-17),Reverified,11/5/2021,No stock available,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,not available
8444,Midazolam Injection,Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 47781-589-91),Reverified,11/5/2021,Available,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8445,Midazolam Injection,Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 70860-600-02),Reverified,11/5/2021,Available,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8446,Midazolam Injection,Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 47781-588-68),Reverified,11/5/2021,Available,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2021,available
8447,Miglitol Tablets,"Hospira, Inc.",25 mg (NDC 0009-5012-01),New,11/17/2020,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/2020,11/17/2020,,2021,discontinued
8448,Miglitol Tablets,"Hospira, Inc.",50 mg (NDC 0009-5013-01),New,11/17/2020,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/2020,11/17/2020,,2021,discontinued
8449,Miglitol Tablets,"Hospira, Inc.",100 mg (NDC 0009-5014-01),New,11/17/2020,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/2020,11/17/2020,,2021,discontinued
8450,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",15mg tablets (NDC 0591-2469-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2021,discontinued
8451,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",30mg tablets (NDC 0591-2470-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2021,discontinued
8452,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",45mg tablets (NDC 0591-2471-15),New,5/29/2018,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/2018,5/29/2018,,2021,discontinued
8453,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 100 (NDC 59762-5008-2),Reverified,11/18/2021,Next Delivery: December 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,not available
8454,Misoprostol Tablets,Lupin,100-mcg tablets Bottles of 60 (NDC 43386-160-06),Revised,4/30/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8455,Misoprostol Tablets,Lupin,100-mcg tablets Bottles of 120 (NDC 43386-160-12),Revised,4/30/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8456,Misoprostol Tablets,Lupin,200-mcg tablets Bottles of 60 (NDC 43386-161-06),Revised,4/30/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8457,Misoprostol Tablets,Lupin,200-mcg tablets Bottles of 100 (NDC 43386-161-01),Revised,4/30/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8458,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 60 (NDC 59762-5007-1),Reverified,11/18/2021,Next Delivery: November 2021; Esimtated Recovery: January 2022,,,Other,Gastroenterology,Current,,,,2021,not available
8459,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 120 (NDC 59762-5007-2),Reverified,11/18/2021,Next Delivery and Estimated Recovery: March 2022,,,Other,Gastroenterology,Current,,,,2021,not available
8460,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 60 (NDC 59762-5008-1),Reverified,11/18/2021,Next Delivery and Estimated Recovery: January 2022,,,Other,Gastroenterology,Current,,,,2021,not available
8461,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; 10x10 blister (NDC 0025-1451-34),Reverified,11/18/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8462,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 60 (NDC 0025-1451-60),Reverified,11/18/2021,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8463,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 100 (NDC 0025-1461-31),Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,not available
8464,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 60 (NDC 0025-1461-60),Reverified,11/18/2021,Next Delivery and Estimated Recovery: TBD,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,unclear
8465,Mometasone Furoate Monohydrate Nasal Spray,Merck Sharp & Dohme Corp.,50 mcg (NDC 0085-1288-01),New,6/9/2021,,,,,Pulmonary/Allergy,To be Discontinued,6/9/2021,6/9/2021,,2021,discontinued
8466,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,4 mg  (NDCs 0093-7424-98 and 0093-7424-56),New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,7/28/2020,7/28/2020,,2021,discontinued
8467,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,5 mg  (NDCs 0093-7425-98 and 0093-7425-56),New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,7/28/2020,7/28/2020,,2021,discontinued
8468,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,"10 mg (NDCs 0093-7426-10, 0093-7426-56, and 0093-7426-98)",New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,7/28/2020,7/28/2020,,2021,discontinued
8469,Montelukast Sodium Chewable Tablet,Sandoz,"4 mg  (NDCs 0781-5554-05, 0781-5554-06, 0781-5554-13, 0781-5554-31, 0781-5554-64, 0781-5554-92)",New,10/12/2021,,,,,Pulmonary/Allergy,To be Discontinued,10/12/2021,10/12/2021,,2021,discontinued
8470,Montelukast Sodium Chewable Tablet,Sandoz,"5 mg  (NDCs 0781-5555-05, 0781-5555-06, 0781-5555-13, 0781-5555-31, 0781-5555-64, 0781-5555-92)",New,10/12/2021,,,,,Pulmonary/Allergy,To be Discontinued,10/12/2021,10/12/2021,,2021,discontinued
8471,Montelukast Sodium Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-5201-93),New,3/20/2018,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,3/20/2018,3/20/2018,,2021,discontinued
8472,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-2658-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8473,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 100s (NDC 0378-2659-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8474,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"60 mg, 100s (NDC 0378-2660-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8475,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100s (NDC 0378-2661-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8476,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100s (NDC 0378-2662-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8477,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-452-01)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,not available
8478,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-454-01)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8479,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","5 mg per 1 mL, Single dose vial, (NDC 63323-455-01)",Revised,11/23/2021,7 month expiry (6/2022 expiry) dating available by request.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,limited availability
8480,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","8 mg per 1 mL, Single dose vial, (NDC 63323-458-01)",Revised,11/23/2021,7 month expiry (6/2022 expiry) dating available by request.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,limited availability
8481,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, (NDC 63323-451-01)",Revised,11/23/2021,Backordered. Next release January 2022.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,not available
8482,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS",Morphine Sulfate 1 mg/mL 30 mg in 30 mL PUMP-JET®  SUITABLE FOR USE WITH COMPATIBLE I.V. INFUSION PUMPS (NDC 76329-1911-1),Reverified,11/2/2021,Available,,,,Analgesia/Addiction,Current,,,,2021,available
8483,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6125-25)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8484,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","8 mg/mL, 1 mL vial (NDC 0641-6126-25)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8485,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-6127-25)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8486,Morphine Sulfate Injection,"Hospira, Inc.",250 mg/10 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1135-02),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8487,Morphine Sulfate Injection,"Hospira, Inc.",2 mg/mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1890-01),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2021,limited availability
8488,Morphine Sulfate Injection,"Hospira, Inc.",2 mg/mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1890-11),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8489,Morphine Sulfate Injection,"Hospira, Inc.",4 mg/mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1891-01),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: December 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2021,not available
8490,Morphine Sulfate Injection,"Hospira, Inc.",4 mg/mL (4 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1891-11),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8491,Morphine Sulfate Injection,"Hospira, Inc.",8 mg/mL (8 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1892-01),Revised,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8492,Morphine Sulfate Injection,"Hospira, Inc.",8 mg/mL (8 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1892-11),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8493,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1893-01),Revised,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8494,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1893-11),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2021,discontinued
8495,Morphine Sulfate Injection,"Hospira, Inc.",5 mg/10 mL (0.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3814-12),Revised,11/18/2021,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8496,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/10 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3815-12),Revised,11/18/2021,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8497,Morphine Sulfate Injection,"Hospira, Inc.","1,000 mg/20 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-03)",Revised,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8498,Morphine Sulfate Injection,"Hospira, Inc.","2,500 mg/50 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-05)",Revised,11/18/2021,Available,,,Other,Analgesia/Addiction,Current,,,,2021,available
8499,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-10)",Revised,11/23/2021,Check wholesalers for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,unclear
8500,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-005-10)",Revised,11/23/2021,Check wholesalers for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,unclear
8501,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","5 mg per 1 mL, Single-use prefilled syringe (NDC 76045-006-10)",Revised,11/23/2021,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,available
8502,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","8 mg per 1 mL, Single-use prefilled syringe (NDC 76045-007-10)",Revised,11/23/2021,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8503,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single-use prefilled syringe (NDC 76045-008-10)",Revised,11/23/2021,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8504,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 1 mg/mL, 10 mL ampul (NDC 0641-6019-10)",Revised,10/12/2021,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8505,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 0.5 mg/mL, 10 mL ampul (NDC 0641-6020-10)",Revised,10/12/2021,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,not available
8506,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 10 mg/mL, 20 mL ampul (NDC 0641-6039-01)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8507,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 25 mg/mL, 20 mL ampul (NDC 0641-6040-01)",Revised,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2021,available
8508,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe, micro vault packaging (NDC 76045-004-11)",Revised,11/23/2021,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,available
8509,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe, micro vault packaging (NDC 76045-005-11)",Revised,11/23/2021,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2021,available
8510,Moxifloxacin (Moxeza) Ophthalmic Solution,Novartis,"5mg/mL, 3mL in 1 bottle, (NDC 0065-0006-03)",New,7/2/2021,,Novartis Pharmaceuticals has made a business decision to permanently discontinue Moxeza (moxifloxacin hydrochloride) Solution 5mg/mL.,,,Ophthalmology,To be Discontinued,7/2/2021,7/2/2021,,2021,discontinued
8511,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 10 mL Single Dose Dual Glass Fliptop Vials (NDC 61703-0434-82),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,discontinued
8512,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 2 x 50 mL Pharmacy Bulk Package Dual Glass Fliptop Vials (NDC 61703-0422-83),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,discontinued
8513,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Pediatric; Single Dose Glass Fliptop Vial (NDC 61703-0421-53),Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,discontinued
8514,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)",Reverified,11/16/2021,Limited supply on allocation,"Drug Product is distributed by Baxter Healthcare, please contact 888-229-0001 for supply related inquires.  For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition",,Demand increase for the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,limited availability
8515,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)",Reverified,11/16/2021,Limited supply on allocation,"Drug Product is distributed by Baxter Healthcare, please contact 888-229-0001 for supply related inquires.  For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition",,Demand increase for the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,limited availability
8516,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5650-2)",Reverified,11/16/2021,Stocked out; Recovery TBD,"Drug Product is distributed by Baxter Healthcare, please contact 888-229-0001 for supply related inquires.  For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition",,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8517,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)",Reverified,11/16/2021,Stocked out; Recovery TBD,"Drug Product is distributed by Baxter Healthcare, please contact 888-229-0001 for supply related inquires.  For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition",,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8518,Nadolol Tablets,Ingenus Pharmaceuticals LLC,20 mg (100 ct) (NDC 50742-178-01),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2021,discontinued
8519,Nadolol Tablets,Ingenus Pharmaceuticals LLC,20 mg (1000 ct) (NDC 50742-178-10 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2021,discontinued
8520,Nadolol Tablets,Ingenus Pharmaceuticals LLC,40 mg (100 ct) (NDC 50742-179-01 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2021,discontinued
8521,Nadolol Tablets,Ingenus Pharmaceuticals LLC,40 mg (1000 ct) (NDC 50742-179-10 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2021,discontinued
8522,Nadolol Tablets,Ingenus Pharmaceuticals LLC,80 mg (100 ct) (NDC 50742-180-01 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2021,discontinued
8523,Nadolol Tablets,Ingenus Pharmaceuticals LLC,80 mg (1000 ct) (NDC 50742-180-10 ),New,9/11/2020,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/2020,9/11/2020,,2021,discontinued
8524,Nafcillin Injection,Pfizer Pharmaceuticals,1 g; Single Dose Vial (Powder)(NDC 0409-3713-01),New,10/20/2021,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/20/2021,10/20/2021,,2021,discontinued
8525,Nafcillin Injection,Pfizer Pharmaceuticals,2 g; Single Dose Vial (Powder)(NDC 0409-3714-01),New,10/20/2021,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/20/2021,10/20/2021,,2021,discontinued
8526,Nafcillin Injection,Pfizer Pharmaceuticals,10 g per Pharmacy Bulk Package; Pharmacy Bulk Vial (Powder)(NDC 0409-3715-01),New,10/20/2021,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/20/2021,10/20/2021,,2021,discontinued
8527,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-3124-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
8528,Nafcillin Sodium Injection,Sandoz,2 gram vial packaged in 10s (NDC 0781-3125-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
8529,Nafcillin Sodium Injection,Sandoz,Pharmacy Bulk Package bottle (NDC 0781-3126-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
8530,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-9124-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
8531,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9224-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
8532,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9225-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
8533,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3128-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
8534,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3129-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,12/23/2019,12/23/2019,,2021,discontinued
8535,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",10 mg/mL; 1 mL Glass Ampul (NDC 00409-1463-01),Revised,6/28/2021,,,Available,,Analgesia/Addiction,Resolved,6/28/2021,,,2021,
8536,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",20 mg/mL; 1 mL Glass Ampul (NDC 00409-1465-01),Revised,6/28/2021,,,Available,,Analgesia/Addiction,Resolved,6/28/2021,,,2021,
8537,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1464-01),Revised,6/28/2021,,,Available,,Analgesia/Addiction,Resolved,6/28/2021,,,2021,
8538,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1467-01),Revised,6/28/2021,,,Available,,Analgesia/Addiction,Resolved,6/28/2021,,,2021,
8539,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,50 mg 100 Tablets (NDC 0093-7178-01),Revised,11/17/2021,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,,2021,not available
8540,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,100 mg 60 Tablets (NDC 0093-1024-06),Revised,11/17/2021,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,,2021,not available
8541,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,150 mg 60 Tablets (NDC 0093-7113-06),Revised,11/17/2021,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,,2021,not available
8542,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,200 mg 60 Tablets (NDC 0093-1025-06),Revised,11/17/2021,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,,2021,not available
8543,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,250 mg 60 Tablets (NDC 0093-1026-06),Revised,11/17/2021,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,,2021,not available
8544,"Neomycin Sulfate, Polymyxin B Sulfate and Hydrocortisone Acetate Cream",Pfizer Pharmaceuticals,"CORTISPORIN (neomycin sulfate, polymyxin b sulfate and hydrocortisone acetate cream); Tube of 7.5 g cream (NDC 61570-032-75)",New,3/9/2021,,Discontinuation of the manufacture of the drug.,,,Dermatology,To be Discontinued,3/9/2021,3/9/2021,,2021,discontinued
8545,"Neomycin Sulfate, Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone Ointment",Pfizer Pharmaceuticals,"Cortisporin (neomycin sulfate, polymyxin b sulfate, bacitracin zinc and hydrocortisone ointment); Tube of 1/2 oz ointment with applicator tip (NDC 61570-031-50)",New,3/9/2021,,Discontinuation of the manufacture of the drug.,,,Dermatology,To be Discontinued,3/9/2021,3/9/2021,,2021,discontinued
8546,Nesiritide Powder (NATRECOR) for Injection,Janssen Pharmaceuticals,1.5 mg (NDC 65847-205-25),New,2/5/2018,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To be Discontinued,2/5/2018,2/5/2018,,2021,discontinued
8547,Nevirapine (Viramune) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",200 mg tablets (NDC 0597-0046-60),New,5/29/2020,,,,,Antiviral,To be Discontinued,5/29/2020,5/29/2020,,2021,discontinued
8548,Nevirapine Oral Suspension,"Boehringer Ingelheim Pharmaceuticals, Inc.",50mg/5mL (NDC 0597-0047-24),New,10/1/2021,,,,,Antiviral,To be Discontinued,10/1/2021,10/1/2021,,2021,discontinued
8549,Nizatidine Capsules,Teva Pharmaceuticals,"300 mg, 30 count bottle (NDC 0591-3138-30)",Revised,11/8/2021,Supply Interruption. Relaunch Mar-Apr 2022,,,Other,Gastroenterology,Current,3/27/2020,,,2021,limited availability
8550,Nizatidine Capsules,Teva Pharmaceuticals,"150 mg, 60 count bottle (NDC 0591-3137-60)",Revised,11/8/2021,Supply Interruption. Relaunch Mar-Apr 2022,,,Other,Gastroenterology,Current,3/27/2020,,,2021,limited availability
8551,Nizatidine Capsules,Glenmark Pharmaceuticals,"300 mg, 30 count bottle (NDC 68462-0426-30)",New,3/27/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,,Gastroenterology,Current,3/27/2020,,,2021,not available
8552,Nizatidine Capsules,Glenmark Pharmaceuticals,"150 mg, 60 count bottle (NDC 68462-0425-60)",New,3/27/2020,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,,Gastroenterology,Current,3/27/2020,,,2021,not available
8553,Norethindrone (NOR QD) Tablets,Allergan,"Nor QD, 0.35 mg norethindrone, Tablets, (NDC  52544-235-28)",New,2/23/2018,,"An authorized generic of the product is currently available as Nora-BE, NDC 52544-629-28.",,,Reproductive,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
8554,Norethindrone Acetate/Ethinyl Estradiol (Femhrt) Tablets,Allergan,Femhrt (NDC 0430-0145-14),New,3/24/2021,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
8555,Norethindrone Acetate/Ethinyl Estradiol/Ferrous Fumarate Kit,Allergan,Tilia Fe (NDC 51862-284-03),New,3/24/2021,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
8556,Norethindrone Acetate/Ethinyl Estradiol/Ferrous Fumarate Kit,Allergan,ESTROSTEP Fe (NDC 0430-0005-31),New,3/24/2021,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
8557,Norethindrone/Ethinyl Estradiol Kit,"Endo Pharmaceuticals, Inc.",(NDC 0603-7521-17),New,12/17/2020,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/17/2020,12/17/2020,,2021,discontinued
8558,Norethindrone/Ethinyl Estradiol Kit,"Endo Pharmaceuticals, Inc.",(NDC 0603-7521-49),New,12/17/2020,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/17/2020,12/17/2020,,2021,discontinued
8559,Norethindrone/Ethinyl Estradiol Kit,"Endo Pharmaceuticals, Inc.",(NDC 0603-7525-17),New,12/17/2020,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/17/2020,12/17/2020,,2021,discontinued
8560,Norethindrone/Ethinyl Estradiol Kit,"Endo Pharmaceuticals, Inc.",(NDC 0603-7525-49),New,12/17/2020,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/17/2020,12/17/2020,,2021,discontinued
8561,Nystatin and Triamcinolone Acetonide Topical Cream,Sandoz,"100,000 units per gram; 0.1%  (NDCs 0168-0081-15, 0168-0081-30, and 0168-0081-60)",New,4/21/2021,,,,,Dermatology,To be Discontinued,4/21/2021,4/21/2021,,2021,discontinued
8562,Nystatin Topical Cream,Sandoz,"100,000 units per gram  (NDCs 0168-0054-15 and 0168-0054-30)",New,4/21/2021,,,,,Dermatology,To be Discontinued,4/21/2021,4/21/2021,,2021,discontinued
8563,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,12mg/50mg per capsule (NDC Package Code 0002-3234-30),New,7/15/2020,,The product distribution will continue until end of December 2020.,,,Psychiatry,To be Discontinued,7/15/2020,7/15/2020,,2021,discontinued
8564,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,6mg/50mg per capsule (NDC Package Code 0002-3233-30),New,7/15/2020,,The product distribution will continue until end of December 2020.,,,Psychiatry,To be Discontinued,7/15/2020,7/15/2020,,2021,discontinued
8565,Olopatadine Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"0.2%, 2.5 mL Bottle (NDC 0093-7684-32)",New,4/27/2021,,Rx to OTC Switch. Current Rx customers on allocation through May 2021.,,,Ophthalmology,To be Discontinued,4/27/2021,4/27/2021,,2021,discontinued
8566,Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets,Abbvie,212.5mg; 75mg; 50mg (NDC 0074-3082-28),New,5/22/2018,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary",,,Antiviral,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
8567,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 2mL vial (NDC 70860-776-02),Reverified,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8568,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 20mL vial (NDC 70860-777-20),Reverified,11/5/2021,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Gastroenterology,Current,,,,2021,available
8569,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,40mg/20mL EA 1 Vial (NDC 25021-782-20),Reverified,9/3/2021,Available,,,,Gastroenterology,Current,,,,2021,available
8570,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,4mg/2mL PK 25 Vials (NDC 25021-777-02),Reverified,9/3/2021,Available,,,,Gastroenterology,Current,,,,2021,available
8571,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 2 mL vial, 25 count (NDC 55150-125-02)",Reverified,11/5/2021,On long term backorder,On long term backorder,,Delay in shipping of the drug,Gastroenterology,Current,,,,2021,not available
8572,Ondansetron Hydrochloride Injection,Heritage Pharma,"4mg/2mL, 10 (NDC 23155-547-41 )",Reverified,10/13/2021,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8573,Ondansetron Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-4759-01),Revised,11/18/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8574,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 2 mL vial (NDC 0641-6078-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8575,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-4755-03),Revised,11/18/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8576,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1120-12),Revised,10/6/2021,,Discontinuation of the manufacture of the drug,,,Gastroenterology,To be Discontinued,10/6/2021,10/6/2021,,2021,discontinued
8577,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 20 mL vial, 1 count (NDC 55150-126-20)",Reverified,11/5/2021,On long term backorder,On long term backorder,,Delay in shipping of the drug,Gastroenterology,Current,,,,2021,not available
8578,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, amber vial, 4 mg per 2 mL (NDC 63323-373-02)",Reverified,11/23/2021,Available,Check wholesalers for inventor,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8579,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Multi dose, amber vial, 40 mg per 20 mL (NDC 63323-374-20)",Reverified,11/23/2021,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2021,not available
8580,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, Simplist syringe, 4 mg per 2 mL (NDC 76045-103-20)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8581,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9890-01)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8582,Ondansetron Hydrochloride Injection,Heritage Pharma,"Inj4mg/2mL, 25 (NDC 23155-549-31)",Reverified,10/13/2021,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8583,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-41),Reverified,10/13/2021,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8584,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-42),Reverified,10/13/2021,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8585,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 2 mL vial (NDC 72266-123-25)",Reverified,11/5/2021,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,,2021,available
8586,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-124-01)",Reverified,11/5/2021,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,,2021,available
8587,Ondansetron Hydrochloride Injection,Baxter Healthcare,"Ondansetron Injection, USP (2 mg/mL) 2 mL Single Use Glass Vial (25 x 2 mL) (NDC 36000-012-25)",Reverified,11/23/2021,Available,For IV or IM injection,,,Gastroenterology,Current,,,,2021,available
8588,Ondansetron Hydrochloride Injection,Apotex Corp.,Ondansetron 2mg/mL 2mL vials Box of 25 vials (NDC 60505-6130-05),Reverified,10/27/2021,Available,,,Available,Gastroenterology,Current,,,,2021,available
8589,Oxalaplatin Injection,Gland Pharma Limited,"50 mg/10 mL, 10 vials per pack (NDC 72266-125-10)",New,9/28/2020,,"50 mg/10 mL and 100 mg/20 mL, 1 vial per packs (NDCs 72266-161-01 and 72266-162-01, respectively) will continue to be available; Gland Pharma Limited, Distributed by Fosun Pharma USA Inc. (Company Contact Information: 833-291-9645)",,,Oncology,To be Discontinued,9/28/2020,9/28/2020,,2021,discontinued
8590,Oxalaplatin Injection,Gland Pharma Limited,"100 mg/20 mL, 10 vials per pack (NDC 72266-126-10)",New,9/28/2020,,"50 mg/10 mL and 100 mg/20 mL, 1 vial per packs (NDCs 72266-161-01 and 72266-162-01, respectively) will continue to be available; Gland Pharma Limited, Distributed by Fosun Pharma USA Inc. (Company Contact Information: 833-291-9645)",,,Oncology,To be Discontinued,9/28/2020,9/28/2020,,2021,discontinued
8591,Oxytocin Injection (Synthetic),"Fresenius Kabi USA, LLC",100 USP Units per 10 mL (10 USP units per mL); Multiple dose vial;  (NDC 63323-012-10),Revised,6/10/2021,,,Available,,Reproductive,Resolved,6/10/2021,,,2021,
8592,Oxytocin Injection (Synthetic),"Fresenius Kabi USA, LLC",300 USP Units per 30 mL (10 USP Units per mL); Multiple dose vial; (NDC 63323-012-30),Revised,6/10/2021,,,Available,,Reproductive,Resolved,6/10/2021,,,2021,
8593,Oxytocin Injection (Synthetic),"Fresenius Kabi USA, LLC",10 USP Units per mL (10 USP units per mL); (NDC 63323-012-01)( NDC 63323-0012-11),Revised,6/10/2021,,,Available,,Reproductive,Resolved,6/10/2021,,,2021,
8594,Oxytocin Injection (Synthetic),Par Pharmaceutical,"Packages of six 50 mL Pharmacy Bulk Packages, each containing 10 units of oxytocin per mL (total = 500 units of oxytocin per vial), (NDC 42023-130-06)",Revised,6/10/2021,,,Available,,Reproductive,Resolved,6/10/2021,,,2021,
8595,Oxytocin Injection (Synthetic),Par Pharmaceutical,"Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin, (NDC 42023-116-25)",Revised,6/10/2021,,,Available,,Reproductive,Resolved,6/10/2021,,,2021,
8596,Oxytocin Injection (Synthetic),Par Pharmaceutical,"Packages of twenty-five 10 mL multiple-dose vial, each containing 10 units of oxytocin per mL (total = 100 units of oxytocin per vial) (NDC 42023-116-02)",Revised,6/10/2021,,,Available,,Reproductive,Resolved,6/10/2021,,,2021,
8597,Paclitaxel Injection (protein-bound particles),Bristol Myers Squibb Co.,"Abraxane® 100 mg, single dose vial (NDC 68817-134-50)",Revised,11/15/2021,Limited supply. Temporarily on allocation through January 2022.,Manufacturing delay,,Other,Oncology,Current,,,,2021,limited availability
8598,"Paclitaxel Injection, USP",Mylan Institutional,"100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17)",New,11/22/2019,,19-Dec,,,Oncology,To be Discontinued,11/22/2019,11/22/2019,,2021,discontinued
8599,Pantoprazole Sodium for Injection,Sun Pharmaceutical Industries Inc.,"40 mg, 10 vials (NDC 62756-129-44)",Revised,8/26/2021,Out of Stock,Expected to be back in stock by October 2021.,,Other,Gastroenterology,Current,,,,2021,not available
8600,Pantoprazole Sodium for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"40 mg, 10 vials (NDC 55150-202-10)",Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8601,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-0923-55)",Revised,11/18/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8602,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-0923-60)",Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,limited availability
8603,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-2001-10; Amerinet)",Revised,11/18/2021,Next Delivery and Estimated Recovery: February 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,not available
8604,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-2001-25; Amerinet)",Revised,11/18/2021,Next Delivery and Estimated Recovery: February 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,not available
8605,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-4001-10; PremierPro)",Revised,11/18/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8606,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-4001-25; PremierPro)",Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,limited availability
8607,Pantoprazole Sodium for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg, 10 vials (NDC 0143-9284-10)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8608,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 0781-3232-95)",Reverified,11/16/2021,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2021,available
8609,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges),Reverified,12/11/2020,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2021,unclear
8610,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,50mcg   Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges),Reverified,12/11/2020,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2021,unclear
8611,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,75mcg   Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges),Reverified,12/11/2020,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2021,unclear
8612,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,100mcg   Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges),Reverified,12/11/2020,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2021,unclear
8613,Paricalcitol Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",(Solution in Multi Dose Vials) [0.01 mg / 2 ml](NDC 67457-389-25),New,1/29/2021,,,,,Endocrinology/Metabolism,To be Discontinued,1/29/2021,1/29/2021,,2021,discontinued
8614,Paricalcitol Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",(Solution in Single Dose Vials) [0.002 mg / 1 ml],New,1/29/2021,,,,,Endocrinology/Metabolism,To be Discontinued,1/29/2021,1/29/2021,,2021,discontinued
8615,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4347-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2021,discontinued
8616,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4348-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2021,discontinued
8617,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4349-01)",New,2/28/2018,,This presentation will be discontinued on or near December 2018.  For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/2018,2/28/2018,,2021,discontinued
8618,Peginterferon alfa-2b Injection,Merck Sharp & Dohme Corp.,"PEGINTRON injection (peginterferon alfa-2b), 50 mcg per 0.5 mL; A box containing one 50 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs (NDC 00085-4353-01)",New,4/23/2021,,To be discontinued on or near May 2021,,,Antiviral,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8619,Pentamidine Isethionate (Nebupent) For Inhalation Solution,"Fresenius Kabi USA, LLC","300 mg per vial, SDV, PF (NDC 63323-877-15)",Revised,9/13/2019,,,,,Anti-Infective,Resolved,9/13/2019,,,2021,
8620,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 100s (NDC 0378-0357-01)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8621,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 500s (NDC 0378-0357-05)",New,5/8/2018,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/2018,5/8/2018,,2021,discontinued
8622,Phenobarbital Oral Solution,Torrent Pharma Inc.,1 pint 473mL (NDC 16571-330-16),New,11/25/2019,,,,,Neurology,To be Discontinued,11/25/2019,11/25/2019,,2021,discontinued
8623,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 2 mL vial (NDC 0641-0493-25)",Revised,9/3/2019,,,Available,,Neurology,Resolved,9/3/2019,,,2021,
8624,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 5 mL vial (NDC 0641-2555-45)",Revised,9/3/2019,,,Available,,Neurology,Resolved,9/3/2019,,,2021,
8625,Physostigmine Salicylate Injection,Akorn Pharmaceuticals,"Physostigmine Salicylate Injection, USP  1mg/mL (10amps/box, 2mL each) (NDC 17478-510-02)",Revised,10/25/2021,Unavailable. Expected to release Q4 2022.,,,Other,Neurology,Current,,,,2021,not available
8626,Pindolol Tablets,Sun Pharmaceutical Industries Inc.,"Pindolol Tablets, 5mg and 10mg (100 count bottles)(NDC 57664-655-88, 57664-656-88)",New,2/21/2020,No product available. Product can be manufactured upon availability of API. Concrete estimated release dates cannot be provided at this moment.,,,Shortage of active ingredient,Cardiovascular,Current,,,,2021,not available
8627,Pindolol Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Pindolol 5mg Tabs 100s (NDC 0378-0052-01),Reverified,11/29/2021,Available,,,,Cardiovascular,Current,,,,2021,available
8628,Pindolol Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Pindolol 10mg Tabs 100s (NDC 0378-0127-01),Reverified,11/29/2021,Available,,,,Cardiovascular,Current,,,,2021,available
8629,Pindolol Tablets,Bayshore Pharmaceuticals,5 mg/ 100 count (NDC 76385-131-01),Revised,11/18/2020,Available,,,,Cardiovascular,Current,,,,2021,available
8630,Pindolol Tablets,Bayshore Pharmaceuticals,10 mg/ 100 count (NDC 76385-132-01),Revised,11/18/2020,Available,,,,Cardiovascular,Current,,,,2021,available
8631,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","5 mg: Bottles of 100 tablets, (NDC 62559-560-01)",Revised,6/22/2021,Available,,,,Cardiovascular,Current,,,,2021,available
8632,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","10 mg; Bottles of 100 tablets, (NDC 62559-561-01)",Revised,6/22/2021,Available,,,,Cardiovascular,Current,,,,2021,available
8633,Pindolol Tablets,"Nostrum Laboratories, Inc.","5 mg, Bottle of 100 tablets (NDC 29033-028-01)",New,11/30/2020,"Currently Available; Predicted Shortage duration: 2 months, January and February 2021
Resupply: March 2021",,,Shortage of an active ingredient,Cardiovascular,Current,,,,2021,limited availability
8634,Pindolol Tablets,"Nostrum Laboratories, Inc.","10 mg, Bottle of 100 tablets (NDC 29033-029-01)",New,11/30/2020,"Currently available; Predicted Shortage duration: 1 month, February 2021
Resupply: March 2021",,,Shortage of an active ingredient,Cardiovascular,Current,,,,2021,limited availability
8635,Pioglitazone/Metformin HCl (ACTOPLUS MET®) Tablets,Takeda Pharmaceuticals USA Inc.,15mg/500mg tablet (NDC 64764-0155-60),New,10/18/2021,,Business reasons for discontinuation,,,Endocrinology/Metabolism,To be Discontinued,10/18/2021,10/18/2021,,2021,discontinued
8636,Piroxicam Capsules,Pfizer Pharmaceuticals,10 mg capsules; Bottles of 100 (NDC 59762-0140-1),New,8/10/2021,,Stock anticipated to be available through February 2022,,,Analgesia/Addiction,To be Discontinued,8/10/2021,8/10/2021,,2021,discontinued
8637,Piroxicam Capsules,Pfizer Pharmaceuticals,20 mg capsules; Bottles of 100 (NDC 59762-0145-1),New,8/10/2021,,Stock anticipated to be available through June 2022,,,Analgesia/Addiction,To be Discontinued,8/10/2021,8/10/2021,,2021,discontinued
8638,Potassium Acetate Injection,"Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3294-51)",Reverified,11/18/2021,Next Delivery: March 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8639,Potassium Acetate Injection,"Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 00409-8183-01)",Reverified,11/18/2021,Next Delivery: December 2021; Estimated Recovery: June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8640,Potassium Acetate Injection,"Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial NovaPlus (NDC 00409-3294-25)",Reverified,11/18/2021,Next Delivery: May 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8641,Potassium Acetate Injection,"Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial NovaPlus (NDC 00409-8183-25)",Reverified,11/18/2021,Next Delivery: December 2021; Estimated Recovery: June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8642,Potassium Acetate Injection,"Exela Pharma Sciences, LLC",Potassium Acetate Inj. 40mEq (2mEq/ml) 20mL (NDC 51754-2001-4),Revised,10/8/2021,Available. Direct shipments to hospitals at 200 vials max per week. Order via on-line portal at www.exelapharma.com,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,limited availability
8643,Potassium Chloride Concentrate Injection,B. Braun Medical Inc.,(2 mEq K /mL) 250mL bulk package Catalog# S9402-11(NDC 0264-1940-20),New,11/2/2021,Product on allocation to contracted customers.,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,limited availability
8644,Potassium Chloride Concentrate Injection,"Hospira, Inc.",10 mEq/5 mL (2 mEq/mL) Single Dose Glass Fliptop Vial (NDC 0409-6635-01),Reverified,11/18/2021,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8645,Potassium Chloride Concentrate Injection,"Hospira, Inc.",20 mEq/10 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial (NDC 0409-6651-06),Reverified,11/18/2021,Next Delivery: January 2022; Estimated Recovery: April 2022,,,Demand Increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8646,Potassium Chloride Concentrate Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial (NDC 00409-6653-05),Reverified,11/18/2021,Next Delivery: November 2021 and Estimated Recovery: February 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8647,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","60 mEq per 30 mL (2 mEq per mL), Multi dose, plastic vial, (NDC 63323-967-30)",Reverified,11/23/2021,Backordered. Next release January 2022.,,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8648,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","10 mEq per 5 mL(2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-05)",Reverified,11/23/2021,Backordered. Next release December 2021.,,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8649,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","20 mEq per 10 mL (2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-10)",Reverified,11/23/2021,Backordered. Next  release December 2021.,,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8650,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","40 mEq per 20 mL (2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-20)",Reverified,11/23/2021,Backordered. Next release December 2021.,,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8651,Pravastatin Sodium (Pravachol) Tablets,Bristol Myers Squibb Co.,20mg (NDC 0003-5178-05),New,3/24/2021,,"Last batch expiry is October 31, 2021.",,,Cardiovascular,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
8652,Pravastatin Sodium (Pravachol) Tablets,Bristol Myers Squibb Co.,40mg (NDC 0003-5194-10),New,3/24/2021,,"Last batch expiry is October 31, 2021.",,,Cardiovascular,To be Discontinued,3/24/2021,3/24/2021,,2021,discontinued
8653,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (Pred Forte) (NDC 11980-180-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8654,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8655,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (NDC 60758-119-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8656,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (NDC 60758-119-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8657,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 5mL in 1 bottle (NDC 61314-637-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8658,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 10mL in 1 bottle (NDC 61314-637-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8659,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 15mL in 1 bottle (NDC 61314-637-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8660,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8661,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (NDC 60758-119-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,10/31/2019,,,2021,
8662,Procardia Capsules,Pfizer Pharmaceuticals,10 mg capsule; Bottle of 100 (NDC 0069-2600-66),New,5/10/2021,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,5/10/2021,5/10/2021,,2021,discontinued
8663,"Progesterone Injection, USP",AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),500 mg/10 mL multiple dose vial (NDC 55150-306-10),Revised,9/23/2019,,,,,Endocrinology/Metabolism,Resolved,9/23/2019,,,2021,
8664,ProHance® (Gadoteridol) Injection,Bracco Diagnostics,"279.3 mg/mL, 5 x 10 mL pre-filled syringe, (NDC 0270-1111-16)",New,6/1/2021,,"Bracco offers ProHance® products in a variety of packaging options including both single-dose vials and ProHance® MultiPackTM  bottles.  All of these options are available: ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 5 mL Vial, NDC 0270-1111-04; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 10mL Vial, NDC 0270-1111-01; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 15 mL Vial, NDC 0270-1111-02; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 20 mL Vial, NDC 0270-1111-03; ProHance® MultiPackTM (Gadoteridol) Injection, 279.3 mg/mL - 5 x 50 mL Bottle, NDC 0270-1111-70",,,Medical Imaging,To be Discontinued,6/1/2021,6/1/2021,,2021,discontinued
8665,ProHance® (Gadoteridol) Injection,Bracco Diagnostics,"279.3 mg/mL, 5 x 17 mL pre-filled syringe, (NDC 0270-111-45)",New,6/1/2021,,"Bracco offers ProHance® products in a variety of packaging options including both single-dose vials and ProHance® MultiPackTM  bottles.  All of these options are available: ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 5 mL Vial, NDC 0270-1111-04; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 10mL Vial, NDC 0270-1111-01; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 15 mL Vial, NDC 0270-1111-02; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 20 mL Vial, NDC 0270-1111-03; ProHance® MultiPackTM (Gadoteridol) Injection, 279.3 mg/mL - 5 x 50 mL Bottle, NDC 0270-1111-70",,,Medical Imaging,To be Discontinued,6/1/2021,6/1/2021,,2021,discontinued
8666,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL vial (NDC 0641-0928-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8667,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL ,1 mL vial (NDC 0641-0929-25)",Reverified,10/12/2021,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8668,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL ampul (NDC 0641-1495-35)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8669,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL ampul (NDC 0641-1496-35)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8670,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL vial (NDC 0641-6084-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8671,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL ,1 mL vial (NDC 0641-6085-25)",Reverified,10/12/2021,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8672,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL ampul (NDC 0641-6082-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8673,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL, 1 mL ampul (NDC 0641-6083-25)",Reverified,10/12/2021,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8674,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","25 mg/mL, Carton of 25 ampuls (NDC 39822-5525-3)",Reverified,2/25/2021,Available,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8675,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","50 mg/mL, Carton of 25 ampuls (NDC 39822-5550-6)",Reverified,2/25/2021,Available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2021,available
8676,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2021,discontinued
8677,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2021,discontinued
8678,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2021,discontinued
8679,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)",New,12/19/2019,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/2019,12/19/2019,,2021,discontinued
8680,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","1000 mg per 100 mL (10 mg per mL), single patient use only, 100 mL (NDC 63323-269-65)",Reverified,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8681,Propofol Injectable Emulsion,Sagent Pharmaceuticals,200mg per 20ml (NDC 25021-608-20),Reverified,9/3/2021,Available. On Allocation,,,Demand increase due to Covid-19,Anesthesia,Current,,,,2021,limited availability
8682,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 10X100ML VL (NDC 0591-2136-68),Revised,11/8/2021,Limited supply available. Next Delivery ETA Late November 2021 and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,,2021,limited availability
8683,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-30),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: May 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
8684,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-33),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
8685,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-24),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
8686,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",200mg/20mL  10ct (NDC 43598-265-58),Revised,11/8/2021,Pack size discontinued,,,,Anesthesia,Current,,,,2021,discontinued
8687,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, individual (NDC 43598-265-20)",Revised,11/8/2021,No current supply,Partial shipments on allocation April-December 2021,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2021,not available
8688,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",500mg/50mL  20ct (NDC 43598-548-21),Revised,11/8/2021,Allocating to Wholesalers,Check Wholesaler Inventory,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2021,limited availability
8689,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","500mg/50mL vial, individual (NDC 43598-548-50)",Revised,11/8/2021,Allocating to Wholesalers,Check Wholesaler Inventory,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2021,limited availability
8690,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 20X50ML VL (NDC 0591-2136-51),Revised,11/8/2021,Limited supply available. Next Delivery ETA Late November 2021 and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,,2021,limited availability
8691,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 25X20ML VL (NDC 0591-2136-95),Revised,11/8/2021,Limited supply available. Next Delivery ETA Late November 2021 and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,,2021,limited availability
8692,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), single patient use only, 10 mL (NDC 63323-269-10)",Reverified,11/23/2021,Available,Check wholesaler inventory,,,Anesthesia,Current,,,,2021,available
8693,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), single patient use only, 20 mL (NDC 63323-269-29)",Reverified,11/23/2021,Available,Check wholesaler inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8694,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL), single patient use only, 50 mL (NDC 63323-269-50)",Reverified,11/23/2021,Available,Check wholesaler inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8695,Propofol Injectable Emulsion,Sagent Pharmaceuticals,500mg per 50ml (NDC 250-21-608-50),Reverified,9/3/2021,Available,,,,Anesthesia,Current,,,,2021,available
8696,Propofol Injectable Emulsion,Sagent Pharmaceuticals,1000mg per 100ml (NDC 25021-608-51),Reverified,9/3/2021,Available,,,,Anesthesia,Current,,,,2021,available
8697,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0209-10),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
8698,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0234-20),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
8699,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0248-10),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,limited availability
8700,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6194-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8701,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 50 mL vial (NDC 0641-6195-20",Revised,10/12/2021,This presentation is temporarily on backorder.  Recovery is TBD at this time.,Additional lots will be scheduled for manufacturing.   Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8702,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 100 mL vial (NDC 0641-6196-10",Revised,10/12/2021,This presentation is temporarily on backorder.  Recovery is TBD at this time.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8703,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, 10ct (NDC 43598-549-10)",Revised,11/8/2021,Allocating to Wholesalers,Check Wholesaler Inventory,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2021,limited availability
8704,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, individual (NDC 43598-549-52)",Revised,11/8/2021,Allocating to Wholesalers,Check Wholesaler Inventory,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2021,limited availability
8705,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, 25ct (NDC 43598-265-25)",Revised,11/8/2021,No current supply,Partial shipments on allocation April-December 2021,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2021,not available
8706,Protamine Sulfate Injection,"Fresenius Kabi USA, LLC","50 mg per 5 mL (10 mg per mL), single dose vial, preservative free,  (NDC 63323-229-05)",Reverified,11/23/2021,Available,Check wholesaler inventory,,,Hematology,Current,,,,2021,available
8707,Protamine Sulfate Injection,"Fresenius Kabi USA, LLC","250 mg per 25 mL (10 mg per mL), single dose vial, preservative free, (NDC 63323-229-30)",Reverified,11/23/2021,Available,Check wholesaler inventory,,,Hematology,Current,,,,2021,available
8708,Rabeprazole Sodium Delayed Release Tablets,Teva Pharmaceuticals,20mg  (NDC 0093-0064-56 ),New,1/22/2021,,,,,Gastroenterology,To be Discontinued,1/22/2021,1/22/2021,,2021,discontinued
8709,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,500 mg  (NDC 45963-418-50),New,7/6/2020,,,,,Cardiovascular,To be Discontinued,7/6/2020,7/6/2020,,2021,discontinued
8710,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,1000 mg  (NDC 45963-419-50),New,7/6/2020,,,,,Cardiovascular,To be Discontinued,7/6/2020,7/6/2020,,2021,discontinued
8711,Repaglinide Tablets,Sandoz,1mg tablets (NDC 0781-5149-01),New,2/2/2018,,,,,Endocrinology/Metabolism,To be Discontinued,2/2/2018,2/2/2018,,2021,discontinued
8712,Rifampin (Rifadin) Capsules,Sanofi-Aventis,150 mg capsules (NDC 0068-0510-30),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,6/15/2020,6/15/2020,,2021,discontinued
8713,Rifampin (Rifadin) Capsules,Sanofi-Aventis,300 mg capsules (NDC 0068-0508-60),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,6/15/2020,6/15/2020,,2021,discontinued
8714,Rifampin Capsules,"Lannett Company, Inc.",150 mg )NDC 0527-1393-30),New,2/2/2021,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/2021,2/2/2021,,2021,discontinued
8715,Rifampin Capsules,"Lannett Company, Inc.",150 mg (NDC 0527-1393-01),New,2/2/2021,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/2021,2/2/2021,,2021,discontinued
8716,Rifampin Capsules,"Lannett Company, Inc.",300 mg (NDC 0527-1315-30),New,2/2/2021,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/2021,2/2/2021,,2021,discontinued
8717,Rifampin Capsules,"Lannett Company, Inc.",300 mg (NDC 0527-1315-06),New,2/2/2021,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/2021,2/2/2021,,2021,discontinued
8718,Rifampin Capsules,"Lannett Company, Inc.",300 mg (NDC 0527-1315-01),New,2/2/2021,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/2021,2/2/2021,,2021,discontinued
8719,Rifampin Injection,"Fresenius Kabi USA, LLC","600 mg per vial, PF, Lyophilized powder (NDC 63323-351-20)",Revised,11/23/2021,Backordered. Next release not available at this time.,Check wholesaler inventory,,,Anti-Infective,Current,,,,2021,not available
8720,Rifampin Injection,Sanofi,"600 mg/10 mL, Lyophilized powder (NDC 0068-0597-01)",Revised,6/22/2021,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,,2021,available
8721,Rifampin Injection,"Mylan Institutional, a Viatris company","600 mg, (Lyophilizate in Single Dose Vials) (NDC 67457-445-60)",Reverified,11/29/2021,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2021,available
8722,Rifampin/Isoniazid (Rifamate) Capsules,Sanofi-Aventis,150 mg/300 mg capsules (NDC 0068-0509-60),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,6/15/2020,6/15/2020,,2021,discontinued
8723,Rifampin/Isoniazid/Pyrazinamide (Rifater) Tablets,Sanofi-Aventis,150 mg/300 mg/120 mg tablets (NDC 0088-0576-41),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,6/15/2020,6/15/2020,,2021,discontinued
8724,Rifapentine Tablets,Sanofi,"Rifapentine (Piftin) Tablets, 150 mg (NDC 0088-2102-24)",Revised,6/22/2021,Available,,,Demand increase for the drug,Anti-Infective,Current,3/25/2020,,,2021,available
8725,Risedronate Tablets,Allergan Sales LLC,5 mg tablets (NDC 0430-0471-15),New,12/9/2019,,,,,Musculoskeletal,To be Discontinued,12/9/2019,12/9/2019,,2021,discontinued
8726,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8727,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8728,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8729,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8730,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8731,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8732,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8733,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8734,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8735,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8736,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8737,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8738,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8739,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-60),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8740,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8741,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-10),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8742,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 3 mg (NDC 50458-330-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8743,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 2 mg (NDC 50458-320-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8744,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 1 mg (NDC 50458-300-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8745,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.5 mg (NDC 50458-302-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8746,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-50),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8747,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-01),New,5/24/2018,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/2018,5/24/2018,,2021,discontinued
8748,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 5mL vial (NDC 70860-651-05),Revised,11/2/2018,Available,,,Available,Anesthesia,Resolved,11/2/2018,,,2021,available
8749,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 10mL vial (NDC 70860-651-10),Revised,11/2/2018,Available,,,Available,Anesthesia,Resolved,11/2/2018,,,2021,available
8750,Ropivacaine Hydrochloride Injection,Akorn Pharmaceuticals,"0.5% 5mg/mL, 30mL, 1 Vial (NDC 17478-0081-30)",Revised,2/12/2021,Available,,,Other,Anesthesia,Current,,,,2021,available
8751,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-10),Reverified,11/18/2021,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8752,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-20),Reverified,11/18/2021,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8753,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9301-30),Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: November 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8754,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/20 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9302-20),Reverified,11/18/2021,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8755,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-10),Reverified,11/18/2021,Available,,,Other,Anesthesia,Current,,,,2021,available
8756,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-20),Reverified,11/18/2021,Available,,,Other,Anesthesia,Current,,,,2021,available
8757,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 20 mL Single Dose Vials (NDC 55150-195-20),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8758,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 100 mL Single Dose Infusion Bottles (NDC 55150-196-99),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8759,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 20 mL Single Dose Vials (NDC 55150-197-20),Reverified,11/5/2021,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8760,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-198-30),Reverified,11/5/2021,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8761,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 20 mL Single Dose Vials (NDC 55150-199-20),Reverified,11/5/2021,"Currently on backorder, next shipment TBD",Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8762,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Single Dose Vials (NDC 55150-200-10),Reverified,11/5/2021,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
8763,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Single Dose Vials (NDC 55150-201-20),Reverified,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
8764,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-10)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8765,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-20)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8766,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-286-20)",Revised,11/23/2021,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,not available
8767,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-287-20)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8768,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Plastic Ampule, Sterile-Pak (63323-288-10)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8769,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-288-20)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8770,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Free Flex Bag (NDC 63323-285-61)",Revised,11/23/2021,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,not available
8771,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Free Flex Bag (NDC 63323-285-63)",Revised,11/23/2021,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,not available
8772,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-285-65)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,,2021,not available
8773,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-285-64)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8774,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (500 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-286-00)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8775,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (1,000 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-286-63)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,,2021,available
8776,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Single Dose Vial (NDC 63323-285-13)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8777,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Single Dose Vial (NDC 63323-285-23)",Revised,11/23/2021,Backordered. Next release April 2021.,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,,2021,not available
8778,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Single Dose Vial (NDC 63323-286-35)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8779,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Single Dose Vial (NDC 63323-286-23)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,,2021,available
8780,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Single Dose Vial (NDC 63323-287-21)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8781,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Single Dose Vial (NDC 63323-288-11)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2021,available
8782,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Single Dose Vial (NDC 63323-288-21)",Revised,11/23/2021,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2021,available
8783,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Sterile-Pack, Single Dose Vial (NDC 63323-286-31)",Revised,11/23/2021,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2021,available
8784,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,500 mg per 100 mL (5 mg per mL 0.5%) (NDC 25021-652-82 ),Reverified,9/3/2021,Available,,,,Anesthesia,Current,,,,2021,available
8785,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,"1,000 mg per 200 mL (5 mg per mL 0.5%) (NDC 25021-652-87)",Reverified,9/3/2021,Available,,,,Anesthesia,Current,,,,2021,available
8786,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x100mL (NDC 25021-671-82),Reverified,9/3/2021,Available,,,,Anesthesia,Current,,,,2021,available
8787,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x200mL (NDC 25021-671-87),Reverified,9/3/2021,Available,,,,Anesthesia,Current,,,,2021,available
8788,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.2%, 40 mg/20 mL (2 mg/mL) single dose vial (NDC 43066-015-10)",New,12/22/2020,Available,Distributed by Baxter Healthcare; Contact Baxter Healthcare: 1-888-229-0001,,,Anesthesia,Current,,,,2021,available
8789,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.5%, 100 mg/20 mL (5 mg/mL) single dose vial (NDC 43066-019-10)",New,12/22/2020,Available,Distributed by Baxter Healthcare; Contact Baxter Healthcare: 1-888-229-0001,,,Anesthesia,Current,,,,2021,available
8790,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.5%, 150 mg/30 mL (5 mg/mL) single dose vial (NDC 43066-023-10)",New,12/22/2020,Available,Distributed by Baxter Healthcare; Contact Baxter Healthcare: 1-888-229-0001,,,Anesthesia,Current,,,,2021,available
8791,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"1%, 200 mg/20 mL (10 mg/mL) single dose vial (NDC 43066-027-10)",New,12/22/2020,Available,Distributed by Baxter Healthcare; Contact Baxter Healthcare: 1-888-229-0001,,,Anesthesia,Current,,,,2021,available
8792,Rosiglitasone Tablets,GlaxoSmithKline,2 mg (NDC 0173-0861-18),New,4/23/2021,,This product discontinuation is a business-related decision. GSK has ceased distribution of this product.,,,Endocrinology/Metabolism,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8793,Rosiglitasone Tablets,GlaxoSmithKline,4 mg (NDC 0173-0863-13),New,4/23/2021,,This product discontinuation is a business-related decision. GSK has ceased distribution of this product.,,,Endocrinology/Metabolism,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8794,Salmeterol Xinafoate Inhalational Powder,GlaxoSmithKline,"50 mcg, 28 blisters (NDC 0173-0520-00)",New,4/23/2021,,This product discontinuation is a business-related decision. GSK has ceased distribution of this product. The 60-blister presentation will continue to be available.,,,Pulmonary/Allergy,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
8795,Samarium SM 153 Lexidronam  (Quadramet) Injection,Lantheus Medical Imaging INC,150mCi (NDC 11994-016-01),New,10/28/2021,,Manufacturing is discontinued.  Please contact 800-362-2668 for additional information.,,,Oncology,To be Discontinued,10/28/2021,10/28/2021,,2021,discontinued
8796,Saquinavir Mesylate (Invirase) 200mg Capsules,"Genentech, Inc",200 mg capsules (NDC 0004-0245-15),New,2/6/2018,,"Roche intends to stop-shipping Saquinavir Mesylate (Invirase) 200 mg Capsules on March 31, 2018 with product availability continuing until the September 2018 expiry date.  Saquinavir Mesylate (Invirase) 500mg Tablets are still available.",,,Antiviral,To be Discontinued,2/6/2018,2/6/2018,,2021,discontinued
8797,Sclerosol Intrapleural Aerosol,Lymol Medical Corp.,Sclerosol 4 GM (NDC 63256-100-30),Reverified,12/11/2019,Unavailable,,,Other,Pulmonary/Allergy,Current,,,,2021,not available
8798,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 24s (NDC 0378-6470-44),Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/2019,,,2021,
8799,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,20mg/ml (NDC 64980-409-06),Revised,4/13/2021,,,Distributed by Rising Pharmaceuticals Contact Rising Pharmaceuticals : +1 (201) 961-9000,,Psychiatry,Resolved,4/13/2021,,,2021,
8800,"Sertraline Hydrochloride Oral Solution, USP","Upjohn US 1 LLC, a Viatris Company","Sertraline Hydrochloride 60 mL (20 mg/mL) oral concentrate, with 12% alcohol; bottle with calibrated dropper (NDC 59762-0067-1)",Revised,4/13/2021,,,"Greenstone label. To order, contact Pfizer at 800-553-4535.",,Psychiatry,Resolved,4/13/2021,,,2021,
8801,"Sertraline Hydrochloride Oral Solution, USP","Upjohn US 1 LLC, a Viatris Company","Zoloft (sertraline hydrochloride) 60 mL (20 mg/mL) oral concentrate, with 12% alcohol; bottle with calibrated dropper (NDC 0049-0050-01)",Revised,4/13/2021,,,"Pfizer label. To order, contact Pfizer at 800-553-4535.",,Psychiatry,Resolved,4/13/2021,,,2021,
8802,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,"20mg/ml, 60ml  (NDC 16714-601-02)",Revised,4/13/2021,,,Northstar Rx label. Product Distributed by McKesson:  +1 (972) 446-4800,,Psychiatry,Resolved,4/13/2021,,,2021,
8803,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 30 count (NDC 16729-215-10)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8804,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 90 count (NDC 16729-215-15)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8805,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 500 count (NDC 16729-215-16)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8806,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 90 count (NDC 16729-216-15)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8807,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 500 count (NDC 16729-216-16)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8808,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 90 count (NDC 16729-217-15)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8809,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 500 count (NDC 16729-217-16)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8810,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 65862-011-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8811,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 65862-011-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8812,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 65862-011-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8813,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 65862-012-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8814,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 65862-012-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8815,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 65862-012-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8816,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 65862-013-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8817,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 65862-013-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8818,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 65862-013-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8819,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 16714-611-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8820,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 16714-611-04)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8821,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 16714-611-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8822,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 1000 count (NDC 16714-611-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8823,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 16714-612-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8824,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 16714-612-04)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8825,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 16714-612-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8826,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 1000 count (NDC 16714-612-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8827,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 16714-613-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8828,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 16714-613-04)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8829,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 16714-613-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8830,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 1000 count (NDC 16714-613-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8831,Sertraline Hydrochloride Tablets,Viatris,Zoloft 25 mg; Bottle of 30 tablets (NDC 0049-4960-30); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8832,Sertraline Hydrochloride Tablets,Viatris,Zoloft 50 mg; Bottle of 30 tablets (NDC 0049-4900-30); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8833,Sertraline Hydrochloride Tablets,Viatris,Zoloft 50 mg; Blister of 10 tablets (NDC 0049-4900-41); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8834,Sertraline Hydrochloride Tablets,Viatris,Zoloft 100 mg; Bottle of 30 tablets (NDC 0049-4910-30); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8835,Sertraline Hydrochloride Tablets,Viatris,Zoloft 100 mg; Blister of 10 tablets (NDC 0049-4910-41); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8836,Sertraline Hydrochloride Tablets,Viatris,25 mg; Bottle of 30 tablets (NDC 59762-6347-1); Greenstone label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8837,Sertraline Hydrochloride Tablets,Viatris,50 mg; Bottle of 30 tablets (NDC 59762-6443-1); Greenstone label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8838,Sertraline Hydrochloride Tablets,Viatris,100 mg; Bottle of 30 tablets (NDC 59762-5160-1); Greenstone label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8839,Sertraline Hydrochloride Tablets,Viatris,100 mg; Bottle of 100 tablets (NDC 59762-5160-2); Greenstone label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/2021,,,2021,
8840,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 30 count (NDC 68180-351-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8841,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 90 count  (NDC 68180-351-09)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8842,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 1000 count (NDC 68180-351-03)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8843,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 30 count (NDC 68180-352-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8844,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 90 count (NDC 68180-352-09)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8845,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 500 count (NDC 68180-352-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8846,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 5000 count (NDC 68180-352-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8847,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 30 count (NDC 68180-353-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8848,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 90 count (NDC 68180-353-09)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8849,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 500 count (NDC 68180-353-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8850,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 5000 count (NDC 68180-353-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8851,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 69097-833-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8852,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 69097-833-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8853,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 69097-833-12)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8854,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 69097-834-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8855,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 69097-834-12)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8856,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 69097-835-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8857,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 69097-835-12)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8858,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 76282-212-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8859,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 60 count (NDC 76282-212-60)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8860,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 76282-212-90)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8861,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 100 count (NDC 76282-212-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8862,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 180 count (NDC 76282-212-18)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8863,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 76282-212-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8864,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 76282-213-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8865,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 60 count (NDC 76282-213-60)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8866,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 90 count (NDC 76282-213-90)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8867,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 100 count (NDC 76282-213-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8868,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 180 count (NDC 76282-213-18)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8869,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 76282-213-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8870,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 76282-214-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8871,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 60 count (NDC 76282-214-60)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8872,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 90 count (NDC 76282-214-90)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8873,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 100 count (NDC 76282-214-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8874,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 180 count (NDC 76282-214-18)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8875,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 76282-214-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,3/9/2021,,,2021,
8876,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/12.5 mL; vial (NDC 0069-0338-01),Revised,10/24/2019,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2021,
8877,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,20 mg; tablets (NDC 0069-4190-68),Revised,10/24/2019,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2021,
8878,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/mL (powder); bottle (NDC 0069-0336-21),Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2021,
8879,Sildenafil Citrate (REVATIO),Novitium Pharma LLC,"10 mg/mL, (NDC 70954-168-10)",Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/2019,,,2021,
8880,Simeprevir Capsules,Janssen Pharmaceuticals,150mg capsules (NDC 59676-225-28),New,5/23/2018,,,,,Antiviral,To be Discontinued,5/23/2018,5/23/2018,,2021,discontinued
8881,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,5 mg (NDC 0093-7152-98),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2021,discontinued
8882,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,10 mg (NDCs 0093-7153-93 / 0093-7153-56 / 0093-7153-19 / 0093-7153-31 / 0093-7153-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2021,discontinued
8883,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,20 mg (NDCs 0093-7154-93 / 0093-7154-56 / 0093-7154-31 / 0093-7154-19 / 0093-7154-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2021,discontinued
8884,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,40 mg (NDCs 0093-7155-93 / 0093-7155-56 / 0093-7155-31 / 0093-7155-19 / 0093-7155-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2021,discontinued
8885,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,80 mg (NDCs 0093-7156-98 / 0093-7156-93 / 0093-7156-56 / 0093-7156-19 / 0093-7156-10),New,2/6/2018,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2021,discontinued
8886,Simvastatin (Zocor) Tablets,Merck Sharp & Dohme Corp.,5 mg Tablets bottles of 30 (NDC 0006-0726-31),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,2/6/2018,2/6/2018,,2021,discontinued
8887,Simvastatin Tablets,Merck Sharp & Dohme Corp.,80 mg (NDCs 0006-0543-31 and 0006-0543-54),New,7/27/2021,,,,,Cardiovascular,To be Discontinued,7/27/2021,7/27/2021,,2021,discontinued
8888,Sincalide (Kinevac) Lyophilized Powder for Injection,Bracco Diagnostics,Supplied in packages of 10 single dose vials containing 5 mcg of sincalide per vial (NDC 0270-0556-15),Reverified,7/16/2021,Available,,,Delay in shipping of the drug,Medical Imaging;Other,Current,12/17/2015,,,2021,available
8889,Sodium Acetate Injection,"Hospira, Inc.",100 mEq/50 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-05),Reverified,11/18/2021,Next Delivery: March 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,,2021,not available
8890,Sodium Acetate Injection,"Hospira, Inc.",200 mEq/100 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-06),Reverified,11/18/2021,Next Delivery: March 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,,2021,not available
8891,Sodium Acetate Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-7299-73),Reverified,11/18/2021,Next Delivery: December 2021; Estimated Recovery: June 2022,,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,,2021,not available
8892,Sodium Acetate Injection,"Fresenius Kabi USA, LLC",32.8% 400 mEq 100mL PBP (NDC 63323-0032-00),Reverified,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,,2021,not available
8893,Sodium Acetate Injection,Milla Pharmaceuticals,100 mEq/50 mL (2 mEq/mL) (NDC 69784-230-20),New,9/1/2021,Available,"Distributed by Woodward Pharma Services LLC Contact Information:
Phone: 248-308-1120
Fax: 248-480-0153
Email: info@woodwardphrma.com",,Other,Total Parenteral Nutrition,Current,,,,2021,available
8894,Sodium Acetate Injection,Milla Pharmaceuticals,200 mEq/100 mL (2 mEq/mL) (NDC 69784-231-20),New,9/1/2021,Available,"Distributed by Woodward Pharma Services LLC Contact Information:
Phone: 248-308-1120
Fax: 248-480-0153
Email: info@woodwardphrma.com",,Other,Total Parenteral Nutrition,Current,,,,2021,available
8895,Sodium Bicarbonate Injection,"Hospira, Inc.",2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial (4.2% Concentration) (NDC 0409-5555-02),Revised,11/2/2021,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,not available
8896,Sodium Bicarbonate Injection,"Hospira, Inc.",2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial Novaplus®  (4.2% Concentration) (NDC 0409-5555-01),Revised,11/2/2021,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,available
8897,Sodium Bicarbonate Injection,"Hospira, Inc.",44.6 mEq/50 mL (0.9 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe (7.5% concentration) (NDC 0409-4916-14) (old NDC 0409-4916-34),Revised,11/18/2021,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,available
8898,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) Single Dose Glass Fliptop Vial (8.4% concentration) (NDC 0409-6625-14) (old NDC 0409-6625-02),Revised,11/18/2021,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,available
8899,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) Single Dose Vial Novaplus® (8.4% concentration) (NDC 0409-6625-35),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,limited availability
8900,Sodium Bicarbonate Injection,"Hospira, Inc.",Pediatric 10 mEq/10 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-4900-14) (old NDC 0409-4900-34),Revised,11/18/2021,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,available
8901,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05)",Revised,11/23/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,available
8902,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL)  (84 mg per mL)(NDC 63323-089-50)",Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,not available
8903,Sodium Bicarbonate Injection,"Hospira, Inc.",Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02),Revised,11/2/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2021,discontinued
8904,Sodium Bicarbonate Injection,"Hospira, Inc.",Infant 5 mEq/10 mL (0.5 mEq/mL) ABBOJECT® Glass Syringe (4.2% Concentration) (NDC 0409-5534-14) (old NDC 0409-5534-34),Revised,11/2/2021,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2021,available
8905,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-6637-14) (old NDC 0409-6637-34),Revised,11/2/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2021,limited availability
8906,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc./IMS","Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1)",Revised,11/2/2021,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/2016,,,2021,available
8907,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate Inj. USP, 8.4%, 50mL (NDC 51754-5001-1)",Revised,5/6/2021,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2021,available
8908,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 76297-001-11)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8909,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container (Legacy Hospira NDC 0409-7984-23)
(ICU Medical NDC 0990-7984-23)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8910,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 76297-001-21)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8911,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 76297-001-31)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8912,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC NDC 76297-001-01)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8913,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC NDC 76297-001-41)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8914,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-11)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8915,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-36)
(ICU Medical NDC 0990-7984-36)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8916,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",25 mL flexible container (NDC 0409-7984-20),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8917,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-06)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8918,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 250 mL, in VIAFLEX Container.   Product code FZB1322 (NDC 0338-9517-50)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8919,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 500 mL, in VIAFLEX Container.   Product code FZB1323 (NDC 0338-9517-30)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8920,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 1,000 mL, in VIAFLEX Container.   Product code FZB1324 (NDC 0338-9517-16)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8921,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,250 mL Product code 2B1322Q (NDC 00338-0049-02),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8922,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,500 mL  Product code 2B1323Q (NDC 00338-0049-03),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8923,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1323D (NDC 0338-9543-04)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8924,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,1000 mL Product code 2B1324X (NDC 00338-0049-04),Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8925,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1324D (NDC 0338-9543-06)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8926,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL, Non-PVC, Dripless Access Container (DAC) VIAFLO Container Product code UE1322D (NDC 0338-9543-02)",Revised,11/13/2019,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/2019,,,2021,
8927,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",100 mL vials (NDC 63323-0088-61),Revised,11/23/2021,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2021,not available
8928,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",200 mL vials (NDC 63323-0088-63),Revised,11/23/2021,Backordered. Next release January 2022.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2021,not available
8929,Sodium Chloride 23.4% Injection,"Hospira, Inc.",400 mEq/100 mL (4 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-1141-02),Reverified,11/18/2021,Limited Supply Available. Next Delivery: March 2022; Estimated Recovery: August 2022,,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2021,limited availability
8930,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",30 mL vials (NDC 63323-0187-30),Revised,11/23/2021,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2021,not available
8931,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose plastic vial, 0.9%, (18 mg per 2 mL)(9 mg per mL) (NDC 63323-186-02)",Revised,11/23/2021,Backordered. Next release Q1-2022.,Check wholesalers for inventory,,Increase in Demand,Other,Current,,,,2021,not available
8932,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (90 mg per 10 mL)(9 mg per mL) (NDC 63323-186-10)",Revised,11/23/2021,Backordered. Next release January 2022.,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,,2021,not available
8933,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (180 mg per 20 mL)(9 mg per mL) (NDC 63323-186-20)",Revised,11/23/2021,Backordered. Next release not available at this time.,,,Manufacturing delay,Other,Current,,,,2021,not available
8934,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose tear top vial, 0.9%, (900 mg per 100 mL)(9 mg per mL) (NDC 63323-186-00)",Revised,11/23/2021,Backordered.  Next release date not available at this time.,,,Increase in Demand,Other,Current,,,,2021,not available
8935,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose Plastic Fliptop Vial (NDC 00409-4888-10),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2022,,,Demand increase for the drug,Other,Current,,,,2021,limited availability
8936,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose LifeShield Plastic Fliptop Vial (NDC 00409-4888-12),Revised,11/18/2021,Next Delivery: January 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Other,Current,,,,2021,not available
8937,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-20),Revised,11/18/2021,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Other,Current,,,,2021,limited availability
8938,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-50),Revised,11/18/2021,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: July 2022,,,Demand increase for the drug,Other,Current,,,,2021,limited availability
8939,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Medefil, Inc.","Sodium Chloride Injection, USP, 0.9%, in a plastic syringe (10 mL) (NDC 64253-202-30)",Reverified,2/23/2021,Available,Check wholesalers for inventory,,Available,Other,Current,,,,2021,available
8940,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.9%, 2 mL vial (NDC 0641-0497-25)",Reverified,10/12/2021,This presentation is temporarily on backorder.  Recovery is TBD at this time.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Other,Current,,,,2021,not available
8941,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-32),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2021,discontinued
8942,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-33),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2021,discontinued
8943,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-35),Revised,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2021,discontinued
8944,Sodium Phosphates Injection,"Hospira, Inc.","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL, vial (NDC 0409-7391-72)",Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8945,Sodium Phosphates Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol/5 mL, Sodium 20 mEq/5 mL, vial (NDC 63323-170-05)",Revised,11/23/2021,Backordered. Next release December 2021.,Manufacturing delay. Check wholesaler for inventory.,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8946,Sodium Phosphates Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL, vial (NDC 63323-170-15)",Revised,11/23/2021,Backordered. Next release December 2021.,Manufacturing delay. Check wholesaler for inventory.,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2021,not available
8947,Somatropin Recombinant (Humatrope) Injection,Eli Lilly and Co.,5 mg kit (NDC 0002-7335-11) contains 5 mg/mL in 1 vial (NDC 0002-7349-01) of Humatrope and 5 mL in 1 vial (NDC 0002-7336-01) of Sterile Diluent,New,7/7/2020,,Other Somatropin Recombinant (Humatrope) Injection products will continue to be available to treat patients.  The product distribution will continue until end of December 2020.,,,Hematology,To be Discontinued,7/7/2020,7/7/2020,,2021,discontinued
8948,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 100 (NDC 0228-2803-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
8949,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 500 (NDC 0228-2803-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
8950,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 100 (NDC 0228-2672-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
8951,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 500 (NDC 0228-2672-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
8952,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 100 (NDC 0228-2673-11)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
8953,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 500 (NDC 0228-2673-50)",New,5/22/2018,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/2018,5/22/2018,,2021,discontinued
8954,Stavudine Capsules,Mylan Pharmaceuticals Inc.,20mg capsules (NDC 0378-5041-91),New,4/30/2018,,,,,Antiviral,To be Discontinued,4/30/2018,4/30/2018,,2021,discontinued
8955,Sterile Water,American Regent/Luitpold,5 mL vial (NDC 00517-3005-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2021,
8956,Sterile Water,American Regent/Luitpold,10 mL vial (NDC 00517-3010-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2021,
8957,Sterile Water,American Regent/Luitpold,20 mL vial (NDC 00517-3020-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2021,
8958,Sterile Water,West-Ward Pharmaceuticals,10 mL Single Dose Vial (NDC 0641-6147-25),Revised,8/2/2019,,,,,Other,Resolved,8/2/2019,,,2021,
8959,Sterile Water for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mL vial (NDC 0641-6147-10),New,11/23/2021,This presentation is temporarily on backorder.,Additional lots have been manufactured and will be available in the December 2021 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Other,Current,11/23/2021,11/23/2021,,2021,not available
8960,Sterile Water for Injection,"Hospira, Inc.",10 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-10),New,11/23/2021,Limited Supply. Next delivery: December 2021; Estimated recovery: December 2022,,,Demand increase for the drug,Other,Current,11/23/2021,11/23/2021,,2021,limited availability
8961,Sterile Water for Injection,"Hospira, Inc.",20 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-20),New,11/23/2021,Next delivery: December 2021; Estimated recovery: April 2022,,,Demand increase for the drug,Other,Current,11/23/2021,11/23/2021,,2021,not available
8962,Sterile Water for Injection,"Hospira, Inc.",50 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-50),New,11/23/2021,Next delivery: December 2021; Estimated recovery: June 2022,,,Demand increase for the drug,Other,Current,11/23/2021,11/23/2021,,2021,not available
8963,Sterile Water for Injection,"Hospira, Inc.",100 mL Single Dose Glass Fliptop Vial (NDC 00409-4887-99),New,11/23/2021,Next delivery: December 2021; Estimated recovery: December 2022,,,Demand increase for the drug,Other,Current,11/23/2021,11/23/2021,,2021,not available
8964,Sterile Water for Injection,"Fresenius Kabi USA, LLC",10 mL Vial (NDC 63323-0185-10),New,11/23/2021,TBD,,,TBD,Other,Current,11/23/2021,11/23/2021,,2021,unclear
8965,Sterile Water for Injection,"Fresenius Kabi USA, LLC",20 mL Vial (NDC 63323-0185-20),New,11/23/2021,TBD,,,TBD,Other,Current,11/23/2021,11/23/2021,,2021,unclear
8966,Sterile Water for Injection,"Fresenius Kabi USA, LLC",50 mL Vial (NDC 63323-0185-50),New,11/23/2021,TBD,,,TBD,Other,Current,11/23/2021,11/23/2021,,2021,unclear
8967,Succimer (Chemet) Capsules,Recordati Rare Diseases,100 mg capsules (NDC 55292-201-11),Revised,9/14/2021,,,Available,,Hematology,Resolved,9/14/2021,9/14/2021,,2021,
8968,Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment,Abbvie,Blephamide S.O.P. (sulfacetamide sodium 10% and prednisolone acetate 0.2%) 1 TUBE in 1 CARTON 3.5 g in 1 TUBE (NDC 0023-0313-04),New,9/13/2021,,Discontinuation of the manufacture of the drug,,,Ophthalmology,To be Discontinued,9/13/2021,9/13/2021,,2021,discontinued
8969,Sulfasalazine Tablets,Chartwell Pharma,500 mg tablets; Bottle of 100 (NDC 23155-019-01),Reverified,9/14/2021,"Product being allocated.  Distributed by Avet. For inquiries, call Customer Service number 1-855-228-9470",,,Other,Gastroenterology,Current,,,,2021,limited availability
8970,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 100 (NDC 0013-0101-10),Reverified,11/18/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8971,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 300 (NDC 0013-0101-20/0013-0101-30),Reverified,11/18/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8972,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 100 (NDC 0013-0102-50),Reverified,11/18/2021,Next Delivery: November 2021; Estimated Recovery: December 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,not available
8973,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 300 (NDC 0013-0102-20/0013-0102-60),Reverified,11/18/2021,Available,,,Other,Gastroenterology,Current,,,,2021,available
8974,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 100 (NDC 59762-0104-1/59762-0104-5),Reverified,11/18/2021,Next Delivery: January 2022; Estimated recovery: April 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,not available
8975,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 300 (NDC 59762-0104-6),Reverified,11/18/2021,Next Delivery: December 2021; Estimated recovery: March 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,not available
8976,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 100 (NDC 59762-5000-1/59762-5000-5),Reverified,11/18/2021,Next Delivery: January 2022; Estimated Recovery: April 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,not available
8977,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 300 (NDC 59762-5000-6),Reverified,11/18/2021,Next Delivery: December 2021; Estimated recovery: March 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,,2021,not available
8978,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 100 Count (NDC 00591-0796-01),Reverified,11/8/2021,Available,This product is on allocation.,,,Gastroenterology,Current,,,,2021,available
8979,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 1000 Count (NDC 00591-0796-10),Reverified,11/8/2021,Available,This product is on allocation.,,,Gastroenterology,Current,,,,2021,available
8980,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 500 Count (NDC 00591-0796-05),Reverified,11/8/2021,Available,This product is on allocation.,,,Gastroenterology,Current,,,,2021,available
8981,Sumatriptan (Sumavel DosePro) Injection,"Endo Pharmaceuticals, Inc.",Sumavel DosePro (sumatriptan injection) 6mg/0.5mL (NDC 63481-367-06),New,2/27/2018,,A business decision has been made to discontinue Sumavel DosePro 6 mg/0.5mL.,,,Neurology,To be Discontinued,2/27/2018,2/27/2018,,2021,discontinued
8982,Sumatriptan Succinate Injection,Teva Pharmaceuticals,6 mg/0.5 mL  (NDC 0703-7351-01),New,12/5/2019,,,,,Neurology,To be Discontinued,12/5/2019,12/5/2019,,2021,discontinued
8983,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","0.5 mg, 100s (NDC 0378-2045-01)",Reverified,11/29/2021,Available,,,,Transplant,Current,,,,2021,available
8984,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","1 mg, 100s (NDC 0378-2046-01)",Reverified,11/29/2021,Available,,,,Transplant,Current,,,,2021,available
8985,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100s (NDC 0378-2047-01)",Reverified,11/29/2021,Available,,,,Transplant,Current,,,,2021,available
8986,Tacrolimus Capsules,Accord Healthcare Inc.,0.5 mg 100 count (NDC 1672904101),Reverified,6/8/2021,Limited supply availability. Product will be allocated until Q3 2021,,,Limited API availability,Transplant,Current,,,,2021,limited availability
8987,Tacrolimus Capsules,Accord Healthcare Inc.,1 mg 100 count (NDC 1672904201),Reverified,6/8/2021,Limited supply availability. Product will be allocated until Q3 2021,,,Limited API availability,Transplant,Current,,,,2021,limited availability
8988,Tacrolimus Capsules,Accord Healthcare Inc.,5 mg 100 count (NDC 1672904301),Reverified,6/8/2021,Product is available,,,,Transplant,Current,,,,2021,available
8989,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 30 count (NDC 68992-3075-3),Reverified,6/14/2021,Available,,,,Transplant,Current,,,,2021,available
8990,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 100 count (NDC 68992-3075-1),Reverified,6/14/2021,Available,,,,Transplant,Current,,,,2021,available
8991,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 30 count (NDC 68992-3010-3),Reverified,6/14/2021,Available,,,,Transplant,Current,,,,2021,available
8992,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 100 count (NDC 68992-3010-1),Reverified,6/14/2021,Available,,,,Transplant,Current,,,,2021,available
8993,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 30 count (NDC 68992-3040-3),Reverified,6/14/2021,Available,,,,Transplant,Current,,,,2021,available
8994,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 100 count (NDC 68992-3040-1),Reverified,6/14/2021,Available,,,,Transplant,Current,,,,2021,available
8995,Tacrolimus Capsules,Strides Pharma Inc.,1 mg 100 count bottles (NDC 64338-721-06),Reverified,11/2/2021,Available,,,,Transplant,Current,,,,2021,available
8996,Tacrolimus Capsules,Strides Pharma Inc.,0.5 mg 100 count bottles (NDC 64380-720-06),Reverified,11/2/2021,Available,,,,Transplant,Current,,,,2021,available
8997,Tacrolimus Capsules,Strides Pharma Inc.,5 mg 100 count bottles (NDC 64380-722-06),Reverified,11/2/2021,Available,,,,Transplant,Current,,,,2021,available
8998,Tacrolimus Capsules,Sandoz,0.5 mg 100 count bottle (NDC 0781-2102-01),Reverified,11/16/2021,Available,,,Demand increase for the drug,Transplant,Current,,,,2021,available
8999,Tacrolimus Capsules,Sandoz,1 mg 100 count bottle (NDC 0781-2103-04),Reverified,11/16/2021,Available,,,Demand increase for the drug,Transplant,Current,,,,2021,available
9000,Tacrolimus Capsules,Sandoz,5 mg 100 count bottle (NDC 0781-2104-01),Reverified,11/16/2021,Available,,,Demand increase for the drug,Transplant,Current,,,,2021,available
9001,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 0.5 mg 100 count bottle (NDC 0469-0607-73),Reverified,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9002,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 5 mg 100 count bottle (NDC 0469-0657-73),Reverified,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9003,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 1 mg 100 count bottle (NDC 0469-0617-73),Reverified,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9004,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 0.5 mg 30 count bottle (NDC 0469-0647-73),Reverified,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9005,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 1 mg 30 count bottle (NDC 0469-0677-73),Reverified,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9006,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 5 mg 30 count bottle (NDC 0469-0687-73),Reverified,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9007,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 0.2 mg unit dose packets (NDC 0469-1230-50),Reverified,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9008,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 1 mg unit dose packets (NDC 0469-1330-50),Reverified,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9009,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-01),Reverified,11/8/2021,Available,,,,Transplant,Current,,,,2021,available
9010,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-01),Reverified,11/8/2021,Available,,,,Transplant,Current,,,,2021,available
9011,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-01),Reverified,11/8/2021,Available,,,,Transplant,Current,,,,2021,available
9012,Tacrolimus Capsules,Ascend Laboratories LLC.,0.5 mg 100’s count (NDC 67877-278-01),Revised,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9013,Tacrolimus Capsules,Ascend Laboratories LLC.,1 mg 100’s count (NDC 67877-279-01),Revised,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9014,Tacrolimus Capsules,Ascend Laboratories LLC.,5 mg 100’s count (NDC 67877-280-01),Revised,6/9/2021,Available,,,,Transplant,Current,,,,2021,available
9015,Tacrolimus Capsules,Glenmark Pharmaceuticals,0.5 mg 100 count bottles (NDC 68462-685-01),Revised,6/10/2021,Available,,,,Transplant,Current,,,,2021,available
9016,Tacrolimus Capsules,Glenmark Pharmaceuticals,1 mg 100 count bottles (NDC 68462-686-01),Revised,6/10/2021,Available,,,,Transplant,Current,,,,2021,available
9017,Tacrolimus Capsules,Glenmark Pharmaceuticals,5 mg 100 count bottles (NDC 68462-687-01),Revised,6/10/2021,Available,,,,Transplant,Current,,,,2021,available
9018,Tacrolimus Capsules,"BPI Labs, LLC",1 mg 100 count bottle (NDC 54288-135-01),Reverified,6/8/2021,Available,,,,Transplant,Current,,,,2021,available
9019,"Talwin (Pentazocine Lactate Injection, USP, CIV)","Hospira, Inc.",30 mg/mL; 1 mL glass ampul (NDC 00409-1941-01),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To be Discontinued,4/16/2018,4/16/2018,,2021,discontinued
9020,Technetium Tc99m Succimer Injection (DMSA),Theragnostics Inc.,ROTOP DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection). One vial contains 1.74 mg powder with the active substance: 1.0 mg succimer.  Five vials included in a carton (NDC 71647-001-01),Revised,1/7/2021,Available,"Due to the current critical shortage of DMSA Kit for the Preparation of Technetium Tc99m Succimer, Theragnostics Inc. (Theragnostics) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of the drug.  Theragnostics has initiated temporary importation of DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection into the U.S. market. This product is marketed in Germany and is manufactured in Dresden, Germany by ROTOP Pharmaka GmbH for Theragnostics.",,Other,Medical Imaging,Current,,,,2021,available
9021,Telmisartan and Amlodipine (Twynsta) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.","Telmisartan and Amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister (NDC 0597-0127-37)",New,3/6/2018,,"Discontinuation is the result of a business decision made by Boehringer lngelheim Pharmaceuticals, Inc. All other strengths of Twynsta® tablets are still available.",,,Cardiovascular,To be Discontinued,3/6/2018,3/6/2018,,2021,discontinued
9022,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 100 mg; child-resistant sachets, 5 count (NDC 0085-1366-03)",New,4/23/2021,,To be discontinued on or near October 2021,,,Oncology,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
9023,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 100 mg; child-resistent sachets, 14-count (NDC 0085-1366-04)",New,4/23/2021,,To be discontinued on or near October 2021,,,Oncology,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
9024,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 140 mg, child-resistant sachets, 14-count (NDC 0085-1425-04)",New,4/23/2021,,To be discontinued on or near October 2021,,,Oncology,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
9025,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 180 mg; child-resistent sachets, 5 count (NDC 0085-1430-03)",New,4/23/2021,,To be discontinued on or near October 2021,,,Oncology,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
9026,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 250 mg; child-resistent sachets, 5 count (NDC 0085-1417-02)",New,4/23/2021,,To be discontinued on or near April 2022,,,Oncology,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
9027,Teprotumumab-trbw,Horizon Therapeutics,500 mg lyophilized powder (NDC 75987-130-15),Revised,3/31/2021,Product available.,Manufacturing delays due to limited capacity at manufacturing facility,,Other,Ophthalmology,Current,,,,2021,available
9028,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","1 mg, 100 count bottle (NDC 0378-1001-01)",Reverified,11/29/2021,Available,,,Other,Psychiatry,Current,,,,2021,available
9029,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg, 100 count bottle (NDC 0378-2002-01)",Reverified,11/29/2021,Available,,,Other,Psychiatry,Current,,,,2021,available
9030,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100 count bottle (NDC 0378-3005-01)",Reverified,11/29/2021,Available,,,Other,Psychiatry,Current,,,,2021,available
9031,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","10 mg, 100 count bottle (NDC 0378-5010-01)",Reverified,11/29/2021,Available,,,Other,Psychiatry,Current,,,,2021,available
9032,Thiothixene Capsules,Novitium Pharma LLC,"1 mg, 100 count bottle (NDC 70954-014-10)",Reverified,4/27/2021,Available,,,,Psychiatry,Current,,,,2021,available
9033,Thiothixene Capsules,Novitium Pharma LLC,"2 mg, 100 count bottle (NDC 70954-015-10)",Reverified,4/27/2021,Available,,,,Psychiatry,Current,,,,2021,available
9034,Thiothixene Capsules,Novitium Pharma LLC,"5 mg, 100 count bottle (NDC 70954-016-10)",Reverified,4/27/2021,Available,,,,Psychiatry,Current,,,,2021,available
9035,Thiothixene Capsules,Novitium Pharma LLC,"10 mg, 100 count bottle (NDC 70954-017-10)",Reverified,4/27/2021,Available,,,,Psychiatry,Current,,,,2021,available
9036,Timolol Maleate Ophthalmic Gel Forming Solution,Sandoz,"Timolol Maleate Ophthalmic Gel Forming Solution 0.5%, 5 mL bottle (NDC 61314-225-05)",Revised,10/4/2021,,,Available,,Ophthalmology,Resolved,10/4/2021,,,2021,
9037,Timolol Maleate Ophthalmic Gel Forming Solution,Sandoz,Timolol Maleate Ophthalmic Gel Forming Solution 0.25% 5 mL bottle (NDC 61314-224-05),Revised,10/4/2021,,,Available,,Ophthalmology,Resolved,10/4/2021,,,2021,
9038,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","TIMOPTIC-XE®, 0.25% timolol equivalent gel forming solution, 5 mL in a 7.5 mL bottle (NDC 24208-814-25)",Revised,10/4/2021,,,,,Ophthalmology,Resolved,10/4/2021,,,2021,
9039,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","TIMOPTIC-XE®, 0.5% timolol equivalent, gel forming solution 5 mL in a 7.5 mL bottle (NDC 24208-816-05)",Revised,10/4/2021,,,,,Ophthalmology,Resolved,10/4/2021,,,2021,
9040,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% timolol gel forming solution, 5 mL in a 7.5 mL bottle (NDC 24208-818-25)",Revised,10/4/2021,,,,,Ophthalmology,Resolved,10/4/2021,,,2021,
9041,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Gel Forming Solution, equivalent and 0.5%, 5 mL in a 7.5 mL bottle (NDC 24208-819-05)",Revised,10/4/2021,,,,,Ophthalmology,Resolved,10/4/2021,,,2021,
9042,Timolol Maleate Ophthalmic Gel Forming Solution,Alembic Pharmaceuticals,Timolol GFS 0.25 % - 5 mL fill (NDC 62332-545-05),Revised,10/4/2021,,,Available,,Ophthalmology,Resolved,10/4/2021,,,2021,
9043,Timolol Maleate Ophthalmic Gel Forming Solution,Alembic Pharmaceuticals,Timolol GFS 0.5 % - 5 mL fill (NDC 62332-546-05),Revised,10/4/2021,,,Available,,Ophthalmology,Resolved,10/4/2021,,,2021,
9044,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.25%, 5 mL in a 7.5 mL bottle (NDC 24208-812-05)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9045,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.5%, 5 mL in a 7.5 mL bottle (NDC 24208-813-05)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9046,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.5%, 10 mL in a 10 mL bottle (NDC 24208-813-10)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9047,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.",Authorized Generic Timolol Maleate Ophthalmic Solution 0.5% 5 mL in a 7.5 mL bottle (NDC 68682-813-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9048,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® in OCUDOSE® (timolol maleate) Sterile Ophthalmic Solution, 0.25% 0.3 mL in 60 individual doses (NDC 0187-1498-25)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9049,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® in OCUDOSE®  (timolol maleate) Sterile Ophthalmic Solution, 0.5% 0.3 mL in 60 individual doses (NDC 0187-1496-05)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9050,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 7.5 mL bottle (NDC 24208-004-01)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9051,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 10 ml bottle (NDC 24208-004-03)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9052,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%,  2.5ml (NDC 68682-045-25)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9053,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%, 5ml (NDC 68682-045-50)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9054,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 5mL (NDC 64980-513-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9055,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25%  10 mL (NDC 64980-513-01),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9056,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 15 mL (NDC 64980-513-15),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9057,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 5mL (NDC 64980-514-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9058,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 10mL (NDC 64980-514-01),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9059,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 15mL (NDC 64980-514-15),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9060,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x5ml BTL (NDC 60758-802-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9061,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x10ml BTL (NDC 60758-802-10),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9062,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x5ml BTL (NDC 60758-801-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9063,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x10ml BTL (NDC 60758-801-10),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9064,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5% 5mg/mL, 5mL, 1 Bottle/EA (NDC 17478-0288-10)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9065,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 10mL, 1 Bottle / EA (NDC 17478-0288-11)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9066,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 15mL, 1 Bottle / EA (NDC 17478-0288-12)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9067,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 5 mL bottle, (NDC 61314-227-05)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9068,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 10 mL bottle (NDC 61314-227-10)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9069,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 15 mL bottle (NDC 61314-227-15)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9070,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 5 mL bottle, ()NDC 61314-226-05",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9071,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 10 mL bottle, (NDC 61314-226-10)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9072,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 15 mL bottle, (NDC 61314-226-15)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9073,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 2.5mL bottle (NDC 60505-1005-04),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9074,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 5mL bottle (NDC 60505-1005-01),Revised,4/16/2021,,,,,Ophthalmology,Resolved,4/16/2021,,,2021,
9075,Tipranavir Oral Solution,"Boehringer Ingelheim Pharmaceuticals, Inc.",100mg/mL (NDC 0597-0002-01),New,6/29/2021,,,,,Antiviral,To be Discontinued,6/29/2021,6/29/2021,,2021,discontinued
9076,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",2 mg  (NDC 49884-611-53),New,6/30/2021,,,,,Neurology,To be Discontinued,6/30/2021,6/30/2021,,2021,discontinued
9077,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",4 mg (NDC 49884-719-53),New,6/30/2021,,,,,Neurology,To be Discontinued,6/30/2021,6/30/2021,,2021,discontinued
9078,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",6 mg (NDC 49884-765-53),New,6/30/2021,,,,,Neurology,To be Discontinued,6/30/2021,6/30/2021,,2021,discontinued
9079,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,4 mg (NDC 0378-0724-19),New,11/21/2019,,,,,Neurology,To be Discontinued,11/21/2019,11/21/2019,,2021,discontinued
9080,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0722-19),New,11/21/2019,,,,,Neurology,To be Discontinued,11/21/2019,11/21/2019,,2021,discontinued
9081,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-51)",Revised,4/12/2021,,,,,Anti-Infective;Pediatric,Resolved,4/12/2021,,,2021,
9082,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-55), Novaplus",Revised,4/12/2021,,,,,Anti-Infective;Pediatric,Resolved,4/12/2021,,,2021,
9083,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, bottle (NDC 39822-0412-1)",Revised,4/12/2021,,,,,Anti-Infective;Pediatric,Resolved,4/12/2021,,,2021,
9084,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, pack of 6 bottles (NDC 39822-0412-6)",Revised,4/12/2021,,,,,Anti-Infective;Pediatric,Resolved,4/12/2021,,,2021,
9085,Tocilizumab Injection,"Genentech, Inc","200mg/10mL, (NDC 50242-0136-01)",Reverified,11/1/2021,Available,,,Demand increase for the drug,Rheumatology,Current,,,,2021,available
9086,Tocilizumab Injection,"Genentech, Inc","400mg/20mL, (NDC 50242-0137-01)",Reverified,11/1/2021,Available,,,Demand increase for the drug,Rheumatology,Current,,,,2021,available
9087,Tocilizumab Injection,"Genentech, Inc","80mg/4mL, (NDC 50242-0135-01)",Reverified,11/1/2021,Available,,,Demand increase for the drug,Rheumatology,Current,,,,2021,available
9088,Tolcapone Tablets,"Endo Pharmaceuticals, Inc.",100mg tablets (NDC 49884-254-09),New,10/5/2020,,,,,Neurology,To be Discontinued,10/5/2020,10/5/2020,,2021,discontinued
9089,Trandolapril Tablets,Teva Pharmaceuticals,"4 mg tablets, 100 count (NDC 16252-543-90)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2021,discontinued
9090,Trandolapril Tablets,Teva Pharmaceuticals,"2 mg tablets, 100 count (NDC 16252-542-90)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2021,discontinued
9091,Trandolapril Tablets,Teva Pharmaceuticals,"1 mg tablets, 100 count (NDC 16252-541-30)",New,4/18/2018,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/2018,4/18/2018,,2021,discontinued
9092,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 30 Tablets per Bottle,  (NDC 60505-3638-3)",New,12/4/2019,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/2019,12/4/2019,,2021,discontinued
9093,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 100 Tablets per Bottle,  (NDC 60505-3638-1)",New,12/4/2019,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/2019,12/4/2019,,2021,discontinued
9094,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1 mg/1g (NDC 40085-029-80),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2021,discontinued
9095,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1mg/1g (NDC 40085-029-16),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2021,discontinued
9096,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,0.25mg/1g (NDC 40085-028-80),New,3/20/2018,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/2018,3/20/2018,,2021,discontinued
9097,Triamcinolone Acetonide Injectable Suspension,Novartis,"40mg/mL vial, 1mL in 1 vial (NDC 0065-0543-01)",Revised,11/23/2021,Availability through wholesalers: Not available. Estimated Duration of Supply Shortage: November 2021,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2021,not available
9098,Triamcinolone Hexacetonide Injectable suspension,Medexus,"Hexatrione 2% (triamcinolone hexacetonide) Injectable suspension, 20mg/ml, 2-mL glass ampoule (NDC 59137-570-01)",Reverified,10/8/2021,Available,"Medexus in conjunction with FDA has initiated a temporary importation of Triamcinolone Hexacetonide (Hexatrione 2%) injectable suspension, to the U.S. market to address drug shortage. To place an order, please contact Medexus at 1-855-336-3322, Option # 9.",,,Rheumatology,Current,,,,2021,available
9099,Triamterene and Hydrochlorothiazide (Dyazide) Capsules,GlaxoSmithKline,25 mg; 37.5 mg (NDC 0007-3650-22),New,11/16/2020,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately December 2020.,,,Cardiovascular,To be Discontinued,11/16/2020,11/16/2020,,2021,discontinued
9100,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 0781-5068-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
9101,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 0781-5068-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
9102,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 0781-5067-01)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
9103,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 0781-5067-05)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
9104,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 68001-0216-00)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
9105,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 68001-0216-03)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
9106,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 68001-0215-00)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
9107,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 68001-0215-03)",New,2/23/2018,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/2018,2/23/2018,,2021,discontinued
9108,Trimethobenzamide Hydrochloride Capsules,Pfizer Pharmaceuticals,"300 mg, 100 count bottle (NDC 61570-079-01)",New,12/14/2020,,Discontinuation of the manufacturing of the drug.,,,Gastroenterology,To be Discontinued,12/14/2020,12/14/2020,,2021,discontinued
9109,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 30 (NDC 43386-660-03)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,,2021,not available
9110,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 100 (NDC 43386-660-24)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,,2021,not available
9111,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 500 (NDC 43386-660-26)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,,2021,not available
9112,Trimethobenzamide Hydrochloride Capsules,Pfizer Pharmaceuticals,"300 mg, bottle of 100 (NDC 61570-079-01)",Reverified,11/18/2021,Discontinued,,,Discontinuation of the manufacture of the drug.,Gastroenterology,Current,,,,2021,discontinued
9113,Trimethobenzamide Hydrochloride Capsules,Sun Pharmaceutical Industries Inc.,"300 mg, bottle of 100 (NDC 53489-376-01)",Revised,10/26/2021,Unavailable,,,Shortage of an active ingredient.,Gastroenterology,Current,,,,2021,not available
9114,Trimethobenzamide Hydrochloride Capsules,Sun Pharmaceutical Industries Inc.,"300 mg, bottle of 100 (NDC 53489-376-01)",New,10/26/2021,,Non-Availability of Active Ingredient.,,,Gastroenterology,To be Discontinued,10/26/2021,10/26/2021,,2021,discontinued
9115,Ursodiol (Actigall) Capsules,Allergan Sales LLC,300 mg (NDC 0023-6145-01),New,1/15/2021,,,,,Urology,To be Discontinued,1/15/2021,1/15/2021,,2021,discontinued
9116,Valacyclovir Tablets,GlaxoSmithKline,"500 mg, 100-count unit dose pack (NDC 0173-0933-56)",New,4/23/2021,,This product discontinuation is a business-related decision. The anticipated date that GSK will cease distribution of the product is approximately November 2021. 30-count and 90-count bottles will continue to be available.,,,Antiviral,To be Discontinued,4/23/2021,4/23/2021,,2021,discontinued
9117,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9785-10)",Revised,10/12/2021,Inventory is currently available.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2021,available
9118,Valproate Sodium Injection,"Fresenius Kabi USA, LLC",500 mg per 5 mL (100 mg per mL) (NDC 63323-494-05),Reverified,11/23/2021,Available,Check wholesaler for inventory,,Manufacturing delays,Neurology,Current,,,,2021,available
9119,Vancomycin Hydrochloride for Injection,"Mylan Institutional, a Viatris company",Vancomycin Hydrochloride Injection (Lyophilisate in Single Dose Vials) [250 mg] (NDC 67457-822-99),New,7/26/2021,,,,,Anti-Infective,To be Discontinued,7/26/2021,7/26/2021,,2021,discontinued
9120,Vardenafil Hydrochloride Tablets,Bayer,Levitra 20mg (NDC 0173-0831-13),New,4/8/2021,,"Discontinue distribution April 30, 2021.  Discontinuation of the manufacture of the drug.",,,Other;Reproductive,To be Discontinued,4/8/2021,4/8/2021,,2021,discontinued
9121,Vardenafil Hydrochloride Tablets,Bayer,Levitra 10 mg (NDC 0173-0830-13),Revised,9/1/2020,,Discontinuation of the manufacture of the drug.,,,Other;Reproductive,To be Discontinued,9/1/2020,9/1/2020,,2021,discontinued
9122,Vardenafil Hydrochloride Tablets,Bayer,Staxyn 10 mg (NDC 0173-0822-04),Revised,9/1/2020,,Discontinuation of the manufacture of the drug.,,,Other;Reproductive,To be Discontinued,9/1/2020,9/1/2020,,2021,discontinued
9123,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 0.5 mg; bottle of 56 tablets (NDC 60505-4765-5),New,7/16/2021,Available,"Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,,Analgesia/Addiction,Current,,,,2021,available
9124,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 1 mg; bottle of 56 tablets (NDC 60505-4766-6),New,7/16/2021,Available,"Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,,Analgesia/Addiction,Current,,,,2021,available
9125,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 0.5 mg and 1 mg; Starter Blister Pack of 53 tablets; (NDC 60505-4767-0),New,7/16/2021,Estimated Date Available; TBD,"Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,,Analgesia/Addiction,Current,,,,2021,unclear
9126,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 1 mg: Continuation Blister Pack of 56 tablets (NDC 60505-4766-5),New,7/16/2021,Estimated Date Available; TBD,"Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,,Analgesia/Addiction,Current,,,,2021,unclear
9127,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix 0.5 mg; bottle of 56 (NDC 0069-0468-56),Reverified,11/18/2021,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Other,Analgesia/Addiction,Current,,,,2021,unclear
9128,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix 1 mg; bottle of 56 (NDC 0069-0469-56),Reverified,11/18/2021,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Other,Analgesia/Addiction,Current,,,,2021,unclear
9129,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix Starting wallet; 0.5 mg 1x11 1 mg FCT 3x14 BLS WL US (NDC 0069-0471-03),Reverified,11/18/2021,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Other,Analgesia/Addiction,Current,,,,2021,unclear
9130,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix Continuing wallet; 1 mg FCT 4x14 BLS WL US (NDC 0069-0469-03),Reverified,11/18/2021,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Other,Analgesia/Addiction,Current,,,,2021,unclear
9131,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,"0.5 mg, 56 ‘s count bottle pack (NDC 49884-155-76)",New,9/22/2021,Available,More batches will be available by end of September or Early October.,,,Analgesia/Addiction,Current,,,,2021,available
9132,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,"1 mg, 56 ‘s count bottle pack (NDC 49884-156-76)",New,9/22/2021,Available,More batches will be available by end of September or Early October.,,,Analgesia/Addiction,Current,,,,2021,available
9133,Vecuronium Bromide for Injection,Teva Pharmaceuticals,10 mg* 10 X 10 mL *1 mg/mL when reconstituted to 10 mL (NDC 0703-2914-03),Reverified,11/8/2021,Backordered – Estimated date of availability TBD,,,,Anesthesia,Current,,,,2021,not available
9134,Vecuronium Bromide for Injection,"Hospira, Inc.",10 mg Single Dose Glass Fliptop Vial (NDC 00409-1632-01),Revised,11/18/2021,Next Delivery: November 2021; Estimated Recovery: July 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
9135,Vecuronium Bromide for Injection,"Hospira, Inc.",20 mg Single Dose Glass Fliptop Vial (NDC 00409-1634-01),Revised,11/18/2021,Next Delivery: January 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2021,not available
9136,Vecuronium Bromide for Injection,"Mylan Institutional, a Viatris company",Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [10 mg](NDC 67457-438-10),Reverified,11/29/2021,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
9137,Vecuronium Bromide for Injection,"Mylan Institutional, a Viatris company",Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [20 mg](NDC 67457-475-20),Reverified,11/29/2021,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
9138,Vecuronium Bromide for Injection,Gland Pharma Limited,10 mg/vial (NDC 63323-781-10),Reverified,10/20/2021,Available,Distributed by marketing partner: Fresenius Kabi  LLC (888-386-1300),,,Anesthesia,Current,,,,2021,available
9139,Vecuronium Bromide for Injection,Gland Pharma Limited,20 mg/vial (NDC 63323-782-20),Reverified,10/20/2021,Available,Distributed by marketing partner: Fresenius Kabi  LLC (888-386-1300),,,Anesthesia,Current,,,,2021,available
9140,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,10 mg (NDC 47335-931-44),Reverified,10/22/2021,Available,,,Demand increase of the drug,Anesthesia,Current,,,,2021,available
9141,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,20 mg (NDC 47335-932-44),Reverified,10/22/2021,Available,,,Demand increase of the drug,Anesthesia,Current,,,,2021,available
9142,Vecuronium Bromide for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"10 mg/vial, packages of 10 (NDC 55150-235-10)",Revised,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
9143,Vecuronium Bromide for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg/vial, packages of 10 (NDC 55150-236-20)",Revised,11/5/2021,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2021,available
9144,Vibramycin Hyclate (Doxycycline Hyclate) for Suspension,Pfizer Pharmaceuticals,25 mg/5 mL oral suspension; 1 x 60 mL bottle (NDC 0069-0970-65),New,11/16/2021,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,11/16/2021,11/16/2021,,2021,discontinued
9145,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-06),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,4/16/2018,4/16/2018,,2021,discontinued
9146,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-09),New,4/16/2018,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,4/16/2018,4/16/2018,,2021,discontinued
9147,Vitamin A Palmitate (Aquasol A) Injection,"Casper Pharma, LLC","50,000 USP units/mL (15 mg retinol), single dose vial (NDC 61703-418-18)",New,10/21/2021,Anticipated availability: January 2022,Delay is due to manufacturing delays at the contract manufacturing facility.,,Manufacturing delay,Endocrinology/Metabolism;Gastroenterology,Current,,,,2021,not available
9148,Zinc Acetate Capsules,Teva Pharmaceuticals,"25 mg, bottle of 250 (NDC 57844-215-52)",Revised,5/18/2021,,,Available,,Other;Pediatric,Resolved,5/18/2021,,,2021,
9149,Zinc Acetate Capsules,Teva Pharmaceuticals,"50 mg, bottle of 250 (NDC 57844-208-52)",Revised,5/18/2021,,,Available,,Other;Pediatric,Resolved,5/18/2021,,,2021,
9150,Zolpidem Tartrate (Edluar) Sublingual Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0037-6010-30),Revised,11/21/2018,,,Available,,Psychiatry,Resolved,11/21/2018,,,2021,
9151,Abiraterone Acetate Tablets,"Janssen Research and Development, LLC",250 mg tablets (NDC 57894-155-12),New,6/5/2020,,,,,Oncology,To be Discontinued,,,,2022,discontinued
9152,Acetaminophen (Ofirmev) Injection,Mallinckrodt,"OFIRMEV® (Acetaminophen) Injection 1 g/100 mL (10 mg/mL), (NDC 43825-102-01, 43825-102-03)",New,6/9/2022,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
9153,Acetazolamide Injection,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",500 mg (NDC 23155-313-31),Revised,6/17/2022,Available,,,,Cardiovascular;Ophthalmology,Resolved,,,,2022,available
9154,Acetazolamide Injection,"Mylan Institutional, a Viatris company","500 mg, Lyophilisate in Single Dose Vials 1PK (NDC 67457-853-50)",Revised,6/17/2022,Available,,,,Cardiovascular;Ophthalmology,Resolved,,,,2022,available
9155,Acetazolamide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9503-01),Revised,6/17/2022,This presentation is temporarily on backorder.,,,,Cardiovascular;Ophthalmology,Resolved,,,,2022,not available
9156,Acetazolamide Injection,"X-GEN Pharmaceuticals, Inc.",500mg per vial (NDC 39822-0190-1),Revised,6/17/2022,Available,,,,Cardiovascular;Ophthalmology,Resolved,,,,2022,available
9157,Acetic Acid Otic Solution,Wockhardt Bio A.G.,"2% 15ml, (NDC 60432-741-15)",New,6/22/2022,,,,,Anti-infective,To be Discontinued,,,,2022,discontinued
9158,Acrivastine and Pseudoephedrine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.","Semprex-D Capsules, 8 mg/ 60mg , 100 capsules, (NDC 52244-404-10)",New,6/2/2020,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
9159,Adalimumab (Humira) Pre-filled Syringe,Abbvie,10 mg/0.2 mL pre-filled syringe (NDC 0074-6347-02),New,7/27/2020,,,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,,,,2022,discontinued
9160,Adalimumab (Humira) Pre-filled Syringe,Abbvie,20 mg/0.4 mL pre-filled syringe (NDC 0074-9374-02),New,7/27/2020,,,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,,,,2022,discontinued
9161,Adefovir Dipivoxil Tablets,"Gilead Sciences, Inc.",10mg  (NDC 61958-0501-1),New,8/1/2022,,,,,Antiviral,To Be Discontinued,8/1/2022,8/1/2022,,2022,discontinued
9162,Adenosine Injection,Hospira,90 mg/30 mL (3 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1932-02),New,6/28/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9163,Adenosine Injection,Teva,NDC 0703-8776-01 (60 mg/20 mL (3 mg/mL)),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Cardiovascular,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9164,Adenosine Injection,Teva,NDC 0703-8777-01 (90 mg/30 mL (3 mg/mL)),New,8/11/2022,,Product is  available with an expected supply duration until JUL 2022.  No future production expected for an extended period.,,,Cardiovascular,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9165,Adenosine Injection,Hospira,60 mg/20 mL (3 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1932-01),New,9/12/2022,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
9166,"Albuterol Sulfate Aerosol, Metered","Endo Pharmaceuticals, Inc.",90 mcg  (NDC 0254-1007-52),New,7/6/2021,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
9167,Aliskiren and Hydrochlorothiazide Tablets,Noden Pharma,150 mg / 12.5 mg (NDC 70839-112-30),New,12/16/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9168,Aliskiren and Hydrochlorothiazide Tablets,Noden Pharma,150 mg / 25 mg (NDC 70839-125-30),New,12/16/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9169,Aliskiren and Hydrochlorothiazide Tablets,Noden Pharma,300 mg / 12.5 mg (NDC 70839-312-30),New,12/16/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9170,Aliskiren and Hydrochlorothiazide Tablets,Noden Pharma,300 mg / 25 mg; (NDC 70839-325-30),New,12/16/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9171,Alprostadil Injection,Teva,NDC 0703-1501-02 (500 mcg/mL 1 mL Single Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Pediatric; Cardiovascular,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9172,Alprostadil Suppository,"Mylan Specialty, a Viatris Company",125 mcg (NDC 0037-8110-06),New,6/14/2021,,,,,Urology,To be Discontinued,,,,2022,discontinued
9173,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Liquid Regular Strength, 95 mg/15mL, 358 mg/15mL, Mint 12oz, (NDC 0135-0094-41)",New,8/6/2021,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
9174,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Liquid Regular Strength, 95 mg/15mL, 358 mg/15mL, Mint 6oz, (NDC 0135-0094-42)",New,8/6/2021,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
9175,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Chewable Tablet, Regular Strength, 80 mg/1, 14.2 mg/1, 100ct Bottle, (NDC 0135-0096-26)",New,8/6/2021,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
9176,Amantadine Hydrochloride Capsules,Sandoz,100 mg capsules  (NDCs 0781-2320-01 and 0781-2320-05),New,7/16/2020,,,,,Antiviral;Neurology,To be Discontinued,,,,2022,discontinued
9177,Ambrisentan Tablets,Par Pharmaceutical,"5 mg (NDC 49884-353-11, 49884-353-62 )",New,12/23/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9178,Ambrisentan Tablets,Par Pharmaceutical,"10 mg (NDC 49884-354-11, 49884-354-62)",New,12/23/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9179,Amifostine Injection,"Clinigen, Inc.",ETHYOL® (amifostine) for injection: 3 x 500 mg vials (NDC 76310-017-50),Reverified,5/16/2022,Shortage anticipated from June 2020; Estimated shortage duration:  Unknown,,,Other,Oncology;Other,Current,,,,2022,limited availability
9180,Amikacin Sulfate Injection,Teva,"NDC 0703-9032-03 (500 mg/2 mL (250 mg/mL), 10 x 2 mL Single Dose Vials)",New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Anti-infective,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9181,Amikacin Sulfate Injection,Teva,"NDC 0703-9040-03  (1 g/4 mL (250 mg/mL), 10 x 4 mL Vials)",New,8/11/2022,,Product is unavailable and no future production expected for an extended period.,,,Anti-infective,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9182,Amino Acids,B. Braun Medical Inc.,"Plenamine 15% Amino Acids Injection 2,000mL S4505 (NDC 00264-4500-05)",New,6/8/2022,Available,,,,Gastroenterology,Current,,,,2022,available
9183,Amino Acids,B. Braun Medical Inc.,"Plenamine 15% Amino Acids Injection 1,000mL S4500 (NDC 00264-4500-00)",Revised,6/8/2022,Available,,,,Gastroenterology,Current,,,,2022,available
9184,Amino Acids,"ICU Medical, Inc.",Aminosyn II 15% Sulfite-Free BLK PK 2000 mL (Legacy Hospira NDC 0409-7171-17)(ICU Medical NDC 0990-7171-17),Reverified,10/3/2022,Unavailable,,,Other,Gastroenterology,Current,,,,2022,not available
9185,Amino Acids,"ICU Medical, Inc.",Aminosyn II 10% Sulfite-Free BLK PK 2000 mL (NDC 0409-7172-17) (ICU Medical NDC 0990-7172-17),Reverified,10/3/2022,Unavailable,,,Other,Gastroenterology,Current,,,,2022,not available
9186,Amino Acids,"ICU Medical, Inc.","AMINOSYN™-PF 7%, Sulfite-Free, 500 mL (NDC 0409-4178-03) (ICU Medical NDC 0990-4178-03)",Reverified,10/3/2022,Available,,,,Gastroenterology,Current,,,,2022,available
9187,Amino Acids,"ICU Medical, Inc.",AMINOSYN-PF 10%, Sulfite-Free," (Pediatric Formula) 1000 mL   (Legacy Hospira NDC 0409-4179-05) (ICU Medical NDC 0990-4179-05)""""",Reverified,10/3/2022,Unavailable,,,Other,Gastroenterology,Current,,2022,unclear
9188,Amino Acids,Baxter Healthcare,"15% CLINISOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion. Product Codes: 2B6189 15% 2000 mL (NDC 0338-0502-06), 2B6187 15% 500 mL (NDC 0338-0502-03)",Reverified,9/28/2022,Available,,,,Gastroenterology,Current,,,,2022,available
9189,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 60 count bottle (NDC 0185-0144-60)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9190,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 90 count bottle (NDC 0185-0144-09)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9191,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 500 count bottle (NDC 0185-0144-05)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9192,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 500 count bottle (NDC 0245-0145-15)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9193,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 30 count bottle (NDC 0245-0145-30)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9194,Amitriptyline Hydrochloride Tablets,"Mylan Specialty, a Viatris Company",10 mg (NDCs 0378-2610-01 and 0378-2610-10),New,8/2/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9195,Amitriptyline Hydrochloride Tablets,"Mylan Specialty, a Viatris Company",25 mg (NDCs 0378-2625-01 and 0378-2625-10),New,8/2/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9196,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.","10mg (NDCs 0603-2212-02, 0603-2212-16, 0603-2212-21, and 0603-2212-32)",New,12/16/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9197,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.","25mg (NDCs 0603-2213-02, 0603-2213-21, 0603-2213-30, and 0603-2213-32)",New,12/16/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9198,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",50mg (NDCs 0603-2214-21 and 0603-2214-32),New,12/16/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9199,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",75mg (NDCs 0603-2215-21 and 0603-2215-25),New,12/16/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9200,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",100mg (NDCs 0603-2216-21 and 0603-2216-25),New,12/16/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9201,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",150mg (NDC 0603-2217-21),New,12/16/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9202,Amoxapine Tablets,Teva Pharmaceuticals,"50 mg, 100 tablets (NDC 0591-5714-01)",Revised,10/5/2022,Available,,,,Psychiatry,Current,,,,2022,available
9203,Amoxapine Tablets,Teva Pharmaceuticals,"25 mg, 100 tablets (NDC 0591-5713-01)",Revised,10/5/2022,"Backorder, Recovery expected Nov-22",,,Other,Psychiatry,Current,,,,2022,not available
9204,Amoxapine Tablets,Teva Pharmaceuticals,"100 mg, 100 tablets (NDC 0591-5715-01)",Revised,10/5/2022,Product is Available,,,,Psychiatry,Current,,,,2022,available
9205,Amoxapine Tablets,Teva Pharmaceuticals,"150 mg, 30 tablets (NDC 00591-5716-30)",Revised,10/5/2022,Allocation,,,,Psychiatry,Current,,,,2022,limited availability
9206,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,12.5  mg 100 count (NDC 0555-0776-02),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9207,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,15  mg 100 count (NDC 0555-0777-02),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9208,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,7.5  mg 100 count (NDC 0555-0775-02),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9209,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,10  mg 100 count (NDC 0555-0972-02),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9210,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,20 mg 100 count (NDC 0555-0973-02),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9211,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,30 mg 100 count (NDC 0555-0974-02),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9212,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,5 mg 100 count (NDC 0555-0971-02),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9213,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"5 mg, 100 Count Bottle (NDC 68382-950-01)",Revised,7/12/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9214,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"7.5 mg, 100 Count Bottle (NDC 68382-951-01)",Revised,7/12/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9215,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"10 mg, 100 Count Bottle (NDC 68382-952-01)",Revised,7/12/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9216,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"12.5 mg, 100 Count Bottle (NDC 68382-953-01)",Revised,7/12/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9217,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"15 mg, 100 Count Bottle (NDC 68382-954-01)",Revised,7/12/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9218,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"20 mg, 100 Count Bottle (NDC 68382-955-01)",Revised,7/12/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9219,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"30 mg, 100 Count Bottle (NDC 68382-956-01)",Revised,7/12/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9220,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"30 mg, 100 Count Bottle (NDC 0185-0864-01)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9221,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"20 mg, 100 Count Bottle (NDC 0185-0853-01)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9222,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"10 mg, 100 Count Bottle (NDC 0185-0842-01)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9223,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"5 mg, 100 Count Bottle (NDC 0185-0831-01)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9224,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 10mg 100 (NDC 57844-0110-01),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9225,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 12.5mg 100 (NDC 57844-0112-01),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9226,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 15mg 100 (NDC 57844-0115-01),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9227,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 20mg 100 (NDC 57844-0120-01),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9228,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 30mg 100 (NDC 57844-0130-01),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9229,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 5mg 100 (NDC 57844-0105-01),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9230,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 7.5mg 100 (NDC 57844-0117-01),Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9231,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",5mg [1.25/1.25/1.25/1.25mg] 100s (NDC 0378-4541-01),Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9232,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",7.5mg [1.875/1.875/1.875/1.875mg] 100s (NDC 0378-4542-01),Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9233,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",10mg [2.5/2.5/2.5/2.5mg] 100s (NDC 0378-4543-01),Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9234,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",12.5mg [3.125/3.125/3.125/3.125mg] 100s (NDC 0378-4544-01),Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9235,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",15mg [3.75/3.75/3.75/3.75mg] 100s (NDC 0378-4545-01),Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9236,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",20mg [5/5/5/5mg] 100s (NDC 0378-4546-01),Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9237,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",30mg [7.5/7.5/7.5/7.5mg] 100s (NDC 0378-4547-01),Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9238,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01)",Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9239,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01)",Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9240,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01)",Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9241,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01)",Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9242,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01)",Revised,5/31/2022,,,,,Psychiatry,Resolved,,,,2022,
9243,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","5 mg, 100 count (NDC 0527-1500-37)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9244,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","7.5 mg, 100 count (NDC 0527-1501-37)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9245,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","10 mg, 100 count (NDC 0527-1502-37)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9246,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","12.5 mg, 100 count (NDC 0527-1503-37)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9247,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","15 mg, 100 count (NDC 0527-1504-37)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9248,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","20 mg, 100 count (NDC 0527-1505-37)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9249,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","30 mg, 100 count (NDC 0527-1506-37)",Revised,5/31/2022,,,Available,,Psychiatry,Resolved,,,,2022,
9250,"Amphetamine Oral Suspension, Extended Release","Tris Pharma, Inc.",Amphetamine (Dyanavel XR) EQ 2.5MG BASE/ML (NDC 27808-102-01),Revised,8/26/2022,,,,,Psychiatry,Resolved,8/26/2022,,,2022,
9251,Ampicillin for Injection,"Mylan Institutional, a Viatris company",250 mg (NDC 67457-353-10),New,9/23/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9252,Ampicillin for Injection,"Mylan Institutional, a Viatris company",500 mg (NDC 67457-350-10),New,9/23/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9253,Ampicillin for Injection,Pfizer,1 g; Single Dose Vial (Powder) (NDC 0409-3726-01),New,7/29/2022,,Supply expected to exhaust 01Aug2022; Discontinuation of the manufacture of the drug.,,,,To Be Discontinued,7/29/2022,7/29/2022,,2022,discontinued
9254,Ampicillin for Injection,Pfizer,2 g; Single Dose Vial (Powder) (NDC 0409-3720-01,New,7/29/2022,,Discontinuation of the manufacture of the drug.,,,,To Be Discontinued,7/29/2022,7/29/2022,,2022,discontinued
9255,Ampicillin for Injection,Pfizer,500 mg; Single Dose Vial (Powder) (NDC 0409-3718-01),New,6/22/2022,,,,,Antibiotic,To be Discontinued,,,,2022,discontinued
9256,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,1 MG 100 Capsules (NDC 0172-5240-60),Revised,7/20/2021,,,,,Hematology,Resolved,,,,2022,
9257,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,0.5 MG 100 Capsules (NDC 0172-5241-60),Revised,7/20/2021,,,,,Hematology,Resolved,,,,2022,
9258,Anagrelide Hydrochloride Capsules,Takeda Pharmaceuticals USA Inc.,"AGRYLIN 0.5 mg Capsule,100 capsules in 1 bottle (NDC 54092-063-01)",Revised,7/20/2021,,,Available,,Hematology,Resolved,,,,2022,
9259,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,0.5 mg per capsule Bottles of 100 (NDC 13668-453-01),Revised,7/20/2021,,,Available,,Hematology,Resolved,,,,2022,
9260,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,"1 mg per capsule, Bottles of 100 (NDC 13668-462-01)",Revised,7/20/2021,,,Available,,Hematology,Resolved,,,,2022,
9261,Aspirin/Dipyridamole (Aggrenox) Extended Release Capsules,"Boehringer Ingelheim Pharmaceuticals, Inc.",25mg/200mg capsules (NDC 0597-0001-60),New,5/26/2020,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9262,Atropine Sulfate Injection,American Regent/Luitpold,"0.4 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-0401-25)",Revised,4/6/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9263,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC",8 mg per 20 mL (0.4 mg per mL); MDV; (NDC 63323-580-20),Reverified,9/14/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9264,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS",0.1 mg/mL; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3340-1),Reverified,8/12/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9265,Atropine Sulfate Injection,"Hospira, Inc.",1 mg/10 mL (0.1 mg/mL); Ansyr Plastic Syringe(NDC 0409-1630-10),Revised,9/30/2022,Next Delivery: November 2022; Estimated Recovery: May 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2022,not available
9266,Atropine Sulfate Injection,"Hospira, Inc.",0.25 mg/5 mL (0.05 mg/mL); Ansyr Plastic Syringe(NDC 0409-9630-05),Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2022,not available
9267,Atropine Sulfate Injection,"Hospira, Inc.",0.5 mg/5 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4910-34),Revised,9/30/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9268,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4911-34, pack of 10; NDC 0409-4911-11, individual)",Revised,9/30/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9269,Atropine Sulfate Injection,American Regent/Luitpold,"1 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-1010-25)",Revised,4/6/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9270,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.4 mg/mL, 20 mL vial (NDC 0641-6006-10)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9271,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.4 mg/mL, 1 mL single dose vial, pack of 25 (NDC 16729-525-08)",Reverified,4/6/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9272,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.4 mg/mL, 20 mL multi-dose vial, pack of 10 (NDC 16729-512-43)",Reverified,4/6/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9273,Atropine Sulfate Injection,Accord Healthcare Inc.,"1 mg/mL, 1 mL single dose vial, pack of 25 (NDC 16729-526-08)",Reverified,4/6/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9274,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.05 mg/mL, 5 mL prefilled syringe, pack of 10 (NDC 16729-483-03)",Reverified,4/6/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9275,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.1 mg/mL, 10 mL prefilled syringe, pack of 10 (NDC 16729-484-45)",Reverified,4/6/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9276,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.1 mg/mL, 5 mL prefilled syringe, pack of 10 (NDC 16729-484-90)",Reverified,4/6/2022,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,,2022,available
9277,Azacitidine for Injection,Celgene Corporation,"100 mg single-dose vial in cartons of 1 vial, (NDC 0781-3253-94)",Revised,10/1/2021,Available,,,,Oncology,Current,,,,2022,available
9278,Azacitidine for Injection,Celgene Corporation,"100 mg single-dose vial in cartons of 1 vial, (NDC 0781-9253-94)",Revised,10/1/2021,Available,,,,Oncology,Current,,,,2022,available
9279,Azacitidine for Injection,Celgene Corporation,"VIDAZA, , 100 mg single-dose vial in cartons of 1 vial, (NDC 59572-102-01)",Revised,10/1/2021,Available,,,,Oncology,Current,,,,2022,available
9280,Azacitidine for Injection,"Fresenius Kabi USA, LLC","100 mg per vial, single dose vial, PF, (NDC 63323-771-39)",Reverified,9/14/2022,Available,,,Demand increase for the drug,Oncology,Current,,,,2022,available
9281,Azacitidine for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg per vial, (NDC 0143-9606-01)",Reverified,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Oncology,Current,,,,2022,available
9282,Azacitidine for Injection,"Dr. Reddy's Laboratories, Inc.","100 mg per vial, (NDC 43598-305-62)",Revised,3/4/2022,Approximately 2 months of inventory on hand,,,Demand increase for the drug,Oncology,Current,,,,2022,limited availability
9283,Azacitidine for Injection,Armas Pharmaceuticals Inc,100 mg per vial (NDC 72485-201-01),Reverified,5/19/2021,Limited availability,,,Demand increase for the drug,Oncology,Current,,,,2022,limited availability
9284,Azacitidine for Injection,Accord Healthcare Inc.,100 mg per vial (NDC 16729-306-10),Revised,6/10/2021,Limited availability.,,,Shortage of an active ingredient,Oncology,Current,,,,2022,limited availability
9285,Azacitidine for Injection,"Mylan Institutional, a Viatris company",100 mg per vial (NDC 67457-254-30),Reverified,9/28/2022,Unavailable,,,Other,Oncology,Current,,,,2022,not available
9286,Azacitidine for Injection,Cipla Limited,100 mg per vial (NDC 69097-805-40),Revised,6/8/2021,Available,,,Demand increase for the drug,Oncology,Current,,,,2022,available
9287,Azacitidine for Injection,Teva Pharmaceuticals,100 mg/vial Lyophilized Powder (NDC 68001-0313-56),Reverified,10/5/2022,"Backorder, Recovery expected TBD",Product is manufactured and labeled for Blue Point Laboratories,,,Oncology,Current,,,,2022,not available
9288,Azacitidine for Injection,Breckenridge Pharmaceutical,100 mg per vial (NDC 51991-797-98),Reverified,2/18/2022,Available,,,,Oncology,Current,,,,2022,available
9289,Azacitidine for Injection,"Meitheal Pharmaceuticals, Inc.",100 mg per vial (NDC 71288-115-30),New,10/7/2021,Available,,,,Oncology,Current,,,,2022,available
9290,Azithromycin (Azasite) Ophthalmic Solution 1%,Thea Pharma Inc.,"Azasite (Azithromycin Ophthalmic Solution) 1% (NDC 82584-307-03), 2.5mL",Revised,6/3/2022,On backorder.,,,Other,Ophthalmology,Current,,,,2022,not available
9291,Bacitracin Ophthalmic Ointment,Padagis US LLC,3.5 g (NDC 0574-4022-35),New,9/10/2021,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
9292,Bacteriostatic 0.9% Sodium Chloride Injection,"Fresenius Kabi USA, LLC","0.9% (90 mg per 10 mL), (9mg/mL), Multiple Dose Plastic Vial, 30 mL (NDC 63323-924-30)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler inventory,,Increase in demand,Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9293,Bacteriostatic 0.9% Sodium Chloride Injection,"Fresenius Kabi USA, LLC","0.9% (90 mg per 10 mL), (9mg/mL), Multiple Dose Plastic Vial, 10 mL, (NDC 63323-924-10)",Revised,9/14/2022,Available,Check wholesaler inventory,,Increase in demand,Gastroenterology;Other;Pediatric,Current,,,,2022,available
9294,Bacteriostatic 0.9% Sodium Chloride Injection,"Hospira, Inc.",10 mL Multiple Dose LifeShield™ Plastic Fliptop Vial (NDC 00409-1966-12),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9295,Bacteriostatic 0.9% Sodium Chloride Injection,"Hospira, Inc.",20 mL Multiple Dose Plastic Fliptop Vial (NDC 00409-1966-05),Revised,9/12/2022,Available,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,,2022,available
9296,Bacteriostatic 0.9% Sodium Chloride Injection,"Hospira, Inc.",30 mL Multiple Dose Plastic Fliptop Vial (NDC 00409-1966-07),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9297,Bacteriostatic Water for Injection,"Hospira, Inc.",30 mL Multiple Dose Plastic Fliptop Vial (NDC 00409-3977-03),Reverified,9/12/2022,Next Delivery: October 2022; Estimated Recovery: May 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,,2022,not available
9298,Belatacept (Nulojix) Lyophilized Powder for Injection,Bristol Myers Squibb Co.,20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13),Revised,2/25/2021,"No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of Nulojix via the US NULOJIX Distribution Program, initiated 2/15/2017. Starting in August 2018, the restrictions of the NDP were eased to al",,,Demand increase for the drug,Transplant,Current,,,,2022,limited availability
9299,Belladonna and Opium Suppositories,Padagis US LLC,16.2mg/60 mg suppository (NDC: 0574-7040),New,8/3/2022,Currently out of stock. No estimated release date available.,Manufacturing delay due to active ingredient shortage,,"Regulatory delay, shortage of active ingredient",Urology,Current,,,,2022,not available
9300,Belladonna and Opium Suppositories,Padagis US LLC,"Belladonna and Opium Suppositories, 16.2mg/30 mg (NDC 0574-7045)",New,8/3/2022,Currently out of stock. No estimated release date available.,Manufacturing delay due to active ingredient shortage,,"Regulatory delay, shortage of active ingredient",Urology,Current,,,,2022,not available
9301,Benzonatate Capsules,Pfizer Pharmaceuticals,Tessalon 100 mg perles; Bottle of 100 (NDC 0069-0122-01),New,6/8/2021,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
9302,Betamethasone Valerate Topical Foam,Ingenus Pharmaceuticals LLC,0.12% (NDCs 50742-315-01 and 50742-315-50),New,11/30/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9303,Bivalirudin in 0.9% Sodium Chloride Injection,Baxter,250 mg/50 mL (NDC 0338-9572-24),New,7/12/2022,,Discontinuation of the manufacture of the drug.,,,Hematology,To be Discontinued,7/12/2022,7/12/2022,,2022,discontinued
9304,Bivalirudin in 0.9% Sodium Chloride Injection,Baxter,500 mg/100 mL (NDC 0338-9576-12),New,7/12/2022,,Discontinuation of the manufacture of the drug.,,,Hemtology,To be Discontinued,7/12/2022,7/12/2022,,2022,discontinued
9305,Bleomycin Injection,Teva,NDC 0703-3154-01 (15 Units/Single Dose Vial),New,8/11/2022,,Product is available with an expected supply duration until SEPT 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9306,Bleomycin Injection,Teva,NDC 0703-3155-01 (30 Units/Single Dose Vial),New,8/11/2022,,Product is available with an expected supply duration until AUG 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9307,"Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup",Wockhardt Bio A.G.,4 Fl Oz (118ml) (NDC 60432-275-04),New,8/26/2022,,Discontinuing the manufacture of the product due to business reasons,,,Pulmonary/Allergy; Gastroenterology,To be Discontinued,8/26/2022,8/26/2022,,2022,discontinued
9308,"Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup",Wockhardt Bio A.G.,1 pint (475ml) (NDC 60432-275-16),New,8/26/2022,,Discontinuing the manufacture of the product due to business reasons,,,Pulmonary/Allergy; Gastroenterology,To be Discontinued,8/26/2022,8/26/2022,,2022,discontinued
9309,Budesonide Capsules,Teva Pharmaceuticals,3 mg capsules (NDC 0093-7445-01),New,12/23/2019,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
9310,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 4 mL vial (NDC 0641-6008-10)",Revised,8/26/2022,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
9311,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 10 mL vial (NDC 0641-6007-10)",Revised,8/26/2022,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
9312,Bumetanide Injection,"Hospira, Inc.",1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04),Revised,9/12/2022,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,not available
9313,Bumetanide Injection,"Hospira, Inc.",2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10),Revised,9/12/2022,Next Delivery and Estimated Recovery: February 2025,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,not available
9314,Bumetanide Injection,Pfizer,1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1412-04),New,7/19/2022,,Stock anticipated to be available through September 2022,,,Cardiology; Renal,To be Discontinued,7/19/2022,7/19/2022,,2022,discontinued
9315,Bumetanide Injection,Pfizer,2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1412-10),New,7/19/2022,,Stock anticipated to be available through August 2022,,,Cardiology; Renal,To be Discontinued,7/19/2022,7/19/2022,,2022,discontinued
9316,Bumetanide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",1mg/4mL vial (NDC 70860-405-04),Reverified,9/28/2022,Available,,,,Cardiovascular,Current,,,,2022,available
9317,Bumetanide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",2.5mg/10mL vial (NDC 70860-406-10),Reverified,9/28/2022,Available,,,,Cardiovascular,Current,,,,2022,available
9318,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-461-57),Revised,9/14/2022,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9319,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.5% (250 mg per 50 mL) (5 mg per mL) MDV (NDC 63323-463-57),Revised,9/14/2022,Backordered.  Next release October 2022.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9320,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.25% (25 mg per 10 mL) (2.5 mg per mL) SDV (NDC 63323-468-17),Revised,9/14/2022,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9321,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI .25% (75 mg per 30 mL) (2.5 mg per mL) SDV (NDC 63323-468-37),Revised,9/14/2022,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9322,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (50 mg per 10 mL) (5 mg per mL) SDV (NDC 63323-462-17),Revised,9/14/2022,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9323,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) SDV (NDC 63323-462-37),Revised,9/14/2022,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9324,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC","Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) Sterile-Pak, SDV (NDC 63323-462-31)",Revised,9/14/2022,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9325,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.75% (225 mg per 30 mL) (7.5 mg per mL)  SDV  (NDC 63323-460-37),Revised,9/14/2022,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9326,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-01),Revised,9/12/2022,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9327,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-17),Revised,9/12/2022,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9328,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9043-01),Revised,9/12/2022,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9329,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-01),Revised,9/12/2022,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9330,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-17),Revised,9/12/2022,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9331,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9046-01),Revised,9/12/2022,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9332,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-10)",Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: March 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9333,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-30)",Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: March 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9334,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-10)",Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: January 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9335,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-29)",Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: March 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9336,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1752-50)",Revised,9/12/2022,Next Delivery and Estimated Recovery: September 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9337,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1755-50)",Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,limited availability
9338,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Sensorcaine 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-465-57),Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9339,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Sensorcaine 0.5% (250 mg per 50 mL) (5 mg per mL)                    MDV (NDC 63323-467-57),Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9340,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.25% (25 mg per 10 mL) (2.5 mg per mL) MPF,         SDV (NDC 63323-464-17)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9341,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine MPF 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF, SDV (NDC 63323-464-37)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9342,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF,             Sterile-Pak, SDV (NDC 63323-464-31)",Revised,9/14/2022,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9343,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (50 mg per 10 mL) (5 mg per mL)  MPF,                 SDV  (NDC 63323-466-17)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9344,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                 SDV (NDC 63323-466-37)",Revised,9/14/2022,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9345,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                Sterile-Pak, SDV (NDC 63323-466-31)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9346,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.75% (75 mg per 10 mL) (7.5 mg per mL) MPF,             SDV (NDC 63323-472-17)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9347,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.75% (225 mg per 30 mL) (7.5 mg per mL) MPF,     SDV (NDC 63323-472-37)",Revised,9/14/2022,4 month expiry (12/2022 & 1/2023 expiry) dating available by request.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2022,unclear
9348,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.25% 10 mL Single Dose Vials (NDC 55150-167-10),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
9349,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.25% 30 mL Single Dose Vials (NDC 55150-168-30),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
9350,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 10 mL Single Dose Vials (NDC 55150-169-10),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
9351,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 30 mL Single Dose Vials (NDC 55150-170-30),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
9352,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.75% 10 mL Single Dose Vials (NDC 55150-171-10),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
9353,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.75% 30 mL Single Dose Vials (NDC 55150-172-30),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
9354,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.25% 50 mL Multiple Dose Vials (NDC 55150-249-50),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
9355,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 50 mL Multiple Dose Vials (NDC 55150-250-50),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
9356,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-01),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: December 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9357,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-02),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9358,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1160-01),Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9359,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-01),Revised,9/12/2022,Next Delivery: November 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9360,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-02),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: July 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9361,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1163-01),Revised,9/12/2022,Limited Supply Available. Next Delivery: March 2023; Estimated Recovery: July 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,limited availability
9362,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",75 mg/10 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-01),Revised,9/12/2022,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9363,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",225 mg/30 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-02),Revised,9/12/2022,Next Delivery: December 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9364,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409-3613-01),Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9365,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 25 mg/10 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-10),Revised,9/12/2022,Next Delivery and Estimated Recovery: February 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9366,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 75 mg/30 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-30),Revised,9/12/2022,Next Delivery and Estimated Recovery: May 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9367,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1587-50),Revised,9/12/2022,Next Delivery and Estimated Recovery: June 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9368,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-10),Revised,9/12/2022,Next Delivery and Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9369,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-29),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9370,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1610-50),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9371,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 75 mg/10 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-10),Revised,9/12/2022,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9372,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 225 mg/30 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-29),Revised,9/12/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9373,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409- 1761-02),Revised,9/12/2022,Next Delivery and Estimated Recovery: TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,unclear
9374,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.25% 5 mL single-dose ampules (NDC 59923-717-05),Revised,12/9/2021,Available,,,,Anesthesia,Current,,,,2022,available
9375,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.25% 10 mL single-dose ampules (NDC 59923-719-10),Revised,12/9/2021,Available,,,,Anesthesia,Current,,,,2022,available
9376,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.5% 5 mL single-dose ampules (NDC 59923-718-05),Revised,12/9/2021,Available,,,,Anesthesia,Current,,,,2022,available
9377,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.5% 10 mL single-dose ampules (NDC 59923-720-10),Revised,12/9/2021,Available,,,,Anesthesia,Current,,,,2022,available
9378,Bupivacaine Hydrochloride Injection,Baxter Healthcare,"Bupivacaine Spinal, USP (7.5 mg/mL in 8.25% dextrose) 2 mL Single Dose Ampule (10 x 2 mL)(NDC 36000-092-10)",Reverified,9/28/2022,Stocked out - recovery TBD,,,Manufacturing Delay,Anesthesia,Current,,,,2022,not available
9379,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","HCl 0.75% & Dextrose 8.25%, Injectable spinal (NDC 73293-0002)",New,6/21/2021,Available,,,,Anesthesia,Current,,,,2022,available
9380,Busulfan Injection,American Regent/Luitpold,6 mg/mL  (NDC 0517-0920-08),New,8/6/2021,,,,,Hematology,To be Discontinued,,,,2022,discontinued
9381,Busulfan Injection,Apotex Corp.,6mg/mL (NDCs 60505-6177-0 and 60505-6177-8),New,10/15/2021,,,,,Hematology,To be Discontinued,,,,2022,discontinued
9382,Calcitonin Salmon Nasal Spray,"Endo Pharmaceuticals, Inc.",200 IU/spray (NDC 49884-161-11),New,8/29/2022,,,,,Musculoskeletal,To be Discontinued,8/29/2022,8/29/2022,,2022,discontinued
9383,Calcium Disodium Versenate Injection,Bausch Health,1000 mg/5 mL (200 mg/mL) (NDC 99207-240-05),Reverified,10/25/2021,Not currently available. Estimated Shortage duration TBD,,,Requirements related to complying with good manufacturing practices,Other,Current,,,,2022,not available
9384,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","1,000 mg calcium gluconate per 10 mL (100 mg/mL), single dose vial (NDC 63323-360-01, 1 vial; NDC 63323-360-19, 25 vials)",Revised,9/14/2022,Available,Check wholesaler inventory,,Available,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
9385,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","5,000 mg calcium gluconate per 50 mL (100 mg/mL), single dose vial (NDC 63323-360-03, 1 vial; NDC 63323-360-59, 25 vials)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase for the drug,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2022,not available
9386,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","10,000 mg calcium gluconate per 100 mL (100 mg/mL), pharmacy bulk package vial (NDC 63323-360-05, 1 vial; NDC 63323-360-61, 20 vials)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase for the drug,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2022,not available
9387,Calcium Gluconate Injection,HQ Specialty Pharma,1000 mg/50 mL (20 mg/mL) single-dose bag (NDC 44567-620-24),Reverified,5/3/2022,Available,,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
9388,Calcium Gluconate Injection,HQ Specialty Pharma,2000 mg/100 mL (20 mg/mL) single-dose bag (NDC 44567-621-24),Reverified,5/3/2022,Available,,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
9389,Calcium Gluconate Injection,HQ Specialty Pharma,1000mg/100mL (10mg/mL) Calcium Gluconate single-dose bag (NDC 44567-0622-24),Reverified,5/3/2022,Available,,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
9390,Capreomycin Injection,Akorn Pharmaceuticals,"Capastat Sulfate (Capreomycin for Injection USP) Eq to 1 g Capreomycin activity, 10mL (NDC 17478-080-50)",Revised,5/5/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9391,Captopril Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",12.5mg; 25mg; 50mg; 100mg (NDC 0378-3007-10; 0378-3007-01; 0378-3012-10; 0378-3012-01; 0378-3017-10; 0378-3017-01; 0378-3022-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9392,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 25mg/15mg 100s Tabs (NDC 00378-0081-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9393,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 25mg/25mg 100s Tabs (NDC 00378-0083-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9394,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 50mg/15mg 100s Tabs (NDC 00378-0084-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9395,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 50mg/25mg 100s Tabs (NDC 00378-0086-01),New,8/9/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9396,Carbamazepine Oral Suspension,Wockhardt Bio A.G.,"100mg/5ml 450mL, (NDC 60432-129-16)",New,6/22/2022,,,,,Neurology; Pediatric,To be Discontinued,,,,2022,discontinued
9397,Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose,"Chiesi USA, Inc.",Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose (NDC 10122-326-10),New,3/20/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9398,Caspofungin Acetate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",50 mg (NDC 67457-831-50),New,7/23/2020,,,,,Anti-Infective;Pediatric,To be Discontinued,,,,2022,discontinued
9399,Cefazolin Injection,"Hospira, Inc.",1g Single-dose ADD-Vantage Vial (NDC 00409-2585-01,Reverified,9/12/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
9400,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 2 g (25 vials) (NDC 60505-6231-05),Reverified,8/22/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9401,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 1 g (25 vials) (NDC 60505-6142-05),Reverified,8/22/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9402,Cefazolin Injection,Sagent Pharmaceuticals,10g 10 vials (NDC 25021-102-99),Reverified,8/22/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9403,Cefazolin Injection,Sagent Pharmaceuticals,500mg 25 vials (NDC 25021-100-10),Reverified,8/22/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9404,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 2 gram/50 mL in DUPLEX Catalog 3105-11 (NDC 00264-3105-11),Reverified,6/10/2022,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,,2022,limited availability
9405,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 1 gram/50 mL in DUPLEX Catalog 3103-11 (NDC 0264-3103-11),Reverified,6/10/2022,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,,2022,limited availability
9406,Cefazolin Injection,WG Critical Care,500mg SDV (NDC 44567-706-25),Reverified,10/3/2022,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
9407,Cefazolin Injection,WG Critical Care,1g SDV (NDC 44567-707-25),Reverified,10/3/2022,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
9408,Cefazolin Injection,WG Critical Care,10g PBP (NDC 44567-708-10),Reverified,10/3/2022,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
9409,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Reverified,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2022,discontinued
9410,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9923-90),Reverified,4/8/2022,Inventory is currently available,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
9411,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9924-90),Reverified,4/8/2022,Inventory is currently available,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
9412,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mg/ 100 mL vial (NDC 0143-9983-03),Reverified,4/8/2022,Inventory is currently available,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
9413,Cefazolin Injection,Sandoz,Cefazolin Na Injection 500 mg (NDC 0781-3450-95),Reverified,10/3/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9414,Cefazolin Injection,Sandoz,Cefazolin Na Injection 1 g (NDC 0781-3451-96),Reverified,10/3/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9415,Cefazolin Injection,Sandoz,Cefazolin Na Injection 10 g (NDC 0781-3452-95),Reverified,10/3/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9416,Cefazolin Injection,Sagent Pharmaceuticals,1g 25 vials (NDC 25021-101-10),Reverified,8/22/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9417,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 1 gram/50 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3503)(NDC 0338-3503-41)",Revised,9/28/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9418,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 2 gram/100 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3508)(NDC 0338-3508-41)",Revised,9/28/2022,Available,,,Manufacturing Delay,Anti-Infective,Current,,,,2022,available
9419,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 10 g (10 vials) (NDC 60505-6143-04),Reverified,8/22/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9420,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1100-1),Reverified,10/6/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9421,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",300 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1300-1),Reverified,10/6/2022,Available,,,,Anti-Infective,Current,,,,2022,available
9422,Cefdinir Capsules,Sandoz,300 mg capsules  (NDC 0781-2176-60),New,7/9/2020,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9423,Cefdinir Powder for Suspension,Sandoz,125 mg/5 mL (NDCs 0781-6077-46 and 0781-6077-61),New,10/29/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9424,Cefdinir Powder for Suspension,Sandoz,250 mg/5 mL (NDCs 0781-6078-46 and 0781-6078-61),New,10/29/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9425,Cefixime Oral Capsules,Ascend Laboratories LLC.,400 mg (50’s HDPE Bottle pack)(NDC 67877-584-50),Revised,3/16/2022,"Currently unavailable, Estimated recovery: June/July 2022",,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,,2022,not available
9426,Cefixime Oral Capsules,Lupin,400 mg Bottle of 50 capsules (NDC 68180-423-08),Reverified,7/12/2022,"Limited availability, Manufacturing and distribution is ongoing.",,,Demand increase for the drug,Anti-Infective,Current,,,,2022,limited availability
9427,Cefixime Oral Capsules,Lupin,400 mg Unit dose Package of 10 (1 blister of 10 capsules) (NDC 68180-423-11),Reverified,7/12/2022,"Limited availability, Manufacturing and distribution is ongoing.",,,Demand increase for the drug,Anti-Infective,Current,,,,2022,limited availability
9428,Cefotaxime Sodium Injection,"SteriMax, Inc.","2g/vial, (NDC 21586-012-2)",Reverified,10/14/2021,Available,,,Other,Anti-Infective;Pediatric,Current,,,,2022,available
9429,Cefotaxime Sodium Injection,"SteriMax, Inc.","1g/vial, (NDC 21586-011-2)",Reverified,10/14/2021,Available,,,Other,Anti-Infective;Pediatric,Current,,,,2022,available
9430,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9930-10),Reverified,4/8/2022,Currently unavailable,,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2022,not available
9431,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9931-25),Reverified,4/8/2022,Currently unavailable,,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2022,not available
9432,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2 g/ 10 mL vial (NDC 0143-9933-25),Reverified,4/8/2022,Currently unavailable,,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2022,not available
9433,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 g/ 100 mL vial (NDC 0143-9935-01),Reverified,4/8/2022,Currently unavailable,,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,,2022,not available
9434,Cefotetan Disodium Injection,B. Braun Medical Inc.,1 gram/50 mL in DUPLEX (NDC 00264-3173-11),Revised,6/9/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9435,Cefotetan Disodium Injection,B. Braun Medical Inc.,2 gram/50 mL in DUPLEX (NDC 00264-3175-11),Revised,6/9/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9436,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",1 g SDV (NDC 63323-0385-10),Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler for inventory,,Manufacturing delay,Anti-Infective,Current,,,,2022,not available
9437,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",2 g SDV (NDC 63323-0386-20),Revised,9/14/2022,Available,Check wholesaler for inventory,,Manufacturing delay,Anti-Infective,Current,,,,2022,available
9438,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",10 g PBP (NDC 63323-0396-61),Revised,9/14/2022,No release date available at this time.,,,Manufacturing delay,Anti-Infective,Current,,,,2022,not available
9439,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),Reverified,10/13/2021,Discontinued,,,,Anti-Infective,Current,,,,2022,discontinued
9440,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1g vial (NDC 0143-9878-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9441,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2g vial (NDC 0143-9877-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9442,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10g vial (NDC 0143-9876-10),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9443,Cefoxitin for Injection,Apotex Corp.,1 g (25 vials) (NDC 60505-0759-05),Revised,11/18/2021,,,,,Anti-Infective,Resolved,,,,2022,
9444,Cefoxitin for Injection,Apotex Corp.,2 g (25 vials) (NDC 60505-0760-05),Revised,11/18/2021,,,,,Anti-Infective,Resolved,,,,2022,
9445,Cefoxitin for Injection,Apotex Corp.,10 g (10 vials) (NDC 60505-0761-04),Revised,11/18/2021,,,,,Anti-Infective,Resolved,,,,2022,
9446,Cefoxitin for Injection,"Fresenius Kabi USA, LLC",1 g per vial; SDV; (NDC 63323-341-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9447,Cefoxitin for Injection,"Fresenius Kabi USA, LLC",2 grams per vial; SDV; (NDC 63323-342-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9448,Cefoxitin for Injection,Sagent Pharmaceuticals,"10 g, package of 10 vials (NDC 25021-111-99)",Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9449,Cefoxitin for Injection,Sagent Pharmaceuticals,"1 g, package of 10 vials (NDC 25021-109-10)",Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9450,Cefoxitin for Injection,Sagent Pharmaceuticals,"2 g, package of 10 vials (NDC 25021-110-20)",Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9451,Cefoxitin for Injection,WG Critical Care,1 g (NDC 44567-245-25),Revised,11/18/2021,Available,,Available,,Anti-Infective,Resolved,,,,2022,available
9452,Cefoxitin for Injection,WG Critical Care,2 g (NDC 44567-246-25),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9453,Cefoxitin for Injection,WG Critical Care,10 g (NDC 44567-247-10),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9454,Cefoxitin for Injection,B. Braun Medical Inc.,Cefoxitin Injection 2 gram/50 mL in DUPLEX Catalog 3125-11 (NDC NDC 00264-3125-11),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9455,Cefoxitin for Injection,B. Braun Medical Inc.,Cefoxitin Injection 1 gram/50 mL in DUPLEX Catalog 3123-11 (NDC 0264-3123-11),Revised,11/18/2021,,,Available,,Anti-Infective,Resolved,,,,2022,
9456,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 1g Bag 24 x 50mL (NDC 24987-0412-00),New,3/20/2018,,,,,Anti-Infective;Pediatric,To be Discontinued,,,,2022,discontinued
9457,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 2g Bag 24 x 50mL (NDC 24987-0413-00),New,3/20/2018,,,,,Anti-Infective;Pediatric,To be Discontinued,,,,2022,discontinued
9458,"Ceftazidime and Avibactam (AVYCAZ®) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution 1 Single-use vials (NDC 0456-2700-01)",Revised,2/7/2022,,,Available,,Anti-Infective,Resolved,,,,2022,
9459,"Ceftazidime and Avibactam (AVYCAZ®) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution Carton containing 10 vials  (NDC 0456-2700-10)",Revised,2/7/2022,,,Available,,Anti-Infective,Resolved,,,,2022,
9460,Ceftolozane and Tazobactam (Zerbaxa) Injection,Merck Sharp & Dohme Corp.,Supplied in single-dose vials containing ceftolozane 1 g (equivalent to 1.147 g of ceftolozane sulfate) and tazobactam 0.5 g (equivalent to 0.537 g of tazobactam sodium) per vial. Vials are supplied in cartons containing 10 vials (NDC 67919-030-01),Revised,3/14/2022,,,Available,,Anti-Infective,Resolved,,,,2022,
9461,Cefuroxime Sodium (Zinacef) Injection,"Teligent Pharma, Inc.",Cefuroxime Sodium (Zinacef) Premix Sol Frozen 1.5g Bag 24 x 50mL (NDC 24987-0425-00),New,3/20/2018,,,,,Anti-Infective;Pediatric,To be Discontinued,,,,2022,discontinued
9462,Cetirizine Hydrochloride Solution,Torrent Pharma Inc.,"Oral Solution, 1 mg/mL 120 mL (NDC 1366859607) and 480 mL (NDC 1366859611)",New,6/9/2022,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
9463,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"25 mg, 500 count (NDC 0555-0159-04)",Reverified,10/5/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9464,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"5 mg, 100 count (NDC 0555-0158-02)",Reverified,10/5/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9465,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"10 mg, 1000 count (NDC 0555-0033-05)",Reverified,10/5/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9466,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"10 mg, 100 count (NDC 0555-0033-02)",Reverified,10/5/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9467,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"25 mg, 100 count (NDC 0555-0159-02)",Reverified,10/5/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9468,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"5 mg, 500 count (NDC 0555-0158-04)",Reverified,10/5/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9469,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","10mg, 100ct (NDC 42806-562-01)",Reverified,3/8/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9470,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","25mg, 100ct (NDC 42806-563-01)",Reverified,3/8/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9471,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","5mg, 100ct (NDC 42806-564-01)",Reverified,3/8/2022,Available,,,,Neurology;Psychiatry,Current,,,,2022,available
9472,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,5 mg (NDC 43547-251-10),New,11/19/2019,,,,,Neurology;Psychiatry,To be Discontinued,,,,2022,discontinued
9473,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,10 mg (NDC 43547-252-10),New,11/19/2019,,,,,Neurology;Psychiatry,To be Discontinued,,,,2022,discontinued
9474,Chloroprocaine Hydrochloride Injection,B. Braun Medical Inc.,"Clorotekal® (Chloroprocaine HCl Injection, USP) 5mL ampules 50 mg/5 mL (10 mg/mL) Catalog D7055 (NDC 0264-7055-05)",New,5/17/2021,Product available,,,Other,Anesthesia,Current,,,,2022,available
9475,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nescacaine 1% (300 mg per 30 mL) (10 mg per mL); MDV; (NDC 63323-475-37),Revised,9/14/2022,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2022,available
9476,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nescacaine 2% (600 mg per 30 mL) (20 mg per mL); MDV; (NDC 63323-476-37),Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler for inventory,,,Anesthesia,Current,,,,2022,not available
9477,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nesacaine 2% (400 mg per 20 mL) (20 mg per mL); SDV; (NDC 63323-477-27),Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2022,not available
9478,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nesacaine 3% (600 mg per 20 mL) (30 mg per mL); SDV; (NDC 63323-478-27),Revised,9/14/2022,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2022,available
9479,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% (20 mg/mL), 20 mL vial (NDC 0143-9209-10)",Revised,4/8/2022,Inventory is currently available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9480,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","3% (30 mg/mL), 20 mL vial (NDC 0143-9210-10)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9481,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"10 mg/5 mL Single Dose Vial, Package of 10 vials (NDC 55150-284-10)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9482,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg / 10 mL Multiple-Dose Vial, Package of 10 vials (ndc 55150-286-10)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9483,Cisatracurium Besylate Injection,Teva Pharmaceuticals,200 mg/20 mL (10 mg/mL) Single-dose vials (NDC 0703-2045-03),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9484,Cisatracurium Besylate Injection,Teva Pharmaceuticals,20 mg/10 mL (2 mg/mL) Multiple-dose vials (NDC 0703-2056-03),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9485,Cisatracurium Besylate Injection,Teva Pharmaceuticals,10 mg/5 mL (2 mg/mL) Single-dose vials (NDC 0703-2033-03),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9486,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/mL 10 vials (NDC 70069-141-10),Revised,7/27/2021,,,,,Anesthesia,Resolved,,,,2022,
9487,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/ml 10 vials (NDC 70069-161-10),Revised,7/27/2021,,,,,Anesthesia,Resolved,,,,2022,
9488,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",10mg/mL 10 vials (NDC 70069-151-10),Revised,7/27/2021,,,,,Anesthesia,Resolved,,,,2022,
9489,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",10 mg per 5 mL single dose vial (NDC 71288-712-06),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9490,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",200 mg per 20 mL single dose vial (NDC 71288-713-21),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9491,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",20 mg per 10 mL  multi dose vial (NDC 71288-712-11),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9492,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","10 mg (base) per 5 mL (2 mg per mL), Single dose vial, PF, (NDC 63323-416-05)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9493,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","20 mg per 10 mL (2 mg per mL), Multiple dose vial, (NDC 63323-417-10)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9494,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), Single dose vial, PF, (NDC 63323-418-20)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9495,Cisatracurium Besylate Injection,Sandoz,2mg/ml; 5mL (NDC 0781-3150-95),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9496,Cisatracurium Besylate Injection,Sandoz,2mg/mL; 10mL (NDC 0781-3152-95),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9497,Cisatracurium Besylate Injection,Sandoz,1-mg/mL; 20mL (NDC 0781-3153-95_,Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9498,Cisatracurium Besylate Injection,"Hospira, Inc.",10mg/5mL (2mg/mL) Single Dose Vial (NDC 00409-1098-02),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9499,Cisatracurium Besylate Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose Vial (NDC 00409-1103-01),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9500,Cisatracurium Besylate Injection,"Hospira, Inc.",20mg/10mL (2mg/mL) Multi-Dose Vial (NDC 00409-1208-01),Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9501,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 5 mL Single-dose vial (NDC 0074-4378-05, 0074-4378-24, 0074-4378-36)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9502,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 10 mL Multiple-dose vial (NDC 0074-4380-10, 0074-4380-79, 0074-4380-81)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9503,Cisatracurium Besylate Injection,Abbvie,"10 mg/mL, 20 mL Single-dose vial (NDC 0074-4382-20, 0074-4382-91, 0074-4382-93)",Revised,7/27/2021,,,Available,,Anesthesia,Resolved,,,,2022,
9504,Cladribine Injection,Mylan Laboratories Ltd.,1 mg/mL (NDC 67457-450-10),New,5/20/2022,,,,,Oncology,To be Discontinued,,,,2022,discontinued
9505,"Clindamycin and Benzoyl Peroxide Gel, 1%/5%","Tolmar Pharmaceuticals, Inc.",45g jar (NDC 0781-7263-68); 35g pump (NDC 0781-7275-43); 50g jar (NDC 0781-7287-50); 50g pump (NDC 0781-7291-46),New,9/30/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9506,"Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5%","Tolmar Pharmaceuticals, Inc.",45 g tube (NDC 0781-7161-19),New,9/30/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9507,Clindamycin Phosphate Topical Solution 1%,"Teligent Pharma, Inc.",30mL (NDC 52565-018-29),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9508,Clindamycin Phosphate Topical Solution 1%,"Teligent Pharma, Inc.",60mL (NDC 52565-018-59),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9509,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-039-15),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9510,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-039-30),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9511,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",45g (NDC 52565-039-45),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9512,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-039-60),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9513,Clobetasol Propionate Topical Foam,Ingenus Pharmaceuticals LLC,0.05% (NDCs 50742-304-01 and 50742-304-50),New,11/16/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9514,Clobetasol Propionate Topical Solution 0.05%,Wockhardt,25 mL (NDC 6432-133-25) || 50 mL (NDC 60432-133-50),New,6/13/2022,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9515,"Clobetasol Propionate Topical Solution, 0.05%","Tolmar Pharmaceuticals, Inc.",25 mL bottle (NDC 63646-500-25),New,11/1/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9516,"Clobetasol Propionate Topical Solution, 0.05%","Tolmar Pharmaceuticals, Inc.",50 mL bottle (NDC 63646-500-50),New,11/1/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9517,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg  (90s)(NDC 0378-1910-77),New,5/8/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9518,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (100s)(NDC 0378-1910-01),New,5/8/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9519,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (1000s)(NDC 0378-1910-10),New,5/8/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9520,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (90s)(NDC 0378-1912-77),New,5/8/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9521,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (100s)(NDC 0378-1912-01),New,5/8/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9522,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (1000s)(NDC 0378-1912-10),New,5/8/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9523,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (100s)(NDC 0378-1914-01),New,5/8/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9524,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (500s)(NDC 0378-1914-05),New,5/8/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9525,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0185-0063-01)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9526,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0185-0063-05)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9527,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0185-0063-10)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9528,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0781-8018-01)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9529,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0781-8018-05)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9530,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0781-8018-10)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9531,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-752-01)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9532,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-752-02)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9533,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-469-01)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9534,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-469-02)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9535,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0185-0064-01)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9536,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0185-0064-05)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9537,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0185-0064-10)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9538,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0781-5567-01)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9539,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0781-5567-05)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9540,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0781-5567-10)",New,6/5/2018,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9541,Clonidine Hydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",0.1mg  (NDC 10370-257-02),New,11/30/2021,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9542,Clonidine Hydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",0.1mg  (NDC 10370-257-02),New,3/22/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9543,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","12.5 mg tablet, 100 CT Bottle (NDC 18860-101-10)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9544,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablets, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-102-01)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9545,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablet, 100  CT bottle (NDC 18860-102-10)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9546,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-104-01)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9547,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-105-01)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9548,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 100 CT Bottle (NDC 18860-105-10)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9549,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-106-01)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9550,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablets, 100 CT Bottle (NDC 18860-106-10)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9551,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg Tablet, 100 CT Bottle (NDC 18860-104-10)",New,11/22/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9552,Codeine Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension,Aytu BioPharma,"14.7 mg of codeine (equivalent to 20 mg codeine phosphate); and chlorpheniramine polistirex, which contains 2.8 mg of chlorpheniramine (equivalent to 4 mg chlorpheniramine maleate) per 5 mL (NDCs 69654-480-01 and 69654-480-02)",New,6/13/2022,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
9553,Conivaptan Hydrochloride (Vaprisol) in 5% Dextrose Plastic Container,Cumberland Pharmaceuticals Inc.,20 mg/100 mL (NDC 66220-160-10),New,3/14/2022,Next delivery April 2022.  Estimated recovery 3Q 2022.,,,Other,Cardiovascular,Current,,,,2022,not available
9554,"Conjugated Estrogens/Bazedoxifene (DUAVEE) Tablet, Film Coated",Pfizer,Conjugated estrogens 0.45 mg/bazedoxifene 20 mg; 2 blisters of 15 each (NDC 0008-1123-12),New,9/21/2022,Next Delivery and Estimated Recovery: Late Q3 2023,Shortage per Manufacturer: Manufacturing Delay,,,Reproductive,Current,,,,2022,not available
9555,"Conjugated Estrogens/Bazedoxifene (DUAVEE) Tablet, Film Coated",Pfizer,Conjugated estrogens 0.45 mg/bazedoxifene 20 mg; blister of 7 each (US Sample) (NDC 63539-122-07),New,9/21/2022,Next Delivery and Estimated Recovery: Late Q3 2023,Shortage per Manufacturer: Manufacturing Delay,,,Reproductive,Current,,,,2022,not available
9556,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BK0/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON-PVC. (NDC 24571-113-06)",Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9557,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK0/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-108-06)",Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9558,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (DC 24571-114-06)",Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9559,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-105-06)",Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9560,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/3.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-103-06)",Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9561,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-102-06)",Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9562,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol B22GK4/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-111-06)",Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9563,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM BK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-116-06),Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9564,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM B22K4/0 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-117-06),Reverified,9/28/2022,,,Available,,Renal,Resolved,9/19/2022,,,2022,
9565,Cortisone Acetate Tablets,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg, bottles of 100 (NDC 0143-9700-01)",Reverified,4/8/2022,Currently Unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient,Endocrinology/Metabolism;Rheumatology,Current,,,,2022,not available
9566,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 2ML (NDC 0065-0359-02)",New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9567,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 5ML (NDC 0065-0359-05)",New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9568,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 0.5% 15ML (NDC 0065-0395-15),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9569,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 2ML (NDC 0065-0396-02),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9570,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 5ML (NDC 0065-0396-05),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9571,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 2ML (NDC 0065-0397-02),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9572,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 5ML (NDC 0065-0397-05),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9573,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 15ML (NDC 0065-0397-15),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9574,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 15ML (NDC 61314-396-01),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9575,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 2ML (NDC 61314-396-03),New,11/9/2020,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,,2022,available
9576,Cyclopentolate Ophthalmic Solution,Bausch & Lomb Incorporated,"Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%, 2 mL bottle (NDC 24208-735-01) and 15 mL bottle (NDC 24208-735-06)",Revised,6/24/2021,On backorder. Estimated availability: Mid-September 2021,,,Other,Ophthalmology,Current,,,,2022,not available
9577,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 15mL 1 Bottle (NDC 17478-097-12)",Revised,6/24/2021,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,,2022,not available
9578,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 2mL, 1 Bottle (NDC 17478-097-02)",Revised,6/24/2021,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,,2022,not available
9579,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 5mL 1 Bottle/EA (NDC 17478-097-10)",Revised,6/24/2021,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,,2022,not available
9580,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Opht Sol 1% 10mg/mL, 2mL, 1 Bottle (NDC 17478-100-02)",Revised,6/24/2021,On backorder. Estimated availability: August 2021,,,Other,Ophthalmology,Current,,,,2022,not available
9581,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Ophth 1% 10mg/mL, 15mL, 1 Bottle (NDC 17478-100-12)",Revised,6/24/2021,On backorder. Estimated availability: August 2021,,,Other,Ophthalmology,Current,,,,2022,not available
9582,Cysteamine Hydrochloride Ophthalmic Solution,"Leadiant Biosciences, Inc.","0.44%, 15 mL bottle (old NDC 54482-020-01) (NEW NDC 54482-020-02)",Revised,6/8/2022,,,"NDC 54482-020-01 has been discontinued and replaced by NDC 54482-020-02, which is available.",,Ophthalmology,Resolved,,,,2022,
9583,Cysteine Hydrochloride Injection,"Exela Pharma Sciences, LLC",Elcys (Cysteine Hydrochloride injection) 500mg/10ml Single-dose vials (NDC 51754-1007-1) Packaged as 10 per carton (NDC 51754-1007-3),Revised,9/3/2019,,,Available,,Other;Pediatric,Resolved,,,,2022,
9584,Cytarabine Injection,"Fresenius Kabi USA, LLC","2 g/20 mL (100 mg/mL), single dose vial (NDC 63323-120-20)",Revised,9/14/2022,Backordered. Next release October 2022.,,,,Oncology;Pediatric,Current,,,,2022,not available
9585,Cytarabine Injection,"Hospira, Inc.","100 mg/5 mL (20 mg/mL), single dose vial (NDC 61703-305-38)",Reverified,9/12/2022,Available,,,,Oncology;Pediatric,Current,,,,2022,available
9586,Cytarabine Injection,"Hospira, Inc.","2 g/20 mL (100 mg/mL), single dose vial (NDC 61703-319-22)",Reverified,9/12/2022,Available,,,Other,Oncology;Pediatric,Current,,,,2022,available
9587,Cytarabine Injection,"Hospira, Inc.","500 mg/25 mL (20 mg/mL), multiple dose vial (NDC 61703-304-36)",Reverified,9/12/2022,Available,,,Other,Oncology;Pediatric,Current,,,,2022,available
9588,Cytarabine Injection,"Hospira, Inc.","1,000 mg/50 mL (20 mg/mL), pharmacy bulk vial (NDC 61703-303-46)",Reverified,9/12/2022,Available,,,Other,Oncology;Pediatric,Current,,,,2022,available
9589,Cytarabine Injection,"Meitheal Pharmaceuticals, Inc.","2 g/20 mL (100 mg/mL), single dose vial (NDC 71288-109-20)",Reverified,5/18/2022,"Currently, no inventory",,,Other,Oncology;Pediatric,Current,,,,2022,not available
9590,Cytarabine Injection,"Mylan Institutional, a Viatris company","2 g/20 mL (100 mg/mL), single dose vial (NDC 67457-452-20)",Reverified,11/10/2021,Unavailable,,,,Oncology;Pediatric,Current,,,,2022,not available
9591,Cytarabine Injection,"Mylan Institutional, a Viatris company","100 mg/5 mL (20 mg/mL), single dose vial (NDC 67457-455-52)",Reverified,11/10/2021,Unavailable,,,,Oncology;Pediatric,Current,,,,2022,not available
9592,Cytarabine Injection,"Mylan Institutional, a Viatris company","1000 mg/50 mL (20 mg/mL), pharmacy bulk vial (NDC 67457-454-50)",Reverified,11/10/2021,Unavailable,,,,Oncology;Pediatric,Current,,,,2022,not available
9593,Cytotec (Misoprostol) Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 120 (NDC 0025-1451-20),New,6/11/2021,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
9594,Dacarbazine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",200 mg/vial (NDC 0143-9245-10),Reverified,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Oncology,Current,,,,2022,available
9595,Dacarbazine Injection,Teva Pharmaceuticals,200 mg 10x20mL (NDC 00703-5075-03),Reverified,10/5/2022,Backordered – Est date of availability TBD,,,Demand increase for the drug,Oncology,Current,,,,2022,not available
9596,Dacarbazine Injection,Teva Pharmaceuticals,200 mg 1x20mL (NDC 00703-5075-01),Reverified,10/5/2022,Backordered – Est date of availability TBD,,,Demand increase for the drug,Oncology,Current,,,,2022,not available
9597,Dacarbazine Injection,"Fresenius Kabi USA, LLC","100 mg per vial, Single Dose Amber Vial (NDC 63323-127-10)",Reverified,9/14/2022,Available,,,Manufacturing delay,Oncology,Current,,,,2022,available
9598,Dacarbazine Injection,"Fresenius Kabi USA, LLC","200 mg per vial, Single Dose Amber Vial (NDC 63323-128-20)",Reverified,9/14/2022,Available,,,Manufacturing delay,Oncology,Current,,,,2022,available
9599,Dacarbazine Injection,Teva,NDC 0703-5075-03 (200 mg 10 X 20 mL Single-Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9600,Dacarbazine Injection,Teva,NDC 0703-5075-01 (200 mg 1 X 20 mL Single-Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9601,Daptomycin Injection,"Merck Sharp & Dohme Corp., a subsidiary of Merck and Co., Inc.",500 mg (NDC 67919-012-01),New,8/2/2022,,,,,Anti-Infective,To Be Discontinued,8/2/2022,8/2/2022,,2022,discontinued
9602,Daptomycin Injection,Pfizer,350 mg lyophilized; 15 mL Single-dose vial (NDC 0409-5933-01),New,7/26/2022,,Supply expected to exhaust 01Sep2022; Replaced with NDC 0409-0120-01; Discontinuation of the manufacture of the drug.,,,Anti-Infective,To Be Discontinued,7/26/2022,7/26/2022,,2022,discontinued
9603,Daptomycin Injection,Pfizer,500 mg lyophilized; 15 mL Single-dose vial (NDC 0409-2757-01),New,7/26/2022,,Supply expected to exhaust 01Oct2022; Replaced with NDC 0409-0122-01; Discontinuation of the manufacture of the drug.,,,Anti-Infective,To Be Discontinued,7/26/2022,7/26/2022,,2022,discontinued
9604,Daptomycin Injection,"Fresenius Kabi USA, LLC",350mg (NDC 63323-585-15),New,5/17/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9605,Daptomycin Injection,"Fresenius Kabi USA, LLC","500mg (NDCs 63323-371-10, 63323-371-19, and 63323-871-15)",New,5/17/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9606,Daptomycin Injection,Merck Sharp & Dohme Corp.,500 mg (NDC 67919-011-01),New,10/8/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9607,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"Extended release, 7.5 mg, 90 count bottle (NDC 0591-4375-19)",New,6/17/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9608,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"15 mg, 30 count bottle (NDC: 0591-4380-30)",New,6/17/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9609,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 30 (NDC 0430-0171-15)",New,6/4/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9610,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of  90 (NDC 0430-0171-23)",New,6/4/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9611,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg , 337500 TABLETS in 1 DRUM (NDC 0430-0171-00)",New,6/4/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9612,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 7 (NDC 0430-0171-96)",New,6/4/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9613,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 0430-0170-15)",New,6/4/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9614,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of  90 (NDC 0430-0170-23)",New,6/4/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9615,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, 337500 TABLETS in 1 DRUM (NDC 0430-0170-00)",New,6/4/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9616,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, Bottle of 7 (NDC 0430-0170-96)",New,6/4/2020,,,,,Urology,To be Discontinued,,,,2022,discontinued
9617,Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets,Abbvie,"200mg; 8.33mg; 50mg; 33.33 tablets, (NDC 0074-0063-28)",New,5/22/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
9618,Daunorubicin Hydrochloride Injection,Teva,"20 mg/4 mL, 10 Single Dose Vial Tray (NDC 0703-5233-13)",New,8/11/2022,,Product is temporarily unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9619,Daunorubicin Hydrochloride Injection (Novaplus®* Label),Teva Pharmaceuticals,"5 mg/mL, 20 mg 4 mL/Vial x 10 (NDC 0703-5233-93)",New,9/13/2022,,Product has not been marketed for at least 5 years,,,Oncology,To be Discontinued,9/13/2022,9/13/2022,,2022,discontinued
9620,Deferasirox Tablets,Teva Pharmaceuticals,180 mg/1 (NDC 00093-3516-56),New,7/20/2020,,,,,Hematology,To be Discontinued,,,,2022,discontinued
9621,Deferasirox Tablets,Teva Pharmaceuticals,90 mg/1 (NDC 00093-3517-56),New,7/20/2020,,,,,Hematology,To be Discontinued,,,,2022,discontinued
9622,Deferasirox Tablets,Teva Pharmaceuticals,360 mg/1 (NDC 00093-3515-56),New,7/20/2020,,,,,Hematology,To be Discontinued,,,,2022,discontinued
9623,Desmopressin Acetate Injection,Teva,NDC 0703-5051-03 (4 mcg/mL 10 x 1 mL  Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Hematology; Endocrinology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9624,Desmopressin Acetate Injection,Teva,NDC 0703-5054-01 (4 mcg/mL 10 mL Muti Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Hematology; Endocrinology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9625,Desmopressin Acetate Nasal Spray,Ferring,10 mcg/0.1mL (NDCs 55566-2500-0 and 69918-501-05),New,5/14/2021,Unavailable,,,Other,Hematology,Current,,,,2022,not available
9626,Desmopressin Acetate Nasal Spray,Apotex Corp.,10 mcg/0.1mL (NDC 60505-0815-0),Reverified,8/22/2022,Available,,,,Hematology,Current,,,,2022,available
9627,Desmopressin Acetate Nasal Spray,Ferring,"1.5 mg/mL, (NDC 0053-6871-00)",Revised,5/14/2021,Unavailable,,,Other,Hematology,Current,,,,2022,not available
9628,Desogestrel and Ethinyl Estradiol Tablets (ORTHO-CEPT),Janssen Pharmaceuticals,ORTHO-CEPT (NDC 50458-196-15),Revised,10/8/2014,,,,Discontinuation of the manufacture of the drug.,,To Be Discontinued,,,,2022,discontinued
9629,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection SDV [4 mg / 1 ml] 25PK (NDC 67457-423-12),Reverified,9/28/2022,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9630,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [20 mg / 5 ml] 25PK (NDC 67457-422-54),Reverified,9/28/2022,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9631,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [120 mg / 30 ml] 25 PK (NDC 67457-421-30),Reverified,9/28/2022,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9632,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [100 mg / 10 ml] 10PK (NDC 67457-420-10),Reverified,9/28/2022,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9633,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),4 mg/1 mL SDV (NDC 55150-237-01),Revised,9/28/2022,On long term backorder,,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,not available
9634,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),20 mg/5 mL MDV  (NDC 55150-238-05),Revised,9/28/2022,On long term backorder,,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,not available
9635,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),120 mg/30 mL MDV (NDC 55150-239-30),Revised,9/28/2022,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9636,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL, 1 mL Single Dose Vial (Preservative Free)(NDC 70069-021-25)",Reverified,4/20/2022,Available,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9637,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",20 mg per 5 mL (4 mg per mL); MDV;  Amber vial (NDC 63323-165-05),Revised,9/14/2022,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9638,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",100 mg per 10 mL (10 mg per mL); MDV;  Amber Vial (NDC 63323-516-10),Revised,9/14/2022,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9639,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",120 mg per 30 mL (4 mg per mL); MDV; Amber Vial (NDC 63323-165-30),Revised,9/14/2022,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9640,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",4 mg per mL (4 mg per mL); SDV; Amber Vial (NDC 63323-165-01),Revised,9/14/2022,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9641,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",10 mg per mL (10 mg per mL); SDV; Preservative Free; Amber Vial (NDC 63323-506-01),Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,not available
9642,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6145-25)",Revised,4/8/2022,This presentation is temporarily on backorder.,,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,not available
9643,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 5 mL vial (NDC 0641-6146-25)",Revised,4/8/2022,This presentation is temporarily on backorder.,,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,not available
9644,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-0367-25)",Revised,4/8/2022,Inventory is currently available,,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9645,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-106-10)",Revised,9/14/2022,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9646,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-109-10)",Revised,9/14/2022,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9647,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),10 mg/1 mL SDV (NDC 55150-304-25),Revised,9/28/2022,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,available
9648,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),100 mg/10 mL MDV (contains preservative)(NDC 55150-305-10),Revised,9/28/2022,Backordered — next shipment TBD,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,,2022,not available
9649,Dexmedetomidine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"200mcg/50mL, single dose bag (NDC 55150-296-10)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9650,Dexmedetomidine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"400mcg/100mL, single dose bag (NDC 55150-297-10)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9651,Dexmedetomidine Injection,Amneal Pharmaceutical,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single-dose bottle (NDC 70121-1388-8 box of 20; NDC 70121-1388-1 individual)",Reverified,4/7/2022,Available,,,,Anesthesia,Current,,,,2022,available
9652,Dexmedetomidine Injection,Amneal Pharmaceutical,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single-dose bottle (NDC 70121-1389-7 box of 10; NDC 70121-1389-1 individual)",Reverified,4/7/2022,Available,,,,Anesthesia,Current,,,,2022,available
9653,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","0.2 mg / 50 ml (Solution in Single Use Vials/Bottles), 20PK (NDC 67457-924-50)",Revised,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9654,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","0.4 mg / 100 ml (Solution in Single Use Vials/Bottles), 10PK (NDC 67457-925-10)",Revised,9/28/2022,Available,,,Demand increase for the drug,,Current,,,,2022,available
9655,Dexmedetomidine Injection,Par Pharmaceutical,"200 mcg/50 mL (4 mcg/mL), 50 mL single dose vial, box of 25 (NDC 42023-186-20)",Reverified,9/21/2022,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,,2022,unclear
9656,Dexmedetomidine Injection,Par Pharmaceutical,"400 mcg/100 mL (4 mcg/mL), 100 mL single dose vial, box of 10 (NDC 42023-187-10)",Reverified,9/21/2022,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,,2022,unclear
9657,Dexmedetomidine Injection,Gland Pharma Limited,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 43598-976-58)",Reverified,9/28/2022,Inventory available,,,,Anesthesia,Current,,,,2022,available
9658,Dexmedetomidine Injection,Gland Pharma Limited,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 43598-975-58)",Reverified,9/28/2022,Inventory available,,,,Anesthesia,Current,,,,2022,available
9659,Dexmedetomidine Injection,Hong Kong King Friend Industrial Co. Ltd.,"200 mcg/2 mL (100 mcg/mL) single dose vial, box of 25 (NDC 71288-505-03)",Reverified,4/7/2022,Available,,,,Anesthesia,Current,,,,2022,available
9660,Dexmedetomidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mcg/mL, 2 mL vial (NDC 0143-9532-25)",Reverified,4/8/2022,Inventory is currently available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9661,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-239-93)",Reverified,4/21/2022,Available,,,,Anesthesia,Current,,,,2022,available
9662,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-432-93), Novaplus",Reverified,4/21/2022,Available,,,,Anesthesia,Current,,,,2022,available
9663,Dexmedetomidine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 55150-209-02)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9664,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 0338-9555-24)",Reverified,9/28/2022,Available,,,,Anesthesia,Current,,,,2022,available
9665,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 0338-9557-12)",Reverified,9/28/2022,Available,,,,Anesthesia,Current,,,,2022,available
9666,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 43066-555-24), Novaplus",Reverified,9/28/2022,Available,,,,Anesthesia,Current,,,,2022,available
9667,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 43066-557-12), Novaplus",Reverified,9/28/2022,Available,,,,Anesthesia,Current,,,,2022,available
9668,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 63323-671-20)",Reverified,9/14/2022,Backordered. Next release September 2022.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
9669,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 25 (NDC 63323-671-50)",Reverified,9/14/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9670,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 63323-671-00)",Reverified,9/14/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9671,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 63323-421-02)",Reverified,9/14/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9672,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/4 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-600-04)",Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9673,Dexmedetomidine Injection,HQ Specialty Pharma,"1000 mcg/10 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-601-04)",Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9674,Dexmedetomidine Injection,HQ Specialty Pharma,"200 mcg/50 mL (4 mcg/mL), single dose bag, box of 24 (NDC 44567-602-24)",Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9675,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/100 mL (4 mcg/mL), box of 24 (NDC 44567-603-24)",Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9676,Dexmedetomidine Injection,Jiangsu Hengrui Medicine Co. Ltd.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 70860-605-03)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9677,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 67457-251-02)",Revised,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
9678,Dexmedetomidine Injection,Par Pharmaceutical,"100 mcg/mL, 2 mL single dose vial, box of 25 (NDC 42023-146-25)",Reverified,9/21/2022,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,,2022,unclear
9679,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 0409-1660-20)",Revised,9/12/2022,Depleted. Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
9680,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 20 (NDC 0409-1660-50)",Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,limited availability
9681,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 0409-1660-10)",Revised,9/12/2022,Available,,,Other,Anesthesia,Current,,,,2022,available
9682,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 0409-1638-02)",Revised,9/12/2022,Available,,,Other,Anesthesia,Current,,,,2022,available
9683,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 50 mL single dose bottle, box of 20 (NDC 71225-126-05)",Revised,6/1/2022,Available,,,,Anesthesia,Current,,,,2022,available
9684,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 100 mL single dose bottle, box of 10 (NDC 71225-126-06)",Revised,6/1/2022,Available,,,,Anesthesia,Current,,,,2022,available
9685,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-1070-01)",New,5/8/2018,,,,,Neurology;Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
9686,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100s (NDC 0378-1071-01)",New,5/8/2018,,,,,Neurology;Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
9687,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-1072-01)",New,5/8/2018,,,,,Neurology;Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
9688,Dextrose 10% Injection,Baxter Healthcare,"10% Dextrose Injection, 250 mL Viaflex Plastic Container. Product Code 2B0162Q (NDC 0338-0023-02)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9689,Dextrose 10% Injection,Baxter Healthcare,"10% Dextrose Injection, 500 mL Viaflex Plastic Container. Product Code 2B0163Q (NDC 0338-0023-03)",Revised,9/28/2022,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9690,Dextrose 10% Injection,Baxter Healthcare,"10% Dextrose Injection, 1000 mL Viaflex Plastic Container. Product Code 2B0164X (NDC 0338-0023-04)",Revised,9/28/2022,Available,,,Manufacturing Delay,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9691,Dextrose 10% Injection,B. Braun Medical Inc.,10% 1000 mL Excel Bag L5200 (NDC 0264-7520-00),New,3/1/2022,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9692,Dextrose 10% Injection,B. Braun Medical Inc.,10% 500 mL Excel Bag L5201 (NDC 0264-7520-10),New,3/1/2022,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9693,Dextrose 10% Injection,B. Braun Medical Inc.,10% 250 mL Excel Bag L5202 (NDC 0264-7520-20),New,3/1/2022,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9694,Dextrose 10% Injection,"Fresenius Kabi USA, LLC","10% Dextrose Injection, Single dose freeflex bag, (100 mg per mL), (25 grams per 250 mL) (NDC 63323-824-74)",Reverified,9/14/2022,Backordered. Next release September 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9695,Dextrose 10% Injection,"Fresenius Kabi USA, LLC","10% Dextrose Injection, Single dose freeflex bag, (100 mg per mL), (50 grams per 500 mL) (NDC 63323-824-75)",Reverified,9/14/2022,Backordered. Next release October 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9696,Dextrose 10% Injection,"Fresenius Kabi USA, LLC","10% Dextrose Injection, Single dose freeflex bag, (100 mg per mL), (100 grams per 1,000 mL) (NDC 63323-824-76)",Reverified,9/14/2022,Backordered. Next release September 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9697,Dextrose 10% Injection,"ICU Medical, Inc.","10% Dextrose Injection, USP, 250 mL (Legacy Hospira NDC 0409-7930-02), (ICU Medical NDC 0990-7930-02)",Reverified,10/3/2022,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9698,Dextrose 10% Injection,"ICU Medical, Inc.","10% Dextrose Injection, USP, 500 mL (Legacy Hospira NDC 0409-7930-03), (ICU Medical NDC 0990-7930-03)",Reverified,10/3/2022,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9699,Dextrose 10% Injection,"ICU Medical, Inc.","10% Dextrose Injection, USP, 1000 mL (Legacy Hospira NDC 0409-7930-09), (ICU Medical NDC 0990-7930-09)",Reverified,10/3/2022,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9700,Dextrose 10% Injection,"ICU Medical, Inc.","10% Dextrose Injection, USP, 500 mL (Legacy Hospira NDC 0409-7938-19) (ICU Medical NDC 0990-7938-19)",Reverified,10/3/2022,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9701,Dextrose 25% Injection,"Hospira, Inc., a Pfizer Company","2.5 g/10 mL (250 mg/mL), plastic syringe, 10 per bundle (NDC 0409-1775-10)",Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
9702,Dextrose 5% Injection,"Hospira, Inc., a Pfizer Company",50 mL; ADD-Vantage Flexible Container (Case of 50)(NDC 0409-7100-66),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9703,Dextrose 5% Injection,"Hospira, Inc., a Pfizer Company",100 mL; ADD-Vantage Flexible Container (Case of 50)(NDC 0409-7100-67),Revised,9/12/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9704,Dextrose 5% Injection,"Hospira, Inc., a Pfizer Company",250 mL; ADD-Vantage Flexible Container (Case of 24)(NDC 0409-7100-02),Revised,9/12/2022,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9705,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (5 grams per 100 mL) (NDC 63323-624-61)",Revised,9/14/2022,Backordered. Next release October 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9706,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (12.5 grams per 250 mL) (NDC 63323-624-74)",Revised,9/14/2022,Backordered. Next release September 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9707,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (25 grams per 500 mL) (NDC 63323-624-75)",Revised,9/14/2022,Backordered. Next release October 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9708,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (50 grams per 1,000 mL) (NDC 63323-624-10)",Revised,9/14/2022,Available,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9709,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (2.5 grams per 50 mL) (NDC 63323-624-50)",Revised,9/14/2022,Backordered. Next release October 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,not available
9710,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 250 mL (Legacy Hospira NDC 0409-7922-02) (ICU Medical NDC 0990-7922-02)",Reverified,10/3/2022,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9711,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 150 mL (Legacy Hospira NDC 0409-7922-61) (ICU Medical NDC 0990-7922-61)",Reverified,10/3/2022,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9712,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 50 mL (Legacy Hospira NDC 0409-7923-13) (ICU Medical NDC 0990-7923-13)",Reverified,10/3/2022,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9713,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 25 mL 4-1 (Legacy Hospira NDC 0409-7923-20) (ICU Medical NDC 0990-7923-20)",Reverified,10/3/2022,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9714,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 100 mL (Legacy Hospira NDC 0409-7923-23) (ICU Medical NDC 0990-7923-23)",Reverified,10/3/2022,Allocated to Contracted Customers Only,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9715,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 50 mL 4-1 (Legacy Hospira NDC 0409-7923-36) (ICU Medical NDC 0990-7923-36)",Reverified,10/3/2022,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9716,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 100 mL 4-1 (Legacy Hospira NDC 0409-7923-37) (ICU Medical NDC 0990-7923-37)",Reverified,10/3/2022,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9717,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 25 mL VIAFLEX Plastic Container Quad Pack, Product Code 2B0080, (NDC 0338-0017-10)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9718,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL VIAFLEX Plastic Container, Product Code 2B0086, (NDC 0338-0017-41)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9719,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL VIAFLEX Plastic Container, Quad Pack, Product Code 2B0081, (NDC 0338-0017-11)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9720,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL VIAFLEX Plastic Container, Multi Pack, Product Code 2B0088, (NDC 0338-0017-31)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9721,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL VIAFLEX Plastic Container, Product Code 2B0087, (NDC 0338-0017-48)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9722,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL VIAFLEX Plastic Container, Quad Pack, Product Code 2B0082, (NDC 0338-0017-18)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9723,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL VIAFLEX Plastic Container, Multi Pack, Product Code 2B0089, (NDC 0338-0017-38)",Revised,9/28/2022,"Limited Supply, Recovery late Sept 2022",,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9724,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL MINI-BAG Plus Container. Quad Pack, Product Code 2B0040, (NDC 0338-0551-11)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9725,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL MINI-BAG Plus Container, Product Code EZPB0040, (NDC 0338-9143-30)",Revised,9/28/2022,Available on allocation,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9726,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, Product Code EZPB0041, (NDC 0338-9147-30)",Revised,9/28/2022,Available on allocation,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9727,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, Product Code 2B0041, (NDC 0338-0551-18)",Revised,9/28/2022,Available,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9728,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 1000 mL VIAFLO Plastic Container, Product Code UE0064D, (NDC 0338-0070-10)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9729,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLEX Plastic Container, Product Code 2B0062Q, (NDC 0338-0017-02)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9730,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLO Plastic Container, Product Code UE0062D, (NDC 0338-0062-30)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9731,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLEX Plastic Container, Product Code 2B0063Q, (NDC 0338-0017-03)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9732,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLO Plastic Container, Product Code UE0063D, (NDC 0338-0066-20)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9733,Dextrose 5% Injection,B. Braun Medical Inc.,5% 500 mL Excel Bag L5101 (NDC 0264-7510-10),New,2/16/2022,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9734,Dextrose 5% Injection,B. Braun Medical Inc.,5% 1000 mL Excel Bag L5100 (NDC 0264-7510-00),New,2/16/2022,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9735,Dextrose 5% Injection,B. Braun Medical Inc.,5% 250 mL Excel Bag L5102 (NDC 0264-7510-20),New,2/16/2022,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9736,Dextrose 5% Injection,B. Braun Medical Inc.,5% 100 mL PAB Bag S5104-5264 (NDC 0264-1510-32),New,2/16/2022,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9737,Dextrose 5% Injection,B. Braun Medical Inc.,5% 50 mL PAB Bag S5104-5364 (NDC 0264-1510-31),New,2/16/2022,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9738,Dextrose 5% Injection,B. Braun Medical Inc.,10% 1000 mL Excel Bag L5200 (NDC 0264-7520-00),New,2/16/2022,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9739,Dextrose 5% Injection,B. Braun Medical Inc.,10% 500 mL Excel Bag L5201 (NDC 0264-7520-10),New,2/16/2022,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9740,Dextrose 5% Injection,B. Braun Medical Inc.,10% 250 mL Excel Bag L5202 (NDC 0264-7520-20),New,2/16/2022,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
9741,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 500 mL (Legacy Hospira NDC 0409-7922-03) (ICU Medical NDC 0990-7922-03)",Reverified,10/3/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9742,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 500 mL (Legacy Hospira NDC 0409-7922-55) (ICU Medical NDC 0990-7922-55)",Reverified,10/3/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9743,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 50 mL VisIV™ Container (Legacy Hospira NDC 0409-7923-06) (ICU Medical NDC 0990-7923-06)",Reverified,10/3/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9744,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 100 mL VisIV™ Container (Legacy Hospira NDC 0409-7923-11) (ICU Medical NDC 0990-7923-11)",Reverified,10/3/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9745,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 250 mL VisIV™ Container (Legacy Hospira NDC 0409-7922-25) (ICU Medical NDC 0990-7922-25)",Reverified,10/3/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9746,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 1000 mL (Legacy Hospira NDC 0409-7922-09) (ICU Medical NDC 0990-7922-09)",Reverified,10/3/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,,2022,available
9747,Dextrose 50% Injection,"Amphastar Pharmaceuticals, Inc./IMS","25 g/50 mL (0.5 g/mL), syringe, 10 per carton (NDC 76329-3302-1) (old NDC 76329-3301-1)",Reverified,8/12/2022,Backorder due to increase in demand,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
9748,Dextrose 50% Injection,"Hospira, Inc.","25 g/50 mL (0.5 g/mL), plastic syringe, 10 per bundle (NDC 0409-7517-16)",Revised,9/30/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,limited availability
9749,Dextrose 50% Injection,"Hospira, Inc.","25 g/50 mL (0.5 g/mL), glass syringe, 10 per bundle (NDC 0409-4902-34)",Revised,9/30/2022,Next Delivery: October 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
9750,Dextrose 50% Injection,"Hospira, Inc.","25 g/50 mL (0.5 g/mL), single dose vial, 25 per tray (NDC 0409-6648-02)",Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: July 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
9751,Diazepam Oral Solution (Concentrate),"Lannett Company, Inc.",5 mg/mL (NDC 0527-1768-36),New,1/5/2022,,,,,Neurology,To be Discontinued,,,,2022,discontinued
9752,Diazepam Rectal Gel,Bausch Health,"Diazepam Rectal Gel - 10mg 2 Syrg per pack, (NDC 68682-652-20)",Revised,9/22/2022,Available,Estimated availability September 2022,,,Neurology,Current,,,,2022,available
9753,Diazepam Rectal Gel,Bausch Health,"Diazepam Rectal Gel – 2.5mg 2 Syrg per pack, (NDC 68682-650-20)",Revised,9/22/2022,Currently unavailable,Estimated availability: TBD,,,Neurology,Current,,,,2022,not available
9754,Diazepam Rectal Gel,Bausch Health,Diastat Rectal Gel 2.5mg (NDC  66490-650-20),Revised,9/22/2022,No longer available,No plans to manufacture.  All volumes converted to generic version,,,Neurology,Current,,,,2022,discontinued
9755,Diazepam Rectal Gel,Bausch Health,Diastat Acudial 10 mg (NDC 0187-0658-20),Revised,9/22/2022,No longer available,No plans to manufacture.  All volumes converted to generic version,,,Neurology,Current,,,,2022,discontinued
9756,Diazepam Rectal Gel,Bausch Health,Diastat Acudial 20 mg (NDC 0187-0659-20),Revised,9/22/2022,No longer available,No plans to manufacture.  All volumes converted to generic version,,,Neurology,Current,,,,2022,discontinued
9757,Diazepam Rectal Gel,Bausch Health,"Diazepam Rectal Gel - 20mg 2 Syrg per pack, (NDC 68682-655-20)",Revised,9/22/2022,Available,,,,Neurology,Current,,,,2022,available
9758,Diclofenac Sodium Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0355-01),New,4/4/2018,,,,,Analgesia/Addiction;Rheumatology,To be Discontinued,,,,2022,discontinued
9759,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 200 mg, 30 count bottles (NDC 0555-0588-01)",New,5/9/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
9760,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 250 mg, 30 count bottles (NDC 0555-0589-01)",New,5/9/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
9761,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 400 mg, 30 count bottles (NDC 0555-0590-01)",New,5/9/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
9762,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",15g (NDC 52565-063-15),New,7/6/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9763,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",30g (NDC 52565-063-30),New,7/6/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9764,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",60g (NDC 52565-063-60),New,7/6/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9765,Diflunisal Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","500 mg, Bottle of 60 (NDC 14539-673-06)",Revised,9/7/2022,"Product is available, on allocation",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,limited availability
9766,Diflunisal Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","500 mg, Bottle of 100 (NDC 14539-673-01)",Revised,9/7/2022,"Product is available, on allocation",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,limited availability
9767,Diflunisal Tablets,Teva Pharmaceuticals,"500 mg, Bottle of 100 (NDC 0093-9222-01)",Revised,10/5/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
9768,Diflunisal Tablets,Teva Pharmaceuticals,"500 mg, Bottle of 500 (NDC 0093-9222-05)",Revised,10/5/2022,"Backorder, Recovery expected Jan-23",,,Other,Analgesia/Addiction,Current,,,,2022,not available
9769,Diflunisal Tablets,Teva Pharmaceuticals,"500 mg, Bottle of 60 (NDC 0093-9222-06)",Revised,10/5/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
9770,Difluprednate (Durezol) Ophthalmic Emulsion,Novartis,0.05% 5mL in 8mL bottle (NDC 0065-9204-07),Revised,10/15/2019,,,,,Ophthalmology,Resolved,,,,2022,
9771,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Adult (500mcg in 2ml) Ampule (NDC 0515-260-10),Revised,10/6/2021,Available,,,Delay in shipping of the drug,Cardiovascular,Current,,,,2022,available
9772,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Adult (500mcg in 2ml) vial (NDC 70515-261-10),Revised,10/6/2021,Available,,,,Cardiovascular,Current,,,,2022,available
9773,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Pediatric (100mcg in 1ml) ampoule (NDC 70515-262-10),Revised,10/6/2021,Available,,,,Cardiovascular,Current,,,,2022,available
9774,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Pediatric (100mcg in 1ml) vial (NDC 70515-263-10),Revised,10/6/2021,Available,,,,Cardiovascular,Current,,,,2022,available
9775,Digoxin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","250 mcg/mL, 2 mL  (NDC 0641-1410-35)",Reverified,4/8/2022,Inventory is currently available,,,Other,Cardiovascular,Current,,,,2022,available
9776,Digoxin Injection,Sandoz,500mcg/2 mL; 10 ampules (NDC 0781-3059-95),Reverified,10/3/2022,"Unavailable, resupply Q4 2022/Q1 2023",,,Shortage of an active ingredient,Cardiovascular,Current,,,,2022,not available
9777,Diltiazem Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1171-02),New,6/8/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9778,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",New,4/8/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9779,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",New,4/8/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9780,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",New,4/8/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9781,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",25 mg/5mL vial (NDC 70860-301-05),Reverified,9/28/2022,On allocation,,,,Cardiovascular,Current,,,,2022,limited availability
9782,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",50 mg/10mL vial (NDC 70860-301-10),Reverified,9/28/2022,Available,,,,Cardiovascular,Current,,,,2022,available
9783,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",125 mg/25mL vial (NDC 70860-301-25),Reverified,9/28/2022,Available,,,,Cardiovascular,Current,,,,2022,available
9784,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 5 mL vial  (NDC 0641-6013-10)",Revised,8/26/2022,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
9785,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial (NDC 0641-6014-10)",Revised,8/26/2022,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
9786,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 30 mL vial (NDC 0641-6015-10)",Revised,8/26/2022,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
9787,Diltiazem Hydrochloride Injection,"Hospira, Inc.",100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2022,limited availability
9788,Diltiazem Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2022,discontinued
9789,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10)",Revised,4/8/2022,"On allocation, then discontinued.",,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2022,discontinued
9790,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",Revised,4/8/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2022,discontinued
9791,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",Revised,4/8/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2022,discontinued
9792,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",Revised,4/8/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2022,discontinued
9793,Dimercaprol (Bal in Oil) Injection,Akorn Pharmaceuticals,"3 mL (100 mg/mL) ampules, box of 10 (NDC 17478-526-03)",Revised,6/29/2021,,,Available,,Hematology;Other,Resolved,,,,2022,
9794,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"100 mg capsules, bottle of 100 (NDC 59762-0386-1)",Reverified,9/12/2022,Available,,,Other,Cardiovascular,Current,,,,2022,available
9795,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"150 mg capsules, bottle of 100 (NDC 59762-0400-1)",Reverified,9/12/2022,Next Delivery & Recovery: October 2022,,,,Cardiovascular,Current,,,,2022,not available
9796,Disopyramide Phosphate (Norpace) Capsules,Teva Pharmaceuticals,"100 mg capsules, bottle of 100 (NDC 0093-3127-01)",Reverified,10/5/2022,Product is Available,,,,Cardiovascular,Current,,,,2022,available
9797,Disopyramide Phosphate (Norpace) Capsules,Teva Pharmaceuticals,"150 mg capsules, bottle of 100 (NDC 0093-3129-01)",Reverified,10/5/2022,"Backorder, Recovery expected March 2023",,,,Cardiovascular,Current,,,,2022,not available
9798,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace CR, 100 mg capsules, bottle of 100 (NDC 0025-2732-31)",Reverified,9/12/2022,Available,,,Other,Cardiovascular,Current,,,,2022,available
9799,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace CR, 150 mg capsules, bottle of 100 (NDC 0025-2742-31)",Reverified,9/12/2022,Available,,,Other,Cardiovascular,Current,,,,2022,available
9800,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace IR, 100 mg capsules; bottle of 100 (NDC 0025-2752-31)",Reverified,9/12/2022,Available,,,Other,Cardiovascular,Current,,,,2022,available
9801,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace IR, 150 mg capsules; bottle of 100 (NDC 0025-2762-31)",Reverified,9/12/2022,Next Delivery and Estimated Recovery: September 2022,,,,Cardiovascular,Current,,,,2022,not available
9802,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100s (NDC 0378-4140-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
9803,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100s (NDC 0378-4141-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
9804,Dobutamine Hydrochloride Injection,Baxter Healthcare,"250 mg/250 mL (NDC 0338-1073-02) Product code 2B0791, 500 mg/250 mL (NDC 0338-1075-02) Product code 2B0792, 1000 mg/250 mL (NDC 0338-1077-02) Product code 2B0793",Reverified,9/28/2022,"Limited Supply on Allocation, Recovery Q4",Third-Party Supplier Issue,,Third-Party Supplier Issue,Cardiovascular;Pediatric;Renal,Current,,,,2022,limited availability
9805,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/250 mL (1 mg/mL); Flexible Container (NDC 00409-2346-32),Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2022,not available
9806,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/250 mL (2 mg/mL); Flexible Container (NDC 00409-2347-32),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2022,not available
9807,Dobutamine Hydrochloride Injection,"Hospira, Inc.",1000 mg/250 mL (4 mg/mL); Flexible Container (NDC 00409-3724-32),Revised,9/12/2022,Next Delivery: November 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular;Pediatric;Renal,Current,,,,2022,not available
9808,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-20),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,,2022,discontinued
9809,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,,2022,discontinued
9810,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-01),Revised,9/12/2022,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: February 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2022,limited availability
9811,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-02),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: February 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,,2022,limited availability
9812,Dofetilide Capsules,Pfizer Pharmaceuticals,125 mcg (0.125 mg) capsules; Bottle of 60 (NDC 59762-0037-2),New,5/21/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9813,Dofetilide Capsules,Pfizer Pharmaceuticals,250 mcg (0.25 mg) capsules; Bottle of 60 (NDC 59762-0038-2),New,5/21/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9814,Dofetilide Capsules,Pfizer Pharmaceuticals,500 mcg (0.5 mg) capsules; Bottle of 60 (NDC 59762-0039-2),New,5/21/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
9815,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg/mL, 5 mL vial (NDC 0143-9252-25)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,not available
9816,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg/mL, 10 mL vial (NDC 0143-9254-25)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,not available
9817,Dopamine Hydrochloride Injection,"Hospira, Inc.","400 mg/250 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-22)",Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,limited availability
9818,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/500 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-24)",Revised,9/12/2022,Next Delivery and Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,,2022,not available
9819,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/250 mL (3,200 mcg/mL); Flexible Container (NDC 00409-7810-22)",Revised,9/12/2022,Next Delivery and Estimated Recovery: November 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,not available
9820,Dopamine Hydrochloride Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-5820-01),Revised,9/12/2022,Available,,,Other,Cardiovascular,Current,,,,2022,available
9821,Dopamine Hydrochloride Injection,"Hospira, Inc.",400 mg/10 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9104-20),Revised,9/12/2022,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
9822,Dopamine Hydrochloride Injection,Baxter Healthcare,"800 mcg/mL (250 mL bag) Product code 2B0832 (NDC 0338-1005-02), 800 mcg/mL (500 mL bag)  Product code 2B0833 (NDC 0338-1005-03), 1600 mcg/mL (250 mL bag) Product code 2B0842 (NDC 0338-1007-02), 1600 mcg/mL (500 mL bag) Product code 2B0843 (NDC 0338-1007-0",Revised,8/12/2022,Available,,,,Cardiovascular,Current,,,,2022,available
9823,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 17478-605-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9824,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 50383-233-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9825,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt-PF® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 0.2 mL single use, 60 count (NDC 17478-604-30)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9826,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 61314-030-02)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9827,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 24208-486-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9828,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Aurobindo Pharma,"Dorzolamide HCl and Timolol Maleate (Cosopt® PF) Ophthalmic Solution 2%/0.5% Preservative Free, 2mL single use container (NDC 65862-0947-60)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9829,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 0591-2482-79)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9830,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride and Timolol Maleate 20 mg and 5 mg/mL, 10 mL (0591-2482-79)",New,4/20/2018,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
9831,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",New,4/20/2018,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
9832,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",New,4/20/2018,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
9833,Dorzolamide Hydrochloride Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 61314-019-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9834,Dorzolamide Hydrochloride Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 50383-232-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9835,Dorzolamide Hydrochloride Ophthalmic Solution,Merck Sharp & Dohme Corp.,"Trusopt® Dorzolamide hydrochloride ophthalmic solution 2%, for topical ophthalmic use 10ml, (NDC 0006-3519-36)",New,4/11/2022,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
9836,Dorzolamide Hydrochloride Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride USP 2%, 10 mL (NDC 24208-485-10)",Revised,5/10/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9837,Doxepin Hydrochloride Oral Solution,Wockhardt Bio A.G.,"10gm/mL, 118 mL (NDC 60432-651-04)",New,7/26/2022,,Discontinuing the manufacture of the product due to business reasons,,,Neurology,To Be Discontinued,7/26/2022,7/26/2022,,2022,discontinued
9838,Doxercalciferol Injection,Hospira,4 mcg/2 mL (2 mcg/mL) Multiple-Dose Vial (NDC 00409-1330-01),New,9/12/2022,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
9839,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",50mg  (NDC 49884-726-01),New,6/28/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9840,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",100mg  (NDCs 49884-0727-03 and 49884-0727-04),New,6/28/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9841,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",150mg  (NDC 49884-0305-02),New,6/28/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9842,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",50mg (NDC 49884-726-01),New,1/31/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9843,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",100mg (NDCs 49884-727-03 and 49884-727-04),New,1/31/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9844,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",150mg (NDC 49884-305-02),New,1/31/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9845,Doxycycline Hyclate Powder for Suspension,"Hospira, Inc.",25mg/5mL (NDC 0069-0970-65),New,11/15/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9846,Doxycycline Hyclate Tablets,Teva Pharmaceuticals,"75 mg tablets, 60 count (NDC 0591-6100-60)",Revised,6/22/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9847,Doxycycline Hyclate Tablets,Teva Pharmaceuticals,150mg  (NDC 0591-6125-60),New,6/21/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9848,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Fera Pharmaceuticals,Phospholine Iodide 0.125% echothiophate iodide for ophthalmic solution 5ml (NDC 48102-053-05),Revised,6/1/2022,"Available starting June 1st, 2022 through limited distribution by AllianceRx Walgreens Prime Specialty Pharmacy.",,,Delay in manufacturing,Ophthalmology,Current,,,,2022,limited availability
9849,Efavirenz Capsules,Bristol-Myers Squibb Co.,50mg (NDC 0056-0470-30),New,9/28/2022,,"Product available until March 31, 2023.",,,Antiviral,To be Discontinued,9/28/2022,9/28/2022,,2022,discontinued
9850,Efavirenz Capsules,Bristol-Myers Squibb Co.,200mg (NDC 0056-0474-92),New,9/28/2022,,"Product available until March 31, 2023.",,,Antiviral,To be Discontinued,9/28/2022,9/28/2022,,2022,discontinued
9851,Efavirenz Tablets,"Mylan Specialty, a Viatris Company",600 mg (NDC 0378-2233-93),New,11/2/2021,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
9852,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2.5mg/2mL, vial (NDC 0143-9786-10)",Reverified,4/8/2022,This presentation is currently available.,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
9853,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1.25mg/mL, vial  (NDC 0143-9787-10)",Reverified,4/8/2022,This presentation is currently available.,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
9854,"Epinephrine Injection, 0.1 mg/mL","Hospira, Inc.",1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4933-01),Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: June 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pulmonary/Allergy,Current,,,,2022,not available
9855,"Epinephrine Injection, 0.1 mg/mL","Amphastar Pharmaceuticals, Inc./IMS","0.1mg/mL, 10mL, (NDC 76329-3316-1)",Reverified,8/12/2022,Backorder due to the increase in demands,,,Demand increase for the drug,Cardiovascular;Pulmonary/Allergy,Current,,,,2022,not available
9856,"Epinephrine Injection, Auto-Injector","Mylan Specialty, a Viatris Company",0.3 mg EpiPen® (NDC 49502-500-02); Authorized Generic (NDC 49502-102-02),Reverified,9/28/2022,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9857,"Epinephrine Injection, Auto-Injector","Mylan Specialty, a Viatris Company",0.15 mg EpiPen® (NDC 49502-501-02); Authorized Generic (NDC 49502-101-02),Reverified,9/28/2022,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9858,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)",Revised,10/3/2022,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9859,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)",Revised,10/3/2022,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9860,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)",Reverified,1/27/2021,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9861,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)",Reverified,1/27/2021,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9862,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)",Reverified,1/27/2021,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9863,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)",Reverified,10/5/2022,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9864,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.3 mg single-dose, pre-filled syringes (NDC 78670-130-02))",Revised,5/19/2022,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9865,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.15 mg single-dose, pre-filled syringes (NDC 78670-131-02)",Revised,5/19/2022,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9866,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.15 MG Epinephrine Injection, USP auto-injector (NDC 0093-5985-27)",Reverified,10/5/2022,Available,,,,Pulmonary/Allergy,Current,,,,2022,available
9867,Epoprostenol Sodium for Injection and Sterile Diluent for Epoprostenol Sodium for Injection,Teva,NDC 0703-9258-09 ( 2 x 50 mL vials Sterile Diluent),New,9/12/2022,,Product is available with an expected supply duration until AUG' 2022.  No future production expected for an extended period.,,,,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
9868,Epoprostenol Sodium for Injection and Sterile Diluent for Epoprostenol Sodium for Injection,Teva,"NDC 0703-1985-01 (0.5 mg/vial (500,000 ng))",New,9/12/2022,,Product is unavailable and no future production expected for an extended period.,,,,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
9869,Epoprostenol Sodium for Injection and Sterile Diluent for Epoprostenol Sodium for Injection,Teva,"NDC 0703-1995-01 (1.5 mg/vial (1,500,000 ng))",New,9/12/2022,,Product is unavailable and no future production expected for an extended period.,,,,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
9870,Eptifibatide Injection,Teva Pharmaceuticals,"0.75 mg/mL, 75 mg, 100 mL/Vial (NDC 0703-1179-01)",New,9/13/2022,,Product has not been marketed for at least 5 years,,,Cardiovascular,To be Discontinued,9/13/2022,9/13/2022,,2022,discontinued
9871,Ergotamine Tartrate and Caffeine (Cafergot) Tablets,Sandoz,1mg/100mg (NDC 0781-5405-01),New,7/2/2020,,,,,Neurology,To be Discontinued,,,,2022,discontinued
9872,Ertapenem Injection,"Merck Sharp & Dohme Corp. a subsidiary of Merck and Co., Inc.",1g (NDC 0006-3843-71),New,8/2/2022,,,,,Anti-Infective,To Be Discontinued,8/2/2022,8/2/2022,,2022,discontinued
9873,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35),Revised,8/1/2022,Unavailable. Estimated availability 1Q2023.,New manufacturing site being qualified.,,Discontinuation of manufacture of the drug (from existing site).,Ophthalmology; Pediatric,Current,,,,2022,not available
9874,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g tube (unit dose) (NDC17478-070-31),Revised,8/1/2022,Unavailable. Estimated availability 1Q2023.,New manufacturing site being qualified.,,Discontinuation of manufacture of the drug (from existing site).,Ophthalmology; Pediatric,Current,,,,2022,not available
9875,Erythromycin Ophthalmic Ointment,Padagis US LLC,"Erythromycin 0.5% Ophthalmic Ointment 1 gram, 50-count (00574-4024-50)",Revised,8/1/2022,Available and shipping,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,2022,available
9876,Erythromycin Ophthalmic Ointment,Padagis US LLC,"Erythromycin 0.5% Ophthalmic Ointment 3.5 gram, 1-count (00574-4024-35)",Revised,8/1/2022,Available and shipping,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,2022,available
9877,Erythromycin Ophthalmic Ointment,Bausch Health,"Erythromycin Ophthalmic Ointment USP, 0.5% 3.5 g in 1 tube (NDC 24208-910-55)",Revised,8/1/2022,Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,2022,limited availability
9878,Erythromycin Ophthalmic Ointment,Padagis US LLC,"Erythromycin 0.5% Ophthalmic Ointment 3.5 gram, 24-count (00574-4024-39)",Revised,8/1/2022,Available and shipping,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,2022,available
9879,Erythromycin Ophthalmic Ointment,Bausch Health,"Erythromycin Ophthalmic Ointment USP, 0.5% 1 g in carton of 50 (NDC 24208-910-19)",Revised,8/1/2022,Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,2022,limited availability
9880,Esomeprazole Sodium for Injection,"Mylan Institutional, a Viatris company","40 mg vial, box of 10 (NDC 67457-392-99)",New,9/16/2021,,,,,Gastroenterology;Pediatric,To be Discontinued,,,,2022,discontinued
9881,Ethambutol Hydrochloride Tablets,Teva Pharmaceuticals,400mg  (NDC 0555-0923-02),New,11/5/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
9882,Etomidate Injection,"Avet Pharmaceuticals, Inc.",20 mg/10mL carton of 10 (NDC 23155-160-41),New,10/5/2022,Product available upon request,,,,Anesthesia,Current,,,,2022,limited availability
9883,Etomidate Injection,"Avet Pharmaceuticals, Inc.",40 mg/20 mL carton of 10 (NDC 23155-160-42),New,10/5/2022,Product available upon request,,,,Anesthesia,Current,,,,2022,limited availability
9884,Etomidate Injection,"Caplin Steriles, Ltd.","2 mg/mL, 20 mL vial (NDC 25021-674-20)",New,10/5/2022,Available,Marketed by Sagent,,,Anesthesiology,Current,,,,2022,available
9885,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 72572-160-10)",New,10/5/2022,Pending information,Distributed by Civica,,,Anesthesiology,Current,,,,2022,unclear
9886,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 72572-161-10)",New,10/5/2022,Pending information,Distributed by Civica,,,Anesthesiology,Current,,,,2022,unclear
9887,Etomidate Injection,"Caplin Steriles, Ltd.","2 mg/mL, 10 mL vial (NDC 65219-445-10)",New,10/5/2022,Available,Marketed by Fresenius Kabi,,,Anesthesiology,Current,,,,2022,available
9888,Etomidate Injection,"Caplin Steriles, Ltd.","2 mg/mL, 20 mL vial (NDC 65219-447-20)",New,10/5/2022,Available,Marketed by Fresenius Kabi,,,Anesthesiology,Current,,,,2022,available
9889,Etomidate Injection,"Caplin Steriles, Ltd.","2 mg/mL, 10 mL vial (NDC 25021-674-10)",New,10/5/2022,Available,Marketed by Sagent,,,Anesthesiology,Current,,,,2022,available
9890,Etomidate Injection,"Eugia US, LLC (formerly AuroMedics Pharma LLC) [mfd. by Eugia Pharma Specialties, Ltd.)","2 mg/mL, 10 mL vial (NDC 55150-221-10)",New,10/5/2022,Currently on backorder,Next shipment anticipated in Oct.,,Other,Anesthesiology,Current,,,,2022,not available
9891,Etomidate Injection,"Eugia US, LLC (formerly AuroMedics Pharma LLC) [mfd. by Eugia Pharma Specialties, Ltd.)","2 mg/mL, 20 mL vial (NDC 55150-222-10)",New,10/5/2022,Currently on backorder,Next shipment TBD,,Other,Anesthesiology,Current,,,,2022,not available
9892,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 10 mL vial (NDC 72266-146-10)",New,10/5/2022,Pending information,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesiology,Current,,,,2022,unclear
9893,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-147-10)",New,10/5/2022,Pending information,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesiology,Current,,,,2022,unclear
9894,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9506-10)",New,10/5/2022,Currently on backorder,,,Demand increase for the drug,Anesthesiology,Current,,,,2022,not available
9895,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9507-10)",New,10/5/2022,Currently on backorder,,,Demand increase for the drug,Anesthesiology,Current,,,,2022,not available
9896,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9310-10), Novaplus",New,10/5/2022,Pending information,,,,Anesthesiology,Current,,,,2022,unclear
9897,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9311-10), Novaplus",New,10/5/2022,Pending information,,,,Anesthesiology,Current,,,,2022,unclear
9898,Etomidate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg/mL, 10 mL vial (NDC 67457-902-10)",New,10/5/2022,Q1 2023,,,Demand increase for the drug,Anesthesiology,Current,,,,2022,unclear
9899,Etomidate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg/mL, 20 mL vial (NDC 67457-903-20)",New,10/5/2022,Available,,,,Anesthesiology,Current,,,,2022,available
9900,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, 2 mg/mL, 10 mL vial (NDC 0409-6695-01)",New,10/5/2022,Next delivery: March 2023; Estimated recovery: December 2023,Manufacturing Delay,,Other,Anesthesiology,Current,,,,2022,not available
9901,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, 2 mg/mL, 20 mL vial (NDC 0409-6695-02)",New,10/5/2022,Next delivery: February 2023; Estimated recovery: March 2023,Manufacturing Delay,,Other,Anesthesiology,Current,,,,2022,not available
9902,Etoposide (Toposar) Injection,Teva,NDC 0703-5653-01 (100 mg/5 mL (20 mg/mL) 5 mL Multiple-dose Vial),New,8/11/2022,,Product is unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9903,Etoposide (Toposar) Injection,Teva,NDC 0703-5656-01 (500 mg/25 mL (20 mg/mL) 25 mL Multiple-dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9904,Etoposide (Toposar) Injection,Teva,DC 0703-5657-01 (1 gram/50 mL (20 mg/mL) 50 mL Multiple-dose Vial ),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
9905,Exenatide (BYDUREON) Extended Release for Injectable Suspension,AstraZeneca,"BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use;  Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)",New,4/3/2018,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
9906,Famotidine Injection,Baxter Healthcare,"Famotidine Injection premix, 20mg/50 mL in GALAXY Plastic Container (NDC 0338-5197-41)",Reverified,9/28/2022,"Stocked Out, Recovery Q4",,Available,,Gastroenterology,Resolved,,,,2022,not available
9907,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 2 mL vial (NDC 0641-6022-25)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9908,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 4 mL vial (NDC 0641-6023-25)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9909,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6021-10)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9910,Famotidine Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 63323-739-12)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9911,Famotidine Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), mutilple dose vial, (NDC 63323-738-09)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9912,Famotidine Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL(10 mg per mL), multiple dose vial, (NDC 63323-738-20)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9913,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [200 mg / 20 ml] 10PK (NDC 67457-457-20),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9914,Famotidine Injection,"Athenex Pharmaceutical Division, LLC (Athenex)","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 70860-751-02 and 41)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9915,Famotidine Injection,"Athenex Pharmaceutical Division, LLC (Athenex)","200 mg per 20 mL(10 mg per mL), multiple dose vial with preservatives, (NDC 70860-751-20 and 41)",Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9916,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Single Dose Vials) [20 mg / 2 ml] 25PK (NDC 67457-433-22),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9917,Famotidine Tablets,Teva Pharmaceuticals,20 MG 100 Count (NDC 0172-5728-60),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9918,Famotidine Tablets,Teva Pharmaceuticals,20 MG 1000 Count (NDC 0172-5728-80),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9919,Famotidine Tablets,Teva Pharmaceuticals,20 MG 500 Count (NDC 0172-5728-70),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9920,Famotidine Tablets,Teva Pharmaceuticals,40 MG 100 Count (NDC 0172-5729-60),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9921,Famotidine Tablets,Teva Pharmaceuticals,40 MG 500 Count (NDC 0172-5729-70),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9922,Famotidine Tablets,Aurobindo Pharma,20 mg - 100/Bottle (NDC 65862-859-01),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9923,Famotidine Tablets,Aurobindo Pharma,40 mg - 100/Bottle (NDC 65862-860-01),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9924,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 100 counts (NDC 62332-001-31),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9925,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 1000 counts (NDC 62332-001-91),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9926,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 100 counts (NDC 62332-002-31),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9927,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 500 counts (NDC 62332-002-71),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9928,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 1000 counts (NDC 62332-002-91),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9929,Famotidine Tablets,"Carlsbad Technology, Inc.",20mg 100 count (NDC 61442-121-01),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9930,Famotidine Tablets,"Carlsbad Technology, Inc.",20 mg 1000 count (NDC 61442-121-10),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9931,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 100 count (NDC 61442-122-01),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9932,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 1000 count (NDC 61442-122-10),Revised,11/10/2021,,,Available,,Gastroenterology,Resolved,,,,2022,
9933,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",40 mg (NDC 55111-796-30),New,11/22/2021,,,,,Rheumatology,To be Discontinued,,,,2022,discontinued
9934,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",80 mg (NDC 55111-797-30),New,11/22/2021,,,,,Rheumatology,To be Discontinued,,,,2022,discontinued
9935,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",40mg  (NDC NDC 55111-796-30),New,11/30/2021,,,,,Rheumatology,To be Discontinued,,,,2022,discontinued
9936,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",80mg  (NDC NDC 55111-797-30),New,11/30/2021,,,,,Rheumatology,To be Discontinued,,,,2022,discontinued
9937,Febuxostat Tablets,"Mylan, A Viatris company",40mg T 30s (NDC 0378-3925-93),New,9/21/2022,,,,,Rheumatology,To be Discontinued,9/21/2022,9/21/2022,,2022,discontinued
9938,Febuxostat Tablets,"Mylan, A Viatris company",80mg T 30s (NDC 0378-3926-93),New,9/21/2022,,,,,Rheumatology,To be Discontinued,9/21/2022,,,2022,discontinued
9939,Fenoldopam Mesylate (Corlopam) Injection,Pfizer,20 mg/2 mL (10 mg/mL) Single Dose Vial (NDC 00409-3373-02),New,8/30/2022,,Discontinuation of the manufacture of the drug.,,,Cardiology,To be Discontinued,8/30/2022,8/30/2022,,2022,discontinued
9940,Fenoldopam Mesylate (Corlopam) Injection,Pfizer,10 mg/mL (10 mg/mL) Single Dose Vial (NDC 00409-3373-01),New,8/30/2022,,Discontinuation of the manufacture of the drug.,,,Cardiology,To be Discontinued,8/30/2022,8/30/2022,,2022,discontinued
9941,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) Single Dose Simplist PFS  (NDC 63323-808-11),Revised,9/14/2022,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2022,available
9942,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 1 mL vial
(NDC 0641-6247-25)",Revised,4/8/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9943,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","1,000 mcg per 20 mL (50 mcg per mL) (0.05 mg per mL)  SDV (NDC 63323-806-20)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9944,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","2,500 mcg per 50 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-50)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2022,available
9945,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-01),Revised,9/14/2022,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2022,available
9946,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",100 mcg per 2 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-02),Revised,9/14/2022,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2022,available
9947,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",250 mcg per 5 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-05),Revised,9/14/2022,Backordered. Next release not available at this time.,,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9948,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1276-32),Revised,9/12/2022,Next Delivery and Estimated Recovery: February 2025,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9949,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-32),Revised,9/12/2022,Next Delivery and Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9950,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-35),Revised,9/12/2022,Limited Supply Available. Next Delivery: January 2023; Estimated Recovery: May 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,limited availability
9951,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",1000 mcg/20 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-38),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,discontinued
9952,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-22),Revised,9/12/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,limited availability
9953,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-25),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: June 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9954,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",500 mcg/10 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-28),Revised,9/12/2022,Limited Supply Available. Next Delivery: December 2022; Estimated Recovery: March 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,limited availability
9955,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","1,000 mcg/20 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-31)",Revised,9/12/2022,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,limited availability
9956,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","2,500 mcg/50 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-61)",Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,limited availability
9957,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 2 mL ampul (NDC 0641-6024-10),Revised,4/8/2022,Currently not available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9958,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 5 mL ampul (NDC 0641-6025-10),Revised,4/8/2022,Currently not available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9959,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL ampul (NDC 0641-6026-05),Revised,4/8/2022,Currently not available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9960,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 2 mL vial
(NDC 0641-6027-25)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,available
9961,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 5 mL vial
(NDC 0641-6028-25)",Revised,4/8/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9962,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL vial (NDC 0641-6029-25),Revised,4/8/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
9963,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL  50 mL vial
(NDC 0641-6030-01)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,,2022,available
9964,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule 10 pack (NDC 17478-0030-02),Revised,2/12/2021,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,available
9965,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule; 25 pack (NDC 17478-0030-25),Revised,2/12/2021,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,,2022,discontinued
9966,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 10 pack (NDC 17478-0030-05),Revised,2/12/2021,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,available
9967,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,20 mL ampule (NDC 17478-0030-20),Revised,2/12/2021,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,,2022,discontinued
9968,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 25 pack (NDC 17478-0030-55),Revised,2/12/2021,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,,2022,discontinued
9969,Finasteride Tablets,Mylan Pharmaceuticals Inc.,5 mg tablet (NDC 0378-5036-05)(NDC 0378-5036-77)(NDC 0378-5036-93),New,5/23/2018,,,,,Urology,To be Discontinued,,,,2022,discontinued
9970,Floxuridine for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9270-01),Reverified,4/8/2022,This presentation is temporarily on backorder.,,,Other,Oncology,Current,,,,2022,not available
9971,Fluconazole (Diflucan) Tablets,"Hospira, Inc.",50 mg tablets; Bottle of 30 (NDC 00049-3410-30),New,9/15/2022,,Stock anticipated to be available through October 2022; Discontinuation of the manufacture of the drug,,,Anti-Infective,To be Discontinued,9/15/2022,9/15/2022,,2022,discontinued
9972,Fludarabine Phosphate Injection,Areva Pharmaceuticals,50 mg/2 mL (NDC 59923-604-02),New,10/3/2022,Product anticipated mid/late October 2022,,,,Oncology,Current,,,,2022,not available
9973,Fludarabine Phosphate Injection,Teva Pharmaceuticals,"Lyophilized Powder for Injection, 50 mg /vial (NDC 45963-0609-55, 1 Single-Dose Vial)",Reverified,10/5/2022,Available,,,Other,Oncology,Current,,,,2022,available
9974,Fludarabine Phosphate Injection,"Fresenius Kabi USA, LLC","50 mg per 2 mL (25 mg per mL), Single dose vial, PF (NDC: 63323-192-02)",Reverified,9/14/2022,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase,Oncology,Current,,,,2022,not available
9975,Fludrocortisone Acetate Tablets,Teva Pharmaceuticals,"0.1 mg, 100 count bottle (NDC 0555-0997-02)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
9976,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 100 count bottle (NDC 0115-7033-01)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
9977,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 500 count bottle (NDC 0115-7033-02)",Revised,8/7/2019,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
9978,Flumazenil Injection,Mylan,"0.5 mg in 5 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-447-53)",New,12/16/2019,,,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
9979,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-054-15),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9980,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-054-30),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9981,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-054-60),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9982,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-040-15),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9983,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-040-30),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9984,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-040-60),New,6/21/2021,,,,,,To be Discontinued,,,,2022,discontinued
9985,Fluocinonide Topical Solution,Teva Pharmaceuticals,0.5 mg/mL  (NDC 0472-0829-02),New,8/3/2021,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
9986,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR ((fluorescein injection, USP) 10% (NDC 17478-253-10), 5mL",Revised,10/4/2022,Currently available,,,Other,Ophthalmology,Current,,,,2022,available
9987,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR ((fluorescein injection, USP) 25% (NDC 17478-250-20), 2mL",Revised,10/4/2022,On backorder.,,,Other,Ophthalmology,Current,,,,2022,not available
9988,Fluorescein Injection,Alcon,Fluorescite 5 mL in vial (NDC 0065-0092-65),New,5/2/2022,Available,,,,Ophthalmology,Current,,,,2022,available
9989,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 1.0 mg 100 sterile strips (NDC 17478-404-01),Revised,6/4/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9990,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 0.6 mg 300 sterile strips (NDC 17478-403-03),Revised,6/4/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9991,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 100 Strips per box (ndc 17238-900-11),Revised,6/4/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9992,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 300 Strips per box (NDC 17238-900-30),Revised,6/4/2021,,,Available,,Ophthalmology,Resolved,,,,2022,
9993,Fluorometholone Ophthalmic Ointment,Abbvie,FML (flourometholone) Ointment 0.1% 1 TUBE in 1 CARTON  3.5 g in 1 TUBE (NDC 0023-0316-04),New,9/13/2021,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
9994,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 100 count bottle (NDC 0781-2823-01)",New,2/23/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9995,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 1000 count bottle (NDC 0781-2823-10)",New,2/23/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9996,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 100 count bottle (NDC 0781-2822-01)",New,2/23/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9997,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 1000 count bottle (NDC 0781-2822-10)",New,2/23/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9998,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 100 count bottle (NDC 0781-2824-01)",New,2/23/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
9999,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 1000 count bottle (NDC 0781-2824-10)",New,2/23/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10000,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 30 count bottle (NDC 0781-2824-31)",New,2/23/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10001,Flurazepam Hydrochloride Capsules,"Rising Pharma Holdings, Inc.",15mg C 100s (NDC 0378-4415-01),New,8/3/2022,Anticipated availability: August 2023.,Delay is due to manufacturing delays at the contract manufacturing facility.,,,Neurology; Other,Current,,,,2022,not available
10002,Flurazepam Hydrochloride Capsules,"Rising Pharma Holdings, Inc.",30mg C 100s (NDC 0378-4430-01),New,8/3/2022,Anticipated availability: August 2023.,Delay is due to manufacturing delays at the contract manufacturing facility.,,,Neurology; Other,Current,,,,2022,not available
10003,Fluvoxamine ER Capsules,Par Pharmaceutical,100 mg. 30’s count (NDC 10370-175-11),Revised,5/24/2022,"A limited inventory will be available in June, July and August 2022. Estimated recovery September 2022",,,Delay in shipping of the drug,Psychiatry,Current,,,,2022,limited availability
10004,Fluvoxamine ER Capsules,Par Pharmaceutical,150 mg. 30’s count (NDC 10370-176-11),Revised,5/24/2022,"A limited inventory will be available in June, July and August 2022. Estimate recovery October 2022",,,Delay in shipping of the drug,Psychiatry,Current,,,,2022,limited availability
10005,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03)",Revised,10/5/2022,Allocation,,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,,2022,limited availability
10006,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03)",Revised,10/5/2022,"Backorder, Recovery expected Oct-22",,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,,2022,not available
10007,Fosphenytoin Sodium Injection,"Mylan Institutional, a Viatris company","100 mg/2 mL, package of 25 vials (NDC 67457-516-25)",New,9/3/2021,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
10008,Fosphenytoin Sodium Injection,"Mylan Institutional, a Viatris company","500 mg/10 mL, package of 10 vials (NDC 67457-517-01)",New,8/4/2021,,,,,Neurology;Pediatric,To be Discontinued,,,,2022,discontinued
10009,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",20 mg/2mL vial (NDC 70860-302-41 and 70860-302-02),Reverified,9/28/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10010,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",40 mg/4mL vial (NDC 70860-302-42 and 70860-302-04),Reverified,9/28/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10011,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",100 mg/10mL vial (NDC 70860-302-43 and 70860-302-10),Reverified,9/28/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10012,Furosemide Injection,Sagent Pharmaceuticals,20 mg/2 mL single-dose vial (NDC 25021-311-02),Reverified,8/22/2022,Backorder. Estimated availability Aug 2022,,,,Cardiovascular,Current,,,,2022,not available
10013,Furosemide Injection,Sagent Pharmaceuticals,40 mg/4 mL single-dose vial (NDC25021-311-04),Reverified,8/22/2022,Backorder. Estimated availability July 2022,,,,Cardiovascular,Current,,,,2022,not available
10014,Furosemide Injection,Sagent Pharmaceuticals,100 mg/10 mL single-dose vial (NDC 25021-311-10),Reverified,8/22/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10015,Furosemide Injection,Gland Pharma Limited,"2 mL in 1 vial, 25 vials/carton (NDC 25021-311-02)",Reverified,7/1/2022,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
10016,Furosemide Injection,Gland Pharma Limited,"4 mL in 1 vial, 25 vials/carton (NDC 25021-311-04)",Reverified,7/1/2022,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
10017,Furosemide Injection,Gland Pharma Limited,"10 mL in 1 vial, 25 vials/carton (NDC 25021-311-10)",Reverified,7/1/2022,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
10018,Furosemide Injection,"Hospira, Inc., a Pfizer Company","100 mg/10 mL (10 mg/mL) syringe, bundle of 10 (NDC 0409-1639-10)",New,9/28/2022,,,,,Cardiovascular,To be Discontinued,9/28/2022,9/28/2022,,2022,discontinued
10019,Furosemide Injection,"Hospira, Inc., a Pfizer Company","100 mg/10 mL (10 mg/mL) syringe, individual (NDC 0409-1639-21)",New,9/28/2022,,,,,Cardiovascular,To be Discontinued,9/28/2022,9/28/2022,,2022,discontinued
10020,Furosemide Injection,"Hospira, Inc., a Pfizer Company","40 mg/4 mL (10 mg/mL) syringe, bundle of 10 (NDC 0409-9631-04)",New,9/28/2022,,,,,Cardiovascular,To be Discontinued,9/28/2022,9/28/2022,,2022,discontinued
10021,Furosemide Injection,"Hospira, Inc., a Pfizer Company","40 mg/4 mL (10 mg/mL) syringe, individual (NDC 0409-9631-14)",New,9/28/2022,,,,,Cardiovascular,To be Discontinued,9/28/2022,9/28/2022,,2022,discontinued
10022,Furosemide Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-02)",Revised,9/14/2022,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
10023,Furosemide Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-04)",Revised,9/14/2022,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,,2022,available
10024,Furosemide Injection,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-10)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,not available
10025,Furosemide Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),20 mg/2 mL single-dose vial (NDC 55150-322-25),Reverified,9/28/2022,"Currently on backorder, next shipment TBD",,,Delay in shipping of the drug,Cardiovascular,Current,,,,2022,not available
10026,Furosemide Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),40 mg/4 mL single-dose vial (NDC 55150-323-25),Reverified,9/28/2022,"Currently on backorder, next shipment TBD",,,Delay in shipping of the drug,Cardiovascular,Current,,,,2022,not available
10027,Furosemide Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),100 mg/10 mL single-dose vial (NDC 55150-324-25),Reverified,9/28/2022,"Currently on backorder, next shipment TBD",,,Delay in shipping of the drug,Cardiovascular,Current,,,,2022,not available
10028,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 10 mL Single Dose Glass Vial (25 x 10 mL) (NDC 36000-284-25)",Reverified,8/26/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10029,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 2 mL Single Dose Glass Vial (25 x 2 mL)(NDC 36000-282-25)",Reverified,8/26/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10030,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 4 mL Single Dose Glass Vial (25 x 4 mL)(NDC 36000-283-25)",Reverified,8/26/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10031,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,20 mg/mL (NDC 23155-473-41),Reverified,8/26/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10032,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,40 mg/4mL (NDC 23155-473-42),Reverified,8/26/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10033,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,100 mg/10mL (NDC 23155-473-44),Reverified,8/26/2022,Available,,,,Cardiovascular,Current,,,,2022,available
10034,Furosemide Injection,"Hospira, Inc.",20 mg/2 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-02),Revised,9/28/2022,Available,,,Other,Cardiovascular,Current,,,,2022,available
10035,Furosemide Injection,"Hospira, Inc.",40 mg/4 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-04),Revised,9/28/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,limited availability
10036,Furosemide Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL): Single Dose Glass Fliptop Vial (NDC 0409-6102-10),Revised,9/28/2022,Next Delivery: September 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Cardiovascular,Current,,,,2022,not available
10037,Furosemide Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL; Ansyr Plastic syringe (NDC 0409-1639-10),Revised,9/28/2022,Unavailable,,,,Cardiovascular,Current,,,,2022,not available
10038,Furosemide Injection,"Hospira, Inc.",40 mg/4 mL (10 mg/mL); Ansyr Plastic syringe (NDC 0409-9631-04),Revised,9/28/2022,Unavailable,,,,Cardiovascular,Current,,,,2022,not available
10039,Furosemide Oral Solution,Wockhardt,"10 mg/mL, 60mL (NDC 60432-0613-60)",New,4/11/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10040,"Furosemide Oral Solution, 10 mg/mL",Wockhardt Bio AG/Morton Grove Pharmaceuticals,"10 mg/mL, 4 oz. (NDC 60432-613-04)",New,5/19/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10041,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 7 Tablets in 1 Blister Pack (NDC 44004-321-07)",Revised,6/8/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10042,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 5 Tablets in 1 Blister Pack (NDC 44004-321-05)",Revised,6/8/2022,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10043,Gentamicin and Prednisolone Acetate Ophthalmic Suspension,Abbvie,"PRED G® (gentamicin and prednisolone acetate ophthalmic suspension) NDC 0023-0106-05/ 1 Bottle, Dropper in 1 Carton> 5 mL in 1 Bottle, Dropper, (NDC 0023-0106-10) / 1 Bottle, Dropper in 1 Carton> 10 mL in 1 Bottle, Dropper",New,6/9/2022,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
10044,Gentamicin Sulfate and Prednisolone Acetate Ophthalmic Ointment,Abbvie,PRED-G- gentamicin sulfate 0.3% and prednisolone acetate 0.6% ointment 1 TUBE in 1 CARTON  3.5 g in 1 TUBE (NDC 0023-0066-04),New,9/13/2021,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
10045,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","80 mg per 2 mL (40 mg per mL), MDV, (NDC 63323-010-02)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase for the drug,Anti-Infective,Current,,,,2022,not available
10046,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","800 mg per 20 mL (40 mg per mL), MDV, (NDC 63323-010-20)",Revised,9/14/2022,Backordered. Next release October 2022.,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,not available
10047,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Pediatric SDV, (NDC 63323-173-02)",Revised,9/14/2022,Available,Check wholesaler inventory,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
10048,Gentamicin Sulfate Injection,"Hospira, Inc.",80 mg/2 mL (40 mg/mL); 2 mL Single Dose Glass Fliptop Vial (NDC 00409-1207-03),Revised,9/12/2022,Next Delivery: December 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,not available
10049,Gentamicin Sulfate Injection,"Hospira, Inc.",80 mg/2 mL (40 mg/mL) Single Dose Glass Fliptop Vial NovaPlus (NDC 00409-1207-25),Revised,9/12/2022,Next Delivery: December 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,not available
10050,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 60 mg/50 mL, (NDC 0338-0507-41)",Revised,8/31/2022,Available,,,,Anti-Infective,Current,,,,2022,available
10051,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 80 mg/50 mL, (NDC 0338-0509-41)",Revised,8/31/2022,Available,,,,Anti-Infective,Current,,,,2022,available
10052,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 80mg/100 mL, (NDC 0338-0503-48)",Revised,8/31/2022,Available,,,,Anti-Infective,Current,,,,2022,available
10053,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 100 mg/50 mL, (NDC 0338-0511-41)",Revised,8/31/2022,Available,,,,Anti-Infective,Current,,,,2022,available
10054,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 100 mg/100 mL, (NDC 0338-0505-48)",Revised,8/31/2022,Available,,,,Anti-Infective,Current,,,,2022,available
10055,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 120 mg/100 mL, (NDC 0338-0507-48)",Revised,8/31/2022,Available,,,,Anti-Infective,Current,,,,2022,available
10056,Gentamicin Sulfate Solution,Abbvie,GENOPTIC® (gentamicin sulfate) Ophthalmic solution/drops (NDC 60758-188-05) -- 5 mL in 10 mL bottle,New,6/9/2022,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
10057,Glipizide Tablets,"Endo Pharmaceuticals, Inc.",Extended-release 10 mg/1 unit (NDC 10370-746-01),New,2/9/2022,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10058,Glipizide Tablets,"Endo Pharmaceuticals, Inc.",Extended-release 10 mg/1 unit (NDC 10370-746-05),New,2/9/2022,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10059,Glipizide Tablets,"Endo Pharmaceuticals, Inc.",Extended-release 5 mg/1 unit (NDC 10370-745-01),New,2/9/2022,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10060,Glipizide Tablets,"Endo Pharmaceuticals, Inc.",Extended-release 5 mg/1 unit (NDC 10370-745-05),New,2/9/2022,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10061,Glipizide Tablets,Teva Pharmaceuticals,"5mg tablets (NDC 0591-0460-10), (NDC 0591-0460-05), (NDC 0591-0460-01)",New,5/28/2020,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10062,Glipizide Tablets,Teva Pharmaceuticals,"10mg tablets, (NDC 0591-0461-10), (NDC 0591-0461-01), (NDC 0591-0461-05)",New,5/28/2020,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10063,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,1.25 mg/250 mg 100 Count (NDC 00228-2751-11),New,9/6/2022,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/2022,9/6/2022,,2022,discontinued
10064,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,2.5 mg/500 mg 100 Count (NDC 00228-2752-11),New,9/6/2022,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/2022,9/6/2022,,2022,discontinued
10065,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,2.5 mg/500 mg 500 Count (NDC 00228-2752-50),New,9/6/2022,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/2022,9/6/2022,,2022,discontinued
10066,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,5 mg/500 mg 100 Count (NDC 00228-2753-11),New,9/6/2022,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/2022,9/6/2022,,2022,discontinued
10067,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,5 mg/500 mg 500 Count (NDC 00228-2753-50),New,9/6/2022,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/2022,9/6/2022,,2022,discontinued
10068,Granisetron Hydrochloride Injection,Teva Pharmauceuticals,"1 mg/mL, 1 mg, 1 mL/Vial (NDC 0703-7971-03)",New,9/13/2022,,Product has not been marketed for at least 5 years,,,Gastroenterology,To be Discontinued,9/13/2022,9/13/2022,,2022,discontinued
10069,Granisetron Hydrochloride Injection,Teva Pharmaceuticals,"1 mg/mL, 4 mg, 4 mL/Vial (NDC 0703-7973-01)",New,9/13/2022,,Product has not been marketed for at least 5 years,,,Gastroenterology,To be Discontinued,9/13/2022,9/13/2022,,2022,discontinued
10070,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 1 mg, 100 Count (NDC 42806-048-01)",Reverified,2/23/2021,Available,,,Other,Cardiovascular,Current,,,,2022,available
10071,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 2 mg, 100 Count (NDC 42806-296-01)",Reverified,2/23/2021,Available,,,Other,Cardiovascular,Current,,,,2022,available
10072,Guanfacine Hydrochloride Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",1 mg (NDC 0378-1160-01),Reverified,12/8/2021,Unavailable,,,Other,Cardiovascular,Current,,,,2022,not available
10073,Guanfacine Hydrochloride Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",2 mg (NDC 0378-1190-01),Reverified,12/8/2021,Unavailable,,,Other,Cardiovascular,Current,,,,2022,not available
10074,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,1mg tablets 100 count bottle (NDC 0591-0444-01),Revised,10/5/2022,"Backorder, Recovery expected Nov-22",,,,Cardiovascular,Current,,,,2022,not available
10075,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,2 mg tablets 100 count bottle (NDC 0591-0453-01),Revised,10/5/2022,Allocation,,,,Cardiovascular,Current,,,,2022,limited availability
10076,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,1 mg bottles of 30 (NDC 65162-711-03); 1 mg bottles of 100 (NDC 65162-711-10),Reverified,8/17/2020,Available,,,Other,Cardiovascular,Current,,,,2022,available
10077,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,2 mg bottles of 30 (NDC 65162-713-03); 2 mg bottles of 100 (NDC 65162-713-10); 2 mg bottles of 500 (NDC 65162-713-50),Reverified,8/17/2020,Available,,,Other,Cardiovascular,Current,,,,2022,available
10078,Haloperidol Decanoate Injection,Teva,NDC 0703-7133-01 (500 mg/5 mL (100 mg/mL) 5 mL Multiple Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Psychiatry,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10079,Haloperidol Decanoate Injection,Teva,NDC 0703-7131-03 (100 mg/mL 10 x 1 mL Single Dose Vials),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Psychiatry,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10080,Haloperidol Decanoate Injection,Teva,NDC 0703-7121-03 (50 mg/mL 10 x 1 mL Single Dose Vials),New,8/11/2022,,Product is available with an expected supply duration until JUL 2022.  No future production expected for an extended period.,,,Psychiatry,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10081,Haloperidol Decanoate Injection,Teva,NDC 0703-7123-01 (250 mg/5 mL (50 mg/mL) 5 mL Multiple Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Psychiatry,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10082,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,0.5 mg (NDC 0378-0351-01) and (NDC 0378-0351-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10083,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-0257-01) and (NDC 0378-0257-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10084,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0214-01) and (NDC 0378-0214-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10085,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-0327-01) and (NDC 0378-0327-10),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10086,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0334-01),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10087,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,20 mg (NDC 0378-0355-01),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10088,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 100 CT (NDC 68382-079-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,,,,2022,
10089,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 1000 CT (NDC 68382-079-10),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,,,,2022,
10090,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 10MG 100 CT (NDC 68382-080-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,,,,2022,
10091,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 20MG 100 CT (NDC 68382-081-01),Revised,11/20/2019,,,Available,,Psychiatry,Resolved,,,,2022,
10092,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-13-9101),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10093,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-83-9101),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10094,Haloperidol Tablets,Sandoz,0.5 mg 100 count unit dose (NDC 0781-13-9113),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10095,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-13-9201),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10096,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-83-9201),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10097,Haloperidol Tablets,Sandoz,1 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10098,Haloperidol Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-13-9801),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10099,Haloperidol Tablets,Sandoz,2 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10100,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-13-9610),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10101,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-83-9610),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10102,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-13-9601),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10103,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-83-9601),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10104,Haloperidol Tablets,Sandoz,5 mg 100 count unit dose (NDC 0781-13-9613),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10105,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-13-9701),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10106,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-83-9701),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10107,Haloperidol Tablets,Sandoz,10 mg 100 count unit dose (NDC 0781-13-9713),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10108,Haloperidol Tablets,Sandoz,20 mg 100 count bottle (NDC 0781-83-9301),Revised,11/20/2019,,,,,Psychiatry,Resolved,,,,2022,
10109,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 2,000 USP units in 1000 mL.  Product code 2B0944  (NDC 0338-0433-04)",Revised,9/28/2022,Available,,,Manufacturing Delay,Hematology,Current,,,,2022,available
10110,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 1,000 USP units in 500 mL.  Product code 2B0953 (NDC 0338-0431-03)",Revised,9/28/2022,Unavailable,,,Other,Hematology,Current,,,,2022,not available
10111,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","1,000 Units/500 mL (2 Units/mL); Flexible Container (NDC 00409-7620-03)",Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Hematology,Current,,,,2022,limited availability
10112,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","2,000 Units/1000 mL (2 Units/mL); Flexible Container (NDC 00409-7620-59)",Revised,9/12/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Hematology,Current,,,,2022,limited availability
10113,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection, 1,000 units / 500 mL (2 units / mL) in VIAFLEX Plastic Container.  Product code AHB0953U (NDC 0338-0424-18)",Revised,9/28/2022,Limited Supply Recovery Q4,,,Manufacturing Delay,Hematology,Current,,,,2022,limited availability
10114,Heparin Sodium and Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"1,000 USP units in 500 mL. Product code P8721 (NDC 0264-9872-10)",Revised,3/25/2022,Available. On 100% allocation.,,,Demand increase for the drug,Hematology,Current,,,,2022,limited availability
10115,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","1,000 Units/500 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-77)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler for inventory,,Other,Hematology,Current,,,,2022,not available
10116,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","2,000 Units/1000 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-10)",Revised,9/14/2022,Available,Check wholesaler for inventory,,Other,Hematology,Current,,,,2022,available
10117,Histrelin Acetate Implant,"Endo Pharmaceuticals, Inc.",Vantas 50 mg Implantation Kit (NDC 67979-500-01),Revised,9/21/2021,,,,,Oncology,To be Discontinued,,,,2022,discontinued
10118,Hydralazine Hydrochloride Injection,American Regent/Luitpold,20mg/ml SDV ( NDC 0517 - 0901-25 ),Revised,6/29/2021,,,Available,,Cardiovascular,Resolved,,,,2022,
10119,Hydralazine Hydrochloride Injection,"Fresenius Kabi USA, LLC","20 mg per mL, SDV (NDC 63323-614-01)",Revised,6/29/2021,,,Available,,Cardiovascular,Resolved,,,,2022,
10120,Hydralazine Hydrochloride Injection,Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 10) (NDC 17478-934-01)",Revised,6/29/2021,,,,,Cardiovascular,Resolved,,,,2022,
10121,Hydralazine Hydrochloride Injection,Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 25) (NDC 17478-934-15)",Revised,6/29/2021,,,,,Cardiovascular,Resolved,,,,2022,
10122,Hydralazine Hydrochloride Injection,"Mylan Institutional, a Viatris company",20 mg / 1 ml] 25PK (NDC 67457-291-01),Revised,6/29/2021,,,,,Cardiovascular,Resolved,,,,2022,
10123,Hydralazine Hydrochloride Injection,"X-GEN Pharmaceuticals, Inc.",20 mg/mL per vial (NDC 39822-0500-4),Revised,6/29/2021,,,,,Cardiovascular,Resolved,,,,2022,
10124,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,20 mg/25 mg (NDC 0378-2025-01),New,5/22/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10125,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,12.5 mg/ 20 mg (NDC 0378-2012-01),New,5/22/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10126,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,10 mg/ 12.5 mg (NDC 0378-1012-01),New,5/22/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10127,Hydrochlorothiazide and Spironolactone (Aldactazide) Tablets,Pfizer,50 mg tablet; bottle of 100 (NDC 0025-1021-31),New,9/8/2022,,Supply expected to exhaust mid September 2022,,,Cardiovascular,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
10128,Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution,Perrigo Pharmaceuticals,Hydrocodone Bitartrate (5 mg/5 mL) and Homatropine Methylbromide (1.5 mg/5 mL)(NDC 0574-1105-16),New,6/5/2018,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10129,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 12 suppositories (NDC 59741-301-12),New,11/25/2019,,,,,Other;Urology,To be Discontinued,,,,2022,discontinued
10130,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 24 suppositories (NDC 59741-301-24),New,11/25/2019,,,,,Other;Urology,To be Discontinued,,,,2022,discontinued
10131,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 100 suppositories (NDC 59741-301-01),New,11/25/2019,,,,,Other;Urology,To be Discontinued,,,,2022,discontinued
10132,Hydrocortisone Tablets,Pfizer Pharmaceuticals,5 mg tablet; bottle of 50 (NDC 59762-0073-1),Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10133,Hydrocortisone Tablets,Pfizer Pharmaceuticals,10 mg tablet; bottle of 100 (NDC 59762-0074-1),Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10134,Hydrocortisone Tablets,Pfizer Pharmaceuticals,20 mg tablet; bottle of 100 (NDC 59762-0075-1),Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10135,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 20 mg tablet; bottle of 100 (NDC 0009-0044-01),Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10136,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 5 mg tablet; bottle of 50 (NDC 0009-0012-01),Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10137,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 10 mg tablet; bottle of 100 (NDC 0009-0031-01),Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10138,Hydrocortisone Tablets,Amneal Pharmaceutical,100mg/100 count (NDC 00115-1697-01),Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10139,Hydrocortisone Tablets,Amneal Pharmaceutical,20mg/100 count (NDC 00115-1700-01),Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10140,Hydrocortisone Tablets,Strides Pharma Inc.,"5 mg, 50 count bottles (NDC 64380-970-25)",Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10141,Hydrocortisone Tablets,Strides Pharma Inc.,"10 mg, 100 count bottles (NDC 64380-971-06)",Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10142,Hydrocortisone Tablets,Strides Pharma Inc.,"20 mg, 100 count bottles (NDC 64380-972-06)",Revised,6/8/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10143,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.2 mg per 1 mL, prefilled syringe, MicroVault packaging (NDC 76045-121-11)",Revised,8/12/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10144,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe, MicroVault packaging (NDC 76045-010-11)",Revised,8/12/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10145,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)                                                                                           Microvault",Revised,8/12/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10146,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-11)                                                                                                                                                                                     Microvault",Revised,8/12/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10147,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","1 mg per 1 mL, Single dose vial, (NDC 63323-852-25)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10148,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-853-25)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10149,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-854-10)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10150,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-10)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10151,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","50 mg per 5 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-15)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10152,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-50)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10153,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)",Revised,9/14/2022,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,unclear
10154,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-10)                                                                                                                                       Blister pack",Revised,9/14/2022,Check wholesalers for inventory,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,unclear
10155,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe (NDC 76045-010-10)",Revised,9/14/2022,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10156,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 4 mg per 1 mL, prefilled syringe (NDC 76045-011-10)",Revised,9/14/2022,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10157,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1ML (NDC0703-0110-03),Reverified,10/5/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10158,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1ML (NDC 0703-0113-03),Reverified,10/5/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10159,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1 ML (NDC 0703-0018-01),Reverified,10/5/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10160,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 1 mL vial (NDC 0641-0121-25)",Revised,4/8/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10161,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0641-2341-41)",Revised,4/8/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10162,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",0.5 mg/0.5 mL (1 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-05),Revised,9/12/2022,Limited Supply Available. Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2022,limited availability
10163,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/1 mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-10),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10164,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1312-10),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10165,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1283-31),Revised,9/12/2022,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10166,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1312-30),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,limited availability
10167,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",4 mg/1 mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1304-31),Revised,9/12/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10168,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/mL); Glass Ampul (NDC 00409-2552-01),Revised,9/12/2022,Next Delivery and Estimated Recovery: September 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10169,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Glass Ampul (NDC 00409-3356-01),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10170,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",4 mg/1 mL (4 mg/mL); Glass Ampul (NDC 00409-2540-01),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10171,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3365-01),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10172,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-01),Revised,9/12/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10173,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-05),Revised,9/12/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10174,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-50),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2022,limited availability
10175,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)",Reverified,5/19/2021,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10176,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)",Reverified,5/19/2021,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10177,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)",Reverified,5/19/2021,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10178,Hydroxocobalamin Injection,SERB SA,"Hydroxocobalamin Injection (Cyanokit) intravenous powder for solution for injection, 5 gram, vial, (NDC 11704-0370-01)",Revised,1/20/2022,,,Available,,Endocrinology/Metabolism;Other,Resolved,,,,2022,
10179,Hydroxocobalamin Injection,Teva Pharmaceuticals,"Hydroxocobalamin Injection 1000MCG/ML, 1X30ML(NDC 0591-2888-30)",Revised,1/21/2022,,,Available,,Endocrinology/Metabolism,Resolved,,,,2022,
10180,Hydroxyprogesterone Caproate Injection,American Regent/Luitpold,"Hydroxyprogesterone Caproate Injection, USP 250mg/mL 1mL Single Dose Vial (NDC 0517-1767-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10181,Hydroxyprogesterone Caproate Injection,Slayback Pharma,"Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml (NDC 71225-104-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10182,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single dose auto-injector 1.1mL for subcutaneous injection: (NDC 64011-247-02),Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10183,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10184,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Multi-dose vial 5mL for intramuscular injection: (NDC 64011-243-01),Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10185,Hydroxyprogesterone Caproate Injection,Prasco Laboratories,Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10186,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),Hydroxyprogesterone Caproate Injection USP 250 mg/1 mL single-dose vial (NDC 55150-309-01),Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10187,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),"Hydroxyprogesterone Caproate Injection USP 1,250 mg/5 mL multiple-dose vial (NDC 55150-310-01)",Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10188,Hydroxyprogesterone Caproate Injection,Slayback Pharma,Hydroxyprogesterone Caproate Injection 250 mg/ 1 ml (NDC 71225-105-01),Revised,8/2/2019,,,,,Reproductive,Resolved,,,,2022,
10189,Hydroxypropyl (Lacrisert) Cellulose Ophthalmic Insert,"Bausch Health Americas, Inc.","Lacrisert, 5 mg per ophthalmic insert, 60 unit dose blister pack (NDC 24208-800-60)",Revised,12/3/2021,"Unavailable, Resupply expected July 2023",,,Other,Ophthalmology,Current,,,,2022,not available
10190,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,100 mg 100 count (NDC 0555-0324-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10191,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 100 count (NDC 0555-0323-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10192,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 500 count (NDC 0555-0323-04),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10193,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 100 count (NDC 0555-0302-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10194,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 500 count (NDC 0555-0302-04),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10195,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 100 count (NDC 0185-0674-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10196,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 500 count (NDC 0185-0674-05),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10197,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10198,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10199,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10200,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10201,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10202,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10203,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10204,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10205,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10206,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05),Revised,2/17/2021,,,,,Psychiatry,Resolved,,,,2022,
10207,Hyoscyamine Sulfate Injection,"Meda Pharmaceuticals Inc, A Viatris company","Levsin® Injection, 0.5mg, (NDC 0037-9001-05)",New,9/13/2022,,Product will be available until stock out or expiry (October 2023).,,,Anesthesia; Gastroenterology; Urology,To be Discontinued,9/13/2022,9/13/2022,,2022,discontinued
10208,Ibutilide Fumarate Injection,"Mylan Institutional, a Viatris company","1 mg/10 mL (0.1 mg/mL), single dose vial (NDC 67457-366-10)",Revised,9/28/2022,Unavailable,Re-supply October 2022.,,Other,Cardiovascular,Current,,,,2022,not available
10209,Ibutilide Fumarate Injection,Pfizer Pharmaceuticals,"1 mg/10 mL (0.1 mg/mL), single dose vial (NDC 0009-3794-01)",Reverified,9/12/2022,Available,,,Other,Cardiovascular,Current,,,,2022,available
10210,Ibutilide Fumarate Injection,Pfizer Pharmaceuticals,"1 mg/10 mL (0.1 mg/mL), single dose vial (NDC 0009-3794-22), Novaplus",Reverified,9/12/2022,Available,,,Other,Cardiovascular,Current,,,,2022,available
10211,Idarubicin Hydrochloride Injection,Teva,NDC 0703-4155-11 (10 mg/10 mL (1 mg/mL) 10 mL Single Dose Vial),New,8/11/2022,,Product is available with an expected supply duration until JUN' 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10212,Idarubicin Hydrochloride Injection,Teva,NDC 0703-4156-11 (20 mg/20 mL (1 mg/mL) 20 mL Single Dose Vial),New,8/11/2022,,Product is available with an expected supply duration until JUL' 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10213,Idarubicin Hydrochloride Injection,Teva,NDC 0703-4154-11 (5 mg/5 mL (1 mg/mL) 5 mL Single Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10214,Ifosfamide Injection,Teva,NDC 0703-3427-11 (1 g/20 mL (50 mg/mL) Single Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10215,Ifosfamide Injection,Teva,NDC 0703-3429-11 (3 g/60 mL (50 mg/mL) Single Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10216,Imipenem and Cilastatin for Injection,HQ Specialty Pharma,"500 mg per vial, single dose vial, sterile powder (NDC 44567-0705-10)",Revised,6/8/2022,,,Available,,Anti-Infective,Resolved,,,,2022,
10217,Imipenem and Cilastatin for Injection,Merck Sharp & Dohme Corp.,500 mg  imipenem  equivalent  and  500 mg  cilastatin  equivalent  and  20 mg  sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3516-59),Revised,6/8/2022,,,Available,,Anti-Infective,Resolved,,,,2022,
10218,Imipenem and Cilastatin for Injection,"Fresenius Kabi USA, LLC","250 mg/250 mg per vial, single dose vial, sterile powder (NDC 63323-349-25)",Revised,6/8/2022,,,Available,,Anti-Infective,Resolved,,,,2022,
10219,Imipenem and Cilastatin for Injection,"Fresenius Kabi USA, LLC","500 mg/500 mg per vial, single dose vial, sterile powder (NDC  63323-322-25)",Revised,6/8/2022,,,Available,,Anti-Infective,Resolved,,,,2022,
10220,Imipramine Tablets,Sandoz,10 mg 100 ct (NDC 0781-1762-01),New,2/28/2022,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10221,Imipramine Tablets,Sandoz,25 mg 100 ct (NDC 0781-1764-01),New,2/28/2022,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10222,Imipramine Tablets,Sandoz,25 mg 1000 ct (NDC 0781-1764-10),New,2/28/2022,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10223,Imipramine Tablets,Sandoz,50 mg 100 ct (NDC 0781-1766-01),New,2/28/2022,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10224,Imipramine Tablets,Sandoz,50 mg 1000 ct (NDC 0781-1766-10),New,2/28/2022,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10225,Indigotindisulfonate Sodium Injection,American Regent,Indigo Carmine injection 5mL ampule (NDC 0517-0375-05),Revised,8/24/2022,"Out of Stock, no plans to manufacture until sometime in 2023",,,Shortage of an active ingredient,Medical Imaging,Current,,,,2022,not available
10226,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 100s (NDC 0378-0143-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10227,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 1000s (NDC 0378-0143-10)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10228,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 100s (NDC 0378-0147-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10229,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 500s (NDC 0378-0147-05)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10230,Indomethacin Injection,Hospira,1 mg Single Dose Vial (NDC 0409-1113-01),New,8/15/2022,,Limited supply available. Product expected to exhaust by November 2022,,,Pediatric; Cardiovascular,To be Discontinued,8/15/2022,8/15/2022,,2022,discontinued
10231,Indomethacin Injection,Navinta LLC,1 mg per vial (NDC 68382-470-01),New,8/17/2022,,Navinta has made a business decision to discontinue this product.,,,Pediatric; Cardiovascular,To be Discontinued,8/17/2022,8/17/2022,,2022,discontinued
10232,Insulin Lispro (Humalog Mix50/50),Eli Lilly and Company,"Humalog (Insulin Lispro) Mix50/50, 10ml vial (NDC 0002-7512-01)",New,6/30/2022,,,,,,To be Discontinued,,,,2022,discontinued
10233,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4350-01)",New,4/23/2021,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10234,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4351-01)",New,4/23/2021,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10235,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01)",New,4/23/2021,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10236,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4350-01),New,9/12/2019,,,,,Antiviral;Oncology,To be Discontinued,,,,2022,discontinued
10237,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent ((NDC 0085-4351-01)),New,9/12/2019,,,,,Antiviral;Oncology,To be Discontinued,,,,2022,discontinued
10238,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01),New,9/12/2019,,,,,Antiviral;Oncology,To be Discontinued,,,,2022,discontinued
10239,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 320 mg Iodine/mL: 100 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-383-10)",Revised,7/18/2022,Available,,,Other,Medical Imaging,Current,,,,2022,available
10240,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 320 mg Iodine/mL: 200 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-383-70)",Revised,7/18/2022,Available,,,Other,Medical Imaging,Current,,,,2022,available
10241,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 320 mg Iodine/mL: 50 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-383-05)",Revised,7/18/2022,Available,,,Other,Medical Imaging,Current,,,,2022,available
10242,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 320 mg Iodine/mL: 150 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-383-50)",Revised,7/18/2022,Available,,,Other,Medical Imaging,Current,,,,2022,available
10243,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 270 mg Iodine/mL: 100 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-381-10)",Revised,7/18/2022,Available,,,Other,Medical Imaging,Current,,,,2022,available
10244,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 270 mg Iodine/mL: 150 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-381-50)",Revised,7/18/2022,Available,,,Other,Medical Imaging,Current,,,,2022,available
10245,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-23), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10246,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-62), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10247,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-66), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10248,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-67), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10249,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2222-16), 270 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10250,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2222-19), 270 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,"Drug Shortage Resolved.  Product Available as of August 26, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10251,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2222-21), 270 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10252,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-16), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of October 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10253,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-19), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order September 05, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10254,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-21), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order October 10, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10255,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-64), 320 mg/1 mL, INJECTION, SOLUTION, IV 10 BOTTLE, PLASTIC in 1 BOX > 100 mL in 1 BOTTLE, PLASTIC",Revised,9/2/2022,"Product available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10256,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-17), 320 mg/1 mL, VISIPAQUE INJECTION, SOLUTION, IV VISIPAQUE 320mgI/ml USB 10x100 VIAL ml USA",Revised,9/2/2022,"Backordered. Product will be available for order September 22, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10257,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2222-17), 270 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order September 05, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10258,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-98), 350 mg/1 mL, OMNIPAQUE INJECTION,  SOLUTION, IV OMNIPAQUE 350mgI/ml USB PH10x500ml USA",Revised,9/2/2022,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10259,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-72), 350 mg/1 mL OMNIPAQUE INJECTION,  SOLUTION, IV OMNIPAQUE 350mgI/ml USB IBP 10x500ml USA",Revised,9/2/2022,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10260,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-88), OMNIPAQUE 350 mg/1 mL, INJECTION, SOLUTION, IV  10 BOTTLE, PLASTIC in 1 BOX > 500 mL in 1 BOTTLE, PLASTIC",Revised,9/2/2022,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10261,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-48), 350 mg/1 mL, INJECTION, SOLUTION, IV 10 BOTTLE, PLASTIC in 1 BOX > 500 mL in 1 BOTTLE, PLASTIC",Revised,9/2/2022,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10262,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-10), 240 mg/1 mL, OMNIPAQUE INJECTION, SOLUTION, IV OMNIPAQUE 240mgI/ml VIAL10x 10 ml USA",Revised,9/2/2022,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10263,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-20), 240 mg/1 mL, OMNIPAQUE INJECTION,  SOLUTION, IV OMNIPAQUE 240mgI/ml VIAL10x 20 ml USA",Revised,9/2/2022,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10264,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-89), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order October 30, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10265,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-91), 350 mg/1 mL, OMNIPAQUE INJECTION, SOLUTION, IV OMNIPAQUE 350mgI/ml USB 10x100 ml USA",Revised,9/2/2022,"Product available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10266,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1411-10), 180 mg/1 mL, OMNIPAQUE INJECTION, SOLUTION, ORAL OMNIPAQUE 180mgI/ml VIAL10x 10 ml USA",Revised,9/2/2022,"Product available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10267,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-68), 300 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10268,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1411-20), 180 mg/1 mL, OMNIPAQUE INJECTION, SOLUTION, ORAL OMNIPAQUE 180mgI/ml VIAL10x 20 ml USA",Revised,9/2/2022,"Product available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10269,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-72),300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order September 5, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10270,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-89), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of August.,,,Other,Medical Imaging,Current,,,,2022,not available
10271,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-48), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of August.,,,Other,Medical Imaging,Current,,,,2022,not available
10272,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1416-12), 12 mg/1 mL, SOLUTION, ORAL",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10273,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1415-09), 9 mg/1 mL, SOLUTION, ORAL",Revised,9/2/2022,"Backordered. Product will be available for order September 5, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10274,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-34), 240 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10275,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-30), 240 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order September 05, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10276,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-35), 240 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10277,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-33), 240 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10278,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-53), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10279,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-10), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10280,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-94), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10281,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-93), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10282,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-95), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10283,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-38), 240 mg/1 mL, INJECTION, SOLUTION, IT",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10284,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1401-52), 140 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order September 05, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10285,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-86), 300 mg/1 mL, INJECTION, SOLUTION, IT",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10286,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-87), 300 mg/1 mL, INJECTION, SOLUTION, IT",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of August.,,,Other,Medical Imaging,Current,,,,2022,not available
10287,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-88), 300 mg/1 mL, INJECTION, SOLUTION, IT",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10288,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-42), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10289,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-90), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,8/12/2022,"Backordered. Product will be available for order September 5, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10290,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-85), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10291,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-84), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,2022,available
10292,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-82), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of September.,,,Other,Medical Imaging,Current,,,,2022,not available
10293,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-87), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10294,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-86), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10295,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-59), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10296,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-65), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10297,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-61), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order October 30, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10298,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-63), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,"Backordered. Product will be available for order September 5, 2022.",,,Other,Medical Imaging,Current,,,,2022,not available
10299,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-62), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10300,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-66), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10301,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-76), 350 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,2022,not available
10302,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-69), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/2022,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,2022,not available
10303,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  350, 6 X 500 ML (NDC 0270-9350-06)",Reverified,9/9/2022,"Estimated Availability: October 4, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10304,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 350, 10 X 200 ML (NDC 0270-7350-20)",Reverified,9/9/2022,"Estimated Availability: September 26, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10305,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 300, 6 X 500 ML (NDC 0270-9300-06)",Reverified,9/9/2022,"Estimated Availability: September 29, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10306,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 400, 9 X 500 ML (NDC 0270-9400-01)",Reverified,9/9/2022,"Estimated Availability: September 9, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10307,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 350, 9 X 500 ML (NDC 0270-9350-09)",Reverified,9/9/2022,"Estimated Availability: September 6, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10308,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  350, 30 X 150 ML (NDC 0270-7350-15)",Reverified,9/9/2022,"Estimated Availability: September 21, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10309,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  400, 6 X 500 ML (NDC 0270-9400-06)",Reverified,9/9/2022,"Estimated Availability: October 11, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10310,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  300, 56 X 100 ML (NDC 0270-7300-10)",Reverified,9/9/2022,"Estimated Availability: September 13, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10311,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  250, 56 X 100 ML (NDC 0270-7250-10)",Reverified,9/9/2022,"Estimated Availability: September 2, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10312,Iomeprol Injection,Bracco,"Iomeprol injection (IOMERON)  400, 56 X 100 ML (NDC 0270-7400-16)",Reverified,9/9/2022,"Estimated Availability: September 16, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10313,Iomeprol Injection,Bracco,"Iomeprol injection (IOMERON)  400, 30 X 200 ML (NDC 0270-7400-20)",Reverified,9/9/2022,"Estimated Availability: September 7, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10314,Iomeprol Injection,Bracco,"Iomeprol injection (IOMERON)  300, 10 X 200 ML (NDC 0270-7300-20)",Reverified,9/9/2022,"Estimated Availability: September 1, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10315,Iomeprol Injection,Bracco,"Iomeprol injection (IOMERON)  400, 6 X 500 ML (NDC 0270-9400-03)",Reverified,9/9/2022,"Estimated Availability: September 15, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10316,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 400, 10 X 100 ML (NDC 0270-7400-10)",Reverified,9/9/2022,"Estimated Availability: September 14, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,,2022,not available
10317,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 41% (Isovue 200), 10x50mL vial, (NDC 0270-1314-30)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10318,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 41% (Isovue 200M), 10x20mL vial, (NDC 0270-1411-25)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10319,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250),  10x150mL bottle, (NDC 0270-1317-09)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10320,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250),  10x50mL bottle, (NDC 0270-1317-05)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10321,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250 PBP),  10x200mL bottle, (NDC 0270-1317-41)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10322,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300), 10x75mL bottle, (NDC 0270-1315-47)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10323,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300 PBP), 6x500mL bottle, (NDC 0270-1315-98)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10324,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300 PBP), 10x200mL bottle, (NDC 0270-1315-41)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10325,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 76% (IsoVue 370 PBP), 6x500mL bottle, (NDC 0270-1316-98)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10326,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 76% (IsoVue 370 PBP), 10x200mL bottle, (NDC 0270-1316-41)",New,7/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10327,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 300 mg Iodine per mL; 10 VIAL, GLASS in 1 CARTON; > 50 mL in 1 VIAL, GLASS (NDC 50419-344-05)",Reverified,9/28/2022,"Product availability is likely impacted until end of 2022, expect stock in Q1 2023","Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,,2022,limited availability
10328,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 370 mg Iodine per mL: 10 VIAL, GLASS in 1 CARTON; > 50 mL in 1 VIAL, GLASS (NDC 50419-346-05)",Reverified,9/28/2022,"Product availability is likely impacted until end of 2022, expect stock in Q1 2023","Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,,2022,limited availability
10329,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 370 mg Iodine per mL: 10 VIAL, GLASS in 1 CARTON; > 100 mL in 1 VIAL, GLASS  (NDC 50419-346-10)",Reverified,9/28/2022,Product available,"Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,,2022,available
10330,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 370 mg Iodine per mL: 10 VIAL, GLASS in 1 CARTON; > 150 mL in 1 VIAL, GLASS  (NDC 50419-346-15)",Reverified,9/28/2022,Product available,"Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,,2022,available
10331,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 300 mg Iodine per mL; 10 VIAL, GLASS in 1 CARTON; > 100 mL in 1 VIAL, GLASS (NDC 50419-344-10)",Reverified,9/28/2022,Product available,"Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,,2022,available
10332,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 300 mg Iodine per mL; 10 VIAL, GLASS in 1 CARTON; > 150 mL in 1 VIAL, GLASS  (NDC 50419-344-15)",Reverified,9/28/2022,Product available,"Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,,2022,available
10333,Isoniazid Injection,Sandoz,10 mL (100 mg/mL) Multiple dose vial (NDC 0781-3056-70),Revised,10/4/2022,Available,,,,Anti-Infective,Current,,,,2022,available
10334,IV Fat Emulsion,B. Braun Medical Inc.,"Nutrilipid (20% IV Fat Emulsion) in 1,000mL Bag Catalog S4600 (NDC 00264-4460-00)",Revised,9/9/2022,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,limited availability
10335,IV Fat Emulsion,B. Braun Medical Inc.,Nutrilipid (20% IV Fat Emulsion) in 500mL Bag Catalog S4601 (NDC 0264-4460-10),Revised,9/9/2022,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,limited availability
10336,IV Fat Emulsion,B. Braun Medical Inc.,Nutrilipid (20% IV Fat Emulsion) in 250mL Bag Catalog S4603 (NDC 00264-4460-30),Revised,9/9/2022,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,limited availability
10337,IV Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (20 grams per 100 mL) (NDC 63323--820-00)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,available
10338,IV Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (50 grams per 250 mL) (NDC 63323--820-74)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,available
10339,IV Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (100 grams per 500 mL) (NDC 63323-820-50)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,available
10340,IV Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20%, PBP (0.2 grams per mL) (200 grams per 1000 mL) (NDC 63323-820-10)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,available
10341,IV Fat Emulsion,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 100 mL, Product Code EADB9520, (NDC 0338-954-005)",Revised,9/28/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,available
10342,IV Fat Emulsion,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 1000 mL, Product Code EADB9524, (NDC 0338-954-008)",Revised,9/28/2022,Available,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,available
10343,IV Fat Emulsion,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 250 mL, Product Code EADB9521, (NDC 0338-954-006)",Revised,9/28/2022,Available,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,available
10344,IV Fat Emulsion,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 500 mL, Product Code EADB9523, (NDC 0338-954-007)",Revised,9/28/2022,Available,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,available
10345,IV Fat Emulsion,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 100 mL, Product Code 2B6061, (NDC 0338-051-958)",Revised,9/28/2022,Available on allocation,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,limited availability
10346,IV Fat Emulsion,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 250 mL, Product Code 2B6062, (NDC 0338-051-909)",Revised,9/28/2022,Available on allocation,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,limited availability
10347,IV Fat Emulsion,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 1000 mL, Pharmacy Bulk Package, Product Code 2B6064, (NDC 0338-051-914)",Revised,9/28/2022,Limited Supply; Recovery November,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,limited availability
10348,IV Fat Emulsion,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 500 mL, Product Code 2B6063, (NDC 0338-051-913)",Revised,9/28/2022,"Limited Supply on Allocation, Recovery late Sep",,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,limited availability
10349,IV Fat Emulsion,Baxter Healthcare,"Intralipid 30% IV Fat Emulsion, 500 mL, Pharmacy Bulk Package, Product Code 2B6065, (NDC 0338-052-013)",Revised,9/28/2022,Available on allocation,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,,2022,limited availability
10350,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL vial (NDC 0143-9508-10)",Revised,6/3/2022,This presentation is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
10351,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9509-10)",Revised,6/3/2022,This presentation is temporarily on backorder.,,,,Anesthesia,Current,,,,2022,not available
10352,Ketamine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),200 mg / 20 mL (NDC 67457-181-20),Revised,9/28/2022,Available,,,,Anesthesia,Current,,,,2022,available
10353,Ketamine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),500 mg / 10 mL (NDC 67457-001-10),Revised,9/28/2022,Available,,,,Anesthesia,Current,,,,2022,available
10354,Ketamine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1000 mg / 10 mL (NDC 67457-108-10),Revised,9/28/2022,"Currently on backorder, next shipment Late November 2022",,,,Anesthesia,Current,,,,2022,not available
10355,Ketamine Injection,"Hospira, Inc.",500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2051-05),Reverified,9/12/2022,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,limited availability
10356,Ketamine Injection,"Hospira, Inc.",500 mg/10 mL (50 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2053-10),Reverified,9/12/2022,Next Delivery and Estimated Recovery: February 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,,2022,not available
10357,Ketamine Injection,Par Pharmaceutical,"10 mg/mL, 20 mL MDV (NDC 42023-113-10)",Revised,8/12/2022,Contact customer service at 1-800-828-9393,,,Demand increase,Anesthesia,Current,,,,2022,unclear
10358,Ketamine Injection,Par Pharmaceutical,"100 mg/mL, 5 mL MDV (NDC 42023-115-10)",Revised,8/12/2022,Releases to be intermittent – Please check wholesalers for inventory,,,Demand increase,Anesthesia,Current,,,,2022,limited availability
10359,Ketamine Injection,Par Pharmaceutical,"50 mg/mL, 10 mL MDV (NDC 42023-114-10)",Revised,8/12/2022,Releases to be intermittent – Please check wholesalers for inventory,,,Demand increase for the drug,Anesthesia,Current,,,,2022,limited availability
10360,Ketoprofen Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","200 mg Extended-Release Capsules, bottle of 100 (NDC 0378-8200-01)",Reverified,9/28/2022,Available,,,Other,Analgesia/Addiction;Rheumatology,Current,,,,2022,available
10361,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",New,11/25/2019,,,,,Analgesia/Addiction;Rheumatology,To be Discontinued,,,,2022,discontinued
10362,Ketoprofen Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0093-3193-01)",Reverified,4/29/2022,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2022,not available
10363,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 100 count bottle (NDC 0093-3195-01)",Reverified,4/29/2022,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2022,not available
10364,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 500 count bottle (NDC 0093-3195-05)",Reverified,4/29/2022,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,,2022,not available
10365,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",New,11/25/2019,,,,,Analgesia/Addiction;Rheumatology,To be Discontinued,,,,2022,discontinued
10366,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 69336-127-10)",Revised,1/19/2021,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2022,available
10367,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 69336-127-11)",Revised,1/19/2021,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2022,available
10368,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",Revised,1/19/2021,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2022,available
10369,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",Revised,1/19/2021,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,,2022,discontinued
10370,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","50 mg, 100 count bottle (NDC 23155-021-01)",Revised,1/19/2021,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2022,available
10371,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","75 mg, 100 count bottle (NDC 23155-022-01)",Revised,1/19/2021,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,,2022,available
10372,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-107-10)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler for inventory.,,,Analgesia/Addiction,Current,,,,2022,not available
10373,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-104-10)",Revised,9/14/2022,Available,Check wholesaler for inventory.,,,Analgesia/Addiction,Current,,,,2022,available
10374,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","60 mg per 2 mL, Single Dose, Simplist Syringe, (NDC 76045-105-20)",Revised,9/14/2022,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2022,available
10375,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 30 mg/ mL.  Single dose glass flip top vial - 25 units per carton (NDC 0338-0072-25)",Revised,9/28/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10376,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 15 mg/mL. Single dose glass flip top vial. 10 units per carton (NDC 0338-0069-10)",Reverified,9/28/2022,Available,,,,Analgesia/Addiction,Current,,,,2022,available
10377,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 1 mL vial (NDC 72266-118-25)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10378,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 2 mL vial (NDC 72266-119-25)",Reverified,9/28/2022,Available,,,Available,Analgesia/Addiction,Current,,,,2022,available
10379,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","15 mg/mL, 1 mL vial (NDC 0641-6041-25)",Reverified,4/8/2022,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,unclear
10380,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 1 mL vial (NDC 0641-6042-25)",Reverified,4/8/2022,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,unclear
10381,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 2 mL vial (NDC 0641-6043-25)",Reverified,4/8/2022,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,unclear
10382,Ketorolac Tromethamine Injection,Virtus Pharmaceuticals,30MG/ML (NDC 69543-0386-25),New,3/26/2018,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10383,Ketorolac Tromethamine Injection,Gland Pharma Limited,15 mg/mL vial (NDC 70860-700-01 and 70860-700-02),Reverified,9/12/2022,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10384,Ketorolac Tromethamine Injection,Gland Pharma Limited,30 mg/mL vial (NDC 70860-701-01 and 70860-701-03),Reverified,9/12/2022,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10385,Ketorolac Tromethamine Injection,Gland Pharma Limited,60 mg/mL vial (NDC 70860-701-02 and 70860-701-04),Reverified,9/12/2022,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10386,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 15MG/ML 25X1ML (NDC 25021-700-01),Reverified,8/22/2022,Backordered. Estimated availability TBD,,,Manufacturing delays,Analgesia/Addiction,Current,,,,2022,not available
10387,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X2ML (NDC 25021-701-02),Reverified,8/22/2022,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,,2022,not available
10388,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X1ML (NDC 25021-701-01),Reverified,8/22/2022,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,,2022,not available
10389,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-2287-23),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10390,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-31),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10391,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-61),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10392,Ketorolac Tromethamine Injection,"Hospira, Inc.",15 mg/mL (15 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3793-01),Revised,9/12/2022,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,limited availability
10393,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3795-01),Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2022,not available
10394,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3796-01),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,limited availability
10395,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose Amber Vial, (NDC 63323-161-01)",Revised,9/14/2022,Available,Check wholesaler for inventory,,Manufacturing delays,Analgesia/Addiction,Current,,,,2022,available
10396,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-01)",Revised,9/14/2022,Available,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,,,,2022,available
10397,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-02)",Revised,9/14/2022,Available,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,,,,2022,available
10398,Lactulose Solution,Wockhardt Bio AG/Morton Grove Pharmaceuticals,"10 g/15 mL- (NDC 60432-037-08) [8 oz (237 mL)], (NDC 60432-037-32) [32 oz (946 mL)], (NDC 60432-038-16) [16 oz (473 mL)] and (NDC 60432-038-64) [64 oz (1892 mL)]",New,5/26/2022,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10399,Lactulose Solution,Torrent Pharma Inc.,10 g/15 mL (ORAL) 8 oz (NDC 13668580-08) || 16 oz. (NDC 13668-580-10) || 32 oz (NDC 13668-580-12),New,6/9/2022,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10400,Lactulose Solution,Torrent Pharma Inc.,10 g / 15 mL (ORAL-RECTAL) 8 oz (NDC 13668-574-08) || 16 oz (NDC 13668-574-10) || 32 oz (NDC 13668-574-12),New,6/9/2022,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10401,Lamivudine and Tenofovir Disoproxil Fumarate Tablets,"Celltrion, Inc.",300 mg; 300 mg (NDC 72606-002-01),New,9/1/2021,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10402,Lamivudine and Zidovudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine and Zidovudine Tablets 150mg and 300mg (NDC 0378-5180-91),New,3/16/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10403,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 100mg (NDC 0378-5168-93),New,3/16/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10404,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 150mg (NDC 0378-5169-91),New,3/16/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10405,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 300mg (NDC 0378-5170-93),New,3/16/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10406,Lanoxin (digoxin) Tablets,Concordia Pharmaceuticals Inc.,Lanoxin (digoxin) 187.5 mcg (0.1875 mg) tablets; 100-count bottles (NDC 59212-245-55),New,5/22/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10407,Leucovorin Calcium for Injection,Teva,NDC 0703-5140-01 (100 mg/vial Single-Dose Vial),New,8/11/2022,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Pediatric,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10408,Leucovorin Calcium for Injection,Teva,NDC 0703-5145-01 (350 mg/vial Single-Dose Vial),New,8/11/2022,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Pediatric,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10409,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-10)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,,2022,not available
10410,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-50)",Revised,9/14/2022,Available,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,,2022,available
10411,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",100 mg vial (NDC 67457-528-10),Reverified,9/28/2022,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,available
10412,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",200 mg vial (NDC 67457-529-20),Reverified,9/28/2022,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,available
10413,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",350 mg vial (NDC 67457-530-35),Reverified,9/28/2022,Unavailable,Re-supply in September 2022.,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,not available
10414,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,500mg vial (NDC 25021-828-50),Revised,8/22/2022,Backordered. Estimated availability Oct 2022,,,Manufacturing delay,Oncology;Pediatric,Current,,,,2022,not available
10415,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",200 mg SDV (NDC 63323-710-50),Revised,9/14/2022,Backordered. Next release September 2022.,Check Wholesaler Inventory,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,not available
10416,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",500 mg SDV (NDC 63323-711-00),Revised,9/14/2022,Backordered. Next release September 2022.,Check Wholesaler Inventory,,Manufacturing delay,Oncology;Pediatric,Current,,,,2022,not available
10417,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,50 mg vial (NDC 25021-813-10),Revised,8/22/2022,Available.,,,Manufacturing delay,Oncology;Pediatric,Current,,,,2022,available
10418,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,100mg vial (NDC 25021-814-30),Revised,8/22/2022,Backordered. Estimated availability Oct 2022,,,Manufacturing delay,Oncology;Pediatric,Current,,,,2022,not available
10419,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,200mg vial (NDC 25021-815-30),Revised,8/22/2022,Available.,,,,Oncology;Pediatric,Current,,,,2022,available
10420,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,350mg vial (NDC 25021-816-30),Revised,8/22/2022,Available,,,,Oncology;Pediatric,Current,,,,2022,available
10421,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,"100mg/vial, 20mL (NDC 0703-5140-01)",Reverified,10/5/2022,Backordered – Estimated date of availability TBD,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,not available
10422,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,350mg/vial 30mL (NDC 0703-5145-01),Reverified,10/5/2022,Backordered – Estimated date of availability TBD,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,not available
10423,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg, 10 mL vial (NDC 0143-9555-01)",Revised,1/13/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,not available
10424,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg, 20 mL vial (NDC 0143-9554-01)",Revised,1/13/2022,Inventory is currently available.,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,available
10425,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","200 mg, 30 mL vial (NDC 0143-9553-01)",Revised,1/13/2022,Inventory is currently available.,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,available
10426,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","350 mg, 50 mL vial (NDC 0143-9552-01)",Revised,1/13/2022,Inventory is currently available.,,,Demand increase for the drug,Oncology;Pediatric,Current,,,,2022,available
10427,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 22.5 mg (NDC 62935-223-05),Reverified,1/12/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10428,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 30 mg (NDC 62935-303-30),Reverified,1/12/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10429,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 45 mg (NDC 62935-453-45),Reverified,1/12/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10430,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Fensolvi 45 mg (NDC 62935-153-50),Reverified,1/12/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10431,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 7.5 mg Kit (NDC 62935-753-75),Reverified,1/12/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10432,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 30mg (NDC 0074-9694-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10433,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 22.5 mg PDS Kit (NDC 0074-3346-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10434,Leuprolide Acetate Injection,Abbvie,Lupron Depot 6 Months 45mg PDS Kit (NDC 0074-3473-03),Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10435,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 7.5 mg PDS Kit (NDC 0074-3642-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10436,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 4 Months 30 mg PDS Kit (NDC 0074-3683-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10437,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 3.75 mg PDS Kit (NDC 0074-3641-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10438,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 11.25 mg PDS Kit (NDC 0074-3663-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10439,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 11.25 mg PDS Kit (NDC 0074-2282-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10440,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 15 mg PDS Kit (NDC 0074-2440-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10441,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 7.5 mg PDS Kit (NDC 0074-2108-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10442,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 11.25mg (NDC 0074-3779-03)",Revised,10/3/2022,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,,2022,available
10443,Levoleucovorin Calcium Pentahydrate Injection,Ingenus Pharmaceuticals LLC,10 mg/1mL (NDC 50742-494-17),New,12/10/2021,,,,,Oncology;Pediatric,To be Discontinued,,,,2022,discontinued
10444,Levoleucovorin Calcium Pentahydrate Injection,Ingenus Pharmaceuticals LLC,10 mg 1mL (NDC 50742-495-25),New,12/10/2021,,,,,Oncology;Pediatric,To be Discontinued,,,,2022,discontinued
10445,Levoleucovorin Injection,Sandoz,175 mg/17.5 mL (10 mg/mL) (NDC 0781-3201-94 ),New,5/5/2022,,,,,Oncology;Pediatric,To be Discontinued,,,,2022,discontinued
10446,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 5 mL (NDC 0591-3012-26)",New,4/27/2018,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
10447,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 30 mL (NDC 0591-3012-30)",New,4/27/2018,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
10448,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/500 mL (4mg/mL) in VIAFLEX Plus container. Product code 2B0973 (NDC 0338-0409-03)",Reverified,8/26/2022,Available on allocation,,,,Cardiovascular,Current,,,,2022,limited availability
10449,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/250 mL (8mg/mL) in VIAFLEX Plus container. Product code 2B0962 (NDC 0338-0411-02)",Reverified,8/26/2022,Available on allocation,,,Demand increase,Cardiovascular,Current,,,,2022,limited availability
10450,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.8% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5982 (NDC 00264-9598-20),Reverified,5/6/2021,Product available,,,Other,Cardiovascular,Current,,,,2022,available
10451,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5942 (NDC 00264-9594-20),Reverified,5/6/2021,Product available,,,Other,Cardiovascular,Current,,,,2022,available
10452,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 500mL Excel Plastic container P5941 (NDC 00264-9594-10),Reverified,5/6/2021,Product available,,,Other,Cardiovascular,Current,,,,2022,available
10453,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 2 mL Ampoule (NDC 55150-158-72),Revised,9/28/2022,Currently on backorder - next shipment anticipated Mid Oct,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10454,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 5 mL Ampoule (NDC 55150-159-74),Revised,9/28/2022,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10455,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 2 mL Ampoule (NDC 55150-160-72),Revised,9/28/2022,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10456,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 2 mL Single Dose Vial (NDC 55150-161-02),Revised,9/28/2022,Currently on backorder - next shipment anticipated End Oct,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10457,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 5 mL Single Dose Vial (NDC 55150-162-05),Revised,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
10458,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 30 mL Single Dose Vial (NDC 55150-163-30),Revised,9/28/2022,Currently on backorder - next shipment anticipated Mid Oct,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10459,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 2 mL Single Dose Vial (NDC 55150-164-02),Revised,9/28/2022,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10460,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 5 mL Single Dose Vial (NDC 55150-165-05),Revised,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
10461,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); Glass Ampul (NDC 0409-4713-02),Revised,9/30/2022,Next Delivery: October 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10462,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL, 50 mL vial (NDC 63323-0484-57)",Revised,9/14/2022,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10463,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10464,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 2 mL vial (NDC 63323-0201-02)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10465,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 10 mL vial (NDC 63323-0201-10)",Revised,9/14/2022,Backordered. Next release September 2022.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10466,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 20 mL vial (NDC 63323-0485-27)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10467,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 50 mL vial (NDC 63323-0485-57)",Revised,9/14/2022,Backordered. Next release October 2022.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10468,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL vial (NDC 63323-0492-27)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10469,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)",Revised,9/14/2022,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10470,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)",Revised,9/14/2022,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10471,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL vial (NDC 63323-0492-57)",Revised,9/14/2022,Backordered. Next release November 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10472,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial (NDC 63323-0492-37)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10473,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)",Revised,9/14/2022,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10474,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); Ansyr Plastic Syringe (NDC 0409-9137-05),Revised,9/30/2022,Next Delivery: November 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2022,not available
10475,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",20 mg/2 mL (1%; 10 mg/mL); Glass Ampul (NDC 0409-4713-32),Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10476,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","200 mg/20 mL (1%; 10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-01, pack of 25; NDC 0409-4276-16, individual)",Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: February 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10477,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/30 mL (1%; 10 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4279-02),Revised,9/12/2022,Next Delivery: November 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10478,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","500 mg/50 mL (1%; 10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-02; NDC 0409-4276-17, individual)",Revised,9/30/2022,Next Delivery: October 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10479,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",40 mg/2 mL (2%; 20 mg/mL); Glass Ampul (NDC 0409-4282-01),Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2022,not available
10480,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/10 mL (2%; 20 mg/mL); Glass Ampul (NDC 0409-4282-02),Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: February 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10481,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4904-34),Revised,9/30/2022,Available,,,,Anesthesia;Pediatric,Current,,,,2022,available
10482,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (2%; 20 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4903-34),Revised,9/30/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2022,limited availability
10483,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (2%; 20 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-2066-05),Revised,9/30/2022,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10484,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","400 mg/20 mL (2%; 20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-01, pack of 25; NDC 0409-4277-16, individual)",Revised,9/30/2022,Limited Supply Available. Next Delivery: January 2023; Estimated Recovery: March 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,limited availability
10485,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","1,000 mg/50 mL (2%; 20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-02)",Revised,9/30/2022,Next Delivery and Estimated Recovery: October 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10486,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/5 mL (4%; 40 mg/mL); Glass Ampul (NDC 0409-4283-01),Revised,9/30/2022,Next Delivery: November 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10487,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",Xylocaine Cardiac 100 mg/5 mL (2%; 20 mg/mL); Ansyr Plastic Syringe (NDC 0409-1323-05),Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2022,not available
10488,Lidocaine Hydrochloride (Xylocaine) Injection,"Amphastar Pharmaceuticals, Inc./IMS","2%, 5mL Luer-Jet Prefilled Syringe (NDC 76329-3390-1)(old NDC 0548-3390-00)",Reverified,8/12/2022,Backordered due to the increase in demands,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10489,Lidocaine Hydrochloride (Xylocaine) Injection,American Regent/Luitpold,"1%, 50 mL vial package of 25 (NDC 00517-0625-25)",Reverified,3/30/2021,Unavailable-No product available for release. No plan to manufacture.,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2022,discontinued
10490,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 10 mL ampule (NDC 63323-0493-97)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10491,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 20 mL ampule (NDC 63323-0493-91)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10492,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% Lidocaine 2% injection 20 mg/mL, 2 mL vial (NDC 63323-0202-02)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10493,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% injection 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10494,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-17)",Revised,9/14/2022,Backordered. Next release October 2022.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10495,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 20 mL vial (NDC 63323-0486-27)",Revised,9/14/2022,Backordered. Next release October 2022.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10496,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-57)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10497,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-10)discontinued",Revised,9/14/2022,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10498,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20)-NDC discontinued",Revised,9/14/2022,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10499,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-50)-NDC discontinued",Revised,9/14/2022,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10500,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 2 mL vial (NDC 63323-0495-27)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10501,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 5 mL vial (NDC 63323-0495-07)",Revised,9/14/2022,Backordered. Next release November 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10502,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 10 mL ampule (NDC 63323-0496-97)",Revised,9/14/2022,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10503,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (0.5%; 5 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4275-01),Revised,9/30/2022,Next Delivery: April 2023; Estimated Recovery: June 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,,2022,not available
10504,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (0.5%; 5 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4278-01),Revised,9/30/2022,Next Delivery: November 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10505,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/20 mL (1.5%; 15 mg/mL); Glass Ampul (NDC 0409-4776-01),Revised,9/30/2022,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10506,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 10 mL Multi Dose Vial (NDC 55150-251-10),Revised,9/28/2022,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10507,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 20 mL Multi Dose Vial (NDC 55150-252-20),Revised,9/28/2022,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10508,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 10 mL Multi Dose Vial (NDC 55150-254-10),Revised,9/28/2022,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10509,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 20 mL Multi Dose Vial (NDC 55150-255-20),Revised,9/28/2022,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10510,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 5 mL vial, Preservative Free (NDC 0143-9595-25)",Revised,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10511,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 5 mL vial, Preservative Free (NDC 0143-9594-25)",Revised,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10512,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 50 mL vial, Preserved (NDC 0143-9577-10)",Revised,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10513,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 50 mL vial, Preserved (NDC 0143-9575-10)",Revised,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10514,Lidocaine Hydrochloride (Xylocaine) Injection,"Spectra Medical Devices, Inc.",1% 5 mL ampule (NDC 65282-1605-1),Revised,1/7/2022,Available,,,Other,Anesthesia,Current,,,,2022,available
10515,Lidocaine Hydrochloride (Xylocaine) Injection,"Huons Co., Ltd. (South Korea)","Methylparaben Free Lidocaine HCl Injection, USP 1% 50mg/5mL (Vial) (NDC 73293-0001-2)",New,9/6/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
10516,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% MDV 1000mg/50mL (NDC 55150-256-50),Revised,9/28/2022,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10517,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","0.5% w/EPI 1:100,000; 1.8 mL Carpule (NDC 00409-0996-01)",Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2022,discontinued
10518,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2.5 g/50 mL (0.5%; 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3177-01)",Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10519,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","200 mg/20 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-01)",Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10520,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","300 mg/30 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-02)",Revised,9/12/2022,Next Delivery: November 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10521,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","500 mg/50 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3178-03)",Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10522,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","75 mg/5 mL (1.5%; 1:200,000); Glass Ampul (NDC 0409-1209-01)",Revised,9/12/2022,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10523,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","450 mg/30 mL (1.5%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3181-01)",Revised,9/12/2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,limited availability
10524,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-01)",Revised,9/12/2022,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: May 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,limited availability
10525,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","600 mg/30 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-02)",Revised,9/12/2022,Next Delivery: November 2022; Estimated Recovery: April 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10526,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","1 g/50 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-03)",Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10527,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3183-01)",Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,,2022,not available
10528,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2% w/EPI 1:50,000; 1.8mL syringe (NDC 00409-7263-01)",Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,,2022,discontinued
10529,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100 mg MDV (NDC 63323-0482-17)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2022,not available
10530,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100mg SDV, MPF (NDC 63323-0487-17)",Revised,9/14/2022,Backordered. Next release August 2022.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2022,not available
10531,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 150 mg, SDV, MPF (NDC 63323-0488-17)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2022,not available
10532,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 200 mg, SDV, MPF (NDC 63323-0489-17)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,,2022,not available
10533,Lindane Shampoo 1%,Wockhardt Bio A.G.,"60 mL, (NDC 60432-834-60)",New,6/22/2022,,,,,Other,To be Discontinued,,,,2022,discontinued
10534,Linezolid Injection,Teva Pharmaceuticals,"600 mg/300 mL, 300 mL/Bag (NDC 0703-9060-33)",New,9/13/2022,,Product has not been marketed for at least 5 years,,,Anti-Infective,To be Discontinued,9/13/2022,9/13/2022,,2022,discontinued
10535,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 5mcg tablets (NDC 0378-3611-01),New,3/28/2018,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10536,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 25mcg tablets (NDC 0378-3612-01),New,3/28/2018,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10537,Lisinopril Tablets,Mylan Pharmaceuticals Inc.,2.5 mg (NDC 0378-2072-01); 5 mg (NDC 0378-2073-01); 5 mg (NDC 0378-2073-10); 10 mg (NDC 0378-2074-01); 10 mg (NDC 0378-2074-10); 20 mg (NDC 0378-2075-01); 20 mg (NDC 0378-2075-10); 30 mg (NDC 0378-2077-01); 40 mg (NDC 0378-2076-01; 40 mg (NDC 0378-2076-05,New,4/11/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10538,Lithium Oral Solution,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",8 mEq/5 mL 500 mL bottle (NDC 0054-3527-63),Reverified,10/6/2022,"Unavailable, Estimated Shortage: TBD",,,Shortage of an active ingredient,Psychiatry,Current,,,,2022,not available
10539,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
10540,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
10541,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
10542,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
10543,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
10544,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
10545,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
10546,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)",Reverified,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
10547,Lorazepam Injection,"Hospira, Inc.",4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,,2022,discontinued
10548,Lorazepam Injection,"Hospira, Inc.",2 mg/mL; Carpuject Luer Lock Glass Syringe  (NDC 00409-1985-30),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Neurology,Current,,,,2022,limited availability
10549,Lorazepam Injection,"Hospira, Inc.",2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02),Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,,2022,not available
10550,Lorazepam Injection,"Hospira, Inc.",4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,,2022,discontinued
10551,Lorazepam Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,,2022,discontinued
10552,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc./IMS","LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)",Reverified,8/12/2022,Backorder due to the increase in demands,,,Other,Neurology,Current,,,,2022,not available
10553,Lorazepam Injection,Akorn Pharmaceuticals,Lorazepam Injection 2 mg/mL (NDC 17478-040-01),Reverified,5/19/2021,Available,,,Demand increase for the drug,Neurology,Current,,,,2022,available
10554,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10555,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10556,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10557,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/2019,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10558,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 100 count bottle (NDC 0527-1394-01)",Revised,6/13/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10559,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 100 count bottle (NDC 0527-1395-01)",Revised,6/13/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10560,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 100 count bottle (NDC 0527-1396-01)",Revised,6/13/2022,,,Available,Other,Psychiatry,Resolved,,,,2022,
10561,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 100 count bottle (NDC 0527-1397-01)",Revised,6/13/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10562,Loxapine Capsules,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0591-0369-01)",Revised,6/14/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10563,Loxapine Capsules,Teva Pharmaceuticals,"25 mg, 100 count bottle (NDC 0591-0371-01)",Revised,6/14/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10564,Loxapine Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0591-0372-01)",Revised,6/14/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10565,Lutetium Lu 177 Dotatate (LUTATHERA) Injection,"Advanced Accelerator Applications USA, Inc.","Lutathera® (lutetium Lu 177 dotatate) injection, for intravenous use 10 mCi/mL; Colorless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium Lu 177 dotatate (NDC 69488-003-01)",Revised,8/1/2022,,,Available,,Oncology,Resolved,8/1/2022,,,2022,
10566,Mannitol Injection,B. Braun Medical Inc.,20% 500 mL Excel Bag L5781 (NDC 0264-7578-20),New,6/10/2022,Product on allocation for contracted customers,,,Other,Renal,Current,,,,2022,limited availability
10567,Mannitol Injection,"Fresenius Kabi USA, LLC",25% (12.5 grams per 50 mL)(250 mg per mL) Single dose vial (NDC 63323-024-25),Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesalers for inventory,,Demand increase for the drug,Renal,Current,,,,2022,not available
10568,Mannitol Injection,"Hospira, Inc.",12.5 g/50 mL (25%); Single Dose Glass Fliptop Vial (NDC 0409-4031-01),Reverified,9/12/2022,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Renal,Current,,,,2022,not available
10569,Mannitol Injection,Baxter Healthcare,"10% OSMITROL Injection (10% Mannitol Injection, USP) 500 mL Viaflex Plastic Container Product Code 2D5613Q (NDC 0338-0535-03)",Revised,8/26/2022,Available,,,,Renal,Current,,,,2022,available
10570,Mannitol Injection,Baxter Healthcare,"20% OSMITROL Injection (20% Mannitol Injection, USP) 500 mL Viaflex Plastic Container Product Code 2D5633Q (NDC 0338-0357-03); 250 mL Viaflex Plastic Container Product Code 2D5632Q (NDC 0338-0357-02)",Revised,8/26/2022,Available,,,,Renal,Current,,,,2022,available
10571,Mannitol Injection,"ICU Medical, Inc.","20% Mannitol Injection, USP 500 mL (Legacy Hospira NDC 0409-7715-03)(ICU Medical NDC 0990-7715-03)",Reverified,10/3/2022,On allocation,,,Other,Renal,Current,,,,2022,limited availability
10572,Mannitol Injection,"ICU Medical, Inc.","20% Mannitol Injection, USP 250 mL (Legacy Hospira NDC 0409-7715-02)(ICU Medical NDC 0990-7715-02)",Reverified,10/3/2022,On allocation,,,Other,Renal,Current,,,,2022,limited availability
10573,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 100 count (NDC 42806-012-01)",New,2/28/2018,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10574,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 1000 count (NDC 42806-012-10)",New,2/28/2018,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10575,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 100 count (NDC 42806-014-01)",New,2/28/2018,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10576,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 1000 count (NDC 42806-014-10)",New,2/28/2018,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10577,Medroxyprogesterone Acetate Injectable Suspension,Teva,NDC 0703-6801-01 (150 mg/mL 1 mL Single-Dose Vial),New,8/11/2022,,Product is currently  unavailable and no future production expected for an extended period.,,,Reproductive,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10578,Medroxyprogesterone Acetate Injectable Suspension,Teva,NDC 0703-6801-04 (150 mg/mL  25 x 1 mL Single-Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Reproductive,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10579,Megestrol Acetate Oral Suspension,Wockhardt Bio AG/Morton Grove Pharmaceuticals,"40 mg/mL (NDC 60432-126-08) [8 oz (240 mL)], (NDC 60432-126-16) [1 Pint (480 mL)]",New,5/26/2022,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10580,Megestrol Acetate Suspension,Par Pharmaceutical,"125mg/1ml, 150ml Bottle (NDC 49884-230-69)",New,12/1/2021,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10581,Meloxicam Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",7.5 mg tablets (NDCs 0597-0029-01 and 0597-0029-94),New,11/1/2021,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10582,Meloxicam Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",15 mg tablets (NDCs 0597-0030-01 and 0597-0030-56),New,11/1/2021,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10583,Memantine Hydrochloride Extended-Release Capsules,"ANI Pharmaceuticals, Inc.",14mg tablets(NDCs 43975-264-03 and 43975-264-09),New,4/8/2022,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10584,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine) 1% (500 mg per 50 mL), (10 mg per mL), MDV, (NDC 63323-0283-57)",Revised,9/14/2022,Available,Check wholesaler inventory,,,Anesthesia,Current,,,,2022,available
10585,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine) 2% (1,000 mg per 50 mL), (20 mg per mL), MDV, (NDC 63323-0296-57)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler inventory,,,Anesthesia,Current,,,,2022,not available
10586,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 1% (300 mg per 30 mL), (10 mg per mL), SDV, (NDC 63323-0260-37)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler inventory,,,Anesthesia,Current,,,,2022,not available
10587,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 1.5% (450 mg per 30 mL), (15 mg per mL), SDV, (NDC 63323-0293-37)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler inventory,,Manufacturing delay,Anesthesia,Current,,,,2022,not available
10588,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 2% (400 mg per 20 mL), (20 mg per mL), SDV, (NDC 63323-0294-27)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler inventory,,Manufacturing delay,Anesthesia,Current,,,,2022,not available
10589,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",300 mg/30 mL (10 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1036-30),Revised,6/10/2022,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
10590,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",400 mg/20 mL (20 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1067-20),Revised,6/10/2022,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
10591,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",450 mg/30 mL (15 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1041-30),Revised,6/10/2022,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
10592,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 0409-1038-50),Revised,6/10/2022,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
10593,Mesalamine (CANASA®)  Suppositories,Allergan,"1 gm, Rectal Suppositories, 42 suppositories in 1 box (NDC 58914-501-42)",New,7/30/2020,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10594,Metaxalone Tablets,Pfizer Pharmaceuticals,Skelaxin 800 mg tablet; Bottle of 100 (NDC 60793-136-01),New,2/25/2022,,,,,Musculoskeletal,To be Discontinued,,,,2022,discontinued
10595,Metaxalone Tablets,Pfizer Pharmaceuticals,Skelaxin 800 mg tablet; Bottle of 500 (NDC 60793-136-05),New,2/25/2022,,,,,Musculoskeletal,To be Discontinued,,,,2022,discontinued
10596,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,750mg tablets (NDC 2037-577-10) and (NDC 62037-577-01 ),New,6/24/2020,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10597,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,500mg tablets (NDC 62037-571-01) and (NDC 62037-571-10),New,6/24/2020,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10598,Methadone Hydrochloride Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",Methadone Hydrochloride Injection (Solution in Multi Dose Vials) [200 mg / 20 ml](NDC 67457-217-20),Revised,6/8/2021,,,Available,,Analgesia/Addiction;Anesthesia,Resolved,,,,2022,
10599,Methadone Hydrochloride Injection,Akorn Pharmaceuticals,"Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) , 20 mL multidose vials (NDC 17478-380-20)",Revised,6/8/2021,,,Available,,Analgesia/Addiction;Anesthesia,Resolved,,,,2022,
10600,Methimazole Tablets,Pfizer Pharmaceuticals,Tapazole 5 mg tablets; bottle of 100 (NDC 60793-104-01),New,11/5/2021,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10601,Methimazole Tablets,Pfizer Pharmaceuticals,Tapazole 10 mg tablets; bottle of 100 (NDC 60793-105-01),New,11/5/2021,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10602,Methocarbamol Injection,"Mylan Specialty, a Viatris Company",100 mg/mL (NDC 67457-273-10),New,5/9/2022,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10603,Methohexital Sodium (Brevital) Injection,Par Pharmaceutical,"500 mg/vial, 50 mL multiple dose vial, box of 1 (NDC 42023-105-01)",Revised,11/15/2021,,,Available,,Anesthesia,Resolved,,,,2022,
10604,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 100s (16729-03-001),Revised,4/7/2022,No additional lots are anticipated at this time.,,,API procurement delay,Cardiovascular,Current,,,,2022,unclear
10605,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 500s (16729-03-016),Revised,4/7/2022,No additional lots are anticipated at this time.,,,API procurement delay,Cardiovascular,Current,,,,2022,unclear
10606,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 100s (16729-03-101),Revised,4/7/2022,No additional lots are anticipated at this time.,,,API procurement delay,Cardiovascular,Current,,,,2022,unclear
10607,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 500s (16729-03-116),Revised,4/7/2022,No additional lots are anticipated at this time.,,,API procurement delay,Cardiovascular,Current,,,,2022,unclear
10608,Methyldopa Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",250 mg (NDC 0378-0611-01),Revised,10/8/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10609,Methyldopa Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",500 mg (NDC 0378-0421-01),Revised,10/8/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10610,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0045-01 (400 mg/10 mL (40 mg/mL) 10 mL Multiple-Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10611,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0043-01 (200 mg/5 mL (40 mg/mL) 5 mL Multiple-Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10612,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0063-01 (400 mg/5 mL (80 mg/mL) 5 mL Multiple-Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10613,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0031-01 (40 mg/mL 1 mL Single-Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10614,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0031-04 (40 mg/mL 25 x 1 mL Single-Dose Vials),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10615,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0051-01 (80 mg/mL 1 mL Single-Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10616,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0051-04 (80 mg/mL 25 x 1 mL Single-Dose Vials),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10617,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","400 mg/5 mL (80 mg/mL), 5 mL multiple dose vial, box of 1 (NDC 42023-240-01)",New,6/16/2022,Available,,,,Rheumatology,Current,,,,2022,available
10618,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,40MG/ML 1X10ML (NDC 25021-820-010),Reverified,8/22/2022,Available,,,,Rheumatology,Current,,,,2022,available
10619,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,40MG/ML 1X5ML (NDC 25021-820-05),Reverified,8/22/2022,Backorder. Estimated availability June 2022,,,,Rheumatology,Current,,,,2022,not available
10620,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,80MG/ML 1x5ML (NDC 25021-821-05),Reverified,8/22/2022,Available,,,,Rheumatology,Current,,,,2022,available
10621,Methylprednisolone Acetate Injection,Amneal Pharmaceutical,"40mg/mL, 1 single-dose vial (NDC 70121-1573-01)",New,12/15/2021,Unavailable,,,Increase in demand,Rheumatology,Current,,,,2022,not available
10622,Methylprednisolone Acetate Injection,Amneal Pharmaceutical,"40 mg/mL, 25 single-dose vials (NDC 70121-1573-05)",New,12/15/2021,Unavailable,,,Increase in demand,Rheumatology,Current,,,,2022,not available
10623,Methylprednisolone Acetate Injection,Amneal Pharmaceutical,"80 mg/mL, 1 single-dose vials (NDC 70121-1574-01)",New,12/15/2021,Unavailable,,,Increase in demand,Rheumatology,Current,,,,2022,not available
10624,Methylprednisolone Acetate Injection,Amneal Pharmaceutical,"80 mg/mL, 25 single-dose vials (NDC 70121-1574-05)",New,12/15/2021,Unavailable,,,Increase in demand,Rheumatology,Current,,,,2022,not available
10625,Methylprednisolone Acetate Injection,Northstar,"40mg/ml, 1ml/1 vial X 25 (NDC 16714-088-25)",New,12/15/2021,Available; Product on allocation,,,Other,Rheumatology,Current,,,,2022,limited availability
10626,Methylprednisolone Acetate Injection,Northstar,"40mg/ml, 1ml/1 vial (NDC 16714-088-01)",New,12/15/2021,Available; Product on allocation,,,Other,Rheumatology,Current,,,,2022,limited availability
10627,Methylprednisolone Acetate Injection,Northstar,200mg/5ml (40mg/ml) (NDC 16714-089-01),New,12/15/2021,Out of Stock,,,Other,Rheumatology,Current,,,,2022,not available
10628,Methylprednisolone Acetate Injection,Northstar,"80mg/ml, 1ml/1 vial X 25 (NDC 16714-472-25)",New,12/15/2021,Available; Product on allocation,,,Other,Rheumatology,Current,,,,2022,limited availability
10629,Methylprednisolone Acetate Injection,Northstar,"80mg/ml, 1ml/1 vial (NDC 16714-472-01)",New,12/15/2021,Available; Product on allocation,,,Other,Rheumatology,Current,,,,2022,limited availability
10630,Methylprednisolone Acetate Injection,Northstar,"400mg/5ml (80mg/ml), 5ml/1 vial (NDC 16714-473-01)",New,12/15/2021,Available; Product on allocation,,,Other,Rheumatology,Current,,,,2022,limited availability
10631,Methylprednisolone Acetate Injection,Northstar,400mg/10ml (40mg/ml) (NDC 16714-090-01),New,12/15/2021,Available; Product on allocation,,,Other,Rheumatology,Current,,,,2022,limited availability
10632,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,400 mg/10 mL (40 mg/mL) 10 mL Multiple-Dose Vial (NDC 0703-0045-01),Reverified,10/5/2022,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,,2022,not available
10633,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,400 mg/5 mL (80 mg/mL) 5 mL Multiple-Dose Vial(NDC 0703-0063-01),Reverified,10/5/2022,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,,2022,not available
10634,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,200 mg/5 mL (40 mg/mL) 5 mL Multiple-Dose Vial(NDC 0703-0043-01),Reverified,10/5/2022,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,,2022,not available
10635,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,40 mg/mL 1 mL Single-Dose Vial (NDC 0703-0031-01),Reverified,10/5/2022,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,,2022,not available
10636,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,80 mg/mL 1 mL Single-Dose Vial(NDC 0703-0051-01),Reverified,10/5/2022,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,,2022,not available
10637,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,40 mg/mL 25 x 1 mL Single-Dose Vial (NDC 0703-0031-04 40),Reverified,10/5/2022,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,,2022,not available
10638,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,80 mg/mL 25 x 1 mL Single-Dose Vial(NDC 0703-0051-04),Reverified,10/5/2022,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,,2022,not available
10639,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,20 mg/mL; Multidose Vial (NDC 0009-0274-01),Revised,9/12/2022,Next Delivery and Estimated Recovery: December 2022,,,Other,Rheumatology,Current,,,,2022,not available
10640,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Multidose Vial (NDC 0009-0280-02),Revised,9/12/2022,Next Delivery and Estimated Recovery: November 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10641,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Multidose Vial (NDC 0009-0280-03),Revised,9/12/2022,Limited Supply Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Rheumatology,Current,,,,2022,limited availability
10642,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Multidose Vial (NDC 0009-0280-51),Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10643,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Multidose Vial (NDC 0009-0280-52),Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10644,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Multidose Vial (NDC 0009-0306-02),Revised,9/12/2022,Available,,,Other,Rheumatology,Current,,,,2022,available
10645,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Multidose Vial (NDC 0009-0306-12),Revised,9/12/2022,Next Delivery and Estimated Recovery: September 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10646,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Single-dose Vial (NDC 0009-3073-01),Revised,9/12/2022,Limited Supply Next Delivery: December 2022; Estimated Recovery: July 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,limited availability
10647,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Single-dose Vial (NDC 0009-3073-03),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Rheumatology,Current,,,,2022,not available
10648,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Single-dose Vial NovaPlus (NDC 0009-3073-22),Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10649,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial NovaPlus (NDC 0009-3073-23),Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10650,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial (NDC 0009-3475-01),Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10651,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial (NDC 0009-3475-03),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: July 2023,,,Demand increase for the drug,Rheumatology,Current,,,,2022,not available
10652,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial NovaPlus (NDC 0009-3475-22),Revised,9/12/2022,Next Delivery and Estimated Recovery: July 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10653,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial NovaPlus (NDC 0009-3475-23),Revised,9/12/2022,Next Delivery: February 2023; Estimated Recovery: July 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,,2022,not available
10654,Methylprednisolone Tablets,Pfizer,32 mg tablet; Bottle of 25 (NDC 0009-0176-01),New,9/12/2022,,Discontinuation of the manufacture of the drug.,,,Rheumatology,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
10655,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg tablets (NDC 0591-0790-01),New,12/5/2019,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10656,Metoclopramide Tablets,Par Pharmaceutical,"10 mg, 500S (NDC 49884-0689-01",New,7/6/2021,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10657,Metoclopramide Tablets,Par Pharmaceutical,"10 mg, 500S (NDC 49884-0689-05)",New,7/6/2021,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10658,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,50 mg tablets (NDCs 0591-0462-01 and 0591-0462-10),New,12/16/2019,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10659,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,100 mg tablets (NDCs 0591-0463-01 and 0591-0463-10),New,12/16/2019,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10660,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,500 mg tablets 1 x 100 bottle (NDC 0025-1821-31),New,10/13/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10661,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,500 mg tablets 1 x 50 bottle (NDC 0025-1821-50),New,10/13/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10662,Metronidazole Injection,B. Braun Medical Inc.,500 mg/100 mL (5 mg/mL) NDC 0264-5535-32 (Product code D5353-5224),New,1/13/2022,Available. On allocation.,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,limited availability
10663,Metronidazole Injection,Baxter Healthcare,"500 mg/100 mL in VIAFLEX Plastic Container. Product Code 2B3421, (NDC 0338-1055-48)",Reverified,8/26/2022,Available,,,,Anti-Infective,Current,,,,2022,available
10664,Metronidazole Injection,Sagent Pharmaceuticals,5mg/ml 500mg per 100mL bag in 24 pack (NDC 25021-113-82),Reverified,8/12/2022,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
10665,Metronidazole Injection,"Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 0409-7811-37),Reverified,9/12/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
10666,Metronidazole Injection,"Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 0409-7811-24),Revised,8/17/2022,,Discontinuation of the manufacture of the drug. Replaced with NDC 00409-0152-24,,,Anti-Infective,To be Discontinued,8/17/2022,8/17/2022,,2022,discontinued
10667,Metronidazole Injection,"Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 0409-0152-24),Reverified,9/12/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
10668,Metronidazole Injection,Gland Pharma Limited,100 mL Single Dose Bag (NDC 47335-993-01),New,4/11/2022,Lots are anticipated in April; with additional inventory arriving in May.,,,Other,Anti-Infective,Current,,,,2022,limited availability
10669,Midazolam Injection,WG Critical Care,50mg/50mL (1mg/mL) in 0.9% Sodium Chloride single-dose bag  (NDC 44567-610-10),Reverified,10/3/2022,Available,,,,Anesthesia;Neurology,Current,,,,2022,available
10670,Midazolam Injection,WG Critical Care,100mg/100mL (1mg/mL) in 0.9% Sodium Chloride single-dose bag  (NDC 44567-611-10),Reverified,10/3/2022,Available,,,,Anesthesia;Neurology,Current,,,,2022,available
10671,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,50 mg/10mL vial (NDC 23155-601-42),Reverified,8/23/2022,Available,,,Other,Anesthesia;Neurology,Current,,,,2022,available
10672,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,25 mg/5mL vial (NDC 23155-601-41),Reverified,8/23/2022,Available,,,Other,Anesthesia;Neurology,Current,,,,2022,available
10673,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,2 mg/2mL vial (NDC 23155-600-41),Reverified,8/23/2022,Available; On allocation due to increased demand,,,Other,Anesthesia;Neurology,Current,,,,2022,limited availability
10674,Midazolam Injection,"Hospira, Inc.",10 mg/10 mL (1 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2587-05),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: April 2023,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,not available
10675,Midazolam Injection,"Hospira, Inc.",2 mg/2 mL (1 mg/mL) CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2306-62),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Neurology,Current,,,,2022,discontinued
10676,Midazolam Injection,"Hospira, Inc.",5 mg/mL CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2307-60),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Neurology,Current,,,,2022,discontinued
10677,Midazolam Injection,Akorn Pharmaceuticals,10 ML Vial - Pack of 10 (NDC 17478-0524-10),Revised,10/22/2021,Available,,,,Anesthesia;Neurology,Current,,,,2022,available
10678,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 10 mL vial, 10 count (NDC 63323-0411-10)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10679,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 2 mL prefilled syringe, 24 count (NDC 76045-0001-20)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10680,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 2 mL vial, 25 count (NDC 63323-0411-12)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,not available
10681,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 5 mL vial, 25 count (NDC 63323-0411-25)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10682,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 1 mL fill in 2 mL vial, 25 count (NDC 63323-0412-25)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10683,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 10 mL vial, 10 count (NDC 63323-0412-10)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10684,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 1 mL prefilled syringe, 24 count (NDC 76045-0002-10)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10685,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 2 mL vial, 25 count (NDC 63323-0412-02)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10686,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 5 mL vial, 10 count (NDC 63323-0412-05)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10687,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 10 mL vial, 10 count (NDC 00641-6056-10)",Revised,8/26/2022,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10688,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 2 mL vial, 25 count (NDC 00641-6057-25)",Revised,8/26/2022,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10689,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 5 mL vial, 10 count (NDC 0641-6059-25)",Revised,8/26/2022,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10690,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 1 mL vial, 25 count (NDC 00641-6061-25)",Revised,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,not available
10691,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial, 10 count (NDC 00641-6060-10)",Revised,8/26/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,not available
10692,Midazolam Injection,"Hospira, Inc.",2 mg/2mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-17),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: April 2023,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,not available
10693,Midazolam Injection,"Hospira, Inc.",5 mg/5 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-05),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology,Current,,,,2022,limited availability
10694,Midazolam Injection,"Hospira, Inc.",5 mg/mL (5 mg/mL)  Single Dose Glass Fliptop Vial (NDC 00409-2308-01),Revised,9/12/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,limited availability
10695,Midazolam Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-05),Revised,9/12/2022,Available,,,Other,Anesthesia;Neurology,Current,,,,2022,available
10696,Midazolam Injection,"Hospira, Inc.",10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2308-02),Revised,9/12/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,limited availability
10697,Midazolam Injection,"Hospira, Inc.",25 mg/5 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-03),Revised,9/12/2022,Next Delivery and Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,not available
10698,Midazolam Injection,Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 70860-601-10),Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10699,Midazolam Injection,Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 70860-601-05),Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10700,Midazolam Injection,Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 47781-589-17),Reverified,9/12/2022,No stock available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,not available
10701,Midazolam Injection,Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 47781-589-91),Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10702,Midazolam Injection,Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 70860-600-02),Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10703,Midazolam Injection,Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 47781-588-68),Reverified,9/12/2022,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,,2022,available
10704,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",15mg tablets (NDC 0591-2469-15),New,5/29/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10705,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",30mg tablets (NDC 0591-2470-15),New,5/29/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10706,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",45mg tablets (NDC 0591-2471-15),New,5/29/2018,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10707,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 100 (NDC 59762-5008-2),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10708,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; 10x10 blister (NDC 0025-1451-34),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10709,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 60 (NDC 0025-1451-60),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10710,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 100 (NDC 0025-1461-31),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10711,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 60 (NDC 0025-1461-60),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10712,Misoprostol Tablets,Lupin,100-mcg tablets Bottles of 60 (NDC 43386-160-06),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10713,Misoprostol Tablets,Lupin,100-mcg tablets Bottles of 120 (NDC 43386-160-12),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10714,Misoprostol Tablets,Lupin,200-mcg tablets Bottles of 60 (NDC 43386-161-06),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10715,Misoprostol Tablets,Lupin,200-mcg tablets Bottles of 100 (NDC 43386-161-01),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10716,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 60 (NDC 59762-5007-1),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10717,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 120 (NDC 59762-5007-2),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10718,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 60 (NDC 59762-5008-1),Revised,3/11/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10719,Mitoxantrone Injection,Teva,NDC 0703-4685-01 (20 mg/10 mL (2 mg/mL) Multiple Dose Vial),New,8/11/2022,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Neurology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10720,Mitoxantrone Injection,Teva,NDC 0703-4680-01 (25 mg/12.5 mL (2 mg/mL) Multiple Dose Vial),New,8/11/2022,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Neurology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10721,Mitoxantrone Injection,Teva,NDC 0703-4686-01 (30 mg/15 mL (2 mg/mL) Multiple Dose Vial),New,8/11/2022,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Neurology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10722,Mometasone Furoate Monohydrate Nasal Spray,Merck Sharp & Dohme Corp.,50 mcg (NDC 0085-1288-01),New,6/9/2021,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10723,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,4 mg  (NDCs 0093-7424-98 and 0093-7424-56),New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10724,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,5 mg  (NDCs 0093-7425-98 and 0093-7425-56),New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10725,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,"10 mg (NDCs 0093-7426-10, 0093-7426-56, and 0093-7426-98)",New,7/28/2020,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10726,Montelukast Sodium Chewable Tablet,Sandoz,"4 mg  (NDCs 0781-5554-05, 0781-5554-06, 0781-5554-13, 0781-5554-31, 0781-5554-64, 0781-5554-92)",New,10/12/2021,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10727,Montelukast Sodium Chewable Tablet,Sandoz,"5 mg  (NDCs 0781-5555-05, 0781-5555-06, 0781-5555-13, 0781-5555-31, 0781-5555-64, 0781-5555-92)",New,10/12/2021,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10728,Montelukast Sodium Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-5201-93),New,3/20/2018,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10729,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-2658-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10730,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 100s (NDC 0378-2659-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10731,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"60 mg, 100s (NDC 0378-2660-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10732,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100s (NDC 0378-2661-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10733,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100s (NDC 0378-2662-01)",New,5/8/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10734,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-452-01)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2022,not available
10735,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-454-01)",Revised,9/14/2022,Backordered. Next release October 2022.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10736,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","5 mg per 1 mL, Single dose vial, (NDC 63323-455-01)",Revised,9/14/2022,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2022,available
10737,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","8 mg per 1 mL, Single dose vial, (NDC 63323-458-01)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10738,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, (NDC 63323-451-01)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2022,not available
10739,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS","30 mg/30 mL (1 mg/1 mL) Single-Dose (Preservative-Free PCA Vial), (NDC 76329-1912-1)",Reverified,8/12/2022,Backorder in the U.S. due to a manufacturing delay,,,,Analgesia/Addiction,Current,,,,2022,not available
10740,Morphine Sulfate Injection,"Hospira, Inc.",250 mg/10 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1135-02),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10741,Morphine Sulfate Injection,"Hospira, Inc.",2 mg/mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1890-01),Revised,9/12/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10742,Morphine Sulfate Injection,"Hospira, Inc.",2 mg/mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1890-11),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10743,Morphine Sulfate Injection,"Hospira, Inc.",4 mg/mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1891-01),Revised,9/12/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10744,Morphine Sulfate Injection,"Hospira, Inc.",4 mg/mL (4 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1891-11),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10745,Morphine Sulfate Injection,"Hospira, Inc.",8 mg/mL (8 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1892-01),Revised,9/12/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10746,Morphine Sulfate Injection,"Hospira, Inc.",8 mg/mL (8 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1892-11),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10747,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1893-01),Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2022,not available
10748,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1893-11),Revised,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2022,discontinued
10749,Morphine Sulfate Injection,"Hospira, Inc.",5 mg/10 mL (0.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3814-12),Revised,9/12/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10750,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/10 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3815-12),Revised,9/12/2022,Available,,,Other,Analgesia/Addiction,Current,,,,2022,available
10751,Morphine Sulfate Injection,"Hospira, Inc.","1,000 mg/20 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-03)",Revised,9/12/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2022,limited availability
10752,Morphine Sulfate Injection,"Hospira, Inc.","2,500 mg/50 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-05)",Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,,2022,not available
10753,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-10)",Revised,9/14/2022,Check wholesalers for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2022,unclear
10754,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-005-10)",Revised,9/14/2022,Check wholesalers for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2022,unclear
10755,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","5 mg per 1 mL, Single-use prefilled syringe (NDC 76045-006-10)",Revised,9/14/2022,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2022,available
10756,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","8 mg per 1 mL, Single-use prefilled syringe (NDC 76045-007-10)",Revised,9/14/2022,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10757,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single-use prefilled syringe (NDC 76045-008-10)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10758,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6125-25)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10759,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","8 mg/mL, 1 mL vial (NDC 0641-6126-25)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10760,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-6127-25)",Revised,4/8/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
10761,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 1 mg/mL, 10 mL ampul (NDC 0641-6019-10)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10762,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 0.5 mg/mL, 10 mL ampul (NDC 0641-6020-10)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10763,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 10 mg/mL, 20 mL ampul (NDC 0641-6039-01)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10764,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 25 mg/mL, 20 mL ampul (NDC 0641-6040-01)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
10765,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe, micro vault packaging (NDC 76045-004-11)",Revised,9/14/2022,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2022,available
10766,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe, micro vault packaging (NDC 76045-005-11)",Revised,9/14/2022,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2022,available
10767,Moxifloxacin (Moxeza) Ophthalmic Solution,Novartis,"5mg/mL, 3mL in 1 bottle, (NDC 0065-0006-03)",New,7/2/2021,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
10768,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 10 mL Single Dose Dual Glass Fliptop Vials (NDC 61703-0434-82),Reverified,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,discontinued
10769,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 2 x 50 mL Pharmacy Bulk Package Dual Glass Fliptop Vials (NDC 61703-0422-83),Reverified,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,discontinued
10770,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Pediatric; Single Dose Glass Fliptop Vial (NDC 61703-0421-53),Reverified,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,discontinued
10771,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)",Reverified,7/1/2022,Available on allocation,,,Demand increase for the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10772,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)",Reverified,7/1/2022,Available on allocation,,,Demand increase for the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10773,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5650-2)",Reverified,7/1/2022,Stocked out; Recovery TBD,,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10774,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)",Reverified,7/1/2022,Stocked out; Recovery TBD,,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10775,Nafcillin Injection,Pfizer Pharmaceuticals,1 g; Single Dose Vial (Powder)(NDC 0409-3713-01),New,10/20/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10776,Nafcillin Injection,Pfizer Pharmaceuticals,2 g; Single Dose Vial (Powder)(NDC 0409-3714-01),New,10/20/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10777,Nafcillin Injection,Pfizer Pharmaceuticals,10 g per Pharmacy Bulk Package; Pharmacy Bulk Vial (Powder)(NDC 0409-3715-01),New,10/20/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10778,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-3124-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10779,Nafcillin Sodium Injection,Sandoz,2 gram vial packaged in 10s (NDC 0781-3125-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10780,Nafcillin Sodium Injection,Sandoz,Pharmacy Bulk Package bottle (NDC 0781-3126-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10781,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-9124-95),New,12/23/2019,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10782,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9224-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10783,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9225-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10784,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3128-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10785,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3129-92)",New,12/23/2019,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
10786,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",10 mg/mL; 1 mL Glass Ampul (NDC 00409-1463-01),Revised,6/28/2021,,,Available,,Analgesia/Addiction,Resolved,,,,2022,
10787,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",20 mg/mL; 1 mL Glass Ampul (NDC 00409-1465-01),Revised,6/28/2021,,,Available,,Analgesia/Addiction,Resolved,,,,2022,
10788,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1464-01),Revised,6/28/2021,,,Available,,Analgesia/Addiction,Resolved,,,,2022,
10789,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1467-01),Revised,6/28/2021,,,Available,,Analgesia/Addiction,Resolved,,,,2022,
10790,Naratriptan Hydrochloride Tablets,GlaxoSmithKline,1 mg 9-count blisterpack (NDC 0173-0561-00),New,4/7/2022,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10791,Naratriptan Hydrochloride Tablets,GlaxoSmithKline,2.5 mg 9-count blisterpack (NDC 0173-0562-00),New,4/7/2022,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10792,Nebivolol Hydrochloride Tablets,Abbvie,"BYSTOLIC® (nebivolol) tablets, NDC 0456-1420-30 (30 tablets in 1 bottle)",New,6/9/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10793,Nedocromil Sodium Ophthalmic Solution,Allergan,2% (NDC 0023-8842-05),New,5/18/2022,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
10794,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,50 mg 100 Tablets (NDC 0093-7178-01),Revised,6/10/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10795,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,100 mg 60 Tablets (NDC 0093-1024-06),Revised,6/10/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10796,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,150 mg 60 Tablets (NDC 0093-7113-06),Revised,6/10/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10797,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,200 mg 60 Tablets (NDC 0093-1025-06),Revised,6/10/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10798,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,250 mg 60 Tablets (NDC 0093-1026-06),Revised,6/10/2022,,,Available,,Psychiatry,Resolved,,,,2022,
10799,Nesiritide Powder (NATRECOR) for Injection,Janssen Pharmaceuticals,1.5 mg (NDC 65847-205-25),New,2/5/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10800,Nevirapine (Viramune) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",200 mg tablets (NDC 0597-0046-60),New,5/29/2020,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10801,Nevirapine Oral Suspension,"Boehringer Ingelheim Pharmaceuticals, Inc.",50mg/5mL (NDC 0597-0047-24),New,10/1/2021,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10802,Nizatidine Capsules,Teva Pharmaceuticals,"300 mg, 30 count bottle (NDC 0591-3138-30)",Reverified,9/21/2022,"Backorder, Recovery expected TBD",,,Other,Gastroenterology,Current,,,,2022,not available
10803,Nizatidine Capsules,Teva Pharmaceuticals,"150 mg, 60 count bottle (NDC 0591-3137-60)",Reverified,9/21/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
10804,Nizatidine Capsules,Glenmark Pharmaceuticals,"300 mg, 30 count bottle (NDC 68462-0426-30)",New,3/27/2020,Unavailable,,,,Gastroenterology,Current,,,,2022,not available
10805,Nizatidine Capsules,Glenmark Pharmaceuticals,"150 mg, 60 count bottle (NDC 68462-0425-60)",New,3/27/2020,Unavailable,,,,Gastroenterology,Current,,,,2022,not available
10806,Norepinephrine Bitartrate Injection,Teva,NDC 0703-1153-03 (4 mg/4 mL (1 mg/mL) 10 Vials),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Cardiology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10807,Norepinephrine Bitartrate Injection,Teva,NDC 0703-1153-83 (4 mg/4 mL (1 mg/mL) 10 Vials) PREMIERProRx®,New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Cardiology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10808,Norethindrone (NOR QD) Tablets,Allergan,"Nor QD, 0.35 mg norethindrone, Tablets, (NDC  52544-235-28)",New,2/23/2018,,,,,Reproductive,To be Discontinued,,,,2022,discontinued
10809,Nystatin and Triamcinolone Acetonide Cream,Teva Pharmaceuticals,"0.1%  (NDCs 0472-0150-15, 0472-0150-30, 0472-0150-60)",New,4/8/2022,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
10810,Nystatin and Triamcinolone Acetonide Ointment,Teva Pharmaceuticals,"0.1%  (NDCs 0472-0155-15, 0472-0155-30, 0472-0155-60)",New,4/8/2022,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
10811,Nystatin Ointment,Sandoz,15 g tube (NDC 0168-0007-15 ),New,6/3/2022,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
10812,Nystatin Ointment,Sandoz,30 g tube (NDC 0168-0007-30 ),New,6/3/2022,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
10813,Octreotide Acetate Injection,Teva,NDC 0703-3343-01 (5000 mcg/5 mL (1000 mcg/mL) 5 mL Multiple Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10814,Octreotide Acetate Injection,Teva,"NDC 0703-3321-04 (500 mcg/mL, 25 x 1 mL Single Dose Vials)",New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10815,Octreotide Acetate Injection,Teva,NDC 0703-3333-01 (1000 mcg/5 mL (200 mcg/mL) 5 mL Multiple Dose Vial),New,8/11/2022,,Product is available with an expected supply duration until JUL 2022.  No future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10816,Octreotide Acetate Injection,Teva,NDC 0703-3311-04 (100 mcg/mL 1 mL Single Dose Vial 25 Vials),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10817,Octreotide Acetate Injection,Teva,NDC 0703-3301-04 (50 mcg/mL 1 mL Single Dose Vial 25 Vials),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
10818,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,12mg/50mg per capsule (NDC Package Code 0002-3234-30),New,7/15/2020,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10819,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,6mg/50mg per capsule (NDC Package Code 0002-3233-30),New,7/15/2020,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
10820,Olopatadine Hydrochloride Nasal Spray,Novartis Pharmaceuticals,"PATANASE (olopatadine hydrochloride) nasal spray, 665 mcg  (NDC 0078-0834-30) 1 BOTTLE in 1 CARTON (0078-0834-30) > 240 SPRAY, METERED in 1 BOTTLE",New,6/21/2022,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10821,Olopatadine Hydrochloride Nasal Spray,Novartis Pharmaceuticals,"Olopatadine hydrochloride nasal spray, 665 mcg (NDC 61314 320-01) 1 BOTTLE in 1 CARTON (61314-320-01) > 30500 uL in 1 BOTTLE",New,6/21/2022,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10822,Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets,Abbvie,212.5mg; 75mg; 50mg (NDC 0074-3082-28),New,5/22/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
10823,Omeprazole and Sodium Bicarbonate Powder for Suspension,Endo Pharmaceuticals. Inc.,40mg and 1680mg  (NDC 49884-269-11),New,6/28/2022,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10824,Omeprazole and Sodium Bicarbonate Powder for Suspension,"Endo Pharmaceuticals, Inc.",20mg and 1680mg  (NDC 49884-268-11),New,6/28/2022,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10825,Omeprazole and Sodium Bicarbonate Powder for Suspension,"Endo Pharmaceuticals, Inc.",20mg; 1680mg  (NDCs 49884-268-52 and 49884-268-11),New,2/2/2022,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10826,Omeprazole and Sodium Bicarbonate Powder for Suspension,"Endo Pharmaceuticals, Inc.",40mg; 1680mg (NDCs 49884-269-11 and 49884-269-52),New,2/2/2022,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10827,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, amber vial, 4 mg per 2 mL (NDC 63323-373-02)",Revised,4/25/2022,Available,,Available,,Gastroenterology,Resolved,,,,2022,available
10828,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Multi dose, amber vial, 40 mg per 20 mL (NDC 63323-374-20)",Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10829,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, Simplist syringe, 4 mg per 2 mL (NDC 76045-103-20)",Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10830,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9890-01)",Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10831,Ondansetron Hydrochloride Injection,Heritage Pharma,"2 mg/mL , 20 mL vials (NDC 23155-549-31)",Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10832,Ondansetron Hydrochloride Injection,Heritage Pharma,"PPRX 2 mg/mL , 2 mL Vial, 25 pack (NDC 23155-548-42)",Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10833,Ondansetron Hydrochloride Injection,Heritage Pharma,"PPRX 2 mg/mL , 2 mL Vial, 10 pack (NDC 23155-548-41)",Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10834,Ondansetron Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"2 mg/mL, 2 mL vial, 25 count (NDC 55150-125-02)",Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10835,Ondansetron Hydrochloride Injection,Heritage Pharma,"2 mg/mL , 2 mL Vial (NDC 23155-547-41)",Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10836,Ondansetron Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-4759-01),Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10837,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 2 mL vial (NDC 0641-6078-25)",Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10838,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-4755-03),Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10839,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1120-12),Revised,10/6/2021,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
10840,Ondansetron Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"2 mg/mL, 20 mL vial, 1 count (NDC 55150-126-20)",Revised,4/25/2022,,,,,Gastroenterology,Resolved,,,,2022,
10841,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 2mL vial (NDC 70860-776-02),Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10842,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 20mL vial (NDC 70860-777-20),Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10843,Ondansetron Hydrochloride Injection,Apotex Corp.,Ondansetron 2mg/mL 2mL vials Box of 25 vials (NDC 60505-6130-05),Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10844,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,40mg/20mL EA 1 Vial (NDC 25021-782-20),Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10845,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,4mg/2mL PK 25 Vials (NDC 25021-777-02),Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10846,Ondansetron Hydrochloride Injection,Baxter Healthcare,"Ondansetron Injection, USP (2 mg/mL) 2 mL Single Use Glass Vial (25 x 2 mL) (NDC 36000-012-25)",Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10847,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 2 mL vial (NDC 72266-123-25)",Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10848,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-124-01)",Revised,4/25/2022,,,Available,,Gastroenterology,Resolved,,,,2022,
10849,Oxaliplatin Injection,Sanofi-Aventis,Eloxatin 50 mg/10 mL vial (NDCs 0024-0590-10),New,9/8/2022,,,,,Oncology,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
10850,Oxaliplatin Injection,Sanofi-Aventis,Eloxatin 100 mg/20 mL vial (NDC 0024-0591-20),New,9/8/2022,,,,,Oncology,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
10851,Oxaliplatin Injection,Sanofi-Aventis,Eloxatin 200 mg/40 mL vial (NDC 0024-0592-40),New,9/8/2022,,,,,Oncology,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
10852,Oxaliplatin Injection,Sanofi-Aventis,Winthrop Oxaliplatin 50 mg/10 mL vial (NDC 0955-1725-10),New,9/8/2022,,,,,Oncology,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
10853,Oxaliplatin Injection,Sanofi-Aventis,Winthrop Oxaliplatin 100 mg/20 mL vial (NDC 0955-1727-20),New,9/8/2022,,,,,Oncology,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
10854,Oxaliplatin Injection,Sanofi-Aventis,Winthrop Premier Oxaliplatin 50 mg/10 mL vial (NDC 0955-1731-10),New,9/8/2022,,,,,Oncology,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
10855,Oxaliplatin Injection,Sanofi-Aventis,Winthrop Premier Oxaliplatin 100 mg/20 mL vial (NDC 0955-1733-20),New,9/8/2022,,,,,Oncology,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
10856,Oxcarbazepine Oral Suspension,Novartis Pharmaceuticals Corporation,300mg/5mL (NDC 0781-6270-43),New,8/8/2022,,,,,Neurology,To Be Discontinued,8/8/2022,8/8/2022,,2022,discontinued
10857,Oxybutynin Chloride Syrup,Wockhardt,"5mg/5mL, 473mL (NDC 60432-0092-16)",New,4/11/2022,,,,,Urology,To be Discontinued,,,,2022,discontinued
10858,Oxytocin Injection,Fresenius Kabi,100 USP Units per 10 mL (10 USP units per mL); Multiple dose vial; (NDC 63323-012-10),New,9/23/2022,Currently unavailable.  Next release October 2022.,,,Manufacturing delay,Anesthesia; Urology; Other,Current,,,,2022,not available
10859,Oxytocin Injection,Fresenius Kabi,300 USP Units per 30 mL (10 USP Units per mL); Multiple dose vial; (NDC 63323-012-30),New,9/23/2022,Currently unavailable. Next release October 2022.,,,Manufacturing delay,Anesthesia; Urology; Other,Current,,,,2022,not available
10860,Oxytocin Injection,Fresenius Kabi,10 USP Units per mL (10 USP units per mL); (NDC 63323-012-01)( NDC 63323-0012-11),New,9/23/2022,Currently unavailable.  Next release October 2022.,,,Manufacturing delay,Anesthesia; Urology; Other,Current,,,,2022,not available
10861,Oxytocin Injection,Par Pharmaceuticals,"Pitocin: Packages of six 50 mL Pharmacy Bulk Packages, each containing 10 units of oxytocin per mL (total = 500 units of oxytocin per vial), (NDC 42023-130-06)",Revised,10/3/2022,Limited availability,Limited supply due to low market share,,,Anesthesia; Urology; Other,Current,,,,2022,limited availability
10862,Oxytocin Injection,Par Pharmaceuticals,"Pitocin: Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin, (NDC 42023-116-25)",Revised,10/3/2022,Limited availability,Limited supply due to low market share,,,Anesthesia; Urology; Other,Current,,,,2022,limited availability
10863,Oxytocin Injection,Par Pharmaceuticals,"Pitocin: Packages of twenty-five 10 mL multiple-dose vial, each containing 10 units of oxytocin per mL (total = 100 units of oxytocin per vial) (NDC 42023-116-02)",Revised,10/3/2022,Limited availability,Limited supply due to low market share,,,Anesthesia; Urology; Other,Current,,,,2022,limited availability
10864,Paclitaxel Injection (protein-bound particles),Bristol Myers Squibb Co.,"100 mg, single dose vial (NDC 24979-710-51)",New,5/27/2022,No supply constraint or anticipated shortage,,,,Oncology,Current,,,,2022,available
10865,Paclitaxel Injection (protein-bound particles),Bristol Myers Squibb Co.,"100 mg, single dose vial (NDC 60505-6230-4)",New,5/27/2022,No supply constraint or anticipated shortage,,,,Oncology,Current,,,,2022,available
10866,Paclitaxel Injection (protein-bound particles),Bristol Myers Squibb Co.,"Abraxane® 100 mg, single dose vial (NDC 68817-134-50)",Revised,5/27/2022,No longer on allocation; recovery to normal inventory levels in progress.,,,Other,Oncology,Current,,,,2022,available
10867,"Paclitaxel Injection, USP",Mylan Institutional,"100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17)",New,11/22/2019,,,,,Oncology,To be Discontinued,,,,2022,discontinued
10868,Pantoprazole Sodium for Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"40 mg, 10 vials (NDC 55150-202-10)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2022,available
10869,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-0923-55)",Revised,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
10870,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-0923-60)",Revised,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
10871,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-2001-10; Amerinet)",Revised,9/12/2022,Next Delivery and Estimated Recovery: February 2025,,,Other,Gastroenterology,Current,,,,2022,not available
10872,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-2001-25; Amerinet)",Revised,9/12/2022,Next Delivery and Estimated Recovery: February 2025,,,Other,Gastroenterology,Current,,,,2022,not available
10873,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-4001-10; PremierPro)",Revised,9/12/2022,Limited Supply Next Delivery and Estimated Recovery: October 2022,Demand increase for the drug,,Other,Gastroenterology,Current,,,,2022,limited availability
10874,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-4001-25; PremierPro)",Revised,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
10875,Pantoprazole Sodium for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg, 10 vials (NDC 0143-9284-10)",Revised,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Gastroenterology,Current,,,,2022,available
10876,Pantoprazole Sodium for Injection,Sun Pharmaceutical Industries Inc.,"40 mg, 10 vials (NDC 62756-129-44)",Revised,4/5/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
10877,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 72572-550-10)",Reverified,10/3/2022,Available,Marketed by Civica,,,Gastroenterology,Current,,,,2022,available
10878,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 65219-433-15)",Reverified,10/3/2022,Limited Supply,Marketed by Fresenius Kabi,,Demand increase for the drug,Gastroenterology,Current,,,,2022,limited availability
10879,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 0781-3232-95)",Reverified,10/3/2022,Limited Availability,,,Demand increase for the drug,Gastroenterology,Current,,,,2022,limited availability
10880,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges),Revised,12/6/2021,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2022,unclear
10881,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,50mcg   Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges),Revised,12/6/2021,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2022,unclear
10882,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,75mcg   Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges),Revised,12/6/2021,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2022,unclear
10883,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,100mcg   Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges),Revised,12/6/2021,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,,2022,unclear
10884,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4347-01)",New,2/28/2018,,,,,Oncology,To be Discontinued,,,,2022,discontinued
10885,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4348-01)",New,2/28/2018,,,,,Oncology,To be Discontinued,,,,2022,discontinued
10886,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4349-01)",New,2/28/2018,,,,,Oncology,To be Discontinued,,,,2022,discontinued
10887,Pentamidine Isethionate (Nebupent) For Inhalation Solution,"Fresenius Kabi USA, LLC","300 mg per vial, SDV, PF (NDC 63323-877-15)",Revised,9/13/2019,,,,,Anti-Infective,Resolved,,,,2022,
10888,Pentostatin Injection,"Hospira, Inc.","10 mg, single dose vial (NDC 0409-0801-01)",Reverified,9/12/2022,Available,,,Other,Oncology,Current,,,,2022,available
10889,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 100s (NDC 0378-0357-01)",New,5/8/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10890,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 500s (NDC 0378-0357-05)",New,5/8/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10891,Phenobarbital Oral Solution,Torrent Pharma Inc.,1 pint 473mL (NDC 16571-330-16),New,11/25/2019,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10892,Physostigmine Salicylate Injection,Akorn Pharmaceuticals,"Physostigmine Salicylate Injection, USP  1mg/mL (10amps/box, 2mL each) (NDC 17478-510-02)",Reverified,1/21/2022,Unavailable. Expected to release Q4 2022.,,,Other,Neurology,Current,,,,2022,not available
10893,Pindolol Tablets,Sun Pharmaceutical Industries Inc.,"Pindolol Tablets, 5mg and 10mg (100 count bottles)(NDC 57664-655-88, 57664-656-88)",Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10894,Pindolol Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Pindolol 5mg Tabs 100s (NDC 0378-0052-01),Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10895,Pindolol Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Pindolol 10mg Tabs 100s (NDC 0378-0127-01),Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10896,Pindolol Tablets,Bayshore Pharmaceuticals,5 mg/ 100 count (NDC 76385-131-01),Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10897,Pindolol Tablets,Bayshore Pharmaceuticals,10 mg/ 100 count (NDC 76385-132-01),Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10898,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","5 mg: Bottles of 100 tablets, (NDC 62559-560-01)",Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10899,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","10 mg; Bottles of 100 tablets, (NDC 62559-561-01)",Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10900,Pindolol Tablets,"Nostrum Laboratories, Inc.","5 mg, Bottle of 100 tablets (NDC 29033-028-01)",Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10901,Pindolol Tablets,"Nostrum Laboratories, Inc.","10 mg, Bottle of 100 tablets (NDC 29033-029-01)",Revised,1/11/2022,,,Available,,Cardiovascular,Resolved,,,,2022,
10902,Pioglitazone Hydrochloride Tablets,Sandoz,15 mg/1 (NDC 0781-5420-64),New,1/10/2022,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10903,Pioglitazone Hydrochloride Tablets,Sandoz,30 mg/1 (NDC 0781-5421-10),New,1/10/2022,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10904,Pioglitazone Hydrochloride Tablets,Sandoz,45 mg/1 (NDC 0781-5422-10),New,1/10/2022,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10905,Pioglitazone/Metformin HCl (ACTOPLUS MET®) Tablets,Takeda Pharmaceuticals USA Inc.,15mg/500mg tablet (NDC 64764-0155-60),New,10/18/2021,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
10906,Piroxicam Capsules,Pfizer Pharmaceuticals,10 mg capsules; Bottles of 100 (NDC 59762-0140-1),New,8/10/2021,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10907,Piroxicam Capsules,Pfizer Pharmaceuticals,20 mg capsules; Bottles of 100 (NDC 59762-0145-1),New,8/10/2021,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
10908,Polymyxin B Sulfate and Trimethoprim Sulfate Ophthalmic Solution,"Allergan Sales, LLC","10,000 units/mL; 1 mg/mL (NDC 0023-7824-10)",New,8/8/2022,,,,,Ophthalmology,To Be Discontinued,8/8/2022,8/8/2022,,2022,discontinued
10909,Potassium Acetate Injection,"Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 0409-3294-51)",Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10910,Potassium Acetate Injection,"Hospira, Inc.","40 mEq/20 mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 00409-8183-01)",Revised,9/12/2022,Next Delivery and Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10911,Potassium Acetate Injection,"Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 0409-3294-25), Novaplus",Revised,9/12/2022,Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10912,Potassium Acetate Injection,"Hospira, Inc.","40 mEq/20 mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 0409-8183-25), Novaplus",Revised,9/12/2022,Next Delivery: November 2022; Estimated Recovery: March 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10913,Potassium Acetate Injection,"Exela Pharma Sciences, LLC",Potassium Acetate Inj. 40mEq (2mEq/ml) 20mL (NDC 51754-2001-4),Revised,5/16/2022,Product shipped to and available in wholesalers. Additional shipment end of May 2022. Increased supply available in mid-June.,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,available
10914,Potassium Chloride Concentrate Injection,B. Braun Medical Inc.,Concentrated Potassium Chloride Injection USP 250 mL Plastic Bag P9402 (NDC 0264-1944-20),Revised,9/14/2022,Backordered.  Next release not available at this time.,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10915,Potassium Chloride Concentrate Injection,"Hospira, Inc.",10 mEq/5 mL (2 mEq/mL) Single Dose Glass Fliptop Vial (NDC 0409-6635-01),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10916,Potassium Chloride Concentrate Injection,"Hospira, Inc.",20 mEq/10 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial (NDC 0409-6651-06),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand Increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10917,Potassium Chloride Concentrate Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial (NDC 00409-6653-05),Revised,9/12/2022,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,available
10918,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","60 mEq per 30 mL (2 mEq per mL), Multi dose, plastic vial, (NDC 63323-967-30)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,available
10919,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","10 mEq per 5 mL(2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-05)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,available
10920,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","20 mEq per 10 mL (2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-10)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10921,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","40 mEq per 20 mL (2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-20)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10922,Potassium Chloride Concentrate Injection,B. Braun Medical Inc.,(2 mEq K /mL) 250mL bulk package Catalog# S9402-11(NDC 0264-1940-20),Revised,9/14/2022,Inventory depleted.,,,Discontinuation of manufacturing,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
10923,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 20 mEq/50 mL (Legacy Hospira NDC 0409-7077-14) (ICU Medical NDC 0990-7077-14)",Reverified,10/3/2022,Allocation,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10924,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 10 mEq/100 mL (Legacy Hospira NDC 0409-7074-26) (ICU Medical NDC 0990-7074-26)",Reverified,10/3/2022,Allocation,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10925,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 10 mEq/50 mL (Legacy Hospira NDC 0409-7075-14) (ICU Medical NDC 0990-7075-14)",Reverified,10/3/2022,Allocation,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10926,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 20 mEq/100 mL (Legacy Hospira NDC 0409-7075-26) (ICU Medical NDC 0990-7075-26)",Reverified,10/3/2022,Allocation,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10927,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 40 mEq/100 mL (Legacy Hospira NDC 0409-7077-26) (ICU Medical NDC 0990-7077-26)",Reverified,10/3/2022,Available,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,available
10928,Potassium Chloride Concentrate Injection,Baxter Healthcare,10 mEq/100 mL in VIAFLEX Plastic Container; Product Code 2B0826 (NDC 0338-0709-48),Reverified,9/28/2022,Available on allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10929,Potassium Chloride Concentrate Injection,Baxter Healthcare,10 mEq/50 mL in VIAFLEX Plastic Container; Product Code 2B0821 (NDC 0338-0705-41),Reverified,9/28/2022,Available on allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10930,Potassium Chloride Concentrate Injection,Baxter Healthcare,20 mEq/100 mL in VIAFLEX Plastic Container; Product Code 2B0827 (NDC 0338-0705-48),Reverified,9/28/2022,Limited Supply on Allocation; Recovery late June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10931,Potassium Chloride Concentrate Injection,Baxter Healthcare,20 mEq/50 mL in VIAFLEX Plastic Container; Product Code 2B0822 (NDC 0338-0703-41),Reverified,9/28/2022,Limited Supply on Allocation; Recovery mid-July 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10932,Potassium Chloride Concentrate Injection,Baxter Healthcare,40 mEq/100 mL in VIAFLEX Plastic Container; Product Code 2B0824 (NDC 0338-0703-48),Reverified,9/28/2022,Available on allocation,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10933,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",29.8 g/L (20 mEq) 50 mL (NDC 14789-107-08),New,2/2/2022,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10934,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",29.8 g/L (40 mEq) 100 mL (NDC 14789-107-16),New,2/2/2022,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10935,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",14.9 g/L (20 mEq) 100 mL (NDC 14789-108-16),New,2/2/2022,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10936,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",14.9 g/L (10 mEq) 50 mL (NDC 14789-108-08),New,2/2/2022,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10937,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",7.45 g/L ( 10 mEq) 100 mL (NDC 14789-109-16),New,2/2/2022,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
10938,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",0.375mg (NDC 10370-251-11),New,12/16/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10939,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",0.75mg (NDC 10370-252-11),New,12/16/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10940,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",1.5mg (NDC 10370-253-11),New,12/16/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10941,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",2.25mg (NDC 10370-305-11),New,12/16/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10942,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",3mg (NDC 10370-254-11),New,12/16/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10943,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",3.75mg (NDC 10370-306-11),New,12/16/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
10944,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (Pred Forte) (NDC 11980-180-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10945,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10946,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (NDC 60758-119-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10947,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (NDC 60758-119-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10948,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 5mL in 1 bottle (NDC 61314-637-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10949,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 10mL in 1 bottle (NDC 61314-637-10),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10950,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 15mL in 1 bottle (NDC 61314-637-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10951,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-15),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10952,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (NDC 60758-119-05),Revised,10/31/2019,,,,,Ophthalmology,Resolved,,,,2022,
10953,Prednisolone Sodium Phosphate Oral Solution,Wockhardt Bio AG/Morton Grove Pharmaceuticals,15 mg/5mL (NDC 60432-212-08) (8 fl oz.),New,5/26/2022,,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10954,Procainamide Hydrochloride Injection,Pfizer,"1,000 mg/2 mL (500 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1903-01)",New,8/30/2022,,Discontinuation of the manufacture of the drug.,,,Cardiology,To be Discontinued,8/30/2022,8/30/2022,,2022,discontinued
10955,Procardia Capsules,Pfizer Pharmaceuticals,10 mg capsule; Bottle of 100 (NDC 0069-2600-66),New,5/10/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10956,ProHance® (Gadoteridol) Injection,Bracco Diagnostics,"279.3 mg/mL, 5 x 10 mL pre-filled syringe, (NDC 0270-1111-16)",New,6/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10957,ProHance® (Gadoteridol) Injection,Bracco Diagnostics,"279.3 mg/mL, 5 x 17 mL pre-filled syringe, (NDC 0270-111-45)",New,6/1/2021,,,,,Medical Imaging,To be Discontinued,,,,2022,discontinued
10958,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL vial (NDC 0641-0928-25)",Reverified,4/8/2022,Inventory is currently available.,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10959,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL ,1 mL vial (NDC 0641-0929-25)",Reverified,4/8/2022,Inventory is currently available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10960,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL ampul (NDC 0641-1495-35)",Reverified,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10961,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL ampul (NDC 0641-1496-35)",Reverified,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10962,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL vial (NDC 0641-6084-25)",Reverified,4/8/2022,Inventory is currently available.,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10963,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL ,1 mL vial (NDC 0641-6085-25)",Reverified,4/8/2022,Inventory is currently available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10964,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL ampul (NDC 0641-6082-25)",Reverified,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10965,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL, 1 mL ampul (NDC 0641-6083-25)",Reverified,4/8/2022,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10966,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","25 mg/mL, Carton of 25 ampuls (NDC 39822-5525-3)",Reverified,2/25/2021,Available,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10967,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","50 mg/mL, Carton of 25 ampuls (NDC 39822-5550-6)",Reverified,2/25/2021,Available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,,2022,available
10968,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01)",New,12/19/2019,,,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10969,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01)",New,12/19/2019,,,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10970,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04)",New,12/19/2019,,,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10971,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)",New,12/19/2019,,,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
10972,Propafenone Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",150mg (NDCs 0603-5448-21 and 0603-5448-25),New,2/2/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10973,Propafenone Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",225mg (NDCs 0603-5449-21 and 0603-5449-25),New,2/2/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10974,Propafenone Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",300mg (NDC 0603-5450-21),New,2/2/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
10975,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0209-10),Revised,9/12/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2022,limited availability
10976,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0234-20),Revised,9/12/2022,Available,,,Other,Anesthesia,Current,,,,2022,available
10977,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0248-10),Revised,9/12/2022,Available,,,,Anesthesia,Current,,,,2022,available
10978,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6194-10)",Reverified,4/8/2022,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10979,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 50 mL vial (NDC 0641-6195-20",Reverified,4/8/2022,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10980,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 100 mL vial (NDC 0641-6196-10",Reverified,4/8/2022,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
10981,Propofol Injectable Emulsion,Avet Pharmaceuticals,200 mg/20mL (pack 10) (NDC 23155-235-41),New,9/7/2022,Available,,,,Anesthesia,Current,,,,2022,available
10982,Propofol Injectable Emulsion,Avet Pharmaceuticals,200 mg/20mL (pack of 20) (NDC 23155-235-44),New,9/7/2022,Available,,,,Anesthesia,Current,,,,2022,available
10983,Propofol Injectable Emulsion,Avet Pharmaceuticals,500 mg/50 mL (pack of 20) (NDC 23155-345-42),New,9/7/2022,Available,,,,Anesthesia,Current,,,,2022,available
10984,Propofol Injectable Emulsion,Avet Pharmaceuticals,"1,000 mg/100 mL (pack of 10) (NDC 23155-345-13)",New,9/7/2022,Available,,,,Anesthesia,Current,,,,2022,available
10985,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 10X100ML VL (NDC 0591-2136-68),Reverified,10/5/2022,Available,Market Exit - Estimated Run Out TBD,,Discontinuance of Manufacturing,Anesthesia,Current,,,,2022,available
10986,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 20X50ML VL (NDC 0591-2136-51),Reverified,10/5/2022,Available,Market Exit - Estimated Run Out TBD,,Discontinuance of Manufacturing,Anesthesia,Current,,,,2022,available
10987,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 25X20ML VL (NDC 0591-2136-95),Reverified,10/5/2022,Available,Market Exit - Estimated Run Out TBD,,Discontinuance of Manufacturing,Anesthesia,Current,,,,2022,available
10988,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, 10ct (NDC 43598-549-10)",Reverified,9/19/2022,Allocating to Wholesalers,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2022,limited availability
10989,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, individual (NDC 43598-549-52)",Reverified,9/19/2022,Allocating to Wholesalers,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2022,limited availability
10990,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, 25ct (NDC 43598-265-25)",Reverified,9/19/2022,No current supply,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2022,not available
10991,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","1000 mg per 100 mL (10 mg per mL), single patient use only, 100 mL (NDC 63323-269-65)",Reverified,9/14/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
10992,Propofol Injectable Emulsion,Sagent Pharmaceuticals,200mg per 20ml (NDC 25021-608-20),Reverified,8/22/2022,Available,,,Demand increase due to Covid-19,Anesthesia,Current,,,,2022,available
10993,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 10X100ML VL (NDC 0591-2136-68),Revised,3/14/2022,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
10994,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-30),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Anesthesia,Current,,,,2022,limited availability
10995,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-33),Revised,9/12/2022,Available,,,Other,Anesthesia,Current,,,,2022,available
10996,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-24),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2022,limited availability
10997,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",200mg/20mL  10ct (NDC 43598-265-58),Reverified,9/19/2022,Pack size discontinued,,,,Anesthesia,Current,,,,2022,discontinued
10998,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, individual (NDC 43598-265-20)",Reverified,9/19/2022,No current supply,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2022,not available
10999,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",500mg/50mL  20ct (NDC 43598-548-21),Reverified,9/19/2022,Allocating to Wholesalers,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2022,limited availability
11000,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","500mg/50mL vial, individual (NDC 43598-548-50)",Reverified,9/19/2022,Allocating to Wholesalers,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,,2022,limited availability
11001,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 20X50ML VL (NDC 0591-2136-51),Revised,3/14/2022,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
11002,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 25X20ML VL (NDC 0591-2136-95),Revised,3/14/2022,,,,,Anesthesia,To be Discontinued,,,,2022,discontinued
11003,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), single patient use only, 10 mL (NDC 63323-269-10)",Reverified,9/14/2022,Available,,,,Anesthesia,Current,,,,2022,available
11004,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), single patient use only, 20 mL (NDC 63323-269-29)",Reverified,9/14/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
11005,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL), single patient use only, 50 mL (NDC 63323-269-50)",Reverified,9/14/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
11006,Propofol Injectable Emulsion,Sagent Pharmaceuticals,500mg per 50ml (NDC 250-21-608-50),Reverified,8/22/2022,Available,,,,Anesthesia,Current,,,,2022,available
11007,Propofol Injectable Emulsion,Sagent Pharmaceuticals,1000mg per 100ml (NDC 25021-608-51),Reverified,8/22/2022,Available,,,,Anesthesia,Current,,,,2022,available
11008,Protamine Sulfate Injection,"Fresenius Kabi USA, LLC","50 mg per 5 mL (10 mg per mL), single dose vial, preservative free,  (NDC 63323-229-05)",Revised,9/14/2022,Available,Check wholesaler inventory,,,Hematology,Current,,,,2022,available
11009,Protamine Sulfate Injection,"Fresenius Kabi USA, LLC","250 mg per 25 mL (10 mg per mL), single dose vial, preservative free, (NDC 63323-229-30)",Revised,9/14/2022,Available,Check wholesaler inventory,,,Hematology,Current,,,,2022,available
11010,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,500 mg  (NDC 45963-418-50),New,7/6/2020,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11011,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,1000 mg  (NDC 45963-419-50),New,7/6/2020,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11012,Remifentanil Injection,"Mylan, a Viatris Company",1 mg (NDC 67457-198-03),Revised,9/28/2022,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
11013,Remifentanil Injection,"Mylan, a Viatris Company",2 mg (NDC 67457-198-05),Revised,9/28/2022,Unavailable,Re-supply in December 2022.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
11014,Remifentanil Injection,"Mylan, a Viatris Company",5 mg (NDC 67457-198-10),Revised,9/28/2022,Unavailable,Re-supply in January 2023.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
11015,Remifentanil Injection,Hikma Pharmaceuticals,1 mg/vial (NDC 0143-9391-10),Revised,8/26/2022,This presentation is on backorder. Product will be available September 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
11016,Remifentanil Injection,Hikma Pharmaceuticals,2 mg/Vial (NDC 0143-9392-10),Revised,8/26/2022,This presentation is on backorder. Product will be available September 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
11017,Remifentanil Injection,Hikma Pharmaceuticals,5 mg/mL (NDC 0143-9393-10),Revised,8/26/2022,Currently available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
11018,Remifentanil Injection,Fresenius Kabi USA,"1 mg per vial, SDV (NDC 63323-723-03)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
11019,Remifentanil Injection,Fresenius Kabi USA,"2 mg per vial, SDV (NDC 63323-724-05)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,not available
11020,Remifentanil Injection,Fresenius Kabi USA,"5 mg per vial, SDV (NDC 63323-725-10)",Revised,9/14/2022,Available,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2022,available
11021,Repaglinide Tablets,Sandoz,1mg tablets (NDC 0781-5149-01),New,2/2/2018,,,,,Endocrinology/Metabolism,To be Discontinued,,,,2022,discontinued
11022,Rifampin (Rifadin) Capsules,Sanofi-Aventis,150 mg capsules (NDC 0068-0510-30),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
11023,Rifampin (Rifadin) Capsules,Sanofi-Aventis,300 mg capsules (NDC 0068-0508-60),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
11024,Rifampin Capsules,Akorn Pharmaceuticals,150 mg Bottles of 30 (NDC 61748-015-30),New,9/12/2022,,Discontinuation of manufacture of the drug.,,,,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
11025,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 30 (NDC 61748-018-30),New,9/12/2022,,Discontinuation of manufacture of the drug.,,,,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
11026,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 60 (NDC 61748-018-60),New,9/12/2022,,Discontinuation of manufacture of the drug.,,,,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
11027,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 100 (NDC 61748-018-01),New,9/12/2022,,Discontinuation of manufacture of the drug.,,,,To be Discontinued,9/12/2022,9/12/2022,,2022,discontinued
11028,Rifampin Capsules,"Epic Pharma, LLC",150 mg (NDC 42806-801-30),Revised,1/11/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
11029,Rifampin Capsules,"Epic Pharma, LLC",150 mg (NDC 42806-801-01),Revised,1/11/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
11030,Rifampin Capsules,"Epic Pharma, LLC",300 mg (NDC 42806-799-30),Revised,1/11/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
11031,Rifampin Capsules,"Epic Pharma, LLC",300 mg (NDC 42806-799-60),Revised,1/11/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
11032,Rifampin Capsules,"Epic Pharma, LLC",300 mg (NDC 42806-799-01),Revised,1/11/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
11033,Rifampin Capsules,"Epic Pharma, LLC",300 mg (NDC 42806-799-05),Revised,1/11/2022,Available,,,Other,Anti-Infective,Current,,,,2022,available
11034,Rifampin Capsules,Lupin,150 mg - Bottles of 30 (NDC 68180-658-06),Reverified,7/15/2022,Limited quantities available. More quantities will be available in coming weeks/months.,,,Shortage of an active ingredient.,Anti-Infective,Current,,,,2022,limited availability
11035,Rifampin Capsules,Lupin,300 mg - Bottles of 30 (NDC 68180-659-06),Reverified,7/15/2022,Limited quantities available. More quantities will be available in coming weeks/months.,,,Shortage of an active ingredient.,Anti-Infective,Current,,,,2022,limited availability
11036,Rifampin Capsules,Lupin,300 mg - Bottles of 60 (NDC 68180-659-07),Reverified,7/15/2022,Limited quantities available. More quantities will be available in coming weeks/months.,,,Shortage of an active ingredient.,Anti-Infective,Current,,,,2022,limited availability
11037,Rifampin Capsules,Akorn Pharmaceuticals,150 mg Bottles of 30 (NDC 61748-015-30),Revised,9/12/2022,Unavailable,Discontinuation of manufacture of the drug.,,Other,Anti-Infective,Current,,,,2022,not available
11038,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 30 (NDC 61748-018-30),Revised,9/12/2022,Unavailable,Discontinuation of manufacture of the drug.,,Other,Anti-Infective,Current,,,,2022,not available
11039,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 60 (NDC 61748-018-60),Revised,9/12/2022,Unavailable,Discontinuation of manufacture of the drug.,,Other,Anti-Infective,Current,,,,2022,not available
11040,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 100 (NDC 61748-018-01),Revised,9/12/2022,Unavailable,Discontinuation of manufacture of the drug.,,Other,Anti-Infective,Current,,,,2022,not available
11041,Rifampin Injection,"Fresenius Kabi USA, LLC","600 mg per vial, PF, Lyophilized powder (NDC 63323-351-20)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler inventory,,,Anti-Infective,Current,,,,2022,not available
11042,Rifampin Injection,Sanofi,"600 mg/10 mL, Lyophilized powder (NDC 0068-0597-01)",Revised,6/22/2021,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,,2022,available
11043,Rifampin Injection,"Mylan Institutional, a Viatris company","600 mg, (Lyophilizate in Single Dose Vials) (NDC 67457-445-60)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,available
11044,Rifampin/Isoniazid (Rifamate) Capsules,Sanofi-Aventis,150 mg/300 mg capsules (NDC 0068-0509-60),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
11045,Rifampin/Isoniazid/Pyrazinamide (Rifater) Tablets,Sanofi-Aventis,150 mg/300 mg/120 mg tablets (NDC 0088-0576-41),New,6/15/2020,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
11046,Rifapentine Tablets,Sanofi,"Rifapentine (Piftin) Tablets, 150 mg (NDC 0088-2102-24)",Revised,6/22/2022,Intermittent supply,,,Demand increase for the drug,Anti-Infective,Current,,,,2022,limited availability
11047,Risankizumab-rzaa Injection,Abbvie,75 mg/0.83 mL Prefilled Syringe (NDC numbers 0074-2042-01 and 0074-2042-02),New,9/20/2022,,,,,Rheumatology,To be Discontinued,9/20/2022,9/20/2022,,2022,discontinued
11048,Risedronate Sodium Tablets,Allergan Sales LLC,30 mg (NDC 0430-0470-15),New,5/9/2022,,,,,Musculoskeletal,To be Discontinued,,,,2022,discontinued
11049,Risedronate Tablets,Allergan Sales LLC,5 mg tablets (NDC 0430-0471-15),New,12/9/2019,,,,,Musculoskeletal,To be Discontinued,,,,2022,discontinued
11050,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-60),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11051,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-10),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11052,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-60),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11053,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11054,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-60),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11055,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11056,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-10),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11057,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-60),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11058,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11059,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-10),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11060,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-60),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11061,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11062,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-10),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11063,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-60),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11064,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11065,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-10),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11066,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 3 mg (NDC 50458-330-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11067,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 2 mg (NDC 50458-320-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11068,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 1 mg (NDC 50458-300-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11069,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.5 mg (NDC 50458-302-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11070,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-50),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11071,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-01),New,5/24/2018,,,,,Pediatric;Psychiatry,To be Discontinued,,,,2022,discontinued
11072,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 5mL vial (NDC 70860-651-05),Revised,11/2/2018,Available,,,Available,Anesthesia,Resolved,,,,2022,available
11073,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 10mL vial (NDC 70860-651-10),Revised,11/2/2018,Available,,,Available,Anesthesia,Resolved,,,,2022,available
11074,Ropivacaine Hydrochloride Injection,Akorn Pharmaceuticals,"0.5% 5mg/mL, 30mL, 1 Vial (NDC 17478-0081-30)",Revised,2/12/2021,Available,,,Other,Anesthesia,Current,,,,2022,available
11075,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-10),Revised,9/8/2022,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/2022,9/12/2022,,2022,discontinued
11076,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-20),Revised,9/8/2022,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
11077,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9301-30),Revised,9/8/2022,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
11078,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/20 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9302-20),Revised,9/8/2022,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
11079,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-10),Revised,9/8/2022,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
11080,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-20),Revised,9/8/2022,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
11081,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.2% 20 mL Single Dose Vials (NDC 55150-195-20),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
11082,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.2% 100 mL Single Dose Infusion Bottles (NDC 55150-196-99),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
11083,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 20 mL Single Dose Vials (NDC 55150-197-20),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
11084,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 30 mL Single Dose Vials (NDC 55150-198-30),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
11085,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.75% 20 mL Single Dose Vials (NDC 55150-199-20),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
11086,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 10 mL Single Dose Vials (NDC 55150-200-10),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
11087,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 20 mL Single Dose Vials (NDC 55150-201-20),Reverified,9/28/2022,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,,2022,not available
11088,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-10)",Revised,9/14/2022,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,available
11089,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-20)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Available,Anesthesia,Current,,,,2022,not available
11090,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-286-20)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Available,Anesthesia,Current,,,,2022,not available
11091,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-287-20)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11092,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Plastic Ampule, Sterile-Pak (63323-288-10)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,Available,Anesthesia,Current,,,,2022,not available
11093,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-288-20)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11094,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Free Flex Bag (NDC 63323-285-61)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11095,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Free Flex Bag (NDC 63323-285-63)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11096,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-285-65)",Revised,9/14/2022,Available,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,,2022,available
11097,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-285-64)",Revised,9/14/2022,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,available
11098,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (500 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-286-00)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11099,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (1,000 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-286-63)",Revised,9/14/2022,Available,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,,2022,available
11100,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Single Dose Vial (NDC 63323-285-13)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11101,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Single Dose Vial (NDC 63323-285-23)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,,2022,not available
11102,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Single Dose Vial (NDC 63323-286-35)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11103,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Single Dose Vial (NDC 63323-286-23)",Revised,9/14/2022,Backordered. Next release September 2022.,,,Manufacturing delays,Anesthesia,Current,,,,2022,not available
11104,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Single Dose Vial (NDC 63323-287-21)",Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11105,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Single Dose Vial (NDC 63323-288-11)",Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,2022,not available
11106,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Single Dose Vial (NDC 63323-288-21)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,2022,not available
11107,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Sterile-Pack, Single Dose Vial (NDC 63323-286-31)",Revised,9/14/2022,Backordered. Next release not available at this time.,,,,Anesthesia,Current,,,,2022,not available
11108,Ropivacaine Hydrochloride Injection,InfoRLife SA,0.2% 2mg/mL 10x100mL (NDC 25021-671-82),Revised,4/25/2022,Available,,,,Anesthesia,Current,,,,2022,available
11109,Ropivacaine Hydrochloride Injection,InfoRLife SA,0.2% 2mg/mL 10x200mL (NDC 25021-671-87),Revised,4/25/2022,Available,,,,Anesthesia,Current,,,,2022,available
11110,Ropivacaine Hydrochloride Injection,InfoRLife SA,500 mg per 100 mL (5 mg per mL 0.5%) (NDC 25021-652-82 ),Revised,4/25/2022,Available,,,,Anesthesia,Current,,,,2022,available
11111,Ropivacaine Hydrochloride Injection,InfoRLife SA,"1,000 mg per 200 mL (5 mg per mL 0.5%) (NDC 25021-652-87)",Revised,4/25/2022,Backordered. Estimated availability TBD,,,,Anesthesia,Current,,,,2022,not available
11112,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","0.5% (5 mg/mL), 30 mL, 1 vial (NDC 70069-064-01)",New,4/20/2022,Available,,,,Anesthesia,Current,,,,2022,available
11113,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","0.5% (5 mg/mL), 30 mL, 10 vials (NDC 70069-064-10)",New,4/20/2022,Available,,,,Anesthesia,Current,,,,2022,available
11114,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","0.5% (5 mg/mL), 30 mL, 25 vials (NDC 70069-064-25)",New,4/20/2022,Available,,,,Anesthesia,Current,,,,2022,available
11115,Ropivacaine Hydrochloride Injection,InfoRLife SA,"0.2% 2mg/mL 10x100mL (NDC 25021-671-66), Novaplus",New,4/25/2022,Available,,,,Anesthesia,Current,,,,2022,available
11116,Ropivacaine Hydrochloride Injection,InfoRLife SA,"0.2% 2mg/mL 10x200mL (NDC 25021-671-67), Novaplus",New,4/25/2022,Available,,,,Anesthesia,Current,,,,2022,available
11117,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.2%, 40 mg/20 mL (2 mg/mL) single dose vial (NDC 43066-015-10)",Revised,9/28/2022,Limited Supply Recovery Q1 2023,,,Demand increase,Anesthesia,Current,,,,2022,limited availability
11118,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.5%, 100 mg/20 mL (5 mg/mL) single dose vial (NDC 43066-019-10)",Revised,9/28/2022,Limited supply. Recovery Q1 2023,,,Demand increase,Anesthesia,Current,,,,2022,limited availability
11119,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.5%, 150 mg/30 mL (5 mg/mL) single dose vial (NDC 43066-023-10)",Revised,9/28/2022,Available:  Recovery Q1 2023,,,Demand increase,Anesthesia,Current,,,,2022,unclear
11120,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"1%, 200 mg/20 mL (10 mg/mL) single dose vial (NDC 43066-027-10)",Revised,9/28/2022,Limited supply. Recovery Q1 2023,,,Demand increase,Anesthesia,Current,,,,2022,limited availability
11121,Rosuvastatin Calcium Tablets,Sandoz,5 mg (NDC 0781-5400-92),New,6/16/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11122,Rosuvastatin Calcium Tablets,Sandoz,10 mg (NDC 0781-5401-92),New,6/16/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11123,Rosuvastatin Calcium Tablets,Sandoz,20 mg (NDC 0781-5402-92),New,6/16/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11124,Rosuvastatin Calcium Tablets,Sandoz,40 mg (NDC 0781-5403-31),New,6/16/2022,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11125,Samarium SM 153 Lexidronam  (Quadramet) Injection,Lantheus Medical Imaging INC,150mCi (NDC 11994-016-01),New,10/28/2021,,,,,Oncology,To be Discontinued,,,,2022,discontinued
11126,Saquinavir Mesylate (Invirase) 200mg Capsules,"Genentech, Inc",200 mg capsules (NDC 0004-0245-15),New,2/6/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
11127,Sclerosol Intrapleural Aerosol,Lymol Medical Corp.,Sclerosol 4 GM (NDC 63256-100-30),Revised,6/14/2022,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
11128,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 24s (NDC 0378-6470-44),Revised,12/10/2019,,,,,Endocrinology/Metabolism;Neurology,Resolved,,,,2022,
11129,"Selenium Sulfide Lotion, 2.5%",Wockhardt,4 fl oz (118 mL) (NDC 60432-528-04),New,6/13/2022,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
11130,Semaglutide (Ozempic) Injection,"Novo Nordisk, Inc.",0.25 mg / 0.5mg (NDC 0169-4132-12),Revised,10/3/2022,Limited availability; Intermittent supply disruption will continue through November 2022,Localized short term stock outages in pharmacies,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2022,limited availability
11131,Semaglutide (Ozempic) Injection,"Novo Nordisk, Inc.",1 mg (NDC 0169-4130-13),Revised,10/3/2022,Currently available,,,,Endocrinology/Metabolism,Current,,,,2022,available
11132,Semaglutide (Ozempic) Injection,"Novo Nordisk, Inc.",2 mg (NDC 0169-4772-12),Revised,10/3/2022,Limited availability; Intermittent supply disruption will continue through October 2022,Localized short term stock outages in pharmacies,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2022,limited availability
11133,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",0.25 mg / 0.5mL (NDC 0169-4525-14),Revised,9/14/2022,"Distribution of this dose temporarily paused, resumption of supply expected towards the end of 2022.",,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,,2022,not available
11134,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",0.5 mg / 0.5mL (NDC 0169-4505-14),Revised,9/14/2022,"Distribution of this dose temporarily paused, resumption of supply expected towards the end of 2022.",,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,,2022,not available
11135,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",1 mg / 0.5mL (NDC 0169-4501-14),Revised,9/14/2022,Currently unavailable; Resumption of supply expected towards the end of 2022.,,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,,2022,not available
11136,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",1.7 mg / 0.75mL (NDC 0169-4517-14),Revised,9/14/2022,Currently available,,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,,2022,available
11137,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",2.4 mg / 0.75mL (NDC 0169-4524-14),Revised,9/14/2022,Currently available,,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,,2022,available
11138,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,"20mg/ml, 60ml  (NDC 16714-601-02)",Revised,4/13/2021,,,Northstar Rx label. Product Distributed by McKesson:  +1 (972) 446-4800,,Psychiatry,Resolved,,,,2022,
11139,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 30 count (NDC 16729-215-10)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11140,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 90 count (NDC 16729-215-15)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11141,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 500 count (NDC 16729-215-16)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11142,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 90 count (NDC 16729-216-15)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11143,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 500 count (NDC 16729-216-16)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11144,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 90 count (NDC 16729-217-15)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11145,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 500 count (NDC 16729-217-16)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11146,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 65862-011-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11147,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 65862-011-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11148,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 65862-011-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11149,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 65862-012-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11150,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 65862-012-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11151,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 65862-012-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11152,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 65862-013-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11153,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 65862-013-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11154,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 65862-013-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11155,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 16714-611-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11156,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 16714-611-04)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11157,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 16714-611-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11158,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 1000 count (NDC 16714-611-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11159,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 16714-612-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11160,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 16714-612-04)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11161,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 16714-612-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11162,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 1000 count (NDC 16714-612-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11163,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 16714-613-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11164,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 16714-613-04)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11165,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 16714-613-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11166,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 1000 count (NDC 16714-613-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11167,Sertraline Hydrochloride Tablets,Viatris,Zoloft 25 mg; Bottle of 30 tablets (NDC 0049-4960-30); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11168,Sertraline Hydrochloride Tablets,Viatris,Zoloft 50 mg; Bottle of 30 tablets (NDC 0049-4900-30); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11169,Sertraline Hydrochloride Tablets,Viatris,Zoloft 50 mg; Blister of 10 tablets (NDC 0049-4900-41); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11170,Sertraline Hydrochloride Tablets,Viatris,Zoloft 100 mg; Bottle of 30 tablets (NDC 0049-4910-30); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11171,Sertraline Hydrochloride Tablets,Viatris,Zoloft 100 mg; Blister of 10 tablets (NDC 0049-4910-41); Pfizer label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11172,Sertraline Hydrochloride Tablets,Viatris,25 mg; Bottle of 30 tablets (NDC 59762-6347-1); Greenstone label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11173,Sertraline Hydrochloride Tablets,Viatris,50 mg; Bottle of 30 tablets (NDC 59762-6443-1); Greenstone label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11174,Sertraline Hydrochloride Tablets,Viatris,100 mg; Bottle of 30 tablets (NDC 59762-5160-1); Greenstone label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11175,Sertraline Hydrochloride Tablets,Viatris,100 mg; Bottle of 100 tablets (NDC 59762-5160-2); Greenstone label,Revised,3/15/2021,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,,2022,
11176,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 30 count (NDC 68180-351-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11177,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 90 count  (NDC 68180-351-09)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11178,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 1000 count (NDC 68180-351-03)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11179,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 30 count (NDC 68180-352-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11180,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 90 count (NDC 68180-352-09)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11181,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 500 count (NDC 68180-352-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11182,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 5000 count (NDC 68180-352-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11183,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 30 count (NDC 68180-353-06)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11184,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 90 count (NDC 68180-353-09)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11185,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 500 count (NDC 68180-353-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11186,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 5000 count (NDC 68180-353-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11187,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 69097-833-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11188,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 69097-833-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11189,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 69097-833-12)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11190,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 69097-834-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11191,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 69097-834-12)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11192,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 69097-835-02)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11193,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 69097-835-12)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11194,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 76282-212-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11195,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 60 count (NDC 76282-212-60)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11196,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 76282-212-90)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11197,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 100 count (NDC 76282-212-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11198,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 180 count (NDC 76282-212-18)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11199,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 76282-212-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11200,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 76282-213-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11201,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 60 count (NDC 76282-213-60)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11202,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 90 count (NDC 76282-213-90)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11203,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 100 count (NDC 76282-213-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11204,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 180 count (NDC 76282-213-18)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11205,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 76282-213-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11206,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 76282-214-30)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11207,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 60 count (NDC 76282-214-60)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11208,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 90 count (NDC 76282-214-90)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11209,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 100 count (NDC 76282-214-01)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11210,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 180 count (NDC 76282-214-18)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11211,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 76282-214-05)",Revised,3/9/2021,,,,,Pediatric;Psychiatry,Resolved,,,,2022,
11212,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/12.5 mL; vial (NDC 0069-0338-01),Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,,,,2022,
11213,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,20 mg; tablets (NDC 0069-4190-68),Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,,,,2022,
11214,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/mL (powder); bottle (NDC 0069-0336-21),Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,,,,2022,
11215,Sildenafil Citrate (REVATIO),Novitium Pharma LLC,"10 mg/mL, (NDC 70954-168-10)",Revised,10/24/2019,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,,,,2022,
11216,Simeprevir Capsules,Janssen Pharmaceuticals,150mg capsules (NDC 59676-225-28),New,5/23/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
11217,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,5 mg (NDC 0093-7152-98),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11218,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,10 mg (NDCs 0093-7153-93 / 0093-7153-56 / 0093-7153-19 / 0093-7153-31 / 0093-7153-10),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11219,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,20 mg (NDCs 0093-7154-93 / 0093-7154-56 / 0093-7154-31 / 0093-7154-19 / 0093-7154-10),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11220,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,40 mg (NDCs 0093-7155-93 / 0093-7155-56 / 0093-7155-31 / 0093-7155-19 / 0093-7155-10),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11221,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,80 mg (NDCs 0093-7156-98 / 0093-7156-93 / 0093-7156-56 / 0093-7156-19 / 0093-7156-10),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11222,Simvastatin (Zocor) Tablets,Merck Sharp & Dohme Corp.,5 mg Tablets bottles of 30 (NDC 0006-0726-31),New,2/6/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11223,Simvastatin Tablets,Merck Sharp & Dohme Corp.,80 mg (NDCs 0006-0543-31 and 0006-0543-54),New,7/27/2021,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11224,Sincalide (Kinevac) Lyophilized Powder for Injection,Bracco Diagnostics,Supplied in packages of 10 single dose vials containing 5 mcg of sincalide per vial (NDC 0270-0556-15),Reverified,7/16/2021,Available,,,Delay in shipping of the drug,Medical Imaging;Other,Current,,,,2022,available
11225,Sodium Acetate Injection,"Hospira, Inc.",100 mEq/50 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 0409-3299-05),Revised,9/12/2022,Next Delivery and Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
11226,Sodium Acetate Injection,"Hospira, Inc.",200 mEq/100 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 0409-3299-06),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
11227,Sodium Acetate Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 0409-7299-73),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
11228,Sodium Acetate Injection,"Fresenius Kabi USA, LLC",32.8% 400 mEq 100mL PBP (NDC 63323-0032-00),Reverified,9/14/2022,Backordered. Next release not available at this time.,,,Manufacturing delay,Total Parenteral Nutrition,Current,,,,2022,not available
11229,Sodium Acetate Injection,Milla Pharmaceuticals,100 mEq/50 mL (2 mEq/mL) (NDC 69784-230-20),Reverified,12/3/2021,Available,,,Other,Total Parenteral Nutrition,Current,,,,2022,available
11230,Sodium Acetate Injection,Milla Pharmaceuticals,200 mEq/100 mL (2 mEq/mL) (NDC 69784-231-20),Reverified,12/3/2021,Available,,,Other,Total Parenteral Nutrition,Current,,,,2022,available
11231,Sodium Bicarbonate Injection,"Hospira, Inc.",2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial (4.2% Concentration) (NDC 0409-5555-02),Revised,9/30/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,limited availability
11232,Sodium Bicarbonate Injection,"Hospira, Inc.",2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial Novaplus®  (4.2% Concentration) (NDC 0409-5555-01),Revised,9/30/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,available
11233,Sodium Bicarbonate Injection,"Hospira, Inc.",44.6 mEq/50 mL (0.9 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe (7.5% concentration) (NDC 0409-4916-14),Revised,9/30/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,available
11234,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) Single Dose Glass Fliptop Vial (8.4% concentration) (NDC 0409-6625-14) (old NDC 0409-6625-02),Revised,9/30/2022,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,limited availability
11235,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) Single Dose Vial Novaplus® (8.4% concentration) (NDC 0409-6625-35),Revised,9/30/2022,Available,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,available
11236,Sodium Bicarbonate Injection,"Hospira, Inc.",Pediatric 10 mEq/10 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-4900-14),Revised,9/30/2022,Limited Supply Available. Next Delivery: November 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,limited availability
11237,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC",10 mEq/10 mL (NDC 2551754-5011-04),New,1/31/2022,Currently on backorder,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
11238,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","5 mEq/10 mL, 4.2%, (NDC 51754-5012-04)",New,1/31/2022,On backorder,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
11239,Sodium Bicarbonate Injection,"Hospira, Inc.",Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02),Revised,9/30/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,discontinued
11240,Sodium Bicarbonate Injection,"Hospira, Inc.",Infant 5 mEq/10 mL (0.5 mEq/mL) ABBOJECT® Glass Syringe (4.2% Concentration) (NDC 0409-5534-14) (old NDC 0409-5534-34),Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
11241,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-6637-14),Revised,9/30/2022,Next Delivery: September 2022; Estimated Recovery: June 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
11242,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc./IMS","Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1)",Reverified,8/12/2022,Backorder due to the increase in demands,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
11243,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05)",Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,available
11244,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL)  (84 mg per mL)(NDC 63323-089-50)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,not available
11245,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","8.4%, 50mL (NDC 51754-5001-05)",Revised,1/31/2022,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,,2022,available
11246,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 50 mL (Legacy Hospira NDC 0409-7984-13)(ICU Medical NDC 0990-7984-13)",Reverified,10/3/2022,Allocated to Contracted Customers Only,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11247,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 50 mL 4-1 (Legacy Hospira NDC 0409-7984-36)(ICU Medical NDC 0990-7984-36)",Reverified,10/3/2022,Available to Contracted Customers Only,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11248,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 100 mL (Legacy Hospira NDC 0409-7984-37)(ICU Medical NDC 0990-7984-37)",Reverified,10/3/2022,Allocated to Contracted Customers Only,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11249,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 100 mL (Legacy Hospira NDC 0409-7984-23)(ICU Medical NDC 0990-7984-23)",Reverified,10/3/2022,Allocated to Contracted Customers Only,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11250,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 25 mL (Legacy Hospira NDC 0409-7984-20)(ICU Medical NDC 0990-7984-20)",Reverified,10/3/2022,Available,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11251,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,1000 mL Excel Bag L8000 (NDC 0264-7800-00),New,12/10/2021,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11252,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,500 mL Excel Bag L8001 (NDC 0264-7800-10),New,12/10/2021,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11253,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,250 mL Excel Bag L8002 (NDC 0264-7800-20),New,12/10/2021,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11254,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,1000 mL E3 Bag E8000 (NDC 0264-7800-09),New,12/10/2021,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11255,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,100 mL PAB Bag S8004-5264 (NDC 0264-1800-32),New,12/10/2021,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11256,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,50 mL PAB Bag S8004-5384 (NDC 0264-1800-31),New,12/10/2021,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11257,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,25 mL PAB Bag S8004-5410 (NDC 0264-1800-36),New,12/10/2021,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11258,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",50 mL ADD-Vantage™ Flexible Container (NDC 00409-7101-66),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11259,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",100 mL ADD-Vantage™ Flexible Container (NDC 00409-7101-67),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11260,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",250 mL ADD-Vantage™ Flexible Container (NDC 00409-7101-02),Revised,9/12/2022,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11261,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 76297-001-21)",New,3/16/2022,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11262,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 76297-001-31)",New,3/16/2022,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11263,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC NDC 76297-001-01)",New,3/16/2022,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11264,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC NDC 76297-001-41)",New,3/16/2022,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11265,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 76297-001-11)",New,3/16/2022,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11266,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (450 mg per 50 mL), (9 mg per mL), Single Dose freeflex bag, 50 mL, (NDC: 63323-623-53)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,not available
11267,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (900 mg per 100 mL), (9 mg per mL), Single Dose freeflex bag, 100 mL, (NDC: 63323-623-61)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,not available
11268,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (2,250 mg per 250 mL), (9 mg per mL), Single dose freeflex bag, 250 mL, (NDC: 63323-623-74)",Revised,9/14/2022,Backordered. Next release August 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,not available
11269,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (4,500 mg per 500 mL), (9 mg per mL), Single dose freeflex bag, 500 mL, (NDC: 63323-623-75)",Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,not available
11270,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (9,000 mg per 1,000 mL), (9 mg per mL), Single dose freeflex bag, 1,000 mL, (NDC: 63323-623-76)",Revised,9/14/2022,Backordered. Next release August 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,not available
11271,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL VIAFLEX Plastic Container, Quad Pack; Product Code 2B1302; (NDC 0338-0049-18)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11272,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL VIAFLEX Plastic Container, Product Code 2B1306 (NDC 0338-0049-41)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11273,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL VIAFLEX Plastic Container, Product Code 2B1307 (NDC 0338-0049-48)",Reverified,9/28/2022,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11274,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL VIAFLEX Plastic Container, Multi Pack, Product Code 2B1308 (NDC 0338-0049-31)",Reverified,9/28/2022,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11275,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL VIAFLEX Plastic Container, Product Code 2B1322Q (NDC 0338-0049-02)",Reverified,9/28/2022,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11276,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL VIAFLEX Plastic Container, Product Code 2B1323Q (NDC 0338-0049-03)",Reverified,9/28/2022,Limited supply; Recovery August,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11277,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL VIAFLEX Plastic Container, Product Code 2B1324X (NDC 0338-0049-04)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11278,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"25 mL VIAFLEX Plastic Container, Quad Pack, Product Code 2B1300 (NDC 0338-0049-10)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11279,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL VIAFLEX Plastic Container, Quad Pack, Product Code 2B1301 (NDC 0338-0049-11)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11280,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL VIAFLEX Plastic Container, Multi Pack, Product Code 2B1309 (NDC 0338-0049-38)",Reverified,9/28/2022,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11281,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL VIAFLO Plastic Container, Product Code UE1322D (NDC 0338-9543-02)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11282,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL VIAFLO Plastic Container, Product Code UE1324D (NDC 0338-9543-06)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11283,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL VIAFLO Plastic Container, Product Code UE1323D (NDC 0338-9543-04)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11284,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL MINI-BAG Plus Container, Quad Pack, Product Code 2B0042 (NDC 0338-0553-11)",Reverified,9/28/2022,Available,,,Manufacturing delay,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11285,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL MINI-BAG Plus Container, Single Pack, Product Code EZPB0042 (NDC 0338-9151-30)",Reverified,9/28/2022,Supply available on allocation,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11286,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL MINI-BAG Plus Container, Single Pack, Product Code EZPB0043 (NDC 0338-9159-30)",Reverified,9/28/2022,"Limited Supply on Allocation, Recovery 2023",,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11287,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL MINI-BAG Plus Container, Quad Pack, Product Code 2B 0043 (NDC 0338-0553-18)",Reverified,9/28/2022,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11288,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL VIAFLO Plastic Container, Product Code UE1322D (NDC 0338-9543-02)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11289,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL VIAFLO Plastic Container, Product Code UE1323D (NDC 0338-9543-04)",Reverified,9/28/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11290,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL VIAFLO Plastic Container, Product Code UE1324D (NDC 0338-9543-06)",Reverified,9/28/2022,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11291,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 79672-613-01)",New,3/16/2022,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11292,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 79672-613-02)",New,3/16/2022,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11293,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 79672-613-03)",New,3/16/2022,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11294,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC 79672-613-04)",New,3/16/2022,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11295,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC 79672-613-05)",New,3/16/2022,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11296,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 500 mL (Legacy Hospira (NDC 0409-7983-03)(ICU Medical NDC 0990-7983-03)",Reverified,10/3/2022,Available,,,,Gastroenterology;Other;Pediatric,Current,,,,2022,available
11297,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 1000 mL (Legacy Hospira NDC 0409-7983-09)(ICU Medical NDC 0990-7983-09)",Reverified,10/3/2022,Allocation,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,,2022,limited availability
11298,Sodium Chloride 14.6% Injection,"Fresenius Kabi USA, LLC","50 mEq per 20 mL (2.5 mEq per mL), Single dose plastic flip top vial, (NDC 63323-090-20)",New,4/5/2022,Backordered. Next release June 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
11299,Sodium Chloride 14.6% Injection,"Fresenius Kabi USA, LLC","100 mEq per 40 mL (2.5 mEq per mL), Single dose plastic flip top vial, (NDC 63323-090-40)",New,4/5/2022,Backordered. Next release June 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
11300,Sodium Chloride 14.6% Injection,"Hospira, Inc.",14.6% 100 mEq/40 mL (2.5 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-6660-75),Reverified,9/12/2022,Next Delivery and Estimated Recovery: March 2023,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,not available
11301,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",100 mL vials (NDC 63323-0095-61),Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2022,not available
11302,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",200 mL vials (NDC 63323-0088-63),Revised,9/14/2022,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2022,not available
11303,Sodium Chloride 23.4% Injection,"Hospira, Inc.",400 mEq/100 mL (4 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-1141-02),Revised,9/12/2022,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2022,not available
11304,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",30 mL vials (NDC 63323-0093-30),Revised,9/14/2022,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,,2022,not available
11305,"Sodium Chloride Injection, 0.9% Vials and Syringes","Medefil, Inc.","Sodium Chloride Injection, USP, 0.9%, in a plastic syringe (10 mL) (NDC 64253-202-30)",Revised,10/3/2022,Available,,,Available,Other,Current,,,,2022,available
11306,"Sodium Chloride Injection, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose plastic vial, 0.9%, (18 mg per 2 mL)(9 mg per mL) (NDC 63323-186-02)",Revised,10/3/2022,Backordered. Next release Q4-2022.,,,Increase in Demand,Other,Current,,,,2022,not available
11307,"Sodium Chloride Injection, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (90 mg per 10 mL)(9 mg per mL) (NDC 63323-186-10)",Revised,10/3/2022,Backordered. Next release October 2022.,Check wholesalers for inventory,,Demand increase,Other,Current,,,,2022,not available
11308,"Sodium Chloride Injection, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (180 mg per 20 mL)(9 mg per mL) (NDC 63323-186-20)",Revised,10/3/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase,Other,Current,,,,2022,not available
11309,"Sodium Chloride Injection, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose tear top vial, 0.9%, (900 mg per 100 mL)(9 mg per mL) (NDC 63323-186-00)",Revised,10/3/2022,Backordered.  Next release date not available at this time.,,,Increase in Demand,Other,Current,,,,2022,not available
11310,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose Plastic Fliptop Vial (NDC 00409-4888-10),Revised,10/3/2022,Available,,,Demand increase for the drug,Other,Current,,,,2022,available
11311,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose LifeShield Plastic Fliptop Vial (NDC 00409-4888-12),Revised,10/3/2022,Next Delivery: October 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Other,Current,,,,2022,not available
11312,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-20),Revised,10/3/2022,Available,,,Other,Other,Current,,,,2022,available
11313,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-50),Revised,10/3/2022,Next Delivery: October 2022; Estimated Recovery: August 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Other,Current,,,,2022,not available
11314,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-32),Revised,10/3/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2022,discontinued
11315,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-33),Revised,10/3/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2022,discontinued
11316,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-35),Revised,10/3/2022,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2022,discontinued
11317,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.9%, 2 mL vial (NDC 0641-0497-25)",Revised,10/3/2022,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Other,Current,,,,2022,not available
11318,"Sodium Chloride Injection, 0.9% Vials and Syringes","Spectra Medical Devices, Inc.",0.9% 10mL Ampule (NDC 65282-1510-1),Revised,10/3/2022,"Currently available, in stock, Production is ongoing",,,Other,Other,Current,,,,2022,available
11319,"Sodium Chloride Injection, 0.9% Vials and Syringes","Spectra Medical Devices, Inc.",0.9% 5mL Ampule (NDC 65282-1505-1),Revised,10/3/2022,"Currently available, in stock, Production is ongoing",,,Other,Other,Current,,,,2022,available
11320,"Sodium Chloride Injection, 0.9% Vials and Syringes",Guerbet LLC,125 mL PFS (NDC 0019-1188-81),Revised,10/3/2022,"On backorder. Next batch will be available in April 2022, and the current demand can be fulfilled by May 2022.",,,Other,Other,Current,,,,2022,not available
11321,"Sodium Chloride Injection, 0.9% Vials and Syringes",Guerbet LLC,125 mL PFS RFID Tag (NDC 0019-1188-27),Revised,10/3/2022,Available; Next batch will be available May 2022.,,,Other,Other,Current,,,,2022,limited availability
11322,Sodium Phosphates Injection,"Hospira, Inc.","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL, vial (NDC 0409-7391-72)",Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,limited availability
11323,Sodium Phosphates Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol/5 mL, Sodium 20 mEq/5 mL, vial (NDC 63323-170-05)",Revised,9/14/2022,Available,Check wholesaler inventory,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,available
11324,Sodium Phosphates Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL, vial (NDC 63323-881-16)",Revised,9/14/2022,Available,Check wholesaler inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,,2022,available
11325,Somatropin Recombinant (Humatrope) Injection,Eli Lilly and Co.,5 mg kit (NDC 0002-7335-11) contains 5 mg/mL in 1 vial (NDC 0002-7349-01) of Humatrope and 5 mL in 1 vial (NDC 0002-7336-01) of Sterile Diluent,New,7/7/2020,,,,,Hematology,To be Discontinued,,,,2022,discontinued
11326,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 100 (NDC 0228-2803-11)",New,5/22/2018,,,,,Renal,To be Discontinued,,,,2022,discontinued
11327,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 500 (NDC 0228-2803-50)",New,5/22/2018,,,,,Renal,To be Discontinued,,,,2022,discontinued
11328,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 100 (NDC 0228-2672-11)",New,5/22/2018,,,,,Renal,To be Discontinued,,,,2022,discontinued
11329,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 500 (NDC 0228-2672-50)",New,5/22/2018,,,,,Renal,To be Discontinued,,,,2022,discontinued
11330,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 100 (NDC 0228-2673-11)",New,5/22/2018,,,,,Renal,To be Discontinued,,,,2022,discontinued
11331,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 500 (NDC 0228-2673-50)",New,5/22/2018,,,,,Renal,To be Discontinued,,,,2022,discontinued
11332,Stavudine Capsules,Mylan Pharmaceuticals Inc.,20mg capsules (NDC 0378-5041-91),New,4/30/2018,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
11333,Sterile Water for Injection,"Medefil, Inc.",10 mL in plastic syringe (NDC 64253-020-30),Revised,3/1/2022,Available,,,Available; Demand Increase for the drug,Other,Current,,,,2022,available
11334,Sterile Water for Injection,"Fresenius Kabi USA, LLC","Single Dose free flex bag, 1,000 mL fill, (NDC 63323-178-76)",Revised,9/14/2022,Backordered. Next release October 2022.,,,,Other,Current,,,,2022,not available
11335,Sterile Water for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mL vial (NDC 0641-6147-10),Revised,6/3/2022,This presentation is temporarily on backorder.,,,Demand increase for the drug,Other,Current,,,,2022,not available
11336,Sterile Water for Injection,"Hospira, Inc.",10 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-10),Revised,9/12/2022,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: May 2023,,,Demand increase for the drug,Other,Current,,,,2022,limited availability
11337,Sterile Water for Injection,"Hospira, Inc.",20 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-20),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Other,Current,,,,2022,not available
11338,Sterile Water for Injection,"Hospira, Inc.",50 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-50),Revised,9/12/2022,Next Delivery: September 2022; Estimated Recovery: October 2023,,,Demand increase for the drug,Other,Current,,,,2022,not available
11339,Sterile Water for Injection,"Hospira, Inc.",100 mL Single Dose Glass Fliptop Vial (NDC 00409-4887-99),Revised,9/12/2022,Next Delivery: February 2023; Estimated Recovery: March 2023,,,Demand increase for the drug,Other,Current,,,,2022,not available
11340,Sterile Water for Injection,"Fresenius Kabi USA, LLC",10 mL Vial (NDC 63323-0185-10),Revised,9/14/2022,Available,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,,2022,available
11341,Sterile Water for Injection,"Fresenius Kabi USA, LLC",20 mL Vial (NDC 63323-0185-20),Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,,2022,not available
11342,Sterile Water for Injection,"Fresenius Kabi USA, LLC",50 mL Vial (NDC 63323-0185-50),Revised,9/14/2022,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,,2022,not available
11343,Sterile Water for Injection,Nephron Pharmaceuticals Corporation,5 mL Plastic Vials (NDC 0487-6105-01),New,2/22/2022,Available,,,Other,Other,Current,,,,2022,available
11344,Sterile Water for Injection,American Regent/Luitpold,10mL Vial (NDC 0517-3010-25),New,5/26/2022,"Backordered, Next release August 2022",,,Demand increase for the drug,Other,Current,,,,2022,not available
11345,Sterile Water for Injection,American Regent/Luitpold,20mL Vial (NDC 0517-3020-25),New,5/26/2022,Backordered Next release July 2022,,,Demand increase for the drug,Other,Current,,,,2022,not available
11346,Streptozocin (Zanosar) Sterile Powder,Teva Pharmaceuticals,Streptozocin (Zanosar®) Sterile Powder: (NDC 0703-4636-01) (1 gram Single Dose Vial),Reverified,10/5/2022,"Backorder, Recovery expected TBD",,,Other,Oncology,Current,,,,2022,not available
11347,Streptozocin (Zanosar) Sterile Powder,Teva,NDC 0703-4636-01 (1 gram Single Dose Vial),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
11348,Succimer (Chemet) Capsules,Recordati Rare Diseases,100 mg capsules (NDC 55292-201-11),Revised,9/14/2021,,,Available,,Hematology,Resolved,,,,2022,
11349,Sufentanil Citrate Injection,"Hospira, Inc.",50 mcg/mL Single Dose Glass Fliptop Vial (NDC 0409-3382-21),Reverified,9/12/2022,Next Delivery and Estimated Recovery: March 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
11350,Sufentanil Citrate Injection,Akorn Pharmaceuticals,"50 mcg/mL (NDC 17478-050-01), 1mL vial, 10 pack",Revised,5/4/2022,On backorder,,,Availability of API,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
11351,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",Information pending,New,5/3/2022,Information pending,,,Information pending,Analgesia/Addiction;Pediatric,Current,,,,2022,unclear
11352,Sufentanil Citrate Injection,Akorn Pharmaceuticals,"50 mcg/mL (NDC 17478-050-02), 2mL vial, 10 pack",New,5/4/2022,On backorder,,,Availability of API,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
11353,Sufentanil Citrate Injection,Akorn Pharmaceuticals,"50 mcg/mL (NDC 17478-050-05), 5mL vial, 10 pack",New,5/4/2022,On backorder,,,Availability of API,Analgesia/Addiction;Pediatric,Current,,,,2022,not available
11354,Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment,Abbvie,Blephamide (prednisolone acetate; sulfacetamide sodium) (NDC 11980-022-05) - 5 mL in 10 mL bottle,New,6/9/2022,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
11355,Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment,Abbvie,Blephamide S.O.P. (sulfacetamide sodium 10% and prednisolone acetate 0.2%) 1 TUBE in 1 CARTON 3.5 g in 1 TUBE (NDC 0023-0313-04),New,9/13/2021,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
11356,Sulfacetamide Sodium Solution,Abbvie,Bleph-10® (sulfacetamide sodium) (NDC 11980-011-05) - 5 mL in 10 mL bottle,New,6/9/2022,,,,,Ophthalmology,To be Discontinued,,,,2022,discontinued
11357,Sulfasalazine Tablets,Chartwell Pharma,500 mg tablets; Bottle of 100 (NDC 23155-019-01),Revised,9/7/2022,"Product Available. Distributed by Chartwell. For inquiries, call Customer Service number 845-268-5000  Ext: 510.",,,Other,Gastroenterology,Current,,,,2022,available
11358,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 100 (NDC 0013-0101-10),Reverified,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
11359,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 300 (NDC 0013-0101-20/0013-0101-30),Reverified,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
11360,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 100 (NDC 0013-0102-50),Reverified,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
11361,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 300 (NDC 0013-0102-20/0013-0102-60),Reverified,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
11362,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 100 (NDC 59762-0104-1/59762-0104-5),Reverified,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
11363,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 300 (NDC 59762-0104-6),Reverified,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
11364,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 100 (NDC 59762-5000-1/59762-5000-5),Reverified,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
11365,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 300 (NDC 59762-5000-6),Reverified,9/12/2022,Available,,,Other,Gastroenterology,Current,,,,2022,available
11366,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 100 Count (NDC 00591-0796-01),Revised,10/5/2022,Allocation,,,,Gastroenterology,Current,,,,2022,limited availability
11367,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 1000 Count (NDC 00591-0796-10),Revised,10/5/2022,Allocation,,,,Gastroenterology,Current,,,,2022,limited availability
11368,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 500 Count (NDC 00591-0796-05),Revised,10/5/2022,Allocation,,,,Gastroenterology,Current,,,,2022,limited availability
11369,Sumatriptan (Sumavel DosePro) Injection,"Endo Pharmaceuticals, Inc.",Sumavel DosePro (sumatriptan injection) 6mg/0.5mL (NDC 63481-367-06),New,2/27/2018,,,,,Neurology,To be Discontinued,,,,2022,discontinued
11370,Sumatriptan Succinate Injection,Teva Pharmaceuticals,6 mg/0.5 mL  (NDC 0703-7351-01),New,12/5/2019,,,,,Neurology,To be Discontinued,,,,2022,discontinued
11371,Synercid Injection,Pfizer,500 mg; 10 mL Single Dose Glass Vial  (NDC 61570-260-10),New,8/30/2022,,Discontinuation of the manufacture of the drug.,,,Antibiotic,To be Discontinued,8/30/2022,8/30/2022,,2022,discontinued
11372,Tacrolimus Capsules,Ascend Laboratories LLC.,0.5 mg 100’s count (NDC 67877-278-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11373,Tacrolimus Capsules,Ascend Laboratories LLC.,1 mg 100’s count (NDC 67877-279-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11374,Tacrolimus Capsules,Ascend Laboratories LLC.,5 mg 100’s count (NDC 67877-280-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11375,Tacrolimus Capsules,Glenmark Pharmaceuticals,0.5 mg 100 count bottles (NDC 68462-685-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11376,Tacrolimus Capsules,Glenmark Pharmaceuticals,1 mg 100 count bottles (NDC 68462-686-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11377,Tacrolimus Capsules,Glenmark Pharmaceuticals,5 mg 100 count bottles (NDC 68462-687-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11378,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11379,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11380,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11381,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","0.5 mg, 100s (NDC 0378-2045-01)",Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11382,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","1 mg, 100s (NDC 0378-2046-01)",Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11383,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100s (NDC 0378-2047-01)",Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11384,Tacrolimus Capsules,Accord Healthcare Inc.,0.5 mg 100 count (NDC 1672904101),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11385,Tacrolimus Capsules,Accord Healthcare Inc.,1 mg 100 count (NDC 1672904201),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11386,Tacrolimus Capsules,Accord Healthcare Inc.,5 mg 100 count (NDC 1672904301),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11387,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 30 count (NDC 68992-3075-3),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11388,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 100 count (NDC 68992-3075-1),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11389,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 30 count (NDC 68992-3010-3),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11390,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 100 count (NDC 68992-3010-1),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11391,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 30 count (NDC 68992-3040-3),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11392,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 100 count (NDC 68992-3040-1),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11393,Tacrolimus Capsules,Strides Pharma Inc.,1 mg 100 count bottles (NDC 64338-721-06),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11394,Tacrolimus Capsules,Strides Pharma Inc.,0.5 mg 100 count bottles (NDC 64380-720-06),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11395,Tacrolimus Capsules,Strides Pharma Inc.,5 mg 100 count bottles (NDC 64380-722-06),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11396,Tacrolimus Capsules,Sandoz,0.5 mg 100 count bottle (NDC 0781-2102-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11397,Tacrolimus Capsules,Sandoz,1 mg 100 count bottle (NDC 0781-2103-04),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11398,Tacrolimus Capsules,Sandoz,5 mg 100 count bottle (NDC 0781-2104-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11399,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 0.5 mg 100 count bottle (NDC 0469-0607-73),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11400,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 5 mg 100 count bottle (NDC 0469-0657-73),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11401,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 1 mg 100 count bottle (NDC 0469-0617-73),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11402,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 0.5 mg 30 count bottle (NDC 0469-0647-73),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11403,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 1 mg 30 count bottle (NDC 0469-0677-73),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11404,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 5 mg 30 count bottle (NDC 0469-0687-73),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11405,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 0.2 mg unit dose packets (NDC 0469-1230-50),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11406,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 1 mg unit dose packets (NDC 0469-1330-50),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11407,Tacrolimus Capsules,"BPI Labs, LLC",1 mg 100 count bottle (NDC 54288-135-01),Revised,5/2/2022,,,Available,,Transplant,Resolved,,,,2022,
11408,"Talwin (Pentazocine Lactate Injection, USP, CIV)","Hospira, Inc.",30 mg/mL; 1 mL glass ampul (NDC 00409-1941-01),New,4/16/2018,,,,,Analgesia/Addiction,To be Discontinued,,,,2022,discontinued
11409,Technetium Tc 99m Sulfur Colloid Injection,Sun Pharmaceutical Industries Inc.,5 Vial Kit (NDC 45567-0030-1),Revised,4/29/2022,,,Available,,Medical Imaging,Resolved,,,,2022,
11410,Technetium TC-99M Mebrofenin Injection,Sun Pharmaceutical Industries Inc.,5 vial kit (NDC 45567-0455-1),Revised,6/28/2022,On backorder.,,,Other,Medical Imaging,Current,,,,2022,not available
11411,Technetium TC-99M Mebrofenin Injection,Sun Pharmaceutical Industries Inc.,30 vial kit (NDC 45567-0455-2),Revised,6/28/2022,On backorder.,,,Other,Medical Imaging,Current,,,,2022,not available
11412,Technetium TC-99M Mebrofenin Injection,Bracco Diagnostics,"CHOLETEC- mebrofenin injection, powder, lyophilized, for solution; Kit for the Preparation of Technetium Tc 99m Mebrofenin, supplied as 10 sterile multidose reaction vials per kit. (NDC 0270-0083-20)",Reverified,9/13/2022,Available,,,Delay in shipping of the drug,Medical Imaging,Current,,,,2022,available
11413,Technetium Tc99m Succimer Injection (DMSA),Theragnostics Inc.,ROTOP DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection). One vial contains 1.74 mg powder with the active substance: 1.0 mg succimer.  Five vials included in a carton (NDC 71647-001-01),Revised,1/7/2021,Available,,,Other,Medical Imaging,Current,,,,2022,available
11414,Telmisartan and Amlodipine (Twynsta) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.","Telmisartan and Amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister (NDC 0597-0127-37)",New,3/6/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11415,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",5mg capsules (NDCs 62559-920-51 and 62559-920-14),New,4/12/2022,,,,,Oncology,To be Discontinued,,,,2022,discontinued
11416,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",20mg capsules (NDCs 62559-921-51 and 62559-921-14),New,4/12/2022,,,,,Oncology,To be Discontinued,,,,2022,discontinued
11417,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",100mg capsules (NDCs 62559-922-51 and 62559-922-14),New,4/12/2022,,,,,Oncology,To be Discontinued,,,,2022,discontinued
11418,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",140mg capsules (NDCs 62559-923-51 and 62559-923-14),New,4/12/2022,,,,,Oncology,To be Discontinued,,,,2022,discontinued
11419,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",180mg capsules (NDCs 62559-924-51 and 62559-924-14),New,4/12/2022,,,,,Oncology,To be Discontinued,,,,2022,discontinued
11420,Teprotumumab-trbw,Horizon Therapeutics,500 mg lyophilized powder (NDC 75987-130-15),Revised,3/31/2021,Product available.,,,Other,Ophthalmology,Current,,,,2022,available
11421,Testosterone Transdermal Gel,"Endo Pharmaceuticals, Inc.",25mg/2.5g  (NDC 49884-418-72),New,8/29/2022,,,,,Urology,To be Discontinued,8/29/2022,8/29/2022,,2022,discontinued
11422,Testosterone Transdermal Gel,"Endo Pharmaceuticals, Inc.",50mg/5g  (NDC 49884-510-72),New,8/29/2022,,,,,Urology,To be Discontinued,8/29/2022,8/29/2022,,2022,discontinued
11423,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","1 mg, 100 count bottle (NDC 0378-1001-01)",Revised,7/1/2022,Limited Availability (until 6.30.22),,,Other,Psychiatry,Current,,,,2022,limited availability
11424,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg, 100 count bottle (NDC 0378-2002-01)",Revised,7/1/2022,Limited Availability (until 6.30.22),,,Other,Psychiatry,Current,,,,2022,limited availability
11425,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100 count bottle (NDC 0378-3005-01)",Revised,7/1/2022,Limited Availability (until 6.30.22),,,Other,Psychiatry,Current,,,,2022,limited availability
11426,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","10 mg, 100 count bottle (NDC 0378-5010-01)",Revised,7/1/2022,Limited Availability (until 6.30.22),,,Other,Psychiatry,Current,,,,2022,limited availability
11427,Thiothixene Capsules,Novitium Pharma LLC,"1 mg, 100 count bottle (NDC 70954-014-10)",Reverified,3/16/2022,Available,,,,Psychiatry,Current,,,,2022,available
11428,Thiothixene Capsules,Novitium Pharma LLC,"2 mg, 100 count bottle (NDC 70954-015-10)",Reverified,3/16/2022,Available,,,,Psychiatry,Current,,,,2022,available
11429,Thiothixene Capsules,Novitium Pharma LLC,"5 mg, 100 count bottle (NDC 70954-016-10)",Reverified,3/16/2022,Available,,,,Psychiatry,Current,,,,2022,available
11430,Thiothixene Capsules,Novitium Pharma LLC,"10 mg, 100 count bottle (NDC 70954-017-10)",Reverified,3/16/2022,Available,,,,Psychiatry,Current,,,,2022,available
11431,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 2.5mL bottle (NDC 60505-1005-04),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11432,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 5mL bottle (NDC 60505-1005-01),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11433,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 7.5 mL bottle (NDC 24208-004-01)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11434,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 10 ml bottle (NDC 24208-004-03)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11435,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%,  2.5ml (NDC 68682-045-25)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11436,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%, 5ml (NDC 68682-045-50)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11437,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 5mL (NDC 64980-513-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11438,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25%  10 mL (NDC 64980-513-01),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11439,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 15 mL (NDC 64980-513-15),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11440,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 5mL (NDC 64980-514-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11441,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 10mL (NDC 64980-514-01),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11442,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 15mL (NDC 64980-514-15),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11443,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x5ml BTL (NDC 60758-802-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11444,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x10ml BTL (NDC 60758-802-10),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11445,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x5ml BTL (NDC 60758-801-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11446,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x10ml BTL (NDC 60758-801-10),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11447,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5% 5mg/mL, 5mL, 1 Bottle/EA (NDC 17478-0288-10)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11448,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 10mL, 1 Bottle / EA (NDC 17478-0288-11)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11449,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 15mL, 1 Bottle / EA (NDC 17478-0288-12)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11450,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 5 mL bottle, (NDC 61314-227-05)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11451,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 10 mL bottle (NDC 61314-227-10)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11452,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 15 mL bottle (NDC 61314-227-15)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11453,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 5 mL bottle, ()NDC 61314-226-05",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11454,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 10 mL bottle, (NDC 61314-226-10)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11455,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 15 mL bottle, (NDC 61314-226-15)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11456,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.25%, 5 mL in a 7.5 mL bottle (NDC 24208-812-05)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11457,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.5%, 5 mL in a 7.5 mL bottle (NDC 24208-813-05)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11458,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.5%, 10 mL in a 10 mL bottle (NDC 24208-813-10)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11459,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.",Authorized Generic Timolol Maleate Ophthalmic Solution 0.5% 5 mL in a 7.5 mL bottle (NDC 68682-813-05),Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11460,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® in OCUDOSE® (timolol maleate) Sterile Ophthalmic Solution, 0.25% 0.3 mL in 60 individual doses (NDC 0187-1498-25)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11461,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® in OCUDOSE®  (timolol maleate) Sterile Ophthalmic Solution, 0.5% 0.3 mL in 60 individual doses (NDC 0187-1496-05)",Revised,4/16/2021,,,,,Ophthalmology,Resolved,,,,2022,
11462,Tipranavir Oral Solution,"Boehringer Ingelheim Pharmaceuticals, Inc.",100mg/mL (NDC 0597-0002-01),New,6/29/2021,,,,,Antiviral,To be Discontinued,,,,2022,discontinued
11463,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",2 mg  (NDC 49884-611-53),New,6/30/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
11464,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",4 mg (NDC 49884-719-53),New,6/30/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
11465,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",6 mg (NDC 49884-765-53),New,6/30/2021,,,,,Neurology,To be Discontinued,,,,2022,discontinued
11466,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,4 mg (NDC 0378-0724-19),New,11/21/2019,,,,,Neurology,To be Discontinued,,,,2022,discontinued
11467,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0722-19),New,11/21/2019,,,,,Neurology,To be Discontinued,,,,2022,discontinued
11468,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-51)",Revised,4/12/2021,,,,,Anti-Infective;Pediatric,Resolved,,,,2022,
11469,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-55), Novaplus",Revised,4/12/2021,,,,,Anti-Infective;Pediatric,Resolved,,,,2022,
11470,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, bottle (NDC 39822-0412-1)",Revised,4/12/2021,,,,,Anti-Infective;Pediatric,Resolved,,,,2022,
11471,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, pack of 6 bottles (NDC 39822-0412-6)",Revised,4/12/2021,,,,,Anti-Infective;Pediatric,Resolved,,,,2022,
11472,Tocilizumab Injection,"Genentech, Inc","200mg/10mL, (NDC 50242-0136-01)",Revised,3/30/2022,,,Available,,Rheumatology,Resolved,,,,2022,
11473,Tocilizumab Injection,"Genentech, Inc","400mg/20mL, (NDC 50242-0137-01)",Revised,3/30/2022,,,Available,,Rheumatology,Resolved,,,,2022,
11474,Tocilizumab Injection,"Genentech, Inc","80mg/4mL, (NDC 50242-0135-01)",Revised,3/30/2022,,,Available,,Rheumatology,Resolved,,,,2022,
11475,Topotecan Injection,Teva,NDC 0703-4714-01 (4 mg/4 mL (1 mg/mL) Single-Dose Vial),New,8/11/2022,,Product is available with an expected supply duration until AUG 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
11476,Trandolapril Tablets,Teva Pharmaceuticals,"4 mg tablets, 100 count (NDC 16252-543-90)",New,4/18/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11477,Trandolapril Tablets,Teva Pharmaceuticals,"2 mg tablets, 100 count (NDC 16252-542-90)",New,4/18/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11478,Trandolapril Tablets,Teva Pharmaceuticals,"1 mg tablets, 100 count (NDC 16252-541-30)",New,4/18/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11479,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 30 Tablets per Bottle,  (NDC 60505-3638-3)",New,12/4/2019,,,,,Hematology,To be Discontinued,,,,2022,discontinued
11480,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 100 Tablets per Bottle,  (NDC 60505-3638-1)",New,12/4/2019,,,,,Hematology,To be Discontinued,,,,2022,discontinued
11481,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1 mg/1g (NDC 40085-029-80),New,3/20/2018,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
11482,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1mg/1g (NDC 40085-029-16),New,3/20/2018,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
11483,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,0.25mg/1g (NDC 40085-028-80),New,3/20/2018,,,,,Dermatology,To be Discontinued,,,,2022,discontinued
11484,Triamcinolone Acetonide Injectable Suspension,Novartis,"40mg/mL vial, 1mL in 1 vial (NDC 0065-0543-01)",Reverified,9/30/2022,Availability through wholesalers: not available. Estimated duration of supply shortage: 3-18 months.,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2022,not available
11485,Triamcinolone Hexacetonide Injectable suspension,Medexus,"Hexatrione 2% (triamcinolone hexacetonide) Injectable suspension, 20mg/ml, 2-mL glass ampoule (NDC 59137-570-01)",Revised,12/8/2021,Available,,,,Rheumatology,Current,,,,2022,available
11486,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 0781-5068-01)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11487,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 0781-5068-05)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11488,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 0781-5067-01)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11489,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 0781-5067-05)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11490,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 68001-0216-00)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11491,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 68001-0216-03)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11492,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 68001-0215-00)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11493,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 68001-0215-03)",New,2/23/2018,,,,,Cardiovascular,To be Discontinued,,,,2022,discontinued
11494,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 30 (NDC 43386-660-03)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,,2022,not available
11495,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 100 (NDC 43386-660-24)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,,2022,not available
11496,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 500 (NDC 43386-660-26)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,,2022,not available
11497,Trimethobenzamide Hydrochloride Capsules,Pfizer Pharmaceuticals,"300 mg, bottle of 100 (NDC 61570-079-01)",Reverified,9/12/2022,Discontinued,,,Discontinuation of the manufacture of the drug.,Gastroenterology,Current,,,,2022,discontinued
11498,Trimethobenzamide Hydrochloride Capsules,Sun Pharmaceutical Industries Inc.,"300 mg, bottle of 100 (NDC 53489-376-01)",Revised,10/26/2021,Unavailable,,,Shortage of an active ingredient.,Gastroenterology,Current,,,,2022,not available
11499,Trimethobenzamide Hydrochloride Capsules,Sun Pharmaceutical Industries Inc.,"300 mg, bottle of 100 (NDC 53489-376-01)",New,10/26/2021,,,,,Gastroenterology,To be Discontinued,,,,2022,discontinued
11500,Umbrasilib Tosylate Tablets,"TG Therapeutics, Inc.","Umbralisib Tosylate (Ukoniq) Tablets, 200 mg (free base), 120 Tablets per bottle (NDC 73150-200-12)",Revised,5/31/2022,,,,,Oncology,To be Discontinued,,,,2022,discontinued
11501,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9785-10)",Reverified,8/26/2022,Currently on backorder.,,,Demand increase for the drug,Neurology,Current,,,,2022,not available
11502,Valproate Sodium Injection,"Fresenius Kabi USA, LLC",500 mg per 5 mL (100 mg per mL) (NDC 63323-494-05),Reverified,8/13/2022,Backordered. Next release Q4 - 2022.,,,Manufacturing delays,Neurology,Current,,,,2022,not available
11503,Valproic Acid Oral Solution,Wockhardt,"250mg/5mL, 473mL (NDC 60432-0621-16)",New,4/11/2022,,,,,Neurology,To be Discontinued,,,,2022,discontinued
11504,Vancomycin Hydrochloride for Injection,"Mylan Institutional, a Viatris company",Vancomycin Hydrochloride Injection (Lyophilisate in Single Dose Vials) [250 mg] (NDC 67457-822-99),New,7/26/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
11505,Vandetanib Tablets,Sanofi,Vandetanib (Caprelsa) 100mg Tablets (NDC 58468-7820-3),Revised,9/9/2022,Available,,,Shortage of an active ingredient,Oncology,Current,,,,2022,available
11506,Vandetanib Tablets,Sanofi,Vandetanib (Caprelsa) 300mg Tablets (NDC 58468-7840-3),Revised,9/9/2022,Out of stock.,,,Shortage of an active ingredient,Oncology,Current,,,,2022,not available
11507,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,Starter Pack (NDC 49884-944-99),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11508,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 0.5 mg; bottle of 56 tablets (NDC 60505-4765-5),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11509,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 1 mg; bottle of 56 tablets (NDC 60505-4766-6),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11510,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 0.5 mg and 1 mg; Starter Blister Pack of 53 tablets; (NDC 60505-4767-0),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11511,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 1 mg: Continuation Blister Pack of 56 tablets (NDC 60505-4766-5),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11512,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,"0.5 mg, 56 ‘s count bottle pack (NDC 49884-155-76)",Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11513,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,"1 mg, 56 ‘s count bottle pack (NDC 49884-156-76)",Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11514,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix 0.5 mg; bottle of 56 (NDC 0069-0468-56),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11515,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix 1 mg; bottle of 56 (NDC 0069-0469-56),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11516,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix Starting wallet; 0.5 mg 1x11 1 mg FCT 3x14 BLS WL US (NDC 0069-0471-03),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11517,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix Continuing wallet; 1 mg FCT 4x14 BLS WL US (NDC 0069-0469-03),Revised,5/26/2022,,,,,Analgesia/Addiction,Resolved,,,,2022,
11518,Vecuronium Bromide for Injection,Teva Pharmaceuticals,NDC 0703-2914-03 (10 mg (1 mg/ml when reconstituted to 10 mL) 10 x 10 mL Vials),Revised,7/20/2022,,Product is temporarily unavailable and no future production expected for an extended period.,,,Anesthesia,To be Discontinued,7/20/2022,7/20/2022,,2022,discontinued
11519,Vecuronium Bromide for Injection,"Hospira, Inc.",10 mg Single Dose Glass Fliptop Vial (NDC 00409-1632-01),Reverified,9/12/2022,Available,,,Other,Anesthesia,Current,,,,2022,available
11520,Vecuronium Bromide for Injection,"Hospira, Inc.",20 mg Single Dose Glass Fliptop Vial (NDC 00409-1634-01),Revised,8/30/2022,,,,,Anesthesia,To be Discontinued,8/30/2022,8/30/2022,,2022,discontinued
11521,Vecuronium Bromide for Injection,"Mylan Institutional, a Viatris company",Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [10 mg](NDC 67457-438-10),Reverified,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
11522,Vecuronium Bromide for Injection,"Mylan Institutional, a Viatris company",Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [20 mg](NDC 67457-475-20),Reverified,9/28/2022,Backordered,Re-supply October 2022.,,Demand increase for the drug,Anesthesia,Current,,,,2022,not available
11523,Vecuronium Bromide for Injection,Fresenius Kabi,10 mg/vial (NDC 63323-781-10),Revised,9/28/2022,Available,,,,Anesthesia,Current,,,,2022,available
11524,Vecuronium Bromide for Injection,Fresenius Kabi,20 mg/vial (NDC 63323-782-20),Revised,9/28/2022,Available,,,,Anesthesia,Current,,,,2022,available
11525,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,10 mg (NDC 47335-931-44),Reverified,9/23/2022,Available,,,,Anesthesia,Current,,,,2022,available
11526,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,20 mg (NDC 47335-932-44),Reverified,9/23/2022,Available,,,,Anesthesia,Current,,,,2022,available
11527,Vecuronium Bromide for Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"10 mg/vial, packages of 10 (NDC 55150-235-10)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
11528,Vecuronium Bromide for Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"20 mg/vial, packages of 10 (NDC 55150-236-20)",Reverified,9/28/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2022,available
11529,Vecuronium Bromide Injection,Teva,NDC 0703-2914-03 (10 mg (1 mg/mL when reconstituted to 10 mL) 10 x 10 mL Vials),New,8/11/2022,,Product is currently unavailable and no future production expected for an extended period.,,,Anesthesia,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
11530,Verapamil Hydrochloride Tablets,Pfizer,240 mg; Bottle of 100 caplets (NDC 0025-1891-31),New,9/8/2022,,Supply expected to exhaust late September 2022; Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,9/8/2022,9/8/2022,,2022,discontinued
11531,Vibramycin Hyclate (Doxycycline Hyclate) for Suspension,Pfizer Pharmaceuticals,25 mg/5 mL oral suspension; 1 x 60 mL bottle (NDC 0069-0970-65),New,11/16/2021,,,,,Anti-Infective,To be Discontinued,,,,2022,discontinued
11532,Vincristine Sulfate (Vincasar PFS) Injection,Teva,NDC 0703-4402-11 (1 mg/mL 1 mL Single-Dose Vial),New,8/11/2022,,Product is available with an expected supply duration until AUG 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/2022,8/11/2022,,2022,discontinued
11533,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-06),New,4/16/2018,,,,,Oncology,To be Discontinued,,,,2022,discontinued
11534,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-09),New,4/16/2018,,,,,Oncology,To Be Discontinued,,,,2022,discontinued
11535,Vitamin A Palmitate (Aquasol A) Injection,"Casper Pharma, LLC","50,000 USP units/mL (15 mg retinol), single dose vial (NDC 70199-0026-11)",Revised,4/14/2022,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,,,,2022,
11536,Zafirlukast Oral Tablets,Par Pharmaceutical,"Zafirlukast 10 mg Tablets, (NDC 49884-549-02)",New,3/17/2022,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
11537,Zafirlukast Oral Tablets,Par Pharmaceutical,"Zafirlukast 20 mg Tablets, (NDC 49884-554-02)",New,3/17/2022,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
11538,Zafirlukast Oral Tablets,Par Pharmaceutical,"Accolate® Zafirlukast 10 mg Tablets, (NDC 49884-589-02)",New,3/17/2022,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
11539,Zafirlukast Oral Tablets,Par Pharmaceutical,"Accolate® Zafirlukast 20 mg Tablets, (NDC 49884-590-02)",New,3/17/2022,,,,,Pulmonary/Allergy,To be Discontinued,,,,2022,discontinued
11540,Zinc Acetate Capsules,Teva Pharmaceuticals,"25 mg, bottle of 250 (NDC 57844-215-52)",Revised,5/18/2021,,,Available,,Other;Pediatric,Resolved,,,,2022,
11541,Zinc Acetate Capsules,Teva Pharmaceuticals,"50 mg, bottle of 250 (NDC 57844-208-52)",Revised,5/18/2021,,,Available,,Other;Pediatric,Resolved,,,,2022,
11542,Zolpidem Tartrate (Edluar) Sublingual Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0037-6010-30),Revised,11/21/2018,,,Available,,Psychiatry,Resolved,,,,2022,
11543,Zolpidem Tartrate Oral Spray,Aytu BioPharma,5 mg per spray (NDCs 69654-510-30 and 69654-510-60),New,6/13/2022,,,,,Psychiatry,To be Discontinued,,,,2022,discontinued
11544,,Etomidate Injection,"2 mg/mL, 20 mL vial (NDC 25021-674-20)",New,10/5/2022,Available,Marketed by Sagent,,,Anesthesiology,Current,,,,2022,available
11545,"Abacavir Sulfate Tablet, Film Coated",GlaxoSmithKline,"Ziagen, Tablet, Film Coated, 300 mg (NDC 49702-221-18)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately November 27, 2023. Ziagen Oral Solution (49702-222-48) will still be available.",,Discontinuation of the manufacture of the drug,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
11546,"Abacavir Sulfate, Lamivudine Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Epzicom, Tablet, Film Coated, 600 mg; 300 mg (NDC 49702-206-13)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.",,,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
11547,"Abacavir Sulfate, Lamivudine, Zidovudine Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Trizivir, Tablet, Film Coated, 300 mg; 150 mg; 300 mg (NDC 49702-217-18)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately November 27, 2023.",,,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
11548,"Albuterol Sulfate Aerosol, Metered",Sandoz Inc.,"Proventil-hfa, Aerosol, Metered, 108 ug (NDC 66758-959-85)",New,4/13/2023,,,,,Pulmonary/Allergy,To Be Discontinued,4/13/2023,4/13/2023,,2023,discontinued
11549,Albuterol Sulfate Solution,Nephron Pharmaceuticals Corporation,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)",Revised,12/20/2023,"This product is currently available on allocation., At least 6 months until it is off allocation",,,Demand increase for the drug,Pulmonary/Allergy; Pediatric,Current,,,,2023,limited availability
11550,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 mg/1 g (NDC 0168-0263-60)",New,11/27/2023,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,11/27/2023,,2023,discontinued
11551,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 mg/1 g (NDC 0168-0263-45)",New,11/27/2023,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,11/27/2023,,2023,discontinued
11552,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 mg/1 g (NDC 0168-0263-15)",New,11/27/2023,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,11/27/2023,,2023,discontinued
11553,Alclometasone Dipropionate Ointment,Sandoz Inc.,"Alclometasone Dipropionate, Ointment, .5 mg/1 g (NDC 0168-0264-15)",Revised,3/16/2023,,,,,Dermatology,To Be Discontinued,3/16/2023,3/16/2023,,2023,discontinued
11554,Alclometasone Dipropionate Ointment,Sandoz Inc.,"Alclometasone Dipropionate, Ointment, .5 mg/1 g (NDC 0168-0264-45)",Revised,3/16/2023,,,,,Dermatology,To Be Discontinued,3/16/2023,3/16/2023,,2023,discontinued
11555,Alclometasone Dipropionate Ointment,Sandoz Inc.,"Alclometasone Dipropionate, Ointment, .5 mg/1 g (NDC 0168-0264-60)",Revised,3/16/2023,,,,,Dermatology,To Be Discontinued,3/16/2023,3/16/2023,,2023,discontinued
11556,Alprostadil Suppository,"Mylan Institutional, a Viatris Company","Muse, Suppository, 250 ug (NDC 0037-8120-06)",Reverified,12/21/2023,Out of stock; Estimated release dates to be determined,,,Delay in shipping of the drug,Urology,Current,,,,2023,not available
11557,Alprostadil Suppository,"Mylan Institutional, a Viatris Company","Muse, Suppository, 500 ug (NDC 0037-8130-06)",Reverified,12/21/2023,Out of stock; Estimated release dates to be determined,,,Delay in shipping of the drug,Urology,Current,,,,2023,not available
11558,Alprostadil Suppository,"Mylan Institutional, a Viatris Company","Muse, Suppository, 1000 ug (NDC 0037-8140-06)",Reverified,12/21/2023,Out of stock; Estimated release dates to be determined,,,Delay in shipping of the drug,Urology,Current,,,,2023,not available
11559,Alvimopan Capsule,Merck Sharp & Dohme LLC,"Entereg, Capsule, 12 mg (NDC 67919-020-10)",New,3/2/2023,,"To be discontinued May 31, 2023",,,Gastroenterology,To Be Discontinued,3/2/2023,3/2/2023,,2023,discontinued
11560,Amifostine Injection,"Clinigen, Inc.","Ethyol, Injection, 500 mg/10 mL (NDC 76310-017-50)",Reverified,5/16/2022,Shortage anticipated from June 2020; Estimated shortage duration:  Unknown,,,,Oncology; Other,Current,,,,2023,limited availability
11561,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-00)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
11562,Amino Acid Injection,"ICU Medical, Inc.","Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7171-17",,,Gastroenterology,Current,,,,2023,available
11563,Amino Acid Injection,"ICU Medical, Inc.","Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7172-17",,,Gastroenterology,Current,,,,2023,available
11564,Amino Acid Injection,"ICU Medical, Inc.","Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)",Reverified,12/20/2023,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-4178-03",,Shortage of an active ingredient,Gastroenterology,Current,,,,2023,not available
11565,Amino Acid Injection,"ICU Medical, Inc.","Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)",Reverified,12/20/2023,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-4179-05",,Shortage of an active ingredient,Gastroenterology,Current,,,,2023,not available
11566,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Reverified,12/21/2023,Available,,,,Gastroenterology,Current,,,,2023,available
11567,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-05)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
11568,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Reverified,12/21/2023,Available,,,,Gastroenterology,Current,,,,2023,available
11569,Aminocaproic Acid Solution,VistaPharm,"Aminocaproic Acid, Solution, .25 g/1 mL (NDC 66689-330-08)",New,3/8/2023,,,,,Hematology,To Be Discontinued,3/8/2023,3/8/2023,,2023,discontinued
11570,Amoxapine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 50 mg (NDC 0591-5714-01)",Revised,12/6/2023,Available,,,,Psychiatry,Current,,,,2023,available
11571,Amoxapine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 25 mg (NDC 0591-5713-01)",Revised,12/6/2023,Available,,,,Psychiatry,Current,,,,2023,available
11572,Amoxapine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0591-5715-01)",Revised,12/6/2023,Allocation,,,Demand increase for the drug,Psychiatry,Current,,,,2023,limited availability
11573,Amoxapine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 150 mg (NDC 0591-5716-30)",Revised,12/6/2023,Available,,,,Psychiatry,Current,,,,2023,available
11574,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-01)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11575,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-01)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11576,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-01)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11577,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-01)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11578,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-01)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11579,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-01)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11580,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-01)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11581,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-01)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11582,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-46)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11583,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-55)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11584,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-58)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11585,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-46)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11586,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-52)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11587,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-57)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11588,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-46)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11589,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-52)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11590,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-57)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11591,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-46)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11592,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-55)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11593,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-58)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11594,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-73)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11595,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-80)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11596,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-79)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11597,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-73)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11598,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-76)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11599,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-78)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11600,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-73)",Revised,12/19/2023,Available,,,,Anti-Infective,Current,,,,2023,available
11601,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-76)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11602,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-78)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11603,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-55)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11604,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-80)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11605,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-50)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11606,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-75)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11607,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-55)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11608,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-80)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11609,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-50)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11610,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-75)",Revised,12/19/2023,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,limited availability
11611,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-15)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11612,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-80)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11613,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-50)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11614,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-75)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11615,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-15)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11616,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-80)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11617,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-50)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11618,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-75)",Revised,12/19/2023,Available,,,,Anti-Infective; Pediatric,Current,,,,2023,available
11619,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11620,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)",Reverified,12/19/2023,Unavailable. Estimated availability: February 2024,,,Demand increase for the drug,Psychiatry,Current,,,,2023,not available
11621,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11622,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)",Reverified,12/19/2023,Unavailable. Estimated availability: February 2024,,,Demand increase for the drug,Psychiatry,Current,,,,2023,not available
11623,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11624,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11625,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11626,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11627,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11628,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11629,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11630,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11631,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11632,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11633,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11634,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11635,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11636,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11637,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11638,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11639,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)",Revised,12/20/2023,Available,,,,Psychiatry,Current,,,,2023,available
11640,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)",Revised,12/20/2023,Available,,,,Psychiatry,Current,,,,2023,available
11641,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)",Revised,12/20/2023,Available,,,,Psychiatry,Current,,,,2023,available
11642,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)",Revised,12/20/2023,Available,,,,Psychiatry,Current,,,,2023,available
11643,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)",Revised,12/20/2023,Available,,,,Psychiatry,Current,,,,2023,available
11644,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)",Reverified,12/19/2023,Available,Supporting contracted business only,,,Psychiatry,Current,,,,2023,available
11645,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)",Reverified,12/19/2023,Available,Supporting contracted business only,,,Psychiatry,Current,,,,2023,available
11646,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)",Reverified,12/19/2023,Available,Supporting contracted business only,,,Psychiatry,Current,,,,2023,available
11647,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)",Reverified,12/19/2023,Available,Supporting contracted business only,,,Psychiatry,Current,,,,2023,available
11648,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)",Reverified,12/19/2023,Available,Supporting contracted business only,,,Psychiatry,Current,,,,2023,available
11649,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11650,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11651,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11652,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11653,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11654,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11655,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11656,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11657,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11658,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11659,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11660,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11661,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)",Reverified,12/19/2023,Estimated availability December 2023,,,,Psychiatry,Current,,,,2023,not available
11662,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)",Reverified,12/19/2023,Estimated availability December 2023,,,,Psychiatry,Current,,,,2023,not available
11663,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)",Reverified,12/19/2023,Estimated availability December 2023,,,,Psychiatry,Current,,,,2023,not available
11664,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)",Reverified,12/19/2023,Estimated availability December 2023,,,,Psychiatry,Current,,,,2023,not available
11665,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)",Reverified,12/19/2023,Estimated availability December 2023,,,,Psychiatry,Current,,,,2023,not available
11666,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)",Reverified,12/19/2023,Estimated availability December 2023,,,,Psychiatry,Current,,,,2023,not available
11667,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11668,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11669,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11670,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11671,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11672,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11673,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11674,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11675,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11676,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11677,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
11678,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11679,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11680,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11681,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11682,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11683,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11684,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11685,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11686,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11687,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11688,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)",Reverified,12/19/2023,Unavailable,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,not available
11689,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)",Reverified,12/19/2023,Limited supply available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,limited availability
11690,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)",Reverified,12/19/2023,Limited supply available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,limited availability
11691,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)",Reverified,12/19/2023,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
11692,"Atropa Belladonna, Opium Suppository",Padagis US LLC,"Belladonna And Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-12)",Reverified,12/19/2023,Currently out of stock. No estimated release date available.,,,Regulatory delay,Urology,Current,,,,2023,not available
11693,"Atropa Belladonna, Opium Suppository",Padagis US LLC,"Belladonna And Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-04)",Reverified,12/19/2023,Currently out of stock. No estimated release date available.,,,Regulatory delay,Urology,Current,,,,2023,not available
11694,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .4 mg/1 mL (NDC 16729-525-08)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11695,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .4 mg/1 mL (NDC 16729-512-43)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11696,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, 1 mg/1 mL (NDC 16729-526-08)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11697,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .05 mg/1 mL (NDC 16729-483-03)",Reverified,12/19/2023,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11698,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-45)",Reverified,12/19/2023,Inventory on hold pending further assessment,Inventory on hold pending further assessment,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,,2023,unclear
11699,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .1 mg/1 mL (NDC 16729-484-90)",Reverified,12/19/2023,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11700,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, .4 mg/1 mL (NDC 63323-580-20)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11701,Atropine Sulfate Injection,"American Regent, Inc.","Injection, .4 mg/1 mL (NDC 0517-1004-25)",Reverified,12/8/2023,Available,old NDC 0517-0401-25,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11702,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, .1 mg/1 mL (NDC 76329-3340-1)",Reverified,12/19/2023,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11703,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-1630-10)",Revised,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,not available
11704,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .05 mg/1 mL (NDC 0409-9630-05)",Revised,9/11/2023,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11705,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-4910-34)",Revised,9/11/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,limited availability
11706,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-4911-34)",Revised,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,not available
11707,Atropine Sulfate Injection,"American Regent, Inc.","Injection, 1 mg/1 mL (NDC 0517-1001-25)",Reverified,12/8/2023,Available,old NDC 0517-1010-25,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11708,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, .4 mg/1 mL (NDC 0641-6251-10)",Reverified,12/19/2023,Inventory is currently available.,Additional lots are scheduled for manufacturing.  Product will be made available as it is released.,,,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11709,Atropine Sulfate Injection,"Medefil, Inc.","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 64253-400-91)",New,6/15/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,,2023,available
11710,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Injection, 0.1 mg/mL, 10 mL (NDC 0409-4911-11)",Reverified,12/19/2023,Next Delivery: August 2023; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,,2023,not available
11711,Atropine Sulfate Ointment,Bausch & Lomb Incorporated,"Ointment, 10 mg/1 g (NDC 24208-825-55)",New,12/6/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia; Neurology; Pediatric,To Be Discontinued,,12/6/2023,,2023,discontinued
11712,Azacitidine Injection,Cipla Limited,"Azacitidine, Injection, 100 mg (NDC 69097-805-40)",New,8/3/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,8/3/2023,8/3/2023,,2023,discontinued
11713,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 mg (NDC 0781-9253-94)",New,8/3/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,8/3/2023,8/3/2023,,2023,discontinued
11714,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 mg (NDC 0781-3253-94)",Revised,12/19/2023,Discontinuation,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,12/19/2023,12/19/2023,,2023,discontinued
11715,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 mg, Powder, Lyoph (NDC 0781-9253-94)",Revised,12/19/2023,Discontinuation,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,12/19/2023,12/19/2023,,2023,discontinued
11716,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 mg (NDC 59572-102-01)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Oncology,Current,,,,2023,available
11717,Azacitidine Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/30 mL (NDC 63323-771-39)",Reverified,12/20/2023,Available,,,,Oncology,Current,,,,2023,available
11718,Azacitidine Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 100 mg/ Vial (NDC 0143-9606-01)",Reverified,12/19/2023,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Oncology,Current,,,,2023,available
11719,Azacitidine Injection,"Dr. Reddy's Laboratories, Inc.","Azacitidine, Injection, 100 mg (NDC 43598-305-62)",Revised,9/28/2023,Available,,,Demand increase for the drug,Oncology,Current,,,,2023,available
11720,Azacitidine Injection,Armas Pharmaceuticals Inc,"Injection, 100 mg (NDC 72485-201-01)",Revised,11/2/2023,Available,Armas can provide product immediately,,,Oncology,Current,,,,2023,available
11721,Azacitidine Injection,Accord Healthcare Inc.,"Injection, 100 mg (NDC 16729-306-10)",Revised,11/2/2023,Unavailable,Back in Stock the Week of Nov. 06 - Nov. 10,,Delay in shipping of the drug,Oncology,Current,,,,2023,not available
11722,Azacitidine Injection,Cipla Limited,"Azacitidine, Injection, 100 mg (NDC 69097-805-40)",Revised,8/3/2023,Discontinuation,,,Discontinuation of the manufacture of the drug,Oncology,Current,,,,2023,discontinued
11723,Azacitidine Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 100 mg (NDC 68001-313-56)",Reverified,12/6/2023,MADE TO ORDER PRODUCT; Estimated Supply December 2023,Product is manufactured and labeled  for Blue Point Laboratories on a made to order basis,,Demand increase for the drug,Oncology,Current,,,,2023,limited availability
11724,Azacitidine Injection,"Breckenridge Pharmaceutical, Inc.","Injection, 100 mg/50 mL (NDC 51991-797-98)",Reverified,12/19/2023,Unavailable,No longer marketed. Expiry of last lot marketed: 01/31/2024,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11725,Azacitidine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 100 mg/30 mL (NDC 71288-115-30)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Oncology,Current,,,,2023,available
11726,Azacitidine Injection,Eugia US LLC,"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)",Reverified,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
11727,AZITHROMYCIN FOR SUSPENSION,Pfizer Inc.,"FOR SUSPENSION, 200 mg/5 mL (NDC 0069-3140-19)",New,9/28/2023,,,,Discontinuation of the manufacture of the drug,Antibiotic,To Be Discontinued,,,,2023,discontinued
11728,Azithromycin For Suspension,Pfizer Inc.,"For Suspension, 300 mg/15mL (NDC 0069-3110-19)",New,9/29/2023,,Discontinuation due to business reasons.,,Discontinuation of the manufacture of the drug,Antibiotic,To Be Discontinued,,9/29/2023,,2023,discontinued
11729,AZITHROMYCIN FOR SUSPENSION,Pfizer Inc.,"ZITHROMAX, FOR SUSPENSION, 1 g (NDC 0069-3051-07)",New,9/29/2023,,Discontinuation due to business reasons.,,Discontinuation of the manufacture of the drug,Antibiotic,To Be Discontinued,,9/29/2023,,2023,discontinued
11730,Azithromycin Monohydrate Solution/ Drops,Thea Pharma Inc.,"Azasite, Solution/ Drops, 10 mg/1 mL (NDC 82584-307-03)",Revised,8/3/2023,,,Available,,Ophthalmology,Resolved,8/3/2023,,,2023,
11731,"Bazedoxifene Acetate, Estrogens, Conjugated Tablet",Pfizer Inc.,"Duavee, Tablet, 20 mg; .45 mg (NDC 0008-1123-12)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Reproductive,Current,,,,2023,available
11732,"Beclomethasone Dipropionate Monohydrate Spray, Suspension",GlaxoSmithKline,"Beconase Aq, Spray, Suspension, 42 ug (NDC 0173-0388-79)",New,7/21/2023,,The anticipated date that GSK will cease distribution of the product is approximately November 2023.,,,Pulmonary/Allergy,To Be Discontinued,7/21/2023,7/21/2023,,2023,discontinued
11733,Belantamab Mafodotin Injection,GlaxoSmithKline,"Blenrep, Injection, 50 mg/1 mL (NDC 0173-0896-01)",New,2/10/2023,,The product is no longer available as the BLA has been withdrawn.,,,Oncology,To Be Discontinued,2/10/2023,2/10/2023,,2023,discontinued
11734,Belatacept Injection,Bristol Myers Squibb Co.,"Nulojix, Injection, 250 mg (NDC 0003-0371-13)",Revised,9/12/2023,,,"Available. BMS will no longer limit distribution of NULOJIXÂ® (belatacept) for appropriate patients as of 1-October-2023. However, physicians must continue to register new patients via the US NULOJIX Distribution Program. This will enable BMS to closely monitor demand and ensure supply. For further information, contact BMS Medical Information at 800-321-1335.",,Transplant,Resolved,9/12/2023,,,2023,
11735,"Betamethasone Dipropionate Cream, Augmented",Sandoz Inc.,"Betamethasone Dipropionate, Cream, Augmented, .5 mg/1 g (NDC 0168-0265-50)",Revised,3/16/2023,,,,,Dermatology,To Be Discontinued,3/16/2023,3/16/2023,,2023,discontinued
11736,"Betamethasone Dipropionate Cream, Augmented",Sandoz Inc.,"Betamethasone Dipropionate, Cream, Augmented, .5 mg/1 g (NDC 0168-0265-15)",Revised,3/16/2023,,,,,Dermatology,To Be Discontinued,3/16/2023,3/16/2023,,2023,discontinued
11737,"Betamethasone Dipropionate, Calcipotriene Ointment","Tolmar, Inc.","Calcipotriene And Betamethasone Dipropionate, Ointment, .5 mg/1 g; 50 ug/1 g (NDC 0781-7165-35)",New,3/2/2023,,,,,Dermatology,To Be Discontinued,3/2/2023,3/2/2023,,2023,discontinued
11738,"Betamethasone Dipropionate, Calcipotriene Ointment","Tolmar, Inc.","Calcipotriene And Betamethasone Dipropionate, Ointment, .5 mg/1 g; 50 ug/1 g (NDC 0781-7165-95)",Revised,6/8/2023,,,,,Dermatology,To Be Discontinued,3/2/2023,3/2/2023,,2023,discontinued
11739,Bivalirudin Injection,Pfizer Inc.,"Bivalirudin, Injection, 250 mg (NDC 0409-8300-15)",New,7/24/2023,,Supply expected to exhaust late September 2023; Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,7/24/2023,7/24/2023,,2023,discontinued
11740,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 125 mg (NDC 0054-0521-22)",New,9/19/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/2023,,2023,discontinued
11741,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 125 mg (NDC 0054-0521-21)",New,9/19/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/2023,,2023,discontinued
11742,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 125 mg (NDC 0054-0521-18)",New,9/19/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/2023,,2023,discontinued
11743,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 62.5 mg (NDC 0054-0520-21)",New,9/19/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/2023,,2023,discontinued
11744,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 62.5 mg (NDC 0054-0520-18)",New,9/19/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/2023,,2023,discontinued
11745,Bumetanide Injection,MSN Laboratories Private Limited,"Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
11746,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
11747,Bumetanide Injection,MSN Laboratories Private Limited,"Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
11748,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
11749,Bumetanide Injection,"Fresenius Kabi USA, LLC","Injection, .25 mg/1 mL (NDC 65219-570-04)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2023,available
11750,Bumetanide Injection,"Fresenius Kabi USA, LLC","Injection, .25 mg/1 mL (NDC 65219-572-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,,2023,available
11751,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 70860-405-04)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
11752,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 70860-406-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
11753,Bumetanide Injection,"Hospira, Inc., a Pfizer Company","Injection, .25 mg/1 mL (NDC 0409-1412-04)",Revised,11/3/2023,,Discontinued,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,12/1/2023,11/3/2023,,2023,discontinued
11754,Bumetanide Injection,"Hospira, Inc., a Pfizer Company","Injection, .25 mg/1 mL (NDC 0409-1412-10)",Revised,11/3/2023,,Discontinued,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,12/1/2023,11/3/2023,,2023,discontinued
11755,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)",Revised,12/19/2023,Inventory is currently available,Additional lots are scheduled for manufacturing and will be available. Product will be made available as it is released.,,,Cardiovascular,Current,,,,2023,available
11756,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)",Revised,12/19/2023,This presentation is temporarily on backorder.,Product will be made available as it is released.,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,not available
11757,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-1159-01)",Revised,9/11/2023,Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Anesthesia,Current,,,,2023,not available
11758,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-1159-02)",Revised,9/11/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,limited availability
11759,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-1160-01)",Revised,9/11/2023,Next Delivery: March 2024; Estimated Recovery: December 2024,,,,Anesthesia,Current,,,,2023,not available
11760,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-1162-01)",Revised,9/11/2023,Next Delivery: September 2023; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11761,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-1162-02)",Revised,9/11/2023,Next Delivery: October 2023; Estimated Recovery: March 2024,,,,Anesthesia,Current,,,,2023,not available
11762,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-1163-01)",Revised,9/11/2023,Next Delivery: January 2024; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11763,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)",Revised,9/11/2023,Limited Supply Available. Next Delivery: October 2023; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,limited availability
11764,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-02)",Revised,9/11/2023,Available,,,,Anesthesia,Current,,,,2023,available
11765,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-3613-01)",Revised,9/11/2023,Depleted,,,,Anesthesia,Current,,,,2023,not available
11766,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 2.5 mg/1 mL (NDC 0409-1559-10)",Revised,9/11/2023,Next Delivery: October 2023; Estimated Recovery: December 2023,,,,Anesthesia,Current,,,,2023,not available
11767,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 2.5 mg/1 mL (NDC 0409-1559-30)",Revised,9/11/2023,Limited Supply Available. Next Delivery: October 2023; Estimated Recovery: December 2023,,,,Anesthesia,Current,,,,2023,limited availability
11768,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 2.5 mg/1 mL (NDC 0409-1587-50)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
11769,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 5 mg/1 mL (NDC 0409-1560-10)",Revised,9/11/2023,Next Delivery: November 2023; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11770,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 5 mg/1 mL (NDC 0409-1560-29)",Revised,9/11/2023,Limited Supply Available. Next Delivery: January 2024; Estimated Recovery: June 2024,,,,Anesthesia,Current,,,,2023,limited availability
11771,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 5 mg/1 mL (NDC 0409-1610-50)",Reverified,12/19/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
11772,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 7.5 mg/1 mL (NDC 0409-1582-10)",Revised,9/11/2023,Limited Supply Available. Next Delivery and Estimated Recovery: September 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,limited availability
11773,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 7.5 mg/1 mL (NDC 0409-1582-29)",Revised,9/11/2023,Available,,,,Anesthesia,Current,,,,2023,available
11774,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)",Revised,11/29/2023,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11775,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11776,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)",Revised,11/29/2023,Unavailable,Next release not available at this time. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11777,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,,2023,available
11778,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)",Revised,11/29/2023,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11779,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)",Revised,11/29/2023,Unavailable,Next release not available at this time. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11780,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,,2023,available
11781,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11782,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,,2023,available
11783,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,,2023,available
11784,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 2.5 mg/1 mL (NDC 55150-167-10)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
11785,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 2.5 mg/1 mL (NDC 55150-168-30)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
11786,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 5 mg/1 mL (NDC 55150-169-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
11787,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 5 mg/1 mL (NDC 55150-170-30)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
11788,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 7.5 mg/1 mL (NDC 55150-171-10)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
11789,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 7.5 mg/1 mL (NDC 55150-172-30)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
11790,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)",Reverified,12/19/2023,Currently on backorder - next shipment November 2023,,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11791,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)",Reverified,12/19/2023,Currently on backorder - next shipment November 2023,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11792,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)",Reverified,12/21/2023,Available,,,,Anesthesia,Current,,,,2023,available
11793,Bupivacaine Hydrochloride Injection,Baxter Healthcare,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 36000-092-10)",Revised,8/1/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia,To Be Discontinued,8/1/2023,8/1/2023,,2023,discontinued
11794,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 59923-717-05)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11795,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 59923-719-10)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11796,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 59923-718-05)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11797,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 59923-720-10)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11798,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)",Reverified,12/19/2023,Available,Meitheal Pharmaceuticals is distributor/labeler,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11799,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)",Reverified,12/19/2023,Available,Meitheal Pharmaceuticals is distributor/labeler,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11800,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)",Revised,11/29/2023,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11801,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)",Revised,11/29/2023,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11802,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)",Revised,11/29/2023,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11803,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)",Revised,11/29/2023,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11804,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)",Revised,11/29/2023,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11805,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)",Revised,11/29/2023,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11806,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)",Revised,11/29/2023,Unavailable,Next release date not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11807,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)",Revised,11/29/2023,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11808,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 2.5 mg/1 mL; 5 ug/1 mL (NDC 0409-9042-01)",Revised,9/11/2023,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11809,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 2.5 mg/1 mL; 5 ug/1 mL (NDC 0409-9042-17)",Revised,9/11/2023,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11810,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 2.5 mg/1 mL; 5 ug/1 mL (NDC 0409-9043-01)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11811,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 5 mg/1 mL; 5 ug/1 mL (NDC 0409-9045-01)",Revised,9/11/2023,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11812,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 5 mg/1 mL; 5 ug/1 mL (NDC 0409-9045-17)",Revised,9/11/2023,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11813,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 5 mg/1 mL; 5 ug/1 mL (NDC 0409-9046-01)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11814,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 2.5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1746-10)",Revised,9/11/2023,Next Delivery: October 2023; Estimated Recovery: March 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11815,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 2.5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1746-30)",Revised,9/11/2023,Next Delivery: October 2023; Estimated Recovery: June 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11816,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1749-10)",Revised,9/11/2023,Next Delivery: September 2023; Estimated Recovery: June 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11817,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1749-29)",Revised,9/11/2023,Next Delivery: September 2023; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
11818,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 2.5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1752-50)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: September 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11819,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1755-50)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: September 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
11820,"Bupropion Hydrochloride Tablet, Extended Release",Endo Pharmaceuticals. Inc.,"Tablet, Extended Release, 150 mg (NDC 10370-101-03)",New,10/2/2023,,Discontinued due to business reasons,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,10/2/2023,,2023,discontinued
11821,"Bupropion Hydrochloride Tablet, Extended Release",Endo Pharmaceuticals. Inc.,"Tablet, Extended Release, 150 mg (NDC 10370-101-50)",New,10/2/2023,,Discontinued due to business reasons,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,,,2023,discontinued
11822,Calcium Acetate Solution,Fresenius Medical Care North America,"Phoslyra, Solution, 667 mg/5 mL (NDC 49230-643-31)",New,4/5/2023,,FMCNA Customer Service Call: 1-800-323-5188 Hours of Operation: 7:00 a.m. – 6:00 p.m. (CT),,Discontinuation of the manufacture of the drug,Renal,To Be Discontinued,4/5/2023,4/5/2023,,2023,discontinued
11823,Calcium Gluconate Injection,HQ Specialty Pharma,"Calcium Gluconate In Sodium Chloride, Injection, 20 mg/1 mL (NDC 44567-620-24)",Revised,9/7/2023,,,"Available; Marketed by WG Critical Care, LLC",Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11824,Calcium Gluconate Injection,HQ Specialty Pharma,"Calcium Gluconate In Sodium Chloride, Injection, 20 mg/1 mL (NDC 44567-621-24)",Revised,9/7/2023,,,"Available; Marketed by WG Critical Care, LLC",Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11825,Calcium Gluconate Injection,HQ Specialty Pharma,"Calcium Gluconate In Sodium Chloride, Injection, 10 mg/1 mL (NDC 44567-622-24)",Revised,9/7/2023,,,"Available; Marketed by WG Critical Care, LLC",Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11826,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 98 mg/1 mL (NDC 63323-360-19)",Revised,9/7/2023,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11827,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 98 mg/1 mL (NDC 63323-360-59)",Revised,9/7/2023,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11828,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 98 mg/1 mL (NDC 63323-360-61)",Revised,9/7/2023,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11829,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 20 mg/1 mL (NDC 65219-162-10)",Revised,9/7/2023,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11830,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 20 mg/1 mL (NDC 65219-164-50)",Revised,9/7/2023,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11831,Calcium Gluconate Injection,"Nivagen Pharmaceuticals, Inc.","Calcium Gluconate, Injection, 98 mg/1 mL (NDC 75834-171-19)",Revised,9/7/2023,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11832,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/mL (NDC 63323-360-01)",Revised,9/7/2023,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11833,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/mL (NDC 63323-360-03)",Revised,9/7/2023,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11834,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/mL (NDC 63323-360-05)",Revised,9/7/2023,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11835,Calcium Gluconate Injection,HQ Specialty Pharma,"Injection, 20 mg/mL (NDC 44567-620-01)",Revised,9/7/2023,,,"Available; Marketed by WG Critical Care, LLC",,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11836,Calcium Gluconate Injection,HQ Specialty Pharma,"Injection, 20 mg/mL (NDC 44567-621-01)",Revised,9/7/2023,,,"Available; Marketed by WG Critical Care, LLC",,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11837,Calcium Gluconate Injection,HQ Specialty Pharma,"Injection, 10 mg/mL (NDC 44567-622-01)",Revised,9/7/2023,,,"Available; Marketed by WG Critical Care, LLC",,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11838,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 20 mg/mL (NDC 65219-162-01)",Revised,9/7/2023,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11839,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 20 mg/mL (NDC 65219-164-01)",Revised,9/7/2023,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/2023,,,2023,
11840,Capecitabine Tablet,Accord Healthcare Inc.,"Tablet, 500 mg (NDC 16729-073-29)",Revised,12/20/2023,"Stock Available; Inventory allocating to orders, 111 days coverage","Manufacturing resumed, manufacturing and packaging plans being put together.",,,Oncology,Current,,,,2023,limited availability
11841,Capecitabine Tablet,"Genentech, Inc","Xeloda, Tablet, 150 mg (NDC 0004-1100-20)",Revised,12/19/2023,Limited supply available,,,Demand increase for the drug,Oncology,Current,,,,2023,limited availability
11842,Capecitabine Tablet,"Genentech, Inc","Xeloda, Tablet, 500 mg (NDC 0004-1101-50)",Revised,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
11843,Capecitabine Tablet,Novadoz Pharmaceuticals LLC,"Capecitabine, Tablet, 500 mg (NDC 72205-007-92)",Revised,12/19/2023,Available,Manufactured by MSN Laboratories Private Limited (Formulation Division),,Demand increase for the drug,Oncology,Current,,,,2023,available
11844,Capecitabine Tablet,Novadoz Pharmaceuticals LLC,"Capecitabine, Tablet, 150 mg (NDC 72205-006-60)",Revised,12/19/2023,Available,Manufactured by MSN Laboratories Private Limited (Formulation Division),,Demand increase for the drug,Oncology,Current,,,,2023,available
11845,Capecitabine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 150 mg (NDC 0093-7473-06)",Revised,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
11846,Capecitabine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-7474-89)",Revised,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
11847,Capecitabine Tablet,Eugia US LLC,"Tablet, 150 mg (NDC 59651-204-60)",Reverified,12/20/2023,On allocation,Intermittent availability expected,,Demand increase for the drug,Oncology,Current,,,,2023,limited availability
11848,Capecitabine Tablet,Eugia US LLC,"Tablet, 500 mg (NDC 59651-205-08)",Reverified,12/20/2023,On allocation,Intermittent availability expected,,Demand increase for the drug,Oncology,Current,,,,2023,limited availability
11849,Capecitabine Tablet,"Dr. Reddy's Laboratories, Inc.","Capecitabine, Tablet, 150 mg (NDC 55111-496-60)",Revised,12/19/2023,Available,,,Demand increase for the drug,Oncology,Current,,,,2023,available
11850,Capecitabine Tablet,"Dr. Reddy's Laboratories, Inc.","Capecitabine, Tablet, 500 mg (NDC 55111-497-04)",Revised,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
11851,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 100 mg (NDC 0781-8016-01)",New,10/23/2023,,"Novartis Pharmaceuticals’ brand product, Tegretol XR 100 mg (NDC 0078-0510-05), will continue to be manufactured and available.",,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,10/23/2023,,2023,discontinued
11852,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 200 mg (NDC 0781-5987-01)",New,10/23/2023,,"Novartis Pharmaceuticals’ brand product, Tegretol XR, 200 mg (NDC 0078-0511-05), will continue to be manufactured and available.",,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,10/23/2023,,2023,discontinued
11853,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 400 mg (NDC 0781-5988-01)",New,10/23/2023,,"Novartis Pharmaceuticals’ brand product, Tegretol XR, 400 mg, (NDC 0078-0512-05), will continue to be manufactured and available.",,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,10/23/2023,,2023,discontinued
11854,Carboplatin Injection,Gland Pharma Limited,"Injection, 50mg/5mL (NDC 54288-164-01)",Reverified,12/19/2023,Available,"Distributed by BPI Labs, LLC",,,Oncology,Current,,,,2023,available
11855,Carboplatin Injection,Gland Pharma Limited,"Injection, 150mg/15mL (NDC 54288-165-01)",Revised,12/19/2023,Available,"Distributed by BPI Labs, LLC",,,Oncology,Current,,,,2023,available
11856,Carboplatin Injection,Gland Pharma Limited,"Injection, 450mg/45mL (NDC 54288-166-01)",Reverified,12/19/2023,On allocation; full availability in November 2023,"Distributed by BPI Labs, LLC",,,Oncology,Current,,,,2023,limited availability
11857,Carboplatin Injection,Gland Pharma Limited,"Injection, 600 mg/65 mL (NDC 54288-167-01)",Revised,12/19/2023,On allocation; full availability in November 2023,"Distributed by BPI Labs, LLC",,,Oncology,Current,,,,2023,limited availability
11858,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Injection, 600 mg/60 mL (NDC 50742-448-60)",Reverified,12/19/2023,,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,,Oncology,Current,,,,2023,
11859,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)",Reverified,12/19/2023,Available,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,,Oncology,Current,,,,2023,available
11860,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)",Reverified,12/19/2023,Currently on backorder - next shipment in November 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11861,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)",Reverified,12/19/2023,Currently on backorder - next shipment in November 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11862,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-295-34)",Reverified,12/19/2023,"Unavailable, 75 days","Manufacturing resumed, manufacturing and packaging plans being put together.",,Requirements related to complying with good manufacturing practices,Oncology,Current,,,,2023,not available
11863,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-295-12)",Reverified,12/19/2023,"Unavailable, 75 days","Manufacturing resumed, manufacturing and packaging plans being put together.",,Requirements related to complying with good manufacturing practices,Oncology,Current,,,,2023,not available
11864,Carboplatin Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-172-60)",Reverified,12/20/2023,Limited availability. Next release December 2023.,Check wholesaler inventory,,Demand increase for the drug,Oncology,Current,,,,2023,limited availability
11865,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-4239-01)",Reverified,12/19/2023,Unavailable,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11866,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-339-18)",Reverified,12/19/2023,Next delivery: September 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11867,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-360-18)",Reverified,12/19/2023,Next delivery: September 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11868,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-339-22)",Reverified,12/19/2023,Next delivery: October 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11869,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-150-05)",Reverified,12/19/2023,Next delivery: October 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11870,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-339-50)",Reverified,12/19/2023,Limited Supply Available. Next delivery: November 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,limited availability
11871,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-262-05)",Reverified,12/19/2023,Next delivery: November 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11872,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-339-56)",Reverified,12/19/2023,Limited Supply Available. Next delivery: September 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,limited availability
11873,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-600-05)",Reverified,12/19/2023,Next delivery: September 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11874,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-4244-01)",Reverified,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
11875,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-4246-01)",Reverified,12/19/2023,Unavailable,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11876,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-4248-01)",Reverified,12/19/2023,Unavailable,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
11877,Cefixime Capsule,"Ascend Laboratories, LLC","Capsule, 400 mg (NDC 67877-584-50)",Revised,11/2/2023,Available,,,,Anti-Infective,Current,,,,2023,available
11878,Cefixime Capsule,"Lupin Pharmaceuticals, Inc.","Suprax, Capsule, 400 mg (NDC 68180-423-08)",Reverified,11/18/2022,"Limited availability, Manufacturing and distribution is ongoing.",,,,Anti-Infective,Current,,,,2023,limited availability
11879,Cefixime Capsule,"Lupin Pharmaceuticals, Inc.","Suprax, Capsule, 400 mg (NDC 68180-423-11)",Reverified,12/19/2023,"Limited availability, Manufacturing and distribution is ongoing.",,,Demand increase for the drug,Anti-Infective,Current,,,,2023,limited availability
11880,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Cefotaxime, Injection, 500 mg (NDC 0143-9930-10)",Revised,10/13/2022,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,not available
11881,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Cefotaxime, Injection, 1 g (NDC 0143-9931-25)",Revised,10/13/2022,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,not available
11882,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Cefotaxime, Injection, 2 g (NDC 0143-9933-25)",Revised,10/13/2022,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,not available
11883,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Cefotaxime, Injection, 10 g (NDC 0143-9935-01)",Revised,10/13/2022,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,,Anti-Infective; Pediatric,Current,,,,2023,not available
11884,Cefotaxime Sodium Injection,"SteriMax, Inc.","Cefotaxime, Injection, 2 g (NDC 21586-012-02)",Revised,6/6/2023,Available,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,available
11885,Cefotaxime Sodium Injection,"SteriMax, Inc.","Cefotaxime, Injection, 1 g (NDC 21586-011-02)",Revised,6/6/2023,Available,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,,2023,available
11886,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC","Injection, 1 g/10 mL (NDC 63323-385-10)",Reverified,12/20/2023,4 & 8 months dating available (03/31/2024 & 07/31/2024 expiry) upon request.  Check wholesalers for inventory.,Check wholesaler for inventory,,Demand increase for the drug,Anti-Infective,Current,,,,2023,limited availability
11887,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC","Injection, 2 g/20 mL (NDC 63323-386-20)",Reverified,12/20/2023,4 & 8 months dating available (03/31/2024 & 07/31/2024 expiry) upon request.  Check wholesalers for inventory.,Check wholesaler for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,limited availability
11888,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC","Injection, 10 g (NDC 63323-396-61)",Reverified,12/20/2023,No release date available at this time.,,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,not available
11889,Cefotetan Disodium Injection,"Teligent Pharma, Inc.","Cefotan, Injection, 2 g/20 mL (NDC 52565-053-10)",Reverified,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,,2023,discontinued
11890,Chloramphenicol Sodium Succinate Injection,"Fresenius Kabi USA, LLC","Injection, 1 g/10 mL (NDC 63323-011-15)",Revised,12/11/2023,,,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,12/11/2023,12/11/2023,,2023,discontinued
11891,Chloroprocaine Hydrochloride Injection,B. Braun Medical Inc.,"Clorotekal, Injection, 10 mg/mL (NDC 0264-7055-05)",Revised,11/2/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia,To Be Discontinued,11/2/2023,11/2/2023,,2023,discontinued
11892,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Nesacaine, Injection, 10 mg/1 mL (NDC 63323-475-37)",Reverified,12/20/2023,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2023,available
11893,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Nesacaine, Injection, 20 mg/1 mL (NDC 63323-476-37)",Reverified,12/20/2023,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2023,available
11894,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Nesacaine, Injection, 20 mg/1 mL (NDC 63323-477-27)",Reverified,12/20/2023,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2023,available
11895,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Nesacaine, Injection, 30 mg/1 mL (NDC 63323-478-27)",Reverified,12/20/2023,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,,2023,available
11896,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Chloroprocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9209-10)",Reverified,5/16/2023,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11897,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Chloroprocaine Hydrochloride, Injection, 30 mg/1 mL (NDC 0143-9210-10)",Reverified,5/16/2023,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
11898,Chlorothiazide Suspension,"Salix Pharmaceuticals, Inc.","Diuril, Suspension, 250 mg/5 mL (NDC 65649-311-12)",Revised,9/13/2023,,,Available,,Cardiovascular,Resolved,9/13/2023,,,2023,
11899,"Ciprofloxacin Hydrochloride, Dexamethasone Suspension/ Drops",Novartis Pharmaceuticals Corporation,"Ciprodex, Suspension/ Drops, 3 mg/1 mL; 1 mg/1 mL (NDC 0078-0799-75)",New,6/26/2023,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue CIPRODEX (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension.Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.  Product will be available until approximately September 2023.  The authorized generic, NDC 0781-6186-67, will continue to be manufactured and available, distributed by Sandoz.  Other generic equivalents are also available.",,,Anti-Infective,To Be Discontinued,6/26/2023,6/26/2023,,2023,discontinued
11900,Ciprofloxacin Injection,Baxter Healthcare,"Ciprofloxacin In Dextrose 5% In Plastic Container, Injection, 2 mg/1 mL (NDC 36000-008-24)",New,1/31/2023,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,1/31/2023,1/31/2023,,2023,discontinued
11901,Ciprofloxacin Injection,Baxter Healthcare,"Ciprofloxacin In Dextrose 5% In Plastic Container, Injection, 2 mg/1 mL (NDC 36000-009-24)",New,1/31/2023,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,1/31/2023,1/31/2023,,2023,discontinued
11902,Cisatracurium Besylate Injection,AbbVie Inc.,"Nimbex, Injection, 2 mg/1 mL (NDC 0074-4378-05)",New,9/11/2023,,,,,Analgesia/Addiction,To Be Discontinued,9/11/2023,9/11/2023,,2023,discontinued
11903,Cisatracurium Besylate Injection,AbbVie Inc.,"Nimbex, Injection, 2 mg/1 mL (NDC 0074-4380-10)",New,9/11/2023,,,,,Analgesia/Addiction,To Be Discontinued,9/11/2023,9/11/2023,,2023,discontinued
11904,Cisatracurium Besylate Injection,AbbVie Inc.,"Nimbex, Injection, 10 mg/1 mL (NDC 0074-4382-20)",New,9/11/2023,,,,,Analgesia/Addiction,To Be Discontinued,9/11/2023,9/11/2023,,2023,discontinued
11905,Cisplatin Injection,Gland Pharma Limited,"Cisplatin, Injection, 1 mg/1 mL (NDC 25021-253-50)",Reverified,12/19/2023,On backorder; Estimated recovery: October 2023,Marketed by Sagent. New launch.,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
11906,Cisplatin Injection,Gland Pharma Limited,"Cisplatin, Injection, 1 mg/1 mL (NDC 25021-253-51)",Reverified,12/19/2023,Available. On allocation due to high demand,Marketed by Sagent. New launch.,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,limited availability
11907,Cisplatin Injection,"Qilu Pharmaceutical Co., Ltd.","Cisplatin, Injection, 50 mg/50 mL (NDC 60505-6277-0)",Reverified,12/19/2023,Not available. All imported product has been distributed.,"Qilu Pharmaceutical Co., Ltd., in coordination with the U.S. FDA and Apotex Corp., has initiated temporary importation of CISplatin Injection 50 mg/50 mL (1 mg/mL) vials into the U.S. market to address a drug shortage of CISplatin. Product is available via Apotex Corp.â€™s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
11908,Cisplatin Injection,Accord Healthcare Inc.,"Cisplatin, Injection, 1 mg/1 mL (NDC 16729-288-11)",Revised,11/13/2023,Available with intermittent releases under allocation,Marketed by Accord Healthcare. Manufacturing has resumed and new batches are being planned.,,Requirements related to complying with good manufacturing practices,Oncology; Pediatric,Current,,,,2023,limited availability
11909,Cisplatin Injection,Accord Healthcare Inc.,"Cisplatin, Injection, 1 mg/1 mL (NDC 16729-288-38)",Revised,11/13/2023,Available with intermittent releases under allocation,Marketed by Accord Healthcare. Manufacturing has resumed and new batches are being planned.,,Requirements related to complying with good manufacturing practices,Oncology; Pediatric,Current,,,,2023,limited availability
11910,Cisplatin Injection,Accord Healthcare Inc.,"Cisplatin, Injection, 1 mg/1 mL (NDC 68001-283-27)",Revised,11/13/2023,Not available,Marketed by BluePoint Laboratories. Manufacturing has resumed and intermittent release for Bluepoint Label is planned.,,Requirements related to complying with good manufacturing practices,Oncology; Pediatric,Current,,,,2023,not available
11911,Cisplatin Injection,Accord Healthcare Inc.,"Cisplatin, Injection, 1 mg/1 mL (NDC 68001-283-32)",Revised,11/13/2023,Not available,Marketed by BluePoint Laboratories. Manufacturing has resumed and intermittent release for Bluepoint Label is planned.,,Requirements related to complying with good manufacturing practices,Oncology; Pediatric,Current,,,,2023,not available
11912,Cisplatin Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-103-51)",Reverified,12/20/2023,Backordered. Next release October 2023.,,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
11913,Cisplatin Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-103-65)",Reverified,12/20/2023,Backordered. Next release October 2023.,Check wholesalers for inventory,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
11914,Cisplatin Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-103-64)",Reverified,12/20/2023,Backordered. Next release October 2023.,,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
11915,Cisplatin Injection,"Hikma Pharmaceuticals USA, Inc.","Cisplatin, Injection, 1 mg/1 mL (NDC 0143-9504-01)",Reverified,12/19/2023,Temporarily on backorder.,Additional lots will be available in the August 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
11916,Cisplatin Injection,"Hikma Pharmaceuticals USA, Inc.","Cisplatin, Injection, 1 mg/1 mL (NDC 0143-9505-01)",Reverified,12/19/2023,Temporarily on backorder.,Additional lots will be available in the September 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
11917,Cisplatin Injection,HQ Specialty Pharma,"Injection, 1 mg/1 mL (NDC 44567-511-01)",Reverified,12/20/2023,Available on allocation,Marketed by WG Critical Care,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,limited availability
11918,Cisplatin Injection,HQ Specialty Pharma,"Injection, 1 mg/1 mL (NDC 44567-530-01)",Reverified,12/20/2023,Available on allocation,Marketed by WG Critical Care,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,limited availability
11919,Cisplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 50 mg/50 mL (NDC 0703-5747-11)",Reverified,12/19/2023,Available,,,,Oncology; Pediatric,Current,,,,2023,available
11920,Cisplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 100 mg/100 mL (NDC 0703-5748-11)",Reverified,12/19/2023,Available,,,,Oncology; Pediatric,Current,,,,2023,available
11921,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-3051-02)",Revised,12/19/2023,Next Delivery and Estimated Recovery: November 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11922,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-5095-06)",Revised,12/19/2023,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11923,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-4073-04)",Revised,12/19/2023,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11924,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-0870-26)",Revised,12/19/2023,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11925,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-0775-26)",Revised,12/19/2023,Estimated Recovery: November 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11926,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-0728-09)",Revised,12/19/2023,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11927,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-0902-18)",Revised,12/19/2023,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11928,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 mg/1 mL (NDC 25021-115-02)",Reverified,12/19/2023,Backorder. Estimated availability TBD,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11929,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 mg/1 mL (NDC 25021-115-04)",Reverified,12/19/2023,Backorder. Estimated availability TBD,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11930,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 mg/1 mL (NDC 25021-115-06)",Reverified,12/19/2023,Backorder. Estimated availability TBD,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11931,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 300 mg/50 mL (NDC 0338-9545-50)",Reverified,12/19/2023,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,limited availability
11932,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 300 mg/50 mL (NDC 0338-9549-50)",Reverified,12/19/2023,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,limited availability
11933,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 900 mg/50 mL (NDC 0338-9553-50)",Reverified,12/19/2023,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,limited availability
11934,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 300 mg/50 mL (NDC 0338-3410-50)",Reverified,12/19/2023,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,limited availability
11935,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 600 mg/50 mL (NDC 0338-3612-50)",Reverified,12/19/2023,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,limited availability
11936,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 900 mg/50 mL (NDC 0338-3814-50)",Reverified,12/19/2023,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,limited availability
11937,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)",Revised,12/19/2023,Unavailable,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11938,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,limited availability
11939,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)",Revised,12/19/2023,Limited Availability,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,limited availability
11940,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)",Revised,12/19/2023,Unavailable,Civica Label,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11941,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)",Revised,12/19/2023,Unavailable,Civica Label,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
11942,Clobazam Tablet,"Breckenridge Pharmaceutical, Inc.","Clobazam, Tablet, 20 mg (NDC 51991-901-01)",New,2/17/2023,,Business decision to discontinue product from the commercial market,,,Neurology,To Be Discontinued,2/17/2023,2/17/2023,,2023,discontinued
11943,Clocortolone Pivalate Cream,EPI Health,"Cream, 1 mg/g (NDC 71403-804-93)",New,10/18/2023,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,10/18/2023,,2023,discontinued
11944,Clocortolone Pivalate Cream,EPI Health,"Cream, 1 mg/g (NDC 71403-804-75)",New,10/18/2023,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,10/18/2023,,2023,discontinued
11945,Clocortolone Pivalate Cream,EPI Health,"Cream, 1 mg/g (NDC 71403-804-45)",New,10/18/2023,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,10/18/2023,,2023,discontinued
11946,Clofarabine Injection,Apotex Corp.,"Injection, 20 mg/20 ml (1mg/ml) (NDC 60505-6166-0)",New,10/26/2023,,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,10/26/2023,,2023,discontinued
11947,Clomipramine Hydrochloride Capsule,Sandoz Inc.,"Clomipramine Hydrochloride, Capsule, 25 mg (NDC 0781-2027-01)",New,2/14/2023,,,,,Psychiatry,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
11948,Clomipramine Hydrochloride Capsule,Sandoz Inc.,"Clomipramine Hydrochloride, Capsule, 50 mg (NDC 0781-2037-01)",New,2/14/2023,,,,,Psychiatry,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
11949,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, .5 mg (NDC 16729-136-00)",New,3/10/2023,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,not available
11950,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, .5 mg (NDC 16729-136-16)",New,3/10/2023,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,not available
11951,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, 1 mg (NDC 16729-137-00)",New,3/10/2023,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,not available
11952,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, 1 mg (NDC 16729-137-16)",New,3/10/2023,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,not available
11953,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, 2 mg (NDC 16729-138-00)",New,3/10/2023,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,not available
11954,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, 2 mg (NDC 16729-138-16)",New,3/10/2023,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,not available
11955,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, .5 mg (NDC 61269-605-10)",New,3/10/2023,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11956,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 1 mg (NDC 61269-610-10)",New,3/10/2023,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11957,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 2 mg (NDC 61269-620-10)",New,3/10/2023,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11958,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-10)",New,3/10/2023,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11959,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-11)",New,3/10/2023,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11960,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-50)",New,3/10/2023,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11961,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-10)",New,3/10/2023,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11962,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-11)",New,3/10/2023,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11963,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-50)",New,3/10/2023,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11964,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-10)",New,3/10/2023,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11965,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-50)",New,3/10/2023,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11966,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, .5 mg (NDC 0093-0832-01)",Revised,12/6/2023,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11967,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, .5 mg (NDC 0093-0832-05)",Revised,12/6/2023,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11968,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 mg (NDC 0093-3212-01)",Revised,12/6/2023,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11969,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 mg (NDC 0093-3212-05)",Revised,12/6/2023,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11970,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 2 mg (NDC 0093-3213-01)",Revised,12/6/2023,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11971,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 2 mg (NDC 0093-3213-05)",Revised,12/6/2023,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11972,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11973,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11974,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11975,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11976,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11977,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11978,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11979,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11980,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)",Revised,4/12/2023,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2023,available
11981,Colestipol Hydrochloride Granule,Pfizer Inc.,"Colestid, Granule, 5 g/5 g (NDC 0009-0260-01)",Revised,3/30/2023,,Supply expected to exhaust late May 2023. Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,3/30/2023,3/30/2023,,2023,discontinued
11982,Colestipol Hydrochloride Granule,Pfizer Inc.,"Granule, 5 g/5 g (NDC 59762-0260-2)",Revised,3/30/2023,,Discontinuation of the manufacture of the drug. This product is distributed by Viatris.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,3/30/2023,3/30/2023,,2023,discontinued
11983,Colestipol Hydrochloride Granule,Pfizer Inc.,"Flavored Colestid, Granule, 5 g/7.5 g (NDC 0009-0370-05)",Revised,3/30/2023,,Supply expected to exhaust early July 2023. Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,3/30/2023,3/30/2023,,2023,discontinued
11984,Colestipol Hydrochloride Granule,Pfizer Inc.,"Flavored Colestid, Granule, 5 g/7.5 g (NDC 0009-0370-03)",Revised,3/30/2023,,Supply expected to exhaust late August 2023. Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,3/30/2023,3/30/2023,,2023,discontinued
11985,Colestipol Hydrochloride Granule,Pfizer Inc.,"Granule, 5 g/5 g (NDC 59762-0260-1)",New,10/17/2023,,Supply expected to exhaust early November 2023. Discontinuation of the manufacture of the drug. This product distributed by Viatris.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,,3/30/2023,,2023,discontinued
11986,Colestipol Hydrochloride Granule,Pfizer Inc.,"Colestid, Granule, 5 g/5 g (NDC 0009-0260-04)",New,11/9/2023,,Supply expected to exhaust December 2023,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,,3/30/2023,,2023,discontinued
11987,Collagenase Clostridium Histolyticum Ointment,"Smith & Nephew, Inc.","Santyl, Ointment, 250 [arb'U]/1 g (NDC 50484-010-30)",Reverified,12/19/2023,Product is available.,,,,Dermatology,Current,,,,2023,available
11988,Collagenase Clostridium Histolyticum Ointment,"Smith & Nephew, Inc.","Santyl, Ointment, 250 [arb'U]/1 g (NDC 50484-010-90)",Reverified,12/19/2023,Product is currently on back order with Smith and Nephew. Shortage duration is unknown at this time.,,,Delay in shipping of the drug,Dermatology,Current,,,,2023,not available
11989,Conivaptan Hydrochloride Injection,Cumberland Pharmaceuticals Inc.,"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)",New,3/14/2022,Next delivery April 2022.  Estimated recovery 3Q 2022.,,,,Cardiovascular,Current,,,,2023,not available
11990,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Concentrate, 100 mg/5 mL (NDC 69784-200-96)",Reverified,12/19/2023,Product is available. Additional volumes expected to early 2024.,Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2,,Delay in shipping of the drug,Pulmonary/Allergy,Current,,,,2023,available
11991,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Concentrate, 100 mg/5 mL (NDC 76204-025-96)",Reverified,12/19/2023,Product is available. Additional volumes expected to early 2024.,"Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300",,Delay in shipping of the drug,Pulmonary/Allergy,Current,,,,2023,available
11992,Cromolyn Sodium Concentrate,"Rising Pharma Holdings, Inc.","Concentrate, 100 mg/5 mL (NDC 16571-600-96)",Reverified,12/21/2023,Unavailable; Anticipate availability January  2024,,,Delay in shipping of the drug,Pulmonary/Allergy,Current,,,,2023,not available
11993,Cromolyn Sodium Concentrate,Micro Labs LTD,"Concentrate, 100 mg/5 mL (NDC 42571-132-52)",Reverified,12/20/2023,Available. On allocation due to high demand,,,Demand increase for the drug,Pulmonary/Allergy,Current,,,,2023,limited availability
11994,Cromolyn Sodium Concentrate,"Mylan Specialty, a Viatris Company","Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)",Reverified,12/19/2023,Available,,,,Pulmonary/Allergy,Current,,,,2023,available
11995,Cromolyn Sodium Oral Solution,"Mylan Institutional, a Viatris Company","Oral Solution, 100mg/5mL (NDC 51525-0470-9)",New,11/1/2023,,Gastrocrom 100mg/5mL Oral Concentrate 96s (NDC: 0037-0678-96) will remain available,,Discontinuation of the manufacture of the drug,Pulmonary/Allergy,To Be Discontinued,,11/1/2023,,2023,discontinued
11996,Cyclopentolate Hydrochloride Ophthalmic Solution,Bausch & Lomb Incorporated,"Pentolair, Ophthalmic Solution, 10 mg/1 mL (NDC 24208-735-06)",Reverified,12/19/2023,Limited availability,Restock projected Q1 2024,,Demand increase for the drug,Ophthalmology,Current,,,,2023,limited availability
11997,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 5 mg/1 mL (NDC 0065-0395-15)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
11998,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 mg/1 mL (NDC 0065-0396-02)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
11999,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 mg/1 mL (NDC 0065-0396-05)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
12000,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 mg/1 mL (NDC 0065-0397-02)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
12001,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 mg/1 mL (NDC 0065-0397-05)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
12002,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 mg/1 mL (NDC 0065-0397-15)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
12003,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 mg/1 mL (NDC 61314-396-01)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
12004,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 mg/1 mL (NDC 61314-396-03)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
12005,Cyclopentolate Hydrochloride Ophthalmic Solution,Bausch & Lomb Incorporated,"Pentolair, Ophthalmic Solution, 10 mg/1 mL (NDC 24208-735-01)",Reverified,12/19/2023,Limited availability,Restock projected Q1 2024,,Demand increase for the drug,Ophthalmology,Current,,,,2023,limited availability
12006,"Cyclopentolate Hydrochloride, Phenylephrine Hydrochloride Ophthalmic Solution",Alcon,"Cyclomydril, Ophthalmic Solution, 2 mg/1 mL; 10 mg/1 mL (NDC 0065-0359-02)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
12007,"Cyclopentolate Hydrochloride, Phenylephrine Hydrochloride Ophthalmic Solution",Alcon,"Cyclomydril, Ophthalmic Solution, 2 mg/1 mL; 10 mg/1 mL (NDC 0065-0359-05)",Reverified,12/19/2023,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,,2023,available
12008,Cyclosporine Injection,Padagis US LLC,"Injection, 250 mg/5 mL (50 mg/mL) in 5 mL Ampule (NDC 0574-0866-10)",New,9/29/2023,,Discontinuation of the manufacture of the product.,,Discontinuation of the manufacture of the drug,Transplant,To Be Discontinued,,9/29/2023,,2023,discontinued
12009,Cytarabine Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/1 mL (NDC 63323-120-20)",Reverified,12/20/2023,Limited Availability,"2, 3, & 4 month expiry (1/31/2024, 2/29/2024, 3/31/2024  expiry) dating available by request. Next release December 2023.",,Regulatory delay,Oncology; Pediatric,Current,,,,2023,limited availability
12010,Cytarabine Injection,"Hospira, Inc., a Pfizer Company","Cytarabine, Injection, 20 mg/1 mL (NDC 61703-305-38)",Reverified,9/11/2023,Limited Supply Available. Next delivery: November 2023; Estimated recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Oncology; Pediatric,Current,,,,2023,limited availability
12011,Cytarabine Injection,"Hospira, Inc., a Pfizer Company","Cytarabine, Injection, 100 mg/1 mL (NDC 61703-319-22)",Reverified,12/19/2023,Available,,,,Oncology; Pediatric,Current,,,,2023,available
12012,Cytarabine Injection,"Hospira, Inc., a Pfizer Company","Cytarabine, Injection, 20 mg/1 mL (NDC 61703-304-36)",Reverified,12/19/2023,Available,,,,Oncology; Pediatric,Current,,,,2023,available
12013,Cytarabine Injection,"Hospira, Inc., a Pfizer Company","Cytarabine, Injection, 20 mg/1 mL (NDC 61703-303-46)",Reverified,12/19/2023,Available,,,,Oncology; Pediatric,Current,,,,2023,available
12014,Cytarabine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 2 g/20 mL (NDC 71288-109-20)",Reverified,12/19/2023,Available,,,,Oncology; Pediatric,Current,,,,2023,available
12015,Dacarbazine Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-127-10)",Reverified,12/20/2023,Next release December 2023.,Check wholesaler inventory,,Regulatory delay,Oncology,Current,,,,2023,not available
12016,Dacarbazine Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-128-20)",Reverified,12/20/2023,Backordered.  Next release December 2023.,Check wholesaler inventory,,Regulatory delay,Oncology,Current,,,,2023,not available
12017,Dacarbazine Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 200 mg per Vial (NDC 0143-9245-10)",Reverified,12/19/2023,This presentation is temporarily on backorder.,Additional lots will be available in the December 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,,2023,not available
12018,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Cosmegen, Injection, .5 mg/1 mL (NDC 55292-811-55)",New,10/16/2023,,,,,Oncology,To Be Discontinued,,10/16/2023,,2023,discontinued
12019,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Injection, .5 mg/1 mL (NDC 66993-489-35)",New,10/16/2023,,Authorized generic distributed by Prasco Laboratories,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,10/16/2023,,2023,discontinued
12020,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Injection, .5 mg/1 mL (NDC 66993-489-83)",New,10/16/2023,,Authorized generic distributed by Prasco Laboratories,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,10/16/2023,,2023,discontinued
12021,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 10 mg (NDC 0781-8218-01)",New,2/14/2023,,,,,Psychiatry,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12022,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 25 mg (NDC 0781-8972-01)",New,2/14/2023,,,,,Psychiatry,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12023,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 50 mg (NDC 0781-8973-01)",New,2/14/2023,,,,,Psychiatry,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12024,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 75 mg (NDC 0781-8974-01)",New,2/14/2023,,,,,Psychiatry,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12025,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 100 mg (NDC 0781-8975-01)",New,2/14/2023,,,,,Psychiatry,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12026,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 150 mg (NDC 0781-8976-50)",New,2/14/2023,,,,,Psychiatry,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12027,Desmopressin Acetate Spray,Apotex Corp.,"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)",Reverified,12/20/2023,Available,,,,Hematology,Current,,,,2023,available
12028,Desmopressin Acetate Spray,Ferring,"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)",Reverified,12/19/2023,Unavailable,,,Demand increase for the drug,Hematology,Current,,,,2023,not available
12029,Desmopressin Acetate Spray,Ferring,"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)",Reverified,12/19/2023,Unavailable,,,Demand increase for the drug,Hematology,Current,,,,2023,not available
12030,Desmopressin Acetate Spray,Ferring,"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)",Reverified,12/19/2023,Unavailable,,,Demand increase for the drug,Hematology,Current,,,,2023,not available
12031,Desmopressin Acetate Tablet,"Teva Pharmaceuticals USA, Inc.","Desmopressin Acetate, Tablet, .1 mg (NDC 0591-2464-01)",New,3/14/2023,,,,,Gastroenterology,To Be Discontinued,3/14/2023,3/14/2023,,2023,discontinued
12032,Desmopressin Acetate Tablet,"Teva Pharmaceuticals USA, Inc.","Desmopressin Acetate, Tablet, .2 mg (NDC 0591-2465-01)",New,3/14/2023,,,,,Gastroenterology,To Be Discontinued,3/14/2023,3/14/2023,,2023,discontinued
12033,"Desvenlafaxine Succinate Tablet, Extended Release",Pfizer Inc.,"Pristiq, Tablet, Extended Release, 100 mg (NDC 59762-1222-3)",New,6/20/2023,,Discontinuation of the manufacture of the drug; Supply expected to exhaust late July 2023,,,Psychiatry,To Be Discontinued,6/20/2023,6/20/2023,,2023,discontinued
12034,"Desvenlafaxine Succinate Tablet, Extended Release",Pfizer Inc.,"Pristiq, Tablet, Extended Release, 50 mg (NDC 59762-1211-3)",New,6/20/2023,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,6/20/2023,6/20/2023,,2023,discontinued
12035,"Desvenlafaxine Succinate Tablet, Extended Release",Pfizer Inc.,"Pristiq, Tablet, Extended Release, 25 mg (NDC 59762-1210-3)",New,9/11/2023,,Discontinuation of the manufacture of the drug; Supply expected to exhaust November 2023,,,Psychiatry,To Be Discontinued,9/11/2023,9/11/2023,,2023,discontinued
12036,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 10 mg/1 mL (NDC 55150-304-25)",Revised,12/20/2023,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12037,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 100 mg/10 mL (NDC 55150-305-10)",Revised,12/20/2023,Currently on backorder - next shipment Jan,Intermittent availability expected,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,not available
12038,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 76045-106-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12039,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 76045-109-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12040,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Injection, 4 mg/1 mL (NDC 67457-423-12)",Reverified,12/21/2023,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12041,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Injection, 4 mg/1 mL (NDC 67457-422-54)",Reverified,12/21/2023,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12042,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Injection, 4 mg/1 mL (NDC 67457-421-30)",Reverified,12/21/2023,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12043,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Injection, 10 mg/1 mL (NDC 67457-420-10)",Reverified,12/21/2023,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12044,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 4 mg/1 mL (NDC 55150-237-01)",Reverified,12/20/2023,On long-term backorder,Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,not available
12045,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 4 mg/1 mL (NDC 55150-238-05)",Reverified,12/20/2023,On long-term backorder,Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,not available
12046,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 4 mg/1 mL (NDC 55150-239-30)",Revised,12/20/2023,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12047,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)",Reverified,12/19/2023,Limited Availability,,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,limited availability
12048,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-165-05)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12049,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-516-10)",Reverified,12/20/2023,Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,not available
12050,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-165-30)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12051,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-165-01)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12052,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12053,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)",Revised,12/19/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the May - June 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,not available
12054,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)",Revised,12/19/2023,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing and will be available in the June 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,not available
12055,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)",Revised,12/19/2023,Inventory is currently available,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2023,available
12056,"Dexamethasone, Tobramycin Suspension/ Drops",Novartis Pharmaceuticals Corporation,"Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-40)",New,6/26/2023,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEXÂ® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.  Product will be available until approximately September 2023.  The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz.  Other generic equivalents are also available.",,,Ophthalmology,To Be Discontinued,6/26/2023,6/26/2023,,2023,discontinued
12057,"Dexamethasone, Tobramycin Suspension/ Drops",Novartis Pharmaceuticals Corporation,"Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-25)",New,6/26/2023,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEXÂ® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.  Product will be available until approximately September 2023.  The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz.  Other generic equivalents are also available.",,,Ophthalmology,To Be Discontinued,6/26/2023,6/26/2023,,2023,discontinued
12058,"Dexamethasone, Tobramycin Suspension/ Drops",Novartis Pharmaceuticals Corporation,"Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-26)",New,6/26/2023,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEXÂ® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.  Product will be available until approximately September 2023.  The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz.  Other generic equivalents are also available.",,,Ophthalmology,To Be Discontinued,6/26/2023,6/26/2023,,2023,discontinued
12059,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12060,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12061,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 4 ug/1 mL (NDC 42023-186-20)",Revised,11/1/2023,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
12062,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 4 ug/1 mL (NDC 42023-187-10)",Revised,11/1/2023,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
12063,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)",Reverified,9/12/2023,Available,,,,Anesthesia,Current,,,,2023,available
12064,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)",Reverified,9/12/2023,Available,,,,Anesthesia,Current,,,,2023,available
12065,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 ug/1 mL (NDC 70121-1388-8)",Revised,11/2/2023,Available,,,,Anesthesia,Current,,,,2023,available
12066,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 ug/1 mL (NDC 70121-1389-7)",Revised,11/2/2023,Available,,,,Anesthesia,Current,,,,2023,available
12067,Dexmedetomidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)",Reverified,5/16/2023,Inventory is currently available,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12068,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)",Reverified,5/9/2023,Inventory available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12069,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)",Reverified,5/9/2023,Inventory available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12070,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12071,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12072,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)",Reverified,4/21/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12073,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)",Reverified,4/21/2022,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12074,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)",Reverified,12/19/2023,Currently on backorder - next shipment TBD,Check wholesalers for inventory,,Delay in shipping of the drug,Anesthesia,Current,,,,2023,not available
12075,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)",Reverified,12/21/2023,Available,,,,Anesthesia,Current,,,,2023,available
12076,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)",Reverified,12/21/2023,Available,,,,Anesthesia,Current,,,,2023,available
12077,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)",Reverified,12/21/2023,Available,,,,Anesthesia,Current,,,,2023,available
12078,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)",Reverified,12/21/2023,Available,,,,Anesthesia,Current,,,,2023,available
12079,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 4 ug/1 mL (NDC 63323-671-20)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12080,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 4 ug/1 mL (NDC 63323-671-50)",Revised,11/29/2023,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12081,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 4 ug/1 mL (NDC 63323-671-00)",Revised,11/29/2023,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12082,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 100 ug/1 mL (NDC 63323-421-02)",Revised,11/29/2023,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12083,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Injection, 100 ug/1 mL (NDC 44567-600-04)",Reverified,12/20/2023,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,,2023,available
12084,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Injection, 100 ug/1 mL (NDC 44567-601-04)",Reverified,12/20/2023,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,,2023,available
12085,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Injection, 4 ug/1 mL (NDC 44567-602-24)",Reverified,12/20/2023,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,,2023,available
12086,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Injection, 4 ug/1 mL (NDC 44567-603-24)",Reverified,12/20/2023,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,,2023,available
12087,Dexmedetomidine Hydrochloride Injection,Jiangsu Hengrui Medicine Co. Ltd.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70860-605-03)",Reverified,3/10/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12088,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)",Reverified,9/12/2023,Available,,,,Anesthesia,Current,,,,2023,available
12089,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 100 ug/1 mL (NDC 42023-146-25)",Revised,11/1/2023,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
12090,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 4 ug/1 mL (NDC 0409-1660-20)",Revised,9/11/2023,Limited Supply Available. Next Delivery: October 2023; Estimated Recovery: December 2023,,,,Anesthesia,Current,,,,2023,limited availability
12091,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 4 ug/1 mL (NDC 0409-1660-50)",Revised,9/11/2023,Available,,,,Anesthesia,Current,,,,2023,available
12092,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 4 ug/1 mL (NDC 0409-1660-10)",Revised,9/11/2023,Available,,,,Anesthesia,Current,,,,2023,available
12093,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 100 ug/1 mL (NDC 0409-1638-02)",Revised,9/11/2023,Limited Supply Available,Limited Supply Available. Check Wholesaler for Availability,,,Anesthesia,Current,,,,2023,limited availability
12094,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)",Reverified,12/28/2022,Available,,,,Anesthesia,Current,,,,2023,available
12095,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)",Reverified,12/28/2022,Available,,,,Anesthesia,Current,,,,2023,available
12096,Dexmedetomidine Hydrochloride Injection,"Meitheal Pharmaceuticals, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)",Revised,2/13/2023,Available on allocation.,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
12097,Dextrose Monohydrate Injection,"Amphastar Pharmaceuticals, Inc.","Dextrose 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)",Reverified,12/19/2023,Backorder due to increase in demand,old NDC 76329-3301-1,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
12098,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose, Injection, 25 g/50 mL (NDC 0409-7517-16)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
12099,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose, Injection, 25 g/50 mL (NDC 0409-4902-34)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
12100,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose, Injection, 25 g/50 mL (NDC 0409-6648-02)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
12101,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 g/100 mL (NDC 0264-7510-10)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12102,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 g/100 mL (NDC 0264-7510-00)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12103,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 g/100 mL (NDC 0264-7510-20)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12104,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12105,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12106,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-00)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12107,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-10)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12108,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-20)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12109,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-03",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12110,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-55",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12111,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-09",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12112,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12113,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12114,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12115,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-00)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12116,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-10)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12117,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-20)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12118,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)",Reverified,12/20/2023,Next release March 2024.,Check wholesalers for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,not available
12119,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12120,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12121,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-02)",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12122,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-03",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12123,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-09",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12124,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)",Reverified,12/19/2023,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7938-19",,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,not available
12125,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose, Injection, 250 mg/1 mL (NDC 0409-1775-10)",Reverified,9/11/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,limited availability
12126,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0409-7100-66)",Reverified,9/11/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12127,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0409-7100-67)",Reverified,9/11/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12128,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0409-7100-02)",Reverified,9/11/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12129,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-61)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12130,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-74)",Reverified,12/20/2023,Next release date not available at this time. Check wholesaler inventory.,Check wholesaler inventory,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,unclear
12131,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-75)",Reverified,12/20/2023,Available. Check wholesaler for inventory,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12132,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-10)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12133,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-50)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12134,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-02",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12135,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-61",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12136,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-13",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12137,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-20",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12138,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-23",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12139,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-36",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12140,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-37",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12141,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12142,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12143,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12144,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12145,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12146,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12147,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12148,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12149,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9143-30)",Reverified,12/21/2023,Available on allocation,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
12150,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9147-30)",Reverified,12/19/2023,Available on allocation,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
12151,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12152,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12153,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12154,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12155,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12156,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2023,available
12157,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12158,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12159,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12160,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 20 mg/4 mL (NDC 68682-655-20)",Reverified,12/21/2023,Available,,,,Neurology,Current,,,,2023,available
12161,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 10 mg/2 mL (NDC 68682-652-20)",Reverified,12/21/2023,Available,,,,Neurology,Current,,,,2023,available
12162,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 2.5 mg/.5 mL (NDC 68682-650-20)",Reverified,12/19/2023,"Currently unavailable, delayed until November 8th",Estimated availability September 2023,,Delay in shipping of the drug,Neurology,Current,,,,2023,not available
12163,Diazepam Gel,"Lupin Pharmaceuticals, Inc.","Gel, 10 mg/2 g (NDC 43386-280-01)",New,11/6/2023,Available,,,,Neurology,Current,,,,2023,available
12164,Diazepam Gel,"Lupin Pharmaceuticals, Inc.","Gel, 20 mg/4 g (NDC 43386-281-01)",Reverified,12/19/2023,Available,,,,Neurology,Current,,,,2023,available
12165,Diclofenac Sodium Gel,Amneal Pharmaceuticals,"Diclofenac Sodium, Gel, 10 mg/1 g (NDC 65162-833-66)",New,8/1/2023,,,,,Analgesia/Addiction,To Be Discontinued,8/1/2023,8/1/2023,,2023,discontinued
12166,Dicyclomine Hydrochloride Injection,"Allergan, Inc.","Bentyl, Injection, 20 mg/2 mL (NDC 58914-080-52)",New,7/31/2023,,Discontinuation of the manufacture of the drug,,,Gastroenterology,To Be Discontinued,7/31/2023,7/31/2023,,2023,discontinued
12167,"Diflunisal Tablet, Film Coated","Avet Pharmaceuticals, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 14539-673-06)",Revised,8/4/2023,,,Available,,Analgesia/Addiction,Resolved,8/4/2023,,,2023,
12168,"Diflunisal Tablet, Film Coated","Avet Pharmaceuticals, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 14539-673-01)",Revised,8/4/2023,,,Available,,Analgesia/Addiction,Resolved,8/4/2023,,,2023,
12169,"Diflunisal Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 0093-9222-01)",Revised,8/4/2023,,,Available,,Analgesia/Addiction,Resolved,8/4/2023,,,2023,
12170,"Diflunisal Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 0093-9222-05)",Revised,8/4/2023,,,Available,,Analgesia/Addiction,Resolved,8/4/2023,,,2023,
12171,"Diflunisal Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 0093-9222-06)",Revised,8/4/2023,,,Available,,Analgesia/Addiction,Resolved,8/4/2023,,,2023,
12172,Difluprednate Emulsion,Amneal Pharmaceuticals,"Emulsion, .5 mg/1 mL (NDC 69238-1380-3)",Reverified,12/19/2023,Available,,,,Ophthalmology,Current,,,,2023,available
12173,Difluprednate Emulsion,Sandoz Inc.,"Durezol, Emulsion, .5 mg/1 mL (NDC 0078-0862-25)",Reverified,12/19/2023,"Unavailable; Resupply November 20, 2023",,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2023,not available
12174,Difluprednate Emulsion,Sandoz Inc.,"Durezol, Emulsion, .5 mg/1 mL (NDC 0781-6000-78)",Reverified,12/19/2023,Available; Currently have 7.5 months of coverage,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2023,available
12175,Difluprednate Emulsion,Cipla Limited,"Difluprednate, Emulsion, .5 mg/1 mL (NDC 69097-341-35)",Reverified,12/19/2023,Currently unavailable,,,Demand increase for the drug,Ophthalmology,Current,,,,2023,not available
12176,Digoxin Injection,"Hikma Pharmaceuticals USA, Inc.","Digoxin, Injection, .25 mg/1 mL (NDC 0641-1410-35)",Reverified,4/8/2022,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,,2023,available
12177,Digoxin Injection,Sandoz Inc.,"Injection, 250 ug/1 mL (NDC 0781-3059-95)",Revised,11/1/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12178,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 250 ug/1 mL (NDC 70515-260-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12179,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 250 ug/1 mL (NDC 70515-261-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12180,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 100 ug/1 mL (NDC 70515-262-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12181,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 100 ug/1 mL (NDC 70515-263-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12182,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 mg/1 mL (NDC 70860-301-05)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12183,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 mg/1 mL (NDC 70860-301-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12184,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 mg/1 mL (NDC 70860-301-25)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12185,Diltiazem Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Diltiazem Hydrochloride, Injection, 100 mg (NDC 0409-4350-03)",Revised,12/19/2023,Limited Supply Available.  Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,limited availability
12186,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Diltiazem Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6013-10)",Revised,12/19/2023,This presentation is temporarily on backorder.,Product will be made available as it is released.,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,not available
12187,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Diltiazem Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6014-10)",Revised,12/19/2023,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Cardiovascular,Current,,,,2023,available
12188,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Diltiazem Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6015-10)",Revised,12/19/2023,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing and will be available in the June 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2023,not available
12189,Diltiazem Hydrochloride Injection,Eugia US LLC,"Injection, 125mg/ 25mL (NDC 55150-427-10)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12190,Diltiazem Hydrochloride Injection,Eugia US LLC,"Injection, 25mg/ 5mL (NDC 55150-425-10)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12191,Diltiazem Hydrochloride Injection,Eugia US LLC,"Injection, 50mg/10mL (NDC 55150-426-10)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12192,"Dipyridamole Tablet, Film Coated",ANI Pharmaceuticals,"Dipyridamole, Tablet, Film Coated, 25 mg (NDC 62559-235-01)",New,5/1/2023,,,,,Cardiovascular,To Be Discontinued,5/1/2023,5/1/2023,,2023,discontinued
12193,"Dipyridamole Tablet, Film Coated",ANI Pharmaceuticals,"Dipyridamole, Tablet, Film Coated, 50 mg (NDC 62559-236-01)",New,5/1/2023,,,,,Cardiovascular,To Be Discontinued,5/1/2023,5/1/2023,,2023,discontinued
12194,"Dipyridamole Tablet, Film Coated",ANI Pharmaceuticals,"Dipyridamole, Tablet, Film Coated, 75 mg (NDC 62559-237-01)",New,5/1/2023,,,,,Cardiovascular,To Be Discontinued,5/1/2023,5/1/2023,,2023,discontinued
12195,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace, Capsule, 100 mg (NDC 59762-0386-1)",Reverified,9/11/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12196,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace, Capsule, 150 mg (NDC 59762-0400-1)",Reverified,9/11/2023,Next Delivery & Estimated Recovery: September 2023,Shortage per Manufacturer: Manufacturing Delay,,,Cardiovascular,Current,,,,2023,not available
12197,Disopyramide Phosphate Capsule,"Teva Pharmaceuticals USA, Inc.","Capsule, 100 mg (NDC 0093-3127-01)",Reverified,12/6/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12198,Disopyramide Phosphate Capsule,"Teva Pharmaceuticals USA, Inc.","Capsule, 150 mg (NDC 0093-3129-01)",Reverified,12/6/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12199,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace Cr, Capsule, 100 mg, Extended Release (NDC 0025-2732-31)",Reverified,9/11/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12200,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace Cr, Capsule, 150 mg, Extended Release (NDC 0025-2742-31)",Reverified,9/11/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12201,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace, Capsule, 100 mg (NDC 0025-2752-31)",Reverified,9/11/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12202,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace, Capsule, 150 mg (NDC 0025-2762-31)",Reverified,9/11/2023,Next Delivery and Estimated Recovery: September 2023,Shortage per Manufacturer: Manufacturing Delay,,,Cardiovascular,Current,,,,2023,not available
12203,Disulfiram Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0054-0357-25)",New,11/2/2023,,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,To Be Discontinued,,11/2/2023,,2023,discontinued
12204,Disulfiram Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0054-0357-13)",New,11/2/2023,,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,To Be Discontinued,,11/2/2023,,2023,discontinued
12205,Disulfiram Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 250 mg (NDC 0054-0356-25)",New,11/2/2023,,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,To Be Discontinued,,11/2/2023,,2023,discontinued
12206,Disulfiram Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 250 mg (NDC 0054-0356-13)",New,11/2/2023,,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,To Be Discontinued,,11/2/2023,,2023,discontinued
12207,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)",Reverified,12/19/2023,Available on Allocation,,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,,2023,limited availability
12208,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)",Reverified,12/21/2023,Available on Allocation,,,,Cardiovascular; Pediatric; Renal,Current,,,,2023,limited availability
12209,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)",Revised,12/19/2023,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,,2023,available
12210,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Injection, 250 mg/20 mL (NDC 70436-203-80)",Reverified,12/19/2023,Available,"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988",,,Cardiovascular; Pediatric; Renal,Current,,,,2023,available
12211,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Injection, 500 mg/40 mL (NDC 70436-204-80)",Revised,11/1/2023,Unavailable,,,Discontinuation of the manufacture of the drug,Cardiovascular; Pediatric; Renal,To Be Discontinued,11/1/2023,11/1/2023,,2023,not available
12212,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)",Reverified,12/21/2023,Available on Allocation,,,,Cardiovascular; Pediatric; Renal,Current,,,,2023,limited availability
12213,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0409-2346-32)",Revised,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,,2023,not available
12214,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0409-2347-32)",Revised,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,,2023,not available
12215,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0409-3724-32)",Revised,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,,2023,not available
12216,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-01)",Reverified,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,,2023,limited availability
12217,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-02)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,,2023,limited availability
12218,"Dolutegravir Sodium Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Tivicay, Tablet, Film Coated, 10 mg (NDC 49702-226-13)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.  Tivicay 50 mg tablets (49702-228-13) will still be available as well as Tivicay PD 5 mg (49702-255-37).",,,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12219,"Dolutegravir Sodium Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Tivicay, Tablet, Film Coated, 25 mg (NDC 49702-227-13)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.  Tivicay 50 mg tablets (49702-228-13) will still be available as well as Tivicay PD 5 mg (49702-255-37).",,,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12220,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1.6 mg/1 mL (NDC 0409-7809-22)",Revised,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,,2023,not available
12221,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1.6 mg/1 mL (NDC 0409-7809-24)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,,2023,limited availability
12222,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 3.2 mg/1 mL (NDC 0409-7810-22)",Revised,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,,2023,not available
12223,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0409-5820-01)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,,2023,limited availability
12224,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0409-9104-20)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,,2023,limited availability
12225,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)",Reverified,12/21/2023,Available on Allocation,,,,Cardiovascular,Current,,,,2023,limited availability
12226,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 40 mg/1 mL (NDC 0143-9252-25)",Reverified,12/19/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024  timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,,2023,not available
12227,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 40 mg/1 mL (NDC 0143-9254-25)",Reverified,12/19/2023,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,,Cardiovascular,Current,,,,2023,available
12228,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)",Reverified,12/21/2023,Available on Allocation,,,,Cardiovascular,Current,,,,2023,limited availability
12229,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)",Reverified,12/21/2023,Available on Allocation,,,,Cardiovascular,Current,,,,2023,limited availability
12230,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)",Reverified,12/21/2023,Available on Allocation,,,,Cardiovascular,Current,,,,2023,limited availability
12231,Doxercalciferol Capsule,Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, .5 ug (NDC 0955-1720-50)",New,5/19/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/2023,5/19/2023,,2023,discontinued
12232,Doxercalciferol Capsule,Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, 1 ug (NDC 0955-1721-50)",New,5/19/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/2023,5/19/2023,,2023,discontinued
12233,Doxercalciferol Capsule,Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, 2.5 ug (NDC 0955-1722-50)",New,5/19/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/2023,5/19/2023,,2023,discontinued
12234,"Doxercalciferol Capsule, Liquid Filled",Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, Liquid Filled, .5 ug (NDC 58468-0120-1)",New,5/19/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/2023,5/19/2023,,2023,discontinued
12235,"Doxercalciferol Capsule, Liquid Filled",Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, Liquid Filled, 1 ug (NDC 58468-0124-1)",New,5/19/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/2023,5/19/2023,,2023,discontinued
12236,"Doxercalciferol Capsule, Liquid Filled",Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, Liquid Filled, 2.5 ug (NDC 58468-0121-1)",New,5/19/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/2023,5/19/2023,,2023,discontinued
12237,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, .75 mg/.5 mL (NDC 0002-1433-80)",Reverified,12/12/2023,Limited Availability through January 2024.,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
12238,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 1.5 mg/.5 mL (NDC 0002-1434-80)",Reverified,12/19/2023,Limited Availability through March 2024.,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
12239,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 3 mg/.5 mL (NDC 0002-2236-80)",Reverified,12/19/2023,Limited Availability through January 2024.,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
12240,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 4.5 mg/.5 mL (NDC 0002-3182-80)",Reverified,12/19/2023,Limited Availability mid-December 2023 to January 2024.,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
12241,Echothiophate Iodide Ophthalmic Solution,Fera Pharmaceuticals,"Phospholine Iodide, Ophthalmic Solution, 0.125%  (NDC 48102-053-05)",Revised,12/11/2023,Available through limited distribution by AllianceRx Walgreens Specialty Pharmacy.,,,Delay in shipping of the drug,Ophthalmology,Current,,,,2023,limited availability
12242,Edetate Calcium Disodium Injection,"Casper Pharma, LLC","Injection, 200 mg/mL; 5 mL in 1 VIAL (NDC 64980-588-05)",Revised,10/24/2023,Available,Available,Available,,Other,Resolved,10/24/2023,,,2023,available
12243,Edetate Calcium Disodium Injection,"Casper Pharma, LLC","Injection, 200 mg/mL; 5 VIAL in 1 CARTON (NDC 64980-588-51)",Revised,10/24/2023,Available,Available,Available,,Other,Resolved,10/24/2023,,,2023,available
12244,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 2.5 mg/2 mL (NDC 0143-9786-10)",Reverified,12/19/2023,This presentation is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Cardiovascular,Current,,,,2023,available
12245,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1.25 mg/1 mL (NDC 0143-9787-10)",Reverified,12/19/2023,This presentation is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Cardiovascular,Current,,,,2023,available
12246,Epinastine Hydrochloride Solution/ Drops,"Breckenridge Pharmaceutical, Inc.","Epinastine Hydrochloride, Solution/ Drops, .5 mg/1 mL (NDC 51991-836-75)",New,4/12/2023,,,,,Ophthalmology,To Be Discontinued,4/12/2023,4/12/2023,,2023,discontinued
12247,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory,,,Anesthesia; Pediatric,Current,,,,2023,available
12248,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)",Revised,11/29/2023,Limited Availability,Next release December 2023. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,limited availability
12249,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)",Revised,11/29/2023,Limited Availability,Next release December 2023. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,limited availability
12250,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)",Revised,11/29/2023,Unavailable,Next release December 2023. Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12251,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,,,2023,available
12252,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)",Revised,11/29/2023,Limited Availability,Next release December 2023. Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,limited availability
12253,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)",Revised,11/29/2023,Available,Available - Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,,,2023,available
12254,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12255,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)",Revised,11/29/2023,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12256,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)",Revised,11/29/2023,Backordered. Next release not available at this time.,,,Delay in shipping of the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12257,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12258,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)",Revised,11/29/2023,Unavailable,Next release December 2023.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12259,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 5 ug/1 mL; 5 mg/1 mL (NDC 0409-3177-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12260,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 10 mg/1 mL (NDC 0409-3178-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12261,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 10 mg/1 mL (NDC 0409-3178-02)",Reverified,9/11/2023,Next Delivery: January 2024; Estimated Recovery: September 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12262,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 10 mg/1 mL (NDC 0409-3178-03)",Reverified,9/11/2023,Depleted,,,,Anesthesia; Pediatric,Current,,,,2023,not available
12263,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 5 ug/1 mL; 15 mg/1 mL (NDC 0409-1209-01)",Reverified,9/11/2023,Next Delivery: July 2024; Estimated Recovery: September 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12264,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 5 ug/1 mL; 15 mg/1 mL (NDC 0409-3181-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12265,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 20 mg/1 mL (NDC 0409-3182-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12266,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 20 mg/1 mL (NDC 0409-3182-02)",Reverified,9/11/2023,Depleted,,,,Anesthesia; Pediatric,Current,,,,2023,not available
12267,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 20 mg/1 mL (NDC 0409-3182-03)",Reverified,9/11/2023,Next Delivery: January 2024; Estimated Recovery: September 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12268,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 5 ug/1 mL; 20 mg/1 mL (NDC 0409-3183-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12269,Epinephrine Injection,"Hospira, Inc., a Pfizer Company","Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01)",Reverified,9/11/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Cardiovascular; Pulmonary/Allergy,Current,,,,2023,limited availability
12270,Epinephrine Injection,"Amphastar Pharmaceuticals, Inc.","Injection, .1 mg/1 mL (NDC 76329-3318-1)",Reverified,12/19/2023,Backorder due to the increase in demands,,,Demand increase for the drug,Cardiovascular; Pulmonary/Allergy,Current,,,,2023,not available
12271,EPINEPHRINE SOLUTION,Adamis Pharmaceuticals Corporation,"SYMJEPI, SOLUTION, 0.15 mg/0.3 mL  (NDC 78670-131-02)",New,9/18/2023,,,,Discontinuation of the manufacture of the drug,Pulmonary/Allergy,To Be Discontinued,,9/18/2023,,2023,discontinued
12272,Erythromycin Ointment,Fera Pharmaceuticals,"Ointment, 5 mg/g (NDC 48102-057-11)",Reverified,12/19/2023,Available,,,,Ophthalmology; Pediatric,Current,,,,2023,available
12273,Erythromycin Ointment,Padagis US LLC,"Ointment, 5 mg/1 g (NDC 0574-4024-50)",Reverified,12/19/2023,"Product available until Mid-November, no availability after November 2023: Estimated Shortage duration TBD",,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,2023,limited availability
12274,Erythromycin Ointment,Padagis US LLC,"Ointment, 5 mg/1 g (NDC 0574-4024-35)",Reverified,12/19/2023,"Product available until Mid-November, no availability after November 2023: Estimated Shortage duration TBD",,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,2023,limited availability
12275,Erythromycin Ointment,"Bausch Health Americas, Inc.","Ointment, 5 mg/1 g (NDC 24208-910-55)",Reverified,12/21/2023,Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.,,,Delay in shipping of the drug,Ophthalmology; Pediatric,Current,,,,2023,limited availability
12276,Erythromycin Ointment,Padagis US LLC,"Ointment, 5 mg/1 g (NDC 0574-4024-39)",Reverified,12/19/2023,"Product available until Mid-November, no availability after November 2023: Estimated Shortage duration TBD",,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,2023,limited availability
12277,Erythromycin Ointment,"Bausch Health Americas, Inc.","Ointment, 5 mg/1 g (NDC 24208-910-19)",Reverified,12/21/2023,Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.,,,Delay in shipping of the drug,Ophthalmology; Pediatric,Current,,,,2023,limited availability
12278,Estramustine Phosphate Sodium Capsule,Pfizer Inc.,"Emcyt, Capsule, 140 mg (NDC 0013-0132-02)",New,5/18/2023,,Supply expected to exhaust late January 2024,,,Oncology,To Be Discontinued,5/18/2023,5/18/2023,,2023,discontinued
12279,"Ethacrynate Sodium Powder, For Solution","Bausch Health Americas, Inc.","Edecrin, Powder, For Solution, 50 mg/50 mL (NDC 68682-012-27)",New,2/24/2023,,"Marketed by Oceanside Pharmaceuticals, a division of Bausch Health U.S.  Current Inventory run out 4/1/23. No further manufacturing is scheduled.",,,Cardiovascular; Pediatric,To Be Discontinued,2/24/2023,2/24/2023,,2023,discontinued
12280,"Ethacrynate Sodium Powder, For Solution","Bausch Health Americas, Inc.","Edecrin, Powder, For Solution, 50 mg/50 mL (NDC 68682-012-50)",New,2/24/2023,,"Marketed by Oceanside Pharmaceuticals, a division of Bausch Health U.S.  Current Inventory run out 4/1/23. No further manufacturing is scheduled.",,,Cardiovascular; Pediatric,To Be Discontinued,2/24/2023,2/24/2023,,2023,discontinued
12281,"Ethacrynate Sodium Powder, For Solution","Bausch Health Americas, Inc.","Edecrin, Powder, For Solution, 50 mg/50 mL (NDC 25010-210-27)",New,2/24/2023,,Current Inventory run out 4/1/23. No further manufacturing is scheduled.,,,Cardiovascular; Pediatric,To Be Discontinued,2/24/2023,2/24/2023,,2023,discontinued
12282,Ethinyl Estradiol/Norethindrone/Ferrous Fumarate Tablet,"Allergan Sales, LLC","Minastrin 24 Fe, Tablet, 1 mg/0.02 mg (NDC 0430-0540-50)",New,4/5/2023,,,,,Reproductive,To Be Discontinued,4/5/2023,4/5/2023,,2023,discontinued
12283,"Etodolac Tablet, Coated",Sandoz Inc.,"Etodolac, Tablet, Coated, 400 mg (NDC 0185-0675-01)",New,2/14/2023,,Discontinuation of the manufacture of the product,,,Analgesia/Addiction,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12284,"Etodolac Tablet, Coated",Sandoz Inc.,"Etodolac, Tablet, Coated, 400 mg (NDC 0185-0675-10)",New,2/14/2023,,Discontinuation of the manufacture of the product,,,Analgesia/Addiction,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12285,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 mg/1 mL (NDC 65219-445-10)",Revised,11/2/2023,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,,,2023,available
12286,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 40 mg/20 mL (NDC 65219-445-20)",Revised,11/2/2023,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,,,2023,available
12287,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 mg/1 mL (NDC 25021-674-10)",Reverified,12/19/2023,Available,Marketed by Sagent,,,Anesthesia,Current,,,,2023,available
12288,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 mg/1 mL (NDC 25021-674-20)",Reverified,12/19/2023,Available,Marketed by Sagent,,,Anesthesia,Current,,,,2023,available
12289,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)",Revised,8/22/2023,Pending information,Distributed by Civica,,,Anesthesia,Current,,,,2023,unclear
12290,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)",Revised,8/22/2023,Pending information,Distributed by Civica,,,Anesthesia,Current,,,,2023,unclear
12291,Etomidate Injection,Eugia US LLC,"Injection, 20 mg/10 mL (NDC 55150-221-10)",Reverified,12/19/2023,Available,"Manufactured by Eugia Pharma Specialties, Ltd.",,,Anesthesia,Current,,,,2023,available
12292,Etomidate Injection,Eugia US LLC,"Injection, 40 mg/20 mL (NDC 55150-222-20)",Reverified,12/19/2023,Available,"Manufactured by Eugia Pharma Specialties, Ltd.",,,Anesthesia,Current,,,,2023,available
12293,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)",Revised,8/22/2023,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12294,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)",Revised,8/22/2023,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12295,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)",Revised,8/22/2023,Currently on backorder,,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12296,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)",Revised,8/22/2023,Currently on backorder,,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12297,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)",Revised,8/22/2023,Pending information,,,,Anesthesia,Current,,,,2023,unclear
12298,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)",Revised,8/22/2023,Pending information,,,,Anesthesia,Current,,,,2023,unclear
12299,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)",Reverified,9/12/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12300,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)",Reverified,9/12/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
12301,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
12302,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-02)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,,2023,not available
12303,"Exemestane Tablet, Film Coated","Hikma Pharmaceuticals USA, Inc.","Exemestane, Tablet, Film Coated, 25 mg (NDC 0054-0080-13)",New,6/28/2023,,,,,Oncology,To Be Discontinued,6/28/2023,6/28/2023,,2023,discontinued
12304,"Famotidine, Ibuprofen Tablet, Coated",Horizon Therapeutics,"Duexis, Tablet, Coated, 26.6 mg; 800 mg (NDC 70748-312-09)",New,8/17/2023,,Business decision to discontinue manufacture of the drug product,,,Analgesia/Addiction,To Be Discontinued,8/17/2023,8/17/2023,,2023,discontinued
12305,"Famotidine, Ibuprofen Tablet, Coated",Horizon Therapeutics,"Duexis, Tablet, Coated, 26.6 mg; 800 mg (NDC 75987-010-03)",New,8/17/2023,,Business decision to discontinue manufacture of the drug product,,,Analgesia/Addiction,To Be Discontinued,8/17/2023,8/17/2023,,2023,discontinued
12306,"Famotidine, Ibuprofen Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Ibuprofen And Famotidine, Tablet, Film Coated, 26.6 mg; 800 mg (NDC 0093-8107-98)",New,1/25/2023,,Business decision to discontinue manufacture of the drug product,,,Analgesia/Addiction,To Be Discontinued,1/25/2023,1/25/2023,,2023,discontinued
12307,Felbamate Oral Suspension,"Mylan Specialty, a Viatris Company","Felbatol® , Oral Suspension, 8 oz Each 5 mL contains 600 mg felbamate (NDC 0037-0442-67)",New,11/27/2023,,,,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,11/27/2023,,2023,discontinued
12308,Felbamate Oral Suspension,"Mylan Specialty, a Viatris Company","Felbatol®, Oral Suspension, 32 oz Each 5 mL contains 600 mg felbamate (NDC 0037-0442-17)",New,11/27/2023,,,,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,11/27/2023,,2023,discontinued
12309,Fenofibrate Tablet,Viatris,"Tablet, 160 mg (NDC 0378-7101-77)",New,10/16/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/16/2023,,2023,discontinued
12310,Fenofibrate Tablet,Viatris,"Tablet, 54 mg (NDC 0378-7100-77)",New,10/16/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/16/2023,,2023,discontinued
12311,Fenofibrate Tablet,AbbVie Inc.,"Tricor, Tablet, 145 mg (NDC 0074-3189-90)",New,10/16/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/16/2023,,2023,discontinued
12312,Fenofibrate Tablet,AbbVie Inc.,"Tricor, Tablet, 48 mg (NDC 0074-3173-90)",New,10/16/2023,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,10/16/2023,10/16/2023,,2023,discontinued
12313,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6247-25)",Revised,12/19/2023,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12314,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Injection, 50 ug/1 mL (NDC 63323-808-11)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12315,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12316,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12317,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12318,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12319,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12320,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate Preservative Free, Injection, 50 ug/1 mL (NDC 0409-1276-32)",Revised,12/19/2023,Next Delivery: February 2025; Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,not available
12321,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9093-32)",Revised,12/19/2023,Next Delivery: January 2024; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,not available
12322,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9093-35)",Revised,12/19/2023,Limited Supply Available. Next Delivery: February 2024; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,limited availability
12323,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-22)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,limited availability
12324,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-25)",Revised,12/19/2023,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12325,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-28)",Revised,12/19/2023,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12326,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-31)",Revised,12/19/2023,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12327,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-61)",Revised,12/19/2023,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12328,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)",Revised,12/19/2023,Unavailable,Inventory available in vial presentations.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,not available
12329,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)",Revised,12/19/2023,Unavailable,Inventory available in vial presentations.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,not available
12330,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)",Revised,12/19/2023,Currently not available,Inventory available in vial presentations.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,not available
12331,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6027-25)",Revised,12/19/2023,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12332,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6028-25)",Revised,12/19/2023,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12333,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6029-25)",Revised,12/19/2023,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12334,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6030-01)",Revised,12/19/2023,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,,2023,available
12335,Fluconazole Injection,Sagent Pharmaceuticals,"Fluconazole In Sodium Chloride 0.9% In Plastic Container, Injection, 2 mg/1 mL (NDC 25021-113-82)",Revised,9/18/2023,Backorder. Estimated availability October 2023,,,Regulatory delay,Anti-Infective,Current,,,,2023,not available
12336,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 50 mg  (NDC 0049-3410-30)",New,10/24/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/24/2023,,2023,discontinued
12337,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 200 mg (NDC 59762-5018-1)",New,8/31/2023,,Supply expected to exhaust September 2023; Discontinuation of the manufacture of the drug.,,,Anti-Infective,To Be Discontinued,8/31/2023,8/31/2023,,2023,discontinued
12338,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 100 mg (NDC 59762-5016-1)",New,6/20/2023,,Discontinuation of the manufacture of the drug; Supply expected to exhaust August 2023,,,Anti-Infective,To Be Discontinued,6/20/2023,6/20/2023,,2023,discontinued
12339,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 150 mg (NDC 59762-5017-1)",New,6/20/2023,,Discontinuation of the manufacture of the drug; Supply expected to exhaust June 2023,,,Anti-Infective,To Be Discontinued,6/20/2023,6/20/2023,,2023,discontinued
12340,Fludarabine Phosphate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 25 mg/1 mL (NDC 45963-621-51)",Reverified,12/19/2023,Temporarily Unavailable,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
12341,Fludarabine Phosphate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 25 mg/1 mL (NDC 0480-9772-01)",Reverified,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
12342,Fludarabine Phosphate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 50 mg/2 mL (NDC 45963-609-55)",Reverified,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
12343,Fludarabine Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 25 mg/1 mL (NDC 63323-192-02)",Reverified,12/20/2023,Available. Check wholesaler for inventory.,Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,,2023,available
12344,Fludarabine Phosphate Injection,"Areva Pharmaceuticals, Inc.","Fludarabine Phosphate, Injection, 25 mg/1 mL (NDC 59923-604-02)",Reverified,12/19/2023,"Available, To order call 1-812-399-0479",,,,Oncology,Current,,,,2023,available
12345,Fluorescein Sodium Injection,Long Grove Pharmaceuticals LLC,"Ak-fluor, Injection, 100 mg/1 mL (NDC 17478-253-10)",Revised,12/5/2023,,,Available,,Ophthalmology,Resolved,12/5/2023,,,2023,
12346,Fluorescein Sodium Injection,Long Grove Pharmaceuticals LLC,"Ak-fluor, Injection, 250 mg/1 mL (NDC 17478-250-20)",Revised,12/5/2023,,,Available,,Ophthalmology,Resolved,12/5/2023,,,2023,
12347,Fluorescein Sodium Injection,"Nexus Pharmaceuticals, LLC","Injection, 500 mg/1 mL (NDC 14789-122-05)",New,12/5/2023,Available,,Available,,Ophthalmology,Resolved,12/5/2023,,,2023,available
12348,Fluorescein Sodium Injection,"Nexus Pharmaceuticals, LLC","Injection, 250 mg/1 mL (NDC 14789-123-05)",Revised,12/5/2023,,,Available,,Ophthalmology,Resolved,12/5/2023,,,2023,
12349,Fluorescein Sodium Injection,Alcon,"Fluorescite, Injection, 100 mg/1 mL (NDC 0065-0092-65)",Revised,12/5/2023,,,Available,,Ophthalmology,Resolved,,,,2023,
12350,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 20 mg (NDC 0093-0807-01)",New,2/8/2023,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/2023,2/8/2023,,2023,discontinued
12351,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 20 mg (NDC 0093-0807-56)",New,2/8/2023,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/2023,2/8/2023,,2023,discontinued
12352,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 60 mg (NDC 0093-5262-56)",New,2/8/2023,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/2023,2/8/2023,,2023,discontinued
12353,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 10 mg (NDC 0093-7188-01)",New,2/8/2023,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/2023,2/8/2023,,2023,discontinued
12354,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 10 mg (NDC 0093-7188-10)",New,2/8/2023,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/2023,2/8/2023,,2023,discontinued
12355,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 10 mg (NDC 0093-7188-56)",New,2/8/2023,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/2023,2/8/2023,,2023,discontinued
12356,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Capsule, 15 mg (NDC 0378-4415-01)",Reverified,12/21/2023,Anticipated availability: June 2024,Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,,,2023,not available
12357,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Capsule, 30 mg (NDC 0378-4430-01)",Reverified,12/21/2023,Anticipated availability: June 2024,Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,,,2023,not available
12358,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Capsule, 15 mg (NDC 62135-736-90)",Reverified,12/20/2023,Product available through all wholesalers,,,,Oncology; Other,Current,,,,2023,available
12359,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Capsule, 30 mg (NDC 62135-737-90)",Reverified,12/20/2023,Product available through all wholesalers,,,,Neurology; Other,Current,,,,2023,available
12360,"Fluticasone Propionate Aerosol, Metered",GlaxoSmithKline,"Flovent Hfa, Aerosol, Metered, 44 ug (NDC 0173-0718-20)",New,6/2/2023,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/2023,6/2/2023,,2023,discontinued
12361,"Fluticasone Propionate Aerosol, Metered",GlaxoSmithKline,"Flovent Hfa, Aerosol, Metered, 110 ug (NDC 0173-0719-20)",New,6/2/2023,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/2023,6/2/2023,,2023,discontinued
12362,"Fluticasone Propionate Aerosol, Metered",GlaxoSmithKline,"Flovent Hfa, Aerosol, Metered, 220 ug (NDC 0173-0720-20)",New,6/2/2023,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/2023,6/2/2023,,2023,discontinued
12363,Fluticasone Propionate Cream,Sandoz Inc.,"Fluticasone Propionate, Cream, .5 mg/1 g (NDC 0168-0332-15)",New,8/7/2023,,,,,Dermatology,To Be Discontinued,8/7/2023,8/7/2023,,2023,discontinued
12364,Fluticasone Propionate Cream,Sandoz Inc.,"Fluticasone Propionate, Cream, .5 mg/1 g (NDC 0168-0332-30)",New,8/7/2023,,,,,Dermatology,To Be Discontinued,8/7/2023,8/7/2023,,2023,discontinued
12365,Fluticasone Propionate Cream,Sandoz Inc.,"Fluticasone Propionate, Cream, .5 mg/1 g (NDC 0168-0332-60)",New,8/7/2023,,,,,Dermatology,To Be Discontinued,8/7/2023,8/7/2023,,2023,discontinued
12366,"Fluticasone Propionate Powder, Metered",GlaxoSmithKline,"Flovent, Powder, Metered, 50 ug (NDC 0173-0600-02)",New,6/2/2023,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/2023,6/2/2023,,2023,discontinued
12367,"Fluticasone Propionate Powder, Metered",GlaxoSmithKline,"Flovent, Powder, Metered, 100 ug (NDC 0173-0602-02)",New,6/2/2023,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/2023,6/2/2023,,2023,discontinued
12368,"Fluticasone Propionate Powder, Metered",GlaxoSmithKline,"Flovent, Powder, Metered, 250 ug (NDC 0173-0601-02)",New,6/2/2023,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/2023,6/2/2023,,2023,discontinued
12369,Fosamprenavir Calcium Suspension,GlaxoSmithKline (ViiV Healthcare),"Lexiva, Suspension, 50 mg/1 mL (NDC 49702-208-53)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.",,,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12370,"Fosamprenavir Calcium Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Lexiva, Tablet, Film Coated, 700 mg (NDC 49702-207-18)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.",,,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12371,Fulvestrant Solution,"Teva Pharmaceuticals USA, Inc.","Solution, 250 mg/5 mL (NDC 0591-5019-02)",New,10/26/2023,,Business Decision to Discontinue.,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,10/26/2023,,2023,discontinued
12372,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 70860-302-02)",Revised,12/19/2023,Available,Use Sagent NDC 25021-311-02,,Demand increase for the drug,Cardiovascular,Current,,,,2023,available
12373,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 70860-302-04)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12374,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 70860-302-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12375,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-500-08)",Revised,12/19/2023,Unavailable,Inventory on hold pending further assessment.,,Regulatory delay,Cardiovascular,Current,,,,2023,not available
12376,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-501-43)",Revised,12/19/2023,Unavailable,Inventory on hold pending further assessment.,,Regulatory delay,Cardiovascular,Current,,,,2023,not available
12377,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-502-43)",Revised,12/19/2023,Unavailable,Inventory on hold pending further assessment.,,Regulatory delay,Cardiovascular,Current,,,,2023,not available
12378,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-27)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12379,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)",Reverified,2/13/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12380,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 71288-203-05)",Revised,12/19/2023,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2023,available
12381,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 71288-203-11)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12382,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/mL, 2 mL (NDC 70860-302-41)",Revised,12/19/2023,No longer ordering APD NDC,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
12383,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/mL, 4 mL (NDC 70860-302-42)",Revised,12/19/2023,No longer ordering APD NDC,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
12384,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/mL, 10 mL (NDC 70860-302-43)",Revised,12/19/2023,No longer ordering APD NDC,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
12385,Furosemide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-280-02)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,,Cardiovascular,Current,,,,2023,available
12386,Furosemide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-280-04)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,,Cardiovascular,Current,,,,2023,available
12387,Furosemide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-280-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,,Cardiovascular,Current,,,,2023,available
12388,Furosemide Injection,Eugia US LLC,"Injection, 20 mg/2 mL (NDC 55150-322-25)",Revised,12/19/2023,Currently on backorder - next shipment TBD,Check wholesalers for inventory,,Demand increase for the drug,Cardiovascular,Current,,,,2023,not available
12389,Furosemide Injection,Eugia US LLC,"Injection, 40 mg/4 mL (NDC 55150-323-25)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12390,Furosemide Injection,Eugia US LLC,"Injection, 100 mg/10 mL (NDC 55150-324-25)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12391,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)",Reverified,12/21/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12392,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)",Reverified,12/21/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12393,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)",Reverified,12/21/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12394,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 23155-473-41)",Reverified,12/21/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12395,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 23155-473-42)",Reverified,12/21/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12396,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 23155-473-44)",Reverified,12/21/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12397,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-02)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,limited availability
12398,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-04)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,limited availability
12399,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-10)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12400,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-25)",Revised,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12401,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-26)",Revised,12/19/2023,Limited Supply Available. Next Delivery: February 2024; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,limited availability
12402,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,12/19/2023,Available.,,,,Cardiovascular,Current,,,,2023,available
12403,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,12/19/2023,Available.,,,,Cardiovascular,Current,,,,2023,available
12404,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,12/19/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12405,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2023,available
12406,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2023,available
12407,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Cardiovascular,Current,,,,2023,available
12408,Gatifloxacin Solution/ Drops,Abbvie,"Zymaxid, Solution/ Drops, 5 mg/1 mL (NDC 0023-3615-25)",New,3/10/2023,,Labeler Allergan. Business decision to discontinue product,,,Ophthalmology,To Be Discontinued,3/10/2023,3/10/2023,,2023,discontinued
12409,Gatifloxacin Solution/ Drops,Abbvie,"Zymaxid, Solution/ Drops, 5 mg/1 mL (NDC 0023-3615-01)",New,3/10/2023,,Labeler Allergan. Business decision to discontinue product,,,Ophthalmology,To Be Discontinued,3/10/2023,3/10/2023,,2023,discontinued
12410,Gatifloxacin Solution/ Drops,Abbvie,"Zymaxid, Solution/ Drops, 5 mg/1 mL (NDC 60758-615-25)",New,3/10/2023,,Labeler Pacific Pharma. Business decision to discontinue product,,,Ophthalmology,To Be Discontinued,3/10/2023,3/10/2023,,2023,discontinued
12411,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 40 mg/1 mL (NDC 63323-010-02)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,,Anti-Infective,Current,,,,2023,available
12412,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 40 mg/1 mL (NDC 63323-010-20)",Revised,11/29/2023,"Available, Available. Check wholesaler for inventory.",Check wholesaler inventory,,,Anti-Infective,Current,,,,2023,available
12413,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-173-02)",Revised,11/29/2023,Available,,,,Anti-Infective,Current,,,,2023,available
12414,Gentamicin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Gentamicin Sulfate, Injection, 40 mg/1 mL (NDC 0409-1207-03)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anti-Infective,Current,,,,2023,not available
12415,Gentamicin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Gentamicin Sulfate, Injection, 40 mg/1 mL (NDC 0409-1207-25)",Reverified,9/11/2023,Discontinued,,,,Anti-Infective,Current,,,,2023,discontinued
12416,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 60 mg/50 mL (NDC 0338-0507-41)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,available
12417,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 80 mg/50 mL (NDC 0338-0509-41)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,available
12418,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-0503-48)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,available
12419,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 100 mg/50 mL (NDC 0338-0511-41)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,available
12420,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-0505-48)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,available
12421,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 60 mg/50 mL (NDC 0338-0507-48)",Reverified,9/27/2023,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,available
12422,Gentamicin Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 40 mg/1 mL (NDC 0143-9128-25)",Reverified,12/19/2023,"This presentation is on backorder., Recovery date TBD",Recovery date has not been determined at this time.,,Demand increase for the drug,Anti-Infective,Current,,,,2023,not available
12423,Glimepiride Tablet,Sanofi-Aventis U.S. LLC,"Amaryl, Tablet, 1 mg (NDC 0039-0221-10)",New,6/20/2023,,"Discontinued due to a business decision. 1mg last lot expires June 30, 2023",,,Endocrinology/Metabolism,To Be Discontinued,6/20/2023,6/20/2023,,2023,discontinued
12424,Glimepiride Tablet,Sanofi-Aventis U.S. LLC,"Amaryl, Tablet, 2 mg (NDC 0039-0222-10)",New,6/20/2023,,"Discontinued due to a business decision. 2mg last lot expires August 31, 2023",,,Endocrinology/Metabolism,To Be Discontinued,6/20/2023,6/20/2023,,2023,discontinued
12425,Glimepiride Tablet,Sanofi-Aventis U.S. LLC,"Amaryl, Tablet, 4 mg (NDC 0039-0223-10)",New,6/20/2023,,"Discontinued due to a business decision. 4mg last lot expires August 31, 2023",,,Endocrinology/Metabolism,To Be Discontinued,6/20/2023,6/20/2023,,2023,discontinued
12426,"Glipizide  TABLET, EXTENDED RELEASE",Pfizer Inc.,"Glucotrol XL , TABLET, EXTENDED RELEASE, 2.5 mg tablet (NDC 0049-0170-01)",New,11/2/2023,,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,,,,2023,discontinued
12427,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 2.5 mg (NDC 59762-0540-1)",New,8/9/2023,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,8/9/2023,8/9/2023,,2023,discontinued
12428,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 5 mg (NDC 59762-0541-1)",New,8/9/2023,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,8/9/2023,8/9/2023,,2023,discontinued
12429,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 10 mg (NDC 59762-0542-1)",New,8/9/2023,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,8/9/2023,8/9/2023,,2023,discontinued
12430,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucotrol XL, Tablet, Extended Release, 10 mg (NDC 0049-0178-07)",New,8/9/2023,,Supply expected to exhaust November 2023,,,Endocrinology/Metabolism,To Be Discontinued,8/9/2023,8/9/2023,,2023,discontinued
12431,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 5 mg (NDC 59762-0541-2)",New,8/9/2023,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,8/9/2023,8/9/2023,,2023,discontinued
12432,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 10 mg (NDC 59762-0542-2)",New,8/9/2023,,Supply expected to exhaust October 2023,,,Endocrinology/Metabolism,To Be Discontinued,8/9/2023,8/9/2023,,2023,discontinued
12433,Glucagon Hydrochloride Injection,Novo Nordisk,"Glucagen, Injection, 1 mg/1 mL (NDC 0169-7065-15)",New,11/15/2023,,"Will be unavailable after July 1, 2024",,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,To Be Discontinued,,11/18/2022,,2023,discontinued
12434,Glyburide Tablet,Pfizer Inc.,"Glynase, Tablet, 1.5 mg (NDC 0009-0341-01)",New,1/3/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust early February 2023.,,,Endocrinology/Metabolism,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12435,Glyburide Tablet,Pfizer Inc.,"Glynase, Tablet, 3 mg (NDC 0009-0352-01)",New,1/3/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust early November 2023.,,,Endocrinology/Metabolism,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12436,Glyburide Tablet,Pfizer Inc.,"Glynase, Tablet, 6 mg (NDC 0009-3449-01)",New,1/3/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust early February 2023.,,,Endocrinology/Metabolism,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12437,Glyburide Tablet,Pfizer Inc.,"Glynase, Tablet, 6 mg (NDC 0009-3449-03)",New,1/3/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust early February 2023.,,,Endocrinology/Metabolism,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12438,Glycopyrrolate Inhalation Solution,"Sunovion Pharmaceuticals, Inc.","Inhalation Solution, 25 mcg/mL (NDC 63402-201-01)",New,4/3/2023,,,,,Pulmonary/Allergy,To Be Discontinued,4/3/2023,4/3/2023,,2023,discontinued
12439,Glycopyrrolate Solution,"Sunovion Pharmaceuticals, Inc.","Lonhala Magnair Kit, Solution, 25 ug/1 mL (NDC 63402-201-00)",New,4/3/2023,,,,,Pulmonary/Allergy,To Be Discontinued,4/3/2023,4/3/2023,,2023,discontinued
12440,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 1 mg (NDC 65162-711-10)",Revised,10/10/2023,Available,,Available,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12441,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 2 mg (NDC 65162-713-10)",Revised,10/10/2023,Available,,Available,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12442,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 2 mg (NDC 65162-713-50)",Revised,10/10/2023,Available,,Available,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12443,Guanfacine Hydrochloride Tablet,"Epic Pharma, LLC","Guanfacine Hydrochloride, Tablet, 1 mg (NDC 42806-048-01)",Revised,10/10/2023,Available,,Available,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12444,Guanfacine Hydrochloride Tablet,"Epic Pharma, LLC","Guanfacine Hydrochloride, Tablet, 2 mg (NDC 42806-296-01)",Revised,10/10/2023,Available,,Available,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12445,Guanfacine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Guanfacine Hydrochloride, Tablet, 1 mg (NDC 0591-0444-01)",Revised,10/10/2023,Product available with short expiration,,1 mg available with short expiration,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12446,Guanfacine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Guanfacine Hydrochloride, Tablet, 2 mg (NDC 0591-0453-01)",Revised,10/10/2023,Available,,2 mg available,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12447,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 1 mg (NDC 65162-711-03)",Revised,10/10/2023,Available,,Available,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12448,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 2 mg (NDC 65162-713-03)",Revised,10/10/2023,Available,,Available,,Cardiovascular,Resolved,10/10/2023,,,2023,available
12449,Halobetasol Propionate Cream,Sandoz Inc.,"Halobetasol Propionate, Cream, .5 mg/1 g (NDC 0168-0355-15)",New,8/7/2023,,,,,Dermatology,To Be Discontinued,8/7/2023,8/7/2023,,2023,discontinued
12450,Halobetasol Propionate Cream,Sandoz Inc.,"Halobetasol Propionate, Cream, .5 mg/1 g (NDC 0168-0355-50)",New,8/7/2023,,,,,Dermatology,To Be Discontinued,8/7/2023,8/7/2023,,2023,discontinued
12451,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)",Reverified,12/21/2023,Available on Allocation,,,,Hematology,Current,,,,2023,limited availability
12452,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)",Reverified,12/21/2023,Unavailable,,,Regulatory delay,Hematology,Current,,,,2023,not available
12453,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 0409-7620-03)",Revised,12/19/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Hematology,Current,,,,2023,limited availability
12454,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 0409-7620-59)",Revised,12/19/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Hematology,Current,,,,2023,limited availability
12455,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18)",Reverified,12/21/2023,Available on allocation.,Product code AHB0953U replaces code 2B0953,,,Hematology,Current,,,,2023,limited availability
12456,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)",Reverified,12/20/2023,Next release December 2023. Check wholesalers for inventory.,Check wholesaler for inventory,,Delay in shipping of the drug,Hematology,Current,,,,2023,not available
12457,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)",Reverified,12/20/2023,Available. Check wholesaler for inventory,Check wholesaler inventory,,Demand increase for the drug,Hematology,Current,,,,2023,available
12458,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)",Reverified,12/19/2023,"Available, N/A",,,,Hematology,Current,,,,2023,unclear
12459,"Hyaluronidase, Ovine Injection",Bausch & Lomb Incorporated,"Vitrase, Injection, 200 USP U/mL (NDC 24208-002-02)",New,8/28/2023,,Discontinuing manufacture of the product.,,,Ophthalmology; Other,To Be Discontinued,8/28/2023,8/28/2023,,2023,discontinued
12460,"Hyaluronidase, Ovine Injection",Bausch & Lomb Incorporated,"Vitrase, Injection, 200USP U/ml  (NDC 24208-002-03)",New,8/28/2023,,Discontinuing manufacture of the product.,,,Ophthalmology; Other,To Be Discontinued,8/28/2023,8/28/2023,,2023,discontinued
12461,HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET,Pfizer Inc.,"ACCURETIC, TABLET, 12.5 mg; 20 mg (NDC 59762-0220-1)",New,10/2/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/2/2023,,2023,discontinued
12462,HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET,Pfizer Inc.,"ACCURETIC, TABLET, 12.5 mg; 10 mg (NDC 59762-0222-1)",New,10/2/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/2/2023,,2023,discontinued
12463,HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET,Pfizer Inc.,"ACCURETIC, TABLET, 25 mg; 20 mg (NDC 59762-0223-1)",New,10/2/2023,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Antibiotic; Cardiovascular,To Be Discontinued,,10/2/2023,,2023,discontinued
12464,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 1000 mg/8 mL (NDC 0009-0005-01)",Revised,12/20/2023,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2023,available
12465,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/2 mL (NDC 0009-0825-01)",Revised,12/20/2023,"Limited Supply Available
Next Delivery: December 2023;
Estimated Recovery: March 2024",,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2023,limited availability
12466,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/2 mL (NDC 0009-0011-04)",Revised,12/20/2023,Next Delivery: Dec 2023; Estimated Recovery: January 2024,,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2023,not available
12467,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-Cortef, Injection, 100 mg/mL (NDC 0009-0011-03)",Revised,12/20/2023,Next Delivery and Estimated Recovery: January 2024,,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2023,not available
12468,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/2 mL (NDC 0009-0013-06)",Revised,12/20/2023,Next Delivery: January 2024; Estimated Recovery: April 2024,,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2023,not available
12469,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/2 mL (NDC 0009-0013-05)",Revised,12/20/2023,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2023,available
12470,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 500 mg/4 mL (NDC 0009-0016-12)",Revised,12/20/2023,Next Delivery and Estimated Recovery: January 2024,,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2023,not available
12471,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12472,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12473,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12474,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-0110-03)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12475,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-0113-03)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12476,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-0018-01)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12477,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)",Revised,12/19/2023,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12478,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-2341-41)",Revised,12/19/2023,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12479,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-05)",Revised,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,,2023,discontinued
12480,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-31)",Revised,12/19/2023,Available,,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,available
12481,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-30)",Revised,12/19/2023,Available,,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,available
12482,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 0409-1304-31)",Revised,12/19/2023,Available,,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,available
12483,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-2552-01)",Revised,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,not available
12484,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)",Revised,12/19/2023,Limited Supply Available. Next Delivery: April 2024; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,limited availability
12485,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-05)",Revised,12/19/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,limited availability
12486,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-50)",Reverified,12/19/2023,Next Delivery: September 2023; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,not available
12487,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-852-25)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12488,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 2 mg/1 mL (NDC 63323-853-25)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12489,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-854-10)",Reverified,12/20/2023,Available - Check wholesaler for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,unclear
12490,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-851-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12491,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-851-15)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12492,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-851-50)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12493,"Hydroxyamphetamine Hydrobromide, Tropicamide Solution",Akorn Pharmaceuticals,"Paremyd, Solution, 10 mg/1 mL; 2.5 mg/1 mL (NDC 17478-704-12)",New,1/31/2023,,Business decision to discontinue product.,,,Ophthalmology,To Be Discontinued,1/31/2023,1/31/2023,,2023,discontinued
12494,"Hydroxychloroquine Sulfate Tablet, Film Coated",Sandoz Inc.,"Hydroxychloroquine Sulfate, Tablet, Film Coated, 200 mg (NDC 0781-5994-01)",New,2/14/2023,,,,,Rheumatology; Anti-Infective,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12495,"Hydroxychloroquine Sulfate Tablet, Film Coated",Sandoz Inc.,"Hydroxychloroquine Sulfate, Tablet, Film Coated, 200 mg (NDC 0781-5994-05)",New,2/14/2023,,,,,Rheumatology; Anti-Infective,To Be Discontinued,,2/14/2023,,2023,discontinued
12496,Hydroxypropyl Cellulose (1600000 Wamw) Insert,Bausch & Lomb Incorporated,"Lacrisert, Insert, 5 mg (NDC 24208-800-60)",Reverified,12/19/2023,"Unavailable, Resupply expected January 2024, Mar-25",Techinical transfer of drug product,,Regulatory delay,Ophthalmology,Current,,,,2023,not available
12497,Hydroxyzine Pamoate Capsule,Pfizer Inc.,"Vistaril, Capsule, 25 mg (NDC 0069-5410-66)",New,3/28/2023,,To be discontinued upon stop sale date May 2025,,,Psychiatry; Analgesia/Addiction,To Be Discontinued,3/28/2023,3/28/2023,,2023,discontinued
12498,Hydroxyzine Pamoate Capsule,Pfizer Inc.,"Vistaril, Capsule, 50 mg (NDC 0069-5420-66)",New,3/28/2023,,To be discontinued upon stop sale date April 2023,,,Psychiatry; Analgesia/Addiction,To Be Discontinued,3/28/2023,3/28/2023,,2023,discontinued
12499,I.V. Fat Emulsion,B. Braun Medical Inc.,"Nutrilipid I.v. Fat Emulsion, Emulsion, 20 g/100 mL (NDC 0264-4460-00)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12500,I.V. Fat Emulsion,B. Braun Medical Inc.,"Nutrilipid I.v. Fat Emulsion, Emulsion, 20 g/100 mL (NDC 0264-4460-10)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12501,I.V. Fat Emulsion,B. Braun Medical Inc.,"Nutrilipid I.v. Fat Emulsion, Solution, Emulsion, 20 g/100 mL (NDC 0264-4460-30)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12502,I.V. Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid 20%, Emulsion, 3 g/100 mL; 6 g/100 mL; 5 g/100 mL; 6 g/100 mL (NDC 63323-820-00)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12503,I.V. Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid 20%, Emulsion, 3 g/100 mL; 6 g/100 mL; 5 g/100 mL; 6 g/100 mL (NDC 63323-820-74)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12504,I.V. Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid 20%, Emulsion, 3 g/100 mL; 6 g/100 mL; 5 g/100 mL; 6 g/100 mL (NDC 63323-820-50)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12505,I.V. Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid 20%, Emulsion, 3 g/100 mL; 6 g/100 mL; 5 g/100 mL; 6 g/100 mL (NDC 63323-820-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12506,I.V. Fat Emulsion,Baxter Healthcare,"Clinolipid 20%, Emulsion, 16 g/100 mL; 4 g/100 mL (NDC 0338-9540-05)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12507,I.V. Fat Emulsion,Baxter Healthcare,"Clinolipid 20%, Emulsion, 16 g/100 mL; 4 g/100 mL (NDC 0338-9540-08)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12508,I.V. Fat Emulsion,Baxter Healthcare,"Clinolipid 20%, Emulsion, 16 g/100 mL; 4 g/100 mL (NDC 0338-9540-06)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12509,I.V. Fat Emulsion,Baxter Healthcare,"Clinolipid 20%, Emulsion, 16 g/100 mL; 4 g/100 mL (NDC 0338-9540-07)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,available
12510,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 20%, Emulsion, 20 g/100 mL (NDC 0338-0519-58)",Reverified,12/21/2023,Limited supply,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,limited availability
12511,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 20%, Emulsion, 20 g/100 mL (NDC 0338-0519-09)",Reverified,12/21/2023,Limited supply,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,limited availability
12512,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 20%, Emulsion, 20 g/100 mL (NDC 0338-0519-14)",Reverified,12/21/2023,Stocked Out,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,not available
12513,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 20%, Emulsion, 20 g/100 mL (NDC 0338-0519-13)",Reverified,12/21/2023,Limited supply,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,limited availability
12514,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 30%, Emulsion, 30 g/100 mL (NDC 0338-0520-13)",Reverified,12/21/2023,Limited supply,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,,2023,limited availability
12515,"Ibrutinib Tablet, Film Coated",AbbVie Inc.,"Imbruvica, Tablet, Film Coated, 560 mg (NDC 57962-560-28)",New,5/22/2023,,No other NDCs are impacted. All other NDCs are still available.,,,Hematology; Oncology,To Be Discontinued,5/22/2023,5/22/2023,,2023,discontinued
12516,Ibutilide Fumarate Injection,"Mylan Institutional, a Viatris Company","Ibutilide Fumarate, Injection, .1 mg/1 mL (NDC 67457-366-10)",Revised,9/14/2023,,,Available,,Cardiovascular,Resolved,9/14/2023,,,2023,
12517,Ibutilide Fumarate Injection,Pfizer Inc.,"Corvert, Injection, .1 mg/1 mL (NDC 0009-3794-01)",Revised,9/14/2023,,,Available,,Cardiovascular,Resolved,9/14/2023,,,2023,
12518,Ibutilide Fumarate Injection,Pfizer Inc.,"Corvert, Injection, .1 mg/1 mL (NDC 0009-3794-22)",Revised,9/14/2023,,,Available,,Cardiovascular,Resolved,9/14/2023,,,2023,
12519,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 50 mg (NDC 49884-056-01)",Revised,9/15/2023,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2023,discontinued
12520,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 50 mg (NDC 49884-056-10)",Revised,9/15/2023,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2023,discontinued
12521,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 25 mg (NDC 49884-055-10)",Revised,9/15/2023,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2023,discontinued
12522,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 25 mg (NDC 49884-055-01)",Revised,9/15/2023,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2023,discontinued
12523,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 10 mg (NDC 49884-054-01)",Revised,9/15/2023,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2023,discontinued
12524,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 10 mg (NDC 49884-054-10)",Revised,9/15/2023,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2023,discontinued
12525,Indigotindisulfonate Sodium Injection,"American Regent, Inc.","Indigo Carmine, Injection, 8 mg/1 mL (NDC 0517-0375-05)",Revised,11/1/2023,,,,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,11/1/2023,11/1/2023,,2023,discontinued
12526,Indigotindisulfonate Sodium Injection,Provepharm SAS,"Bludigo, Injection, 8 mg/1 mL (NDC 81284-315-05)",Revised,11/3/2023,Available,,,,Medical Imaging,Current,12/6/2023,,,2023,available
12527,Insulin Detemir Injection,Novo Nordisk,"Levemir, Injection, 100 [iU]/1 mL (NDC 0169-6432-10)",New,11/8/2023,,"Supply disruptions for Levemir® FlexPen® anticipated to start in mid-January 2024 followed by discontinuation on April 1, 2024",,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Other,To Be Discontinued,,11/8/2023,,2023,discontinued
12528,Insulin Detemir Injection,Novo Nordisk,"Levemir, Injection, 100 [iU]/1 mL (NDC 0169-3687-12)",New,11/8/2023,,"Levemir® vials will be available until the end of 2024. Full brand discontinuation, including Levemir® vials, will occur on December 31, 2024.",,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Other,To Be Discontinued,,11/8/2023,,2023,discontinued
12529,Interferon Beta-1b Injection,Novartis Pharmaceuticals Corporation,"Extavia, Injection, 0.3 mg/mL (NDC 0078-0569-12)",New,6/23/2023,,,,,Neurology,To Be Discontinued,6/23/2023,6/23/2023,,2023,discontinued
12530,Iobenguane I-131 Injection,Progenics Pharmaceuticals Inc.,"Azedra, Injection, 15 mCi/1 mL (NDC 71258-015-02)",New,8/23/2023,,This product is being discontinued for lack of commercial demand.,,,Oncology,To Be Discontinued,8/23/2023,8/23/2023,,2023,discontinued
12531,Iobenguane I-131 Injection,Progenics Pharmaceuticals Inc.,"Azedra, Injection, 15 mCi/1 mL (NDC 71258-015-22)",New,8/23/2023,,This product is being discontinued for lack of commercial demand.,,,Oncology,To Be Discontinued,8/23/2023,8/23/2023,,2023,discontinued
12532,Isoniazid Injection,Sandoz Inc.,"Isoniazid, Injection, 100 mg/1 mL (NDC 0781-3056-70)",Revised,9/20/2023,,,Available,,Anti-Infective,Resolved,9/20/2023,,,2023,
12533,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0555-0066-02)",Revised,12/19/2023,Available,,,,Anti-Infective,Current,,,,2023,available
12534,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-02)",Revised,12/19/2023,Limited Supply Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,limited availability
12535,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-01)",Revised,12/19/2023,Available,,,,Anti-Infective,Current,,,,2023,available
12536,Itraconazole Capsule,"Par Pharmaceutical, Inc.","Itraconazole, Capsule, 100 mg (NDC 49884-239-11)",New,9/14/2023,,Business decision to discontinue manufacturing of the drug,,,Anti-Infective; Other,To Be Discontinued,9/14/2023,9/14/2023,,2023,discontinued
12537,Itraconazole Solution,Janssen Research and Development,"Sporanox, Solution, 10 mg/1 mL (NDC 50458-295-15)",New,3/21/2023,,Business decision to discontinue manufacturing of this product.,,,Anti-Infective; Other,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
12538,Itraconazole Solution,Janssen Research and Development,"Sporanox, Solution, 10 mg/1 mL (NDC 10147-0150-1)",New,3/21/2023,,Distributed by Patriot Pharmaceuticals. Business decision to discontinue manufacturing of this product.,,,Anti-Infective; Other,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
12539,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 25021-682-20)",Reverified,12/19/2023,Tentatively available by end of October 2023,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,Regulatory delay,Anesthesia,Current,,,,2023,not available
12540,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 25021-683-10)",Reverified,12/19/2023,Available by September 2023,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,Regulatory delay,Anesthesia,Current,,,,2023,not available
12541,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 25021-684-05)",Reverified,12/19/2023,Tentatively available by end of October 2023,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,Regulatory delay,Anesthesia,Current,,,,2023,not available
12542,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 0143-9508-10)",Revised,12/19/2023,This presentation is on backorder.,Recovery: TBD,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12543,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 0143-9509-10)",Revised,12/19/2023,This presentation is on backorder.,Recovery: TBD,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12544,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 10 mg/1 mL (NDC 42023-113-10)",Revised,12/19/2023,This presentation is on backorder.,Recovery: TBD,,Shortage of an active ingredient,Anesthesia,Current,,,,2023,not available
12545,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 100 mg/1 mL (NDC 42023-115-10)",Revised,12/19/2023,This presentation is on backorder.,Recovery: TBD,,Shortage of an active ingredient,Anesthesia,Current,,,,2023,not available
12546,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 50 mg/1 mL (NDC 42023-114-10)",Revised,12/19/2023,This presentation is on backorder.,Recovery: TBD,,Shortage of an active ingredient,Anesthesia,Current,,,,2023,not available
12547,Ketamine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/1 mL (NDC 55150-438-10)",Revised,12/20/2023,Currently on backorder - next shipment Jan,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12548,Ketamine Hydrochloride Injection,Eugia US LLC,"Injection, 50 mg/1 mL (NDC 55150-439-10)",Revised,12/20/2023,Currently on backorder - next shipment TBD,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12549,Ketamine Hydrochloride Injection,Eugia US LLC,"Injection, 100 mg/1 mL (NDC 55150-440-10)",Revised,12/20/2023,Currently on backorder - next shipment TBD,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12550,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Injection, 100 mg/1 mL (NDC 0409-2051-05)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12551,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 0409-2053-10)",Reverified,12/19/2023,Next Delivery: February 2025; Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12552,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 15 mg/1 mL (NDC 63323-161-01)",Reverified,12/20/2023,Available. Check wholesaler for inventory,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12553,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 30 mg/1 mL (NDC 63323-162-01)",Reverified,12/20/2023,Backordered. Next release December 2023. Check wholesaler for inventory.,Check wholesaler for inventory.,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,not available
12554,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 30 mg/1 mL (NDC 63323-162-02)",Reverified,12/20/2023,Available,Check wholesaler for inventory.,,,Analgesia/Addiction,Current,,,,2023,available
12555,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 15 mg/1 mL (NDC 70860-700-01)",Revised,12/19/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12556,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 70860-701-01)",Revised,12/19/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12557,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 70860-701-02)",Revised,12/19/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12558,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 15 mg/1 mL (NDC 25021-700-01)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12559,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 30 mg/1 mL (NDC 25021-701-02)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12560,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 30 mg/1 mL (NDC 25021-701-01)",Reverified,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12561,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Analgesia/Addiction,Current,,,,2023,not available
12562,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Analgesia/Addiction,Current,,,,2023,not available
12563,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 0409-3796-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Analgesia/Addiction,Current,,,,2023,not available
12564,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)",Reverified,12/19/2023,Limited Supply; Recovery: May 2024,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,limited availability
12565,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)",Reverified,5/16/2023,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,unclear
12566,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)",Reverified,5/16/2023,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,unclear
12567,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)",Reverified,5/16/2023,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,unclear
12568,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)",Reverified,12/19/2023,Limited supply; Recovery: June 2024,FOR INTRAVENOUS AND INTRAMUSCULAR USE. 30mg/mL (1 mL fill volume/ 2 mL container),,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,limited availability
12569,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 15 mg/1 mL (NDC 76045-107-10)",Reverified,12/20/2023,Not available at this time.,Check wholesaler for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,not available
12570,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 30 mg/1 mL (NDC 76045-104-10)",Reverified,12/20/2023,RFID NDC 76045-0209-10 release January 2024.,Check wholesaler for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,not available
12571,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 60 mg/2 mL (NDC 76045-105-20)",Reverified,12/20/2023,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12572,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 72266-118-25)",Revised,12/19/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12573,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 72266-119-25)",Revised,12/19/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12574,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 15 mg/1 mL (NDC 62332-599-25)",Revised,12/19/2023,Product available,,,,Analgesia/Addiction,Current,,,,2023,available
12575,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 30 mg/1 mL (NDC 62332-600-25)",Revised,12/19/2023,Product available,,,,Analgesia/Addiction,Current,,,,2023,available
12576,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 60 mg/2 mL (NDC 62332-601-25)",Revised,12/19/2023,Product available,,,,Analgesia/Addiction,Current,,,,2023,available
12577,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 70860-701-03)",Revised,12/19/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12578,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 15 mg/1 mL (NDC 70860-700-02)",Revised,12/19/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12579,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 70860-701-04)",Revised,12/19/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12580,"Ketorolac Tromethamine Tablet, Film Coated",Virtus Pharmaceuticals,"Ketorolac Tromethamine, Tablet, Film Coated, 10 mg (NDC 69543-388-10)",Revised,6/6/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12581,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 25021-828-50)",Revised,12/19/2023,Replenishment due in January,,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
12582,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 50 mg/5 mL (NDC 0143-9555-01)",Reverified,12/19/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
12583,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 100 mg/10 mL (NDC 0143-9554-01)",Reverified,12/19/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
12584,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 200 mg/20 mL (NDC 0143-9553-01)",Reverified,12/19/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
12585,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 350 mg/17.5 mL (NDC 0143-9552-01)",Reverified,12/19/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
12586,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-10)",Reverified,12/20/2023,Next release February 2024.  Check wholesalers for inventory.,Check wholesalers for inventory.,,Delay in shipping of the drug,Oncology; Pediatric,Current,,,,2023,not available
12587,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-50)",Reverified,12/20/2023,Next release January 2024. Check wholesaler for inventory.,Check wholesalers for inventory.,,Delay in shipping of the drug,Oncology; Pediatric,Current,,,,2023,not available
12588,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 100 mg/10 mL (NDC 67457-528-10)",Reverified,12/21/2023,Re-supply in January 2024,,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,not available
12589,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 200 mg/20 mL (NDC 67457-529-20)",Reverified,12/21/2023,Available,,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,available
12590,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 350 mg/17.5 mL (NDC 67457-530-35)",Reverified,12/21/2023,Available,,,Demand increase for the drug,Oncology; Pediatric,Current,,,,2023,available
12591,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 20 mg/mL (NDC 55150-256-50)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12592,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 15 mg/1 mL (NDC 0409-4776-01)",Revised,9/11/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12593,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/mL (NDC 55150-251-10)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12594,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/mL (NDC 55150-252-20)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12595,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 20 mg/mL (NDC 55150-254-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
12596,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 20 mg/mL (NDC 55150-255-20)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12597,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)",Revised,3/24/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the May timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12598,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)",Revised,3/24/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the May timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12599,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)",Revised,3/24/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the May timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12600,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)",Revised,3/24/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the April timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12601,Lidocaine Hydrochloride Injection,"Spectra Medical Devices, LLC","Injection, 10 mg/1 mL (NDC 65282-1605-1)",Reverified,12/20/2023,Available,,,,Anesthesia,Current,,,,2023,available
12602,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/mL (NDC 55150-158-72)",Reverified,12/19/2023,On long term backorder,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12603,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 55150-159-74)",Revised,11/1/2023,On long term backorder,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12604,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 55150-160-72)",Reverified,12/19/2023,On long term backorder,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
12605,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 55150-161-02)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12606,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 55150-162-05)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12607,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 55150-163-30)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
12608,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/mL (NDC 55150-164-02)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
12609,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 55150-165-05)",Reverified,12/19/2023,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
12610,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)",Revised,11/29/2023,Not available at this time.,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12611,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)",Reverified,12/20/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12612,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12613,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12614,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12615,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12616,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12617,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12618,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12619,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12620,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 10 mg/1 mL (NDC 0409-9137-05)",Revised,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12621,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 0409-4713-32)",Revised,9/11/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12622,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 0409-4276-01)",Revised,9/11/2023,Limited Supply Available. Next Delivery: October 2023; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,limited availability
12623,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-4279-02)",Revised,9/11/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,limited availability
12624,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 0409-4276-02)",Revised,9/11/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Anesthesia; Pediatric,Current,,,,2023,limited availability
12625,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0409-4282-01)",Revised,9/11/2023,Limited Supply Available. Next Delivery and Estimated Recovery: September 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,limited availability
12626,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0409-4282-02)",Revised,9/11/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12627,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-4904-34)",Revised,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12628,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0409-4903-34)",Revised,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12629,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0409-2066-05)",Revised,9/11/2023,Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Anesthesia; Pediatric,Current,,,,2023,not available
12630,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 20 mg/1 mL (NDC 0409-4277-01)",Revised,9/11/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12631,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 20 mg/1 mL (NDC 0409-4277-02)",Revised,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12632,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 40 mg/1 mL (NDC 0409-4283-01)",Revised,9/11/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12633,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 20 mg/1 mL (NDC 0409-1323-05)",Revised,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12634,Lidocaine Hydrochloride Injection,"Amphastar Pharmaceuticals, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)",Reverified,12/19/2023,Available,old NDC 0548-3390-00,,,Anesthesia; Pediatric,Current,,,,2023,available
12635,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12636,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12637,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12638,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12639,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12640,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12641,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12642,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12643,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)",Revised,11/29/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12644,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)",Revised,11/29/2023,Unavailable,Next release date not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,not available
12645,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 5 mg/1 mL (NDC 0409-4275-01)",Revised,9/11/2023,Next Delivery: October 2024; Estimated Recovery: December 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,,2023,not available
12646,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-4278-01)",Revised,9/11/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12647,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)",Reverified,12/21/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12648,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)",Reverified,12/21/2023,Available,,,,Cardiovascular,Current,,,,2023,available
12649,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 0409-4713-02)",Revised,9/11/2023,Available,,,,Anesthesia; Pediatric,Current,,,,2023,available
12650,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)",Revised,3/29/2023,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,available
12651,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)",Revised,3/29/2023,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,available
12652,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)",Revised,3/29/2023,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,available
12653,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)",Revised,3/29/2023,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,available
12654,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)",Revised,3/29/2023,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,available
12655,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)",Revised,3/29/2023,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,available
12656,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)",Revised,3/29/2023,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,,2023,available
12657,Lidocaine Hydrochloride Injection,"Huons Co., Ltd. (South Korea)","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)",Revised,10/3/2023,Available,,,,Anesthesia,Current,,,,2023,available
12658,Lidocaine Hydrochloride Injection,Afaxys Pharma,"Injection, 10 mg/1 mL (NDC 50102-400-10)",New,11/2/2023,Available,"Inventory available through ANDA, ASD Healthcare, Henry Schein, McKesson Medical-Surgical and R&S",,,Anesthesia; Pediatric,Current,,,,2023,available
12659,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous, Solution, 20 mg/1 mL (NDC 0054-3500-49)",Reverified,12/19/2023,Available to current customers,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
12660,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous, Solution, 20 mg/1 mL (NDC 0054-0548-44)",Reverified,12/19/2023,Available to current customers,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
12661,Lidocaine Hydrochloride Solution,Chartwell Molecular Holdings LLC,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 62135-712-42)",Reverified,11/2/2023,Available,Product available in all wholesalers,,,Anesthesia,Current,,,,2023,available
12662,Lidocaine Patch,Endo Pharmaceuticals. Inc.,"Lidoderm, Patch, 50 mg/1 g (NDC 63481-687-06)",New,1/25/2023,,Permanent discontinuation on 1/18/2023,,,Analgesia/Addiction,To Be Discontinued,1/25/2023,1/25/2023,,2023,discontinued
12663,"Linezolid Tablet, Film Coated",Pfizer Inc.,"Zyvox, Tablet, Film Coated, 600 mg (NDC 0009-5138-02)",New,8/3/2023,,Supply expected to exhaust late September 2023; Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,8/3/2023,8/3/2023,,2023,discontinued
12664,Liothyronine Sodium Injection,Par Sterile Products LLC,"Triostat, Injection, 10 ug/1 mL (NDC 42023-120-01)",Revised,2/23/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,2/23/2023,2/23/2023,,2023,discontinued
12665,Liothyronine Sodium Injection,Par Sterile Products LLC,"Triostat, Injection, 10 ug/1 mL (NDC 42023-120-06)",New,2/23/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,2/23/2023,2/23/2023,,2023,discontinued
12666,Liraglutide Injection,"Novo Nordisk, Inc.","Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)",Revised,12/11/2023,Limited availability,Limited availability through the end of 2023,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
12667,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12668,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12669,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12670,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12671,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12672,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12673,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12674,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 10 mg (NDC 60505-4739-1)",Reverified,12/20/2023,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12675,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 20 mg (NDC 60505-4740-1)",Reverified,12/20/2023,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12676,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 30 mg (NDC 60505-4741-1)",Reverified,12/20/2023,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12677,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 40 mg (NDC 60505-4742-1)",Reverified,12/20/2023,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12678,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 50 mg (NDC 60505-4743-1)",Reverified,12/20/2023,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12679,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 60 mg (NDC 60505-4744-1)",Reverified,12/20/2023,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12680,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 70 mg (NDC 60505-4745-1)",Reverified,12/20/2023,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12681,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 10 mg (NDC 0378-6854-77)",Reverified,12/21/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12682,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 20 mg (NDC 0378-6855-77)",Reverified,12/21/2023,Allocating limited inventory,Allocating limited inventory,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12683,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 30 mg (NDC 0378-6856-77)",Reverified,12/21/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12684,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 40 mg (NDC 0378-6857-77)",Reverified,12/21/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12685,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 50 mg (NDC 0378-6858-77)",Reverified,12/21/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12686,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 60 mg (NDC 0378-6859-77)",Reverified,12/21/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12687,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 70 mg (NDC 0378-6860-77)",Reverified,12/21/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12688,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 10 mg (NDC 57664-046-88)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
12689,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 30 mg (NDC 57664-048-88)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
12690,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 30 mg (NDC 57664-048-88)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
12691,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 40 mg (NDC 57664-049-88)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
12692,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 50 mg (NDC 57664-050-88)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
12693,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 60 mg (NDC 57664-051-88)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
12694,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 70 mg (NDC 57664-052-88)",Reverified,12/19/2023,Available,,,Demand increase for the drug,Psychiatry,Current,,,,2023,available
12695,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 10 mg (NDC 0406-5111-01)",Reverified,12/19/2023,Available,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,available
12696,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 20 mg (NDC 0406-5112-01)",Reverified,12/19/2023,Available; Shortage anticipated in December 2023,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12697,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 30 mg (NDC 0406-5113-01)",Reverified,12/19/2023,Available; Shortage anticipated in January 2024,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12698,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 40 mg (NDC 0406-5114-01)",Reverified,12/19/2023,Available; Shortage anticipated in October 2023,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12699,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 50 mg (NDC 0406-5115-01)",Revised,12/19/2023,"On backorder, Estimated shortage duration December 2023",,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,not available
12700,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 60 mg (NDC 0406-5116-01)",Reverified,12/19/2023,Available; Shortage anticipated in September 2023,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12701,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 70 mg (NDC 0406-5117-01)",Reverified,12/19/2023,Available; Shortage anticipated in December 2023,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12702,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 20 mg (NDC 0054-0370-25)",Reverified,12/19/2023,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12703,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 30 mg (NDC 0054-0371-25)",Reverified,12/19/2023,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12704,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 40 mg (NDC 0054-0372-25)",Reverified,12/19/2023,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12705,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 50 mg (NDC 0054-0373-25)",Reverified,12/19/2023,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12706,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 60 mg (NDC 0054-0374-25)",Reverified,12/19/2023,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12707,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 70 mg (NDC 0054-0375-25)",Reverified,12/19/2023,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12708,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 10 mg (NDC 0527-4661-37)",Reverified,12/19/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12709,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 20 mg (NDC 0527-4662-37)",Reverified,12/19/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12710,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 30 mg (NDC 0527-4663-37)",Reverified,12/19/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12711,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 40 mg (NDC 0527-4664-37)",Reverified,12/19/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12712,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 50 mg (NDC 0527-4665-37)",Reverified,12/19/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12713,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 60 mg (NDC 0527-4666-37)",Reverified,12/19/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12714,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 70 mg (NDC 0527-4667-37)",Reverified,12/19/2023,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12715,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 20 mg (NDC 65162-023-09)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12716,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 30 mg (NDC 65162-024-09)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12717,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 40 mg (NDC 65162-025-09)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12718,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 50 mg (NDC 65162-026-09)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12719,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 60 mg (NDC 65162-027-09)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12720,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 70 mg (NDC 65162-028-09)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12721,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 10 mg (NDC 43547-602-10)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12722,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 20 mg (NDC 43547-603-10)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12723,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 30 mg (NDC 43547-604-10)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12724,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 40 mg (NDC 43547-605-10)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12725,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 50 mg (NDC 43547-606-10)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12726,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 60 mg (NDC 43547-607-10)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12727,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 70 mg (NDC 43547-608-10)",Reverified,12/19/2023,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,limited availability
12728,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 10 mg (NDC 57664-083-88)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12729,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 20 mg (NDC 57664-084-88)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12730,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 30 mg (NDC 57664-085-88)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12731,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 50 mg (NDC 57664-087-88)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12732,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 60 mg (NDC 57664-088-88)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12733,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 40 mg (NDC 57664-086-88)",Reverified,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12734,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12735,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12736,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12737,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12738,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12739,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12740,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Lithium Carbonate, Tablet, Extended Release, 300 mg (NDC 0378-1300-01)",New,10/4/2023,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,10/4/2023,,2023,discontinued
12741,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Lithium Carbonate, Tablet, Extended Release, 300 mg (NDC 0378-1300-05)",New,10/4/2023,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,10/4/2023,,2023,discontinued
12742,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Lithium Carbonate, Tablet, Extended Release, 450 mg (NDC 0378-1450-01)",New,10/4/2023,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,10/4/2023,,2023,discontinued
12743,Lithium Citrate Solution,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lithium Citrate, Solution, 8 meq/5 mL (NDC 0054-3527-63)",Revised,1/30/2023,,Discontinued,,,Psychiatry,To Be Discontinued,1/30/2023,1/30/2023,,2023,discontinued
12744,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection,  (NDC 0024-5745-02)",Revised,2/3/2023,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/2023,2/3/2023,,2023,discontinued
12745,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection, 100 ug/1 mL (NDC 0024-5747-02)",Revised,2/3/2023,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/2023,2/3/2023,,2023,discontinued
12746,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection,  (NDC 0024-5741-01)",Revised,2/3/2023,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/2023,2/3/2023,,2023,discontinued
12747,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection,  (NDC 0024-5740-00)",Revised,2/3/2023,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/2023,2/3/2023,,2023,discontinued
12748,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection,  (NDC 0024-5740-00)",Revised,2/3/2023,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/2023,2/3/2023,,2023,discontinued
12749,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL (NDC 0409-6778-02)",New,7/18/2023,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,7/18/2023,7/18/2023,,2023,discontinued
12750,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)",Revised,11/9/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the November - December 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2023,not available
12751,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)",Revised,11/9/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2023,not available
12752,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)",Revised,11/9/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Neurology,Current,,,,2023,available
12753,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)",Revised,11/9/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Neurology,Current,,,,2023,available
12754,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6044-25)",Revised,11/9/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the November - December 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2023,not available
12755,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6046-10)",Revised,11/9/2023,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,,2023,not available
12756,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6045-25)",Revised,11/9/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Neurology,Current,,,,2023,available
12757,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)",Revised,11/9/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Neurology,Current,,,,2023,available
12758,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL (NDC 0409-1985-30)",Reverified,9/11/2023,Available,,,,Neurology,Current,,,,2023,available
12759,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL (NDC 0409-6778-02)",Reverified,9/11/2023,Discontinued,,,,Neurology,Current,,,,2023,discontinued
12760,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 2 mg/1 mL (NDC 76329-8261-1)",Reverified,12/19/2023,Available,,,,Neurology,Current,,,,2023,available
12761,Lutetium Lu-177 Vipivotide Tetraxetan Injection,"Advanced Accelerator Applications USA, Inc.","Pluvicto, Injection, 27 mCi/1 mL (NDC 69488-010-61)",Revised,10/25/2023,Available,Available,Available,,Oncology,Resolved,10/25/2023,,,2023,available
12762,Mafenide Acetate Solution,"Par Pharmaceutical, Inc.","Solution, 50 g (NDC 49884-902-78)",New,11/30/2023,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,11/30/2023,,2023,discontinued
12763,Mannitol Injection,Baxter Healthcare,"Osmitrol, Injection, 20 g/100 mL (NDC 0338-0357-02)",Reverified,12/21/2023,Available,,,,Renal,Current,,,,2023,available
12764,Mannitol Injection,B. Braun Medical Inc.,"Injection, 20 g/100 mL (NDC 0264-7578-20)",Reverified,12/19/2023,Available,,,,Renal,Current,,,,2023,available
12765,Mannitol Injection,Baxter Healthcare,"Osmitrol, Injection, 0.1 (NDC 0338-0535-03)",Reverified,12/19/2023,Available,,,,Renal,Current,,,,2023,available
12766,Mannitol Injection,Baxter Healthcare,"Osmitrol, Injection, 20 g/100 mL (NDC 0338-0357-03)",Reverified,12/21/2023,Available,,,,Renal,Current,,,,2023,available
12767,Mannitol Injection,"ICU Medical, Inc.","Mannitol 20% In Plastic Container, Injection, 20 g/100 mL (NDC 0990-7715-03)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7715-03",,,Renal,Current,,,,2023,available
12768,Mannitol Injection,"ICU Medical, Inc.","Mannitol 20% In Plastic Container, Injection, 20 g/100 mL (NDC 0990-7715-02)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7715-02",,,Renal,Current,,,,2023,available
12769,Mannitol Injection,"Fresenius Kabi USA, LLC","Mannitol 25%, Injection, 250 mg/1 mL (NDC 63323-024-25)",Reverified,12/20/2023,Next release December 2023. Check wholesaler for inventory.,Check wholesalers for inventory,,Demand increase for the drug,Renal,Current,,,,2023,not available
12770,Mannitol Injection,"Hospira, Inc., a Pfizer Company","Mannitol, Injection, 12.5 g/50 mL (NDC 0409-4031-01)",Revised,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Renal,Current,,,,2023,not available
12771,"Maraviroc Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Selzentry, Tablet, Film Coated, 25 mg (NDC 49702-233-08)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.  Selzentry 150mg (49702-223-18), Selzentry 300 mg (49702-224-18) and Selzentry Oral Solution (49702-260-55) will still be available.",,,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12772,"Maraviroc Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Selzentry, Tablet, Film Coated, 75 mg (NDC 49702-235-08)",New,1/3/2023,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.  Selzentry 150mg (49702-223-18), Selzentry 300 mg (49702-224-18) and Selzentry Oral Solution (49702-260-55) will still be available.",,,Antiviral,To Be Discontinued,1/3/2023,1/3/2023,,2023,discontinued
12773,Mebrofenin Injection,"Sun Pharmaceutical Industries, Inc.","Technetium Tc-99m Mebrofenin, Injection, 45 mg/10 mL (NDC 45567-0455-1)",Revised,8/10/2023,,,Available,,Medical Imaging,Resolved,8/10/2023,,,2023,
12774,Mebrofenin Injection,"Sun Pharmaceutical Industries, Inc.","Technetium Tc-99m Mebrofenin, Injection, 45 mg/10 mL (NDC 45567-0455-2)",Revised,8/10/2023,,,Available,,Medical Imaging,Resolved,8/10/2023,,,2023,
12775,Mebrofenin Injection,Bracco Diagnostics,"Choletec, Injection, 45 mg (NDC 0270-0083-20)",Revised,8/10/2023,,,Available,,Medical Imaging,Resolved,8/10/2023,,,2023,
12776,Memantine Hydrochloride Capsule,AbbVie Inc.,"Namenda, Capsule, 7 mg/14 mg/21 mg/28 mg (NDC 0456-3200-14)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12777,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 7 mg (NDC 0456-3407-33)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12778,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 14 mg (NDC 0456-3414-33)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12779,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 14 mg (NDC 0456-3414-90)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12780,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 21 mg (NDC 0456-3421-33)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12781,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 28 mg (NDC 0456-3428-33)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12782,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 28 mg (NDC 0456-3428-90)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12783,Memantine Hydrochloride Tablet,AbbVie Inc.,"Namenda, Tablet, 5 mg (NDC 0456-3205-63)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12784,Memantine Hydrochloride Tablet,AbbVie Inc.,"Namenda, Tablet, 10 mg (NDC 0456-3210-60)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12785,Memantine Hydrochloride Tablet,AbbVie Inc.,"Namenda, Tablet, 10 mg (NDC 0456-3210-63)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12786,Memantine Hydrochloride Tablet,AbbVie Inc.,"Namenda, Tablet, 5 mg/10 mg (NDC 0456-3200-14)",New,7/11/2023,,,,,Neurology,To Be Discontinued,7/11/2023,7/11/2023,,2023,discontinued
12787,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine, Injection, 10 mg/1 mL (NDC 63323-283-57)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
12788,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine, Injection, 20 mg/1 mL (NDC 63323-296-57)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
12789,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine-mpf, Injection, 10 mg/1 mL (NDC 63323-260-37)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
12790,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine-mpf, Injection, 15 mg/1 mL (NDC 63323-293-37)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,,2023,available
12791,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine-mpf, Injection, 20 mg/1 mL (NDC 63323-294-27)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
12792,"Mesalamine Capsule, Delayed Release",AbbVie Inc.,"Delzicol, Capsule, Delayed Release, 400 mg (NDC 0023-5853-18)",New,10/25/2023,,Sales expected to last until June 2024,,Discontinuation of the manufacture of the drug,Gastroenterology,To Be Discontinued,,10/25/2023,,2023,discontinued
12793,"Mesalamine Capsule, Delayed Release",AbbVie Inc.,"Capsule, Delayed Release, 400 mg (NDC 59762-0117-1)",New,10/25/2023,,Sales expected to last until June 2024,,Discontinuation of the manufacture of the drug,Gastroenterology,To Be Discontinued,,10/25/2023,,2023,discontinued
12794,"Metformin Hydrochloride, Saxagliptin Hydrochloride Tablet, Film Coated, Extended Release",AstraZeneca Pharmaceuticals LP,"Kombiglyze Xr, Tablet, Film Coated, Extended Release, 1000 mg; 2.5 mg (NDC 0310-6125-60)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
12795,"Metformin Hydrochloride, Saxagliptin Hydrochloride Tablet, Film Coated, Extended Release",AstraZeneca Pharmaceuticals LP,"Kombiglyze Xr, Tablet, Film Coated, Extended Release, 500 mg; 5 mg (NDC 0310-6135-30)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
12796,"Metformin Hydrochloride, Saxagliptin Hydrochloride Tablet, Film Coated, Extended Release",AstraZeneca Pharmaceuticals LP,"Kombiglyze Xr, Tablet, Film Coated, Extended Release, 1000 mg; 5 mg (NDC 0310-6145-30)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
12797,"Metformin Hydrochloride, Saxagliptin Hydrochloride Tablet, Film Coated, Extended Release",AstraZeneca Pharmaceuticals LP,"Kombiglyze Xr, Tablet, Film Coated, Extended Release, 1000 mg; 5 mg (NDC 0310-6145-95)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
12798,Methamphetamine Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 5 mg (NDC 68308-115-01)",Revised,12/19/2023,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,not available
12799,Methamphetamine Hydrochloride Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 5 mg (NDC 0054-0389-25)",Revised,12/19/2023,Currently unavailable,,,,Psychiatry,Current,,,,2023,not available
12800,Methamphetamine Hydrochloride Tablet,"Key Therapeutics, Inc.","Desoxyn, Tablet, 5 mg (NDC 70868-820-05)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12801,Methotrexate Injection,Nordic Group BV,"Reditrex, Injection, 15 mg/.6 mL (NDC 66220-815-22)",New,6/13/2023,,Expiry of last lot marketed: 2023-10-31,,Discontinuation of the manufacture of the drug,Dermatology; Rheumatology,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
12802,Methotrexate Injection,Nordic Group BV,"RediTrex, Injection, 15 mg/0.6 mL (NDC 66220-815-11)",New,6/13/2023,,Expiry of last lot marketed: 2023-10-31,,,Dermatology; Rheumatology,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
12803,Methotrexate Injection,Nordic Group BV,"Reditrex, Injection, 20 mg/.8 mL (NDC 66220-820-22)",New,6/13/2023,,Expiry of last lot marketed: 2023-10-31,,Discontinuation of the manufacture of the drug,Dermatology; Rheumatology,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
12804,Methotrexate Injection,Nordic Group BV,"RediTrex, Injection, 20 mg/0.8 mL (NDC 66220-820-11)",New,6/13/2023,,Expiry of last lot marketed: 2023-10-31,,,Dermatology; Rheumatology,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
12805,Methotrexate Injection,Nordic Group BV,"Reditrex, Injection, 25 mg/1 mL (NDC 66220-825-22)",New,6/13/2023,,Expiry of last lot marketed: 2023-10-31,,Discontinuation of the manufacture of the drug,Dermatology; Rheumatology,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
12806,Methotrexate Injection,Nordic Group BV,"RediTrex, Injection, 25 mg/mL (NDC 66220-825-11)",New,6/13/2023,,Expiry of last lot marketed: 2023-10-31,,,Dermatology; Rheumatology,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
12807,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 1 g (NDC 0143-9830-01)",Reverified,12/19/2023,Temporarily on backorder.,Additional lots will be available in the September 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Rheumatology; Oncology,Current,,,,2023,not available
12808,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)",Reverified,12/19/2023,Temporarily on backorder.,Additional lots will be available in the August â€“ September 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Rheumatology; Oncology,Current,,,,2023,not available
12809,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)",Reverified,12/19/2023,Available,,,,Rheumatology; Oncology,Current,,,,2023,available
12810,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)",Reverified,12/19/2023,Available,,,,Rheumatology; Oncology,Current,,,,2023,available
12811,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)",Reverified,12/19/2023,Available,,,,Rheumatology; Oncology,Current,,,,2023,available
12812,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-350-38)",Revised,9/11/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Rheumatology; Oncology,Current,,,,2023,limited availability
12813,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-350-10)",Revised,9/11/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023Estimated recovery: September 2023,,,,Rheumatology; Oncology,Current,,,,2023,limited availability
12814,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-408-41)",Reverified,12/19/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Rheumatology; Oncology,Current,,,,2023,limited availability
12815,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-408-25)",Reverified,12/19/2023,Next Delivery: September 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Rheumatology; Oncology,Current,,,,2023,not available
12816,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-124-40)",Reverified,12/19/2023,Next Delivery: October 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Rheumatology; Oncology,Current,,,,2023,not available
12817,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)",Reverified,12/20/2023,Available,Available. Check wholesaler for inventory,,,Rheumatology; Oncology,Current,,,,2023,available
12818,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Injection, 25 mg/1 mL (NDC 63323-123-10)",Reverified,12/20/2023,Available,Available. Check wholesaler for inventory.,,,Rheumatology; Oncology,Current,,,,2023,available
12819,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)",Revised,11/7/2023,"Limited Availability, Manufacturing resumed",,,Demand increase for the drug,Rheumatology; Oncology,Current,,,,2023,available
12820,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-03)",Reverified,12/19/2023,"Not Available, Manufacturing pending",,,Demand increase for the drug,Rheumatology; Oncology,Current,,,,2023,not available
12821,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)",Revised,11/7/2023,"Limited Availability, Manufacturing resumed",,,Demand increase for the drug,Rheumatology; Oncology,Current,,,,2023,available
12822,Methotrexate Sodium Tablet,Eugia US LLC,"Methotrexate Sodium, Tablet, 2.5 mg (NDC 59651-182-01)",Revised,12/20/2023,On allocation,,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,limited availability
12823,Methotrexate Sodium Tablet,Accord Healthcare Inc.,"Tablet, 2.5 mg (NDC 16729-486-01)",Revised,12/20/2023,"Stock Available; Inventory allocating to orders, > 365 days coverage","Manufacturing resumed, manufacturing and packaging plans being put together.",,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,limited availability
12824,Methotrexate Sodium Tablet,"Sun Pharmaceutical Industries, Inc.","Methotrexate Sodium, Tablet, 2.5 mg (NDC 47335-235-83)",Revised,12/19/2023,Limited Availability. Additional POâ€™s are in the pipeline,,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,limited availability
12825,Methotrexate Sodium Tablet,"Sun Pharmaceutical Industries, Inc.","Methotrexate Sodium, Tablet, 2.5 mg (NDC 47335-235-96)",Revised,12/19/2023,Limited Availability. Additional POâ€™s are in the pipeline,,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,limited availability
12826,Methotrexate Sodium Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 2.5 mg (NDC 0054-4550-25)",Revised,12/19/2023,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,available
12827,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 2.5 mg (NDC 0555-0572-02)",Revised,12/19/2023,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,available
12828,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 2.5 mg (NDC 0555-0572-35)",Revised,12/19/2023,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,available
12829,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Trexall, Tablet, 5 mg (NDC 51285-366-01)",Revised,12/19/2023,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,available
12830,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Trexall, Tablet, 7.5 mg (NDC 51285-367-01)",Revised,12/19/2023,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,available
12831,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Trexall, Tablet, 10 mg (NDC 51285-368-01)",Revised,12/19/2023,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,available
12832,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Trexall, Tablet, 15 mg (NDC 51285-369-01)",Revised,12/19/2023,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,available
12833,Methotrexate Sodium Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Tablet, 2.5 mg (NDC 0378-0014-01)",Reverified,12/21/2023,Available on allocation,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,limited availability
12834,Methotrexate Sodium Tablet,Zydus Pharmaceuticals USA Inc.,"Tablet, 2.5 mg (NDC 68382-775-01)",Revised,12/19/2023,Currently available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,available
12835,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 mg (NDC 69238-1423-6)",Reverified,12/19/2023,"Not commercialized, N/A",Non-preferred customer packaging configuration,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,not available
12836,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 mg (NDC 69238-1423-1)",Reverified,12/19/2023,Supplying existing customers with possibility to expand mid-Novemebr 2023,Supplying existing customers with possibility to expand mid-Novemebr 2023,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,limited availability
12837,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 mg (NDC 42291-505-01)",Reverified,12/19/2023,"Not commercialized, N/A",Labeler is AvKARE,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,not available
12838,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 mg (NDC 50268-527-15)",Reverified,12/19/2023,"Not commercialized, N/A",Labeler is AvPAK,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,,2023,not available
12839,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 250 mg (NDC 16729-030-01)",Revised,11/2/2023,No additional lots are anticipated at this time.,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,unclear
12840,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 250 mg (NDC 16729-030-16)",Revised,11/2/2023,No additional lots are anticipated at this time.,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,unclear
12841,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 500 mg (NDC 16729-031-01)",Revised,11/2/2023,No additional lots are anticipated at this time.,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,unclear
12842,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 500 mg (NDC 16729-031-16)",Revised,11/2/2023,No additional lots are anticipated at this time.,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,unclear
12843,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 18 mg (NDC 62175-310-37)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12844,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 27 mg (NDC 62175-311-37)",Revised,12/19/2023,Out of Stock; new lot available in December 2023,,,Demand increase for the drug,Psychiatry,Current,,,,2023,not available
12845,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 36 mg (NDC 62175-312-37)",Revised,12/19/2023,Out of Stock; new lot available in December 2023,,,Demand increase for the drug,Psychiatry,Current,,,,2023,not available
12846,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 54 mg (NDC 62175-313-37)",Revised,12/19/2023,Out of Stock; new lot available in November 2023,,,Demand increase for the drug,Psychiatry,Current,,,,2023,not available
12847,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12848,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12849,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12850,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12851,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Tablet, Extended Release, 18 mg (NDC 43598-438-01)",Revised,12/19/2023,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,not available
12852,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Tablet, Extended Release, 27 mg (NDC 43598-439-01)",Revised,12/19/2023,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,not available
12853,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Tablet, Extended Release, 36 mg (NDC 43598-440-01)",Revised,12/19/2023,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,not available
12854,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Tablet, Extended Release, 54 mg (NDC 43598-441-01)",Revised,12/19/2023,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,,2023,not available
12855,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12856,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12857,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12858,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Relexxii, Tablet, Extended Release, 45 mg (NDC 13811-711-30)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12859,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12860,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Relexxii, Tablet, Extended Release, 63 mg (NDC 13811-700-30)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12861,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12862,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12863,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12864,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12865,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)",Revised,12/19/2023,Available,,,,Psychiatry,Current,,,,2023,available
12866,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)",Revised,12/19/2023,Not currently marketing,,,Delay in shipping of the drug,Psychiatry,Current,,,,2023,discontinued
12867,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)",Revised,12/19/2023,Not currently marketing,,,Delay in shipping of the drug,Psychiatry,Current,,,,2023,discontinued
12868,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)",Revised,12/19/2023,Not currently marketing,,,Delay in shipping of the drug,Psychiatry,Current,,,,2023,discontinued
12869,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)",Revised,12/19/2023,Not currently marketing,,,Delay in shipping of the drug,Psychiatry,Current,,,,2023,discontinued
12870,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)",Revised,12/19/2023,On backorder through November 2023,,,Demand increase for the drug,Psychiatry,Current,,,,2023,not available
12871,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)",Revised,12/19/2023,Supply available to current customers only,,,,Psychiatry,Current,,,,2023,limited availability
12872,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Tablet, Extended Release, 27 mg (NDC 0406-0127-01)",Revised,12/19/2023,Available; Shipping on allocation to all customers,,,,Psychiatry,Current,,,,2023,limited availability
12873,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Tablet, Extended Release, 36 mg (NDC 0406-0136-01)",Revised,12/19/2023,Available; Shipping on allocation to all customers,,,,Psychiatry,Current,,,,2023,limited availability
12874,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Tablet, Extended Release, 54 mg (NDC 0406-0154-01)",Revised,12/19/2023,Available; Shipping on allocation to all customers,,,,Psychiatry,Current,,,,2023,limited availability
12875,Methylprednisolone Acetate Injection,Eugia US LLC,"Injection, 40 mg/1 mL (NDC 55150-313-01)",Revised,12/20/2023,Available,Check wholesalers for inventory,,,Rheumatology,Current,,,,2023,available
12876,Methylprednisolone Acetate Injection,Eugia US LLC,"Injection, 80 mg/1 mL (NDC 55150-314-01)",Revised,12/20/2023,Available,Check wholesalers for inventory,,,Rheumatology,Current,,,,2023,available
12877,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 40 mg/1 mL (NDC 25021-820-10)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12878,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 40 mg/1 mL (NDC 25021-820-05)",Reverified,12/19/2023,Available.,,,,Rheumatology,Current,,,,2023,available
12879,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 80 mg/1 mL (NDC 25021-821-05)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12880,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","Injection, 80 mg/1 mL (NDC 42023-240-01)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12881,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12882,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12883,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12884,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12885,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12886,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12887,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)",Revised,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12888,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12889,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12890,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)",Revised,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12891,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12892,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12893,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12894,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12895,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12896,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12897,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)",Reverified,12/19/2023,Available,,,,Rheumatology,Current,,,,2023,available
12898,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-22)",Reverified,12/19/2023,Next Delivery: February 2025; Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing delay,,Demand increase for the drug,Rheumatology,Current,,,,2023,not available
12899,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-23)",Reverified,12/19/2023,Next Delivery: February 2025; Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing delay,,Demand increase for the drug,Rheumatology,Current,,,,2023,not available
12900,Methylprednisolone Tablet,Sandoz Inc.,"Methylprednisolone, Tablet, 4 mg (NDC 0781-5022-01)",New,2/14/2023,,,,,Neurology,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12901,Methylprednisolone Tablet,Sandoz Inc.,"Methylprednisolone, Tablet, 4 mg (NDC 0781-5022-07)",New,2/14/2023,,,,,Neurology,To Be Discontinued,2/14/2023,2/14/2023,,2023,discontinued
12902,Metronidazole Gel,"Tolmar, Inc.","Metronidazole, Gel, 10 mg/1 g (NDC 0781-7080-35)",New,2/16/2023,,,,,Dermatology,To Be Discontinued,2/16/2023,2/16/2023,,2023,discontinued
12903,Metronidazole Gel,"Tolmar, Inc.","Metronidazole, Gel, 10 mg/1 g (NDC 0781-7080-55)",New,2/16/2023,,,,,Dermatology,To Be Discontinued,2/16/2023,2/16/2023,,2023,discontinued
12904,Metronidazole Injection,B. Braun Medical Inc.,"Metro I.v. In Plastic Container, Injection, 500 mg/100 mL (NDC 0264-5535-32)",Reverified,12/19/2023,Available. On allocation.,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,limited availability
12905,Metronidazole Injection,Baxter Healthcare,"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)",Reverified,12/21/2023,Available,,,,Anti-Infective,Current,,,,2023,available
12906,Metronidazole Injection,Gland Pharma Limited,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)",Reverified,12/19/2023,Lots are anticipated in April; with additional inventory arriving in May.,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,limited availability
12907,Metronidazole Injection,"Hospira, Inc., a Pfizer Company","Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 0409-7811-37)",Revised,9/11/2023,Discontinued,,,,Anti-Infective,Current,,,,2023,discontinued
12908,Metronidazole Injection,"Hospira, Inc., a Pfizer Company","Metronidazole In Plastic Container, Injection, 5 mg/1 mL (NDC 0409-0152-24)",Revised,9/11/2023,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Anti-Infective,Current,,,,2023,limited availability
12909,Metronidazole Injection,Pfizer Inc.,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 0409-7811-37)",New,4/6/2023,,Supply expected to exhaust late May/early June 2023; Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,4/6/2023,4/6/2023,,2023,discontinued
12910,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)",Revised,11/2/2023,Available,Please check wholesalers and distributors for inventory.,,,Anesthesia; Neurology,Current,,,,2023,available
12911,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)",Revised,11/2/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12912,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-10)",Reverified,3/10/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2023,available
12913,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-05)",Reverified,3/10/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2023,available
12914,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-17)",Reverified,3/10/2023,No stock available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2023,not available
12915,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-91)",Reverified,3/10/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2023,available
12916,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 70860-600-02)",Reverified,3/10/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2023,available
12917,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 47781-588-68)",Reverified,3/10/2023,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2023,available
12918,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-411-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2023,available
12919,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-001-20)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2023,available
12920,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-411-12)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2023,available
12921,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-411-25)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2023,available
12922,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 5 mg/1 mL (NDC 63323-412-25)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2023,available
12923,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 5 mg/1 mL (NDC 63323-412-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2023,available
12924,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 5 mg/1 mL (NDC 63323-412-02)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,,2023,available
12925,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0641-6056-10)",Revised,11/2/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12926,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0641-6057-25)",Revised,11/2/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12927,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/mL, 5 mL (NDC 0641-6059-25)",Revised,11/2/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12928,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 5 mg/1 mL (NDC 0641-6061-25)",Revised,11/2/2023,Unavailable,This presentation is temporarily on backorder.,,Demand increase for the drug,Anesthesia; Neurology,Current,,,,2023,not available
12929,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 5 mg/1 mL (NDC 0641-6060-10)",Revised,11/2/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12930,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 1 mg/1 mL (NDC 0409-2305-17)",Reverified,9/11/2023,Limited Supply Available.,,,,Anesthesia; Neurology,Current,,,,2023,limited availability
12931,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 1 mg/1 mL (NDC 0409-2305-05)",Reverified,9/11/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12932,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/1 mL (NDC 0409-2308-01)",Reverified,9/11/2023,Depleted,,,,Anesthesia; Neurology,Current,,,,2023,not available
12933,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-2596-05)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology,Current,,,,2023,not available
12934,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/1 mL (NDC 0409-2308-02)",Reverified,9/11/2023,Depleted,,,,Anesthesia; Neurology,Current,,,,2023,not available
12935,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-2596-03)",Reverified,9/11/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology,Current,,,,2023,limited availability
12936,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-2587-05)",Reverified,9/11/2023,Depleted,,,,Anesthesia; Neurology,Current,,,,2023,not available
12937,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 5 mg/1 mL (NDC 23155-601-42)",Revised,11/1/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12938,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 5 mg/1 mL (NDC 23155-601-41)",Revised,11/1/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12939,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 1 mg/1 mL (NDC 23155-600-41)",Revised,11/1/2023,Available,,,,Anesthesia; Neurology,Current,,,,2023,available
12940,Minocycline Extended Release Tablet,EPI Health,"Minolira, Extended Release Tablet, 135 mg (NDC 71403-102-30)",New,11/2/2023,,,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,11/2/2023,,2023,discontinued
12941,Minocycline Extended Release Tablets,EPI Health,"Minolira, Extended Release Tablets, 105mg (NDC 71403-101-30)",New,11/2/2023,,,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,11/2/2023,,2023,discontinued
12942,"MINOCYCLINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE",Journey Medical Corporation,"XIMINO, CAPSULE, EXTENDED RELEASE, 45 mg (NDC 69489-121-30)",New,9/29/2023,,Discontinuation due to business reasons.,,Discontinuation of the manufacture of the drug,Antibiotic,To Be Discontinued,,9/29/2023,,2023,discontinued
12943,"Minocycline Hydrochloride Tablet, Extended Release",Sandoz Inc.,"Minocycline Hydrochloride, Tablet, Extended Release, 45 mg (NDC 0781-5385-31)",New,6/28/2023,,Discontinuing due to a business decision.,,,Anti-Infective,To Be Discontinued,6/28/2023,6/28/2023,,2023,discontinued
12944,"Minocycline Hydrochloride Tablet, Extended Release",Sandoz Inc.,"Minocycline Hydrochloride, Tablet, Extended Release, 90 mg (NDC 0781-5386-31)",New,6/28/2023,,Discontinuing due to a business decision.,,,Anti-Infective,To Be Discontinued,6/28/2023,6/28/2023,,2023,discontinued
12945,"Minocycline Hydrochloride Tablet, Extended Release",Sandoz Inc.,"Minocycline Hydrochloride, Tablet, Extended Release, 135 mg (NDC 0781-5387-31)",New,6/28/2023,,Discontinuing due to a business decision.,,,Anti-Infective,To Be Discontinued,6/28/2023,6/28/2023,,2023,discontinued
12946,Montelukast Sodium Granule,"Teva Pharmaceuticals USA, Inc.","Montelukast Sodium, Granule, 4 mg (NDC 0093-7487-56)",New,6/6/2023,,,,,Pulmonary/Allergy,To Be Discontinued,6/6/2023,6/6/2023,,2023,discontinued
12947,Montelukast Sodium Granules,"Teva Pharmaceuticals USA, Inc.","Granules, 4 mg (NDC 0093-7487-19)",New,6/6/2023,,,,,Pulmonary/Allergy,To Be Discontinued,6/6/2023,6/6/2023,,2023,discontinued
12948,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 1 mg/30 mL (NDC 76329-1912-1)",Reverified,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12949,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)",Revised,12/19/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured in the May 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12950,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)",Revised,12/19/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12951,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 200, Injection, 10 mg/1 mL (NDC 0641-6039-01)",Revised,12/19/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12952,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 500, Injection, 25 mg/1 mL (NDC 0641-6040-01)",Revised,12/19/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12953,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 2 mg/1 mL (NDC 63323-452-01)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12954,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-454-01)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12955,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 5 mg/1 mL (NDC 63323-455-01)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12956,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-451-01)",Reverified,12/20/2023,Next release not available at this time.,Check wholesalers for inventory,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,not available
12957,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-01)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12958,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-01)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12959,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12960,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)",Revised,12/19/2023,Available,,,,Analgesia/Addiction,Current,,,,2023,available
12961,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, .5 mg/1 mL (NDC 0409-3814-12)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,limited availability
12962,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 1 mg/1 mL (NDC 0409-3815-12)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,,2023,limited availability
12963,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-03)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,not available
12964,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,not available
12965,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)",Revised,12/19/2023,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12966,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)",Revised,12/19/2023,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured in the May - June 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,not available
12967,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)",Revised,12/19/2023,Inventory is currently available.,Additional lots are scheduled for manufacturing and will be available in the May - June 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
12968,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 2 mg/1 mL (NDC 76045-004-11)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12969,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 76045-005-11)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,,2023,available
12970,Moxetumomab Pasudotox Injection,AstraZeneca Pharmaceuticals LP,"Lumoxiti, Injection, 1 mg/1 mL (NDC 0310-4700-01)",New,1/10/2023,,"The planned permanent discontinuation of moxetumomab pasudotox-tdfk) for injection from the U.S. market is August 31, 2023.",,,Oncology,To Be Discontinued,1/10/2023,1/10/2023,,2023,discontinued
12971,Moxifloxacin Hydrochloride Tablet,Torrent Pharmaceuticals Limited,"Moxifloxacin Hydrochloride, Tablet, 400 mg (NDC 13668-201-30)",New,3/28/2023,,Business decision to discontinue manufacture of this product.,,,Anti-Infective,To Be Discontinued,3/28/2023,3/28/2023,,2023,discontinued
12972,Moxifloxacin Hydrochloride Tablet,Torrent Pharmaceuticals Limited,"Moxifloxacin Hydrochloride, Tablet, 400 mg (NDC 13668-201-01)",New,3/28/2023,,Business decision to discontinue manufacture of this product.,,,Anti-Infective,To Be Discontinued,3/28/2023,3/28/2023,,2023,discontinued
12973,Moxifloxacin Hydrochloride Tablet,Torrent Pharmaceuticals Limited,"Moxifloxacin Hydrochloride, Tablet, 400 mg (NDC 13668-201-05)",New,3/28/2023,,Business decision to discontinue manufacture of this product.,,,Anti-Infective,To Be Discontinued,3/28/2023,3/28/2023,,2023,discontinued
12974,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 400 mg (NDC 55111-112-66)",New,10/4/2023,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/4/2023,,2023,discontinued
12975,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 400 mg (NDC 55111-112-01)",New,10/4/2023,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/4/2023,,2023,discontinued
12976,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 400 mg (NDC 55111-112-05)",New,10/4/2023,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/4/2023,,2023,discontinued
12977,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 400 mg (NDC 55111-112-66)",New,10/4/2023,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/4/2023,,2023,discontinued
12978,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Fresenius Kabi USA, LLC","Vitalipid N, Injection, 1 [iU]/1 mL; 20 [iU]/1 mL; 15 ug/1 mL; 330 [iU]/1 mL (NDC 65219-335-82)",Revised,12/20/2023,Available for direct orders.,,,Demand increase for the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
12979,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Fresenius Kabi USA, LLC","Vitalipid N, Injection, .7 [iU]/1 mL; 40 [iU]/1 mL; 20 ug/1 mL; 230 [iU]/1 mL (NDC 65219-337-62)",Revised,12/20/2023,Available for direct orders.,,,Demand increase for the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
12980,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Fresenius Kabi USA, LLC","Vitalipid N, Injection, .7 [iU]/1 mL; 40 [iU]/1 mL; 20 ug/1 mL; 230 [iU]/1 mL (NDC 65219-339-64)",Revised,12/20/2023,Available for direct orders.,,,Demand increase for the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
12981,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Hospira, Inc., a Pfizer Company","M.v.i. Adult, Injection, 10 Kit In 1 Package (61703-434-82) (NDC 61703-434-82)",Revised,10/30/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/2023,10/30/2023,,2023,discontinued
12982,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Hospira, Inc., a Pfizer Company","M.v.i. Adult, Injection, 2 Box In 1 Case (61703-422-83)  (NDC 61703-422-83)",Revised,10/30/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/2023,10/30/2023,,2023,discontinued
12983,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Hospira, Inc., a Pfizer Company","M.v.i. Pediatric, Injection, 7 mg/5 mL; 80 mg/5 mL; 20 ug/5 mL; 1 ug/5 mL; 5 mg/5 mL; 10 ug/5 mL; 140 ug/5 mL; 17 mg/5 mL; 200 ug/5 mL; 1 mg/5 mL; .7 mg/5 mL; 1.4 mg/5 mL; 1.2 mg/5 mL (NDC 61703-421-53)",Revised,10/30/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/2023,10/30/2023,,2023,discontinued
12984,Multi-Vitamin Infusion (Adult and Pediatric) Injection,Sandoz Inc.,"Pediatric Infuvite Multiple Vitamins For Infusion, Injection, 7 [iU]/5 mL; 80 mg/5 mL; 20 ug/5 mL; 400 [iU]/5 mL; 1 ug/5 mL; 5 mg/5 mL; 140 ug/5 mL; 17 mg/5 mL; .2 mg/5 mL; 1 mg/5 mL; 1.4 mg/5 mL; 1.2 mg/5 mL; 2300 [iU]/5 mL (NDC 54643-5646-1)",Reverified,12/19/2023,Available,Distributed by BaxterCustomer Service Number 888-229-0001,,,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
12985,Multi-Vitamin Infusion (Adult and Pediatric) Injection,Sandoz Inc.,"Infuvite Adult, Injection, 10 [iU]/10 mL; 200 mg/10 mL; 60 ug/10 mL; 200 [iU]/10 mL; 5 ug/10 mL; 15 mg/10 mL; 600 ug/10 mL; 40 mg/10 mL; 150 ug/10 mL; 6 mg/10 mL; 3.6 mg/10 mL; 6 mg/10 mL; 3300 [iU]/10 mL (NDC 54643-5649-1)",Reverified,12/19/2023,Available,Distributed by BaxterCustomer Service Number 888-229-0001,,,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
12986,Multi-Vitamin Infusion (Adult and Pediatric) Injection,Sandoz Inc.,"Infuvite Adult Multiple Vitamins, Injection, 10 [iU]/10 mL; 200 mg/10 mL; 60 ug/10 mL; 200 [iU]/10 mL; 5 ug/10 mL; 15 mg/10 mL; 600 ug/10 mL; 40 mg/10 mL; 150 ug/10 mL; 6 mg/10 mL; 3.6 mg/10 mL; 6 mg/10 mL; 3300 [iU]/10 mL (NDC 54643-5650-2)",Reverified,12/19/2023,Available,Distributed by BaxterCustomer Service Number 888-229-0001,,,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
12987,Multi-Vitamin Infusion (Adult and Pediatric) Injection,Sandoz Inc.,"Pediatric Infuvite Multiple Vitamins, Injection, 40 mL in 1 VIAL * 10 mL in 1 VIAL (NDC 54643-5647-0)",Reverified,12/19/2023,Available,Distributed by BaxterCustomer Service Number 888-229-0001,,,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
12988,"Mycophenolate Sodium Tablet, Delayed Release","Lupin Pharmaceuticals, Inc.","Mycophenolic Sodium, Tablet, Delayed Release, 180 mg (NDC 70748-217-16)",New,4/6/2023,,,,,Anti-Infective,To Be Discontinued,4/6/2023,4/6/2023,,2023,discontinued
12989,"Mycophenolate Sodium Tablet, Delayed Release","Lupin Pharmaceuticals, Inc.","Mycophenolic Sodium, Tablet, Delayed Release, 360 mg (NDC 70748-218-16)",New,4/6/2023,,,,,Anti-Infective,To Be Discontinued,4/6/2023,4/6/2023,,2023,discontinued
12990,Neomycin Sulfate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-1177-01)",Reverified,12/6/2023,Available,,,,Anti-Infective,Current,,,,2023,available
12991,Neomycin Sulfate Tablet,"XGen Pharmaceuticals DJB, Inc.","Neomycin Sulfate, Tablet, 500 mg (NDC 39822-0310-5)",Revised,10/12/2023,Available,,,,Anti-Infective,Current,,,,2023,available
12992,Nicotine Inhalant,Pfizer Inc.,"Nicotrol, Inhalant, 4 mg (NDC 0009-5400-01)",New,4/26/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust late August 2023,,,Other,To Be Discontinued,4/26/2023,4/26/2023,,2023,discontinued
12993,Nifedipine Capsule,Pfizer Inc.,"Capsule, 10 mg (NDC 59762-1004-1)",New,10/26/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust November 2023.,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/26/2023,,2023,discontinued
12994,Nitroglycerin Injection,Baxter Healthcare,"NITROGLYCERIN IN DEXTROSE 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)",Reverified,12/19/2023,"On Allocation, Recovery late November",,,Demand increase for the drug,Cardiovascular,Current,10/3/2023,,,2023,limited availability
12995,Nitroglycerin Injection,Baxter Healthcare,"NITROGLYCERIN IN DEXTROSE 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)",Reverified,12/19/2023,"On Allocation, Recovery late November",,,Demand increase for the drug,Cardiovascular,Current,10/3/2023,,,2023,limited availability
12996,Nitroglycerin Injection,Baxter Healthcare,"NITROGLYCERIN IN DEXTROSE 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)",Reverified,12/19/2023,"On Allocation, Recovery late November",,,Demand increase for the drug,Cardiovascular,Current,10/3/2023,,,2023,limited availability
12997,Nitroglycerin Injection,"American Regent, Inc.","Injection, 5 mg/1 mL (NDC 0517-4810-25)",Reverified,12/19/2023,"Check wholesaler, ETA January 2024",,,Regulatory delay,Cardiovascular,Current,10/3/2023,,,2023,not available
12998,Nizatidine Capsule,"Teva Pharmaceuticals USA, Inc.","Capsule, 300 mg (NDC 0591-3138-30)",Revised,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
12999,Nizatidine Capsule,"Teva Pharmaceuticals USA, Inc.","Capsule, 150 mg (NDC 0591-3137-60)",Revised,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13000,Nystatin Ointment,Torrent Pharmaceuticals Limited,"Nystatin, Ointment, 100000 U/1 g (NDC 13668-534-01)",New,3/21/2023,,,,,Dermatology,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
13001,Nystatin Ointment,Torrent Pharmaceuticals Limited,"Nystatin, Ointment, 100000 U/1 g (NDC 13668-534-02)",Revised,3/21/2023,,,,,Dermatology,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
13002,Ofatumumab Injection,Novartis Pharmaceuticals Corporation,"Arzerra, Injection, 20 mg/1 mL (NDC 0078-0669-13)",New,11/3/2023,,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,11/3/2023,,2023,discontinued
13003,Ofatumumab Injection,Novartis Pharmaceuticals Corporation,"Arzerra, Injection, 20 mg/1 mL (NDC 0078-0690-61)",New,11/3/2023,,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,11/3/2023,,2023,discontinued
13004,Omacetaxine Mepesuccinate Injection,"Teva Pharmaceuticals USA, Inc.","Synribo, Injection, 3.5 mg/1 mL (NDC 63459-177-14)",New,6/13/2023,,,,,Hematology; Oncology,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
13005,Omeprazole; Sodium Bicarbonate	 For Suspension,"Par Pharmaceutical, Inc.","For Suspension, 20 mg; 1680 mg (NDC 49884-268-11)",New,12/7/2023,,,,Discontinuation of the manufacture of the drug,Gastroenterology,To Be Discontinued,,12/7/2023,,2023,discontinued
13006,Omeprazole; Sodium Bicarbonate Suspension,"Par Pharmaceutical, Inc.","Suspension, 40 mg; 1680 mg (NDC 49884-269-11)",New,12/7/2023,,,,Discontinuation of the manufacture of the drug,Gastroenterology,To Be Discontinued,,12/7/2023,,2023,discontinued
13007,Oxandrolone Tablet,Endo Pharmaceuticals. Inc.,"Oxandrolone, Tablet, 2.5 mg (NDC 49884-301-01)",New,7/10/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,7/10/2023,7/10/2023,,2023,discontinued
13008,Oxandrolone Tablet,Endo Pharmaceuticals. Inc.,"Oxandrolone, Tablet, 10 mg (NDC 49884-302-02)",New,7/10/2023,,,,,Endocrinology/Metabolism,To Be Discontinued,7/10/2023,7/10/2023,,2023,discontinued
13009,Oxaprozin Tablet,Sandoz Inc.,"Oxaprozin, Tablet, 600 mg (NDC 0185-0141-01)",New,3/17/2023,,Discontinuation of the manufacture of the product,,,Analgesia/Addiction,To Be Discontinued,3/17/2023,3/17/2023,,2023,discontinued
13010,Oxybutynin Chloride Gel,AbbVie Inc.,"Gelnique, Gel, 100 mg/1 g (NDC 0023-5861-11)",New,6/14/2023,,Discontinuation of the manufacture of the drug,,,Urology,To Be Discontinued,6/14/2023,6/14/2023,,2023,discontinued
13011,Oxybutynin Chloride Gel,AbbVie Inc.,"Gel, 100 mg/g (NDC 0023-5861-10)",New,6/14/2023,,Discontinuation of the manufacture of the drug,,,Urology,To Be Discontinued,6/14/2023,6/14/2023,,2023,discontinued
13012,Oxybutynin Chloride Syrup,Chartwell Molecular Holdings LLC,"Syrup, 5 mg/5 mL (NDC 62135-520-47)",Reverified,12/20/2023,Product available in all wholesalers,,,,Urology,Current,,,,2023,available
13013,Oxybutynin Chloride Syrup,"Lannett Company, Inc.","Syrup, 5 mg/5 mL (NDC 54838-510-80)",Revised,12/19/2023,Limited Availability,Estimated Delivery: December 2023,,Shortage of an active ingredient,Urology,Current,,,,2023,limited availability
13014,Oxycodone Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Oxycodone Hydrochloride, Tablet, 30 mg (NDC 0228-2879-11)",New,5/9/2023,,,,,,To Be Discontinued,5/9/2023,5/9/2023,,2023,discontinued
13015,Oxycodone Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Oxycodone Hydrochloride, Tablet, 15 mg (NDC 0228-2878-11)",New,5/9/2023,,,,,,To Be Discontinued,5/9/2023,5/9/2023,,2023,discontinued
13016,Oxycodone Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Oxycodone Hydrochloride, Tablet, 5 mg (NDC 0228-2876-11)",New,5/9/2023,,,,,,To Be Discontinued,5/9/2023,5/9/2023,,2023,discontinued
13017,Oxytocin Injection,"Fresenius Kabi USA, LLC","Oxytocin, Injection, 10 [USP'U]/1 mL (NDC 63323-012-11)",Revised,8/14/2023,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/2023,,,2023,
13018,Oxytocin Injection,"Fresenius Kabi USA, LLC","Oxytocin, Injection, 10 [USP'U]/1 mL (NDC 63323-012-10)",Revised,8/14/2023,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/2023,,,2023,
13019,Oxytocin Injection,"Fresenius Kabi USA, LLC","Oxytocin, Injection, 10 [USP'U]/1 mL (NDC 63323-012-30)",Revised,8/14/2023,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/2023,,,2023,
13020,Oxytocin Injection,"Fresenius Kabi USA, LLC","Injection, 10 USP units (NDC 63323-112-01)",Revised,8/14/2023,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/2023,,,2023,
13021,Oxytocin Injection,"Par Pharmaceutical, Inc.","Pitocin, Injection, 10 [iU]/1 mL (NDC 42023-130-06)",Revised,8/14/2023,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/2023,,,2023,
13022,Oxytocin Injection,"Par Pharmaceutical, Inc.","Pitocin, Injection, 10 [iU]/1 mL (NDC 42023-116-25)",Revised,8/14/2023,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/2023,,,2023,
13023,Oxytocin Injection,"Par Pharmaceutical, Inc.","Pitocin, Injection, 10 [iU]/1 mL (NDC 42023-116-02)",Revised,8/14/2023,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/2023,,,2023,
13024,Palifermin Injection,Swedish Orphan Biovitrum AB,"Kepivance, Injection, 6.25 mg/1.2 mL (NDC 66658-112-03)",Revised,10/18/2023,Available,,Available,,Other,Resolved,10/18/2023,,,2023,available
13025,Palifermin Injection,Swedish Orphan Biovitrum AB,"Kepivance, Injection, 6.25 mg/1.2 mL (NDC 66658-112-06)",Revised,10/18/2023,Available,,Available,,Other,Resolved,10/18/2023,,,2023,available
13026,"Paliperidone Tablet, Extended Release",Janssen Research and Development,"Invega, Tablet, Extended Release, 1.5 mg (NDC 50458-554-01)",New,2/3/2023,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To Be Discontinued,2/3/2023,2/3/2023,,2023,discontinued
13027,"Paliperidone Tablet, Extended Release",Janssen Research and Development,"Invega, Tablet, Extended Release, 1.5 mg (NDC 50458-554-10)",New,2/3/2023,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To Be Discontinued,2/3/2023,2/3/2023,,2023,discontinued
13028,Pantoprazole Sodium Injection,Sandoz Inc.,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 65219-433-15)",Revised,9/15/2023,,Marketed by Fresenius Kabi,Available. NDC 72572-550-10 marketed by Civica. NDC 65219-433-15 marketed by Fresenius Kabi.,,Gastroenterology,Resolved,9/15/2023,,,2023,
13029,Pantoprazole Sodium Injection,Sandoz Inc.,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 72572-550-10)",Revised,9/15/2023,,,Available. NDC 72572-550-10 marketed by Civica. NDC 65219-433-15 marketed by Fresenius Kabi.,,Gastroenterology,Resolved,9/15/2023,,,2023,
13030,Pantoprazole Sodium Injection,Sandoz Inc.,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 0781-3232-95)",Revised,9/15/2023,,,Available. NDC 72572-550-10 marketed by Civica. NDC 65219-433-15 marketed by Fresenius Kabi.,,Gastroenterology,Resolved,9/15/2023,,,2023,
13031,Pantoprazole Sodium Injection,Eugia US LLC,"Pantoprazole Sodium, Injection, 40 mg (NDC 55150-202-10)",Revised,9/15/2023,,,Available,,Gastroenterology,Resolved,9/15/2023,,,2023,
13032,Pantoprazole Sodium Injection,"Hospira, Inc., a Pfizer Company","Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-0923-55)",Revised,9/15/2023,,,Available,,Gastroenterology,Resolved,9/15/2023,,,2023,
13033,Pantoprazole Sodium Injection,"Hospira, Inc., a Pfizer Company","Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-0923-60)",Revised,9/15/2023,,,Available,,Gastroenterology,Resolved,9/15/2023,,,2023,
13034,Pantoprazole Sodium Injection,"Hospira, Inc., a Pfizer Company","Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-4001-10)",Revised,9/15/2023,,,Available,,Gastroenterology,Resolved,9/15/2023,,,2023,
13035,Pantoprazole Sodium Injection,"Hospira, Inc., a Pfizer Company","Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-4001-25)",Revised,9/15/2023,,,Available,,Gastroenterology,Resolved,9/15/2023,,,2023,
13036,Pantoprazole Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Pantoprazole Sodium, Injection, 40 mg (NDC 0143-9284-10)",Revised,9/15/2023,,,Limited availability,Demand increase for the drug,Gastroenterology,Resolved,9/15/2023,,,2023,
13037,Pantoprazole Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Pantoprazole Sodium, Injection, 40 mg (NDC 0143-9300-10)",Revised,9/15/2023,,,Limited availability,Demand increase for the drug,Gastroenterology,Resolved,9/15/2023,,,2023,
13038,Pantoprazole Sodium Injection,"ACIC Pharmaceuticals, Inc.","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 67850-150-10)",Revised,9/15/2023,,,"Available. Marketed by Methapharm, Inc.",Demand increase for the drug,Gastroenterology,Resolved,9/15/2023,,,2023,
13039,Pantoprazole Sodium Injection,"ACIC Pharmaceuticals, Inc.","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 67850-150-25)",Revised,9/15/2023,,,"Available. Marketed by Methapharm, Inc.",Demand increase for the drug,Gastroenterology,Resolved,9/15/2023,,,2023,
13040,Pantoprazole Sodium Injection,"Meitheal Pharmaceuticals, Inc.","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 71288-600-11)",Revised,9/15/2023,,,Available. NDC 72603-128-10 marketed by Northstar Rx.,,Gastroenterology,Resolved,9/15/2023,,,2023,
13041,Pantoprazole Sodium Injection,"Meitheal Pharmaceuticals, Inc.","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 72603-128-10)",Revised,9/15/2023,,,Available. NDC 72603-128-10 marketed by Northstar Rx.,,Gastroenterology,Resolved,9/15/2023,,,2023,
13042,Pantoprazole Sodium Injection,Gland Pharma Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 25021-751-10)",Revised,9/15/2023,,,Available. NDCs 25021-751-10 and 25021-751-11 marketed by Sagent. NDCs 70095-024-02 and 70095-024-03 marketed by Sun.,Demand increase for the drug,Gastroenterology,Resolved,9/15/2023,,,2023,
13043,Pantoprazole Sodium Injection,Gland Pharma Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 25021-751-11)",Revised,9/15/2023,,,Available. NDCs 25021-751-10 and 25021-751-11 marketed by Sagent. NDCs 70095-024-02 and 70095-024-03 marketed by Sun.,Demand increase for the drug,Gastroenterology,Resolved,9/15/2023,,,2023,
13044,Pantoprazole Sodium Injection,Gland Pharma Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 70095-024-02)",Revised,9/15/2023,,,Available. NDCs 25021-751-10 and 25021-751-11 marketed by Sagent. NDCs 70095-024-02 and 70095-024-03 marketed by Sun.,Demand increase for the drug,Gastroenterology,Resolved,9/15/2023,,,2023,
13045,Pantoprazole Sodium Injection,Gland Pharma Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 70095-024-03)",Revised,9/15/2023,,,Available. NDCs 25021-751-10 and 25021-751-11 marketed by Sagent. NDCs 70095-024-02 and 70095-024-03 marketed by Sun.,Demand increase for the drug,Gastroenterology,Resolved,9/15/2023,,,2023,
13046,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Revised,12/21/2023,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details â€“ https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,,2023,discontinued
13047,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Revised,12/21/2023,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details â€“ https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,,2023,discontinued
13048,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Revised,12/21/2023,The 100 mcg cartridge is no longer available and Takeda is unable to resupply prior to ceasing of manufacturing of Natpara at the end of 2024. Please refer to the following link for more details â€“ https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,,2023,discontinued
13049,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Revised,12/21/2023,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details â€“ https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,,2023,discontinued
13050,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-a, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)",Revised,9/11/2023,Next delivery: TBD; Estimated recovery 2024,,,,Anti-Infective,Current,,,,2023,unclear
13051,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-a, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)",Revised,9/11/2023,Limited Supply. Next delivery: September 2023; Estimated recovery: Q2 2024,On allocation. Check Wholesaler for Availability,,,Anti-Infective,Current,,,,2023,limited availability
13052,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-a, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)",Revised,9/11/2023,Limited Supply. Next delivery: September 2023; Estimated recovery: Q2 2024,On allocation. Check Wholesaler for Availability,,,Anti-Infective,Current,,,,2023,limited availability
13053,Penicillin G Procaine Injection,Pfizer Inc.,"Penicillin G Procaine, Injection, 600000 [iU]/1 mL (NDC 60793-130-10)",New,6/13/2023,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
13054,Penicillin G Procaine Injection,Pfizer Inc.,"Penicillin G Procaine, Injection, 1200000 [iU]/2 mL (NDC 60793-131-10)",New,6/13/2023,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,6/13/2023,6/13/2023,,2023,discontinued
13055,Piroxicam Capsule,Pfizer Inc.,"Feldene, Capsule, 10 mg (NDC 0069-3220-66)",New,4/4/2023,,Supply expected to exhaust late May 2023; Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,4/4/2023,4/4/2023,,2023,discontinued
13056,Piroxicam Capsule,Pfizer Inc.,"Feldene, Capsule, 20 mg (NDC 0069-3230-66)",New,8/24/2023,,Supply expected to exhaust late October 2023; Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,8/24/2023,8/24/2023,,2023,discontinued
13057,Podofilox Solution,"Teva Pharmaceuticals USA, Inc.","Condylox, Solution, 5 mg/1 mL (NDC 0591-3204-13)",New,5/9/2023,,Business decision:  Discontinuation of the manufacture of the drug,,,Dermatology,To Be Discontinued,5/9/2023,5/9/2023,,2023,discontinued
13058,Posaconazole Oral Suspension,Merck Sharp & Dohme LLC,"Noxafil, Oral Suspension, 40MG/ML (NDC 0085-1328-01)",New,11/15/2023,,"To be discontinued 
on December 18th, 2023.",,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,11/15/2023,,2023,discontinued
13059,Potassium Acetate Injection,"Hospira, Inc., a Pfizer Company","Potassium Acetate, Injection, 196.3 mg/1 mL (NDC 0409-3294-51)",Reverified,9/11/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,limited availability
13060,Potassium Acetate Injection,"Hospira, Inc., a Pfizer Company","Potassium Acetate, Injection, 3.93 g/20 mL (NDC 0409-8183-01)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13061,Potassium Acetate Injection,"Hospira, Inc., a Pfizer Company","Potassium Acetate, Injection, 196.3 mg/1 mL (NDC 0409-3294-25)",Reverified,9/11/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13062,Potassium Acetate Injection,"Hospira, Inc., a Pfizer Company","Potassium Acetate, Injection, 3.93 g/20 mL (NDC 0409-8183-25)",Reverified,9/11/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13063,Potassium Acetate Injection,"Exela Pharma Sciences, LLC","Injection, 3.93 g/20 mL (NDC 51754-2001-4)",Revised,11/2/2023,Limited Availability,Batch released 10/25. Seven Additional batches pending packaging and release; Recovery estimated by Nov 15,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,limited availability
13064,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 20mEq In Plastic Container, Injection, 400 meq/1000 mL (NDC 0990-7077-14)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7077-14",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13065,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 10mEq In Plastic Container, Injection, 10 meq/100 mL (NDC 0990-7074-26)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7074-26",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13066,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 10mEq In Plastic Container, Injection, 200 meq/1000 mL (NDC 0990-7075-14)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7075-14",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13067,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 20mEq In Plastic Container, Injection, 200 meq/1000 mL (NDC 0990-7075-26)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7075-26",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13068,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 40mEq In Plastic Container, Injection, 400 meq/1000 mL (NDC 0990-7077-26)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7077-26",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13069,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 20 mEq (NDC 14789-107-08)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13070,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 40 mEq (NDC 14789-107-16)",Reverified,12/19/2023,Unavailable,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13071,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 20 mEq (NDC 14789-108-16)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13072,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 10 mEq (NDC 14789-108-08)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13073,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 10 mEq (NDC 14789-109-16)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13074,Potassium Chloride Injection,B. Braun Medical Inc.,"Injection, 14.9 g/100 mL (NDC 0264-1944-20)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13075,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 7.46 g/1000 mL (NDC 0338-0709-48)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13076,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 14.9 g/1000 mL (NDC 0338-0705-41)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13077,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 14.9 g/1000 mL (NDC 0338-0705-48)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13078,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 29.8 g/1000 mL (NDC 0338-0703-41)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13079,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 29.8 g/1000 mL (NDC 0338-0703-48)",Reverified,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13080,Potassium Chloride Injection,"Hospira, Inc., a Pfizer Company","Potassium Chloride, Injection, 149 mg/1 mL (NDC 0409-6635-01)",Revised,9/11/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13081,Potassium Chloride Injection,"Hospira, Inc., a Pfizer Company","Potassium Chloride, Injection, 149 mg/1 mL (NDC 0409-6651-06)",Revised,9/11/2023,Depleted,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13082,Potassium Chloride Injection,"Hospira, Inc., a Pfizer Company","Potassium Chloride, Injection, 149 mg/1 mL (NDC 0409-6653-05)",Revised,9/11/2023,Limited Supply Available. Next Delivery and Estimated Recovery: December 2023,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,limited availability
13083,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","Potassium Chloride In Plastic Container, Injection, 2 meq/1 mL (NDC 63323-967-30)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13084,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","Potassium Chloride In Plastic Container, Injection, 2 meq/1 mL (NDC 63323-965-05)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13085,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","Potassium Chloride In Plastic Container, Injection, 2 meq/1 mL (NDC 63323-965-10)",Reverified,12/20/2023,Available. Check wholesaler for inventory.,Check wholesalers for inventory,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13086,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","Potassium Chloride In Plastic Container, Injection, 2 meq/1 mL (NDC 63323-965-20)",Reverified,12/20/2023,Next release not available at this time.,Check wholesalers for inventory,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13087,Potassium Chloride Injection,B. Braun Medical Inc.,"Injection, 14.9 g/100 mL (NDC 0264-1940-20)",Reverified,12/19/2023,Inventory depleted.,Discontinuation of manufacturing,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13088,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, 1.5 mg (NDC 0597-0113-30)",New,8/1/2023,,,,,Neurology,To Be Discontinued,8/1/2023,8/1/2023,,2023,discontinued
13089,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, 4.5 mg (NDC 0597-0116-30)",New,8/1/2023,,,,,Neurology,To Be Discontinued,8/1/2023,8/1/2023,,2023,discontinued
13090,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, 3.75 mg (NDC 0597-0287-30)",New,8/1/2023,,,,,Neurology,To Be Discontinued,8/1/2023,8/1/2023,,2023,discontinued
13091,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, 2.25 mg (NDC 0597-0286-30)",New,8/1/2023,,,,,Neurology,To Be Discontinued,8/1/2023,8/1/2023,,2023,discontinued
13092,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, .75 mg (NDC 0597-0285-30)",New,8/1/2023,,,,,Neurology,To Be Discontinued,8/1/2023,8/1/2023,,2023,discontinued
13093,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, .375 mg (NDC 0597-0109-30)",New,8/1/2023,,,,,Neurology,To Be Discontinued,8/1/2023,8/1/2023,,2023,discontinued
13094,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 1 mg (NDC 0069-4310-71)",New,4/28/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023,,,Cardiovascular,To Be Discontinued,4/28/2023,4/28/2023,,2023,discontinued
13095,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 2 mg (NDC 0069-4370-71)",New,4/28/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/2023,4/28/2023,,2023,discontinued
13096,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 5 mg (NDC 0069-4380-71)",New,4/28/2023,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/2023,4/28/2023,,2023,discontinued
13097,Prednicarbate Ointment,Sandoz Inc.,"Prednicarbate, Ointment, 1 mg/1 g (NDC 0168-0410-15)",Revised,3/16/2023,,,,,Dermatology,To Be Discontinued,3/16/2023,3/16/2023,,2023,discontinued
13098,Prednicarbate Ointment,Sandoz Inc.,"Prednicarbate, Ointment, 1 mg/1 g (NDC 0168-0410-60)",Revised,3/16/2023,,,,,Dermatology,To Be Discontinued,3/16/2023,3/16/2023,,2023,discontinued
13099,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)",Reverified,12/19/2023,Product Expected January 2024,,,Delay in shipping of the drug,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,,2023,not available
13100,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)",Reverified,12/19/2023,Product Expected January 2024,,,Delay in shipping of the drug,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,,2023,not available
13101,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)",New,11/21/2023,Product is temporarily on backorder,Additional lots will be available in the December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,12/1/2022,,,2023,not available
13102,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)",New,11/21/2023,Product is temporarily on backorder,Additional lots will be available in the December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/2023,,,2023,not available
13103,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)",New,11/21/2023,Product is temporarily on backorder,Additional lots will be available in the November - December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/2023,,,2023,not available
13104,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)",New,11/21/2023,Product is temporarily on backorder,Additional lots will be available in the November - December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/2023,,,2023,not available
13105,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)",New,11/21/2023,Product is temporarily on backorder,Additional lots will be available in the December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/2023,,,2023,not available
13106,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)",New,11/21/2023,Inventory is currently available,Additional lots will be available in the December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/2023,,,2023,available
13107,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)",New,11/21/2023,Product is temporarily on backorder,Additional lots will be available in the November - December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/2023,,,2023,not available
13108,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)",New,11/21/2023,Inventory is currently available,Additional lots will be available in the November - December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/2023,,,2023,available
13109,Propranolol Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-604-01)",Reverified,12/20/2023,Backordered. Next release January 2024.,Backordered. Next release January 2024.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2023,not available
13110,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0143-9872-10)",Reverified,12/19/2023,This presentation is currently unavailable.,This presentation is currently unavailable.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2023,not available
13111,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0143-9872-10)",Reverified,12/19/2023,,This presentation is currently unavailable.,,Shortage of an active ingredient,Cardiovascular,Current,,,,2023,
13112,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Tablet, 5 1 (NDC 43547-410-09)",Revised,12/19/2023,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,,Shortage of an active ingredient,Cardiovascular,Current,,,,2023,not available
13113,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Tablet, 10 mg (NDC 43547-411-09)",Revised,12/19/2023,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,,Shortage of an active ingredient,Cardiovascular,Current,,,,2023,not available
13114,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Tablet, 20 mg (NDC 43547-412-09)",Revised,12/19/2023,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,,Shortage of an active ingredient,Cardiovascular,Current,,,,2023,not available
13115,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Tablet, 40 mg (NDC 43547-413-09)",Revised,12/19/2023,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,,Shortage of an active ingredient,Cardiovascular,Current,,,,2023,not available
13116,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)",Revised,12/19/2023,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2023,not available
13117,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)",Revised,12/19/2023,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2023,not available
13118,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)",Revised,12/19/2023,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2023,not available
13119,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)",Revised,12/19/2023,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,,2023,not available
13120,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)",Revised,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
13121,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Revised,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
13122,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Revised,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
13123,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)",Revised,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
13124,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 40 mg (NDC 0071-0535-23)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,unclear
13125,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 10 mg (NDC 0071-0530-23)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,unclear
13126,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 20 mg (NDC 0071-0532-23)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,unclear
13127,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 5 mg (NDC 0071-0527-23)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,unclear
13128,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)",Reverified,9/11/2023,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,,Cardiovascular,Current,,,,2023,unclear
13129,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)",Reverified,9/11/2023,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,,Cardiovascular,Current,,,,2023,unclear
13130,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 mg; 20 mg (NDC 0071-0223-23)",Revised,12/19/2023,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,,2023,unclear
13131,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)",Revised,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
13132,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)",Revised,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
13133,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)",Revised,12/19/2023,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,,2023,discontinued
13134,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 500 mg (NDC 61958-1003-1)",Revised,12/22/2022,,,,,Cardiovascular,To Be Discontinued,12/22/2022,12/22/2022,,2023,discontinued
13135,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 1000 mg (NDC 61958-1004-1)",Revised,12/22/2022,,,,,Cardiovascular,To Be Discontinued,12/22/2022,12/22/2022,,2023,discontinued
13136,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 500 mg (NDC 61958-1003-2)",Revised,12/22/2022,,,,,Cardiovascular,To Be Discontinued,12/22/2022,12/22/2022,,2023,discontinued
13137,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 500 mg (NDC 61958-1003-3)",Revised,12/22/2022,,,,,Cardiovascular,To Be Discontinued,12/22/2022,12/22/2022,,2023,discontinued
13138,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 1000 mg (NDC 61958-1004-2)",Revised,12/22/2022,,,,,Cardiovascular,To Be Discontinued,12/22/2022,12/22/2022,,2023,discontinued
13139,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 1000 mg (NDC 61958-1004-3)",Revised,12/22/2022,,,,,Cardiovascular,To Be Discontinued,12/22/2022,12/22/2022,,2023,discontinued
13140,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)",Reverified,12/21/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
13141,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 2 mg (NDC 72078-035-02)",Reverified,12/21/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
13142,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 5 mg (NDC 67457-198-10)",Reverified,12/21/2023,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
13143,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0143-9391-10)",Revised,12/19/2023,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2023,available
13144,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 2 mg/2 mL (NDC 0143-9392-10)",Revised,12/19/2023,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2023,available
13145,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 5 mg/5 mL (NDC 0143-9393-10)",Revised,12/19/2023,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction,Current,,,,2023,available
13146,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-723-03)",Reverified,12/20/2023,Available. Check wholesaler for inventory.,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
13147,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-724-05)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,,,2023,available
13148,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-725-10)",Reverified,12/20/2023,Available. Check wholesaler for inventory.,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,,2023,available
13149,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 150 mg (NDC 42806-801-30)",Revised,12/20/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13150,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 150 mg (NDC 42806-801-01)",Revised,12/20/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13151,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 300 mg (NDC 42806-799-30)",Revised,12/20/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13152,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 300 mg (NDC 42806-799-60)",Revised,12/20/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13153,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 300 mg (NDC 42806-799-01)",Revised,12/20/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13154,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 300 mg (NDC 42806-799-05)",Revised,12/20/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13155,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 150 mg (NDC 68180-658-06)",Revised,12/19/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13156,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-06)",Revised,12/19/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13157,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-07)",Revised,12/19/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13158,Rifampin Injection,"Fresenius Kabi USA, LLC","Injection, 600 mg (NDC 63323-351-20)",Reverified,12/20/2023,Available. Check wholesaler for inventory.,Check wholesaler inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,,2023,available
13159,Rifampin Injection,Sanofi-Aventis U.S. LLC,"Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)",Reverified,12/19/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13160,Rifampin Injection,"Mylan Institutional, a Viatris Company","Injection, 600 mg/10 mL (NDC 67457-445-60)",Reverified,12/21/2023,Available,,,Demand increase for the drug,Anti-Infective,Current,,,,2023,available
13161,"Rifapentine Tablet, Film Coated",Sanofi-Aventis U.S. LLC,"Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)",Reverified,12/19/2023,Available,,,,Anti-Infective,Current,,,,2023,available
13162,Ritonavir Solution,AbbVie Inc.,"Norvir, Solution, 80 mg/1 mL (NDC 0074-1940-63)",New,2/1/2023,,Discontinuation,,,Antiviral,To Be Discontinued,2/1/2023,2/1/2023,,2023,discontinued
13163,"Rivaroxaban Granule, For Suspension",Janssen Pharmaceuticals,"Xarelto, Granule, For Suspension, 155 mg (NDC 50458-575-01)",Revised,7/12/2023,,,Available,,Hematology,Resolved,7/12/2023,,,2023,
13164,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 71288-700-06)",Revised,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
13165,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 71288-718-11)",Revised,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
13166,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)",Reverified,12/21/2023,Available,,,,Anesthesia,Current,,,,2023,available
13167,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 65219-065-05)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,,Anesthesia,Current,,,,2023,available
13168,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)",Reverified,12/21/2023,Available,,,,Anesthesia,Current,,,,2023,available
13169,Rocuronium Bromide Injection,Sandoz Inc.,"Injection, 10 mg/1 mL (NDC 0781-3220-95)",Revised,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
13170,Rocuronium Bromide Injection,Sandoz Inc.,"Injection, 10 mg/1 mL (NDC 0781-3220-92)",Revised,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
13171,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0409-9558-05)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13172,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0409-9558-49)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13173,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0409-9558-10)",Revised,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13174,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0409-9558-50)",Revised,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13175,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-426-05)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,,Anesthesia,Current,,,,2023,available
13176,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-426-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory.,,,Anesthesia,Current,,,,2023,available
13177,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Injection, 50 mg/5 mL (NDC 39822-4200-2)",Revised,12/19/2023,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,,,2023,available
13178,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Injection, 100 mg/10 mL (NDC 39822-4200-6)",Revised,12/19/2023,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,,,2023,available
13179,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-662-05)",Revised,12/19/2023,Available in January as NDC 25021-687-05,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
13180,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-662-10)",Reverified,12/19/2023,Not currently offered,,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13181,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)",Reverified,12/21/2023,Available,Tamarang is the application holder and Baxter is the distributor/labeler,,,Anesthesia,Current,,,,2023,available
13182,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)",Reverified,12/19/2023,Limited supply; Recovery: February 2024,Tamarang is the application holder and Baxter is the distributor/labeler,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13183,Rocuronium Bromide Injection,Eugia US LLC,"Injection, 100 mg/10 mL (NDC 55150-226-10)",Revised,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
13184,Rocuronium Bromide Injection,Eugia US LLC,"Injection, 50 mg/5 mL (NDC 55150-225-05)",Revised,12/20/2023,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,,2023,available
13185,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)",Revised,12/19/2023,This presentation is temporarily on backorder.,Additional lots will be available in the March 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13186,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)",Revised,12/19/2023,This presentation is temporarily on backorder.,Additional lots will be available in the March - April 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13187,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)",Reverified,12/19/2023,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13188,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)",Reverified,12/19/2023,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13189,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)",Reverified,12/19/2023,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13190,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)",Reverified,12/19/2023,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13191,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)",Reverified,12/19/2023,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13192,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)",Reverified,12/19/2023,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13193,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)",Reverified,12/19/2023,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13194,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)",Reverified,12/19/2023,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2023,available
13195,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)",Reverified,12/19/2023,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2023,available
13196,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)",Reverified,12/19/2023,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2023,available
13197,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)",Reverified,12/19/2023,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2023,available
13198,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)",Reverified,12/19/2023,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2023,available
13199,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)",Reverified,12/19/2023,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2023,available
13200,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 2 mg/1 mL (NDC 43066-015-10)",Revised,11/2/2023,Limited supply; Recovery: April 2024,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13201,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 5 mg/1 mL (NDC 43066-019-10)",Revised,11/2/2023,Available,,,,Anesthesia,Current,,,,2023,available
13202,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 5 mg/1 mL (NDC 43066-023-10)",Revised,11/2/2023,Limited supply; Recovery: April 2024,,,Demand increase for the drug,Anesthesia,Current,,,,2023,limited availability
13203,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 10 mg/1 mL (NDC 43066-027-10)",Revised,11/2/2023,Available,,,,Anesthesia,Current,,,,2023,available
13204,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 2 mg/1 mL (NDC 55150-195-20)",Revised,11/1/2023,Available,Sporadic availability expected.,,,Anesthesia,Current,,,,2023,available
13205,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 2 mg/1 mL (NDC 55150-196-99)",Revised,11/1/2023,Available,Sporadic availability expected.,,,Anesthesia,Current,,,,2023,available
13206,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 5 mg/1 mL (NDC 55150-197-20)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
13207,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 5 mg/1 mL (NDC 55150-198-30)",Reverified,12/19/2023,Available,,,,Anesthesia,Current,,,,2023,available
13208,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 7.5 mg/1 mL (NDC 55150-199-20)",Revised,11/1/2023,Available,Sporadic availability expected.,,,Anesthesia,Current,,,,2023,available
13209,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/1 mL (NDC 55150-200-10)",Revised,11/1/2023,Available,Sporadic availability expected.,,,Anesthesia,Current,,,,2023,available
13210,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/1 mL (NDC 55150-201-20)",Reverified,12/19/2023,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13211,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13212,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13213,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13214,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13215,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13216,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13217,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13218,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13219,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13220,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,,2023,available
13221,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13222,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory,,,Anesthesia,Current,,,,2023,available
13223,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13224,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13225,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13226,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13227,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)",Revised,11/29/2023,Available,Available. Check wholesaler for inventory,,,Anesthesia,Current,,,,2023,available
13228,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13229,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)",Revised,11/29/2023,Available,,,,Anesthesia,Current,,,,2023,available
13230,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)",Revised,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,,2023,not available
13231,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 2.5 mg (NDC 0310-6100-30)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
13232,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 2.5 mg (NDC 0310-6100-90)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
13233,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 2.5 mg (NDC 0310-6100-95)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
13234,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 5 mg (NDC 0310-6105-30)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
13235,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 5 mg (NDC 0310-6105-90)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
13236,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 5 mg (NDC 0310-6105-95)",New,3/21/2023,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/2023,3/21/2023,,2023,discontinued
13237,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, .68 mg/1 mL (NDC 0169-4181-13)",Revised,12/11/2023,Currently available,,44796,,Endocrinology/Metabolism,Current,,,,2023,available
13238,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, .25 mg/.5 mL (NDC 0169-4525-14)",Revised,12/11/2023,Limited availability.  Estimated shortage duration TBD,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13239,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, .5 mg/.5 mL (NDC 0169-4505-14)",Revised,12/11/2023,Limited availability.  Estimated shortage duration TBD,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13240,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 1 mg/.5 mL (NDC 0169-4501-14)",Revised,12/11/2023,Limited availability.  Estimated shortage duration TBD,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13241,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 1.7 mg/.75 mL (NDC 0169-4517-14)",Revised,12/11/2023,Limited availability.  Estimated shortage duration TBD,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13242,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 2.4 mg/.75 mL (NDC 0169-4524-14)",Revised,12/11/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13243,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, 1.34 mg/1 mL (NDC 0169-4130-13)",Revised,12/11/2023,Currently available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13244,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, 2.68 mg/1 mL (NDC 0169-4772-12)",Revised,12/11/2023,Limited availability through end of 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13245,Sincalide Injection,Bracco Diagnostics,"Kinevac, Injection, 5 ug/5 mL (NDC 0270-0556-15)",Revised,7/11/2023,,,Available,,Medical Imaging; Other,Resolved,7/11/2023,,,2023,
13246,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 164 mg/1 mL (NDC 0409-3299-05)",Revised,9/18/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,limited availability
13247,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 164 mg/1 mL (NDC 0409-3299-06)",Revised,9/18/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13248,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 3.28 g/20 mL (NDC 0409-7299-73)",Revised,9/18/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13249,Sodium Acetate Injection,"Fresenius Kabi USA, LLC","Injection, 4 meq/100 mL (NDC 63323-032-00)",Reverified,11/29/2023,Unavailable,Next release not available at this time.,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,,2023,not available
13250,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 164 mg/1 mL (NDC 69784-230-10)",Revised,12/21/2023,Available,,,,Total Parenteral Nutrition,Current,,,,2023,available
13251,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 164 mg/1 mL (NDC 69784-231-10)",Revised,12/21/2023,Available,,,,Total Parenteral Nutrition,Current,,,,2023,available
13252,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 164 mg/1 mL (NDC 0409-3299-25)",Revised,9/18/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,limited availability
13253,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 164 mg/1 mL (NDC 0409-3299-26)",Revised,9/18/2023,Next Delivery and Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13254,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 3.28 g/20 mL (NDC 0409-7299-25)",Revised,9/18/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13255,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 328 mg/1 mL (NDC 69784-232-01)",New,12/21/2023,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13256,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Injection, 84 mg/1 mL (NDC 51754-5011-4)",Revised,12/19/2023,Unavailable,"On backorder, anticipated release Jan 15, 2024",,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
13257,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Injection, 42 mg/1 mL (NDC 51754-5012-4)",Revised,12/19/2023,Unavailable,"On backorder, anticipated release Jan 15, 2024",,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
13258,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 42 mg/1 mL (NDC 0409-5534-14)",Reverified,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
13259,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 84 mg/1 mL (NDC 0409-6637-14)",Reverified,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
13260,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 84 mg/1 mL (NDC 76329-3352-1)",Reverified,12/19/2023,"Backorder due to the increase in demands, We are regularly releasing this product but demands are higher than what we can supply. We put this product under allocation program.",old NDC 0548-3352-00,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,limited availability
13261,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Injection, 42 mg/1 mL (NDC 63323-083-05)",Reverified,12/20/2023,Next release December 2023. Check wholesaler for inventory.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
13262,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Injection, 84 mg/1 mL (NDC 63323-089-50)",Reverified,12/20/2023,Next release December 2023. Check wholesaler for inventory.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
13263,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 42 mg/1 mL (NDC 0409-5555-02)",Reverified,12/19/2023,Limited Supply Available.,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,limited availability
13264,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 42 mg/1 mL (NDC 0409-5555-01)",Reverified,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,limited availability
13265,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 75 mg/1 mL (NDC 0409-4916-14)",Reverified,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
13266,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 84 mg/1 mL (NDC 0409-6625-14)",Reverified,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,limited availability
13267,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 84 mg/1 mL (NDC 0409-6625-35)",Reverified,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,limited availability
13268,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 84 mg/1 mL (NDC 0409-4900-14)",Reverified,12/19/2023,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,not available
13269,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Injection, 84 mg/1 mL (NDC 51754-5001-5)",Reverified,12/19/2023,Available,Available in NDC 51754-5001-4,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2023,available
13270,Sodium Chloride 0.9% Injection,"Hikma Pharmaceuticals USA, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 0641-0497-25)",Reverified,12/1/2023,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Other,Current,,,,2023,not available
13271,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9%, Injection, 234 mg/1 mL (NDC 0409-1141-02)",Revised,9/28/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,,2023,limited availability
13272,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride, Injection, 4 meq/1 mL (NDC 63323-095-61)",Reverified,12/20/2023,Available,Check wholesaler inventory; old NDC 63323-088-61,,Demand increase for the drug,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,,2023,available
13273,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-02)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Other,Current,,,,2023,available
13274,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Other,Current,,,,2023,available
13275,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-20)",Reverified,12/20/2023,Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,,2023,not available
13276,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride, Injection, 9 mg/1 mL (NDC 63323-186-00)",Reverified,12/20/2023,Next release date not available at this time.,,,Demand increase for the drug,Other,Current,,,,2023,not available
13277,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-4888-10)",Revised,9/28/2023,Available,,,Demand increase for the drug,Other,Current,,,,2023,available
13278,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-4888-12)",Revised,9/28/2023,Available,,,Demand increase for the drug,Other,Current,,,,2023,available
13279,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-4888-20)",Revised,9/28/2023,Available,,,Demand increase for the drug,Other,Current,,,,2023,available
13280,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-4888-50)",Revised,9/28/2023,Available,,,Demand increase for the drug,Other,Current,,,,2023,available
13281,Sodium Chloride 0.9% Injection,"Medefil, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 64253-202-30)",Reverified,12/20/2023,Available,,,,Other,Current,,,,2023,available
13282,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9%, Injection, 5.84 g/40 mL (NDC 0409-6660-75)",Revised,9/28/2023,Next Delivery and Estimated Recovery: June 2024,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13283,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-03)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-03",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13284,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-09)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-09",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13285,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 50 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)",Reverified,12/20/2023,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13286,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 100 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)",Reverified,12/20/2023,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13287,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 250 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)",Reverified,12/20/2023,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13288,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 500 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)",Reverified,12/20/2023,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13289,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 1000 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)",Reverified,12/20/2023,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13290,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 g/100 mL (NDC 0264-7800-00)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13291,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 g/100 mL (NDC 0264-7800-10)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13292,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 g/100 mL (NDC 0264-7800-20)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13293,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 g/100 mL (NDC 0264-7800-09)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13294,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-32)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13295,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-31)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13296,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-36)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13297,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0409-7101-66)",Revised,9/28/2023,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13298,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0409-7101-67)",Revised,9/28/2023,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13299,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0409-7101-02)",Revised,9/28/2023,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13300,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-21)",Revised,11/15/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13301,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-31)",Revised,11/15/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13302,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-01)",Revised,11/15/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13303,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-41)",Revised,11/15/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13304,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-11)",Revised,11/15/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13305,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-623-53)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13306,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-623-61)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13307,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-472-20)",Reverified,12/20/2023,Available,Check wholesaler inventory; old NDC 63323-623-75,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13308,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-474-10)",Reverified,12/20/2023,Available,Check wholesaler inventory; old NDC 63323-623-76,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13309,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-18)",Reverified,12/21/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13310,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-41)",Reverified,12/21/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13311,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-48)",Reverified,12/21/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13312,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-31)",Reverified,12/21/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13313,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-02)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13314,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-03)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13315,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-04)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13316,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-10)",Reverified,12/21/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13317,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-11)",Reverified,12/21/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13318,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-38)",Reverified,12/21/2023,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13319,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13320,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13321,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13322,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-11)",Revised,9/27/2023,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13323,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 450 mg/100 mL (NDC 0338-9151-30)",Revised,9/27/2023,Limited supply on allocation; Recovery: December 2024,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13324,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-9159-30)",Revised,9/27/2023,Available on Allocation,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13325,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-18)",Revised,9/27/2023,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13326,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13327,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13328,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,9/27/2023,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13329,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-81)",Reverified,12/19/2023,Product is not available as of today,,,Delay in shipping of the drug,Other,Current,,,,2023,not available
13330,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-27)",Reverified,12/19/2023,Sodium Chloride Injection in RFID presentation is not available and the plan is to discontinue this presentation from sales,,,Discontinuation of the manufacture of the drug,Other,Current,,,,2023,discontinued
13331,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-30)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13332,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-10)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13333,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-1966-12)",Revised,9/28/2023,Depleted,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,not available
13334,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-1966-05)",Revised,9/28/2023,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13335,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-1966-07)",Revised,9/28/2023,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13336,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-13)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-13",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13337,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-36)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-36",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13338,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-37)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-37",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13339,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-23)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-23",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13340,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-20)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-20",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13341,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1510-1)",Reverified,12/20/2023,"Currently available, in stock, Production is ongoing",,,,Other,Current,,,,2023,available
13342,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1505-1)",Reverified,12/20/2023,"Currently available, in stock, Production is ongoing",,,,Other,Current,,,,2023,available
13343,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-61)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-61",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13344,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-02)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-02",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13345,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-55)",Reverified,12/20/2023,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-55",,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13346,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .45 g/100 mL (NDC 0264-7802-00)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13347,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .45 g/100 mL (NDC 0264-7802-10)",Reverified,12/19/2023,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,,2023,available
13348,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 g/100mL (NDC 0264-7388-60)",Revised,12/1/2023,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13349,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 g/100mL (NDC 0264-7388-50)",Reverified,12/19/2023,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13350,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 g/100mL (NDC 0264-2201-10)",Reverified,12/19/2023,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13351,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 g/100mL (NDC 0264-2201-00)",Reverified,12/19/2023,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13352,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-02)",Reverified,12/21/2023,"Limited Supply On Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13353,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-03)",Reverified,12/21/2023,"Limited Supply On Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13354,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-04)",Reverified,12/21/2023,"Limited Supply On Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13355,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-22)",Reverified,12/20/2023,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6138-22",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13356,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-03)",Reverified,12/20/2023,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6138-03",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13357,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-09)",Reverified,12/20/2023,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7138-09",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13358,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-36)",Reverified,12/20/2023,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7138-36",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,not available
13359,Sodium Chloride 14.6% Injection,"Hospira, Inc., a Pfizer Company","Injection, 100 mEq/40 mL (2.5 mEq/mL) (NDC 0409-6660-75)",New,12/12/2023,"Next Delivery and Estimated Recovery: January 2024, Shortage per Manufacturer: Manufacturing Delays",,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,limited availability
13360,Sodium Chloride 14.6% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 14.6%, Injection, 2.5 meq/1 mL (NDC 63323-090-20)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13361,Sodium Chloride 14.6% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 14.6%, Injection, 2.5 meq/1 mL (NDC 63323-090-40)",Reverified,12/20/2023,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,available
13362,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-099-63)",Reverified,12/20/2023,Available,Check wholesaler inventory; old NDC 63323-088-63,,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,,2023,available
13363,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-093-30)",Reverified,12/20/2023,Available,Check wholesaler inventory; old NDC 63323-187-30,,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,,2023,available
13364,Sodium Chloride 23.4% Injection,"Hospira, Inc., a Pfizer Company","Injection, 400 mEq/100 mL (4 mEq/mL) (NDC 0409-1141-02)",New,12/12/2023,"Next Delivery: April 2024
Estimated Recovery: May 2024
, Shortage per Manufacturer: Manufacturing Delays",,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,limited availability
13365,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi USA, LLC","Sodium Phosphates, Injection, 142 mg/1 mL; 276 mg/1 mL (NDC 63323-886-56)",Revised,11/29/2023,Unavailable,Backordered. Next release January 2024. Check wholesaler for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13366,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Hospira, Inc., a Pfizer Company","Sodium Phosphates In Plastic Container, Injection, 142 mg/1 mL; 276 mg/1 mL (NDC 0409-7391-72)",Revised,9/11/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,limited availability
13367,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi USA, LLC","Sodium Phosphates, Injection, 142 mg/1 mL; 276 mg/1 mL (NDC 63323-884-06)",Revised,11/29/2023,Unavailable,Next release January 2024. Check wholesaler for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13368,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi USA, LLC","Sodium Phosphates, Injection, 142 mg/1 mL; 276 mg/1 mL (NDC 63323-881-16)",Revised,11/29/2023,Unavailable,Next release January 2024. Check wholesaler for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2023,not available
13369,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 5 mg/1.5 mL (NDC 0169-7704-21)",Revised,12/19/2023,Intermittent supply until end of Q1 2024,,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13370,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 10 mg/1.5 mL (NDC 0169-7705-21)",Revised,12/19/2023,Intermittent supply until end of Q1 2024,,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13371,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 15 mg/1.5 mL (NDC 0169-7708-21)",Revised,12/19/2023,Intermittent supply until end of Q1 2024,,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13372,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)",Revised,12/19/2023,Intermittent supply until end of Q1 2024,,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13373,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 5 mg/1.5 mL (NDC 0781-3001-07)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13374,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 10 mg/1.5 mL (NDC 0781-3004-07)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13375,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 12 mg/vial (NDC 0002-8148-01)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13376,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 24 mg/vial (NDC 0002-8149-01)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13377,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 5 mg/mL (NDC 0013-2626-81)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13378,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 12 mg/vial (NDC 0013-2646-81)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13379,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.2 mg/vial (NDC 0013-2649-02)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13380,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.4 mg/vial (NDC 0013-2650-02)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13381,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.6 mg/vial (NDC 0013-2651-02)",Reverified,12/19/2023,Next Delivery: September 2023; Estimated Recovery: Q1 2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13382,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.8 mg/vial (NDC 0013-2652-02)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: December 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13383,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.0 mg/vial (NDC 0013-2653-02)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: January 2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13384,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.2 mg/vial (NDC 0013-2654-02)",Reverified,12/19/2023,Next Delivery and Estimated Recover: January 2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13385,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.4 mg/vial (NDC 0013-2655-02)",Reverified,12/19/2023,Next Delivery and Estimated Recvoery: December 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13386,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.6 mg/vial (NDC 0013-2656-02)",Reverified,12/19/2023,Next Delivery and Estimated Recvoery: December 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13387,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.8 mg/vial (NDC 0013-2657-02)",Reverified,12/19/2023,Next Delivery and Estimated Recovery: December 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13388,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 2.0 mg/vial (NDC 0013-2658-02)",Reverified,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13389,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 10 mg/2 mL (NDC 50242-074-01)",New,12/19/2023,"Limited Supply, expected supply stability mid-2024",,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,limited availability
13390,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 5 mg/2 mL (NDC 50242-075-01)",New,12/19/2023,Not Available.  Next supply expected in Feb 2024 with supply stability by mid-2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13391,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 20 mg/2 mL (NDC 50242-076-01)",New,12/19/2023,Not Available.  Next supply expected in Jan 2024 with supply stability by mid-2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,,2023,not available
13392,Somatropin Injection,"EMD Serono, Inc.","Saizen, Injection, 5 mg/vial (NDC 44087-1005-2)",Revised,1/9/2023,,Discontinuation of the manufacture of the product,,,Endocrinology/Metabolism,To Be Discontinued,1/9/2023,1/9/2023,,2023,discontinued
13393,Somatropin Injection,"EMD Serono, Inc.","Saizen, Injection, 8.8 mg/vial (NDC 44087-1088-1)",Revised,1/9/2023,,Discontinuation of the manufacture of the product,,,Endocrinology/Metabolism,To Be Discontinued,1/9/2023,1/9/2023,,2023,discontinued
13394,Somatropin Injection,"EMD Serono, Inc.","Saizen, Injection, 8.8 mg/vial (NDC 44087-0016-1)",Revised,1/9/2023,,Discontinuation of the manufacture of the product,,,Endocrinology/Metabolism,To Be Discontinued,1/9/2023,1/9/2023,,2023,discontinued
13395,Sterile Water Injection,"Hikma Pharmaceuticals USA, Inc.","Sterile Water For Injection, Injection, 1 mL/1 mL (NDC 0641-6147-10)",Revised,9/18/2023,Available,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,,Other,Current,,,,2023,available
13396,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mL/1 mL (NDC 0409-4887-10)",Revised,9/11/2023,Available,,,,Other,Current,,,,2023,available
13397,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mL/1 mL (NDC 0409-4887-20)",Revised,9/11/2023,Available,,,,Other,Current,,,,2023,available
13398,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mL/1 mL (NDC 0409-4887-50)",Revised,9/11/2023,Limited Supply Available. Next Delivery and Estimated Recovery: September 2023,,,,Other,Current,,,,2023,limited availability
13399,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mL/1 mL (NDC 0409-4887-99)",Revised,9/11/2023,Available,,,,Other,Current,,,,2023,available
13400,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Other,Current,,,,2023,available
13401,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)",Reverified,12/20/2023,Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,,2023,not available
13402,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Other,Current,,,,2023,available
13403,Sterile Water Injection,"Medefil, Inc.","Injection, 100 mL/100 mL (NDC 64253-020-30)",Reverified,12/20/2023,Available,,,,Other,Current,,,,2023,available
13404,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)",Reverified,12/19/2023,Available,,,,Other,Current,,,,2023,available
13405,Sterile Water Injection,"Fresenius Kabi USA, LLC","Injection, 1000 mL/1000 mL (NDC 63323-178-76)",Reverified,12/20/2023,Available,Check wholesalers for inventory,,,Other,Current,,,,2023,available
13406,Sterile Water Injection,Nephron Pharmaceuticals Corporation,"Injection, 1 mL/1 mL (NDC 0487-6105-01)",Reverified,12/19/2023,Available,,,,Other,Current,,,,2023,available
13407,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",Reverified,12/19/2023,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13408,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",Reverified,12/19/2023,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13409,Sterile Water Irrigant,"ICU Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)",Reverified,12/20/2023,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6139-22",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13410,Sterile Water Irrigant,"ICU Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)",Reverified,12/20/2023,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6139-03",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13411,Sterile Water Irrigant,"ICU Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)",Reverified,12/20/2023,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7139-09",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13412,Sterile Water Irrigant,"ICU Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)",Reverified,12/20/2023,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7139-36",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13413,Sterile Water Irrigant,Baxter Healthcare,"Irrigant, 100 mL/100 mL (NDC 0338-0004-02)",Reverified,12/19/2023,"Limited Supply on Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13414,Sterile Water Irrigant,Baxter Healthcare,"Irrigant, 100 mL/100 mL (NDC 0338-0004-03)",Reverified,12/21/2023,"Limited Supply on Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13415,Sterile Water Irrigant,Baxter Healthcare,"Irrigant, 100 mL/100 mL (NDC 0338-0004-04)",Reverified,12/21/2023,"Limited Supply on Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13416,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",Reverified,12/19/2023,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13417,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",Reverified,12/19/2023,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,,2023,limited availability
13418,"Streptozocin Powder, For Solution","Teva Pharmaceuticals USA, Inc.","Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)",Revised,12/19/2023,Temporarily Unavailable,,,Demand increase for the drug,Oncology,Current,,,,2023,not available
13419,"Streptozocin Powder, For Solution","ESTEVE PHARMACEUTICALS, S.A.","Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)",Reverified,12/19/2023,Available,,,,Oncology,Current,,,,2023,available
13420,Sucralfate Tablet,Amneal Pharmaceuticals,"Tablet, 1 g (NDC 69238-1656-1)",Revised,11/2/2023,Available,Supplying existing customers with possibility to expand mid-November 2023,,,Gastroenterology,Current,,,,2023,available
13421,Sucralfate Tablet,"Nostrum Laboratories, Inc.","Tablet, 1 g (NDC 29033-003-01)",Reverified,11/2/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13422,Sucralfate Tablet,"Nostrum Laboratories, Inc.","Tablet, 1 g (NDC 29033-003-05)",Reverified,11/2/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13423,Sucralfate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 g (NDC 0093-2210-01)",Revised,12/6/2023,Limited Supply Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2023,limited availability
13424,Sucralfate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 g (NDC 0093-2210-05)",Revised,12/6/2023,Limited Supply Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2023,limited availability
13425,Sucralfate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 g (NDC 0093-2210-98)",Revised,12/6/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13426,Sucralfate Tablet,"Allergan, Inc.","Carafate, Tablet, 1 g (NDC 58914-171-10)",Revised,11/2/2023,Available,Healthy inventory for demand of the Brand,,,Gastroenterology,Current,,,,2023,available
13427,Sucralfate Tablet,"Allergan, Inc.","Tablet, 1 g (NDC 59762-040-11)",Revised,11/2/2023,Unavailable,Recovery in December 2023,,Delay in shipping of the drug,Gastroenterology,Current,,,,2023,not available
13428,Sucralfate Tablet,"Allergan, Inc.","Tablet, 1 g (NDC 59762-040-15)",Revised,11/2/2023,Unavailable,Recovery in December 2023,,Delay in shipping of the drug,Gastroenterology,Current,,,,2023,not available
13429,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 50 mcg/1 mL (NDC 17478-050-02)",Reverified,12/19/2023,Unavailable,Not currently manufactured,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,not available
13430,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 50 mcg/1 mL (NDC 17478-050-05)",Reverified,12/19/2023,Unavailable,Not currently manufactured,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,not available
13431,Sufentanil Citrate Injection,"Hospira, Inc., a Pfizer Company","Injection, 50 ug/1 mL (NDC 0409-3382-21)",Reverified,12/19/2023,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,limited availability
13432,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 50 mcg/1 mL (NDC 17478-050-01)",Reverified,12/19/2023,Unavailable,Not currently manufactured,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,,2023,not available
13433,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 62135-960-01)",Revised,12/20/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13434,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 62135-960-05)",Revised,12/20/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13435,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 62135-960-10)",Revised,12/20/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13436,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 62135-960-31)",Revised,12/20/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13437,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0101-10)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13438,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0101-20)",Revised,12/19/2023,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2023,available
13439,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0102-50)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13440,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0102-20)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13441,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 mg (NDC 59762-0104-1)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13442,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 mg (NDC 59762-0104-6)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13443,Sulfasalazine Tablet,Pfizer Inc.,"Sulfasalazine, Tablet, 500 mg (NDC 59762-5000-1)",Revised,12/19/2023,Available,,,Demand increase for the drug,Gastroenterology,Current,,,,2023,available
13444,Sulfasalazine Tablet,Pfizer Inc.,"Sulfasalazine, Tablet, 500 mg (NDC 59762-5000-6)",Reverified,12/19/2023,Next Delivery: September 2023; Estimated Recovery: January 2024,,,Demand increase for the drug,Gastroenterology,Current,,,,2023,not available
13445,Sulfasalazine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-3234-01)",Revised,12/19/2023,Available,NDC: 0591-0796-01 has been changed to NDC: 0093-3234-01,,,Gastroenterology,Current,,,,2023,available
13446,Sulfasalazine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-3234-10)",Revised,12/19/2023,Available,NDC: 0591-0796-10 has been changed to NDC: 0093-3234-10,,,Gastroenterology,Current,,,,2023,available
13447,Sulfasalazine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-3234-05)",Revised,12/19/2023,Available,NDC: 0591-0796-05 has been changed to NDC: 0093-3234-05,,,Gastroenterology,Current,,,,2023,available
13448,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 23155-019-01)",Revised,12/20/2023,"Product Available. Distributed by Chartwell. For inquiries, call Customer Service number 845-268-5000  Ext: 510.",,,,Gastroenterology,Current,,,,2023,available
13449,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0101-30)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13450,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0102-60)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13451,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 mg (NDC 59762-0104-5)",Reverified,12/19/2023,Available,,,,Gastroenterology,Current,,,,2023,available
13452,Sulfasalazine Tablet,Pfizer Inc.,"Sulfasalazine, Tablet, 500 mg (NDC 59762-5000-5)",Reverified,12/19/2023,Next Delivery: September 2023; Estimated Recovery: January 2024,,,Demand increase for the drug,Gastroenterology,Current,,,,2023,not available
13453,Sumatriptan Spray,GlaxoSmithKline,"Imitrex, Spray, 5 mg (NDC 0173-0524-00)",New,8/8/2023,,"The last date the product will be available for ordering is January 31, 2024.",,,Neurology,To Be Discontinued,8/8/2023,8/8/2023,,2023,discontinued
13454,Sumatriptan Spray,GlaxoSmithKline,"Imitrex, Spray, 20 mg (NDC 0173-0523-00)",New,8/8/2023,,"The last date the product will be available for ordering is January 31, 2024.",,,Neurology,To Be Discontinued,8/8/2023,8/8/2023,,2023,discontinued
13455,Technetium Tc-99m Sodium Pertechnetate Generator,"NorthStar Medical Radioisotopes, LLC","RadioGenix® System, Generator, 7.5 Ci/7.5 Ci (NDC 71612-075-02)",New,10/17/2023,,"The RadioGenix System is a technetium Tc 99m generator that produces Sodium Pertechnetate Tc 99m Injection, USP from a non-uranium potassium molybdate Mo-99 source solution, which is shielded within a source container that completely encases a vial containing 22-30 mL of solution; The company has made a business decision to discontinue production and distribution. The production date for the last batch of Mo-99 source vessels is October 30, 2023 with an expiration date of November 20, 2023.",,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,,10/17/2023,,2023,discontinued
13456,Technetium Tc-99m Sodium Pertechnetate Generator,"NorthStar Medical Radioisotopes, LLC","RadioGenix® System, Generator, 12 Ci/12 Ci (NDC 71612-120-02)",New,10/17/2023,,"The RadioGenix System is a technetium Tc 99m generator that produces Sodium Pertechnetate Tc 99m Injection, USP from a non-uranium potassium molybdate Mo-99 source solution, which is shielded within a source container that completely encases a vial containing 22-30 mL of solution. The company has made a business decision to discontinue production and distribution. The production date for the last batch of Mo-99 source vessels is October 30, 2023 with an expiration date of November 20, 2023.",,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,,10/17/2023,,2023,discontinued
13457,Technetium Tc-99m Sodium Pertechnetate Generator,"NorthStar Medical Radioisotopes, LLC","RadioGenix® System, Generator, 19 Ci/19 Ci (NDC 71612-190-02)",New,10/17/2023,,"The RadioGenix System is a technetium Tc 99m generator that produces Sodium Pertechnetate Tc 99m Injection, USP from a non-uranium potassium molybdate Mo-99 source solution, which is shielded within a source container that completely encases a vial containing 22-30 mL of solution. The company has made a business decision to discontinue production and distribution. The production date for the last batch of Mo-99 source vessels is October 30, 2023 with an expiration date of November 20, 2023.",,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,,10/17/2023,,2023,discontinued
13458,Technetium Tc-99m Sodium Pertechnetate Generator,"NorthStar Medical Radioisotopes, LLC","RadioGenix® System, Generator, 15 Ci/15 Ci (NDC 71612-150-02)",New,10/17/2023,,"The RadioGenix System is a technetium Tc 99m generator that produces Sodium Pertechnetate Tc 99m Injection, USP from a non-uranium potassium molybdate Mo-99 source solution, which is shielded within a source container that completely encases a vial containing 22-30 mL of solution; The company has made a business decision to discontinue production and distribution. The production date for the last batch of Mo-99 source vessels is October 30, 2023 with an expiration date of November 20, 2023.",,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,,10/17/2023,,2023,discontinued
13459,Testosterone Cypionate Injection,"Teva Pharmaceuticals USA, Inc.","Testosterone Cypionate, Injection, 200 mg/1 mL (NDC 0591-4128-79)",New,4/18/2023,,,,,Urology,To Be Discontinued,4/18/2023,4/18/2023,,2023,discontinued
13460,"Testosterone Gel, Metered",Endo Pharmaceuticals. Inc.,"Fortesta, Gel, Metered, 10 mg/.5 g (NDC 63481-183-18)",New,12/7/2023,,,,Discontinuation of the manufacture of the drug,Urology,To Be Discontinued,,12/7/2023,,2023,discontinued
13461,"Testosterone Gel, Metered",Endo Pharmaceuticals. Inc.,"Fortesta, Gel, Metered, 10 mg/.5 g (NDC 63481-183-17)",New,12/7/2023,,,,Discontinuation of the manufacture of the drug,Urology,To Be Discontinued,,12/7/2023,,2023,discontinued
13462,"Testosterone Gel, Metered",Endo Pharmaceuticals. Inc.,"Fortesta, Gel, Metered, 10 mg/.5 g (NDC 63481-183-16)",New,12/7/2023,,,,Discontinuation of the manufacture of the drug,Urology,To Be Discontinued,,12/7/2023,,2023,discontinued
13463,"Testosterone Gel, Metered",Endo Pharmaceuticals. Inc.,"Fortesta, Gel, Metered, 10 mg/.5 g (NDC 0603-7831-88)",New,8/25/2023,,,,,Urology,To Be Discontinued,8/25/2023,8/25/2023,,2023,discontinued
13464,Testosterone Patch,AbbVie Inc.,"Androderm, Patch, 2 mg/1 d (NDC 0023-5990-60)",New,1/10/2023,,The discontinuation is limited to only the NDCs listed.  Other NDCs of the same or similar products will continue to be available.,,,Urology,To Be Discontinued,1/10/2023,1/10/2023,,2023,discontinued
13465,Testosterone Patch,AbbVie Inc.,"Androderm, Patch, 4 mg/1 d (NDC 0023-5992-30)",New,1/10/2023,,The discontinuation is limited to only the NDCs listed.  Other NDCs of the same or similar products will continue to be available.,,,Urology,To Be Discontinued,1/10/2023,1/10/2023,,2023,discontinued
13466,Tirofiban Hydrochloride Injection,Medicure Pharma Inc.,"Aggrastat, Injection, 5 mg/100 mL (NDC 25208-002-03)",New,2/24/2023,,"The discontinuation is limited to only the NDC listed.  Tirofiban hydrochloride injection 5 mg/100 mL bag, 50 mcg/mL (NDC 25208-002-01) will continue to be available",,,Cardiovascular,To Be Discontinued,2/24/2023,2/24/2023,,2023,discontinued
13467,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 2.5 mg/.5 mL (NDC 0002-1506-80)",Revised,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13468,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 7.5 mg/.5 mL (NDC 0002-1484-80)",Revised,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13469,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 12.5 mg/.5 mL (NDC 0002-1460-80)",Revised,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13470,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 15 mg/.5 mL (NDC 0002-1457-80)",Revised,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13471,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 10 mg/.5 mL (NDC 0002-1471-80)",Revised,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13472,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 5 mg/.5 mL (NDC 0002-1495-80)",Revised,12/19/2023,Available,,,,Endocrinology/Metabolism,Current,,,,2023,available
13473,Triamcinolone Acetonide Injection,Novartis Pharmaceuticals Corporation,"Triesence, Injection, 40 mg/1 mL (NDC 0065-0543-01)",Revised,11/1/2023,"Availability through wholesalers: Unavailable,  3-18 months",There are no therapeutic equivalents.,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,2023,not available
13474,Triamcinolone Hexacetonide Injection,Medexus,"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)",Reverified,12/19/2023,Unavailable,,,Delay in shipping of the drug,Rheumatology,Current,,,,2023,not available
13475,Trimethobenzamide Hydrochloride Capsule,"Lupin Pharmaceuticals, Inc.","Trimethobenzamide Hydrochloride, Capsule, 300 mg (NDC 43386-660-03)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,,Gastroenterology,Current,,,,2023,not available
13476,Trimethobenzamide Hydrochloride Capsule,"Lupin Pharmaceuticals, Inc.","Trimethobenzamide Hydrochloride, Capsule, 300 mg (NDC 43386-660-24)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,,Gastroenterology,Current,,,,2023,not available
13477,Trimethobenzamide Hydrochloride Capsule,"Lupin Pharmaceuticals, Inc.","Trimethobenzamide Hydrochloride, Capsule, 300 mg (NDC 43386-660-26)",Reverified,10/25/2021,Currently unavailable. Estimated shortage duration: TBD,,,,Gastroenterology,Current,,,,2023,not available
13478,Trimethobenzamide Hydrochloride Capsule,Pfizer Inc.,"Tigan, Capsule, 300 mg (NDC 61570-079-01)",Reverified,11/28/2022,Discontinued,,,,Gastroenterology,Current,,,,2023,discontinued
13479,Trimethobenzamide Hydrochloride Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 300 mg (NDC 53489-376-01)",Revised,11/1/2023,Unavailable,,,Shortage of an active ingredient,Gastroenterology,Current,,,,2023,not available
13480,Ursodiol Tablet,AbbVie Inc.,"Ursodiol, Tablet, 500 mg (NDC 0591-3005-01)",New,6/23/2023,,,,,Other,To Be Discontinued,6/23/2023,6/23/2023,,2023,discontinued
13481,Ursodiol Tablet,AbbVie Inc.,"Ursodiol, Tablet, 250 mg (NDC 0591-2998-01)",New,6/23/2023,,,,,Other,To Be Discontinued,6/23/2023,6/23/2023,,2023,discontinued
13482,"Ursodiol Tablet, Film Coated",AbbVie Inc.,"Urso 250, Tablet, Film Coated, 250 mg (NDC 58914-785-10)",New,6/23/2023,,,,,Other,To Be Discontinued,6/23/2023,6/23/2023,,2023,discontinued
13483,"Ursodiol Tablet, Film Coated",AbbVie Inc.,"Urso Forte, Tablet, Film Coated, 500 mg (NDC 58914-790-01)",New,6/23/2023,,,,,Other,To Be Discontinued,6/23/2023,6/23/2023,,2023,discontinued
13484,"Ursodiol Tablet, Film Coated",AbbVie Inc.,"Urso Forte, Tablet, Film Coated, 500 mg (NDC 58914-790-10)",New,6/23/2023,,,,,Other,To Be Discontinued,6/23/2023,6/23/2023,,2023,discontinued
13485,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)",Revised,5/16/2023,Inventory is currently available.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,,Neurology,Current,,,,2023,available
13486,Valproate Sodium Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/1 mL (NDC 63323-494-05)",Reverified,12/20/2023,Next release not available at this time.,Check wholesaler inventory,,Demand increase for the drug,Neurology,Current,,,,2023,not available
13487,Valproate Sodium Injection,Sagent Pharmaceuticals,"Injection, 100 mg/mL, 5 mL (NDC 70860-784-41)",Revised,10/31/2023,Available,,,,Neurology,Current,,,,2023,available
13488,Vecuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Vecuronium Bromide, Injection, 1 mg/1 mL (NDC 0409-1632-01)",Reverified,9/11/2023,Available,,,,Anesthesia,Current,,,,2023,available
13489,Vecuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Injection, 1 mg/1 mL (NDC 67457-438-10)",Reverified,12/21/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
13490,Vecuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Injection, 1 mg/1 mL (NDC 67457-475-20)",Reverified,12/21/2023,Available,,,Demand increase for the drug,Anesthesia,Current,,,,2023,available
13491,Vecuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-781-10)",Reverified,12/20/2023,6 month expiry (4/30/2024 expiry) dating available by request.,Check wholesaler inventory,,Delay in shipping of the drug,Anesthesia,Current,,,,2023,limited availability
13492,Vecuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-782-20)",Reverified,12/20/2023,Not available at this time.,,,Delay in shipping of the drug,Anesthesia,Current,,,,2023,not available
13493,Vecuronium Bromide Injection,"Sun Pharmaceutical Industries, Inc.","Vecuronium Bromide, Injection, 1 mg/1 mL (NDC 47335-931-44)",Reverified,9/23/2022,Available,,,,Anesthesia,Current,,,,2023,available
13494,Vecuronium Bromide Injection,"Sun Pharmaceutical Industries, Inc.","Vecuronium Bromide, Injection, 1 mg/1 mL (NDC 47335-932-44)",Reverified,9/23/2022,Available,,,,Anesthesia,Current,,,,2023,available
13495,Vecuronium Bromide Injection,Eugia US LLC,"Injection, 10 mg (NDC 55150-235-10)",Revised,11/1/2023,Available,Sporadic availability expected.,,,Anesthesia,Current,,,,2023,available
13496,Vecuronium Bromide Injection,Eugia US LLC,"Injection, 20 mg (NDC 55150-236-20)",Revised,11/1/2023,Available,Sporadic availability expected.,,,Anesthesia,Current,,,,2023,available
13497,Vinblastine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-278-10)",Reverified,12/20/2023,Backordered. Next release expected December 2023.,Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,,2023,not available
13498,Voriconazole Injection,"XGen Pharmaceuticals DJB, Inc.","Voriconazole, Injection, 10 mg/1 mL (NDC 39822-1077-1)",New,5/19/2023,,Final lot to be received for distribution in May/June 2023; anticipated inventory depletion by end of year 2023,,,Anti-Infective,To Be Discontinued,5/19/2023,5/19/2023,,2023,discontinued
13499,"Voriconazole Tablet, Film Coated",Pfizer Inc.,"Vfend, Tablet, Film Coated, 200 mg (NDC 0049-3180-30)",New,5/10/2023,,Discontinuation of the manufacture of the drug; Supply expected to exhaust late June 2023,,,Anti-Infective,To Be Discontinued,5/10/2023,5/10/2023,,2023,discontinued
13500,Zoledronic Acid Injection,"Hospira, Inc., a Pfizer Company","Zoledronic Acid, Injection, 4 mg/5 mL (NDC 0409-4215-01)",New,5/4/2023,,Discontinuation of the manufacture of the drug,,,Oncology; Endocrinology/Metabolism,To Be Discontinued,5/4/2023,5/4/2023,,2023,discontinued
13501,Zolmitriptan Tablet,IPR PHARMACEUTICALS INC,"Zomig, Tablet, 2.5 mg (NDC 64896-671-51)",New,3/3/2023,,,,,Neurology,To Be Discontinued,3/3/2023,3/3/2023,,2023,discontinued
13502,Zolmitriptan Tablet,IPR PHARMACEUTICALS INC,"Zomig, Tablet, 5 mg (NDC 64896-672-50)",New,3/3/2023,,,,,Neurology,To Be Discontinued,3/3/2023,3/3/2023,,2023,discontinued
13503,"Zolmitriptan Tablet, Orally Disintegrating",AstraZeneca Pharmaceuticals LP,"Zomig-zmt, Tablet, Orally Disintegrating, 2.5 mg (NDC 64896-691-51)",New,3/3/2023,,,,,Neurology,To Be Discontinued,3/3/2023,3/3/2023,,2023,discontinued
13504,"Zolmitriptan Tablet, Orally Disintegrating",AstraZeneca Pharmaceuticals LP,"Zomig-zmt, Tablet, Orally Disintegrating, 5 mg (NDC 64896-692-50)",New,3/3/2023,,,,,Neurology,To Be Discontinued,3/3/2023,3/3/2023,,2023,discontinued
13505,Acyclovir Tablet,Apotex Corp.,"Tablet, 400 Mg/1 (NDC 60505-5306-1)",New,4/26/2024,,Business Related Decision To Discontinue The Product,,,Antiviral,To Be Discontinued,,4/26/2024,,2024,discontinued
13506,Acyclovir Tablet,Apotex Corp.,"Tablet, 400 Mg/1 (NDC 60505-5306-8)",New,4/26/2024,,Business Related Decision To Discontinue The Product,,,Antiviral,To Be Discontinued,,4/26/2024,,2024,discontinued
13507,Acyclovir Tablet,Apotex Corp.,"Tablet, 800 Mg/1 (NDC 60505-5307-1)",New,4/26/2024,,Business Related Decision To Discontinue The Product,,,Antiviral,To Be Discontinued,,4/26/2024,,2024,discontinued
13508,Acyclovir Tablet,Apotex Corp.,"Tablet, 800 Mg/1 (NDC 60505-5307-5)",New,4/26/2024,,Business Related Decision To Discontinue The Product,,,Antiviral,To Be Discontinued,,4/26/2024,,2024,discontinued
13509,"Albuterol Sulfate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Proair Digihaler, Powder, Metered, 90 Ug (NDC 59310-117-20)",New,4/30/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/2024,,2024,discontinued
13510,Albuterol Sulfate Solution,Nephron Pharmaceuticals Corporation,"Albuterol Sulfate, Solution, 2.5 Mg/.5 Ml (NDC 0487-9901-30)",Revised,7/17/2024,Available,,,,Pulmonary/Allergy; Pediatric,Current,,,,2024,available
13511,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 Mg/1 G (NDC 0168-0263-15)",New,11/27/2023,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,11/27/2023,,2024,discontinued
13512,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 Mg/1 G (NDC 0168-0263-45)",New,11/27/2023,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,11/27/2023,,2024,discontinued
13513,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 Mg/1 G (NDC 0168-0263-60)",New,11/27/2023,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,11/27/2023,,2024,discontinued
13514,Alprostadil Suppository,"Mylan Institutional, A Viatris Company","Muse, Suppository, 1000 Ug (NDC 0037-8140-06)",Revised,8/12/2024,,,,,Urology,To Be Discontinued,8/12/2024,8/12/2024,,2024,discontinued
13515,Alprostadil Suppository,"Mylan Institutional, A Viatris Company","Muse, Suppository, 500 Ug (NDC 0037-8130-06)",Revised,8/12/2024,,,,,Urology,To Be Discontinued,8/12/2024,8/12/2024,,2024,discontinued
13516,Alprostadil Suppository,"Mylan Institutional, A Viatris Company","Muse, Suppository, 250 Ug (NDC 0037-8120-06)",Revised,8/12/2024,,,,,Urology,To Be Discontinued,8/12/2024,8/12/2024,,2024,discontinued
13517,Amifostine Injection,"Clinigen, Inc.","Ethyol, Injection, 500 Mg/10 Ml (NDC 76310-017-50)",Revised,4/18/2024,Unavailable,Temporary Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Oncology; Other,Current,,,,2024,not available
13518,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Reverified,9/5/2024,Available,,,,Gastroenterology,Current,,,,2024,available
13519,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-05)",Reverified,9/3/2024,Available,,,,Gastroenterology,Current,,,,2024,available
13520,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Reverified,9/5/2024,Available,,,,Gastroenterology,Current,,,,2024,available
13521,Amino Acid Injection,"Icu Medical, Inc.","Aminosyn-Pf 10%, Injection, 0.1 (NDC 0990-4179-05)",Reverified,9/4/2024,Unavailable,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-4179-05",,Shortage Of An Active Ingredient,Gastroenterology,Current,,,,2024,not available
13522,Amino Acid Injection,"Icu Medical, Inc.","Aminosyn-Pf 7%, Injection, 0.07 (NDC 0990-4178-03)",Reverified,9/4/2024,Unavailable,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-4178-03",,Shortage Of An Active Ingredient,Gastroenterology,Current,,,,2024,not available
13523,Amino Acid Injection,"Icu Medical, Inc.","Aminosyn Ii 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7172-17",,,Gastroenterology,Current,,,,2024,available
13524,Amino Acid Injection,"Icu Medical, Inc.","Aminosyn Ii 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7171-17",,,Gastroenterology,Current,,,,2024,available
13525,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-00)",Reverified,9/3/2024,Available,,,,Gastroenterology,Current,,,,2024,available
13526,Amoxapine Tablet,"Teva Pharmaceuticals Usa, Inc.","Amoxapine Tablets, Usp, Tablet, 150 Mg (NDC 0591-5716-30)",Revised,9/4/2024,Unavailable,Estimated Recovery October 2024,,Other,Psychiatry,Current,,,,2024,not available
13527,Amoxapine Tablet,"Teva Pharmaceuticals Usa, Inc.","Amoxapine Tablets, Usp, Tablet, 100 Mg (NDC 0591-5715-01)",Revised,9/4/2024,Unavailable,Estimated Recovery October 2024,,Other,Psychiatry,Current,,,,2024,not available
13528,Amoxapine Tablet,"Teva Pharmaceuticals Usa, Inc.","Amoxapine Tablets, Usp, Tablet, 25 Mg (NDC 0591-5713-01)",Revised,9/4/2024,Unavailable,Estimated Recovery October 2024,,Other,Psychiatry,Current,,,,2024,not available
13529,Amoxapine Tablet,"Teva Pharmaceuticals Usa, Inc.","Amoxapine Tablets, Usp, Tablet, 50 Mg (NDC 0591-5714-01)",Reverified,9/4/2024,Unavailable,Estimated Recovery September 2024,,Other,Psychiatry,Current,,,,2024,not available
13530,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 400 Mg/5 Ml (NDC 0143-9887-75)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13531,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 400 Mg/5 Ml (NDC 0143-9887-50)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13532,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 250 Mg/5 Ml (NDC 0143-9889-80)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13533,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Amoxicillin, Powder, For Suspension, 250 Mg/5 Ml (NDC 0143-9889-15)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13534,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 200 Mg/5 Ml (NDC 0143-9886-75)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13535,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 200 Mg/5 Ml (NDC 0143-9886-50)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13536,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 125 Mg/5 Ml (NDC 0143-9888-80)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13537,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 125 Mg/5 Ml (NDC 0143-9888-15)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13538,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 400 Mg/5 Ml (NDC 65862-071-75)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13539,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 400 Mg/5 Ml (NDC 65862-071-50)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13540,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 250 Mg/5 Ml (NDC 65862-707-80)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13541,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 250 Mg/5 Ml (NDC 65862-707-55)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13542,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 200 Mg/5 Ml (NDC 65862-070-75)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13543,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 200 Mg/5 Ml (NDC 65862-070-50)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13544,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 125 Mg/5 Ml (NDC 65862-706-80)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13545,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 125 Mg/5 Ml (NDC 65862-706-55)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13546,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 400 Mg/5 Ml (NDC 0093-4161-78)",Revised,9/4/2024,Available,Estimated Recovery May 2025,,,Anti-Infective; Pediatric,Current,,,,2024,available
13547,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 400 Mg/5 Ml (NDC 0093-4161-76)",Revised,9/4/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13548,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 400 Mg/5 Ml (NDC 0093-4161-73)",Reverified,9/4/2024,Available,Estimated Recovery December 2024,,Demand Increase For The Drug,Anti-Infective,Current,,,,2024,available
13549,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 200 Mg/5 Ml (NDC 0093-4160-78)",Revised,9/4/2024,Available,Estimated Recovery January 2025,,,Anti-Infective; Pediatric,Current,,,,2024,available
13550,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 200 Mg/5 Ml (NDC 0093-4160-76)",Revised,9/4/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13551,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 200 Mg/5 Ml (NDC 0093-4160-73)",Revised,9/4/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13552,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 250 Mg/5 Ml (NDC 0093-4155-79)",Reverified,9/4/2024,Available,Estimated Recovery January 2025,,,Anti-Infective; Pediatric,Current,,,,2024,available
13553,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 250 Mg/5 Ml (NDC 0093-4155-80)",Reverified,9/4/2024,Available,Estimated Recovery November 2024,,,Anti-Infective; Pediatric,Current,,,,2024,available
13554,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 250 Mg/5 Ml (NDC 0093-4155-73)",Reverified,9/4/2024,Available,Estimated Recovery January 2025,,,Anti-Infective; Pediatric,Current,,,,2024,available
13555,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 250 Mg/5 Ml (NDC 0781-6041-58)",Reverified,8/5/2024,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,limited availability
13556,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 250 Mg/5 Ml (NDC 0781-6041-55)",Reverified,8/5/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13557,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 250 Mg/5 Ml (NDC 0781-6041-46)",Reverified,8/5/2024,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,limited availability
13558,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 400 Mg/5 Ml (NDC 0781-6157-57)",Reverified,8/5/2024,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,limited availability
13559,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 400 Mg/5 Ml (NDC 0781-6157-52)",Reverified,8/5/2024,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,limited availability
13560,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 400 Mg/5 Ml (NDC 0781-6157-46)",Reverified,8/5/2024,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,limited availability
13561,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 200 Mg/5 Ml (NDC 0781-6156-57)",Reverified,8/5/2024,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,limited availability
13562,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 200 Mg/5 Ml (NDC 0781-6156-52)",Reverified,8/5/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13563,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 200 Mg/5 Ml (NDC 0781-6156-46)",Reverified,8/5/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13564,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 125 Mg/5 Ml (NDC 0781-6039-58)",Reverified,8/5/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13565,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 125 Mg/5 Ml (NDC 0781-6039-55)",Reverified,8/5/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13566,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 125 Mg/5 Ml (NDC 0781-6039-46)",Reverified,8/5/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13567,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 400 Mg/5 Ml (NDC 0143-9887-01)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13568,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 250 Mg/5 Ml (NDC 0143-9889-01)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13569,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 200 Mg/5 Ml (NDC 0143-9886-01)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13570,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 125 Mg/5 Ml (NDC 0143-9888-01)",Reverified,8/28/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13571,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 400 Mg/5 Ml (NDC 65862-071-01)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13572,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 250 Mg/5 Ml (NDC 65862-707-01)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13573,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 200 Mg/5 Ml (NDC 65862-070-01)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13574,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 125 Mg/5 Ml (NDC 65862-706-01)",Revised,5/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13575,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 70010-117-01)",Reverified,8/26/2024,Available,,,,Psychiatry,Current,,,,2024,available
13576,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 70010-116-01)",Reverified,8/26/2024,Available,,,,Psychiatry,Current,,,,2024,available
13577,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 70010-115-01)",Reverified,8/26/2024,Available,,,,Psychiatry,Current,,,,2024,available
13578,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 70010-114-01)",Reverified,7/23/2024,Unavailable,Estimated Availability: July 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
13579,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 70010-113-01)",Reverified,8/26/2024,Available,,,,Psychiatry,Current,,,,2024,available
13580,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 70010-112-01)",Reverified,7/23/2024,Unavailable,Estimated Availability: July 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
13581,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 70010-111-01)",Reverified,8/26/2024,Available,,,,Psychiatry,Current,,,,2024,available
13582,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 64850-506-01)",Reverified,9/2/2024,Available,,,,Psychiatry,Current,,,,2024,available
13583,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 64850-505-01)",Reverified,9/2/2024,Available,,,,Psychiatry,Current,,,,2024,available
13584,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 64850-504-01)",Reverified,9/2/2024,Available,,,,Psychiatry,Current,,,,2024,available
13585,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 64850-503-01)",Reverified,9/2/2024,Available,,,,Psychiatry,Current,,,,2024,available
13586,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 64850-502-01)",Reverified,9/2/2024,Available,,,,Psychiatry,Current,,,,2024,available
13587,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 64850-501-01)",Reverified,9/2/2024,Available,,,,Psychiatry,Current,,,,2024,available
13588,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 64850-500-01)",Reverified,9/2/2024,Available,,,,Psychiatry,Current,,,,2024,available
13589,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 13107-070-01)",Revised,1/31/2024,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
13590,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 13107-069-01)",Revised,1/31/2024,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
13591,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 13107-068-01)",Revised,1/31/2024,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
13592,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 0527-0766-37)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13593,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 0527-1505-37)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13594,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 0527-0764-37)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13595,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 0527-0763-37)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13596,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 0527-1502-37)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13597,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 0527-0761-37)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13598,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 0527-0760-37)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13599,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 13107-074-01)",Revised,1/31/2024,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
13600,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 13107-073-01)",Revised,1/31/2024,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
13601,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 13107-072-01)",Revised,1/31/2024,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
13602,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 11534-196-01)",Reverified,5/1/2024,Available,,,,Psychiatry,Current,,,,2024,available
13603,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 11534-195-01)",Reverified,5/1/2024,Available,,,,Psychiatry,Current,,,,2024,available
13604,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 11534-194-01)",Reverified,5/1/2024,Available,,,,Psychiatry,Current,,,,2024,available
13605,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 11534-193-01)",Reverified,5/1/2024,Available,,,,Psychiatry,Current,,,,2024,available
13606,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 11534-191-01)",Reverified,5/1/2024,Available,,,,Psychiatry,Current,,,,2024,available
13607,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 11534-192-01)",Reverified,5/1/2024,Available,,,,Psychiatry,Current,,,,2024,available
13608,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 11534-190-01)",Reverified,5/1/2024,Available,,,,Psychiatry,Current,,,,2024,available
13609,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 47781-180-01)",Reverified,5/18/2024,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,,2024,available
13610,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 47781-179-01)",Reverified,7/2/2024,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,,2024,available
13611,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 47781-178-01)",Reverified,8/16/2024,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,,2024,available
13612,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 47781-176-01)",Reverified,9/4/2024,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,,2024,available
13613,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 47781-174-01)",Reverified,7/2/2024,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,,2024,available
13614,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 42806-339-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13615,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 42806-345-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13616,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 42806-343-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13617,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 42806-341-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13618,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 42806-344-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13619,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 0406-8894-01)",Revised,8/15/2024,Limited Availability,Available To Primary Customers Only. Next Release Late Aug With Intermittent Backorder Through Oct 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
13620,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 0406-8893-01)",Revised,8/15/2024,Limited Availability,Available For Primary Customers Only. Backorder Projected In November,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
13621,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 0406-8892-01)",Revised,8/15/2024,Limited Availability,Available For Primary Customers Only. Backorder Projected In November,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
13622,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 0406-8891-01)",Revised,8/15/2024,Limited Availability,Available To Primary Customers Only.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
13623,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 0406-8885-01)",Revised,8/15/2024,Limited Availability,Available For Primary Customers Only; Backorder Expected In August 2024 With Recovery Late Sept.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
13624,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 0406-8884-01)",Revised,8/15/2024,Available,Available For Primary Customers,,,Psychiatry,Current,,,,2024,available
13625,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 72516-011-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13626,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 72516-012-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13627,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 72516-013-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13628,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 72516-014-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13629,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 72516-016-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
13630,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 0555-0971-02)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13631,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 0555-0974-02)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13632,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 0555-0973-02)",Revised,8/23/2024,Available,,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,available
13633,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 0555-0972-02)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13634,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 0555-0775-02)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13635,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 0555-0777-02)",Revised,8/23/2024,Limited Availability,Estimated Recovery September 2024,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,limited availability
13636,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 0555-0776-02)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13637,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 57844-117-01)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13638,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 57844-105-01)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13639,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 57844-130-01)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13640,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 57844-120-01)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13641,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 57844-115-01)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13642,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 57844-112-01)",Reverified,9/4/2024,Available,Estimated Recovery September 2024,,,Psychiatry,Current,,,,2024,available
13643,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 57844-110-01)",Revised,8/23/2024,Available,,,,Psychiatry,Current,,,,2024,available
13644,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 0185-2098-01)",Reverified,8/5/2024,Available,,,,Psychiatry,Current,,,,2024,available
13645,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 0185-0842-01)",Revised,8/5/2024,Limited Availability,Intermittent Backorders Through Oct 2024,,Other,Psychiatry,Current,,,,2024,limited availability
13646,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 0185-0853-01)",Revised,8/5/2024,Limited Availability,Intermittent Backorders Through Oct 2024,,Other,Psychiatry,Current,,,,2024,limited availability
13647,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 0185-2099-01)",Revised,8/5/2024,Limited Availability,Intermittent Backorders Through Oct 2024,,Other,Psychiatry,Current,,,,2024,limited availability
13648,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 125 Mg (NDC 0781-9401-95)",New,3/4/2024,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/2024,,2024,discontinued
13649,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 500 Mg (NDC 0781-9250-95)",New,3/4/2024,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/2024,,2024,discontinued
13650,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 250 Mg (NDC 0781-9242-95)",New,3/4/2024,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/2024,,2024,discontinued
13651,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 125 Mg (NDC 0781-3400-95)",New,3/4/2024,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/2024,,2024,discontinued
13652,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 500 Mg (NDC 0781-9407-95)",New,3/4/2024,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/2024,,2024,discontinued
13653,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 250 Mg (NDC 0781-9402-95)",New,3/4/2024,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/2024,,2024,discontinued
13654,"Atropa Belladonna, Opium Suppository",Padagis Us Llc,"Belladonna And Opium, Suppository, 16.2 Mg; 60 Mg (NDC 0574-7040-04)",Revised,7/1/2024,Available,,,,Urology,Current,,,,2024,available
13655,"Atropa Belladonna, Opium Suppository",Padagis Us Llc,"Belladonna And Opium, Suppository, 16.2 Mg; 60 Mg (NDC 0574-7040-12)",Revised,7/1/2024,Available,,,,Urology,Current,,,,2024,available
13656,Atropine Sulfate Injection,"Medefil, Inc.","Atropine Sulfate, Injection, .1 Mg/1 Ml (NDC 64253-400-91)",Revised,9/3/2024,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2024,available
13657,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .05 Mg/1 Ml (NDC 16729-483-03)",Reverified,8/19/2024,Unavailable,Temporarily Discontinued,,Other,Anesthesia; Neurology; Pediatric,Current,,,,2024,not available
13658,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .1 Mg/1 Ml (NDC 16729-484-90)",Reverified,8/19/2024,Unavailable,Temporarily Discontinued,,Other,Anesthesia; Neurology; Pediatric,Current,,,,2024,not available
13659,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .1 Mg/1 Ml (NDC 16729-484-45)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia; Neurology; Pediatric,Current,,,,2024,not available
13660,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, 1 Mg/1 Ml (NDC 16729-526-08)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia; Neurology; Pediatric,Current,,,,2024,not available
13661,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .4 Mg/1 Ml (NDC 16729-512-43)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia; Neurology; Pediatric,Current,,,,2024,not available
13662,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .4 Mg/1 Ml (NDC 16729-525-08)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia; Neurology; Pediatric,Current,,,,2024,not available
13663,Atropine Sulfate Injection,"American Regent, Inc.","Injection, .4 Mg/1 Ml (NDC 0517-1004-25)",Reverified,7/15/2024,Available,Old Ndc 0517-0401-25,,,Anesthesia; Neurology; Pediatric,Current,,,,2024,available
13664,Atropine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, .4 Mg/1 Ml (NDC 63323-580-20)",Revised,9/4/2024,Limited Availability,2 Month Dating Available On Request. Next Release September 2024.,,Other,Anesthesia; Neurology; Pediatric,Current,,,,2024,limited availability
13665,Atropine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Atropine Sulfate Injection, Usp, Injection, 0.4 Mg/1 Ml (NDC 0641-6251-10)",Reverified,8/28/2024,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2024,available
13666,Atropine Sulfate Injection,"American Regent, Inc.","Injection, 1 Mg/1 Ml (NDC 0517-1001-25)",Reverified,7/15/2024,Available,Old Ndc 0517-1010-25,,,Anesthesia; Neurology; Pediatric,Current,,,,2024,available
13667,Atropine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Atropine Sulfate, Injection, 1 Mg/10 Ml (0.1 Mg/Ml) Syringes (NDC 0409-4911-34)",Revised,8/26/2024,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Anesthesia; Neurology; Pediatric,Current,,,,2024,not available
13668,Atropine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Atropine Sulfate, Injection, 0.5 Mg/5 Ml (0.1 Mg/Ml) Syringes (NDC 0409-4910-34)",Revised,8/26/2024,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Anesthesia; Neurology; Pediatric,Current,,,,2024,not available
13669,Atropine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Atropine Sulfate, Injection, 0.25 Mg/5 Ml (0.05 Mg/Ml) Syringes (NDC 0409-9630-05)",Reverified,8/26/2024,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2024,available
13670,Atropine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Atropine Sulfate, Injection, 1 Mg/10 Ml (0.1 Mg/Ml) Syringes (NDC 0409-1630-10)",Reverified,8/26/2024,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2024,available
13671,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, .1 Mg/1 Ml (NDC 76329-3340-1)",Reverified,8/20/2024,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,,2024,available
13672,Atropine Sulfate Ointment,Bausch & Lomb Incorporated,"Ointment, 10 Mg/1 G (NDC 24208-825-55)",New,12/6/2023,,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anesthesia; Neurology; Pediatric,To Be Discontinued,,12/6/2023,,2024,discontinued
13673,Azacitidine Injection,Eugia Us Llc,"Injection, 100 Mg/4 Ml (NDC 55150-393-01)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,,2024,available
13674,Azacitidine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 100 Mg/30 Ml (NDC 71288-115-30)",Reverified,7/3/2024,Available,,,,Oncology,Current,,,,2024,available
13675,Azacitidine Injection,Cipla Limited,"Injection, 100 Mg (NDC 69097-805-40)",Reverified,3/5/2024,,This Presentation Has Been Discontinued.,,,Oncology,To Be Discontinued,3/5/2024,3/5/2024,,2024,discontinued
13676,Azacitidine Injection,Accord Healthcare Inc.,"Injection, 100 Mg (NDC 16729-306-10)",Revised,8/19/2024,"Unavailable, 45-60 Days",Manufacturing Capacity,,Other,Oncology,Current,,,,2024,not available
13677,Azacitidine Injection,Armas Pharmaceuticals Inc,"Injection, 100 Mg (NDC 72485-201-01)",Reverified,7/15/2024,Available,,,,Oncology,Current,,,,2024,available
13678,Azacitidine Injection,"Dr. Reddy'S Laboratories, Inc.","Injection, 100 Mg (NDC 43598-305-62)",Reverified,7/23/2024,Available,,,,Oncology,Current,,,,2024,available
13679,Azacitidine Injection,"Hikma Pharmaceuticals Usa, Inc.","Azacitidine For Injection, Injection, 100 Mg/ Vial (NDC 0143-9606-01)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Oncology,Current,,,,2024,available
13680,Azacitidine Injection,"Fresenius Kabi Usa, Llc","Injection, 100 Mg/30 Ml (NDC 63323-771-39)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Oncology,Current,,,,2024,available
13681,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 Mg (NDC 59572-102-01)",Reverified,5/27/2024,Available,,,,Oncology,Current,,,,2024,available
13682,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 Mg, Powder, Lyoph (NDC 0781-9253-94)",Revised,12/19/2023,Discontinuation,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,12/19/2023,12/19/2023,,2024,discontinued
13683,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 Mg (NDC 0781-3253-94)",Revised,12/19/2023,Discontinuation,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,12/19/2023,12/19/2023,,2024,discontinued
13684,Azacitidine Injection,"Teva Pharmaceuticals Usa, Inc.","Azacitidine For Injection, Injection, 100 Mg (NDC 68001-313-56)",Revised,9/4/2024,Available,,,,Oncology,Current,,,,2024,available
13685,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 0069-3051-75)",New,7/26/2024,,,,,Anti-Infective,To Be Discontinued,,7/26/2024,,2024,discontinued
13686,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 59762-3051-1)",New,5/17/2024,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/2024,,2024,discontinued
13687,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 59762-3051-2)",New,5/17/2024,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/2024,,2024,discontinued
13688,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 200 Mg/5 Ml (NDC 59762-3120-1)",New,5/17/2024,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/2024,,2024,discontinued
13689,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 900 Mg/22.5 Ml (NDC 59762-3130-1)",New,5/17/2024,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/2024,,2024,discontinued
13690,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1200 Mg/30 Ml (NDC 59762-3140-1)",New,5/17/2024,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/2024,,2024,discontinued
13691,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 0069-3051-75)",New,3/26/2024,,Discontinuation Due To Business Reasons.,,,Anti-Infective,To Be Discontinued,,3/26/2024,,2024,discontinued
13692,Azithromycin For Suspension,Pfizer Inc.,"For Suspension, 200 Mg/5 Ml (NDC 0069-3140-19)",New,9/28/2023,,,,,Antibiotic,To Be Discontinued,,2/28/2024,,2024,discontinued
13693,Azithromycin For Suspension,Pfizer Inc.,"For Suspension, 300 Mg/15ml (NDC 0069-3110-19)",New,9/28/2023,,Discontinuation Due To Business Reasons.,,,Antibiotic,To Be Discontinued,,9/28/2023,,2024,discontinued
13694,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 0069-3051-07)",New,9/28/2023,,Discontinuation Due To Business Reasons.,,,Antibiotic,To Be Discontinued,,9/28/2023,,2024,discontinued
13695,Barium Sulfate Cream,Bracco Diagnostics,"E-Z-Paste, Cream, .6 G/1 G (NDC 32909-770-01)",New,3/26/2024,,Discontinued Due To Business Reasons.,,,Medical Imaging,To Be Discontinued,,3/26/2024,,2024,discontinued
13696,Barium Sulfate Suspension,Bracco Diagnostics,"Neulumex, Suspension, 1 Mg/1 Ml (NDC 32909-927-03)",New,5/2/2024,,Discontinued Due To Business Reasons.,,,Cardiovascular,To Be Discontinued,,5/2/2024,,2024,discontinued
13697,Barium Sulfate Suspension,Bracco Diagnostics,"Liquid Polibar Plus, Suspension, 1.05 G/1 Ml (NDC 32909-167-55)",New,5/2/2024,,Discontinued Due To Business Reasons.,,,Medical Imaging,To Be Discontinued,,5/2/2024,,2024,discontinued
13698,Betaxolol Hydrochloride Ophthalmic Suspension,Novartis Pharmaceuticals Corporation,"Betoptic S, Ophthalmic Suspension, 2.8 Mg/1 Ml (NDC 0078-0729-10)",New,7/2/2024,,"Novartis Has Made A Business Decision To Permanently Discontinue Betoptic S® (Betaxolol Hydrochloride Ophthalmic Suspension), 0.25% As Base.Discontinuation Of The Product Is Not Due To Manufacturing, Product Quality, Safety, Or Efficacy Concerns.",,,Ophthalmology,To Be Discontinued,,7/2/2024,,2024,discontinued
13699,Betaxolol Hydrochloride Ophthalmic Suspension,Novartis Pharmaceuticals Corporation,"Betoptic S, Ophthalmic Suspension, 2.8 Mg/1 Ml (NDC 0078-0729-15)",New,7/2/2024,,"Novartis Has Made A Business Decision To Permanently Discontinue Betoptic S® (Betaxolol Hydrochloride Ophthalmic Suspension), 0.25% As Base.Discontinuation Of The Product Is Not Due To Manufacturing, Product Quality, Safety, Or Efficacy Concerns.",,,Ophthalmology,To Be Discontinued,,7/2/2024,,2024,discontinued
13700,Bisoprolol Fumarate; Hydrochlorothiazide Tablet,"Teva Pharmaceuticals Usa, Inc.","Ziac, Tablet, 10 Mg; 6.25 Mg (NDC 51285-040-01)",New,7/26/2024,,,,,Cardiovascular,To Be Discontinued,,7/26/2024,,2024,discontinued
13701,Bisoprolol Fumarate; Hydrochlorothiazide Tablet,"Teva Pharmaceuticals Usa, Inc.","Ziac, Tablet, 2.5 Mg; 6.25 Mg (NDC 51285-047-02)",New,7/26/2024,,,,,Cardiovascular,To Be Discontinued,,7/26/2024,,2024,discontinued
13702,Bisoprolol Fumarate; Hydrochlorothiazide Tablet,"Teva Pharmaceuticals Usa, Inc.","Ziac, Tablet, 5 Mg; 6.25 Mg (NDC 51285-050-02)",New,7/26/2024,,,,,Cardiovascular,To Be Discontinued,,7/26/2024,,2024,discontinued
13703,Bromocriptine Mesylate Tablet,Sandoz Inc.,"Tablet, 2.5 Mg (NDC 0781-5325-01)",New,8/8/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,8/8/2024,,2024,discontinued
13704,Bromocriptine Mesylate Tablet,Sandoz Inc.,"Tablet, 2.5 Mg (NDC 0781-5325-31)",New,8/8/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,8/8/2024,,2024,discontinued
13705,Bumetanide Injection,Msn Laboratories Private Limited,"Bumetanide, Injection, .25 Mg/1 Ml (NDC 72205-102-07)",Reverified,7/18/2024,Available,,,,Cardiovascular,Current,,,,2024,available
13706,Bumetanide Injection,Msn Laboratories Private Limited,"Bumetanide, Injection, 0.25 Mg/Ml, 10 Ml (NDC 72205-102-01)",Revised,7/18/2024,Available,,,,Cardiovascular,Current,,,,2024,available
13707,Bumetanide Injection,Msn Laboratories Private Limited,"Bumetanide, Injection, .25 Mg/1 Ml (NDC 72205-101-07)",Reverified,7/18/2024,Available,,,,Cardiovascular,Current,,,,2024,available
13708,Bumetanide Injection,Msn Laboratories Private Limited,"Bumetanide, Injection, 0.25 Mg/Ml, 4ml (NDC 72205-101-01)",Revised,7/18/2024,Available,,,,Cardiovascular,Current,,,,2024,available
13709,Bumetanide Injection,"Fresenius Kabi Usa, Llc","Injection, .25 Mg/1 Ml (NDC 65219-572-10)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Cardiovascular,Current,,,,2024,available
13710,Bumetanide Injection,"Fresenius Kabi Usa, Llc","Injection, .25 Mg/1 Ml (NDC 65219-570-04)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Cardiovascular,Current,,,,2024,available
13711,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 Mg/1 Ml (NDC 70860-406-10)",Reverified,7/1/2024,Available,,,,Cardiovascular,Current,,,,2024,available
13712,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 Mg/1 Ml (NDC 70860-405-04)",Reverified,7/1/2024,Available,,,,Cardiovascular,Current,,,,2024,available
13713,Bumetanide Injection,"Hikma Pharmaceuticals Usa, Inc.","Bumetanide Injection, Usp, Injection, .25 Mg/1 Ml (NDC 0641-6007-10)",Reverified,8/28/2024,Available,,,,Cardiovascular,Current,,,,2024,available
13714,Bumetanide Injection,"Hikma Pharmaceuticals Usa, Inc.","Bumetanide Injection, Usp, Injection, .25 Mg/1 Ml (NDC 0641-6008-10)",Reverified,8/28/2024,Available,,,,Cardiovascular,Current,,,,2024,available
13715,Bumetanide Injection,"Hospira, Inc., A Pfizer Company","Injection, .25 Mg/1 Ml (NDC 0409-1412-10)",Revised,11/3/2023,,Discontinued,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,12/1/2023,11/3/2023,,2024,discontinued
13716,Bumetanide Injection,"Hospira, Inc., A Pfizer Company","Injection, .25 Mg/1 Ml (NDC 0409-1412-04)",Revised,11/3/2023,,Discontinued,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,12/1/2023,11/3/2023,,2024,discontinued
13717,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 5 Mg/1 Ml (NDC 71288-726-52)",Reverified,7/11/2024,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,,2024,available
13718,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 2.5 Mg/1 Ml (NDC 71288-723-52)",Reverified,7/11/2024,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,,2024,available
13719,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","Bupivacaine Hydrochloride, Injection, 7.5 Mg/1 Ml (NDC 73293-0002-2)",Reverified,8/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
13720,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 2.5 Mg/1 Ml (NDC 55150-167-10)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13721,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 225 Mg/30 Ml (7.5 Mg/Ml) (NDC 0409-1582-29)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13722,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 75 Mg/10 Ml (7.5 Mg/Ml) (NDC 0409-1582-10)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13723,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 250 Mg/50 Ml (5 Mg/Ml) (NDC 0409-1610-50)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery And Estimated Recovery: December 2027,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,limited availability
13724,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 150 Mg/30 Ml (5 Mg/Ml) (NDC 0409-1560-29)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13725,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 50 Mg/10 Ml (5 Mg/Ml) (NDC 0409-1560-10)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13726,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 125 Mg/50 Ml (2.5 Mg/Ml) (NDC 0409-1587-50)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13727,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 75 Mg/30 Ml (2.5 Mg/Ml) (NDC 0409-1559-30)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13728,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 25 Mg/10 Ml (2.5 Mg/Ml) (NDC 0409-1559-10)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13729,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 Mg/2 Ml (7.5 Mg/Ml In 8.25% Dextrose) (NDC 0409-3613-01)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13730,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 225 Mg/30 Ml (7.5 Mg/Ml) (NDC 0409-1165-02)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13731,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 Mg/1 Ml (NDC 0409-1165-01)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13732,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 250 Mg/50 Ml (5 Mg/Ml) (NDC 0409-1163-01)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13733,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 150 Mg/30 Ml (5 Mg/Ml) (NDC 0409-1162-02)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13734,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 50 Mg/10 Ml (5 Mg/Ml) (NDC 0409-1162-01)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13735,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 125 Mg/50 Ml (2.5 Mg/Ml) (NDC 0409-1160-01)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13736,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 75 Mg/30 Ml (2.5 Mg/Ml) (NDC 0409-1159-02)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13737,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 25 Mg/10 Ml (2.5 Mg/Ml) (NDC 0409-1159-01)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13738,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 7.5 Mg/1 Ml (NDC 63323-472-37)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13739,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 7.5 Mg/1 Ml (NDC 63323-472-17)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13740,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml (NDC 63323-466-31)",Reverified,9/4/2024,Unavailable,Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
13741,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml (NDC 63323-466-37)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13742,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml (NDC 63323-466-17)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13743,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml (NDC 63323-464-31)",Reverified,9/4/2024,Unavailable,Not Available At This Time.,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
13744,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml (NDC 63323-464-37)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13745,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml (NDC 63323-464-17)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13746,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml (NDC 63323-467-57)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13747,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride, Injection, 5 Mg/1 Ml (NDC 55150-250-50)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13748,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride, Injection, 2.5 Mg/1 Ml (NDC 55150-249-50)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13749,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 7.5 Mg/1 Ml (NDC 55150-172-30)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
13750,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 7.5 Mg/1 Ml (NDC 55150-171-10)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
13751,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 5 Mg/1 Ml (NDC 55150-170-30)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
13752,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 5 Mg/1 Ml (NDC 55150-169-10)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13753,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 2.5 Mg/1 Ml (NDC 55150-168-30)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13754,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml (NDC 63323-465-57)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
13755,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, 0.75% 15 Mg/2 Ml (NDC 0409-1761-62)",Revised,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
13756,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 0.25%; 75 Mg/30 Ml (2.5 Mg/Ml) (NDC 0409-1159-10)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13757,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, 0.75% 15 Mg/2 Ml (7.5 Mg/Ml) In Dextrose 8.25% (NDC 0409-1761-10)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
13758,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 5 Mg/1 Ml (NDC 70069-753-25)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
13759,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2.5 Mg/1 Ml (NDC 70069-752-25)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
13760,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 5 Mg/1 Ml (NDC 71288-725-32)",Reverified,7/11/2024,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,,2024,available
13761,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 7.5 Mg/1 Ml (NDC 71288-728-32)",Reverified,7/11/2024,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,,2024,available
13762,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 2.5 Mg/1 Ml (NDC 71288-722-32)",Reverified,7/11/2024,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,,2024,available
13763,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 250 Mg/50 Ml (5 Mg/Ml 1:200,000) (NDC 0409-1755-50)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: September 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,limited availability
13764,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 125 Mg/50 Ml (2.5 Mg/Ml 1:200,000) (NDC 0409-1752-50)",Revised,8/26/2024,Limited Availability,Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,limited availability
13765,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 150 Mg/30 Ml (5 Mg/Ml 1:200,000) (NDC 0409-1749-29)",Revised,8/26/2024,Limited Availability,Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,limited availability
13766,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 50 Mg/10 Ml (5 Mg/Ml 1:200,000) (NDC 0409-1749-10)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,limited availability
13767,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 75 Mg/30 Ml (2.5 Mg/Ml 1:200,000) (NDC 0409-1746-30)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: September 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,limited availability
13768,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 25 Mg/10 Ml (2.5 Mg/Ml 1:200,000) (NDC 0409-1746-10)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: September 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,limited availability
13769,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 250 Mg/50 Ml (5 Mg/Ml) (NDC 0409-9046-01)",Revised,8/26/2024,Unavailable,Next Delivery: April 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
13770,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 150 Mg/30 Ml (5 Mg/Ml) (NDC 0409-9045-17)",Revised,8/26/2024,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
13771,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 50 Mg/10 Ml (5 Mg/Ml) (NDC 0409-9045-01)",Revised,8/26/2024,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
13772,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 125 Mg/50 Ml (2.5 Mg/Ml) (NDC 0409-9043-01)",Revised,8/26/2024,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
13773,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 75 Mg/30 Ml (2.5 Mg/Ml) (NDC 0409-9042-17)",Revised,8/26/2024,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
13774,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 25 Mg/10 Ml (2.5 Mg/Ml) (NDC 0409-9042-01)",Revised,8/26/2024,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
13775,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 7.5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-460-37)",Revised,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
13776,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-462-31)",Reverified,9/4/2024,Unavailable,Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
13777,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-462-37)",Reverified,9/4/2024,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,,2024,available
13778,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-462-17)",Reverified,9/4/2024,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,,2024,available
13779,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-468-37)",Reverified,9/4/2024,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,,2024,available
13780,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-468-17)",Reverified,9/4/2024,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,,2024,available
13781,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-463-57)",Reverified,9/4/2024,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,,2024,available
13782,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-461-57)",Reverified,9/4/2024,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,,2024,available
13783,"Bupropion Hydrochloride Tablet, Extended Release","Endo Pharmaceuticals, Inc.","Tablet, Extended Release, 300 Mg (NDC 10370-102-03)",New,12/28/2023,,,,,Psychiatry,To Be Discontinued,,12/28/2023,,2024,discontinued
13784,"Bupropion Hydrochloride Tablet, Extended Release","Endo Pharmaceuticals, Inc.","Tablet, Extended Release, 300 Mg (NDC 10370-102-50)",New,12/28/2023,,,,,Psychiatry,To Be Discontinued,,12/28/2023,,2024,discontinued
13785,"Bupropion Hydrochloride Tablet, Extended Release","Endo Pharmaceuticals, Inc.","Tablet, Extended Release, 150 Mg (NDC 10370-101-03)",New,10/2/2023,,,,,Psychiatry,To Be Discontinued,,10/2/2023,,2024,discontinued
13786,"Bupropion Hydrochloride Tablet, Extended Release","Endo Pharmaceuticals, Inc.","Tablet, Extended Release, 150 Mg (NDC 10370-101-50)",New,10/2/2023,,,,,Psychiatry,To Be Discontinued,,,,2024,discontinued
13787,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Delflex, Peritoneal Dialysis Solution, 18.4 Mg/100 Ml; 1.5 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-206-20)",New,3/21/2024,,,,,Renal,To Be Discontinued,,3/21/2024,,2024,discontinued
13788,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Delflex, Peritoneal Dialysis Solution, 18.4 Mg/100 Ml; 2.5 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-209-23)",New,3/21/2024,,,,,Renal,To Be Discontinued,,3/21/2024,,2024,discontinued
13789,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Delflex, Peritoneal Dialysis Solution, 18.4 Mg/100 Ml; 4.25 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-212-23)",New,3/21/2024,,,,,Renal,To Be Discontinued,,3/21/2024,,2024,discontinued
13790,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 25.7 Mg/100 Ml; 1.5 G/100 Ml; 15.2 Mg/100 Ml; 567 Mg/100 Ml; 392 Mg/100 Ml (NDC 49230-188-50)",New,6/4/2024,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/2024,,2024,discontinued
13791,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 25.7 Mg/100 Ml; 2.5 G/100 Ml; 15.2 Mg/100 Ml; 567 Mg/100 Ml; 392 Mg/100 Ml (NDC 49230-191-50)",New,6/4/2024,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/2024,,2024,discontinued
13792,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 18.4 Mg/100 Ml; 1.5 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-206-50)",New,6/4/2024,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/2024,,2024,discontinued
13793,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 18.4 Mg/100 Ml; 2.5 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-209-50)",New,6/4/2024,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/2024,,2024,discontinued
13794,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 18.4 Mg/100 Ml; 4.25 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-212-50)",New,6/4/2024,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/2024,,2024,discontinued
13795,Capecitabine Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 500 Mg (NDC 55111-497-04)",Revised,6/27/2024,,,Available,,Oncology,Resolved,6/27/2024,,,2024,
13796,Capecitabine Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 150 Mg (NDC 55111-496-60)",Revised,6/27/2024,,,Available,,Oncology,Resolved,6/27/2024,,,2024,
13797,Capecitabine Tablet,Eugia Us Llc,"Tablet, 500 Mg (NDC 59651-205-08)",Revised,5/21/2024,,,,,Oncology,Resolved,5/21/2024,,,2024,
13798,Capecitabine Tablet,Eugia Us Llc,"Tablet, 150 Mg (NDC 59651-204-60)",Revised,5/21/2024,,,,,Oncology,Resolved,5/21/2024,,,2024,
13799,Capecitabine Tablet,"Teva Pharmaceuticals Usa, Inc.","Capecitabine Tablets Usp, Tablet, 500 Mg (NDC 0093-7474-89)",Revised,5/21/2024,,,,,Oncology,Resolved,5/21/2024,,,2024,
13800,Capecitabine Tablet,"Teva Pharmaceuticals Usa, Inc.","Capecitabine Tablets Usp, Tablet, 150 Mg (NDC 0093-7473-06)",Revised,5/21/2024,,,,,Oncology,Resolved,5/21/2024,,,2024,
13801,Capecitabine Tablet,Novadoz Pharmaceuticals Llc,"Capecitabine, Tablet, 150 Mg (NDC 72205-006-60)",Revised,5/21/2024,,,Manufactured By Msn Laboratories Private Limited (Formulation Division),,Oncology,Resolved,5/21/2024,,,2024,
13802,Capecitabine Tablet,Novadoz Pharmaceuticals Llc,"Capecitabine, Tablet, 500 Mg (NDC 72205-007-92)",Revised,5/21/2024,,,Manufactured By Msn Laboratories Private Limited (Formulation Division),,Oncology,Resolved,5/21/2024,,,2024,
13803,Capecitabine Tablet,"Genentech, Inc","Xeloda, Tablet, 500 Mg (NDC 0004-1101-50)",Revised,1/23/2024,,Product Was Discontinued In March 2023.,,,Oncology,To Be Discontinued,1/23/2024,1/23/2024,,2024,discontinued
13804,Capecitabine Tablet,"Genentech, Inc","Xeloda, Tablet, 150 Mg (NDC 0004-1100-20)",Revised,1/23/2024,,Product Was Discontinued In March 2023.,,,Oncology,To Be Discontinued,1/23/2024,1/23/2024,,2024,discontinued
13805,Capecitabine Tablet,Accord Healthcare Inc.,"Tablet, 500 Mg (NDC 16729-073-29)",Revised,6/27/2024,,,Available,,Oncology,Resolved,6/27/2024,,,2024,
13806,"Carbamazepine Capsule, Extended Release",Takeda Pharmaceuticals Usa Inc.,"Capsule, Extended Release, 300 Mg (NDC 66993-409-32)",New,2/6/2024,,The Brand Carbatrol Will Continue To Be Available.,,,Neurology,To Be Discontinued,,2/6/2024,,2024,discontinued
13807,"Carbamazepine Capsule, Extended Release",Takeda Pharmaceuticals Usa Inc.,"Capsule, Extended Release, 100 Mg (NDC 66993-407-32)",New,2/6/2024,,The Brand Carbatrol Will Continue To Be Available.,,,Neurology,To Be Discontinued,,2/6/2024,,2024,discontinued
13808,"Carbamazepine Capsule, Extended Release",Takeda Pharmaceuticals Usa Inc.,"Capsule, Extended Release, 200 Mg (NDC 66993-408-32)",New,2/6/2024,,The Brand Carbatrol Will Continue To Be Available.,,,Neurology,To Be Discontinued,,2/6/2024,,2024,discontinued
13809,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 200 Mg (NDC 0781-5987-01)",New,10/23/2023,,"Novartis Pharmaceuticals’ Brand Product, Tegretol Xr, 200 Mg (Ndc 0078-0511-05), Will Continue To Be Manufactured And Available.",,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,10/23/2023,,2024,discontinued
13810,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 400 Mg (NDC 0781-5988-01)",New,10/23/2023,,"Novartis Pharmaceuticals’ Brand Product, Tegretol Xr, 400 Mg, (Ndc 0078-0512-05), Will Continue To Be Manufactured And Available.",,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,10/23/2023,,2024,discontinued
13811,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 100 Mg (NDC 0781-8016-01)",New,10/23/2023,,"Novartis Pharmaceuticals’ Brand Product, Tegretol Xr 100 Mg (Ndc 0078-0510-05), Will Continue To Be Manufactured And Available.",,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,10/23/2023,,2024,discontinued
13812,Carbidopa And Levodopa Tablet,"Mylan Pharmaceuticals Inc., A Viatris Company","Tablet, 25/250 Mg (NDC 0378-1133-01)",New,3/26/2024,,,,,Neurology,To Be Discontinued,,3/26/2024,,2024,discontinued
13813,Carbidopa And Levodopa Tablet,"Mylan Pharmaceuticals Inc., A Viatris Company","Tablet, 25/100 Mg (NDC 0378-0085-01)",New,3/26/2024,,,,,Neurology,To Be Discontinued,,3/26/2024,,2024,discontinued
13814,Carbidopa And Levodopa Tablet,"Mylan Pharmaceuticals Inc., A Viatris Company","Tablet, 10/100 Mg (NDC 0378-0078-01)",New,3/26/2024,,,,,Neurology,To Be Discontinued,,3/26/2024,,2024,discontinued
13815,Carboplatin Injection,Ingenus Pharmaceuticals Llc,"Injection, 450 Mg/45 Ml (NDC 50742-447-45)",Reverified,6/24/2024,Available,"For Any Other Information, Please Contact The Ingenus Customer Service Team At 866-321-5031.",,,Oncology,Current,,,,2024,available
13816,Carboplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Carboplatin Injection, Injection, 10 Mg/1 Ml (NDC 0703-4248-01)",Revised,8/23/2024,Limited Availability,,,Demand Increase For The Drug,Oncology,Current,,,,2024,limited availability
13817,Carboplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Carboplatin Injection, Injection, 10 Mg/1 Ml (NDC 0703-4246-01)",Revised,8/23/2024,Available,,,,Oncology,Current,,,,2024,available
13818,Carboplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Carboplatin Injection, Injection, 10 Mg/1 Ml (NDC 0703-4244-01)",Revised,8/23/2024,Available,,,,Oncology,Current,,,,2024,available
13819,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 600 Mg/60 Ml (10 Mg/Ml) (NDC 61703-600-05)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: October 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Oncology,Current,,,,2024,limited availability
13820,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 600 Mg/60 Ml (10 Mg/Ml) (NDC 61703-339-56)",Reverified,8/26/2024,Available,,,,Oncology,Current,,,,2024,available
13821,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 450 Mg/45 Ml (10 Mg/Ml) (NDC 61703-262-05)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: October 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Oncology,Current,,,,2024,limited availability
13822,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 450 Mg/45 Ml (10 Mg/Ml) (NDC 61703-339-50)",Reverified,8/26/2024,Available,,,,Oncology,Current,,,,2024,available
13823,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 150 Mg/15 Ml (10 Mg/Ml) (NDC 61703-150-05)",Reverified,8/26/2024,Available,,,,Oncology,Current,,,,2024,available
13824,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 150 Mg/15 Ml (10 Mg/Ml) (NDC 61703-339-22)",Reverified,8/26/2024,Available,,,,Oncology,Current,,,,2024,available
13825,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 61703-360-18)",Revised,8/26/2024,Available,,,,Oncology,Current,,,,2024,available
13826,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 61703-339-18)",Reverified,8/26/2024,Available,,,,Oncology,Current,,,,2024,available
13827,Carboplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Carboplatin Injection, Injection, 10 Mg/1 Ml (NDC 0703-4239-01)",Revised,8/23/2024,Available,,,,Oncology,Current,,,,2024,available
13828,Carboplatin Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-172-60)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,,2024,available
13829,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-295-12)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Oncology,Current,,,,2024,not available
13830,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-295-34)",Revised,8/19/2024,"Unavailable, 15-30 Days",Inventory At Dc; Awaiting Quality Review,,Requirements Related To Complying With Good Manufacturing Practices,Oncology,Current,,,,2024,not available
13831,Carboplatin Injection,Eugia Us Llc,"Carboplatin, Injection, 600 Mg/60 Ml (NDC 55150-386-01)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,,2024,available
13832,Carboplatin Injection,Eugia Us Llc,"Carboplatin, Injection, 450 Mg/45 Ml (NDC 55150-335-01)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,,2024,available
13833,Carboplatin Injection,Teyro Labs,"Injection, 600 Mg/60 Ml (10 Mg/Ml) Multiple Dose Vial (NDC 60505-6282-7)",Reverified,9/3/2024,Available,Wholesaler & Distributor Through Marketing Partner (Apotex Inc.),,,Oncology,Current,,,,2024,available
13834,Carboplatin Injection,Teyro Labs,"Injection, 50 Mg/5 Ml (10 Mg/Ml) Multiple Dose Vial (NDC 60505-6282-1)",Reverified,9/3/2024,Available,Wholesaler & Distributor Through Marketing Partner (Apotex Inc.),,,Oncology,Current,,,,2024,available
13835,Carboplatin Injection,Teyro Labs,"Injection, 450 Mg/45 Ml (10 Mg/Ml) Multiple Dose Vial (NDC 60505-6282-6)",Reverified,9/3/2024,Available,Wholesaler & Distributor Through Marketing Partner (Apotex Inc.),,,Oncology,Current,,,,2024,available
13836,Carboplatin Injection,Teyro Labs,"Injection, 150 Mg/15 Ml (10 Mg/Ml) Multiple Dose Vial (NDC 60505-6282-3)",Reverified,9/3/2024,Available,Wholesaler & Distributor Through Marketing Partner (Apotex Inc.),,,Oncology,Current,,,,2024,available
13837,Carboplatin Injection,Ingenus Pharmaceuticals Llc,"Injection, 600 Mg/60 Ml (NDC 50742-448-60)",Reverified,6/24/2024,Available,"For Any Other Information, Please Contact The Ingenus Customer Service Team At 866-321-5031.",,,Oncology,Current,,,,2024,available
13838,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 50mg/5ml (NDC 54288-164-01)",Revised,7/15/2024,Available,"Distributed By Bpi Labs, Llc",,,Oncology,Current,,,,2024,available
13839,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 450mg/45ml (NDC 54288-166-01)",Revised,7/15/2024,Available,"Distributed By Bpi Labs, Llc",,,Oncology,Current,,,,2024,available
13840,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 150mg/15ml (NDC 54288-165-01)",Revised,7/15/2024,Available,"Distributed By Bpi Labs, Llc",,,Oncology,Current,,,,2024,available
13841,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 600 Mg/65 Ml (NDC 54288-167-01)",Revised,7/15/2024,Available,"Distributed By Bpi Labs, Llc",,,Oncology,Current,,,,2024,available
13842,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-295-31)",Revised,8/19/2024,Unavailable,Temporarily Discontinued,,Other,Oncology,Current,,,,2024,not available
13843,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-295-33)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Oncology,Current,,,,2024,not available
13844,Caspofungin Acetate Injection,Merck Sharp & Dohme Corp.,"Cancidas, Injection, 7 Mg/1 Ml (NDC 0006-3823-10)",New,6/27/2024,,,,,Anti-Infective,To Be Discontinued,,6/27/2024,,2024,discontinued
13845,Cefazolin Sodium Injection,Sandoz Inc.,"Injection, 500 Mg (NDC 0781-3450-95)",New,12/12/2023,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,12/12/2023,,2024,discontinued
13846,Cefazolin Sodium Injection,Sandoz Inc.,"Injection, 10 G (NDC 0781-3452-95)",New,12/12/2023,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,12/12/2023,,2024,discontinued
13847,Cefixime Capsule,"Lupin Pharmaceuticals, Inc.","Suprax, Capsule, 400 Mg (NDC 68180-423-11)",Revised,3/19/2024,,,Available,,Anti-Infective,Resolved,3/19/2024,,,2024,
13848,Cefixime Capsule,"Lupin Pharmaceuticals, Inc.","Suprax, Capsule, 400 Mg (NDC 68180-423-08)",Revised,3/19/2024,,,Available,,Anti-Infective,Resolved,3/19/2024,,,2024,
13849,Cefixime Capsule,"Ascend Laboratories, Llc","Capsule, 400 Mg (NDC 67877-584-50)",Revised,3/19/2024,,,Available,,Anti-Infective,Resolved,3/19/2024,,,2024,
13850,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Cefotaxime For Injection, Usp, Injection, 10 G (NDC 0143-9935-01)",Reverified,8/28/2024,Unavailable,Shortage Duration Is Unknown At This Time.,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,not available
13851,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Cefotaxime For Injection, Usp, Injection, 2 G (NDC 0143-9933-25)",Reverified,8/28/2024,Unavailable,Shortage Duration Is Unknown At This Time.,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,not available
13852,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Cefotaxime For Injection, Usp, Injection, 1 G (NDC 0143-9931-25)",Reverified,8/28/2024,Unavailable,Shortage Duration Is Unknown At This Time.,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,not available
13853,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Cefotaxime For Injection, Usp, Injection, 500 Mg (NDC 0143-9930-10)",Reverified,8/28/2024,Unavailable,Shortage Duration Is Unknown At This Time.,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,,2024,not available
13854,Cefotaxime Sodium Injection,"Sterimax, Inc.","Injection, 1 G (NDC 21586-011-02)",Reverified,3/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13855,Cefotaxime Sodium Injection,"Sterimax, Inc.","Cefotaxime, Injection, 2 G (NDC 21586-012-02)",Revised,3/15/2024,Available,,,,Anti-Infective; Pediatric,Current,,,,2024,available
13856,Cefotetan Disodium Injection,"Teligent Pharma, Inc.","Cefotan, Injection, 2 G/20 Ml (NDC 52565-053-10)",Revised,9/10/2024,,,Available,,Anti-Infective,Resolved,9/10/2024,,,2024,
13857,Cefotetan Disodium Injection,"Fresenius Kabi Usa, Llc","Injection, 10 G (NDC 63323-396-61)",Revised,9/10/2024,,,Available,,Anti-Infective,Resolved,9/10/2024,,,2024,
13858,Cefotetan Disodium Injection,"Fresenius Kabi Usa, Llc","Injection, 2 G/20 Ml (NDC 63323-386-20)",Revised,9/10/2024,,,Available,,Anti-Infective,Resolved,9/10/2024,,,2024,
13859,Cefotetan Disodium Injection,"Fresenius Kabi Usa, Llc","Injection, 1 G/10 Ml (NDC 63323-385-10)",Revised,9/10/2024,,,Available,,Anti-Infective,Resolved,9/10/2024,,,2024,
13860,Cefotetan Disodium Injection,Pai Pharma,"Cefotan, Injection, 1 G/10 Ml (NDC 0121-0976-10)",Revised,9/10/2024,,,Available,,Anti-Infective,Resolved,9/10/2024,,,2024,
13861,Cefotetan Disodium Injection,Pai Pharma,"Cefotan, Injection, 2 G/20 Ml (NDC 0121-0977-10)",Revised,9/10/2024,,,Available,,Anti-Infective,Resolved,9/10/2024,,,2024,
13862,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 Mg (NDC 60505-3849-5)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2024,discontinued
13863,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 Mg (NDC 60505-3849-1)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2024,discontinued
13864,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 Mg (NDC 60505-3848-5)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2024,discontinued
13865,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 Mg (NDC 60505-3848-1)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2024,discontinued
13866,Celecoxib Capsule,Apotex Corp.,"Capsule, 50 Mg (NDC 60505-3847-6)",New,9/9/2024,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/2024,,2024,discontinued
13867,Chloramphenicol Sodium Succinate Injection,"Fresenius Kabi Usa, Llc","Injection, 1 G/10 Ml (NDC 63323-011-15)",Revised,12/11/2023,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,12/11/2023,12/11/2023,,2024,discontinued
13868,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Chloroprocaine Hcl Injection, Usp, Injection, 30 Mg/1 Ml (NDC 0143-9210-10)",Reverified,8/28/2024,Unavailable,Additional Lots Will Be Available In The September - October 2024 Timeframe.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
13869,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Chloroprocaine Hcl Injection, Usp, Injection, 20 Mg/1 Ml (NDC 0143-9209-10)",Reverified,8/28/2024,Unavailable,Additional Lots Will Be Available In The September - October 2024 Timeframe.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
13870,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Nesacaine, Injection, 30 Mg/1 Ml (NDC 63323-478-27)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
13871,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Nesacaine, Injection, 20 Mg/1 Ml (NDC 63323-477-27)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory.,,,Anesthesia,Current,,,,2024,available
13872,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Nesacaine, Injection, 20 Mg/1 Ml (NDC 63323-476-37)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory.,,,Anesthesia,Current,,,,2024,available
13873,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Nesacaine, Injection, 10 Mg/1 Ml (NDC 63323-475-37)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory.,,,Anesthesia,Current,,,,2024,available
13874,Chloroprocaine Hydrochloride Injection,B. Braun Medical Inc.,"Clorotekal, Injection, 10 Mg/Ml (NDC 0264-7055-05)",Revised,11/2/2023,,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anesthesia,To Be Discontinued,11/2/2023,11/2/2023,,2024,discontinued
13875,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 30 Mg (NDC 65862-831-05)",New,4/29/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/2024,,2024,discontinued
13876,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 30 Mg (NDC 65862-831-30)",New,4/29/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/2024,,2024,discontinued
13877,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 60 Mg (NDC 65862-832-05)",New,4/29/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/2024,,2024,discontinued
13878,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 60 Mg (NDC 65862-832-30)",New,4/29/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/2024,,2024,discontinued
13879,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 90 Mg (NDC 65862-833-05)",New,4/29/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/2024,,2024,discontinued
13880,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 90 Mg (NDC 65862-833-30)",New,4/29/2024,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/2024,,2024,discontinued
13881,Cisatracurium Besylate Injection,"Hospira, Inc., A Pfizer Company","Injection, 10 Mg/1 Ml (NDC 0409-3670-10)",New,4/15/2024,,,,,Analgesia/Addiction,To Be Discontinued,,4/15/2024,,2024,discontinued
13882,Cisatracurium Besylate Injection,"Hospira, Inc., A Pfizer Company","Injection, 10 Mg/5ml (2 Mg/Ml) Single Dose Vial Premierprorx® (NDC 0409-5547-10)",New,4/15/2024,,Supply Expected To Exhaust July 2024,,,Analgesia/Addiction,To Be Discontinued,,4/15/2024,,2024,discontinued
13883,Cisatracurium Besylate Injection,"Hospira, Inc., A Pfizer Company","Injection, 2 Mg/1 Ml (NDC 0409-7083-10)",New,4/15/2024,,,,,Analgesia/Addiction,To Be Discontinued,,4/15/2024,,2024,discontinued
13884,Cisplatin Injection,Gland Pharma Limited,"Injection, 100 Ml Vial, 1 Mg/Ml (NDC 25021-253-51)",Revised,6/27/2024,,,Available.  Ndc 25021-253-50 And Ndc 25021-253-51 Marketed By Sagent Pharmaceuticals.  Ndc 72266-252-01 And Ndc 72266-253-01) Marketed By Fosun Pharma Usa Inc.,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13885,Cisplatin Injection,Gland Pharma Limited,"Injection, 50 Ml Vial, 1 Mg/Ml (NDC 25021-253-50)",Revised,6/27/2024,,,Available.  Ndc 25021-253-50 And Ndc 25021-253-51 Marketed By Sagent Pharmaceuticals.  Ndc 72266-252-01 And Ndc 72266-253-01) Marketed By Fosun Pharma Usa Inc.,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13886,Cisplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Injection, 100 Ml Vial, 1 Mg/Ml (NDC 0703-5748-11)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13887,Cisplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Injection, 50 Ml Vial, 1 Mg/Ml (NDC 0703-5747-11)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13888,Cisplatin Injection,Hq Specialty Pharma,"Injection, 50 Mg (NDC 44567-530-01)",Revised,6/27/2024,,,Available. Marketed By Wg Critical Care.,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13889,Cisplatin Injection,Hq Specialty Pharma,"Injection, 200 Ml Vial, 1 Mg/Ml (NDC 44567-511-01)",Revised,6/27/2024,,,Available. Marketed By Wg Critical Care.,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13890,Cisplatin Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 100 Ml Vial, 1 Mg/Ml (NDC 0143-9505-01)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13891,Cisplatin Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 50 Ml Vial, 1 Mg/Ml (NDC 0143-9504-01)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13892,Cisplatin Injection,"Fresenius Kabi Usa, Llc","Injection, 200 Ml Vial, 1 Mg/Ml (NDC 63323-103-64)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13893,Cisplatin Injection,"Fresenius Kabi Usa, Llc","Injection, 100 Ml Vial, 1 Mg/Ml (NDC 63323-103-65)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13894,Cisplatin Injection,"Fresenius Kabi Usa, Llc","Injection, 50 Ml Vial, 1 Mg/Ml (NDC 63323-103-51)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13895,Cisplatin Injection,Accord Healthcare Inc.,"Injection, 100 Ml Vial, 1 Mg/Ml (NDC 68001-283-32)",Revised,6/27/2024,,Marketed By Bluepoint Laboratories,,,Oncology; Pediatric,To Be Discontinued,6/27/2024,6/27/2024,,2024,discontinued
13896,Cisplatin Injection,Accord Healthcare Inc.,"Injection, 50 Ml Vial, 1 Mg/Ml (NDC 68001-283-27)",Revised,6/27/2024,,Marketed By Bluepoint Laboratories,,,Oncology; Pediatric,To Be Discontinued,6/27/2024,6/27/2024,,2024,discontinued
13897,Cisplatin Injection,Accord Healthcare Inc.,"Injection, 100 Ml Vial, 1 Mg/Ml (NDC 16729-288-38)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13898,Cisplatin Injection,Accord Healthcare Inc.,"Injection, 50 Ml Vial, 1 Mg/Ml (NDC 16729-288-11)",Revised,6/27/2024,,,Available,,Oncology; Pediatric,Resolved,6/27/2024,,,2024,
13899,Cisplatin Injection,Gland Pharma Limited,"Injection, 100 Ml Vial, 1 Mg/Ml (NDC 72266-253-01)",Revised,6/27/2024,,,Available. Ndc 25021-253-50 And Ndc 25021-253-51 Marketed By Sagent Pharmaceuticals. Ndc 72266-252-01 And Ndc 72266-253-01) Marketed By Fosun Pharma Usa Inc.,,Oncology; Pediatric,Resolved,,,,2024,
13900,Cisplatin Injection,"Qilu Pharmaceutical Co., Ltd.","Injection, 50 Ml Vial, 1 Mg/Ml (NDC 60505-6279-0)",Revised,6/27/2024,,,Estimated Availability August 2024. Marketed By Apotex Corp.,,Oncology; Pediatric,Resolved,,,,2024,
13901,Cisplatin Injection,Gland Pharma Limited,"Injection, 50 Ml Vial, 1 Mg/Ml (NDC 72266-252-01)",Revised,6/27/2024,,,Available. Ndc 25021-253-50 And Ndc 25021-253-51 Marketed By Sagent Pharmaceuticals. Ndc 72266-252-01 And Ndc 72266-253-01) Marketed By Fosun Pharma Usa Inc.,,Oncology; Pediatric,Resolved,,,,2024,
13902,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 600 Mg/4 Ml (150 Mg/Ml) (NDC 0009-4073-04)",Revised,8/26/2024,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,Check Wholesaler For Availability Shortage Per Manufacturer: Manufacturing Delay,,Delay In Shipping Of The Drug,Anti-Infective,Current,,,,2024,limited availability
13903,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 900 Mg/6 Ml (150 Mg/Ml) (NDC 0009-5095-06)",Reverified,8/26/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13904,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 300 Mg/2 Ml (150 Mg/Ml) (NDC 0009-3051-02)",Revised,8/26/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13905,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 Mg/1 Ml (NDC 72572-074-24)",Reverified,8/5/2024,Available,Civica Label,,,Anti-Infective,Current,,,,2024,available
13906,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 Mg/1 Ml (NDC 25021-115-06)",Reverified,7/1/2024,Unavailable,Backorder. Estimated Availability Tbd,,Demand Increase For The Drug,Anti-Infective,Current,,,,2024,not available
13907,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 Mg/1 Ml (NDC 25021-115-04)",Reverified,7/1/2024,Unavailable,Backorder. Estimated Availability Tbd,,Demand Increase For The Drug,Anti-Infective,Current,,,,2024,not available
13908,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 Mg/1 Ml (NDC 25021-115-02)",Reverified,7/1/2024,Unavailable,Backorder. Estimated Availability Tbd,,Demand Increase For The Drug,Anti-Infective,Current,,,,2024,not available
13909,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 900 Mg/6 Ml (150 Mg/Ml) (NDC 0009-0902-18)",Reverified,8/26/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13910,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 9 G/60 Ml (150 Mg/Ml) (NDC 0009-0728-09)",Reverified,8/26/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13911,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 600 Mg/4 Ml (150 Mg/Ml) (NDC 0009-0775-26)",Reverified,8/26/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13912,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 300 Mg/2 Ml (150 Mg/Ml) (NDC 0009-0870-26)",Reverified,8/26/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13913,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 Mg/1 Ml (NDC 72572-076-24)",Reverified,8/5/2024,Available,Civica Label,,,Anti-Infective,Current,,,,2024,available
13914,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 Mg/1 Ml (NDC 0781-3290-09)",Reverified,8/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13915,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 Mg/1 Ml (NDC 0781-3289-09)",Reverified,8/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13916,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 Mg/1 Ml (NDC 0781-3288-09)",Reverified,8/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13917,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 Mg/50 Ml (NDC 0338-3814-50)",Reverified,9/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13918,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 600 Mg/50 Ml (NDC 0338-3612-50)",Reverified,9/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13919,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 Mg/50 Ml (NDC 0338-3410-50)",Reverified,9/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13920,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 Mg/50 Ml (NDC 0338-9553-50)",Reverified,9/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13921,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 Mg/50 Ml (NDC 0338-9549-50)",Reverified,9/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13922,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 Mg/50 Ml (NDC 0338-9545-50)",Reverified,9/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
13923,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0163-15)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13924,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0163-30)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13925,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0163-46)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13926,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0163-60)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13927,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0293-15)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13928,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0293-30)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13929,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0293-60)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13930,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Clobetasol Propionate (Emollient), Cream, .5 Mg/1 G (NDC 0168-0301-30)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13931,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Clobetasol Propionate (Emollient), Cream, .5 Mg/1 G (NDC 0168-0301-60)",New,4/3/2024,,,,,Dermatology,To Be Discontinued,,4/3/2024,,2024,discontinued
13932,Clobetasol Propionate Spray,"Actavis Pharma, Inc.","Clobex, Spray, .05 G/1 Ml (NDC 0591-4039-46)",New,8/28/2024,,,,,Dermatology,To Be Discontinued,,8/28/2024,,2024,discontinued
13933,Clobetasol Propionate Spray,"Actavis Pharma, Inc.","Clobex, Spray, .05 G/1 Ml (NDC 0591-4039-74)",New,8/28/2024,,,,,Dermatology,To Be Discontinued,,8/28/2024,,2024,discontinued
13934,Clocortolone Pivalate Cream,Epi Health,"Cream, 1 Mg/G (NDC 71403-804-45)",New,10/18/2023,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,10/18/2023,,2024,discontinued
13935,Clocortolone Pivalate Cream,Epi Health,"Cream, 1 Mg/G (NDC 71403-804-75)",New,10/18/2023,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,10/18/2023,,2024,discontinued
13936,Clocortolone Pivalate Cream,Epi Health,"Cream, 1 Mg/G (NDC 71403-804-93)",New,10/18/2023,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,10/18/2023,,2024,discontinued
13937,Clofarabine Injection,Apotex Corp.,"Injection, 20 Mg/20 Ml (1mg/Ml) (NDC 60505-6166-0)",New,10/26/2023,,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,10/26/2023,,2024,discontinued
13938,Clomipramine Hydrochloride Capsule,Amneal Pharmaceuticals,"Capsule, 50 Mg (NDC 69238-1109-9)",New,4/30/2024,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/2024,,2024,discontinued
13939,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 Mg (NDC 72888-154-05)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13940,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 Mg (NDC 72888-154-01)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13941,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 Mg (NDC 72888-154-30)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13942,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 Mg (NDC 72888-153-05)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13943,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 Mg (NDC 72888-153-01)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13944,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 Mg (NDC 72888-153-30)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13945,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 Mg (NDC 72888-152-05)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13946,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 Mg (NDC 72888-152-01)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13947,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 Mg (NDC 72888-152-30)",Reverified,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13948,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, 2 Mg (NDC 0093-3213-05)",Revised,9/4/2024,Available,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13949,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, 2 Mg (NDC 0093-3213-01)",Revised,9/4/2024,Available,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13950,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, 1 Mg (NDC 0093-3212-05)",Revised,9/4/2024,Limited Availability,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,,2024,limited availability
13951,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, 1 Mg (NDC 0093-3212-01)",Revised,9/4/2024,Available,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13952,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, .5 Mg (NDC 0093-0832-05)",Revised,9/4/2024,Limited Availability,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,,2024,limited availability
13953,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, .5 Mg (NDC 0093-0832-01)",Revised,9/4/2024,Limited Availability,Estimated Recovery October 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,,2024,limited availability
13954,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 Mg (NDC 43547-408-50)",Reverified,6/18/2024,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13955,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 Mg (NDC 43547-408-10)",Reverified,6/18/2024,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13956,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 Mg (NDC 43547-407-50)",Reverified,6/18/2024,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13957,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 Mg (NDC 43547-407-11)",Reverified,6/18/2024,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13958,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 Mg (NDC 43547-407-10)",Reverified,6/18/2024,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13959,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 Mg (NDC 43547-406-50)",Reverified,6/18/2024,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13960,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 Mg (NDC 43547-406-11)",Reverified,6/18/2024,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13961,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 Mg (NDC 43547-406-10)",Reverified,6/18/2024,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13962,Clonazepam Tablet,Cheplapharm Arzneimittel Gmbh,"Klonopin, Tablet, 2 Mg (NDC 61269-620-10)",Reverified,9/4/2024,Available,Marketed By H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13963,Clonazepam Tablet,Cheplapharm Arzneimittel Gmbh,"Klonopin, Tablet, 1 Mg (NDC 61269-610-10)",Reverified,9/4/2024,Available,Marketed By H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13964,Clonazepam Tablet,Cheplapharm Arzneimittel Gmbh,"Klonopin, Tablet, .5 Mg (NDC 61269-605-10)",Reverified,9/4/2024,Available,Marketed By H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13965,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, 2 Mg (NDC 16729-138-16)",Revised,8/19/2024,"Unavailable, 30 Days",Batches Ready At Manufacturing Facilty Awaiting Qa Release,,Requirements Related To Complying With Good Manufacturing Practices,Neurology; Pediatric; Psychiatry,Current,,,,2024,not available
13966,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, 2 Mg (NDC 16729-138-00)",Revised,8/19/2024,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Neurology; Pediatric; Psychiatry,Current,,,,2024,not available
13967,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, 1 Mg (NDC 16729-137-16)",Reverified,8/19/2024,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13968,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, 1 Mg (NDC 16729-137-00)",Reverified,8/19/2024,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13969,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, .5 Mg (NDC 16729-136-16)",Reverified,8/19/2024,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,,2024,available
13970,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, .5 Mg (NDC 16729-136-00)",Revised,8/19/2024,"Unavailable, 30 Days",Batches Ready At Manufacturing Facilty Awaiting Qa Release,,Requirements Related To Complying With Good Manufacturing Practices,Neurology; Pediatric; Psychiatry,Current,,,,2024,not available
13971,"Clonidine Hydrochloride Tablet, Extended Release",Concordia Pharmaceuticals Inc.,"Kapvay, Tablet, Extended Release, .1 Mg (NDC 59212-658-13)",New,12/13/2023,,,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,12/13/2023,,2024,discontinued
13972,"Clonidine Hydrochloride Tablet, Extended Release",Concordia Pharmaceuticals Inc.,"Kapvay, Tablet, Extended Release, .1 Mg (NDC 59212-658-60)",New,12/13/2023,,"A Business Decision Was Made To Discontinue Manufacture And Supply Of Kapvay® (Clonidine Hydrochloride) Extended Release Tablets, 0.1 Mg. This Product Discontinuation Is Not Related To Product Quality, Safety, Or Efficacy.  All Existing Lots On The Market Are Already Expired.",,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,12/13/2023,,2024,discontinued
13973,Colestipol Hydrochloride Granule,Pfizer Inc.,"Colestid, Granule, 5 G/5 G (NDC 0009-0260-04)",New,11/9/2023,,Supply Expected To Exhaust December 2023,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,To Be Discontinued,,3/30/2023,,2024,discontinued
13974,Colestipol Hydrochloride Granule,Pfizer Inc.,"Granule, 5 G/5 G (NDC 59762-0260-1)",New,10/17/2023,,Supply Expected To Exhaust Early November 2023. Discontinuation Of The Manufacture Of The Drug. This Product Distributed By Viatris.,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,To Be Discontinued,,3/30/2023,,2024,discontinued
13975,Collagenase Clostridium Histolyticum Ointment,"Smith & Nephew, Inc.","Santyl, Ointment, 250 [Arb'U]/1 G (NDC 50484-010-90)",Revised,4/8/2024,,,Available,,Dermatology,Resolved,4/8/2024,,,2024,
13976,Collagenase Clostridium Histolyticum Ointment,"Smith & Nephew, Inc.","Santyl, Ointment, 250 [Arb'U]/1 G (NDC 50484-010-30)",Revised,4/8/2024,,,Available,,Dermatology,Resolved,4/8/2024,,,2024,
13977,Conivaptan Hydrochloride Injection,Cumberland Pharmaceuticals Inc.,"Vaprisol Dextrose In Plastic Container, Injection, 20 Mg/100 Ml (NDC 66220-160-10)",Reverified,9/3/2024,Unavailable,,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
13978,Cromolyn Sodium Concentrate,"Mylan Specialty, A Viatris Company","Gastrocrom, Concentrate, 20 Mg/1 Ml (NDC 0037-0678-96)",Reverified,9/5/2024,Available,,,,Pulmonary/Allergy,Current,,,,2024,available
13979,Cromolyn Sodium Concentrate,Micro Labs Ltd,"Concentrate, 100 Mg/5 Ml (NDC 42571-132-52)",Reverified,9/4/2024,Available,,,,Pulmonary/Allergy,Current,,,,2024,available
13980,Cromolyn Sodium Concentrate,"Rising Pharma Holdings, Inc.","Concentrate, 100 Mg/5 Ml (NDC 16571-600-96)",Revised,7/2/2024,Limited Availability,Shipping Limited Quantities.,,Demand Increase For The Drug,Pulmonary/Allergy,Current,,,,2024,limited availability
13981,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Concentrate, 100 Mg/5 Ml (NDC 76204-025-96)",Reverified,7/15/2024,Available,"Distributed By Ritedose Pharmaceuticals, Llc (855) 806 3300",,,Pulmonary/Allergy,Current,,,,2024,available
13982,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Concentrate, 100 Mg/5 Ml (NDC 69784-200-96)",Reverified,7/15/2024,Available,Distributed By Woodward Pharma Services Llc (248) 308-1120 Ext 2,,,Pulmonary/Allergy,Current,,,,2024,available
13983,Cromolyn Sodium Oral Solution,"Mylan Institutional, A Viatris Company","Oral Solution, 100mg/5ml (NDC 51525-0470-9)",New,11/1/2023,,Gastrocrom 100mg/5ml Oral Concentrate 96s (Ndc: 0037-0678-96) Will Remain Available,,Discontinuation Of The Manufacture Of The Drug,Pulmonary/Allergy,To Be Discontinued,,11/1/2023,,2024,discontinued
13984,Cyanocobalamin Spray,"Endo Pharmaceuticals, Inc.","Nascobal, Spray, 500 Ug (NDC 49884-270-82)",New,7/12/2024,,,,,Hematology,To Be Discontinued,,7/12/2024,,2024,discontinued
13985,Cyclopentolate Hydrochloride Ophthalmic Solution,Bausch & Lomb Incorporated,"Pentolair, Ophthalmic Solution, 10 Mg/1 Ml (NDC 24208-735-06)",Reverified,9/4/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13986,Cyclopentolate Hydrochloride Ophthalmic Solution,Bausch & Lomb Incorporated,"Pentolair, Ophthalmic Solution, 10 Mg/1 Ml (NDC 24208-735-01)",Reverified,9/4/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13987,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclopentolate Hydrochloride Ophthalmic Solution, Usp 1%, Ophthalmic Solution, 10 Mg/1 Ml (NDC 61314-396-03)",Reverified,8/27/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13988,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclopentolate Hydrochloride Ophthalmic Solution, Usp 1%, Ophthalmic Solution, 10 Mg/1 Ml (NDC 61314-396-01)",Reverified,8/27/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13989,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 Mg/1 Ml (NDC 0065-0397-15)",Reverified,8/27/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13990,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 Mg/1 Ml (NDC 0065-0397-05)",Reverified,8/27/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13991,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 Mg/1 Ml (NDC 0065-0397-02)",Reverified,8/27/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13992,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 Mg/1 Ml (NDC 0065-0396-05)",Revised,8/27/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13993,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 Mg/1 Ml (NDC 0065-0396-02)",Revised,8/27/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13994,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 5 Mg/1 Ml (NDC 0065-0395-15)",Reverified,8/27/2024,Available,,,,Ophthalmology,Current,,,,2024,available
13995,Cyclosporine Injection,Padagis Us Llc,"Injection, 250 Mg/5 Ml (50 Mg/Ml) In 5 Ml Ampule (NDC 0574-0866-10)",New,9/29/2023,,Discontinuation Of The Manufacture Of The Product.,,Discontinuation Of The Manufacture Of The Drug,Transplant,To Be Discontinued,,9/29/2023,,2024,discontinued
13996,Cyclosporine Solution,Novartis Pharmaceuticals Corporation,"Sandimmune, Solution, 100 Mg/1 Ml (NDC 0078-0110-22)",New,8/20/2024,,"Novartis Pharmaceuticals Has Made A Business Decision To Permanently Discontinue Sandimmune® Oral Solution (Cyclosporine Oral Solution, Usp).The Product Is Not Available.",,,Transplant,To Be Discontinued,,8/20/2024,,2024,discontinued
13997,Cytarabine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 2 G/20 Ml (NDC 71288-109-20)",Revised,7/12/2024,,,Available,,Oncology; Pediatric,Resolved,7/12/2024,,,2024,
13998,Cytarabine Injection,"Hospira, Inc., A Pfizer Company","Cytarabine, Injection, 50 Ml Vial, 20 Mg/Ml (NDC 61703-303-46)",Revised,7/12/2024,,,Available,,Oncology; Pediatric,Resolved,7/12/2024,,,2024,
13999,Cytarabine Injection,"Hospira, Inc., A Pfizer Company","Cytarabine, Injection, 25 Ml Vial, 20 Mg/Ml (NDC 61703-304-36)",Revised,7/12/2024,,,Available,,Oncology; Pediatric,Resolved,7/12/2024,,,2024,
14000,Cytarabine Injection,"Hospira, Inc., A Pfizer Company","Cytarabine, Injection, 20 Ml Vial, 100 Mg/Ml (NDC 61703-319-22)",Revised,7/12/2024,,,Available,,Oncology; Pediatric,Resolved,7/12/2024,,,2024,
14001,Cytarabine Injection,"Hospira, Inc., A Pfizer Company","Cytarabine, Injection, 5 Ml Vial, 20 Mg/Ml (NDC 61703-305-38)",Revised,7/12/2024,,,Available,,Oncology; Pediatric,Resolved,7/12/2024,,,2024,
14002,Cytarabine Injection,"Fresenius Kabi Usa, Llc","Injection, 20 Ml Vial, 100 Mg/Ml (NDC 63323-120-20)",Revised,7/12/2024,,,Available,,Oncology; Pediatric,Resolved,7/12/2024,,,2024,
14003,Cytarabine Injection,Gland Pharma Limited,"Injection, 5 Ml Vial, 20 Mg/Ml (NDC 25021-229-05)",Revised,7/12/2024,,,Available. Marketed By Sagent Pharmaceuticals.,,Oncology; Pediatric,Resolved,7/12/2024,,,2024,
14004,Cytarabine Injection,Gland Pharma Limited,"Injection, 20 Ml Vial, 100 Mg/Ml (NDC 25021-223-20)",Revised,7/12/2024,,,Available. Marketed By Sagent Pharmaceuticals.,,Oncology; Pediatric,Resolved,7/12/2024,,,2024,
14005,Dacarbazine Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-127-10)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,,2024,available
14006,Dacarbazine Injection,"Hikma Pharmaceuticals Usa, Inc.","Dacarbazine For Injection, Usp, Injection, 200 Mg Per Vial (NDC 0143-9245-10)",Revised,7/25/2024,Unavailable,Additional Lots Will Be Available In The August 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Oncology,Current,,,,2024,not available
14007,Dacarbazine Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-128-20)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,,2024,available
14008,Dacarbazine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 200 Mg/20 Ml (NDC 71288-174-21)",New,7/22/2024,Available,New Launch,,,Oncology,Current,,,,2024,available
14009,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Injection, .5 Mg/1 Ml (NDC 66993-489-35)",New,10/16/2023,,Authorized Generic Distributed By Prasco Laboratories,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,10/16/2023,,2024,discontinued
14010,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Cosmegen, Injection, .5 Mg/1 Ml (NDC 55292-811-55)",New,10/16/2023,,,,,Oncology,To Be Discontinued,,10/16/2023,,2024,discontinued
14011,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Injection, .5 Mg/1 Ml (NDC 66993-489-83)",New,10/16/2023,,Authorized Generic Distributed By Prasco Laboratories,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,10/16/2023,,2024,discontinued
14012,Desmopressin Acetate Spray,Ferring,"Desmopressin Acetate, Spray, 10 Ug/.1 Ml (NDC 69918-501-05)",Reverified,3/15/2024,Unavailable,,,Demand Increase For The Drug,Hematology,Current,,,,2024,not available
14013,Desmopressin Acetate Spray,Apotex Corp.,"Desmopressin Acetate (Needs No Refrigeration), Spray, 10 Ug (NDC 60505-0815-0)",Reverified,9/3/2024,Available,,,,Hematology,Current,,,,2024,available
14014,Desmopressin Acetate Spray,Ferring,"Ddavp, Spray, .1 Ug/1 Ml (NDC 55566-2500-0)",Reverified,3/15/2024,Unavailable,,,Demand Increase For The Drug,Hematology,Current,,,,2024,not available
14015,Desmopressin Acetate Spray,Ferring,"Stimate, Spray, 1.5 Mg/1 Ml (NDC 0053-6871-00)",Reverified,3/15/2024,Unavailable,,,Demand Increase For The Drug,Hematology,Current,,,,2024,not available
14016,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 76045-109-10)",Revised,9/4/2024,Limited Availability,8 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,limited availability
14017,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 76045-106-10)",Revised,9/4/2024,Unavailable,Not Available At This Time.,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,not available
14018,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 100 Mg/10 Ml (NDC 55150-305-10)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,not available
14019,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 10 Mg/1 Ml (NDC 55150-304-25)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,not available
14020,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals Usa, Inc.","Dexamethasone Sodium Phosphate Injection, Usp, Injection, 10 Mg/1 Ml (NDC 0641-0367-25)",Reverified,8/28/2024,Available,Additional Lots Will Be Scheduled For Manufacturing.  Product Will Be Made Available As It Is Released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14021,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals Usa, Inc.","Dexamethasone Sodium Phosphate Injection, Usp, Injection, 4 Mg/1 Ml (NDC 0641-6146-25)",Reverified,8/28/2024,Available,Currently Available.  Additional Product Will Be Made Available As It Is Released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14022,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals Usa, Inc.","Dexamethasone Sodium Phosphate Injection, Usp, Injection, 4 Mg/1 Ml (NDC 0641-6145-25)",Reverified,8/28/2024,Available,Currently Available.  Additional Product Will Be Made Available As It Is Released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14023,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 Mg/1 Ml (NDC 63323-506-01)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,not available
14024,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-165-01)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14025,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-165-30)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14026,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-516-10)",Revised,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,not available
14027,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-165-05)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14028,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, Llc","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 Mg/1 Ml (NDC 70069-021-25)",Reverified,8/30/2024,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14029,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 4 Mg/1 Ml (NDC 55150-239-30)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,not available
14030,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 4 Mg/1 Ml (NDC 55150-238-05)",Revised,8/5/2024,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,not available
14031,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 4 Mg/1 Ml (NDC 55150-237-01)",Revised,8/5/2024,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,not available
14032,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, A Viatris Company","Injection, 10 Mg/1 Ml (NDC 67457-420-10)",Reverified,9/5/2024,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14033,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, A Viatris Company","Injection, 4 Mg/1 Ml (NDC 67457-421-30)",Reverified,9/5/2024,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14034,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, A Viatris Company","Injection, 4 Mg/1 Ml (NDC 67457-422-54)",Reverified,9/5/2024,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14035,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, A Viatris Company","Injection, 4 Mg/1 Ml (NDC 67457-423-12)",Reverified,9/5/2024,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,,2024,available
14036,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 Mcg/Ml, 100 Ml (NDC 70121-1389-1)",Revised,7/9/2024,Available,Sufficient Inventory Available (20 To 25 Wk) As Per Current Demand,,,Anesthesia,Current,,,,2024,available
14037,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 Mcg/Ml, 50 Ml (NDC 70121-1388-1)",Revised,7/9/2024,Available,Sufficient Inventory Available (16 To 20 Wk) As Per Current Demand,,,Anesthesia,Current,,,,2024,available
14038,Dexmedetomidine Hydrochloride Injection,"Meitheal Pharmaceuticals, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 Ug/1 Ml (NDC 71288-505-03)",Revised,7/3/2024,Available,Estimated Recovery End Of August 2024,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,available
14039,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 Ug/1 Ml (NDC 70121-1389-7)",Reverified,7/9/2024,Available,,,,Anesthesia,Current,,,,2024,available
14040,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 Ug/1 Ml (NDC 70121-1388-8)",Reverified,7/9/2024,Available,,,,Anesthesia,Current,,,,2024,available
14041,Dexmedetomidine Hydrochloride Injection,Eugia Us Llc,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 55150-297-10)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14042,Dexmedetomidine Hydrochloride Injection,Eugia Us Llc,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 55150-296-10)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14043,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Dexmedetomidine Hydrochloride, Injection, 400 Ug/100 Ml (NDC 67457-925-10)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14044,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Dexmedetomidine Hydrochloride, Injection, 200 Ug/50 Ml (NDC 67457-924-50)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14045,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 4 Ug/1 Ml (NDC 42023-187-10)",Revised,9/3/2024,Available,Please Check Wholesalers For Inventory,,Other,Anesthesia,Current,,,,2024,available
14046,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 4 Ug/1 Ml (NDC 42023-186-20)",Reverified,9/3/2024,Limited Availability,Please Check Wholesalers For Inventory,,Other,Anesthesia,Current,,,,2024,limited availability
14047,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 43598-975-58)",Revised,7/15/2024,Available,,,,Anesthesia,Current,,,,2024,available
14048,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 43598-976-58)",Revised,7/15/2024,Available,,,,Anesthesia,Current,,,,2024,available
14049,Dexmedetomidine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 Ug/1 Ml (NDC 0143-9532-25)",Reverified,8/28/2024,Available,,,,Anesthesia,Current,,,,2024,available
14050,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 71225-126-06)",Revised,1/15/2024,Available,,,,Anesthesia,Current,,,,2024,available
14051,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 71225-126-05)",Revised,1/15/2024,Available,,,,Anesthesia,Current,,,,2024,available
14052,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 Mcg/2 Ml (100 Mcg/Ml) (NDC 0409-1638-02)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14053,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 Mcg/100 Ml (4 Mcg/Ml) (NDC 0409-1596-10)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14054,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 Mcg/50 Ml (4 Mcg/Ml) (NDC 0409-1660-50)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14055,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 Mcg/20 Ml (4 Mcg/Ml) (NDC 0409-1660-20)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: June 2025,,Other,Anesthesia,Current,,,,2024,limited availability
14056,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 100 Ug/1 Ml (NDC 42023-146-25)",Reverified,9/3/2024,Unavailable,Recovery: Tbd,,Other,Anesthesia,Current,,,,2024,not available
14057,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Dexmedetomidine Hydrochloride, Injection, 100 Ug/1 Ml (NDC 67457-251-02)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14058,Dexmedetomidine Hydrochloride Injection,Hq Specialty Pharma,"Injection, 4 Ug/1 Ml (NDC 44567-603-24)",Reverified,5/18/2024,Available,Marketed By Wg Critical Care,,,Anesthesia,Current,,,,2024,available
14059,Dexmedetomidine Hydrochloride Injection,Hq Specialty Pharma,"Injection, 4 Ug/1 Ml (NDC 44567-602-24)",Reverified,5/18/2024,Available,Marketed By Wg Critical Care,,,Anesthesia,Current,,,,2024,available
14060,Dexmedetomidine Hydrochloride Injection,Hq Specialty Pharma,"Injection, 100 Ug/1 Ml (NDC 44567-601-04)",Reverified,5/18/2024,Available,Marketed By Wg Critical Care,,,Anesthesia,Current,,,,2024,available
14061,Dexmedetomidine Hydrochloride Injection,Hq Specialty Pharma,"Injection, 100 Ug/1 Ml (NDC 44567-600-04)",Reverified,5/18/2024,Available,Marketed By Wg Critical Care,,,Anesthesia,Current,,,,2024,available
14062,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 100 Ug/1 Ml (NDC 63323-421-02)",Revised,9/4/2024,Unavailable,Backordered. Next Release November 2024; Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14063,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Ug/1 Ml (NDC 63323-671-00)",Reverified,9/4/2024,Unavailable,Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
14064,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Ug/1 Ml (NDC 63323-671-50)",Reverified,9/4/2024,Unavailable,Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
14065,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Ug/1 Ml (NDC 63323-671-20)",Revised,9/4/2024,Unavailable,Not Available At This Time.,,Other,Anesthesia,Current,,,,2024,not available
14066,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 Ug/100 Ml (NDC 43066-557-12)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14067,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 Ug/50 Ml (NDC 43066-555-24)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14068,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 Ug/100 Ml (NDC 0338-9557-12)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14069,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 Ug/50 Ml (NDC 0338-9555-24)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14070,Dexmedetomidine Hydrochloride Injection,Eugia Us Llc,"Dexmedetomidine Hydrochloride, Injection, 100 Ug/1 Ml (NDC 55150-209-02)",Reverified,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14071,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Injection, 100 Ug/1 Ml (NDC 16729-432-93)",Reverified,8/19/2024,Unavailable,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anesthesia,Current,,,,2024,not available
14072,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Injection, 100 Ug/1 Ml (NDC 16729-239-93)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia,Current,,,,2024,not available
14073,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Injection, 400 Mcg/100 Ml (NDC 0781-3495-95)",Revised,7/11/2024,Available,Marketed By Sandoz Inc.; Customer Service: 800-525-8747,,,Anesthesia,Current,,,,2024,available
14074,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Injection, 80 Mcg/20 Ml  (NDC 0781-3493-95)",Revised,7/11/2024,Available,Marketed By Sandoz Inc.; Customer Service: 800-525-8747,,,Anesthesia,Current,,,,2024,available
14075,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Injection, 200 Mcg/50 Ml  (NDC 0781-3494-95)",Revised,7/11/2024,Available,Marketed By Sandoz Inc.; Customer Service: 800-525-8747,,,Anesthesia,Current,,,,2024,available
14076,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 Mcg/250 Ml Glass Bottle Novaplus (NDC 0409-2815-01)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14077,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 Mcg/50 Ml (4 Mcg/Ml) (NDC 0409-4596-20)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14078,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 Mcg/250 Ml Single Dose Glass Bottle (NDC 0409-1434-01)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14079,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 Mcg/50 Ml (4 Mcg/Ml) (NDC 0409-1454-20)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14080,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 Mcg/20 Ml (4 Mcg/Ml) (NDC 0409-3301-10)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14081,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 Mcg/100 Ml (4 Mcg/Ml) (NDC 0409-1174-10)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14082,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 Mcg/100 Ml (4 Mcg/Ml) (NDC 0409-0155-02)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14083,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Injection, 200 Ug/2 Ml (NDC 66794-230-42)",Revised,7/15/2024,Available,Marketed By Piramal Critical Care Inc.: 800-414-1901,,,Anesthesia,Current,,,,2024,available
14084,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 G/100 Ml (NDC 0990-7938-19)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7938-19",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14085,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-13)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-13",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14086,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-10)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14087,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 G/100 Ml (NDC 0990-7930-09)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7930-09",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14088,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 G/100 Ml (NDC 0990-7930-03)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7930-03",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14089,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 G/100 Ml (NDC 0990-7930-02)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7930-02",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14090,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 10% In Plastic Container, Injection, 100 Mg/1 Ml (NDC 63323-824-76)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14091,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 10% In Plastic Container, Injection, 100 Mg/1 Ml (NDC 63323-824-75)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14092,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 10% In Plastic Container, Injection, 100 Mg/1 Ml (NDC 63323-824-74)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14093,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 G/100 Ml (NDC 0264-7520-20)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14094,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 G/100 Ml (NDC 0264-7520-10)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14095,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 G/100 Ml (NDC 0264-7520-00)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14096,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 G/1000 Ml (NDC 0338-0023-04)",Revised,6/21/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14097,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 G/1000 Ml (NDC 0338-0023-03)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14098,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 G/1000 Ml (NDC 0338-0023-02)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14099,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-09)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-09",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14100,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-55)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-55",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14101,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-03)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-03",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14102,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 0264-1510-31)",Reverified,9/3/2024,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14103,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 0264-1510-32)",Reverified,9/3/2024,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14104,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 G/100 Ml (NDC 0264-7510-20)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14105,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 G/100 Ml (NDC 0264-7510-00)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14106,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 G/100 Ml (NDC 0264-7510-10)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14107,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0066-20)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14108,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-03)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14109,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0062-30)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14110,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-02)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14111,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0070-10)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14112,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0551-18)",Reverified,9/5/2024,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14113,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-9147-30)",Reverified,9/5/2024,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14114,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 2.5 G/50 Ml (NDC 0338-9143-30)",Reverified,9/5/2024,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14115,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0551-11)",Reverified,9/5/2024,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14116,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-38)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14117,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-18)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14118,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-48)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14119,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-31)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14120,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-11)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14121,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-41)",Reverified,9/5/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14122,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose, Injection, 25 G/50 Ml (50%, 0.5 G/Ml) (NDC 0409-6648-02)",Revised,8/26/2024,Unavailable,Estimated Recovery: September 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
14123,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose, Injection, 25 G/50 Ml (50%, 0.5 G/Ml) Syringes (NDC 0409-4902-34)",Revised,8/26/2024,Unavailable,Next Delivery: January 2025; Estimated Recovery: June 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
14124,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose, Injection, 25 G/50 Ml (50%, 0.5 G/Ml) Syringes (NDC 0409-7517-16)",Revised,8/26/2024,Unavailable,Estimated Recovery: March 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
14125,Dextrose Monohydrate Injection,"Amphastar Pharmaceuticals, Inc.","Dextrose 50%, Injection, 25 G/50 Ml (NDC 76329-3302-1)",Reverified,8/20/2024,Limited Availability,On Allocation,,Demand Increase For The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,limited availability
14126,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose, Injection, 2.5 G/10ml (25%, 250 Mg/ Ml) Syringes (NDC 0409-1775-10)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery And Estimated Recovery: September 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,limited availability
14127,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-37)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-37",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14128,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-36)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-36",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14129,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-23)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-23",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14130,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-20)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-20",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14131,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-61)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-61",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14132,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-02)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-02",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14133,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-50)",Revised,9/4/2024,Limited Availability,7 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,Demand Increase For The Drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
14134,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-10)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14135,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-75)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14136,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-74)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14137,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-61)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14138,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose 5% In Plastic Container, Injection, 12.5 G/250ml (5%) (NDC 0409-7100-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14139,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose 5% In Plastic Container, Injection, 5 G/100ml (5%) Plastic (NDC 0409-7100-67)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14140,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose 5% In Plastic Container, Injection, 2.5 G/50ml (5%, 50mg/Ml) (NDC 0409-7100-66)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,,2024,available
14141,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 G/100 Ml; .4 G/100 Ml (NDC 0264-9594-10)",Reverified,9/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14142,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 G/100 Ml; .4 G/100 Ml (NDC 0264-9594-20)",Reverified,9/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14143,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 G/100 Ml; .8 G/100 Ml (NDC 0264-9598-20)",Reverified,9/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14144,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 2.5 Mg/.5 Ml (NDC 68682-650-20)",Revised,4/19/2024,,,Available,,Neurology,Resolved,4/19/2024,,,2024,
14145,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 10 Mg/2 Ml (NDC 68682-652-20)",Revised,4/19/2024,,,Available,,Neurology,Resolved,4/19/2024,,,2024,
14146,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 20 Mg/4 Ml (NDC 68682-655-20)",Revised,4/19/2024,,,Available,,Neurology,Resolved,4/19/2024,,,2024,
14147,Diazepam Gel,"Lupin Pharmaceuticals, Inc.","Gel, 20 Mg/4 G (NDC 43386-281-01)",Revised,4/19/2024,,,Available,,Neurology,Resolved,4/19/2024,,,2024,
14148,Diazepam Gel,"Lupin Pharmaceuticals, Inc.","Gel, 10 Mg/2 G (NDC 43386-280-01)",Revised,4/19/2024,,,Available,,Neurology,Resolved,4/19/2024,,,2024,
14149,Difluprednate Emulsion,Sandoz Inc.,"Durezol, Emulsion, .5 Mg/1 Ml (NDC 0078-0862-25)",Revised,4/24/2024,,,Available,,Ophthalmology,Resolved,4/24/2024,,,2024,
14150,Difluprednate Emulsion,Amneal Pharmaceuticals,"Difluprednate Ophthalmic Emulsion, Emulsion, .5 Mg/1 Ml (NDC 69238-1380-3)",Revised,4/24/2024,,,Available,,Ophthalmology,Resolved,4/24/2024,,,2024,
14151,Difluprednate Emulsion,Cipla Limited,"Emulsion, .5 Mg/1 Ml (NDC 69097-341-35)",Revised,4/24/2024,,,Available,,Ophthalmology,Resolved,4/24/2024,,,2024,
14152,Difluprednate Emulsion,Sandoz Inc.,"Durezol, Emulsion, .5 Mg/1 Ml (NDC 0781-6000-78)",Revised,4/24/2024,,,Available,,Ophthalmology,Resolved,4/24/2024,,,2024,
14153,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 100 Ug/1 Ml (NDC 70515-263-10)",Revised,5/2/2024,,,Available,,Cardiovascular,Resolved,5/2/2024,,,2024,
14154,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 100 Ug/1 Ml (NDC 70515-262-10)",Revised,5/2/2024,,,Available,,Cardiovascular,Resolved,5/2/2024,,,2024,
14155,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 250 Ug/1 Ml (NDC 70515-261-10)",Revised,5/2/2024,,,Available,,Cardiovascular,Resolved,5/2/2024,,,2024,
14156,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 250 Ug/1 Ml (NDC 70515-260-10)",Revised,5/2/2024,,,Available,,Cardiovascular,Resolved,5/2/2024,,,2024,
14157,Digoxin Injection,Sandoz Inc.,"Injection, 250 Ug/1 Ml (NDC 0781-3059-95)",Revised,5/2/2024,,,Available,,Cardiovascular,Resolved,5/2/2024,,,2024,
14158,Digoxin Injection,"Hikma Pharmaceuticals Usa, Inc.","Digoxin Injection, Usp, Injection, .25 Mg/1 Ml (NDC 0641-1410-35)",Revised,5/2/2024,,,Available,,Cardiovascular,Resolved,5/2/2024,,,2024,
14159,Diltiazem Hydrochloride Injection,Eugia Us Llc,"Injection, 50mg/10ml (NDC 55150-426-10)",Revised,5/22/2024,,,Available,,Cardiovascular,Resolved,5/22/2024,,,2024,
14160,Diltiazem Hydrochloride Injection,Eugia Us Llc,"Injection, 25mg/ 5ml (NDC 55150-425-10)",Revised,5/22/2024,,,Available,,Cardiovascular,Resolved,5/22/2024,,,2024,
14161,Diltiazem Hydrochloride Injection,Eugia Us Llc,"Injection, 125mg/ 25ml (NDC 55150-427-10)",Revised,5/22/2024,,,Available,,Cardiovascular,Resolved,5/22/2024,,,2024,
14162,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 Mg/1 Ml (NDC 70860-301-25)",Reverified,5/22/2024,,,,,Cardiovascular,Resolved,5/22/2024,,,2024,
14163,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 Mg/1 Ml (NDC 70860-301-10)",Reverified,5/22/2024,,,,,Cardiovascular,Resolved,5/22/2024,,,2024,
14164,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 Mg/1 Ml (NDC 70860-301-05)",Reverified,5/22/2024,,,,,Cardiovascular,Resolved,5/22/2024,,,2024,
14165,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 5 Mg/1 Ml (NDC 0641-6015-10)",Revised,5/22/2024,,,,,Cardiovascular,Resolved,5/22/2024,,,2024,
14166,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 5 Mg/1 Ml (NDC 0641-6014-10)",Revised,5/22/2024,,,,,Cardiovascular,Resolved,5/22/2024,,,2024,
14167,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 5 Mg/1 Ml (NDC 0641-6013-10)",Revised,5/22/2024,,,,,Cardiovascular,Resolved,5/22/2024,,,2024,
14168,Diltiazem Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Diltiazem Hydrochloride, Injection, 100 Mg (NDC 0409-4350-03)",Revised,5/22/2024,,,,,Cardiovascular,Resolved,5/22/2024,,,2024,
14169,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, Norpace Ir, 150 Mg  (NDC 0025-2762-31)",Revised,6/4/2024,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/2024,,,2024,
14170,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, Norpace Ir, 100 Mg (NDC 0025-2752-31)",Revised,6/4/2024,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/2024,,,2024,
14171,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, 100 Mg (NDC 59762-0386-1)",Revised,6/4/2024,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/2024,,,2024,
14172,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, Norpace Cr, 150 Mg Extended Release (NDC 0025-2742-31)",Revised,6/4/2024,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/2024,,,2024,
14173,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, Norpace Cr, 100 Mg Extended Release (NDC 0025-2732-31)",Revised,6/4/2024,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/2024,,,2024,
14174,Disopyramide Phosphate Capsule,"Teva Pharmaceuticals Usa, Inc.","Capsule, 150 Mg (NDC 0093-3129-01)",Revised,6/4/2024,,,Available,,Cardiovascular,Resolved,6/4/2024,,,2024,
14175,Disopyramide Phosphate Capsule,"Teva Pharmaceuticals Usa, Inc.","Capsule, 100 Mg (NDC 0093-3127-01)",Revised,6/4/2024,,,Available,,Cardiovascular,Resolved,6/4/2024,,,2024,
14176,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, 150 Mg (NDC 59762-0400-1)",Revised,6/4/2024,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/2024,,,2024,
14177,Disopyramide Phosphate Capsule,"Dr. Reddy'S Laboratories, Inc.","Capsule, 150 Mg (NDC 51862-096-01)",Revised,6/4/2024,,,Available. Marketed By Mayne Pharmaceuticals.,,Cardiovascular,Resolved,,,,2024,
14178,Disopyramide Phosphate Capsule,"Dr. Reddy'S Laboratories, Inc.","Capsule, 100 Mg (NDC 51862-095-01)",Revised,6/4/2024,,,Available. Marketed By Mayne Pharmaceuticals.,,Cardiovascular,Resolved,,,,2024,
14179,Disulfiram Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 250 Mg (NDC 0054-0356-13)",New,11/2/2023,,,,Discontinuation Of The Manufacture Of The Drug,Analgesia/Addiction,To Be Discontinued,,11/2/2023,,2024,discontinued
14180,Disulfiram Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 250 Mg (NDC 0054-0356-25)",New,11/2/2023,,,,Discontinuation Of The Manufacture Of The Drug,Analgesia/Addiction,To Be Discontinued,,11/2/2023,,2024,discontinued
14181,Disulfiram Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 500 Mg (NDC 0054-0357-13)",New,11/2/2023,,,,Discontinuation Of The Manufacture Of The Drug,Analgesia/Addiction,To Be Discontinued,,11/2/2023,,2024,discontinued
14182,Disulfiram Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 500 Mg (NDC 0054-0357-25)",New,11/2/2023,,,,Discontinuation Of The Manufacture Of The Drug,Analgesia/Addiction,To Be Discontinued,,11/2/2023,,2024,discontinued
14183,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride, Injection, 250 Mg/20ml (12.5 Mg/1 Ml) (NDC 0409-2344-02)",Reverified,8/26/2024,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,,2024,available
14184,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 Mg/100 Ml (NDC 0338-1077-02)",Revised,7/17/2024,Available,On Allocation,,,Cardiovascular; Pediatric; Renal,Current,,,,2024,available
14185,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 Mg/100 Ml (NDC 0338-1075-02)",Reverified,9/5/2024,Available,On Allocation,,,Cardiovascular; Pediatric; Renal,Current,,,,2024,available
14186,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Injection, 500 Mg/40 Ml (NDC 70436-204-80)",Revised,11/1/2023,Unavailable,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular; Pediatric; Renal,To Be Discontinued,11/1/2023,11/1/2023,,2024,not available
14187,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Dobutamine Hydrochloride, Injection, 250 Mg/20 Ml (NDC 70436-203-80)",Revised,7/15/2024,"Available, Not Applicable","Distributed By Slate Run Pharmaceuticals, Llc, 1-844-529-8988",,,Cardiovascular; Pediatric; Renal,Current,,,,2024,available
14188,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride, Injection, 250 Mg/20ml (12.5 Mg/1 Ml) (NDC 0409-2344-88)",Reverified,8/26/2024,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,,2024,available
14189,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride, Injection, 250 Mg/20ml (12.5 Mg/1 Ml) (NDC 0409-2344-01)",Reverified,8/26/2024,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,,2024,available
14190,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 Mg/250ml (400 Mg/Ml) (NDC 0409-3724-32)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: September 2024,,Demand Increase For The Drug,Cardiovascular; Pediatric; Renal,Current,,,,2024,not available
14191,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 Mg/250ml (200 Mg/Ml) (NDC 0409-2347-32)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: October 2024; Estimated Recovery: December 2024,,Demand Increase For The Drug,Cardiovascular; Pediatric; Renal,Current,,,,2024,limited availability
14192,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 Mg/250ml (100 Mg/Ml) (NDC 0409-2346-32)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: September 2024,,Demand Increase For The Drug,Cardiovascular; Pediatric; Renal,Current,,,,2024,not available
14193,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 Mg/100 Ml (NDC 0338-1073-02)",Reverified,9/5/2024,Available,On Allocation,,,Cardiovascular; Pediatric; Renal,Current,,,,2024,available
14194,Dofetilide Capsule,Pfizer Inc.,"Tikosyn, Capsule, .125 Mg (NDC 0069-5800-43)",New,4/23/2024,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,4/23/2024,,2024,discontinued
14195,Dofetilide Capsule,Pfizer Inc.,"Tikosyn, Capsule, .25 Mg (NDC 0069-5810-43)",New,4/23/2024,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,4/23/2024,,2024,discontinued
14196,Dofetilide Capsule,Pfizer Inc.,"Tikosyn, Capsule, .5 Mg (NDC 0069-5820-43)",New,4/23/2024,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,4/23/2024,,2024,discontinued
14197,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 Mg/100 Ml (NDC 0338-1007-03)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14198,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 Mg/100 Ml (NDC 0338-1007-02)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14199,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 Mg/100 Ml (NDC 0338-1005-03)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14200,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Dopamine Hcl Injection, Usp, Injection, 40 Mg/1 Ml (NDC 0143-9254-25)",Reverified,8/28/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14201,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Dopamine Hcl Injection, Usp, Injection, 40 Mg/1 Ml (NDC 0143-9252-25)",Revised,7/25/2024,Unavailable,Additional Lots Will Be Available In The October 2024 Timeframe.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Cardiovascular,Current,,,,2024,not available
14202,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 Mg/500 Ml (1.6 Mg/1 Ml) (NDC 0409-7809-24)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: September 2024,,Demand Increase For The Drug,Cardiovascular,Current,,,,2024,not available
14203,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 Mg/250 Ml (1.6 Mg/1 Ml) (NDC 0409-7809-22)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,,Demand Increase For The Drug,Cardiovascular,Current,,,,2024,limited availability
14204,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 Mg/100 Ml (NDC 0338-1005-02)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14205,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride, Injection, 400 Mg/10ml (40 Mg/1 Ml) (NDC 0409-9104-20)",Reverified,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14206,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride, Injection, 200 Mg/5ml (40 Mg/1 Ml) (NDC 0409-5820-01)",Reverified,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14207,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 Mg/250 Ml (3.2 Mg/1 Ml) (NDC 0409-7810-22)",Revised,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14208,Doxycycline Hyclate Capsule,Pfizer Inc.,"Vibramycin, Capsule, 100 Mg (NDC 0069-0950-50)",New,2/1/2024,,Supply Expected To Exhaust Early April 2024,,,Anti-Infective,To Be Discontinued,,,,2024,discontinued
14209,Doxycycline Hyclate Tablet,Apotex Corp.,"Tablet, 75 Mg (NDC 60505-4382-6)",New,4/30/2024,,,,,Anti-Infective,To Be Discontinued,,4/30/2024,,2024,discontinued
14210,Doxycycline Hyclate Tablet,Apotex Corp.,"Tablet, 150 Mg (NDC 60505-4384-6)",New,4/30/2024,,,,,Anti-Infective,To Be Discontinued,,4/30/2024,,2024,discontinued
14211,Dulaglutide Injection,Eli Lilly And Co.,"Trulicity, Injection, 4.5 Mg/.5 Ml (NDC 0002-3182-80)",Revised,9/5/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
14212,Dulaglutide Injection,Eli Lilly And Co.,"Trulicity, Injection, 3 Mg/.5 Ml (NDC 0002-2236-80)",Revised,9/5/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
14213,Dulaglutide Injection,Eli Lilly And Co.,"Trulicity, Injection, 1.5 Mg/.5 Ml (NDC 0002-1434-80)",Revised,9/5/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
14214,Dulaglutide Injection,Eli Lilly And Co.,"Trulicity, Injection, .75 Mg/.5 Ml (NDC 0002-1433-80)",Revised,9/5/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
14215,Echothiophate Iodide Ophthalmic Solution,Fera Pharmaceuticals,"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)",Reverified,1/15/2024,Available Through Limited Distribution By Alliancerx Walgreens Specialty Pharmacy.,,,Delay In Shipping Of The Drug,Ophthalmology,Current,,,,2024,limited availability
14216,Enalaprilat Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 1.25 Mg/1 Ml (NDC 0143-9787-10)",Revised,6/26/2024,,,Available,,Cardiovascular,Resolved,6/26/2024,,,2024,
14217,Enalaprilat Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 2.5 Mg/2 Ml (NDC 0143-9786-10)",Revised,6/26/2024,,,Available,,Cardiovascular,Resolved,6/26/2024,,,2024,
14218,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 20 Mg/1 Ml (NDC 63323-489-27)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14219,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 15 Mg/1 Ml (NDC 63323-488-37)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14220,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-487-37)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14221,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 20 Mg/1 Ml (NDC 63323-483-57)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14222,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 20 Mg/1 Ml (NDC 63323-483-27)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14223,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-482-57)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14224,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-482-27)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14225,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 5 Mg/1 Ml (NDC 63323-481-57)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14226,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 Mg/20 Ml (2%; 1:200,000) (NDC 0409-3183-01)",Revised,8/26/2024,Unavailable,Next Delivery: February 2025; Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14227,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 1 G/50 Ml (2%; 1:100,000) (NDC 0409-3182-03)",Revised,8/26/2024,Unavailable,Next Delivery: July 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14228,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 600 Mg/30 Ml (2%; 1:100,000) (NDC 0409-3182-02)",Revised,8/26/2024,Unavailable,Next Delivery: July 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14229,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 Mg/20 Ml (2%; 1:100,000) (NDC 0409-3182-01)",Revised,8/26/2024,Unavailable,Next Delivery: July 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14230,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 450 Mg/30 Ml (1.5%; 1:200,000) (NDC 0409-3181-01)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14231,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 75 Mg/5 Ml (1.5%; 1:200,000) (NDC 0409-1209-01)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14232,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 500 Mg/50 Ml (1%; 1:100,000) (NDC 0409-3178-03)",Revised,8/26/2024,Unavailable,Next Delivery: February 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14233,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 300 Mg/30 Ml (1%; 1:100,000) (NDC 0409-3178-02)",Revised,8/26/2024,Unavailable,Next Delivery: November 2024; Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14234,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 200 Mg/20 Ml (1%; 1:100,000) (NDC 0409-3178-01)",Revised,8/26/2024,Unavailable,Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14235,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 G/50 Ml (0.5%; 1:200,000) (NDC 0409-3177-01)",Revised,8/26/2024,Unavailable,Next Delivery: April 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14236,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 20 Mg/1 Ml (NDC 63323-489-17)",Revised,9/4/2024,Available,8 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,,Anesthesia; Pediatric,Current,,,,2024,available
14237,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 15 Mg/1 Ml (NDC 63323-488-17)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14238,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-487-17)",Revised,9/4/2024,Available,8 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,,Anesthesia; Pediatric,Current,,,,2024,available
14239,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-482-17)",Revised,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14240,"Epinephrine Injection, Syringes","Amphastar Pharmaceuticals, Inc.","Injection, Syringes, 0.1 Mg/Ml (NDC 76329-3318-1)",Revised,8/20/2024,Available,Available On Allocation,,,Cardiovascular; Pulmonary/Allergy,Current,,,,2024,available
14241,"Epinephrine Injection, Syringes","Hospira, Inc., A Pfizer Company","Injection, Syringes, 1 Mg/10 Ml (0.1 Mg/1 Ml) (NDC 0409-4933-01)",Revised,8/26/2024,Unavailable,Next Delivery: January 2025; Estimated Recovery: June 2025,,Other,Cardiovascular; Pulmonary/Allergy,Current,,,,2024,not available
14242,Epinephrine Solution,Adamis Pharmaceuticals Corporation,"Symjepi, Solution, 0.15 Mg/0.3 Ml  (NDC 78670-131-02)",New,9/18/2023,,,,,Pulmonary/Allergy,To Be Discontinued,,9/18/2023,,2024,discontinued
14243,Erythromycin Ointment,Bausch & Lomb Incorporated,"Erythromycin, Ointment, 5 Mg/1 G (NDC 24208-910-19)",Revised,7/2/2024,,,Available,,Ophthalmology; Pediatric,Resolved,7/2/2024,,,2024,
14244,Erythromycin Ointment,Bausch & Lomb Incorporated,"Erythromycin, Ointment, 5 Mg/1 G (NDC 24208-910-55)",Revised,7/2/2024,,,Available,,Ophthalmology; Pediatric,Resolved,7/2/2024,,,2024,
14245,Erythromycin Ointment,Armas Pharmaceuticals Inc,"Ointment, 0.5% 1 -Gram Tube (NDC 72485067031)",Revised,7/2/2024,,,Available,,Ophthalmology; Pediatric,Resolved,7/2/2024,,,2024,
14246,Erythromycin Ointment,Armas Pharmaceuticals Inc,"Ointment, 0.5% 3.5-Gram Tubes (NDC 72485067035)",Revised,7/2/2024,,,Available,,Ophthalmology; Pediatric,Resolved,7/2/2024,,,2024,
14247,Estradiol Valerate Injection,"Par Pharmaceutical, Inc.","Delestrogen, Injection, 40 Mg/1 Ml (NDC 42023-112-01)",New,6/4/2024,,,,,Reproductive,To Be Discontinued,,6/4/2024,,2024,discontinued
14248,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 72572-161-10)",Reverified,8/28/2024,Pending Information,Distributed By Civica,,,Anesthesia,Current,,,,2024,unclear
14249,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 72572-160-10)",Reverified,8/28/2024,Pending Information,Distributed By Civica,,,Anesthesia,Current,,,,2024,unclear
14250,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 40 Mg/20 Ml (NDC 65219-445-20)",Reverified,7/16/2024,Available,Check Wholesalers For Inventory; Marketed By Fresenius Kabi,,,Anesthesia,Current,,,,2024,available
14251,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 65219-445-10)",Reverified,7/16/2024,Available,Check Wholesalers For Inventory; Marketed By Fresenius Kabi,,,Anesthesia,Current,,,,2024,available
14252,Etomidate Injection,"Hospira, Inc., A Pfizer Company","Amidate, Injection, 2 Mg/Ml (NDC 0409-6695-02)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14253,Etomidate Injection,"Hospira, Inc., A Pfizer Company","Amidate, Injection, 2 Mg/1 Ml (NDC 0409-6695-01)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14254,Etomidate Injection,"Mylan Institutional, A Viatris Company","Etomidate, Injection, 2 Mg/1 Ml (NDC 67457-903-20)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14255,Etomidate Injection,"Mylan Institutional, A Viatris Company","Etomidate, Injection, 2 Mg/1 Ml (NDC 67457-902-10)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14256,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0143-9311-10)",Reverified,8/28/2024,Pending Information,Novaplus,,,Anesthesia,Current,,,,2024,unclear
14257,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0143-9310-10)",Reverified,8/28/2024,Pending Information,Novaplus,,,Anesthesia,Current,,,,2024,unclear
14258,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0143-9507-10)",Reverified,8/28/2024,Available,Additional Lots Will Be Available.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,,2024,available
14259,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0143-9506-10)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,,2024,available
14260,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 Mg/1 Ml (NDC 72266-147-10)",Reverified,7/15/2024,Available,"Distributed By Fosun Pharma Usa, Inc.. To Order, Contact: 833-291-9645.",,,Anesthesia,Current,,,,2024,available
14261,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 Mg/1 Ml (NDC 72266-146-10)",Reverified,7/15/2024,Available,"Distributed By Fosun Pharma Usa, Inc.. To Order, Contact: 833-291-9645.",,,Anesthesia,Current,,,,2024,available
14262,Etomidate Injection,Eugia Us Llc,"Injection, 40 Mg/20 Ml (NDC 55150-222-20)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14263,Etomidate Injection,Eugia Us Llc,"Injection, 20 Mg/10 Ml (NDC 55150-221-10)",Reverified,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14264,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 65219-447-20)",Revised,8/14/2024,Available,Check Wholesalers For Inventory; Marketed By Fresenius Kabi,,,Anesthesia,Current,,,,2024,available
14265,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 72485-508-10)",Revised,8/14/2024,Available,"Check Wholesalers For Inventory; Marketed By Armas Pharmaceuticals, Inc.",,,Anesthesia,Current,,,,2024,available
14266,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 72485-509-10)",Revised,8/14/2024,Available,"Check Wholesalers For Inventory; Marketed By Armas Pharmaceuticals, Inc.",,,Anesthesia,Current,,,,2024,available
14267,Evolocumab Injection,Amgen Inc.,"Repatha, Injection, 1 Kit In 1 Carton (55513-770-01) * 1 Cartridge In 1 Tray / 3.5 Ml In 1 Cartridge (NDC 55513-770-01)",New,4/12/2024,,,,,Cardiovascular,To Be Discontinued,,4/12/2024,,2024,discontinued
14268,Evolocumab Injection,Amgen Inc.,"Repatha, Injection, 1 Kit In 1 Carton (72511-770-01) * 1 Cartridge In 1 Tray / 3.5 Ml In 1 Cartridge (NDC 72511-770-01)",New,4/12/2024,,,,,Cardiovascular,To Be Discontinued,,4/12/2024,,2024,discontinued
14269,Felbamate Oral Suspension,"Mylan Specialty, A Viatris Company","Felbatol®, Oral Suspension, 32 Oz Each 5 Ml Contains 600 Mg Felbamate (NDC 0037-0442-17)",New,11/27/2023,,,,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,11/27/2023,,2024,discontinued
14270,Felbamate Oral Suspension,"Mylan Specialty, A Viatris Company","Felbatol® , Oral Suspension, 8 Oz Each 5 Ml Contains 600 Mg Felbamate (NDC 0037-0442-67)",New,11/27/2023,,,,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,11/27/2023,,2024,discontinued
14271,Fenofibrate Tablet,Viatris,"Tablet, 54 Mg (NDC 0378-7100-77)",New,10/16/2023,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,10/16/2023,,2024,discontinued
14272,Fenofibrate Tablet,Viatris,"Tablet, 160 Mg (NDC 0378-7101-77)",New,10/16/2023,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,10/16/2023,,2024,discontinued
14273,Fenofibrate Tablet,Abbvie Inc.,"Tricor, Tablet, 48 Mg (NDC 0074-3173-90)",New,10/16/2023,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,10/16/2023,10/16/2023,,2024,discontinued
14274,Fenofibrate Tablet,Abbvie Inc.,"Tricor, Tablet, 145 Mg (NDC 0074-3189-90)",New,10/16/2023,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,10/16/2023,,2024,discontinued
14275,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6247-25)",Reverified,8/28/2024,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14276,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Injection, 50 Ug/1 Ml (NDC 63323-808-11)",Reverified,8/15/2024,Unavailable,Backordered. Next Releast August 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,,2024,not available
14277,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-05)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14278,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-02)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14279,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-01)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14280,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-50)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14281,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-20)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14282,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6030-01)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14283,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6029-25)",Reverified,8/28/2024,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14284,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6028-25)",Reverified,7/25/2024,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14285,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6027-25)",Reverified,8/28/2024,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14286,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Ug/1 Ml (NDC 0641-6026-05)",Reverified,8/28/2024,Unavailable,Inventory Available In Vial Presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2024,not available
14287,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Ug/1 Ml (NDC 0641-6025-10)",Reverified,8/28/2024,Unavailable,Inventory Available In Vial Presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2024,not available
14288,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Ug/1 Ml (NDC 0641-6024-10)",Reverified,8/28/2024,Unavailable,Inventory Available In Vial Presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,,2024,not available
14289,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 2500 Mcg/50 Ml (50 Ug/1 Ml) (NDC 0409-9094-61)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14290,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 1000 Mcg/20 Ml (50 Ug/1 Ml) (NDC 0409-9094-31)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14291,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 500 Mcg/10 Ml (50 Ug/1 Ml) (NDC 0409-9094-28)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14292,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 250 Mcg/5 Ml (50 Ug/1 Ml) (NDC 0409-9094-25)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14293,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 100 Mcg/2 Ml (50 Ug/1 Ml) (NDC 0409-9094-22)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction; Pediatric,Current,,,,2024,available
14294,"Fesoterodine Fumarate  Tablet, Extended Release",Ani Pharmaceuticals,"Tablet, Extended Release, 8 Mg (NDC 62559-376-90)",New,4/30/2024,,,,,Urology,To Be Discontinued,,4/30/2024,,2024,discontinued
14295,"Fesoterodine Fumarate  Tablet, Extended Release",Ani Pharmaceuticals,"Tablet, Extended Release, 8 Mg (NDC 62559-376-30)",New,4/30/2024,,,,,Urology,To Be Discontinued,,4/30/2024,,2024,discontinued
14296,"Fesoterodine Fumarate  Tablet, Extended Release",Ani Pharmaceuticals,"Tablet, Extended Release, 4 Mg (NDC 62559-375-30)",New,4/30/2024,,,,,Urology,To Be Discontinued,,4/30/2024,,2024,discontinued
14297,"Fesoterodine Fumarate  Tablet, Extended Release",Ani Pharmaceuticals,"Tablet, Extended Release, 4 Mg (NDC 62559-375-90)",New,4/30/2024,,,,,Urology,To Be Discontinued,,4/30/2024,,2024,discontinued
14298,Fluconazole Injection,Sagent Pharmaceuticals,"Fluconazole In Sodium Chloride 0.9% In Plastic Container, Injection, 2 Mg/1 Ml (NDC 25021-184-82)",Reverified,5/21/2024,,,,,Anti-Infective,Resolved,5/21/2024,,,2024,
14299,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 50 Mg  (NDC 0049-3410-30)",Revised,10/24/2023,,Discontinuation Of The Manufacture Of The Drug,,,Anti-Infective,To Be Discontinued,,10/24/2023,,2024,discontinued
14300,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 100 Mg (NDC 0049-3420-41)",New,6/14/2024,,Discontinuation Of The Manufacture Of The Drug.,,,Anti-Infective,To Be Discontinued,,6/14/2024,,2024,discontinued
14301,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 200 Mf (NDC 0049-3430-41)",New,3/28/2024,,Discontinuation Of The Manufacture Of The Drug.,,,Anti-Infective,To Be Discontinued,,3/28/2024,,2024,discontinued
14302,Fludarabine Phosphate Injection,"Teva Pharmaceuticals Usa, Inc.","Cytostatikum Fludarabin Actavis 25 Mg/Ml, Injection, 25 Mg/1 Ml (NDC 0480-9772-01)",Revised,4/17/2024,,,Available,,Oncology,Resolved,4/17/2024,,,2024,
14303,Fludarabine Phosphate Injection,"Teva Pharmaceuticals Usa, Inc.","Fludarabine Phosphate For Injection, Usp (Lyophilized), Injection, 25 Mg/1 Ml (NDC 45963-621-51)",Revised,4/17/2024,,,Available,,Oncology,Resolved,4/17/2024,,,2024,
14304,Fludarabine Phosphate Injection,Accord Healthcare Inc.,"Fludarabine Phosphate, Injection, 25 Mg/1 Ml (NDC 16729-131-30)",Revised,11/14/2022,Product Anticipated 11/21/2022,,,,Oncology,Current,,,,2024,not available
14305,Fludarabine Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 25 Mg/1 Ml (NDC 63323-192-02)",Revised,4/17/2024,,,Available,,Oncology,Resolved,4/17/2024,,,2024,
14306,Fludarabine Phosphate Injection,"Teva Pharmaceuticals Usa, Inc.","Fludarabine Phosphate For Injection, Usp (Lyophilized), Injection, 50 Mg/2 Ml (NDC 45963-609-55)",Revised,4/17/2024,,,Available,,Oncology,Resolved,4/17/2024,,,2024,
14307,Fludarabine Phosphate Injection,"Areva Pharmaceuticals, Inc.","Injection, 25 Mg/1 Ml (NDC 59923-604-02)",Revised,4/17/2024,,,Available,,Oncology,Resolved,4/17/2024,,,2024,
14308,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings Llc,"Flurazepam Hydrochloride, Capsule, 30 Mg (NDC 62135-737-90)",Reverified,9/2/2024,Available,,,,Neurology; Other,Current,,,,2024,available
14309,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings Llc,"Flurazepam Hydrochloride, Capsule, 15 Mg (NDC 62135-736-90)",Reverified,9/2/2024,Available,,,,Oncology; Other,Current,,,,2024,available
14310,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Capsule, 30 Mg (NDC 0378-4430-01)",Revised,7/2/2024,Unavailable,Anticipated Availability: Q1 2025; Delay Is Due To Manufacturing Delays At The Contract Manufacturing Facility.,,Regulatory Delay,Neurology; Other,Current,,,,2024,not available
14311,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Capsule, 15 Mg (NDC 0378-4415-01)",Revised,7/2/2024,Unavailable,Anticipated Availability: Q1 2025; Delay Is Due To Manufacturing Delays At The Contract Manufacturing Facility.,,Regulatory Delay,Neurology; Other,Current,,,,2024,not available
14312,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings Llc,"Capsule, 30 Mg (NDC 62135-737-30)",Reverified,9/2/2024,Available,,,,Neurology; Other,Current,,,,2024,available
14313,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings Llc,"Capsule, 15 Mg (NDC 62135-736-30)",Reverified,9/2/2024,Available,,,,Neurology; Other,Current,,,,2024,available
14314,"Fluticasone Propionate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Armonair Digihaler, Powder, Metered, 55 Ug (NDC 59310-114-06)",New,4/30/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/2024,,2024,discontinued
14315,"Fluticasone Propionate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Armonair Digihaler, Powder, Metered, 113 Ug/1 (NDC 59310-200-06)",New,4/30/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/2024,,2024,discontinued
14316,"Fluticasone Propionate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Armonair Digihaler, Powder, Metered, 232 Ug/1 (NDC 59310-311-06)",New,4/30/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/2024,,2024,discontinued
14317,"Fluticasone Propionate; Salmeterol Xinafoate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Airduo Digihaler, Powder, Metered, 55 Ug; 14 Ug (NDC 59310-111-06)",New,4/30/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/2024,,2024,discontinued
14318,"Fluticasone Propionate; Salmeterol Xinafoate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Airduo Digihaler, Powder, Metered, 113 Ug; 14 Ug (NDC 59310-129-06)",New,4/30/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/2024,,2024,discontinued
14319,"Fluticasone Propionate; Salmeterol Xinafoate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Airduo Digihaler, Powder, Metered, 232 Ug; 14 Ug (NDC 59310-136-06)",New,4/30/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/2024,,2024,discontinued
14320,Fulvestrant Solution,"Teva Pharmaceuticals Usa, Inc.","Solution, 250 Mg/5 Ml (NDC 0591-5019-02)",New,10/26/2023,,Business Decision To Discontinue.,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,10/26/2023,,2024,discontinued
14321,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 70860-302-10)",Revised,7/30/2024,Unavailable,Use Sagent Ndc 25021-311-10,,Other,Cardiovascular,Current,,,,2024,not available
14322,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 70860-302-04)",Revised,7/30/2024,Unavailable,Use Sagent Ndc 25021-311-04,,Other,Cardiovascular,Current,,,,2024,not available
14323,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 70860-302-02)",Revised,7/30/2024,Unavailable,Use Sagent Ndc 25021-311-02,,Other,Cardiovascular,Current,,,,2024,not available
14324,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 71288-203-11)",Reverified,7/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14325,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 71288-203-05)",Reverified,7/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14326,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/Ml, 2 Ml (NDC 71288-205-03)",Reverified,7/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14327,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Injection, 100 Mg/ 10ml (10 Mg/1 Ml) (NDC 0409-6102-27)",Reverified,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14328,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-502-43)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,,2024,not available
14329,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-501-43)",Reverified,8/19/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14330,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-500-08)",Revised,8/19/2024,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,,2024,not available
14331,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/Ml, 10 Ml (NDC 70860-302-43)",Revised,3/6/2024,,This Presentation Has Been Discontinued,,,Cardiovascular,To Be Discontinued,3/6/2024,3/6/2024,,2024,discontinued
14332,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/Ml, 4 Ml (NDC 70860-302-42)",Revised,3/6/2024,,This Presentation Has Been Discontinued,,,Cardiovascular,To Be Discontinued,3/6/2024,3/6/2024,,2024,discontinued
14333,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/Ml, 2 Ml (NDC 70860-302-41)",Revised,3/6/2024,,This Presentation Has Been Discontinued,,,Cardiovascular,To Be Discontinued,3/6/2024,3/6/2024,,2024,discontinued
14334,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 25021-311-10)",Reverified,7/1/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14335,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 25021-311-04)",Reverified,7/1/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14336,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 25021-311-02)",Reverified,7/1/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14337,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 Mg/1 Ml (NDC 25021-311-10)",Revised,7/15/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14338,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 Mg/1 Ml (NDC 25021-311-04)",Revised,7/15/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14339,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 Mg/1 Ml (NDC 25021-311-02)",Revised,7/15/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14340,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 Mg/1 Ml (NDC 36000-283-25)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14341,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 Mg/1 Ml (NDC 36000-282-25)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14342,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 Mg/1 Ml (NDC 36000-284-25)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14343,Furosemide Injection,Eugia Us Llc,"Injection, 100 Mg/10 Ml (NDC 55150-324-25)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Cardiovascular,Current,,,,2024,available
14344,Furosemide Injection,Eugia Us Llc,"Injection, 40 Mg/4 Ml (NDC 55150-323-25)",Reverified,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Cardiovascular,Current,,,,2024,not available
14345,Furosemide Injection,Eugia Us Llc,"Injection, 20 Mg/2 Ml (NDC 55150-322-25)",Reverified,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Cardiovascular,Current,,,,2024,not available
14346,Furosemide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-280-10)",Reverified,8/15/2024,Available,Check Wholesalers For Inventory.,,,Cardiovascular,Current,,,,2024,available
14347,Furosemide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-280-04)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
14348,Furosemide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-280-02)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Cardiovascular,Current,,,,2024,available
14349,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Injection, 40 Mg/4 Ml (10 Mg/1 Ml) (NDC 0409-6102-26)",Reverified,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14350,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Furosemide, Injection, 20 Mg/2 Ml (10 Mg/1 Ml) (NDC 0409-6102-25)",Reverified,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14351,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Furosemide, Injection, 100 Mg/ 10ml (10 Mg/1 Ml) (NDC 0409-6102-10)",Reverified,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14352,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Injection, 40 Mg/4 Ml (10 Mg/1 Ml) (NDC 0409-6102-04)",Reverified,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14353,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Injection, 20 Mg/2 Ml (10 Mg/1 Ml) (NDC 0409-6102-02)",Reverified,8/26/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14354,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 23155-473-44)",Reverified,9/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14355,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 23155-473-42)",Reverified,9/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14356,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 23155-473-41)",Reverified,9/3/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14357,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml; 4ml Vial (NDC 83634-302-04)",Revised,9/3/2024,Available,Distributed By Avenacy; Contact Information: 877-283-6229,,,Cardiovascular,Current,,,,2024,available
14358,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml; 2ml Vial (NDC 83634-302-02)",Revised,9/3/2024,Available,Distributed By Avenacy; Contact Information: 877-283-6229,,,Cardiovascular,Current,,,,2024,available
14359,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 83634-302-10)",Reverified,9/3/2024,Available,Distributed By Avenacy; Contact Information: 877-283-6229,,,Cardiovascular,Current,,,,2024,available
14360,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 60 Mg/50 Ml (NDC 0338-0507-48)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14361,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 100 Mg/100 Ml (NDC 0338-0505-48)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14362,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 100 Mg/50 Ml (NDC 0338-0511-41)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14363,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 80 Mg/100 Ml (NDC 0338-0503-48)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14364,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 80 Mg/50 Ml (NDC 0338-0509-41)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14365,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 60 Mg/50 Ml (NDC 0338-0507-41)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14366,Gentamicin Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 40 Mg/1 Ml (NDC 0143-9128-25)",Revised,7/24/2024,,,,,Anti-Infective,Resolved,7/24/2024,,,2024,
14367,Gentamicin Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 40 Mg/1 Ml (NDC 63323-010-02)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14368,Gentamicin Sulfate Injection,"Hospira, Inc., A Pfizer Company","Gentamicin Sulfate, Injection, 40 Mg/1 Ml (NDC 0409-1207-25)",Revised,3/29/2024,,,,,Anti-Infective,To Be Discontinued,3/29/2024,3/29/2024,,2024,discontinued
14369,Gentamicin Sulfate Injection,"Hospira, Inc., A Pfizer Company","Injection, 80 Mg/2 Ml (40 Mg/Ml) (NDC 0409-1207-03)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14370,Gentamicin Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-173-02)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14371,Gentamicin Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 40 Mg/1 Ml (NDC 63323-010-20)",Revised,7/24/2024,,,Available,,Anti-Infective,Resolved,7/24/2024,,,2024,
14372,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucotrol Xl, Tablet, Extended Release, 5 Mg (NDC 0049-0174-02)",New,8/5/2024,,Supply Expected To Exhaust Mid September 2024; Discontinuation Of The Manufacture Of The Drug,,,Endocrinology/Metabolism,To Be Discontinued,,8/5/2024,,2024,discontinued
14373,Glucagon Hydrochloride Injection,Novo Nordisk,"Glucagen, Injection, 1 Mg/1 Ml (NDC 0169-7065-15)",New,11/15/2023,,"Will Be Unavailable After July 1, 2024",,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,To Be Discontinued,,11/18/2022,,2024,discontinued
14374,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [Usp'U]/100 Ml (NDC 0264-9872-10)",Reverified,9/3/2024,Available,,,,Hematology,Current,,,,2024,available
14375,Heparin Sodium Injection,"Fresenius Kabi Usa, Llc","Injection, 200 [Usp'U]/100 Ml (NDC 63323-519-10)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Hematology,Current,,,,2024,available
14376,Heparin Sodium Injection,"Fresenius Kabi Usa, Llc","Injection, 200 [Usp'U]/100 Ml (NDC 63323-519-77)",Reverified,9/4/2024,Available,Check Wholesaler For Inventory,,,Hematology,Current,,,,2024,available
14377,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [Usp'U]/100 Ml (NDC 0338-0424-18)",Reverified,9/5/2024,Available,On Allocation; Product Code Ahb0953u Replaces Code 2b0953,,,Hematology,Current,,,,2024,available
14378,Heparin Sodium Injection,"Hospira, Inc., A Pfizer Company","Heparin Sodium, Injection, 2,000 Units/1,000 Ml (2 Units/Ml) (NDC 0409-7620-59)",Revised,8/26/2024,Limited Availability,Estimated Recovery: September 2024,,Other,Hematology,Current,,,,2024,limited availability
14379,Heparin Sodium Injection,"Hospira, Inc., A Pfizer Company","Heparin Sodium, Injection, 1,000 Units/500 Ml (2 Units/Ml) (NDC 0409-7620-03)",Reverified,8/26/2024,Available,,,,Hematology,Current,,,,2024,available
14380,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [Usp'U]/100 Ml (NDC 0338-0431-03)",Reverified,9/5/2024,Unavailable,,,,Hematology,Current,,,,2024,not available
14381,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [Usp'U]/100 Ml (NDC 0338-0433-04)",Revised,5/13/2024,Limited Availability,On Allocation; Recovery June 2024,,Demand Increase For The Drug,Hematology,Current,,,,2024,limited availability
14382,Hydrochlorothiazide; Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 Mg; 20 Mg (NDC 59762-0223-1)",New,10/2/2023,,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Antibiotic; Cardiovascular,To Be Discontinued,,10/2/2023,,2024,discontinued
14383,Hydrochlorothiazide; Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accuretic, Tablet, 12.5 Mg; 10 Mg (NDC 59762-0222-1)",New,10/2/2023,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,10/2/2023,,2024,discontinued
14384,Hydrochlorothiazide; Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accuretic, Tablet, 12.5 Mg; 20 Mg (NDC 59762-0220-1)",New,10/2/2023,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,10/2/2023,,2024,discontinued
14385,Hydrocortisone Probutate Cream,Ani Pharmaceuticals,"Pandel, Cream, 1 Mg/1 G (NDC 62559-325-26)",New,8/21/2024,,"Business Decision To Discontinue Product Manufacturing. Ani Anticipates Ceasing Distribution Of All Configurations On September 30, 2024.",,,Dermatology,To Be Discontinued,,8/21/2024,,2024,discontinued
14386,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 500 Mg/Vial (NDC 0009-0016-12)",Reverified,8/26/2024,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2024,available
14387,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 250 Mg/Vial (NDC 0009-0013-05)",Reverified,8/26/2024,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2024,available
14388,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 250 Mg/Vial (NDC 0009-0013-06)",Reverified,8/26/2024,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2024,available
14389,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 100 Mg/Vial (NDC 0009-0011-03)",Reverified,8/26/2024,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2024,available
14390,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 100 Mg/Vial (NDC 0009-0011-04)",Reverified,8/26/2024,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2024,available
14391,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 100 Mg/Vial (NDC 0009-0825-01)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,,Demand Increase For The Drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2024,limited availability
14392,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 1000 Mg/Vial (NDC 0009-0005-01)",Reverified,8/26/2024,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,,2024,available
14393,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Dilaudid, Injection, 2 Mg/1 Ml (NDC 76045-010-11)",Reverified,9/4/2024,Unavailable,Backordered. Next Release Not Available At This Time. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14394,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Dilaudid, Injection, .2 Mg/1 Ml (NDC 76045-121-11)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14395,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Dilaudid, Injection, 1 Mg/1 Ml (NDC 76045-009-11)",Revised,8/21/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14396,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-851-50)",Reverified,9/4/2024,Unavailable,Backordered. Next Release Not Available At This Time. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14397,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-851-15)",Reverified,8/15/2024,Unavailable,Backordered. Next Release August 2024; Check Wholesalers For Inventory.,,Delay In Shipping Of The Drug,Analgesia/Addiction,Current,,,,2024,not available
14398,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-851-10)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14399,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-854-10)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14400,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 2 Mg/1 Ml (NDC 63323-853-25)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024;  Check Wholesalers For Inventory,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14401,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-852-25)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14402,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Hydromorphone Hcl Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0641-2341-41)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14403,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Hydromorphone Hcl Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0641-0121-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14404,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals Usa, Inc.","Hydromorphone Hydrochloride Injection, Usp Cii, Injection, 10 Mg/1 Ml (NDC 0703-0018-01)",Revised,8/23/2024,Unavailable,Estimated Recovery Tbd,,Other,Analgesia/Addiction,Current,,,,2024,not available
14405,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals Usa, Inc.","Hydromorphone Hydrochloride Injection, Usp Cii, Injection, 10 Mg/1 Ml (NDC 0703-0113-03)",Revised,8/23/2024,Unavailable,Estimated Recovery Tbd,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14406,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals Usa, Inc.","Hydromorphone Hydrochloride Injection, Usp Cii, Injection, 10 Mg/1 Ml (NDC 0703-0110-03)",Revised,8/23/2024,Unavailable,Estimated Recovery Tbd,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14407,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 Mg/1 Ml (NDC 0409-2552-01)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: June 2025,,Other,Analgesia/Addiction,Current,,,,2024,not available
14408,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 500 Mg/50 Ml (10 Mg/Ml) (NDC 0409-2634-50)",Revised,8/26/2024,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Other,Analgesia/Addiction,Current,,,,2024,not available
14409,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 0409-2634-05)",Revised,8/26/2024,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Other,Analgesia/Addiction,Current,,,,2024,not available
14410,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 Mg/1 Ml (NDC 0409-2634-01)",Revised,8/26/2024,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Other,Analgesia/Addiction,Current,,,,2024,not available
14411,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 4 Mg/1 Ml Syringes (NDC 0409-1304-31)",Revised,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14412,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 Mg/1 Ml Syringes (NDC 0409-1312-30)",Revised,8/26/2024,Limited Availability,Limited Supply Available; Estimated Recovery: September 2024,,Other,Analgesia/Addiction,Current,,,,2024,limited availability
14413,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 Mg/1 Ml Syringes (NDC 0409-1283-31)",Revised,8/26/2024,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Analgesia/Addiction,Current,,,,2024,limited availability
14414,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Dilaudid, Injection, 1 Mg/1 Ml (NDC 76045-009-06)",Revised,8/21/2024,Unavailable,Backordered. Next Release August 2024.  Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
14415,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 2 Mg/1 Ml (NDC 0409-1312-36)",Revised,8/26/2024,Unavailable,Next Delivery: November 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Analgesia/Addiction,Current,,,,2024,not available
14416,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Mg/1 Ml (NDC 0409-1283-37)",Revised,8/26/2024,Unavailable,Next Delivery: October 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Analgesia/Addiction,Current,,,,2024,not available
14417,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 2 Mg/1 Ml (NDC 0409-3365-10)",Revised,8/26/2024,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Analgesia/Addiction,Current,,,,2024,not available
14418,Hydroxocobalamin Injection,"Teva Pharmaceuticals Usa, Inc.","Hydroxocobalamin Injection Usp, Injection, 1000 Ug/1 Ml (NDC 0591-2888-30)",Revised,9/12/2024,,,,,Endocrinology/Metabolism,Resolved,9/12/2024,,,2024,
14419,Hydroxypropyl Cellulose (1600000 Wamw) Insert,Bausch & Lomb Incorporated,"Lacrisert, Insert, 5 Mg (NDC 24208-800-60)",Reverified,9/4/2024,Unavailable,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Ophthalmology,Current,,,,2024,not available
14420,Iloprost Solution,Actelion Pharmaceuticals,"Ventavis, Solution, 10 Ug/1 Ml (NDC 66215-302-30)",New,5/9/2024,,"Philips Respironics Has Decided To Discontinue The I-Neb® Aad® System And Its Associated Supplies, Including The Medication Discs Required For Administering Ventavis® Inhalation Solution.",,,Pulmonary/Allergy,To Be Discontinued,,5/9/2024,,2024,discontinued
14421,Iloprost Solution,Actelion Pharmaceuticals,"Ventavis, Solution, 20 Ug/1 Ml (NDC 66215-303-30)",New,5/9/2024,,"Philips Respironics Has Decided To Discontinue The I-Neb® Aad® System And Its Associated Supplies, Including The Medication Discs Required For Administering Ventavis® Inhalation Solution.",,,Pulmonary/Allergy,To Be Discontinued,,5/9/2024,,2024,discontinued
14422,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 10 Mg (NDC 49884-054-10)",Revised,9/15/2023,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2024,discontinued
14423,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 10 Mg (NDC 49884-054-01)",Revised,9/15/2023,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2024,discontinued
14424,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 25 Mg (NDC 49884-055-01)",Revised,9/15/2023,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2024,discontinued
14425,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 25 Mg (NDC 49884-055-10)",Revised,9/15/2023,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2024,discontinued
14426,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 50 Mg (NDC 49884-056-10)",Revised,9/15/2023,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2024,discontinued
14427,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 50 Mg (NDC 49884-056-01)",Revised,9/15/2023,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/2023,9/14/2023,,2024,discontinued
14428,Indigotindisulfonate Sodium Injection,"American Regent, Inc.","Indigo Carmine, Injection, 8 Mg/1 Ml (NDC 0517-0375-05)",Revised,11/1/2023,,,,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,11/1/2023,11/1/2023,,2024,discontinued
14429,Indocyanine Green Injection,Renew Pharmaceuticals Limited,"Injection, 25 Mg (NDC 70100-424-02)",Reverified,9/5/2024,Limited Availability,Limited Availability Through December 2024,,Delay In Shipping Of The Drug,Medical Imaging; Ophthalmology; Other,Current,,,,2024,limited availability
14430,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-937-26)",Revised,8/26/2024,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,,2024,available
14431,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-937-16)",Revised,8/26/2024,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,,2024,available
14432,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-306-23)",Revised,8/26/2024,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,,2024,available
14433,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-903-24)",Revised,8/26/2024,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,,2024,available
14434,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-936-25)",Revised,8/26/2024,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,,2024,available
14435,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-306-13)",Revised,8/26/2024,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,,2024,available
14436,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-903-14)",Revised,8/26/2024,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,,2024,available
14437,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-936-15)",Revised,8/26/2024,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,,2024,available
14438,Insulin (Human) Injection,Eli Lilly And Co.,"Humulin-R, Injection, 100 [Iu]/1 Ml, 3ml Vial (NDC 0002-0213-01)",New,3/1/2024,,Humulin R U-100 Will Continue To Be Available In 10ml Vials.,,,Endocrinology/Metabolism,To Be Discontinued,,3/1/2024,,2024,discontinued
14439,Insulin (Human) Injection,Eli Lilly And Co.,"Humulin-R, Injection, 100 [Iu]/1 Ml, 3 Ml Vial (NDC 0002-8215-17)",New,3/1/2024,,Humulin R U-100 Will Continue To Be Available In 10ml Vials.,,,Endocrinology/Metabolism,To Be Discontinued,,3/1/2024,,2024,discontinued
14440,Insulin Detemir Injection,Novo Nordisk,"Levemir, Injection, 100 [Iu]/1 Ml (NDC 0169-3687-12)",New,11/8/2023,,"Levemir® Vials Will Be Available Until The End Of 2024. Full Brand Discontinuation Will Occur On December 31, 2024.",,,Endocrinology/Metabolism; Other,To Be Discontinued,,11/8/2023,,2024,discontinued
14441,Insulin Detemir Injection,Novo Nordisk,"Levemir, Injection, 100 [Iu]/1 Ml (NDC 0169-6432-10)",New,11/8/2023,,"Limited Supply Of Levemir® Flexpen® Through The End Of 2024. Full Brand Discontinuation Will Occur On December 31, 2024.",,,Endocrinology/Metabolism; Other,To Be Discontinued,,11/8/2023,,2024,discontinued
14442,Insulin Glargine Injection,Sanofi-Aventis U.S. Llc,"Insulin Glargine Solostar, Injection, 100 [Iu]/Ml (NDC 0955-1728-05)",New,5/24/2024,,Sanofi Has Discontinued This Product Due To A Business Decision.,,,Endocrinology/Metabolism; Other,To Be Discontinued,,5/24/2024,,2024,discontinued
14443,Insulin Glargine Injection,Sanofi-Aventis U.S. Llc,"Insulin Glargine, Injection, 100 [Iu]/Ml (NDC 0955-1729-01)",New,5/24/2024,,Sanofi Has Discontinued This Product Due To A Business Decision.,,,Endocrinology/Metabolism; Other,To Be Discontinued,,5/24/2024,,2024,discontinued
14444,Insulin Lispro Injection,Eli Lilly And Co.,"Humalog, Injection, 3ml Vial (NDC 0002-7510-17)",New,3/27/2024,,Alternatives Include 10 Ml Vial And Kwikpen Presentations Of Humalog And Insulin Lispro Injection,,,Endocrinology/Metabolism,To Be Discontinued,,3/27/2024,,2024,discontinued
14445,Insulin Lispro Injection,Eli Lilly And Co.,"Humalog, Injection, 3ml Vial (NDC 0002-7533-01)",New,3/27/2024,,Alternatives Include 10 Ml Vial And Kwikpen Presentations Of Humalog And Insulin Lispro Injection,,,Endocrinology/Metabolism,To Be Discontinued,,3/27/2024,,2024,discontinued
14446,Isoniazid Tablet,"Teva Pharmaceuticals Usa, Inc.","Isoniazid Tablets, Usp, Tablet, 300 Mg (NDC 0555-0071-01)",Revised,9/4/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14447,Isoniazid Tablet,"Teva Pharmaceuticals Usa, Inc.","Isoniazid Tablets, Usp, Tablet, 300 Mg (NDC 0555-0071-02)",Revised,9/4/2024,Available,,,Demand Increase For The Drug,Anti-Infective,Current,,,,2024,available
14448,Isoniazid Tablet,"Teva Pharmaceuticals Usa, Inc.","Isoniazid Tablets, Usp, Tablet, 100 Mg (NDC 0555-0066-02)",Revised,9/4/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14449,Isoniazid Tablet,Chartwell Molecular Holdings Llc,"Laniazid, Tablet, 300 Mg (NDC 62135-709-90)",Reverified,9/2/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14450,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 100 Mg/1 Ml (NDC 25021-684-05)",Revised,7/15/2024,Available,Distributed By Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia,Current,,,,2024,available
14451,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 50 Mg/1 Ml (NDC 25021-683-10)",Revised,7/15/2024,Available,Distributed By Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia,Current,,,,2024,available
14452,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 25021-682-20)",Revised,7/15/2024,Available,Distributed By Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia,Current,,,,2024,available
14453,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketamine Hcl Injection, Usp, Injection, 50 Mg/1 Ml (NDC 0143-9508-10)",Reverified,8/28/2024,Available,,,,Anesthesia,Current,,,,2024,available
14454,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketamine Hcl Injection, Usp, Injection, 100 Mg/1 Ml (NDC 0143-9509-10)",Reverified,8/28/2024,Available,,,,Anesthesia,Current,,,,2024,available
14455,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 50 Mg/1 Ml (NDC 42023-114-10)",Reverified,9/3/2024,Unavailable,Recovery: Tbd,,Shortage Of An Active Ingredient,Anesthesia,Current,,,,2024,not available
14456,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 100 Mg/1 Ml (NDC 42023-115-10)",Reverified,9/3/2024,Unavailable,Recovery: Tbd,,Shortage Of An Active Ingredient,Anesthesia,Current,,,,2024,not available
14457,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 10 Mg/1 Ml (NDC 42023-113-10)",Reverified,9/3/2024,Available,,,,Anesthesia,Current,,,,2024,available
14458,Ketamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Ketamine Hydrochloride, Injection, 500 Mg/10 Ml (50 Mg/Ml) (NDC 0409-2053-10)",Revised,8/26/2024,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
14459,Ketamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 500 Mg/5 Ml (100 Mg/Ml) (NDC 0409-0040-10)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14460,Ketamine Hydrochloride Injection,Eugia Us Llc,"Injection, 100 Mg/1 Ml (NDC 55150-440-10)",Reverified,8/5/2024,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14461,Ketamine Hydrochloride Injection,Eugia Us Llc,"Injection, 50 Mg/1 Ml (NDC 55150-439-10)",Reverified,8/5/2024,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14462,Ketamine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/1 Ml (NDC 55150-438-10)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14463,Ketamine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 65219-184-20)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Anesthesia,Current,,,,2024,available
14464,Ketamine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 50 Mg/1 Ml (NDC 65219-188-10)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Anesthesia,Current,,,,2024,available
14465,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 70860-701-04)",Revised,7/15/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14466,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 15 Mg/1 Ml (NDC 70860-700-02)",Revised,7/15/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14467,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 70860-701-03)",Revised,7/15/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14468,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 60 Mg/2 Ml (NDC 62332-601-25)",Reverified,9/4/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14469,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 30 Mg/1 Ml (NDC 62332-600-25)",Reverified,9/4/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14470,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 15 Mg/1 Ml (NDC 62332-599-25)",Reverified,9/4/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14471,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 15 Mg/1 Ml (NDC 0338-0069-10)",Revised,7/17/2024,Limited Availability,Recovery September 2024,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,limited availability
14472,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 60 Mg/2 Ml (NDC 76045-105-20)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14473,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 30 Mg/1 Ml (NDC 76045-104-10)",Reverified,9/4/2024,Unavailable,Not Available At This Time.,,Other,Analgesia/Addiction,Current,,,,2024,not available
14474,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 15 Mg/1 Ml (NDC 76045-107-10)",Reverified,9/4/2024,Unavailable,Not Available At This Time.,,Other,Analgesia/Addiction,Current,,,,2024,not available
14475,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 0338-0072-25)",Reverified,9/5/2024,Available,For Intravenous And Intramuscular Use. 30mg/Ml (1 Ml Fill Volume/ 2 Ml Container),,,Analgesia/Addiction,Current,,,,2024,available
14476,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 72266-119-25)",Revised,7/15/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14477,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 72266-118-25)",Revised,7/15/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14478,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketorolac Tromethamine Injection, Usp, Injection, 30 Mg/1 Ml (NDC 0641-6043-25)",Reverified,8/28/2024,Unavailable,Shortage Recovery: Tbd,,Other,Analgesia/Addiction,Current,,,,2024,not available
14479,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketorolac Tromethamine Injection, Usp, Injection, 30 Mg/1 Ml (NDC 0641-6042-25)",Reverified,8/28/2024,Unavailable,Shortage Recovery: Tbd,,Other,Analgesia/Addiction,Current,,,,2024,not available
14480,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketorolac Tromethamine Injection, Usp, Injection, 15 Mg/1 Ml (NDC 0641-6041-25)",Reverified,8/28/2024,Unavailable,Shortage Recovery: Tbd,,Other,Analgesia/Addiction,Current,,,,2024,not available
14481,Ketorolac Tromethamine Injection,"Hospira, Inc., A Pfizer Company","Injection, 60 Mg/2 Ml (30 Mg/Ml) (NDC 0409-3796-01)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14482,Ketorolac Tromethamine Injection,"Hospira, Inc., A Pfizer Company","Injection, 30 Mg/1 Ml (NDC 0409-3795-01)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14483,Ketorolac Tromethamine Injection,"Hospira, Inc., A Pfizer Company","Injection, 15 Mg/1 Ml (NDC 0409-3793-01)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14484,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 30 Mg/1 Ml (NDC 25021-701-01)",Reverified,7/1/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14485,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 30 Mg/1 Ml (NDC 25021-701-02)",Reverified,7/1/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14486,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 15 Mg/1 Ml (NDC 25021-700-01)",Reverified,7/1/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14487,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 70860-701-02)",Revised,7/15/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14488,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 70860-701-01)",Revised,7/15/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14489,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 15 Mg/1 Ml (NDC 70860-700-01)",Revised,7/15/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14490,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 30 Mg/1 Ml (NDC 63323-162-02)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14491,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 30 Mg/1 Ml (NDC 63323-162-01)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14492,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 15 Mg/1 Ml (NDC 63323-161-01)",Reverified,9/4/2024,Available,Check Wholesaler Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14493,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 100 Mg (NDC 0591-0605-01)",New,3/11/2024,,,,,Cardiovascular,To Be Discontinued,,3/11/2024,,2024,discontinued
14494,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 100 Mg (NDC 0591-0605-05)",New,3/11/2024,,,,,Cardiovascular,To Be Discontinued,,3/11/2024,,2024,discontinued
14495,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 200 Mg (NDC 0591-0606-01)",New,3/11/2024,,,,,Cardiovascular,To Be Discontinued,,3/11/2024,,2024,discontinued
14496,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 200 Mg (NDC 0591-0606-05)",New,3/11/2024,,,,,Cardiovascular,To Be Discontinued,,3/11/2024,,2024,discontinued
14497,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 300 Mg (NDC 0591-0607-01)",New,3/11/2024,,,,,Cardiovascular,To Be Discontinued,,3/11/2024,,2024,discontinued
14498,Lacosamide Tablet,Amneal Pharmaceuticals,"Tablet, 50 Mg (NDC 65162-923-06)",New,4/15/2024,,,,,Neurology,To Be Discontinued,,4/15/2024,,2024,discontinued
14499,Lacosamide Tablet,Amneal Pharmaceuticals,"Tablet, 100 Mg (NDC 65162-924-06)",New,4/15/2024,,,,,Neurology,To Be Discontinued,,4/15/2024,,2024,discontinued
14500,Lacosamide Tablet,Amneal Pharmaceuticals,"Tablet, 150 Mg (NDC 65162-925-06)",New,4/15/2024,,,,,Neurology,To Be Discontinued,,4/15/2024,,2024,discontinued
14501,Lacosamide Tablet,Amneal Pharmaceuticals,"Tablet, 200 Mg (NDC 65162-926-06)",New,4/15/2024,,,,,Neurology,To Be Discontinued,,4/15/2024,,2024,discontinued
14502,Lanadelumab-Flyo Injection,Takeda Pharmaceuticals Usa Inc.,"Takhzyro, Injection, 300 Mg/2 Ml (NDC 47783-644-01)",New,9/4/2024,,,,,Pulmonary/Allergy,To Be Discontinued,,9/4/2024,,2024,discontinued
14503,"Lanthanum Carbonate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Tablet, Chewable, 500 Mg (NDC 66993-422-85)",New,2/6/2024,,30 Apr 2024; Branded Fosrenol Will Continue To Be Available,,,Renal,To Be Discontinued,,2/6/2024,,2024,discontinued
14504,"Lanthanum Carbonate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Tablet, Chewable, 750 Mg (NDC 66993-423-85)",New,2/6/2024,,30 Apr 2024; Branded Fosrenol Will Continue To Be Available,,,Renal,To Be Discontinued,,2/6/2024,,2024,discontinued
14505,"Lanthanum Carbonate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Tablet, Chewable, 1000 Mg (NDC 66993-424-85)",New,2/6/2024,,30 Apr 2024; Branded Fosrenol Will Continue To Be Available,,,Renal,To Be Discontinued,,2/6/2024,,2024,discontinued
14506,Leucovorin Calcium Injection,"Mylan Institutional, A Viatris Company","Leucovorin Calcium Preservative Free, Injection, 350 Mg/17.5 Ml (NDC 67457-530-35)",Reverified,9/5/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14507,Leucovorin Calcium Injection,"Mylan Institutional, A Viatris Company","Leucovorin Calcium Preservative Free, Injection, 200 Mg/20 Ml (NDC 67457-529-20)",Reverified,9/5/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14508,Leucovorin Calcium Injection,"Mylan Institutional, A Viatris Company","Leucovorin Calcium Preservative Free, Injection, 100 Mg/10 Ml (NDC 67457-528-10)",Reverified,9/5/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14509,Leucovorin Calcium Injection,"Fresenius Kabi Usa, Llc","Leucovorin Calcium, Injection, 10 Mg/1 Ml (NDC 63323-631-50)",Reverified,8/15/2024,Available,Check Wholesaler Inventory,,,Oncology; Pediatric,Current,,,,2024,available
14510,Leucovorin Calcium Injection,"Fresenius Kabi Usa, Llc","Leucovorin Calcium, Injection, 10 Mg/1 Ml (NDC 63323-631-10)",Reverified,8/15/2024,Available,Check Wholesaler Inventory,,,Oncology; Pediatric,Current,,,,2024,available
14511,Leucovorin Calcium Injection,"Hikma Pharmaceuticals Usa, Inc.","Leucovorin Calcium For Injection, Usp, Injection, 350 Mg/17.5 Ml (NDC 0143-9552-01)",Reverified,8/28/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14512,Leucovorin Calcium Injection,"Hikma Pharmaceuticals Usa, Inc.","Leucovorin Calcium For Injection, Usp, Injection, 200 Mg/20 Ml (NDC 0143-9553-01)",Reverified,8/28/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14513,Leucovorin Calcium Injection,"Hikma Pharmaceuticals Usa, Inc.","Leucovorin Calcium For Injection, Usp, Injection, 100 Mg/10 Ml (NDC 0143-9554-01)",Reverified,8/28/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14514,Leucovorin Calcium Injection,"Hikma Pharmaceuticals Usa, Inc.","Leucovorin Calcium For Injection, Usp, Injection, 50 Mg/5 Ml (NDC 0143-9555-01)",Reverified,8/28/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14515,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium Preservative Free, Injection, 500 Mg/50 Ml (NDC 25021-828-50)",Reverified,7/1/2024,Out Of Stock,Estimated Delivery August 2024,,Demand Increase For The Drug,Oncology; Pediatric,Current,,,,2024,not available
14516,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Injection, 100 Mg (NDC 70436-117-80)",Reverified,8/15/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14517,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Injection, 200 Mg (NDC 70436-118-80)",Reverified,8/15/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14518,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Injection, 500 Mg (NDC 70436-120-80)",Reverified,8/15/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14519,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Injection, 200 Mg/20 Ml (NDC 25021-815-30)",Reverified,7/1/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14520,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Injection, 100 Mg/10 Ml (NDC 25021-814-30)",Reverified,7/1/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14521,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Injection, 50 Mg/5 Ml (NDC 25021-813-10)",Reverified,7/1/2024,Limited Availability,,,Demand Increase For The Drug,Oncology; Pediatric,Current,,,,2024,limited availability
14522,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Injection, 50 Mg (NDC 70436-116-82)",Reverified,8/15/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14523,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Injection, 350 Mg/17.5 Ml (NDC 25021-816-30)",Reverified,7/1/2024,Available,,,,Oncology; Pediatric,Current,,,,2024,available
14524,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 500 Mg/50 Ml (NDC 71288-164-50)",Revised,7/30/2024,Available,"Estimated Recovery October 2024; Marketed By Meitheal Pharmaceuticals, Inc.",,Demand Increase For The Drug,Oncology; Pediatric,Current,,,,2024,available
14525,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 350 Mg/17.5 Ml (NDC 71288-163-30)",Revised,7/11/2024,Available,"Marketed By Meitheal Pharmaceuticals, Inc.",,,Oncology; Pediatric,Current,,,,2024,available
14526,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 100 Mg/10 Ml (NDC 71288-161-20)",Revised,7/11/2024,Available,"Marketed By Meitheal Pharmaceuticals, Inc.",,,Oncology; Pediatric,Current,,,,2024,available
14527,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 200 Mg/20 Ml (NDC 71288-162-30)",Revised,7/11/2024,Available,"Marketed By Meitheal Pharmaceuticals, Inc.",,,Oncology; Pediatric,Current,,,,2024,available
14528,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 50 Mg/5 Ml (NDC 71288-160-10)",Revised,7/30/2024,Available,"Marketed By Meitheal Pharmaceuticals, Inc.",,,Oncology; Pediatric,Current,,,,2024,available
14529,Leucovorin Calcium Injection,"Fresenius Kabi Usa, Llc","Injection, 200 Mg/20 Ml (NDC 63323-710-50)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Oncology; Pediatric,Current,,,,2024,available
14530,Leucovorin Calcium Injection,"Fresenius Kabi Usa, Llc","Leucovorin Calcium Preservative Free, Injection, 500 Mg/50 Ml (NDC 63323-711-00)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024; Check Wholesalers For Inventory,,Demand Increase For The Drug,Oncology; Pediatric,Current,,,,2024,not available
14531,Lidocaine Hydrochloride Injection,Afaxys Pharma,"Injection, 10 Mg/1 Ml (NDC 50102-400-10)",Reverified,7/15/2024,Available,"Inventory Available Through Anda, Asd Healthcare, Henry Schein, Mckesson Medical-Surgical And R&S",,,Anesthesia; Pediatric,Current,,,,2024,available
14532,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 40 Mg/1 Ml (NDC 83090-007-10)",Reverified,9/3/2024,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 4% 10x5ml)  Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,,2024,available
14533,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 83090-006-10)",Reverified,9/3/2024,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 2% 10x10ml) Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,,2024,available
14534,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 83090-005-10)",Reverified,9/3/2024,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 2% 10x5ml)  Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,,2024,available
14535,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 83090-004-10)",Reverified,9/3/2024,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 2% 10x2ml)  Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,,2024,available
14536,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 83090-003-10)",Reverified,9/3/2024,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 1% 10x10ml) Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,,2024,available
14537,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 83090-002-10)",Reverified,9/3/2024,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 1% 10x5ml)  Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,,2024,available
14538,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 83090-001-10)",Reverified,9/3/2024,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 1% 10x2ml) Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,,2024,available
14539,Lidocaine Hydrochloride Injection,"Huons Co., Ltd. (South Korea)","Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 73293-0001-2)",Reverified,8/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
14540,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 20 Mg/Ml (NDC 55150-256-50)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14541,Lidocaine Hydrochloride Injection,"Spectra Medical Devices, Llc","Injection, 10 Mg/1 Ml (NDC 65282-1605-1)",Reverified,6/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
14542,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Hcl Injection, Usp, Injection, 20 Mg/1 Ml (NDC 0143-9575-10)",Revised,8/28/2024,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,,2024,available
14543,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Hcl Injection, Usp, Injection, 10 Mg/1 Ml (NDC 0143-9577-10)",Revised,8/28/2024,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,,2024,available
14544,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Hcl Injection, Usp Preservative Free, Injection, 20 Mg/1 Ml (NDC 0143-9594-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,,2024,available
14545,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Hcl Injection, Usp Preservative Free, Injection, 10 Mg/1 Ml (NDC 0143-9595-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,,2024,available
14546,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 20 Mg/Ml (NDC 55150-255-20)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14547,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 20 Mg/Ml (NDC 55150-254-10)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14548,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/Ml (NDC 55150-252-20)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14549,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/Ml (NDC 55150-251-10)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14550,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 300 Mg/20 Ml (1.5%; 15 Mg/Ml) (NDC 0409-4776-01)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14551,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 20 Mg/1 Ml (NDC 55150-165-05)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14552,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 20 Mg/Ml (NDC 55150-164-02)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14553,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/1 Ml (NDC 55150-163-30)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14554,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/1 Ml (NDC 55150-162-05)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14555,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/1 Ml (NDC 55150-161-02)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
14556,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 20 Mg/1 Ml (NDC 55150-160-72)",Revised,8/5/2024,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14557,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/1 Ml (NDC 55150-159-74)",Revised,8/5/2024,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14558,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/Ml (NDC 55150-158-72)",Revised,8/5/2024,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
14559,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 8 Mg/1 Ml (NDC 0338-0411-02)",Reverified,7/17/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14560,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 4 Mg/1 Ml (NDC 0338-0409-03)",Reverified,7/17/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14561,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 50 Mg/5 Ml (1%; 10 Mg/Ml) (NDC 0409-4713-02)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14562,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 250 Mg/50 Ml (0.5%; 5 Mg/Ml) (NDC 0409-4278-01)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14563,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 250 Mg/50 Ml (0.5%; 5 Mg/Ml) (NDC 0409-4275-01)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: December 2026,,,Anesthesia; Pediatric,Current,,,,2024,not available
14564,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-496-97)",Reverified,9/4/2024,Unavailable,Next Release Date Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14565,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-495-07)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14566,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-495-27)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14567,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-486-57)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14568,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-486-27)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14569,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-486-17)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,,2024,available
14570,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Lidocaine Hydrochloride Preservative Free, Injection, 20 Mg/1 Ml (NDC 63323-208-05)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14571,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 63323-202-02)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14572,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 15 Mg/1 Ml (NDC 63323-493-91)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14573,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 15 Mg/1 Ml (NDC 63323-493-97)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14574,Lidocaine Hydrochloride Injection,"Amphastar Pharmaceuticals, Inc.","Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 76329-3390-1)",Reverified,8/20/2024,Available,Old Ndc 0548-3390-00,,,Anesthesia; Pediatric,Current,,,,2024,available
14575,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 Mg/5ml (2%,20 Mg/1 Ml) Syringes (NDC 0409-1323-05)",Revised,8/26/2024,Unavailable,Next Delivery: November 2024; Estimated Recovery: March 2025,,,Anesthesia; Pediatric,Current,,,,2024,not available
14576,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 Mg/5 Ml (4%; 40 Mg/Ml) (NDC 0409-4283-01)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: October 2024; Estimated Recovery: December 2024,,,Anesthesia; Pediatric,Current,,,,2024,limited availability
14577,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 Mg/50 Ml (2%; 20 Mg/Ml) (NDC 0409-4277-02)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14578,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 400 Mg/20 Ml (2%; 20 Mg/Ml) (NDC 0409-4277-01)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14579,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 100 Mg/5 Ml (2%; 20 Mg/Ml) (NDC 0409-2066-05)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14580,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 100 Mg/5ml (2%, 20 Mg/1 Ml) Syringes (NDC 0409-4903-34)",Revised,8/26/2024,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14581,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 50 Mg/5ml (1%,10 Mg/1 Ml) Syringes (NDC 0409-4904-34)",Revised,8/26/2024,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14582,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 200 Mg/10 Ml (2%; 20 Mg/Ml) (NDC 0409-4282-02)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14583,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 40 Mg/2 Ml (2%; 20 Mg/Ml) (NDC 0409-4282-01)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14584,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 500 Mg/50 Ml (1%; 10 Mg/Ml) (NDC 0409-4276-02)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14585,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 300 Mg/30 Ml (1%; 10 Mg/Ml) (NDC 0409-4279-02)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14586,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 200 Mg/20 Ml (1%; 10 Mg/Ml) (NDC 0409-4276-01)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14587,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 Mg/2 Ml (1%; 10 Mg/Ml) (NDC 0409-4713-32)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14588,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 Mg/5ml (1%, 10 Mg/1 Ml) Syringes (NDC 0409-9137-05)",Reverified,8/26/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14589,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-492-31)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14590,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-492-37)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14591,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-492-57)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14592,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/Ml, 5 Ml (NDC 63323-492-89)",Revised,10/13/2023,Not Available At This Time.,,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14593,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/Ml, 2 Ml (NDC 63323-492-80)",Revised,10/13/2023,Not Available At This Time.,,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14594,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-492-27)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14595,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-485-57)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14596,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-485-27)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14597,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 63323-201-10)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14598,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Lidocaine Hydrochloride In Plastic Container, Injection, 10 Mg/1 Ml (NDC 63323-201-02)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14599,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 5 Mg/1 Ml (NDC 63323-491-57)",Reverified,9/4/2024,Available,,,,Anesthesia; Pediatric,Current,,,,2024,available
14600,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 5 Mg/1 Ml (NDC 63323-484-57)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,,2024,not available
14601,Lidocaine Hydrochloride Solution,Chartwell Molecular Holdings Llc,"Lidocaine Hydrochloride Viscous, Solution, 20 Mg/1 Ml (NDC 62135-712-42)",Reverified,9/2/2024,Available,,,,Anesthesia,Current,,,,2024,available
14602,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride Oral Topical Solution, Usp), Solution, 20 Mg/1 Ml (NDC 0054-0548-44)",Reverified,8/28/2024,Limited Availability,Available To Current Customers.,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,limited availability
14603,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride Oral Topical Solution, Usp), Solution, 20 Mg/1 Ml (NDC 0054-3500-49)",Reverified,8/28/2024,Limited Availability,Available To Current Customers.,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,limited availability
14604,Lidocaine Hydrochloride Solution,Pai Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 Mg/1 Ml (NDC 0121-0950-03)",Revised,6/24/2024,Available,,,,Anesthesia,Current,,,,2024,available
14605,Lidocaine Hydrochloride Solution,Pai Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 Mg/1 Ml (NDC 0121-4950-40)",Revised,6/24/2024,Available,,,,Anesthesia,Current,,,,2024,available
14606,Lidocaine Hydrochloride Solution,Rubicon Research Private Limited,"Solution, 20 Mg/1 Ml (NDC 72888-125-26)",Revised,6/18/2024,Available,Marketed By Advagen Pharma Ltd.,,,Anesthesia,Current,,,,2024,available
14607,Linezolid Tablet,Pfizer Inc.,"Zyvox, Tablet, 600 Mg (NDC 0009-5138-03)",New,3/28/2024,,Discontinuation Of The Manufacture Of The Drug.,,,Anti-Infective,To Be Discontinued,,3/28/2024,,2024,discontinued
14608,Liothyronine Sodium Injectable,"Xgen Pharmaceuticals Djb, Inc.","Injectable, 10 Ug/1 Ml (NDC 39822-0151-1)",New,10/19/2023,Available,"Even Though We Requested New Posting Information, We Did Not Post It And It'S Resolved Now.",Please Do Not Publish. Obsolete And Needs To Be Deleted.,Regulatory Delay,Endocrinology/Metabolism,Resolved,12/1/2023,,,2024,available
14609,Liraglutide Injection,"Novo Nordisk, Inc.","Saxenda, Injection, 6 Mg/1 Ml (NDC 0169-2800-15)",Revised,9/6/2024,Limited Availability,Estimated Shortage Duration Tbd,,Demand Increase For The Drug,Endocrinology/Metabolism,Current,,,,2024,limited availability
14610,Liraglutide Injection,"Novo Nordisk, Inc.","Injection, 6 Mg/1 Ml (NDC 0480-3667-22)",Revised,9/6/2024,Available,Distributed By Teva,,,Endocrinology/Metabolism,Current,,,,2024,available
14611,Liraglutide Injection,"Novo Nordisk, Inc.","Injection, 6 Mg/1 Ml (NDC 0480-3667-20)",Revised,9/6/2024,Available,Distributed By Teva,,,Endocrinology/Metabolism,Current,,,,2024,available
14612,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 Mg/1 Ml (NDC 0169-4060-13)",Revised,9/6/2024,Limited Availability,Estimated Shortage Duration Tbd,,Delay In Shipping Of The Drug,Endocrinology/Metabolism,Current,,,,2024,limited availability
14613,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 Mg/1 Ml (NDC 0169-4060-12)",Revised,9/6/2024,Limited Availability,Estimated Shortage Duration Tbd,,Delay In Shipping Of The Drug,Endocrinology/Metabolism,Current,,,,2024,limited availability
14614,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 70 Mg (NDC 59417-107-10)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14615,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 60 Mg (NDC 59417-106-10)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14616,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 50 Mg (NDC 59417-105-10)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14617,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 40 Mg (NDC 59417-104-10)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14618,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 30 Mg (NDC 59417-103-10)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14619,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 20 Mg (NDC 59417-102-10)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14620,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 10 Mg (NDC 59417-101-10)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14621,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 70 Mg (NDC 47781-568-01)",Revised,5/7/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14622,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 60 Mg (NDC 47781-567-01)",Revised,5/7/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14623,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 10 Mg (NDC 47781-562-01)",Revised,5/7/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14624,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 10 Mg (NDC 42858-161-01)",Reverified,8/15/2024,Available,,,,Psychiatry,Current,,,,2024,available
14625,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 50 Mg (NDC 47781-566-01)",Reverified,4/17/2024,Unavailable,Resupply End Of April 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14626,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 40 Mg (NDC 47781-565-01)",Reverified,4/17/2024,Unavailable,Resupply End Of April 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14627,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 70 Mg (NDC 42858-167-01)",Revised,8/15/2024,"Unavailable, Unknown",,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14628,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 60 Mg (NDC 42858-166-01)",Revised,8/15/2024,"Unavailable, Unknown",,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14629,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 50 Mg (NDC 42858-165-01)",Revised,8/15/2024,"Unavailable, Unknown",,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14630,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 20 Mg (NDC 42858-162-01)",Reverified,8/15/2024,Available,,,,Psychiatry,Current,,,,2024,available
14631,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 40 Mg (NDC 42858-164-01)",Reverified,8/15/2024,Available,,,,Psychiatry,Current,,,,2024,available
14632,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 30 Mg (NDC 42858-163-01)",Revised,8/15/2024,Available,,,,Psychiatry,Current,,,,2024,available
14633,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 30 Mg (NDC 47781-564-01)",Revised,5/7/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14634,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 20 Mg (NDC 47781-563-01)",Revised,5/7/2024,Limited Availability,Resupply End Of April2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14635,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 10 Mg (NDC 60505-4739-1)",Revised,7/16/2024,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14636,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 50 Mg (NDC 60505-4743-1)",Revised,7/16/2024,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14637,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 20 Mg (NDC 60505-4740-1)",Revised,7/16/2024,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14638,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 70 Mg (NDC 60505-4745-1)",Revised,7/16/2024,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14639,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 60 Mg (NDC 60505-4744-1)",Revised,7/16/2024,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14640,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 40 Mg (NDC 60505-4742-1)",Revised,7/16/2024,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14641,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 30 Mg (NDC 60505-4741-1)",Revised,7/16/2024,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14642,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 60 Mg (NDC 65162-027-09)",Reverified,7/9/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14643,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 30 Mg (NDC 65162-024-09)",Reverified,7/9/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14644,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 50 Mg (NDC 65162-026-09)",Reverified,7/9/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14645,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 70 Mg (NDC 65162-028-09)",Reverified,7/9/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14646,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 20 Mg (NDC 65162-023-09)",Reverified,7/9/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14647,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 40 Mg (NDC 65162-025-09)",Reverified,7/9/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14648,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 10 Mg (NDC 57664-046-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14649,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 50 Mg (NDC 57664-050-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14650,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 60 Mg (NDC 57664-051-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14651,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 40 Mg (NDC 57664-049-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14652,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 70 Mg (NDC 57664-052-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14653,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 30 Mg (NDC 57664-048-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14654,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 30 Mg (NDC 57664-048-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14655,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 50 Mg (NDC 0378-6858-77)",Reverified,9/5/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14656,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 10 Mg (NDC 0378-6854-77)",Reverified,9/5/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14657,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 70 Mg (NDC 0378-6860-77)",Reverified,9/5/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14658,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 60 Mg (NDC 0378-6859-77)",Reverified,9/5/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14659,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 30 Mg (NDC 0378-6856-77)",Reverified,9/5/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14660,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 40 Mg (NDC 0378-6857-77)",Reverified,9/5/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14661,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 30 Mg (NDC 0378-6857-77)",Revised,9/20/2023,Available On Allocation,,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,limited availability
14662,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 40 Mg (NDC 0378-6857-77)",Revised,9/20/2023,Available On Allocation,,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,limited availability
14663,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 20 Mg (NDC 0378-6855-77)",Reverified,9/5/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14664,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 50 Mg (NDC 0054-0373-25)",Reverified,8/28/2024,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14665,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 30 Mg (NDC 0054-0371-25)",Reverified,8/28/2024,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14666,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 60 Mg (NDC 0054-0374-25)",Reverified,8/28/2024,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14667,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 20 Mg (NDC 0054-0370-25)",Reverified,8/28/2024,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14668,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 40 Mg (NDC 0054-0372-25)",Reverified,8/28/2024,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14669,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 70 Mg (NDC 0054-0375-25)",Reverified,8/28/2024,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14670,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 40 Mg (NDC 0406-5114-01)",Revised,8/15/2024,Unavailable,Backorder. Next Release Mid August. Backorder Expected Again In September,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14671,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 60 Mg (NDC 0406-5116-01)",Revised,8/15/2024,Unavailable,On Backorder,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14672,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 10 Mg (NDC 0406-5111-01)",Revised,8/15/2024,Unavailable,Allocations To All Customers. Backorder Projected In October,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14673,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 30 Mg (NDC 0406-5113-01)",Revised,8/15/2024,Limited Availability,Available To Primary Customers Only. Backorder Projected In Mid August,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14674,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 50 Mg (NDC 0406-5115-01)",Revised,8/15/2024,Unavailable,Backorder. Next Release Mid August. Backorder Expected Again In October,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14675,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 70 Mg (NDC 0406-5117-01)",Revised,8/15/2024,Unavailable,On Backorder,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14676,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 20 Mg (NDC 0406-5112-01)",Revised,8/15/2024,Limited Availability,Available To Primary Customers Only. Intermittent Backorder Expected Through Sept.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14677,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 30 Mg (NDC 43547-604-10)",Reverified,9/3/2024,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14678,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 20 Mg (NDC 43547-603-10)",Reverified,9/3/2024,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14679,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 60 Mg (NDC 43547-607-10)",Reverified,9/3/2024,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14680,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 10 Mg (NDC 43547-602-10)",Reverified,9/3/2024,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14681,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 70 Mg (NDC 43547-608-10)",Reverified,9/3/2024,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14682,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 50 Mg (NDC 43547-606-10)",Reverified,9/3/2024,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14683,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 40 Mg (NDC 43547-605-10)",Reverified,9/3/2024,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14684,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 60 Mg (NDC 0527-4666-37)",Reverified,9/3/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14685,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 20 Mg (NDC 0527-4662-37)",Revised,9/3/2024,Unavailable,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14686,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 40 Mg (NDC 0527-4664-37)",Reverified,9/3/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14687,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 50 Mg (NDC 0527-4665-37)",Revised,9/3/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14688,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 30 Mg (NDC 0527-4663-37)",Reverified,9/3/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14689,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 10 Mg (NDC 0527-4661-37)",Revised,9/3/2024,Unavailable,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14690,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 70 Mg (NDC 0527-4667-37)",Reverified,9/3/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14691,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 60 Mg (NDC 59417-120-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14692,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 50 Mg (NDC 59417-119-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14693,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 40 Mg (NDC 59417-118-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14694,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 30 Mg (NDC 59417-117-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14695,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 20 Mg (NDC 59417-116-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14696,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 10 Mg (NDC 59417-115-01)",Reverified,9/3/2024,Available,,,,Psychiatry,Current,,,,2024,available
14697,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 Mg (NDC 72205-132-91)",Revised,7/18/2024,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,available
14698,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 Mg (NDC 72205-137-91)",Revised,7/18/2024,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,available
14699,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 Mg (NDC 72205-136-91)",Revised,7/18/2024,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,available
14700,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 Mg (NDC 72205-135-91)",Revised,7/18/2024,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,available
14701,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 Mg (NDC 72205-134-91)",Revised,7/18/2024,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,available
14702,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 Mg (NDC 72205-133-91)",Revised,7/18/2024,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,available
14703,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 40 Mg (NDC 57664-086-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14704,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 60 Mg (NDC 57664-088-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14705,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 50 Mg (NDC 57664-087-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14706,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 30 Mg (NDC 57664-085-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14707,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 20 Mg (NDC 57664-084-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14708,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 10 Mg (NDC 57664-083-88)",Revised,8/26/2024,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14709,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., A Viatris Company","Lithium Carbonate, Tablet, Extended Release, 300 Mg (NDC 0378-1300-01)",New,10/4/2023,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,10/4/2023,,2024,discontinued
14710,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., A Viatris Company","Lithium Carbonate, Tablet, Extended Release, 450 Mg (NDC 0378-1450-01)",New,10/4/2023,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,10/4/2023,,2024,discontinued
14711,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., A Viatris Company","Lithium Carbonate, Tablet, Extended Release, 300 Mg (NDC 0378-1300-05)",New,10/4/2023,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,10/4/2023,,2024,discontinued
14712,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Lorazepam Injection, Usp, Injection, 4 Mg/1 Ml (NDC 0641-6045-25)",Reverified,8/28/2024,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,,2024,not available
14713,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Lorazepam Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0641-6046-10)",Reverified,8/28/2024,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,,2024,not available
14714,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Lorazepam Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0641-6044-25)",Reverified,8/28/2024,Unavailable,Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,,2024,not available
14715,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Ativan Injection (Lorazepam Injection, Usp), Injection, 4 Mg/1 Ml (NDC 0641-6002-10)",Reverified,8/28/2024,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,,2024,not available
14716,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Ativan Injection (Lorazepam Injection, Usp), Injection, 4 Mg/1 Ml (NDC 0641-6003-25)",Reverified,8/28/2024,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,,2024,not available
14717,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Ativan Injection (Lorazepam Injection, Usp), Injection, 2 Mg/1 Ml (NDC 0641-6000-10)",Reverified,8/28/2024,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,,2024,not available
14718,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Ativan Injection (Lorazepam Injection, Usp), Injection, 2 Mg/1 Ml (NDC 0641-6001-25)",Reverified,8/28/2024,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,,2024,not available
14719,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 2 Mg/1 Ml (NDC 76329-8261-1)",Reverified,8/20/2024,Limited Availability,,,Demand Increase For The Drug,Neurology,Current,,,,2024,limited availability
14720,Lorazepam Injection,"Hospira, Inc., A Pfizer Company","Injection, 2 Mg/1 Ml Syringes (NDC 0409-1985-30)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,,Demand Increase For The Drug,Neurology,Current,,,,2024,limited availability
14721,Mafenide Acetate Solution,"Par Pharmaceutical, Inc.","Solution, 50 G (NDC 49884-902-78)",New,11/30/2023,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,11/30/2023,,2024,discontinued
14722,Mefloquine Hydrochloride Tablet,"Teva Pharmaceuticals Usa, Inc.","Tablet, 250 Mg (NDC 0555-0171-78)",Revised,8/23/2024,Unavailable,Estimated Recovery November 2024,,Delay In Shipping Of The Drug,Anti-Infective,Current,,,,2024,not available
14723,Melphalan Tablet,Alvogen,"Tablet, 2 Mg (NDC 47781-200-50)",New,2/23/2024,,"Discontinuation Due To Low Sales Volume.   Supply Currently Available With April, 2024 Expiry Dating.",,,Oncology,To Be Discontinued,,2/23/2024,,2024,discontinued
14724,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 28 Mg (NDC 0456-3428-90)",New,8/7/2024,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/2024,,2024,discontinued
14725,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 14mg (NDC 0456-3414-90)",New,8/7/2024,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/2024,,2024,discontinued
14726,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 7mg +14 Mg+21 Mg+28mg (NDC 0456-3400-29)",New,8/7/2024,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/2024,,2024,discontinued
14727,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 28 Mg (NDC 0456-3428-33)",New,8/7/2024,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/2024,,2024,discontinued
14728,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 21 Mg (NDC 0456-3421-33)",New,8/7/2024,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/2024,,2024,discontinued
14729,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 14 Mg (NDC 0456-3414-33)",New,8/7/2024,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/2024,,2024,discontinued
14730,"Mesalamine Capsule, Delayed Release",Abbvie Inc.,"Delzicol, Capsule, Delayed Release, 400 Mg (NDC 0023-5853-18)",New,10/25/2023,,Sales Expected To Last Until June 2024,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology,To Be Discontinued,,10/25/2023,,2024,discontinued
14731,"Mesalamine Capsule, Delayed Release",Abbvie Inc.,"Capsule, Delayed Release, 400 Mg (NDC 59762-0117-1)",New,10/25/2023,,Sales Expected To Last Until June 2024,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology,To Be Discontinued,,10/25/2023,,2024,discontinued
14732,"Mesalamine Tablet, Delayed Release",Takeda Pharmaceuticals Usa Inc.,"Tablet, Delayed Release, 1.2 G (NDC 54092-100-01)",New,2/6/2024,,The Brand Lialda Will Continue To Be Available,,,Gastroenterology,To Be Discontinued,,2/6/2024,,2024,discontinued
14733,Methamphetamine Hydrochloride Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 5 Mg (NDC 0054-0389-25)",Reverified,8/28/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14734,Methamphetamine Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 5 Mg (NDC 68308-115-01)",Reverified,7/23/2024,Available,Available To Existing Customers,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,available
14735,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 16729-277-35)",Revised,8/19/2024,"Limited Availability, 30 Days",Short Dated Inventory Available; Fresh Manufacturing In Process At Plant Site,,Requirements Related To Complying With Good Manufacturing Practices,Rheumatology; Oncology,Current,,,,2024,limited availability
14736,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 16729-277-03)",Revised,2/5/2024,,,,,Rheumatology; Oncology,To Be Discontinued,2/5/2024,2/5/2024,,2024,discontinued
14737,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 16729-277-30)",Revised,8/19/2024,"Limited Availability, 30 Days",Short Dated Inventory Available; Inventory On Hold Pending Further Assessment,,Requirements Related To Complying With Good Manufacturing Practices,Rheumatology; Oncology,Current,,,,2024,limited availability
14738,Methotrexate Sodium Injection,"Fresenius Kabi Usa, Llc","Injection, 25 Mg/1 Ml (NDC 63323-123-10)",Revised,9/4/2024,Available,"6, 7 & 8 Month Expiry Available.  Check Wholesalers For Inventory.",,,Rheumatology; Oncology,Current,,,,2024,available
14739,Methotrexate Sodium Injection,"Fresenius Kabi Usa, Llc","Methotrexate Preservative Free, Injection, 1 G (NDC 63323-122-50)",Reverified,9/4/2024,Available,Check Wholesaler For Inventory,,,Rheumatology; Oncology,Current,,,,2024,available
14740,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 1 G/40 Ml (25 Mg/Ml) (NDC 61703-124-40)",Reverified,8/26/2024,Available,,,,Rheumatology; Oncology,Current,,,,2024,available
14741,Methotrexate Sodium Injection,"Teva Pharmaceuticals Usa, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 0703-3678-01)",Revised,9/4/2024,Available,Estimated Recovery January 2025,,,Rheumatology; Oncology,Current,,,,2024,available
14742,Methotrexate Sodium Injection,"Teva Pharmaceuticals Usa, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 0703-3675-01)",Revised,9/4/2024,Available,,,Demand Increase For The Drug,Rheumatology; Oncology,Current,,,,2024,available
14743,Methotrexate Sodium Injection,"Teva Pharmaceuticals Usa, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 0703-3671-01)",Revised,9/4/2024,Available,,,,Rheumatology; Oncology,Current,,,,2024,available
14744,Methotrexate Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Methotrexate Injection,Usp Preservative Free, Injection, 25 Mg/1 Ml (NDC 0143-9519-10)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Rheumatology; Oncology,Current,,,,2024,available
14745,Methotrexate Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Methotrexate Injection, Usp Preservative Free, Injection, 1 G (NDC 0143-9830-01)",Reverified,8/28/2024,Available,Currently Available.  Additional Product Will Be Made Available As It Is Released.,,,Rheumatology; Oncology,Current,,,,2024,available
14746,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 1 G/40 Ml (25 Mg/Ml) (NDC 61703-408-25)",Reverified,8/26/2024,Available,,,,Rheumatology; Oncology,Current,,,,2024,available
14747,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 1 G/40 Ml (25 Mg/Ml) (NDC 61703-408-41)",Reverified,8/26/2024,Available,,,,Rheumatology; Oncology,Current,,,,2024,available
14748,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 50 Mg/2 Ml  (25 Mg/Ml) (NDC 61703-350-10)",Revised,8/26/2024,Available,Check Wholesaler For Availability Shortage Per Manufacturer: Manufacturing Delay,,,Rheumatology; Oncology,Current,,,,2024,available
14749,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 50 Mg/2 Ml (25 Mg/Ml) (NDC 61703-350-38)",Revised,8/26/2024,Limited Availability,Estimated Recovery: December 2024,,Demand Increase For The Drug,Rheumatology; Oncology,Current,,,,2024,limited availability
14750,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 Mg (NDC 69238-1423-1)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14751,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 Mg (NDC 69238-1423-6)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14752,Methotrexate Sodium Tablet,Zydus Pharmaceuticals Usa Inc.,"Tablet, 2.5 Mg (NDC 68382-775-01)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14753,Methotrexate Sodium Tablet,"Mylan Pharmaceuticals Inc., A Viatris Company","Tablet, 2.5 Mg (NDC 0378-0014-01)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14754,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Trexall, Tablet, 15 Mg (NDC 51285-369-01)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14755,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Trexall, Tablet, 10 Mg (NDC 51285-368-01)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14756,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Trexall, Tablet, 7.5 Mg (NDC 51285-367-01)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14757,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Trexall, Tablet, 5 Mg (NDC 51285-366-01)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14758,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Tablet, 2.5 Mg (NDC 0555-0572-35)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14759,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Tablet, 2.5 Mg (NDC 0555-0572-02)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14760,Methotrexate Sodium Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 2.5 Mg (NDC 0054-4550-25)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14761,Methotrexate Sodium Tablet,"Sun Pharmaceutical Industries, Inc.","Methotrexate Sodium, Tablet, 2.5 Mg (NDC 47335-235-96)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14762,Methotrexate Sodium Tablet,"Sun Pharmaceutical Industries, Inc.","Methotrexate Sodium, Tablet, 2.5 Mg (NDC 47335-235-83)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14763,Methotrexate Sodium Tablet,Accord Healthcare Inc.,"Tablet, 2.5 Mg (NDC 16729-486-01)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14764,Methotrexate Sodium Tablet,Eugia Us Llc,"Tablet, 2.5 Mg (NDC 59651-182-01)",Revised,6/27/2024,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/2024,,,2024,
14765,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 250 Mg (NDC 16729-030-01)",Revised,2/5/2024,,,,,Cardiovascular,To Be Discontinued,2/5/2024,2/5/2024,,2024,discontinued
14766,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 500 Mg (NDC 16729-031-16)",Revised,2/5/2024,,,,,Cardiovascular,To Be Discontinued,2/5/2024,2/5/2024,,2024,discontinued
14767,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 500 Mg (NDC 16729-031-01)",Revised,2/5/2024,,,,,Cardiovascular,To Be Discontinued,2/5/2024,2/5/2024,,2024,discontinued
14768,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 250 Mg (NDC 16729-030-16)",Revised,2/5/2024,,,,,Cardiovascular,To Be Discontinued,2/5/2024,2/5/2024,,2024,discontinued
14769,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, Usp   Cii, Tablet, Extended Release, 18 Mg (NDC 62037-725-01)",Revised,8/23/2024,Available,,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,available
14770,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 54 Mg (NDC 62175-313-37)",Reverified,9/3/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14771,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 36 Mg (NDC 62175-312-37)",Reverified,9/3/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14772,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 27 Mg (NDC 62175-311-37)",Reverified,9/3/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14773,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 18 Mg (NDC 62175-310-37)",Reverified,9/3/2024,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14774,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Tablet, Extended Release, 54 Mg (NDC 0406-0154-01)",Revised,8/15/2024,Limited Availability,Backorder. Next Release Mid Sept. Intermittent Backorder Through November.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14775,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Tablet, Extended Release, 36 Mg (NDC 0406-0136-01)",Revised,8/15/2024,Unavailable,Backorder. Next Release Mid Sept. Intermittent Backorder Through November,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14776,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Tablet, Extended Release, 27 Mg (NDC 0406-0127-01)",Revised,8/15/2024,Limited Availability,Allocation To All Customers.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14777,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Methylin Er, Tablet, Extended Release, 20 Mg (NDC 0406-1473-01)",Revised,8/15/2024,Limited Availability,Allocation To All Customers; Expected Backorder Late Sept.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14778,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Methylin Er, Tablet, Extended Release, 10 Mg (NDC 0406-1445-01)",Revised,8/15/2024,Limited Availability,Allocations To All Customers. Backorder Projected October.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,limited availability
14779,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 Mg (NDC 57664-609-88)",Reverified,8/26/2024,Unavailable,Currently Not Marketed,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,Current,,,,2024,not available
14780,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 Mg (NDC 57664-608-88)",Reverified,8/26/2024,Unavailable,Currently Not Marketed,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,Current,,,,2024,not available
14781,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 Mg (NDC 57664-607-88)",Reverified,8/26/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14782,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 Mg (NDC 57664-606-88)",Reverified,8/26/2024,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,,2024,not available
14783,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, Usp   Cii, Tablet, Extended Release, 27 Mg (NDC 62037-734-01)",Revised,8/23/2024,Available,,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,available
14784,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 72 Mg (NDC 13811-710-30)",Revised,3/7/2024,Available,,,,Psychiatry,Current,,,,2024,available
14785,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 54 Mg (NDC 50458-587-01)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14786,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 36 Mg (NDC 50458-586-01)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14787,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 27 Mg (NDC 50458-588-01)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14788,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 18 Mg (NDC 50458-585-01)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14789,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 63 Mg (NDC 13811-700-30)",Revised,3/7/2024,Available,,,,Psychiatry,Current,,,,2024,available
14790,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 Mg (NDC 13811-709-10)",Revised,3/7/2024,Available,Allocation To Current Contracted Customers,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,available
14791,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 45 Mg (NDC 13811-711-30)",Revised,3/7/2024,Available,,,,Psychiatry,Current,,,,2024,available
14792,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 Mg (NDC 13811-708-10)",Revised,3/7/2024,Available,Allocation To Current Contracted Customers,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,available
14793,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 Mg (NDC 13811-707-10)",Revised,3/7/2024,Available,Allocation To Current Contracted Customers,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,available
14794,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 Mg (NDC 13811-706-10)",Revised,3/7/2024,Available,Allocation To Current Contracted Customers,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,available
14795,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy'S Laboratories, Inc.","Tablet, Extended Release, 54 Mg (NDC 43598-441-01)",Revised,7/23/2024,Unavailable,Estimated Availability Tbd,,Other,Psychiatry,Current,,,,2024,not available
14796,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy'S Laboratories, Inc.","Tablet, Extended Release, 36 Mg (NDC 43598-440-01)",Revised,7/23/2024,Unavailable,Unavailable. Estimated Limited Supplies From Aug 2024,,Other,Psychiatry,Current,,,,2024,not available
14797,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy'S Laboratories, Inc.","Tablet, Extended Release, 27 Mg (NDC 43598-439-01)",Revised,7/23/2024,Unavailable,Estimated Availability Tbd,,Other,Psychiatry,Current,,,,2024,not available
14798,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy'S Laboratories, Inc.","Tablet, Extended Release, 18 Mg (NDC 43598-438-01)",Revised,7/23/2024,Unavailable,Estimated Availability Tbd,,Other,Psychiatry,Current,,,,2024,not available
14799,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, Usp   Cii, Tablet, Extended Release, 54 Mg (NDC 62037-727-01)",Revised,8/23/2024,Limited Availability,Estimated Recovery October 2024,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,limited availability
14800,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, Usp   Cii, Tablet, Extended Release, 36 Mg (NDC 62037-726-01)",Revised,8/23/2024,Limited Availability,Estimated Recovery 'October 2024,,Demand Increase For The Drug,Psychiatry,Current,,,,2024,limited availability
14801,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 36 Mg (NDC 68025-097-10)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14802,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 18 Mg (NDC 68025-095-10)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14803,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 72 Mg (NDC 68025-084-30)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14804,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 45 Mg (NDC 68025-088-30)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14805,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 54 Mg (NDC 68025-098-10)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14806,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 27 Mg (NDC 68025-096-10)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14807,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 63 Mg (NDC 68025-089-30)",Reverified,9/4/2024,Available,,,,Psychiatry,Current,,,,2024,available
14808,Methylprednisolone Acetate Injection,Eugia Us Llc,"Injection, 80 Mg/1 Ml (NDC 55150-314-01)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Rheumatology,Current,,,,2024,not available
14809,Methylprednisolone Acetate Injection,Eugia Us Llc,"Injection, 40 Mg/1 Ml (NDC 55150-313-01)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Rheumatology,Current,,,,2024,available
14810,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","Injection, 80 Mg/1 Ml (NDC 42023-240-01)",Revised,9/3/2024,Unavailable,Recovery: Nov 2024,,Other,Rheumatology,Current,,,,2024,not available
14811,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 80 Mg/1 Ml (NDC 25021-821-05)",Reverified,7/1/2024,Available,,,,Rheumatology,Current,,,,2024,available
14812,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 40 Mg/1 Ml (NDC 25021-820-05)",Reverified,7/1/2024,Available,,,,Rheumatology,Current,,,,2024,available
14813,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 40 Mg/1 Ml (NDC 25021-820-10)",Reverified,7/1/2024,Available,,,,Rheumatology,Current,,,,2024,available
14814,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 80 Mg/1 Ml (NDC 0009-3475-03)",Revised,8/26/2024,Next Delivery: August 2024; Estimated Recovery: September 2024,Shortage Per Manufacturer: Manufacturing Delay,,Delay In Shipping Of The Drug,Rheumatology,Current,,,,2024,not available
14815,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 80 Mg/1 Ml (NDC 0009-3475-01)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14816,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-3073-23)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14817,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-3073-22)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14818,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-3073-03)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14819,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Injection, 80 Mg/1 Ml (NDC 70121-1574-1)",Revised,7/9/2024,Available,Sufficient Inventory Available (02 To 04 Wk) As Per Current Demand.Next Supply From Wk. Of 7th July-24,,,Rheumatology,Current,,,,2024,available
14820,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Injection, 40 Mg/1 Ml (NDC 70121-1573-5)",Revised,7/9/2024,Available,Sufficient Inventory Available (02 To 04 Wk) As Per Current Demand.Next Supply From Wk. Of 7th July-24,,,Rheumatology,Current,,,,2024,available
14821,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Injection, 40 Mg/1 Ml (NDC 70121-1573-1)",Revised,7/9/2024,Available,Sufficient Inventory Available (02 To 04 Wk) As Per Current Demand.Next Supply From Wk. Of 14th July-24,,,Rheumatology,Current,,,,2024,available
14822,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-3073-01)",Revised,8/26/2024,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,Check Wholesaler For Availability Shortage Per Manufacturer: Manufacturing Delay,,Delay In Shipping Of The Drug,Rheumatology,Current,,,,2024,limited availability
14823,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 80 Mg/1 Ml (NDC 0009-0306-12)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14824,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 80 Mg/1 Ml (NDC 0009-0306-02)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14825,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-0280-52)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14826,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-0280-51)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14827,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-0280-03)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14828,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-0280-02)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14829,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 20 Mg/1 Ml (NDC 0009-0274-01)",Reverified,8/26/2024,Available,,,,Rheumatology,Current,,,,2024,available
14830,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Injection, 80 Mg/1 Ml (NDC 70121-1574-5)",Revised,7/9/2024,Available,Available Inventory For 1 Week As Per Current Demand.Next Supply From Wk. Of 14th July-24,,,Rheumatology,Current,,,,2024,available
14831,Metronidazole Injection,Gland Pharma Limited,"Metronidazole In Plastic Container, Injection, 500 Mg/100 Ml (NDC 47335-993-01)",Reverified,7/15/2024,Limited Availability,,,Demand Increase For The Drug,Anti-Infective,Current,,,,2024,limited availability
14832,Metronidazole Injection,Baxter Healthcare,"Flagyl I.V. Rtu In Plastic Container, Injection, 500 Mg/100 Ml (NDC 0338-1055-48)",Reverified,7/17/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14833,Metronidazole Injection,B. Braun Medical Inc.,"Metro I.V. In Plastic Container, Injection, 500 Mg/100 Ml (NDC 0264-5535-32)",Reverified,9/3/2024,Available,On Allocation,,,Anti-Infective,Current,,,,2024,available
14834,Midazolam Hydrochloride Injection,Wg Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 Mg/1 Ml (NDC 44567-611-10)",Reverified,9/1/2024,Available,Please Check Wholesalers And Distributors For Inventory.,,,Anesthesia; Neurology,Current,,,,2024,available
14835,Midazolam Hydrochloride Injection,Wg Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 Mg/1 Ml (NDC 44567-610-10)",Reverified,9/1/2024,Available,Please Check Wholesalers And Distributors For Inventory.,,,Anesthesia; Neurology,Current,,,,2024,available
14836,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 1 Mg/1 Ml (NDC 23155-600-41)",Reverified,9/3/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14837,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 5 Mg/1 Ml (NDC 23155-601-41)",Revised,9/3/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14838,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 5 Mg/1 Ml (NDC 23155-601-42)",Revised,9/3/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14839,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 10 Mg/10 Ml (1 Mg/Ml) (NDC 0409-2587-05)",Revised,8/26/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14840,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 25 Mg/5 Ml (5 Mg/Ml) (NDC 0409-2596-03)",Reverified,8/26/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14841,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 10 Mg/2 Ml (5 Mg/Ml) (NDC 0409-2308-02)",Reverified,8/26/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14842,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/10 Ml (5 Mg/Ml) (NDC 0409-2596-05)",Revised,8/26/2024,Unavailable,Next Delivery: July 2026; Estimated Recovery: September 2026,,Demand Increase For The Drug,Anesthesia; Neurology,Current,,,,2024,not available
14843,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 Mg/Ml (5 Mg/Ml) (NDC 0409-2308-01)",Reverified,8/26/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14844,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 Mg/5 Ml (1 Mg/Ml) (NDC 0409-2305-05)",Reverified,8/26/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14845,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 2 Mg/2ml (1 Mg/Ml) (NDC 0409-2305-17)",Reverified,8/26/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14846,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 5 Mg/1 Ml (NDC 0641-6060-10)",Revised,8/28/2024,Unavailable,Additional Lots Will Be Available In The September - October 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Anesthesia; Neurology,Current,,,,2024,not available
14847,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 5 Mg/1 Ml (NDC 0641-6061-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Anesthesia; Neurology,Current,,,,2024,available
14848,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0641-6059-01)",Revised,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Anesthesia; Neurology,Current,,,,2024,available
14849,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0641-6057-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Anesthesia; Neurology,Current,,,,2024,available
14850,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0641-6056-10)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Anesthesia; Neurology,Current,,,,2024,available
14851,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 5 Mg/1 Ml (NDC 63323-412-02)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,,2024,available
14852,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 5 Mg/1 Ml (NDC 63323-412-10)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,,2024,available
14853,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 5 Mg/1 Ml (NDC 63323-412-25)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,,2024,available
14854,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-411-25)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,,2024,available
14855,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-411-12)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,,2024,available
14856,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Midazolam Hydrochloride Preservative Free, Injection, 2 Mg/2 Ml (NDC 76045-001-20)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,,2024,available
14857,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-411-10)",Revised,9/4/2024,Limited Availability,3 & 6 Mos Dating Available For Wholesalers. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia; Neurology,Current,,,,2024,limited availability
14858,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 Mg/2 Ml (NDC 47781-588-68)",Revised,7/15/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14859,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 Mg/2 Ml (NDC 70860-600-02)",Revised,7/15/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14860,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 Mg/1 Ml (NDC 47781-589-91)",Revised,7/15/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14861,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 Mg/1 Ml (NDC 47781-589-17)",Revised,7/15/2024,Unavailable,,,Demand Increase For The Drug,Anesthesia; Neurology,Current,,,,2024,not available
14862,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 Mg/1 Ml (NDC 70860-601-05)",Revised,7/15/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14863,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 Mg/1 Ml (NDC 70860-601-10)",Revised,7/15/2024,Available,,,,Anesthesia; Neurology,Current,,,,2024,available
14864,Minocycline Extended Release Tablet,Epi Health,"Minolira, Extended Release Tablet, 135 Mg (NDC 71403-102-30)",New,11/2/2023,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,11/2/2023,,2024,discontinued
14865,Minocycline Extended Release Tablets,Epi Health,"Minolira, Extended Release Tablets, 105mg (NDC 71403-101-30)",New,11/2/2023,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,11/2/2023,,2024,discontinued
14866,"Minocycline Hydrochloride Capsule, Extended Release",Journey Medical Corporation,"Ximino, Capsule, Extended Release, 45 Mg (NDC 69489-121-30)",New,9/29/2023,,Discontinuation Due To Business Reasons.,,Discontinuation Of The Manufacture Of The Drug,Antibiotic,To Be Discontinued,,9/29/2023,,2024,discontinued
14867,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 76045-005-11)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14868,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 2 Mg/1 Ml (NDC 76045-004-11)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14869,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 Mg/1 Ml (NDC 0641-6040-01)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14870,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 Mg/1 Ml (NDC 0641-6039-01)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14871,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Duramorph (Morphine Sulfate Injection, Usp), Injection, .5 Mg/1 Ml (NDC 0641-6020-10)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14872,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Duramorph (Morphine Sulfate Injection, Usp), Injection, 1 Mg/1 Ml (NDC 0641-6019-10)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14873,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-451-01)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14874,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 5 Mg/1 Ml (NDC 63323-455-01)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14875,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-454-01)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14876,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 2 Mg/1 Ml (NDC 63323-452-01)",Revised,8/2/2024,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,,2024,available
14877,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 1 Mg/1 Ml (NDC 76329-1912-1)",Reverified,8/20/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14878,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 8 Mg/1 Ml Syringes (NDC 0409-1892-01)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14879,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Morphine Sulfate Injection, Usp, Injection, 10 Mg/1 Ml (NDC 0641-6127-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14880,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Morphine Sulfate Injection, Usp, Injection, 8 Mg/1 Ml (NDC 0641-6126-25)",Reverified,8/28/2024,Available,Currently Available.  Additional Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14881,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Morphine Sulfate Injection, Usp, Injection, 4 Mg/1 Ml (NDC 0641-6125-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,,2024,available
14882,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 50 Mg/1 Ml (NDC 0409-1134-05)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: December 2024,,Other,Analgesia/Addiction,Current,,,,2024,not available
14883,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 50 Mg/1 Ml (NDC 0409-1896-20)",Revised,8/26/2024,Unavailable,Next Delivery: December 2024; Estimated Recovery: March 2025,,Other,Analgesia/Addiction,Current,,,,2024,not available
14884,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 10 Mg/10 Ml (1 Mg/Ml) (NDC 0409-3815-12)",Revised,8/26/2024,Limited Availability,Limited Supply Available; Estimated Recovery: September 2024,,Other,Analgesia/Addiction,Current,,,,2024,limited availability
14885,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 5 Mg/10 Ml (0.5 Mg/Ml) (NDC 0409-3814-12)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Other,Analgesia/Addiction,Current,,,,2024,limited availability
14886,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 10 Mg/1 Ml Syringes (NDC 0409-1893-01)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14887,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 4 Mg/1 Ml Syringes (NDC 0409-1891-01)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14888,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 2 Mg/1 Ml Syringes (NDC 0409-1890-01)",Reverified,8/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14889,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, Usp), Injection, 500 Mg/20 Ml (NDC 66794-162-02)",Revised,6/19/2024,Limited Availability,,,Shortage Of An Active Ingredient,Analgesia/Addiction,Current,,,,2024,limited availability
14890,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, Usp), Injection, 200 Mg/20 Ml (NDC 66794-160-02)",Revised,6/26/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14891,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 15 Mg (NDC 0228-4270-11)",New,4/3/2024,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/2024,,2024,discontinued
14892,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 15 Mg (NDC 0228-4270-11)",New,3/5/2024,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/2024,,2024,discontinued
14893,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 30 Mg (NDC 0228-4271-11)",New,4/3/2024,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/2024,,2024,discontinued
14894,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 30 Mg (NDC 0228-4271-11)",New,3/5/2024,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/2024,,2024,discontinued
14895,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 60 Mg (NDC 0228-4311-11)",New,4/3/2024,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/2024,,2024,discontinued
14896,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 60 Mg (NDC 0228-4311-11)",New,3/5/2024,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/2024,,2024,discontinued
14897,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 100 Mg (NDC 0228-4323-11)",New,4/3/2024,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/2024,,2024,discontinued
14898,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 100 Mg (NDC 0228-4323-11)",New,3/5/2024,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/2024,,2024,discontinued
14899,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 200 Mg (NDC 0228-4347-11)",New,4/3/2024,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/2024,,2024,discontinued
14900,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 200 Mg (NDC 0228-4347-11)",New,3/5/2024,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/2024,,2024,discontinued
14901,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 400 Mg (NDC 55111-112-01)",New,10/4/2023,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,10/4/2023,,2024,discontinued
14902,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 400 Mg (NDC 55111-112-05)",New,10/4/2023,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,10/4/2023,,2024,discontinued
14903,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 400 Mg (NDC 55111-112-66)",New,10/4/2023,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,10/4/2023,,2024,discontinued
14904,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 400 Mg (NDC 55111-112-66)",New,10/4/2023,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,10/4/2023,,2024,discontinued
14905,Multi-Vitamin Infusion (Adult And Pediatric) Injection,"Hospira, Inc., A Pfizer Company","M.V.I. Pediatric, Injection, 7 Mg/5 Ml; 80 Mg/5 Ml; 20 Ug/5 Ml; 1 Ug/5 Ml; 5 Mg/5 Ml; 10 Ug/5 Ml; 140 Ug/5 Ml; 17 Mg/5 Ml; 200 Ug/5 Ml; 1 Mg/5 Ml; .7 Mg/5 Ml; 1.4 Mg/5 Ml; 1.2 Mg/5 Ml (NDC 61703-421-53)",Revised,10/30/2023,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/2023,10/30/2023,,2024,discontinued
14906,Multi-Vitamin Infusion (Adult And Pediatric) Injection,"Hospira, Inc., A Pfizer Company","M.V.I. Adult, Injection, 2 Box In 1 Case (61703-422-83)  (NDC 61703-422-83)",Revised,10/30/2023,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/2023,10/30/2023,,2024,discontinued
14907,Multi-Vitamin Infusion (Adult And Pediatric) Injection,"Hospira, Inc., A Pfizer Company","M.V.I. Adult, Injection, 10 Kit In 1 Package (61703-434-82) (NDC 61703-434-82)",Revised,10/30/2023,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/2023,10/30/2023,,2024,discontinued
14908,Naltrexone Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Tablet, 50 Mg (NDC 62135-242-60)",Reverified,9/2/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
14909,Naltrexone Hydrochloride Tablet,Specgx Llc,"Tablet, 50 Mg (NDC 0406-1170-03)",Revised,8/15/2024,Limited Availability,Long Term Allocations To Primary Customers With Intermittent Backorder Expected Through Mid 2025.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,limited availability
14910,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Tablet, 50 Mg (NDC 47335-326-08)",Reverified,8/26/2024,Unavailable,Currently Not Marketed,,Other,Analgesia/Addiction,Current,,,,2024,not available
14911,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Tablet, 50 Mg (NDC 47335-326-83)",Reverified,8/26/2024,Limited Availability,,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,limited availability
14912,Naltrexone Hydrochloride Tablet,Specgx Llc,"Tablet, 50 Mg (NDC 0406-1170-01)",Revised,8/15/2024,Limited Availability,Long Term Allocations To Primary Customers With Intermittent Backorder Expected Through Mid 2025.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,limited availability
14913,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Tablet, 50 Mg (NDC 47335-326-18)",Reverified,8/26/2024,Unavailable,Currently Not Marketed,,Other,Analgesia/Addiction,Current,,,,2024,not available
14914,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Tablet, 50 Mg (NDC 47335-326-88)",Reverified,8/26/2024,Limited Availability,,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,limited availability
14915,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Tablet, 50 Mg (NDC 51224-206-30)",Reverified,9/2/2024,Available,Marketed By Tagi Pharma,,,Analgesia/Addiction,Current,,,,2024,available
14916,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Tablet, 50 Mg (NDC 51224-206-50)",Reverified,9/2/2024,Available,Marketed By Tagi Pharma,,,Analgesia/Addiction,Current,,,,2024,available
14917,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Tablet, 50 Mg (NDC 68094-909-30)",Reverified,9/2/2024,Available,Marketed By Precision Dose,,,Analgesia/Addiction,Current,,,,2024,available
14918,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Tablet, 50 Mg (NDC 68094-909-50)",Reverified,9/2/2024,Available,Marketed By Precision Dose,,,Analgesia/Addiction,Current,,,,2024,available
14919,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Tablet, 50 Mg (NDC 16729-081-10)",Revised,7/23/2024,Limited Availability,,,Shortage Of An Active Ingredient,Analgesia/Addiction,Current,,,,2024,limited availability
14920,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Tablet, 50 Mg (NDC 16729-081-01)",Revised,7/23/2024,Unavailable,,,Shortage Of An Active Ingredient,Analgesia/Addiction,Current,,,,2024,not available
14921,Neomycin Sulfate Tablet,"Xgen Pharmaceuticals Djb, Inc.","Tablet, 500 Mg (NDC 39822-0310-5)",Revised,5/17/2024,,,Available,,Anti-Infective,Resolved,5/17/2024,,,2024,
14922,Neomycin Sulfate Tablet,"Teva Pharmaceuticals Usa, Inc.","Neomycin Sulfate Tablets, Usp, Tablet, 500 Mg (NDC 0093-1177-01)",Revised,5/17/2024,,,Available,,Anti-Infective,Resolved,5/17/2024,,,2024,
14923,Nifedipine Capsule,Pfizer Inc.,"Procardia, Capsule, 10 Mg (NDC 59762-1004-1)",New,12/27/2023,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,11/26/2023,,2024,discontinued
14924,Nifedipine Capsule,Pfizer Inc.,"Capsule, 10 Mg (NDC 59762-1004-1)",New,10/26/2023,,Discontinuation Of The Manufacture Of The Drug. Supply Expected To Exhaust November 2023.,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,10/26/2023,,2024,discontinued
14925,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin In Dextrose 5%, Injection, 40 Mg/100 Ml (NDC 0338-1051-02)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14926,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin In Dextrose 5%, Injection, 20 Mg/100 Ml (NDC 0338-1049-02)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14927,Nitroglycerin Injection,"American Regent, Inc.","Injection, 5 Mg/1 Ml (NDC 0517-4810-25)",Reverified,7/15/2024,Unavailable,Estimated Availability: Q3 2024,,Demand Increase For The Drug,Cardiovascular,Current,,,,2024,not available
14928,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin In Dextrose 5%, Injection, 10 Mg/100 Ml (NDC 0338-1047-02)",Reverified,9/5/2024,Available,,,,Cardiovascular,Current,,,,2024,available
14929,Norethindrone Acetate / Ethinyl Estradiol / Ferrous Fumarate Capsule,Amneal Pharmaceuticals,"Taysofy™, Capsule, 1mg/20mcg  (NDC 1111-1111-11)",New,2/6/2024,,,,,Reproductive,To Be Discontinued,,2/6/2024,,2024,discontinued
14930,Ofatumumab Injection,Novartis Pharmaceuticals Corporation,"Arzerra, Injection, 20 Mg/1 Ml (NDC 0078-0669-13)",New,11/3/2023,,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,11/3/2023,,2024,discontinued
14931,Ofatumumab Injection,Novartis Pharmaceuticals Corporation,"Arzerra, Injection, 20 Mg/1 Ml (NDC 0078-0690-61)",New,11/3/2023,,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,11/3/2023,,2024,discontinued
14932,Omeprazole; Sodium Bicarbonate	 For Suspension,"Par Pharmaceutical, Inc.","For Suspension, 20 Mg; 1680 Mg (NDC 49884-268-11)",New,12/7/2023,,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology,To Be Discontinued,,12/7/2023,,2024,discontinued
14933,Omeprazole; Sodium Bicarbonate Suspension,"Par Pharmaceutical, Inc.","Suspension, 40 Mg; 1680 Mg (NDC 49884-269-11)",New,12/7/2023,,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology,To Be Discontinued,,12/7/2023,,2024,discontinued
14934,Oxaliplatin Injection,"Actavis Pharma, Inc.","Injection, 5 Mg/1 Ml (NDC 45963-611-53)",New,3/25/2024,,,,,Oncology,To Be Discontinued,,3/25/2024,,2024,discontinued
14935,Oxaliplatin Injection,"Actavis Pharma, Inc.","Injection, 5 Mg/1 Ml (NDC 45963-611-59)",New,3/25/2024,,,,,Oncology,To Be Discontinued,,3/25/2024,,2024,discontinued
14936,Oxybutynin Chloride Syrup,"Lannett Company, Inc.","Syrup, 5 Mg/5 Ml (NDC 54838-510-80)",Revised,8/29/2024,,,Available,,Urology,Resolved,8/29/2024,,,2024,
14937,Oxybutynin Chloride Syrup,Chartwell Molecular Holdings Llc,"Syrup, 5 Mg/5 Ml (NDC 62135-520-47)",Revised,8/29/2024,,,Available,,Urology,Resolved,8/29/2024,,,2024,
14938,Pantoprazole Sodium Injection,Aspiro Pharma Ltd.,"Pantoprazole Sodium, Injection, 40 Mg (NDC 31722-204-10)",Revised,9/15/2023,,,"Available. Marketed By Camber Pharmaceuticals, Inc.",,Gastroenterology,Resolved,9/15/2023,,,2024,
14939,Parathyroid Hormone Injection,Takeda Pharmaceuticals Usa Inc.,"Natpara, Injection, 100 Ug/.08 Ml, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Reverified,9/3/2024,Unavailable,The 100 Mcg Cartridge Is No Longer Available And Takeda Is Unable To Resupply Prior To Ceasing Of Manufacturing Of Natpara At The End Of 2024. Please Refer To The Following Link For More Details Â€“ Https://Www.Takeda.Com/En-Us/Newsroom/Statements/2022/Takeda-To-Discontinue-Manufacturing-Of-Natpar-Natpara/,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,,2024,not available
14940,Parathyroid Hormone Injection,Takeda Pharmaceuticals Usa Inc.,"Natpara, Injection, 75 Ug/.08 Ml, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Reverified,9/3/2024,Unavailable,Takeda Will Be Ceasing Manufacturing Of Natpara At The End Of 2024 With A Priority To Maintain Treatment Continuity For Patients Enrolled In The U.S. Special Use Program Until Inventory Is Depleted Or Expired. Please Refer To The Following Link For More Details Â€“ Https://Www.Takeda.Com/En-Us/Newsroom/Statements/2022/Takeda-To-Discontinue-Manufacturing-Of-Natpar-Natpara/,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,,2024,not available
14941,Parathyroid Hormone Injection,Takeda Pharmaceuticals Usa Inc.,"Natpara, Injection, 50 Ug/.08 Ml, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Reverified,9/3/2024,Unavailable,Takeda Will Be Ceasing Manufacturing Of Natpara At The End Of 2024 With A Priority To Maintain Treatment Continuity For Patients Enrolled In The U.S. Special Use Program Until Inventory Is Depleted Or Expired. Please Refer To The Following Link For More Details Â€“ Https://Www.Takeda.Com/En-Us/Newsroom/Statements/2022/Takeda-To-Discontinue-Manufacturing-Of-Natpar-Natpara/,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,,2024,not available
14942,Parathyroid Hormone Injection,Takeda Pharmaceuticals Usa Inc.,"Natpara, Injection, 25 Ug/.08 Ml, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Reverified,9/3/2024,Unavailable,Takeda Will Be Ceasing Manufacturing Of Natpara At The End Of 2024 With A Priority To Maintain Treatment Continuity For Patients Enrolled In The U.S. Special Use Program Until Inventory Is Depleted Or Expired. Please Refer To The Following Link For More Details Â€“ Https://Www.Takeda.Com/En-Us/Newsroom/Statements/2022/Takeda-To-Discontinue-Manufacturing-Of-Natpar-Natpara/,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,,2024,not available
14943,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 2400000 [Iu]/4 Ml (NDC 60793-702-10)",Revised,9/6/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14944,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 1200000 [Iu]/2 Ml (NDC 60793-701-10)",Revised,9/6/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14945,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 600000 [Iu]/1 Ml (NDC 60793-700-10)",Revised,9/6/2024,Unavailable,"Next Delivery And Estimated Recovery:  Q1, 2025",,Delay In Shipping Of The Drug,Anti-Infective,Current,,,,2024,not available
14946,Penicillin G Benzathine Injection,Laboratorios Atral,"Lentocilin, Injection, 1200000 U/4 Ml (NDC 84383-110-01)",Revised,9/3/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14947,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 1,200,000 Units (NDC 81284-521-01)",Revised,7/24/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14948,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 2,400,000 Units (NDC 81284-522-01)",Revised,7/24/2024,Available,,,,Anti-Infective,Current,,,,2024,available
14949,Phenytoin Oral Suspension,Vistapharm,"Oral Suspension, 125 Mg/5 Ml (NDC 66689-036-50)",New,2/28/2024,,,,,Neurology,To Be Discontinued,,2/28/2024,,2024,discontinued
14950,Phenytoin Oral Suspension,Vistapharm,"Oral Suspension, 125 Mg/5 Ml (NDC 66689-775-08)",New,2/28/2024,,,,,Neurology,To Be Discontinued,,2/28/2024,,2024,discontinued
14951,Phenytoin Sodium Extended-Release Capsule,Amneal Pharmaceuticals,"Extended-Release Capsule, 100 Mg (NDC 65162-212-10)",New,3/21/2024,,,,,Neurology,To Be Discontinued,,3/21/2024,,2024,discontinued
14952,Phenytoin Sodium Extended-Release Capsule,Amneal Pharmaceuticals,"Extended-Release Capsule, 100 Mg (NDC 65162-212-11)",New,3/21/2024,,,,,Neurology,To Be Discontinued,,3/21/2024,,2024,discontinued
14953,Phenytoin Sodium Extended-Release Capsule,Amneal Pharmaceuticals,"Extended-Release Capsule, 100 Mg (NDC 65162-212-50)",New,3/21/2024,,,,,Neurology,To Be Discontinued,,3/21/2024,,2024,discontinued
14954,Posaconazole Oral Suspension,Merck Sharp & Dohme Llc,"Noxafil, Oral Suspension, 40mg/Ml (NDC 0085-1328-01)",New,11/15/2023,,"To Be Discontinued On December 18th, 2023.",,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,11/15/2023,,2024,discontinued
14955,Posaconazole Suspension,Merck Sharp & Dohme Llc,"Noxafil, Suspension, 40 Mg/1 Ml (NDC 0085-1328-01)",New,11/27/2023,,To Be Discontinued On18 Dec 2023.,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,11/27/2023,,2024,discontinued
14956,"Posaconazole Tablet, Delayed Release","Merck Sharp & Dohme Corp., A Subsidiary Of Merck And Co., Inc.","Noxafil, Tablet, Delayed Release, 100 Mg (NDC 0085-4324-02)",New,7/22/2024,,,,,Anti-Infective,To Be Discontinued,,7/22/2024,,2024,discontinued
14957,Potassium Acetate Injection,"Exela Pharma Sciences, Llc","Injection, 3.93 G/20 Ml (NDC 51754-2001-4)",Revised,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,available
14958,Potassium Acetate Injection,"Hospira, Inc., A Pfizer Company","Potassium Acetate, Injection, 40 Meq/20 Ml (2 Meq/Ml) (NDC 0409-8183-25)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,available
14959,Potassium Acetate Injection,"Hospira, Inc., A Pfizer Company","Potassium Acetate, Injection, 100 Meq/50 Ml (2 Meq/Ml) (NDC 0409-3294-25)",Revised,8/26/2024,Unavailable,Next Delivery: November 2024; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,not available
14960,Potassium Acetate Injection,"Hospira, Inc., A Pfizer Company","Potassium Acetate, Injection, 40 Meq/20 Ml (2 Meq/Ml) (NDC 0409-8183-01)",Revised,8/26/2024,Unavailable,Estimated Recovery: September 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,not available
14961,Potassium Acetate Injection,"Hospira, Inc., A Pfizer Company","Potassium Acetate, Injection, 100 Meq/50 Ml (2 Meq/Ml) (NDC 0409-3294-51)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,limited availability
14962,Potassium Chloride Injection,B. Braun Medical Inc.,"Injection, 14.9 G/100 Ml (NDC 0264-1944-20)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14963,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 29.8 G/1000 Ml (NDC 0338-0703-41)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14964,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 14.9 G/1000 Ml (NDC 0338-0705-48)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14965,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 14.9 G/1000 Ml (NDC 0338-0705-41)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14966,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 7.46 G/1000 Ml (NDC 0338-0709-48)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14967,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 10 Meq (NDC 14789-109-16)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14968,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 10 Meq (NDC 14789-108-08)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14969,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 20 Meq (NDC 14789-108-16)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14970,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 40 Meq (NDC 14789-107-16)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14971,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 20 Meq (NDC 14789-107-08)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14972,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 40meq In Plastic Container, Injection, 400 Meq/1000 Ml (NDC 0990-7077-26)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14973,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 20meq In Plastic Container, Injection, 200 Meq/1000 Ml (NDC 0990-7075-26)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14974,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 10meq In Plastic Container, Injection, 200 Meq/1000 Ml (NDC 0990-7075-14)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14975,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 10meq In Plastic Container, Injection, 10 Meq/100 Ml (NDC 0990-7074-26)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14976,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 20meq In Plastic Container, Injection, 400 Meq/1000 Ml (NDC 0990-7077-14)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14977,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 29.8 G/1000 Ml (NDC 0338-0703-48)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14978,Potassium Chloride Injection,B. Braun Medical Inc.,"Injection, 14.9 G/100 Ml (NDC 0264-1940-20)",Revised,2/2/2024,,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,2/6/2024,2/2/2024,,2024,discontinued
14979,Potassium Chloride Injection,"Fresenius Kabi Usa, Llc","Potassium Chloride In Plastic Container, Injection, 2 Meq/1 Ml (NDC 63323-965-20)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14980,Potassium Chloride Injection,"Fresenius Kabi Usa, Llc","Potassium Chloride In Plastic Container, Injection, 2 Meq/1 Ml (NDC 63323-965-10)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14981,Potassium Chloride Injection,"Fresenius Kabi Usa, Llc","Potassium Chloride In Plastic Container, Injection, 2 Meq/1 Ml (NDC 63323-965-05)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14982,Potassium Chloride Injection,"Fresenius Kabi Usa, Llc","Potassium Chloride In Plastic Container, Injection, 2 Meq/1 Ml (NDC 63323-967-30)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14983,Potassium Chloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 149 Mg/1 Ml (NDC 0409-6653-05)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14984,Potassium Chloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 149 Mg/1 Ml (NDC 0409-6651-06)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14985,Potassium Chloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 149 Mg/1 Ml (NDC 0409-6635-01)",Revised,5/7/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/2024,,,2024,
14986,Pralatrexate Solution,"Fresenius Kabi Usa, Llc","Folotyn, Solution, 20 Mg/1 Ml (NDC 65219-550-01)",New,3/21/2024,,,,,Hematology; Oncology,To Be Discontinued,,3/21/2024,,2024,discontinued
14987,Pralatrexate Solution,"Fresenius Kabi Usa, Llc","Folotyn, Solution, 40 Mg/2 Ml (NDC 65219-552-02)",New,3/21/2024,,,,,Hematology; Oncology,To Be Discontinued,,3/21/2024,,2024,discontinued
14988,Praziquantel Tablet,Bayer Healthcare Pharmaceuticals Inc.,"Biltricide, Tablet, 600 Mg (NDC 50419-747-01)",New,3/5/2024,,,,,Anti-Infective,To Be Discontinued,,3/5/2024,,2024,discontinued
14989,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Phenergan Injection (Promethazine Hcl Injection,Usp, Injection, 50 Mg/1 Ml (NDC 0641-6085-25)",Reverified,8/28/2024,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2024,available
14990,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Phenergan Injection (Promethazine Hcl Injection,Usp, Injection, 50 Mg/1 Ml (NDC 0641-6083-25)",Reverified,8/28/2024,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2024,available
14991,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Phenergan Injection (Promethazine Hcl Injection,Usp, Injection, 25 Mg/1 Ml (NDC 0641-6082-25)",Revised,8/28/2024,Unavailable,Additional Lots Will Be Available In The September - October 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2024,not available
14992,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Phenergan Injection (Promethazine Hcl Injection,Usp, Injection, 25 Mg/1 Ml (NDC 0641-6084-25)",Reverified,8/28/2024,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2024,available
14993,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Promethazine Hcl Injection, Usp, Injection, 50 Mg/1 Ml (NDC 0641-1496-35)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2024,available
14994,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Promethazine Hcl Injection, Usp, Injection, 25 Mg/1 Ml (NDC 0641-1495-35)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2024,available
14995,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Promethazine Hcl Injection, Usp, Injection, 50 Mg/1 Ml (NDC 0641-0929-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2024,available
14996,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Promethazine Hcl Injection, Usp, Injection, 25 Mg/1 Ml (NDC 0641-0928-25)",Reverified,8/28/2024,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,,2024,available
14997,Promethazine Hydrochloride Injection,"Xgen Pharmaceuticals Djb, Inc.","Promethazine Hydrochloride, Injection, 25 Mg/1 Ml (NDC 39822-5525-3)",Reverified,7/16/2024,Available,,,,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,,2024,available
14998,Promethazine Hydrochloride Injection,"Xgen Pharmaceuticals Djb, Inc.","Promethazine Hydrochloride, Injection, 50 Mg/1 Ml (NDC 39822-5550-6)",Reverified,7/16/2024,Available,,,,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,,2024,available
14999,Propranolol Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-604-01)",Revised,8/15/2024,Unavailable,Backordered. Next Release August 2024; Check Wholesalers For Inventory,,Demand Increase For The Drug,Cardiovascular,Current,,,,2024,not available
15000,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Propranolol Hcl Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0143-9872-10)",Reverified,8/28/2024,Unavailable,,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,,2024,not available
15001,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Propranolol Hcl Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0143-9872-10)",Reverified,8/28/2024,Unavailable,,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,,2024,not available
15002,Quinapril Hydrochloride Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride, Tablet, 10 Mg (NDC 65862-618-90)",Reverified,7/2/2024,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,,2024,discontinued
15003,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 10 Mg (NDC 68180-557-09)",Reverified,8/19/2024,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,,2024,not available
15004,Quinapril Hydrochloride Tablet,"Solco Healthcare Us, Llc","Tablet, 40 Mg (NDC 43547-413-09)",Reverified,9/3/2024,Unavailable,Not Available. Long-Term Backorder For All Ndcs. No Estimated Release Date At This Time.,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,,2024,not available
15005,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 5 Mg (NDC 0071-0527-23)",Reverified,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
15006,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 20 Mg (NDC 0071-0532-23)",Reverified,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
15007,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 10 Mg (NDC 0071-0530-23)",Reverified,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
15008,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 40 Mg (NDC 0071-0535-23)",Reverified,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
15009,Quinapril Hydrochloride Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride, Tablet, 40 Mg (NDC 65862-620-90)",Reverified,7/2/2024,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,,2024,discontinued
15010,Quinapril Hydrochloride Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride, Tablet, 10 Mg (NDC 65862-618-90)",Reverified,7/2/2024,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,,2024,discontinued
15011,Quinapril Hydrochloride Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride, Tablet, 5 Mg (NDC 65862-617-90)",Reverified,7/2/2024,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,,2024,discontinued
15012,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 40 Mg (NDC 68180-554-09)",Reverified,8/19/2024,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,,2024,not available
15013,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 20 Mg (NDC 68180-558-09)",Reverified,8/19/2024,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,,2024,not available
15014,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 5 Mg (NDC 68180-556-09)",Reverified,8/19/2024,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,,2024,not available
15015,Quinapril Hydrochloride Tablet,"Solco Healthcare Us, Llc","Tablet, 20 Mg (NDC 43547-412-09)",Reverified,9/3/2024,Unavailable,Not Available. Long-Term Backorder For All Ndcs. No Estimated Release Date At This Time.,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,,2024,not available
15016,Quinapril Hydrochloride Tablet,"Solco Healthcare Us, Llc","Tablet, 10 Mg (NDC 43547-411-09)",Reverified,9/3/2024,Unavailable,Not Available. Long-Term Backorder For All Ndcs. No Estimated Release Date At This Time.,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,,2024,not available
15017,Quinapril Hydrochloride Tablet,"Solco Healthcare Us, Llc","Tablet, 5 Mg (NDC 43547-410-09)",Reverified,9/3/2024,Unavailable,Not Available. Long-Term Backorder For All Ndcs. No Estimated Release Date At This Time.,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,,2024,not available
15018,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Quinapril Hydrochloride, Tablet, 5 Mg (NDC 62135-484-60)",Reverified,9/2/2024,Available,,,,Cardiovascular,Current,,,,2024,available
15019,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Quinapril Hydrochloride, Tablet, 10 Mg (NDC 62135-485-90)",Reverified,9/2/2024,Available,,,,Cardiovascular,Current,,,,2024,available
15020,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Quinapril Hydrochloride, Tablet, 20 Mg (NDC 62135-486-90)",Reverified,9/2/2024,Available,,,,Cardiovascular,Current,,,,2024,available
15021,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Quinapril Hydrochloride, Tablet, 40 Mg (NDC 62135-487-90)",Reverified,9/2/2024,Available,,,,Cardiovascular,Current,,,,2024,available
15022,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 Mg; 20 Mg (NDC 65862-163-90)",Reverified,7/2/2024,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,,2024,discontinued
15023,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 Mg; 20 Mg (NDC 65862-162-90)",Reverified,7/2/2024,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,,2024,discontinued
15024,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 Mg; 10 Mg (NDC 65862-161-90)",Reverified,7/2/2024,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,,2024,discontinued
15025,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 Mg/20 Mg (NDC 0071-0223-23)",Reverified,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
15026,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 20 Mg/12.5 Mg (NDC 0071-0220-23)",Reverified,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
15027,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 10 Mg/12.5 Mg (NDC 0071-0222-23)",Reverified,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,,2024,not available
15028,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings Llc,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 Mg; 10 Mg (NDC 62135-667-90)",Reverified,9/2/2024,Available,,,,Cardiovascular,Current,,,,2024,available
15029,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings Llc,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 Mg; 20 Mg (NDC 62135-668-90)",Reverified,9/2/2024,Available,,,,Cardiovascular,Current,,,,2024,available
15030,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings Llc,"Quinapril/Hydrochlorothiazide, Tablet, 25 Mg; 20 Mg (NDC 62135-669-90)",Reverified,9/2/2024,Available,,,,Cardiovascular,Current,,,,2024,available
15031,Remifentanil Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Ultiva, Injection, 1 Mg/1 Ml (NDC 72078-034-01)",Reverified,9/5/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
15032,Remifentanil Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-725-10)",Reverified,9/4/2024,Unavailable,Backordered. Next Release Not Available At This Time; Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
15033,Remifentanil Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-724-05)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
15034,Remifentanil Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-723-03)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
15035,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Remifentanil Hcl For Injection, Injection, 5 Mg Per Vial (NDC 0143-9393-10)",Revised,7/25/2024,Unavailable,,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
15036,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Remifentanil Hcl For Injection, Injection, 2 Mg Per Vial (NDC 0143-9392-10)",Revised,7/25/2024,Unavailable,Additional Lots Will Be Available In The August 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
15037,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Remifentanil Hcl For Injection, Injection, 1 Mg Per Vial (NDC 0143-9391-10)",Revised,7/25/2024,Unavailable,Additional Lots Will Be Available In The August 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
15038,Remifentanil Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Ultiva, Injection, 5 Mg (NDC 67457-198-10)",Reverified,9/5/2024,Unavailable,Next Supply In Q4-2024.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,,2024,not available
15039,Remifentanil Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Ultiva, Injection, 2 Mg (NDC 72078-035-02)",Reverified,9/5/2024,Available,,,,Analgesia/Addiction,Current,,,,2024,available
15040,Reteplase Injection,"Chiesi Usa, Inc.","Retavase, Injection, 10 Ml/Vial (NDC 10122-143-01)",New,9/5/2024,,,,,Cardiovascular,To Be Discontinued,,9/5/2024,,2024,discontinued
15041,Reteplase Injection,"Chiesi Usa, Inc.","Retavase, Injection, 10 Ml/Vial (NDC 10122-141-02)",New,9/5/2024,,,,,Cardiovascular,To Be Discontinued,,9/5/2024,,2024,discontinued
15042,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 Mg (NDC 68180-659-07)",Reverified,8/19/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15043,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 Mg (NDC 68180-659-06)",Reverified,8/19/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15044,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 150 Mg (NDC 68180-658-06)",Reverified,8/19/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15045,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 300 Mg (NDC 42806-799-05)",Reverified,9/3/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15046,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 300 Mg (NDC 42806-799-01)",Reverified,9/3/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15047,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 300 Mg (NDC 42806-799-60)",Reverified,9/3/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15048,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 300 Mg (NDC 42806-799-30)",Reverified,9/3/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15049,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 150 Mg (NDC 42806-801-01)",Reverified,9/3/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15050,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 150 Mg (NDC 42806-801-30)",Reverified,9/3/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15051,Rifampin Injection,"Mylan Institutional, A Viatris Company","Injection, 600 Mg/10 Ml (NDC 67457-445-60)",Reverified,9/5/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15052,Rifampin Injection,Sanofi-Aventis U.S. Llc,"Rifadin, Injection, 600 Mg/10 Ml (NDC 0068-0597-01)",Reverified,7/1/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15053,Rifampin Injection,"Fresenius Kabi Usa, Llc","Injection, 600 Mg (NDC 63323-351-20)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anti-Infective,Current,,,,2024,available
15054,"Rifapentine Tablet, Film Coated",Sanofi-Aventis U.S. Llc,"Priftin, Tablet, Film Coated, 150 Mg (NDC 0088-2102-24)",Reverified,7/1/2024,Available,,,,Anti-Infective,Current,,,,2024,available
15055,Riluzole Oral Suspension,"Edw Pharma, Inc. (Formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 Mg/1 Ml (NDC 70726-0306-1)",Reverified,9/3/2024,Available,,,,Neurology,Current,,,,2024,available
15056,Riluzole Oral Suspension,"Edw Pharma, Inc. (Formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 Mg/1 Ml (NDC 70726-0305-1)",Reverified,9/3/2024,Available,,,,Neurology,Current,,,,2024,available
15057,Riluzole Oral Suspension,"Edw Pharma, Inc. (Formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 Mg/1 Ml (NDC 70726-0304-1)",Reverified,9/3/2024,Available,,,,Neurology,Current,,,,2024,available
15058,Riluzole Oral Suspension,"Edw Pharma, Inc. (Formerly Italfarmaco Pharma, Inc.)","Tiglutik, Oral Suspension, 50 Mg/10 Ml (NDC 70726-0303-2)",Reverified,9/3/2024,Unavailable,Next Release Not Available At This Time; Shortage Per Manufacturer: Product Manufacturing Interrupted Due To Viscosity Testing,,Requirements Related To Complying With Good Manufacturing Practices,Neurology,Current,,,,2024,not available
15059,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 71288-718-11)",Reverified,7/3/2024,Available,,,,Anesthesia,Current,,,,2024,available
15060,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 71288-700-06)",Reverified,7/3/2024,Available,,,,Anesthesia,Current,,,,2024,available
15061,Rocuronium Bromide Injection,"Mylan Institutional, A Viatris Company","Rocuronium Bromide, Injection, 10 Mg/1 Ml (NDC 67457-228-10)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
15062,Rocuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 65219-065-05)",Revised,9/4/2024,Limited Availability,5 Month Expiry Available Upon Request; Check Wholesalers For Inventory,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,limited availability
15063,Rocuronium Bromide Injection,"Hikma Pharmaceuticals Usa, Inc.","Rocuronium Bromide Injection, Injection, 10 Mg/1 Ml (NDC 0143-9251-10)",Reverified,8/28/2024,Available,,,,Anesthesia,Current,,,,2024,available
15064,Rocuronium Bromide Injection,"Hikma Pharmaceuticals Usa, Inc.","Rocuronium Bromide Injection, Injection, 10 Mg/1 Ml (NDC 0143-9250-10)",Reverified,8/28/2024,Available,Additional Lots Will Be Available.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,,2024,available
15065,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 100 Mg/10 Ml (NDC 43066-013-10)",Reverified,9/5/2024,Available,Tamarang Is The Application Holder And Baxter Is The Distributor/Labeler,,,Anesthesia,Current,,,,2024,available
15066,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 50 Mg/5 Ml (NDC 43066-007-10)",Reverified,9/5/2024,Available,Tamarang Is The Application Holder And Baxter Is The Distributor/Labeler,,,Anesthesia,Current,,,,2024,available
15067,Rocuronium Bromide Injection,Eugia Us Llc,"Injection, 50 Mg/5 Ml (NDC 55150-225-05)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
15068,Rocuronium Bromide Injection,Eugia Us Llc,"Injection, 100 Mg/10 Ml (NDC 55150-226-10)",Revised,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
15069,Rocuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Rocuronium Bromide, Injection, 100 Mg/10 Ml (10 Mg/Ml) (NDC 0409-5160-10)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
15070,Rocuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Injection, 100 Mg/10 Ml (10 Mg/Ml) (NDC 0409-7037-10)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
15071,Rocuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 0409-1403-10)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
15072,Rocuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 0409-3189-10)",Reverified,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
15073,Rocuronium Bromide Injection,Sandoz Inc.,"Injection, 10 Mg/1 Ml (NDC 0781-3220-92)",Reverified,8/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
15074,Rocuronium Bromide Injection,Sandoz Inc.,"Injection, 10 Mg/1 Ml (NDC 0781-3220-95)",Reverified,8/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
15075,Rocuronium Bromide Injection,"Mylan Institutional, A Viatris Company","Rocuronium Bromide, Injection, 10 Mg/1 Ml (NDC 67457-228-05)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
15076,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 25021-687-05)",Reverified,7/1/2024,Available,,,,Anesthesia,Current,,,,2024,available
15077,Rocuronium Bromide Injection,"Xgen Pharmaceuticals Djb, Inc.","Injection, 100 Mg/10 Ml (NDC 39822-4200-6)",Reverified,7/16/2024,Available,Tamarang Is The Application Holder And X-Gen Is The Distributor/Labeler,,,Anesthesia,Current,,,,2024,available
15078,Rocuronium Bromide Injection,"Xgen Pharmaceuticals Djb, Inc.","Injection, 50 Mg/5 Ml (NDC 39822-4200-2)",Reverified,7/16/2024,Available,Tamarang Is The Application Holder And X-Gen Is The Distributor/Labeler,,,Anesthesia,Current,,,,2024,available
15079,Rocuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-426-10)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15080,Rocuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-426-05)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15081,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Injection, 50 Mg/5 Ml (NDC 66794-228-41)",Revised,6/26/2024,Limited Availability,,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,limited availability
15082,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Injection, 100 Mg/10 Ml (NDC 66794-229-41)",Revised,6/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
15083,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 2 Mg/1 Ml (NDC 25021-671-67)",Reverified,7/1/2024,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2024,available
15084,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 2 Mg/1 Ml (NDC 25021-671-66)",Reverified,7/1/2024,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2024,available
15085,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 5 Mg/1 Ml (NDC 70069-064-25)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
15086,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 5 Mg/1 Ml (NDC 70069-064-10)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
15087,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 5 Mg/1 Ml (NDC 70069-064-01)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
15088,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2 Mg/1 Ml (NDC 70069-062-25)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
15089,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2 Mg/1 Ml (NDC 70069-062-10)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
15090,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2 Mg/1 Ml (NDC 70069-061-25)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
15091,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2 Mg/1 Ml (NDC 70069-061-10)",Reverified,8/30/2024,Available,,,,Anesthesia,Current,,,,2024,available
15092,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 10 Mg/1 Ml (NDC 43066-027-10)",Reverified,7/16/2024,Available,Check Wholesalers For Inventory; Marketed By Baxter,,,Anesthesia,Current,,,,2024,available
15093,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 5 Mg/1 Ml (NDC 43066-023-10)",Reverified,7/16/2024,Limited Availability,Limited Supply; Check Wholesalers For Inventory; Marketed By Baxter,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,limited availability
15094,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 5 Mg/1 Ml (NDC 43066-019-10)",Reverified,7/16/2024,Available,Check Wholesalers For Inventory; Marketed By Baxter,,,Anesthesia,Current,,,,2024,available
15095,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 43066-015-10)",Reverified,7/16/2024,Limited Availability,Check Wholesalers For Inventory; Marketed By Baxter,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,limited availability
15096,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 5 Mg/1 Ml (NDC 25021-652-87)",Reverified,7/1/2024,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2024,available
15097,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 5 Mg/1 Ml (NDC 25021-652-82)",Reverified,7/1/2024,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2024,available
15098,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 2 Mg/1 Ml (NDC 25021-671-87)",Reverified,7/1/2024,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2024,available
15099,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 2 Mg/1 Ml (NDC 25021-671-82)",Reverified,7/1/2024,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,,2024,available
15100,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-31)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
15101,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 10 Mg/1 Ml (NDC 63323-288-21)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15102,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 10 Mg/1 Ml (NDC 63323-288-11)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15103,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 7.5 Mg/1 Ml (NDC 63323-287-21)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15104,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-23)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15105,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-35)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15106,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-23)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15107,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-13)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15108,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-63)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15109,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-00)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15110,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-64)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15111,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-65)",Reverified,9/4/2024,Available,,,,Anesthesia,Current,,,,2024,available
15112,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-63)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
15113,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-61)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
15114,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 10 Mg/1 Ml (NDC 63323-288-20)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
15115,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 10 Mg/1 Ml (NDC 63323-288-10)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
15116,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 7.5 Mg/1 Ml (NDC 63323-287-20)",Revised,9/4/2024,Limited Availability,7 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,limited availability
15117,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-20)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
15118,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-20)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,,2024,not available
15119,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-10)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
15120,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/1 Ml (NDC 55150-201-20)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15121,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/1 Ml (NDC 55150-200-10)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15122,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 7.5 Mg/1 Ml (NDC 55150-199-20)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15123,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 5 Mg/1 Ml (NDC 55150-198-30)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15124,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 5 Mg/1 Ml (NDC 55150-197-20)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15125,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 2 Mg/1 Ml (NDC 55150-196-99)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15126,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 2 Mg/1 Ml (NDC 55150-195-20)",Revised,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15127,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, 2.68 Mg/1 Ml (NDC 0169-4772-12)",Revised,8/6/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15128,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, 1.34 Mg/1 Ml (NDC 0169-4130-13)",Revised,8/6/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15129,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 2.4 Mg/.75 Ml (NDC 0169-4524-14)",Revised,8/6/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15130,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 1.7 Mg/.75 Ml (NDC 0169-4517-14)",Revised,8/6/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15131,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 1 Mg/.5 Ml (NDC 0169-4501-14)",Revised,8/6/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15132,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, .5 Mg/.5 Ml (NDC 0169-4505-14)",Revised,8/6/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15133,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, .25 Mg/.5 Ml (NDC 0169-4525-14)",Revised,8/6/2024,Limited Availability,Estimated Shortage Duration Tbd,,Demand Increase For The Drug,Endocrinology/Metabolism,Current,,,,2024,limited availability
15134,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, .68 Mg/1 Ml (NDC 0169-4181-13)",Revised,8/6/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15135,"Sildenafil Powder, For Suspension","Mylan Specialty, A Viatris Company","Revatio 10mg/Ml Pos 1x1 Gbtl Us, Powder, For Suspension, 10mg/Ml (NDC 0069-0336-21)",New,8/14/2024,,,,,Cardiovascular,To Be Discontinued,,8/14/2024,,2024,discontinued
15136,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 40 Meq/20 Ml (2 Meq/Ml) (NDC 0409-7299-25)",Revised,8/26/2024,Unavailable,Estimated Recovery: September 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,not available
15137,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 100 Meq/50 Ml (2 Meq/Ml) (NDC 0409-3299-26)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,not available
15138,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 200 Meq/100 Ml (2 Meq/Ml) (NDC 0409-3299-25)",Revised,8/26/2024,Unavailable,Next Delivery: December 2024; Estimated Recovery: March 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,not available
15139,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 200 Meq/100ml (2 Meq/Ml) (NDC 69784-231-10)",Reverified,9/3/2024,Available,,,,Total Parenteral Nutrition,Current,,,,2024,available
15140,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 100 Meq/50ml (2 Meq/Ml) (NDC 69784-230-10)",Reverified,9/3/2024,Available,,,,Total Parenteral Nutrition,Current,,,,2024,available
15141,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 100 Meq/50 Ml (2 Meq/Ml) (NDC 0409-3299-05)",Revised,8/26/2024,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,limited availability
15142,Sodium Acetate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Meq/100 Ml (NDC 63323-032-00)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Total Parenteral Nutrition,Current,,,,2024,available
15143,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 40 Meq/20 Ml (2 Meq/Ml) (NDC 0409-7299-73)",Revised,8/26/2024,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,limited availability
15144,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 200 Meq/100 Ml (2 Meq/Ml) (NDC 0409-3299-06)",Revised,8/26/2024,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,limited availability
15145,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 40 Meq/20ml (2 Meq/Ml) (NDC 69784-229-10)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,available
15146,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 400 Meq/100ml (4 Meq/Ml) (NDC 69784-232-01)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,available
15147,Sodium Benzoate; Sodium Phenylacetate Injection,"Bausch Health Americas, Inc.","Ammonul, Injection, 100 Mg/1 Ml; 100 Mg/1 Ml (NDC 0187-0010-50)",New,7/3/2024,,Discontinuation Due To Business Decision,,,Inborn Errors; Other,To Be Discontinued,,7/3/2024,,2024,discontinued
15148,Sodium Benzoate; Sodium Phenylacetate Injection,"Bausch Health Americas, Inc.","Ammonul, Injection, 100 Mg/1 Ml; 100 Mg/1 Ml (NDC 68682-001-50)",New,7/3/2024,,Discontinuation Due To Business Decision,,,Inborn Errors; Other,To Be Discontinued,,7/3/2024,,2024,discontinued
15149,Sodium Bicarbonate Injection,"Exela Pharma Sciences, Llc","Injection, 42 Mg/1 Ml (NDC 51754-5012-4)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,available
15150,Sodium Bicarbonate Injection,"Exela Pharma Sciences, Llc","Injection, 84 Mg/1 Ml (NDC 51754-5011-4)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,available
15151,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 10 Meq/10 Ml (8.4%, 1 Meq/Ml) Syringes (NDC 0409-4900-14)",Revised,8/26/2024,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
15152,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Meq/50 Ml (8.4%, 1 Meq/Ml) (NDC 0409-6625-35)",Revised,8/26/2024,Unavailable,Next Delivery: April 2025; Estimated Recovery: June 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
15153,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Meq/50 Ml (8.4%, 1 Meq/Ml) (NDC 0409-6625-14)",Revised,8/26/2024,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,limited availability
15154,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 44.6 Meq/50 Ml (7.5%, 0.9 Meq/Ml) Syringes (NDC 0409-4916-14)",Revised,8/26/2024,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
15155,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 2.5 Meq/5 Ml (4.2%, 0.5 Meq/Ml) (NDC 0409-5555-01)",Revised,8/26/2024,Unavailable,Next Delivery: April 2025; Estimated Recovery: June 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
15156,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 2.5 Meq/5 Ml (4.2%, 0.5 Meq/Ml) (NDC 0409-5555-02)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,limited availability
15157,Sodium Bicarbonate Injection,"Exela Pharma Sciences, Llc","Injection, 84 Mg/1 Ml (NDC 51754-5001-5)",Reverified,9/3/2024,Available,Available In Ndc 51754-5001-4 Which Is Carton Of 25 Vials. The 521754-5001-05 Was Discontinued Over A Year Ago.,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,available
15158,Sodium Bicarbonate Injection,"Fresenius Kabi Usa, Llc","Injection, 84 Mg/1 Ml (NDC 63323-089-50)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,available
15159,Sodium Bicarbonate Injection,"Fresenius Kabi Usa, Llc","Injection, 42 Mg/1 Ml (NDC 63323-083-05)",Reverified,9/4/2024,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory,,Demand Increase For The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
15160,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 84 Mg/1 Ml (NDC 76329-3352-1)",Reverified,8/20/2024,Limited Availability,On Allocation,,Demand Increase For The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,limited availability
15161,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Sodium Bicarbonate, Injection, 50 Meq/50 Ml (8.4%, 1 Meq/Ml) Syringes (NDC 0409-6637-14)",Revised,8/26/2024,Unavailable,Next Delivery: January 2025; Estimated Recovery: June 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
15162,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Sodium Bicarbonate, Injection, 5 Meq/10 Ml (4.2%, 0.5 Meq/Ml) Syringes (NDC 0409-5534-14)",Revised,8/26/2024,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,,2024,not available
15163,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-23)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-23",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15164,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .45 G/100 Ml (NDC 0264-7802-10)",Reverified,9/3/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15165,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .45 G/100 Ml (NDC 0264-7802-00)",Reverified,9/3/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15166,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-09)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-09",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15167,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-03)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-03",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15168,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-55)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-55",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15169,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-02)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-02",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15170,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-61)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-61",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15171,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 1000 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)",Reverified,5/18/2024,Available,Product Available For Contracted Customers.,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15172,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 500 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)",Reverified,5/18/2024,Available,Product Available For Contracted Customers.,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15173,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 250 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)",Reverified,5/18/2024,Available,Product Available For Contracted Customers.,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15174,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 100 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)",Reverified,5/18/2024,Available,Product Available For Contracted Customers.,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15175,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 50 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)",Revised,5/18/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15176,Sodium Chloride 0.9% Injection,Guerbet Llc,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 Mg/1 Ml (NDC 0019-1188-27)",Reverified,5/31/2024,Unavailable,Sodium Chloride Injection In Rfid Presentation Is Not Available And The Plan Is To Discontinue This Presentation From Sales,,Discontinuation Of The Manufacture Of The Drug,Other,Current,,,,2024,not available
15177,Sodium Chloride 0.9% Injection,Guerbet Llc,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 Mg/1 Ml (NDC 0019-1188-81)",Revised,5/31/2024,Available,,,,Other,Current,,,,2024,available
15178,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-20)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-20",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15179,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-37)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-37",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15180,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-36)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-36",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15181,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-13)",Reverified,9/4/2024,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-13",,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15182,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, Llc","Sodium Chloride 0.9%, Injection, 9 Mg/1 Ml (NDC 65282-1505-1)",Reverified,6/26/2024,Available,,,,Other,Current,,,,2024,available
15183,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, Llc","Sodium Chloride 0.9%, Injection, 9 Mg/1 Ml (NDC 65282-1510-1)",Reverified,6/26/2024,Available,,,,Other,Current,,,,2024,available
15184,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-623-61)",Revised,9/4/2024,Available,Check Wholesalers For Inventory,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15185,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-623-53)",Reverified,9/4/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15186,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-11)",Reverified,5/18/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15187,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-41)",Reverified,5/18/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15188,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-01)",Reverified,5/18/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15189,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-31)",Reverified,5/18/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15190,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-21)",Reverified,5/18/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15191,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (9%, 9mg/Ml) (NDC 0409-7101-02)",Reverified,8/26/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15192,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (9%, 9mg/Ml) (NDC 0409-7101-67)",Reverified,8/26/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15193,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (9%, 9mg/Ml) (NDC 0409-7101-66)",Reverified,8/26/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15194,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 0264-1800-36)",Reverified,9/3/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15195,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 0264-1800-31)",Reverified,9/3/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15196,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 0264-1800-32)",Reverified,9/3/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15197,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 G/100 Ml (NDC 0264-7800-09)",Reverified,9/3/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15198,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 G/100 Ml (NDC 0264-7800-20)",Reverified,9/3/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15199,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 G/100 Ml (NDC 0264-7800-10)",Reverified,9/3/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15200,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 G/100 Ml (NDC 0264-7800-00)",Reverified,9/3/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15201,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-1966-07)",Reverified,8/26/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15202,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-1966-05)",Reverified,8/26/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15203,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-1966-12)",Revised,8/26/2024,Unavailable,Next Delivery And Estimated Recovery: September 2024,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,not available
15204,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-924-10)",Reverified,9/4/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15205,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-924-30)",Reverified,9/4/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15206,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-06)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15207,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-04)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15208,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-02)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15209,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0338-0553-18)",Reverified,7/17/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15210,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0338-9159-30)",Reverified,6/21/2024,Limited Availability,On Allocation; Recovery Q3,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15211,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 450 Mg/100 Ml (NDC 0338-9151-30)",Reverified,9/5/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15212,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0338-0553-11)",Reverified,9/5/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15213,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-04)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15214,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-06)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15215,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-02)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15216,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-38)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15217,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-11)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15218,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-10)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15219,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-04)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15220,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-03)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15221,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-02)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15222,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-31)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15223,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-48)",Revised,6/21/2024,Limited Availability,Recovery Late July 2024,,Delay In Shipping Of The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15224,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-41)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15225,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-18)",Reverified,9/5/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15226,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 65219-474-10)",Reverified,9/4/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15227,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 65219-472-20)",Reverified,9/4/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15228,Sodium Chloride 0.9% Injection,"Medefil, Inc.","Sodium Chloride 0.9%, Injection, 9 Mg/1 Ml (NDC 64253-202-30)",Revised,9/3/2024,Available,,,,Other,Current,,,,2024,available
15229,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-4888-50)",Reverified,8/26/2024,Available,,,,Other,Current,,,,2024,available
15230,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-4888-20)",Reverified,8/26/2024,Available,,,,Other,Current,,,,2024,available
15231,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-4888-12)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery And Estimated Recovery: December 2024,,Demand Increase For The Drug,Other,Current,,,,2024,limited availability
15232,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-4888-10)",Reverified,8/26/2024,Available,,,,Other,Current,,,,2024,available
15233,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride, Injection, 9 Mg/1 Ml (NDC 63323-186-00)",Reverified,9/4/2024,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Other,Current,,,,2024,not available
15234,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-186-20)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Other,Current,,,,2024,available
15235,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-186-10)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,Demand Increase For The Drug,Other,Current,,,,2024,available
15236,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-186-02)",Revised,9/4/2024,Limited Availability,1 & 4 Month Expiry Available Upon Request; Check Wholesalers For Inventory,,Demand Increase For The Drug,Other,Current,,,,2024,limited availability
15237,Sodium Chloride 0.9% Injection,"Hikma Pharmaceuticals Usa, Inc.","Sodium Chloride Injection Usp, 0.9%, Injection, 9 Mg/1 Ml (NDC 0641-0497-25)",Reverified,8/28/2024,Unavailable,This Presentation Is Temporarily On Backorder.  Recovery Is Tbd At This Time.,,Demand Increase For The Drug,Other,Current,,,,2024,not available
15238,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride, Injection, 4 Meq/1 Ml (NDC 63323-095-61)",Revised,9/4/2024,Available,Check Wholesalers For Inventory,,Demand Increase For The Drug,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,,2024,available
15239,Sodium Chloride 0.9% Irrigation,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0990-7138-09)",Reverified,9/4/2024,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7138-09",,Other,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15240,Sodium Chloride 0.9% Irrigation,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0990-6138-03)",Reverified,9/4/2024,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-6138-03",,Other,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15241,Sodium Chloride 0.9% Irrigation,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0990-6138-22)",Reverified,9/4/2024,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-6138-22",,Other,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15242,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0338-0048-04)",Reverified,6/21/2024,Limited Availability,On Allocation; Recovery Q3,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15243,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0338-0048-03)",Reverified,6/21/2024,Limited Availability,On Allocation; Recovery Q3,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15244,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0338-0048-02)",Reverified,6/21/2024,Limited Availability,On Allocation; Recovery Q3,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15245,Sodium Chloride 0.9% Irrigation,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0990-7138-36)",Reverified,9/4/2024,Unavailable,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7138-36",,Other,Gastroenterology; Other; Pediatric,Current,,,,2024,not available
15246,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 G/100ml (NDC 0264-2201-10)",Reverified,9/3/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15247,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 G/100ml (NDC 0264-7388-50)",Reverified,9/3/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15248,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 G/100ml (NDC 0264-2201-00)",Reverified,9/3/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15249,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 G/100ml (NDC 0264-7388-60)",Reverified,9/3/2024,Available,,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15250,Sodium Chloride 14.6% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 14.6%, Injection, 2.5 Meq/1 Ml (NDC 63323-090-40)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,available
15251,Sodium Chloride 14.6% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 14.6%, Injection, 2.5 Meq/1 Ml (NDC 63323-090-20)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,available
15252,Sodium Chloride 14.6% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride, Injection, 14.6% 100 Meq/40 Ml (2.5 Meq/Ml) (NDC 0409-6660-75)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,available
15253,Sodium Chloride 23.4% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 23.4%, Injection, 4 Meq/1 Ml (NDC 63323-099-63)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,,2024,available
15254,Sodium Chloride 23.4% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 23.4%, Injection, 4 Meq/1 Ml (NDC 63323-093-30)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,,2024,available
15255,Sodium Chloride 23.4% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride, Injection, 400 Meq/100 Ml (4 Meq/Ml) (NDC 0409-1141-02)",Revised,8/26/2024,Limited Availability,Estimated Recovery: September 2024,,Delay In Shipping Of The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,,2024,limited availability
15256,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi Usa, Llc","Injection, 50 Ml Vial (NDC 63323-886-56)",Revised,8/2/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/2024,,,2024,
15257,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi Usa, Llc","Injection, 15 Ml Vial (NDC 63323-881-16)",Revised,8/2/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/2024,,,2024,
15258,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi Usa, Llc","Injection, 5 Ml Vial (NDC 63323-884-06)",Revised,8/2/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/2024,,,2024,
15259,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Hospira, Inc., A Pfizer Company","Injection, 15 Ml Vial (NDC 0409-7391-72)",Revised,8/2/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/2024,,,2024,
15260,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","American Regent, Inc.","Injection, 50 Ml Vial (NDC 0517-7350-25)",Revised,8/2/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/2024,,,2024,
15261,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","American Regent, Inc.","Injection, 5 Ml Vial (NDC 0517-7305-25)",Revised,8/2/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/2024,,,2024,
15262,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","American Regent, Inc.","Injection, 15 Ml Vial (NDC 0517-7315-25)",Revised,8/2/2024,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/2024,,,2024,
15263,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 20 Mg/2 Ml (NDC 50242-076-01)",Revised,3/22/2024,Limited Availability,,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,,2024,limited availability
15264,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 5 Mg/2 Ml (NDC 50242-075-01)",Revised,3/22/2024,Limited Availability,,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,,2024,limited availability
15265,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 10 Mg/2 Ml (NDC 50242-074-01)",Revised,3/22/2024,Limited Availability,,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,,2024,limited availability
15266,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 2.0 Mg Preservative Free (NDC 0013-2658-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15267,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.8 Mg Preservative Free (NDC 0013-2657-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15268,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.6 Mg Preservative Free (NDC 0013-2656-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15269,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.4 Mg Preservative Free (NDC 0013-2655-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15270,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 5 Mg/Ml, W/ Preservative (NDC 0013-2626-81)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15271,Somatropin Injection,Eli Lilly And Co.,"Humatrope, Injection, 24 Mg/Vial (NDC 0002-8149-01)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15272,Somatropin Injection,Eli Lilly And Co.,"Humatrope, Injection, 12 Mg/Vial (NDC 0002-8148-01)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15273,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 10 Mg/1.5 Ml (NDC 0781-3004-07)",Reverified,8/5/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15274,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 5 Mg/1.5 Ml (NDC 0781-3001-07)",Reverified,8/5/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15275,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 30 Mg/3 Ml (NDC 0169-7703-21)",Revised,7/31/2024,Unavailable,Unavailable Until End Of 2024,,Delay In Shipping Of The Drug,Endocrinology/Metabolism,Current,,,,2024,not available
15276,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 15 Mg/1.5 Ml (NDC 0169-7708-21)",Revised,7/31/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15277,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 10 Mg/1.5 Ml (NDC 0169-7705-21)",Revised,7/31/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15278,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 5 Mg/1.5 Ml (NDC 0169-7704-21)",Revised,7/31/2024,Limited Availability,Intermittent Supply Until End Of Q2 2024,,Delay In Shipping Of The Drug,Endocrinology/Metabolism,Current,,,,2024,limited availability
15279,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.2 Mg Preservative Free (NDC 0013-2654-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15280,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.0 Mg Preservative Free (NDC 0013-2653-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15281,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.8 Mg Preservative Free (NDC 0013-2652-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15282,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.6 Mg Preservative Free (NDC 0013-2651-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15283,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.4 Mg Preservative Free (NDC 0013-2650-02)",Reverified,8/26/2024,Unavailable,Next Delivery: September 2024; Estimated Recovery: December 2024,,Demand Increase For The Drug,Endocrinology/Metabolism,Current,,,,2024,not available
15284,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.2 Mg Preservative Free (NDC 0013-2649-02)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15285,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 12 Mg/Ml, W/ Preservative (NDC 0013-2646-81)",Reverified,8/26/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15286,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 10 Mg/2 Ml (NDC 50242-074-01)",New,3/22/2024,,"The Decision To Discontinue Commercial Distribution Of Nutropin Aq In The United States Is A Business Decision, Taken In View Of The Availability Of Generic And Alternative Treatments For Patients, And Is Not Related To Any Quality, Safety Or Efficacy Concerns With The Product.",,,Endocrinology/Metabolism,To Be Discontinued,,3/22/2024,,2024,discontinued
15287,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 5 Mg/2 Ml (NDC 50242-075-01)",New,3/22/2024,,"The Decision To Discontinue Commercial Distribution Of Nutropin Aq In The United States Is A Business Decision, Taken In View Of The Availability Of Generic And Alternative Treatments For Patients, And Is Not Related To Any Quality, Safety Or Efficacy Concerns With The Product.",,,Endocrinology/Metabolism,To Be Discontinued,,3/22/2024,,2024,discontinued
15288,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 20 Mg/2 Ml (NDC 50242-076-01)",New,3/22/2024,,"The Decision To Discontinue Commercial Distribution Of Nutropin Aq In The United States Is A Business Decision, Taken In View Of The Availability Of Generic And Alternative Treatments For Patients, And Is Not Related To Any Quality, Safety Or Efficacy Concerns With The Product.",,,Endocrinology/Metabolism,To Be Discontinued,,3/22/2024,,2024,discontinued
15289,Sterile Water Injection,Nephron Pharmaceuticals Corporation,"Injection, 1 Ml/1 Ml (NDC 0487-6105-01)",Reverified,7/17/2024,"Product Will Be Made Available As It Is Released, Tbd",,,Requirements Related To Complying With Good Manufacturing Practices,Other,Current,,,,2024,unclear
15290,Sterile Water Injection,"Fresenius Kabi Usa, Llc","Injection, 1000 Ml/1000 Ml (NDC 63323-178-76)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Other,Current,,,,2024,available
15291,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Bacteriostatic Water For Injection In Plastic Container, Injection, 1 Ml/1 Ml (NDC 0409-3977-03)",Reverified,8/26/2024,Available,,,,Other,Current,,,,2024,available
15292,Sterile Water Injection,"Medefil, Inc.","Injection, 10 Ml/10 Ml (NDC 64253-020-30)",Revised,9/3/2024,Available,,,,Other,Current,,,,2024,available
15293,Sterile Water Injection,"Fresenius Kabi Usa, Llc","Sterile Water For Injection In Plastic Container, Injection, 1 Ml/1 Ml (NDC 63323-185-50)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Other,Current,,,,2024,available
15294,Sterile Water Injection,"Fresenius Kabi Usa, Llc","Sterile Water For Injection In Plastic Container, Injection, 1 Ml/1 Ml (NDC 63323-185-20)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Other,Current,,,,2024,available
15295,Sterile Water Injection,"Fresenius Kabi Usa, Llc","Sterile Water For Injection In Plastic Container, Injection, 1 Ml/1 Ml (NDC 63323-185-10)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Other,Current,,,,2024,available
15296,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Ml/1 Ml (NDC 0409-4887-99)",Reverified,8/26/2024,Available,,,,Other,Current,,,,2024,available
15297,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Ml/1 Ml (NDC 0409-4887-50)",Reverified,8/26/2024,Available,,,,Other,Current,,,,2024,available
15298,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Ml/1 Ml (NDC 0409-4887-20)",Reverified,8/26/2024,Available,,,,Other,Current,,,,2024,available
15299,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Ml/1 Ml (NDC 0409-4887-10)",Reverified,8/26/2024,Available,,,,Other,Current,,,,2024,available
15300,Sterile Water Injection,"Hikma Pharmaceuticals Usa, Inc.","Sterile Water For Injection, Injection, 1 Ml/1 Ml (NDC 0641-6147-10)",Reverified,8/28/2024,Available,,,,Other,Current,,,,2024,available
15301,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0264-2101-00)",Reverified,9/3/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15302,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0264-2101-10)",Reverified,9/3/2024,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,,2024,available
15303,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 Ml/100 Ml (NDC 0338-0004-04)",Reverified,6/21/2024,Limited Availability,On Allocation; Recovery Q3 2024,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15304,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 Ml/100 Ml (NDC 0338-0004-03)",Reverified,6/21/2024,Limited Availability,On Allocation; Recovery Q3 2024,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15305,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 Ml/100 Ml (NDC 0338-0004-02)",Reverified,6/21/2024,Limited Availability,On Allocation; Recovery Q3 2024,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15306,Sterile Water Irrigant,"Icu Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0990-7139-36)",Reverified,9/4/2024,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7139-36",,Other,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15307,Sterile Water Irrigant,"Icu Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0990-7139-09)",Reverified,9/4/2024,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7139-09",,Other,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15308,Sterile Water Irrigant,"Icu Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0990-6139-22)",Reverified,9/4/2024,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-6139-22",,Other,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15309,Sterile Water Irrigant,"Icu Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0990-6139-03)",Reverified,9/4/2024,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-6139-03",,Other,Gastroenterology; Other; Pediatric,Current,,,,2024,limited availability
15310,"Streptozocin Powder, For Solution","Esteve Pharmaceuticals, S.A.","Zanosar, Powder, For Solution, 1 G/10 Ml (NDC 68118-100-01)",Reverified,1/15/2024,Available,,,,Oncology,Current,,,,2024,available
15311,"Streptozocin Powder, For Solution","Teva Pharmaceuticals Usa, Inc.","Zanosar, Powder, For Solution, 100 Mg/1 Ml (NDC 0703-4636-01)",Reverified,9/4/2024,Unavailable,Estimated Recovery Tbd,,Other,Oncology,Current,,,,2024,not available
15312,Sucralfate Tablet,Amneal Pharmaceuticals,"Tablet, 1 G (NDC 69238-1656-1)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15313,Sucralfate Tablet,"Allergan, Inc.","Tablet, 1 G (NDC 59762-040-15)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15314,Sucralfate Tablet,"Allergan, Inc.","Tablet, 1 G (NDC 59762-040-11)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15315,Sucralfate Tablet,"Allergan, Inc.","Carafate, Tablet, 1 G (NDC 58914-171-10)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15316,Sucralfate Tablet,"Teva Pharmaceuticals Usa, Inc.","Sucralfate Tablets, Usp, Tablet, 1 G (NDC 0093-2210-98)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15317,Sucralfate Tablet,"Teva Pharmaceuticals Usa, Inc.","Sucralfate Tablets, Usp, Tablet, 1 G (NDC 0093-2210-05)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15318,Sucralfate Tablet,"Teva Pharmaceuticals Usa, Inc.","Sucralfate Tablets, Usp, Tablet, 1 G (NDC 0093-2210-01)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15319,Sucralfate Tablet,"Nostrum Laboratories, Inc.","Tablet, 1 G (NDC 29033-003-05)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15320,Sucralfate Tablet,"Nostrum Laboratories, Inc.","Tablet, 1 G (NDC 29033-003-01)",Revised,7/15/2024,,,Available,,Gastroenterology,Resolved,7/15/2024,,,2024,
15321,Sufentanil Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Sufentanil Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 17478-050-01)",Reverified,8/28/2024,Unavailable,Not Currently Manufactured,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,,2024,not available
15322,Sufentanil Citrate Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Ug/1 Ml (NDC 0409-3382-21)",Revised,8/26/2024,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,,2024,limited availability
15323,Sufentanil Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Sufentanil Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 17478-050-05)",Reverified,8/28/2024,Unavailable,Not Currently Manufactured,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,,2024,not available
15324,Sufentanil Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Sufentanil Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 17478-050-02)",Reverified,8/28/2024,Unavailable,Not Currently Manufactured,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,,2024,not available
15325,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-5000-5)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15326,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-0104-5)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15327,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0102-60)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15328,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0101-30)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15329,Sulfasalazine Tablet,Chartwell Molecular Holdings Llc,"Sulfasalazine, Tablet, 500 Mg (NDC 62135-960-31)",Revised,5/21/2024,,,Available,,Gastroenterology,Resolved,5/21/2024,,,2024,
15330,Sulfasalazine Tablet,Chartwell Molecular Holdings Llc,"Sulfasalazine, Tablet, 500 Mg (NDC 62135-960-10)",Revised,5/21/2024,,,Available,,Gastroenterology,Resolved,5/21/2024,,,2024,
15331,Sulfasalazine Tablet,Chartwell Molecular Holdings Llc,"Sulfasalazine, Tablet, 500 Mg (NDC 62135-960-05)",Revised,5/21/2024,,,Available,,Gastroenterology,Resolved,5/21/2024,,,2024,
15332,Sulfasalazine Tablet,Chartwell Molecular Holdings Llc,"Sulfasalazine, Tablet, 500 Mg (NDC 62135-960-01)",Revised,5/21/2024,,,Available,,Gastroenterology,Resolved,5/21/2024,,,2024,
15333,Sulfasalazine Tablet,"Teva Pharmaceuticals Usa, Inc.","Sulfasalazine Tablets, Usp, Tablet, 500 Mg (NDC 0093-3234-05)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15334,Sulfasalazine Tablet,"Teva Pharmaceuticals Usa, Inc.","Sulfasalazine Tablets, Usp, Tablet, 500 Mg (NDC 0093-3234-10)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15335,Sulfasalazine Tablet,"Teva Pharmaceuticals Usa, Inc.","Sulfasalazine Tablets, Usp, Tablet, 500 Mg (NDC 0093-3234-01)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15336,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-5000-6)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15337,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-5000-1)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15338,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-0104-6)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15339,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-0104-1)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15340,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0102-20)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15341,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0102-50)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15342,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0101-20)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15343,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0101-10)",Revised,5/21/2024,,,,,Gastroenterology,Resolved,5/21/2024,,,2024,
15344,Technetium Tc-99m Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","Cis-Pyro, Injection, 12 Mg/10 Ml (NDC 45567-0060-1)",Revised,8/26/2024,Unavailable,Estimated Return Of Supply: October'2024,,Shortage Of An Active Ingredient,Medical Imaging,Current,,,,2024,not available
15345,Technetium Tc-99m Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","Cis-Pyro, Injection, 12 Mg/10 Ml (NDC 45567-0060-2)",Revised,8/26/2024,Unavailable,Estimated Return Of Supply: October'2024,,Shortage Of An Active Ingredient,Medical Imaging,Current,,,,2024,not available
15346,Technetium Tc-99m Pyrophosphate Kit Injection,Curium Us Llc,"Technescan Pyp, Injection, 11.9 Mg/10 Ml; 3.2 Mg/10 Ml (NDC 69945-094-20)",Reverified,9/2/2024,Unavailable,,,Shortage Of An Active Ingredient,Medical Imaging,Current,,,,2024,not available
15347,Technetium Tc-99m Sodium Pertechnetate Generator,"Northstar Medical Radioisotopes, Llc","Radiogenix® System, Generator, 12 Ci/12 Ci (NDC 71612-120-02)",New,10/17/2023,,"The Radiogenix System Is A Technetium Tc 99m Generator That Produces Sodium Pertechnetate Tc 99m Injection, Usp From A Non-Uranium Potassium Molybdate Mo-99 Source Solution, Which Is Shielded Within A Source Container That Completely Encases A Vial Containing 22-30 Ml Of Solution. The Company Has Made A Business Decision To Discontinue Production And Distribution. The Production Date For The Last Batch Of Mo-99 Source Vessels Is October 30, 2023 With An Expiration Date Of November 20, 2023.",,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,,10/17/2023,,2024,discontinued
15348,Technetium Tc-99m Sodium Pertechnetate Generator,"Northstar Medical Radioisotopes, Llc","Radiogenix® System, Generator, 7.5 Ci/7.5 Ci (NDC 71612-075-02)",New,10/17/2023,,"The Radiogenix System Is A Technetium Tc 99m Generator That Produces Sodium Pertechnetate Tc 99m Injection, Usp From A Non-Uranium Potassium Molybdate Mo-99 Source Solution, Which Is Shielded Within A Source Container That Completely Encases A Vial Containing 22-30 Ml Of Solution; The Company Has Made A Business Decision To Discontinue Production And Distribution. The Production Date For The Last Batch Of Mo-99 Source Vessels Is October 30, 2023 With An Expiration Date Of November 20, 2023.",,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,,10/17/2023,,2024,discontinued
15349,Technetium Tc-99m Sodium Pertechnetate Generator,"Northstar Medical Radioisotopes, Llc","Radiogenix® System, Generator, 15 Ci/15 Ci (NDC 71612-150-02)",New,10/17/2023,,"The Radiogenix System Is A Technetium Tc 99m Generator That Produces Sodium Pertechnetate Tc 99m Injection, Usp From A Non-Uranium Potassium Molybdate Mo-99 Source Solution, Which Is Shielded Within A Source Container That Completely Encases A Vial Containing 22-30 Ml Of Solution; The Company Has Made A Business Decision To Discontinue Production And Distribution. The Production Date For The Last Batch Of Mo-99 Source Vessels Is October 30, 2023 With An Expiration Date Of November 20, 2023.",,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,,10/17/2023,,2024,discontinued
15350,Technetium Tc-99m Sodium Pertechnetate Generator,"Northstar Medical Radioisotopes, Llc","Radiogenix® System, Generator, 19 Ci/19 Ci (NDC 71612-190-02)",New,10/17/2023,,"The Radiogenix System Is A Technetium Tc 99m Generator That Produces Sodium Pertechnetate Tc 99m Injection, Usp From A Non-Uranium Potassium Molybdate Mo-99 Source Solution, Which Is Shielded Within A Source Container That Completely Encases A Vial Containing 22-30 Ml Of Solution. The Company Has Made A Business Decision To Discontinue Production And Distribution. The Production Date For The Last Batch Of Mo-99 Source Vessels Is October 30, 2023 With An Expiration Date Of November 20, 2023.",,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,,10/17/2023,,2024,discontinued
15351,Temazepam Capsule,Amneal Pharmaceuticals,"Capsule, 15 Mg (NDC 65162-556-10)",New,4/30/2024,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/2024,,2024,discontinued
15352,Temazepam Capsule,Amneal Pharmaceuticals,"Capsule, 15 Mg (NDC 65162-556-50)",New,4/30/2024,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/2024,,2024,discontinued
15353,Temazepam Capsule,Amneal Pharmaceuticals,"Capsule, 30 Mg (NDC 65162-557-10)",New,4/30/2024,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/2024,,2024,discontinued
15354,Temazepam Capsule,Amneal Pharmaceuticals,"Capsule, 30 Mg (NDC 65162-557-50)",New,4/30/2024,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/2024,,2024,discontinued
15355,"Testosterone Gel, Metered","Endo Pharmaceuticals, Inc.","Fortesta, Gel, Metered, 10 Mg/.5 G (NDC 63481-183-16)",New,12/7/2023,,,,,Urology,To Be Discontinued,,12/7/2023,,2024,discontinued
15356,"Testosterone Gel, Metered","Endo Pharmaceuticals, Inc.","Fortesta, Gel, Metered, 10 Mg/.5 G (NDC 63481-183-17)",New,12/7/2023,,,,,Urology,To Be Discontinued,,12/7/2023,,2024,discontinued
15357,"Testosterone Gel, Metered","Endo Pharmaceuticals, Inc.","Fortesta, Gel, Metered, 10 Mg/.5 G (NDC 63481-183-18)",New,12/7/2023,,,,,Urology,To Be Discontinued,,12/7/2023,,2024,discontinued
15358,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 5 Mg/.5 Ml (NDC 0002-1495-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15359,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 15 Mg/.5 Ml (NDC 0002-1457-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15360,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 12.5 Mg/.5 Ml (NDC 0002-1460-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15361,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 7.5 Mg/.5 Ml (NDC 0002-1484-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15362,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 2.5 Mg/.5 Ml (NDC 0002-1506-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15363,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 10 Mg/.5 Ml (NDC 0002-1471-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15364,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 7.5 Mg/.5 Ml (NDC 0002-2484-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15365,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 2.5 Mg/.5 Ml (NDC 0002-2506-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15366,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 10 Mg/.5 Ml (NDC 0002-2471-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15367,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 15 Mg/.5 Ml (NDC 0002-2457-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15368,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 12.5 Mg/.5 Ml (NDC 0002-2460-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15369,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 5 Mg/.5 Ml (NDC 0002-2495-80)",Reverified,9/3/2024,Available,,,,Endocrinology/Metabolism,Current,,,,2024,available
15370,Tobramycin Sulfate Injection,"Fresenius Kabi Usa, Llc","Tobramycin Sulfate, Injection, 1200 Mg/30 Ml (NDC 63323-303-55)",Revised,4/12/2021,,,,,Anti-Infective; Pediatric,Resolved,,,,2024,
15371,Tobramycin Sulfate Injection,"Fresenius Kabi Usa, Llc","Tobramycin Sulfate, Injection, 1200 Mg/30 Ml (NDC 63323-303-51)",Revised,4/12/2021,,,,,Anti-Infective; Pediatric,Resolved,,,,2024,
15372,Triamcinolone Acetonide Injection,"Harrow Eye, Llc","Triesence, Injection, 40 Mg/1 Ml (NDC 0065-0543-01)",Revised,8/14/2024,Unavailable,Supply Expected To Be Available October 2024. There Are No Therapeutic Equivalents.,,Requirements Related To Complying With Good Manufacturing Practices,Ophthalmology,Current,,,,2024,not available
15373,Triamcinolone Hexacetonide Injection,Medexus,"Hexatrione, Injection, 40 Mg/2 Ml (NDC 59137-570-01)",Reverified,12/19/2023,Unavailable,,,Delay In Shipping Of The Drug,Rheumatology,Current,,,,2024,not available
15374,Triazolam Tablet,Pfizer Inc.,"Halcion, Tablet, .25 Mg (NDC 0009-0017-55)",New,6/27/2024,,,,,Psychiatry,To Be Discontinued,,6/27/2024,,2024,discontinued
15375,Triazolam Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, .125 Mg (NDC 0054-4858-25)",New,1/30/2024,,,,,Psychiatry,To Be Discontinued,,1/30/2024,,2024,discontinued
15376,Triazolam Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, .25 Mg (NDC 0054-4859-25)",New,1/30/2024,,,,,Psychiatry,To Be Discontinued,,1/30/2024,,2024,discontinued
15377,Triazolam Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, .25 Mg (NDC 0054-4859-29)",New,1/30/2024,,,,,Psychiatry,To Be Discontinued,,1/30/2024,,2024,discontinued
15378,Valproate Sodium Injection,Sagent Pharmaceuticals,"Injection, 100 Mg/Ml, 5 Ml (NDC 70860-784-41)",Revised,1/9/2024,,No Longer Ordering Apd Ndc,,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,1/9/2024,1/9/2024,,2024,discontinued
15379,Valproate Sodium Injection,"Fresenius Kabi Usa, Llc","Injection, 100 Mg/1 Ml (NDC 63323-494-05)",Revised,9/4/2024,Unavailable,Backordered. Next Release Not Available At This Time. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Neurology,Current,,,,2024,not available
15380,Valproate Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Valproate Sodium Injection, Usp, Injection, 500 Mg/5 Ml (NDC 0143-9785-10)",Reverified,8/28/2024,Available,Additional Lots Will Be Scheduled For Manufacturing. Product Will Be Made Available As It Is Released.,,,Neurology,Current,,,,2024,available
15381,Vecuronium Bromide Injection,Eugia Us Llc,"Injection, 20 Mg (NDC 55150-236-20)",Reverified,8/5/2024,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,,2024,available
15382,Vecuronium Bromide Injection,Eugia Us Llc,"Injection, 10 Mg (NDC 55150-235-10)",Reverified,8/5/2024,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,,2024,not available
15383,Vecuronium Bromide Injection,"Sun Pharmaceutical Industries, Inc.","Vecuronium Bromide, Injection, 1 Mg/1 Ml (NDC 47335-932-44)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
15384,Vecuronium Bromide Injection,"Sun Pharmaceutical Industries, Inc.","Vecuronium Bromide, Injection, 1 Mg/1 Ml (NDC 47335-931-44)",Revised,8/26/2024,Available,,,,Anesthesia,Current,,,,2024,available
15385,Vecuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-782-20)",Revised,3/22/2024,,,,,Anesthesia,To Be Discontinued,3/22/2024,3/22/2024,,2024,discontinued
15386,Vecuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-781-10)",Revised,3/22/2024,,,,,Anesthesia,To Be Discontinued,3/22/2024,3/22/2024,,2024,discontinued
15387,Vecuronium Bromide Injection,"Mylan Institutional, A Viatris Company","Injection, 1 Mg/1 Ml (NDC 67457-475-20)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
15388,Vecuronium Bromide Injection,"Mylan Institutional, A Viatris Company","Injection, 1 Mg/1 Ml (NDC 67457-438-10)",Reverified,9/5/2024,Available,,,,Anesthesia,Current,,,,2024,available
15389,Vecuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Vecuronium Bromide, Injection, 1 Mg/1 Ml (NDC 0409-1632-01)",Revised,3/22/2024,,,,,Anesthesia,To Be Discontinued,3/22/2024,3/22/2024,,2024,discontinued
15390,Verteporfin Injection,Bausch & Lomb Incorporated,"Visudyne, Injection, 15 Mg (NDC 0187-5600-15)",Revised,2/9/2023,,,Available,,Ophthalmology,Resolved,2/9/2023,,,2024,
15391,Vinblastine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-278-10)",Reverified,9/4/2024,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,,2024,available
15392,Vitamin A Palmitate Injection,"Casper Pharma, Llc","Aquasol A, Injection, 15 Mg/1 Ml (NDC 70199-026-11)",New,6/10/2024,Unavailable,Next Delivery And Estimated Recovery: August 2024,,Delay In Shipping Of The Drug,Endocrinology/Metabolism; Ophthalmology,Current,,,,2024,not available
15393,"Zolpidem Tartrate Tablet, Extended Release",Sandoz Inc.,"Tablet, Extended Release, 6.25 Mg (NDC 0781-5315-01)",New,1/26/2024,,,,,Psychiatry,To Be Discontinued,,1/26/2024,,2024,discontinued
15394,"Zolpidem Tartrate Tablet, Extended Release",Sandoz Inc.,"Tablet, Extended Release, 12.5 Mg (NDC 0781-5316-01)",New,1/26/2024,,,,,Psychiatry,To Be Discontinued,,1/26/2024,,2024,discontinued
